<SEC-DOCUMENT>0001193125-22-295453.txt : 20221130
<SEC-HEADER>0001193125-22-295453.hdr.sgml : 20221130
<ACCEPTANCE-DATETIME>20221130165237
ACCESSION NUMBER:		0001193125-22-295453
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		105
FILED AS OF DATE:		20221130
DATE AS OF CHANGE:		20221130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OmniAb, Inc.
		CENTRAL INDEX KEY:			0001846253
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268613
		FILM NUMBER:		221436128

	BUSINESS ADDRESS:	
		STREET 1:		5980 HORTON STREET
		STREET 2:		SUITE 600
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-250-7800

	MAIL ADDRESS:	
		STREET 1:		5980 HORTON STREET
		STREET 2:		SUITE 600
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avista Public Acquisition Corp. II
		DATE OF NAME CHANGE:	20210212
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d305908ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:oabi="http://om.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To09_30_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To09_30_2022">0001846253</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="oabi-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis" >oabi:FirstRequirementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:EarnoutStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis" >oabi:SecondRequirementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis" >oabi:FirstRequirementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:RoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ClassCommonStockSharesNotSubjectToRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:RelatedPartyLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandThirtyTwoMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >oabi:TwoThousandThirtyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandThirtySevenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >oabi:TwoThousandThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CaliforniaResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >oabi:CaliforniaResearchAndDevelopmentCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FederalResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >oabi:FederalResearchAndDevelopmentCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputFairValueOfUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputCommodityForwardPriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputExpectedRedemptionRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ClassCommonStockSharesNotSubjectToRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:RelatedPartyLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis" >oabi:FirstRequirementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis" >oabi:SecondRequirementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:OmniabIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_SponsorInsiderAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:SponsorInsiderAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:EarnoutStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:EarnoutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_NewOmniabCommonStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:NewOmniabCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:EarnoutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_RelatedPartiesOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:RelatedPartiesOfApacMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SponsorOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:SponsorOfApacMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_ApacsExistingPublicShareholdersMembersrtOwnershipAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:ApacsExistingPublicShareholdersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-12</xbrli:startDate> <xbrli:endDate>2021-08-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseWarrantsAndBackstopMemberusgaapClassOfWarrantOrRightAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:ForwardPurchaseWarrantsAndBackstopMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_15_2022To03_15_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-15</xbrli:startDate> <xbrli:endDate>2022-03-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:RelatedPartyLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:RoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputFairValueOfUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputCommodityForwardPriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >oabi:MeasurementInputExpectedRedemptionRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >oabi:SeparationAndDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:LigandMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:RoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To09_30_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_23_2022To03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-23</xbrli:startDate> <xbrli:endDate>2022-03-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-23</xbrli:startDate> <xbrli:endDate>2022-03-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >oabi:ApacCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-23</xbrli:startDate> <xbrli:endDate>2022-03-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-23</xbrli:startDate> <xbrli:endDate>2022-03-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_24_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-24</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-05</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-12</xbrli:startDate> <xbrli:endDate>2021-02-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >oabi:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_XcellaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_XcellaMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:AbInitioAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XCellaAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:TaurusAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShareBasedPaymentArrangementNonemployeeDirectorsMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >oabi:ShareBasedPaymentArrangementNonemployeeDirectorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsAndPhantomShareUnitsMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >oabi:RestrictedStockUnitsAndPhantomShareUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_17_2022To08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-17</xbrli:startDate> <xbrli:endDate>2022-08-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedBalanceSheetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-16</xbrli:startDate> <xbrli:endDate>2021-06-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >oabi:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-22</xbrli:startDate> <xbrli:endDate>2021-03-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-23</xbrli:startDate> <xbrli:endDate>2021-06-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:CrystalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_IcagenMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >oabi:PartnerCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:RoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >oabi:MilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_XcellaMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >oabi:XcellaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:TaurusAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-09</xbrli:startDate> <xbrli:endDate>2020-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:TaurusAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-09</xbrli:startDate> <xbrli:endDate>2020-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:TaurusAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_09_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:TaurusAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XCellaAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_08_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XCellaAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2020To09_08_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XCellaAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-08</xbrli:startDate> <xbrli:endDate>2020-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:XCellaAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-08</xbrli:startDate> <xbrli:endDate>2020-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2020_EarnoutRightsMemberusgaapContingentConsiderationByTypeAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:IcagenAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis" >oabi:EarnoutRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:AbInitioAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-07-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:AbInitioAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-07-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:AbInitioAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-23</xbrli:startDate> <xbrli:endDate>2019-07-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >oabi:AbInitioAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-23</xbrli:startDate> <xbrli:endDate>2019-07-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" >oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_item" > <xbrli:measure>oabi:item</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_ITEM" > <xbrli:measure>oabi:ITEM</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_VOTE" > <xbrli:measure>oabi:VOTE</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Number" > <xbrli:measure>oabi:Number</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the Securities and Exchange Commission on November&#160;30, 2022 </div></div></div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549 </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To09_30_2022">S-1</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To09_30_2022">OMNIAB, INC.</ix:nonNumeric> </div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8731</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">98-1584818</div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Primary Standard Industrial</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Classification Code Number)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer<br/>Identification No.)</div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">5980 Horton Street, Suite 600 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Emeryville, California 94608 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(510) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">250-7800</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew W. Foehr </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Executive Officer </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">5980 Horton Street, Suite 600 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Emeryville, California 94608 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(510) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">250-7800</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew T. Bush</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Scott Shean</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Latham&#160;&amp; Watkins LLP</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">12670 High Bluff Drive</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California 92130</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(858) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">523-5400</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Charles S. Berkman</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Legal Officer</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc.</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">5980 Horton Street, Suite 600</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Emeryville, California 94608</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(510) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">250-7800</div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximate date of commencement of proposed sale to the public: </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">As soon as practicable after the effective date of this Registration Statement. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9746; </div></div></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;12b-2</div> of the Exchange Act. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 55%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 22%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To09_30_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To09_30_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;</div></div><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To09_30_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#eb0029"><span style="font-weight:bold">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#eb0029"><span style="font-weight:bold">Subject to Completion </span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#eb0029"><span style="font-weight:bold">Preliminary Prospectus dated November&#160;30, 2022. </span></span></p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PROSPECTUS </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g99c14.jpg" alt="LOGO" />
 </p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">OmniAb, Inc. </p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 36,345,645 Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 11,345,489 Warrants </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 19,012,156 Shares of Common Stock Issuable Upon Exercise of Warrants </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to: (i)&#160;the resale of 3,920,440 shares of common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), issued in connection with the Business Combination (as defined below), including 843,736 earnout shares of Common Stock (the &#8220;Earnout Shares&#8221;) that may become tradeable upon the achievement of certain stock price-based vesting conditions in accordance with the terms of the Merger Agreement (as defined below), by certain of the selling securityholders named in this prospectus (each a &#8220;Selling Securityholder&#8221; and, collectively, the &#8220;Selling Securityholders&#8221;); (ii) the resale of 15,817,934 shares of Common Stock issued to Avista Acquisition LP II (the &#8220;Sponsor&#8221;) in private placements in connection with our initial public offering (the &#8220;IPO&#8221;), the Redemption Backstop (as defined below) and the Forward Purchase (as defined below), including 1,293,299 earnout shares (the &#8220;Sponsor Earnout Shares&#8221;); (iii) the resale of 11,345,489 shares of Common Stock issuable upon the exercise of up to 11,345,489 Private Placement Warrants (as defined below); (iv) the issuance by us and resale of 5,261,782 shares of Common Stock upon the exercise of options to purchase Common Stock and the vesting of restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;); and (v)&#160;the issuance by us of up to 19,012,156 shares of Common Stock upon the exercise of outstanding warrants to purchase Common Stock (the &#8220;Warrants&#8221;), which includes 7,666,667 warrants (the &#8220;Public Warrants&#8221;) issued to investors in the IPO and 11,345,489 warrants (the &#8220;Private Placement Warrants&#8221;) issued to the Sponsor in a private placement in connection with the IPO, the Redemption Backstop and the Forward Purchase. This prospectus also relates to the resale of the Private Placement Warrants by the holders thereof. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the securities for resale pursuant to the Selling Securityholders&#8217; registration rights under certain agreements between us and the Selling Securityholders. Our registration of the securities covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the shares of Common Stock or Warrants. The Selling Securityholders may offer, sell or distribute all or a portion of their shares of Common Stock or Warrants publicly or through private transactions at prevailing market prices or at negotiated prices. We provide more information about how the Selling Securityholders may sell the shares of Common Stock or Warrants in the section entitled &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; We will receive the proceeds from any exercise of the Warrants or options for cash, but not from the resale of the shares of Common Stock or Warrants by the Selling Securityholders. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and are subject to reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;OABI.&#8221; Our Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;OABIW.&#8221; On November&#160;29, 2022, the closing price of our Common Stock was $2.84, and the closing price of our Warrants was $0.42. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock and Private Placement Warrants. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the shares of Common Stock or Private Placement Warrants. </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><span style="font-weight:bold">Our business and investment in our Common Stock and Warrants involve significant risks. These risks are described in the section titled &#8220;</span><span style="font-weight:bold"><span style="font-style:italic"><a href="#rom305908_5">Risk Factors</a></span></span><span style="font-weight:bold">&#8221; beginning on page&#160;9 of this prospectus. </span></p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">ii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">iii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_4">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_6">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_7">DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_8">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_9">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_10">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_11">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_12">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_13">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_14">PRINCIPAL STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_15">SELLING SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_16">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_17">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_18">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_19">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_20">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_21">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_22">INFORMATION NOT REQUIRED IN PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">II-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom305908_23">SIGNATURES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. We will not receive any proceeds from the sale by the Selling Securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of options and the Warrants and upon the vesting of restricted stock units and performance stock units. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants and options pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants or options for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Securityholders take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. We and the Selling Securityholders will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any post-effective amendment and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus contains, and any post-effective amendment or any prospectus supplement may contain, market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. We believe this information is reliable as of the applicable date of its publication, however, we have not independently verified the accuracy or completeness of the information included in or assumptions relied on in these third-party publications. In addition, the market and industry data and forecasts that may be included in this prospectus, any post-effective amendment or any prospectus supplement may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; contained in this prospectus, any post-effective amendment and the applicable prospectus supplement. Accordingly, investors should not place undue reliance on this information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own or have rights to trademarks, trade names and service marks that we use in connection with the operation of our business. In addition, our name, logos and website name and address are our trademarks or service marks. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to in this prospectus are listed without the applicable <sup style="font-size:75%; vertical-align:top">&#174;</sup>, <sup style="font-size:75%; vertical-align:top">&#8482;</sup> and SM symbols, but we will assert, to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks. Other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, &#8220;forward-looking statements.&#8221; These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;seeks,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;may&#8221; or &#8220;should&#8221; or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this prospectus and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our future results of operations and financial position, business strategy, the effects of the separation or the distribution, our expectations regarding the application of, and the rate and degree of market acceptance of, our OmniAb technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate, the potential for and timing of receipt of milestones and royalties under our license agreements with partners, our research and development plans, the potential for our partnered or internal programs to progress in their development, the anticipated timing of the initiation and completion of preclinical studies and clinical trials by our partners or us, the timing and likelihood of regulatory filings and product approvals by our partners or us, the potential for and timing and geographic markets of any commercial product launches by our partners and potential for commercial success, our ability to enter into any new, or maintain existing, strategic partnerships or collaborative relationships, the impact of <span style="white-space:nowrap">COVID-19</span> on our business and that of our partners, our ability to obtain and maintain intellectual property protection for our platform, products and technologies, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated business development and product development efforts. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as a result of our separation (the &#8220;Separation&#8221;) from Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221;), we lost Ligand&#8217;s brand, reputation, capital base and other resources, and may experience difficulty operating as a standalone company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated benefits of the Separation may not be achieved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our historical combined financial data and pro&#160;forma financial statements are not necessarily representative of the results we would have achieved as a standalone company and may not be a reliable indicator of our future results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our operating results and financial performance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by new and existing partners in our market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our future success is dependent on the eventual approval and commercialization of products developed by our partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to manage and grow our business and execution of our business and growth strategies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks arising from changes in technology; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competitive environment in the life sciences and biotechnology platform market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain, protect and defend our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting our business; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties with performance of third parties we will rely on for our business growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties developing and sustaining relationships with commercial counterparties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be able to engage in certain transactions and equity issuances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may have certain indemnification obligations to Ligand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of general economic conditions and geopolitical risk, including as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic or the conflict between Russia and Ukraine, on our financial condition and results of operations and those of our partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our future capital needs following the Business Combination (as defined herein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reliance on a limited number of suppliers, or in some cases single suppliers, and third-party contract research organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">litigation, complaints, product liability claims and/or adverse publicity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privacy and data protection laws, privacy or data breaches, or the loss of data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to achieve and maintain profitability in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to meet Nasdaq&#8217;s continued listing standards for our Common Stock and Warrants; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to remediate existing and potential future material weaknesses in our internal control over financial reporting and to maintain effective internal control over financial reporting, which, if unsuccessful, may result in material misstatements of our consolidated financial statements or failure to meet periodic reporting obligations or impair access to the capital markets; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section titled &#8220;Risk Factors&#8221; in this prospectus. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this prospectus and the other documents filed by us from time to time with the SEC. The forward-looking statements contained in this prospectus and in any document incorporated by reference are based on current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_3">PROSPECTUS SUMMARY </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you in making your investment decision. You should read this entire prospectus carefully, especially the &#8220;Risk Factors&#8221; section and our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our Common Stock or Warrants. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OmniAb technology platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of September&#160;30, 2022, we had 68 active partners with 282 active programs using the OmniAb technology, 25 OmniAb-derived antibodies in clinical development by our partners, and three approved products of our partners: (i)&#160;zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma, (ii)&#160;sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) <span style="white-space:nowrap">non-small</span> cell lung cancer in combination with chemotherapy, as well as for patients with unresectable stage III <span style="white-space:nowrap">non-small</span> cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy, and (iii)&#160;teclistamab, which received accelerated approval in the U.S. for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and conditional marketing authorization in Europe as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our robust experience and development activity with our partners gives us critical insights into the industry and creates a positive feedback loop through which we plan to continue to advance our platform. Our business model is dependent on the eventual progression of therapeutic candidates discovered or initially developed utilizing our platform into clinical trials and commercialization by our partners, and our receipt of milestone and royalty payments from our partners. However, our future success and the potential to receive these payments are entirely dependent on our partners&#8217; efforts over which we have no control. If our partners determine not to proceed with the future development of a drug candidate, we will not receive any future payments related to that program. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners&#8217; clinical trial results, including serious adverse events, or ongoing communications with the FDA regarding our partners&#8217; current clinical programs, which limits our visibility into how such programs may be progressing. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the heart of the OmniAb technology platform lies the Biological Intelligence of our proprietary transgenic animals, including OmniRat, OmniMouse and OmniChicken, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. Biological Intelligence refers to the ability of the immune system in our transgenic animals to create optimized antibodies through a process that has evolved over 500&#160;million years. The immune system function is to adaptively respond to a given target through an iterative process of diversification and selection that produces novel antibodies with high affinity, specificity, and expression levels. Through its proprietary and carefully designed transgenes, OmniAb&#8217;s Biological Intelligence taps into this powerful in vivo process to generate human antibodies directly from its transgenic animals. OmniFlic and OmniClic are common light-chain rats and chickens, respectively, designed to generate bispecific antibodies. OmniTaur provides <span style="white-space:nowrap">cow-inspired</span> antibodies with unique structural characteristics for challenging targets. To our knowledge, we are the industry&#8217;s only four-species in vivo antibody discovery platform, making OmniAb the most diverse host system available in the industry. We believe natural antibodies are superior to other antibody generation methods because they are naturally optimized through an iterative<span style="font-style:italic"> in vivo </span>process that preferentially selects antibodies to effectively bind to a specific antigen. Our technology can be leveraged to develop multiple therapeutic formats including mono-, <span style="white-space:nowrap">bi-</span> and multi-specific antibodies, antibody-drug conjugates (&#8220;ADCs&#8221;) and chimeric antigen receptor T cell <span style="white-space:nowrap">(&#8220;CAR-T&#8221;).</span> By generating large and diverse pools of high-quality antibodies, we believe Biological Intelligence increases the probability of success of therapeutic antibody discovery and helps limit the attrition of antibody product candidates in the clinic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology investments are methodical and deliberate, designed to enable our partner-centric business model to leverage the most cutting-edge solutions to solve the biggest challenges in antibody drug discovery. Some partners prefer integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> discovery capabilities, while others prefer to use certain of our technologies within their own labs. This flexibility not only provides value to our partners, but also allows for greater scalability of our business since we do not have to build out capacity for partners that prefer to use some of their own technologies in the process. The breadth and depth of our partner-centric model benefits our investment decision making by providing critical insights into the needs and direction of the industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to <span style="font-style:italic">Vaccines</span> journal, antibodies are among the fastest growing class of drugs and are used across multiple therapeutic areas including oncology, inflammation, neurodegeneration. In 2021, approved antibody-based therapeutics accounted for over $215.0&#160;billion in sales and 49 antibody therapeutics reached blockbuster status in 2021 with sales higher than $1.0&#160;billion, according to data published by La Merie Publishing. Furthermore, Fatpos Global estimates that antibody-based therapeutic sales are expected to grow to approximately $365.0&#160;billion by 2030. The favorable drug-like properties of antibodies, including high specificity, limited <span style="white-space:nowrap">off-target</span> toxicity, superior immune stimulation, and the ability to modulate half-life circulation in serum, have accelerated investment in antibody therapeutics. This has resulted in higher success rates for antibody therapeutics when compared to small molecule modalities, according to Clinical Development Success Rates and Contributing Factors 2011-2020, a study of over 9,000 clinical development programs published by PharmaIntelligence. These factors have led to substantial investment in antibody discovery, which we believe will continue to expand the total addressable market for antibody discovery technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite industry momentum that has resulted in an overall increase in the number of antibody therapeutic approvals per year, drug discovery and development has become increasingly fragmented, outdated and <span style="white-space:nowrap">non-robust.</span> While many biotechnology companies bring a focused approach to science, their biological hypotheses are often tested utilizing suboptimal antibody discovery methods due to reliance on legacy technologies. Meanwhile, many larger companies have also continued to rely on legacy technologies, often due to the inability to selectively integrate newer technologies at their facilities or because the benefits of technological updates are limited by outdated workflows. Additionally, outsourced technologies that have tried to address these shortcomings often lack flexibility. These legacy approaches are burdened with critical </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disadvantages including low antibody diversity, lengthy discovery timelines, limited functional parameter data, excess costs or lack of flexibility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that by eliminating the need for each company to build a comprehensive antibody discovery engine, we can unlock innovation and value across a broad network of partners. Many emerging and established life sciences companies have been built around technologies that focus on a single or a limited number of steps in the discovery process, including antigen design, transgenic animal platforms, single-cell analysis, sequencing, bioinformatics, and proprietary assays. We believe our comprehensive, biologically-driven technology platform provides the industry with a cutting-edge solution for all critical components of the antibody discovery continuum. By providing leading antibody discovery solutions to the industry, we aim to increase the probability of success, reduce costs and shorten development timelines for our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were initially incorporated as Avista Public Acquisition Corp. II (&#8220;APAC&#8221;), an exempted company in the Cayman Islands, on February&#160;5, 2021. On October&#160;31, 2022, APAC filed a notice of deregistration with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and filed a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the State of Delaware, under which APAC was domesticated and continues as a Delaware corporation (the &#8220;Domestication&#8221;), and in connection with which APAC changed its name to &#8220;OmniAb, Inc.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;1, 2022 (the &#8220;Closing Date&#8221;), we consummated the previously announced merger pursuant to that certain Merger Agreement, dated as of March&#160;23, 2022 (the &#8220;Merger Agreement&#8221;), by and among us (formerly known as APAC), Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221;), OmniAb Operations, Inc. (formerly known as OmniAb, Inc.) (&#8220;Legacy OmniAb&#8221;), and Orwell Merger Sub Inc.(&#8220;Merger Sub&#8221;), pursuant to which Merger Sub merged with and into Legacy OmniAb, with Legacy OmniAb becoming our wholly owned subsidiary (the &#8220;Business Combination&#8221; and, collectively with the other transactions described in the Merger Agreement, the &#8220;Transactions&#8221;). On the Closing Date, and in connection with the closing of the Transactions (the &#8220;Closing&#8221;), we changed our name to OmniAb, Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;OmniAb&#8221; and the &#8220;Company&#8221; refer to OmniAb, Inc., a Delaware corporation (formely known as APAC), and its subsidiaries following the Closing. Unless the context otherwise requires, references to &#8220;APAC&#8221; refer to Avista Public Acquisition Corp. II prior to the Closing. All references herein to the &#8220;Board&#8221; refer to the board of directors of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As contemplated by the Merger Agreement: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on October&#160;31, 2022, as a result of and upon the effective time of the Domestication, each of APAC&#8217;s then issued and outstanding (i)&#160;Class&#160;A ordinary shares, par value $0.0001 (&#8220;APAC Class&#160;A Ordinary Shares&#8221;) were automatically exchanged, on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis, into common stock of OmniAb, par value $0.0001 per share (&#8220;Common Stock&#8221;), (ii) Class&#160;B ordinary shares, par value $0.0001 (&#8220;APAC Class&#160;B Ordinary Shares&#8221;) were automatically exchanged, on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis, into Common Stock, (iii)&#160;warrants were automatically exchanged, on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis, into warrants to acquire one share of Common Stock (&#8220;OmniAb Warrants&#8221;) pursuant to the Warrant Agreement, dated August&#160;9, 2022 (the &#8220;Warrant Agreement&#8221;), between APAC and Continental Stock Transfer&#160;&amp; Trust Company (&#8220;Continental&#8221;), as warrant agent, as amended by the Assignment, Assumption and Amendment Agreement, dated November&#160;1, 2022, by and among OmniAb, Continental and Computershare Trust Company, N.A., and (iv)&#160;units were separated into one share of Common Stock and <span style="white-space:nowrap">one-third</span> of one OmniAb Warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on November&#160;1, 2022, in accordance with the terms of the Separation and Distribution Agreement, dated as of March&#160;23, 2022, by and among APAC, Ligand and Legacy OmniAb (the &#8220;Separation </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
Agreement&#8221;), Ligand transferred the Legacy OmniAb business, including certain related subsidiaries of Ligand, to Legacy OmniAb and made a contribution to the capital of Legacy OmniAb of $1,840,240, after deducting certain transaction and other expenses reimbursable by Legacy OmniAb (the &#8220;Separation&#8221;); </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">following the Separation, as contemplated by the Separation Agreement, Ligand distributed on a pro rata basis to its stockholders all of the shares of common stock, par value $0.001 per share, of Legacy OmniAb (&#8220;Legacy OmniAb Common Stock&#8221;) held by Ligand, such that each holder of shares of common stock, par value $0.001 per share, of Ligand (&#8220;Ligand Common Stock&#8221;) was entitled to receive one share of Legacy OmniAb Common Stock for each share of Ligand Common Stock held by such holder as of the record date for the distribution, October&#160;26, 2022 (the &#8220;Distribution&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">pursuant to the Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022 (the &#8220;A&amp;R Employee Matters Agreement&#8221;), by and among, Ligand, Legacy OmniAb, APAC and Merger Sub, at the time of the Distribution, (i)&#160;each existing Ligand equity award granted prior to March&#160;2, 2022, with limited certain exceptions, was split into (A)&#160;a new Ligand equity award and (B)&#160;a new Legacy OmniAb equity award, with any <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> value in the original Ligand equity award split between such awards based on the relative values of Ligand and OmniAb at the time of the Distribution, and (ii)&#160;each existing Ligand equity award granted on or after March&#160;2, 2022 was converted into either (A)&#160;an adjusted Ligand equity award, if the holder was a Ligand service provider following the Distribution, or (B)&#160;a Legacy OmniAb equity award, if the holder was a Legacy OmniAb service provider following the Distribution; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">pursuant to the Amended and Restated Forward Purchase Agreement, dated as of March&#160;23, 2022 (the &#8220;A&amp;R FPA&#8221;), by and among APAC, Avista Acquisition LP II (the &#8220;Sponsor&#8221;) and Legacy OmniAb, following the Domestication but before the Merger (as defined below) OmniAb issued and sold to the Sponsor 1,500,000 shares of Common Stock and 1,666,667 OmniAb Warrants for an aggregate purchase price of $15,000,000; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">also pursuant to the A&amp;R FPA, following the Domestication but before the Merger, the Sponsor purchased 8,672,934 shares of Common Stock and 1,445,489 OmniAb Warrants for an aggregate purchase price of $86,729,340 in order to backstop shareholder redemptions which would have otherwise resulted in the cash proceeds available to OmniAb following the Business Combination from OmniAb&#8217;s trust account (the &#8220;Trust Account&#8221;) to be less than $100,000,000; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">following these steps, Merger Sub merged with and into Legacy OmniAb, with Legacy OmniAb surviving as a direct, wholly owned subsidiary of OmniAb (the &#8220;Merger&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">as a result of and automatically upon the consummation of the Merger, each outstanding share of Legacy OmniAb Common Stock (other than treasury shares) was cancelled in exchange for the right to receive 4.90007 shares of Common Stock and 0.75842 shares of Common Stock subject to certain price-based earnout triggers (the &#8220;Earnout Shares&#8221;). In addition, all outstanding Legacy OmniAb equity awards were converted into OmniAb equity awards to purchase, in the case of options, or receive, in the case of restricted stock units and performance-vesting restricted stock units, shares of Common Stock, in each case, equal to the number of shares underlying such Legacy OmniAb equity awards multiplied by 4.90007. Each holder of an outstanding Legacy OmniAb equity award also received Earnout Shares equal to the number of shares of Legacy OmniAb Common Stock underlying such equity award multiplied by 0.75842. Fifty percent of the Earnout Shares will vest on the date on which the volume-weighted average price (&#8220;VWAP&#8221;) equals or exceeds $12.50 on any 20 trading days in any 30 consecutive <span style="white-space:nowrap">trading-day</span> period, and all remaining Earnout Shares will vest on the date on which the VWAP equals or exceeds $15.00 on any 20 trading days in any 30 consecutive <span style="white-space:nowrap">trading-day</span> period, in each case provided such vesting </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
occurs during the five-year period following the Closing (as defined below), provided, that in the event of a Change of Control (as defined in the Merger Agreement) between the date of the Closing to and including the fifth anniversary of the date of the Closing pursuant to which OmniAb or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to 50% of the Earnout Shares) or $15.00 (with respect to all Earnout Shares) per share of Common Stock, and such Change of Control has been approved by a majority of the independent directors of the OmniAb Board, then such Earnout Shares shall be deemed to have vested immediately prior to such Change of Control (the transactions contemplated by clauses (a)&#160;through (h) collectively, the &#8220;Business Combination&#8221;). </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting and the Domestication, on November&#160;1, 2022 (the &#8220;Closing Date&#8221;), the Business Combination was consummated (the &#8220;Closing&#8221;).&#160;&#160;&#160;&#160; </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are governed by our certificate of incorporation (the &#8220;certificate of incorporation&#8221;), our bylaws (the &#8220;bylaws&#8221;), and the Delaware General Corporation Law (the &#8220;DGCL&#8221;), and, in the case of the Warrants, the Warrant Agreement. See &#8220;<span style="font-style:italic">Description of Our Securities</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this prospectus immediately following this prospectus summary. These risks include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred losses on an <span style="white-space:nowrap">as-reported</span> basis for the last three years, and we may not be able to generate sufficient revenue to achieve and maintain profitability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our commercial success depends on the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future success is dependent on the eventual approval and commercialization of products developed by our partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we cannot maintain and expand current partnerships and enter into new partnerships, our future operating results would be adversely affected. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business is subject to risks arising from <span style="white-space:nowrap">COVID-19</span> and other epidemic diseases. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to host our mouse and rat colonies and to supply laboratory equipment and materials. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As a result of the Separation, we lost Ligand&#8217;s brand, reputation, capital base and other resources, and may experience difficulty operating as a standalone company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain and maintain sufficient intellectual property protection for our platform and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our platform and services may be impaired. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on <span style="white-space:nowrap">in-licenses</span> from third parties. If we lose these rights, our business may be materially and adversely affected, our ability to develop improvements to our technology platform and antibody discovery platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation, as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our Common Stock and Warrants is likely to be highly volatile, and you may lose some or all of your investment<span style="font-weight:bold"><span style="font-style:italic">.</span></span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the Cayman Islands Companies Law on February&#160;5, 2021 under the name Avista Public Acquisition Corp. II. In connection with the consummation of the Domestication on October&#160;31, 2022, we changed our name to &#8220;OmniAb, Inc.&#8221; Our Common Stock and Warrants are listed on Nasdaq under the symbols &#8220;OABI&#8221; and &#8220;OABIW,&#8221; respectively. Our principal executive offices are located at 5980 Horton Street, Suite 600, Emeryville, CA 94608, and our telephone number is (510) <span style="white-space:nowrap">250-7800.</span> Our website address is www.omniab.com. The information contained in, or accessible through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.235&#160;billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;). An &#8220;emerging growth company&#8221; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the option to present only two&#160;years of audited financial statements and only two&#160;years of related &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; in this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding a nonbinding advisory vote of stockholders on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of our chief executive officer to the median compensation of our employees. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of APAC&#8217;s IPO. However, if (i)&#160;our annual gross revenue exceeds $1.235&#160;billion, (ii)&#160;we issue more than $1.0&#160;billion of <span style="white-space:nowrap">non-convertible</span> debt in any three-year period or (iii)&#160;we become a &#8220;large accelerated filer&#8221; (as defined in <span style="white-space:nowrap">Rule&#160;12b-2</span> under the Exchange Act) prior to the end of such five-year period, we will cease to be an emerging growth company. We will be deemed to be a &#8220;large accelerated filer&#8221; at such time that we (a)&#160;have an aggregate worldwide market value of common equity securities held by <span style="white-space:nowrap">non-affiliates</span> of $700.0&#160;million or more as of the last business day of our most recently completed second fiscal quarter, (b)&#160;have been required to file annual and quarterly reports under the Exchange Act, for a period of at least 12&#160;months and (c)&#160;have filed at least one annual report pursuant to the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June&#160;30, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June 30. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_4">THE OFFERING </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by us </p></td>
<td>24,273,938 shares, consisting of 4,610,001 shares issuable upon exercise of options to purchase shares of Common Stock, 651,781 shares issuable upon vesting of RSUs and PSUs, and 19,012,156 shares issuable upon exercise of Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by the Selling Securityholders </p></td>
<td>36,345,645 shares, consisting of 3,076,704 shares issued in the Business Combination, 2,137,035 Earnout Shares, 4,610,001 shares issuable upon exercise of options, 651,781 shares issuable upon vesting of RSUs and PSUs, 14,524,635 shares issued to the Sponsor and 11,345,489 shares issuable upon exercise of Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding </p></td>
<td>114,820,859 shares (as of November&#160;1, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants offered by the Selling Securityholders </p></td>
<td>11,345,489 Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants outstanding </p></td>
<td>19,012,156 Warrants (as of November&#160;1, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Exercise price per share pursuant to the Warrants </p></td>
<td>$11.50 </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will not receive any proceeds from the sale of shares by the Selling Securityholders. We will receive the proceeds from any exercise of the Warrants or options for cash, which we intend to use for general corporate and working capital purposes. See &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221; for additional information. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>You should carefully read the &#8220;Risk Factors&#8221; and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Common Stock or Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq symbol for our Common Stock </p></td>
<td>&#8220;OABI&#8221; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq symbol for our Warrants </p></td>
<td>&#8220;OABIW&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock outstanding as of November&#160;1, 2022 set forth above includes 2,137,035 Earnout Shares and excludes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">19,012,156 shares of Common Stock issuable upon exercise of the Warrants outstanding as of November&#160;1, 2022, with an exercise price of $11.50; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">4,610,001 shares of Common Stock issuable upon exercise of options outstanding as of November&#160;1, 2022, with a weighted-average exercise price of $10.83 per shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">557,032 shares of Common Stock issuable upon vesting of RSUs outstanding as of November&#160;1, 2022; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">94,749 shares of Common Stock issuable upon vesting of PSUs outstanding as of November&#160;1, 2022. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an investment in our Common Stock or Warrants. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our Common Stock and Warrants could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred losses on an <span style="white-space:nowrap">as-reported</span> basis for the last three years, and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have incurred net losses, as reported on a combined basis. For the years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the three and nine months ended September&#160;30, 2022 our revenue was $6.9&#160;million and $23.7&#160;million, respectively, and for the three and nine months ended September&#160;30, 2021 was $6.3&#160;million and $19.5&#160;million, respectively. For the years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million) and $(13.6 million), respectively. For the three and nine months ended September&#160;30, 2022 our net loss was $(12.6) million and $(29.2) million, respectively, and for the three and nine months ended September&#160;30, 2021 was $(7.9) million and $(24.0) million, respectively. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our OmniAb technology platform, market and sell our technologies to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expenses could increase beyond expectations for a variety of reasons, including as a result of our growth strategy and the expansion of our operations. We will need to generate significant additional revenue to achieve and sustain profitability and even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. We may never be able to generate sufficient revenue to achieve or sustain profitability and our recent and historical growth should not be considered indicative of our future performance. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business and maintain our research and development efforts. A decline in the value of our company could also cause you to lose all or part of your investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our revenue has fluctuated from period to period, and our revenue for any historical period may not be indicative of results that may be expected for any future period. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service and license revenue are generated by research activities that we perform for our partners and technology access fees, the timing and nature of which are dictated by the commencement of discovery campaigns selected by our partners. We also generate milestone payments upon the achievement of development milestones by our partners with respect to the antibodies discovered using our platform and royalties based on the net sales of any products commercialized by our partners. As a result, we will be prone to fluctuations in our revenue depending on the timing of our entry into license agreements with our partners, our partners initiating discovery programs, and our partners achieving development milestones or commercial sales with respect to therapeutic candidates utilizing antibodies discovered using our platform. The timing and likelihood of payments to us under these agreements is dependent on our partners&#8217; successful utilization of the antibodies discovered using our platform, which is outside of our control. Because of these factors, our revenue could vary materially from quarter to quarter from our forecasts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the level of demand for our technology platform and solutions, which may vary significantly; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and cost of, and level of investment in, research, development and commercialization activities relating to our platform and technology and any of our internal development programs, which may change from time to time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the start and completion of programs in which our platform is utilized; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of and the degree to which our partners successfully develop, secure marketing approvals for and commercialize any therapeutic candidates based on the antibodies discovered using our platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of new technologies, platform features or software, by us or others in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenditures that we may incur to acquire, develop or commercialize additional platform technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the level of demand for any products commercialized by our partners, which may vary significantly; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, outbreaks of disease or public health crises, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and nature of any future acquisitions or strategic partnerships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future accounting pronouncements or changes in our accounting policies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in general market and economic conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our commercial success depends on the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize our OmniAb technology platform to discover antibodies for further development and potential commercialization by our partners. As a result, the quality and sophistication of our platform is critical to our ability to conduct our research discovery activities and to deliver more promising antibodies and other drugs and to accelerate and lower the costs of discovery as compared to traditional methods for our partnerships. In particular, our business depends, among other things, on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our platform&#8217;s ability to successfully identify antibodies with therapeutic potential on the desired timeframes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to execute on our strategy to enter into new partnerships with new or existing partners with economic terms that are acceptable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to increase awareness of the capabilities of our technology and solutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our partners&#8217; and potential partners&#8217; willingness to adopt new technologies; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether our platform reliably provides advantages over legacy and other alternative technologies and is perceived by partners to be cost effective; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rate of adoption of our technologies by pharmaceutical and biotechnology companies of all sizes and capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prices we charge for our technology access and the research services we perform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative reliability and robustness of our platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to develop new solutions for partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether competitors develop a platform that enables antibody discovery more effectively than our platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the status of the market for next-generation biologics, which may become less attractive due to business, competitive or regulatory factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and scope of any approval that may be required by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), comparable foreign authorities or any other regulatory body to commercialize therapeutic candidates that are developed based on antibodies or other drugs discovered using our platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of our investments in innovation and commercial growth; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to further validate our technology through research and accompanying publications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will successfully address any of these or other factors that may affect the market acceptance of our platform. Failure of antibodies discovered using our platform can occur at any stage of discovery, preclinical or clinical development, and any such failures may reduce our partners&#8217; confidence in our platform. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful acceleration of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our platform will meet the expectations of pharmaceutical and biotechnology companies. If we are unsuccessful in achieving and maintaining market acceptance of our platform, our business, financial condition, results of operations and prospects could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future success is dependent on the eventual approval and commercialization of products developed by our partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business model is dependent on the eventual progression of therapeutic candidates discovered or initially developed utilizing our platform into clinical trials and commercialization. This requires us to attract partners and enter into agreements with them that contain obligations for the partners to pay us milestone payments as well as royalties on sales of approved products for the therapeutic candidates they develop that are generated utilizing our platform. Given the nature of our relationships with our partners, we do not control the progression, clinical development, regulatory strategy or eventual commercialization, if approved, of these therapeutic candidates. As a result, our future success and the potential to receive milestones and royalties are entirely dependent on our partners&#8217; efforts over which we have no control. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners&#8217; clinical trial results, including serious adverse events, or ongoing communications with the FDA regarding our partners&#8217; current clinical programs, which limits our visibility into how such programs may be progressing. If our partners determine not to proceed with the future development of a drug candidate discovered or initially developed utilizing our platform, or if they implement clinical or regulatory strategies that ultimately do not result in the further development or approval of the therapeutic candidates, we will not receive the benefits of our partnerships, which may have a material and adverse effect on our operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, biopharmaceutical development is inherently uncertain and very few therapeutic candidates ultimately progress through clinical development and receive approval for commercialization. If our partners do not receive regulatory approval for a sufficient number of therapeutic candidates originating from our partnerships, we may not be able to sustain our business model. Further, we have little control over how diversified our portfolio of potential milestone payments or royalties will end up being. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not control the timing of disclosure by our partners of any milestones or other information related to any therapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject to one of our partnerships. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to raise additional capital to fund our existing operations and achieve our goals. If we are unable to raise additional capital when needed on acceptable terms or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, results of operations, and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current business plan, we believe our cash and cash equivalents following the Business Combination, together with our anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months following the date of this proxy statement/prospectus/information statement. If such cash and cash equivalents, together with our anticipated cash flow from operations, are insufficient to satisfy our liquidity requirements including because of increased expenditures or lower demand for our platform, or the realization of other risks described in this proxy statement/prospectus/information statement, we may be required to raise additional capital prior to such time through issuances of public or private equity or debt financings or other capital sources. Such additional financing may not be available on terms acceptable to us or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments or acquisitions, to take advantage of favorable market conditions or financing opportunities or for other reasons, even if we believe we have sufficient funds for our current or future operating plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to achieve revenue growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of expanding our operations, including our business development and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our rate of progress in selling access to our platform and marketing activities associated therewith; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our rate of progress in, and cost of research and development activities associated with, our platform technologies and our internal development programs to the extent we pursue any such programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the continued impact of the <span style="white-space:nowrap">COVID-19</span> pandemic on global social, political and economic conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property and proprietary rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with any technologies that we may <span style="white-space:nowrap">in-license</span> or acquire. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various ways we could raise additional capital carry potential risks. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain adequate financing, if we require it, when needed or on terms acceptable to us, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we cannot maintain and expand current partnerships and enter into new partnerships, our future operating results would be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We primarily focus our efforts on the discovery of antibodies for our partners, who can select a target and define the antibody properties needed for therapeutic development or use our technology directly in their own labs. As a result, our success depends on our ability to maintain and expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners&#8217; satisfaction with our solutions and technologies, our partners&#8217; ability to successfully develop, secure regulatory approval for and commercialize therapeutic candidates using antibodies discovered using our platform, our partners&#8217; internal priorities (including fluctuations in research and developments budgets), our partners&#8217; resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction. Our existing partners may cease to use our technologies depending on their own technological developments, availability of other competing technologies and internal decisions regarding allocation of time and resources to the discovery and development of therapeutic candidates, over which we have no control. Our existing and future partners may have limited bandwidth to initiate new programs, which could limit their adoption or scale of application of our technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to our inability to discover any usable antibodies for the selected targets or the antibodies that we do discover may not be successfully developed or commercialized by our partners. In such circumstances, we would not generate any substantial revenues from such a partnership in the form of technology access fees, service fees, milestone payments, royalties or otherwise. Speculation in the industry about our existing or potential partnerships may be a catalyst for adverse speculation about us, or our platform, which can adversely affect our reputation and our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure investors that we will be able to maintain or expand our existing partnerships or that our technologies will achieve adequate market adoption among new partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the nine months ended September&#160;30, 2022 and the year ended December&#160;31, 2021, three of our partners accounted for 29%, 20% and 13% and 28%, 24% and 11%, respectively, of our revenue, and 33 and 28 partners accounted for the remaining 38% and 37%, respectively, of our revenue. While moving forward we expect to diversify the number of partners and programs, in the near term these partners represent a large portion of potential revenue. Our license agreements are typically terminable by our partners without penalty with specified notice, which would terminate their access to our technology platform, although we would retain downstream economics on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any OmniAb-derived antibody. As a result, if we fail to maintain our relationships with these partners or if these partners discontinue their programs, our future results of operations could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biopharmaceutical development is inherently uncertain, and it is possible that none of the therapeutic candidates discovered using our platform that are further developed by our partners will become viable commercial products, on a timely basis or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our platform to offer antibody drug-discovery programs to partners who are engaged in drug discovery and development. These partners include pharmaceutical and biotechnology companies of all sizes. While we receive upfront payments generated through our receipt of service revenue and technology access fees, we expect that the vast majority of the economic value of the agreements we enter into with our partners is in the downstream payments that we may receive upon achievement of development milestones and royalties on sales of any approved products. As a result, our future growth is dependent on the ability of our partners to successfully develop and commercialize therapies based on antibodies discovered using our platform. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us derivatively through the activities of our partners. While we believe our platform is capable of identifying high quality antibodies, there can be no assurance that our partners will successfully develop, secure marketing approvals for and commercialize any therapeutic candidates based on the antibodies discovered using our platform. As a result, we may not realize the intended benefits of our partnerships. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor our partners are permitted to market any therapeutic candidate in the United States until we or they receive regulatory approval of a New Drug Application (NDA) or Biologics License Application (BLA) from the FDA or until we or they receive regulatory approval from foreign regulatory authorities. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a therapeutic candidate&#8217;s clinical development and may vary among jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January&#160;31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January&#160;31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January&#160;31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is currently unclear to what extent the United Kingdom (UK) will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January&#160;17, 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) launched an eight-week consultation on reframing the UK </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legislation for clinical trials. The consultation closed on March&#160;14, 2022 and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation will be closely watched and will determine whether the UK chooses to align with the regulation or diverge from it to maintain regulatory flexibility. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our partners are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, development plans may be impacted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a therapeutic candidate in the United States or abroad, our partners must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or comparable foreign regulatory agencies, that such therapeutic candidates are safe and effective, or in the case of biologics in the U.S., safe, pure, and potent, for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we or our partners believe the nonclinical or clinical data for any therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory bodies can delay, limit or deny approval of therapeutic candidates or could require our partners to conduct additional nonclinical or clinical testing or abandon a program for a number of reasons. Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, our partners may not successfully develop any therapeutic candidates with the antibodies discovered using our platform, or our partners may choose to discontinue the development of these therapeutic candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations or prioritization of their resources. It is possible that substantially all of these therapeutic candidates will never receive regulatory approval and, even if approved, such therapeutic candidates may never be successfully commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if these therapeutic candidates receive regulatory approval in the United States, our partners may never obtain approval or commercialize such therapeutic candidates outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved therapeutic candidates may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Likewise, our partners have to make decisions about which clinical stage and preclinical therapeutic candidates to develop and advance, and our partners may not have the resources to invest in all of the therapeutic candidates that contain antibodies discovered using our platform, or clinical data and other development considerations may not support the advancement of one or more therapeutic candidates. Decision-making about which therapeutic candidates to prioritize involves inherent uncertainty, and our partners&#8217; development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug candidate that utilizes an OmniAb-derived antibody. If one of our strategic partners terminates its agreement with us, we may find it more difficult to attract new partners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to industry-wide FDA and other regulatory risk. The number of BLAs and NDAs approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of BLAs or NDAs approved by the FDA, the industry would contract and our business would be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our partners&#8217; failure to effectively advance, market and sell suitable therapeutic candidates with the antibodies that discovered using our platform could have a material adverse effect on our business, financial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addresses above, our ability to forecast our future revenues may be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The failure of our partners to meet their contractual obligations to us could adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of products using our antibodies or result in litigation or arbitration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and data security risk, as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our partners have significant discretion in determining when and whether to make announcements about the status of our partnerships, including about preclinical and clinical developments and timelines for advancing antibodies discovered using our platform. We do not plan to disclose the development status and progress of individual therapeutic candidates of our partners, unless and until those partners do so first. Our partners may wish to report such information more or less frequently than we desire to or may not wish to report such information at all, in which case we would not report that information either. In addition, if partners choose to announce a collaboration with us, there is no guarantee that we will recognize research discovery fees in that quarter or even the following quarter, as such fees are not payable to us until our partner begins discovery activities. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Our partners may from time to time make statements about their goals and expectations for partnerships with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; discovery and development programs, the amount of time, effort, and resources committed by us and our current and future partners, and the numerous uncertainties inherent in the development of therapeutics. As a result, there can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect. If our partners fail to achieve one or more of these milestones or other key events as planned, our business could be materially and adversely affected and the price of our common stock could decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to manage our current and future growth effectively, which could make it difficult to execute our business strategy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to execute on our business strategy, we anticipate further growth in our business operations. This growth requires managing complexities across all aspects of our business, including complexities associated with increased research and development and business development and marketing operations. As we seek to increase the number of our partnered programs, expand the scope of our existing partnerships and further develop our technological capabilities, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with specialized qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher technology development costs, declining technology development quality, deteriorating program management success, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our platform, and could damage our reputation and the prospects for our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To manage our anticipated growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management team may need to divert a disproportionate amount of its attention away from its <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities and devote a substantial amount of time to managing our growth. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, and our ability to develop and commercialize our platform and compete effectively, will depend, in part, on our ability to effectively manage increased program demand and the growth in our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our platform utilizes various species of animals that could contract disease or die and could otherwise subject us to controversy and adverse publicity, which may interrupt our business operations or harm our reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform utilizes animals to discover and produce antibodies. We cannot completely eliminate the risks of animals contracting disease, which from time to time has occurred, or a natural or <span style="white-space:nowrap">man-made</span> disaster that could cause death to valuable production animals, in our vivarium facilities, which house our chickens, or those of the contract research organizations (CROs) that maintain our mouse and rat colonies. We cannot make any assurance that we or our CROs will be able to contain or reverse any such instance of disease. Although we maintain backup colonies of our animals, disease or death on a broad scale could materially interrupt business operations as animals are a key part of our antibody discovery programs, which could have a material adverse effect on our results of operations and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, genetic engineering and testing of animals has been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals in the United States, the European Union (EU) and other jurisdictions have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities and the ability for us and our partners to use our technology platform could be interrupted or delayed, our costs could increase and our reputation could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have invested, and expect to continue to invest, in research and development efforts that further enhance our antibody discovery platform. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically dedicated a substantial portion of our resources on the development of our platform and the technology that it incorporates. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect operating results and that such investments may not generate sufficient technological advantage relative to alternatives in the market which would, in turn, impact revenues to offset liabilities assumed and expenses associated with these new investments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The industry in which we operate changes rapidly as a result of technological and drug developments, which may render our solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our platform and technology to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, or if our technology platform is not able to accelerate the process of antibody drug discovery as quickly as we anticipate, our revenue and operating results may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business is subject to risks arising from <span style="white-space:nowrap">COVID-19</span> and other epidemic diseases. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">COVID-19</span> worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken and continue to take actions in an effort to slow the spread of <span style="white-space:nowrap">COVID-19,</span> including issuing varying forms of <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;stay-at-home&#8221;</span></span> orders, and restricting business functions outside of one&#8217;s home. We have generally restricted <span style="white-space:nowrap">in-person</span> access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations. While it is not possible at this time to estimate the impact that <span style="white-space:nowrap">COVID-19</span> could have on our business in the future, the continued spread of <span style="white-space:nowrap">COVID-19</span> or variants thereof and the measures taken by the governmental authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities by us and our partners; interrupt or delay the operations of the FDA, EMA, comparable foreign authorities or other regulatory bodies, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if <span style="white-space:nowrap">COVID-19</span> infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees or our subcontractor&#8217;s employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The <span style="white-space:nowrap">COVID-19</span> pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the <span style="white-space:nowrap">COVID-19</span> pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in the market for technologies that enable the discovery and development of therapeutic antibodies. Our technologies address antibody therapeutic discovery challenges that are addressed by other platform technologies controlled by companies that have a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. Examples of technical competition at different steps of our technology platform include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in discovery using genetically engineered rodents, we face technical competition from companies that provide access to similar technologies, such as AbCellera Biologics Inc., Ablexis LLC, Alloy Therapeutics, Inc. Crescendo Biologics Ltd., Harbour Antibodies BV, Merus N.V., Regeneron Pharmaceuticals, Inc. and RenBio Inc.; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the field of single-cell screening, we face technical competition from companies that provide access to similar technologies, such as AbCellera Biologics Inc., Berkeley Lights Inc., HiFiBio Inc., and Sphere Fluidics Ltd.; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in ion channel drug discovery, we face technical competition from companies that provide similar technologies, or biological expertise, such as Charles River Labs Inc., Evotec SE, Metrion Biosciences Ltd., and WuXi AppTec. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also face direct business competition from companies that provide antibody discovery services using technologies, such as hybridoma and display. Companies with discovery business models that include downstream payments include AbCellera Biologics Inc. and Adimab LLC. In addition, we compete with a variety of <span style="white-space:nowrap"><span style="white-space:nowrap">fee-for-service</span></span> contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our technology platform. In addition, our partners may also elect to develop their workflows on legacy systems rather than rely on our platform. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors and potential competitors may enjoy a number of competitive advantages over us. For example these may include longer operating histories, larger customer bases, greater brand recognition and market penetration, greater financial resources, greater technological and research and development resources, better system reliability and robustness, greater selling and marketing capabilities, and integrated manufacturing capabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their platforms or instruments than we can or sell their platforms or instruments, or offer solutions competitive with our platform and solutions at prices designed to win significant levels of market share. In addition, we may encounter challenges in marketing our solutions with our pricing model, which is structured to capture the potential downstream revenues associated with therapeutic candidates that were discovered using our platform. Our partners and potential partners may prefer one or more pricing models employed by our competitors that involve upfront payments rather than downstream revenues. We may not be able to compete effectively against these organizations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to technology and platform development than we can. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption and sales of our platform, which could prevent us from increasing our revenue or sustaining profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our financial results, our management regularly reviews a number of operating and financial metrics, including the number of active partners, the number of active programs, the number and progress of active clinical programs, and the number and commercial progress of approved products, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that these metrics are representative of our current business; however, these metrics may not accurately reflect all aspects of our business, and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business grows and as we introduce new solutions. In addition, we are highly dependent on information provided by our partners as to the status of their development </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs. To the extent such information is later shown to be inaccurate, our metrics and forecasts could be materially and adversely affected. If our management fails to review other relevant information or change or substitute the key business metrics they review as our business grows, or if our metrics prove inaccurate or unrepresentative based on information provided by our partners or otherwise, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to host our mouse and rat colonies and expect to continue to do so for the foreseeable future, and these third parties may not perform satisfactorily which could delay, prevent or impair our partnership programs and research and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate vivarium facilities for our mouse and rat colonies and have no plans to expand our vivarium facilities beyond those that house our chickens. We rely, and expect to continue to rely, on third-party CROs to host our mice and rats and to conduct certain research services for us and our partners, such as animal breeding, genotyping and animal distribution. We have limited control over the performance by these third parties, including with respect to maintaining adequate quality control, quality assurance and qualified personnel, and to performing their services in compliance with applicable scientific and regulatory requirements. If these third parties are unable to continue maintaining our mice and rats in accordance with our specifications or on commercially reasonable terms, or otherwise perform in a substandard manner, the discovery activities for our partners may be delayed. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional vivarium facilities involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a new facility commences work. As a result, delays may occur, which can materially impact our ability to meet our partners&#8217; discovery timelines. Though we carefully manage our relationships with these third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on a limited number of suppliers for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a limited number of suppliers, or in some cases single suppliers, to provide certain consumables and equipment that we use in our laboratory operations, as well as reagents and other laboratory materials involved in the development of our technology. Fluctuations in the availability and price of laboratory materials and equipment could have an adverse effect on our ability to meet our technology development goals with our partners and thus our results from operations as well as future partnership opportunities. An interruption in our laboratory operations or technology transfer could occur if we encounter delays, quality issues or other difficulties in securing these consumables, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, while we believe suitable additional or alternative suppliers are available to accommodate our operations, if needed, any transition to new or additional suppliers may cause delays in our processing of samples or development and commercialization of our technology. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The sizes of the markets and forecasts of market growth for the demand of our OmniAb technology platform and other of our key performance indicators are based on a number of complex assumptions and estimates, and may be inaccurate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate annual total addressable markets and forecasts of market growth for our platform and technologies and for antibody-based therapeutics generally. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third party estimates and other business data, including </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. As a result, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from technology access fees, service fees, milestone payments or royalties may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our platform is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party payor coverage and reimbursement status of newly approved therapeutics is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products and services could limit our partners&#8217; ability to fully commercialize therapeutic candidates generated using our platform, which would decrease our ability to generate revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford any therapeutics generated using our platform that our partners may develop and sell. In addition, because the therapeutics we generate may represent new classes of treatments for diseases, we and our partners cannot accurately estimate how such therapeutics would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of such therapeutics will depend substantially, both domestically and internationally, on the extent to which the costs of such therapeutics are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, our partners may not be able to successfully commercialize some therapeutics generated with our technology. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow our partners to establish or maintain pricing sufficient to realize a sufficient return on their investment in such therapeutics, and may lead to discontinuation or deprioritization of marketing and sales efforts for such products. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our technology development services and/or therapeutics generated using our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved therapeutics in the United States, the EU and other jurisdictions. Due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes, we expect our partners to experience pricing pressures on therapeutics generated using our platform that our partners may commercialize. The downward pressure on healthcare costs in general, particularly novel therapeutics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products, which would negatively impact our ability to generate revenues. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform efforts aimed at lowering the price of biopharmaceutical products may impact our ability to maintain sufficient profits. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, in the United States, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (ACA), was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid rebate obligation to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations, if any, will impact our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January&#160;1, 2024. Further, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension that lasted from May&#160;1, 2020 through March&#160;31, 2022 due to the <span style="white-space:nowrap">COVID-19</span> pandemic. Following the suspension, a 1% payment reduction began April&#160;1, 2022, lasting through June&#160;30, 2022. The 2% payment reduction resumed on July&#160;1, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, heightened governmental scrutiny is likely to continue over the manner in which product manufacturers set prices for their marketed products, which has already resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional U.S. federal or foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government or foreign governments will pay for healthcare products and services, which could result in reduced demand for our products and therapeutic </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, if approved, or additional pricing pressures. If efforts to contain the price of biopharmaceutical products are successful, the magnitude of milestone payments and royalties we would expect to receive in connection with our partners&#8217; future prioritization and investment in developing novel biologics may be impacted. For instance, in December 2021, Regulation No 2021/2282 on Health Technology Assessment (HTA) amending Directive 2011/24/EU, was adopted in the European Union (EU). This regulation which entered into force in January 2022 intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing <span style="white-space:nowrap">non-clinical</span> (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We must adapt to rapid and significant technological change and respond to introductions of new products and technologies by competitors to remain competitive. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide our antibody discovery solutions and capabilities in industries that are characterized by significant enhancements and evolving industry standards. As a result, our partners&#8217; needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our platform may become less desirable in the markets we serve, and our partners could move to new technologies offered by our competitors, or engage in antibody discovery themselves. Without the timely introduction of new solutions and technological enhancements, our offerings will likely become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new technologies and markets to further broaden and deepen our capabilities and expertise in antibody drug discovery and development. To the extent we fail to timely introduce new and innovative technologies or solutions, adequately predict our partners&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on our information technology systems, and any failure of these systems could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting, our platform, our advanced automation systems, and advanced application software. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. These implementations were expensive and required a significant effort in terms of both time and effort. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, data analysis, quality control, customer service and support, billing, research and development activities, scientific and general administrative activities. A significant risk in implementing these systems, for example, is the integration of separate information technology and telecommunications systems. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious software, bugs or viruses, human acts and natural disasters. Moreover, despite network security and <span style="white-space:nowrap">back-up</span> measures, some of our servers are potentially vulnerable to physical or electronic <span style="white-space:nowrap">break-ins,</span> computer viruses and similar disruptive problems. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business development and marketing organizations are currently limited, and if we are unable to expand our personnel to reach our existing and potential partners, our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business development and marketing functions are currently limited, with only two dedicated business development and two marketing employees, as of November&#160;1, 2022. We have supported these functions with research and development staff attending a variety of scientific conferences which has helped increase the business development pipeline. We will need to expand our commercial organization in order to effectively market our solutions to existing and new partners. Competition for employees capable of negotiating and entering into partnerships with pharmaceutical and biotechnology companies is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our platform and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular service may be difficult to justify in light of the revenue generated or projected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to successfully sell our programs and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success is dependent on our ability to attract and retain highly qualified management and other scientific and engineering personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our continued ability to attract, retain, manage, and motivate highly qualified management, scientific and engineering personnel, and we face significant competition for experienced personnel. We are highly dependent upon our senior management, as well as our senior scientists and engineers and other members of our management team. The individual and collective efforts of these employees will be important as we continue to develop and market our platform and technology. The loss or incapacity of existing members of our senior management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Although we intend to execute employment agreements or offer letters with each member of our senior management team, these agreements will be terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to attract or retain qualified scientists and engineers in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific and engineering personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. A key risk in this area, for example, is that certain of our employees are <span style="white-space:nowrap">at-will,</span> which means that either we or the employee may terminate their employment at any time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have made technology acquisitions and expect to acquire businesses or assets or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business includes numerous acquisitions completed by Ligand, including the acquisition of Crystal Bioscience in October 2017, Ab Initio in July 2019, the Icagen ion channel platform through the acquisition of the core assets of Icagen in April 2020, xCella Biosciences in September 2020, and Taurus Biosciences in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September 2020. We expect to pursue additional acquisitions of businesses and assets in the future. We may not be able to find suitable partners or acquisition or asset purchase candidates in the future, and we may not be able to complete such transactions on favorable terms, if at all. The competition for strategic partners or acquisition candidates may be intense, and the negotiation process will be time-consuming and complex. If we make any additional acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by partners or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or partners of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in process research and development charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Acquisitions may also expose us to a variety of international and business related risks, including intellectual property, regulatory laws, local laws, tax and accounting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions or asset purchase, we may choose to issue securities as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire companies or assets using our securities as consideration. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our operating facilities become damaged or inoperable or if we move or are otherwise required to vacate our facilities, our ability to conduct and pursue our research and development efforts may be jeopardized. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific and engineering research and development and testing is conducted at our facilities located in Emeryville, California, Durham, North Carolina, and Tucson, Arizona. Our facilities and equipment could be harmed or rendered inoperable or inaccessible by natural or <span style="white-space:nowrap">man-made</span> disasters or other circumstances beyond our control, including fire, earthquake, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our partners and develop updates, upgrades and other improvements to our platform, advanced automation systems, and advanced application and workflow software for some period of time. The inability to address system issues could develop if our facilities are inoperable or suffer a loss of utilization for even a short period of time, may result in the loss of partners or harm to our reputation, and we may be unable to regain those partners or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility or license or transfer our proprietary technology to a third party. Even in the event we are able to find a third party to assist in research and development efforts, we may be unable to negotiate commercially reasonable terms to engage with the third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we plan to plan to move and expand the vivarium facilities housing our chickens in 2022. Such a move could disrupt our operations as we ramp up the new facility, result in animal injury or death, or otherwise impair the research services conducted using such animals. Adverse consequences resulting from our planned move could harm our relationships with our partners and our reputation, and could affect our ability to generate revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella and directors&#8217; and officers&#8217; insurance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful liability claim or series of claims in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the use of our platform to discover antibodies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board, our Board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we generate and store sensitive data, including research data, intellectual property and proprietary business information owned or controlled by ourselves or our employees, partners and other parties. We manage and maintain our applications and data utilizing a combination of <span style="white-space:nowrap">on-site</span> systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, accidental exposure, unauthorized access, inappropriate modification and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf. Further, to the extent our employees are working at home during the <span style="white-space:nowrap">COVID-19</span> pandemic, additional risks may arise as a result of depending on the networking and security put into place by the employees. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may experience security breaches that may remain undetected for an extended period. Our third-party service providers and partners are also subject to these heightened risks. The secure processing, storage, maintenance and transmission of this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or infections by viruses or other malware or breached due to erroneous actions or inactions by our employees or contractors, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, any of which could adversely affect our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, although we maintain cybersecurity insurance coverage, we cannot be certain that such coverage will be adequate for data security liabilities actually incurred, will cover any indemnification claims against us relating to any incident, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or <span style="white-space:nowrap">co-insurance</span> requirements, could adversely affect our reputation, business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could become subject to more extensive government regulation than we currently anticipate, and regulatory compliance obligations and the investigational exemption and approval processes to which our animals may become subject are expensive, time-consuming and uncertain both in timing and in outcome. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our operations are currently subject to limited direct regulation by the FDA, comparable foreign authorities or other regulatory bodies. However, our business could in future become subject to more direct oversight by the FDA, EMA or other comparable domestic or international agencies. For example, we may be subject to evolving and variable regulations governing the production of genetically engineered organisms. In particular, the FDA regulates animals whose genomes have been intentionally altered, and the FDA considers such alterations to be new animal drugs that may require approvals or exemptions in order to be commercially marketed or for investigational use in the United States. For example, we have been in communication with the FDA regarding the regulatory requirements applicable to our OmniChickens designed to produce human immunoglobulins, and the FDA has advised us that such approvals or exemptions are not required in light of the early stage of our research. However, the FDA may determine that we are not in compliance with the conditions imposed upon us to avoid the requirement for such approvals or exemptions at present or we may later become subject to such approvals or exemptions. Furthermore, while we have no active plans to operate a manufacturing facility designed to comply with current good manufacturing practices (cGMPs), future market pressures or the lack of available capacity at cGMP manufacturing facilities may necessitate our entry into this market. Complying with such regulations may be expensive, time-consuming and uncertain, and if we fail to comply with any applicable requirements enforced by the FDA with respect to our intentionally genetically altered animals or otherwise, we may be subject to administratively or judicially imposed sanctions, including restrictions on our products or operations, warning or untitled letters, civil or criminal penalties, injunctions, product seizures, product detentions, import bans, product recalls, or adverse publicity requirements, any of which could have an adverse effect on our business, financial condition and operating results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business operations and current and future relationships with investigators, healthcare professionals, and partners may be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us and/or our partners to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare professionals, physicians and third-party payors will play a primary role in the recommendation and prescription of any therapeutic candidates generated by our platform for which our partners obtain marketing approval. Our arrangements with our partners may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal False Claims Act and civil monetary penalties laws, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or service. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report to the Department of Health and Human Services information related to certain financial interactions with physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other <span style="white-space:nowrap">non-physician</span> practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), and teaching hospitals, as well as the ownership and investment interests of physicians and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <span style="white-space:nowrap">non-governmental</span> third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare professionals or marketing expenditures and pricing information; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">EU and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities may conclude that our or our partners&#8217; business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our or our partners&#8217; operations were to be found to be in violation of any of these laws or any other governmental regulations that may apply, we and/or our partners may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our partners may be subject to federal, state, and foreign laws and regulations that govern data privacy and security. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of personal information, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation (GDPR) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area (EEA). Among other things, the GDPR imposes requirements regarding the security of personal data, the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed, includes requirements relating to the consent of individuals to whom the personal data relates, requires detailed notices for clinical trial participants and investigators and regulates transfers of personal data from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the United States. In addition, the GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20.0&#160;million or 4% of our annual global revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, from January&#160;1, 2021, companies have been subject to the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20.0&#160;million (&#163;17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission <span style="white-space:nowrap">re-assesses</span> and renews/extends that decision, and remains under review by the Commission during this period. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes may lead to additional costs and increase our overall risk exposure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with applicable data privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Separation and Distribution and Our Relationship with Ligand </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As a result of the Separation, we lost Ligand&#8217;s brand, reputation, capital base and other resources, and may experience difficulty operating as a standalone company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our association with Ligand has contributed to our building relationships with our customers due to Ligand&#8217;s globally recognized brand and reputation for innovation in drug discovery and development. The Separation could adversely affect our ability to attract and retain customers, which could result in reduced sales of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of Ligand&#8217;s scale, capital base and financial strength may also prompt suppliers to reprice, modify or terminate their relationships with us. In addition, Ligand&#8217;s elimination of its ownership of our company could potentially cause some of our existing agreements and licenses to be terminated. We do not currently anticipate any material terminations in connection with the transactions. Nevertheless, we cannot predict with certainty the effect that the Separation, Distribution or Merger will have on our business, our clients, vendors or other persons, or whether our OmniAb brand will be accepted in the marketplace. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, because we have not operated as a standalone company in the past, we may have difficulty doing so. We may need to acquire assets and resources in addition to those provided by Ligand to our company, and in connection with the Separation, may also face difficulty in separating our assets from Ligand&#8217;s assets and integrating newly acquired assets into our business. Our business, financial condition and results of operations could be materially and adversely affected if we have difficulty operating as a standalone company, fail to acquire assets that prove to be important to our operations or incur unexpected costs in separating our assets from Ligand&#8217;s assets or integrating newly-acquired assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We incurred significant charges in connection with the Business Combination and will incur incremental costs as a standalone public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incurred significant transaction costs in connection with the Business Combination, including accounting, legal, underwriting, financial and capital markets advisory and other fees and expenses. These estimated transaction costs are reflected in the unaudited pro forma condensed combined financial information contained elsewhere in this prospectus. In addition, we will need to replicate or replace certain arrangements, functions, systems and infrastructure to which we will no longer have the same access after the Separation. We expect to make investments and hire additional employees, or <span style="white-space:nowrap">out-source</span> certain functions, systems and infrastructure through contracts with third parties, to operate without access to Ligand&#8217;s existing operational and administrative infrastructure. These initiatives may be costly to implement. To the extent we implement any of these initiatives, we may incur additional operating costs beyond what is included in our historical and pro forma financial statements, and the amount and timing of such costs is uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand performed or supported many important corporate functions for our company. Our combined financial statements reflect charges for these services on an allocated basis. Following the Separation, many of these services are governed by our Transition Services Agreement. Under the Transition Services Agreement, we are able to use these Ligand services for a fixed term established on a <span style="white-space:nowrap"><span style="white-space:nowrap">service-by-service</span></span> basis. The Transition Services Agreement may be terminated by us with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pay Ligand fees for the transition services as a flat monthly fee and reimburse Ligand for all reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses that it incurs in connection with providing the transition services. In addition, while these services are being provided to us by Ligand, our operational flexibility to modify or implement changes with respect to such services or the amounts we pay for them is limited. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to replace these services or enter into appropriate third-party arrangements on terms and conditions, including cost, comparable to those that we will receive from Ligand under our Transition Services Agreement. Additionally, after the Transition Services Agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Ligand. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Ligand, which may not be addressed in our Transition Services Agreement. The level of this informal support will diminish or be eliminated following the Separation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our historical combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Ligand corporate level but which are specifically identifiable or attributable to the businesses transferred to us in connection with the Separation. The value of the assets and liabilities we assumed in connection with the Separation could ultimately be materially different than such attributions, which could have a material adverse effect on our financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Separation, we also entered into a second Transition Services Agreement under which we will provide services relating to corporate functions, legal administration and other administrative functions to Ligand. These are services that we historically provided to Ligand prior to the Separation. Under this Transition Services Agreement, Ligand is able to use our services for a fixed term established on a <span style="white-space:nowrap"><span style="white-space:nowrap">service-by-service</span></span> basis. The Transition Services Agreement may be terminated by Ligand with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. Ligand pays us fees for the transition services as a flat monthly fee and reimbursea us for all reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses that we incur in connection with providing the transition services. In addition, while these services are being provided to Ligand by us, our operational flexibility to modify or implement changes with respect to our capabilities to provide such services will be limited, and we may be obligated to maintain certain functions and capabilities solely to be able to meet our obligations to Ligand under the Transition Services Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our historical combined financial data and pro forma financial statements are not necessarily representative of the results we would have achieved as a standalone company and may not be a reliable indicator of our future results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical combined financial data included in this prospectus does not reflect the financial condition, results of operations or cash flows we would have achieved as a standalone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our historical combined financial data does not reflect the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our historical combined financial data reflects expense allocations for certain support functions that are provided on a centralized basis within Ligand, such as expenses for executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations that may be higher or lower than the comparable expenses we would have actually incurred, or will incur in the future, as a standalone company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our cost of debt and our capital structure will be different from that reflected in our historical combined financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant increases may occur in our cost structure as a result of the Business Combination, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Separation may have a material effect on our customers and other business relationships, including supplier relationships, and may result in the loss of preferred pricing available by virtue of our reduced relationship with Ligand. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial condition and future results of operations, after giving effect to the Business Combination, will be materially different from amounts reflected in our historical combined financial statements included elsewhere in this proxy statement/prospectus/information statement. As a result of the Business Combination, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ligand may compete with us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand is not restricted from competing with us in the antibody discovery business. Although Ligand has informed us it has no current intention to compete with us in the antibody discovery business, if Ligand in the future decides to engage in the type of business we conduct, it may have a competitive advantage over us, which may cause our business, financial condition and results of operations to be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Distribution, together with certain related transactions, fails to qualify as a reorganization under Sections 355 and 368(a)(1)(D) of the Code, or the Merger fails to qualify as a reorganization under Section&#160;368(a) of the Code, Ligand and its stockholders could incur significant tax liabilities, and APAC and OmniAb could be required to indemnify Ligand for taxes that could be material pursuant to indemnification obligations under the Tax Matters Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand received the Distribution Tax Opinion from Latham&#160;&amp; Watkins LLP, tax counsel to Ligand, which provided that the Distribution, together with certain related transactions, will qualify as a reorganization under Sections 355 and 368(a)(1)(D) of the Code and that the Merger will not cause Section&#160;355(e) of the Code to apply to the Distribution. In addition, the obligations of Ligand and OmniAb to complete the Merger were conditioned upon, among other things, Ligand&#8217;s receipt of the Distribution Tax Opinion and an opinion of Latham&#160;&amp; Watkins LLP that the Merger would be treated as a reorganization under Section&#160;368(a) of the Code. The obligation of APAC to complete the Merger was conditioned upon, among other things, receipt of an opinion of Weil, Gotshal&#160;&amp; Manges LLP, tax counsel to APAC, that the Merger would be treated as a reorganization under Section&#160;368(a) of the Code. The conditions in the Merger Agreement related to the receipt by Ligand and APAC of the foregoing tax opinions could be waived by Ligand and OmniAb in writing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax opinions were delivered in connection with the closing of the Merger and were based on, among other things, certain facts, assumptions, representations and undertakings from Ligand, OmniAb and APAC, including those regarding the past and future conduct of the Companies&#8217; respective businesses and other matters. If any of these facts, assumptions, representations, or undertakings are incorrect or not satisfied, Ligand may not be able to rely on the opinions, and Ligand and its stockholders could be subject to significant U.S. federal income tax liabilities. In addition, the opinions will not be binding on the IRS or the courts. Notwithstanding the opinions, the IRS could determine on audit that the Distribution or Merger does not qualify as a reorganization if it determines that any of the facts, assumptions, representations or undertakings on which the opinions are based are not correct or have been violated or that the Distribution or Merger should be taxable for other reasons, including as a result of a significant change in stock or asset ownership after the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Distribution, together with certain related transactions, is ultimately determined not to qualify as a reorganization, the Distribution could be treated as a taxable disposition of shares of OmniAb stock by Ligand and as a taxable distribution to Ligand&#8217;s stockholders for U.S. federal income tax purposes. If the Merger is ultimately determined not to qualify as a reorganization, the Merger could be treated as a taxable disposition of OmniAb stock by Ligand stockholders. In either such case, Ligand and its stockholders that are subject to U.S. federal income tax could incur significant U.S. federal income tax liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Tax Matters Agreement that APAC and OmniAb entered into with Ligand, APAC and OmniAb will generally be required to indemnify Ligand against certain taxes incurred by Ligand that arise in connection with the Distribution as a result of certain actions or omissions by APAC or OmniAb. Further, even if APAC and OmniAb are not responsible for tax liabilities of Ligand under the Tax Matters Agreement, OmniAb nonetheless </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could be liable under applicable U.S. federal tax law for such liabilities if Ligand were to fail to pay them. If APAC or OmniAb are required to pay any liabilities under the circumstances set forth in the Tax Matters Agreement or pursuant to applicable tax law, the amounts may be significant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We might not be able to engage in certain transactions and equity issuances as a result of the Distribution. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to engage in equity transactions could be limited or restricted in order to preserve, for U.S. federal income tax purposes, the qualification of the Distribution, together with certain related transactions, as a generally <span style="white-space:nowrap">tax-free</span> reorganization under Sections 355 and 368(a)(1)(D) of the Code. Even if the Distribution otherwise qualifies for <span style="white-space:nowrap">tax-free</span> treatment to Ligand&#8217;s stockholders under Section&#160;355 of the Code, it may result in corporate-level taxable gain to Ligand if there is a 50% or greater change in ownership, by vote or value, of our shares of common stock, Ligand&#8217;s stock or the stock of a successor of any of the foregoing occurring as part of a plan or series of related transactions that includes the Distribution. Any acquisitions or issuances of shares of our Common Stock or Ligand Common Stock within two years of the Distribution are generally presumed to be part of such a plan, although we or Ligand may be able to rebut that presumption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Tax Matters Agreement that we entered into with Ligand, we will be required to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand received regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement also restricts our ability to take or fail to take any action if such action or failure to act could adversely affect the intended tax treatment of the Distribution, together with certain related transactions. In particular, except in specific circumstances, in the two years following the Distribution, we will be restricted from, among other things, (i)&#160;entering into certain transactions pursuant to which all or a portion of shares of our common stock would be acquired, whether by merger, consolidation, certain stock issuances, or otherwise and (ii)&#160;ceasing to actively conduct certain of the OmniAb businesses. These restrictions may limit for a period of time our ability to pursue certain transactions that we may believe to be in the best interests of our stockholders or that might increase the value of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential indemnification obligations to Ligand pursuant to the Separation Agreement could materially and adversely affect our businesses, financial condition, results of operations and cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Separation Agreement, among other things, provides for indemnification obligations (for uncapped amounts) designed to make us financially responsible for all liabilities that Ligand may incur or may exist relating to our business activities (as currently and historically conducted), whether incurred prior to or after the Separation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Separation, Ligand will indemnify us for certain liabilities. However, there can be no assurance that such indemnity will be sufficient to insure us against the full amount of such liabilities, or that Ligand&#8217;s ability to satisfy its indemnification obligations will not be impaired in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Separation Agreement and certain other agreements with Ligand, Ligand will agree to indemnify us for certain liabilities. However, third parties could also seek to hold us responsible for any of the liabilities that Ligand has agreed to retain, and there can be no assurance that the indemnity from Ligand will be sufficient to protect us against the full amount of such liabilities, or that Ligand will be able to fully satisfy its indemnification obligations. In addition, Ligand&#8217;s insurance will not necessarily be available to us for liabilities associated with occurrences of indemnified liabilities prior to the Separation, and in any event Ligand&#8217;s insurers may deny coverage to us for liabilities associated with certain occurrences of indemnified liabilities prior to the Separation. Moreover, even if we ultimately succeed in recovering from Ligand or such insurance providers any amounts for which we are held liable, we may be temporarily required to bear these losses. Each of these risks could negatively affect our businesses, financial position, results of operations and cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Separation and Distribution may expose us to potential liabilities arising out of state and federal fraudulent conveyance laws and legal dividend requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Separation and Distribution are subject to review under various state and federal fraudulent conveyance laws. Fraudulent conveyance laws generally provide that an entity engages in a constructive fraudulent conveyance when (i)&#160;the entity transfers assets and does not receive fair consideration or reasonably equivalent value in return; and (ii)&#160;the entity: (a)&#160;is insolvent at the time of the transfer or is rendered insolvent by the transfer; (b)&#160;has unreasonably small capital with which to carry on its business; or (c)&#160;intends to incur or believes it will incur debts beyond its ability to repay its debts as they mature. An unpaid creditor or an entity acting on behalf of a creditor (including without limitation a trustee or <span style="white-space:nowrap"><span style="white-space:nowrap">debtor-in-possession</span></span> in a bankruptcy by us or Ligand or any of our respective subsidiaries) may bring an action alleging that the Separation or Distribution or any of the related transactions constituted a constructive fraudulent conveyance. If a court accepts these allegations, it could impose a number of remedies, including without limitation, voiding our claims against Ligand, requiring our stockholders to return to Ligand some or all of the shares of our common stock issued in the Distribution, or providing Ligand with a claim for money damages against us in an amount equal to the difference between the consideration received by Ligand and our fair market value at the time of the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The measure of insolvency for purposes of the fraudulent conveyance laws will vary depending on which jurisdiction&#8217;s law is applied. Generally, an entity would be considered insolvent if (i)&#160;the present fair saleable value of its assets is less than the amount of its liabilities (including contingent liabilities); (ii) the present fair saleable value of its assets is less than its probable liabilities on its debts as such debts become absolute and matured; (iii)&#160;it cannot pay its debts and other liabilities (including contingent liabilities and other commitments) as they mature; or (iv)&#160;it has unreasonably small capital for the business in which it is engaged. We cannot assure you what standard a court would apply to determine insolvency or that a court would determine that we, Ligand or any of our respective subsidiaries were solvent at the time of or after giving effect to the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Distribution of our common stock is also subject to review under state corporate distribution statutes. Under the DGCL, a corporation may only pay dividends to its stockholders either (i)&#160;out of its surplus (net assets minus capital) or (ii)&#160;if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared or the preceding fiscal year. Although Ligand intends to make the Distribution of our common stock entirely from surplus, we cannot assure you that a court will not later determine that some or all of the Distribution to Ligand stockholders was unlawful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain and maintain sufficient intellectual property protection for our platform and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our platform and services may be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on patent protection, as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions, to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict the use of our intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage to exclude our competitors from making products or providing services claimed in our patents, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our platform and related technologies and uses thereof, as we deem appropriate. Certain of our patents and patent applications in the United States and certain foreign jurisdictions relate to our technology. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using, importing, offering for sale, or selling our products or services that are substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties or deemed unenforceable by a court. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that in the future some of our patents, licensed patents or patent applications may be challenged in court in the United States or outside of the United States, at the United States Patent and Trademark Office (USPTO) or in proceedings before the patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third party challenge to our patents could result in loss of exclusivity, patent claims being narrowed, or the unenforceability or invalidity of such patents, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, limit the duration of the patent protection of our technology, and increase competition to our business. We may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceedings can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and involve substantial cost, and may divert our efforts and attention from other aspects of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes we make to our technology, including changes that may be required for commercialization or that cause them to have what we view as more advantageous properties, may not be covered by our existing patent portfolio, and we may be required to file new applications and/or seek other forms of protection for any such alterations to our technology. There can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technology. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming that other requirements for patentability are met, prior to March&#160;16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March&#160;16, 2013, under the Leahy-Smith America Invents Act (the America Invents Act), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March&#160;16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our technology or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way patent applications are now prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications and the enforcement or defense of our owned or <span style="white-space:nowrap">in-licensed</span> issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United States Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and may facilitate third party challenges to any owned or licensed patents. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Issued patents directed to our platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that any resulting protection may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, Regeneron Pharmaceuticals filed an opposition to our European Patent No.&#160;2931030 directed to <span style="white-space:nowrap">human-rat</span> chimeric antibodies. The opposition is ongoing. If the opposition is successful in invalidating the claims of the patent, or narrowing their scope, the loss in ability to assert the patent in its current form may lead to increased competition to our business, which could harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third party intellectual property rights potentially relating to our platform or technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions included in each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on <span style="white-space:nowrap">in-licenses</span> from third parties. If we lose these rights, our business may be materially and adversely affected, our ability to develop improvements to our technology platform and antibody discovery platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation, as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to royalty-bearing license agreements that grant us rights to practice certain patent rights that are related to our systems, including our microcapillary assay technology, methods for selecting agents that bind to transmembrane receptors in a conformationally selective manner, and bovine antibody humanization technology. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. Some of our license agreements impose, and we expect that any future <span style="white-space:nowrap">in-license</span> agreements will impose, various development, diligence, commercialization and other obligations on us. We may enter into engagements in the future, with other licensors or other third parties under which we obtain certain </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property rights relating to our platform and technology. These engagements may take the form of an exclusive license or purchase of intellectual property rights or technology from third parties. Our rights to use the technology we license are subject to the continuation of and compliance with the terms of those agreements. In some cases, we may not control the prosecution, maintenance or filing of the patents to which we hold licenses, or the enforcement of those patents against third parties. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Moreover, disputes may arise with respect to our licensing or other upstream agreements, including: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the agreements and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which our systems and consumables, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sublicensing of patent and other rights under our license agreements with our partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations under the license agreements and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the priority of invention of patented technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our efforts to comply with our obligations under our <span style="white-space:nowrap">in-license</span> agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such <span style="white-space:nowrap">in-license</span> is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. In addition, absent the rights granted to us under our license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities that are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which ultimately may not be successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our rights to certain components of our technology platform, are licensed to us on a <span style="white-space:nowrap">non-exclusive</span> basis. The owners of these <span style="white-space:nowrap">non-exclusively</span> licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the third party, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we cannot acquire or license rights to use technologies on reasonable terms or if we fail to comply with our obligations under such agreements, we may not be able to commercialize new technologies or services in the future and our business could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may identify third party intellectual property and technology we may need to acquire or license in order to engage in our business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, <span style="white-space:nowrap">in-license</span> or use this technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, such licenses may not be available to us on acceptable terms or at all. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, <span style="white-space:nowrap">lump-sum</span> payments, payments based on certain milestones such as sales volumes, or royalties based on sales of our platform. In addition, such licenses may be <span style="white-space:nowrap">non-exclusive,</span> which could give our competitors access to the same intellectual property licensed to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these license agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our or our partners&#8217; ability to further commercialize our technology or products generated using our technology may be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we <span style="white-space:nowrap">in-license.</span> If other third parties have ownership rights to patents or patent applications we <span style="white-space:nowrap">in-license,</span> they may be able to license such patents to our competitors, and our competitors could market competing technology and services. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unenforceable. Moreover, we could encounter delays in the introduction of new technology or services while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing our platform and technology and advancing partnerships, which could harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our platform, technology, software, systems, workflows and processes in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Further, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own platform or technologies and may also sell their products or services to territories where we have patent protection, but enforcement is not as strong as that in the United States. These platforms and technologies may compete with ours. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make products that are similar to any therapeutic candidates generated by our platform that our partners may develop but that are not covered by the claims of the patents that we or our partners have or license or may own or license in the future; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our current or future partners, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we or our partners have or license or may have or license in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our current or future partners, might not have been the first to file patent applications covering certain of our or their inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our pending patent applications or those that we may hold in the future will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable technology or therapeutic candidates of our partners or will provide us or our partners with any competitive advantages; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we cannot ensure that our commercial activities or partners&#8217; therapeutic candidates will not infringe the patents of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we cannot ensure that we will be able to further commercialize our technology on a substantial scale, if approved, before the relevant patents that we hold or license expire; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our technology; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents or intellectual property rights of others may harm our business; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose not to file a patent application in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially and adversely affected and our business could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets and confidentiality agreements to protect our unpatented <span style="white-space:nowrap">know-how,</span> technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position. However, trade secrets and <span style="white-space:nowrap">know-how</span> can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, <span style="white-space:nowrap">non-disclosure</span> agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. Further, we may need to share our trade secrets and confidential <span style="white-space:nowrap">know-how</span> with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have employed and expect to employ individuals who were previously employed at universities or other companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our technologies or platform. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet registered certain of our trademarks in all of our potential markets. If we apply to register these trademarks in other countries, and/or other trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all; and further, our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may in the future be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third party rights, we may not be able to use these trademarks to market our technologies in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business, financial condition, results of operations and prospects. And, over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially and adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our or our <span style="white-space:nowrap">in-licensed</span> patents, trade secrets or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or <span style="white-space:nowrap">in-licensed</span> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables, reagents, and transgenic animals. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may from time to time become involved in litigation and other proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, financial condition, results of operations and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology, pharmaceutical and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and inter partes review, as well as corresponding proceedings in foreign courts and foreign patent offices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are, and may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our business, visibility and partnership base expands, and as the level of competition in our industry increases. Any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of the business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments, or result in potential or existing partners delaying entering into engagements with us pending resolution of the dispute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. Given that the therapeutics discovery field is a highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our technologies. The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. An unfavorable outcome in any such proceeding could require us to cease using the related technology or developing or commercializing our technology, or to attempt to license rights to it from the prevailing party, which may not be available on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our technologies infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be <span style="white-space:nowrap">non-exclusive,</span> which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our technologies could materially affect our business and our ability to gain market acceptance for our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any uncertainties resulting from the initiation and continuation of any litigation or administrative proceeding could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on issued United States and most foreign patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications in order to maintain such patents and patent applications. We have systems in place to remind us to pay these fees, and we engage an outside service and rely on those services and our outside counsel to pay these fees. The USPTO and various <span style="white-space:nowrap">non-U.S.</span> governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals and services to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <span style="white-space:nowrap">non-compliance</span> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. In such an event, if we or our licensors fail to maintain the patents and patent applications covering our technology and products, our competitors may be able to enter the market with similar or identical technology or products without infringing our patents and this circumstance would have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect our competitive position on our technology for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <span style="white-space:nowrap">non-provisional</span> filing date. This term can be reduced by the filing of a terminal disclaimer. Some of our patents have terminal disclaimers. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our platform or technology are obtained, once the patent life has expired, we may be open to competition from others. If our platform or technologies require extended development and/or regulatory review, patents protecting our platform or technologies might expire before or shortly after we are able to successfully commercialize them. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing processes or technologies similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our use of open source software could compromise our ability to offer our data packages and subject us to possible litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use open source software in connection with our technology and computational engine of our platform. Companies that incorporate open source software into their technologies and services have, from time to time, faced claims challenging their use of open source software and compliance with open source license terms. As a result, we could be subject to lawsuits by parties claiming ownership of what we believe to be open source </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to the licensee&#8217;s software that incorporates, links or uses such open source software, and make available to third parties for no cost, any derivative works of the open source code created by the licensee, which could include the licensee&#8217;s own valuable proprietary code. While we monitor our use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source license terms are often ambiguous. There is little legal precedent in this area and any actual or claimed requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop technologies that are similar to or better than ours. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Some of our intellectual property rights may have been discovered through government funded programs and thus may be subject to federal regulations such as <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> manufacturers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our intellectual property rights may have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our technology pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act), and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a <span style="white-space:nowrap">non-exclusive,</span> <span style="white-space:nowrap">non-transferable,</span> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or <span style="white-space:nowrap">non-exclusive</span> licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as <span style="white-space:nowrap">&#8220;march-in</span> rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with regulatory standards and requirements, and insider trading. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by state and federal authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly <span style="white-space:nowrap">clean-up</span> and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. We could face criminal liability and other serious consequences for violations, which could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the US Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the US Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. We are also subject to other U.S. laws and regulations governing export controls, as well as economic sanctions and embargoes on certain countries and persons. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that future deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We incur significant costs as a result of operating as a standalone public company, and our management is required to devote substantial time to new compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a standalone public company, we incur significant legal, accounting, insurance and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board, our Board committees or as executive officers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our Common Stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our shares could decrease, which might cause our stock price and trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have identified material weaknesses in our internal control over financial reporting. If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of the Business Combination, management of Legacy OmniAb concluded that its procedures and internal controls over financial reporting were not effective as of December&#160;31, 2020, due solely to a material weakness in internal controls over financial reporting related to recording transactions between Legacy OmniAb and Ligand. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. Management of Legacy OmniAb identified an error in the accumulation of information for the preparation of the <span style="white-space:nowrap">carve-out</span> financial statements. The errors resulted in a $7.0&#160;million understatement of accounts receivable, net, as well as a $7.0&#160;million overstatement of cash flows from operating activities, and a $7.0&#160;million understatement of cash flows from financing activities. As a result of the errors, management of Legacy OmniAb restated the financial statements at December&#160;31, 2020 and 2019 and the years then ended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the recent restatement of APAC&#8217;s financial statements, APAC&#8217;s management concluded that its disclosure controls and procedures were not effective as of September&#160;30, 2022 and December&#160;31, 2021 due to a material weakness in internal control over financial reporting solely related to its accounting for complex financial instruments. As previously disclosed in APAC&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on December&#160;1, 2021, after consultation with its independent registered public accounting firm, APAC&#8217;s management team and its audit committee concluded that it was appropriate to restate its previously issued audited balance sheet as of August&#160;12, 2021 (the &#8220;Audited Balance Sheet&#8221;) included as Exhibit 99.1 to its Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;18, 2021 and APAC&#8217;s unaudited and interim financial statements as of and for the three months ended September&#160;30, 2021 contained in APAC&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the SEC on November&#160;10, 2021 (the &#8220;Q3 Form <span style="white-space:nowrap">10-Q&#8221;).</span> Accordingly, on January&#160;12, 2022 and January&#160;28, 2022, APAC filed Amendment No.&#160;1 to the Q3 Form <span style="white-space:nowrap">10-Q</span> and a restated Audited Balance Sheet, respectively. As part of such process, APAC identified a material weakness in its internal control over financial reporting, solely related to its accounting for complex financial instruments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to remediate the above material weaknesses including the implementation of changes to our process for preparing the <span style="white-space:nowrap">carve-out</span> financial statements as well as plans to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects. If we are unable to maintain an effective system of disclosure controls and procedures and internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and financial results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to meet the continued listing requirements of the Nasdaq Global Market or the Nasdaq Capital Market, as applicable, could result in a delisting of our Common Stock or Warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy the continued listing requirements of the Nasdaq Global Market or the Nasdaq Capital Market, as applicable, such as the minimum closing bid price, stockholders&#8217; equity or round lot holders requirements or the corporate governance requirements, Nasdaq may take steps to delist our Common Stock or Warrants. Such a delisting would likely have a negative effect on the price of our Common Stock and Warrants and would impair your ability to sell or purchase our securities when you wish to do so. Such a delisting could also result in a limited amount of news and analyst coverage for the Company; and a decreased ability for us to issue additional securities or obtain additional financing in the future. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Common Stock and Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Common Stock and Warrants is likely to be highly volatile, and you may lose some or all of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our Common Stock and Warrants may fluctuate significantly due to a number of factors, some of which may be beyond our control, including those factors discussed in this &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; section and many others, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in its quarterly and annual results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to establish additional partnerships, the termination of license agreements by our existing partners or announcements by our partners regarding therapeutic candidates generated using our platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of new technologies or enhancements to existing technology by us or others in the industry; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">departures of key scientific or management personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to meet the estimates and projections of the investment community or that it may otherwise provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports about us or the industry, or antibody discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements or actions taken by Ligand as our previous principal stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of any natural disasters or public health emergencies, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic, industry and market conditions other events or factors, many of which are beyond our control; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in accounting standards, policies, guidelines, interpretations or principles. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock markets have experienced extreme price and volume fluctuations that affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our Common Stock and Warrants, regardless of our actual operating performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Volatility in our share price could subject us to securities class action litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Sponsor beneficially owns a significant equity interest in the Company and may take actions that conflict with the interests of our public shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interests of the Sponsor may not align with the interests of our public shareholders in the future. The Sponsor and its affiliates are in the business of making investments in companies and may acquire and hold interests in businesses that compete directly or indirectly with us. In addition, the Sponsor may have an interest in us pursuing acquisitions, divestitures and other transactions that, in their judgment, could enhance their investment, even though such transactions might involve risks to the us and our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports about us, or publish negative reports, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock and Warrants will depend, in part, on the research and reports that securities or industry analysts publish about us. We do not have any control over these analysts. If our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our Common Stock or Warrants or change their opinion, the trading price of our Common Stock and Warrants would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, it could lose visibility in the financial markets, which could cause the trading price or trading volume of our Common Stock and Warrants to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our Common Stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of the business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of Common Stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares of Common Stock may depress its stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions, the A&amp;R Registration Rights Agreement provides for certain restrictions on transfer with respect to our securities, including Founder Shares, Private Placement Warrants, and securities held by former directors and officers of APAC and certain directors and officers of OmniAb and Ligand. Such restrictions will begin upon closing and end (i)&#160;with respect to the Founder Shares, at the earliest of (A)&#160;one year after the Closing Date and (B)&#160;the first date on which (x)&#160;the last reported sale price of a share of Common Stock equals or exceeds $12.00 per share for any 20 trading days within any <span style="white-space:nowrap">30-trading</span> day period commencing at least 150 days after the Closing Date or (y)&#160;we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in our stockholders having the right to exchange their shares of Common Stock for cash, securities or other property; (ii)&#160;with respect to the Private Placement Warrants that are held by the initial purchasers of such warrants (or permitted transferees under the A&amp;R Registration Rights Agreement), and any of the shares of Common Stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers of the applicable warrants being converted (or permitted transferees under the A&amp;R Registration Rights Agreement), the period ending 30 days after the Closing; and (iii)&#160;with respect to the shares of Common Stock issued to the New Holders (as defined in the A&amp;R Registration Rights Agreement), each of whom are the directors and officers of Ligand and/or OmniAb, in connection with the consummation of the Merger and held by the New Holders (or their permitted transferees under the A&amp;R Registration Rights Agreement), the period ending on the earliest of (A)&#160;three months after the Closing and (B)&#160;the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of Common Stock for cash, securities or other property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, following the expiration of the applicable <span style="white-space:nowrap">lock-up</span> period, such equityholders will not be restricted from selling shares of Common Stock held by them, other than by applicable securities laws. Further, because we are not expected to generate revenue in the near future, there is a likelihood that we will need to continue to raise capital through one or more equity financings in order to continue developing our product candidates. As such, sales of a substantial number of shares of Common Stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our Common Stock. As restrictions on resale end and registration statements (filed after the Closing to provide for the resale of such shares from time to time) are available for use, the sale or possibility of sale of these shares could have the effect of increasing the volatility in our share price or the market price of our Common Stock could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions in our certificate of incorporation and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our Board. The provisions in our charter documents include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the exclusive right of our Board, unless the Board grants such a right to the holders of any series of preferred stock, to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the required approval of at least <span style="white-space:nowrap">66-2/3%</span> of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of our Board to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of our Board to alter our bylaws without obtaining stockholder approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the required approval of at least <span style="white-space:nowrap">66-2/3%</span> of the shares entitled to vote to adopt, amend or repeal our bylaws or repeal the provisions of our certificate of incorporation regarding the election and removal of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the requirement that a special meeting of stockholders may be called only by the Board, the chair of the Board, the chief executive officer or the president, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance notice procedures that stockholders must comply with in order to nominate candidates to our Board or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the DGCL. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the Board has approved the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees or the underwriters or any offering giving rise to such claim. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duty, any action asserting a claim against us arising pursuant to the DGCL, our certificate of incorporation or our bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. In addition, our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors and officers, which may discourage such lawsuits against us and our directors and officers. If a court were to find the choice of forum provisions in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect its business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The exclusive forum clause set forth in the Warrant Agreement may have the effect of limiting an investor&#8217;s rights to bring legal action against us and could limit the investor&#8217;s ability to obtain a favorable judicial forum for disputes with us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrant Agreement provides that (i)&#160;any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York and (ii)&#160;we irrevocably submit to such jurisdiction, which jurisdiction will be exclusive. We have waived or will waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. We note, however, that there is uncertainty as to whether a court would enforce these provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, these provisions of the Warrant Agreement will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in any of our Warrants shall be deemed to have notice of and to have consented to the forum provisions in the Warrant Agreement. If any action, the subject matter of which is within the scope of the forum provisions of the Warrant Agreement, is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York (a &#8220; foreign action&#8221;) in the name of any holder of the Warrants, such holder shall be deemed to have consented to: (x)&#160;the personal jurisdiction of the state and federal courts located within the State of New York or the United States District Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an &#8220;enforcement action&#8221;), and (y)&#160;having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#8217;s counsel in the foreign action as agent for such warrant holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="white-space:nowrap"><span style="white-space:nowrap">choice-of-forum</span></span> provision may limit a warrant holder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us, which may discourage such lawsuits. Alternatively, if a court were to find this provision of the Warrant Agreement inapplicable or unenforceable with respect to one or more of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company and smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our shares less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including exemption from compliance with the auditor attestation requirements under Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO (December 31, 2026), (b) in which we have total annual gross revenue of at least $1.235&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of shares of Common Stock that are held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a smaller reporting company as defined in the Exchange Act. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&#160;404 and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We will be able to take advantage of these scaled disclosures for so long as our voting and <span style="white-space:nowrap">non-voting</span> Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million measured on the last business day of its second fiscal quarter, or our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and our voting and <span style="white-space:nowrap">non-voting</span> Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million measured on the last business day of our second fiscal quarter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for the Common Stock and our market price may be more volatile. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We will base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-style:italic">&#160;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#160;</span><span style="font-style:italic">Critical Accounting Policies and Estimates</span>.&#8221; The results of these estimates form the basis for making judgments about </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our financial statements include the estimated variable consideration included in the transaction price in our contracts with customers, stock-based compensation, and valuation of our equity investments in early-stage biotechnology companies. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the combined company will regularly monitor its compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to it. As a result of new standards, changes to existing standards and changes in their interpretation, the combined company might be required to change its accounting policies, alter its operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or the combined company may be required to restate its published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on its reputation, business, financial position, and profit. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securityholders exercise their Public Warrants on a &#8220;cashless basis,&#8221; they will receive fewer shares of Common Stock from such exercise than if such securityholders were to exercise such Warrants for cash. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are circumstances in which the exercise of the Public Warrants may be required or permitted to be made on a cashless basis. First, if a registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrants is not effective by the 60th business day after the closing of the Merger, warrantholders may, until such time as there is an effective registration statement, exercise Warrants on a cashless basis in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption. Second, if our Common Stock is at any time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of Public Warrants who exercise their Warrants to do so on a cashless basis in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, and in the event we do not so elect, we will use our best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Third, if we call the </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Warrants for redemption, our management will have the option to require all holders that wish to exercise Warrants to do so on a cashless basis. In the event of an exercise on a cashless basis, a holder would pay the warrant exercise price by surrendering the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying the Warrants, multiplied by the difference between the exercise price of the Warrants and the &#8220;fair market value&#8221; (as defined in the next sentence) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; is the average reported last sale price of the Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of exercise is received by the warrant agent or on which the notice of redemption is sent to the holders of Warrants, as applicable. As a result, you would receive fewer shares of Common Stock from such exercise than if you were to exercise such Warrants for cash. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Public Warrants may never be in the money, and they may expire worthless and the terms of the Public warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants were issued in registered form under a Warrant Agreement. The Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. Although our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of shares of Common Stock purchasable upon exercise of a Public Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrants will be exercisable for shares of Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants to purchase an aggregate of 19,012,156 shares of Common Stock are exercisable in accordance with the terms of the warrant agreement governing those securities. The exercise price of the Warrants will be $11.50 per share. To the extent such warrants are exercised, additional shares of Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem unexpired Public Warrants prior to their exercise at a time that is disadvantageous to securitholders, thereby making such Public Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at $0.01 per warrant, provided that the last reported sales price (or the closing bid price of our Common Stock in the event the shares of Common Stock are not traded on any specific trading day) of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and the like) for any 20 trading days within a 30 <span style="white-space:nowrap">trading-day</span> period ending on the third trading day prior to the date we send proper notice of such redemption, provided that on the date we give notice of redemption and during the entire period thereafter until the time we redeem the Public Warrants, we have an effective registration statement under the Securities Act covering the shares of Common Stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Public Warrants could force securityholders: (i)&#160;to exercise Public Warrants and pay the exercise price therefor at a time when it may be disadvantageous for them to do so, (ii)&#160;to sell Public Warrants at the then-current market price when they might otherwise wish to hold Public Warrants or (iii)&#160;to accept the nominal redemption price which, at the time the outstanding Public Warrants are called for redemption, is likely to be substantially less than the market value of such Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_6">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale of shares of Common Stock or Warrants by the Selling Securityholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including underwriters&#8217; or agents&#8217; commissions and discounts, brokerage fees, underwriter marketing costs and all reasonable fees and expenses of any legal counsel representing the Selling Securityholders, except that we will pay the reasonable fees and expenses of one legal counsel for the Selling Securityholders, in the event of an underwritten offering of their securities. We will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus, including, without limitation, all registration and filing fees, printing and delivery fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive the proceeds from any exercise of Warrants or options for cash. We intend to use the proceeds the exercise of Warrants or options for cash for general corporate and working capital purposes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_7">DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, or the development, operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our Board after considering our financial condition, results of operations, capital requirements, business prospects and other factors the Board deems relevant, and subject to the restrictions contained in any future financing instruments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_8">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Legacy OmniAb and APAC adjusted to give effect to the Business Combination. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11&#160;of&#160;Regulation <span style="white-space:nowrap">S-X.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 combines the historical balance sheets of Legacy OmniAb and APAC on a pro forma basis as if the Business Combination had been consummated on September&#160;30, 2022. The unaudited pro forma condensed combined statements of operations for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021 combine the historical statements of operations of Legacy OmniAb and APAC for such period on a pro forma basis as if the Business Combination had been consummated on January&#160;1, 2021, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma condensed combined financial information may not be useful in predicting the future financial condition and results of operations of the Company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Business Combination, each of APAC&#8217;s public shareholders had the right to redeem all or a portion of such shareholder&#8217;s public shares for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account. The unaudited condensed combined pro forma financial information reflects actual redemptions of 21,713,864 shares of APAC Class&#160;A Ordinary Shares at approximately $10.32 per share, or $224,048,747&#160;in the aggregate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma capitalization of the Company immediately after the Business Combination: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC&#8217;s public shareholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,286,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor and related parties<sup style="font-size:75%; vertical-align:top">(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,922,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy OmniAb stockholders<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,611,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pro Forma Common Stock<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">114,820,859</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">100.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects actual redemptions of 21,713,864 shares of APAC&#8217;s Class A Ordinary Shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 1,293,299 Sponsor Earnout Shares held by Sponsor. The Sponsor Earnout Shares were included in the pro forma capitalization as, during the Earnout Period, holders of the Sponsor Earnout Shares are entitled to vote such Sponsor Earnout Shares and receive dividends and other distributions in respect thereof, pursuant to the Sponsor Insider Agreement, dated March&#160;23, 2022, by and among Legacy OmniAb, APAC, Avista Acquisition LP II and the other parties signatory thereto. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 4,351,701 shares of APAC&#8217;s Class B Ordinary Shares held by the Sponsor and 105,000 shares of APAC&#8217;s Class B Ordinary Shares held by three former directors of APAC that converted on a one-for-one basis into shares of OmniAb Common Stock in connection with the Domestication. Pursuant to the A&amp;R FPA, includes 1,500,000 shares of OmniAb Common Stock purchased by the Sponsor in the Forward Purchase and 8,672,934 shares of OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 15,000,000 Earnout Shares as, during the Earnout Period, Earnout Shares are entitled to exercise the voting rights carried by such Earnout Shares and receive any dividends or other distributions in respect of such Earnout Shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma capitalization excludes the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">12,620,608 Legacy OmniAb Options </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,679,867 Legacy OmniAb RSUs and PSUs </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">7,666,667 APAC Public Warrants </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">8,233,333 APAC Private Placement Warrants </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,666,667 APAC Warrants issued in the Forward Purchase </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,445,489 APAC Warrants issued in the Redemption Backstop </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OmniAb was determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb&#8217;s existing stockholders have the greatest voting interest in the Company with approximately 85% of the voting interest; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb nominated a majority of the initial members of the Company&#8217;s Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb&#8217;s senior management is the senior management of the Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb is the larger entity based on historical operating activity and has the larger employee base; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The post-combination company assumed a Legacy OmniAb branded name: &#8220;OmniAb, Inc.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC was treated as the acquired company and Legacy OmniAb was treated as the acquirer. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC were stated at historical cost, with no goodwill or other intangible assets recorded. Subsequent presentations of the results of operations presented for the period prior to the Business Combination are those of Legacy OmniAb. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assumptions and estimates underlying the unaudited pro forma adjustments included in the unaudited pro forma condensed combined financial statements are described in the accompanying notes. The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and are not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial statements do not purport to project the future operating results or financial position of the Company following the completion of the Business Combination. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date on which these unaudited pro forma condensed combined financial statements are prepared and are subject to change as additional information becomes available and analyses are performed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER&#160;30, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Legacy<br />OmniAb<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">APAC<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Autonomous<br />Entity<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br />Accounting<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro<br />Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(a)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(b)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(c)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(e)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(i)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(224,049</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(m)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(n)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,722</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(j)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,015</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">424</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,840</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">83,124</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">98,403</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(237,189</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(b)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">902</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">902</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">306,450</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">237,613</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,840</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(154,065</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">391,838</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(214</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,061</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(j)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(j)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory note</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(i)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative&#8212;Forward Purchase and Backstop Securities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(f)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of contingent liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of finance lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">22,793</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,267</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(19,854</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,206</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term contingent liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(c)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of deferred revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">73,740</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">14,292</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(23,879</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">64,153</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Legacy<br />OmniAb<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">APAC<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Autonomous<br />Entity<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br />Accounting<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro<br />Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&#160;A ordinary shares subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(237,189</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(g)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&#160;A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(g)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(h)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&#160;B</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(h)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent company net investment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">232,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(a)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(j)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(238,308</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(k)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OmniAb Common Stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(e)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(h)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(k)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(m)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(n)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,278</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(g)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(e)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(f)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">238,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(k)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,811</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(l)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(224,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(m)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(n)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,869</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(942</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(d)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(l)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">232,710</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(13,868</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,840</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">107,003</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">327,685</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total liabilities and stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">306,450</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">237,613</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,840</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(154,065</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">391,838</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share data) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Legacy<br />OmniAb<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">APAC<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Autonomous<br />Entity<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br />Accounting<br />Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>Royalty</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License and milestone revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>23,732</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expense:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(90</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(aa</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangibles</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense (income)&#8212;net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(486</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(486</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59,430</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(90</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">68,084</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(35,698</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">90</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(44,352</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,439</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(cc</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Forward Purchase and Backstop Securities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(dd</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(292</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,698</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,452</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(202</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(44,352</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>6,544</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>4,544</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>(ee</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>11,088</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(29,154</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,452</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,342</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(33,264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend&#8212;Forward Purchase and Backstop Securities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">225</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(ff</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(29,154</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,677</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,567</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(33,264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,750,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,777,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(gg</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPERATIONS FOR THE YEAR ENDED DECEMBER&#160;31, 2021 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share data) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended</span><br /><span style="font-weight:bold">December&#160;31,&#160;2021</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the period<br />from</span><br /><span style="font-weight:bold">February&#160;5, 2021<br />(inception)<br />through</span><br /><span style="font-weight:bold">December&#160;31,&#160;2021</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td colspan="2" rowspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Autonomous<br />Entity</span><br /><span style="font-weight:bold">Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td colspan="2" rowspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br />Accounting</span><br /><span style="font-weight:bold">Adjustments<br />(Note 3)</span></td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="3">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,&#160;2021</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Legacy</span><br /><span style="font-weight:bold">OmniAb<br />(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">APAC</span><br /><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>License and milestone revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>20,084</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expense:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(aa</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangibles</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense&#8212;net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">70,357</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">516</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160; </span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(46</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">70,827</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(35,609</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(516</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160; </span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">46</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(36,079</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>Interest expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>1,266</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(942</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(bb</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(942</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>(34,350</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(896</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160; </span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(ee</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(27,042</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(516</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#160;&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">737</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(26,821</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,178,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,348,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(gg</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. Basis of Presentation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC was treated as the acquired company and Legacy OmniAb was treated as the acquirer. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC were stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination are those of Legacy OmniAb. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 gives pro forma effect to the Business Combination as if it had been consummated on September&#160;30, 2022. The unaudited pro forma condensed combined statements of operations for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021 give pro forma effect to the Business Combination as if it had been consummated on January&#160;1, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 has been prepared using, and should be read in conjunction with, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb&#8217;s unaudited combined balance sheet as of September&#160;30, 2022 and the related notes included in Amendment No. 2 to our Current Report on Form 8-K with which this Exhibit is being filed; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">APAC&#8217;s unaudited condensed consolidated balance sheet as of September&#160;30, 2022 and the related notes included in APAC&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined statement of operations for the nine months ended September&#160;30, 2022 has been prepared using, and should be read in conjunction with, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb&#8217;s unaudited combined statement of operations for the nine months ended September&#160;30, 2022 and the related notes included in Amendment No. 2 to our Current Report on Form&#160;8-K with which this Exhibit is being filed; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">APAC&#8217;s unaudited condensed consolidated statement of operations for the nine months ended September&#160;30, 2022 and the related notes included in APAC&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined statement of operations for the year ended December&#160;31, 2021 has been prepared using, and should be read in conjunction with, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy OmniAb&#8217;s audited combined statement of operations for the year ended December&#160;31, 2021 and the related notes included in the Proxy Statement/Prospectus/ Information Statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">APAC&#8217;s audited statement of operations for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 and the related notes included in the Proxy Statement/Prospectus/ Information Statement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to any synergies, operating efficiencies, tax savings or cost savings that may be associated with the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma adjustments reflecting the completion of the Business Combination are based on currently available information and assumptions and methodologies that management believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments and it is possible the difference may be material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Business Combination based on information available to management at the current time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of the Company. They should be read in conjunction with the historical financial statements and notes thereto of Legacy OmniAb and APAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Accounting Policies and Reclassifications </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with closing of the Business Combination, management performed a review of Legacy OmniAb&#8217;s and APAC&#8217;s accounting policies and did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Adjustments to Unaudited Pro Forma Condensed Combined Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11&#160;of&#160;Regulation <span style="white-space:nowrap">S-X.</span> The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and has been prepared for informational purposes only. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma combined provision for income taxes does not necessarily reflect the amounts that would have resulted had the post-combination company filed consolidated income tax returns during the periods presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma basic and diluted earnings per share amounts presented in the unaudited pro forma condensed combined consolidated statement of operations are based upon the number of the Company&#8217;s shares outstanding, assuming the Business Combination occurred on January&#160;1, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Autonomous Entity Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The autonomous entity adjustments included in the unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents Ligand&#8217;s contribution to Legacy OmniAb of approximately $1,840,000 prior to the Distribution in accordance with the Separation Agreement. The $1,840,000 contribution amount represents $15,000,000 less approximately $13,160,000 of certain transaction and other expenses incurred by Ligand, which are eligible to be offset against the contribution amount in accordance with the Separation Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022, are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the reclassification of cash held in the Trust Account that became available following the Business Combination. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the settlement of the deferred underwriting fee payable upon the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents transaction costs incurred by Legacy OmniAb and APAC of approximately $14,164,000 and $8,622,000, respectively, for legal, financial and capital markets advisory and other professional fees. APAC&#8217;s estimated transaction costs exclude the deferred underwriting fee as described in Note 3(c) above. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For Legacy OmniAb&#8217;s transaction costs: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.2&#160;million were deferred in other current assets and accrued in accounts payables as of September&#160;30, 2022; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.7&#160;million were deferred in other current assets and accrued in accrued liabilities as of September&#160;30, 2022; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$4.2&#160;million were deferred in other current assets and paid by Ligand as of September&#160;30, 2022. Amounts paid by Ligand as of September 30, 2022 were offset against the contribution amount in accordance with the Separation Agreement as described in Note 3(a) above; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$8.1&#160;million was reflected as a reduction of cash, which represents Legacy OmniAb&#8217;s transaction costs less amounts previously paid by Ligand as of September 30, 2022, and amounts accrued in accounts payable and accrued liabilities as of September 30, 2022, which were retained by Ligand pursuant to the Separation Agreement as described in Note 3(j) below; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$12.3&#160;million were capitalized and offset against the proceeds from the Business Combination and reflected as a decrease in additional <span style="white-space:nowrap">paid-in</span> capital, which represents Legacy OmniAb&#8217;s transaction costs less the amounts accrued in accounts payable and accrued liabilities as of September 30, 2022, which were retained by Ligand pursuant to the Separation Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For APAC&#8217;s transaction costs: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$5.9&#160;million was accrued by APAC in accounts payable and recognized in expense as of September&#160;30, 2022; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.2&#160;million was accrued by APAC in accrued liabilities and recognized in expense as of September&#160;30, 2022; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.5&#160;million was recognized in expense and paid as of September&#160;30, 2022; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$8.1&#160;million was reflected as a reduction of cash, which represents APAC&#8217;s transaction costs less amounts previously paid by APAC as of September&#160;30, 2022; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.9&#160;million was reflected as an adjustment to accumulated deficit as of September&#160;30, 2022, which represents the total APAC transaction costs less $7.7&#160;million previously recognized by APAC as of September&#160;30, 2022. The costs expensed through accumulated deficit are included in the unaudited pro forma condensed combined statement of operations for the year ended December&#160;31, 2021, as discussed in Note 3(bb) below. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects proceeds of $15,000,000 from the issuance and sale of 1,500,000 shares of OmniAb Common Stock, par value of $0.0001 per share, and 1,666,667 OmniAb Warrants in the Forward Purchase. The OmniAb Warrants issued in the Forward Purchase are equity classified under Financial Accounting Standards Board (<span style="font-style:italic">&#8220;FASB&#8221;</span>) Accounting Standards Codification (<span style="font-style:italic">&#8220;ASC&#8221;</span>) <span style="white-space:nowrap">Topic&#160;815-40,</span> Derivatives and Hedging&#160;-&#160;Contracts in Entity&#8217;s Own Equity (<span style="font-style:italic">&#8220;ASC <span style="white-space:nowrap">815-40&#8221;</span></span>). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the settlement of the Forward Purchase and Backstop Securities in the Forward Purchase and Redemption Backstop upon the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the reclassification of $237,188,875 of APAC Class&#160;A Ordinary Shares, par value of $0.0001 per share, subject to possible redemption to permanent equity. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of 23,000,000 APAC Class&#160;A Ordinary Shares and 5,750,000 APAC Class&#160;B Ordinary Shares into 28,750,000 shares of OmniAb Common Stock in the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the repayment of the convertible promissory note upon the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(j)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects adjustment to remove Legacy OmniAb&#8217;s accounts receivable, accounts payable and accrued liabilities at the Distribution Time. Pursuant to the Separation Agreement, accounts receivable, accounts payable and accrued liabilities accrued by Legacy OmniAb at any time up to and until the Distribution Time were retained by Ligand. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(k)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the recapitalization of Legacy OmniAb&#8217;s parent company net investment into 97,611,789 shares of OmniAb Common Stock, par value of $0.0001 per share. The shares of OmniAb Common Stock include 82,611,789 shares of OmniAb Common Stock issued to holders of Legacy OmniAb Common Stock and 15,000,000 Earnout Shares. The Earnout Shares, which are issued and legally outstanding upon the closing of the Business Combination, are equity classified under&#160;ASC <span style="white-space:nowrap">815-40.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(l)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of APAC&#8217;s historical accumulated deficit after recording the transaction costs to be incurred by APAC as described in Note 3(d) above. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(m)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents redemptions of 21,713,864 APAC Class&#160;A Ordinary Shares for $224,048,747 allocated to shares of OmniAb Class&#160;A Common Stock and additional <span style="white-space:nowrap">paid-in</span> capital using par value of $0.0001 per share and at a redemption price of $10.32 per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(n)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects proceeds of $86,729,340 from the issuance and sale of 8,672,934 shares of OmniAb Common Stock, par value of $0.0001 per share, and 1,445,489 OmniAB Warrants to the Sponsor in the Redemption Backstop. The OmniAb Warrants issued in the Redemption Backstop are equity classified under&#160;ASC <span style="white-space:nowrap">815-40.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Autonomous Entity Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Autonomous Entity Adjustments&#160; </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined statements of operations for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021 do not reflect an amount for an autonomous entity adjustment as management does not anticipate that the net costs derived from expected contractual arrangements, primarily related to the Transition Services Agreements and Employee Matters Agreement will be materially different than the historical costs for these same services that have been allocated by Ligand to Legacy OmniAb in its historical combined financial statements for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Management Adjustments for Incremental Costs&#160; </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OmniAb expects to incur incremental costs based on management actions and other <span style="white-space:nowrap">dis-synergies</span> that will result as a separate public company, which may be material to the Company&#8217;s financial results. These incremental costs, which are additional to the net costs expected to be incurred under the Transition Services Agreement and other contractual arrangements executed at closing, primarily include additional compensation expense from potential headcount increases, higher audit and tax fees, and other costs related to our IT, investor relations, finance and general and administrative functions. As these costs are based on certain discretionary management actions for which contractual agreements are not yet known or will occur following closing of the transaction, they are not considered as autonomous entity adjustments. Management has elected not to present Management&#8217;s Adjustments related to these incremental costs in the unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma adjustments included in the unaudited pro forma condensed combined statements of operations for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(aa)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents pro forma adjustment to eliminate historical expenses related to APAC&#8217;s administrative, financial and support services paid to the Sponsor, which terminated upon consummation of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(bb)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects APAC transaction costs that were expensed upon the closing of the Business Combination. These costs are reflected as if incurred on January&#160;1, 2021, the date the Business Combination is deemed to have occurred for the purposes of the unaudited pro forma condensed combined statement of operations. This is a <span style="white-space:nowrap">non-recurring</span> item. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(cc)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents pro forma adjustment to eliminate gain on investments held in the Trust Account. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(dd)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of the change in fair value of the Forward Purchase and Backstop Securities, which was settled in the Forward Purchase and Redemption Backstop upon the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ee)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the adjustment to income tax benefit as a result of the tax impact on the Business Combination at the estimated combined statutory tax rate of 25.0%. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ff)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of the deemed dividend on the Forward Purchase and Backstop Securities, which was settled in the Forward Purchase and Redemption Backstop upon the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(gg)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The following reflects the adjustment to basic and diluted weighted average shares outstanding: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Nine&#160;Months</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Year Ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Ended&#160;September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares of OmniAb Common Stock to holders of Legacy OmniAb Common Stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,611,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,611,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on APAC&#8217;s weighted average shares outstanding assuming APAC&#8217;s shares were outstanding since January&#160;1, 2021, the beginning of the earlier period presented</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,571,428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares of OmniAb Common Stock in the Forward Purchase and Redemption Backstop</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,172,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,172,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemptions of APAC Class&#160;A Ordinary Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,713,864</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,713,864</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusion of Sponsor Earnout Shares<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,293,299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,293,299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,777,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,348,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Sponsor Earnout Shares are subject to certain vesting restrictions pursuant to the Sponsor Insider Agreement and the Merger Agreement, which are considered contingently issuable shares for which the milestones have not yet been achieved. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Refer to Note 4 &#8220;Loss Per Share&#8221; of this Unaudited Pro Forma Condensed Combined Financial Information for further information on the calculation of pro forma weighted average shares outstanding. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Net Loss per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Represents the net loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire period presented. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Nine&#160;Months</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Year Ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Ended&#160;September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss (in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33,264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,821</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares outstanding, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pro forma weighted average shares calculation, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APAC&#8217;s public shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,286,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,286,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor&#160;&amp; related parties<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,629,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,629,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy OmniAb stockholders<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,611,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,611,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pro forma weighted average shares calculation, basic and diluted<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,527,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma basic and diluted shares exclude 1,293,299 Sponsor Earnout Shares, which are subject to certain vesting restrictions pursuant to the Sponsor Insider Agreement and the Merger Agreement and are considered contingently issuable shares for which the milestones have not yet been achieved. The number of shares included reflects 4,351,701 shares held by the Sponsor and 105,000 shares held by three former directors of APAC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma basic and diluted shares include 1,500,000 shares of OmniAb Common Stock purchased by the Sponsor in the Forward Purchase and 8,672,934 shares of OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma basic and diluted shares exclude 15,000,000 Earnout Shares subject to certain vesting restrictions pursuant to the Merger Agreement. These Earnout Shares are considered contingently issuable shares for which the milestones have not yet been achieved. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma diluted shares for the nine months ended September&#160;30, 2022 and year ended December&#160;31, 2021 exclude the following because including them would be antidilutive: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">12,620,608 Legacy OmniAb Options </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,679,867 Legacy OmniAb RSUs and Legacy OmniAb PSUs </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">7,666,667 APAC Public Warrants </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">8,233,333 APAC Private Placement Warrants </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,666,667 APAC Warrants issued in the Forward Purchase </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,445,489 APAC Warrants issued in the Redemption Backstop </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_9">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless the context otherwise requires, references in this MD&amp;A to &#8220;OmniAb,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Legacy OmniAb and its subsidiaries prior to the Closing of the Business Combination. This MD&amp;A is designed to provide a reader of our financial statements with a narrative from the perspective of the OmniAb business&#8217;s management. This MD&amp;A should be read in conjunction with &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8221; and OmniAb&#8217;s audited Combined Financial Statements, unaudited Condensed Combined Financial Statements and related notes included elsewhere in this prospectus. This MD&amp;A includes forward-looking statements. For a discussion of important factors that could cause actual results to differ materially from the results referred to in these forward-looking statements, see &#8220;Cautionary Statement Concerning Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Separation from Ligand </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to completion of the Separation, OmniAb was a wholly owned subsidiary of Ligand. We have historically operated as part of Ligand and not as a separate, publicly-traded company. Our combined financial statements have been derived from Ligand&#8217;s historical accounting records and are presented on a <span style="white-space:nowrap">carve-out</span> basis. All sales and costs as well as assets and liabilities directly associated with our business activity are included as a component of the combined financial statements. The combined financial statements also include allocations of certain general, administrative, sales and marketing expenses and cost of sales from Ligand&#8217;s corporate office and from other Ligand businesses to us and allocations of related assets, liabilities, and Ligand&#8217;s investment, as applicable. We believe the allocations have been determined on a reasonable basis; however, the amounts are not necessarily representative of the amounts that would have been reflected in the combined financial statements had we been an entity that operated separately from Ligand during the periods presented. Further, the historical financial statements may not be reflective of what our results of operations, income (loss), historical financial position, equity or cash flows might be in the future as a separate public company. We have entered into the Separation Agreement and various other agreements with Ligand (and in certain cases APAC and/or Merger Sub) to provide for the allocation between us and Ligand of Ligand&#8217;s assets, employees, liabilities and obligations attributable to periods prior to, at and after the Separation and will govern certain relationships between us and Ligand after the Separation. Following the Separation, we expect Ligand to continue to provide certain services to us on a transitional basis for associated fees, including services related to information technology, facilities, certain accounting and other financial functions and administrative functions, and we will provide transitional services to Ligand, including services related to legal, corporate, and other administrative functions as we and Ligand may decide from time to time. For additional information regarding the Separation Agreement, Transition Services Agreements and other agreements related to the Separation, please see the section titled, &#8220;<span style="font-style:italic">Certain Relationships and Related Person Transactions &#8211; OmniAb &#8211; Agreements with Ligand</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Basis of Presentation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying audited combined financial statements present the historical financial position, results of operations, changes in equity and cash flows of OmniAb in accordance with GAAP for the preparation of <span style="white-space:nowrap">carve-out</span> combined financial statements. We are a biotechnology company enabling the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. Our partners include pharmaceutical and biotechnology companies engaged in drug development. OmniAb&#8217;s products are marketed to partners primarily under the OmniAb brand name. Historically, our business has comprised the OmniAb business of Ligand. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical combined financial statements include expense allocations for certain support functions that have historically been provided on a centralized basis within Ligand, such as corporate costs, shared services and other general and administrative costs that benefit OmniAb, among others. Following the Separation, pursuant to agreements with Ligand, we expect that Ligand will continue to provide us with some of the services related to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Ligand. We will also incur additional costs as a separate public company. As a separate public company, our total costs related to such support functions may differ from the costs that were historically allocated to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These additional costs are primarily for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional personnel costs, including salaries, benefits and potential bonuses and/or stock-based compensation awards for staff additions to replace support provided by Ligand that is not covered by the Transition Services Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporate governance costs, including board of director compensation and expenses, insurance costs, audit and other professional services fees, annual report and proxy statement costs, SEC filing fees, transfer agent fees, consulting and legal fees and stock exchange listing fees. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain factors could impact the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniAb has historically operated as part of Ligand and not as a stand-alone company. The financial statements have been derived from Ligand&#8217;s historical accounting records and are presented on a <span style="white-space:nowrap">carve-out</span> basis. All revenues and costs as well as assets and liabilities directly associated with the business activity of OmniAb are included as a component of the financial statements. The financial statements also include allocations of certain general and administrative expenses from Ligand&#8217;s corporate office. The allocations have been determined on a reasonable basis; however, the amounts are not necessarily representative of the amounts that would have been reflected in the financial statements had OmniAb been an entity that operated independently of Ligand. Further, the historical financial statements may not be reflective of what our results of operations, comprehensive income, historical financial position, equity or cash flows might be in the future as a separate public company. Certain factors could impact the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs. Following the Separation, pursuant to agreements with Ligand, we expect that Ligand will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Ligand. Related party allocations are discussed further in Note 9, &#8220;Relationship with Parent and Related Entities&#8221; in the accompanying audited combined financial statements contained elsewhere in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of Ligand, OmniAb is dependent on Ligand for all of its working capital and financing requirements, which utilizes a centralized approach to cash management and financing of its operations. Financing transactions relating to OmniAb are accounted for through the Net Parent investment account of OmniAb. Accordingly, none of Ligand&#8217;s cash, cash equivalents or debt has been assigned to OmniAb in the accompanying audited combined financial statements included elsewhere in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Parent investment, which includes retained earnings, represents Ligand&#8217;s interest in the recorded net assets of OmniAb. All significant transactions between OmniAb and Ligand have been included in the accompanying combined financial statements. Transactions with Ligand are reflected in the accompanying Combined Statements of Equity as &#8220;Transfers (to) from Parent, net&#8221; and in the accompanying combined balance sheets within &#8220;Net Parent investment.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OmniAb technology platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of September&#160;30, 2022, we had 68 active partners with 282 active programs using the OmniAb technology, 25 OmniAb-derived antibodies in clinical development by our partners, and three approved products of our partners: (i)&#160;zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma, (ii)&#160;sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) <span style="white-space:nowrap">non-small</span> cell lung cancer in combination with chemotherapy, as well as for patients with unresectable stage III <span style="white-space:nowrap">non-small</span> cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy, and (iii)&#160;teclistamab, which received accelerated approval in the U.S. for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and conditional marketing authorization in Europe as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We partner with numerous pharmaceutical and biotechnology companies, varying in size, clinical stage, geography and therapeutic focus. Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with partners to typically include: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue); and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests. Our typical royalty rates for antibody discovery contracts are currently in the <span style="white-space:nowrap">low-</span> to <span style="white-space:nowrap">mid-single</span> digits, and can vary depending on the other economic terms in the agreement. Our future success and the potential to receive these payments are entirely dependent on our partners&#8217; efforts over which we have no control. If our partners determine not to proceed with the future development of a drug candidate, we will not receive any future payments related to that program. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners&#8217; clinical trial results, including serious adverse events, or ongoing communications with the FDA regarding our partners&#8217; current clinical programs, which limits our visibility into how such programs may be progressing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the three and nine months ended September&#160;30, 2022 our revenue was $6.9&#160;million and $23.7&#160;million, respectively, and for the three and nine months ended September&#160;30, 2021 was $6.3&#160;million and $19.5&#160;million, respectively. For the years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million) and $(13.6 million), respectively. For the three and nine months ended September&#160;30, 2022 our net loss was $(12.6) million and $(29.2) million, respectively, and for the three and nine months ended September&#160;30, 2021 was $(7.9) million and $(24.0) million, respectively. Historically, our revenue has been derived from payments for technology access, collaborative research services and milestones. We believe the long-term value of our business will be driven by partner royalties as such payments are based on global sales of potential future partner antibodies, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. While in the first nine months of 2022, we recognized royalty revenue from our partner&#8217;s sales of zimberelimab and sugemalimab in China, we believe our revenue will be materially driven by milestones, in the shorter term, and by royalties, in the longer term, from our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partnered programs in the United States and Europe. However, drug discovery and development has significant uncertainty in timing and likelihood of reaching marketing authorization, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of antibodies discovered using our platform, and as a result, we are entirely dependent on our partners&#8217; efforts and decisions with respect to such antibodies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Business Metrics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understanding our current business. These metrics may change or may be substituted for additional or different metrics as our business continues to grow. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:59%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Metric</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">September&#160;30,<br />2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br />2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Active partners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Active programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Active clinical programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approved products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Active partners</span></span>&#160;represents the number of partners that have an active program or have executed a license agreement in advance of initiating an active program. We do not include academic partners with a license to the OmniAb platform in our active partner count. We view this metric as an indication of the competitiveness of our platform and our current level of market penetration. The metric also relates to our opportunities to secure additional active programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Active programs</span></span>&#160;represents a program for which an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. This number includes active clinical programs and approved products separately disclosed below. We view this metric as an indication of the usage of our technology and the potential for <span style="white-space:nowrap">mid-</span> and long-term milestone and royalty payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Active clinical programs</span></span>&#160;represents the number of unique programs for which an Investigational New Drug (&#8220;IND&#8221;) or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development by our partners and we continue to count programs as active as long as they are actively being developed or commercialized. Where the date of such application is not known to us, we use the official start date from clinical trial registries for the purpose of calculating this metric. This number includes approved products separately disclosed below. We view this metric as an indication of our near- and <span style="white-space:nowrap">mid-term</span> potential revenue from milestone fees and potential royalty payments in the long term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Approved products</span></span>&#160;represents an OmniAb-derived antibody for which our partner has received marketing approval. We view this metric as an indication of our near- and <span style="white-space:nowrap">mid-term</span> potential revenue from royalty payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impact of <span style="white-space:nowrap">COVID-19</span> Pandemic </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not experienced material disruptions in our business operations or financial impacts as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic. While it is not possible at this time to estimate the impact that <span style="white-space:nowrap">COVID-19</span> could have on our business in the future, the continued spread of <span style="white-space:nowrap">COVID-19</span> and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. In addition, if <span style="white-space:nowrap">COVID-19</span> infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees or subcontractor&#8217;s employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Three and Nine Months Ended September&#160;30, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:66%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Three&#160;Months&#160;Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">NM</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">6,910</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$6,277</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">633</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-style:italic">(1)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">percentage change is not meaningful </span></p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">NM</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">23,732</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">19,468</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">4,264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-style:italic">(1)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">percentage change is not meaningful </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue increased $0.6&#160;million, or 10%, in the three months ended September&#160;30, 2022 as compared to 2021 driven primarily by royalty revenue from our partner&#8217;s sales of zimberelimab and sugemalimab. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue increased $4.3&#160;million, or 22%, in the nine months ended September&#160;30, 2022 as compared to 2021 driven primarily by (1)&#160;additional milestone revenue primarily related to two partners reaching multiple development milestones during the nine months ended September&#160;30, 2022, (2) royalty revenue from our partner&#8217;s sales of zimberelimab and sugemalimab and (3)&#160;additional service revenue related to a significant contract executed in December 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Three Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,885</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangibles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense (income), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(817</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">21,819</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">16,083</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">5,736</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangibles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense (income), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(486</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(546</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">59,430</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">50,004</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">9,426</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our R&amp;D expenses increased $3.3&#160;million, or 33%, in the three months ended September&#160;30, 2022 compared with 2021, primarily due to (1)&#160;increased personnel-related costs driven by our increased investment in the growth and development of the OmniAb business and (2)&#160;an increase in rent expense for newly leased facilities. General and administrative expenses increased $1.9&#160;million, or 51% in the three months ended September&#160;30, 2022 compared with 2021, primarily due to increased personnel-related costs driven by our increased investment in the growth and development of the OmniAb business. The amortization of intangibles remained consistent for the three months ended September&#160;30, 2022 compared with 2021. Other operating income, net, was $(0.2) million for the three months ended September&#160;30, 2022 compared with $(0.8) million for the same period in 2021 due to fair value adjustments related to contingent earnout liabilities issued in connection with the acquisition of Icagen. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our R&amp;D expenses increased $7.2&#160;million, or 26%, in the nine months ended September&#160;30, 2022 compared with 2021, primarily due to (1)&#160;an increase in rent expense for newly leased facilities, (2)&#160;increased personnel-related costs driven by our increased investment in the growth and development of the OmniAb business and (3)&#160;services related to a significant contract executed in 2021. General and administrative expenses increased $2.1&#160;million, or 17% in the nine months ended September&#160;30, 2022 compared with 2021, primarily due to increased personnel-related costs driven by our increased investment in the growth and development of the OmniAb business. The amortization of intangibles and other operating income, net remained consistent for the nine months ended September&#160;30, 2022 compared with 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income (expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&#160;30, 2021 was related to certain equipment financing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income tax benefit </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Three Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,909</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,806</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,890</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,706</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Tax Rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:61%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,698</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,542</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,156</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,154</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,970</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,184</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Tax Rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">18.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">21.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our effective tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions. The tax rate is also affected by discrete items that may occur in any given year, but are not consistent from year to year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth in the section titled &#8220;Liquidity and Capital Resources&#8221; in note 2 of the notes to our unaudited condensed combined financial statements attached as Exhibit 99.2 to Amendment No.&#160;2 to the Current Report on Form <span style="white-space:nowrap">8-K</span> with which this Exhibit is being filed is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flow Summary </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:57%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(Dollars in thousands)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2020</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2019</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,672</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,195</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,112</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,548</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,980</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,095</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by Operating Activities: </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2022, cash provided by operating activities of $3.6&#160;million primarily reflected our net loss of $(29.2) million for the period, adjusted by net <span style="white-space:nowrap">non-cash</span> charges of $18.2&#160;million which primarily included $12.3&#160;million in share-based compensation, and $13.4&#160;million in depreciation and amortization, partially offset by $(6.8) million of deferred income taxes, net, as well as changes in our working capital accounts in the amount of $14.5&#160;million, primarily consisting of cash inflow from changes in accounts receivable, net, other long-term liabilities and other long-term assets, partially offset by cash outflow from changes in deferred revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2021, cash provided by operating activities of $(1.2) million primarily reflected our net loss of $(24.0) million for the period, adjusted by net <span style="white-space:nowrap">non-cash</span> charges of $18.5&#160;million, which primarily included $13.8&#160;million in depreciation and amortization, $11.6&#160;million in share-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based compensation, partially offset by $(6.3) million of deferred income taxes, net, as well as changes in our working capital accounts in the amount of $4.2&#160;million, primarily consisting of cash inflow from changes in accounts receivable, net, partially offset by cash outflow from changes in deferred revenue and other long-term liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Investing Activities: </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2022 and 2021, cash used in investing activities consisted of $(13.1) million and $(2.5) million of cash paid for property and equipment, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Financing Activities: </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Ligand managed our cash and financing arrangements prior to the completion of the Separation, all excess cash generated through earnings was deemed remitted to Ligand and all sources of cash were deemed funded by Ligand. Cash provided by financing activities in the nine months ended September&#160;30, 2022 and 2021 primarily included cash transferred to us from Ligand based on changes in our cash used for operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2022, cash provided by financing activities was $9.6&#160;million, which consisted of $15.3&#160;million net transfer from parent, partially offset by $(1.5) million of payments to CVR holders and $(4.2) million payments for deferred transaction costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2021, cash provided by financing activities was $3.8&#160;million, which consisted of $4.8&#160;million net transfer from parent partially offset by $(1.1) million of payments to CVR holders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being an Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). As an emerging growth company, we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure obligations regarding executive compensation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the earlier of: (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700.0&#160;million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in this proxy statement/prospectus/information statement and in the registration statement of which this proxy statement/prospectus/information statement is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this proxy statement/prospectus/information statement and that we provide to our stockholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We intend to rely on this and other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section&#160;404(b) of Sarbanes-Oxley. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quantitative and Qualitative Disclosures about Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our cash and cash equivalents will consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effects of Inflation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented in OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_10">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OmniAb technology platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of September&#160;30, 2022, we had 68 active partners with 282 active programs using the OmniAb technology, 25 OmniAb-derived antibodies in clinical development by our partners, and three approved products of our partners: (i)&#160;zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma, (ii)&#160;sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) <span style="white-space:nowrap">non-small</span> cell lung cancer in combination with chemotherapy, as well as for patients with unresectable stage III <span style="white-space:nowrap">non-small</span> cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy, and (iii)&#160;teclistamab, which received accelerated approval in the U.S. for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and conditional marketing authorization in Europe as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our robust experience and development activity with our partners gives us critical insights into the industry and creates a positive feedback loop through which we plan to continue to advance our platform. Our business model is dependent on the eventual progression of therapeutic candidates discovered or initially developed utilizing our platform into clinical trials and commercialization by our partners, and our receipt of milestone and royalty payments from our partners. However, our future success and the potential to receive these payments are entirely dependent on our partners&#8217; efforts over which we have no control. If our partners determine not to proceed with the future development of a drug candidate, we will not receive any future payments related to that program. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners&#8217; clinical trial results, including serious adverse events, or ongoing communications with the FDA regarding our partners&#8217; current clinical programs, which limits our visibility into how such programs may be progressing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the heart of the OmniAb technology platform lies the Biological Intelligence of our proprietary transgenic animals, including OmniRat, OmniMouse and OmniChicken, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. Biological Intelligence refers to the ability of the immune system in our transgenic animals to create optimized antibodies through a process that has evolved over 500&#160;million years. The immune system function is to adaptively respond to a given target through an iterative process of diversification and selection that produces novel antibodies with high affinity, specificity, and expression levels. Through its proprietary and carefully designed transgenes, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OmniAb&#8217;s Biological Intelligence taps into this powerful in vivo process to generate human antibodies directly from its transgenic animals. OmniFlic and OmniClic are common light-chain rats and chickens, respectively, designed to generate bispecific antibodies. OmniTaur provides <span style="white-space:nowrap">cow-inspired</span> antibodies with unique structural characteristics for challenging targets. To our knowledge, we are the industry&#8217;s only four-species in vivo antibody discovery platform, making OmniAb the most diverse host system available in the industry. We believe natural antibodies are superior to other antibody generation methods because they are naturally optimized through an iterative in vivo process that preferentially selects antibodies to effectively bind to a specific antigen. Our technology can be leveraged to develop multiple therapeutic formats including mono-, <span style="white-space:nowrap">bi-</span> and multi-specific antibodies, antibody-drug conjugates (&#8220;ADCs&#8221;) and chimeric antigen receptor T cell <span style="white-space:nowrap">(&#8220;CAR-T&#8221;).</span> By generating large and diverse pools of high-quality antibodies, we believe Biological Intelligence increases the probability of success of therapeutic antibody discovery and helps limit the attrition of antibody product candidates in the clinic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology investments are methodical and deliberate, designed to enable our partner-centric business model to leverage the most cutting-edge solutions to solve the biggest challenges in antibody drug discovery. Some partners prefer integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> discovery capabilities, while others prefer to use certain of our technologies within their own labs. This flexibility not only provides value to our partners, but also allows for greater scalability of our business since we do not have to build out capacity for partners that prefer to use some of their own technologies in the process. The breadth and depth of our partner-centric model benefits our investment decision making by providing critical insights into the needs and direction of the industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to <span style="font-style:italic">Vaccines</span> journal, antibodies are among the fastest growing class of drugs and are used across multiple therapeutic areas including oncology, inflammation, neurodegeneration. In 2021, approved antibody-based therapeutics accounted for over $215.0&#160;billion in sales and 49 antibody therapeutics reached blockbuster status in 2021 with sales higher than $1.0&#160;billion, according to data published by La Merie Publishing. Furthermore, Fatpos Global estimates that antibody-based therapeutic sales are expected to grow to approximately $365.0&#160;billion by 2030. The favorable drug-like properties of antibodies, including high specificity, limited <span style="white-space:nowrap">off-target</span> toxicity, superior immune stimulation, and the ability to modulate half-life circulation in serum, have accelerated investment in antibody therapeutics. This has resulted in higher success rates for antibody therapeutics when compared to small molecule modalities, according to Clinical Development Success Rates and Contributing Factors 2011-2020, a study of over 9,000 clinical development programs published by PharmaIntelligence. These factors have led to substantial investment in antibody discovery, which we believe will continue to expand the total addressable market for antibody discovery technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite industry momentum that has resulted in an overall increase in the number of antibody therapeutic approvals per year, drug discovery and development has become increasingly fragmented, outdated and <span style="white-space:nowrap">non-robust.</span> While many biotechnology companies bring a focused approach to science, their biological hypotheses are often tested utilizing suboptimal antibody discovery methods due to reliance on legacy technologies. Meanwhile, many larger companies have also continued to rely on legacy technologies, often due to the inability to selectively integrate newer technologies at their facilities or because the benefits of technological updates are limited by outdated workflows. Additionally, outsourced technologies that have tried to address these shortcomings often lack flexibility. These legacy approaches are burdened with critical disadvantages including low antibody diversity, lengthy discovery timelines, limited functional parameter data, excess costs or lack of flexibility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that by eliminating the need for each company to build a comprehensive antibody discovery engine, we can unlock innovation and value across a broad network of partners. Many emerging and established life sciences companies have been built around technologies that focus on a single or a limited number of steps in the discovery process, including antigen design, transgenic animal platforms, single-cell analysis, sequencing, bioinformatics, and proprietary assays. We believe our comprehensive, biologically-driven technology platform provides the industry with a cutting-edge solution for all critical components of the antibody discovery continuum. By providing leading antibody discovery solutions to the industry, we aim to increase the probability of success, reduce costs and shorten development timelines for our partners. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As depicted in Figure 1 below, our technology platform is a suite of integrated technologies designed to discover a wide range of high-quality therapeutic antibodies that leverage the inherent diversity produced by our transgenic animals. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 1: The OmniAb Technology Platform </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g72q97.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technologies within the OmniAb platform improve the productivity and efficiency of each step of the discovery process: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Create Diverse Antibody Pools</span></span>.&#160;&#160;&#160;&#160;We believe generating large and diverse pools of high-quality antibodies increases the likelihood of discovering the antibody with the most desirable therapeutic characteristics. At the heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, technology that we own. Our animals have been genetically modified to produce a large number of naturally optimized, high-quality, fully-human antibodies. We offer the industry&#8217;s only four-species platform to address a wide range of biological challenges facing our partners in their antibody discovery efforts. We pair our Biological Intelligence with computational antigen design to generate robust antibody responses to biological targets, including but not limited to difficult and complex targets such as ion channels, G protein-coupled receptors (&#8220;GPCRs&#8221;), transporters, and other transmembrane proteins. Our antigen design technology includes transmembrane and cell-surface protein technology that we own or exclusively license. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Screen Antibody Candidates.</span></span>&#160;&#160;&#160;&#160;Our proprietary xPloration microcapillary technology, which we own or license, and Gel Encapsulated Microenvironment (&#8220;GEM&#8221;) technology, which we own, screen pools of antibody-secreting B cells at a single-cell level to quickly identify antibodies in as little as a few hours, saving weeks compared to traditional technologies. xPloration characterizes tens of millions of antibody producing cells on multiple parameters, then leverages AI to analyze immense amounts of phenotypic data to automatically select and rank thousands of promising therapeutic candidates. Our industry-leading throughput allows for the discovery of rare antibodies that may otherwise be missed with traditional technologies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Identify the Right Antibody</span></span>.&#160;&#160;&#160;&#160;Our discovery teams are able, as needed, to work closely with partners to identify the right antibody for a particular target profile. Antibody candidates identified through our </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
screening technologies are further characterized through a cascade of performance assays. The data from multi-parameter screening and performance assays is used in combination with bioinformatics to analyze the antibody repertoire and enable our partners to select the right antibody. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our antibody discovery solutions, we possess extensive biological capabilities focused on ion channels, transporters and <span style="white-space:nowrap">x-ray</span> fluorescence. Ion channels and transporters are key components in a wide variety of biological processes and have broad therapeutic applicability across cancer, metabolic disease, pain, neurological diseases, infectious diseases and others. In the search for new drugs, ion channels are a frequent, but challenging target. We believe our capabilities in the ion channel area are leverageable for both small molecule and antibody approaches to therapeutic development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We partner with pharmaceutical and biotechnology companies that vary in size, clinical stage, geography and therapeutic focus. Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with partners to typically include: (i)&#160;payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests. As of September&#160;30, 2022, we had 68 active partners with 282 active programs using the OmniAb technology, 25 OmniAb-derived antibodies in clinical development by our partners, and three approved products of our partners. An active program is counted once an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. An active partner is counted if such partner has an active program or has executed a license agreement in advance of initiating an active program. As of September&#160;30, 2022 and 2021, our partners with active antibody programs included Amgen, Boehringer Ingelheim, Genmab, Janssen, Merck KGaA, Pfizer, Sanofi, and Seagen, among others. In addition, we work with academic partners including The Scripps Research Institute, Oxford University, University of Maryland, and the Wistar Institute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the three and nine months ended September&#160;30, 2022 our revenue was $6.9&#160;million and $23.7&#160;million, respectively, and for the three and nine months ended September&#160;30, 2021 was $6.3&#160;million and $19.5&#160;million, respectively. For the years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million) and $(13.6 million), respectively. For the three and nine months ended September&#160;30, 2022 our net loss was $(12.6) million and $(29.2) million, respectively, and for the three and nine months ended September&#160;30, 2021 was $(7.9) million and $(24.0) million, respectively. Historically, our revenue has been derived from payments for technology access, collaborative research services and milestones. We believe the long-term value of our business will be driven by partner royalties as such payments are based on global sales of potential future partner antibodies, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. While in the first nine months of 2022, we recognized royalty revenue from our partner&#8217;s sales of zimberelimab and sugemalimab in China, we believe our revenue will be materially driven by milestones, in the shorter term, and by royalties, in the longer term, from our partnered programs in the United States and Europe. However, drug discovery and development has significant uncertainty in timing and likelihood of reaching marketing authorization, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of antibodies discovered using our platform, and as a result, we are entirely dependent on our partners&#8217; efforts and decisions with respect to such antibodies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates and by being the partner of choice for pharmaceutical and biotechnology companies. Our strategy to accomplish this is as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Enable discovery of high-quality antibody candidates through our platform</span></span>.&#160;&#160;&#160;&#160;We have a technologically differentiated platform that provides our partners with <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> antibody discovery capabilities, as well as customized solutions for individual steps of the antibody discovery process. We believe that pairing the power of Biological Intelligence built into our proprietary transgenic animals with our high-throughput screening technologies will continue to enable the discovery of high-quality, fully-human antibody therapeutic candidates for a wide range of diseases. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Expand upon our existing partnerships</span></span>.&#160;&#160;&#160;&#160;We have 68 active partners as of September&#160;30, 2022, consisting of pharmaceutical and biotechnology organizations, varying in size, clinical stage, geography and therapeutic focus. We intend to continue to identify and capture new opportunities with existing partners by building upon our trusted relationships. The quality and breadth of our platform enables our partners to succeed in new campaigns and has also enabled them to pursue programs that would otherwise not be pursued due to technical challenges. In addition, collaboration between our scientists and partners has expanded partners&#8217; usage to other offerings within our technology platform, such as bispecific, screening, and antigen technologies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Increase the number of our partnerships</span></span>.&#160;&#160;&#160;&#160;We intend to forge new partnerships with pharmaceutical and biotechnology companies focused on antibody development. We plan to continue to gain new customers through increased business development activities, and through continued technological expansion. We also intend to increase the number of partnerships with smaller early-stage biotechnology companies by offering flexible deal structures and offerings. Through continual investment and expansion of our capabilities, we believe we have the opportunity to further enable our partners to capture additional value from our technologies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Further our technological differentiation through intelligent expansion</span></span>.&#160;&#160;&#160;&#160;We employ a methodical and deliberate approach to expanding our technology platform. Serving a broad partner base has provided us a unique insight into the needs and direction of the industry, and we continue to leverage this insight for our decision-making. In recent years, we have successfully integrated a number of technology acquisitions covering antigen generation, additional animal species, deep screening capabilities, and ion channel expertise. We intend to continue to invest in enabling technologies and evaluate strategic technology acquisitions to broaden our capabilities in the antibody discovery continuum. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Drive partner adoption through a customizable and flexible offering</span></span>.&#160;&#160;&#160;&#160;We meet our partners&#8217; specific needs by offering access to all or certain components of our technology platform. Some partners prefer integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> discovery capabilities, while others prefer to use our technologies within their own labs. This flexibility not only provides value to our partners, but it allows for greater scalability of our business since we do not have to build capacity for partners that prefer to use some of their own resources in the process. This approach helps increase the partnership funnel and provides an initial forum for us to expand our relationship moving forward. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Key Competitive Strengths </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following capabilities and competitive strengths will enable us to become the partner of choice for antibody discovery: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">A discovery platform with a track record of success</span></span>.&#160;&#160;&#160;&#160;As of September&#160;30, 2022, our partners had generated 25&#160;unique antibodies using our platform that our partners have progressed into the clinic, of which 22 are in clinical trials for initial marketing approval and three have been approved for marketing in one or more markets. We believe that clinical success, including regulatory approval, has demonstrated our platform&#8217;s capability to successfully discover antibodies and reduced the technical risk associated with our technology, which may lead to new partnerships and expansion of existing </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
partnerships. In addition, our large portfolio of 282 active partnered programs demonstrates our successful track record of partnering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">A complete antibody discovery solution, leveraging proprietary and differentiated technologies</span></span>.&#160;&#160;&#160;&#160;We have built a cutting-edge <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> antibody discovery solution using <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> genetic engineering technologies. Our technology platform includes a suite of next-generation transgenic animals, computationally powered antigen design, high-throughput microcapillary single-cell analysis, next-generation sequencing, proprietary assays and bioinformatics. Our <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> solution allows us to efficiently generate and deliver lead antibodies for our partners&#8217; development efforts. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Proprietary Biological Intelligence that is designed to yield one of the industry&#8217;s most diverse set of high-quality antibodies</span></span>.&#160;&#160;&#160;&#160;Not all genetically engineered antibody discovery technologies are created equal. Each host animal provides a distinct immune response profile, and we believe the availability of multiple species provides an increased probability of success to find the ideal therapeutic candidate. Our animals have been genetically modified to produce naturally optimized, high-quality, antibodies with human sequences. Our technologies were developed by industry leaders in genetic engineering to elicit strong immune responses not only to biologically validated targets but also to the most difficult targets. Our team of world-renowned genetic engineers continue to work on next-generation transgenic animals to address industry challenges. To our knowledge, we are the only four-species platform with a transgenic rat, mouse, and chicken, as well as cow antibody humanization technology. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Rapid deep sequencing of immune repertoires.</span></span>&#160;&#160;&#160;&#160;Our xPloration and GEM technologies can screen tens of millions of cells and recover thousands of antibody-secreting B cells for further analysis in a matter of hours. Our technologies generate multidimensional profiling data on a single-cell level that provides higher resolution. To our knowledge, xPloration has the industry&#8217;s highest screening and recovery throughput of single-cell deep profiling and sorting platforms. This throughput enables us to capture a significant portion of the antibody repertoire, including rare cells that might be missed with traditional or competing systems. We believe these technologies combined with our OmniAb transgenic animals reduce timelines, costs and technical risk associated with traditional antibody generation methods. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Ion channel target capabilities.</span></span>&#160;&#160;&#160;&#160;We have extensive biological capabilities focused on ion channels and transporters, along with an established track record in novel drug discovery from screening to lead optimization. These capabilities provide novel reagent generation and proprietary assays that can support OmniAb antibody discovery programs and other therapeutic modalities which can be accessed by partners as part of the OmniAb Technology Platform when pursuing targets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Diversified and scalable business model.</span></span>&#160;&#160;&#160;&#160;Our business is built on the success of our partners and the strength of our technology. Our business applies to a broad universe of potential partners and aligns with their economic and scientific interests. Furthermore, our technologies are modular whereby each step feeds into the next, creating a complete and scalable solution. Certain of our technology can also be used directly by our partners, enhancing the flexibility of our offerings. We believe this capital-efficient model allows us to build a diversified portfolio of royalty streams that reach far into the future therapeutic antibody market. Because we focus on improving the process of drug discovery, we will continue to make critical investments in technology that benefit the entire industry. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Robust IP portfolio with multiple long duration patent families.</span></span>&#160;&#160;&#160;&#160;Our patent portfolio reflects our innovative position and <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> capabilities in antibody discovery, including antigen design, transgenic animals, microcapillary single-cell screening, and ion channel assays. As of November&#160;19, 2022, we have 324 issued patents with expiry dates to 2039, and 169 pending patent applications worldwide. Our license agreements with our partners are often structured with royalties that are linked to the patents for the antibodies discovered using OmniAb, thereby creating royalty rights that extend longer than our current technology patent coverage. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Industry Background </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Antibodies: 500 Million Years of Immune System Evolution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibodies are blood proteins produced by the adaptive immune system in response to a specific foreign antigen. Antibodies bind to substances which the body recognizes as foreign, such as bacteria, viruses, cancer cells, and proteins in the blood. Antibodies can also be used to target cell surface proteins critical to biological functions and disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system creates antibodies through a process of random shuffling of DNA fragments known as V(D)J recombination. During this process two separate genes, referred to as the heavy and light chain, are assembled to create a <span style="white-space:nowrap">Y-shaped</span> antibody protein. The shuffling of these DNA fragments, as well as random DNA insertions, deletions and edits, results in over 100 trillion different antibody possibilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any one time, the human body typically has approximately one billion different antibodies circulating in the bloodstream. Each antibody is created by one immune B cell. When antibody expressing B cell binds to an antigen, the B cell quickly proliferates and differentiates into a family of closely related cells producing slightly differentiated antibodies. This iterative process preferentially selects antibodies that are naturally optimized to be most effective in neutralizing the specific antigen. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This process, referred to as <span style="font-style:italic">in vivo </span>affinity maturation, has evolved over 500&#160;million years to naturally select antibodies that are optimized for their intended function. Antibodies discovered from natural immune systems generally have favorable therapeutic characteristics, such as high specificity, limited <span style="white-space:nowrap">off-target</span> toxicity, superior immune stimulation, and the ability to modulate half-life circulation in serum. Despite <span style="white-space:nowrap">man-made</span> technologies that try to imitate the natural selection process, over 90% of approved therapeutics are derived from natural immune systems. Our OmniAb transgenic animals take advantage of the immune system&#8217;s ability to produce high-quality antibodies, and have been genetically modified so the antibodies generated have human sequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The evolutionary divergence of different species has resulted in some animals developing unique mechanisms that increase their immune system effectiveness to certain antigens. Each species taps a signature combination of antigen recognition, diversification mechanisms, and distinct structural features that support survival in the face of persistent exposure to evolving environmental threats. Our four-species platform harnesses these characteristics, while maintaining the human genetic sequences needed to generate diverse pools of high-quality, fully-human therapeutic antibodies that fit almost any discovery campaign. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market Opportunity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to <span style="font-style:italic">Vaccines</span> journal, antibodies are among the fastest growing class of drugs and are used across many therapeutic areas, including oncology, inflammation and neurodegeneration. EvaluatePharma data indicates that monoclonal antibodies have represented the majority of the top 10 bestselling drugs over the last five years. In 2021, approved antibody-based therapeutics accounted for over $215.0&#160;billion in sales, according to data published by La Merie Publishing. Also according to La Merie Publishing, in 2021, 49 antibody therapeutics reached blockbuster status with sales higher than $1.0&#160;billion, up from 41 antibodies in 2020. Furthermore, Fatpos Global estimates that antibody-based therapeutic sales are expected to grow to approximately $365.0&#160;billion by 2030. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite advances in other therapeutic modalities, investment in antibodies has accelerated over the past decade, which has translated into clinical productivity and ultimately new drug approvals. According to data from the Antibody Society, the number of antibodies in the clinic has increased at an estimated 11% CAGR from approximately 500 in 2015 to approximately 950 in 2021. The expansion of clinical development has led to an accelerating pace of regulatory approvals as depicted in Figure 3 below. The FDA approved the first therapeutic antibody in 1986. By 2015, the FDA approved its 50th antibody, and 6 years later in 2021, approved its 100th antibody. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 2: Antibody Sales (US and EU) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g71w52.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Source: Fatpos Global, Global Next-Generation Antibody Therapeutics Market Report: 2019-2030, March&#160;11, 2021; La Merie Publishing, 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars&#160;&amp; Other Biologics, March&#160;11, 2021.) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 3: Antibody Regulatory Approvals (FDA and EMA) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g93t94.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Source: The Antibody Society Database of Antibody Regulatory Approvals, December&#160;31, 2021.) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much of the success of antibodies as a therapeutic class is attributable to their favorable qualities relative to other therapeutic modalities. Antibodies can offer high affinity, potency and specificity, limited <span style="white-space:nowrap">off-target</span> toxicity, low immunogenicity, superior immune stimulation and the ability to modulate half-life circulation in serum. Industry statistics suggest that these properties have also translated to an increased probability of success relative to other modalities. According to PharmaIntelligence&#8217;s Clinical Development Success Rates and Contributing Factors 2011-2020, which summarizes a study of over 9,000 drugs being developed for the U.S. market, monoclonal antibodies and monoclonal antibody conjugate drugs have had an approximately 12% likelihood of receiving market authorization from the start of Phase 1 clinical trials. This is higher than the success rate of small molecule modalities, which had an approximately 8% likelihood of receiving market authorization from the start of Phase 1 clinical trials in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business model allows us to participate in the high growth antibody therapeutic market through technology access fees and services fees, as well as downstream success-based payments in the form of milestones and royalties on therapeutic candidates that have been discovered using our platform. As of September&#160;30, 2022, we had 68 active partners with 282 active programs using the OmniAb technology, 25&#160;OmniAb-derived antibodies in clinical development by our partners, and three approved products of our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Existing Industry Limitations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite industry momentum which has resulted in an overall increase in the number of antibody therapeutic approvals per year, drug discovery and development has become increasingly fragmented, outdated and <span style="white-space:nowrap">non-robust.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reduced large pharmaceutical investment has intensified fragmentation and created ripple effects for small biotechnology companies due to reduced investment in enabling technologies. While many of these biotechnology companies bring a focused approach to science that prioritizes nimble movement and efficient decision making, their biological hypotheses are often tested utilizing suboptimal antibody discovery methods due to reliance on legacy technologies. Meanwhile, many larger companies have also continued to rely on legacy technologies for many processes related to antibody discovery, often due to the inability to selectively integrate newer technologies at their facilities or because the benefits of technological updates are limited by outdated workflows. Key examples of the frequently utilized legacy technologies and their shortcomings include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Humanized wild-type antibodies</span>.&#160;&#160;&#160;&#160;This process has been utilized over the last 25 years and attempts to capture the benefits of natural antibody optimization. However, the process that converts the animal antibody into a human format introduces conformational changes that impact the desired therapeutic properties of the antibody and may cause immunogenicity concerns. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">First generation transgenics</span>.&#160;&#160;&#160;&#160;Earlier transgenic systems demonstrated <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> and did deliver therapeutic antibodies, however it became apparent that flaws in transgene design limited the robustness of immune responses from these animals. In addition, other technical issues, legacy agreement structures and industry consolidation presented further obstacles for the access to and use of the early platforms. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Display technology</span>.&#160;&#160;&#160;&#160;The commonly utilized technologies were invented over 35 years ago and do not benefit from in vivo affinity maturation and optimization. Some display libraries are engineered to capture benefits from natural immune systems, however they still carry limitations including loss of the heavy and light chain pairing, need for high quality soluble antigen, and they often require downstream sequence optimization for high production in a mammalian manufacturing cell line. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Hybridoma screening</span>.&#160;&#160;&#160;&#160;This method has been utilized for over 45 years and results in a loss of over 99% of antibody diversity, drastically reducing the pool of potential therapeutic candidates to choose from. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a significant and growing disparity between today&#8217;s widely used legacy antibody discovery tools and the latest advances in antibody discovery technologies. Despite the increased investment into antibody drug development, there is often a slow adoption of newer technologies due to the lack of flexibility integrating these technologies into existing workflows. These existing industry approaches are burdened with critical disadvantages including low antibody diversity, lengthy discovery timelines, limited functional parameter data, excess costs and lack of flexibility. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OmniAb technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. This platform aims to overcome the existing industry challenges and provides our partners access to antibody candidates based on unparalleled biological diversity that are optimized through tight integration across a full range of discovery technologies. These technologies include computationally powered antigen design, transgenic animals, high-throughput microcapillary single-cell analysis, next-generation sequencing, proprietary assays and bioinformatics. We believe that by providing our partners with access to these technologies we will ultimately shorten the discovery timelines, reduce costs, and increase the probability of success. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investments in our technologies are methodical and deliberate, with the goal to continue to provide our partners with the most cutting-edge technologies to solve the biggest challenges in antibody discovery. Our technologies are modular and sequential, creating a complete and scalable solution. These technologies also can be individually integrated into our partners internal or external workflows, which allows us to provide our partners with both integrated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> discovery solutions and highly customizable, <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> offerings, which address critical industry challenges and provide our partners with optimized antibody discovery </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solutions. As depicted below, our technology platform is a suite of integrated technologies designed to discover a wide range of high-quality therapeutic antibodies that leverage the inherent diversity produced by transgenic animals and high throughput single-cell screening. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt; margin-left:0%;text-align:center">


<img src="g305908g72q97.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technologies within the OmniAb platform improve the productivity and efficiency of each step of the discovery process: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Create Diverse Antibody Pools</span></span>.&#160;&#160;&#160;&#160;We believe generating large and diverse pools of high-quality antibodies increases the chances of discovering the antibody with the most desirable therapeutic characteristics. At the heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, technology that we own. Our animals have been genetically modified to produce a large number of naturally optimized, high-quality, antibodies with human sequences. We offer the industry&#8217;s only four-species platform to address a wide range of biological challenges facing our partners in their antibody discovery efforts. We can pair our Biological Intelligence with computational antigen design to generate robust antibody responses to biological targets, including but not limited to difficult and complex targets such as ion channels, GPCRs, transporters, and other transmembrane proteins. Our antigen design technology includes transmembrane and cell-surface protein technology that we own or exclusively license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Screen Antibody Candidates</span></span>.&#160;&#160;&#160;&#160;Our proprietary xPloration microcapillary technology, which we own or license, and GEM technology, which we own, screen antibody pools at a single-cell level to quickly identify antibodies in as little as a few hours, saving weeks compared to traditional technologies. xPloration screens tens of millions of immune cells on multiple parameters, then leverages AI to analyze immense amounts of phenotypic data to automatically select and rank thousands of promising therapeutic candidates. Our industry-leading throughput allows for the discovery of rare antibodies that may otherwise be missed with traditional technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Identify the Right Antibody</span></span>.&#160;&#160;&#160;&#160;Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody for a particular target profile. Antibody candidates identified through our screening technologies are further characterized through a cascade of performance assays. The data from multi-parameter screening and performance assays is used in combination with bioinformatics to analyze the antibody repertoire and enable our partners to select the right antibody. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Create Diverse Antibody Pools </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe generating large and diverse pools of high-quality antibodies increases the chances of discovering the antibody with the most desirable therapeutic characteristics. We have assembled a suite of transgenic animal and antigen technologies that are designed to generate a large and diverse pool of high-quality antibodies. The heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation. We combine our transgenic animals with proprietary antigen technology and immunization techniques to generate high-quality antibodies for even the most difficult biological challenges. The various OmniAb animal technologies are depicted in Figure 4 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 4: OmniAb Animal Technologies </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g77s33.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that natural antibodies are superior to other antibody generation methods due to the immune system&#8217;s ability to naturally select quality, and already optimized antibodies through a process that has evolved over 500&#160;million years. According to the TAB Database of Therapeutic Antibodies, as of December&#160;30, 2021, over 90% of all approved antibody drugs had been derived from natural immune systems, which we believe is due to their superior drug-like properties. The evolutionary divergence of different species has resulted in some animals developing unique mechanisms that increase their immune system effectiveness to certain antigens. Our four-species platform harnesses these characteristics, while maintaining the human genetic sequences needed to generate diverse pools of high-quality, fully-human therapeutic antibodies that fit almost any discovery campaign. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team of world-renowned scientists use a variety of gene editing techniques to alter the genomes of animals to produce antibodies that use human sequences, while retaining the animal&#8217;s ability to illicit a strong immune response to antigen. We then set up breeding colonies of our genetically modified animals for use in partner&#8217;s discovery efforts. While there are several options when considering transgenic mice, OmniAb is the only four-species platform, with the world&#8217;s only transgenic mouse, rat, chicken, and cow antibody humanization technology. Each animal has unique characteristics which address key challenges in antibody discovery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pair our animal technologies with antigen design to further enhance the robust antibody repertoires for antibody campaigns. Ab Initio offers antigen design technology, which we own or exclusively license, for production of challenging therapeutic targets. Most drug targets are membrane proteins which are inherently unstable and challenging to investigate. The technology produces full-length membrane proteins, including <span style="white-space:nowrap">multi-Tm</span> proteins, such as ion channels and GPCRs, the largest class of therapeutic drug targets. Our antigen production works in tandem with our therapeutic antibody discovery platform, providing access to high-quality membrane protein antigens for immunization campaigns. Guided by molecular modeling and protein design capabilities, our antigen design team manages the cloning, expression, purification, reconstitution, and quality control of purified native-conformation membrane proteins for immunization and screening purposes. Antigens </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can be prepared in particular conformations with protein or small molecule conformational chaperones. The range of accessible antigen formats improves the probability of success in generating robust immune response with desired specificities from any of the OmniAb animals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collectively, we believe our transgenic animal and antigen technologies provide the foundation for a successful drug discovery campaign. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Screen Antibody Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finding the best antibody means finding the best antibody producing cell. Each antibody is made by an antibody producing cell, known as a B cell, that contains the genetic sequence that encodes its unique antibody. When presented with an antigen, the immune system will respond by creating millions of different antibodies and preferentially selecting antibodies that best neutralize the perceived threat. These large antibody pools can present a challenge in identifying the antibodies with the most optimal candidate drug profiles from millions of possibilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the enormous number of different antibodies generated, individual B cells are microscopic, generate only a miniscule amount of antibody protein, and are difficult to grow in culture conditions. The amount of antibody produced by an individual B cell is too small to be tested directly in conventional <span style="white-space:nowrap">96-well</span> plates. Because of this, scientists have relied on the hybridoma method for antibody discovery for the past 45 years. During this process, B cells are fused with a certain type of cancer cell, which immortalizes the B cell allowing them to be grown into sufficient quantities for the antibodies to be tested in conventional <span style="white-space:nowrap">96-well</span> plates. This process takes approximately 8 to 12 weeks, and is extremely inefficient, leading to losses of 99.9% of the relevant immune diversity from the beginning of the process. Despite these significant limitations, hybridoma remains a commonly used technology in the industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We analyze B cells individually using microcapillaries and industry leading throughput with our proprietary xPloration and GEM platforms. The xPloration platform is an <span style="white-space:nowrap">AI-powered</span> single-cell microcapillary platform that provides multi-dimensional profiling data on tens of millions of cells. Our proprietary technology uses a chip with 1.5&#160;million microscopic capillaries that are loaded with B cells. Chips are processed through automated imaging, then <span style="white-space:nowrap">AI-powered</span> algorithms analyze and identify thousands of B cells that express antibodies with the desired characteristics. Our AI algorithms are empowered by the industry leading LandingLensTM platform developed by Landing AI. Using technology we own or license from Stanford University, thousands of <span style="white-space:nowrap">AI-selected</span> B cells are recovered within minutes using lasers that break the capillary forces and drop the B cell into wells for sequencing. The whole process can screen up to 40&#160;million cells and recover thousands of paired sequences all within a few hours. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the xPloration platform represents industry-leading screening and cell recovery. The screening throughput enables the discovery of rare cells that would be missed with other systems that only evaluate a small sliver of the repertoire. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Identify the Right Antibody </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both xPloration and GEM identify potentially thousands of therapeutic antibody candidates which must then be narrowed to a small number of lead candidates. Our OmniAb team is flexibly positioned to work directly with partners to develop work plans and screening cascades that are customized to their antibody design specifications. We also assist our partners in their own downstream activities to ultimately find the right antibody for further development. Paired chains are cloned in high throughput and expressed as recombinant antibodies in a variety of format options for confirmation and further characterization. Assays include high throughput epitope binning and kinetics analysis, and target-specific functional assays. Functional data combined with the large amounts of data generated from xPloration provide a comprehensive view of the immune response and allow our partners to select antibodies with even the most stringent design criteria. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Often the right antibody must be further modified to enhance certain desired characteristics in a process known as antibody optimization. Introducing changes to the DNA sequence that enhance one characteristic, can be detrimental to others. This results in a process that is lengthy, costly, and reliant on <span style="white-space:nowrap"><span style="white-space:nowrap">trial-and-error</span></span> experimentation. We believe many of these challenges are averted by using natural immune systems that have evolved over 500&#160;million years to naturally selects antibodies that are optimized for their intended function. Our antibody pools are large, diverse, and full of high-quality antibodies that provide our partners with a significant number of fully optimized leads. In the most challenging discovery programs, our team can provide hit expansion through xPloration deep dives and/or NGS data mining to identify variants of confirmed clones with improved affinity, improved manufacturability, or other favorable characteristics, while avoiding the time and technical risk associated with traditional optimization methods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In situations where characteristics need to be improved beyond what is available in the repertoire, we can filter sequence variants through a battery of in silico evaluations to remove sequences with liabilities or potential developability problems, and potentially improve potency. Optimized sequences are then <span style="white-space:nowrap">re-expressed</span> in antibody format of choice and performance is further evaluated in analytical and bioassay evaluation to create a ranked list of potential leads. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Partnership Business Model </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We partner with pharmaceutical and biotechnology companies that vary in size, clinical stage, geography and therapeutic focus. Our partners have access to wide repertoires of antibodies and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> screening technologies designed to enable efficient discovery of next-generation novel therapeutics and deliver high-quality therapeutic antibody candidates for a wide range of diseases. Our partners can select a target and define the antibody properties needed for therapeutic development or use certain of our technologies directly in their own laboratories. We typically structure our license agreements with each partner so that they are indifferent to the species used to generate antibodies. To the extent our partners request us to provide additional discovery work beyond screening, we capture additional fees either in terms of upfront payments or downstream via additional milestones or royalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license agreements with partners typically include: (i)&#160;upfront or annual payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to take advantage of the upside of approved antibody therapeutics. As of September&#160;30, 2022, we had 68 active partners, with 282 active programs. Our license agreements typically include annual reporting requirements which provide us updates from our partners on the status of their programs. In addition, we track our active partnered programs by reviewing our partners&#8217; public announcements and maintaining close communications with our partners to the extent possible. In some instances, a partner may not publicly announce milestones in which case we are generally dependent on our partners to track and disclose milestones at the time of achievement. Our license agreements are typically terminable by our partners without penalty with specified notice. However, all milestone payments and royalties survive termination and continue with respect to any OmniAb-derived antibodies. The royalty term is typically the longer of 10 years from the first commercial sale or through the last expiration in any jurisdiction of the patents covering such OmniAb-derived antibody. We believe the long-term value of our business will be driven by downstream royalty payments. Our typical royalty rates for antibody discovery contracts are currently in the <span style="white-space:nowrap">low-</span> to <span style="white-space:nowrap">mid-single</span> digits, and can vary depending on other economic terms in the agreement. Although our license agreements typically include technology access fees, milestone payments and royalties, each agreement is negotiated separately and as a result, the financial terms and contractual provisions vary from agreement to agreement. By providing a full suite of antibody discovery technologies with streamlined economics, we believe we offer an attractive option to industry stakeholders that are often forced to pay multiple royalty obligations for enabling technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 5 below shows the growth in active partners, active programs and clinical programs since our acquisition by Ligand in January 2016 and the number of programs that have entered clinical trials. As of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September&#160;30, 2022, there were 282 active antibody programs. An active program is counted once an antigen is introduced into our animals and includes active clinical programs and approved products. An active partner is one that has an active program or has executed a license agreement in advance of initiating an active program. Active clinical programs represents the number of unique programs for which an IND or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development. Approved products represents an OmniAb-derived antibody for which our partner has received marketing approval. We do not include academic partners with a license to the OmniAb platform in our active partner count. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 5: Active Partners, Active Programs, and Active Clinical Programs and Approved Products </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g02y03.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left"><span style="font-style:italic">*</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Active programs not tracked prior to acquisition of Open Monoclonal Technology, Inc. in January 2016. </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our partners&#8217; active clinical programs include monoclonal and bispecific antibodies discovered using OmniRat, OmniMouse, OmniFlic, or OmniChicken and target a range of therapeutic indications including oncology, immunology, and metabolic disorders. As our partners&#8217; discovery and preclinical programs continue to mature, we expect the number of OmniAb-derived antibodies in clinical development by our partners to expand to include antibodies discovered using our newer OmniClic and OmniTaur technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Technology </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foundational technologies that power our OmniAb Technology Platform are described below: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniRat </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniRat was launched in 2012 and is the first example of a successful <span style="white-space:nowrap">knock-out</span> of the endogenous rat immunoglobulin genes coupled with transgenesis of human counterparts. OmniRat produces a diverse repertoire of antibodies with human idiotypes and immunological characteristics that are comparable to antibodies from wildtype animals. OmniRat provides cross-reactivity against a mouse, which may streamline preclinical development by obviating the need for surrogate antibodies, and thereby may decrease clinical risks. The OmniRat has been engineered to contain functional recombinant immunoglobulin loci, use genes with similar </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
frequency as humans, and rearrange functional human immunoglobulin genes. The animals are bred on a mixed genetic background to further diversify the antibody repertoire and feature different light chain isotypes which is designed to provide flexibility around partners&#8217; needs and technology. The OmniRat shows high expression, normal human <span style="white-space:nowrap">CDR-H3</span> length distribution, and normal hypermutation and affinity maturation. As of September&#160;30, 2022, there are three approved OmniRat-derived antibodies and 16 additional antibodies in clinical development by our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniMouse </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniMouse was launched in 2014, and we designed this technology using the same transgenes as OmniRat to deliver fully human antibodies utilizing standard mouse-based protocols. OmniMouse expands the sequence diversity of our <span style="white-space:nowrap">rat-based</span> platforms (OmniRat and OmniFlic), offering easy conversion from wildtype mice while utilizing the same protocols. OmniMouse produces a diverse repertoire of antibodies with human idiotypes and provides a complementary murine system for additional sequence diversity. Like OmniRat, OmniMouse is currently bred to generate a mixed genetic background to further increase sequence diversity. For partners who prefer to work with mice, OmniMouse provides a rapid solution to deliver fully-human antibodies. As of September&#160;30, 2022, there are two OmniMouse-derived antibodies in clinical development by our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniChicken </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniChicken was launched in 2016 and is the first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires for the discovery of therapeutic antibodies. OmniChicken and OmniClic, our bispecific transgenic chicken platform, offer affinity matured antibodies in an evolutionarily distant chicken host environment. As depicted in Figure 6 below, more than 300&#160;million years of evolutionary distance drives divergence between mammalian and avian orthologs, which are genes in different species that evolved from a common ancestral gene by speciation. This evolutionary distance enables generation of a diverse repertoire of antibody panels to highly conserved therapeutic target antigens that are not immunogenic in mammals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniChicken features a high level of functional diversity, with sequence diversity focused on the CDR regions, while maintaining conserved, well-validated human framework regions. OmniChicken antibodies bind to diverse epitopes on human targets with high affinity, and therefore we believe offer excellent developability profiles. As of September&#160;30, 2022, there is one OmniChicken-derived antibody in clinical development by our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6: OmniChicken Yields Greater Antibody Diversity </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g17b02.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Due to the phylogenic evolutionary distance between humans and chickens, the OmniChicken can generate an immune response against targets that are not immunogenic in mammals. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniTaur </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniTaur was launched in 2020 and provides <span style="white-space:nowrap">cow-derived</span> ultralong <span style="white-space:nowrap">CDR-H3</span> antibodies with a human framework. <span style="white-space:nowrap">CDR-H3</span> is the region of the antibody that makes primary contact with the target and ultralong <span style="white-space:nowrap">CDR-H3</span> antibodies have been shown to bind to targets with deep or cryptic epitopes. We believe these antibodies could be leveraged for a variety of targets with cryptic epitopes which may be difficult to reach with conventional antibodies, including channel blockers, ion channels, transporters, and viral proteins. As depicted below in Figure 7, OmniTaur features a fully human variable framework, and a <span style="white-space:nowrap">CDR-H3</span> region, which we believe makes OmniTaur antibodies well suited for therapeutic development. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 7: Cow Antibodies Have Unique Characteristics for Binding Cryptic Epitopes </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g76r13.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniChicken with <span style="white-space:nowrap">cow-inspired</span> properties (in development) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently developing a next generation OmniChicken with <span style="white-space:nowrap">cow-inspired</span> <span style="white-space:nowrap">CDR-H3</span> motifs. If successful, this will combine the OmniChicken&#8217;s ability to generate antibodies against highly conserved targets, with OmniTaur&#8217;s ability to target highly cryptic epitopes. We believe these combined benefits may enable antibody discovery for a number of high-value targets that are undruggable with today&#8217;s technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Bispecific antibody platforms </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer the only rat and chicken platform for generation of bispecific antibodies. Although bispecific antibody drugs have been researched for more than 30 years, only a limited number of bispecific antibodies have achieved regulatory approval. There are very few successful examples of large-scale manufacturing for a bispecific antibody, and the &#8220;common light chain format&#8221; is a technology designed to simplify and improve the efficiency of the production and purification of a whole IgG&#8212;type bispecific antibody. Our bispecific antibodies are IgG antibodies, with a common light chain and different heavy chains. Common light chain antibodies allow for combining targeting arms for bispecific and multi-specific antibodies without the complexity of correct heavy and light chain pairing. Using this IgG format, the bispecific function can be introduced while maintaining the natural shape of the antibody. Both OmniFlic, our bispecific rat, and OmniClic, our bispecific chicken, express the same light chain which enables the formation of bispecific therapeutics through the combination of antibodies generated from either platform. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the characteristics of our platforms offer several advantages over current generation bispecific antibody technologies. To generate bispecific antibodies, we conduct parallel immunizations with two antigens and then engineer the two targeting arms of the antibody as depicted in Figure 8 below. We then use functional screening to identify heavy chain pairs with balanced affinities for their targets and support robust purification of the bispecific antibodies for manufacturing purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniFlic (Bispecific rat platform) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniFlic was launched in 2014 and is a fixed light-chain variation of OmniRat. The OmniFlic transgenic rat expresses a fixed <span style="white-space:nowrap">VK3-15</span> light chain. OmniFlic features the same heavy chain transgene as OmniRat, which </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generates diverse repertoires upon immunization. OmniFlic is a fixed light-chain transgenic rat developed to facilitate the generation of bispecific antibodies. As of September&#160;30, 2022, there are three OmniFlic-derived antibodies in clinical development by our partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniClic (Bispecific chicken platform) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniClic was launched in 2019 and is a common light-chain transgenic chicken developed to facilitate the generation of bispecific antibodies. OmniClic was engineered to focus sequence diversity on the CDRs of the VH domain. OmniAb expresses the <span style="white-space:nowrap">VH3-23</span> and <span style="white-space:nowrap">VK3-15</span> light chains, with a modified light chain transgene to minimize diversification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 8: Bispecific antibody platforms </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g86l12.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bispecific antibodies are IgG, antibodies, with a common light chain and different heavy chains. To generate these antibodies, we conduct parallel immunizations with two antigens and then engineer a bespoke version of the transgenic platform to generate a diverse set of heavy chains and ultimately bispecific therapeutic antibodies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">HCO/OmnidAb</span></span><span style="font-family:Times New Roman"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">&#8482;</sup></span><span style="font-weight:bold"><span style="font-style:italic"></span></span></span><span style="font-weight:bold"><span style="font-style:italic"> chicken (in development) </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniAb scientists are currently developing a next generation OmniChicken designed to express antibodies comprised of principally heavy chains, without the light chains found in conventional IgG antibodies, also referred to as heavy chain only (HCO) antibodies. In addition to other unique benefits and uses, HCO antibodies, similar to common light chain antibodies, can be used to generate bispecific and multispecific antibodies while avoiding the complexity of correct heavy and light chain pairing. HCO antibodies resemble camelid antibodies, which are smaller than conventional antibodies, allowing for the targeting of cryptic epitopes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Screening Technologies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the xPloration platform offers greatly improved screening and cell recovery compared to other leading, commercially available single-cell multi-dimensional profiling technologies. The xPloration screening throughput is designed to enable the discovery of rare cells that would likely be missed with other systems that are only able to evaluate a small sliver of the repertoire. We pair this with next-generation sequencing to further expand the repertoire for potential hit expansion downstream if necessary. Our laser-based recovery process retains heavy/light chain paring of the antibodies, which directly provides potential lead antibody sequences bypassing the need for pairing algorithms that attempt to reconstruct the repertoire. The considerable throughput combined with retaining heavy/light chain antibody pairing can cut weeks or months of traditional discovery workflows. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For certain development programs, we leverage our proprietary GEM technology. The GEM technology incorporates many of the same principles of the xPloration platform by isolating and performing multi-dimensional profiling of single B cells from an immunized animal. Small droplets encapsulate single B cells and Reporters that present the target antigen on the surface of a bead or cell. Secreted antibodies from the B Cell </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diffuse locally in the microenvironment where they can bind to Reporters, which in turn can be detected with a fluorescent probe. Using different types of Reporters in the microenvironment can generate a multi-parameter binding profile of each antibody. Antigen specificity is determined by colocalization of signal with alternative bead and/or cell types. Millions of GEMs can be examined in parallel. GEMs containing B cells and antibodies of interest can be harvested, cloned, and expressed as recombinant antibodies for further characterization studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both xPloration and GEM are compatible with a wide variety of assay formats, including cell surface binding assays, reporter cell stimulation, multiplex target binding, and cross-reactivity screening. These assays enable us to tackle high value, challenging targets, such as ion channels and GPCRs. High throughput <span style="white-space:nowrap">B-cell</span> screening is particularly valuable within the OmniAb ecosystem because of our unique animal offerings. While mouse hybridoma techniques have been available for decades, the hybridoma generation methods for other species including chickens, and cows is not available. As such, <span style="white-space:nowrap">B-cell</span> screening with OmniAb&#8217;s platforms enable the discovery of unique antibodies from any host systems. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 9: xPloration Core Components </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g11i99.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Next generation xPloration (in development) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniAb scientists and engineers are currently developing a next generation xPloration platform as depicted in Figure 10 below. We believe this platform has the potential to further expand our position as the industry leader in speed, throughput, reliability, and ease of use. The next generation xPloration is designed as a deployable instrument that could give certain strategic partners or collaborators the option to access xPloration in their own labs for their OmniAb discovery efforts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 10: Prototype Next Generation xPloration Platform </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g73a33.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ion Channel Differentiated Capabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ion channels and transporters are key components in a wide variety of biological processes that involve rapid changes in cells and have broad therapeutic applicability across multiple therapeutic areas including oncology, metabolic disease, pain, neurological diseases, infectious diseases and others. Ion channels make particularly challenging drug targets due to (i)&#160;difficulty with antigen purification (ii)&#160;poor immunogenicity (iii)&#160;high homology with rodents used in immunization campaigns and (iv)&#160;small binding regions with the majority of protein embedded in cell membranes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to these challenges in developing effective therapeutics, patients suffering from ion channel and transporter related diseases are severely underserved. Icagen has extensive biological capabilities focused on ion channels and transporters, and decades of experience in novel drug discovery from screening to lead optimization, with an active set of big pharma discovery and asset-based partnerships. The differentiated core capabilities at Icagen can provide novel reagent generation and proprietary assays that can also support antibody discovery programs and can be accessed by partners when pursuing ion channels and transporter targets. We believe we are well positioned to provide the tools necessary to generate and discover antibodies and small molecules to target ion channel and transporter targets. Our computational antigen generation technology has been validated in successfully generating, stabilizing, and purifying antigen for these targets and our four-species transgenic animal platform is validated in successfully generating antibodies for poorly immunogenic, high homology, and cryptic targets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the drug design challenges, it is difficult to develop effective functional assays to test potential therapeutics. OmniAb&#8217;s proprietary Icagen ion channel platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and in silico and computational chemistry applications to enable the discovery of ion channel targeting therapeutics. We believe this suite of technologies provides and differentiated capability for advancing high value ion channel and transporter drug discovery programs regardless of modality including small molecules, mono-, <span style="white-space:nowrap">bi-and</span> multi-specific antibodies, and antibody-drug conjugates (ADCs). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Investing in Differentiated Technology </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We built the OmniAb technology platform through acquisition, investment, and innovation. We acquired OMT in January 2016, Crystal Bioscience in October 2017, Ab Initio in July 2019, Icagen in April 2020, xCella Biosciences in September 2020 and Taurus Biosciences in September 2020. In addition to acquisitions, we have advanced our technology platform through internal investment and innovation. Over the past five years, the OmniAb team has launched new transgenic animals, introduced computational antigen design, expanded internal capabilities in downstream processing, and developed internal data management and bioinformatics software. We have several internal projects in development including multiple new transgenic animals, a next generation high-throughput microcapillary deep screening platform, and a number of undisclosed projects. The key technologies obtained through acquisition are listed below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Acquisition Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Technologies Acquired</p></td></tr>


<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Open Monoclonal Technology (OMT)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">January&#160;2016</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OmniRat</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OmniMouse</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">OmniFlic</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Crystal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">October&#160;2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OmniChicken</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GEM screening</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ab Initio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">July&#160;2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Antigen design</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Icagen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">April&#160;2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Ion channel technology</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">xCella</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">xPloration screening</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taurus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">September&#160;2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">OmniTaur</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Technology in Action&#8212;Selected Case Studies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Partner A:&#160;&#160;&#160;&#160;Emerging Biotech </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Problem</span>:&#160;&#160;&#160;&#160;Partner wanted to generate antibodies against a novel multi-transmembrane target for triple negative breast cancer. All previously-known antibodies for the target could only bind to denatured or fixed form, therefore unsuitable for therapeutic use. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Solution</span>:&#160;&#160;&#160;&#160;Our antigen technology was applied to deliver <span style="white-space:nowrap">mg-scale</span> quantities of purified receptor in native conformation for immunization and screening. We then performed an OmniChicken immunization campaign which led to discovery of a large and diverse panel of fully-human antibodies capable of binding target on live tissues. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Partner B:&#160;&#160;&#160;&#160;Big Pharma </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Problem</span>:&#160;&#160;&#160;&#160;Partner attempted to generate antibodies using internal discovery tools towards a growth factor target that is highly conserved among mammals. The human version of the target is <span style="white-space:nowrap">non-immunogenic</span> in other rodents, therefore no titer was achieved despite numerous immunization attempts by the partner. Additionally, the genetic knockout of target gene attempted in mice was lethal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Solution</span>:&#160;&#160;&#160;&#160;An OmniChicken immunization campaign led to robust titers and diverse antibody panels. &gt;90% of sequences recovered had excellent developability profiles based on multi-parameter in silico analysis, and the partner was able to proceed with the program. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Partner C:&#160;&#160;&#160;&#160;Established Biotech </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Problem</span>:&#160;&#160;&#160;&#160;Partner has a history of success in developing antibodies, with a large discovery group and expanding novel biology. The partner needed a flexible, scalable, antibody discovery solution to start dozens of new programs every year to achieve development objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Solution</span>:&#160;&#160;&#160;&#160;OmniAb technologies were transferred to the partner, with an OmniRat breeding colony established. In its own labs, the partner utilizes the OmniAb technology to discover multiple OmniAb antibodies each year, with clinical candidates routinely identified, and currently targeting Phase 1 and 2 data readouts in the next 18 months, and multiple candidates to enter clinical development in the coming years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Outcomes</span>:&#160;&#160;&#160;&#160;As a result of the solutions that OmniAb provided and our expertise in genetic engineering, Partner C entered a deep collaboration for OmniAb to develop next generation rodents, which were tested in parallel with active novel programs. OmniAb wholly owns rights to next-generation animals and can include them in the OmniAb technology offering to other partners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Partner D:&#160;&#160;&#160;&#160;Global Pharma </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Problem</span>:&#160;&#160;&#160;&#160;Partner is an Asia-based global pharma company that is establishing a new and substantial presence in the antibody space with large investment and expansion of its global antibody team. Partner D needed our antibody discovery engine to power their growth in the antibody space. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Solution</span>:&#160;&#160;&#160;&#160;Partner D selected OmniAb as its core technology to feed robust discovery and development efforts. Satisfaction with the relationship resulted in a <span style="white-space:nowrap">three-way</span> collaboration with deep repertoire analysis to rapidly identify best binders for bispecific antibodies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for technologies that enable the discovery and development of therapeutic antibodies, such as ours, is global, characterized by intense competition and subject to significant intellectual property barriers. The solutions and applications offered by our competitors vary in size, breadth and scope, and given the broad promise of antibody therapeutics, we face competition from many different sources, including companies developing single-cell screening technologies, transgenic animals and antibody engineering technologies, using a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. We also face competition from companies who use internal resources and technologies for their discovery capabilities, as well as integrated contract research organizations that use traditional hybridoma, phage, and yeast display technologies in discovery. Due to the significant interest and growth in antibody therapeutics more broadly, we expect the intensity of this competition to increase. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to provide our partners with the most advanced technologies for antibody drug discovery, including antigen design, transgenic animal platforms and single-cell analysis. Many emerging and established life sciences companies have been built around technologies that focus on one or a limited number of these steps. Examples include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in discovery using genetically engineered rodents, we face technical competition from companies that provide access to similar technologies, such as AbCellera Biologics Inc., Ablexis LLC, Alloy Therapeutics, Inc. Crescendo Biologics Ltd., Harbour Antibodies BV, Merus N.V., Regeneron Pharmaceuticals, Inc. and RenBio Inc.; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the field of single-cell screening, we face technical competition from companies that provide access to similar technologies, such as AbCellera Biologics Inc., Berkeley Lights Inc., HiFiBio Inc., and Sphere Fluidics Ltd.; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in ion channel drug discovery, we face technical competition from companies that provide similar technologies, or biological expertise, such as Charles River Labs Inc., Evotec SE, Metrion Biosciences Ltd., and WuXi AppTec. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also face direct business competition from companies that provide antibody discovery services using technologies, such as hybridoma and display. Companies with discovery business models that include downstream payments include AbCellera Biologics Inc. and Adimab LLC. In addition, we compete with a variety of <span style="white-space:nowrap"><span style="white-space:nowrap">fee-for-service</span></span> contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our technology platform. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the risks we face relating to competition, see <span style="font-style:italic">&#8220;Risk Factors</span><span style="font-style:italic"></span><span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">Risks Related to Our Business</span>&#8212;<span style="font-style:italic">The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that patents and other proprietary rights are important to our business. Our practice is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, <span style="white-space:nowrap">know-how,</span> continuing technological innovations and licensing opportunities to develop and maintain our competitive position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents are issued or pending for the technology families described below. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and disclaimers, and patent terms referenced below do not take into consideration such adjustments, extensions, or disclaimers. For each technology family, the patents and/or applications referred to are in force in at least the United States, European jurisdictions, Japan and other jurisdictions as indicated. The patents and patent applications referenced below are in each case, as of November&#160;19, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniAb Technology Platform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OmniAb therapeutic antibody platforms, including OmniRat, OmniMouse and OmniChicken, produce naturally optimized antibodies with human sequences in animals. Our OmniAb antibody platform patent portfolio includes patents and applications obtained upon the acquisition of Open Monoclonal Technology, Inc. in January 2016 and Crystal Bioscience in October 2017. We own patents directed to OmniAb animals and related inventions, including 25 issued patents in the United States, six issued patents in Europe, five issued patents in Japan, three issued patents in China, and counterpart patents granted in other countries. These patents include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">four U.S. patents directed to rodent germ cells, transgenic rodents, methods of generating transgenic rodents, and antibodies produced from transgenic rodents, and foreign counterparts including in Europe, Japan, China, and Canada, all having an expiration date in 2028 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">two U.S. patents directed to our GEM assay, including gel microdrops, their use, and their method of manufacture, and foreign counterparts including in Europe, Japan, and Canada, all having an expiration date in 2029 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seven U.S. patents directed to transgenic animals including chickens, B cells isolated from transgenic chickens, and methods of producing antibodies, all having an expiration date in 2030 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">one U.S. patent directed to avian gonocytes and their method of manufacture, each having an expiration date in 2031 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">three U.S. patents directed to transgenic chickens and chicken germ cells, and foreign counterparts including in Europe and Canada, all having an expiration date in 2032 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">three U.S. patents directed to transgenic chickens, methods of producing antibodies, and isolated antibody-producing cells, all having an expiration date in 2032 without accounting for potentially available patent term adjustments and extensions or disclaimers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">two U.S. patents directed to transgenic rodents, methods of producing antibodies, and chimeric polynucleotides, and foreign counterparts including in Europe, China, and Japan, all having an expiration date in 2033 without accounting for potentially available patent term adjustments and extensions or disclaimers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">one U.S. patent directed to transgenic chickens and methods of producing antibodies having an expiration date in 2036 without accounting for potentially available patent term adjustments and extensions or disclaimers. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also own 15 pending U.S. patent applications, ten pending European patent applications, nine pending Japanese patent applications, four pending Chinese patent applications, and counterpart patent applications pending in other countries. Any patents issuing from these applications are expected to expire between 2028 and 2041, without accounting for potentially available patent term adjustments and extensions or disclaimers. Our partners who use the OmniAb patented technology to generate novel antibodies may be entitled to separate, additional patent protection on such antibodies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Icagen Ion Channel Platform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, we acquired the core assets of Icagen, LLC, an early-stage drug discovery company focused on ion channel and transporter targets. Icagen owns a portfolio of issued patent and pending patent applications directed to <span style="white-space:nowrap">X-ray</span> fluorescence-based detection of binding events and transport across barriers and related inventions, including 23 issued patents in the United States, six issued patents in Europe, eight issued patents in Japan, and three issued patents in China. Icagen&#8217;s portfolio also includes six pending U.S. patent applications and three pending European patent applications. These patents and applications are directed to methods and apparatus. Icagen also owns a pending Patent Cooperation Treaty patent application directed to branched-chain amino acid aminotransferase modulator <span style="white-space:nowrap"><span style="white-space:nowrap">composition-of-matter</span></span> and method of use. The patents and applications in Icagen&#8217;s portfolio are expected to expire between 2023 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">xCella Biosciences </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we acquired xCella Biosciences. xCella&#8217;s technology includes a microcapillary platform that can screen single B cells for specificity and bioactivity, which expand our existing single- B cell assay capabilities in the OmniAb technology platform. xCella owns a patent portfolio that includes four issued patents in the United States, one issued patent in China, five pending U.S. patent applications, six pending European patent applications, six pending Japanese patent applications, three pending Chinese patent applications, counterpart patent applications pending in other countries, and one pending Patent Cooperation Treaty patent application. These patents and applications are directed to methods and apparatus. The patents and applications in xCella&#8217;s owned portfolio are expected to expire between 2036 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through xCella, we also have a <span style="white-space:nowrap">non-exclusive</span> license from Stanford University to a patent family directed to methods for extracting samples from microcapillary arrays, which includes two issued patents in the U.S., two issued patents in Europe, three issued patents in Japan, two issued patents in China, one pending application the U.S. and one pending application in Europe. These licensed patents and applications have an expected expiry date in 2033 and 2036, without accounting for potentially available patent term adjustments and extensions or disclaimers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taurus Biosciences </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we acquired Taurus Biosciences, which added technologies for discovery and humanization of antibodies from immunized cows or <span style="white-space:nowrap">cow-derived</span> libraries to our OmniAb platform technology </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
platform. These antibodies feature some of the longest <span style="white-space:nowrap">CDR-H3s</span> of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. Through this acquisition, we own issued patents and pending patent applications relating to screening methods and antibody engineering. Taurus&#8217; owned patent portfolio includes five U.S. patents, two pending U.S. patent applications, two granted European patents, two granted Japanese patents, one pending Japanese patent application, one granted Australian patent, one granted Chinese patent, one pending Chinese patent application, one granted Canadian patent and one pending Canadian patent application. These patents and applications are directed to methods of generating combinatorial human antibody libraries, methods of affinity maturation of antibodies, humanized antibodies with ultralong CDRs, and bovinized human antibodies comprising ultralong CDRs. The patents and applications in Taurus&#8217; owned portfolio are expected to expire between 2029 and 2034, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through Taurus, we also have an exclusive license from The Scripps Research Institute to technology related to ultralong <span style="white-space:nowrap">CDR-H3s.</span> This licensed portfolio includes three issued patents in the U.S., one issued patent in Europe, one issued patent in Japan, and two issued patents in Australia. These licensed patents have an expected expiry date in 2033, without accounting for potentially available patent term adjustments and extensions or disclaimers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ab Initio </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we acquired Ab Initio. Ab Initio owns a portfolio of issued patents and pending patent applications directed to SIRP-gamma polypeptides and apelin (APJ) receptor binding domains that includes three issued patents in the United States, one issued patent in Europe, two pending U.S. patent applications, one pending patent application in Europe, one issued patent and one pending patent application in Japan, one issued patent and one pending patent application in China and one pending patent application in Canada. These patents and applications are directed to <span style="white-space:nowrap"><span style="white-space:nowrap">composition-of-matter</span></span> and methods of use. The patents and applications in Ab Initio&#8217;s owned portfolio are expected to expire between 2036 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through Ab Initio, we also have an exclusive license from Stanford University directed to screening methods using transmembrane and cell-surface proteins and related compositions and kits. This licensed portfolio includes four issued patents and one pending application in the U.S., two pending applications in Japan, one pending application in Europe and an issued patent in China. The patents and application in the licensed portfolio are expected to expire between 2034 and 2035, without accounting for potentially available patent term adjustments and extensions or disclaimers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also use trademark rights to protect our brand. As of November&#160;19, 2022, we own a total of 22 registered United States trademarks, 8 pending United States trademarks, 133 registered foreign trademarks in various countries including China, the European Union, and Japan, and nine pending foreign trademarks in various countries around the world. Our trademarks include our company name OMNIAB and product-specific names such as OMNICHICKEN, OMNICLIC, OMNIFLIC, OMNIMOUSE, OMNIRAT, and OMNITAUR, as well as slogans and marketing taglines such as &#8220;3 SPECIES, 1 LICENSE,&#8221; &#8220;ABSOLUTELY OMNIAB,&#8221; &#8220;ANIMAL INTELLIGENCE,&#8221; &#8220;BIOLOGICAL INTELLIGENCE,&#8221; and &#8220;NATURALLY OPTIMIZED HUMAN ANTIBODIES.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercial </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with our partners to include: (i)&#160;payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We partner with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. Our partners are predominantly based in the United States, Europe, and China. As of September&#160;30, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2022, we had a total of 68 active partners. For the year ended December&#160;31, 2021 and nine months ended September&#160;30, 2022, our top three partners represented 63% and 62% of revenue, respectively. See &#8220;&#8212; <span style="font-style:italic">Partner License Agreements</span>&#8221; below for a description of our license agreements with these three partners. We do not believe the loss of any one or more of our partners would have a material adverse effect on us and our subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;1, 2022, we had 90 full-time employees in the United States including 75 employees engaged in research and development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy involves: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Providing the best antibody discovery engine to our partners through continued investment and innovation </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Giving our partners optionality and flexibility to use components of our technology to broaden our potential customer base </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Working with partners to guide our investment and development priorities to expand our current partnerships </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expand the reach of our technology to new partners of all sizes in the drug development industry </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Deliver a complete solution through investment in infrastructure, resources and expertise to execute early-stage discovery </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;1, 2022, our business development and marketing function had two dedicated business development professional, and two dedicated marketing professionals. Our business development and marketing team has been complemented with research and development staff attending a variety of scientific conferences, which has helped increase the business development pipeline. We plan to further expand our commercial sales, marketing and business development teams. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Partner License Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Antibody License Agreement with CNA Development LLC </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2012, OMT entered into an Antibody License Agreement (the CNA Agreement) with CNA Development LLC (CNA), an affiliate of Janssen Pharmaceuticals, Inc. (Janssen), and we acquired OMT on January&#160;8, 2016. Under the CNA Agreement, we granted to CNA a <span style="white-space:nowrap">fee-bearing,</span> <span style="white-space:nowrap">non-exclusive,</span> worldwide, sublicensable license under our patent rights relating to the generation of human antibodies using our transgenic rat platform to develop and commercialize pharmaceutical products derived from antibodies generated and selected during the research term against a low single digit number of antigens provided to us by CNA. Upon payment of a commercial fee, CNA became the sole and exclusive owner of such antibodies and any products generated from such antibodies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the CNA Agreement, we received from CNA an initial research fee in the low six digits and a commercial fee in the mid six digits. We are eligible to receive development and commercialization milestone payments from CNA of up to an aggregate of $42.0&#160;million for the first product directed to each antigen, regardless of the number of products directed to each such antigen that reaches the development milestones. Since we acquired OMT in January 2016, we have received an aggregate of $25.3 million under the CNA Agreement, as of September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;1, 2022, several product candidates under the CNA Agreement are in clinical development, with other programs in the preclinical or discovery stages. The most advanced product candidate under the CNA Agreement is teclistamab, a bispecific antibody. In August 2022, Janssen received conditional marketing authorization from the European Commission for teclistamab as monotherapy for the treatment of adult patients </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with relapsed and refractory multiple myeloma. In October 2022, Janssen received accelerated approval from the FDA for teclistamab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is expected that Janssen will complete additional clinical trials of teclistamab, including studies in combination with other drugs, as is customary in the pharmaceutical industry. Upon the first commercial sales of teclistamab in the U.S. and Europe, OmniAb will receive milestone payments of $25.0&#160;million and $10.0&#160;million, respectively, under the CNA Agreement. In November 2022, Janssen notified us that the first commercial sale in the United States had occurred, and we now expect to receive the related $25&#160;million milestone payment and expect to book $25&#160;million of milestone revenue in the fourth quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the CNA Agreement will continue until all of CNA&#8217;s payment obligations are met. CNA has the right to terminate the CNA Agreement at its discretion upon prior written notice. Either party may terminate the CNA Agreement for the other party&#8217;s uncured material breach after a certain notice and cure period, or immediately if such breach is incurable. Either party may terminate the CNA Agreement for the other party&#8217;s insolvency. Unless we terminate the CNA Agreement for CNA&#8217;s material breach, under all other termination scenarios CNA may continue to develop and commercialize licensed products for which it has paid one or more milestone payments, provided it continues to pay us the remaining milestone payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research, Development and Commercialization Agreement with the Cystic Fibrosis Foundation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, Icagen entered into Research, Development and Commercialization Agreement (the CFF Agreement), with the Cystic Fibrosis Foundation (CFF), as amended in June 2018, April 2020 and September 2021. Since we acquired Icagen in April 2020, we have received an aggregate of $7.0 million under the CFF Agreement, as of September&#160;30, 2022. The research term under the CFF Agreement expired on July&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CFF Agreement, during the research term CFF agreed to fund a research program under which we worked to identify lead compounds from a third party compound library for potential treatment of cystic fibrosis and other rare diseases. We were solely responsible for the conduct of research programs in accordance with research plans and agreed to use commercially reasonable efforts to complete such plans, identify lead compounds and, if appropriate at our sole discretion, develop and commercialize a product derived from such lead compounds in the U.S. and major European countries. Prior to the research term expiring, we identified one or more lead compounds. At this time, we do not intend to develop and commercialize a product candidate under the CFF Agreement but may enter into future relationships to do so with a partner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do develop and commercialize a product candidate under the CFF Agreement, we are obligated to pay CFF milestone payments of up to an aggregate of approximately $56.0&#160;million upon achievement of certain regulatory and commercial milestone events. We are also obligated to pay CFF tiered royalties equal to <span style="white-space:nowrap">low-single</span> digit percentages on net sales of each product developed under the CFF Agreement. Furthermore, if we undergo a change of control or enter into a transaction in which we license, sell or otherwise transfer a product candidate developed under the CFF Agreement to a third party prior to the first commercial sale of such product candidate, we are obligated to pay to CFF a royalty equal to a <span style="white-space:nowrap">low-double</span> digit percentage of the consideration we receive in connection with such change of control or other transaction. We do not anticipate incurring the foregoing payment obligations unless we license, sell or otherwise transfer a product candidate to a third party for further development and potential commercialization, or if we decide in the future to continue and develop a product candidate. There are no similar agreements under which we play a development or commercialization role. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the CFF Agreement will continue until all of our payment obligations to CFF are fulfilled. CFF has the right to terminate the CFF Agreement at its discretion upon prior written notice. We have the right to terminate the CFF Agreement for scientific cause, such as a lack of safety or efficacy, upon prior notice to and an opportunity for discussion with CFF. Either party may terminate the CFF Agreement for the other party&#8217;s uncured material breach after a notice and cure period or for the other party&#8217;s insolvency. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amended and Restated License Agreement with F. <span style="white-space:nowrap">Hoffman-La</span> Roche Ltd and <span style="white-space:nowrap">Hoffman-La</span> Roche Inc. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2018, Icagen entered into an Amended and Restated License Agreement (the Roche Agreement), with F. <span style="white-space:nowrap">Hoffman-La</span> Roche Ltd and <span style="white-space:nowrap">Hoffman-La</span> Roche Inc. (Roche), as amended in June 2021. Under the Roche Agreement, we granted Roche an exclusive, world-wide, <span style="white-space:nowrap">non-transferable,</span> sublicensable license under certain of our patent rights and <span style="white-space:nowrap">know-how</span> relating to our ion channel integrated drug discovery platform to research, develop, manufacture, and commercialize small molecule compounds (and products containing such compounds) that modulate specified targets for all therapeutic, prophylactic and diagnostic uses. We agreed to collaborate with Roche to use commercially reasonable efforts to conduct, at Roche&#8217;s cost, research programs in accordance with research plans and as overseen by a committee, to discover and identify compounds that modulate each specified target. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we acquired Icagen on April&#160;1, 2020, we have received an aggregate of $22.4 million under the Roche Agreement, as of September&#160;30, 2022. Pursuant to the Roche Agreement, we received an upfront payment from Roche of $5.0&#160;million. For the second target and each target thereafter, if we and Roche agree to begin any new research programs, we will receive an initiation payment from Roche in the <span style="white-space:nowrap">low-single</span> digit millions for each new research program. We are eligible to receive development milestone payments from Roche up to an aggregate of $144.0&#160;million for each selected target, regardless of the number of products directed to such target that reach the development milestones. We are eligible to receive sales milestone payments of up to an aggregate of $130.0&#160;million for each product if total worldwide nets sales of such product exceeds certain thresholds. Further, Roche is obligated to pay us tiered royalties on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis ranging from <span style="white-space:nowrap">low-single</span> digit to high-single digit percentages on net sales of the applicable product, subject to certain customary reductions and offsets. Roche&#8217;s obligation to pay us royalties will expire on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis on the later of (i)&#160;ten years after the first commercial sale of such product in such country or (ii)&#160;the expiration of the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> licensed patent claim covering the composition of matter of such product in such country. Such <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> licensed patent claims are expected to expire in 2042, without accounting for potential patent term adjustment or extension. As of September&#160;30, 2022, there are several product candidates in preclinical development or discovery under the Roche Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the Roche Agreement will continue until the expiration of all royalty and payment obligations. Either party may terminate the Roche Agreement in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis for the other party&#8217;s uncured material breach after a certain notice and cure period. Either party may terminate the Roche Agreement in its entirety for the other party&#8217;s insolvency. Roche has the right to terminate the Roche Agreement at its discretion in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> or <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis upon prior written notice. If we or Roche undergo a change of control during the term of the Roche Agreement, there will be restrictions on the acquirer&#8217;s ability to use sensitive information of the <span style="white-space:nowrap">non-acquired</span> party, and the <span style="white-space:nowrap">non-acquired</span> party may restrict the acquired party&#8217;s participation in certain committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacturing, quality control, safety, effectiveness, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drugs and biological products such as those that our partners develop. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. If we or our partners fail to comply with applicable laws or regulations at any time, we or our partners may become subject to administrative or judicial sanctions or other legal consequences, including among other things, restrictions on marketing or manufacturing, withdrawal of products, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or revocation of product approvals, product seizure or detention, refusal to permit the import or export of products, consent decrees, corporate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
integrity agreements, debarment or exclusion from federal healthcare programs, mandated modification of promotional materials, issuance of safety alerts, Dear Healthcare Provider letters, injunctions or the imposition of civil or criminal penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our partners must obtain the requisite approvals from the applicable regulatory authority prior to the commencement of clinical studies or marketing of a drug or biological product in any country in which they wish to initiate such activities. In the United States, the U.S. Food and Drug Administration (FDA) regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act and their implementing regulations. FDA approval of a New Drug Application (NDA) or Biologics License Application (BLA) or supplement is required before any new unapproved drug, biologic or dosage form, including a new use of a previously approved drug or biologic, can be marketed in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before such therapeutic candidates may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive preclinical laboratory tests and preclinical animal studies, which may need to be performed in accordance with the Good Laboratory Practices (GLP) regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an investigational new drug application (IND) which must become effective before human clinical trials may begin and must be updated annually; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent Institutional Review Board (IRB) or ethics committee representing each clinical site before each clinical study may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP) requirements to establish the safety and efficacy, or with respect to biologics, the safety, purity and potency of the therapeutic candidate for each proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation of and submission to the FDA of an NDA or BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential review of the product application by an FDA advisory committee, where appropriate and if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facilities where the proposed product drug substance and drug product are produced to assess compliance with current Good Manufacturing Practice requirements (cGMPs), and audits of selected clinical trial sites to ensure compliance with GCP; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug or biologic in the United States. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess potential safety and efficacy. The conduct of certain preclinical studies is subject to federal regulations and requirements, including GLP regulations applicable to certain safety/toxicology studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol for the proposed clinical trial. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the therapeutic candidate, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <span style="white-space:nowrap">30-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP, which includes the requirement that all research subjects, or their legal representative, provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may recommend that the clinical trial be halted if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Study sponsors also must comply with requirements governing the reporting of clinical trials and clinical study results to public registries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1.&#160;&#160;&#160;&#160;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2.&#160;&#160;&#160;&#160;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3.&#160;&#160;&#160;&#160;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for labeling. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-marketing studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, such as with drugs approved under FDA&#8217;s accelerated approval pathway, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the therapeutic candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be capable of consistently producing quality batches of the therapeutic candidate and must include methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of clinical development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the therapeutic candidate for one or more indications. The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced and of select clinical trial sites, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data. supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA or BLA in condition for approval, including requests for additional information or clarification. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may include limitations on the indicated uses for which such product may be marketed. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <span style="white-space:nowrap">pre-</span> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drugs or biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual program fees for any marketed products. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw any marketing authorization if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions. Other potential consequences include, among other things: restrictions on the marketing or manufacturing of the product, complete withdrawal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the product from the market, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA to approve pending applications or supplements to approved applications, product seizures or detention, refusal to permit the import or export of products, consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs, the issuance of corrective information, injunctions, or the imposition of civil or criminal penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Regulation of Animals with Intentionally Altered Genomic DNA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA provides FDA with authority to regulate as a drug the portion of an animal&#8217;s genome that has been intentionally altered, including where such animals with intentionally altered genomes are intended to produce medical products, such as human drugs. In particular, the FDCA defines the term &#8220;drug&#8221; to include, among other things, articles (other than food) intended to affect the structure or any function of the body of man or other animals. Subject to certain exceptions, the FDA considers each specific DNA alteration utilized in genetically modified animals to be an article meeting the FDCA&#8217;s definition of a new animal drug, because such altered DNA is intended to affect the structure or function of the body of the animal. Consequently, the FDA considers intentionally genetically altered (IGA) animals to be subject to regulation under the new animal drug provisions of the FDCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any new animal drug is deemed unsafe and adulterated unless FDA has approved a new animal drug application (NADA) for its intended use, or unless such drug is only for investigational use and conforms to specified exemptions for such use under an Investigational New Animal Drug (INAD) exemption. However, although IGA animals may be subject to premarket approval requirements or the requirement for an INAD when used in research and development, in some circumstances the FDA has not required INADs or NADAs for such IGA animals. For example, in a draft guidance issued in January 2017, FDA stated its intention to exercise enforcement discretion in a risk-based manner with regard to INAD and NADA requirements for certain IGA animals that are nonfood-producing species, taking into consideration the relative human, animal and environmental risks posed by such animals. The FDA has also stated it may modify its approach with respect to INAD or NADA requirements for other kinds or uses of animals based on its evaluation of risks. Failure to comply with applicable requirements may subject a company to FDA enforcement action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation Governing Medicinal Products in the European Union </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly to the United States, our partners are subject to stringent regulations governing the development, and marketing of medicinal products in the European Union (EU). The various phases of <span style="white-space:nowrap">non-clinical</span> and clinical research in the EU are subject to significant regulatory controls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-clinical</span> studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. <span style="white-space:nowrap">Non-clinical</span> studies must be conducted in compliance with the principles of good laboratory practice (GLP) as set forth in EU Directive 2004/10/EC. In particular, <span style="white-space:nowrap">non-clinical</span> studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for <span style="white-space:nowrap">non-clinical</span> studies. These GLP standards reflect the Organization for Economic <span style="white-space:nowrap">Co-operation</span> and Development requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January&#160;31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January&#160;31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January&#160;31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice (GMP). Other national and <span style="white-space:nowrap">EU-wide</span> regulatory requirements may also apply and compliance with these requirements is subject to inspections by competent authorities of the EU member states. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of <span style="white-space:nowrap">non-clinical</span> studies and clinical trials are submitted to the European Medicines Agency (EMA) or national competent authorities of the EU member states as part of a marketing authorization application (MAA) requesting authorization to market the therapeutic candidate for one or more indications. The submission of a MAA requires payment of a substantial application fee to the EMA or national competent authorities depending on the approval procedure used by the applicant, subject to some exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the process for submitting a MAA depends, among other things, on the nature of the medicinal product candidate. There are two types of MAs: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and are valid throughout the EU. It is compulsory for certain types of products, such as (i)&#160;medicinal products derived from biotechnological processes, (ii)&#160;designated orphan medicinal products, (iii)&#160;advanced-therapy medicinal products (ATMPs) such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv)&#160;medicinal products containing a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any other products containing new active substances not authorized in the EU or for product candidates which constitute a significant therapeutic, scientific, or technical innovation or for which the granting of authorization would be in the interests of public health in the EU. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the Mutual Recognition Procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;normal&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders, manufacturers and distributors of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU member states. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAA must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety and/or efficacy studies. Similar to the FDA, the EMA or national competent authorities of the EU member states may limit further marketing of the product based on the results of these post-authorization safety and/or efficacy studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with substantial requirements is imposed to manufacturers and distributors of medicinal products. Manufacturing and distribution activities are subject to authorizations in the EU member states where these activities take place, referred to as manufacturing and wholesale distribution authorizations. Such authorizations are only valid for the authorized product categories and specific types of manufacturing/distribution activities. Medicinal products must be manufactured in accordance with the principles of GMP and compliance with GMP requirements is monitored via periodic unannounced inspections by the competent regulatory authorities of the EU member states. EU legislation also requires investigation and correction of any deviations from GMP and imposes reporting requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area (EEA) which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Brexit and the Regulatory Framework in the United Kingdom </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United Kingdom (UK) left the EU on January&#160;31, 2020, following which existing EU medicinal product legislation continued to apply in the UK during the transition period under the terms of the <span style="white-space:nowrap">EU-UK</span> Withdrawal Agreement. The transition period, which ended on December&#160;31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement (TCA) and became effective on the January&#160;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law.&#8221; However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) is the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain, or GB. Broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December&#160;31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019 (the Exit Regulations). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a <span style="white-space:nowrap">150-day</span> assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January&#160;1, 2021, unless the MA holder chooses to <span style="white-space:nowrap">opt-out.</span> After Brexit, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other U.S. and Foreign Regulatory Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA and EMA regulation, pharmaceutical and biologics companies are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which such companies research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Coverage and Reimbursement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a <span style="white-space:nowrap"><span style="white-space:nowrap">plan-by-plan</span></span> basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Healthcare Reform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of therapeutic candidates, restrict or regulate post-approval activities, and affect the profitable sale of therapeutic candidates, and similar healthcare laws and regulations exist in the European Union (EU) and other jurisdictions. Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of example, in March 2010, the Patient Protection and Affordable Care Act (the ACA) was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; extended the Medicaid rebate obligation to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; imposed a <span style="white-space:nowrap">non-deductible</span> annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, executive and political challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January&#160;1, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, heightened governmental scrutiny is likely to continue over the manner in which manufacturers set prices for their marketed products, which has already resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in implementing state laws and regulations addressing pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Data Privacy&#160;&amp; Security </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, including clinical trial data, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters and research and development facilities are located in Emeryville, California, where we lease approximately 31,000 square feet of space under leases expiring between 2023 and 2032. In 2022, we expanded our headquarters and research and development facilities in Emeryville to approximately 35,000 square feet of space under leases expiring in 2032. Icagen, our wholly owned subsidiary, leases approximately 30,000 square feet of research and development space in Durham, North Carolina and Tucson, Arizona, under leases that expire between 2026 and 2029. We believe our facilities are adequate and suitable for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our current needs and that, should it be needed, suitable additional or alternative space will be available to accommodate our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of November&#160;1, 2022, we have 90 employees, including 75 employees engaged in research and development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on skilled, experienced, and innovative employees to conduct the operations of our company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">equity awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subsidized health insurance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">401(k) Plan with matching contributions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tuition assistance program; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">paid time off. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. However, regardless of outcome, litigation can have an adverse impact on our business because of defense and settlement costs, diversion of management resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_11">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Management and Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of November&#160;1, 2022, concerning the persons who serve as our executive officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:63%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Foehr</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President, Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles S. Berkman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Legal Officer and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt A. Gustafson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, Finance and Chief Financial Officer</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Matthew W. Foehr</span></span> has served as our President and Chief Executive Officer and as a member of our Board since November 2022. Mr.&#160;Foehr had served as a member of Legacy OmniAb&#8217;s board of directors since December 2015 and previously served as Legacy OmniAb&#8217;s Vice President until March 2022, when he became Legacy OmniAb&#8217;s President and Chief Executive Officer. Mr.&#160;Foehr had also served as Ligand&#8217;s President and Chief Operating Officer from January 2015 until the consummation of the Business Combination. Prior to that time, Mr.&#160;Foehr served as Ligand&#8217;s Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining Ligand in 2011, he was Vice President and Head of Consumer Dermatology R&amp;D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (NYSE: GSK). Following GSK&#8217;s acquisition of Stiefel in 2009, Mr.&#160;Foehr led the R&amp;D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr.&#160;Foehr served as Senior Vice President of Global R&amp;D Operations, Senior Vice President of Product Development&#160;&amp; Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr.&#160;Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr.&#160;Foehr serves on the board of directors of Viking Therapeutics, Inc. (Nasdaq: VKTX), a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from February 2015 until its merger with Qualigen Therapeutics, Inc. (Nasdaq: QLGN) in May 2020. Mr.&#160;Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University. Mr.&#160;Foehr&#8217;s experience as an executive officer of Ligand and intimate knowledge of our business contributed to our decision to designate Mr.&#160;Foehr to serve as a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Charles S. Berkman</span></span> has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr.&#160;Berkman had served as a member of Legacy OmniAb&#8217;s board of directors and as OmniAb&#8217;s Secretary since December 2015 and as Legacy OmniAb&#8217;s Chief Legal Officer since March 2022. Mr.&#160;Berkman had also served as Ligand&#8217;s Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr.&#160;Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr.&#160;Berkman was an attorney at the international law firm of Baker&#160;&amp; McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon&#160;&amp; Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr.&#160;Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Kurt A. Gustafson</span></span> has served as our Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr.&#160;Gustafson had served as Legacy OmniAb&#8217;s Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr.&#160;Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he has held since June 2013. Prior to joining Spectrum, Mr.&#160;Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2009, Mr.&#160;Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr.&#160;Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr.&#160;Gustafson is currently a member of the board of directors of Xencor, Inc., a clinical stage biopharmaceutical company and is also a member of the board of directors of ChromaDex Corporation, a proprietary ingredient company. Mr.&#160;Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of November&#160;1, 2022, concerning the persons who serve as members of our Board. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:63%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Foehr</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;I Director, President and Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John L. Higgins<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director, Chairman of the Board</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carolyn R. Bertozzi, Ph.D<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Boyce<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Cochran, Ph.D.<sup style="font-size:75%; vertical-align:top">(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;I Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sunil Patel<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Tamaroff<sup style="font-size:75%; vertical-align:top">(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the human capital management and compensation committee </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biography of Matthew W. Foehr is set forth under the section entitled &#8220;&#8212;Executive Officers.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">John L. Higgins</span></span> has served as the Chairman of our Board since November 2022. Mr.&#160;Higgins previously served as Legacy OmniAb&#8217;s President from December 2015 until March 2022 and as a member of Legacy OmniAb&#8217;s board of directors since December 2015. Mr.&#160;Higgins has served as Ligand&#8217;s Chief Executive Officer since January 2007 and a member of the Ligand Board since March 2007. Prior to joining Ligand, Mr.&#160;Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX). Prior to BioCryst, Mr.&#160;Higgins was a member of the healthcare banking team of Dillon, Read&#160;&amp; Co. Inc., an investment banking firm. Mr.&#160;Higgins serves on the board, audit committee and nominations and governance committee of <span style="white-space:nowrap">Bio-Techne</span> Corporation (Nasdaq: TECH), a publicly-traded life sciences services company. Mr.&#160;Higgins has served as a director on numerous public and private companies. He also serves as the chairperson of the board of trustees of Academy of Whole Learning, a <span style="white-space:nowrap">non-profit</span> organization dedicated to providing educational and therapy services to children of underrepresented communities. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Mr.&#160;Higgins&#8217; executive experience operating and managing public biotechnology companies, his intimate knowledge of our business, his prior service on other company boards and his financial transaction experience as an investment banker in the biopharmaceutical industry contributed to our decision to designate Mr.&#160;Higgins to serve as a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Carolyn R. Bertozzi, Ph.D.</span></span> has served as a member of our Board since November 2022. Since June 2015, Dr.&#160;Bertozzi has served at Stanford University, where she is currently the Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family <span style="white-space:nowrap">Co-Director</span> of Stanford <span style="white-space:nowrap">ChEM-H.</span> Since 2000, Dr.&#160;Bertozzi has also served as an Investigator at the Howard Hughes Medical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Previously, Dr.&#160;Bertozzi served as a member of the board of directors of Eli Lilly and Company (NYSE: LLY) from February 2017 to August 2021. She holds an undergraduate degree in Chemistry from Harvard University and a Ph.D. in Chemistry from the University of California, Berkeley and was awarded the 2022 Wolf Prize in Chemistry. Dr.&#160;Bertozzi&#8217;s deep expertise in chemistry and biology and her corporate governance experience in the pharmaceutical industry contributed to our decision to designate Ms.&#160;Bertozzi to serve as a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Sarah Boyce</span></span> has served as a member of our Board since November 2022. Ms.&#160;Boyce had served on the Ligand Board since October 2019, and resigned from the Ligand board prior to the Distribution. Since October 2019, Ms.&#160;Boyce has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms.&#160;Boyce served as Chief Business Officer at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms.&#160;Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG. Ms.&#160;Boyce also served on the board of directors of Berkeley Lights Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company, from July 2019 until May 2022. Ms.&#160;Boyce received a B.S. degree in microbiology from the University of Manchester, England. Ms.&#160;Boyce&#8217;s executive experience in the biopharmaceutical industry and knowledge of our business contributed to our decision to designate Ms.&#160;Boyce to serve a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jennifer Cochran, Ph.D.</span></span> has served as a member of our Board since November 2022. Dr.&#160;Cochran had served on the Ligand Board since July 2021, and resigned from the Ligand board prior to the Distribution. She has served in numerous roles at Stanford University since 2005, where she is currently a Professor of Bioengineering and (by courtesy) of Chemical Engineering (appointed to the faculty as an Assistant Professor in January 2005, promoted to Professor in 2018), and the Shriram Chair of Bioengineering, a position she has held since September 2017. Dr.&#160;Cochran also serves as the Chief Scientific Advisor to Red Tree Venture Capital, a life-sciences-focused investment fund, since she <span style="white-space:nowrap">co-founded</span> it in August 2020. Dr.&#160;Cochran was also the Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October 2015 to April 2020. Prior to Stanford, she held several research positions at the Massachusetts Institute of Technology, most recently as a Postdoctoral Fellow. Dr.&#160;Cochran currently serves on the boards of directors of privately-held biotechnology companies Virsti Therapeutics, Inc., Revel Pharmaceuticals, and Trapeze Therapeutics, Inc. She has also served on the boards of directors of privately-held biotechnology companies Nodus Therapeutics, Inc. and Combangio, Inc., as well as xCella Biosciences until its acquisition by Ligand in 2020. Dr.&#160;Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology. Dr.&#160;Cochran&#8217;s extensive bioengineering background and knowledge of the biopharmaceutical industry contributed to our decision to designate Dr.&#160;Cochran as a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Sunil Patel</span></span> has served as a member of our Board since November 2022. Mr.&#160;Patel had served on the Ligand Board since October 2010, and resigned from the Ligand board prior to the Distribution. He has more than 20 years of senior management and R&amp;D experience in the biotechnology industry. Mr.&#160;Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr.&#160;Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr.&#160;Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. (Nasdaq: GILD). Mr.&#160;Patel also worked at McKinsey&#160;&amp; Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation. Mr.&#160;Patel received his undergraduate degree in Chemistry at the University of California, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Berkeley, and master&#8217;s degree in Molecular Bioengineering/Biotechnology at the University of Washington. Mr.&#160;Patel&#8217;s executive and corporate development experience in the biopharmaceutical industry contributed to our decision to designate Mr.&#160;Patel to serve as a director of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Joshua Tamaroff </span></span>has served as a member of our Board since November 2022. Mr.&#160;Tamaroff joined Avista in 2009 and serves as a Partner. Prior to joining Avista, Mr.&#160;Tamaroff worked as an Analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr.&#160;Tamaroff currently serves as a director of Cosette Pharmaceuticals, Inc., GCM Holding Corporation, Probo Medical, Solmetex and United BioSource Corporation, and previously served as a director of InvestorPlace Media, IWCO Direct, OptiNose, Inc. (NASDAQ: OPTN), Organogenesis Holdings, Inc. (NASDAQ: ORGO) and WideOpenWest, Inc. (NYSE: WOW). Mr.&#160;Tamaroff received a Bachelor of Science from Cornell University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar. Mr.&#160;Tamaroff was selected to serve on our Board of Directors because of his private equity investment and company oversight experience and background with respect to acquisitions, debt financings and equity financings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Composition and Election of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Independence </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of seven (7)&#160;members. We have determined that all of our directors, other than Mr.&#160;Foehr and Mr.&#160;Higgins, are independent directors in accordance with the listing requirements of Nasdaq. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his, her or their family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our certificate of incorporation, our Board is divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until the third annual meeting following reelection. Our directors are divided among the three classes as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;I directors are Dr.&#160;Cochran and Mr.&#160;Foehr, and their terms will expire at our 2023 annual meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;II directors will be Ms.&#160;Boyce and Mr.&#160;Patel, and their terms will expire at our 2024 annual meeting of stockholders; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;III directors will be Joshua Tamaroff, Dr.&#160;Bertozzi and Mr.&#160;Higgins, and their terms will expire at our 2025 annual meeting of stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that the authorized number of directors may be changed only by resolution of the Board. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <span style="white-space:nowrap">one-third</span> of the directors. The division of our Board into three classes with staggered three-year terms may delay or prevent a change of our Board or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <span style="white-space:nowrap">two-thirds</span> of our outstanding voting stock then entitled to vote in an election of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the A&amp;R Registration Rights Agreement provides that the Sponsor has the right to designate one (1)&#160;individual to our Board, and that such right will terminate upon the later of (i)&#160;such time as the Sponsor ceases to beneficially own at least ten percent (10%) of our outstanding voting stock and (ii)&#160;subject to compliance with the rules of Nasdaq, the third anniversary of the date of the Merger Agreement, or March&#160;23, 2025. Moreover, any individual nominated by the Sponsor requires the consent of our Board, subject to certain exceptions. Mr.&#160;Tamaroff was designated as a member of our Board by the Sponsor pursuant to A&amp;R Registration Rights Agreement. See &#8220;Certain Relationships and Related Person Transactions&#8212;<span style="font-weight:bold"><span style="font-style:italic"></span></span>Registration Rights and Board Designation Rights&#8221; for additional information on the agreement, including termination provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is currently chaired by Mr.&#160;Higgins. Our Board recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of chief executive officer and chair of the Board in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> leadership and performance of our company, while the chair of the Board provides guidance to the chief executive officer and presides over meetings of the full Board. We believe that this separation of responsibilities provides a balanced approach to managing the Board and overseeing our company. Our Board has concluded that our current leadership structure is appropriate. However, our Board will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has responsibility for the oversight of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from Board committees and members of senior management to enable our Board to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the Board, corporate disclosure practices and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by our Board as a whole. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees and Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of an audit committee, a human capital management and compensation committee and a nominating and corporate governance committee. The composition of each committee is set forth below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee&#8217;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This committee&#8217;s responsibilities will include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing our independent registered public accounting firm; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving the audit and <span style="white-space:nowrap">non-audit</span> services to be performed by our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and critical accounting policies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, overseeing and monitoring the integrity of our financial statements and compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our Board any changes to such investment policy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparing the report that the SEC requires in our annual proxy statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Mr.&#160;Patel, Mr.&#160;Tamaroff and Dr.&#160;Cochran. Mr.&#160;Patel serves as the chair of the committee. All members of our audit committee are independent directors and meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Mr.&#160;Patel is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. The audit committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Human Capital Management and Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital management and compensation committee approves policies relating to compensation and benefits of our officers and employees. The human capital management and compensation committee approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The human capital management and compensation committee also approves the issuance of stock options and other awards under our equity plans. The human capital management and compensation committee will review and evaluate, at least annually, the performance of the human capital management and compensation committee and its members, including compliance by the committee with its charter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our human capital management and compensation committee are Ms.&#160;Boyce, Mr.&#160;Patel and Mr.&#160;Higgins. Ms.&#160;Boyce serves as the chair of the committee. Our Board has determined that each of Ms.&#160;Boyce and Mr.&#160;Patel is independent under the applicable Nasdaq listing standards and is a <span style="white-space:nowrap">&#8220;non-employee</span> director&#8221; as defined in Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act. Under applicable Nasdaq rules, we are permitted to phase in our compliance with the independent compensation committee requirements of Nasdaq, which requires all members to be independent within one year of us ceasing to be a &#8220;controlled company&#8221; upon the consummation of the Business Combination. We will comply with the <span style="white-space:nowrap">phase-in</span> requirements of the Nasdaq rules and within one year of the consummation of the Business Combination, all members of this committee will be independent under Nasdaq rules.The human capital management and compensation committee operates under a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written charter, which the human capital management and compensation committee will review and evaluate at least annually. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for assisting our Board in discharging the Board&#8217;s responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any vacancies on our Board and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies, reporting and making recommendations to our Board concerning governance matters and oversight of the evaluation of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are Dr.&#160;Cochran, Mr.&#160;Tamaroff and Dr.&#160;Bertozzi. Dr.&#160;Cochran serves as the chair of the committee. All members of our nominating and corporate governance committee are independent directors under the applicable Nasdaq listing standards. The nominating and corporate governance committee operates under a written charter, which the nominating and corporate governance committee will review and evaluate at least annually. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of the human capital management and compensation committee serves or served during the fiscal year ended December&#160;31, 2021, as a member of our Board or compensation committee of a company that has one or more executive officers serving as a member of the Board of directors or compensation committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee is responsible for reviewing with our Board, on an annual basis, the appropriate characteristics, skills and experience required for the Board as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the Board will take into account many factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">personal and professional integrity, ethics and values; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience in corporate management, such as serving as an officer or former officer of a publicly-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience as a board member or executive officer of another publicly-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strong finance experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience relevant to our business industry and with relevant social policy concerns; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">relevant academic expertise or other proficiency in an area of our business operations. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board evaluates, each individual in the context of the Board as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nasdaq Board Diversity Matrix </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following Board Diversity Matrix presents our Board&#8217;s diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by the director nominees. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Board Diversity Matrix (As of November&#160;1, 2022)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Number of Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#160;</td>
<td colspan="5" style="vertical-align:bottom;white-space:nowrap" align="center">7</td>
<td style="vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Female</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Male</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part&#160;I: Gender Identity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part&#160;II: Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#160;</td>
<td colspan="5" style="vertical-align:bottom;white-space:nowrap" align="center">1</td>
<td style="vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ESG </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue and build upon Ligand&#8217;s commitment to delivering long-term sustainable value to stakeholders by promoting a diverse, inclusive and supportive culture and inspiring innovation. Our corporate sustainability program is designed to identify, assess and manage the environmental, social and governance (&#8220;ESG&#8221;) factors that are relevant to the scale and scope of our business and its long-term performance. Our corporate sustainability program takes into account the interests of our key stakeholders including employees, partners and shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESG priorities include employee and board diversity, workplace health and safety, human capital management, business ethics and compliance, energy and resource efficiency, and data privacy and protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will review and assess our corporate sustainability program to ensure alignment with stakeholders. In addition, members of our Board have committed themselves to various environmental and social diversity initiatives such as leading research and technology development relating to climate change, advising <span style="white-space:nowrap">start-up</span> companies developing green products, supporting diversity, equity and inclusion initiatives at universities and funding programs focused on supporting children with mental health, behavioral and learning disorders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our code of business conduct and ethics is available under the Corporate Governance section of our website at www.omniab.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through it&#8217;s website, and you should not consider it to be a part of this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_12">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following section provides compensation information applicable to &#8220;emerging growth companies&#8221; under the SEC disclosure rules. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of APAC&#8217;s executive officers or directors received any cash compensation for services rendered to APAC prior to the Business Combination. Since the consummation of the IPO and until the Closing of the Business Combination, APAC reimbursed the Sponsor for office space, secretarial and administrative services provided to APAC in the amount of $10,000 per month. In addition, APAC&#8217;s Sponsor, executive officers and directors, or their respective affiliates were reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on APAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. APAC&#8217;s audit committee reviewed on a quarterly basis all payments that were made by APAC to its Sponsor, executive officers or directors, or their affiliates. Any such payments prior to the Business Combination were made using funds held outside the trust account. Other than these payments and reimbursements, no compensation of any kind, including finder&#8217;s and consulting fees, was paid by APAC to the Sponsor, executive officers and directors, or their respective affiliates, prior to completion of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the Distribution and Business Combination, Legacy OmniAb was a wholly-owned subsidiary of Ligand and each of the named executive officers identified below was employed by Ligand or one of its subsidiaries. Accordingly, all <span style="white-space:nowrap">pre-Distribution</span> payments and benefits described below were provided by Ligand. For purposes of this registration statement, our executive officers whose compensation is discussed in this Executive Compensation section and whom we refer to as our named executive officers are Matthew W. Foehr, who serves as our President and Chief Executive Officer, and Charles S. Berkman, who serves as our Chief Legal Officer and Secretary. Decisions regarding past compensation of our named executive officers were made by Ligand&#8217;s Human Capital Management and Compensation Committee prior to the Distribution. Kurt Gustafson, who serves as our Executive Vice President, Finance and Chief Financial Officer, commenced employment with Legacy OmniAb in March&#160;2022 and is therefore not included in the following discussion as it relates to prior&#160;years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Executive Compensation section sets forth certain information regarding total compensation earned by our named executive officers for fiscal&#160;years 2020 and 2021. Our compensation package for our named executive officers primarily consists of salary, an annual performance bonus, and long-term equity incentive awards. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The share numbers and exercise prices reflected in this Executive Compensation section with respect to outstanding Ligand stock options, RSUs and PSUs granted to our named executive officers prior to the Distribution have not been adjusted to reflect the adjustment of such awards pursuant to the Distribution and the Business Combination. See &#8220;Treatment of Outstanding Equity Awards at the Time of the Distribution&#8221; above for a description of the adjustment of outstanding Ligand equity awards in connection with the Distribution and the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain information regarding the compensation earned by our named executive officers during the fiscal&#160;years ended December&#160;31, 2021 and 2020. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock</span><br /><span style="font-weight:bold">Awards<sup style="font-size:75%; vertical-align:top">(1)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">Awards<sup style="font-size:75%; vertical-align:top">(1)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span></span><br /><span style="font-weight:bold">Incentive Plan</span><br /><span style="font-weight:bold">Compensation<sup style="font-size:75%; vertical-align:top">(2)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other</span><br /><span style="font-weight:bold">Compensation<sup style="font-size:75%; vertical-align:top">(3)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Matthew W. Foehr</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">518,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,146,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,226,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">259,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,603</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,282,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">503,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,242,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,303,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158,001</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,484,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Charles S. Berkman</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">451,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,665,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">649,308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">203,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,980,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Legal Officer and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">441,917</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">644,168</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">675,820</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">176,767</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">6,180</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,944,852</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the grant date fair value for stock and option awards covering shares of Ligand Common Stock granted by Ligand in 2020 and 2021, calculated in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation, (Topic 718). The assumptions used to calculate the value of stock and option awards granted in 2020 and 2021 are set forth under Note 9 of the Notes to Consolidated Financial Statements included in Ligand&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. The grant date fair value of the RSUs granted in 2020 and 2021 was determined based on the closing price per share of Ligand Common Stock on the date of grant for each RSU granted. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With respect to the PSU awards included in the Summary Compensation Table, these amounts include the grant date fair value of such PSUs granted to the named executive officers based on the estimated probable outcome of the performance based objectives applicable to such awards on the grant date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With respect to the PSUs granted in 2020, the number of PSUs that were eligible to vest were determined based on the measurement of two equally weighted metrics, the compound annual growth rate for Ligand&#8217;s adjusted EPS over a <span style="white-space:nowrap">two-year</span> performance period and Ligand&#8217;s relative TSR ranked on a percentile basis against the NASDAQ Biotechnology Index over a three-year performance period measured from January&#160;1, 2020. The grant date fair value of the PSUs granted during 2020 included in this column that are tied to the compound annual growth rate for Ligand&#8217;s adjusted EPS was calculated based on the probable achievement of the performance goals as determined at the date of grant, which was determined to be the target level of performance. The grant date fair value of the PSUs that are tied to relative TSR was calculated using the Monte Carlo simulation which utilizes the stock volatility, dividend yield and market correlation of Ligand and the NASDAQ Biotechnology Index. For the PSUs granted during 2020, such inputs consisted of: (a)&#160;an expected term that was based on the actual 2.81 year term of the award; (b)&#160;a risk-free interest rate of 0.4% derived from the yield on U.S. government bonds of appropriate term from the U.S. Department of Treasury; (c)&#160;a dividend yield of 0.0% based on historic and future dividend yield estimates; (d)&#160;stock price volatility of 39.75% based on an analysis of the historical stock price volatility of Ligand and each company in the NASDAQ Biotechnology Index over the three years prior to the date of grant to conform to the term of the awards; and (e)&#160;initial TSR performance of <span style="white-space:nowrap">-11.48%</span> based on actual historical TSR performance for Ligand and each company in the NASDAQ Biotechnology Index. Based on this methodology, the valuation of the PSUs tied to relative TSR performance granted during 2020 was 52.81% of the closing price of Ligand Common Stock on the date of grant. The highest level of performance that may be achieved for the PSUs is 200% of the target. The full grant date fair value of the PSUs awarded to our named executive officers during fiscal year 2020, assuming maximum achievement of the applicable performance objectives, is $1,049,603 for Mr.&#160;Foehr and $544,291 for Mr.&#160;Berkman. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With respect to the PSUs granted in 2021, the number of PSUs that were eligible to vest were determined based on the measurement of two equally weighted metrics, the initiation of partnered OmniAb antibody programs over a <span style="white-space:nowrap">two-year</span> performance period measured from January&#160;1, 2021 and Ligand&#8217;s relative TSR ranked on a percentile basis against the NASDAQ Biotechnology Index over a three-year performance period measured from January&#160;1, 2021. The grant date fair value of the PSUs granted during 2021 included </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in this column that are tied to the initiation of partnered OmniAb antibody programs was calculated based on the probable achievement of the performance goals as determined at the date of grant, which was determined to be the target level of performance. The grant date fair value of the PSUs that are tied to relative TSR was calculated using the Monte Carlo simulation which utilizes the stock volatility, dividend yield and market correlation of Ligand and the NASDAQ Biotechnology Index. For the PSUs granted during 2021, such inputs consisted of: (a)&#160;an expected term that was based on the actual 2.9 year term of the award; (b)&#160;a risk-free interest rate of 0.18% derived from the yield on U.S. government bonds of appropriate term from the U.S. Department of Treasury; (c)&#160;a dividend yield of 0.0% based on historic and future dividend yield estimates; (d)&#160;stock price volatility of 52.56% based on an analysis of the historical stock price volatility of Ligand and each company in the NASDAQ Biotechnology Index over the three years prior to the date of grant to conform to the term of the awards; and (e)&#160;initial TSR performance of 84.38% based on actual historical TSR performance for Ligand and each company in the NASDAQ Biotechnology Index. Based on this methodology, the valuation of the PSUs tied to relative TSR performance granted during 2020 was 176.27% of the closing price of Ligand Common Stock on the date of grant. The highest level of performance that may be achieved for the PSUs is 200% of the target. The full grant date fair value of the PSUs awarded to our named executive officers during fiscal year 2021, assuming maximum achievement of the applicable performance objectives, is $2,333,894 for Mr.&#160;Foehr and $1,235,551 for Mr.&#160;Berkman. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These awards were adjusted at the time of the Distribution and Business Combination into both Ligand and OmniAb Equity Awards. For more information about the adjustment of Integra equity awards in connection with the <span style="white-space:nowrap">Spin-Off,</span> see &#8220;<span style="font-style:italic">Treatment of Outstanding Equity Awards at the Time of the Distribution</span>&#8221; below. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents performance bonus awards under Ligand&#8217;s annual performance-based bonus program. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Mr.&#160;Berkman, represents life insurance premiums paid by Ligand of $1,380 for each of 2021 and 2020, taxable fringe benefits of $3,510 for 2021, and 401(k) matching funds paid by Ligand of $6,000 in 2021 and $4,800 in 2020. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pursuant to the management rights letter between Viking Therapeutics, Inc. (Viking) and Ligand dated May&#160;21, 2014, Ligand nominated Mr.&#160;Foehr to serve as a member of Viking&#8217;s board of directors. During 2021, in connection with Mr.&#160;Foehr&#8217;s service as a director of Viking, Mr.&#160;Foehr received (1) $38,000 in cash payments and (2) $85,603 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance). Additionally, Mr.&#160;Foehr received life insurance premiums paid by Ligand for 2021 of $900, taxable fringe benefits of $100, and $6,000 in 401(k) matching funds paid by Ligand in 2021. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">During 2020, in connection with Mr.&#160;Foehr&#8217;s service as a director of Viking, Mr.&#160;Foehr received (1) $38,000 in cash payments and (2) $114,001 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance). Additionally, Mr.&#160;Foehr received life insurance premiums paid by Ligand for 2020 of $900, taxable fringe benefits of $300, and $4,800 in 401(k) matching funds paid by Ligand in 2020. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Base Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Distribution</span> Ligand Practice </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution, annual base salary increases for our named executive officers were based upon the performance of the executive officers, internal pay equity considerations, and peer practices, as assessed by the chief executive officer (for executives other than himself) and approved by Ligand&#8217;s Human Capital Management and Compensation Committee. Ligand&#8217;s Human Capital Management and Compensation Committee assesses these factors with respect to the chief executive officer. Ligand provides its executive officers with a base salary that falls between the 25th and 50th percentiles for similar positions at its peer group, but may vary from such level based on the factors listed above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For 2021, our named executive officers each received an approximately 3% increase to his base salary, effective as of February&#160;1, 2021. This increase was determined to be appropriate by the Human Capital Management and Compensation Committee to ensure that the base salaries of Ligand&#8217;s executive officers (including our named executive officers) continued to be generally consistent with its pay positioning philosophy, as described above. The base salary paid to our named executive officers for 2021 was $520,200 for Mr.&#160;Foehr and $456,300 for Mr.&#160;Berkman. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">OmniAb Practice Following Distribution and Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Human Capital Management and Compensation Committee will set base salary levels for executive officers taking into account base salary levels for positions with similar roles and scope of responsibilities within our peer group, as well as the executive officer&#8217;s performance. No adjustments were made to the base salaries of our named executive officers in connection with the Distribution and Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Annual Performance-Based Cash Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Distribution</span> Ligand Practice </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand&#8217;s Human Capital Management and Compensation Committee aims to have a substantial portion of each executive officer&#8217;s compensation contingent upon company performance. Ligand&#8217;s annual performance-based bonus program provides for cash bonus payments tied to achievement of key annual corporate performance objectives established by the Ligand Board for such purpose. Ligand&#8217;s annual performance-based bonus program is intended to complement its long-term equity program, which more directly aligns realized executive compensation with longer-term share price and corporate objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Target Annual Bonus Opportunities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand sets annual incentive targets so that each executive&#8217;s total target cash compensation (inclusive of base salary) is positioned between the 25th and 50th percentiles of target total cash opportunities offered by its peer group. The target incentive opportunity for Mr.&#160;Berkman for 2021 was increased from 40% to 45% of his base salary. The target incentive opportunity for Mr.&#160;Foehr for 2021 did not increase as compared to his 2020 target. Each named executive officer&#8217;s annual bonus for 2021 is tied 100% to corporate performance. For 2021, Mr.&#160;Foehr&#8217;s target incentive opportunity was 50% of his base salary, and Mr.&#160;Berkman&#8217;s target incentive opportunity was 45% of his base salary. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2021 Corporate Performance Objectives and Achievements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the beginning of each year, the Ligand Board sets corporate objectives for the year in a number of areas after considering management input and its overall strategic objectives. Following the conclusion of each year, Ligand&#8217;s Human Capital Management and Compensation Committee assesses the level of achievement relative to these corporate objectives. This achievement level is then applied to each executive officer&#8217;s target bonus to determine that year&#8217;s total annual bonus. The Human Capital Management and Compensation Committee retains the discretion to reduce the final bonus payout to an executive officer based on other factors deemed relevant to assessing the company&#8217;s performance in comparison to its peers and the industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, Ligand&#8217;s Human Capital Management and Compensation Committee and the Ligand Board approved the performance objectives for the 2021 annual bonus program. The metrics were established after careful consideration of key short-term corporate goals. While Ligand&#8217;s business was considerably impacted by the <span style="white-space:nowrap">COVID-19</span> pandemic, the goals set at the beginning of the year were not adjusted to take into account the impact of the pandemic. Objectives included the following: finance (revenue, EBITDA), licensing (completion of at least three new major contracts from the Icagen and Pfenex technology platforms), OmniAb (build computer-aided antigen design capability and position antigen library to leverage in partnerships, acquire </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or build new cell screening and discovery capabilities, complete at least one <span style="white-space:nowrap">out-license</span> or major <span style="white-space:nowrap">buy-out</span> transaction), Captisol (expand IP footprint, optimize cost structure and processing efficiencies), and pipeline (management of partners and portfolio to support high-value, late-stage assets). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, Ligand&#8217;s Board and Human Capital Management and Compensation Committee determined to pay the following bonus amounts to our named executive officers for 2021 based on Ligand&#8217;s achievement of the performance objectives discussed above: $259,467 for Mr.&#160;Foehr and $203,257 for Mr.&#160;Berkman. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">OmniAb Practice Following Distribution and Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Human Capital Management and Compensation Committee will develop an annual performance-based cash compensation plan focused on corporate objectives that support our long-term business goals, while also allowing for meaningful pay differentiation tied to performance of individuals and groups. Our named executive officers&#8217; 2022 annual bonuses will generally be determined based on Ligand&#8217;s 2022 annual bonus program in place at the time of the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Long-Term Equity Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution, our named executive officers participated in Ligand&#8217;s equity plans. Ligand&#8217;s long-term performance-based compensation is designed to link the ultimate level of an executive officer&#8217;s compensation to Ligand&#8217;s stock price performance and long-term stockholder interests while creating an incentive for sustained growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand provides equity compensation to its executive officers through grants of stock options, performance stock units (PSUs) and restricted stock units (RSUs). For 2021, these equity vehicles were weighted at 40%, 33%, and 27%, respectively. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Time-based stock options</span> granted to the executive officers generally have a four-year vesting schedule designed to provide an incentive for continued employment. Options have a <span style="white-space:nowrap">ten-year</span> term and an exercise price equal to 100% of the fair market value of the underlying stock on the date of grant. Accordingly, options will provide a return to the executive officer only if the market price of the shares appreciates over the option term. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Time-based restricted stock units</span> generally vest in equal installments over three years. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Performance stock units</span> are a significant component of Ligand&#8217;s annual long-term equity incentive awards for executive officers that vest based on key corporate and financial objectives over multi-year performance periods. At the time of grant, Ligand&#8217;s Human Capital Management and Compensation Committee conducts a review of the performance measures and associated payout levels, the rigor of the performance goals and their alignment with performance. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Ligand Human Capital Management and Compensation Committee views granting equity awards as a retention device and therefore also reviews the status of vesting and number of vested versus unvested awards at the time of grant. Guidelines for the number of equity awards granted to each executive officer are determined using a procedure approved by the Ligand Human Capital Management and Compensation Committee based upon several factors, including the executive officer&#8217;s level of responsibility, salary grade, performance and the value of the equity awards at the time of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the position of executive cash compensation relative to market (which is set between the 25th and 50th percentiles), the Ligand Human Capital Management and Compensation Committee has emphasized long-term equity incentive compensation to ensure total compensation is competitive. The long-term equity incentive awards granted to its executive officers in 2021 fell between the 50th and 75th percentiles of equity awards for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar positions at the peer group companies, adjusted using the above factors and taking into consideration such equivalency factors as the number of shares outstanding and market capitalization, compared to the peer group companies. As a result of the weighting of the short-term cash and long-term equity components of total compensation, the total target annual compensation for Ligand&#8217;s executive officers approximates the 50th to 75th percentile range of the peer group. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2021 Long-Term Incentive Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, Ligand&#8217;s Human Capital Management and Compensation Committee approved long-term incentive awards to our named executive officers as described in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total Stock<br />Option&#160;Target<br />Value (40%)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Stock&#160;Options<br />Granted<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;RSU<br />Target&#160;Value<br />(27%)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />RSUs<br />Granted<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total PSU<br />Target&#160;Value<br />(33%)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />PSUs&#160;Granted<br />(at Target)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Matthew W. Foehr</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">918,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,122,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Charles S. Berkman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">720,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">486,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">594,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The actual number of options awarded was calculated using the Black-Scholes option pricing model (utilizing the same assumptions that Ligand utilizes in the preparation of its financial statements). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The actual number of RSUs and PSUs awarded is calculated by dividing (a)&#160;the target grant value of the RSU award, by (b)&#160;the average closing price per share of Ligand&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the <span style="white-space:nowrap">30-calendar</span> day period through and including February&#160;3, 2021. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with prior years, the PSUs granted by the Ligand Human Capital Management and Compensation Committee in 2021 (the &#8220;2021 PSUs&#8221;) were divided into two equally weighted components: one subject to three-year relative TSR performance conditions and one subject to the number of partnered OmniAb antibody programs initiated over the <span style="white-space:nowrap">two-year</span> period commencing on January&#160;1, 2021. The Ligand Human Capital Management and Compensation Committee selected these performance measures in order to drive the key behaviors that the Ligand Human Capital Management and Compensation Committee wants to reinforce and align pay with stockholder returns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Threshold, target and maximum performance levels for both components of the 2021 PSUs were as described below. The Ligand Human Capital Management and Compensation Committee selected the foregoing performance measures because they represent the key financial and operational performance metrics for which the executives are responsible as well as align with stockholders&#8217; interests, thereby creating the clearest link between executive actions, corporate results and Ligand&#8217;s continued long-term success. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Relative TSR Component</span>.&#160;&#160;&#160;&#160;The performance-based vesting requirement for the 2021 PSUs tied to Ligand&#8217;s relative TSR was based on the percentile level of Ligand&#8217;s TSR for the three-year performance period from January&#160;1, 2021 through December&#160;31, 2023, relative to the members of the NASDAQ Biotechnology Index. The NASDAQ Biotechnology Index was selected for comparison because it enabled the Ligand Human Capital Management and Compensation Committee to assess Ligand&#8217;s performance against an objective peer group. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:24%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">TSR PERCENTILE VS. NASDAQ BIOTECHNOLOGY INDEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;OF&#160;TARGET&#160;PAID</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">95<sup style="font-size:75%; vertical-align:top">th</sup> percentile</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55<sup style="font-size:75%; vertical-align:top">th</sup> percentile</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30<sup style="font-size:75%; vertical-align:top">th</sup> percentile</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 30<sup style="font-size:75%; vertical-align:top">th</sup> percentile</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To receive the earned shares, an executive officer must generally remain employed with Ligand through the last day of the applicable performance period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">OmniAb Antibody Programs Component.</span>&#160;&#160;&#160;&#160;The second performance-based vesting component for the 2021 PSUs is tied to the number of partnered OmniAb antibody programs initiated during the <span style="white-space:nowrap">two-year</span> performance period from January&#160;1, 2021 through December&#160;31, 2022. The programs may be a combination of new platform rodent partnerships, cow or heavy chain-only technology programs and/or programs leveraging the OmniChicken technology and services. Each program must be potentially royalty-bearing. A &#8220;new&#8221; platform rodent partnership is defined as rodent programs initiated by partners that are added during the performance period. The portion of the 2021 PSUs tied to OmniAb antibody programs were eligible to vest as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:21%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number of OmniAb Programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;of&#160;Target&#160;Paid</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">35 or more</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 15</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand&#8217;s Human Capital Management and Compensation Committee amended the outstanding Ligand PSUs granted prior to the Equity Cutoff Date to convert those PSUs into time-based RSUs immediately prior to the Distribution based on its assessment of Ligand&#8217;s achievement relative to the applicable performance objectives s of such dates. As a result of such determination, the portion of the 2021 PSUs tied to Ligand&#8217;s TSR was determined to be 168% and the portion of the 2021 PSUs tiled to OmniAb program initiation was determined to be 150%. The 2021 PSUs, after giving effect to these achievement levels, were converted into time-based Ligand RSUs and will vest on December&#160;31, 2022 (with respect to the portion tied to OmniAb program initiation) and December&#160;31, 2023 (with respect to the portion formerly tied to Ligand&#8217;s TSR), subject to continued employment through each applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time-based stock options and RSUs granted to our named executive officers by Ligand in 2021 vest in accordance with the standard vesting schedules described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2020 Performance-Based Restricted Stock Units Earned </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and March 2020, our named executive officers were granted PSUs (the &#8220;2020 PSUs&#8221;) that were eligible to vest based on the following two equally-weighted objectives: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the first component of the 2020 PSUs was tied to Ligand&#8217;s adjusted EPS growth for the two year performance period commencing January&#160;1, 2020 and ending December&#160;31, 2021. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the second component of the 2020 PSUs is tied to Ligand&#8217;s TSR during the performance period commencing January&#160;1, 2020 and ending December&#160;31, 2022, relative to the members of the NASDAQ Biotechnology Index. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, the Ligand Human Capital Management and Compensation Committee certified Ligand&#8217;s achievement relative to the adjusted EPS growth objective for purposes of the 2020 PSUs following the end of the applicable <span style="white-space:nowrap">two-year</span> performance period. The threshold, target and maximum performance levels for the adjusted EPS growth component of these awards (which equated to 50%, 100% and 200% payout levels, respectively, with performance between these levels determined by linear interpolation and no payout for performance below threshold), the performance achievement relative to such performance levels and the actual number of 2020 PSUs that vested are set forth in the table below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Objective</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Weighting</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">(0%)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Threshold<br />(50%)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Target<br />(100%)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Maximum<br />(200%)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Actual<br />Performance</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Percentage<br />Earned</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EPS Growth<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&lt;10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&gt;24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">%<sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Adjusted earnings per share (EPS) represents GAAP net income/loss excluding the impact of the (a)&#160;share-based compensation expense, (b)&#160;amortization of intangible assets, <span style="white-space:nowrap">(c)&#160;non-cash</span> interest expense, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
(d)&#160;amortization of commercial license and other economic rights, (e)&#160;fair value changes in contingent liabilities, (f)&#160;acquisition and integration costs, (g)&#160;transaction costs, (h)&#160;unrealized gain/loss from short-term investments, (i)&#160;other <span style="white-space:nowrap">non-recurring</span> items, (j)&#160;tax effect, if any, of the foregoing adjustments, and (k)&#160;excess tax benefits and tax deficiencies relating to equity awards vested and exercised since January&#160;1, 2017, divided by diluted weighted average common shares outstanding during the period. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The actual number of units that vested and issued in January 2022 with respect to the portion of the 2020 PSUs tied to incremental revenue are as follows: Mr.&#160;Foehr, 7,396; and Mr.&#160;Berkman, 3,836. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#8220;target&#8221; number of 2020 PSUs that remained eligible to vest as of December&#160;31, 2021 based on Ligand&#8217;s three-year relative TSR are reported in the &#8220;Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End&#8221;</span> table below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand&#8217;s Human Capital Management and Compensation Committee amended the outstanding Ligand PSUs granted prior to the Equity Cutoff Date to convert those PSUs into time-based RSUs immediately prior to the Distribution based on its assessment of Ligand&#8217;s achievement relative to the applicable performance objectives as of such dates. As a result of such determination, the portion of the 2020 PSUs tied to Ligand&#8217;s TSR were assigned a 0% achievement level and were forfeited. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2019 Performance-Based Restricted Stock Units Earned </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, our named executive officers were granted PSUs (the &#8220;2019 PSUs&#8221;) that were eligible to vest based on the following two equally-weighted objectives (and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to both objectives): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the first component of the 2019 PSUs was tied to Ligand&#8217;s incremental revenue from acquisitions, new licensing deals and Captisol sales above projections for the two year performance period commencing January&#160;1, 2019 and ending December&#160;31, 2020. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the second component of the 2019 PSUs was tied to new licenses for internally funded programs during the performance period commencing January&#160;1, 2019 and ending December&#160;31, 2021. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021 and January 2022, the Human Capital Management and Compensation Committee certified our achievement relative to the objectives for purposes of the 2019 PSUs following the end of the applicable <span style="white-space:nowrap">two-year</span> or three-year performance period. The threshold, target and maximum performance levels for the incremental revenue component of these awards (which equated to 50%, 100% and 150% payout levels, respectively, with performance between these levels determined by linear interpolation and no payout for performance below threshold), the performance achievement relative to such performance levels and the actual number of 2019 PSUs that vested are set forth in the table below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Objective</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Weighting</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Threshold<br />(0%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Target<br />(100%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Maximum<br />(150%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Actual<br />Performance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Percentage<br />Earned</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incremental Revenue<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">50%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$10&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$15&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$20&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$109&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">150%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Licenses for Internally Funded Programs<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">50%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">0</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2 licenses</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3 licenses</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5 licenses</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">150%</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The actual number of units that vested and issued in January 2021 with respect to the portion of the 2019 PSUs tied to incremental revenue are as follows: Mr.&#160;Foehr, 5,604; and Mr.&#160;Berkman, 2,401. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The actual number of units that vested and issued in January 2022 with respect to the portion of the 2019 PSUs tied to new licenses for internally funded programs are as follows: Mr.&#160;Foehr, 5,604; and Mr.&#160;Berkman, 2,401. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity awards granted under Ligand&#8217;s 2002 Stock Incentive Plan (the 2002 Plan) to our named executive officers may be subject to accelerated vesting in the event of a &#8220;change in control.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand equity award agreements under the 2002 Plan entered into by our named executive officers provide that such equity awards will automatically vest in the event of a &#8220;change in control&#8221; where the option is not assumed or replaced by a successor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2002 Plan, a &#8220;change in control&#8221; is generally defined as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a merger, consolidation or reorganization of the company in which 50% or more of Ligand&#8217;s voting securities change ownership; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sale, transfer or other disposition of all or substantially all of Ligand&#8217;s assets in complete liquidation or dissolution of the company; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a change in control of the company effected through a successful tender offer for more than 50% of Ligand&#8217;s outstanding common stock or through a change in the majority of the Ligand Board as a result of one or more contested elections for board membership. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Treatment of Outstanding Equity Awards at the Time of the Distribution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Employee Matters Agreement (as amended), each outstanding Ligand stock option, RSU award and PSU award held by Ligand and Legacy OmniAb service providers as of the time of the Distribution and granted prior to March&#160;2, 2022 (the &#8220;Equity Cutoff Date&#8221;) was split at the time of the Distribution into two equity awards which included a Ligand equity award and a Legacy OmniAb Equity Award. The adjusted Ligand equity awards and Legacy OmniAb Equity Awards generally are subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Ligand PSU awards granted in 2020 and 2021 were amended to provide that such PSUs will vest solely based on continued service with Ligand or OmniAb, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above under &#8220;&#8212;2021 Long-Term Incentive Awards&#8221;, the 2021 PSUs were eligible to vest based on the following two equally weighted components (and a possible performance multiplier of 150% for the relative TSR component and 200% for the OmniAb program initiative component): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the first component of the 2021 PSUs was tied to the percentile level of Ligand&#8217;s TSR for the three-year performance period from January&#160;1, 2021 through December&#160;31, 2023, relative to the members of the NASDAQ Biotechnology Index. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The vesting of the second component of the 2021 PSUs was tied to OmniAb program initiation performance conditions during the <span style="white-space:nowrap">two-year</span> performance period from January&#160;1, 2021 through December&#160;31, 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand&#8217;s Human Capital Management and Compensation Committee amended the outstanding Ligand PSUs granted prior to the Equity Cutoff Date to convert those PSUs into time-based RSUs immediately prior to the Distribution based on its assessment of Ligand&#8217;s achievement relative to the applicable performance objectives s of such dates. As a result of such determination, the portion of the 2020 PSUs tied to Ligand&#8217;s TSR were assigned a 0% achievement level and were forfeited. With respect to the 2021 PSUs, the portion of the 2021 PSUs tied to Ligand&#8217;s TSR was determined to be 168% and the portion of the 2021 PSUs tiled to OmniAb program initiation was determined to be 150%. The 2021 PSUs, after giving effect to these achievement levels, were converted into time-based Ligand RSUs and will vest on December&#160;31, 2022 (with respect to the portion tied to OmniAb program initiation) and December&#160;31, 2023 (with respect to the portion formerly tied to Ligand&#8217;s TSR), subject to continued employment through each applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding Ligand stock option, RSU award and PSU award that was granted on or after the Equity Cutoff Date to an individual who was a current or former Ligand service provider as of the time of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Distribution generally was adjusted solely into a Ligand equity award at the time of the Distribution. The adjusted Ligand equity awards generally are subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution. The performance metrics for the outstanding Ligand PSU awards were amended to provide that such PSUs will vest solely based on continued service with Ligand. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding Ligand stock option, RSU award and PSU award that was granted after the Equity Cutoff Date to an individual who was a Legacy OmniAb service provider as of the time of the Distribution generally was adjusted solely into a Legacy OmniAb Equity Award at the time of the Distribution. The adjusted Legacy OmniAb Equity Awards generally are subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution. The performance metrics for the outstanding Ligand PSU awards were amended to provide that such PSUs will vest solely based on continued service with OmniAb, as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, all Legacy OmniAb Options, Legacy OmniAb RSU awards and Legacy OmniAb PSU awards, in each case, that were outstanding as of immediately prior to the Effective Time were converted into awards relating to shares of OmniAb Common Stock, respectively, in each case, with substantially the same terms and conditions as were applicable to the Legacy OmniAb Equity Award immediately prior to the Closing (other than terms that have been rendered inoperative by the Distribution and Business Combination), including with respect to vesting and termination-related provisions, as adjusted by the Base Exchange Ratio. In addition, at the Effective Time, each holder of a Legacy OmniAb Equity Award was issued a number of Earnout Shares equal to the product of the number of shares of Legacy OmniAb Common Stock subject to the Legacy OmniAb Equity Award multiplied by the Earnout Exchange Ratio, which Earnout Shares are subject to the restrictions set forth in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the foregoing adjustments, in the case of Ligand equity awards that were converted into both adjusted Ligand equity awards and Legacy OmniAb Equity Awards (or, following the Closing, OmniAb Equity Awards), continued employment with or service to Ligand or its affiliates is treated as employment or other continued service with OmniAb and its affiliates with respect to OmniAb Equity Awards held by Ligand service providers, and continued employment with or other service to OmniAb and its affiliates is treated as employment or other continued service with Ligand and its affiliates with respect to Ligand equity awards held by OmniAb service providers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, with respect to any unvested OmniAb Equity Award or unvested Ligand equity award granted or adjusted, as applicable, in connection with the Distribution and Business Combination, if the original Ligand equity award was subject to accelerated vesting provisions in connection with a termination of service with Ligand and/or a &#8220;change in control&#8221; (as defined in the applicable award agreements or equity plan) of Ligand, then the OmniAb Equity Award or Ligand equity award, as applicable, is subject to the same acceleration provisions in connection with the holder&#8217;s termination of service with his or her post-spin employer, as applicable, and/or change in control of such entity. In addition, any unvested OmniAb Equity Award granted to a Ligand service provider in connection with the Distribution and Business Combination will vest in full upon a change in control of New OmniAb, and any unvested Ligand equity award held by an OmniAb service provider that is adjusted in connection with the Distribution and Business Combination will vest in full upon a change in control of Ligand. Additionally, if our Board or the Ligand Board, as applicable, determines to accelerate in full the vesting of all of such entity&#8217;s equity awards that are held by its current and former service providers, then such board of directors shall also accelerate in full the vesting of all of its equity awards that are held by current and former service providers of the other entities, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, our long-term incentive award program is similar to Ligand&#8217;s program. The Human Capital Management and Compensation Committee will review our program with the goal of ensuring it is effective in attracting, retaining and motivating skilled executives and aligning the interests of management and stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distribution Equity Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April and June 2022, Ligand granted stock options and RSUs to our named executive officers and certain of our employees, which represent such executives&#8217; and employees&#8217; annual equity awards for 2022. Such stock options and RSUs contain terms substantially similar to those of the Ligand equity awards described above. Our named executive officers were granted the following Ligand stock options and Ligand RSUs in April and June 2022: Mr.&#160;Foehr, 34,214 stock options and 9,137 RSUs, and Mr.&#160;Berkman, 20,126 stock options and 5,375 RSUs. In connection with his commencement of employment, in April 2022, Mr.&#160;Gustafson was granted 40,000 Ligand options and 8,000 Ligand RSUs. Mr.&#160;Gustafson&#8217;s Ligand RSUs were granted under the 2002 Plan, and the options subject to the Gustafson Inducement Award were granted as a standalone &#8220;employment inducement&#8221; award within the meaning of Nasdaq Stock Market Rule 5635(c)(4). Additionally, in July 2022, Ligand granted PSUs to our named executive officers and certain management employees, 50% of which will vest based on the achievement of certain combined total shareholder return goals of Ligand and OmniAb relative to the Nasdaq Biotechnology Index during a period of approximately two years following the Closing of the Business Combination, and the remaining 50% of which were eligible to vest based on the calendar quarter during which the completion of the Distribution occurred. The PSUs are eligible to vest in up to 162.5% of the &#8220;target&#8221; number of PSUs based on performance relative to the performance objectives. Our named executive officers and Mr.&#160;Gustafson were granted the following number of PSUs at &#8220;target&#8221; in July 2022: Mr.&#160;Foehr, 11,167 PSUs at &#8220;target&#8221;; Mr.&#160;Berkman, 6,569 PSUs at &#8220;target&#8221;; and Mr.&#160;Gustafson, 4,000 PSUs at &#8220;target.&#8221; Upon the closing of the Distribution on November&#160;1, 2022, our named executive officers vested in the portion of these PSUs tied to that performance metric at a 100% achievement level. The actual number of&#160;units that vested and issued in connection with the Distribution with respect to the portion of the 2022 PSUs tied to the completion of the Distribution was 5,584 for Mr.&#160;Foehr, 3,285 for Mr.&#160;Berkman and 2,000 for Mr.&#160;Gustafson. The &#8220;target&#8221; number of 2022 PSUs that remain eligible to vest based on the achievement of certain combined total shareholder return goals of Ligand and OmniAb relative to the Nasdaq Biotechnology Index are 5,583 for Mr.&#160;Foehr, 3,284 for Mr.&#160;Berkman and 2,000 for Mr.&#160;Gustafson. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity Compensation Plans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Incentive Award Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board and our stockholders have adopted the 2022 Incentive Award Plan, or the 2022 Plan, which became effective upon the Closing of the Business Combination. Under the 2022 Plan, we may grant cash and equity incentive awards to eligible employees, directors and consultants in order to attract, motivate and retain the talent for which we compete. The material terms of the 2022 Plan are summarized below. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligibility and Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees, consultants and directors of the company and its subsidiaries are eligible to receive awards under the 2022 Plan. The 2022 Plan is administered by our Board with respect to awards to <span style="white-space:nowrap">non-employee</span> directors and by our Human Capital Management and Compensation Committee with respect to other participants, each of which may delegate its duties and responsibilities to one or more committees of its directors and/or officers (referred to collectively as the plan administrator), subject to the limitations imposed under the 2022 Plan, Section&#160;16 of the Exchange Act, stock exchange rules and other applicable laws. The plan administrator has the authority to take all actions and make all determinations under the 2022 Plan, to interpret the 2022 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2022 Plan as it deems advisable. The plan administrator also has the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2022 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2022 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shares Available for Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial aggregate number of shares of our common stock that is available for issuance under the 2022 Plan is equal to the sum of (i) 16,409,022 shares, and (ii)&#160;any shares which, as of the effective date of the 2022 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan, are subject to awards under the OmniAb Prior Plans (as defined below) which, on or following the effective date of the 2022 Plan, become available for issuance pursuant to the 2022 Plan recycling provisions, described below. In addition, the number of shares of our common stock available for issuance under the 2022 Plan will be annually increased on January&#160;1 of each calendar year beginning in 2023 and ending in 2032 by an amount equal to the lesser of (i)&#160;a number equal to 5% of the fully-diluted shares on the final day of the immediately preceding calendar year or (ii) such smaller number of shares as is determined by our Board. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options (&#8220;ISOs&#8221;) granted under the 2022 Plan, is 250,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award under the 2022 Plan or the OmniAb Prior Plans expires, lapses or is terminated, exchanged for or settled in cash, any shares subject to such award (or portion thereof) may, to the extent of such expiration, lapse, termination or cash settlement, be used again for new grants under the 2022 Plan. Shares tendered or withheld to satisfy the exercise price or tax withholding obligation for any award under the 2022 Plan or the OmniAb Prior Plans may, to the extent of such tender or withholding, be used for new grants under the 2022 Plan. Further, the payment of dividend equivalents in cash in conjunction with any awards under the 2022 Plan will not reduce the shares available for grant under the 2022 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards granted under the 2022 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2022 Plan but will count against the maximum number of shares that may be issued upon the exercise of ISOs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 Plan provides that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all awards granted to a <span style="white-space:nowrap">non-employee</span> director as compensation for services as a <span style="white-space:nowrap">non-employee</span> director during any fiscal year, or director limit, may not exceed an amount equal to $750,000 (increased to $1,000,000 in the calendar year of a <span style="white-space:nowrap">non-employee</span> director&#8217;s initial service as a <span style="white-space:nowrap">non-employee</span> director or any calendar year during which a <span style="white-space:nowrap">non-employee</span> director serves as chairman of the board or lead independent director) (which limits shall not apply to the compensation for any <span style="white-space:nowrap">non-employee</span> director who serves in any capacity in addition to that of a <span style="white-space:nowrap">non-employee</span> director for which he or she receives additional compensation or any compensation paid to any <span style="white-space:nowrap">non-employee</span> director prior to the calendar year following the calendar year in which the Closing occurs). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 Plan provides for the grant of stock options, including ISOs and nonqualified stock options (&#8220;NSOs&#8221;), SARs, restricted stock, dividend equivalents, RSUs and other stock or cash based awards. Certain awards under the 2022 Plan may constitute or provide for payment of &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2022 Plan will be evidenced by award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the applicable award agreement may provide for cash settlement of any award. A brief description of each award type follows. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Stock Options and SARs</span>.&#160;&#160;&#160;&#160;Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, in contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. Unless otherwise determined by the board, the exercise price of a stock option or SAR may not be less than 100% of the fair market value of the underlying share on the grant date (or 110% </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Restricted Stock</span>.&#160;&#160;&#160;&#160;Restricted stock is an award of nontransferable shares of our common stock that are subject to certain vesting conditions and other restrictions. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">RSUs</span>.&#160;&#160;&#160;&#160;RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares (i.e., dividend equivalent rights). The plan administrator may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to RSUs will be determined by the plan administrator, subject to the conditions and limitations contained in the 2022 Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Other Stock or Cash Based Awards</span>.&#160;&#160;&#160;&#160;Other stock or cash based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Dividend Equivalents</span>.&#160;&#160;&#160;&#160;Dividend equivalents represent the right to receive the equivalent value of dividends paid on shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of the dividend record dates during the period between the date an award is granted and the date such award vests, is exercised, is distributed or expires, as determined by the plan administrator. Dividend equivalents payable with respect to an award prior to the vesting of such award instead will be paid out to the participant only to the extent that the vesting conditions are subsequently satisfied and the award vests. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Certain Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator has broad discretion to take action under the 2022 Plan, as well as make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, in the event of certain <span style="white-space:nowrap">non-reciprocal</span> transactions with our stockholders known as &#8220;equity restructurings,&#8221; the plan administrator will make equitable adjustments to the 2022 Plan and outstanding awards. In the event of a change in control (as defined in the 2022 Plan), to the extent that the surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards will become fully vested and exercisable in connection with the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Repricing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may, without approval of the stockholders, reduce the exercise price of any stock option or SAR, or cancel any stock option or SAR in exchange for cash, other awards or stock options or SARs with an exercise price per share that is less than the exercise price per share of the original stock options or SARs. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan Amendment and Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or our Human Capital Management and Compensation Committee may amend or terminate the 2022 Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under the 2022 Plan, may materially and adversely affect an award outstanding under the 2022 Plan </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without the consent of the affected participant, and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws. The 2022 Plan will remain in effect until October 2032, unless earlier terminated. No awards may be granted under the 2022 Plan after its termination. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Foreign Participants, Claw-Back Provisions, Transferability and Participant Payments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the United States. All awards will be subject to any company clawback policy as set forth in such clawback policy or the applicable award agreement. Awards under the 2022 Plan are generally <span style="white-space:nowrap">non-transferable,</span> except by will or the laws of descent and distribution, or, subject to the plan administrator&#8217;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2022 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common stock that meet specified conditions, a &#8220;market sell order&#8221; or such other consideration as it deems suitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board and our stockholders have adopted the 2022 Employee Stock Purchase Plan, or the ESPP, which became effective upon the Closing of the Business Combination. The ESPP is comprised of two distinct components in order to provide increased flexibility to grant purchase rights under the ESPP to U.S. and to <span style="white-space:nowrap">non-U.S.</span> employees. Specifically, the ESPP authorizes (i)&#160;the grant of purchase rights to U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section&#160;423 of the Code (the &#8220;Section&#160;423 Component&#8221;) and (ii)&#160;the grant of purchase rights that are not intended to be <span style="white-space:nowrap">tax-qualified</span> under Section&#160;423 of the Code to facilitate participation for employees located outside of the United States who do not benefit from favorable U.S. tax treatment and to provide flexibility to comply with <span style="white-space:nowrap">non-U.S.</span> law and other considerations (the <span style="white-space:nowrap">&#8220;Non-Section</span> 423 Component&#8221;). Where possible under local law and custom, we expect that the <span style="white-space:nowrap">Non-Section</span> 423 Component generally will be operated and administered on terms and conditions similar to the Section&#160;423 Component. The material terms of the ESPP are summarized below. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Human Capital Management and Compensation Committee, or any other committee to whom our Board delegates such power or authority, serves as the administrator of the ESPP. The plan administrator may delegate administrative tasks under the ESPP to agents or employees to assist in the administration of the ESPP. Subject to the terms and conditions of the ESPP, the plan administrator has the authority to determine when rights to purchase shares will be offered and the provisions of each offering under the ESPP, to determine which subsidiaries will participate as &#8220;designated subsidiaries&#8221; in the ESPP (including in the <span style="white-space:nowrap">Non-Section</span> 423 and the Section&#160;423 Components), and to make all other determinations and to take all other actions necessary or advisable for the administration of the ESPP. The plan administrator is also authorized to establish, amend or revoke rules relating to administration of the ESPP and to adopt annexes or <span style="white-space:nowrap">sub-plans</span> that apply to certain participating subsidiaries or jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shares Available for Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate number of shares of our common stock that may be issued pursuant to rights granted under the ESPP equals 1,758,109 shares of our common stock . In addition, on the first day of each calendar year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, the number of shares available for issuance under the ESPP will be increased by a number of shares equal to the lesser of (i) 1% of the fully diluted shares outstanding on the final day of the immediately preceding calendar year, and (ii)&#160;such smaller number of shares as determined by our Board. If any right granted under the ESPP terminates for any reason without having been exercised, the shares subject thereto that are not purchased under such right will again be available for issuance under the ESPP. Notwithstanding the foregoing, no more than 100,000,000 shares of common stock may be issued under the Section&#160;423 Component of the ESPP. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligible Employees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees eligible to participate in the ESPP for a given offering generally include employees who are employed by us or one of our designated subsidiaries on the first trading day of the offering period, or the enrollment date. However, an employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value of all classes of our or one of our subsidiaries&#8217; stock will not be allowed to participate in the ESPP (unless otherwise required under applicable law). In addition, the plan administrator may provide that an employee may not be eligible to participate in an offering under the Section&#160;423 Component if the employee is a citizen or resident of a <span style="white-space:nowrap">non-U.S.</span> jurisdiction and the grant of a right to purchase shares would be prohibited under applicable law or would cause the Section&#160;423 Component (or any offering thereunder) to violate the requirements of Section&#160;423 of the Code. Additionally, the plan administrator may provide that certain highly compensated, seasonal and/or part-time employees may not be eligible to participate in an offering or, with respect to offerings under the <span style="white-space:nowrap">Non-Section</span> 423 Component, that only certain employees are eligible to participate in such offerings (regardless of the foregoing rules). </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Participation; Offerings; Purchase Periods </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees may become participants in the ESPP for an offering period by completing a subscription agreement prior to the enrollment date of the applicable offering period, which will designate a whole percentage of the employee&#8217;s compensation to be withheld by us as payroll deductions under the ESPP during the offering period. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Offerings; Purchase Periods</span>.&#160;&#160;&#160;&#160;Under the ESPP, participants are offered the right to purchase shares of our common stock at a discount during a series of offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to twenty-seven (27)&#160;months long. Accumulated employee payroll deductions will be used to purchase shares of our common stock on each purchase date during an offering period. The number of purchase periods within, and purchase dates during, each offering will be established by the plan administrator. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offerings. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Enrollment and Contributions</span>.&#160;&#160;&#160;&#160;The ESPP permits participants to purchase our common stock through payroll deductions of a whole percentage of their eligible compensation, which may not be less than 1% and may be up to a maximum percentage determined by the plan administrator (which, in the absence of a contrary designation, will be 20% of eligible compensation). The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be 100,000 shares for an offering period and 100,000 shares for a purchase period. In addition, a participant may not, with respect to the Section&#160;423 Component, subscribe for more than $25,000 worth of shares under the ESPP per calendar year in which such rights to purchase stock are outstanding (considered together with any other ESPP maintained by us or certain parent or subsidiary entities) based on the fair market value of the shares at the time the purchase right is granted. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Purchase Rights</span>.&#160;&#160;&#160;&#160;On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. Unless a participant has previously withdrawn his or her participation in, or has otherwise become ineligible to participate in, the ESPP prior to any applicable purchase date, the option will be exercised on the applicable purchase date(s) during the offering period to the extent of the payroll deductions accumulated during the offering period. The participant will purchase the maximum number of whole shares of our common stock that his or her accumulated payroll deductions will buy at the purchase price, subject to the participation limitations described above, and any fractional shares will be credited to the participant&#8217;s account and carried forward and applied toward the purchase of whole shares on the next purchase date, unless the plan administrator provides that such amounts should be returned to the participant in a lump sum. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Purchase Price</span>.&#160;&#160;&#160;&#160;The purchase price for each offering period will be designated by the plan administrator in the applicable offering document (which purchase price, for purposes of the Section&#160;423 Component, will not be less than 85% of the closing trading price of a share of our common stock on the enrollment date or purchase date of the applicable offering period, whichever is lower) or, in the absence of a designation by the plan administrator, the purchase price will be the lower of 85% of the closing trading price per share of our common stock on the enrollment date of the applicable offering period or 85% of the closing trading price per share on the applicable purchase date, which will be the last trading day of each purchase period. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Payroll Deduction Changes; Withdrawals; Terminations of Employment</span>.&#160;&#160;&#160;&#160;A participant may decrease (but not increase) or suspend his or her payroll deductions once during any offering period. In addition, a participant may withdraw his or her participation from the ESPP at any time by submitting written notice to us at least one week prior to the end of the then-current offering period for the offering in which such participant is enrolled. Upon any withdrawal, the participant will receive a refund of the participant&#8217;s account balance in cash, and his or her payroll deductions shall cease. Participation in the ESPP ends automatically upon a participant&#8217;s termination of employment. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transfer Restrictions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not transfer (other than by will or the laws of descent and distribution) any right granted under the ESPP and, during a participant&#8217;s lifetime, purchase rights granted under the ESPP shall be exercisable only by such participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Adjustments; Changes in Capitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the ESPP administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control or change in applicable law or accounting principles, the plan administrator may, in order to prevent the dilution or enlargement of intended benefits under the ESPP or facilitate or give effect to such transactions, events or changes, provide for one or more of the following: (i)&#160;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii)&#160;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, (iii)&#160;the adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&#160;the use of participants&#8217; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v)&#160;the termination of all outstanding rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment and Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may amend, suspend or terminate the ESPP at any time, subject to stockholder approval to increase the number (or change the type) of securities that may be issued under the ESPP or to change the corporations or classes of corporations whose employees may be granted rights under the ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OmniAb Prior Plans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Legacy OmniAb adopted the OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan and the OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan, collectively referred to as the OmniAb Prior Plans, which govern the OmniAb Equity Awards issued upon adjustment of outstanding Ligand equity awards in connection with the Distribution as described above under &#8220;&#8212;Treatment of Outstanding Equity Awards at the Time of the Distribution.&#8221; The terms and conditions of the OmniAb Prior Plans are substantively the same as the terms and conditions set forth in Ligand&#8217;s 2002 Stock Incentive Plan. All awards under the OmniAb Prior Plans that are outstanding as of the Closing will continue to be governed by the terms, conditions and procedures set forth in the OmniAb Prior Plans and any applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
award agreements, as those terms may be equitably adjusted in connection with the Business Combination, as described above under &#8220;&#8212;Treatment of Outstanding Equity Awards at the Time of the Distribution.&#8221; We assumed the OmniAb Prior Plans in connection with the Closing of the Business Combination, and each of the awards thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the Distribution, and after giving effect to the adjustment of the OmniAb Equity Awards to reflect the Business Combination, awards representing the right to receive an aggregate of 5,997,765 and 8,302,710 shares of our common stock were outstanding under the OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan and the OmniAb, Inc. and the 2022 OmniAb Service Provider Assumed Award Plan, respectively. No future awards will be granted under the OmniAb Prior Plans. Shares subject to outstanding awards under the OmniAb Prior Plans as of the effective date of the 2022 Plan may, on or following the effective date of the 2022 Plan, become available for issuance pursuant to the 2022 Plan recycling provisions, described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Severance and Change in Control Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Control Severance Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the Closing, we entered into a change in control severance agreement with each of Messrs. Foehr, Gustafson and Berkman. Under the terms of the change in control severance agreements, in the event an executive officer&#8217;s employment is terminated by us without cause or he resigns for good reason within 24 months following a change in control of our company, he will be eligible to receive a severance benefit equal to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">one times the annual rate of base salary in effect for such officer at the time of involuntary termination; plus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">one times the greater of: (a)&#160;the maximum target bonus for the fiscal year in which the termination occurs; or (b)&#160;the maximum target bonus for the fiscal year in which the change in control occurs, if different; plus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">twelve multiplied by the monthly premium the executive would be required to pay for continued health coverage for himself and his eligible dependents. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing severance amount will be payable in a lump sum following the officer&#8217;s termination of employment, subject to the officer&#8217;s execution of a general release of claims acceptable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in control severance agreements also provide that all of an executive officer&#8217;s outstanding stock awards will vest in the event of such a termination. In addition, the post-termination exercise period of an executive officer&#8217;s stock options will be extended from three months to the date that is nine months following the date of termination (but in no event beyond the original expiration date of such options). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the change in control severance agreements, an involuntary termination is either a termination of the named executive officer&#8217;s employment by us without cause or his resignation for good reason. &#8220;Cause&#8221; is generally defined as an officer&#8217;s conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any state thereof, an officer&#8217;s willful and material breach of any obligation or duty under the employment agreement, any confidentiality and proprietary rights agreement or any written employment or other written policies that have previously been furnished to the officer, which breach is not cured within 30 days after written notice thereof is received by the officer, if such breach is capable of cure, the officer&#8217;s gross negligence or willful misconduct, including without limitation, fraud, dishonesty or embezzlement, in the performance of his duties, or the officer&#8217;s continuing failure or refusal to perform his assigned duties or to comply with reasonable directives of the board of directors that are consistent with the officer&#8217;s job duties (which directives are not in conflict with applicable law), which failure is not cured within 30 days after written notice thereof is received by the officer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the change in control severance agreements, &#8220;good reason&#8221; is generally defined as a material diminution in the officer&#8217;s authority, duties or responsibilities, a material diminution in the officer&#8217;s base compensation, a material change in the geographic location at which the officer must perform his duties, or any other action or inaction that constitutes a material breach by us or any successor or affiliate of its obligations to the officer under the employment agreement. An officer must provide written notice to us of the occurrence of any of the foregoing events or conditions without his written consent within 90 days of the occurrence of such event. We will have a period of 30 days to cure such event or condition after receipt of written notice of such event from the officer. Any voluntary termination of an officer&#8217;s employment for &#8220;good reason&#8221; must occur no later than the date that is six months following the initial occurrence of one of the foregoing events or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the change in control severance agreements, a &#8220;change in control&#8221; has generally the same definition as given to such term under the 2022 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Severance Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the Closing, the Human Capital Management and Compensation Committee of our Board adopted the OmniAb, Inc. Severance Plan, or the Severance Plan, to provide severance payments to our employees and the employees of our subsidiaries upon an involuntary termination of employment without cause. Our executive officers are each eligible to participate in the severance plan, provided that he or she is not subject to disciplinary action or a formal performance improvement plan at the time of termination. However, if, as a result of his or her involuntary termination by us without &#8220;cause,&#8221; the executive officer would be eligible to receive severance under any individual change in control severance agreement, employment agreement or other arrangement providing severance benefits, as approved by our Board or a committee thereof, the executive officer will not be eligible for benefits under the severance plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the severance plan, participants will be eligible to receive (1)&#160;a lump sum payment in cash for his or her fully earned but unpaid base salary and accrued but unused vacation through the date of termination, (2)&#160;an amount equal to his or her base salary for the severance period, which period will be equal to (a)&#160;two months plus (b)&#160;one week for each year of service as of the date of termination and (c)&#160;continued health coverage at the same cost as was in effect for the participant at the date of termination throughout such severance period, provided that such participant elects continued coverage under COBRA. The foregoing cash severance benefit will be payable in a lump sum following the participant&#8217;s termination of employment, subject to the participant&#8217;s execution of a general release of claims acceptable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the severance plan, &#8220;cause&#8221; is generally defined as an executive officer&#8217;s conviction of (or entry of a plea of no contest to) any felony or any other criminal act, an officer&#8217;s commission of any act of fraud or embezzlement, an executive officer&#8217;s unauthorized use or disclosure of our confidential or proprietary information or trade secrets, an executive officer&#8217;s commission of any material violation of our policies, or an executive officer&#8217;s commission of any other intentional misconduct which adversely affects our business or affairs in a material manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Elements of Compensation and Perquisites </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Distribution</span> Ligand Practice </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers were eligible for the following benefits and perquisites offered by Ligand to its employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Health and Welfare Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each named executive officer and his spouse and children was eligible for such health, dental and vision insurance coverage as Ligand made available to its other executives of the same level of employment. Ligand paid a portion of the premiums for this insurance for all employees. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers were also eligible for such disability and/or life insurance as Ligand made available to its other employees of the same level of employment. Ligand paid the premiums for this life insurance coverage for the named executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Defined Contribution Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand and its designated affiliates offer the Section&#160;401(k) Savings/Retirement Plan (the 401(k) Plan), a <span style="white-space:nowrap">tax-qualified</span> retirement plan, to their eligible employees. The 401(k) Plan permits eligible employees to defer from 1% to 90% of their annual eligible compensation, subject to certain limitations imposed by the Internal Revenue Code. The employees&#8217; elective deferrals are immediately vested and <span style="white-space:nowrap">non-forfeitable</span> in the 401(k) Plan. Ligand also makes matching contributions to the 401(k) Plan. In 2021, the match was equal to 50% with respect to the first $12,000 contributed by an employee up to an annual maximum of $6,000 per employee per year. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Limited Perquisites and Other Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand makes available certain other perquisites or fringe benefits to executive officers and other employees, such as tuition reimbursement, professional society dues and food and recreational fees incidental to official company functions, including board meetings. The aggregate of these other benefits was less than $10,000 for each of our named executive officers in the last fiscal year. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Tax <span style="white-space:nowrap">Gross-Ups</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ligand has not made <span style="white-space:nowrap">gross-up</span> payments to cover our named executive officers&#8217; personal income taxes that may pertain to any of the compensation paid or provided by Ligand. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">OmniAb Practice Following Distribution and Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our benefits and retirement programs are generally similar to those of Ligand immediately prior to completion of the Distribution. Our Human Capital Management and Compensation Committee will review these programs and benefits and may make changes to align them with our business needs and strategic priorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Health and Welfare Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each named executive officer and his spouse and children is eligible for such health, dental and vision insurance coverage as Ligand made available to its other executives of the same level of employment. We pay a portion of the premiums for this insurance for all employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are also eligible for such disability and/or life insurance as Ligand made available to its other employees of the same level of employment. We pay the premiums for this life insurance coverage for the named executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Defined Contribution Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until December&#160;1, 2022, our employees continued to participate in Ligand&#8217;s 401(k) Plan. Effective December&#160;1, 2022, we will offer a 401(k) plan to our eligible employees. Our 401(k) plan permits eligible employees to defer from 1% to 90% of their annual eligible compensation, subject to certain limitations imposed by the Internal Revenue Code. The employees&#8217; elective deferrals are immediately vested and <span style="white-space:nowrap">non-forfeitable</span> in the 401(k) Plan. Ligand also makes matching contributions to the 401(k) Plan. Commencing in 2023, the match will be equal to 50% with respect to the first $14,000 contributed by an employee up to an annual maximum of $7,000 per employee per year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Limited Perquisites and Other Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available certain other perquisites or fringe benefits to executive officers and other employees, such as tuition reimbursement, professional society dues and food and recreational fees incidental to official company functions, including board meetings. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Tax <span style="white-space:nowrap">Gross-Ups</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not made <span style="white-space:nowrap">gross-up</span> payments to cover our named executive officers&#8217; personal income taxes that may pertain to any of the compensation paid or provided by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information on all stock and option awards held by our named executive officers as of December&#160;31, 2021. All outstanding equity awards are in shares of Ligand Common Stock. The share numbers and exercise prices reflected in the table below with respect to outstanding stock options, RSUs and PSUs of Ligand as of December&#160;31, 2021 have not been adjusted to reflect the adjustment of such awards pursuant to the Distribution and the Business Combination. See &#8220;Treatment of Outstanding Equity Awards at the Time of the Distribution&#8221; above for a description of the adjustment of outstanding Ligand equity awards in connection with the Distribution and the Business Combination. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Unexercisable<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Equity<br />Incentive<br />Plan<br />Awards:<br />Number of<br />Securities<br />Underlying<br />Unexercised<br />Unearned<br />Options (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option<br />Exercise<br />Price</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option<br />Expiration<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of<br />Shares or<br />Units of<br />Stock&#160;That<br />Have Not<br />Vested&#160;(#)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Market<br />Value of<br />Shares or<br />Units of<br />Stock That<br />Have Not<br />Vested&#160;($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Equity<br />Incentive<br />Plan<br />Awards:<br />Number<br />of<br />Unearned<br />Shares,<br />Unit or<br />Other<br />Rights<br />That<br />Have Not<br />Vested<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Equity<br />incentive<br />Plan<br />Awards:<br />Market or<br />Payout<br />Value of<br />Unearned<br />Shares,<br />Units or<br />Other<br />Rights<br />That Have<br />Not Vested<br />($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Matthew W.&#160;Foehr</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/10/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/24/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/2/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/13/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/3/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,015</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,164,757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,396</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,142,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,060</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,244,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td>
<td style="height:3pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Charles S. Berkman</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/10/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/24/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/2/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/13/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/3/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,114</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,098,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,835</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">592,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,267</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">659,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">Each option grant to the named executive officers has a ten year term from the date of grant. Except as described below, each option vests 12.5% after six months from grant and the remainder in 42 equal monthly installments. For a description of the change in control provisions applicable to the stock option awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">The RSU awards granted to the named executive officers vest over a three year period in equal installments on February&#160;15 of the first three calendar years following the year in which the date of grant occurs. For a description of the change in control provisions applicable to the stock awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">Computed by multiplying the closing market price of Ligand&#8217;s common stock on December&#160;31, 2021, the last trading day of 2021, of $154.46, by the number of shares of common stock subject to such award. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">The table above reflects the remaining unvested RSUs from the following grants of RSUs to Mr.&#160;Foehr, which vest in equal installments over a three year period from the date of grant: 2,490 unvested RSUs granted on February&#160;11, 2019, 4,930 unvested RSUs granted on February&#160;13, 2020, and 6,595 unvested RSUs granted on February&#160;3, 2021. For a description of the change in control provisions applicable to the stock awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">Represents the &#8220;target&#8221; number of PSUs granted to the named executive officers in 2020. The PSUs granted in 2020 were eligible to vest based on objectives related to the compound annual growth rate of Ligand&#8217;s adjusted EPS growth for the two year performance period commencing January&#160;1, 2020 and ending December&#160;31, 2021 and Ligand&#8217;s relative TSR for the three year performance period commencing January&#160;1, 2020 and ending December&#160;31, 2022, with each such objective equally weighted (and a possible performance multiplier of 200% for &#8220;maximum&#8221; performance relative to earnings per share growth objective). Threshold performance levels, below which no vesting would have been awarded, were also established for each performance objective. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:Times New Roman">In January 2022, the Ligand Human Capital Management and Compensation Committee certified Ligand&#8217;s achievement relative to the adjusted EPS growth objective for purposes of the 2020 PSUs and determined that a 200% of &#8220;target&#8221; payout with respect to the units eligible to vest based on the adjusted EPS growth objective was earned. The actual number of units that vested and issued in January 2022 with respect to the portion of the 2020 awards tied to adjusted EPS growth is as follows: Mr.&#160;Foehr, 7,396; and Mr.&#160;Berkman, 3,836. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:Times New Roman">The &#8220;target&#8221; number of PSUs granted to the named executive officers reflected in the column above represented the portion of the award that was eligible to vest based on Ligand&#8217;s relative TSR. In connection with the Distribution, Ligand&#8217;s Human Capital Management and Compensation Committee amended the outstanding Ligand PSUs granted prior to the Equity Cutoff Date to convert those PSUs into time-based RSUs immediately prior to the Distribution based on its assessment of Ligand&#8217;s achievement relative to the applicable performance objectives of such date. As a result of such determination, the portion of the 2020 PSUs tied to Ligand&#8217;s relative TSR were assigned a 0% achievement level and were forfeited. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">Represents the &#8220;target&#8221; number of PSUs granted to the named executive officers in 2021. The PSUs granted in 2021 were eligible to vest based on objectives related to the number of partnered OmniAb antibody programs initiated for a two year performance period commencing January&#160;1, 2021 and ending December&#160;31, 2022 (up to a maximum of 150% of the target PSUs tied to this objective) and Ligand&#8217;s relative TSR for the three year performance period commencing January&#160;1, 2021 and ending December&#160;31, 2023 (up to a maximum of 200% of the target PSUs tied to this objective), with each such objective equally weighted. Threshold performance levels, below which no vesting would have been awarded, were also established for each performance objective. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. The &#8220;target&#8221; number of PSUs granted to the named executive officers reflected in the column above is 8,060 for Mr.&#160;Foehr and 4,267 for Mr.&#160;Berkman. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:Times New Roman">Ligand&#8217;s Human Capital Management and Compensation Committee amended the outstanding Ligand PSUs granted prior to the Equity Cutoff Date to convert those PSUs into time-based RSUs immediately prior to the Distribution based on its assessment of Ligand&#8217;s achievement relative to the applicable performance objectives of such date. With respect to the 2021 PSUs, the portion of the 2021 PSUs tied to Ligand&#8217;s relative TSR was determined to be 168% and the portion of the 2021 PSUs tiled to OmniAb program initiation was determined to be 150%. The 2021 PSUs, after giving effect to these achievement levels, were converted into time-based Ligand RSUs and will vest on December&#160;31, 2022 (with respect to the portion tied to OmniAb program initiation) and December&#160;31, 2023 (with respect to the portion formerly tied to Ligand&#8217;s relative TSR), subject to continued employment through each applicable vesting date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:left">The table above reflects the remaining unvested RSUs from the following grants of RSUs to Mr.&#160;Berkman, which vest in equal installments over a three year period: 1,067 unvested RSUs granted February&#160;11, 2019, 2,556 unvested RSUs granted on February&#160;13, 2020, and 3,491 unvested RSUs granted on February&#160;3, 2021. For a description of the change in control provisions applicable to the stock awards, see &#8220;<span style="font-style:italic">Acceleration of Equity Awards upon a Change in Control</span>&#8221; above. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, we adopted a <span style="white-space:nowrap">non-employee</span> director compensation policy. The material terms of the <span style="white-space:nowrap">non-employee</span> director compensation policy are summarized below. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our <span style="white-space:nowrap">non-employee</span> director compensation policy, each director will be eligible to receive an annual retainer of $50,000. No meeting fees will be paid. In addition, the chair of our Board will receive an additional annual retainer of $30,000. <span style="white-space:nowrap">Non-employee</span> directors also receive additional annual retainers for service on committees of our Board, as provided in the table below. Directors may elect to receive their retainers in cash or vested shares of our common stock, which shares will be issued under the 2022 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-employee</span> members of the Board will also be reimbursed for expenses incurred in connection with such service. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Service</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Annual&#160;Retainer<br />(Chair)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Annual&#160;Retainer<br />(Member)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Human Capital Management and Compensation Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our <span style="white-space:nowrap">non-employee</span> director compensation policy, Dr.&#160;Bertozzi and Mr.&#160;Tamaroff, who did not previously serve on the Ligand Board, will receive an initial grant of stock options and RSUs under the 2022 Plan, as described below. Our <span style="white-space:nowrap">non-employee</span> directors who previously served on the Ligand Board will not receive an initial award in connection with the Closing of the Business Combination. Following the Closing, new <span style="white-space:nowrap">non-employee</span> directors will receive initial awards effective on the date on which the individual first becomes a <span style="white-space:nowrap">non-employee</span> director. In addition, on the date of each annual meeting of our stockholders following the Closing of the Business Combination, each <span style="white-space:nowrap">non-employee</span> director will receive an annual grant of stock options and RSUs under the 2022 Plan. The equity compensation to be provided to our <span style="white-space:nowrap">non-employee</span> directors is provided in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:46%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target&#160;Value&#160;of<br />RSU Award<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target&#160;Value&#160;of<br />Option&#160;Award<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Target&#160;Value<br />of Award</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Grant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">280,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">425,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Grant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">260,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Except as described below with respect to the initial awards to Dr.&#160;Bertozzi and Mr.&#160;Tamaroff, the actual number of RSUs to be awarded is calculated by dividing (a)&#160;the target grant value of the RSU award, by (b)&#160;the average closing price per share of our common stock on the Nasdaq Stock Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the <span style="white-space:nowrap">60-calendar</span> day period prior to the date of grant. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Except as described below with respect to the initial awards to Dr.&#160;Bertozzi and Mr.&#160;Tamaroff, the actual number of options to be awarded is calculated using the Black-Scholes option pricing model (utilizing the same assumptions that we utilize in the preparation of our financial statements) and the same average closing price per share of the Company&#8217;s common stock as described in (b)&#160;above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of options granted to <span style="white-space:nowrap">non-employee</span> directors will be equal to the fair market value of our common stock on the Nasdaq Stock Market (or such other established stock exchange or national quotation system on which the stock is quoted) on the effective date of grant. The initial awards vest in three equal annual installments on each of the first three anniversaries following the date on which the director commences service on the Board. The annual awards vest in full on the earlier of (1)&#160;the date of the annual meeting of stockholders following the grant date, and (2)&#160;on the first anniversary of the date of grant. In addition, all awards will vest in full in the event of a change in control, as defined under the 2022 Plan. A <span style="white-space:nowrap">non-employee</span> director is able to exercise his or her stock options that were vested at the time of his or her cessation of Board service until the first to occur of (1)&#160;the third anniversary of the date of his or her cessation of Board service, or (2)&#160;the original expiration date of the term of such stock options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the Closing of the Business Combination, we approved equity awards to Dr.&#160;Bertozzi and Mr.&#160;Tamaroff with an aggregate grant date fair value of $425,000 (comprised of a stock option having a value of $280,000 and a RSU award having a value of $145,000), in accordance with the terms of our <span style="white-space:nowrap">non-employee</span> director compensation policy. The foregoing value for the RSU award will be converted into a number of RSUs based on the average closing price per share of our common stock on the Nasdaq Stock Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the period from November&#160;2, 2022 through and including November&#160;30, 2022. The foregoing value for the option award will be converted into a number options based on the Black-Scholes value of a share of our common stock on the grant date (using the foregoing average closing price per share of our common stock as the stock price input for such calculation). The grant date of the RSUs will be the date on which the Company&#8217;s Form <span style="white-space:nowrap">S-8</span> Registration Statement filed with respect to the 2022 Plan becomes effective and the grant date of the options will be December&#160;1, 2022. The options and RSUs will vest as described above for initial awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_13">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">APAC </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founder Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000, or approximately $0.004 per share, to cover certain APAC expenses in consideration of 5,750,000 APAC Class&#160;B Ordinary Shares. The number of APAC Class&#160;B Ordinary Shares issued was determined based on the expectation that such APAC Class&#160;B Ordinary Shares would represent 20% of the outstanding shares upon completion of the IPO. Prior to the closing of the IPO, the Sponsor transferred 35,000 APAC Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White and Wendel Barr, each of whom served on the APAC Board. In connection with the Domestication, all then-outstanding APAC Class&#160;B Ordinary Shares were automatically exchanged, on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis, into Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2021, APAC completed the sale to the Sponsor of an aggregate of 8,233,333 Private Placement Warrants for a purchase price of $1.50 per whole warrant for an aggregate of $12,350,000. Each Private Placement Warrant entitles the holder to purchase one share of Common Stock at $11.50 per share. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except that (a)&#160;subject to certain exceptions, the Private Placement Warrants are not transferable, assignable or saleable until 30 days after the completion of the Business Combination, (b)&#160;the Private Placement Warrants are exercisable on a cashless basis and are <span style="white-space:nowrap">non-redeemable</span> so long as they are held by the initial purchasers or their permitted transferees and (c)&#160;the Sponsor is entitled to registration rights in respect of the Private Placement Warrants. The Private Placement Warrants are redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Original Sponsor Insider Letter Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2021, APAC entered into the Sponsor Insider Letter Agreements with each of the Insiders, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve a proposed business combination (including any proposals recommended by the APAC Board in connection with such business combination and not to redeem any APAC shares held by them in connection with such shareholder approval in order to induce APAC and the underwriters in the IPO to enter into an underwriting agreement and to proceed with the IPO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Insider Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, OmniAb, the Sponsor, APAC and the Insiders entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor Insider Agreement also provides, among other things, that the holders of the Sponsor Earnout Shares may not transfer their Sponsor Earnout Shares until the date in which vesting has occurred, other than in a distribution made by the Sponsor to its members in accordance with the Cayman Governance Documents of APAC and the A&amp;R Registration Rights Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor Insider Agreement will terminate on the earlier of (i)&#160;termination of the Merger Agreement or (ii)&#160;the vesting in full of all Sponsor Earnout Shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Loans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of APAC&#8217;s officers and directors could, but were not obligated, to loan APAC funds as may be required (&#8220;Working Capital Loans&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2021, APAC and the Sponsor entered into promissory notes pursuant to which the Sponsor agreed to loan up to an aggregate of $300,000 to APAC for working capital purposes (the &#8220;First Promissory Note&#8221;). The Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the promissory note as of March&#160;22, 2021. On June&#160;23, 2021, APAC borrowed $119,275 under a Working Capital Loan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2021, APAC repaid the outstanding balance under the promissory note of $175,000. On March&#160;14, 2022, APAC entered into a promissory note with the Sponsor (the &#8220;Second Promissory Note&#8221;) pursuant to which APAC could borrow up to an aggregate of $750,000. The loan under the Second Promissory Note was <span style="white-space:nowrap">non-interest</span> bearing and payable upon the completion of the Business Combination. As of September&#160;30, 2022, the outstanding balance on the promissory note was $750,000. The outstanding balance under the promissory note was paid in full in connection with the Closing out of the proceeds of the trust account released to APAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administrative Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From August&#160;9, 2021 until the completion of the Business Combination, APAC was party to an administrative services agreement pursuant to which APAC paid an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. For the three and nine months ended September&#160;30, 2022, APAC incurred $30,000 and $90,000 of administrative expenses respectively, and accrued $86,129 of administrative expenses as of September&#160;30, 2022. For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, APAC incurred $46,129 of administrative services under this arrangement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights and Board Designation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger, the Company, the Sponsor and the other parties thereto entered into the A&amp;R Registration Rights Agreement, which amended and restated APAC&#8217;s original registration rights agreement in its entirety. The holders of Common Stock and the Private Placement Warrants are entitled to shelf registration rights pursuant to the A&amp;R Registration Rights Agreement requiring the Company to use commercially reasonable efforts to, within thirty (30)&#160;days after the Closing, file a registration statement on Form <span style="white-space:nowrap">S-1</span> to permit the public resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule 415 under the Securities Act. In addition, the holders have certain customary &#8220;piggy back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the A&amp;R Registration Rights Agreement provides that the Sponsor has the right to designate one (1)&#160;individual to our Board, and that such right will terminate upon the later of (i)&#160;such time as the Sponsor ceases to beneficially own at least ten percent (10%) of our outstanding voting stock and (ii)&#160;subject to compliance with the rules of Nasdaq, the third anniversary of the date of the Merger Agreement, or March&#160;23, 2025. Moreover, any individual nominated by the Sponsor requires the consent of our Board, subject to certain exceptions. Mr.&#160;Tamaroff was designated as a member of our Board by the Sponsor pursuant to A&amp;R Registration Rights Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding the A&amp;R Registration Rights Agreement, see &#8220;<span style="font-style:italic">Description of our Securities&#8212;Registration Rights</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the entry into the A&amp;R Registration Rights Agreement, the Original Registration Rights Agreement was terminated as of the Effective Time, and replaced with the A&amp;R Registration Rights Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2021, APAC entered into the Forward Purchase Agreement with Sponsor. Pursuant to the Forward Purchase Agreement, the Sponsor agreed to purchase 10,000,000 APAC Class&#160;A Ordinary Shares, plus an aggregate of 3,333,333 redeemable warrants to purchase one APAC Class&#160;A Ordinary Share at $11.50 per share, for an aggregate purchase price of $100,000,000, or $10.00 per APAC Class&#160;A Ordinary Shares, in a private placement to occur concurrently with the closing of APAC&#8217;s initial business combination. On March&#160;23, 2022, the Forward Purchase Agreement was amended and restated in its entirety by the A&amp;R FPA in connection with the pending Business Combination, and entered into by APAC, Sponsor and OmniAb. Pursuant to the A&amp;R FPA, APAC agreed to issue and sell to the Sponsor 1,500,000 shares of Common Stock and warrants to acquire 1,666,667 shares of Common Stock for an aggregate purchase price of $15,000,000, with such purchases consummated immediately following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor purchase an additional 8,672,934 shares of Common Stock and an additional 1,445,489 Private Placement Warrants, for an aggregate additional purchase price of $86,729,340, in order to backstop shareholder redemptions which would have otherwise resulted cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000 as of immediately prior to the Closing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OmniAb </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Agreements with Ligand </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Separation, OmniAb entered into various agreements to effect the Separation and provide a framework for OmniAb&#8217;s relationship with Ligand after the Separation, including the Separation Agreement, two Transition Services Agreements, an Employee Matters Agreement and a Tax Matters Agreement. These agreements provide for the allocation between OmniAb and Ligand of Ligand&#8217;s assets, employees, liabilities and obligations (including its property and employee benefits and <span style="white-space:nowrap">tax-related</span> assets and liabilities) attributable to periods prior to, at and after OmniAb&#8217;s separation from Ligand and govern certain relationships between OmniAb and Ligand after the Separation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summaries of each of the agreements listed above are qualified in their entireties by reference to the full text of the applicable agreements which are filed as exhibits to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Separation Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Ligand, Legacy OmniAb and APAC entered into the Separation Agreement which sets forth the principal actions taken in connection with the Separation. The Separation Agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ligand and Legacy OmniAb as part of the internal reorganization described therein and requires the Ligand Contribution to be made to Legacy OmniAb. The Separation Agreement also sets forth other agreements that govern certain aspects of the Company&#8217;s and Legacy OmniAb&#8217;s relationship with Ligand following the Separation, Distribution and Merger. On the Closing Date, pursuant to the Separation Agreement, Legacy OmniAb issued additional shares of Common Stock to Ligand. Ligand then distributed on a pro rata basis all of the outstanding shares of Common Stock to the holders of Ligand Common Stock as of the record date set for the Distribution by delivering to the distribution agent a book-entry authorization representing the shares of Common Stock being distributed for the account of Ligand&#8217;s stockholders. The distribution agent held such book-entry shares for the account of Legacy OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transition Services Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Separation, Legacy OmniAb and Ligand entered into two Transition Services Agreements pursuant to which Ligand and its affiliates and Legacy OmniAb and its affiliates will provide to each other various <span style="white-space:nowrap">non-scientific</span> and <span style="white-space:nowrap">non-technical</span> services set forth in the applicable Transition Services Agreement, which services are of the type that Legacy OmniAb and Ligand provided to, and received from, each other prior to the Separation. Ligand will provide services relating to information technology, facilities, accounting and finance, business development, investor relations, human resources, and other corporate and administrative functions, and Legacy OmniAb will provide services relating to corporate functions, legal administration, and other administrative functions. The fees for each of the transition services are set forth in the applicable Transition Services Agreement as a flat monthly fee, and the receiving party will reimburse the providing party for all reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs and expenses that the providing party incurs in connection with providing the transition services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Transition Services Agreements will terminate on the expiration of the term of the last service provided under it, unless earlier terminated by the receiving party with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. The transition services are generally expected to last up to one year and the receiving party for a particular service may terminate such service prior to the scheduled expiration date with prior written notice. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tax Matters Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution, the Company, Legacy OmniAb, and Ligand entered into the Tax Matters Agreement that governs each party&#8217;s respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and certain other matters regarding taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, we will be liable for all U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are (i)&#160;imposed with respect to tax returns that include both Legacy OmniAb and Ligand, to the extent such taxes are attributable to Legacy OmniAb or the OmniAb Business (as defined in the Tax Matters Agreement), or (ii)&#160;imposed with respect to tax returns that include the Company or Legacy OmniAb but not Ligand, in each case, for tax periods (or portions thereof) beginning after the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, we may be liable for certain taxes resulting from the restructuring transactions undertaken to effectuate the Distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Distribution, together with certain related transactions, is intended to qualify as a reorganization under Sections 355 and 368(a)(1)(D) of the Code. Pursuant to the Tax Matters Agreement, taxes incurred by Ligand, the Company or Legacy OmniAb relating to or arising out of the failure of the intended tax treatment will generally be shared equally by Ligand, on the one hand, and us, on the other hand. If, however, such failure is attributable to certain acts or omissions by the Company or Legacy OmniAb, inaccuracies, misrepresentations or misstatements relating to the Company or Legacy OmniAb or certain events involving our stock or the assets of the OmniAb Business, we will generally bear all such taxes. Under certain circumstances, including if the failure is attributable to Ligand or an event involving Ligand&#8217;s stock or assets, Ligand will bear all such taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Matters Agreement requires us to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand received regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement also restricts our ability to take or fail to take any action if such action or failure to act could reasonably be expected to adversely affect the intended tax treatment. In particular, in the two years following the Distribution, we will be subject to certain restrictions, generally including being prevented from (i)&#160;entering into any transaction which could, when </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combined with other transactions (including the Merger), result in a 45% or greater change in ownership of shares of our Common Stock, Ligand Common Stock or the stock of a successor of any of the foregoing occurring as part of a plan or series of related transactions that includes the Distribution, (ii)&#160;ceasing the active conduct of certain of our businesses, (iii)&#160;voluntarily dissolving or liquidating the Company or Legacy OmniAb and (iv)&#160;causing, permitting, or agreeing to the sale, transfer, or disposal of our assets that, in the aggregate, constitute more than 30% of our consolidated gross assets, in each case, unless we obtain a private letter ruling from the IRS, an unqualified opinion of a nationally recognized tax advisor that such action will not cause a failure of the intended tax treatment, or Ligand consents to the undertaking of such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding receipt of such ruling, opinion or consent, in the event that such action causes a failure of the intended tax treatment, we could be responsible for all taxes arising therefrom. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the Tax Matters Agreement are not limited in amount or subject to any cap. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employee Matters Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC, Ligand, Legacy OmniAb and Merger Sub entered into the Employee Matters Agreement, which sets forth the terms and conditions of certain employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and Legacy OmniAb, treatment of incentive equity awards in the Distribution and the Business Combination and related covenants and commitments of the parties. On August&#160;18, 2022, the parties entered into the A&amp;R Employee Matters Agreement in order to update the treatment of certain incentive equity awards in the Distribution and the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The A&amp;R Employee Matters Agreement provides for the treatment of outstanding Ligand equity awards held by our employees upon completion of the Distribution and the treatment of outstanding OmniAb Equity Awards in connection with the Business Combination, each as described in further detail in the section entitled &#8220;<span style="font-style:italic">Executive and Director Compensation</span><span style="font-style:italic"></span><span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">Narrative to Summary Compensation Table</span><span style="font-style:italic"></span><span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">Treatement of Outstanding Equity Awards at the Time of the Distribution</span>,&#8221; and also provides for certain other incentive arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The A&amp;R Employee Matters Agreement provides that, following the Distribution and Business Combination, our employees generally will continue to participate in benefit plans sponsored or maintained by Ligand until the earlier to occur of (i)&#160;January&#160;1, 2023 or (ii)&#160;such earlier date as may be agreed among the parties. Following the respective plan transition date, our employees will commence participation in our respective benefit plans, which are expected to be generally similar to the existing Ligand benefit plans. Additionally, the A&amp;R Employee Matters Agreement provided that APAC shall approve and adopt the 2022 Plan and the ESPP, effective as of the Closing of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The A&amp;R Employee Matters Agreement also sets forth the general principles relating to employee matters, including with respect to the assignment and transfer of employees, the assumption and retention of liabilities and related assets, workers&#8217; compensation, payroll taxes, regulatory filings, the provision of comparable benefits, employee service credit, the sharing of employee information, and the duplication or acceleration of benefits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The A&amp;R Employee Matters Agreement may be amended or modified only by a written agreement among the parties and will terminate automatically upon the termination of the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies and Procedures for Related Person Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted a written related person transaction policy that sets forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act, any transaction, arrangement or relationship, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any series of similar transactions, arrangements or relationships in which our company was or is to be a participant, where the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occured prior to the adoption of this policy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_14">PRINCIPAL STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of Common Stock following the consummation of the Business Combination by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is known to be the beneficial owner of more than 5% of shares of Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our current named executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all current executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of Common Stock is based on 114,820,859 shares of Common Stock outstanding as of November&#160;1, 2022, which includes 2,137,035 outstanding Earnout Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days after that date through (a)&#160;the exercise of any option, warrant or right, (b)&#160;the conversion of a security, (c)&#160;the power to revoke a trust, discretionary account or similar arrangement, or (d)&#160;the automatic termination of a trust, discretionary account or similar arrangement. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to options or other rights (as set forth above) held by that person that are currently exercisable, or will become exercisable within 60 days thereafter, are deemed outstanding, while such shares are not deemed outstanding for purposes of computing percentage ownership of any other person. The table below includes the beneficial ownership of the Earnout Shares but does not reflect the beneficial ownership of shares of Common Stock issuable upon the exercise of Public Warrants. Each person named in the table has sole voting and investment power with respect to all of the shares shown as beneficially owned by such person, except as otherwise indicated in the table or footnotes below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to the voting securities beneficially owned by them. To our knowledge, no shares of Common Stock beneficially owned by any executive officer or director have been pledged as security. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">5% Holders</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avista Acquisition LP II<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,163,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thompson Dean<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,163,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Burgstahler<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,163,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,439,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,412,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Group plc<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,061,418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair Investment Management, LLC<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,861,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Directors and Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Foehr<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,276,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles S. Berkman<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">550,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt A. Gustafson<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">148,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John L. Higgins<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,139,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carolyn R. Bertozzi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Boyce<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Cochran, Ph.D.<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sunil Patel<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">262,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Tamaroff<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All directors and executive officers as a group (9 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,471,899</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise noted, the business address of each of those listed in the table above is 5980 Horton Street, Suite 600, Emeryville, CA 94608. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Common Stock benefically owned by the Sponsor, Mr.&#160;Dean and Mr.&#160;Burgstahler (the &#8220;Reporting Persons&#8221;) at November&#160;1, 2022, as indicated in the Reporting Persons&#8217; Schedule 13D filed with the SEC on November&#160;14, 2022. Consists of (i)&#160;15,817,934 shares of Common Stock, (ii)&#160;8,233,333 shares of Common Stock issuable to Sponsor pursuant to the APAC Private Placement Warrants exercisable within 60&#160;days of November&#160;1, 2022, (iii)&#160;1,666,667 shares of Common Stock issuable to Sponsor pursuant to the OmniAb Warrants issued in the Forward Purchase exercisable within 60 days of November&#160;1, 2022, and (iv)&#160;1,445,489 shares of Common Stock issuable to Sponsor pursuant to the OmniAb Warrants issued in the Redemption Backstop exercisable within 60 days of November&#160;1, 2022. The shares reported above are held in the name of the Sponsor. Mr.&#160;Dean and Mr.&#160;Burgstahler may be deemed to beneficially own shares held by the Sponsor by virtue of their shared control over Avista Acquisition GP LLC II, which is the general partner of the Sponsor. Each of Messrs. Dean and Burgstahler disclaims beneficial ownership of the shares held by the Sponsor. The business address of the Reporting Persons is 65 East 55th Street 18th Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Common Stock owned by funds affiliated with BlackRock, Inc. at December&#160;31, 2021, as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on January&#160;27, 2022. The business address for BlackRock, Inc. is 55 East 52nd Street, New York, New York 10055. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Common Stock beneficially owned by The Vanguard Group at December&#160;31, 2021 as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on February&#160;10, 2022. The business address for The Vanguard Group is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Common Stock owned by funds affiliated with Janus Henderson Group plc. at December&#160;31, 2021, as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on February&#160;10, 2022. The business address for Janus Henderson Group plc. is 201 Bishopsgate EC2M 3AE, United Kingdom. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Common Stock beneficially owned by William Blair Investment Management, LLC at December&#160;31, 2021 as indicated in the entity&#8217;s Schedule 13G/A filed with the SEC on February&#160;10, 2022. The business address for William Blair Investment Management, LLC is 150 North Riverside Plaza, Chicago, Illinois 60606. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,129,274 shares of Common Stock, (ii) 29,620 shares of Common Stock issuable to Mr.&#160;Foehr upon settlement of outstanding restricted stock units vesting within 60 days of November&#160;1, 2022 and (iii) 1,117,365 shares of Common Stock Mr.&#160;Foehr has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 255,947 shares of Common Stock, (ii) 15,685 shares of Common Stock issuable to Mr.&#160;Berkman upon settlement of outstanding restricted stock units vesting within 60 days of November&#160;1, 2022 and (iii) 278,422 shares of Common Stock Mr.&#160;Berkman has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 90,310 shares of Common Stock and (ii) 58,127 shares of Common Stock Mr.&#160;Gustafson has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,993,137 shares of Common Stock, (ii) 56,630 shares of Common Stock issuable to Mr.&#160;Higgins upon settlement of outstanding restricted stock units vesting within 60 days of November&#160;1, 2022 and (iii) 278,422 shares of Common Stock Mr.&#160;Higgins has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 28,684 shares of Common Stock and (ii) 47,175 shares of Common Stock issuable to Ms.&#160;Boyce within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 12,681 shares of Common Stock and (ii) 6,433 shares of Common Stock Dr.&#160;Cochran has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 163,759 shares of Common Stock and (ii) 99,026 shares of Common Stock Mr.&#160;Patel has the right to acquire pursuant to outstanding options that are exercisable within 60 days of November&#160;1, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Although Mr.&#160;Tamaroff does not beneficially own any shares of Common Stock, he may have an indirect economic interest in OmniAb through entities that have an interest in Avista Acquisition LP II. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_15">SELLING SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders listed in the table below may from time to time offer and sell any or all of the shares of Common Stock and Warrants set forth below pursuant to this prospectus. The table also includes shares of Common Stock issuable to certain &#8220;affiliates&#8221; of our company (as defined in Rule 405 under the Securities Act) upon the exercise of options to purchase Common Stock, or vesting of RSUs and PSUs, held by such affiliates irrespective of whether such securities are exercisable or will vest within 60 days of the date of this prospectus. When we refer to the &#8220;Selling Securityholders&#8221; in this prospectus, we refer to the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors and other permitted transferees that hold any of the Selling Securityholders&#8217; interest in the shares of Common Stock and Warrants after the date of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information provided by or on behalf of the Selling Securityholders concerning the Common Stock and Warrants that may be offered from time to time by each Selling Securityholder pursuant to this prospectus. The Selling Securityholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities. Moreover, the securities identified below include only the securities being registered for resale and may not incorporate all shares deemed to be beneficially held by the Selling Securityholders. Any changed or new information given to us by the Selling Securityholders, including regarding the identity of, and the securities held by, each Selling Securityholder, will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus is a part, if and when necessary. A Selling Securityholder may sell all, some or none of such securities in this offering. See &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Percentage ownership is based on 114,820,859 shares of Common Stock, which includes 2,137,035 Earnout Shares, and 19,012,156 Warrants outstanding as of November&#160;1, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below or elsewhere in this prospectus, none of the Selling Securityholders has any material relationship with us or any of our predecessors or affiliates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Names and Addresses<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Securities<br />Beneficially<br />Owned prior<br />to this Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Securities<br />to be Sold<br />in this Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Securities&#160;Beneficially&#160;Owned&#160;after&#160;this<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;of<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avista Acquisition LP II<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,163,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,345,489</td>
<td style="white-space:nowrap;vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,163,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,345,489</td>
<td style="white-space:nowrap;vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Foehr<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,742,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,742,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles S. Berkman<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">819,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">819,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt A. Gustafson<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">526,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">526,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John L. Higgins<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,580,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,580,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carolyn R. Bertozzi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Boyce<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Cochran, Ph.D.<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sunil Patel<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309,378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309,378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Tamaroff<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise noted, the business address of each of those listed in the table above is 5980 Horton Street, Suite 600, Emeryville, CA 94608. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 27,163,423 shares of Common Stock (consisting of 15,817,934 shares of Common Stock directly held by Avista Acquisition LP II and 11,345,489 shares of Common Stock issuable upon the exercise of 11,345,489 Private Placement Warrants held directly by Avista Acquisition LP II) and (ii) 11,345,489 APAC Private Placement Warrants. The shares and Private Placement Warrants reported above are held in the name of the Sponsor. Mr.&#160;Dean and Mr.&#160;Burgstahler may be deemed to beneficially own shares held by our sponsor by virtue of their shared control over Avista Acquisition GP LLC II, which is the general partner of the Sponsor. Each of Messrs. Dean and Burgstahler disclaims beneficial ownership of our ordinary shares held by the Sponsor. The business address of the Sponsor, Mr.&#160;Dean and Mr.&#160;Burgstahler is 65 East 55th Street 18th Floor, New York, NY 10022. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,129,274 shares of Common Stock, including 264,760 Earnout Shares, (ii) 224,754 shares of Common Stock issuable to Mr.&#160;Foehr upon vesting of RSUs and PSUs and (iii) 1,388,459 shares of Common Stock issuable to Mr.&#160;Foehr upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 255,947 shares of Common stock, including 96,038 Earnout Shares, (ii) 126,402 shares of Common Stock issuable to Mr.&#160;Berkman upon vesting of RSUs and PSUs and (iii) 436,806 issuable to Mr.&#160;Berkman upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 96,310 shares of Common stock, including 72,872 Earnout Shares, (ii) 87,190 shares of Common Stock issuable to Mr.&#160;Gustafson upon vesting of RSUs and PSUs and (iii) 348,760 issuable to Mr.&#160;Gustafson upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,239,785 shares of Common Stock, including 362,232 Earnout Shares, (ii) 183,384 shares of Common Stock issuable to Mr.&#160;Higgins upon vesting of RSUs and (iii) 2,156,957 shares of Common Stock issuable to Mr.&#160;Higgins upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 28,684 shares of Common Stock, including 14,512 Earnout Shares, (ii) 8,753 shares of Common Stock issuable to Ms.&#160;Boyce upon vesting of RSUs and (iii) 85,015 shares of Common Stock issuable to Ms.&#160;Boyce upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 12,681 shares of Common Stock, including 10,784 Earnout Shares, (ii) 12,545 shares of Common Stock issuable to Dr.&#160;Cochran upon vesting of RSUs and (iii) 57,138 shares of Common Stock issuable to Dr.&#160;Cochran upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 163,759 shares of Common Stock, including 22,538 Earnout Shares, (ii) 8,753 shares of Common Stock issuable to Mr.&#160;Patel upon vesting of RSUs, and (iii) 136,866 shares of Common Stock issuable to Mr.&#160;Patel upon the exercise of options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Although Mr.&#160;Tamaroff does not beneficially own any shares of Common Stock, he may have an indirect economic interest in OmniAb through entities that have an interest in Avista Acquisition LP II. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_16">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes some of the terms of our certificate of incorporation and bylaws and the DGCL, as well as the terms of the Warrants. This description is summarized from, and qualified in its entirety by reference to, our certificate of incorporation, our bylaws and the Warrant Agreement, each of which has been publicly filed with the SEC, as well as the relevant provisions of the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Capital Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of shares of our authorized capital stock is 1,100,000,000. The total amount of our authorized capital stock consists of 1,000,000,000 shares of Common Stock and 100,000,000 shares of preferred stock. As of the date of this prospectus, no shares of preferred stock are issued or outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our Common Stock are entitled to receive ratably those dividends, if any, as may be declared by the Board out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of Common Stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of our Common Stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the Common Stock. All outstanding shares of Common Stock are duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our certificate of incorporation, our Board has the authority, without further action by our stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deterring or preventing a change in our control and may adversely affect the market price of the Common Stock and the voting and other rights of the holders of our Common Stock. We have no current plans to issue any shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Registration Rights Agreement, we are required to use commercially reasonable efforts to, within thirty (30)&#160;days after the Closing, file a registration statement on Form <span style="white-space:nowrap">S-1</span> to permit the public </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule&#160;415 under the Securities Act, and to provide certain equityholders of Legacy OmniAb as of immediately prior to the Closing of the Business Combination with customary registration rights. In addition, the holders have certain customary &#8220;piggy back&#8221; registration rights with respect to registration statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer restrictions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transfer Restrictions Applicable to the Sponsor and the Directors and Officers of the Combined Company </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The A&amp;R Registration Rights Agreement provides for certain restrictions on transfer with respect to our securities, including Founder Shares, Private Placement Warrants, Backstop Warrants, Forward Purchase Warrants, and securities held by directors and officers of APAC prior to the Business Combination and certain directors and officers of OmniAb and Ligand. Such restrictions will begin upon Closing and end (i)&#160;with respect to the Founder Shares, at the earliest of (A)&#160;one year after the closing date and (B)&#160;the first date on which (x)&#160;the last reported sale price of a share of Common Stock equals or exceeds $12.00 per share for any 20 trading days within any <span style="white-space:nowrap">30-trading</span> day period commencing at least 150 days after the closing date or (y)&#160;APAC completing a liquidation, merger, share exchange, reorganization or other similar transaction that results in our stockholders having the right to exchange their shares of Common Stock for cash, securities or other property; (ii)&#160;with respect to the Private Placement Warrants, Backstop Warrants and Forward Purchase Warrants that are held by the initial purchasers of such warrants (or permitted transferees under the A&amp;R Registration Rights Agreement), and any of the shares of Common Stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers of the applicable warrants being converted (or permitted transferees under the A&amp;R Registration Rights Agreement), the period ending 30 days after the closing; and (iii)&#160;mean with respect to the shares of Common Stock issued to the New Holders (as defined in the A&amp;R Registration Rights Agreement), each of whom are the directors and officers of Ligand and/or OmniAb, in connection with the consummation of the Merger and held by the New Holders (or their permitted transferees under the A&amp;R Registration Rights Agreement), the period ending on the earliest of (A)&#160;three months after the closing and (B)&#160;the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of Common Stock for cash, securities or other property. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Earnout Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement and our bylaws, OmniAb Earnout Shares and Sponsor Earnout Shares may not be transferred until the applicable OmniAb Triggering Event or a Sponsor Triggering Event has occurred. OmniAb Earnout Shares and Sponsor Earnout Shares are issued and outstanding will be automatically forfeited for no consideration if an applicable OmniAb Triggering Event or Sponsor Triggering Event has not occurred with respect to such OmniAb Earnout Shares or Sponsor Triggering during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment as discussed herein, at any time after December&#160;1, 2022 (which is 30 days after the completion of the Business Combination), except as discussed in the immediately succeeding paragraph. Pursuant to the Warrant Agreement, a warrant holder may exercise its Public Warrants only for a whole number of shares of Common Stock. Consequently, only a whole Public Warrant may be exercised at a given time by a warrant holder. The Public Warrants will expire on November&#160;1, 2027 (which is five years after the completion of the Business Combination), at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not be obligated to deliver any shares of Common Stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying such warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration, or a valid exemption from registration is available. No Public Warrant will be exercisable and we will not be obligated to issue shares of Common Stock upon exercise of a Public Warrant unless the Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of such warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Public Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrants has not been declared effective within 60 business days after the completion of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise such warrants on a cashless basis pursuant to the exemption provided by Section&#160;3(a)(9) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that as soon as practicable, we will use our commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which this prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Public Warrants, and we will use our commercially reasonable efforts to cause the same to become effective, and to maintain the effectiveness of such registration statement and a current prospectus relating to such shares until the Public Warrants expire or are redeemed, as specified in the Warrant Agreement; provided that if shares of Common Stock are at the time of any exercise of a Public Warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of Warrants who exercise their Warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, and we will use our commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrants is not effective by the 60th business day after the completion of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise such warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and we will use our commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying such warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the Public Warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of shares of Common Stock for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the Public Warrants become exercisable, we may redeem such outstanding warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon a minimum of 30 days&#8217; prior written notice of redemption to each warrant holder; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of shares of Common Stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of such warrant as described under the heading &#8220;&#8212;Warrants&#8212;Anti-dilution Adjustments&#8221;) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending three trading days before we send the notice of redemption to the warrant holders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not redeem the Public Warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of Common Stock issuable upon exercise of such warrants is then effective and a current prospectus relating to those shares of Common Stock is available throughout the <span style="white-space:nowrap">30-day</span> redemption period. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption, each warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. However, the price of the shares of Common Stock may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of such warrant as described under the heading &#8220;&#8212;Warrants&#8212;Anti-dilution Adjustments&#8221;) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of Common Stock will be issued upon warrant exercise. If, upon warrant exercise, a warrant holder would be entitled to receive a fractional interest in a share, we will round down to the nearest whole number of the number of shares of Common Stock to be issued to the holder. If, at the time of redemption, the Public Warrants are exercisable for a security other than shares of Common Stock pursuant to the Warrant Agreement, such warrants may be exercised for such security. At such time as the Public Warrants become exercisable for a security other than shares of Common Stock, we will use our commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of such warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A warrant holder may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the shares of Common Stock issued and outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Dilution Adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Common Stock is increased by a capitalization or share dividend payable in shares of Common Stock, or by a <span style="white-space:nowrap">sub-division</span> of shares of Common Stock or other similar event, then, on the effective date of such capitalization or share dividend, <span style="white-space:nowrap">sub-division</span> or similar event, the number of shares of Common Stock issuable on exercise of each Public Warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering made to all or substantially all holders of shares of Common Stock entitling holders to purchase shares of Common Stock at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of shares of Common Stock equal to the product of (i)&#160;the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for shares of Common Stock) and (ii)&#160;one minus the quotient of (x)&#160;the price per share of Common Stock paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for shares of Common Stock, in determining the price payable for shares of Common Stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means the volume weighted average price of shares of Common Stock as reported during the 10 trading day period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we, at any time while the Public Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to all or substantially all of the holders of the shares of Common Stock on account of such shares (or other securities into which the Public Warrants are convertible), other than (a)&#160;as described above or (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the shares of Common Stock during the <span style="white-space:nowrap">365-day</span> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of shares of Common Stock issuable on exercise of each Public Warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Common Stock in respect of such event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Common Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant will be decreased in proportion to such decrease in outstanding shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of such warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants were issued in registered form under the Warrant Agreement. The Warrant Agreement provides that the terms of such warrants may be amended without the consent of any holder for the purpose of (i)&#160;curing any ambiguity or correct any mistake, including to conform the provisions of the Warrant Agreement to the descriptions of the terms of such warrants and the Warrant Agreement set forth in this prospectus, or defective provision or (ii)&#160;making any amendments that are necessary in the good faith determination of our board of directors to allow for such warrants to continue to be classified as equity in our financial statements; provided that no such amendment shall increase the warrant exercise price, shorten the warrant exercise period or, in the aggregate, materially affect the legal rights of registered holders of the then-outstanding Public Warrants under the Warrant Agreement, (iii)&#160;removing or reducing our ability to redeem the Warrants or (iv)&#160;adding or changing any provisions with respect to matters or questions arising under the Warrant Agreement as the parties to the Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the warrant holders, provided that in the case of this clause (iv)&#160;the approval by the registered holders of at least 50% of the then-outstanding Public Warrants is required to make any change that adversely affects the legal rights of such holders under the Warrant Agreement. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a warrant holder if the holders of at least 50% of the then-outstanding Public Warrants approve of such amendment and, solely with respect to any amendment to the terms of the Private Placement Warrants or any provision of the Warrant Agreement with respect to the Private Placement Warrants, 50% of the number of the then outstanding Private Placement Warrants; provided that the Warrant Agreement may be amended with the vote or written consent of holders of at least 50% of the then outstanding Private Placement Warrants without the consent of any other holder to provide that the Private Placement Warrants (a)&#160;will remain Private Placement Warrants, as applicable, when transferred to any party, including parties that are not permitted transferees, or (b)&#160;have the same terms as the Public Warrants, subject to any applicable contractual restrictions or securities law restrictions. You should review a copy of the Warrant Agreement for a complete description of the terms and conditions applicable to the Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant holders do not have the rights or privileges of holders of shares of Common Stock or any voting rights until they exercise the Warrants and receive shares of Common Stock. After the issuance of shares of Common Stock shares upon exercise of the Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, subject to applicable law, any action, proceeding or claim against us rising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act, but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Private Placement Warrant entitles the holder to purchase one share of Common Stock at $11.50 per share. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except that (a)&#160;subject to certain exceptions, the Private Placement Warrants are not transferable, assignable or saleable until 30 days after the completion of the Business Combination, (b)&#160;the Private Placement Warrants are exercisable on a cashless basis and are <span style="white-space:nowrap">non-redeemable</span> so long as they are held by the initial purchasers or their permitted transferees and (c)&#160;the Sponsor is entitled to registration rights in respect of the Private Placement Warrants. The Private Placement Warrants are redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-takeover effects of Delaware law and our certificate of incorporation and bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of OmniAb to first negotiate with OmniAb&#8217;s board of directors. OmniAb believes that the benefits of the increased protection of its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure OmniAb outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Undesignated preferred stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of our Board, without action by the stockholders, to issue up to 100,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by the board of directors could impede the success of any attempt to change our control. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in our control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that a special meeting of stockholders may be called only by our Board or chair of the board of directors, chief executive officer or president. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Requirements for advance notification of stockholder nominations and proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with respect to Shareholder Proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Elimination of stockholder action by written consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation expressly eliminates the right of our stockholders to act by written consent. Stockholder action must take place at the annual or a special meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Staggered board of directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incororation provides that our Board is divided into three classes. The directors in each class will serve for a three-year term, with one class being elected each year by our stockholders. This system of electing directors may tend to discourage a third party from attempting to obtain control of OmniAb, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incororation provides that no member of our Board may be removed from office except for cause and, in addition to any other vote required by law, upon the approval of not less than <span style="white-space:nowrap">two-thirds</span> of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholders not entitled to cumulative voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incororation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of Common Stock who are entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware anti-takeover statute </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniAb is subject to Section&#160;203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Choice of forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, in the event the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on OmniAb&#8217;s behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty by any of our directors, officers or stockholders to us or our stockholders; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws (as each may be amended from time to time); or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. In addition, the certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. However, we note that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in any security of OmniAb will be deemed to have notice of and to have consented to these choice of forum provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of charter provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our certificate of incorporation and bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that the affirmative vote of the holders of at least <span style="white-space:nowrap">two-thirds</span> of the total voting power of our outstanding shares entitled to vote thereon, voting as a single class, is required to amend certain provisions relating to the issuance of preferred stock, the number, term, classification, removal and filling of vacancies with respect to the board of directors, the advance notice to be given for nominations for elections of directors, the calling of special meetings of stockholders, stockholder action by written consent, forum selection, the ability to amend the bylaws, the elimination of liability of directors and officers to the extent permitted by Delaware law, director and officer indemnification and any provision relating to the amendment of any of these provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that our bylaws may only be amended by the Board or by the affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> of the total voting power of our outstanding shares entitled to vote thereon, voting as a single class. Additionally, the certificate of incorporation provides that our bylaws may be adopted, amended, altered or repealed by our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar and Warrant Agent </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock and the warrant agent for the Warrants is Computershare Trust Company, N.A. (&#8220;Computershare&#8221;). Computershare&#8217;s address is 150 Royall Street, Canton, Massachusetts 02021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Nasdaq Stock Market Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock listed on the Nasdaq Global Market under the symbol &#8220;OABI,&#8221; and our Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;OABIW.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations of Liability and Indemnification Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of liability and indemnification, see &#8220;Executive and Director Compensation &#8212; Limitations of Liability and Indemnification Matters.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_17">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering (i)&#160;the resale of 3,920,440 shares of Common Stock issued in connection with the Business Combination, including 843,736 Earnout Shares that may become tradeable upon the achievement of certain stock price-based vesting conditions in accordance with the terms of the Merger Agreement, by certain of the Selling Securityholders; (ii)&#160;the resale of 15,817,934 shares of Common Stock issued to the Sponsor in private placements in connection with the IPO, the Redemption Backstop and the Forward Purchase, including 1,293,299 Sponsor Earnout Shares; (iii)&#160;the resale of 11,345,489 shares of Common Stock issuable upon the exercise of up to 11,345,489 Private Placement Warrants; (iv)&#160;the issuance by us and resale of 5,261,782 shares of Common Stock reserved for issuance upon the exercise of options to purchase Common Stock and the vesting of RSUs and PSUs; and (v)&#160;the issuance by us of up to 19,012,156 shares of Common Stock upon the exercise of the Warrants. The Selling Securityholders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including underwriters&#8217; or agents&#8217; commissions and discounts, brokerage fees, underwriter marketing costs and all reasonable fees and expenses of any legal counsel representing the Selling Securityholders, except that we will pay the reasonable fees and expenses of one legal counsel for the Selling Securityholders in the event of an underwritten offering of their shares of Common Stock or Warrants. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares of Common Stock and Warrants covered by this prospectus, including, without limitation, all registration and filing fees, printing and delivery fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock and Warrants beneficially owned by the Selling Securityholders covered by this prospectus may be offered and sold from time to time by the Selling Securityholders. The term &#8220;Selling Securityholders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a Selling Securityholder as a gift, pledge, partnership distribution or other transfer. The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, in private transactions or otherwise, at prices and under terms then prevailing, at fixed prices, at prices related to the then-current market price or in negotiated transactions. The Selling Securityholders may sell their shares of Common Stock and Warrants by one or more of, or a combination of, the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> distribution in accordance with the rules of Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through trading plans entered into by a Selling Securityholder pursuant to <span style="white-space:nowrap">Rule&#160;10b5-1</span> under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to or through underwriters or broker-dealers, including the resale by any such broker-dealers for its own account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in &#8220;at the market&#8221; offerings, as defined in Rule&#160;415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in short sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the writing or settlement of options or other hedging transactions; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the distribution of the securities by any Selling SecurityHolder to its partners, members or stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through an exchange distribution in accordance with the rules of the applicable exchange </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through a combination of any of the above methods of sale; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any shares that qualify for sale pursuant to Rule&#160;144 may be sold under Rule&#160;144 rather than pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Selling Securityholder that is an entity may elect to make an <span style="white-space:nowrap">in-kind</span> distribution of Common Stock to its members, partners, stockholders or other equityholders pursuant to the registration statement of which this prospectus forms a part by delivering a prospectus. To the extent that such members, partners, stockholders or other equityholders are not affiliates of ours, such members, partners, stockholders or other equityholders would thereby receive freely tradable shares of Common Stock pursuant to a distribution pursuant to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the shares or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of shares of Common Stock in the course of hedging the positions they assume with Selling Securityholders. The Selling Securityholders may also sell shares of Common Stock short and redeliver the shares to close out such short positions. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions that require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Selling Securityholders may also pledge shares to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Selling Securityholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by any Selling Securityholder or borrowed from any Selling Securityholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from any Selling Securityholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any Selling Securityholder may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In effecting sales, broker-dealers or agents engaged by the Selling Securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may use this prospectus in connection with the resales of our Common Stock or the Warrants. This prospectus and any accompanying prospectus supplement will identify the Selling Securityholders. The terms of our Common Stock or Warrants, as applicable, and any material relationships </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between us and the Selling Securityholders. In offering the securities covered by this prospectus, the Selling Securityholders and any broker-dealers who execute sales for the Selling Securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the Selling Securityholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholders that the anti-manipulation rules of Regulation&#160;M under the Exchange Act may apply to sales of securities in the market and to the activities of the Selling Securityholders and their affiliates. In addition, we will make copies of this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of Warrants may exercise its Warrants in accordance with the Warrant Agreement on or before the expiration date by surrendering, at the office of the warrant agent, Computershare, the certificate evidencing such warrant, an election to purchase, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes due in connection with the warrant exercise, subject to any applicable provisions relating to cashless exercises in accordance with the Warrant Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the A&amp;R Registration Rights Agreement, we have agreed to indemnify the Selling Securityholders party thereto against certain liabilities that they may incur in connection with the sale of the securities registered hereunder, including liabilities under the Securities Act, and to contribute to payments that the Selling Securityholders may be required to make with respect thereto. In addition, we and the Selling Securityholders have agreed to indemnify any underwriter against certain liabilities related to the selling of the securities, including liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay all expenses in connection with this offering and maintaining the effectiveness of the registration statement for as long as we are required to do so pursuant to the A&amp;R Registration Rights Agreement, other than underwriting commissions and discounts, brokerage fees, underwriter marketing costs, and certain legal expenses. The Selling Securityholders will pay any underwriting commissions and discounts, brokerage fees, underwriter marketing costs, and certain legal expenses relating to the offering, except for the fees of one counsel in an underwritten offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_18">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of Common Stock and the Warrants offered hereby will be passed upon for us by Latham&#160;&amp; Watkins LLP, San Diego, California. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_19">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Avista Public Acquisition Corp. II as of December&#160;31, 2021, and for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, appearing in this prospectus have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere in this prospectus, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined financial statements of OmniAb, Inc. at December&#160;31, 2021 and 2020, and for each of the three years in the period ended December&#160;31, 2021, included in this prospectus and Registration Statement, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_20">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <span style="white-space:nowrap">S-1</span> under the Securities Act with respect to the shares of Common Stock and the Warrants offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the shares of Common Stock and the Warrants offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is <span style="font-style:italic">www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.omniab.com. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonFraction name="oabi:NumberOfWarrantsIssuedPerUnit" id="hidden60239985" contextRef="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="2">0.33</ix:nonFraction><ix:nonFraction name="oabi:NumberOfWarrantsIssuedPerUnit" id="hidden60240047" contextRef="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="2">0.33</ix:nonFraction><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" id="hidden60239967" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="6">0.000067</ix:nonFraction><ix:nonNumeric name="oabi:ThresholdBusinessDaysForRedemptionOfPublicShares" id="hidden60240023" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P10D</ix:nonNumeric><ix:nonNumeric name="oabi:ThresholdBusinessDaysForRedemptionOfPublicShares" id="hidden60239959" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P10D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="oabi-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="rom305908_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OMNIAB, INC. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Financial Statements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_13">Report of Independent Registered Public Accounting Firm </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_14">Combined Balance Sheets as of December&#160;31, 2021 and 2020 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_15">Combined Statements of Operations for the Years Ended December 2021, 2020 and 2019 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_16">Combined Statements of Changes in Parent Company Net Investment for the Years Ended December&#160;31, 2021, 2020 and 2019 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_17">Combined Statements of Cash Flows for the Years Ended December&#160;31, 2021, 2020 and 2019 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_18">Notes to Combined Financial Statements </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Combined Financial Statements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_19">Condensed Combined Balance Sheets as of September&#160;30, 2022 (Unaudited) and December&#160;31, 2021 (Audited) </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_20">Unaudited Condensed Combined Statements of Operations for the Three and Nine Months ended September&#160;30, 2022 and September&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_21">Unaudited Condensed Combined Statements of Changes in Parent Company Net Investment for the Three and Nine Months ended September&#160;30, 2022 and September&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_22">Unaudited Condensed Combined Statements of Cash Flows for the Three and Nine Months ended September&#160;30, 2022 and September&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_23">Notes to Unaudited Condensed Combined Financial Statements </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Financial Statements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">References to the &#8216;&#8216;Company&#8217;&#8217; in the Avista Public Acquisition Corp. II financial statements are to Avista Public Acquisition Corp. II.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_2">Report of Independent Registered Public Accounting Firm </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_3">Balance Sheet as of December&#160;31, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-46</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_4">Statement of Operations for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_5">Statement of Changes in Shareholders&#8217; Deficit for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_6">Statement of Cash Flows for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_7">Notes to Financial Statements </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Consolidated Financial Statements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">References to the &#8216;&#8216;Company&#8217;&#8217; in the Avista Public Acquisition Corp. II financial statements are to Avista Public Acquisition Corp. II.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_8">Condensed Consolidated Balance Sheets as of September&#160;30, 2022 (Unaudited) and December&#160;31, 2021 (Audited) </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-67</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_9">Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months ended September&#160;30, 2022, for the Three Months ended September&#160;30, 2021, and for the period from February&#160;5, 2021 (inception) Through September&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-68</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_10">Condensed Consolidated Statement of Changes in Shareholders&#8217; Equity (Deficit) for the Three and Nine Months ended September&#160;30, 2022, for the Three Months ended September&#160;30, 2021, and for the period from February&#160;5, 2021 (inception) September June&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-69</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_11">Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months ended September&#160;30, 2022 and for the period from February&#160;5, 2021 (inception) Through September&#160;30, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#prewrkfin305908_12">Notes to Unaudited Condensed Consolidated Financial Statements </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="prewrkfin305908_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Management of Ligand Pharmaceuticals Incorporated </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying combined balance sheets of OmniAb, Inc., Crystal Bioscience, Inc., xCella Biosciences, Inc., Taurus Biosciences LLC, Icagen, Inc. and Ab Initio Biotherapeutics, Inc., (each of which is a subsidiary of Ligand Pharmaceuticals Incorporated, collectively &#8220;OmniAb, A Business of Ligand Pharmaceuticals Incorporated,&#8221; or the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related combined statements of operations, changes in parent company net investment, and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;combined financial statements&#8221;). In our opinion, the combined financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the each of the three years in the period ended December&#160;31, 2021 in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement of the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 2 to the combined financial statements, the December&#160;31, 2020 and December&#160;31, 2019 combined financial statements have been restated to correct misstatements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;27, 2022 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED BALANCE SHEETS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Restated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">176,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">304,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LIABILITIES AND PARENT COMPANY NET INVESTMENT</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,089</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Commitments and contingencies <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Note 10) </div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">234,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">304,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 65pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 65pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 50pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to these combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Restated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Restated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,304</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other operating expense (income), net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,891</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expense):</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">34,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 130pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to these combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent&#160;company<br/>net investment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opening balance at January&#160;1, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">204,882</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019 (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020 (as restated)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,065</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">234,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 155pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 155pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 180pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to these combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED STATEMENTS OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Restated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Restated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in estimated fair value of contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,065</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain from short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain from sale of intellectual property license</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">938</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for acquisitions, net of cash and restricted cash acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of intellectual property license</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:OtherInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OtherInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OtherInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash, cash equivalents, and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of fixed assets recorded in accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to these combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2021To12_31_2021" escape="true"><div id="prewrkfin305908_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Nature of Operations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Parent&#8221;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#8220;OmniAb,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;). OmniAb is a biotechnology company with a Biological Intelligence powered multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand acquired OMT, pursuant to a multi-step transaction that resulted in Ligand&#8217;s acquisition of OMT. On November&#160;10, 2021 OMT&#8217;s name was changed to OmniAb, Inc. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ErrorCorrectionTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240581"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Restatement of Previously Issued Combined Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subsequent to the issuance of the audited combined financial statements for the year ended December&#160;31, 2020 and 2019, the Company determined the balance of accounts receivable, net, as of December&#160;31, 2020, was understated by $<ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.0</ix:nonFraction>&#160;million and general and administrative expense was understated by $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million for the year ended December&#160;31, 2019. The error as of December&#160;31, 2020 was the result of the omission of an unbilled amount which was also improperly excluded from net transfers from parent company in the combined statement of changes in parent company net investment for the year ended December&#160;31, 2020, resulting in an understatement of parent company net investment. The error as of December&#160;31, 2019 related to bad debt expense that was not properly included in general and administrative expense on the combined statements of operations and was improperly recorded as part of the net transfers from parent company in the combined statements of changes in parent company net investment. The errors identified as of December&#160;31, 2020 and 2019, each resulted in the overstatement of cash provided by operating activities and an understatement of cash provided by financing activities in the combined statements of cash flows, in the respective periods. The Company has concluded that the errors identified were material to the combined financial statements as of and for the year ended December&#160;31, 2020 and 2019. Accordingly, previously reported amounts have been revised to reflect the correction of the error as well as other immaterial errors identified through the process of compiling the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">carve-out</div> financial statements. </div> <ix:nonNumeric name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" contextRef="P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" escape="true" continuedAt="TextSelection_60240592"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the revised results for the year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">288,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">7</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240581" continuedAt="TextSelectionAppend_60240581_1"><ix:continuation id="TextSelection_60240592" continuedAt="TextSelectionAppend_60240592_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">228,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">288,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation> <ix:nonNumeric name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" contextRef="P01_01_2021To12_31_2021_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" escape="true" continuedAt="TextSelection_60240579"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,891</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" contextRef="P01_01_2021To12_31_2021_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" escape="true" continuedAt="TextSelection_60240578"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;January 1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">228,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" contextRef="P01_01_2021To12_31_2021_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" escape="true" continuedAt="TextSelection_60240577"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">8</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240581_1" continuedAt="TextSelectionAppend_60240581_2"><ix:continuation id="TextSelection_60240577" continuedAt="TextSelectionAppend_60240577_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the revised results for the year ended December&#160;31, 2019, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). </div></div> <ix:continuation id="TextSelectionAppend_60240592_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">262,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">262,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">262,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">262,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation><ix:continuation id="TextSelection_60240579"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,685</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">657</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">9</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240581_2"><ix:continuation id="TextSelection_60240578"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation><ix:continuation id="TextSelectionAppend_60240577_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredRevenueRecordedInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240435"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60241634"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent </div></div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">10</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240435" continuedAt="TextSelectionAppend_60240435_1"><ix:continuation id="TextSelection_60241634"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div> for additional discussion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:LiquidityAndCapitalResourcesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s revenue was $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.7</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.3</ix:nonFraction>&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s net loss was ($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">27.0</ix:nonFraction> million), ($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">17.6</ix:nonFraction> million) and ($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">13.6</ix:nonFraction> million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">11</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_1" continuedAt="TextSelectionAppend_60240435_2"> <ix:nonNumeric name="oabi:EmergingGrowthCompanyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb qualifies as an &#8220;emerging growth company&#8221; (EGC) as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb&#8217;s historical results are included as a part of the Parent&#8217;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This may make comparison of OmniAb&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#8217;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Business Risk </div></div></div></div> <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year-ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A, B and C in 2019 represent different customers than 2020 and 2021. </div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60241339"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">12</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_2" continuedAt="TextSelectionAppend_60240435_3"><ix:continuation id="TextSelection_60241339"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and recorded an adjustment of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million of allowance for credit losses as of December&#160;31, 2021. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">13</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_3" continuedAt="TextSelectionAppend_60240435_4"> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill, Intangible Assets and Other Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill attributed to OmniAb&#8217;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#8217; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60241222"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">14</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_4" continuedAt="TextSelectionAppend_60240435_5"><ix:continuation id="TextSelection_60241222"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgment. If our estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone <div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> regulatory approval. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:DeferredRevenuePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.4</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">15</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_5" continuedAt="TextSelectionAppend_60240435_6"> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our employees participated in our Parent&#8217;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#8217;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted stock&#160;units (RSU) and performance stock&#160;units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#8217;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#8217;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> in the period of adjustment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $<ix:nonFraction name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.50</ix:nonFraction> per share, our Parent has <ix:nonFraction name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We grant options, RSUs and PSUs to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under Ligand&#8217;s equity plan. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> directors are accounted for as employees. Options and RSUs granted to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors typically vest <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_ShareBasedPaymentArrangementNonemployeeDirectorsMemberusgaapGranteeStatusAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> from the date of grant. <ix:nonNumeric name="oabi:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options granted to employees typically vest&#160;1/8 on the six m</div>onth anniversary of the date of grant, and 1/48 each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two</div> months.</ix:nonNumeric> RSUs and PSUs granted to employees vest over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsAndPhantomShareUnitsMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. All option awards generally expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240446"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;Topic 740&#8221;). Accordingly, our income tax provision was prepared following the &#8220;Separate Return Method.&#8221; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">16</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_6" continuedAt="TextSelectionAppend_60240435_7"><ix:continuation id="TextSelection_60240446"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#8217;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:ImpactOfCovidNineteenPandemicPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60241636"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> initially, including issuing varying forms of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;stay-at-home&#8221;</div></div> orders, and restricting business functions outside of one&#8217;s home. We have generally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could have on our business in the future, the continued spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">17</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240435_7"><ix:continuation id="TextSelection_60241636"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4,</div> of which this proxy statement/prospectus/information statement forms a part. </div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="oabi:BusinessCombinationAndAssetAcquisitionTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60241351"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Acquisitions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As set forth below, we completed <ix:nonFraction name="oabi:NumberOfAcquisitions" contextRef="P01_01_2019To12_31_2021" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> acquisitions from January&#160;1, 2019 through December&#160;31, 2021, of which <ix:nonFraction name="us-gaap:NumberOfBusinessesAcquired" contextRef="P01_01_2019To12_31_2021" unitRef="Unit_Number" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> (Icagen and Ab Initio) were accounted for as business combinations and Taurus and xCella were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. We did not incur any material acquisition related costs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taurus Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;9, 2020, we acquired Taurus, which discovers and humanize antibodies from immunized cows and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cow-derived</div> libraries. These antibodies feature some of the longest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CDR-H3s</div> of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The purchase price of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction>&#160;million included $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.6</ix:nonFraction>&#160;million in cash, and a $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million holdback to satisfy indemnification obligations which were settled in September&#160;2021. Taurus stockholders also received nontransferable contingent value rights (CVRs) representing the right to receive up to $<ix:nonFraction name="oabi:BusinessCombinationConsiderationTransferredEarnoutRights" contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million tied to partnered and internal research and development and up to $<ix:nonFraction name="oabi:BusinessCombinationConsiderationTransferredEarnoutRights" contextRef="PAsOn09_09_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million as a <ix:nonFraction name="oabi:PercentageShareOfPostClinicalAcquireeProductRevenues" contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% share of post-clinical Taurus product revenues (including milestone payments) received by us. We evaluated this acquisition in accordance with ASC 805, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations</div></div>, to discern whether the assets and operations of Taurus met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">18</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60241351" continuedAt="TextSelectionAppend_60241351_1"> <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">xCella Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;8, 2020, we acquired xCella Biosciences, an antibody discovery company. xCella&#8217;s xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity which expand our existing single <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> assay capabilities in the OmniAb technology platform. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We paid $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.1</ix:nonFraction>&#160;million in cash (including a $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million holdback to satisfy indemnification obligations which was settled in September&#160;2021), and issued earnout rights for up to $<ix:nonFraction name="oabi:BusinessCombinationConsiderationTransferredEarnoutRights" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>&#160;million tied to our use of the xCella technology for partnered research and development and for up to $<ix:nonFraction name="oabi:BusinessCombinationConsiderationTransferredEarnoutRights" contextRef="PAsOn09_08_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal">25.75</ix:nonFraction>&#160;million as a <ix:nonFraction name="oabi:PercentageShareOfFutureMilestonePayments" contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805 to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2021To12_31_2021_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P09_08_2020To09_08_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:duryear">15</ix:nonNumeric>&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Icagen Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;1, 2020, we acquired the core assets of Icagen and certain of its affiliates. The Icagen Technology Platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and in silico and computational chemistry applications for the discovery of therapeutics targeting ion channel pathways. Icagen is partnered with several globally recognized pharmaceutical companies for ion channel drug discovery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The purchase price of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.9</ix:nonFraction>&#160;million included $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.1</ix:nonFraction>&#160;million cash consideration paid upon acquisition, and a contingent earnout payment to the selling shareholders of up to $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" contextRef="PAsOn04_01_2020_EarnoutRightsMemberusgaapContingentConsiderationByTypeAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million of cash payments based on certain revenue milestones with an estimated fair value of $<ix:nonFraction name="oabi:BusinessCombinationContingentConsiderationRevenueMilestonePayment" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction>&#160;million. The fair value of the earnout liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants&#8217; cost of debt reflective of Icagen. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 5, Fair Value Measurement</div></div>, for further discussion. The liability will be periodically assessed based on events and circumstances related to the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">19</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60241351_1" continuedAt="TextSelectionAppend_60241351_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">underlying milestones, and any change in fair value will be recorded in our combined statements of operations. The carrying amount of the liability may fluctuate significantly and the actual amount paid may be materially different than the carrying amount of the liability. The results of Icagen have been included in our results of operations since the date of acquisition. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2021To12_31_2021_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaids and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities assumed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,685</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.1</ix:nonFraction>&#160;million of customer relationships and $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction>&#160;million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of <ix:nonFraction name="oabi:BusinessCombinationCashFlowDiscountedRate" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">17</ix:nonFraction>%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:duryear">9.6</ix:nonNumeric>&#160;years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction name="oabi:BusinessCombinationCashFlowDiscountedRate" contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">17</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years. The total acquired intangibles are being amortized on a straight-line basis over the estimated weighted average useful life of <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:duryear">9.7</ix:nonNumeric>&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ab Initio Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;23, 2019, we acquired Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has licensed a patented antigen technology owned by Stanford for the discovery of therapeutic antibodies including against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">difficult-to-access</div></div> cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase price of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million included $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction>&#160;million cash consideration paid upon acquisition, net of cash acquired, and a $<ix:nonFraction name="oabi:BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal">0.15</ix:nonFraction>&#160;million cash holdback for potential indemnification claims. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">20</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60241351_2"> <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2021To12_31_2021_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction name="oabi:BusinessCombinationCashFlowDiscountedRate" contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.0</ix:nonFraction>%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">20</ix:nonNumeric>&#160;years. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240345"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Fair Value Measurement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;&#8212;&#160;Observable inputs such as quoted prices in active markets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;&#8212;&#160;Inputs other than the quoted prices in active markets that are observable either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;&#8212;&#160;Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities Measured on a Recurring Basis </div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240781"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Crystal contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">21</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240345"><ix:continuation id="TextSelection_60240781">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million contingent liability on development milestones to former Crystal shareholders. During the year ended December&#160;31, 2021, we made <ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> payments former Crystal shareholders for contingent liability on development milestones. </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To12_31_2020_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the year ended December&#160;31, 2021, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;million contingent liability based on revenue milestones to former Icagen shareholders. </div></div> </td> </tr> </table> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders and other contingent payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from Icagen acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,770</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that <ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2020_XcellaMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> earnout liability would be recognized at the acquisition date in September&#160;2020. During the year ended December&#160;31, 2021, management paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2021To12_31_2021_XcellaMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million of </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement. </td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to relatively short periods to maturity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Measured on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recurring</div> Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We apply fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level&#160;3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level&#160;3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the&#160;years ended December&#160;31, 2021 and 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">22</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240925"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain legal entities included in this combined financials lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten&#160;years, some of which include options to extend the leases for up to ten&#160;years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12&#160;months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.7</ix:nonFraction>&#160;million and lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.2</ix:nonFraction>&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. </div></div> <ix:nonNumeric name="oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">23</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240925"> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity Dates</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ReceivableWithImputedInterestNetAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">9.3</ix:nonNumeric>&#160;years and a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">4.7</ix:nonNumeric>&#160;years and a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:BalanceSheetAccountDetailsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240868"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Balance Sheet Account Details </div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">three</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis"><br/>ten years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is <br/>shorter. Depreciation expense of $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, <br/>respectively, and was included in operating expenses. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">24</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240868"> <ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and identifiable intangible assets consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">227,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">224,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">260,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">270,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">20</ix:nonNumeric>&#160;years. Amortization expense of $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction>&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Estimated amortization expense for the&#160;years ending December&#160;31, 2022 through 2026 is $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction>&#160;million per year. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, there was <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of intangible assets with finite lives. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subcontractor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:SubcontractorLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:SubcontractorLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions related liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AcquisitionsRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AcquisitionsRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240706"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have historically operated as part of Ligand and not as a stand-alone company. We determined the OmniAb income tax provision as if OmniAb had joined in the consolidated federal income tax return and combined state income tax returns separate from Ligand. We recorded a current state income tax expense for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 for certain OmniAb state minimum taxes. We recorded a deferred federal and state income tax benefit for the year ended December&#160;31, 2021 and 2020 to reflect the change in the net deferred tax liability for the period. We recorded a deferred federal tax benefit and deferred state tax expense for the year ended December&#160;31, 2019 to reflect the change in the net deferred tax liability for the period. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">25</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240706" continuedAt="TextSelectionAppend_60240706_1"> <ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at federal statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,983</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,253</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">847</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">573</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in uncertain tax positions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction>%. Significant components of the our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of the our deferred tax assets will be realized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">26</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240706_1" continuedAt="TextSelectionAppend_60240706_2"> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredTaxAssetsDeferredRevenue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredTaxAssetsDeferredRevenue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">772</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,088</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance for deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identified intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DeferredTaxLiabilitiesOperatingLeaseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DeferredTaxLiabilitiesOperatingLeaseAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_TwoThousandThirtySevenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_TwoThousandThirtyTwoMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction>&#160;million of state net operating loss carryforwards that begin to expire in 2032. We also have $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_FederalResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;million of federal research and development credit carryforwards, which expire through 2028. We have $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_CaliforniaResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million of California research and development credit carryforwards that have no expiration date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Sections&#160;382 and 383. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying combined balance sheet. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions based on tax positions related to the current year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions for tax positions of prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions for tax positions in prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">27</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240706_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million of tax benefits that, if recognized would impact the effective rate. There are <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve&#160;months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021, 2020 and 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States and various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating loss and research credit carryforwards arising prior to these&#160;years are also open to examination if and when utilized. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_60240462"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Relationship with Parent and Related Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in the future by OmniAb. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Corporate Overhead </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> method based on project-related costs or other measures that management believes are consistent and reasonable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To12_31_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">6.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively, have been reflected in the general and administrative expenses in our combined statements of operations for our allocated share of Parent&#8217;s corporate overhead. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Management and Financing </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We participate in Ligand&#8217;s centralized cash management and financing programs and will continue to participate in Ligand&#8217;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a separation agreement, to be entered into between Ligand and OmniAb. Completion of the separation and distribution is subject to certain conditions, including final approval by Ligand&#8217;s board of directors. Ligand is targeting the separation of OmniAb during the second quarter of 2022. The separation is anticipated to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> to Ligand stockholders. Accordingly, after the anticipated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> separation, all of the related tax attributes of Ligand will remain with Ligand. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">28</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240462"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-Based Incentive Plans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our employees participate in our Parent&#8217;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options or incentive stock options, restricted stock&#160;units (RSUs), performance stock&#160;units (PSUs) and other cash-based or share-based awards. Awards granted to our employees under the incentive plans typically vest <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">1/8 on the six month</ix:nonNumeric> anniversary of the date of grant, and <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">1/48 each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two months</div></ix:nonNumeric><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">.</div> We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation costs associated with our employees&#8217; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. Total costs charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations, were $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.1</ix:nonFraction>&#160;million ($<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.0</ix:nonFraction>&#160;million in research and development expenses and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.1</ix:nonFraction>&#160;million in general and administrative expenses), $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.2</ix:nonFraction>&#160;million ($<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction>&#160;million in research and development expenses and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million in general and administrative expenses) and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction>&#160;million ($<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction>&#160;million in research and development expenses and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;million in general and administrative expenses) during the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our eligible employees participate in our Parent&#8217;s ESPP. The ESPP permits eligible participants to purchase Ligand&#8217;s shares at a discount through regular payroll deductions of up to <ix:nonFraction name="oabi:PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% of their eligible compensation during the offering period. The ESPP is typically implemented through consecutive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> offering periods. The purchase price of the shares is <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lesser of the fair market value of the closing price per share on the first day of the offering period and the fair market value of the closing price per share on the last day of the offering period. No participant may purchase more than $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,000</ix:nonFraction> worth of common stock per calendar year. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs charged to us related to our employees&#8217; participation in our Parent&#8217;s ESPP were $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div></ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies: Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">29</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(which changed its name to OmniAb Operations, Inc. on October 31, 2022) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED COMBINED BALANCE SHEETS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">785</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:TransactionCostsCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:TransactionCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">902</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">176,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">306,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">304,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND PARENT COMPANY NET INVESTMENT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,693</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of financing lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,016</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term portion of deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Commitments and contingencies<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> (Note 5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">232,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">234,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">306,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">304,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 48pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 48pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited condensed combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">30</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(which changed its name to OmniAb Operations, Inc. on October 31, 2022) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED COMBINED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other operating expense (income), net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited condensed combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">31</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(which changed its name to OmniAb Operations, Inc. on October 31, 2022) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent&#160;company</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net investment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,861</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">227,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,417</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">226,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">228,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">234,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">224,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">226,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent allocation of share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseInEquityContributionFromParent" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">232,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited condensed combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">32</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(which changed its name to OmniAb Operations, Inc. on October 31, 2022) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED COMBINED STATEMENTS OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Ended&#160;September&#160;30,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in estimated fair value of contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,721</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred transaction cost payment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of fixed assets recorded in accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 48pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited condensed combined financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">33</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="prewrkfin305908_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(which changed its name to OmniAb Operations, Inc. on October 31, 2022) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A Business of Ligand Pharmaceuticals Incorporated) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Condensed Combined Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Nature of Operations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Parent&#8221;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#8220;OmniAb&#8221;, &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221;). OmniAb is powered by Biological Intelligence, a multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand completed a multi-step transaction that resulted in Ligand&#8217;s acquisition of OMT. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;1, 2022, Ligand completed (the &#8220;Closing&#8221;) the separation of its antibody discovery business and certain related assets and liabilities through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">spin-off</div> of OmniAb to Ligand&#8217;s shareholders of record as of October&#160;26, 2022 on a pro rata basis and merger of OmniAb with a wholly owned subsidiary of OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II, a Cayman Islands exempted company, prior to its domestication as a corporation incorporated in the state of Delaware (&#8220;APAC&#8221;)) in a Reverse Morris Trust transaction pursuant to the Agreement and Plan of Merger, dated as of March 23, 2022 (the &#8220;Merger Agreement&#8221;), among Ligand, OmniAb, APAC and Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of APAC, and the Separation and Distribution Agreement, dated as of March 23, 2022 (the &#8220;Separation Agreement&#8221;), among Ligand, OmniAb and APAC. The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#8220;New OmniAb&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Closing, New OmniAb expected to have approximately $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn11_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">95.8</ix:nonFraction> million of net cash. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;2, 2022, New OmniAb began <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">regular-way</div> trading on NASDAQ under the ticker symbol &#8220;OABI.&#8221; Ligand continues to trade under the ticker symbol &#8220;LGND.&#8221; See further details regarding the transaction in Note 9: Subsequent Event. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240352"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241490"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s interim condensed combined financial statement accounting records. The interim condensed combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records certain transactions at the parent entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">34</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240352" continuedAt="TextSelectionAppend_60240352_1"><ix:continuation id="TextSelection_60241490"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January 2016. Transactions between Ligand and the Company are accounted for through the Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The interim condensed combined financial statements include all revenues, expenses, assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a percentage of total operating expenses or other measures that management believes are consistent and reasonable. See Note 8. Relationship with Parent and Related Entities<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. The share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See Note 8. Relationship with Parent and Related Entities for additional discussion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the interim condensed combined financial statements are based on assumptions that management believes are reasonable. However, the interim condensed combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:UnauditedInterimFinancialInformationPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Financial Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined balance sheet as of September&#160;30, 2022, the condensed combined statements of operations, condensed combined statements of changes in parent company net investment for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed combined statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related footnote disclosures are unaudited. In management&#8217;s opinion, the unaudited interim combined financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, its results of operations for the three and nine months ended September&#160;30, 2022 and 2021, and its statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 in accordance with U.S. GAAP. The results for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:LiquidityAndCapitalResourcesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241276"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. Therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of Parent company net investment in the combined balance sheets and as a financing activity allocation on the accompanying combined statements of cash flows. </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">35</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240352_1" continuedAt="TextSelectionAppend_60240352_2"><ix:continuation id="TextSelection_60241276"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s revenue was $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.5</ix:nonFraction>&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s net loss was $(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">29.2</ix:nonFraction>) million and $(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">24.0</ix:nonFraction>) million, respectively. OmniAb expects to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the merger between the Company and a subsidiary of APAC, New OmniAb was capitalized with approximately $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn11_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">95.8</ix:nonFraction> million in net cash. This cash and cash the Company generates from operations provide us the flexibility we need to meet operating, investing, and financing needs and support operations through at least 12 months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have described our significant accounting policies in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Summary of Significant Accounting Policies</div></div> of the Notes to Combined Financial Statements included in the registration statement on Form S-4 filed on September 27, 2022. </div> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of interim condensed combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the interim condensed combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the three and nine months ended September&#160;30, 2022, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and the allowance for credit losses was $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million as of September&#160;30, 2022. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241274"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">36</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240352_2" continuedAt="TextSelectionAppend_60240352_3"><ix:continuation id="TextSelection_60241274"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, we have generated revenue from intellectual property and development milestones, and have only recently begun to generate revenue from commercial milestone payments and royalties on product sales this year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and the milestone is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:DeferredRevenuePolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241562"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the three and nine months ended </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">37</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_60240352_3"> <ix:continuation id="TextSelection_60241562"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022, the amount recognized as revenue that was previously deferred was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.9</ix:nonFraction>&#160;million, respectively. During the three and nine months ended September&#160;30, 2021, the amount recognized as revenue that was previously deferred was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction>&#160;million, respectively. </div></div></ix:continuation> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation&#160;of&#160;Revenue </div></div></div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240444"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 - Observable inputs such as quoted prices in active markets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3 - Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities Measured on a Recurring Basis </div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241336"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">xCella contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of </div></div></td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">38</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240444"><ix:continuation id="TextSelection_60241336">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">certain developmental and regulatory milestones. During the year ended December&#160;31, 2021, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. During the nine months ended September&#160;30, 2022, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2022To09_30_2022_IcagenMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liability is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September 2020. During the year ended December&#160;31, 2021, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2021To12_31_2021_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. During the nine months ended September&#160;30, 2022, we paid $<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2022To09_30_2022_XcellaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. </div></div> </td> </tr> </table> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of September&#160;30, 2022 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,505</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to their relatively short periods to maturity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Measured on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recurring</div> Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We apply fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on level 3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There was <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P04_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the nine months ended September&#160;30, 2022 and 2021. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Income Tax </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in various state jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> expenses, stock award activities and other permanent differences between income (loss) before income taxes and taxable income. The effective tax rate for the three and nine months ended September&#160;30, 2022 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">15.5</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">18.3</ix:nonFraction>%, respectively. The variance from the U.S. federal statutory tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction>% was primarily due to the benefit related to tax credits, as well as the difference in statutory state rates and the tax impact of stock award activities. The variance is also a result of the valuation allowance established for state attributes. The effective tax rate for the three and nine months ended September&#160;30, 2021 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">19.5</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.5</ix:nonFraction>%, respectively. The variance from the U.S. federal statutory tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction>% was primarily due to the benefit related to tax credits, state taxes, the tax impact of stock award activities and the valuation allowance established for state attributes. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">39</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Commitment and Contingencies: Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240610"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain OmniAb legal entities lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. </div></div> <ix:nonNumeric name="oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,016</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">40</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240610"> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of September&#160;30, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity Dates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining three months ending December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,787</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ReceivableWithImputedInterestNetAmount" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September 30, 2022, we had a lease commence in our Emeryville office, which resulted in </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an increase in lease assets and liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.9</ix:nonFraction></ix:nonFraction> million each during the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, our operating leases had a weighted-average remaining lease term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2022" format="ixt-sec:duryear">8.8</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.3</ix:nonFraction>%. As of December&#160;31, 2021, our operating leases had a weighted-average remaining lease term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">9.3</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.9</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;million, respectively, for the three and nine months ended September&#160;30, 2022. The operating lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The operating lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2021, respectively. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:BalanceSheetAccountDetailsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240924"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Balance Sheet Account Details </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment </div></div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis">three</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis">ten years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;million, respectfully. Depreciation expense for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">41</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240924"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and identifiable intangible assets </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and other identifiable intangible assets consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,979</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">227,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">227,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">250,253</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">260,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:duryear">20</ix:nonNumeric> years. Amortization expense for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.8</ix:nonFraction>&#160;million, respectively. Amortization expense for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.7</ix:nonFraction>&#160;million, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Liabilities </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition related liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AcquisitionsRelatedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AcquisitionsRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240461"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Relationship with Parent and Related Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the future by OmniAb. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Corporate Overhead </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> method based on project-related costs or other measures that management believes are consistent and reasonable. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">42</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240461"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P07_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.9</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P07_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction>&#160;million for the three and nine months ended 2021, respectively, have been reflected in the general and administrative expenses in our interim condensed combined statements of operations for our allocated share of Parent&#8217;s corporate overhead. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Management and Financing </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We participate in Ligand&#8217;s centralized cash management and financing programs and will continue to participate in Ligand&#8217;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a Separation Agreement, entered into among Ligand, OmniAb and APAC. Completion of the separation and distribution is subject to certain conditions. The separation is anticipated to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> to Ligand stockholders. Accordingly, after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> separation, all of the related tax attributes of Ligand will remain with Ligand. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-Based Incentive Plans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our employees participate in our Parent&#8217;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options or incentive stock options, restricted stock units (RSUs), performance stock units (PSUs) and other cash-based or share-based awards. Stock options granted to our employees under the incentive plans typically vest <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1/8</div> on the six month</ix:nonNumeric> anniversary of the date of grant, and <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1/48</div> each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two</div> months</ix:nonNumeric>. We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation costs associated with our employees&#8217; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60241442">The following table summarizes total share-based compensation (SBC) charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations (in thousands):</ix:nonNumeric> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_60241442">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,079</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,902</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_60240394"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Subsequent Event </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of the financial statements as of September 30, 2022 and the three and nine months then ended, the Company has evaluated subsequent events through the date on which the financial statements were issued. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">43</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_60240394"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination closing of APAC and OmniAb </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November 1, 2022, Ligand completed the separation (the &#8220;Separation&#8221;) of its antibody discovery business and certain related assets and liabilities through a spin-off of OmniAb to Ligand&#8217;s shareholders of record as of October 26, 2022 (the &#8220;Record Date&#8221;) on a pro rata basis (the &#8220;Distribution&#8221;) and merger (the &#8220;Merger&#8221;) of OmniAb with a wholly owned subsidiary of APAC in a Reverse Morris Trust transaction (collectively, the &#8220;Transactions&#8221;) pursuant to the Merger Agreement and the Separation Agreement (collectively with the other related transaction documents, the &#8220;Transaction Agreements&#8221;). The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#8220;New OmniAb&#8221;). Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain assets and liabilities constituting the OmniAb business, including certain related subsidiaries of Ligand, to OmniAb (the &#8220;Contribution&#8221;). In consideration for the Contribution, OmniAb issued to Ligand additional shares of OmniAb common stock such that the number of shares of OmniAb common stock then outstanding equaled the number of shares of OmniAb common stock necessary to effect the Distribution. Pursuant to the Distribution, Ligand shareholders as of the Record Date received one share of OmniAb common stock for each share of Ligand common stock held as of such date. Pursuant to the Merger Agreement, each share of OmniAb common stock was thereafter exchanged for the right to receive <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn11_01_2022_NewOmniabCommonStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="5" scale="0" format="ixt:num-dot-decimal">4.90007</ix:nonFraction> shares of New OmniAb common stock and <ix:nonFraction name="oabi:CommonStockSubjectToPriceBasedEarnoutTriggers" contextRef="PAsOn11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="5" scale="0" format="ixt:num-dot-decimal">0.75842</ix:nonFraction> shares of New OmniAb common stock subject to price-based earnout triggers (the &#8220;Earnout Shares&#8221;). The Earnout Shares will vest based upon the achievement of certain volume-weighted average trading prices (VWAP) for shares of New OmniAb for any <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:NumberOfTradingDaysForDeterminingTheSharePrice" contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durday">20</ix:nonNumeric></div> trading days over a consecutive <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durday">30</ix:nonNumeric></div> trading-day period during the five-year period following the Closing, with (i) fifty percent of such Earnout Shares vesting upon achievement of a VWAP of $<ix:nonFraction name="oabi:VolumeWeightedAverageTradingPrices" contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.50</ix:nonFraction> per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $<ix:nonFraction name="oabi:ExcessPricePerShare" contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.50</ix:nonFraction>, and (ii) the remaining fifty percent of the Earnout Shares vesting upon achievement of a VWAP of $<ix:nonFraction name="oabi:VolumeWeightedAverageTradingPrices" contextRef="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $<ix:nonFraction name="oabi:ExcessPricePerShare" contextRef="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction>. The Earnout Shares are not transferable until the vesting condition for the applicable tranche of Earnout Shares has been achieved. Upon the closing of the Transactions, the ownership of the outstanding stock of New OmniAb (including the Earnout Shares) was as follows: Ligand&#8217;s existing shareholders held approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn11_01_2022_ApacsExistingPublicShareholdersMembersrtOwnershipAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">85.0</ix:nonFraction>%, APAC&#8217;s existing public shareholders held approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SponsorOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.1</ix:nonFraction>% and the sponsor and related parties of APAC held approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_RelatedPartiesOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.9</ix:nonFraction>%. Fractional shares of New OmniAb common stock were not issued pursuant to the Merger. Instead, shareholders received cash in lieu of any fractional share (other than with respect to Earnout Shares). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Closing, New OmniAb expected to have approximately $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">95.8</ix:nonFraction> million of net cash. On November 2, 2022, New OmniAb began regular-way trading on NASDAQ under the ticker symbol &#8220;OABI.&#8221; Ligand continues to trade under the ticker symbol &#8220;LGND.&#8221; </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-44 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="prewrkfin305908_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and Board of Directors of </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avista Public Acquisition Corp. II </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheet of Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) as of December&#160;31, 2021, the related statements of operations, changes in shareholders&#8217; deficit and cash flows for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021, and the results of its operations and its cash flows for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, in conformity with accounting principles generally accepted in the United States of America. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Explanatory Paragraph&#160;&#8212;&#160;Going Concern </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company&#8217;s business plan is dependent on the completion of a business combination and the Company&#8217;s cash and working capital as of December&#160;31, 2021 are not sufficient to complete its planned activities for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Marcum LLP </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marcum LLP </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2021. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, NY </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;25, 2022 </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-45 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt;">&#160;</div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BALANCE SHEET </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">744,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">934,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash held in trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">236,684,513</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedExpenses" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">107,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedOfferingCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">314,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">438,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,488,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments (see Note 6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value, subject to possible redemption; <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> shares at redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding (excluding <ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> shares subject to possible redemption)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,554,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,553,698</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">236,684,513</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 124pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-46 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;5, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation and operating costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">516,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">516,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,857,143</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,321,429</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 80pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">7</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;5, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A<br/>Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at February&#160;5, 2021 (inception)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;B ordinary shares to Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,232,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,232,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,298,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,298,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of Class&#160;A ordinary shares to redemption value</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">21,555,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,037,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,593,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">516,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">516,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,554,273</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,553,698</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 68pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">48</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;5, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">516,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">744,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseDecreaseInDueToRelatedPartyCurrent" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">107,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,136,926</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div>&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash into Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:PaymentsForInvestmentOfCashInTrustAccount" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div>&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Class&#160;B ordinary shares to Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from initial public offering, net of underwriter&#8217;s discount paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ProceedsFromIssuanceInitialPublicOfferingNet" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">225,400,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from Sponsor note</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of Sponsor note</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:RepaymentFromRelatedPartyDebt" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">698,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,076,897</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8211;&#160;beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8211;&#160;end of period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of Class&#160;A ordinary shares to redemption value</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,593,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">314,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredUnderwritingFeePayable" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 70pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">49</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239696"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with <ix:nonFraction name="oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>or more businesses (a &#8220;Business Combination&#8221;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction>&#160;units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction>&#160;Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction> (see Note 3). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;), including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction> (see Note 4). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="oabi:TransactionCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,662,256</ix:nonFraction> consisting of $<ix:nonFraction name="oabi:SaleOfStockUnderwritingFees" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction> of underwriting fees, $<ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction> of deferred underwriting fees, and $<ix:nonFraction name="oabi:SaleOfStockOtherOfferingCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,012,256</ix:nonFraction> of other offering costs. In addition, as of December&#160;31, 2021, cash of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction> is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and will be invested only in U.S. government treasury obligations with maturities of <ix:nonNumeric name="oabi:InvestmentsMaximumMaturityTerm" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durday">185</ix:nonNumeric>&#160;days or less or in money market funds meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering, (ii)&#160;the redemption of the Company&#8217;s Public Shares if the Company has not consummated an Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Company&#8217;s Public Shares if the Company does not complete the initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing the Company&#8217;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60239696" continuedAt="TextSelectionAppend_60239696_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The public shareholders will be entitled to redeem their Public Shares for a pro&#160;rata portion of the amount then in the Trust Account ($<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share, plus any pro&#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#8220;Amended and Restated Memorandum and Articles of Association&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#8217;t vote at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction name="oabi:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% or more of the Public Shares, without the prior consent of the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of its Public Shares if the Company does not complete an initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering. However, if the Sponsor acquires </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">51</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239696_1" continuedAt="TextSelectionAppend_60239696_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has until <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:hidden60240023">ten </span>business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $<ix:nonFraction name="oabi:MaximumNetInterestToPayDissolutionExpenses" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction> in cash held outside of the Trust Account and a working capital surplus of $<ix:nonFraction name="oabi:WorkingCapitalSurplus" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">496,302</ix:nonFraction>. The Company has incurred and expects to continue to incur significant </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5<div style="display:inline;">2</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_60239696_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $<ix:nonFraction name="oabi:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million was deposited in an operating account for the Company&#8217;s working capital needs. The amounts held in the operating account are not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve&#160;months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern Consideration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction> in cash held outside of the Trust Account and a working capital surplus of $<ix:nonFraction name="oabi:WorkingCapitalSurplus" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">496,302</ix:nonFraction>. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239860"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:EmergingGrowthCompanyPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60241621"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">5<div style="display:inline;">3</div></div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><ix:continuation id="TextSelection_60239860" continuedAt="TextSelectionAppend_60239860_1"><ix:continuation id="TextSelection_60241621"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240165"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the <ix:nonFraction name="oabi:Unitsissuedduringperiodsharesnewissues." contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">54</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_60239860_1" continuedAt="TextSelectionAppend_60239860_2"><ix:continuation id="TextSelection_60240165"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:TemporaryEquityProceedsAllocatedToWarrants" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,813,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:TemporaryEquityIssuanceCosts" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,029,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,593,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs associated with the Initial Public Offering </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A&#160;&#8212;&#160;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses of Offering</div></div>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $<ix:nonFraction name="oabi:TransactionCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,662,256</ix:nonFraction> as a result of the Initial Public Offering (consisting of $<ix:nonFraction name="oabi:SaleOfStockUnderwritingFees" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction> of cash underwriting discounts, $<ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction> in deferred underwriting fees and $<ix:nonFraction name="oabi:SaleOfStockOtherOfferingCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,012,256</ix:nonFraction> of other offering costs). As such, the Company recorded $<ix:nonFraction name="oabi:OfferingCostsReductionOfTemporaryEquity" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,029,901</ix:nonFraction> of offering costs as a reduction of temporary equity and $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">632,355</ix:nonFraction> of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240220"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February&#160;5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> unrecognized tax benefits and <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">5<div style="display:inline;">5</div></div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><ix:continuation id="TextSelectionAppend_60239860_2" continuedAt="TextSelectionAppend_60239860_3"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_60240220"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman <div style="letter-spacing: 0px; top: 0px;;display:inline;">Islands </div>Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement. </div> </ix:continuation></div> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,900,000</ix:nonFraction> shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from&#160;February&#160;5,<br/>2021 (inception) Through<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">335,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">181,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,857,143</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,321,429</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240217"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">56</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_60239860_3"><ix:continuation id="TextSelection_60240217"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note&#160;&#8212;&#160;related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;&#8212;&#160;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;&#8212;&#160;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;&#8212;&#160;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August&#160;2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#160;amends</div> the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for the Company on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="oabi:InitialPublicOfferingTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction>&#160;Units, including <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction>&#160;Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction>. Each Unit consists of <ix:nonFraction name="oabi:NumberOfSharesIssuedPerUnit" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60240047">one</span>-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A ordinary share at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per whole share (see Note 7). </div></ix:nonNumeric> <ix:nonNumeric name="oabi:PrivatePlacementTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240039"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> Private Placement Warrants, including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per Private Placement Warrant ($<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction> in the aggregate). Each Private Placement Warrant is exercisable to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">57</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><ix:continuation id="TextSelection_60240039"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary share at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239961"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> to cover certain expenses on behalf of the Company in exchange for the issuance of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares include an aggregate of up to <ix:nonFraction name="oabi:NumberOfSharesSubjectToForfeiture" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, <ix:nonFraction name="oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction> Class&#160;B ordinary shares each to three members of the Company&#8217;s board of directors (or <ix:nonFraction name="oabi:NumberOfSharesSubjectToForfeiture" contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;<ix:nonNumeric name="oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#8217;s Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction> per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">20</ix:nonNumeric>&#160;trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">30</ix:nonNumeric>-</div> trading day period commencing at least <ix:nonNumeric name="oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">150 day</div>s</ix:nonNumeric> after an initial Business Combination or (2)&#160;if the Company consummates a transaction after an initial Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $<ix:nonFraction name="oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> to cover expenses related to the Initial Public Offering. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $<ix:nonFraction name="oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty" contextRef="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,725</ix:nonFraction>, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $<ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">119,275</ix:nonFraction> on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction>. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $<ix:nonFraction name="oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" contextRef="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">46,129</ix:nonFraction> of expenses were incurred during the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">58</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><ix:continuation id="TextSelection_60239961"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s sponsor or an affiliate of the sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;Working Capital Loans&#8221;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#8217;s trust account would be used to repay such loaned amounts. Up to $<ix:nonFraction name="oabi:MaximumLoansConvertibleIntoWarrants" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction> of such loans may be convertible into warrants of the post-Business Combination entity at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#8217;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December&#160;31, 2021, there was <ix:nonFraction name="oabi:WorkingCapitalLoansOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> balance outstanding under the Working Capital Loans. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240315"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to <ix:nonFraction name="oabi:MaximumNumberOfDemandsForRegistrationOfSecurities" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_ITEM" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters were paid a cash underwriting discount of $<ix:nonFraction name="oabi:DeferredFeePerUnit" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.20</ix:nonFraction> per Unit, or $<ix:nonFraction name="oabi:AggregateDeferredUnderwritingFeePayable" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction> in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August&#160;12, 2021. In addition, $<ix:nonFraction name="oabi:Underwritingcashdiscountperunit" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.35</ix:nonFraction> per unit, or $<ix:nonFraction name="oabi:Underwritercashdiscount" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction> in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the Underwriting Agreement. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">59</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><ix:continuation id="TextSelection_60240315"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Purchase Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of <ix:nonFraction name="oabi:SharesToBePurchasedPursuantToAgreements" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Class&#160;A ordinary shares plus an aggregate of <ix:nonFraction name="oabi:WarrantsToBePurchasedPursuantToAgreements" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,333,333</ix:nonFraction> redeemable warrants to purchase Class&#160;A ordinary shares at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#8217;s public shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240065"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference shares &#8212;</div></div></div></div> The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares &#8212;</div></div></div></div> The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> Class&#160;A ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. Holders of Class&#160;A ordinary shares are entitled to <ix:nonFraction name="oabi:CommonStockNumberOfVotesPerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote for each share. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares issued and outstanding, including <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> Class&#160;A ordinary shares subject to possible redemption. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B ordinary shares &#8212;</div></div></div></div> The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> Class&#160;B ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. Holders of Class&#160;B ordinary shares are entitled to <ix:nonFraction name="oabi:CommonStockNumberOfVotesPerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote for each share. As of December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, <ix:nonFraction name="oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three&#160;years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">60</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240065" continuedAt="TextSelectionAppend_60240065_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Warrants &#8212;</div></div></div></div> Each whole warrant entitles the registered holder to purchase one Class&#160;A ordinary share at a price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, subject to adjustment as discussed below, at any time commencing <ix:nonNumeric name="oabi:WarrantExercisePeriodConditionTwo" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric>&#160;days after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. Accordingly, unless you purchase at least three&#160;units, you will not be able to receive or trade a whole warrant. The warrants will expire <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric name="oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">20</ix:nonNumeric> business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within <ix:nonNumeric name="oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">60</ix:nonNumeric> business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class&#160;A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">61</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60240065_1" continuedAt="TextSelectionAppend_60240065_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">10</ix:nonNumeric> trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric>&#160;days&#8217; prior written notice of redemption to each warrant holder; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction name="oabi:WarrantRedemptionConditionMinimumSharePrice" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric>-trading</div> day period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div> redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> (for whole shares) warrant exercise price after the redemption notice is issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">62</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60240065_2" continuedAt="TextSelectionAppend_60240065_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;&#8220;historical fair market value&#8221; means the volume weighted average price of Class&#160;A ordinary shares as reported during the <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">10</ix:nonNumeric> trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">365</ix:nonNumeric>-day</div> period ending on the date of declaration of such dividend or distribution does not exceed $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction> (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction> per share , (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the public shares if the Company does not complete its initial Business Combination within 18&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#8217;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">63</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60240065_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Company&#8217;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than <ix:nonFraction name="oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the <ix:nonNumeric name="oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="oabi:WarrantExercisePriceAdjustmentMultiple" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">115</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price, the $<ix:nonFraction name="oabi:WarrantRedemptionConditionMinimumSharePrice" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="oabi:WarrantRedemptionPriceAdjustmentMultiple" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">180</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the&#160;units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until <ix:nonNumeric name="oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">30 days</ix:nonNumeric> after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the&#160;units being sold in the Initial Public Offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for the <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,900,000</ix:nonFraction> warrants issued in connection with the Initial Public Offering (including <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,666,667</ix:nonFraction> Public Warrants and <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> Private Placement Warrants), and will account for the <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,333,333</ix:nonFraction> Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div>. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240040"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. SUBSEQUENT EVENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $<ix:nonFraction name="us-gaap:DebtDefaultLongtermDebtAmount" contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction>. The Sponsor Working Capital Loan is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">64</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240040" continuedAt="TextSelectionAppend_60240040_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per warrant. The warrants would be identical to the Private Placement Warrants. On March&#160;15, 2022, the Company drew down $<ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P03_15_2022To03_15_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> under the Sponsor Working Capital Loan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed Business Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221; and, together with Ligand, collectively, the &#8220;Companies&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), pursuant to which we will combine with OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement, (the &#8220;Employee Matters Agreement&#8221;), (b)&#160;OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c)&#160;we amended and restated that certain forward purchase agreement, dated August&#160;9, 2021, by entering into the amended and restated forward purchase agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company, our sponsor and OmniAb. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and OmniAb (the &#8220;Separation Agreement&#8221;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001 (the &#8220;OmniAb Common Stock&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i)&#160;we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#8220;Domestication&#8221;), (ii)&#160;Ligand will transfer the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, OmniAb, and contribute $15&#160;million in capital thereto (less certain transaction and other expenses), and (iii)&#160;following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;tax-free&#8221;</div> transactions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $0.0001 per share (the &#8220;APAC Common Stock&#8221;), which will be listed on Nasdaq under the ticker symbol &#8220;OABI.&#8221; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#8220;OABIW.&#8221; </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">65</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <ix:continuation id="TextSelectionAppend_60240040_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At the time the proposed OmniAb Business Combination is effected (the &#8220;Closing&#8221;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-money</div> equity value for OmniAb of $850&#160;million. Holders of OmniAb options, restricted stock&#160;units and performance stock&#160;units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 shares of APAC Common Stock (the &#8220;OmniAb Earnout Shares&#8221;), with 50% of such earnout shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $12.50 per share of APAC Common Stock for any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of APAC Common Stock for any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, in each case provided such vesting occurs during the five-year period following the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the proposed OmniAb Business Combination, upon the Domestication (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares will convert automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into shares of APAC Common Stock, (ii)&#160;all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii)&#160;all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one warrant to purchase APAC Common Stock. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">66</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED BALANCE SHEETS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,847</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">404,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">744,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">423,868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">934,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,188,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,612,743</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">236,684,513</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,302,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedExpenses" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,217,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedExpenses" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">107,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedOfferingCosts" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">314,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccruedOfferingCosts" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">314,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible promissory note</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">88,294</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative - Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,267,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">438,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">14,292,408</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,488,211</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies (see Note 6)</div></div></div> </td>
<td style="vertical-align: bottom;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, subject to possible redemption; <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction> shares at redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,188,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding (excluding <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction> shares subject to possible redemption)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,869,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,554,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,868,540</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,553,698</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,612,743</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">236,684,513</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 100pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">67</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">from&#160;February&#160;5,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021 (inception)</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">through<br/>September&#160;30,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation and operating costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,344,863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">170,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,744,341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">180,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,344,863</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,579</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,744,341</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">180,550</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,090,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,438,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,212,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,147,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,466,430</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,579</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,452,586</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">180,550</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deemed dividend - Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeemedDividend" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeemedDividend" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DeemedDividend" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">225,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeemedDividend" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="oabi:NetIncomeLossAttributableToOrdinaryShareholders" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,466,430</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="oabi:NetIncomeLossAttributableToOrdinaryShareholders" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,579</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="oabi:NetIncomeLossAttributableToOrdinaryShareholders" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,677,586</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="oabi:NetIncomeLossAttributableToOrdinaryShareholders" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">180,550</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,755,274</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.29</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,399,457</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,155,063</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;B ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.29</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 155pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 155pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">68</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 </div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A<br/>Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B<br/>Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at January&#160;1, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,554,273</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,553,698</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of Forward Purchase Agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:ReclassificationOfForwardPurchaseAgreement" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">223,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:ReclassificationOfForwardPurchaseAgreement" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">223,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deemed dividend - Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DeemedDividend" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">225,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:DeemedDividend" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">225,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,361,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,361,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,363,893</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,363,318</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">348,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">348,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,624,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,624,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">14,337,141</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">14,336,566</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,090,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,090,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Waiver of deferred underwriting commissions by underwriter (see Note&#160;6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:WaiverOfUnderwritingCommissionByUnderwriters" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:WaiverOfUnderwritingCommissionByUnderwriters" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,466,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,466,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,869,115</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,868,540</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THREE MONTHS ENDED SEPTEMBER&#160;30, 2021 AND FOR THE PERIOD FROM FEBRUARY&#160;5, 2021 (INCEPTION) THROUGH SEPTEMBER&#160;30, 2021 </div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/>Paid-in</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholder&#8217;s</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity<br/>(Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at February&#160;5, 2021 (inception)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;B ordinary shares to Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,425</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,786</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">17,214</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30,&#160;2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,425</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,971</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,029</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,245,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,245,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,314,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,314,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Class&#160;A ordinary shares to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">21,584,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,723,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,307,828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30,&#160;2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,904,229</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,903,654</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">69</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/>Ended<br/>September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;5,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021 (inception)<br/>through<br/>September&#160;30,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,452,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">180,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,438,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,147,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">340,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">880,112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,286,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">33,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseDecreaseInDueToRelatedPartyCurrent" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">87,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseDecreaseInDueToRelatedPartyCurrent" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,109,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">40,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">920,124</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">966,382</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash into Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:PaymentsForInvestmentOfCashInTrustAccount" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:PaymentsForInvestmentOfCashInTrustAccount" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from promissory note - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">119,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from initial public offering, net of underwriter&#8217;s discount paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ProceedsFromIssuanceInitialPublicOfferingNet" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:ProceedsFromIssuanceInitialPublicOfferingNet" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">225,400,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">615,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from convertible promissory note</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,078,585</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">170,124</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">362,203</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash - Beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash - End of period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,847</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">362,203</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash investing and financing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares subject to redemption to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,438,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,307,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial classification of the Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">448,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Waiver of deferred underwriting commissions by underwriter (see Note&#160;6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:WaiverOfUnderwritingCommissionByUnderwriters" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:WaiverOfUnderwritingCommissionByUnderwriters" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredUnderwritingFeePayable" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredUnderwritingFeePayable" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid by Sponsor and included in promissory note - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,725</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid by Sponsor in exchange for issuance of Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OfferingCostsPaidInExchangesForIssuanceOfShares" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:OfferingCostsPaidInExchangesForIssuanceOfShares" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">70</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="prewrkfin305908_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239695"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avista Public Acquisition Corp. II was a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. As used herein, the references to the &#8220;Company&#8221; are to Avista Public Acquisition Corp. II, prior to its domestication as a corporation incorporated in the state of Delaware and change of name to OmniAb, Inc., and its then wholly-owned and controlled subsidiary, Orwell Merger Sub Inc. (&#8220;Merger Sub&#8221;), unless the context indicates otherwise. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with <ix:nonFraction name="oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>or more businesses (a &#8220;Business Combination&#8221;). The Company was not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company was an early stage and emerging growth company and, as such, the Company was subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through September&#160;30, 2022 related to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination, which is described below. The Company generated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest and dividend income or gains on investments on the cash and investments held in the Trust Account (as defined below) from the proceeds derived from the Initial Public Offering. The Company had selected December&#160;31 as its fiscal year end. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction> (see Note&#160;3). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;), including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction> (see Note&#160;4). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, cash of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,847</ix:nonFraction> was held outside of the Trust Account and was available for the payment of accrued offering costs and for working capital purposes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and invested in only in U.S. government treasury obligations with maturities of <ix:nonNumeric name="oabi:InvestmentsMaximumMaturityTerm" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">185 days</ix:nonNumeric> or less or in money market funds meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public&#160;Offering, (ii)&#160;the redemption of the Company&#8217;s Public Shares if the Company had not consummated an Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Company&#8217;s Public Shares if the Company did </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">71</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60239695" continuedAt="TextSelectionAppend_60239695_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not complete the initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing the Company&#8217;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company provided its holders of the outstanding Public Shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision was made by the Company to seek shareholder approval of a Business Combination. The Public Shareholders were entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share, plus any pro rata interest and dividends or gains on investments earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There were no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company proceeded with the Business Combination as the Company had net tangible assets of at least $<ix:nonFraction name="oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> upon consummation of the Business Combination and at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60239967">two</span>-thirds</div> of the shares voted were voted in favor of the Business Combination. As the Company decided to obtain shareholder approval the Company offered to redeem shares in conjunction with the proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. The Sponsor agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of the Business Combination. Additionally, each Public Shareholder was given the option to redeem their Public Shares irrespective of whether they voted for or against the proposed transaction or didn&#8217;t vote at all. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of the Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of its Public Shares if the Company did not complete an initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company failed to complete an initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering. However, if the Sponsor had acquired Public Shares in or after the Initial Public Offering, such Public Shares would have been be entitled to liquidating distributions from the Trust Account if the Company failed to complete a Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had until <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company was unable to complete a Business Combination within the Combination Period, the Company would have (i)&#160;ceased all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:hidden60239959">ten </span>business&#160;days thereafter, redeemed the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $<ix:nonFraction name="oabi:MaximumNetInterestToPayDissolutionExpenses" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption would have completely extinguished Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">72</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239695_1" continuedAt="TextSelectionAppend_60239695_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidated and dissolved, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There would have been be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which would have expired worthless if the Company failed to complete a Business Combination within the Combination Period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters have agreed to waive their rights to a portion of their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company did not complete a Business Combination within the Combination Period and, in such event, such amounts would have been included with the other funds held in the Trust Account that would have been available to fund the redemption of the Public Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb Business Combination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb, Inc., a Delaware corporation and then wholly-owned subsidiary of Ligand (&#8220;Legacy OmniAb&#8221;), and Orwell Merger Sub Inc. (&#8220;Merger Sub&#8221;), pursuant to which the Company combined with Legacy OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, Legacy OmniAb and Merger Sub entered into that certain Employee Matters Agreement, as amended by that certain Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022 (the &#8220;Employee Matters Agreement&#8221;), (b) Legacy OmniAb and the Sponsor entered into that certain Sponsor Insider Letter Agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c)&#160;the Company amended and restated that certain previously disclosed Forward Purchase Agreement, dated August&#160;9, 2021, by entering into the Amended and Restated Forward Purchase Agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company, the Sponsor and Legacy OmniAb pursuant to which they consummated the OmniAb Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and Legacy OmniAb (the &#8220;Separation Agreement&#8221;), Ligand transferred the OmniAb Business, including certain related subsidiaries of Ligand, to Legacy OmniAb and, in connection therewith, distributed (the &#8220;Distribution&#8221;) to Ligand stockholders <ix:nonFraction name="oabi:PercentageOfCommonStockSharesIssuedUnderDistribution" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the common stock of Legacy OmniAb, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share (the &#8220;Legacy OmniAb Common Stock&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Legacy OmniAb (the &#8220;Merger&#8221;), with Legacy OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement, along with the Separation Agreement and the other transaction documents entered into in connection therewith, provided for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i) the Company redomiciled by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) (the &#8220;Domestication&#8221;), (ii) Ligand transferred the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, Legacy OmniAb, and contributed $<ix:nonFraction name="oabi:CapitalContributedNetOfExpenses" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million in capital thereto (less certain reimbursable transaction and other expenses), and (iii)&#160;following the Separation, Ligand distributed <ix:nonFraction name="oabi:PercentageOfCommonStockSharesIssuedUnderDistribution" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the shares of Legacy OmniAb Common Stock to Ligand stockholders by way of the Distribution. Following the completion of </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">73</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239695_2" continuedAt="TextSelectionAppend_60239695_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties consummated the Merger. The Distribution and Merger are intended to qualify as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;tax-free&#8221;</div> transactions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;28, 2022, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-264525)</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Form&#160;S-4&#8221;,</div> as amended on June&#160;13, 2022, July&#160;26, 2022, August&#160;22, 2022, September&#160;13, 2022 and September&#160;27, 2022) with the SEC, which includes the proxy statement/prospectus/information statement distributed to holders of the Company&#8217;s ordinary shares in connection with the Company&#8217;s solicitation for proxies for the vote by the Company&#8217;s shareholders in connection with the OmniAb Business Combination and other matters as described in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4.</div> The Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> was declared effective by the SEC on September&#160;30, 2022, and the definitive proxy statement/prospectus/information statement was mailed to the Company&#8217;s shareholders of record on the record date for voting on the OmniAb Business Combination. The OmniAb Business Combination closed on November&#160;1, 2022. Upon consummation of the OmniAb Business Combination, and after the Domestication, the Company has one class of common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share, which is listed on Nasdaq under the ticker symbol &#8220;OABI&#8221;. The Company&#8217;s warrants are listed on Nasdaq under the ticker symbol &#8220;OABIW&#8221;. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP, whereby the Company is treated as the acquired company and Legacy OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy OmniAb issuing stock for the net assets of the Company, accompanied by a recapitalization. The net assets of the Company were stated at historical cost, with no goodwill or other intangible assets recorded. Subsequent presentations of the results of operations presented for the period prior to the Business Combination will be for those of Legacy OmniAb. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb&#8217;s existing stockholders have the greatest voting interest in the combined entity; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb has the ability to nominate a majority of the initial members of the OmniAb Board; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb&#8217;s senior management is the senior management of the combined entity; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb is the larger entity based on historical operating activity and has the larger employee base; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The post-combination company has assumed a Legacy OmniAb branded name: &#8220;OmniAb, Inc.&#8221; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreement and Plan of Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the closing of the OmniAb Business Combination, each share of Legacy OmniAb&#8217;s common stock outstanding prior to the effective time of the OmniAb Business Combination was converted on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-for-one</div></div> basis into shares of common stock in the newly formed company (&#8220;OmniAb Common Stock&#8221;). Holders of Legacy OmniAb options, restricted stock units and performance stock units (determined after the Distribution (as defined below) and the division of Ligand equity awards into Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) had their awards converted into equity awards of the Company and adjusted pursuant to the exchange ratio. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, at the closing of the OmniAb Business Combination, holders of Legacy OmniAb Common Stock and equity awards received shares of OmniAb Common Stock subject to certain price-based earnout triggers (&#8220;Earnout Shares&#8221;), with <ix:nonFraction name="oabi:VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of such Earnout Shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $<ix:nonFraction name="oabi:VolumeWeightedAveragePriceTriggerPrice" contextRef="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.50</ix:nonFraction> per share of OmniAb Common Stock for </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">74</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239695_3" continuedAt="TextSelectionAppend_60239695_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">any <ix:nonNumeric name="oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days over a consecutive <ix:nonNumeric name="oabi:SharesToVestMeasurementPeriod" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, and the remainder vesting upon achievement of a post-transaction VWAP of $<ix:nonFraction name="oabi:VolumeWeightedAveragePriceTriggerPrice" contextRef="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">15</ix:nonFraction> per share of OmniAb Common Stock for any <ix:nonNumeric name="oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days over a consecutive <ix:nonNumeric name="oabi:SharesToVestMeasurementPeriod" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis" format="ixt-sec:durday">30</ix:nonNumeric> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, in each case provided such vesting occurs during the five-year period following the closing of the OmniAb Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the OmniAb Business Combination, upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> of the Company to Delaware (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares converted automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-for-one</div></div> basis, into shares of OmniAb Common Stock, (ii)&#160;all issued and outstanding warrants converted automatically into warrants to acquire shares of OmniAb Common Stock and (iii)&#160;all issued and outstanding Units separated and converted automatically into <ix:nonFraction name="oabi:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of OmniAb Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of <ix:nonFraction name="oabi:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> warrant to purchase OmniAb Common Stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Separation and Distribution Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Seperation Agreement, pursuant to which the Separation and Distribution were effected. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Separation Agreement also sets forth other agreements among Ligand and Legacy OmniAb, including provisions concerning the termination and settlement of intercompany accounts and the obtaining of necessary governmental approvals and third-party consents. The Separation Agreement also sets forth agreements that will govern certain aspects of the relationship between Ligand and Legacy OmniAb after the Distribution, including provisions with respect to release of claims, indemnification, access to financial and other information and access to and provision of records. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Matters Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Employee Matters Agreement, as amended by the Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022, which provides for employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and Legacy OmniAb, treatment of incentive equity awards in the Distribution and the OmniAb Business Combination and related covenants and commitments of the parties. Each existing Ligand equity award at the time of the Distribution granted prior to March&#160;2, 2022, with certain limited exceptions, was split into (i)&#160;a new Ligand equity award and (ii)&#160;a new Legacy OmniAb equity award, with any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> value in the original Ligand equity award split between such awards based on the relative values of Ligand and OmniAb at the time of the Distribution. Each existing Ligand equity award at the time of the Distribution granted on or after March&#160;2, 2022 was converted into either an adjusted Ligand equity award, if the holder was a Ligand service provider following the Distribution, or a Legacy OmniAb equity award, if the holder was a Legacy OmniAb service provider following the Distribution. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Insider Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Legacy OmniAb and the Sponsor entered into the Sponsor Insider Agreement with the Company and the Insiders, pursuant to which, among other things, the Insiders agreed to vote any of our securities held by them to approve the OmniAb Business Combination and the other Company shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their Company securities in connection with the consummation of the OmniAb Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to <ix:nonFraction name="oabi:MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_SponsorInsiderAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,916,667</ix:nonFraction> Earnout Founder Shares (as defined in the Sponsor Insider Agreement), to the same price-based vesting conditions as the OmniAb Earnout Shares. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">75</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239695_4" continuedAt="TextSelectionAppend_60239695_5"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Forward Purchase Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into Amended and Restated Forward Purchase Agreement (the &#8220;A&amp;R FPA&#8221;) with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;R FPA, the Company agreed to, in connection with the consummation of the OmniAb Business Combination, issue and sell to the Sponsor <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction> shares of OmniAb Common Stock (the &#8220;Forward Purchase Shares&#8221;) and warrants to acquire <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> shares of OmniAb Common Stock (the &#8220;Forward Purchase Warrants&#8221;) for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million with such purchases having been consummated immediately following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> to Delaware. In addition, the Sponsor agreed to purchase up to an additional <ix:nonFraction name="oabi:AdditionalNumberOfCommonStock" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares of OmniAb Common Stock (the &#8220;Backstop Shares&#8221;) and up to an additional <ix:nonFraction name="oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> warrants, (The &#8220;Backstop Warrants&#8221; and, together with the Forward Purchase Shares, Forward Purchase Warrants and Backstop Shares, the &#8220;Forward Purchase and Backstop Securities&#8221;) for an aggregate additional purchase price of up to $<ix:nonFraction name="oabi:AdditionalAggregatePurchasePrice" contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $<ix:nonFraction name="oabi:MaximumAdditionalAggregatePurchasePrice" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million. Pursuant to the A&amp;R FPA, in connection with the Business Combination, the Sponsor was issued <ix:nonFraction name="oabi:SponsorPurchaseBackstop" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,672,934</ix:nonFraction> Backstop Shares and <ix:nonFraction name="oabi:SharesBackstopWarrants" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,445,489</ix:nonFraction> Backstop Warrants for an aggregate purchase price of $<ix:nonFraction name="oabi:AdditionalAggregatePurchasePrice" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">86,729,340</ix:nonFraction> in order to backstop the redemptions. In addition, pursuant to the A&amp;R FPA, the Sponsor was issued <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction> Forward Purchase Shares and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> Forward Purchase Warrants for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction>, on a private placement basis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.25</ix:nonFraction> per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern Consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,847</ix:nonFraction> in cash held outside of the Trust Account and a working capital deficit of $<ix:nonFraction name="oabi:WorkingCapitalDeficit" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,843,540</ix:nonFraction>. The Company incurred significant costs in pursuit of its acquisition plans. In connection with the Company&#8217;s assessment of going concern considerations in accordance with FASB&#8217;s ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Presentation of Financial Statements - Going Concern, management has determined those conditions raised substantial doubt about the Company&#8217;s ability to continue as a going concern within the earlier of the Combination Period, which will end on February&#160;12, 2023, or one year after the date that the condensed consolidated financial statements are issued. Moreover, the Company needed to obtain additional financing to complete the Business Combination and to redeem <ix:nonFraction name="oabi:NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,713,864</ix:nonFraction> public shares upon completion of the Business </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">76</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239695_5"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Combination, in which case the Company issued additional securities in connection with the Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $<ix:nonFraction name="oabi:AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million was deposited in an operating account for the Company&#8217;s working capital needs. In addition, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $<ix:nonFraction name="oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction>. As of September&#160;30, 2022, the Company has borrowed $<ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> under the Sponsor Working Capital Loan. The amounts held in the operating account were not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the remainder of the Combination Period. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry, the geopolitical conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals and entities and the status of debt and equity markets and has concluded that while it is reasonably possible that any of the foregoing could have a negative effect on the Company&#8217;s financial position and results of its operations, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a 1% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> U.S. corporations beginning in 2023, with certain exceptions (the &#8220;Excise Tax&#8221;). Because the Company became a Delaware corporation upon the Domestication and the securities traded on Nasdaq, we would have likely been considered a &#8220;covered corporation&#8221; within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax would have applied to any redemptions of our common stock after December&#160;31, 2022, including redemptions in connection with an initial Business Combination and any amendment to a certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239905"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> as filed with the SEC on March&#160;28, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">77</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60239905" continuedAt="TextSelectionAppend_60239905_1"> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:EmergingGrowthCompanyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The valuation of the Forward Purchase and Backstop Securities required management to exercise significant judgement in its estimate. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240341"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 or </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">78</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60239905_1" continuedAt="TextSelectionAppend_60239905_2"><ix:continuation id="TextSelection_60240341"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">December&#160;31, 2021. As <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div>September&#160;30, 2022 and December&#160;31, 2021, the Company had operating cash (i.e., cash held outside the Trust Account) of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,847</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">189,971</ix:nonFraction>, respectively. </div> </ix:continuation> <ix:nonNumeric name="oabi:AssetsHeldInTrustAccountPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in Trust Account </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury bills. The Company&#8217;s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in gain on investments held in Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of the investments held in the Trust Account are determined using available market information. At December&#160;31, 2021, the assets held in the Trust Account were held in cash. </div></div></ix:nonNumeric> <ix:nonNumeric name="oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240339"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares Previously Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contained a redemption feature which allowed for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognized changes in redemption value immediately as they occurred and adjusted the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares were affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:TemporaryEquityProceedsAllocatedToWarrants" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,813,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="oabi:TemporaryEquityIssuanceCosts" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">13,029,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,593,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">235,750,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,438,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,188,875</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">21,713,864</ix:nonFraction> shares of the Company&#8217;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">79</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_60239905_2" continuedAt="TextSelectionAppend_60239905_3"><ix:continuation id="TextSelection_60240339"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">their right to redeem those shares for a <div style="letter-spacing: 0px; top: 0px;;display:inline;">pro </div>rata portion of the Trust Account holding the proceeds from the Company&#8217;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.32</ix:nonFraction> per share, for an aggregate of approximately $<ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">224</ix:nonFraction>&#160;million. </div></div> </ix:continuation> <ix:nonNumeric name="oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $<ix:nonFraction name="oabi:TransactionCosts" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,662,256</ix:nonFraction> as a result of the Initial Public Offering (consisting of $<ix:nonFraction name="oabi:SaleOfStockUnderwritingFees" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction> of cash underwriting discounts, $<ix:nonFraction name="oabi:DeferredOfferingCostsNoncurrent" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction> in deferred underwriting fees and $<ix:nonFraction name="oabi:SaleOfStockOtherOfferingCosts" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,012,256</ix:nonFraction> of other offering costs). As such, the Company recorded $<ix:nonFraction name="oabi:OfferingCostsReductionOfTemporaryEquity" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,029,901</ix:nonFraction> of offering costs as a reduction of temporary equity and $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">632,355</ix:nonFraction> of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, Income Taxes (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed consolidated financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>unrecognized tax benefits and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>amounts accrued for interest and penalties as of September&#160;30, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s condensed consolidated financial statements. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240334"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Ordinary Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,900,000</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>shares in the calculation of diluted </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">80</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><ix:continuation id="TextSelectionAppend_60239905_3" continuedAt="TextSelectionAppend_60239905_4"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240334"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income per share as the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;5, 2021</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,973,144</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">493,286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">118,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">52,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,762,069</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,690,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">12,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,399,457</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,755,274</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,155,063</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.29</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.29</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The Forward Purchase and Backstop Securities contained within the A&amp;R FPA (see Note 6) are classified as derivatives in the condensed consolidated balance sheet with changes in the fair value recognized in the condensed consolidated statements of operations. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240330"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">81</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><ix:continuation id="TextSelectionAppend_60239905_4"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240330"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note - related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed consolidated financial statements. </div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="oabi:InitialPublicOfferingTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;3. INITIAL PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction> Units, including <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">230,000,000</ix:nonFraction>. Each Unit consists of <ix:nonFraction name="oabi:NumberOfSharesIssuedPerUnit" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60239985">one</span>-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A ordinary share at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction>&#160;per whole share (see Note 7). </div></ix:nonNumeric> <ix:nonNumeric name="oabi:PrivatePlacementTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> Private Placement Warrants, including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per Private Placement Warrant ($<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,350,000</ix:nonFraction> in the aggregate). Each Private Placement Warrant was exercisable to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Class&#160;A ordinary share at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company did not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants would have been used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants would have expired worthless. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">82</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240081"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> to cover certain expenses on behalf of the Company in exchange for the issuance of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares included an aggregate of up to <ix:nonFraction name="oabi:NumberOfSharesSubjectToForfeiture" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part, so that the holders of the Founder Shares would own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, <ix:nonFraction name="oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction> Class&#160;B ordinary shares each to three members of the Company&#8217;s board of directors (or <ix:nonFraction name="oabi:TotalNumberOfSharesTransferred" contextRef="PAsOn06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;<ix:nonNumeric name="oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric>&#160;after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#8217;s Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction> per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">30</ix:nonNumeric>-</div> trading day period commencing at least <ix:nonNumeric name="oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">150</ix:nonNumeric> days after the OmniAb Business Combination or (2)&#160;if the Company consummates a transaction after the OmniAb Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note&#160;&#8212; Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $<ix:nonFraction name="oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="PAsOn02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> to cover expenses related to the Initial Public Offering. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $<ix:nonFraction name="oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty" contextRef="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,725</ix:nonFraction>, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $<ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">119,275</ix:nonFraction> on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction>. The Promissory Note is no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $<ix:nonFraction name="oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" contextRef="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per month for administrative, financial and support services. Upon the completion of the OmniAb Business Combination, the Company ceased paying these monthly fees. For the three months and nine months ended September&#160;30, 2022, the Company incurred expenses of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P07_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">90,000</ix:nonFraction>, respectively, under the agreement. For the three months ended September&#160;30, 2021 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021 the Company incurred expenses of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P02_05_2021To09_30_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction> under the agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party consists of payments made by the Sponsor and/or an affiliate of the Sponsor on behalf of the Company for formation and operating costs, along with the administrative support monthly fee and are payable on demand. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">83</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240081"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Promissory Note </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;working capital loans&#8221;). If the Company completed the initial Business Combination, it could repay such loaned amounts out of the proceeds of the Trust Account released to us. Otherwise, such loans could be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination did not close, the Company could use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Company&#8217;s Trust Account would be used to repay such loaned amounts. Up to $<ix:nonFraction name="oabi:MaximumLoansConvertibleIntoWarrants" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction> of such loans could have been convertible into warrants of the post-Business Combination entity at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction>&#160;per warrant at the option of the lender. The warrants would have been identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. The Company did not seek loans from parties other than the Sponsor, its affiliates or any members of the management team as the Company did not believe third parties would be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;14, 2022, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $<ix:nonFraction name="oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction>. The Sponsor Working Capital Loan is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per warrant. The warrants would be identical to the Private Placement Warrants. As of September&#160;30, 2022, the outstanding balance on the convertible promissory note is $<ix:nonFraction name="oabi:WorkingCapitalLoansOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction>. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;24, 2022, the board of directors elected Charles Harwood to serve as a director of the Company and appointed Mr.&#160;Harwood to serve as a member of the audit committee. The board of directors has determined that Mr.&#160;Harwood satisfies all applicable independence requirements to serve on the board of directors and the audit committee, including without limitation the applicable independence requirements of the Nasdaq Capital Market and the Exchange Act, as amended. In connection with Mr.&#160;Harwood&#8217;s appointment to the audit committee, L&#226;le White has stepped down from the audit committee, which currently consists of Wendel Barr, Charles Harwood and William Klitgaard. The changes to the audit committee&#8217;s composition relate to the Company&#8217;s communications with the staff of Nasdaq on August&#160;22, 2022, regarding whether the Company was in compliance with Nasdaq Listing Rule 5605(c)(2) following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">phase-in</div> period provided under Nasdaq Listing Rule 5615(b)(1) because the Audit Committee was not comprised of at least three independent directors. The Company is in compliance with the applicable rules following the board of directors and audit committee changes described herein. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the OmniAb Business Combination, the Company paid Mr.&#160;Harwood a $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> fee for his services as a director and member of the audit committee. This fee is included as part of accrued expenses on the balance sheet as of September&#160;30, 2022. In connection with Mr.&#160;Harwood&#8217;s appointment, he and the Company entered into an indemnification agreement and a letter agreement, the terms of which were described in, and the forms of which were filed as exhibits to, the Company&#8217;s registration statement relating to the Company&#8217;s Initial Public Offering. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">84</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240138"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration and Shareholder Rights Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) had registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities were entitled to make up to <ix:nonFraction name="oabi:MaximumNumberOfDemandsForRegistrationOfSecurities" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_ITEM" decimals="0" scale="0" format="ixt-sec:numwordsen">three </ix:nonFraction>demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters purchased Units at a purchase price of $<ix:nonFraction name="oabi:PurchasePricePerUnit" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.80</ix:nonFraction> per Unit (i.e., at a cash underwriting discount of $<ix:nonFraction name="oabi:DeferredFeePerUnit" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.20</ix:nonFraction>&#160;per Unit, or $<ix:nonFraction name="oabi:AggregateDeferredUnderwritingFeePayable" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction> in the aggregate) upon the closing of the Initial Public Offering and the exercise of the over-allotment in full on August&#160;12, 2021. In addition, the Company agreed to pay the underwriters a deferred underwriting fee of up to $<ix:nonFraction name="oabi:AdditionalDeferredFeePerUnit" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.35</ix:nonFraction> per Unit, or $<ix:nonFraction name="oabi:AdditionalAggregateDeferredUnderwritingFeePayable" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,050,000</ix:nonFraction> in the aggregate, which would be payable to the underwriters upon the consummation of the initial Business Combination, except that the Company&#8217;s management team would be permitted, in its sole discretion, to allocate up to <ix:nonFraction name="oabi:PercentageOfDeferredUnderwritingFeePayableToThirdParties" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the deferred underwriting fee, or $<ix:nonFraction name="oabi:AggregateDeferredUnderwritingFeePayableToThirdParties" contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction> in the aggregate, to third parties that assist in identifying and consummating an initial Business Combination. On August&#160;17, 2022, Credit Suisse waived its right to <ix:nonFraction name="oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" contextRef="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">50</ix:nonFraction>%, or $<ix:nonFraction name="oabi:AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" contextRef="P08_17_2022To08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction> in the aggregate, of the deferred underwriting fee, and the Company has determined not to pay the <ix:nonFraction name="oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" contextRef="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">50</ix:nonFraction>% to any other advisors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Purchase Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor which provides for the purchase of an aggregate of <ix:nonFraction name="oabi:SharesToBePurchasedPursuantToAgreements" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Class&#160;A ordinary shares plus an aggregate of <ix:nonFraction name="oabi:WarrantsToBePurchasedPursuantToAgreements" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,333,333</ix:nonFraction> redeemable warrants to purchase Class&#160;A ordinary shares at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#8217;s Public Shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward purchase securities were issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities were used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the A&amp;R FPA with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;R FPA, the Company agreed that, in connection with the consummation of the OmniAb Business Combination, they would issue and sell to the Sponsor <ix:nonFraction name="oabi:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction> shares of OmniAb Common Stock and warrants to acquire <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> shares of OmniAb Common Stock for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million with such purchases to be consummated immediately following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> to Delaware and prior to the OmniAb Business Combination. In addition, the Sponsor agreed to purchase up to an additional <ix:nonFraction name="oabi:AdditionalNumberOfCommonStock" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares of OmniAb Common Stock and up to an additional <ix:nonFraction name="oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> warrants, for an aggregate additional purchase price of up to $<ix:nonFraction name="oabi:AdditionalAggregatePurchasePrice" contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million, in </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">85</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240138"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $<ix:nonFraction name="oabi:MaximumAdditionalAggregatePurchasePrice" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million. The A&amp;R FPA also provided that in the event the Merger Agreement was terminated by Ligand under circumstances in which the Termination Fee (as defined in the Merger Agreement) would be payable under the Merger Agreement, Ligand would pay the Sponsor a termination fee of $<ix:nonFraction name="us-gaap:BusinessExitCosts1" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.5</ix:nonFraction>&#160;million in connection therewith. Pursuant to the A&amp;R FPA, in connection with the Business Combination, the Sponsor was issued <ix:nonFraction name="oabi:SponsorPurchaseBackstop" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,672,934</ix:nonFraction> Backstop Shares and <ix:nonFraction name="oabi:SharesBackstopWarrants" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,445,489</ix:nonFraction> Backstop Warrants for an aggregate purchase price of $<ix:nonFraction name="oabi:AdditionalAggregatePurchasePrice" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">86,729,340</ix:nonFraction> in order to backstop the redemptions. In addition, pursuant to the A&amp;R FPA, the Sponsor was issued <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction> Forward Purchase Shares and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,666,667</ix:nonFraction> Forward Purchase Warrants for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction>, on a private placement basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the A&amp;R FPA, the Company evaluated the modification of the equity contract, which resulted in a reclassification between equity and a liability, in which the difference between the fair value at issuance of the original forward purchase agreement and the fair value at issuance of the A&amp;R FPA (the modification date) was treated as a deemed dividend. An amount of $<ix:nonFraction name="oabi:DeemedDividend" contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction> was recorded to accumulated deficit as a deemed dividend upon modification of the forward purchase agreement on March&#160;23, 2022. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240195"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;7. SHAREHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference shares</div></div></div></div> &#8212; The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction> preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of September&#160;30,&#160;2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares</div></div></div></div> &#8212; The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. Holders of Class&#160;A ordinary shares are entitled to <ix:nonFraction name="oabi:CommonStockNumberOfVotesPerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>vote for each share. At September&#160;30,&#160;2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares issued and outstanding, including <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">23,000,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares subject to possible redemption. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B ordinary shares</div></div></div></div> &#8212; The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. Holders of Class&#160;B ordinary shares are entitled to <ix:nonFraction name="oabi:CommonStockNumberOfVotesPerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>vote for each share. As of September&#160;30, 2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, <ix:nonFraction name="oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s issued and outstanding shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ordinary shareholders of record are entitled to <ix:nonFraction name="oabi:CommonStockNumberOfVotesPerShare" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than <ix:nonFraction name="oabi:PercentageOfVotingRightsShareHolders" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">86</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60240195" continuedAt="TextSelectionAppend_60240195_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Warrants</div></div></div></div> &#8212; Each whole warrant entitles the registered holder to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>Class&#160;A ordinary share at a price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, subject to adjustment as discussed below, at any time commencing <ix:nonNumeric name="oabi:WarrantExercisePeriodConditionTwo" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#160;after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>&#160;after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric name="oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">20</ix:nonNumeric> business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within <ix:nonNumeric name="oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">60</ix:nonNumeric>&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class&#160;A ordinary shares are at the time of any exercise of a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">87</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_60240195_1" continuedAt="TextSelectionAppend_60240195_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the <ix:nonNumeric name="oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">60</ix:nonNumeric>th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">10</ix:nonNumeric> trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice of redemption to each warrant holder; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction name="oabi:WarrantRedemptionConditionMinimumSharePrice" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric>-trading</div> day period ending <ix:nonFraction name="oabi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_Day" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> trading days before the Company sends the notice of redemption to the warrant holders. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div> redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $<ix:nonFraction name="oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> (for whole shares) warrant exercise price after the redemption notice is issued. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">88</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:continuation id="TextSelectionAppend_60240195_2" continuedAt="TextSelectionAppend_60240195_3"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume weighted average price of Class&#160;A ordinary shares as reported during the <ix:nonNumeric name="oabi:RedemptionPeriod" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" format="ixt-sec:durday">10</ix:nonNumeric> trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">365</ix:nonNumeric>-day</div> period ending on the date of declaration of such dividend or distribution does not exceed $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction> (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction> per share, (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction name="oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the public shares if the Company does not complete its initial Business Combination within <ix:nonNumeric name="oabi:MonthsToCompleteInitialBusinessCombination" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#8217;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">89</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_60240195_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction name="oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the <ix:nonNumeric name="oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction name="oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="oabi:WarrantExercisePriceAdjustmentMultiple" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">115</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price, the $<ix:nonFraction name="oabi:WarrantRedemptionConditionMinimumSharePrice" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="oabi:WarrantRedemptionPriceAdjustmentMultiple" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">180</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until <ix:nonNumeric name="oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durmonth">30</ix:nonNumeric> days&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,900,000</ix:nonFraction> warrants issued in connection with the Initial Public Offering (including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,666,667</ix:nonFraction> Public Warrants and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,233,333</ix:nonFraction> Private Placement Warrants ), and will account for the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseWarrantsAndBackstopMemberusgaapClassOfWarrantOrRightAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,333,334</ix:nonFraction> Forward Purchase Warrants and Backstop Warrants to be issued in connection with the OmniAb Business Combination, in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">90</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240016"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of September&#160;30, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount&#160;at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,188,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,188,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liability - Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Forward Purchase and Backstop Securities were fair valued based on the difference between the current fair values of each of the underlying components of the agreement (i.e. the Class&#160;A ordinary shares and the warrants) and the present value of the contractual forward prices. As the Backstop Securities only apply in the event of and to the extent that the funds in the Company&#8217;s Trust Account falls below $<ix:nonFraction name="oabi:MaximumAdditionalAggregatePurchasePrice" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction>&#160;million as the result of redemptions, the valuation considered an expected redemption rate based on redemption rates exhibited by similar companies in the market during the third quarter of 2022 and the expected post-redemption Trust Account balance. As the Forward Purchase and Backstop Securities will only apply in the event that the Company completes an initial business combination, the value reflects the probability of completing an initial business combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the derivative liability for the Forward Purchase and Backstop Securities is classified as Level&#160;3 due to the use of unobservable inputs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of March&#160;23, 2022 (initial measurement): </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60239969"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 21%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;23,&#160;2022</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Initial&#160;Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:num-dot-decimal">10.34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">0.52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">99.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">85.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">32.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">448,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">91</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:continuation id="TextSelection_60240016"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of September&#160;30, 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_60239969">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 19%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:num-dot-decimal">10.20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">99.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">85.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_item" decimals="2" scale="0" format="ixt:num-dot-decimal">50.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of the Company&#8217;s Level&#160;3 financial instruments that are measured at fair value: </div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement as of March&#160;23, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="oabi:InitialMeasurementOfForwardPurchase" contextRef="P03_23_2022To03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">448,380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P03_24_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">591,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,039,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">656,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">383,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,212,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,212,110</ix:nonFraction> and $<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the three months ended September&#160;30, 2022 and for the three months ended September&#160;30, 2021, respectively. The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,147,120</ix:nonFraction> and $<ix:nonFraction name="oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_60240058"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;9. SUBSEQUENT EVENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as mentioned below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">92</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AVISTA PUBLIC ACQUISITION CORP. II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:continuation id="TextSelection_60240058"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,713,864</ix:nonFraction> shares of the Company&#8217;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised their right to redeem those shares for a pro rata portion of the Trust Account holding the proceeds from the Company&#8217;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $<ix:nonFraction name="oabi:SaleOfStockCashPricePerShare" contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.32</ix:nonFraction> per share, for an aggregate of approximately $<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">224</ix:nonFraction>&#160;million. The per share redemption price of approximately $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.32</ix:nonFraction> for public shareholders electing redemption was paid out of the Trust Account. For more information regarding the Business Combination, see Note 1, Note 2, Note 6 and OmniAb&#8217;s Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on November&#160;7, 2022. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">93</div></div><br/></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares </p> <p style="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g305908g06r21.jpg" alt="LOGO" />
 </p> <p style="margin-top:100pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common stock </p> <p style="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Preliminary Prospectus </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022 </p> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom305908_22">Part&#160;II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:81%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,948.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial printing and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection (a)&#160;of Section&#160;145 of the General Corporation Law of the State of Delaware (referred to as the &#8220;DGCL&#8221;) empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection (b)&#160;of Section&#160;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL or (iv)&#160;for any transaction from which the director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our bylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we entered into indemnification agreements with each of our directors and officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We intend to enter into indemnification agreements with our future directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of capital stock issued by us within the past three&#160;years. Also included is the consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2021, the Sponsor purchased 5,750,000 APAC Class&#160;B Ordinary Shares for $25,000, or approximately $0.004 per share. In July 2021, the Sponsor transferred 35,000 APAC Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White, and Wendel Barr, each of whom served on APAC&#8217;s board of directors, at their original purchase price. The IPO was consummated on August&#160;12, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the consummation of the IPO, the Sponsor purchased from APAC an aggregate of 8,233,333 Private Placement Warrants at a price of $1.50 per Private Placement Warrant (or an aggregate purchase price of $12,350,000. Each Private Placement Warrant entitles the holder to purchase one share of Common Stock at $11.50 per share. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except that (a)&#160;subject to certain exceptions, the Private Placement Warrants are not transferable, assignable or saleable until 30 days after Closing Date, (b)&#160;the Private Placement Warrants are exercisable on a cashless basis and are <span style="white-space:nowrap">non-redeemable</span> so long as they are held by the initial purchasers or their permitted transferees and (c)&#160;the Sponsor is entitled to registration rights in respect of the Private Placement Warrants. The Private Placement Warrants are redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sales of the above securities by APAC were exempt from registration in reliance on Section&#160;4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Closing Date, we consummated the Transactions pursuant to the Merger Agreement. As contemplated by the A&amp;R FPA, following the Domestication but before the Merger: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the Sponsor purchased 1,500,000 shares of Common Stock and 1,666,667 OmniAb Warrants for an aggregate purchase price of $15,000,000; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the Sponsor purchased 8,672,934 shares of Common Stock and 1,445,489 OmniAb Warrants for an aggregate purchase price of $86,729,340 in order to backstop shareholder redemptions which would have otherwise resulted in the Trust Account to be less than $100,000,000. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OmniAb issued the foregoing securities under Section&#160;4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act, as a transaction not requiring registration under Section&#160;5 of the Securities Act. The parties receiving the securities represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution, and appropriate restrictive legends were affixed to the certificates representing the securities (or reflected in restricted book entry with OmniAb&#8217;s transfer agent and warrant agent). The parties also had adequate access, through business or other relationships, to information about OmniAb. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;16. Exhibits and Financial Statement Schedules. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<span style="font-weight:bold">&#160;&#160;&#160;&#160;</span><span style="font-weight:bold">Exhibits. </span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:88%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922103339/tm2212114-19_s4a.htm#tANNEA">Agreement and Plan of Merger, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub Inc., Ligand Pharmaceuticals Incorporated and OmniAb, Inc. (incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.2+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922103339/tm2212114-19_s4a.htm#tANNEXB">Separation and Distribution Agreement, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc. (incorporated by reference to Exhibit 2.2 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex31.htm">Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex32.htm">Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex4-1.htm">Warrant Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;12, 2021).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex42.htm">Assignment, Assumption and Amendment Agreement, dated November&#160;1, 2022, by and among OmniAb, Inc., Continental Stock Transfer&#160;&amp; Trust Company and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 4.2 of Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921097011/tm2110146d9_ex4-4.htm">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on July&#160;28, 2021).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922070237/ahpa-20220513xex4d5.htm">Specimen Common Stock Certificate of OmniAb, Inc. (incorporated by reference to Exhibit 4.5 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d305908dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-3.htm">Private Placement Warrants Purchase Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;12, 2021). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-5.htm">Form of Letter Agreements, dated August&#160;9, 2021, by and among Avista Public Acquisition Corp. II, each of Avista Public Acquisition Corp. II&#8217;s officers and directors and Avista Acquisition LP II (incorporated by reference to Exhibit 10.5 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;12, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-6.htm">Form of Indemnity Agreements, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II, each of its officers and directors and Avista Acquisition LP II (incorporated by reference to Exhibit 10.6 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;12, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-7.htm">Forward Purchase Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit 10.7 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;12, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146d7_ex10-7.htm">Securities Subscription Agreement, dated February&#160;12, 2021, between Avista Public Acquisition Corp. II and the Sponsor (incorporated by reference to Exhibit 10.7 to Avista Public Acquisition Corp. II&#8217;s Form <span style="white-space:nowrap">S-1/A</span> filed with the SEC on July&#160;28, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1846253/000110465922051436/ahpa-20220416xs4.htm#AnnexC_741582">Sponsor Insider Agreement, dated March&#160;23, 2022, by and among OmniAb, Inc., Avista Public Acquisition Corp. II, Avista Acquisition LP II and the other parties signatory thereto (incorporated by reference to Exhibit 10.11 of Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex107.htm">Amended and Restated Registration and Stockholder Rights Agreement, dated November&#160;1, 2022 by and among OmniAb, Inc., Avista Acquisition LP II and the other parties named therein (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Form 8-K filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1846253/000110465922051436/ahpa-20220416xs4.htm#AnnexD_88451">Amended and Restated Forward Purchase Agreement, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Avista Acquisition LP II and OmniAb, Inc. (incorporated by reference to Exhibit 10.12 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922103339/tm2212114-19_s4a.htm#tANNEXK">Amended and Restated Employee Matters Agreement, dated August&#160;18, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub Inc., Ligand Pharmaceuticals Incorporated and OmniAb, Inc. (incorporated by reference to Exhibit 10.13 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10&#8224;+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1010.htm">Tax Matters Agreement, dated November&#160;1, 2022, by and among OmniAb, Inc., Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc. (incorporated by reference to Exhibit&#160;10.10 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1011.htm">Transition Services Agreement, dated November&#160;1, 2022, by and between Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc., with respect to services provided by Ligand Pharmaceuticals Incorporated to OmniAb Operations, Inc. (incorporated by reference to Exhibit&#160;10.11 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1012.htm">Transition Services Agreement, dated November&#160;1, by and between Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc., with respect to services provided by OmniAb Operations, Inc. to Ligand Pharmaceuticals Incorporated (incorporated by reference to Exhibit&#160;10.12 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922110957/tm2228794d1_ex10-1.htm">OmniAb, Inc. 2022 Incentive Award Plan (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on October&#160;24, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1014.htm">Form of Stock Option Agreement under the OmniAb, Inc. 2022 Incentive Award Plan (incorporated by reference to Exhibit 10.14 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.15#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1015.htm">Form of Restricted Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan (incorporated by reference to Exhibit 10.15 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.16#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1016.htm">Form of Performance Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan (incorporated by reference to Exhibit 10.16 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.17#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922110957/tm2228794d1_ex10-2.htm">OmniAb, Inc. 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on October&#160;24, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.18#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1018.htm">OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan (incorporated by reference to Exhibit 10.18 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.19#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1019.htm">OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan (incorporated by reference to Exhibit 10.19 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.20#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1020.htm">OmniAb, Inc. Director Compensation and Stock Ownership Policy (incorporated by reference to Exhibit 10.20 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.21#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex1021.htm">OmniAb, Inc. Severance Plan (incorporated by reference to Exhibit 10.21 of the Registrant&#8217;s <span style="white-space:nowrap">Form&#160;8-K</span> filed with the SEC on November 7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.22#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922070237/ahpa-20220513xex10d21.htm">Form of OmniAb, Inc. Change in Control Severance Agreement (incorporated by reference to Exhibit 10.23 of Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed on September&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.23#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922051436/ahpa-20220416xex10d23.htm">Form of OmniAb, Inc. Indemnification Agreement for Directors and Officers (incorporated by reference to Exhibit 10.25 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.24+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922099352/tm2212114d17_ex10-26.htm">Office/Laboratory Lease between Emery Station Office II, LLC and Ligand Pharmaceuticals Incorporated, dated June&#160;8, 2021 (incorporated by reference to Exhibit 10.26 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.25&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922082841/tm2212114d8_ex10-25.htm">Antibody License Agreement between CNA Development LLC and OmniAb, Inc. dated December&#160;20, 2012 (incorporated by reference to Exhibit 10.27 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.26&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922082841/tm2212114d8_ex10-26.htm">Research, Development and Commercialization Agreement between Cystic Fibrosis Foundation and Icagen, LLC, dated May&#160;1, 2018, as amended (incorporated by reference to Exhibit 10.28 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.27&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000110465922082841/tm2212114d8_ex10-27.htm">Amended and Restated License Agreement between F. <span style="white-space:nowrap">Hoffmann-La</span> Roche Ltd, <span style="white-space:nowrap">Hoffmann-La</span> Roche Inc. and Icagen, LLC, dated May&#160;29, 2020, as amended (incorporated by reference to Exhibit 10.29 of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264525)</span> filed with the SEC on September&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1846253/000119312522279194/d305922dex211.htm">List of Subsidiaries of OmniAb, Inc. (incorporated by reference to Exhibit 21.1 of the Registrant&#8217;s Form <span style="white-space:nowrap">8-K</span> filed with the SEC on November&#160;7, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d305908dex231.htm">Consent of Marcum LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d305908dex232.htm">Consent of Ernst&#160;&amp; Young LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d305908dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit 5.1) </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on signature page of the initial filing of this Registration Statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d305908dexfilingfees.htm">Filing Fee Table </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document&#160;&#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Calculation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Definition Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit&#160;101)</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been omitted for confidentiality purposes. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<span style="font-weight:bold">&#160;&#160;&#160;&#160;</span><span style="font-weight:bold">Financial Statement Schedules. </span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;17. Undertakings. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i)&#160;to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; (ii)&#160;to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and (iii)&#160;to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (i), (ii) and (iii)&#160;do not apply if the registration statement is on Form <span style="white-space:nowrap">S-1</span> and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <span style="font-style:italic">bona fide</span> offering thereof; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) that, for the purpose of determining liability under the Securities Act to any purchaser: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <span style="font-style:italic">Provided</span>, <span style="font-style:italic">however</span>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) that, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of an undersigned registrant; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig"><span id="rom305908_23"></span>SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned hereunto duly authorized, on this 30th day of November, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Omniab, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew W. Foehr</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Matthew W. Foehr</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President and Chief&#160;Executive&#160;Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints Matthew W, Foehr and Kurt A. Gustafson as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement (and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act of 1933 (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew W. Foehr</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew W. Foehr</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">President, Chief Executive Officer and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kurt A. Gustafson</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kurt A. Gustafson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Executive Vice President, Finance and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief&#160;Financial&#160;Officer</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Financial Officer and</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Principal Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carolyn R. Bertozzi, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Carolyn R. Bertozzi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sarah Boyce</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sarah Boyce</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Cochran, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jennifer Cochran, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John L. Higgins</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John L. Higgins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sunil Patel</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sunil Patel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua Tamaroff</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Joshua Tamaroff</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;30, 2022</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d305908dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">12670 High Bluff Drive</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">San Diego, California 92130</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Tel: +1.858.523.5400 Fax: +1.858.523.5450</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">www.lw.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2">


<IMG SRC="g305908g57q23.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">FIRM / AFFILIATE OFFICES</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Austin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Milan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Beijing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Munich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Boston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">New York</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Brussels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Orange&nbsp;County</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Century&nbsp;City</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Paris</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman; font-size:10pt">November&nbsp;30, 2022</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Chicago</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Riyadh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Dubai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">San Diego</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">D&uuml;sseldorf</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">San Francisco</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Frankfurt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Seoul</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Hamburg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Shanghai</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Hong Kong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Silicon Valley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OmniAb, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5980 Horton Street,
Suite 600</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Emeryville, California 94608</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Houston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Singapore</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">London</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Tel Aviv</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Los&nbsp;Angeles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Tokyo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Madrid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Washington,&nbsp;D.C.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>OmniAb, Inc. &#150; Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have acted as special counsel to OmniAb, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with its filing on the date hereof with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) of
a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), relating to the registration of
(i)&nbsp;the offer and sale from time to time of (a) 19,738,374 outstanding shares (the &#147;<B><I>Resale Shares</I></B>&#148;) of common stock, par value $0.0001 per share (the &#147;<B><I>common stock</I></B>&#148;), of the Company, in each case,
by the selling securityholders named in the Registration Statement, (b) 11,345,489 warrants (the &#147;<B><I>Resale</I></B> <B><I>Warrants</I></B>&#148;) to acquire shares of common stock, in each case, by the selling securityholders named in the
Registration Statement, (ii)&nbsp;the issuance by the Company and offer and sale from time to time of up to 5,261,782 shares of common stock (the &#147;<B><I>Equity Award Shares</I></B>&#148;) upon the exercise of options to purchase shares of
common stock and the vesting of restricted stock units (&#147;<B><I>RSUs</I></B>&#148;) and performance stock units (&#147;<B><I>PSUs</I></B>&#148;) issuable under the OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan or the OmniAb, Inc.
2022 Ligand Service Provider Assumed Award Plan, as applicable (collectively, the &#147;<B><I>Plan</I></B>&#148;), and (iii)&nbsp;the issuance by the Company of up to 19,012,156 shares of common stock (the &#147;<B><I>Warrant Shares</I></B>&#148;)
upon the exercise of warrants to purchase shares of common stock (the &#147;<B><I>Warrants</I></B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with
the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus or
prospectus supplement (collectively, the &#147;<B><I>Prospectus</I></B>&#148;) other than as expressly stated herein with respect to the issue of Resale Shares, the Resale Warrants, the Equity Award Shares, and the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent,
we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of
Delaware (the &#147;<B><I>DGCL</I></B>&#148;) and, with respect to the opinions set forth in paragraph 3 below, the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon,
of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>November&nbsp;30, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B> Page&nbsp;
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g305908g88n35.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date
hereof: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resale Shares have been duly authorized by all necessary corporate action of the Company and are validly
issued, fully paid and nonassessable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the Equity Award Shares have been duly registered on the books of the transfer agent and registrar
therefor in the name or on behalf of the recipients thereof, and have been issued by the Company in the circumstances contemplated by and pursuant to the Plan and assuming in each case that the individual issuances, grants or awards under the Plan
are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of applicable law and the Plan (and the agreements and awards duly adopted thereunder and in accordance
therewith), the issue and sale of the Equity Award Shares will have been duly authorized by all necessary corporate action of the Company and will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed
that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resale Warrants are the legally valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the Warrant Shares shall have been duly registered on the books of the transfer agent and registrar
therefor in the name of or on behalf of the Warrant holders and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Warrants, the Warrant Shares will have been duly authorized
by all necessary corporate action of the Company and will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding
uncertificated shares provided in the DGCL. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions set forth in numbered paragraph 3 are subject to: (i)&nbsp;the effect of
bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii)&nbsp;the effect of general principles of equity, whether considered in a
proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), concepts of materiality, reasonableness, good faith and fair dealing, and the discretion of the court before which a proceeding is
brought; (iii)&nbsp;the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is
contrary to public policy; and (iv)&nbsp;we express no opinion as to (a)&nbsp;any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are
deemed to constitute a penalty, (b)&nbsp;consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief, (c)&nbsp;waivers of rights or defenses, (d)&nbsp;any provision requiring the payment of
attorneys&#146; fees, where such payment is contrary to law or public policy, (e)&nbsp;the creation, validity, attachment, perfection, or priority of any lien or security interest, (f)&nbsp;advance waivers of claims, defenses, rights granted by law,
or notice, opportunity for hearing, evidentiary requirements, statutes of limitation, trial by jury or at law, or other procedural rights, (g)&nbsp;waivers of broadly or vaguely stated rights, (h)&nbsp;provisions for exclusivity, election or
cumulation of rights or remedies, (i)&nbsp;provisions authorizing or validating conclusive or discretionary determinations, (j)&nbsp;grants of setoff rights, (k)&nbsp;proxies, powers and trusts, (l)&nbsp;provisions prohibiting, restricting, or
requiring consent to assignment or transfer of any right or property, and (m)&nbsp;the severability, if invalid, of provisions to the foregoing effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>November&nbsp;30, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B> Page&nbsp;
 3
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g305908g88n35.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With your consent, we have assumed (a)&nbsp;that the Warrants and the Warrant Agreement, dated August&nbsp;9,
2021, as amended by that certain Assignment, Assumption and Amendment Agreement, dated November&nbsp;1, 2022, by and among the Company, Continental Stock Transfer&nbsp;&amp; Trust Company and Computershare Trust Company, N.A., as warrant agent (the
&#147;<B><I>Warrant Agreement</I></B>&#148;), relating to the Warrants, have been duly authorized, executed and delivered by the parties thereto other than the Company, (b)&nbsp;that the Warrants and the Warrant Agreement constitute or will
constitute legally valid and binding obligations of the parties thereto other than the Company, enforceable against each of them in accordance with their respective terms and (c)&nbsp;that the status of the Warrants as legally valid and binding
obligations of the parties will not be affected by any (i)&nbsp;breaches of, or defaults under, agreements or instruments, (ii)&nbsp;violations of statutes, rules, regulations or court or governmental orders or (iii)&nbsp;failures to obtain required
consents, approvals or authorizations from, or to make required registrations, declarations or filings with, governmental authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is
for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the
Registration Statement and to the reference to our firm contained in the Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under
Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d305908dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II) on Form S-1 of our report
dated March 25, 2022, which includes an explanatory paragraph as to Avista Public Acquisition Corp. II&#146;s (now known as OmniAb, Inc.) ability to continue as a going concern with respect to our audit of the financial statements of Avista Public
Acquisition Corp. II&#146;s (now known as OmniAb, Inc.) as of December 31, 2021 and for the period from February 5, 2021 (inception) through December 31, 2021, which report appears in the Prospectus, which is part of this Registration Statement. We
were dismissed as auditors on November 1, 2022, effective immediately following the filing of the OmniAb, Inc.&#146;s quarterly report on Form 10-Q for the quarter ended September 30, 2022, which consists only of the accounts of the pre-Business
Combination special purpose acquisition company, Avista Public Acquisition Corp. II and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing in such Prospectus for the periods after
the date of our dismissal. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum
<SMALL>LLP</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d305908dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated April&nbsp;27, 2022, in the Registration
Statement <FONT STYLE="white-space:nowrap">(Form&nbsp;S-1)&nbsp;and</FONT> related Prospectus of OmniAb, Inc. for the registration of up to 36,345,645 shares of its common stock, up to 11,345,489 warrants to purchase shares of its common stock and
up to 19,012,156 shares of its common stock issuable upon exercise of warrants to purchase shares of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d305908dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>OmniAb, Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Security&nbsp;&nbsp;<BR>Type&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class
Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fee&nbsp;&nbsp;<BR>Calculation&nbsp;&nbsp;<BR>or
Carry&nbsp;&nbsp;<BR>Forward&nbsp;&nbsp;<BR>Rule&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Amount<BR>Registered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Proposed&nbsp;&nbsp;<BR>Maximum&nbsp;&nbsp;<BR>Offering&nbsp;&nbsp;<BR>Price
Per&nbsp;&nbsp;<BR>Unit&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Maximum<BR>Aggregate<BR>Offering Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fee Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Amount of&nbsp;&nbsp;<BR>Registration&nbsp;&nbsp;<BR>Fee&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Fees to be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, $0.0001 par value per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(g)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">19,012,156&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$11.50<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$218,639,794&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0.00011020&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$24,094.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Fees to be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, $0.0001 par value per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">36,345,645&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$2.71<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$98,496,698&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0.00011020&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$10,854.34</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Fees to be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Warrants to purchase Common Stock</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11,345,489&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;(4)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Carry Forward Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$317,136,492&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$34,948.45</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$34,948.45</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act of 1933, as amended (&#148;Securities Act&#148;), this
registration statement also covers any additional number of shares of common stock issuable upon stock splits, stock dividends or other distribution, recapitalization or similar events with respect to the shares of common stock being registered
pursuant to this registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(g) under the Securities Act, based on the exercise price of the warrants
($11.50). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated in accordance with Rule 457(c) under the Securities Act, based on the average high and low prices
reported for the registrant&#146;s common stock on November&nbsp;25, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 457(g), the entire registration fee for the warrants is allocated to the shares of
common stock underlying the warrants, and no separate fee is payable for the warrants. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>oabi-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [06:14:29] {AM}-->
<schema targetNamespace="http://om.com/20220930" elementFormDefault="qualified" xmlns:oabi="http://om.com/20220930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://om.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<link:definition>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment" id="CombinedStatementsOfChangesInParentCompanyNetInvestment">
<link:definition>1006 - Statement - COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/OrganisationAndNatureOfOperations" id="OrganisationAndNatureOfOperations">
<link:definition>1008 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements" id="RestatementOfPreviouslyIssuedCombinedFinancialStatements">
<link:definition>1009 - Disclosure - Restatement of Previously Issued Combined Financial Statements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/Acquisitions" id="Acquisitions">
<link:definition>1011 - Disclosure - Acquisitions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/InitialPublicOffering" id="InitialPublicOffering">
<link:definition>1012 - Disclosure - INITIAL PUBLIC OFFERING</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>1013 - Disclosure - PRIVATE PLACEMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntities" id="RelationshipWithParentAndRelatedEntities">
<link:definition>1014 - Disclosure - Relationship with Parent and Related Entities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1015 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CommitmentAndContingenciesLegalProceedings" id="CommitmentAndContingenciesLegalProceedings">
<link:definition>1016 - Disclosure - Commitment and Contingencies: Legal Proceedings</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/Leases" id="Leases">
<link:definition>1017 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetails" id="BalanceSheetAccountDetails">
<link:definition>1018 - Disclosure - Balance Sheet Account Details</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/ShareholdersEquityDeficit" id="ShareholdersEquityDeficit">
<link:definition>1019 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1020 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables">
<link:definition>1023 - Disclosure - Restatement of Previously Issued Combined Financial Statements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/AcquisitionsTables" id="AcquisitionsTables">
<link:definition>1025 - Disclosure - Acquisitions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1026 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1027 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables" id="RelationshipWithParentAndRelatedEntitiesTables">
<link:definition>1028 - Disclosure - Relationship with Parent and Related Entities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/LeasesTables" id="LeasesTables">
<link:definition>1029 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetailsTables" id="BalanceSheetAccountDetailsTables">
<link:definition>1030 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/OrganisationAndNatureOfOperationsDetails" id="OrganisationAndNatureOfOperationsDetails">
<link:definition>1031 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1032 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails">
<link:definition>1033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails">
<link:definition>1034 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails">
<link:definition>1035 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails">
<link:definition>1036 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails">
<link:definition>1037 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails">
<link:definition>1038 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" id="AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
<link:definition>1039 - Disclosure - Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/AcquisitionsAdditionalInformationDetails" id="AcquisitionsAdditionalInformationDetails">
<link:definition>1040 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails">
<link:definition>1041 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails">
<link:definition>1042 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails">
<link:definition>1043 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails">
<link:definition>1044 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails" id="RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails">
<link:definition>1045 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/InitialPublicOfferingDetails" id="InitialPublicOfferingDetails">
<link:definition>1046 - Disclosure - INITIAL PUBLIC OFFERING (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/PrivatePlacementDetails" id="PrivatePlacementDetails">
<link:definition>1047 - Disclosure - PRIVATE PLACEMENT (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails" id="RelationshipWithParentAndRelatedEntitiesFounderSharesDetails">
<link:definition>1048 - Disclosure - Relationship with Parent and Related Entities - Founder Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail" id="RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail">
<link:definition>1049 - Disclosure - Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails" id="RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails">
<link:definition>1050 - Disclosure - Relationship with Parent and Related Entities - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>1051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails" id="CommitmentsAndContingenciesForwardPurchaseAgreementDetails">
<link:definition>1052 - Disclosure - COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" id="IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
<link:definition>1053 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<link:definition>1054 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1055 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1056 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails" id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails">
<link:definition>1057 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail" id="LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail">
<link:definition>1058 - Disclosure - Leases - Schedule of Operating Lease Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail" id="LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail">
<link:definition>1059 - Disclosure - Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail" id="BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail">
<link:definition>1061 - Disclosure - Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetailsDetail" id="BalanceSheetAccountDetailsDetail">
<link:definition>1062 - Disclosure - Balance Sheet Account Details (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" id="BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail">
<link:definition>1063 - Disclosure - Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" id="BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail">
<link:definition>1064 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails" id="ShareholdersEquityDeficitPreferredStockSharesDetails">
<link:definition>1065 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails" id="ShareholdersEquityDeficitCommonStockSharesDetails">
<link:definition>1066 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/ShareholdersEquityDeficitWarrantsDetails" id="ShareholdersEquityDeficitWarrantsDetails">
<link:definition>1067 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
<link:definition>1068 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" id="FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails">
<link:definition>1069 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails" id="FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails">
<link:definition>1070 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails" id="FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails">
<link:definition>1071 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" id="FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails">
<link:definition>1072 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails" id="FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails">
<link:definition>1073 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://om.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>1074 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="oabi-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="TransactionCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_TransactionCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_AccruedOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredOfferingCostsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DeferredOfferingCostsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonClassaSubjectToRedemptionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CommonClassaSubjectToRedemptionMember" substitutionGroup="xbrli:item" />
<element name="AvistaPublicAcquisitionCorp.IiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_AvistaPublicAcquisitionCorp.IiMember" substitutionGroup="xbrli:item" />
<element name="ClassCommonStockSharesNotSubjectToRedemptionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" substitutionGroup="xbrli:item" />
<element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DeemedDividend" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetIncomeLossAttributableToOrdinaryShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NetIncomeLossAttributableToOrdinaryShareholders" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseAndMilestoneRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_LicenseAndMilestoneRevenueMember" substitutionGroup="xbrli:item" />
<element name="AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WaiverOfUnderwritingCommissionByUnderwriters" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WaiverOfUnderwritingCommissionByUnderwriters" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReclassificationOfForwardPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ReclassificationOfForwardPurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInEquityContributionFromParent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_IncreaseInEquityContributionFromParent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInDueToRelatedPartyCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInAccruedLiabilitiesRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForInvestmentOfCashInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PaymentsForInvestmentOfCashInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OtherInvestingActivities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromIssuanceInitialPublicOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ProceedsFromIssuanceInitialPublicOfferingNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentFromRelatedPartyDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_RepaymentFromRelatedPartyDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OfferingCostsPaidInExchangesForIssuanceOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InitialClassificationOfForwardPurchaseAndBackstopSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfferingCostsIncludedInAccountsPayableAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredRevenueRecordedInAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DeferredRevenueRecordedInAccountsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BusinessCombinationAndAssetAcquisitionTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_BusinessCombinationAndAssetAcquisitionTextBlock" substitutionGroup="xbrli:item" />
<element name="InitialPublicOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_InitialPublicOfferingAbstract" substitutionGroup="xbrli:item" />
<element name="InitialPublicOfferingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_InitialPublicOfferingTextBlock" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PrivatePlacementAbstract" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PrivatePlacementTextBlock" substitutionGroup="xbrli:item" />
<element name="BalanceSheetAccountDetailsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_BalanceSheetAccountDetailsAbstract" substitutionGroup="xbrli:item" />
<element name="BalanceSheetAccountDetailsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_BalanceSheetAccountDetailsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AssetsHeldInTrustAccountPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="UnauditedInterimFinancialInformationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_UnauditedInterimFinancialInformationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="LiquidityAndCapitalResourcesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_LiquidityAndCapitalResourcesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ImpactOfCovidNineteenPandemicPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_EmergingGrowthCompanyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DeferredRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_DeferredRevenuePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CombinedBalanceSheetMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CombinedBalanceSheetMember" substitutionGroup="xbrli:item" />
<element name="CombinedStatementOfCashFlowsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CombinedStatementOfCashFlowsMember" substitutionGroup="xbrli:item" />
<element name="CombinedStatementOfChangesInParentCompanyNetInvestmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" substitutionGroup="xbrli:item" />
<element name="CombinedStatementOfOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CombinedStatementOfOperationsMember" substitutionGroup="xbrli:item" />
<element name="IcagenAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_IcagenAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="AbInitioAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_AbInitioAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="TaurusAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_TaurusAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="XCellaAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_XCellaAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOperatingLeaseAssetsAndLiabilities" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SponsorMember" substitutionGroup="xbrli:item" />
<element name="ApacCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ApacCommonStockMember" substitutionGroup="xbrli:item" />
<element name="EarnoutStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_EarnoutStockMember" substitutionGroup="xbrli:item" />
<element name="OmniabIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_OmniabIncMember" substitutionGroup="xbrli:item" />
<element name="LigandMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_LigandMember" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedForwardPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_AmendedAndRestatedForwardPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="SponsorInsiderAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SponsorInsiderAgreementMember" substitutionGroup="xbrli:item" />
<element name="VestingRequirementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_VestingRequirementsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="VestingRequirementsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_VestingRequirementsDomain" substitutionGroup="xbrli:item" />
<element name="FirstRequirementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_FirstRequirementsMember" substitutionGroup="xbrli:item" />
<element name="SecondRequirementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SecondRequirementsMember" substitutionGroup="xbrli:item" />
<element name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" substitutionGroup="xbrli:item" />
<element name="MonthsToCompleteInitialBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_MonthsToCompleteInitialBusinessCombination" substitutionGroup="xbrli:item" />
<element name="UnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_UnitsIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="InvestmentsMaximumMaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_InvestmentsMaximumMaturityTerm" substitutionGroup="xbrli:item" />
<element name="PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" substitutionGroup="xbrli:item" />
<element name="NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" substitutionGroup="xbrli:item" />
<element name="MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ThresholdBusinessDaysForRedemptionOfPublicShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" substitutionGroup="xbrli:item" />
<element name="MaximumNetInterestToPayDissolutionExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_MaximumNetInterestToPayDissolutionExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfCommonStockSharesIssuedUnderDistribution" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" substitutionGroup="xbrli:item" />
<element name="CapitalContributedNetOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_CapitalContributedNetOfExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WorkingCapitalDeficit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" substitutionGroup="xbrli:item" />
<element name="VolumeWeightedAveragePriceTriggerPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_VolumeWeightedAveragePriceTriggerPrice" substitutionGroup="xbrli:item" />
<element name="SharesToVestMeasurementPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_SharesToVestMeasurementPeriod" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfSharesIssuedPerUnit" substitutionGroup="xbrli:item" />
<element name="NumberOfWarrantsIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfWarrantsIssuedPerUnit" substitutionGroup="xbrli:item" />
<element name="MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" substitutionGroup="xbrli:item" />
<element name="AdditionalNumberOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_AdditionalNumberOfCommonStock" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="AdditionalAggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AdditionalAggregatePurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SponsorPurchaseBackstop" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SponsorPurchaseBackstop" substitutionGroup="xbrli:item" />
<element name="SharesBackstopWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SharesBackstopWarrants" substitutionGroup="xbrli:item" />
<element name="MaximumAdditionalAggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_MaximumAdditionalAggregatePurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" substitutionGroup="xbrli:item" />
<element name="TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_TransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SaleOfStockUnderwritingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SaleOfStockUnderwritingFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SaleOfStockOtherOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SaleOfStockOtherOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalSurplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WorkingCapitalSurplus" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyLoansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_RelatedPartyLoansMember" substitutionGroup="xbrli:item" />
<element name="SeparationAndDistributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SeparationAndDistributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="OmniabBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_OmniabBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="Unitsissuedduringperiodsharesnewissues." type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_Unitsissuedduringperiodsharesnewissues." substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentArrangementNonemployeeDirectorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockUnitsAndPhantomShareUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" substitutionGroup="xbrli:item" />
<element name="MilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_MilestoneMember" substitutionGroup="xbrli:item" />
<element name="PartnerAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PartnerAMember" substitutionGroup="xbrli:item" />
<element name="PartnerBMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PartnerBMember" substitutionGroup="xbrli:item" />
<element name="PartnerCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PartnerCMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityProceedsAllocatedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TemporaryEquityProceedsAllocatedToWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TemporaryEquityIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfferingCostsReductionOfTemporaryEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OfferingCostsReductionOfTemporaryEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EarnoutRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_EarnoutRightsMember" substitutionGroup="xbrli:item" />
<element name="NumberOfAcquisitions" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfAcquisitions" substitutionGroup="xbrli:item" />
<element name="PercentageShareOfPostClinicalAcquireeProductRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" substitutionGroup="xbrli:item" />
<element name="PercentageShareOfFutureMilestonePayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageShareOfFutureMilestonePayments" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationContingentConsiderationRevenueMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationCashFlowDiscountedRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationCashFlowDiscountedRate" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationConsiderationTransferredEarnoutRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_BusinessCombinationConsiderationTransferredEarnoutRights" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContingentConsiderationByTrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ContingentConsiderationByTrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ContingentConsiderationByTrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ContingentConsiderationByTrancheDomain" substitutionGroup="xbrli:item" />
<element name="LicenseAndMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_LicenseAndMilestoneMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesSubjectToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfSharesSubjectToForfeiture" substitutionGroup="xbrli:item" />
<element name="TotalNumberOfSharesTransferred" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_TotalNumberOfSharesTransferred" substitutionGroup="xbrli:item" />
<element name="PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" substitutionGroup="xbrli:item" />
<element name="ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" substitutionGroup="xbrli:item" />
<element name="OfferingCostsIncludedInPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumLoansConvertibleIntoWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_MaximumLoansConvertibleIntoWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WorkingCapitalLoansOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_WorkingCapitalLoansOutstanding" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." substitutionGroup="xbrli:item" />
<element name="AdministrativeSupportAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_AdministrativeSupportAgreementMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteWithRelatedPartyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_PromissoryNoteWithRelatedPartyMember" substitutionGroup="xbrli:item" />
<element name="GeneralCorporateOverheadMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_GeneralCorporateOverheadMember" substitutionGroup="xbrli:item" />
<element name="EquityBasedIncentivePlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_EquityBasedIncentivePlansMember" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_EmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="PurchasePricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PurchasePricePerUnit" substitutionGroup="xbrli:item" />
<element name="DeferredFeePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DeferredFeePerUnit" substitutionGroup="xbrli:item" />
<element name="MaximumNumberOfDemandsForRegistrationOfSecurities" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" substitutionGroup="xbrli:item" />
<element name="AggregateDeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AggregateDeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalDeferredFeePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_AdditionalDeferredFeePerUnit" substitutionGroup="xbrli:item" />
<element name="AdditionalAggregateDeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AdditionalAggregateDeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfDeferredUnderwritingFeePayableToThirdParties" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" substitutionGroup="xbrli:item" />
<element name="AggregateDeferredUnderwritingFeePayableToThirdParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" substitutionGroup="xbrli:item" />
<element name="Underwritingcashdiscountperunit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_Underwritingcashdiscountperunit" substitutionGroup="xbrli:item" />
<element name="Underwritercashdiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_Underwritercashdiscount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ForwardPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ForwardPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="SharesToBePurchasedPursuantToAgreements" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_SharesToBePurchasedPursuantToAgreements" substitutionGroup="xbrli:item" />
<element name="WarrantsToBePurchasedPursuantToAgreements" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WarrantsToBePurchasedPursuantToAgreements" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TwoThousandThirtySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_TwoThousandThirtySevenMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirtyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_TwoThousandThirtyTwoMember" substitutionGroup="xbrli:item" />
<element name="FederalResearchAndDevelopmentCreditMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_FederalResearchAndDevelopmentCreditMember" substitutionGroup="xbrli:item" />
<element name="CaliforniaResearchAndDevelopmentCreditMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CaliforniaResearchAndDevelopmentCreditMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DeferredTaxAssetsDeferredRevenue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesOperatingLeaseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_OperatingLeaseAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseLiabilitiesTenantImprovementAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfIntangibleAssetsAndGoodwillTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfIntangibleAssetsAndGoodwillLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" substitutionGroup="xbrli:item" />
<element name="BalanceSheetAccountDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_BalanceSheetAccountDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BalanceSheetAccountDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_BalanceSheetAccountDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfAccruedLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfAccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ScheduleOfAccruedLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="SubcontractorLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SubcontractorLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquisitionsRelatedLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_AcquisitionsRelatedLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_CommonStockNumberOfVotesPerShare" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" substitutionGroup="xbrli:item" />
<element name="PercentageOfVotingRightsShareHolders" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_PercentageOfVotingRightsShareHolders" substitutionGroup="xbrli:item" />
<element name="ForwardPurchaseWarrantsAndBackstopMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ForwardPurchaseWarrantsAndBackstopMember" substitutionGroup="xbrli:item" />
<element name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" substitutionGroup="xbrli:item" />
<element name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" substitutionGroup="xbrli:item" />
<element name="MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" substitutionGroup="xbrli:item" />
<element name="PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" substitutionGroup="xbrli:item" />
<element name="WarrantExercisePeriodConditionTwo" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WarrantExercisePeriodConditionTwo" substitutionGroup="xbrli:item" />
<element name="WarrantRedemptionConditionMinimumSharePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WarrantRedemptionConditionMinimumSharePrice" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" substitutionGroup="xbrli:item" />
<element name="RedemptionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_RedemptionPeriod" substitutionGroup="xbrli:item" />
<element name="SharePriceTriggerUsedToMeasureDilutionOfWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" substitutionGroup="xbrli:item" />
<element name="PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" substitutionGroup="xbrli:item" />
<element name="TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" substitutionGroup="xbrli:item" />
<element name="WarrantExercisePriceAdjustmentMultiple" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WarrantExercisePriceAdjustmentMultiple" substitutionGroup="xbrli:item" />
<element name="WarrantRedemptionPriceAdjustmentMultiple" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_WarrantRedemptionPriceAdjustmentMultiple" substitutionGroup="xbrli:item" />
<element name="RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" substitutionGroup="xbrli:item" />
<element name="MeasurementInputFairValueOfUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_MeasurementInputFairValueOfUnitMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputExpectedRedemptionRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_MeasurementInputExpectedRedemptionRateMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="InitialMeasurementOfForwardPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_InitialMeasurementOfForwardPurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_BusinessCombinationContingentConsiderationLiabilityMember" substitutionGroup="xbrli:item" />
<element name="IcagenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_IcagenMember" substitutionGroup="xbrli:item" />
<element name="XcellaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_XcellaMember" substitutionGroup="xbrli:item" />
<element name="CrystalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_CrystalMember" substitutionGroup="xbrli:item" />
<element name="SaleOfStockCashPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_SaleOfStockCashPricePerShare" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToPriceBasedEarnoutTriggers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" substitutionGroup="xbrli:item" />
<element name="NumberOfTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="ExcessPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_ExcessPricePerShare" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="VolumeWeightedAverageTradingPrices" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="oabi_VolumeWeightedAverageTradingPrices" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalLoansWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_WorkingCapitalLoansWarrantMember" substitutionGroup="xbrli:item" />
<element name="NewOmniabCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_NewOmniabCommonStockMember" substitutionGroup="xbrli:item" />
<element name="EarnoutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_EarnoutSharesMember" substitutionGroup="xbrli:item" />
<element name="ApacsExistingPublicShareholdersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_ApacsExistingPublicShareholdersMember" substitutionGroup="xbrli:item" />
<element name="SponsorOfApacMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_SponsorOfApacMember" substitutionGroup="xbrli:item" />
<element name="RelatedPartiesOfApacMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="oabi_RelatedPartiesOfApacMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>oabi-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [06:14:29] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://om.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" />
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedExpenses" xlink:label="loc_OABI_AccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_OABI_AccruedExpenses" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedOfferingCosts" xlink:label="loc_OABI_AccruedOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_OABI_AccruedOfferingCosts" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xlink:label="loc_OABI_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_OABI_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xlink:label="loc_OABI_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_OABI_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_OABI_DeferredOfferingCostsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_OABI_DeferredOfferingCostsNoncurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xlink:label="loc_OABI_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_OABI_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCostsCurrent" xlink:label="loc_OABI_TransactionCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_OABI_TransactionCostsCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="37" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NetIncomeLossAttributableToOrdinaryShareholders" xlink:label="loc_OABI_NetIncomeLossAttributableToOrdinaryShareholders" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_OABI_DeemedDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OABI_NetIncomeLossAttributableToOrdinaryShareholders" xlink:to="loc_OABI_DeemedDividend" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OABI_NetIncomeLossAttributableToOrdinaryShareholders" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_OABI_PaymentsForInvestmentOfCashInTrustAccount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_OABI_PaymentsForInvestmentOfCashInTrustAccount" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xlink:label="loc_OABI_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_OABI_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OtherInvestingActivities" xlink:label="loc_OABI_OtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_OABI_OtherInvestingActivities" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xlink:label="loc_OABI_IncreaseDecreaseInDueToRelatedPartyCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OABI_IncreaseDecreaseInDueToRelatedPartyCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xlink:label="loc_OABI_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OABI_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OABI_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="loc_OABI_ProceedsFromIssuanceInitialPublicOfferingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OABI_ProceedsFromIssuanceInitialPublicOfferingNet" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="38" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RepaymentFromRelatedPartyDebt" xlink:label="loc_OABI_RepaymentFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OABI_RepaymentFromRelatedPartyDebt" use="optional" order="40" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="41" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_OABI_DeferredTaxAssetsDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_OABI_DeferredTaxAssetsDeferredRevenue" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_OABI_DeferredTaxAssetsOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_OABI_DeferredTaxAssetsOperatingLeaseLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="7" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:label="loc_OABI_DeferredTaxLiabilitiesOperatingLeaseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_OABI_DeferredTaxLiabilitiesOperatingLeaseAssets" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_Goodwill" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_OABI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_OABI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_OABI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_OABI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" use="optional" order="15" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SubcontractorLiabilitiesCurrent" xlink:label="loc_OABI_SubcontractorLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_OABI_SubcontractorLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AcquisitionsRelatedLiabilitiesCurrent" xlink:label="loc_OABI_AcquisitionsRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_OABI_AcquisitionsRelatedLiabilitiesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>oabi-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [06:14:29] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://om.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CombinedStatementsOfChangesInParentCompanyNetInvestment" roleURI="http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#OrganisationAndNatureOfOperations" roleURI="http://om.com/role/OrganisationAndNatureOfOperations" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#InitialPublicOffering" roleURI="http://om.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#PrivatePlacement" roleURI="http://om.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntities" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntities" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentAndContingenciesLegalProceedings" roleURI="http://om.com/role/CommitmentAndContingenciesLegalProceedings" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficit" roleURI="http://om.com/role/ShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurements" roleURI="http://om.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#SubsequentEvents" roleURI="http://om.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsTables" roleURI="http://om.com/role/AcquisitionsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsTables" roleURI="http://om.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#OrganisationAndNatureOfOperationsDetails" roleURI="http://om.com/role/OrganisationAndNatureOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsAdditionalInformationDetails" roleURI="http://om.com/role/AcquisitionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#InitialPublicOfferingDetails" roleURI="http://om.com/role/InitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#PrivatePlacementDetails" roleURI="http://om.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesFounderSharesDetails" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://om.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentsAndContingenciesForwardPurchaseAgreementDetails" roleURI="http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://om.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesAdditionalInformationDetail" roleURI="http://om.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitPreferredStockSharesDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitCommonStockSharesDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitWarrantsDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://om.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" roleURI="http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails" roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails" roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails" roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#SubsequentEventsDetails" roleURI="http://om.com/role/SubsequentEventsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatements" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#Leases" roleURI="http://om.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesTables" roleURI="http://om.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxes" roleURI="http://om.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail" roleURI="http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetails" roleURI="http://om.com/role/BalanceSheetAccountDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsTables" roleURI="http://om.com/role/BalanceSheetAccountDetailsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesTables" roleURI="http://om.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail" roleURI="http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#Acquisitions" roleURI="http://om.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesTables" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CoverPage" roleURI="http://om.com/role/CoverPage" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_118" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_118" xlink:to="loc_us-gaap_AssetsAbstract_119" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_AssetsCurrentAbstract_120" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_AssetsCurrent_128" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707291" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1707292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_OtherAssetsCurrent_1707292" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCostsCurrent" xlink:label="loc_oabi_TransactionCostsCurrent_1707448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_oabi_TransactionCostsCurrent_1707448" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_129" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_Assets_130" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1707293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1707293" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_Goodwill_1707294" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1707295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1707295" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707296" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1707297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1707297" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1707452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1707452" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_118" xlink:to="loc_us-gaap_StatementTable_114" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_us-gaap_StatementClassOfStockAxis_115" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_115" xlink:to="loc_us-gaap_ClassOfStockDomain_116" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_116_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_115" xlink:to="loc_us-gaap_ClassOfStockDomain_116_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_us-gaap_CommonClassBMember_125" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_124" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_us-gaap_CommonClassAMember_117" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1710380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1710379" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1710380" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_dei_LegalEntityAxis_1707061" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707061" xlink:to="loc_dei_EntityDomain_1707062" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707061" xlink:to="loc_dei_EntityDomain_1707062_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707062" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707063" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1710378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_srt_RestatementAxis_1710378" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1710379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1710378" xlink:to="loc_srt_RestatementDomain_1710379" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1710379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1710378" xlink:to="loc_srt_RestatementDomain_1710379_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_118" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_122" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_AccountsPayableCurrent_131" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedExpenses" xlink:label="loc_oabi_AccruedExpenses_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_AccruedExpenses_132" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedOfferingCosts" xlink:label="loc_oabi_AccruedOfferingCosts_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_AccruedOfferingCosts_133" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xlink:label="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty_134" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_135" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_136" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_LiabilitiesCurrent_137" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707300" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition_1707305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition_1707305" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1707307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1707307" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707309" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707310" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_146" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_138" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_Liabilities_139" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_CommitmentsAndContingencies_140" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_141" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_StockholdersEquityAbstract_123" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_PreferredStockValue_142" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_CommonStockValue_143" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_144" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_StockholdersEquity_145" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707318" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707319" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition_1707315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition_1707315" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1707320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1707320" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1707322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1707322" use="optional" order="60" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_173" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_StatementTable_169" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_169" xlink:to="loc_us-gaap_StatementClassOfStockAxis_170" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_170" xlink:to="loc_us-gaap_ClassOfStockDomain_171" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_170" xlink:to="loc_us-gaap_ClassOfStockDomain_171_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_us-gaap_CommonClassAMember_172" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_174" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xlink:label="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember_175" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_us-gaap_CommonClassBMember_176" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_169" xlink:to="loc_dei_LegalEntityAxis_1707065" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707065" xlink:to="loc_dei_EntityDomain_1707066" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707066_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707065" xlink:to="loc_dei_EntityDomain_1707066_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707066" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707067" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_177" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_178" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesIssued_179" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_180" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_182" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesIssued_183" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_184" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_186" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_211" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_StatementTable_208" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_us-gaap_StatementClassOfStockAxis_209" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_209" xlink:to="loc_us-gaap_ClassOfStockDomain_210" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_209" xlink:to="loc_us-gaap_ClassOfStockDomain_210_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_210" xlink:to="loc_us-gaap_CommonClassAMember_212" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_210" xlink:to="loc_us-gaap_CommonClassBMember_213" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_dei_LegalEntityAxis_1707069" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707069" xlink:to="loc_dei_EntityDomain_1707070" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707069" xlink:to="loc_dei_EntityDomain_1707070_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707070" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707071" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_srt_ProductOrServiceAxis_1707545" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1707545" xlink:to="loc_srt_ProductsAndServicesDomain_1707546" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707546_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1707545" xlink:to="loc_srt_ProductsAndServicesDomain_1707546_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneRevenueMember" xlink:label="loc_oabi_LicenseAndMilestoneRevenueMember_1707547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_oabi_LicenseAndMilestoneRevenueMember_1707547" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_us-gaap_ServiceMember_1707549" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1707590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_us-gaap_RoyaltyMember_1707590" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_214" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingIncomeLoss_215" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_NetIncomeLoss_218" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_oabi_DeemedDividend_219" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NetIncomeLossAttributableToOrdinaryShareholders" xlink:label="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders_220" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareBasic_223" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareDiluted_224" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1707493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_RevenuesAbstract_1707493" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1707493" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707495" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1707497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1707497" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1707498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1707498" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707502" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1707505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1707505" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1707507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1707507" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1707510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_OperatingExpenses_1707510" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_GainLossOnInvestments_216" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_217" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1707516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_InterestExpense_1707516" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1707519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1707519" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1707520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1707520" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707522" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707524" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_258" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_258" xlink:to="loc_us-gaap_StatementTable_255" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_262_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassAMember_260" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassBMember_261" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_257" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_257" xlink:to="loc_us-gaap_EquityComponentDomain_266" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_266_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_257" xlink:to="loc_us-gaap_EquityComponentDomain_266_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_CommonStockMember_263" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_264" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_RetainedEarningsMember_265" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_dei_LegalEntityAxis_1707083" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707083" xlink:to="loc_dei_EntityDomain_1707084" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707084_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707083" xlink:to="loc_dei_EntityDomain_1707084_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707084" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707085" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_258" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_269" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockholdersEquity_267" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_SharesIssued_268" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_270" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_271" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:label="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_272" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_273" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_274" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_275" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ReclassificationOfForwardPurchaseAgreement" xlink:label="loc_oabi_ReclassificationOfForwardPurchaseAgreement_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_ReclassificationOfForwardPurchaseAgreement_276" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_DeemedDividend_277" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_NetIncomeLoss_278" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707573" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_StatementTable_1707572" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseInEquityContributionFromParent" xlink:label="loc_oabi_IncreaseInEquityContributionFromParent_1707577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_oabi_IncreaseInEquityContributionFromParent_1707577" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_StockholdersEquity_1707574" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_NetIncomeLoss_1707575" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1707576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_ShareBasedCompensation_1707576" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707095" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_ProfitLoss_325" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnInvestments_326" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_327" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1707340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1707340" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1707377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1707377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1707384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_ShareBasedCompensation_1707384" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1707473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1707473" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707462" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_1707671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_1707671" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1707673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1707673" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_332" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_328" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_329" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xlink:label="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent_330" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xlink:label="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty_331" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707491" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1707500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1707500" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707526" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1707517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1707517" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1707551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1707551" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_1709830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_1709830" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount_334" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_335" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1707560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1707560" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707561" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1707682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1707682" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xlink:label="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired_1707689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired_1707689" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1707695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1707695" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OtherInvestingActivities" xlink:label="loc_oabi_OtherInvestingActivities_1707702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_OtherInvestingActivities_1707702" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_336" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet_337" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_338" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_339" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_340" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_341" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_342" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RepaymentFromRelatedPartyDebt" xlink:label="loc_oabi_RepaymentFromRelatedPartyDebt_1707102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_oabi_RepaymentFromRelatedPartyDebt_1707102" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1707103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1707103" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707564" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707565" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_343" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_344" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xlink:label="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares_352" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_346" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xlink:label="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities_347" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:label="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_348" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredUnderwritingFeePayable" xlink:label="loc_oabi_DeferredUnderwritingFeePayable_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredUnderwritingFeePayable_349" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty_350" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:label="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses_351" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1707600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1707600" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:label="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707711" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_StatementTable_1707092" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707092" xlink:to="loc_dei_LegalEntityAxis_1707096" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707096" xlink:to="loc_dei_EntityDomain_1707097" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707096" xlink:to="loc_dei_EntityDomain_1707097_default" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707097" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707098" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707092" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707093" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707093" xlink:to="loc_us-gaap_ClassOfStockDomain_1707094" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707093" xlink:to="loc_us-gaap_ClassOfStockDomain_1707094_default" use="optional" order="66" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/OrganisationAndNatureOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1706976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1706976" xlink:to="loc_us-gaap_NatureOfOperations_358" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1706973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1706976" xlink:to="loc_us-gaap_StatementTable_1706973" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1706973" xlink:to="loc_dei_LegalEntityAxis_1706979" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1706979" xlink:to="loc_dei_EntityDomain_1706980" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706980_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1706979" xlink:to="loc_dei_EntityDomain_1706980_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1706980" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706982" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707144" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707144" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_364" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707144" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" xlink:to="loc_dei_LegalEntityAxis_1707142" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707142" xlink:to="loc_dei_EntityDomain_1707143" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707142" xlink:to="loc_dei_EntityDomain_1707143_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707143" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707146" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707009" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingTextBlock" xlink:label="loc_oabi_InitialPublicOfferingTextBlock_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707009" xlink:to="loc_oabi_InitialPublicOfferingTextBlock_370" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707009" xlink:to="loc_us-gaap_StatementTable_1707006" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707006" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707007" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707007" xlink:to="loc_us-gaap_ClassOfStockDomain_1707008" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707008_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707007" xlink:to="loc_us-gaap_ClassOfStockDomain_1707008_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707006" xlink:to="loc_dei_LegalEntityAxis_1707010" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707010" xlink:to="loc_dei_EntityDomain_1707011" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707011_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707010" xlink:to="loc_dei_EntityDomain_1707011_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707011" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707013" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707022" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementTextBlock" xlink:label="loc_oabi_PrivatePlacementTextBlock_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707022" xlink:to="loc_oabi_PrivatePlacementTextBlock_376" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707022" xlink:to="loc_us-gaap_StatementTable_1707019" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707019" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707020" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707020" xlink:to="loc_us-gaap_ClassOfStockDomain_1707021" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707021_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707020" xlink:to="loc_us-gaap_ClassOfStockDomain_1707021_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707019" xlink:to="loc_dei_LegalEntityAxis_1707023" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707023" xlink:to="loc_dei_EntityDomain_1707024" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707023" xlink:to="loc_dei_EntityDomain_1707024_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707024" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707025" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707054" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707054" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_382" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707054" xlink:to="loc_us-gaap_StatementTable_1707051" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707051" xlink:to="loc_dei_LegalEntityAxis_1707055" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707055" xlink:to="loc_dei_EntityDomain_1707056" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707056_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707055" xlink:to="loc_dei_EntityDomain_1707056_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707056" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707057" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentAndContingenciesLegalProceedings">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707233" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707233" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_388" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707233" xlink:to="loc_us-gaap_StatementTable_1707229" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707229" xlink:to="loc_dei_LegalEntityAxis_1707230" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707230" xlink:to="loc_dei_EntityDomain_1707231" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707231_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707230" xlink:to="loc_dei_EntityDomain_1707231_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707231" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707232" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1707087" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1707087" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_394" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1707086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1707087" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1707086" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1707086" xlink:to="loc_dei_LegalEntityAxis_1707088" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707088" xlink:to="loc_dei_EntityDomain_1707089" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707088" xlink:to="loc_dei_EntityDomain_1707089_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707089" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707090" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_400" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" xlink:to="loc_dei_LegalEntityAxis_1707034" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707034" xlink:to="loc_dei_EntityDomain_1707036" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707036_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707034" xlink:to="loc_dei_EntityDomain_1707036_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707036" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707037" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1706971" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1706971" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_406" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1706970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1706971" xlink:to="loc_us-gaap_SubsequentEventTable_1706970" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1706970" xlink:to="loc_dei_LegalEntityAxis_1706977" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1706977" xlink:to="loc_dei_EntityDomain_1706978" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706978_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1706977" xlink:to="loc_dei_EntityDomain_1706978_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1706978" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706983" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707197" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_425" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:label="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_432" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_437" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_433" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_434" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_435" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_436" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_426" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_UseOfEstimates_428" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_429" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_430" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xlink:label="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock_431" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" xlink:to="loc_dei_LegalEntityAxis_1707153" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707153" xlink:to="loc_dei_EntityDomain_1707154" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707153" xlink:to="loc_dei_EntityDomain_1707154_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707154" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707155" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock_1707515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock_1707515" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock_1707570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock_1707570" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1707592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1707592" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1707594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1707594" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1707599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1707599" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1707823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1707823" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xlink:label="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock_1707829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock_1707829" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xlink:label="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock_1707838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock_1707838" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_oabi_EmergingGrowthCompanyPolicyTextBlock_1707843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_EmergingGrowthCompanyPolicyTextBlock_1707843" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1707881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1707881" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1707883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1707883" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xlink:label="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock_1707884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock_1707884" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1707885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1707885" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1707886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1707886" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1709212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1709212" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenuePolicyTextBlock" xlink:label="loc_oabi_DeferredRevenuePolicyTextBlock_1710467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_DeferredRevenuePolicyTextBlock_1710467" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedBalanceSheetMember" xlink:label="loc_oabi_CombinedBalanceSheetMember_1707136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedBalanceSheetMember_1707136" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfCashFlowsMember" xlink:label="loc_oabi_CombinedStatementOfCashFlowsMember_1707150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfCashFlowsMember_1707150" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:label="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707149" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfOperationsMember" xlink:label="loc_oabi_CombinedStatementOfOperationsMember_1707147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfOperationsMember_1707147" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1707138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1707138" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707200" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_445" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_446" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" xlink:to="loc_dei_LegalEntityAxis_1707187" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707187" xlink:to="loc_dei_EntityDomain_1707188" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707188_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707187" xlink:to="loc_dei_EntityDomain_1707188_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707188" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707189" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1707637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1707637" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1709214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1709214" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1707720" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707720" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707730" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_IcagenAcquisitionMember_1707732" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707733" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_TaurusAcquisitionMember_1710391" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_XCellaAcquisitionMember_1710392" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1707729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707720" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1707729" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_454" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_455" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" xlink:to="loc_dei_LegalEntityAxis_1707044" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707044" xlink:to="loc_dei_EntityDomain_1707045" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707045_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707044" xlink:to="loc_dei_EntityDomain_1707045_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707045" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707046" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1707395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1707395" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/OrganisationAndNatureOfOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_549" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_550" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_550_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_550_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_550" xlink:to="loc_us-gaap_WarrantMember_551" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_550" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_572" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_547" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_547" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_547" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_PrivatePlacementMember_570" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_OverAllotmentOptionMember_571" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_IPOMember_569" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" xlink:to="loc_us-gaap_RelatedPartyDomain_544" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_544_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" xlink:to="loc_us-gaap_RelatedPartyDomain_544_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_544" xlink:to="loc_oabi_SponsorMember_565" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_StatementClassOfStockAxis_545" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_545" xlink:to="loc_us-gaap_ClassOfStockDomain_546" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_546_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_545" xlink:to="loc_us-gaap_ClassOfStockDomain_546_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_us-gaap_CommonClassAMember_566" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacCommonStockMember" xlink:label="loc_oabi_ApacCommonStockMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_oabi_ApacCommonStockMember_567" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutStockMember" xlink:label="loc_oabi_EarnoutStockMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_oabi_EarnoutStockMember_568" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_dei_LegalEntityAxis_552" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_552" xlink:to="loc_dei_EntityDomain_553" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_552" xlink:to="loc_dei_EntityDomain_553_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabIncMember" xlink:label="loc_oabi_OmniabIncMember_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_OmniabIncMember_574" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LigandMember" xlink:label="loc_oabi_LigandMember_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_LigandMember_575" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706989" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1709272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1709271" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1709272" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:label="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" xlink:to="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_577" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorInsiderAgreementMember" xlink:label="loc_oabi_SponsorInsiderAgreementMember_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" xlink:to="loc_oabi_SponsorInsiderAgreementMember_576" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsAxis" xlink:label="loc_oabi_VestingRequirementsAxis_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_oabi_VestingRequirementsAxis_556" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsDomain" xlink:label="loc_oabi_VestingRequirementsDomain_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oabi_VestingRequirementsAxis_556" xlink:to="loc_oabi_VestingRequirementsDomain_557" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsDomain" xlink:label="loc_oabi_VestingRequirementsDomain_557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oabi_VestingRequirementsAxis_556" xlink:to="loc_oabi_VestingRequirementsDomain_557_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FirstRequirementsMember" xlink:label="loc_oabi_FirstRequirementsMember_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_VestingRequirementsDomain_557" xlink:to="loc_oabi_FirstRequirementsMember_578" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SecondRequirementsMember" xlink:label="loc_oabi_SecondRequirementsMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_VestingRequirementsDomain_557" xlink:to="loc_oabi_SecondRequirementsMember_579" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_558" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_558" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_559" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_559_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_558" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_559_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyLoansMember" xlink:label="loc_oabi_RelatedPartyLoansMember_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_559" xlink:to="loc_oabi_RelatedPartyLoansMember_580" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_TypeOfArrangementAxis_560" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_560" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_560" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SeparationAndDistributionAgreementMember" xlink:label="loc_oabi_SeparationAndDistributionAgreementMember_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" xlink:to="loc_oabi_SeparationAndDistributionAgreementMember_581" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_562" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_562" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_562" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" xlink:to="loc_oabi_OmniabBusinessCombinationMember_582" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1709270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_srt_OwnershipAxis_1709270" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1709271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1709270" xlink:to="loc_srt_OwnershipDomain_1709271" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1709271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1709270" xlink:to="loc_srt_OwnershipDomain_1709271_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_583" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MonthsToCompleteInitialBusinessCombination" xlink:label="loc_oabi_MonthsToCompleteInitialBusinessCombination_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MonthsToCompleteInitialBusinessCombination_594" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_584" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_585" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_586" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_587" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_588" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_589" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_590" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_591" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_SharePrice_592" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InvestmentsMaximumMaturityTerm" xlink:label="loc_oabi_InvestmentsMaximumMaturityTerm_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_InvestmentsMaximumMaturityTerm_593" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_595" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xlink:label="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest_606" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_596" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_597" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares_598" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNetInterestToPayDissolutionExpenses" xlink:label="loc_oabi_MaximumNetInterestToPayDissolutionExpenses_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumNetInterestToPayDissolutionExpenses_599" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xlink:label="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution_600" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_601" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CapitalContributedNetOfExpenses" xlink:label="loc_oabi_CapitalContributedNetOfExpenses_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_CapitalContributedNetOfExpenses_602" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalDeficit" xlink:label="loc_oabi_WorkingCapitalDeficit_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_WorkingCapitalDeficit_603" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xlink:label="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice_604" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAveragePriceTriggerPrice" xlink:label="loc_oabi_VolumeWeightedAveragePriceTriggerPrice_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_VolumeWeightedAveragePriceTriggerPrice_605" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToVestMeasurementPeriod" xlink:label="loc_oabi_SharesToVestMeasurementPeriod_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SharesToVestMeasurementPeriod_607" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_608" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesIssuedPerUnit" xlink:label="loc_oabi_NumberOfSharesIssuedPerUnit_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfSharesIssuedPerUnit_609" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_oabi_NumberOfWarrantsIssuedPerUnit_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfWarrantsIssuedPerUnit_610" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xlink:label="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions_611" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalNumberOfCommonStock" xlink:label="loc_oabi_AdditionalNumberOfCommonStock_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AdditionalNumberOfCommonStock_612" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_613" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregatePurchasePrice" xlink:label="loc_oabi_AdditionalAggregatePurchasePrice_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AdditionalAggregatePurchasePrice_614" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorPurchaseBackstop" xlink:label="loc_oabi_SponsorPurchaseBackstop_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SponsorPurchaseBackstop_615" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesBackstopWarrants" xlink:label="loc_oabi_SharesBackstopWarrants_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SharesBackstopWarrants_616" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_617" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xlink:label="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings_619" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_620" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_621" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xlink:label="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination_622" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1706995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1706995" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCosts" xlink:label="loc_oabi_TransactionCosts_1707000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_TransactionCosts_1707000" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockUnderwritingFees" xlink:label="loc_oabi_SaleOfStockUnderwritingFees_1707001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SaleOfStockUnderwritingFees_1707001" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_1707002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_1707002" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockOtherOfferingCosts" xlink:label="loc_oabi_SaleOfStockOtherOfferingCosts_1707003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SaleOfStockOtherOfferingCosts_1707003" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_1707017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_1707017" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalSurplus" xlink:label="loc_oabi_WorkingCapitalSurplus_1707033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_WorkingCapitalSurplus_1707033" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_1707038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_1707038" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146632894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_Cash_2146632894" use="optional" order="102" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710236" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1710233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_StatementTable_1710233" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1710244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1710244" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1710245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710244" xlink:to="loc_us-gaap_EquityComponentDomain_1710245" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1710245_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710244" xlink:to="loc_us-gaap_EquityComponentDomain_1710245_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1710246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1710245" xlink:to="loc_us-gaap_CommonStockMember_1710246" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1710234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1710234" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1710235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1710234" xlink:to="loc_us-gaap_ClassOfStockDomain_1710235" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1710235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1710234" xlink:to="loc_us-gaap_ClassOfStockDomain_1710235_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1710237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1710235" xlink:to="loc_us-gaap_CommonClassAMember_1710237" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1710240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" xlink:to="loc_us-gaap_IPOMember_1710240" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1710241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_dei_LegalEntityAxis_1710241" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1710242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1710241" xlink:to="loc_dei_EntityDomain_1710242" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1710242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1710241" xlink:to="loc_dei_EntityDomain_1710242_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1710243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1710242" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1710243" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1710247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1710247" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710247" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710247" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1710249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1710249" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis_1710250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_GranteeStatusAxis_1710250" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1710251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_1710250" xlink:to="loc_us-gaap_GranteeStatusDomain_1710251" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1710251_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_1710250" xlink:to="loc_us-gaap_GranteeStatusDomain_1710251_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember_1710252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_1710251" xlink:to="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember_1710252" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1710253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_1710251" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1710253" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1710254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_AwardTypeAxis_1710254" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1710254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1710254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1710256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1710256" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" xlink:label="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember_1710257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" xlink:to="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember_1710257" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1710258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1710258" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1710259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1710259" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1710260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1710260" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1710261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1710261" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_1710262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CashFDICInsuredAmount_1710262" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1710263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1710263" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1710264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1710264" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1710266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1710266" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Unitsissuedduringperiodsharesnewissues." xlink:label="loc_oabi_Unitsissuedduringperiodsharesnewissues._1710267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_oabi_Unitsissuedduringperiodsharesnewissues._1710267" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1710268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_Cash_1710268" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1710269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_Revenues_1710269" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1710270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_NetIncomeLoss_1710270" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1710271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1710271" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1710272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1710272" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_1710273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_1710273" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1710274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1710274" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1710275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1710275" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xlink:label="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod_1710276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod_1710276" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1710277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1710277" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1710278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1710278" use="optional" order="51" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1707696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1707696" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1707696" xlink:to="loc_srt_ProductOrServiceAxis_1707700" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1707700" xlink:to="loc_srt_ProductsAndServicesDomain_1707701" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707701_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1707700" xlink:to="loc_srt_ProductsAndServicesDomain_1707701_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1707704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_RoyaltyMember_1707704" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1707705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_LicenseMember_1707705" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_ServiceMember_1707707" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MilestoneMember" xlink:label="loc_oabi_MilestoneMember_1707708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_oabi_MilestoneMember_1707708" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707698" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1709218" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1709219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1709218" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1709219" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1709217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1709218" xlink:to="loc_us-gaap_ConcentrationRiskTable_1709217" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1709224_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1709224_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1709225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1709225" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1709226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_srt_MajorCustomersAxis_1709226" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1709227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1709226" xlink:to="loc_srt_NameOfMajorCustomerDomain_1709227" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1709227_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1709226" xlink:to="loc_srt_NameOfMajorCustomerDomain_1709227_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerAMember" xlink:label="loc_oabi_PartnerAMember_1709228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerAMember_1709228" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerBMember" xlink:label="loc_oabi_PartnerBMember_1709229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerBMember_1709229" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerCMember" xlink:label="loc_oabi_PartnerCMember_1709230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerCMember_1709230" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1709222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" xlink:to="loc_us-gaap_SalesRevenueNetMember_1709222" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707216" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_680" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityProceedsAllocatedToWarrants" xlink:label="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants_681" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityIssuanceCosts" xlink:label="loc_oabi_TemporaryEquityIssuanceCosts_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_TemporaryEquityIssuanceCosts_682" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_683" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_684" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" xlink:to="loc_dei_LegalEntityAxis_1707213" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707213" xlink:to="loc_dei_EntityDomain_1707214" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707214_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707213" xlink:to="loc_dei_EntityDomain_1707214_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707214" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707215" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707221" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockOtherOfferingCosts" xlink:label="loc_oabi_SaleOfStockOtherOfferingCosts_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_SaleOfStockOtherOfferingCosts_698" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCosts" xlink:label="loc_oabi_TransactionCosts_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_TransactionCosts_695" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockUnderwritingFees" xlink:label="loc_oabi_SaleOfStockUnderwritingFees_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_SaleOfStockUnderwritingFees_696" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_697" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsReductionOfTemporaryEquity" xlink:label="loc_oabi_OfferingCostsReductionOfTemporaryEquity_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_OfferingCostsReductionOfTemporaryEquity_699" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_700" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" xlink:to="loc_dei_LegalEntityAxis_1707218" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707218" xlink:to="loc_dei_EntityDomain_1707219" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707218" xlink:to="loc_dei_EntityDomain_1707219_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707219" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707220" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" xlink:to="loc_us-gaap_WarrantMember_715" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xlink:to="loc_dei_LegalEntityAxis_1707223" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707223" xlink:to="loc_dei_EntityDomain_1707224" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707224_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707223" xlink:to="loc_dei_EntityDomain_1707224_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707224" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707225" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_716" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710455" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710455" xlink:to="loc_us-gaap_EarningsPerShareAbstract_739" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_739" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_744" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_739" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_746" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_EarningsPerShareBasic_747" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_EarningsPerShareDiluted_748" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710455" xlink:to="loc_us-gaap_StatementTable_735" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_736" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_736" xlink:to="loc_us-gaap_ClassOfStockDomain_737" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_737_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_736" xlink:to="loc_us-gaap_ClassOfStockDomain_737_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_737" xlink:to="loc_us-gaap_CommonClassAMember_742" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_737" xlink:to="loc_us-gaap_CommonClassBMember_743" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_dei_LegalEntityAxis_1707226" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707226" xlink:to="loc_dei_EntityDomain_1707227" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707227_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707226" xlink:to="loc_dei_EntityDomain_1707227_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707227" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707228" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707786" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707779" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707779" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707779" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_IcagenAcquisitionMember_1707781" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707782" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_TaurusAcquisitionMember_1710393" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_XCellaAcquisitionMember_1710394" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1707797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1707797" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_Goodwill_1707800" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1707801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1707801" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1707787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1707787" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1707788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1707788" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1707789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1707789" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1707790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1707790" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1707791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1707791" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1707792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1707792" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1707793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1707793" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_1707795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_1707795" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1707796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1707796" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1710396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1710396" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_1710399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_1710399" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1707812" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_1707822_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_1707822_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutRightsMember" xlink:label="loc_oabi_EarnoutRightsMember_1707830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" xlink:to="loc_oabi_EarnoutRightsMember_1707830" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheAxis" xlink:label="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheDomain" xlink:label="loc_oabi_ContingentConsiderationByTrancheDomain_1707817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" xlink:to="loc_oabi_ContingentConsiderationByTrancheDomain_1707817" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheDomain" xlink:label="loc_oabi_ContingentConsiderationByTrancheDomain_1707817_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" xlink:to="loc_oabi_ContingentConsiderationByTrancheDomain_1707817_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707827" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1707848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1707848" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707844" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707844" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707844" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_IcagenAcquisitionMember_1707846" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707847" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_TaurusAcquisitionMember_1710426" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_XCellaAcquisitionMember_1710427" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1710432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1710432" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1710433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1710432" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1710433" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1710433_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1710432" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1710433_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1710434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1710433" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1710434" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAcquisitions" xlink:label="loc_oabi_NumberOfAcquisitions_1707831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_NumberOfAcquisitions_1707831" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_1707832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_1707832" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xlink:label="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues_1707837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues_1707837" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1707840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1707840" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfFutureMilestonePayments" xlink:label="loc_oabi_PercentageShareOfFutureMilestonePayments_1707841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_PercentageShareOfFutureMilestonePayments_1707841" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1707850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1707850" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1707851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1707851" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1707852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1707852" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment_1707854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment_1707854" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1707855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1707855" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationCashFlowDiscountedRate" xlink:label="loc_oabi_BusinessCombinationCashFlowDiscountedRate_1707856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationCashFlowDiscountedRate_1707856" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims_1707858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims_1707858" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1710429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1710429" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights_1710431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights_1710431" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedBalanceSheetMember" xlink:label="loc_oabi_CombinedBalanceSheetMember_1707165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" xlink:to="loc_oabi_CombinedBalanceSheetMember_1707165" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xlink:to="loc_srt_RestatementAxis_1707170" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1707170" xlink:to="loc_srt_RestatementDomain_1707171" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1707170" xlink:to="loc_srt_RestatementDomain_1707171_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707171" xlink:to="loc_srt_RestatementAdjustmentMember_1707173" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707171" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707172" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1707181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_LiabilitiesAbstract_1707181" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707183" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1707184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_LiabilitiesCurrent_1707184" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707185" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1707186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1707186" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1707190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_Liabilities_1707190" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707182" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1707199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_AccountsPayableCurrent_1707199" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1707175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_AssetsAbstract_1707175" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707176" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1707177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_AssetsCurrent_1707177" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1707178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1707178" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_Goodwill_1707179" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1707180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_Assets_1707180" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1707191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1707191" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1707191" xlink:to="loc_us-gaap_StockholdersEquity_1707192" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1707193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1707191" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1707193" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_srt_RestatementAxis_1707239" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1707239" xlink:to="loc_srt_RestatementDomain_1707240" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707240_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1707239" xlink:to="loc_srt_RestatementDomain_1707240_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707240" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707241" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707240" xlink:to="loc_srt_RestatementAdjustmentMember_1707242" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_srt_ProductOrServiceAxis_1707252" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1707252" xlink:to="loc_srt_ProductsAndServicesDomain_1707253" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707253_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1707252" xlink:to="loc_srt_ProductsAndServicesDomain_1707253_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707253" xlink:to="loc_us-gaap_ServiceMember_1707255" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneMember" xlink:label="loc_oabi_LicenseAndMilestoneMember_1707254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1707253" xlink:to="loc_oabi_LicenseAndMilestoneMember_1707254" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfOperationsMember" xlink:label="loc_oabi_CombinedStatementOfOperationsMember_1707527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" xlink:to="loc_oabi_CombinedStatementOfOperationsMember_1707527" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707248" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707249" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_NetIncomeLoss_1707250" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1707251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_Revenues_1707251" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1707244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1707244" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707245" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1707246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_OperatingExpenses_1707246" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1707247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_OperatingIncomeLoss_1707247" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_NetIncomeLoss_1707265" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707266" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_StockholdersEquity_1707264" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xlink:to="loc_srt_RestatementAxis_1707259" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1707259" xlink:to="loc_srt_RestatementDomain_1707260" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707260_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1707259" xlink:to="loc_srt_RestatementDomain_1707260_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707260" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707261" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707260" xlink:to="loc_srt_RestatementAdjustmentMember_1707262" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:label="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" xlink:to="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707538" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xlink:to="loc_srt_RestatementAxis_1707271" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1707271" xlink:to="loc_srt_RestatementDomain_1707272" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1707271" xlink:to="loc_srt_RestatementDomain_1707272_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707272" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707273" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707272" xlink:to="loc_srt_RestatementAdjustmentMember_1707274" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfCashFlowsMember" xlink:label="loc_oabi_CombinedStatementOfCashFlowsMember_1707544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" xlink:to="loc_oabi_CombinedStatementOfCashFlowsMember_1707544" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707359" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1707360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1707360" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:label="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" xlink:to="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707364" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707284" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707285" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1707287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1707287" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1707288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1707288" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1707289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1707289" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_NetIncomeLoss_1707277" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707280" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1707281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1707281" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" xlink:to="loc_srt_RestatementAxis_1707416" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1707416" xlink:to="loc_srt_RestatementDomain_1707417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1707416" xlink:to="loc_srt_RestatementDomain_1707417_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1707417" xlink:to="loc_srt_RestatementAdjustmentMember_1707418" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707421" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707427" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/InitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_778" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_779" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" xlink:to="loc_us-gaap_IPOMember_775" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" xlink:to="loc_us-gaap_OverAllotmentOptionMember_776" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_772" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_772" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_773" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_773_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_772" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_773_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PublicWarrantsMember" xlink:label="loc_oabi_PublicWarrantsMember_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_773" xlink:to="loc_oabi_PublicWarrantsMember_777" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_dei_LegalEntityAxis_1707014" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707014" xlink:to="loc_dei_EntityDomain_1707015" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707015_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707014" xlink:to="loc_dei_EntityDomain_1707015_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707015" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707016" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_780" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesIssuedPerUnit" xlink:label="loc_oabi_NumberOfSharesIssuedPerUnit_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_NumberOfSharesIssuedPerUnit_781" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_oabi_NumberOfWarrantsIssuedPerUnit_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_NumberOfWarrantsIssuedPerUnit_782" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_783" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_784" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_807" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_807_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_807" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_811" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_804" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_804" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_804" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" xlink:to="loc_us-gaap_OverAllotmentOptionMember_809" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" xlink:to="loc_us-gaap_PrivatePlacementMember_810" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_dei_LegalEntityAxis_1707026" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707026" xlink:to="loc_dei_EntityDomain_1707027" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707027_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707026" xlink:to="loc_dei_EntityDomain_1707027_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707027" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707029" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_812" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_813" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_814" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_815" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_816" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_850" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_844" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_845" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_845_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_845_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FounderSharesMember" xlink:label="loc_oabi_FounderSharesMember_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_845" xlink:to="loc_oabi_FounderSharesMember_851" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" xlink:to="loc_us-gaap_RelatedPartyDomain_847" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" xlink:to="loc_us-gaap_RelatedPartyDomain_847_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_847" xlink:to="loc_oabi_SponsorMember_852" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_848" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_848" xlink:to="loc_us-gaap_ClassOfStockDomain_849" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_849_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_848" xlink:to="loc_us-gaap_ClassOfStockDomain_849_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_849" xlink:to="loc_us-gaap_CommonClassBMember_853" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_849" xlink:to="loc_us-gaap_CommonClassAMember_854" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_dei_LegalEntityAxis_1707099" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707099" xlink:to="loc_dei_EntityDomain_1707100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707100_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707099" xlink:to="loc_dei_EntityDomain_1707100_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707100" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707101" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesSubjectToForfeiture" xlink:label="loc_oabi_NumberOfSharesSubjectToForfeiture_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_NumberOfSharesSubjectToForfeiture_858" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_855" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_856" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TotalNumberOfSharesTransferred" xlink:label="loc_oabi_TotalNumberOfSharesTransferred_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TotalNumberOfSharesTransferred_857" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_859" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_860" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_861" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_862" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_863" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_864" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1707642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1707642" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707642" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707643" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707643_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707642" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707643_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707643" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707644" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707643" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707645" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1707647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1707647" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_895" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_901" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" xlink:to="loc_us-gaap_RelatedPartyDomain_894" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_894_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" xlink:to="loc_us-gaap_RelatedPartyDomain_894_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_894" xlink:to="loc_srt_DirectorMember_900" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_891" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_891" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_892" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_892_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_891" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_892_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdministrativeSupportAgreementMember" xlink:label="loc_oabi_AdministrativeSupportAgreementMember_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_AdministrativeSupportAgreementMember_897" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyLoansMember" xlink:label="loc_oabi_RelatedPartyLoansMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_RelatedPartyLoansMember_898" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_us-gaap_ServiceMember_899" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_oabi_PromissoryNoteWithRelatedPartyMember_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_PromissoryNoteWithRelatedPartyMember_896" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_GeneralCorporateOverheadMember" xlink:label="loc_oabi_GeneralCorporateOverheadMember_1707382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_GeneralCorporateOverheadMember_1707382" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_dei_LegalEntityAxis_1707205" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707205" xlink:to="loc_dei_EntityDomain_1707206" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707205" xlink:to="loc_dei_EntityDomain_1707206_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707206" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707208" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1707436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_srt_RangeAxis_1707436" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1707436" xlink:to="loc_srt_RangeMember_1707437" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1707436" xlink:to="loc_srt_RangeMember_1707437_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1707440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1707437" xlink:to="loc_srt_MaximumMember_1707440" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1707441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1707437" xlink:to="loc_srt_MinimumMember_1707441" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1707444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_PlanNameAxis_1707444" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1707445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1707444" xlink:to="loc_us-gaap_PlanNameDomain_1707445" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1707445_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1707444" xlink:to="loc_us-gaap_PlanNameDomain_1707445_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EquityBasedIncentivePlansMember" xlink:label="loc_oabi_EquityBasedIncentivePlansMember_1707449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1707445" xlink:to="loc_oabi_EquityBasedIncentivePlansMember_1707449" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmployeeStockPurchasePlanMember" xlink:label="loc_oabi_EmployeeStockPurchasePlanMember_1707559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1707445" xlink:to="loc_oabi_EmployeeStockPurchasePlanMember_1707559" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1707506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1707506" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707506" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707508" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707506" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707508_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707508" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707513" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707508" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707529" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty_902" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_903" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_904" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_905" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_906" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_oabi_MaximumLoansConvertibleIntoWarrants_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_MaximumLoansConvertibleIntoWarrants_907" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_908" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansOutstanding" xlink:label="loc_oabi_WorkingCapitalLoansOutstanding_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_WorkingCapitalLoansOutstanding_909" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_910" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2146633154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2146633154" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146633160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146633160" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2146633182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2146633182" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2146633187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2146633187" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xlink:label="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod._2146633189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod._2146633189" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146633193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146633193" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707234" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PurchasePricePerUnit" xlink:label="loc_oabi_PurchasePricePerUnit_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PurchasePricePerUnit_926" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredFeePerUnit" xlink:label="loc_oabi_DeferredFeePerUnit_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_DeferredFeePerUnit_927" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities_925" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayable_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayable_928" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalDeferredFeePerUnit" xlink:label="loc_oabi_AdditionalDeferredFeePerUnit_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AdditionalDeferredFeePerUnit_929" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable_930" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties_931" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties_932" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties_933" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties_934" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritingcashdiscountperunit" xlink:label="loc_oabi_Underwritingcashdiscountperunit_1707316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_Underwritingcashdiscountperunit_1707316" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritercashdiscount" xlink:label="loc_oabi_Underwritercashdiscount_1707326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_Underwritercashdiscount_1707326" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_us-gaap_StatementTable_1707166" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707166" xlink:to="loc_dei_LegalEntityAxis_1707168" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707168" xlink:to="loc_dei_EntityDomain_1707169" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707169_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707168" xlink:to="loc_dei_EntityDomain_1707169_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707169" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707174" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_980" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregatePurchasePrice" xlink:label="loc_oabi_AdditionalAggregatePurchasePrice_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_AdditionalAggregatePurchasePrice_996" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_SharesToBePurchasedPursuantToAgreements_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SharesToBePurchasedPursuantToAgreements_988" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantsToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_WarrantsToBePurchasedPursuantToAgreements_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_WarrantsToBePurchasedPursuantToAgreements_989" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_990" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_991" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_992" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_993" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalNumberOfCommonStock" xlink:label="loc_oabi_AdditionalNumberOfCommonStock_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_AdditionalNumberOfCommonStock_994" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_995" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_997" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_BusinessExitCosts1_998" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_DeemedDividend_999" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorPurchaseBackstop" xlink:label="loc_oabi_SponsorPurchaseBackstop_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SponsorPurchaseBackstop_1000" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesBackstopWarrants" xlink:label="loc_oabi_SharesBackstopWarrants_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SharesBackstopWarrants_1001" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1002" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_StatementTable_971" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_StatementClassOfStockAxis_972" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_972" xlink:to="loc_us-gaap_ClassOfStockDomain_973" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_972" xlink:to="loc_us-gaap_ClassOfStockDomain_973_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_973" xlink:to="loc_us-gaap_CommonClassAMember_981" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacCommonStockMember" xlink:label="loc_oabi_ApacCommonStockMember_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_973" xlink:to="loc_oabi_ApacCommonStockMember_982" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_974" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_975" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_975_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_975_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_975" xlink:to="loc_us-gaap_WarrantMember_983" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_975" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_984" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:label="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" xlink:to="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_985" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseAgreementMember" xlink:label="loc_oabi_ForwardPurchaseAgreementMember_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" xlink:to="loc_oabi_ForwardPurchaseAgreementMember_986" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" xlink:to="loc_us-gaap_RelatedPartyDomain_979" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_979_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" xlink:to="loc_us-gaap_RelatedPartyDomain_979_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_979" xlink:to="loc_oabi_SponsorMember_987" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_dei_LegalEntityAxis_1707194" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707194" xlink:to="loc_dei_EntityDomain_1707195" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707195_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707194" xlink:to="loc_dei_EntityDomain_1707195_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707195" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707196" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureLineItems" xlink:label="loc_oabi_IncomeTaxDisclosureLineItems_1707604" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureTable" xlink:label="loc_oabi_IncomeTaxDisclosureTable_1707591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_oabi_IncomeTaxDisclosureTable_1707591" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1707614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_IncomeTaxDisclosureTable_1707591" xlink:to="loc_us-gaap_TaxPeriodAxis_1707614" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1707615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1707614" xlink:to="loc_us-gaap_TaxPeriodDomain_1707615" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1707615_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1707614" xlink:to="loc_us-gaap_TaxPeriodDomain_1707615_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtySevenMember" xlink:label="loc_oabi_TwoThousandThirtySevenMember_1707616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1707615" xlink:to="loc_oabi_TwoThousandThirtySevenMember_1707616" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtyTwoMember" xlink:label="loc_oabi_TwoThousandThirtyTwoMember_1707618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1707615" xlink:to="loc_oabi_TwoThousandThirtyTwoMember_1707618" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_IncomeTaxDisclosureTable_1707591" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FederalResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_FederalResearchAndDevelopmentCreditMember_1707623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" xlink:to="loc_oabi_FederalResearchAndDevelopmentCreditMember_1707623" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CaliforniaResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember_1707625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" xlink:to="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember_1707625" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_1707595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_1707595" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1707596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1707596" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1707598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1707598" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1707612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1707612" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1707627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1707627" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1710438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1710438" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710348" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1707472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1707472" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707465" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707467" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1707471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1707471" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1707479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeasePayments_1707479" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1707509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseExpense_1707509" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1710345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_StatementTable_1710345" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1710349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1710345" xlink:to="loc_srt_RangeAxis_1710349" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1710351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1710349" xlink:to="loc_srt_RangeMember_1710351" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1710351_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1710349" xlink:to="loc_srt_RangeMember_1710351_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1710352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1710351" xlink:to="loc_srt_MaximumMember_1710352" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1707442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1707442" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1707443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1707443" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" xlink:to="loc_us-gaap_Goodwill_1707429" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1707431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1707431" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1707433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1707433" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1707435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1707435" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsLineItems" xlink:label="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsTable" xlink:label="loc_oabi_BalanceSheetAccountDetailsTable_1707371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_oabi_BalanceSheetAccountDetailsTable_1707371" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1707499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oabi_BalanceSheetAccountDetailsTable_1707371" xlink:to="loc_srt_RangeAxis_1707499" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1707499" xlink:to="loc_srt_RangeMember_1707501" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1707499" xlink:to="loc_srt_RangeMember_1707501_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1707503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1707501" xlink:to="loc_srt_MaximumMember_1707503" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1707504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1707501" xlink:to="loc_srt_MinimumMember_1707504" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1707375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1707375" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1707378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_Depreciation_1707378" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1707379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1707379" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1707381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1707381" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1707383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1707383" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1707400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1707400" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1707401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_ComputerEquipmentMember_1707401" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_1707398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_OfficeEquipmentMember_1707398" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1707390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1707390" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1707392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1707392" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1707394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1707394" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesTable_1707469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_oabi_ScheduleOfAccruedLiabilitiesTable_1707469" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SubcontractorLiabilitiesCurrent" xlink:label="loc_oabi_SubcontractorLiabilitiesCurrent_1707485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_oabi_SubcontractorLiabilitiesCurrent_1707485" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1707477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1707477" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1707480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1707480" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1707483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1707483" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AcquisitionsRelatedLiabilitiesCurrent" xlink:label="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent_1707492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent_1707492" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1707494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1707494" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707496" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710456" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1011" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1012" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1013" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1014" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_StatementTable_1707111" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1707111" xlink:to="loc_dei_LegalEntityAxis_1707112" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707112" xlink:to="loc_dei_EntityDomain_1707113" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707112" xlink:to="loc_dei_EntityDomain_1707113_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707113" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707114" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1036" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1032" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1032" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1033" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1033" xlink:to="loc_us-gaap_ClassOfStockDomain_1034" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1033" xlink:to="loc_us-gaap_ClassOfStockDomain_1034_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_us-gaap_CommonClassAMember_1035" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_1037" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_us-gaap_CommonClassBMember_1038" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1032" xlink:to="loc_dei_LegalEntityAxis_1707117" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707117" xlink:to="loc_dei_EntityDomain_1707118" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707117" xlink:to="loc_dei_EntityDomain_1707118_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707118" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707119" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1043" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1039" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1040" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockNumberOfVotesPerShare" xlink:label="loc_oabi_CommonStockNumberOfVotesPerShare_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_CommonStockNumberOfVotesPerShare_1041" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesIssued_1042" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1044" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_1707121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_1707121" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfVotingRightsShareHolders" xlink:label="loc_oabi_PercentageOfVotingRightsShareHolders_1707125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_PercentageOfVotingRightsShareHolders_1707125" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1095_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1095_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" xlink:to="loc_us-gaap_WarrantMember_1096" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_1106" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PublicWarrantsMember" xlink:label="loc_oabi_PublicWarrantsMember_1107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_PublicWarrantsMember_1107" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseWarrantsAndBackstopMember" xlink:label="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember_1108" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" xlink:to="loc_us-gaap_IPOMember_1112" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1103" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1103" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1103" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" xlink:to="loc_oabi_OmniabBusinessCombinationMember_1113" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1099" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1100" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1100_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1100_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_srt_StatementScenarioAxis_1097" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1097" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1098" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1098_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1097" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1098_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1098" xlink:to="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_1109" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1098" xlink:to="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_1110" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_dei_LegalEntityAxis_1707104" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707104" xlink:to="loc_dei_EntityDomain_1707105" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707104" xlink:to="loc_dei_EntityDomain_1707105_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707105" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707106" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1116" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_1117" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_1118" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePeriodConditionTwo" xlink:label="loc_oabi_WarrantExercisePeriodConditionTwo_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantExercisePeriodConditionTwo_1115" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MonthsToCompleteInitialBusinessCombination" xlink:label="loc_oabi_MonthsToCompleteInitialBusinessCombination_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_MonthsToCompleteInitialBusinessCombination_1119" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_oabi_WarrantRedemptionConditionMinimumSharePrice_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantRedemptionConditionMinimumSharePrice_1120" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_1121" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1122" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1123" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_1124" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionPeriod" xlink:label="loc_oabi_RedemptionPeriod_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_RedemptionPeriod_1125" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_1126" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_1127" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_1128" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantExercisePriceAdjustmentMultiple_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantExercisePriceAdjustmentMultiple_1129" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple_1131" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1134" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1135" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_SharePrice_1136" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_1132" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_1133" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1167" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1165" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1166" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_dei_LegalEntityAxis_1707047" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707047" xlink:to="loc_dei_EntityDomain_1707048" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707048_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707047" xlink:to="loc_dei_EntityDomain_1707048_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707048" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707049" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_1168" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1169" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1170" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1707761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_AssetImpairmentCharges_1707761" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1194" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1194" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1195" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1195_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1194" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1195_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputFairValueOfUnitMember" xlink:label="loc_oabi_MeasurementInputFairValueOfUnitMember_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputFairValueOfUnitMember_1198" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputCommodityForwardPriceMember" xlink:label="loc_us-gaap_MeasurementInputCommodityForwardPriceMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputCommodityForwardPriceMember_1199" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1200" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1201" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1202" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputExpectedRedemptionRateMember" xlink:label="loc_oabi_MeasurementInputExpectedRedemptionRateMember_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputExpectedRedemptionRateMember_1203" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xlink:label="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember_1204" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1197" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_dei_LegalEntityAxis_1707077" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707077" xlink:to="loc_dei_EntityDomain_1707078" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707077" xlink:to="loc_dei_EntityDomain_1707078_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707078" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707079" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_1205" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1206" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1227" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_dei_LegalEntityAxis_1707080" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1707080" xlink:to="loc_dei_EntityDomain_1707081" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1707080" xlink:to="loc_dei_EntityDomain_1707081_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1707081" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707082" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationLiabilityMember" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember_1707681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" xlink:to="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember_1707681" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707684" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707684" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707684" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" xlink:to="loc_oabi_IcagenMember_1707687" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1707691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1707691" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707691" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707693" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707691" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707693_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1707694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1707693" xlink:to="loc_oabi_XcellaMember_1707694" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1228" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialMeasurementOfForwardPurchase" xlink:label="loc_oabi_InitialMeasurementOfForwardPurchase_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_InitialMeasurementOfForwardPurchase_1229" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1230" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_1232" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1707626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1707626" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition_1707631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition_1707631" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition_1707641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition_1707641" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1707724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1707724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707724" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707726" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707724" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707726_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1707727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1707726" xlink:to="loc_oabi_XcellaMember_1707727" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1707717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1707717" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707719" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1707518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1707518" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1707553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1707553" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1707556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1707556" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1707558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1707558" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707530" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707530" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707530" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_IcagenMember_1707543" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CrystalMember" xlink:label="loc_oabi_CrystalMember_1707537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_CrystalMember_1707537" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1709247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_XcellaMember_1709247" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1707488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1707488" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1707478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1707478" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707587" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707583" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707583" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707583" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CrystalMember" xlink:label="loc_oabi_CrystalMember_1707585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_CrystalMember_1707585" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_IcagenMember_1707586" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1709248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_XcellaMember_1709248" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://om.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1249" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_1253" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_SubsequentEventTable_1246" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1247" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1247" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1248" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1247" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1248_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1248" xlink:to="loc_us-gaap_SubsequentEventMember_1250" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_dei_LegalEntityAxis_1706984" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1706984" xlink:to="loc_dei_EntityDomain_1706985" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706985_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1706984" xlink:to="loc_dei_EntityDomain_1706985_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1706985" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706986" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansWarrantMember" xlink:label="loc_oabi_WorkingCapitalLoansWarrantMember_1706994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" xlink:to="loc_oabi_WorkingCapitalLoansWarrantMember_1706994" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1706997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" xlink:to="loc_us-gaap_RelatedPartyDomain_1706997" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1706997_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" xlink:to="loc_us-gaap_RelatedPartyDomain_1706997_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_1706998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1706997" xlink:to="loc_oabi_SponsorMember_1706998" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707669" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707669" xlink:to="loc_us-gaap_ClassOfStockDomain_1707670" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707670_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707669" xlink:to="loc_us-gaap_ClassOfStockDomain_1707670_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NewOmniabCommonStockMember" xlink:label="loc_oabi_NewOmniabCommonStockMember_1707672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1707670" xlink:to="loc_oabi_NewOmniabCommonStockMember_1707672" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutSharesMember" xlink:label="loc_oabi_EarnoutSharesMember_1707675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1707670" xlink:to="loc_oabi_EarnoutSharesMember_1707675" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1707734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_srt_OwnershipAxis_1707734" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1707735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1707734" xlink:to="loc_srt_OwnershipDomain_1707735" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1707735_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1707734" xlink:to="loc_srt_OwnershipDomain_1707735_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacsExistingPublicShareholdersMember" xlink:label="loc_oabi_ApacsExistingPublicShareholdersMember_1707736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_ApacsExistingPublicShareholdersMember_1707736" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorOfApacMember" xlink:label="loc_oabi_SponsorOfApacMember_1707737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_SponsorOfApacMember_1707737" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartiesOfApacMember" xlink:label="loc_oabi_RelatedPartiesOfApacMember_1707738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_RelatedPartiesOfApacMember_1707738" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1710457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1710457" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710457" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710457" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_1710460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" xlink:to="loc_oabi_OmniabBusinessCombinationMember_1710460" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_1251" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockCashPricePerShare" xlink:label="loc_oabi_SaleOfStockCashPricePerShare_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_SaleOfStockCashPricePerShare_1252" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1254" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1706990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1706990" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_1706999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_1706999" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_1707004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_1707004" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1707649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1707649" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xlink:label="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers_1707662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers_1707662" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1707683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_Cash_1707683" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice_1707699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice_1707699" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1707690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1707690" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ExcessPricePerShare" xlink:label="loc_oabi_ExcessPricePerShare_1707713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_ExcessPricePerShare_1707713" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1707703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1707703" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAverageTradingPrices" xlink:label="loc_oabi_VolumeWeightedAverageTradingPrices_1707709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_VolumeWeightedAverageTradingPrices_1707709" use="optional" order="47" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>oabi-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [06:14:29] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash held outside of the Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCostsCurrent" xlink:label="loc_oabi_TransactionCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TransactionCostsCurrent" xml:lang="en-US">Transaction Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TransactionCostsCurrent" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TransactionCostsCurrent" xlink:to="lab_oabi_TransactionCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TransactionCostsCurrent" xml:lang="en-US">Transaction costs current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Assets Held-in-trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">operating lease right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income taxes, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedExpenses" xlink:label="loc_oabi_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AccruedExpenses" xml:lang="en-US">Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AccruedExpenses" xlink:to="lab_oabi_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AccruedExpenses" xml:lang="en-US">Represents the accrued expense as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedOfferingCosts" xlink:label="loc_oabi_AccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AccruedOfferingCosts" xml:lang="en-US">Accrued Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_AccruedOfferingCosts" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AccruedOfferingCosts" xlink:to="lab_oabi_AccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AccruedOfferingCosts" xml:lang="en-US">Amount of offering costs accrued but not yet paid as of the period date.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xlink:label="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xml:lang="en-US">Notes Payable, Related Parties, Current, Excluding Due to Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xml:lang="en-US">Convertible promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xlink:to="lab_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xml:lang="en-US">The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer), excluding the amount due to related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xml:lang="en-US">Derivative Forward Purchase And Backstop Securities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xml:lang="en-US">Derivative - Forward Purchase and Backstop Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xml:lang="en-US">Derivative liability - Forward Purchase and Backstop Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:to="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xml:lang="en-US">Carrying amount as of the balance sheet date of the derivative - forward purchase and backstop securities, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Contingent Consideration Payable Current Asset And Business Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Current portion of contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xlink:to="lab_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Contingent consideration payable current asset and business acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Current portion of deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and parent company net investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredOfferingCostsNoncurrent" xml:lang="en-US">Deferred Offering Cost Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredOfferingCostsNoncurrent" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredOfferingCostsNoncurrent" xlink:to="lab_oabi_DeferredOfferingCostsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredOfferingCostsNoncurrent" xml:lang="en-US">The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Class A ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Parent company net investment:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the end</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Parent company net investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income taxes, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income taxes, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Contingent Consideration Payable Non Current Asset And Business Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Long-term contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xlink:to="lab_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xml:lang="en-US">Contingent consideration payable non current asset and business acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Long-term portion of deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CommonClassaSubjectToRedemptionMember" xml:lang="en-US">Class A Common Stock Subject to Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CommonClassaSubjectToRedemptionMember" xlink:to="lab_oabi_CommonClassaSubjectToRedemptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CommonClassaSubjectToRedemptionMember" xml:lang="en-US">Classification of common stock representing ownership interest in a corporation that is subject to redemption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AvistaPublicAcquisitionCorp.IiMember" xml:lang="en-US">Avista Public Acquisition Corp. II [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AvistaPublicAcquisitionCorp.IiMember" xml:lang="en-US">Avista Public Acquisition Corp. II [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:to="lab_oabi_AvistaPublicAcquisitionCorp.IiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AvistaPublicAcquisitionCorp.IiMember" xml:lang="en-US">Avista public acquisition corp. II</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xlink:label="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xml:lang="en-US">Class A Common Stock Not Subject to Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xlink:to="lab_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xml:lang="en-US">Classification of common stock representing ownership interest in a corporation that is not subject to redemption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value, (per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value, (per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred shares, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred shares, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred shares, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares, par value, (per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common shares, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common shares, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common shares, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common shares, shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common shares, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common shares, shares outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Class A common stock par value subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Class A common stock subject to possible redemption, outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Formation and operating costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss (as restated)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeemedDividend" xml:lang="en-US">Deemed Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_DeemedDividend" xml:lang="en-US">Deemed dividend - Forward Purchase and Backstop Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeemedDividend" xml:lang="en-US">Deemed dividend upon modification of the forward purchase agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeemedDividend" xlink:to="lab_oabi_DeemedDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeemedDividend" xml:lang="en-US">Amount of deemed dividends related to the Forward Purchase and Backstop Securities.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NetIncomeLossAttributableToOrdinaryShareholders" xlink:label="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NetIncomeLossAttributableToOrdinaryShareholders" xml:lang="en-US">Net Income (Loss) Attributable to Ordinary Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_oabi_NetIncomeLossAttributableToOrdinaryShareholders" xml:lang="en-US">Net loss attributable to ordinary shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders" xlink:to="lab_oabi_NetIncomeLossAttributableToOrdinaryShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NetIncomeLossAttributableToOrdinaryShareholders" xml:lang="en-US">Amount of Net Income (Loss) attributable to ordinary shareholders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding, basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted average shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding, diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted weighted average shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net loss per ordinary share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net loss per ordinary share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other operating expense (income), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain on investments held in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain on investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xml:lang="en-US">Derivative Forward Purchase and Backstop Securities, Fair Value, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xml:lang="en-US">Change in fair value of Forward Purchase and Backstop Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xml:lang="en-US">Change in fair value of Forward Purchase and Backstop Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:to="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xml:lang="en-US">Amount of increase (decrease) in the fair value of derivatives - Forward Purchase and Backstop Securities recognized in the income statement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneRevenueMember" xlink:label="loc_oabi_LicenseAndMilestoneRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_LicenseAndMilestoneRevenueMember" xml:lang="en-US">License And Milestone Revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_LicenseAndMilestoneRevenueMember" xlink:to="lab_oabi_LicenseAndMilestoneRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_LicenseAndMilestoneRevenueMember" xml:lang="en-US">License and milestone revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServiceMember" xml:lang="en-US">Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServiceMember" xml:lang="en-US">Service revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyMember" xml:lang="en-US">Royalty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyMember" xml:lang="en-US">Royalty revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Class B ordinary shares to Sponsor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance at the beginning (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance at the end (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Class B ordinary shares to Sponsor (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xml:lang="en-US">Accretion of Class Ordinary Shares Subject to Redemption to Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xml:lang="en-US">Remeasurement of Class A ordinary shares to redemption amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xml:lang="en-US">Remeasurement of Class A ordinary shares to redemption amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:to="lab_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xml:lang="en-US">Amount accretion of Class A ordinary shares subject to redemption to redemption value.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:label="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WaiverOfUnderwritingCommissionByUnderwriters" xml:lang="en-US">Waiver Of Underwriting Commission By Underwriters</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WaiverOfUnderwritingCommissionByUnderwriters" xml:lang="en-US">Waiver of deferred underwriting commissions by underwriter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:to="lab_oabi_WaiverOfUnderwritingCommissionByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WaiverOfUnderwritingCommissionByUnderwriters" xml:lang="en-US">The amount of Underwriting commission waived by Underwriters.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xml:lang="en-US">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Accretion of Class A ordinary shares to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ReclassificationOfForwardPurchaseAgreement" xlink:label="loc_oabi_ReclassificationOfForwardPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ReclassificationOfForwardPurchaseAgreement" xml:lang="en-US">Reclassification Of Forward Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_ReclassificationOfForwardPurchaseAgreement" xml:lang="en-US">Reclassification of Forward Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ReclassificationOfForwardPurchaseAgreement" xlink:to="lab_oabi_ReclassificationOfForwardPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ReclassificationOfForwardPurchaseAgreement" xml:lang="en-US">Equity impact of the value of reclassification of forward purchase agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseInEquityContributionFromParent" xlink:label="loc_oabi_IncreaseInEquityContributionFromParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IncreaseInEquityContributionFromParent" xml:lang="en-US">Increase In Equity Contribution From Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_IncreaseInEquityContributionFromParent" xml:lang="en-US">Net transfers from parent company (as restated)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IncreaseInEquityContributionFromParent" xlink:to="lab_oabi_IncreaseInEquityContributionFromParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_IncreaseInEquityContributionFromParent" xml:lang="en-US">Increase in equity contribution from parent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Parent allocation of share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Change in estimated fair value of contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xml:lang="en-US">Gain (Loss) on Sale of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xml:lang="en-US">Gain from short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xml:lang="en-US">Gain from sale of intellectual property license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xlink:label="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xml:lang="en-US">Increase Decrease In Due To Related Party Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xml:lang="en-US">Due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xlink:to="lab_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xlink:label="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xml:lang="en-US">Accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xlink:to="lab_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of expenses of related party incurred but not yet paid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PaymentsForInvestmentOfCashInTrustAccount" xml:lang="en-US">Payments for investment of cash in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_PaymentsForInvestmentOfCashInTrustAccount" xml:lang="en-US">Investment of cash into Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount" xlink:to="lab_oabi_PaymentsForInvestmentOfCashInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PaymentsForInvestmentOfCashInTrustAccount" xml:lang="en-US">The amount of cash outflow for investment of cash in trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xml:lang="en-US">Payments to CVR holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xml:lang="en-US">Payment for contingent consideration liability, Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US">Proceeds from sale of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xlink:label="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xml:lang="en-US">Cash paid for acquisitions, net of cash and restricted cash acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xml:lang="en-US">Cash paid for acquisitions, net of cash and restricted cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xlink:to="lab_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xml:lang="en-US">Cash paid for acquisitions, net of cash and restricted cash acquired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from Sale of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from sale of intellectual property license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OtherInvestingActivities" xlink:label="loc_oabi_OtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OtherInvestingActivities" xml:lang="en-US">Other Investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_OtherInvestingActivities" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OtherInvestingActivities" xlink:to="lab_oabi_OtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OtherInvestingActivities" xml:lang="en-US">Other investing activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from promissory note - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xml:lang="en-US">Proceeds From Issuance Initial Public Offering, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xml:lang="en-US">Proceeds from initial public offering, net of underwriter's discount paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:to="lab_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xml:lang="en-US">Net cash inflow from initial public offering after deducting offering expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from sale of Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Deferred transaction cost payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of promissory note - related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of related party promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from convertible promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Amount of drew down promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RepaymentFromRelatedPartyDebt" xlink:label="loc_oabi_RepaymentFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RepaymentFromRelatedPartyDebt" xml:lang="en-US">Repayment From Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_RepaymentFromRelatedPartyDebt" xml:lang="en-US">Repayment of Sponsor note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RepaymentFromRelatedPartyDebt" xlink:to="lab_oabi_RepaymentFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RepaymentFromRelatedPartyDebt" xml:lang="en-US">Repayment from related party debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of Class B ordinary shares to Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payments to CVR holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payment for contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xml:lang="en-US">Proceeds from Contributions from Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xml:lang="en-US">Net transfer from parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xml:lang="en-US">Net transfer from parent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromParent" xlink:to="lab_us-gaap_ProceedsFromContributionsFromParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xlink:label="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xml:lang="en-US">Offering Costs Paid In Exchanges For Issuance Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xml:lang="en-US">Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xlink:to="lab_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xml:lang="en-US">The amount of offering costs paid in exchange of shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xlink:label="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xml:lang="en-US">Initial classification Of Forward Purchase And Backstop Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xml:lang="en-US">Initial classification of the Forward Purchase and Backstop Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xlink:to="lab_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xml:lang="en-US">The amount of initial classification of the Forward Purchase and Backstop Securities</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredUnderwritingFeePayable" xlink:label="loc_oabi_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred Underwriting Fee Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredUnderwritingFeePayable" xlink:to="lab_oabi_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredUnderwritingFeePayable" xml:lang="en-US">Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">Deferred Offering Costs Included In Promissory Note - Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">Offering costs paid by Sponsor and included in promissory note - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:to="lab_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">The amount of Deferred offering costs included in promissory note - related party.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:label="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xml:lang="en-US">Offering Costs Included In Accounts Payable Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xml:lang="en-US">Offering costs included in accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:to="lab_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xml:lang="en-US">The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Purchase of fixed assets recorded in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:label="loc_oabi_DeferredRevenueRecordedInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredRevenueRecordedInAccountsReceivable" xml:lang="en-US">Deferred Revenue Recorded In Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredRevenueRecordedInAccountsReceivable" xml:lang="en-US">Deferred revenue recorded in accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:to="lab_oabi_DeferredRevenueRecordedInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredRevenueRecordedInAccountsReceivable" xml:lang="en-US">Deferred revenue recorded in accounts receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">ORGANISATION AND NATURE OF OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xml:lang="en-US">Error Correction [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xml:lang="en-US">Restatement of Previously Issued Combined Financial Statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionTextBlock" xlink:to="lab_us-gaap_ErrorCorrectionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_oabi_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Schedule that describes and identifies summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xlink:label="loc_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xml:lang="en-US">Business Combination And Asset Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xlink:to="lab_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xml:lang="en-US">Business combination and asset acquisition.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingAbstract" xlink:label="loc_oabi_InitialPublicOfferingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_InitialPublicOfferingAbstract" xml:lang="en-US">INITIAL PUBLIC OFFERING</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_InitialPublicOfferingAbstract" xlink:to="lab_oabi_InitialPublicOfferingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_InitialPublicOfferingAbstract" xml:lang="en-US">No definition available.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingTextBlock" xlink:label="loc_oabi_InitialPublicOfferingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_InitialPublicOfferingTextBlock" xml:lang="en-US">Initial Public Offering [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_InitialPublicOfferingTextBlock" xml:lang="en-US">INITIAL PUBLIC OFFERING</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_InitialPublicOfferingTextBlock" xlink:to="lab_oabi_InitialPublicOfferingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_InitialPublicOfferingTextBlock" xml:lang="en-US">The entire disclosure on information about initial public offering.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementAbstract" xlink:label="loc_oabi_PrivatePlacementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PrivatePlacementAbstract" xml:lang="en-US">PRIVATE PLACEMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PrivatePlacementAbstract" xlink:to="lab_oabi_PrivatePlacementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PrivatePlacementAbstract" xml:lang="en-US">No definition available.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementTextBlock" xlink:label="loc_oabi_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PrivatePlacementTextBlock" xml:lang="en-US">Private Placement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PrivatePlacementTextBlock" xml:lang="en-US">PRIVATE PLACEMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PrivatePlacementTextBlock" xlink:to="lab_oabi_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PrivatePlacementTextBlock" xml:lang="en-US">The entire disclosure on information about private placement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Relationship with Parent and Related Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BalanceSheetAccountDetailsAbstract" xml:lang="en-US">Balance Sheet Account Details [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract" xlink:to="lab_oabi_BalanceSheetAccountDetailsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BalanceSheetAccountDetailsAbstract" xml:lang="en-US">Balance sheet account details.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xlink:label="loc_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xml:lang="en-US">Balance Sheet Account Details Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xml:lang="en-US">Balance Sheet Account Details</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xlink:to="lab_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xml:lang="en-US">Balance sheet account details disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">SHAREHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">SHAREHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:label="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xml:lang="en-US">Offering Costs Associated with the Initial Public Offering [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xml:lang="en-US">Offering Costs Associated with the Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:to="lab_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for offering costs associated with the initial public offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Accounting Standards Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Ordinary Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Business Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xml:lang="en-US">Assets Held In Trust Account, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xml:lang="en-US">Investments Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="lab_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for assets held in trust.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xlink:label="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xml:lang="en-US">Common Stock Subject to Possible Redemption Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xml:lang="en-US">Class A Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xlink:to="lab_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy on common stock subject to possible redemption.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited Interim Financial Information [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="lab_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited interim financial information [Policy text block].</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xml:lang="en-US">Liquidity And Capital Resources [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xml:lang="en-US">Liquidity and Capital Resources</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="lab_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xml:lang="en-US">Liquidity and capital resources [Policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Disaggregation of Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xlink:label="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xml:lang="en-US">Impact Of Covid Nineteen Pandemic [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xml:lang="en-US">Impact of COVID-19 Pandemic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xlink:to="lab_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xml:lang="en-US">Impact of covid nineteen pandemic [Policy text block].</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xlink:label="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xml:lang="en-US">Basis Of Accounting Policy And Business Combination [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xlink:to="lab_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xml:lang="en-US">Basis of accounting policy and business combination [Policy text block].</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_oabi_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EmergingGrowthCompanyPolicyTextBlock" xlink:to="lab_oabi_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging growth company [Policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xlink:label="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xml:lang="en-US">Business Combination And Asset Acquisitions [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xlink:to="lab_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xml:lang="en-US">Business combination and asset acquisitions [Policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenuePolicyTextBlock" xlink:label="loc_oabi_DeferredRevenuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredRevenuePolicyTextBlock" xml:lang="en-US">Deferred Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredRevenuePolicyTextBlock" xml:lang="en-US">Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredRevenuePolicyTextBlock" xlink:to="lab_oabi_DeferredRevenuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredRevenuePolicyTextBlock" xml:lang="en-US">Deferred revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xml:lang="en-US">Error Correction, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xml:lang="en-US">Error Correction, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedBalanceSheetMember" xlink:label="loc_oabi_CombinedBalanceSheetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CombinedBalanceSheetMember" xml:lang="en-US">Combined Balance Sheet [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CombinedBalanceSheetMember" xlink:to="lab_oabi_CombinedBalanceSheetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CombinedBalanceSheetMember" xml:lang="en-US">Combined balance sheet.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfCashFlowsMember" xlink:label="loc_oabi_CombinedStatementOfCashFlowsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CombinedStatementOfCashFlowsMember" xml:lang="en-US">Combined Statement Of Cash Flows [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CombinedStatementOfCashFlowsMember" xlink:to="lab_oabi_CombinedStatementOfCashFlowsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CombinedStatementOfCashFlowsMember" xml:lang="en-US">Combined Statement of Cash flows.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:label="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xml:lang="en-US">Combined Statement Of Changes In Parent Company Net Investment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:to="lab_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xml:lang="en-US">Combined statement of changes in parent company net investment.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfOperationsMember" xlink:label="loc_oabi_CombinedStatementOfOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CombinedStatementOfOperationsMember" xml:lang="en-US">Combined Statement Of Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CombinedStatementOfOperationsMember" xlink:to="lab_oabi_CombinedStatementOfOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CombinedStatementOfOperationsMember" xml:lang="en-US">Combined statement of operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of calculation of basic and diluted net loss per ordinary share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Summary of Disaggregation of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Summary of Revenue from Significant Partners</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of recognized identified assets acquired and liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IcagenAcquisitionMember" xml:lang="en-US">Icagen Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IcagenAcquisitionMember" xlink:to="lab_oabi_IcagenAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_IcagenAcquisitionMember" xml:lang="en-US">Icagen acquisition.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AbInitioAcquisitionMember" xml:lang="en-US">Ab Initio Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AbInitioAcquisitionMember" xlink:to="lab_oabi_AbInitioAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AbInitioAcquisitionMember" xml:lang="en-US">Ab initio acquisition.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TaurusAcquisitionMember" xml:lang="en-US">Taurus Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TaurusAcquisitionMember" xlink:to="lab_oabi_TaurusAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TaurusAcquisitionMember" xml:lang="en-US">Taurus acquisition.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_XCellaAcquisitionMember" xml:lang="en-US">x Cella Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_XCellaAcquisitionMember" xml:lang="en-US">xCella Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_XCellaAcquisitionMember" xlink:to="lab_oabi_XCellaAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_XCellaAcquisitionMember" xml:lang="en-US">xCella Acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of company's financial assets and liabilities that are measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Summary of significant inputs to the valuation for the Forward Purchase and Backstop Securities liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of changes in the fair value of the Company's Level 3 financial instruments that are measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of the hierarchy for liabilities measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xlink:label="loc_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xml:lang="en-US">Schedule of Operating Lease Assets and Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xml:lang="en-US">Schedule of Operating Lease Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xlink:to="lab_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xml:lang="en-US">Schedule of operating lease assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment are Stated at Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PrivatePlacementWarrantsMember" xlink:to="lab_oabi_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PrivatePlacementWarrantsMember" xml:lang="en-US">Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SponsorMember" xml:lang="en-US">Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SponsorMember" xlink:to="lab_oabi_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SponsorMember" xml:lang="en-US">This member stands for sponsor.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacCommonStockMember" xlink:label="loc_oabi_ApacCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ApacCommonStockMember" xml:lang="en-US">APAC Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ApacCommonStockMember" xml:lang="en-US">APAC Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ApacCommonStockMember" xlink:to="lab_oabi_ApacCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ApacCommonStockMember" xml:lang="en-US">Classification of common stock representing ownership interest in the newly formed company.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutStockMember" xlink:label="loc_oabi_EarnoutStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EarnoutStockMember" xml:lang="en-US">Earnout Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EarnoutStockMember" xlink:to="lab_oabi_EarnoutStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EarnoutStockMember" xml:lang="en-US">Classification of common stock representing the earnout.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabIncMember" xlink:label="loc_oabi_OmniabIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OmniabIncMember" xml:lang="en-US">OmniAb Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OmniabIncMember" xlink:to="lab_oabi_OmniabIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OmniabIncMember" xml:lang="en-US">Represents information pertaining to OmniAb, Inc. ("OmniAb").</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LigandMember" xlink:label="loc_oabi_LigandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_LigandMember" xml:lang="en-US">Ligand</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_LigandMember" xlink:to="lab_oabi_LigandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_LigandMember" xml:lang="en-US">This member stands for Ligand.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:label="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xml:lang="en-US">Amended and Restated Forward Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xml:lang="en-US">Amended and Restated Forward Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:to="lab_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xml:lang="en-US">Represents information pertaining to the Amended and Restated Forward Purchase Agreement (the "A&amp;R FPA").</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorInsiderAgreementMember" xlink:label="loc_oabi_SponsorInsiderAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SponsorInsiderAgreementMember" xml:lang="en-US">Sponsor Insider Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SponsorInsiderAgreementMember" xlink:to="lab_oabi_SponsorInsiderAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SponsorInsiderAgreementMember" xml:lang="en-US">Represents information pertaining to the Sponsor Insider Agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsAxis" xlink:label="loc_oabi_VestingRequirementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_VestingRequirementsAxis" xml:lang="en-US">Vesting Requirements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_VestingRequirementsAxis" xlink:to="lab_oabi_VestingRequirementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_VestingRequirementsAxis" xml:lang="en-US">Categorizes the requirements in order to trigger vesting of shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsDomain" xlink:label="loc_oabi_VestingRequirementsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_VestingRequirementsDomain" xml:lang="en-US">Vesting Requirements [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_VestingRequirementsDomain" xlink:to="lab_oabi_VestingRequirementsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_VestingRequirementsDomain" xml:lang="en-US">The requirements needed to be met in order to trigger vesting of shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FirstRequirementsMember" xlink:label="loc_oabi_FirstRequirementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_FirstRequirementsMember" xml:lang="en-US">First Requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_FirstRequirementsMember" xlink:to="lab_oabi_FirstRequirementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_FirstRequirementsMember" xml:lang="en-US">Represents information pertaining to the first set of requirements needed to be met for vesting.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SecondRequirementsMember" xlink:label="loc_oabi_SecondRequirementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SecondRequirementsMember" xml:lang="en-US">Second Requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SecondRequirementsMember" xlink:to="lab_oabi_SecondRequirementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SecondRequirementsMember" xml:lang="en-US">Represents information pertaining to the second set of requirements needed to be met for vesting.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Initial Public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xml:lang="en-US">Condition for future business combination number of businesses minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xml:lang="en-US">Condition for future business combination, number of businesses, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="lab_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xml:lang="en-US">The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MonthsToCompleteInitialBusinessCombination" xlink:label="loc_oabi_MonthsToCompleteInitialBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MonthsToCompleteInitialBusinessCombination" xml:lang="en-US">Months to Complete Initial Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MonthsToCompleteInitialBusinessCombination" xml:lang="en-US">Months to complete initial business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MonthsToCompleteInitialBusinessCombination" xlink:to="lab_oabi_MonthsToCompleteInitialBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MonthsToCompleteInitialBusinessCombination" xml:lang="en-US">Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Units Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of units issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="lab_oabi_UnitsIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of new units issued during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Share issued price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of warrants to purchase shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xml:lang="en-US">Price of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xml:lang="en-US">Price of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="lab_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xml:lang="en-US">Price per share or per unit of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from sale of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Aggregate purchase price private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InvestmentsMaximumMaturityTerm" xlink:label="loc_oabi_InvestmentsMaximumMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_InvestmentsMaximumMaturityTerm" xml:lang="en-US">Investments Maximum Maturity Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_InvestmentsMaximumMaturityTerm" xml:lang="en-US">Maturity term of U.S. government securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_InvestmentsMaximumMaturityTerm" xlink:to="lab_oabi_InvestmentsMaximumMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_InvestmentsMaximumMaturityTerm" xml:lang="en-US">The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xml:lang="en-US">Percentage of Obligation to Redeem Public Shares If Entity Does Not Complete Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xml:lang="en-US">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="lab_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xml:lang="en-US">Percentage of obligation to redeem public shares if Entity does not complete business combination.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xlink:label="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xml:lang="en-US">Number of Days at Volume Weighted Average Price for Shares to Vest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xml:lang="en-US">Number of days at volume-weighted average price to trigger vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xlink:to="lab_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xml:lang="en-US">The number of consecutive trading days within a specified range when the reported volume-weighted average price must exceed the specified amount.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xml:lang="en-US">Minimum Net Tangible Assets upon Consummation of Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xml:lang="en-US">Minimum net tangible assets upon consummation of the business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:to="lab_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xml:lang="en-US">Represents the minimum net tangible assets upon consummation of the Business Combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business combination shares voted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xml:lang="en-US">Threshold Business Days for Redemption of Public Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xml:lang="en-US">Threshold business days for redemption of public shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:to="lab_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xml:lang="en-US">Represents the threshold business days for redemption of public shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNetInterestToPayDissolutionExpenses" xlink:label="loc_oabi_MaximumNetInterestToPayDissolutionExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumNetInterestToPayDissolutionExpenses" xml:lang="en-US">Maximum Net Interest to Pay Dissolution Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumNetInterestToPayDissolutionExpenses" xml:lang="en-US">Maximum net interest to pay dissolution expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumNetInterestToPayDissolutionExpenses" xlink:to="lab_oabi_MaximumNetInterestToPayDissolutionExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumNetInterestToPayDissolutionExpenses" xml:lang="en-US">Represents the maximum net interest to pay dissolution expenses.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xlink:label="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xml:lang="en-US">Percentage Of Common Stock Shares Issued Under Distribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xml:lang="en-US">Percentage of common stock shares issued under distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xlink:to="lab_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xml:lang="en-US">Represents the percentage of common stock shares issued under the distribution.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CapitalContributedNetOfExpenses" xlink:label="loc_oabi_CapitalContributedNetOfExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CapitalContributedNetOfExpenses" xml:lang="en-US">Capital Contributed, Net Of Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_CapitalContributedNetOfExpenses" xml:lang="en-US">Capital contributed, net of expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CapitalContributedNetOfExpenses" xlink:to="lab_oabi_CapitalContributedNetOfExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CapitalContributedNetOfExpenses" xml:lang="en-US">Represents the amount of capital, net of expenses.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalDeficit" xlink:label="loc_oabi_WorkingCapitalDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WorkingCapitalDeficit" xml:lang="en-US">Working Capital Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WorkingCapitalDeficit" xml:lang="en-US">Working capital deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WorkingCapitalDeficit" xlink:to="lab_oabi_WorkingCapitalDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WorkingCapitalDeficit" xml:lang="en-US">Amount of working capital deficit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xlink:label="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xml:lang="en-US">Vested Percent of Shares Upon Achievement of Post Transaction Volume Weight Average Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xml:lang="en-US">Percent of shares vested upon the combined company's achievement of the post-transaction volume-weighted average price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xlink:to="lab_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xml:lang="en-US">Percent of shares that will vest upon the achievement of a post-transaction volume-weighted average price as determined by the company.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAveragePriceTriggerPrice" xlink:label="loc_oabi_VolumeWeightedAveragePriceTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_VolumeWeightedAveragePriceTriggerPrice" xml:lang="en-US">Volume Weighted Average Price, Trigger Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_VolumeWeightedAveragePriceTriggerPrice" xml:lang="en-US">Volume-weighted average price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_VolumeWeightedAveragePriceTriggerPrice" xlink:to="lab_oabi_VolumeWeightedAveragePriceTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_VolumeWeightedAveragePriceTriggerPrice" xml:lang="en-US">Volume-weighted average price that would trigger the 50% of earnout shares vesting.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToVestMeasurementPeriod" xlink:label="loc_oabi_SharesToVestMeasurementPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SharesToVestMeasurementPeriod" xml:lang="en-US">Shares To Vest Measurement Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SharesToVestMeasurementPeriod" xml:lang="en-US">Number of consecutive days volume-weighted average price to be within</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SharesToVestMeasurementPeriod" xlink:to="lab_oabi_SharesToVestMeasurementPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SharesToVestMeasurementPeriod" xml:lang="en-US">The number of trading days over which the reported sale price is measured when determining the redemption price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Number of Class A common stock issued upon conversion of each share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesIssuedPerUnit" xlink:label="loc_oabi_NumberOfSharesIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Number of Shares Issued Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Number of shares in a unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfSharesIssuedPerUnit" xlink:to="lab_oabi_NumberOfSharesIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Represents the number of shares in a unit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_oabi_NumberOfWarrantsIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Number of Warrants Issued Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Number of warrants in a unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfWarrantsIssuedPerUnit" xlink:to="lab_oabi_NumberOfWarrantsIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Represents the number of warrants in a unit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xlink:label="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xml:lang="en-US">Maximum Number of Shares Subject to Price Based Vesting Conditions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xml:lang="en-US">Maximum number of shares subject to the price-based vesting conditions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xlink:to="lab_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xml:lang="en-US">The maximum number of shares that could be subject to the price-based vesting conditions.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalNumberOfCommonStock" xlink:label="loc_oabi_AdditionalNumberOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AdditionalNumberOfCommonStock" xml:lang="en-US">Additional Number of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AdditionalNumberOfCommonStock" xml:lang="en-US">Additional number of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AdditionalNumberOfCommonStock" xlink:to="lab_oabi_AdditionalNumberOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AdditionalNumberOfCommonStock" xml:lang="en-US">Number of additional common stock to be purchased.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Additional number of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of additional securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregatePurchasePrice" xlink:label="loc_oabi_AdditionalAggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AdditionalAggregatePurchasePrice" xml:lang="en-US">Additional Aggregate Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AdditionalAggregatePurchasePrice" xml:lang="en-US">Additional aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AdditionalAggregatePurchasePrice" xlink:to="lab_oabi_AdditionalAggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AdditionalAggregatePurchasePrice" xml:lang="en-US">The aggregate purchase price of the additional shares and additional warrants under an agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorPurchaseBackstop" xlink:label="loc_oabi_SponsorPurchaseBackstop" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SponsorPurchaseBackstop" xml:lang="en-US">Sponsor Purchase Backstop</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SponsorPurchaseBackstop" xml:lang="en-US">Sponsor purchased backstop</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SponsorPurchaseBackstop" xlink:to="lab_oabi_SponsorPurchaseBackstop" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SponsorPurchaseBackstop" xml:lang="en-US">Represents the Sponsor purchased backstop.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesBackstopWarrants" xlink:label="loc_oabi_SharesBackstopWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SharesBackstopWarrants" xml:lang="en-US">Shares Backstop Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_SharesBackstopWarrants" xml:lang="en-US">Shares backstop warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SharesBackstopWarrants" xlink:to="lab_oabi_SharesBackstopWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SharesBackstopWarrants" xml:lang="en-US">Represents the Shares back shop warrants .</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumAdditionalAggregatePurchasePrice" xml:lang="en-US">Maximum Additional Aggregate Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumAdditionalAggregatePurchasePrice" xml:lang="en-US">Maximum additional aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumAdditionalAggregatePurchasePrice" xlink:to="lab_oabi_MaximumAdditionalAggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumAdditionalAggregatePurchasePrice" xml:lang="en-US">The maximum aggregate purchase price of the additional shares and additional warrants under an agreement in order to backstop shareholder redemptions for cash proceeds to be limited to the maximum.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xlink:label="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xml:lang="en-US">Amount Deposited in Operating Account for Working Capital Out of the Proceeds from Offerings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xml:lang="en-US">Amount deposited in an operating account for the working capital needs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xlink:to="lab_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xml:lang="en-US">Represents the amount deposited in operating account for working capital purposes out of proceeds from the Initial Public Offering and sale of the Private Placement Warrants.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xml:lang="en-US">Maximum Borrowing Capacity of Related Party Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xml:lang="en-US">Maximum borrowing capacity of related party promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="lab_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xml:lang="en-US">Amount of maximum borrowing capacity of related party promissory note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Outstanding balance of related party note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xlink:label="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xml:lang="en-US">Number Of Additional Financing Public Shares Issued Upon Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xml:lang="en-US">Number of additional financing public shares issued upon business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xlink:to="lab_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xml:lang="en-US">Number of additional financing public shares issued upon business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCosts" xlink:label="loc_oabi_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TransactionCosts" xml:lang="en-US">Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_TransactionCosts" xml:lang="en-US">Offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TransactionCosts" xlink:to="lab_oabi_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TransactionCosts" xml:lang="en-US">Represents the amount of transaction costs incurred.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockUnderwritingFees" xlink:label="loc_oabi_SaleOfStockUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SaleOfStockUnderwritingFees" xml:lang="en-US">Sale of Stock, Underwriting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SaleOfStockUnderwritingFees" xml:lang="en-US">Underwriting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SaleOfStockUnderwritingFees" xlink:to="lab_oabi_SaleOfStockUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SaleOfStockUnderwritingFees" xml:lang="en-US">Represents the amount of offering fees incurred and paid for underwriters.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockOtherOfferingCosts" xlink:label="loc_oabi_SaleOfStockOtherOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SaleOfStockOtherOfferingCosts" xml:lang="en-US">Sale of Stock, Other Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SaleOfStockOtherOfferingCosts" xml:lang="en-US">Other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SaleOfStockOtherOfferingCosts" xlink:to="lab_oabi_SaleOfStockOtherOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SaleOfStockOtherOfferingCosts" xml:lang="en-US">Represents the amount of other offering costs incurred.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xml:lang="en-US">Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xml:lang="en-US">Threshold percentage of public shares subject to redemption without the company's prior written consent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:to="lab_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xml:lang="en-US">Threshold percentage of public shares subject to redemption without the company's prior written consent.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalSurplus" xlink:label="loc_oabi_WorkingCapitalSurplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WorkingCapitalSurplus" xml:lang="en-US">Working Capital Surplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WorkingCapitalSurplus" xml:lang="en-US">Working capital surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WorkingCapitalSurplus" xlink:to="lab_oabi_WorkingCapitalSurplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WorkingCapitalSurplus" xml:lang="en-US">Working capital surplus.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xml:lang="en-US">Proceeds From Initial Public Offering And Sale Of Private Placement Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xml:lang="en-US">Proceeds from the Initial Public offering and sale of the private placement warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:to="lab_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xml:lang="en-US">Proceeds from the initial public offering and sale of the private placement warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyLoansMember" xlink:label="loc_oabi_RelatedPartyLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RelatedPartyLoansMember" xml:lang="en-US">Related Party Loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RelatedPartyLoansMember" xlink:to="lab_oabi_RelatedPartyLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RelatedPartyLoansMember" xml:lang="en-US">This member stands for related party loans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SeparationAndDistributionAgreementMember" xlink:label="loc_oabi_SeparationAndDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SeparationAndDistributionAgreementMember" xml:lang="en-US">Separation And Distribution Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SeparationAndDistributionAgreementMember" xlink:to="lab_oabi_SeparationAndDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SeparationAndDistributionAgreementMember" xml:lang="en-US">This member stands for separation and distribution agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OmniabBusinessCombinationMember" xml:lang="en-US">OmniAb</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OmniabBusinessCombinationMember" xlink:to="lab_oabi_OmniabBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OmniabBusinessCombinationMember" xml:lang="en-US">This member stands for omniab business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized tax benefits accrued for interest and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Federal depository insurance coverage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business acquisition for share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business acquisition for per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Unitsissuedduringperiodsharesnewissues." xlink:label="loc_oabi_Unitsissuedduringperiodsharesnewissues." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_Unitsissuedduringperiodsharesnewissues." xml:lang="en-US">UnitsIssuedDuringPeriodSharesNewIssues.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_Unitsissuedduringperiodsharesnewissues." xml:lang="en-US">Sale of Units, net of underwriting discounts (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_Unitsissuedduringperiodsharesnewissues." xlink:to="lab_oabi_Unitsissuedduringperiodsharesnewissues." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_Unitsissuedduringperiodsharesnewissues." xml:lang="en-US">UnitsIssuedDuringPeriodSharesNewIssues</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xml:lang="en-US">Common stock, dividends, per share, declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xml:lang="en-US">Common stock, dividends, per share, cash paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xlink:label="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Description Of Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award description of award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xlink:to="lab_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award description of award vesting period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with customer liability revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GranteeStatusAxis" xml:lang="en-US">Grantee Status [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GranteeStatusDomain" xml:lang="en-US">Grantee Status [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xml:lang="en-US">Share Based Payment Arrangement Nonemployee Directors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:to="lab_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" xlink:label="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" xml:lang="en-US">Restricted Stock Units And Phantom Share Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" xlink:to="lab_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MilestoneMember" xlink:label="loc_oabi_MilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MilestoneMember" xml:lang="en-US">Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MilestoneMember" xml:lang="en-US">Milestone revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MilestoneMember" xlink:to="lab_oabi_MilestoneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTable" xml:lang="en-US">Concentration Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerAMember" xlink:label="loc_oabi_PartnerAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PartnerAMember" xml:lang="en-US">Partner A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PartnerAMember" xlink:to="lab_oabi_PartnerAMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerBMember" xlink:label="loc_oabi_PartnerBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PartnerBMember" xml:lang="en-US">Partner B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PartnerBMember" xlink:to="lab_oabi_PartnerBMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerCMember" xlink:label="loc_oabi_PartnerCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PartnerCMember" xml:lang="en-US">Partner C [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PartnerCMember" xlink:to="lab_oabi_PartnerCMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xml:lang="en-US">Concentration Risk [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityProceedsAllocatedToWarrants" xlink:label="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TemporaryEquityProceedsAllocatedToWarrants" xml:lang="en-US">Temporary Equity , Proceeds Allocated To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TemporaryEquityProceedsAllocatedToWarrants" xml:lang="en-US">Proceeds allocated to Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants" xlink:to="lab_oabi_TemporaryEquityProceedsAllocatedToWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TemporaryEquityProceedsAllocatedToWarrants" xml:lang="en-US">Amount of gross proceeds allocated from temporary equity to warrants.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityIssuanceCosts" xlink:label="loc_oabi_TemporaryEquityIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TemporaryEquityIssuanceCosts" xml:lang="en-US">Temporary Equity, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TemporaryEquityIssuanceCosts" xml:lang="en-US">Issuance costs allocated to Class A ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TemporaryEquityIssuanceCosts" xlink:to="lab_oabi_TemporaryEquityIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TemporaryEquityIssuanceCosts" xml:lang="en-US">Amount of issuance costs related to temporary equity.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsReductionOfTemporaryEquity" xlink:label="loc_oabi_OfferingCostsReductionOfTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OfferingCostsReductionOfTemporaryEquity" xml:lang="en-US">Offering Costs Reduction Of Temporary Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_OfferingCostsReductionOfTemporaryEquity" xml:lang="en-US">Offering costs reduction of temporary equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OfferingCostsReductionOfTemporaryEquity" xlink:to="lab_oabi_OfferingCostsReductionOfTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OfferingCostsReductionOfTemporaryEquity" xml:lang="en-US">Amount of offering costs reduction of temporary equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Offering costs as a reduction of equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Basic and diluted net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xml:lang="en-US">Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xml:lang="en-US">Schedule of recognized identified assets acquired and liabilities assumed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xml:lang="en-US">Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xml:lang="en-US">Schedule of recognized identified assets acquired and liabilities assumed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Recognized identified assets acquired and liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaids and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xml:lang="en-US">Deferred tax assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Acquired intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:to="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutRightsMember" xlink:label="loc_oabi_EarnoutRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EarnoutRightsMember" xml:lang="en-US">Earnout Rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EarnoutRightsMember" xlink:to="lab_oabi_EarnoutRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EarnoutRightsMember" xml:lang="en-US">Earnout rights.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAcquisitions" xlink:label="loc_oabi_NumberOfAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfAcquisitions" xml:lang="en-US">Number Of Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfAcquisitions" xml:lang="en-US">Number of acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfAcquisitions" xlink:to="lab_oabi_NumberOfAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfAcquisitions" xml:lang="en-US">Number of acquisitions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xml:lang="en-US">Number of Businesses Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xml:lang="en-US">Number of businesses acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xlink:label="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xml:lang="en-US">Percentage Share Of Post Clinical Acquiree Product Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xml:lang="en-US">Percentage share of post clinical acquire product revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xlink:to="lab_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xml:lang="en-US">Percentage share of post clinical acquiree product revenues.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired finite lived intangible assets weighted average useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfFutureMilestonePayments" xlink:label="loc_oabi_PercentageShareOfFutureMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageShareOfFutureMilestonePayments" xml:lang="en-US">Percentage Share Of Future Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageShareOfFutureMilestonePayments" xml:lang="en-US">Percentage share of future milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageShareOfFutureMilestonePayments" xlink:to="lab_oabi_PercentageShareOfFutureMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageShareOfFutureMilestonePayments" xml:lang="en-US">Percentage share of future milestone payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business combination consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to acquire businesses gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xml:lang="en-US">Business combination contingent consideration arrangements range of outcomes value high</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xml:lang="en-US">Business Combination Contingent Consideration Revenue Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xml:lang="en-US">Business combination contingent consideration revenue milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xlink:to="lab_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xml:lang="en-US">Business combination contingent consideration revenue milestone payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite lived intangible assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationCashFlowDiscountedRate" xlink:label="loc_oabi_BusinessCombinationCashFlowDiscountedRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationCashFlowDiscountedRate" xml:lang="en-US">Business Combination Cash Flow Discounted Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationCashFlowDiscountedRate" xml:lang="en-US">Business combination cash flow discounted rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationCashFlowDiscountedRate" xlink:to="lab_oabi_BusinessCombinationCashFlowDiscountedRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationCashFlowDiscountedRate" xml:lang="en-US">Business combination cash flow discounted rate.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xml:lang="en-US">Business Combination Consideration Transferred Holdback For Potential Indemnification Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xml:lang="en-US">Business combination consideration transferred to holdback for potential indemnification claims</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xlink:to="lab_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xml:lang="en-US">Business combination consideration transferred holdback for potential indemnification claims.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business combination consideration transferred liabilities incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xml:lang="en-US">Business Combination, Consideration Transferred, Earnout Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xml:lang="en-US">Business combination consideration transferred earnout rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xlink:to="lab_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xml:lang="en-US">Business combination, consideration transferred, earnout rights.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheAxis" xlink:label="loc_oabi_ContingentConsiderationByTrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ContingentConsiderationByTrancheAxis" xml:lang="en-US">Contingent Consideration By Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ContingentConsiderationByTrancheAxis" xlink:to="lab_oabi_ContingentConsiderationByTrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ContingentConsiderationByTrancheAxis" xml:lang="en-US">Contingent consideration by tranche.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheDomain" xlink:label="loc_oabi_ContingentConsiderationByTrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ContingentConsiderationByTrancheDomain" xml:lang="en-US">Contingent Consideration By Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ContingentConsiderationByTrancheDomain" xlink:to="lab_oabi_ContingentConsiderationByTrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ContingentConsiderationByTrancheDomain" xml:lang="en-US">Contingent consideration by tranche.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xml:lang="en-US">Customer Relationships [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneMember" xlink:label="loc_oabi_LicenseAndMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_LicenseAndMilestoneMember" xml:lang="en-US">License And Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_LicenseAndMilestoneMember" xlink:to="lab_oabi_LicenseAndMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_LicenseAndMilestoneMember" xml:lang="en-US">License and milestone.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PublicWarrantsMember" xlink:label="loc_oabi_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PublicWarrantsMember" xml:lang="en-US">Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PublicWarrantsMember" xlink:to="lab_oabi_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PublicWarrantsMember" xml:lang="en-US">Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Number of shares issuable per warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Number of shares per warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FounderSharesMember" xlink:label="loc_oabi_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_FounderSharesMember" xml:lang="en-US">Founder Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_FounderSharesMember" xlink:to="lab_oabi_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_FounderSharesMember" xml:lang="en-US">N/A</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesSubjectToForfeiture" xlink:label="loc_oabi_NumberOfSharesSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfSharesSubjectToForfeiture" xml:lang="en-US">Number Of Shares Subject To Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfSharesSubjectToForfeiture" xml:lang="en-US">Shares subject to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfSharesSubjectToForfeiture" xlink:to="lab_oabi_NumberOfSharesSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfSharesSubjectToForfeiture" xml:lang="en-US">The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TotalNumberOfSharesTransferred" xlink:label="loc_oabi_TotalNumberOfSharesTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TotalNumberOfSharesTransferred" xml:lang="en-US">Total Number Of Shares Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TotalNumberOfSharesTransferred" xml:lang="en-US">Total number of shares transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TotalNumberOfSharesTransferred" xlink:to="lab_oabi_TotalNumberOfSharesTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TotalNumberOfSharesTransferred" xml:lang="en-US">Represents the total number of shares transferred.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xml:lang="en-US">Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xml:lang="en-US">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:to="lab_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xml:lang="en-US">The expected ownership percentage by the founders after completion of the proposed public offering.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xml:lang="en-US">Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:to="lab_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xml:lang="en-US">The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xml:lang="en-US">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xml:lang="en-US">The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xml:lang="en-US">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xml:lang="en-US">When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xml:lang="en-US">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xml:lang="en-US">When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xml:lang="en-US">Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xml:lang="en-US">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="lab_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xml:lang="en-US">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">Offering Costs Included In Promissory Note - Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">Offering costs paid by Sponsor and included in promissory note - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:to="lab_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xml:lang="en-US">The amount of offering costs included in promissory note - related party.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party Per Month</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xml:lang="en-US">Expenses per month</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="lab_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xml:lang="en-US">The contractual monthly amount to be paid for support services.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Expenses incurred and paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_oabi_MaximumLoansConvertibleIntoWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumLoansConvertibleIntoWarrants" xml:lang="en-US">Maximum Loans Convertible Into Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumLoansConvertibleIntoWarrants" xml:lang="en-US">Loan conversion agreement warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumLoansConvertibleIntoWarrants" xlink:to="lab_oabi_MaximumLoansConvertibleIntoWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumLoansConvertibleIntoWarrants" xml:lang="en-US">The maximum amount which a potential loan could have repaid through issuance of warrants.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansOutstanding" xlink:label="loc_oabi_WorkingCapitalLoansOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WorkingCapitalLoansOutstanding" xml:lang="en-US">Working capital loans, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WorkingCapitalLoansOutstanding" xml:lang="en-US">Working capital loans, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WorkingCapitalLoansOutstanding" xlink:to="lab_oabi_WorkingCapitalLoansOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WorkingCapitalLoansOutstanding" xml:lang="en-US">The amount of working capital loans, outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Service fee paid to a director</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, terms of award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Selling, general and administrative expenses from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Purchase price of common stock expressed as a percentage of its fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for repurchase of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xlink:label="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xml:lang="en-US">Percentage of Their Eligible Compensation During the Offering Period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xml:lang="en-US">Percentage of their eligible compensation during the offering period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xlink:to="lab_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xml:lang="en-US">Percentage of their eligible compensation during the offering period.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdministrativeSupportAgreementMember" xlink:label="loc_oabi_AdministrativeSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AdministrativeSupportAgreementMember" xml:lang="en-US">Administrative Support Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AdministrativeSupportAgreementMember" xlink:to="lab_oabi_AdministrativeSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AdministrativeSupportAgreementMember" xml:lang="en-US">This member stands for Administrative Support Agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_oabi_PromissoryNoteWithRelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PromissoryNoteWithRelatedPartyMember" xml:lang="en-US">Promissory Note with Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PromissoryNoteWithRelatedPartyMember" xlink:to="lab_oabi_PromissoryNoteWithRelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PromissoryNoteWithRelatedPartyMember" xml:lang="en-US">This member stands for promissory note with related party.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_GeneralCorporateOverheadMember" xlink:label="loc_oabi_GeneralCorporateOverheadMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_GeneralCorporateOverheadMember" xml:lang="en-US">General Corporate Overhead [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_GeneralCorporateOverheadMember" xlink:to="lab_oabi_GeneralCorporateOverheadMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_GeneralCorporateOverheadMember" xml:lang="en-US">General corporate overhead.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EquityBasedIncentivePlansMember" xlink:label="loc_oabi_EquityBasedIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EquityBasedIncentivePlansMember" xml:lang="en-US">Equity Based Incentive Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EquityBasedIncentivePlansMember" xlink:to="lab_oabi_EquityBasedIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EquityBasedIncentivePlansMember" xml:lang="en-US">Equity based incentive plans.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmployeeStockPurchasePlanMember" xlink:label="loc_oabi_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EmployeeStockPurchasePlanMember" xlink:to="lab_oabi_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PurchasePricePerUnit" xlink:label="loc_oabi_PurchasePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PurchasePricePerUnit" xml:lang="en-US">Purchase Price Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PurchasePricePerUnit" xml:lang="en-US">Purchase price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PurchasePricePerUnit" xlink:to="lab_oabi_PurchasePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PurchasePricePerUnit" xml:lang="en-US">Represents the purchase price per unit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredFeePerUnit" xlink:label="loc_oabi_DeferredFeePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredFeePerUnit" xml:lang="en-US">Deferred Fee Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredFeePerUnit" xml:lang="en-US">Deferred fee per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredFeePerUnit" xlink:to="lab_oabi_DeferredFeePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredFeePerUnit" xml:lang="en-US">Represents the deferred fee per unit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xml:lang="en-US">Maximum Number Of Demands For Registration Of Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xml:lang="en-US">Maximum number of demands for registration of securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:to="lab_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xml:lang="en-US">Represents the maximum number of demands for registration of securities.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayable" xml:lang="en-US">Aggregated deferred underwriting fees payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayable" xml:lang="en-US">Aggregate deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AggregateDeferredUnderwritingFeePayable" xlink:to="lab_oabi_AggregateDeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayable" xml:lang="en-US">The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalDeferredFeePerUnit" xlink:label="loc_oabi_AdditionalDeferredFeePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AdditionalDeferredFeePerUnit" xml:lang="en-US">Additional Deferred Fee Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AdditionalDeferredFeePerUnit" xml:lang="en-US">Deferred underwriting fee per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AdditionalDeferredFeePerUnit" xlink:to="lab_oabi_AdditionalDeferredFeePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AdditionalDeferredFeePerUnit" xml:lang="en-US">Represents the additional deferred fee per unit.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xml:lang="en-US">Additional aggregate deferred underwriting fees payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xml:lang="en-US">Additional aggregate deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xlink:to="lab_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xml:lang="en-US">The additional value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Percentage of deferred underwriting fees payable to third parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Percentage of deferred underwriting fee payable to third parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xlink:to="lab_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Represents the percentage of deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Aggregate deferred underwriting fees payable to third parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Aggregate deferred underwriting fee payable to third parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xlink:to="lab_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xml:lang="en-US">Represents the aggregate deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xml:lang="en-US">Aggregate Deferred Underwriting Fee Payable, Not To Pay For Third Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xml:lang="en-US">Aggregate deferred underwriting fee company not to pay or allocate to third parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xlink:to="lab_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xml:lang="en-US">Represents the aggregate deferred underwriting fee payable decided by the company not to pay or allocate to third parties.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xml:lang="en-US">Percentage of deferred underwriting fees payable not allocated to the third parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xml:lang="en-US">Percentage of deferred underwriting fee payable not allocated to third parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xlink:to="lab_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xml:lang="en-US">Represents the percentage of deferred underwriting fee payable decided by the company not to pay or allocate to third parties.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritingcashdiscountperunit" xlink:label="loc_oabi_Underwritingcashdiscountperunit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_Underwritingcashdiscountperunit" xml:lang="en-US">UnderwritingCashDiscountPerUnit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_Underwritingcashdiscountperunit" xml:lang="en-US">Underwriting cash discount per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_Underwritingcashdiscountperunit" xlink:to="lab_oabi_Underwritingcashdiscountperunit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_Underwritingcashdiscountperunit" xml:lang="en-US">UnderwritingCashDiscountPerUnit</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritercashdiscount" xlink:label="loc_oabi_Underwritercashdiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_Underwritercashdiscount" xml:lang="en-US">UnderwriterCashDiscount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_Underwritercashdiscount" xml:lang="en-US">Underwriter cash discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_Underwritercashdiscount" xlink:to="lab_oabi_Underwritercashdiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_Underwritercashdiscount" xml:lang="en-US">UnderwriterCashDiscount.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseAgreementMember" xlink:label="loc_oabi_ForwardPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ForwardPurchaseAgreementMember" xml:lang="en-US">Forward Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ForwardPurchaseAgreementMember" xlink:to="lab_oabi_ForwardPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ForwardPurchaseAgreementMember" xml:lang="en-US">Represents information pertaining to the Forward Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_SharesToBePurchasedPursuantToAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SharesToBePurchasedPursuantToAgreements" xml:lang="en-US">Shares To Be Purchased Pursuant To Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_SharesToBePurchasedPursuantToAgreements" xml:lang="en-US">Shares To Be Purchased Pursuant To Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SharesToBePurchasedPursuantToAgreements" xlink:to="lab_oabi_SharesToBePurchasedPursuantToAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SharesToBePurchasedPursuantToAgreements" xml:lang="en-US">Shares to be purchased pursuant to agreements.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantsToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_WarrantsToBePurchasedPursuantToAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WarrantsToBePurchasedPursuantToAgreements" xml:lang="en-US">Warrants to be purchased pursuant to agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WarrantsToBePurchasedPursuantToAgreements" xml:lang="en-US">Aggregate warrants to be purchase pursuant to agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WarrantsToBePurchasedPursuantToAgreements" xlink:to="lab_oabi_WarrantsToBePurchasedPursuantToAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WarrantsToBePurchasedPursuantToAgreements" xml:lang="en-US">Warrants to be purchased pursuant to agreements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessExitCosts1" xml:lang="en-US">Business Exit Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessExitCosts1" xml:lang="en-US">Termination fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current expense (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred expense (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax at federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xml:lang="en-US">Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xml:lang="en-US">State tax rate change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Research and development credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureTable" xlink:label="loc_oabi_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IncomeTaxDisclosureTable" xlink:to="lab_oabi_IncomeTaxDisclosureTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtySevenMember" xlink:label="loc_oabi_TwoThousandThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TwoThousandThirtySevenMember" xml:lang="en-US">Two Thousand Thirty seven [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TwoThousandThirtySevenMember" xlink:to="lab_oabi_TwoThousandThirtySevenMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtyTwoMember" xlink:label="loc_oabi_TwoThousandThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TwoThousandThirtyTwoMember" xml:lang="en-US">Two Thousand Thirty Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TwoThousandThirtyTwoMember" xlink:to="lab_oabi_TwoThousandThirtyTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FederalResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_FederalResearchAndDevelopmentCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_FederalResearchAndDevelopmentCreditMember" xml:lang="en-US">Federal Research and Development Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_FederalResearchAndDevelopmentCreditMember" xlink:to="lab_oabi_FederalResearchAndDevelopmentCreditMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CaliforniaResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CaliforniaResearchAndDevelopmentCreditMember" xml:lang="en-US">California Research and Development Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember" xlink:to="lab_oabi_CaliforniaResearchAndDevelopmentCreditMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureLineItems" xlink:label="loc_oabi_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems" xlink:to="lab_oabi_IncomeTaxDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_oabi_DeferredTaxAssetsDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredTaxAssetsDeferredRevenue" xml:lang="en-US">Deferred Tax Assets Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_DeferredTaxAssetsDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredTaxAssetsDeferredRevenue" xlink:to="lab_oabi_DeferredTaxAssetsDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredTaxAssetsDeferredRevenue" xml:lang="en-US">Deferred Tax Assets Deferred Revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Identified intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:label="loc_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xml:lang="en-US">Operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="lab_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Net deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred income taxes, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Additions based on tax positions related to the current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Additions for tax positions of prior&#160;years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Reductions for tax positions in prior&#160;years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OperatingLeaseAssetsAbstract" xlink:label="loc_oabi_OperatingLeaseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OperatingLeaseAssetsAbstract" xml:lang="en-US">Operating Lease Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_OperatingLeaseAssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OperatingLeaseAssetsAbstract" xlink:to="lab_oabi_OperatingLeaseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OperatingLeaseAssetsAbstract" xml:lang="en-US">Operating lease assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xlink:label="loc_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xml:lang="en-US">Operating Lease Liabilities, Tenant Improvement Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xml:lang="en-US">Less tenant improvement allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xlink:to="lab_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xml:lang="en-US">Operating lease liabilities, tenant improvement allowance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024-2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023-2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026-2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025-2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022-2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Remaining three months ending December&#160;31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestNetAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xml:lang="en-US">Schedule Of Intangible Assets And Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xlink:to="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xml:lang="en-US">Schedule of intangible assets and goodwill.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xml:lang="en-US">Schedule Of Intangible Assets And Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xlink:to="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xml:lang="en-US">Schedule of intangible assets and goodwill.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsTable" xlink:label="loc_oabi_BalanceSheetAccountDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BalanceSheetAccountDetailsTable" xml:lang="en-US">Balance Sheet Account Details [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BalanceSheetAccountDetailsTable" xlink:to="lab_oabi_BalanceSheetAccountDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BalanceSheetAccountDetailsTable" xml:lang="en-US">Balance sheet account details.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsLineItems" xlink:label="loc_oabi_BalanceSheetAccountDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BalanceSheetAccountDetailsLineItems" xml:lang="en-US">Balance Sheet Account Details [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems" xlink:to="lab_oabi_BalanceSheetAccountDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BalanceSheetAccountDetailsLineItems" xml:lang="en-US">Balance sheet account details.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">impairment of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment and software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Lab and office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfAccruedLiabilitiesTable" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesTable" xlink:to="lab_oabi_ScheduleOfAccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfAccruedLiabilitiesTable" xml:lang="en-US">Schedule of accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ScheduleOfAccruedLiabilitiesLineItems" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems" xlink:to="lab_oabi_ScheduleOfAccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ScheduleOfAccruedLiabilitiesLineItems" xml:lang="en-US">Schedule of accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SubcontractorLiabilitiesCurrent" xlink:label="loc_oabi_SubcontractorLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SubcontractorLiabilitiesCurrent" xml:lang="en-US">Subcontractor Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SubcontractorLiabilitiesCurrent" xml:lang="en-US">Subcontractor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SubcontractorLiabilitiesCurrent" xlink:to="lab_oabi_SubcontractorLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SubcontractorLiabilitiesCurrent" xml:lang="en-US">Subcontractor liabilities current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Accrued Royalties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Royalties owed to third parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AcquisitionsRelatedLiabilitiesCurrent" xlink:label="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_AcquisitionsRelatedLiabilitiesCurrent" xml:lang="en-US">Acquisitions Related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_AcquisitionsRelatedLiabilitiesCurrent" xml:lang="en-US">Acquisition related liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent" xlink:to="lab_oabi_AcquisitionsRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_AcquisitionsRelatedLiabilitiesCurrent" xml:lang="en-US">Acquisitions related liabilities, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockNumberOfVotesPerShare" xlink:label="loc_oabi_CommonStockNumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CommonStockNumberOfVotesPerShare" xml:lang="en-US">Common Stock, Number Of Votes Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_CommonStockNumberOfVotesPerShare" xml:lang="en-US">Common shares, votes per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CommonStockNumberOfVotesPerShare" xlink:to="lab_oabi_CommonStockNumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CommonStockNumberOfVotesPerShare" xml:lang="en-US">The number of votes that each common share is entitled.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xml:lang="en-US">Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xml:lang="en-US">Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:to="lab_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xml:lang="en-US">Percentage of adjustment of redemption price of stock based on market value and newly issued price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfVotingRightsShareHolders" xlink:label="loc_oabi_PercentageOfVotingRightsShareHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfVotingRightsShareHolders" xml:lang="en-US">Percentage of voting rights, share holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfVotingRightsShareHolders" xml:lang="en-US">Percentage of voting rights on share holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfVotingRightsShareHolders" xlink:to="lab_oabi_PercentageOfVotingRightsShareHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfVotingRightsShareHolders" xml:lang="en-US">Represents the Percentage of voting rights, share holders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseWarrantsAndBackstopMember" xlink:label="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ForwardPurchaseWarrantsAndBackstopMember" xml:lang="en-US">Forward Purchase Warrants And Backstop</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember" xlink:to="lab_oabi_ForwardPurchaseWarrantsAndBackstopMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ForwardPurchaseWarrantsAndBackstopMember" xml:lang="en-US">This member stands for forward purchase warrants and backstop warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xml:lang="en-US">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:to="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xml:lang="en-US">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xml:lang="en-US">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:to="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xml:lang="en-US">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">SHAREHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Public warrants expiration term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xml:lang="en-US">Maximum Period After Business Combination In Which To File Registration Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xml:lang="en-US">Maximum period after business combination in which to file registration statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:to="lab_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xml:lang="en-US">The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xml:lang="en-US">Period Of Time Within Which Registration Statement Is Expected To Become Effective</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xml:lang="en-US">Period of time within which registration statement is expected to become effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:to="lab_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xml:lang="en-US">The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePeriodConditionTwo" xlink:label="loc_oabi_WarrantExercisePeriodConditionTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WarrantExercisePeriodConditionTwo" xml:lang="en-US">Warrant Exercise Period Condition Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WarrantExercisePeriodConditionTwo" xml:lang="en-US">Warrant exercise period condition two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WarrantExercisePeriodConditionTwo" xlink:to="lab_oabi_WarrantExercisePeriodConditionTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WarrantExercisePeriodConditionTwo" xml:lang="en-US">The alternate period of time after completion of an initial public offering before a warrant may be exercised.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_oabi_WarrantRedemptionConditionMinimumSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WarrantRedemptionConditionMinimumSharePrice" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WarrantRedemptionConditionMinimumSharePrice" xml:lang="en-US">Warrant redemption condition minimum share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WarrantRedemptionConditionMinimumSharePrice" xlink:to="lab_oabi_WarrantRedemptionConditionMinimumSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WarrantRedemptionConditionMinimumSharePrice" xml:lang="en-US">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Redemption price per public warrant (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="lab_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Redemption price per share or per unit of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xml:lang="en-US">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xml:lang="en-US">Threshold trading days for redemption of public warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xml:lang="en-US">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xml:lang="en-US">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xml:lang="en-US">Threshold consecutive trading days for redemption of public warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xml:lang="en-US">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xml:lang="en-US">Threshold Number of Business Days Before Sending Notice of Redemption to Warrant Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xml:lang="en-US">Threshold number of business days before sending notice of redemption to warrant holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:to="lab_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xml:lang="en-US">Threshold number of business days before sending notice of redemption to warrant holders.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionPeriod" xlink:label="loc_oabi_RedemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RedemptionPeriod" xml:lang="en-US">Redemption Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_RedemptionPeriod" xml:lang="en-US">Redemption period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RedemptionPeriod" xlink:to="lab_oabi_RedemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RedemptionPeriod" xml:lang="en-US">Represents the redemption period.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xml:lang="en-US">Share Price Trigger Used To Measure Dilution Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xml:lang="en-US">Share price trigger used to measure dilution of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:to="lab_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xml:lang="en-US">The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xml:lang="en-US">Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xml:lang="en-US">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="lab_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xml:lang="en-US">The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xml:lang="en-US">Trading Period After Business Combination Used To Measure Dilution of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xml:lang="en-US">Trading period after business combination used to measure dilution of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="lab_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xml:lang="en-US">The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantExercisePriceAdjustmentMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WarrantExercisePriceAdjustmentMultiple" xml:lang="en-US">Warrant Exercise Price Adjustment Multiple</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WarrantExercisePriceAdjustmentMultiple" xml:lang="en-US">Warrant exercise price adjustment multiple</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WarrantExercisePriceAdjustmentMultiple" xlink:to="lab_oabi_WarrantExercisePriceAdjustmentMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WarrantExercisePriceAdjustmentMultiple" xml:lang="en-US">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WarrantRedemptionPriceAdjustmentMultiple" xml:lang="en-US">Warrant Redemption Price Adjustment Multiple</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_WarrantRedemptionPriceAdjustmentMultiple" xml:lang="en-US">Warrant redemption price adjustment multiple</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple" xlink:to="lab_oabi_WarrantRedemptionPriceAdjustmentMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WarrantRedemptionPriceAdjustmentMultiple" xml:lang="en-US">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xml:lang="en-US">Restrictions On Transfer Period Of Time After Business Combination Completion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xml:lang="en-US">Restrictions on transfer period of time after business combination completion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="lab_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xml:lang="en-US">The period of time after completion of a business combination during which the shares or warrant may not be transferred.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset impairment charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputFairValueOfUnitMember" xlink:label="loc_oabi_MeasurementInputFairValueOfUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MeasurementInputFairValueOfUnitMember" xml:lang="en-US">Fair value of unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MeasurementInputFairValueOfUnitMember" xml:lang="en-US">Fair value of Forward Purchase and Backstop Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MeasurementInputFairValueOfUnitMember" xlink:to="lab_oabi_MeasurementInputFairValueOfUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MeasurementInputFairValueOfUnitMember" xml:lang="en-US">Measurement input using fair value of unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputCommodityForwardPriceMember" xlink:label="loc_us-gaap_MeasurementInputCommodityForwardPriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputCommodityForwardPriceMember" xml:lang="en-US">Measurement Input, Commodity Forward Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputCommodityForwardPriceMember" xml:lang="en-US">Present value of Forward Purchase and Backstop Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputCommodityForwardPriceMember" xlink:to="lab_us-gaap_MeasurementInputCommodityForwardPriceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Time to Business Combination (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Discount factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputExpectedRedemptionRateMember" xlink:label="loc_oabi_MeasurementInputExpectedRedemptionRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MeasurementInputExpectedRedemptionRateMember" xml:lang="en-US">Expected redemption rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MeasurementInputExpectedRedemptionRateMember" xml:lang="en-US">Expected redemption rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MeasurementInputExpectedRedemptionRateMember" xlink:to="lab_oabi_MeasurementInputExpectedRedemptionRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MeasurementInputExpectedRedemptionRateMember" xml:lang="en-US">Measurement input using expected redemption rate.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xlink:label="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xml:lang="en-US">Probability of completing an initial Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xml:lang="en-US">Probability of completing an initial Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xlink:to="lab_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xml:lang="en-US">This member stands for Measurement Input, Probability Of Completing An Initial Business Combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Fair value of forward purchase and backstop securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialMeasurementOfForwardPurchase" xlink:label="loc_oabi_InitialMeasurementOfForwardPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_InitialMeasurementOfForwardPurchase" xml:lang="en-US">Initial Measurement Of Forward Purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_InitialMeasurementOfForwardPurchase" xml:lang="en-US">Initial measurement as of March 23, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_InitialMeasurementOfForwardPurchase" xlink:to="lab_oabi_InitialMeasurementOfForwardPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_InitialMeasurementOfForwardPurchase" xml:lang="en-US">Represents the amount of initial classification of the Forward Purchase.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Payments to CVR holders and other contingent payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Liabilities From Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xml:lang="en-US">Contingent liabilities from Icagen acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xlink:to="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from acquisition.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Liabilities From Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xml:lang="en-US">Contingent liabilities from xCella asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xlink:to="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from asset acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationLiabilityMember" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_BusinessCombinationContingentConsiderationLiabilityMember" xml:lang="en-US">Business Combination Contingent Consideration Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember" xlink:to="lab_oabi_BusinessCombinationContingentConsiderationLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_BusinessCombinationContingentConsiderationLiabilityMember" xml:lang="en-US">Business combination contingent consideration liability.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_IcagenMember" xml:lang="en-US">Icagen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_IcagenMember" xlink:to="lab_oabi_IcagenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_IcagenMember" xml:lang="en-US">Icagen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_XcellaMember" xml:lang="en-US">xCella [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_XcellaMember" xlink:to="lab_oabi_XcellaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_XcellaMember" xml:lang="en-US">xCella.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset acquisition, Contingent consideration, Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CrystalMember" xlink:label="loc_oabi_CrystalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CrystalMember" xml:lang="en-US">Crystal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CrystalMember" xlink:to="lab_oabi_CrystalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CrystalMember" xml:lang="en-US">Crystal.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Stock Redeemed or Called During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Shares sold in IPO redeemed for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xml:lang="en-US">Shares sold in IPO redeemed for cash (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockCashPricePerShare" xlink:label="loc_oabi_SaleOfStockCashPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SaleOfStockCashPricePerShare" xml:lang="en-US">Sale of Stock, Cash Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_SaleOfStockCashPricePerShare" xml:lang="en-US">Shares issued cash price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SaleOfStockCashPricePerShare" xlink:to="lab_oabi_SaleOfStockCashPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SaleOfStockCashPricePerShare" xml:lang="en-US">Per share amount in Cash received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Redemption price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xml:lang="en-US">Debt Instrument, Debt Default, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xml:lang="en-US">Aggregate borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="lab_us-gaap_DebtDefaultLongtermDebtAmount" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xlink:label="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xml:lang="en-US">Common Stock Subject To Price Based Earnout Triggers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xml:lang="en-US">Common stock subject to price-based earnout triggers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xlink:to="lab_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xml:lang="en-US">Common stock subject to price based earnout triggers.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number Of Trading Days For Determining The Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="lab_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ExcessPricePerShare" xlink:label="loc_oabi_ExcessPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ExcessPricePerShare" xml:lang="en-US">Excess Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_oabi_ExcessPricePerShare" xml:lang="en-US">Excess price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ExcessPricePerShare" xlink:to="lab_oabi_ExcessPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ExcessPricePerShare" xml:lang="en-US">Excess price per share.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number Of Consecutive Trading Days For Determining The Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:to="lab_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAverageTradingPrices" xlink:label="loc_oabi_VolumeWeightedAverageTradingPrices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_VolumeWeightedAverageTradingPrices" xml:lang="en-US">Volume Weighted Average Trading Prices</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_oabi_VolumeWeightedAverageTradingPrices" xml:lang="en-US">Volume-weighted average trading prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_VolumeWeightedAverageTradingPrices" xlink:to="lab_oabi_VolumeWeightedAverageTradingPrices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_VolumeWeightedAverageTradingPrices" xml:lang="en-US">Volume weighted average trading prices.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansWarrantMember" xlink:label="loc_oabi_WorkingCapitalLoansWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_WorkingCapitalLoansWarrantMember" xml:lang="en-US">Working Capital Loans Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_WorkingCapitalLoansWarrantMember" xlink:to="lab_oabi_WorkingCapitalLoansWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_WorkingCapitalLoansWarrantMember" xml:lang="en-US">Working capital loans warrant.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NewOmniabCommonStockMember" xlink:label="loc_oabi_NewOmniabCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_NewOmniabCommonStockMember" xml:lang="en-US">New OmniAb Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_NewOmniabCommonStockMember" xlink:to="lab_oabi_NewOmniabCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_NewOmniabCommonStockMember" xml:lang="en-US">New omniAb common stock.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutSharesMember" xlink:label="loc_oabi_EarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_EarnoutSharesMember" xml:lang="en-US">Earnout Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_EarnoutSharesMember" xlink:to="lab_oabi_EarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_EarnoutSharesMember" xml:lang="en-US">Earnout shares.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacsExistingPublicShareholdersMember" xlink:label="loc_oabi_ApacsExistingPublicShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_ApacsExistingPublicShareholdersMember" xml:lang="en-US">APACs Existing Public Shareholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_ApacsExistingPublicShareholdersMember" xlink:to="lab_oabi_ApacsExistingPublicShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_ApacsExistingPublicShareholdersMember" xml:lang="en-US">APAC's existing public shareholders.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorOfApacMember" xlink:label="loc_oabi_SponsorOfApacMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_SponsorOfApacMember" xml:lang="en-US">Sponsor Of APAC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_SponsorOfApacMember" xlink:to="lab_oabi_SponsorOfApacMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_SponsorOfApacMember" xml:lang="en-US">Sponsor of APAC.</label>
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartiesOfApacMember" xlink:label="loc_oabi_RelatedPartiesOfApacMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_oabi_RelatedPartiesOfApacMember" xml:lang="en-US">Related Parties Of APAC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oabi_RelatedPartiesOfApacMember" xlink:to="lab_oabi_RelatedPartiesOfApacMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_oabi_RelatedPartiesOfApacMember" xml:lang="en-US">Related parties of APAC.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>oabi-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [06:14:29] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CoverPage" roleURI="http://om.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://om.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CombinedStatementsOfChangesInParentCompanyNetInvestment" roleURI="http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#OrganisationAndNatureOfOperations" roleURI="http://om.com/role/OrganisationAndNatureOfOperations" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatements" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#Acquisitions" roleURI="http://om.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#InitialPublicOffering" roleURI="http://om.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#PrivatePlacement" roleURI="http://om.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntities" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntities" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxes" roleURI="http://om.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentAndContingenciesLegalProceedings" roleURI="http://om.com/role/CommitmentAndContingenciesLegalProceedings" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#Leases" roleURI="http://om.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetails" roleURI="http://om.com/role/BalanceSheetAccountDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficit" roleURI="http://om.com/role/ShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurements" roleURI="http://om.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#SubsequentEvents" roleURI="http://om.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsTables" roleURI="http://om.com/role/AcquisitionsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsTables" roleURI="http://om.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesTables" roleURI="http://om.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesTables" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesTables" roleURI="http://om.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsTables" roleURI="http://om.com/role/BalanceSheetAccountDetailsTables" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#OrganisationAndNatureOfOperationsDetails" roleURI="http://om.com/role/OrganisationAndNatureOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails" roleURI="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#AcquisitionsAdditionalInformationDetails" roleURI="http://om.com/role/AcquisitionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails" roleURI="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#InitialPublicOfferingDetails" roleURI="http://om.com/role/InitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#PrivatePlacementDetails" roleURI="http://om.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesFounderSharesDetails" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails" roleURI="http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://om.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#CommitmentsAndContingenciesForwardPurchaseAgreementDetails" roleURI="http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://om.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails" roleURI="http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail" roleURI="http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail" roleURI="http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#LeasesAdditionalInformationDetail" roleURI="http://om.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" roleURI="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitPreferredStockSharesDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitCommonStockSharesDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#ShareholdersEquityDeficitWarrantsDetails" roleURI="http://om.com/role/ShareholdersEquityDeficitWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://om.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" roleURI="http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails" roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails" roleURI="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails" roleURI="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails" />
<roleRef xlink:type="simple" xlink:href="oabi-20220930.xsd#SubsequentEventsDetails" roleURI="http://om.com/role/SubsequentEventsDetails" />
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1707868" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1707869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_DocumentType_1707869" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1707876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_AmendmentFlag_1707876" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1707875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntityCentralIndexKey_1707875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1707870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntityRegistrantName_1707870" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1707871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntityFilerCategory_1707871" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1707872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntitySmallBusiness_1707872" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1707873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntityEmergingGrowthCompany_1707873" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1707874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1707868" xlink:to="loc_dei_EntityExTransitionPeriod_1707874" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_113" xlink:to="loc_us-gaap_StatementTable_114" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_us-gaap_StatementClassOfStockAxis_115" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_115" xlink:to="loc_us-gaap_ClassOfStockDomain_116" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_us-gaap_CommonClassAMember_117" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_124" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_116" xlink:to="loc_us-gaap_CommonClassBMember_125" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_dei_LegalEntityAxis_1707061" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707061" xlink:to="loc_dei_EntityDomain_1707062" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707062" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707063" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1710378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_srt_RestatementAxis_1710378" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1710379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1710378" xlink:to="loc_srt_RestatementDomain_1710379" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1710380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1710379" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1710380" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114" xlink:to="loc_us-gaap_StatementLineItems_118" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_118" xlink:to="loc_us-gaap_AssetsAbstract_119" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_AssetsCurrentAbstract_120" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_127" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707291" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCostsCurrent" xlink:label="loc_oabi_TransactionCostsCurrent_1707448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_oabi_TransactionCostsCurrent_1707448" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1707292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_OtherAssetsCurrent_1707292" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_120" xlink:to="loc_us-gaap_AssetsCurrent_128" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1707452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1707452" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_129" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1707293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1707293" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_Goodwill_1707294" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1707295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1707295" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707296" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1707297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1707297" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_119" xlink:to="loc_us-gaap_Assets_130" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_118" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_122" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_AccountsPayableCurrent_131" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedExpenses" xlink:label="loc_oabi_AccruedExpenses_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_AccruedExpenses_132" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccruedOfferingCosts" xlink:label="loc_oabi_AccruedOfferingCosts_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_AccruedOfferingCosts_133" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty" xlink:label="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty_134" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_135" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_136" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707300" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition_1707305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition_1707305" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1707307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1707307" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707309" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707310" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_122" xlink:to="loc_us-gaap_LiabilitiesCurrent_137" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_138" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition" xlink:label="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition_1707315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition_1707315" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707318" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707319" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1707320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1707320" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1707322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1707322" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_Liabilities_139" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_CommitmentsAndContingencies_140" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_141" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_StockholdersEquityAbstract_123" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_PreferredStockValue_142" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_CommonStockValue_143" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_144" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_123" xlink:to="loc_us-gaap_StockholdersEquity_145" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_146" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_168" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_168" xlink:to="loc_us-gaap_StatementTable_169" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_169" xlink:to="loc_us-gaap_StatementClassOfStockAxis_170" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_170" xlink:to="loc_us-gaap_ClassOfStockDomain_171" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_us-gaap_CommonClassAMember_172" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_174" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassCommonStockSharesNotSubjectToRedemptionMember" xlink:label="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_oabi_ClassCommonStockSharesNotSubjectToRedemptionMember_175" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_171" xlink:to="loc_us-gaap_CommonClassBMember_176" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_169" xlink:to="loc_dei_LegalEntityAxis_1707065" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707065" xlink:to="loc_dei_EntityDomain_1707066" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707066" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707067" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_169" xlink:to="loc_us-gaap_StatementLineItems_173" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_177" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_178" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesIssued_179" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_180" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_182" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesIssued_183" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_184" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_185" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_186" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_207" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207" xlink:to="loc_us-gaap_StatementTable_208" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_us-gaap_StatementClassOfStockAxis_209" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_209" xlink:to="loc_us-gaap_ClassOfStockDomain_210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_210" xlink:to="loc_us-gaap_CommonClassAMember_212" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_210" xlink:to="loc_us-gaap_CommonClassBMember_213" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_dei_LegalEntityAxis_1707069" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707069" xlink:to="loc_dei_EntityDomain_1707070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707070" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707071" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_srt_ProductOrServiceAxis_1707545" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1707545" xlink:to="loc_srt_ProductsAndServicesDomain_1707546" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_us-gaap_ServiceMember_1707549" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneRevenueMember" xlink:label="loc_oabi_LicenseAndMilestoneRevenueMember_1707547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_oabi_LicenseAndMilestoneRevenueMember_1707547" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1707590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707546" xlink:to="loc_us-gaap_RoyaltyMember_1707590" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_208" xlink:to="loc_us-gaap_StatementLineItems_211" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1707493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_RevenuesAbstract_1707493" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1707493" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707495" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1707497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1707497" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1707498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1707498" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707502" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1707505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1707505" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1707507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1707507" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1707510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1707497" xlink:to="loc_us-gaap_OperatingExpenses_1707510" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_214" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_OperatingIncomeLoss_215" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_GainLossOnInvestments_216" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_217" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1707520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1707520" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1707516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_InterestExpense_1707516" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1707519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1707514" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1707519" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707522" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707524" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_NetIncomeLoss_218" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_oabi_DeemedDividend_219" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NetIncomeLossAttributableToOrdinaryShareholders" xlink:label="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_oabi_NetIncomeLossAttributableToOrdinaryShareholders_220" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareBasic_223" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareDiluted_224" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_254" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_254" xlink:to="loc_us-gaap_StatementTable_255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassAMember_260" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassBMember_261" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_257" xlink:to="loc_us-gaap_EquityComponentDomain_266" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_CommonStockMember_263" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_264" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_266" xlink:to="loc_us-gaap_RetainedEarningsMember_265" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_dei_LegalEntityAxis_1707083" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707083" xlink:to="loc_dei_EntityDomain_1707084" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707084" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707085" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementLineItems_258" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_258" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockholdersEquity_267" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_SharesIssued_268" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_269" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_270" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_271" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:label="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_272" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_273" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_274" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_275" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ReclassificationOfForwardPurchaseAgreement" xlink:label="loc_oabi_ReclassificationOfForwardPurchaseAgreement_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_ReclassificationOfForwardPurchaseAgreement_276" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_oabi_DeemedDividend_277" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_NetIncomeLoss_278" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_StockholdersEquity_279" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_259" xlink:to="loc_us-gaap_SharesIssued_280" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1707569" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1707569" xlink:to="loc_us-gaap_StatementTable_1707572" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707572" xlink:to="loc_us-gaap_StatementLineItems_1707573" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_StockholdersEquity_1707574" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_NetIncomeLoss_1707575" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1707576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_ShareBasedCompensation_1707576" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseInEquityContributionFromParent" xlink:label="loc_oabi_IncreaseInEquityContributionFromParent_1707577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_oabi_IncreaseInEquityContributionFromParent_1707577" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707573" xlink:to="loc_us-gaap_StockholdersEquity_1707578" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_318" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_318" xlink:to="loc_us-gaap_StatementTable_1707092" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707092" xlink:to="loc_dei_LegalEntityAxis_1707096" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707096" xlink:to="loc_dei_EntityDomain_1707097" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707097" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707098" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707092" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707093" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707093" xlink:to="loc_us-gaap_ClassOfStockDomain_1707094" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707092" xlink:to="loc_us-gaap_StatementLineItems_1707095" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_ProfitLoss_325" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnInvestments_326" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_327" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1707340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1707340" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1707377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1707377" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1707384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_ShareBasedCompensation_1707384" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707462" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_1707671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_1707671" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1707673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1707673" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1707473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_320" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1707473" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_328" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_329" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInDueToRelatedPartyCurrent" xlink:label="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent_330" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty" xlink:label="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty_331" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_332" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707491" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1707500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1707500" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1707517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1707517" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707526" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_1709830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_1709830" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1707551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_321" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1707551" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_319" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_PaymentsForInvestmentOfCashInTrustAccount_334" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1707560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1707560" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707561" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1707682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1707682" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired" xlink:label="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired_1707689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired_1707689" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1707695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1707695" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OtherInvestingActivities" xlink:label="loc_oabi_OtherInvestingActivities_1707702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_oabi_OtherInvestingActivities_1707702" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_335" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1707103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1707103" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_336" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_oabi_ProceedsFromIssuanceInitialPublicOfferingNet_337" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_338" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_339" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_340" use="optional" order="48" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_341" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RepaymentFromRelatedPartyDebt" xlink:label="loc_oabi_RepaymentFromRelatedPartyDebt_1707102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_oabi_RepaymentFromRelatedPartyDebt_1707102" use="optional" order="50" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707564" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1707582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1707582" use="optional" order="52" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707565" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_342" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_343" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_344" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707095" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_346" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities" xlink:label="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities_347" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WaiverOfUnderwritingCommissionByUnderwriters" xlink:label="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_WaiverOfUnderwritingCommissionByUnderwriters_348" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredUnderwritingFeePayable" xlink:label="loc_oabi_DeferredUnderwritingFeePayable_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredUnderwritingFeePayable_349" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty_350" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:label="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses_351" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsPaidInExchangesForIssuanceOfShares" xlink:label="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares_352" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:label="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707711" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1707600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_324" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1707600" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/OrganisationAndNatureOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1706973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_357" xlink:to="loc_us-gaap_StatementTable_1706973" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1706973" xlink:to="loc_dei_LegalEntityAxis_1706979" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1706979" xlink:to="loc_dei_EntityDomain_1706980" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1706980" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706982" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1706976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1706973" xlink:to="loc_us-gaap_StatementLineItems_1706976" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1706976" xlink:to="loc_us-gaap_NatureOfOperations_358" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707123" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock_1707124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707123" xlink:to="loc_us-gaap_ErrorCorrectionTextBlock_1707124" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_363" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_363" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" xlink:to="loc_dei_LegalEntityAxis_1707142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707142" xlink:to="loc_dei_EntityDomain_1707143" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707143" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707146" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707141" xlink:to="loc_us-gaap_StatementLineItems_1707144" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707144" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_364" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/Acquisitions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707622" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationAndAssetAcquisitionTextBlock" xlink:label="loc_oabi_BusinessCombinationAndAssetAcquisitionTextBlock_1707624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707622" xlink:to="loc_oabi_BusinessCombinationAndAssetAcquisitionTextBlock_1707624" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingAbstract" xlink:label="loc_oabi_InitialPublicOfferingAbstract_369" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_InitialPublicOfferingAbstract_369" xlink:to="loc_us-gaap_StatementTable_1707006" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707006" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707007" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707007" xlink:to="loc_us-gaap_ClassOfStockDomain_1707008" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707006" xlink:to="loc_dei_LegalEntityAxis_1707010" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707010" xlink:to="loc_dei_EntityDomain_1707011" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707011" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707013" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707006" xlink:to="loc_us-gaap_StatementLineItems_1707009" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingTextBlock" xlink:label="loc_oabi_InitialPublicOfferingTextBlock_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707009" xlink:to="loc_oabi_InitialPublicOfferingTextBlock_370" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementAbstract" xlink:label="loc_oabi_PrivatePlacementAbstract_375" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_PrivatePlacementAbstract_375" xlink:to="loc_us-gaap_StatementTable_1707019" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707019" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707020" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707020" xlink:to="loc_us-gaap_ClassOfStockDomain_1707021" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707019" xlink:to="loc_dei_LegalEntityAxis_1707023" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707023" xlink:to="loc_dei_EntityDomain_1707024" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707024" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707025" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707019" xlink:to="loc_us-gaap_StatementLineItems_1707022" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementTextBlock" xlink:label="loc_oabi_PrivatePlacementTextBlock_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707022" xlink:to="loc_oabi_PrivatePlacementTextBlock_376" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_381" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_381" xlink:to="loc_us-gaap_StatementTable_1707051" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707051" xlink:to="loc_dei_LegalEntityAxis_1707055" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707055" xlink:to="loc_dei_EntityDomain_1707056" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707056" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707057" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707051" xlink:to="loc_us-gaap_StatementLineItems_1707054" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707054" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_382" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1707313" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1707321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707313" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1707321" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentAndContingenciesLegalProceedings">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_387" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_387" xlink:to="loc_us-gaap_StatementTable_1707229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707229" xlink:to="loc_dei_LegalEntityAxis_1707230" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707230" xlink:to="loc_dei_EntityDomain_1707231" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707231" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707232" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707229" xlink:to="loc_us-gaap_StatementLineItems_1707233" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707233" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_388" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1707301" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1707303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707301" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1707303" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetails">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707328" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsDisclosureTextBlock" xlink:label="loc_oabi_BalanceSheetAccountDetailsDisclosureTextBlock_1707332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707328" xlink:to="loc_oabi_BalanceSheetAccountDetailsDisclosureTextBlock_1707332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_393" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1707086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_393" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1707086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1707086" xlink:to="loc_dei_LegalEntityAxis_1707088" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707088" xlink:to="loc_dei_EntityDomain_1707089" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707089" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707090" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1707087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1707086" xlink:to="loc_us-gaap_ClassOfStockLineItems_1707087" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1707087" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_394" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_399" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" xlink:to="loc_dei_LegalEntityAxis_1707034" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707034" xlink:to="loc_dei_EntityDomain_1707036" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707036" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707037" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707031" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707032" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_400" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_405" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1706970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_405" xlink:to="loc_us-gaap_SubsequentEventTable_1706970" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1706970" xlink:to="loc_dei_LegalEntityAxis_1706977" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1706977" xlink:to="loc_dei_EntityDomain_1706978" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1706978" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1706971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1706970" xlink:to="loc_us-gaap_SubsequentEventLineItems_1706971" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1706971" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_406" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_424" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" xlink:to="loc_dei_LegalEntityAxis_1707153" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707153" xlink:to="loc_dei_EntityDomain_1707154" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707154" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707155" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707152" xlink:to="loc_us-gaap_StatementLineItems_1707197" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock" xlink:label="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock_1707838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock_1707838" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_425" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock_1707570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_LiquidityAndCapitalResourcesPolicyTextBlock_1707570" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_oabi_EmergingGrowthCompanyPolicyTextBlock_1707843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_EmergingGrowthCompanyPolicyTextBlock_1707843" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_426" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_429" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock_1707515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_UnauditedInterimFinancialInformationPolicyTextBlock_1707515" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1707881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1707881" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_UseOfEstimates_428" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_435" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_430" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock" xlink:label="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock_431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:label="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_432" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_434" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_436" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_437" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1707592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1707592" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1707883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1707883" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock" xlink:label="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock_1707884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock_1707884" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1707885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1707885" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1707594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1707594" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenuePolicyTextBlock" xlink:label="loc_oabi_DeferredRevenuePolicyTextBlock_1710467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_DeferredRevenuePolicyTextBlock_1710467" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1707599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1707599" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1707886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1707886" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1709212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1709212" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_433" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock" xlink:label="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock_1707829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock_1707829" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1707823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707197" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1707823" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707127" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707127" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707134" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedBalanceSheetMember" xlink:label="loc_oabi_CombinedBalanceSheetMember_1707136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedBalanceSheetMember_1707136" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfOperationsMember" xlink:label="loc_oabi_CombinedStatementOfOperationsMember_1707147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfOperationsMember_1707147" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:label="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707149" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfCashFlowsMember" xlink:label="loc_oabi_CombinedStatementOfCashFlowsMember_1707150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707135" xlink:to="loc_oabi_CombinedStatementOfCashFlowsMember_1707150" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707128" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1707138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707137" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_1707138" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_444" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_444" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" xlink:to="loc_dei_LegalEntityAxis_1707187" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707187" xlink:to="loc_dei_EntityDomain_1707188" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707188" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707189" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707151" xlink:to="loc_us-gaap_StatementLineItems_1707200" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_445" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_446" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1707637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1707637" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1709214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707200" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1709214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707716" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707716" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707730" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707730" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_TaurusAcquisitionMember_1710391" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_XCellaAcquisitionMember_1710392" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_IcagenAcquisitionMember_1707732" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707731" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707733" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1707720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707718" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1707720" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1707729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707720" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1707729" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_453" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" xlink:to="loc_dei_LegalEntityAxis_1707044" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707044" xlink:to="loc_dei_EntityDomain_1707045" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707045" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707046" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707042" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_454" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_455" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1707395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707043" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1707395" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1707339" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1707341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707339" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1707341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1707344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707339" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1707344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1707347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707339" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1707347" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_1707351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707339" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_1707351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1707629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1707630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1707629" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1707630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1707308" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities" xlink:label="loc_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities_1707311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707308" xlink:to="loc_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities_1707311" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1707314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707308" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1707314" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsTables">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707334" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1707335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707334" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1707335" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1707336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707334" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1707336" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1707451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707334" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1707451" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/OrganisationAndNatureOfOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_543" xlink:to="loc_us-gaap_RelatedPartyDomain_544" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_544" xlink:to="loc_oabi_SponsorMember_565" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_StatementClassOfStockAxis_545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_545" xlink:to="loc_us-gaap_ClassOfStockDomain_546" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_us-gaap_CommonClassAMember_566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacCommonStockMember" xlink:label="loc_oabi_ApacCommonStockMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_oabi_ApacCommonStockMember_567" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutStockMember" xlink:label="loc_oabi_EarnoutStockMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_546" xlink:to="loc_oabi_EarnoutStockMember_568" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_547" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_IPOMember_569" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_PrivatePlacementMember_570" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_548" xlink:to="loc_us-gaap_OverAllotmentOptionMember_571" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_549" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_550" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_550" xlink:to="loc_us-gaap_WarrantMember_551" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_550" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_572" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_dei_LegalEntityAxis_552" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_552" xlink:to="loc_dei_EntityDomain_553" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabIncMember" xlink:label="loc_oabi_OmniabIncMember_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_OmniabIncMember_574" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LigandMember" xlink:label="loc_oabi_LigandMember_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_LigandMember_575" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706989" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1709270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_srt_OwnershipAxis_1709270" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1709271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1709270" xlink:to="loc_srt_OwnershipDomain_1709271" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1709272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1709271" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1709272" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_554" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorInsiderAgreementMember" xlink:label="loc_oabi_SponsorInsiderAgreementMember_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" xlink:to="loc_oabi_SponsorInsiderAgreementMember_576" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:label="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_555" xlink:to="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_577" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsAxis" xlink:label="loc_oabi_VestingRequirementsAxis_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_oabi_VestingRequirementsAxis_556" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestingRequirementsDomain" xlink:label="loc_oabi_VestingRequirementsDomain_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_VestingRequirementsAxis_556" xlink:to="loc_oabi_VestingRequirementsDomain_557" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FirstRequirementsMember" xlink:label="loc_oabi_FirstRequirementsMember_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_VestingRequirementsDomain_557" xlink:to="loc_oabi_FirstRequirementsMember_578" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SecondRequirementsMember" xlink:label="loc_oabi_SecondRequirementsMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_VestingRequirementsDomain_557" xlink:to="loc_oabi_SecondRequirementsMember_579" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_558" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_558" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_559" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyLoansMember" xlink:label="loc_oabi_RelatedPartyLoansMember_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_559" xlink:to="loc_oabi_RelatedPartyLoansMember_580" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_TypeOfArrangementAxis_560" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_560" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SeparationAndDistributionAgreementMember" xlink:label="loc_oabi_SeparationAndDistributionAgreementMember_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_561" xlink:to="loc_oabi_SeparationAndDistributionAgreementMember_581" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_562" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_562" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_563" xlink:to="loc_oabi_OmniabBusinessCombinationMember_582" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_542" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_583" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_584" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_585" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_586" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_587" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_588" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_589" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_590" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_591" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_SharePrice_592" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InvestmentsMaximumMaturityTerm" xlink:label="loc_oabi_InvestmentsMaximumMaturityTerm_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_InvestmentsMaximumMaturityTerm_593" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MonthsToCompleteInitialBusinessCombination" xlink:label="loc_oabi_MonthsToCompleteInitialBusinessCombination_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MonthsToCompleteInitialBusinessCombination_594" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_595" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_596" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_597" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares_598" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNetInterestToPayDissolutionExpenses" xlink:label="loc_oabi_MaximumNetInterestToPayDissolutionExpenses_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumNetInterestToPayDissolutionExpenses_599" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfCommonStockSharesIssuedUnderDistribution" xlink:label="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution_600" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_601" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CapitalContributedNetOfExpenses" xlink:label="loc_oabi_CapitalContributedNetOfExpenses_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_CapitalContributedNetOfExpenses_602" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalDeficit" xlink:label="loc_oabi_WorkingCapitalDeficit_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_WorkingCapitalDeficit_603" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice" xlink:label="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice_604" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAveragePriceTriggerPrice" xlink:label="loc_oabi_VolumeWeightedAveragePriceTriggerPrice_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_VolumeWeightedAveragePriceTriggerPrice_605" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest" xlink:label="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest_606" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToVestMeasurementPeriod" xlink:label="loc_oabi_SharesToVestMeasurementPeriod_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SharesToVestMeasurementPeriod_607" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_608" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesIssuedPerUnit" xlink:label="loc_oabi_NumberOfSharesIssuedPerUnit_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfSharesIssuedPerUnit_609" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_oabi_NumberOfWarrantsIssuedPerUnit_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfWarrantsIssuedPerUnit_610" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions" xlink:label="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions_611" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalNumberOfCommonStock" xlink:label="loc_oabi_AdditionalNumberOfCommonStock_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AdditionalNumberOfCommonStock_612" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_613" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregatePurchasePrice" xlink:label="loc_oabi_AdditionalAggregatePurchasePrice_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AdditionalAggregatePurchasePrice_614" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorPurchaseBackstop" xlink:label="loc_oabi_SponsorPurchaseBackstop_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SponsorPurchaseBackstop_615" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesBackstopWarrants" xlink:label="loc_oabi_SharesBackstopWarrants_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SharesBackstopWarrants_616" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_617" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings" xlink:label="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings_619" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_620" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_621" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination" xlink:label="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination_622" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1706995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1706995" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCosts" xlink:label="loc_oabi_TransactionCosts_1707000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_TransactionCosts_1707000" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockUnderwritingFees" xlink:label="loc_oabi_SaleOfStockUnderwritingFees_1707001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SaleOfStockUnderwritingFees_1707001" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_1707002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_1707002" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockOtherOfferingCosts" xlink:label="loc_oabi_SaleOfStockOtherOfferingCosts_1707003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_SaleOfStockOtherOfferingCosts_1707003" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_1707017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_1707017" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalSurplus" xlink:label="loc_oabi_WorkingCapitalSurplus_1707033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_WorkingCapitalSurplus_1707033" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_1707038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_1707038" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146632894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_564" xlink:to="loc_us-gaap_Cash_2146632894" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1710227" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1710233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1710227" xlink:to="loc_us-gaap_StatementTable_1710233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1710234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1710234" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1710235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1710234" xlink:to="loc_us-gaap_ClassOfStockDomain_1710235" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1710237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1710235" xlink:to="loc_us-gaap_CommonClassAMember_1710237" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1710238" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1710240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1710239" xlink:to="loc_us-gaap_IPOMember_1710240" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1710241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_dei_LegalEntityAxis_1710241" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1710242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1710241" xlink:to="loc_dei_EntityDomain_1710242" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1710243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1710242" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1710243" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1710244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1710244" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1710245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1710244" xlink:to="loc_us-gaap_EquityComponentDomain_1710245" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1710246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1710245" xlink:to="loc_us-gaap_CommonStockMember_1710246" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1710247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1710247" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710247" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1710249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710248" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1710249" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis_1710250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_GranteeStatusAxis_1710250" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1710251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_1710250" xlink:to="loc_us-gaap_GranteeStatusDomain_1710251" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember_1710252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_1710251" xlink:to="loc_oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember_1710252" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1710253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_1710251" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1710253" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1710254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_AwardTypeAxis_1710254" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1710254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1710256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1710256" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictedStockUnitsAndPhantomShareUnitsMember" xlink:label="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember_1710257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1710255" xlink:to="loc_oabi_RestrictedStockUnitsAndPhantomShareUnitsMember_1710257" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710233" xlink:to="loc_us-gaap_StatementLineItems_1710236" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1710258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1710258" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1710259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1710259" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1710260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1710260" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1710261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1710261" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_1710262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CashFDICInsuredAmount_1710262" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1710263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1710263" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1710264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1710264" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1710266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1710266" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Unitsissuedduringperiodsharesnewissues." xlink:label="loc_oabi_Unitsissuedduringperiodsharesnewissues._1710267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_oabi_Unitsissuedduringperiodsharesnewissues._1710267" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1710268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_Cash_1710268" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1710269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_Revenues_1710269" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1710270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_NetIncomeLoss_1710270" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1710271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1710271" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1710272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1710272" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_1710273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_1710273" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1710274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1710274" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1710275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1710275" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod" xlink:label="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod_1710276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod_1710276" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1710277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1710277" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1710278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710236" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1710278" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1707692" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1707696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1707692" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1707696" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1707696" xlink:to="loc_srt_ProductOrServiceAxis_1707700" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1707700" xlink:to="loc_srt_ProductsAndServicesDomain_1707701" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1707704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_RoyaltyMember_1707704" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1707705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_LicenseMember_1707705" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MilestoneMember" xlink:label="loc_oabi_MilestoneMember_1707708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_oabi_MilestoneMember_1707708" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707701" xlink:to="loc_us-gaap_ServiceMember_1707707" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1707696" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1707697" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1707698" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_1709216" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1709217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_1709216" xlink:to="loc_us-gaap_ConcentrationRiskTable_1709217" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1709220" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1709222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1709221" xlink:to="loc_us-gaap_SalesRevenueNetMember_1709222" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1709223" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1709225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1709224" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1709225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1709226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_srt_MajorCustomersAxis_1709226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1709227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1709226" xlink:to="loc_srt_NameOfMajorCustomerDomain_1709227" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerAMember" xlink:label="loc_oabi_PartnerAMember_1709228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerAMember_1709228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerBMember" xlink:label="loc_oabi_PartnerBMember_1709229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerBMember_1709229" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PartnerCMember" xlink:label="loc_oabi_PartnerCMember_1709230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1709227" xlink:to="loc_oabi_PartnerCMember_1709230" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1709218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1709217" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1709218" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1709219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1709218" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1709219" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_679" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_679" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" xlink:to="loc_dei_LegalEntityAxis_1707213" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707213" xlink:to="loc_dei_EntityDomain_1707214" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707214" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707212" xlink:to="loc_us-gaap_StatementLineItems_1707216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_680" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityProceedsAllocatedToWarrants" xlink:label="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_TemporaryEquityProceedsAllocatedToWarrants_681" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TemporaryEquityIssuanceCosts" xlink:label="loc_oabi_TemporaryEquityIssuanceCosts_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_TemporaryEquityIssuanceCosts_682" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_683" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707216" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_684" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_694" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_694" xlink:to="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" xlink:to="loc_dei_LegalEntityAxis_1707218" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707218" xlink:to="loc_dei_EntityDomain_1707219" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707219" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707220" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_SummaryOfSignificantAccountingPoliciesTable_1707217" xlink:to="loc_us-gaap_StatementLineItems_1707221" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransactionCosts" xlink:label="loc_oabi_TransactionCosts_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_TransactionCosts_695" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockUnderwritingFees" xlink:label="loc_oabi_SaleOfStockUnderwritingFees_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_SaleOfStockUnderwritingFees_696" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredOfferingCostsNoncurrent" xlink:label="loc_oabi_DeferredOfferingCostsNoncurrent_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_DeferredOfferingCostsNoncurrent_697" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockOtherOfferingCosts" xlink:label="loc_oabi_SaleOfStockOtherOfferingCosts_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_SaleOfStockOtherOfferingCosts_698" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsReductionOfTemporaryEquity" xlink:label="loc_oabi_OfferingCostsReductionOfTemporaryEquity_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_oabi_OfferingCostsReductionOfTemporaryEquity_699" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707221" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_700" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_710" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_710" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_712" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_713" xlink:to="loc_us-gaap_WarrantMember_715" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xlink:to="loc_dei_LegalEntityAxis_1707223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707223" xlink:to="loc_dei_EntityDomain_1707224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707224" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_711" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_716" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_734" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_734" xlink:to="loc_us-gaap_StatementTable_735" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_736" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_736" xlink:to="loc_us-gaap_ClassOfStockDomain_737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_737" xlink:to="loc_us-gaap_CommonClassAMember_742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_737" xlink:to="loc_us-gaap_CommonClassBMember_743" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_dei_LegalEntityAxis_1707226" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707226" xlink:to="loc_dei_EntityDomain_1707227" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707227" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707228" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_StatementLineItems_1710455" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710455" xlink:to="loc_us-gaap_EarningsPerShareAbstract_739" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_739" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_740" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_744" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_739" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_746" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_EarningsPerShareBasic_747" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_741" xlink:to="loc_us-gaap_EarningsPerShareDiluted_748" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707776" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707776" xlink:to="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707779" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707779" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_TaurusAcquisitionMember_1710393" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_XCellaAcquisitionMember_1710394" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_IcagenAcquisitionMember_1707781" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707780" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707782" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707784" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707785" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707786" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable_1707777" xlink:to="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1707787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1707787" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1707788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1707788" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1707789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1707789" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1707790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1707790" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1707791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_1707791" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1707792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1707792" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1707793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1707793" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_1710399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_1710399" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_1707795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_1707795" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1707796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1707796" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1707797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1707797" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_Goodwill_1707800" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1710396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1710396" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1707801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems_1707778" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1707801" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/AcquisitionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707810" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1707810" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheAxis" xlink:label="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ContingentConsiderationByTrancheDomain" xlink:label="loc_oabi_ContingentConsiderationByTrancheDomain_1707817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ContingentConsiderationByTrancheAxis_1707816" xlink:to="loc_oabi_ContingentConsiderationByTrancheDomain_1707817" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1707820" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutRightsMember" xlink:label="loc_oabi_EarnoutRightsMember_1707830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_1707822" xlink:to="loc_oabi_EarnoutRightsMember_1707830" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707825" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1707827" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1707848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707826" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1707848" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707844" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707844" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TaurusAcquisitionMember" xlink:label="loc_oabi_TaurusAcquisitionMember_1710426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_TaurusAcquisitionMember_1710426" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XCellaAcquisitionMember" xlink:label="loc_oabi_XCellaAcquisitionMember_1710427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_XCellaAcquisitionMember_1710427" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenAcquisitionMember" xlink:label="loc_oabi_IcagenAcquisitionMember_1707846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_IcagenAcquisitionMember_1707846" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AbInitioAcquisitionMember" xlink:label="loc_oabi_AbInitioAcquisitionMember_1707847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707845" xlink:to="loc_oabi_AbInitioAcquisitionMember_1707847" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1710432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1710432" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1710433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1710432" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1710433" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1710434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1710433" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1710434" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1707812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1707811" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1707812" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfAcquisitions" xlink:label="loc_oabi_NumberOfAcquisitions_1707831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_NumberOfAcquisitions_1707831" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_1707832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_1707832" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfPostClinicalAcquireeProductRevenues" xlink:label="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues_1707837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues_1707837" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1707840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1707840" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageShareOfFutureMilestonePayments" xlink:label="loc_oabi_PercentageShareOfFutureMilestonePayments_1707841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_PercentageShareOfFutureMilestonePayments_1707841" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1707850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1707850" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1707851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1707851" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1707852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1707852" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment_1707854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment_1707854" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1707855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1707855" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationCashFlowDiscountedRate" xlink:label="loc_oabi_BusinessCombinationCashFlowDiscountedRate_1707856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationCashFlowDiscountedRate_1707856" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims_1707858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims_1707858" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1710429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1710429" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationConsiderationTransferredEarnoutRights" xlink:label="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights_1710431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1707812" xlink:to="loc_oabi_BusinessCombinationConsiderationTransferredEarnoutRights_1710431" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707161" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707163" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedBalanceSheetMember" xlink:label="loc_oabi_CombinedBalanceSheetMember_1707165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707164" xlink:to="loc_oabi_CombinedBalanceSheetMember_1707165" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xlink:to="loc_srt_RestatementAxis_1707170" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1707170" xlink:to="loc_srt_RestatementDomain_1707171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707171" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707172" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707171" xlink:to="loc_srt_RestatementAdjustmentMember_1707173" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707162" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1707175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_AssetsAbstract_1707175" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707176" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1707177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_AssetsCurrent_1707177" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1707178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1707178" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_Goodwill_1707179" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1707180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1707175" xlink:to="loc_us-gaap_Assets_1707180" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1707181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_LiabilitiesAbstract_1707181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707182" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1707199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_AccountsPayableCurrent_1707199" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1707183" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1707184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_LiabilitiesCurrent_1707184" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1707185" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1707186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1707186" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1707190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1707181" xlink:to="loc_us-gaap_Liabilities_1707190" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1707191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707167" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1707191" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1707191" xlink:to="loc_us-gaap_StockholdersEquity_1707192" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1707193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1707191" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1707193" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707237" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707237" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_srt_RestatementAxis_1707239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1707239" xlink:to="loc_srt_RestatementDomain_1707240" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707240" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707241" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707240" xlink:to="loc_srt_RestatementAdjustmentMember_1707242" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1707252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_srt_ProductOrServiceAxis_1707252" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1707253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1707252" xlink:to="loc_srt_ProductsAndServicesDomain_1707253" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_LicenseAndMilestoneMember" xlink:label="loc_oabi_LicenseAndMilestoneMember_1707254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707253" xlink:to="loc_oabi_LicenseAndMilestoneMember_1707254" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1707255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1707253" xlink:to="loc_us-gaap_ServiceMember_1707255" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707521" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfOperationsMember" xlink:label="loc_oabi_CombinedStatementOfOperationsMember_1707527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707523" xlink:to="loc_oabi_CombinedStatementOfOperationsMember_1707527" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707238" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1707251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_Revenues_1707251" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1707244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1707244" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707245" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1707246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_OperatingExpenses_1707246" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1707247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_OperatingIncomeLoss_1707247" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1707248" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707249" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707243" xlink:to="loc_us-gaap_NetIncomeLoss_1707250" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707257" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707257" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xlink:to="loc_srt_RestatementAxis_1707259" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1707259" xlink:to="loc_srt_RestatementDomain_1707260" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707260" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707260" xlink:to="loc_srt_RestatementAdjustmentMember_1707262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707533" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember" xlink:label="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707534" xlink:to="loc_oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember_1707538" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707258" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_StockholdersEquity_1707264" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_NetIncomeLoss_1707265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707266" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1707267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707263" xlink:to="loc_us-gaap_StockholdersEquity_1707267" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707269" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707269" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xlink:to="loc_srt_RestatementAxis_1707271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1707271" xlink:to="loc_srt_RestatementDomain_1707272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1707273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707272" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1707273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707272" xlink:to="loc_srt_RestatementAdjustmentMember_1707274" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1707541" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CombinedStatementOfCashFlowsMember" xlink:label="loc_oabi_CombinedStatementOfCashFlowsMember_1707544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1707542" xlink:to="loc_oabi_CombinedStatementOfCashFlowsMember_1707544" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707270" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1707277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_NetIncomeLoss_1707277" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707280" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1707281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1707278" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1707281" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1707284" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1707285" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1707287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1707287" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1707288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1707283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1707288" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1707289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1707276" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1707289" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707275" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_1707359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_1707359" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1707360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1707360" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1707290" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredRevenueRecordedInAccountsReceivable" xlink:label="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1707361" xlink:to="loc_oabi_DeferredRevenueRecordedInAccountsReceivable_1707364" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707405" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1707405" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1707416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" xlink:to="loc_srt_RestatementAxis_1707416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1707417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1707416" xlink:to="loc_srt_RestatementDomain_1707417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_1707418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1707417" xlink:to="loc_srt_RestatementAdjustmentMember_1707418" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1707407" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1707421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1707421" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1707427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_1707409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1707427" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/InitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialPublicOfferingAbstract" xlink:label="loc_oabi_InitialPublicOfferingAbstract_768" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_InitialPublicOfferingAbstract_768" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" xlink:to="loc_us-gaap_IPOMember_775" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_771" xlink:to="loc_us-gaap_OverAllotmentOptionMember_776" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_772" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_772" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_773" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PublicWarrantsMember" xlink:label="loc_oabi_PublicWarrantsMember_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_773" xlink:to="loc_oabi_PublicWarrantsMember_777" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_dei_LegalEntityAxis_1707014" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707014" xlink:to="loc_dei_EntityDomain_1707015" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707015" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707016" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_769" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_778" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_779" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_780" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesIssuedPerUnit" xlink:label="loc_oabi_NumberOfSharesIssuedPerUnit_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_NumberOfSharesIssuedPerUnit_781" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_oabi_NumberOfWarrantsIssuedPerUnit_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_oabi_NumberOfWarrantsIssuedPerUnit_782" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_783" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_784" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementAbstract" xlink:label="loc_oabi_PrivatePlacementAbstract_802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_PrivatePlacementAbstract_802" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_804" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_804" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" xlink:to="loc_us-gaap_OverAllotmentOptionMember_809" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_805" xlink:to="loc_us-gaap_PrivatePlacementMember_810" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_806" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_807" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_807" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_811" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_dei_LegalEntityAxis_1707026" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707026" xlink:to="loc_dei_EntityDomain_1707027" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707027" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707029" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_803" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_812" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_813" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_814" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_815" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_808" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_816" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_842" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_845" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FounderSharesMember" xlink:label="loc_oabi_FounderSharesMember_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_845" xlink:to="loc_oabi_FounderSharesMember_851" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_846" xlink:to="loc_us-gaap_RelatedPartyDomain_847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_847" xlink:to="loc_oabi_SponsorMember_852" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_848" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_848" xlink:to="loc_us-gaap_ClassOfStockDomain_849" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_849" xlink:to="loc_us-gaap_CommonClassBMember_853" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_849" xlink:to="loc_us-gaap_CommonClassAMember_854" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_dei_LegalEntityAxis_1707099" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707099" xlink:to="loc_dei_EntityDomain_1707100" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707100" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707101" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_843" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_850" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_855" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_856" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TotalNumberOfSharesTransferred" xlink:label="loc_oabi_TotalNumberOfSharesTransferred_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TotalNumberOfSharesTransferred_857" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfSharesSubjectToForfeiture" xlink:label="loc_oabi_NumberOfSharesSubjectToForfeiture_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_NumberOfSharesSubjectToForfeiture_858" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_859" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_860" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_861" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_862" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_863" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_850" xlink:to="loc_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_864" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1707639" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1707639" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1707642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1707642" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707642" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707643" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707643" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707644" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707643" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707645" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1707640" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1707647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1707646" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1707647" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_889" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_889" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_891" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_891" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_892" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_oabi_PromissoryNoteWithRelatedPartyMember_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_PromissoryNoteWithRelatedPartyMember_896" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdministrativeSupportAgreementMember" xlink:label="loc_oabi_AdministrativeSupportAgreementMember_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_AdministrativeSupportAgreementMember_897" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyLoansMember" xlink:label="loc_oabi_RelatedPartyLoansMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_RelatedPartyLoansMember_898" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_us-gaap_ServiceMember_899" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_GeneralCorporateOverheadMember" xlink:label="loc_oabi_GeneralCorporateOverheadMember_1707382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_892" xlink:to="loc_oabi_GeneralCorporateOverheadMember_1707382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_893" xlink:to="loc_us-gaap_RelatedPartyDomain_894" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_894" xlink:to="loc_srt_DirectorMember_900" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_dei_LegalEntityAxis_1707205" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707205" xlink:to="loc_dei_EntityDomain_1707206" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707206" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707208" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1707436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_srt_RangeAxis_1707436" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1707436" xlink:to="loc_srt_RangeMember_1707437" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1707440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1707437" xlink:to="loc_srt_MaximumMember_1707440" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1707441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1707437" xlink:to="loc_srt_MinimumMember_1707441" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1707444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_PlanNameAxis_1707444" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1707445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1707444" xlink:to="loc_us-gaap_PlanNameDomain_1707445" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EquityBasedIncentivePlansMember" xlink:label="loc_oabi_EquityBasedIncentivePlansMember_1707449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1707445" xlink:to="loc_oabi_EquityBasedIncentivePlansMember_1707449" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EmployeeStockPurchasePlanMember" xlink:label="loc_oabi_EmployeeStockPurchasePlanMember_1707559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1707445" xlink:to="loc_oabi_EmployeeStockPurchasePlanMember_1707559" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1707506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1707506" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1707508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1707506" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1707508" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707508" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1707513" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1707508" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1707529" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_890" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_895" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_901" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty_902" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_903" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_904" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_905" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_906" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_oabi_MaximumLoansConvertibleIntoWarrants_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_MaximumLoansConvertibleIntoWarrants_907" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_908" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansOutstanding" xlink:label="loc_oabi_WorkingCapitalLoansOutstanding_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_WorkingCapitalLoansOutstanding_909" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_910" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2146633154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2146633154" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146633160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146633160" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2146633182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2146633182" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2146633187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2146633187" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod." xlink:label="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod._2146633189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod._2146633189" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146633193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_895" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146633193" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_924" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_924" xlink:to="loc_us-gaap_StatementTable_1707166" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707166" xlink:to="loc_dei_LegalEntityAxis_1707168" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707168" xlink:to="loc_dei_EntityDomain_1707169" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707169" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1707234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707166" xlink:to="loc_us-gaap_StatementLineItems_1707234" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities_925" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PurchasePricePerUnit" xlink:label="loc_oabi_PurchasePricePerUnit_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PurchasePricePerUnit_926" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredFeePerUnit" xlink:label="loc_oabi_DeferredFeePerUnit_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_DeferredFeePerUnit_927" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayable_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayable_928" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalDeferredFeePerUnit" xlink:label="loc_oabi_AdditionalDeferredFeePerUnit_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AdditionalDeferredFeePerUnit_929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregateDeferredUnderwritingFeePayable" xlink:label="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AdditionalAggregateDeferredUnderwritingFeePayable_930" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties_931" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableToThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties_932" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties" xlink:label="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties_933" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties" xlink:label="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties_934" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritingcashdiscountperunit" xlink:label="loc_oabi_Underwritingcashdiscountperunit_1707316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_Underwritingcashdiscountperunit_1707316" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_Underwritercashdiscount" xlink:label="loc_oabi_Underwritercashdiscount_1707326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1707234" xlink:to="loc_oabi_Underwritercashdiscount_1707326" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_970" xlink:to="loc_us-gaap_StatementTable_971" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_StatementClassOfStockAxis_972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_972" xlink:to="loc_us-gaap_ClassOfStockDomain_973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_973" xlink:to="loc_us-gaap_CommonClassAMember_981" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacCommonStockMember" xlink:label="loc_oabi_ApacCommonStockMember_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_973" xlink:to="loc_oabi_ApacCommonStockMember_982" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_974" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_975" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_975" xlink:to="loc_us-gaap_WarrantMember_983" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_975" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_984" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AmendedAndRestatedForwardPurchaseAgreementMember" xlink:label="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" xlink:to="loc_oabi_AmendedAndRestatedForwardPurchaseAgreementMember_985" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseAgreementMember" xlink:label="loc_oabi_ForwardPurchaseAgreementMember_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_977" xlink:to="loc_oabi_ForwardPurchaseAgreementMember_986" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_978" xlink:to="loc_us-gaap_RelatedPartyDomain_979" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_979" xlink:to="loc_oabi_SponsorMember_987" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_dei_LegalEntityAxis_1707194" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707194" xlink:to="loc_dei_EntityDomain_1707195" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707195" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707196" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_971" xlink:to="loc_us-gaap_StatementLineItems_980" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_SharesToBePurchasedPursuantToAgreements_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SharesToBePurchasedPursuantToAgreements_988" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantsToBePurchasedPursuantToAgreements" xlink:label="loc_oabi_WarrantsToBePurchasedPursuantToAgreements_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_WarrantsToBePurchasedPursuantToAgreements_989" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_990" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_991" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_992" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_993" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalNumberOfCommonStock" xlink:label="loc_oabi_AdditionalNumberOfCommonStock_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_AdditionalNumberOfCommonStock_994" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights_995" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AdditionalAggregatePurchasePrice" xlink:label="loc_oabi_AdditionalAggregatePurchasePrice_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_AdditionalAggregatePurchasePrice_996" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_997" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_BusinessExitCosts1_998" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeemedDividend" xlink:label="loc_oabi_DeemedDividend_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_DeemedDividend_999" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorPurchaseBackstop" xlink:label="loc_oabi_SponsorPurchaseBackstop_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SponsorPurchaseBackstop_1000" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharesBackstopWarrants" xlink:label="loc_oabi_SharesBackstopWarrants_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_oabi_SharesBackstopWarrants_1001" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_980" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1002" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707404" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707404" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1707419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707415" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1707419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1707450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707415" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1707450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1707453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707415" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1707453" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707404" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1707461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1707461" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1707463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1707463" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1707468" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1707458" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707470" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1707486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1707486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1707489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1707489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1707528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1707528" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1707532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1707532" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1707535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1707535" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1707536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1707536" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_1707540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_1707540" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1707567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1707567" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1707554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1707554" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1707555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1707484" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1707555" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1707589" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureTable" xlink:label="loc_oabi_IncomeTaxDisclosureTable_1707591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1707589" xlink:to="loc_oabi_IncomeTaxDisclosureTable_1707591" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1707614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureTable_1707591" xlink:to="loc_us-gaap_TaxPeriodAxis_1707614" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1707615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1707614" xlink:to="loc_us-gaap_TaxPeriodDomain_1707615" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtySevenMember" xlink:label="loc_oabi_TwoThousandThirtySevenMember_1707616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1707615" xlink:to="loc_oabi_TwoThousandThirtySevenMember_1707616" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TwoThousandThirtyTwoMember" xlink:label="loc_oabi_TwoThousandThirtyTwoMember_1707618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1707615" xlink:to="loc_oabi_TwoThousandThirtyTwoMember_1707618" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureTable_1707591" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1707619" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FederalResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_FederalResearchAndDevelopmentCreditMember_1707623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" xlink:to="loc_oabi_FederalResearchAndDevelopmentCreditMember_1707623" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CaliforniaResearchAndDevelopmentCreditMember" xlink:label="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember_1707625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1707620" xlink:to="loc_oabi_CaliforniaResearchAndDevelopmentCreditMember_1707625" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IncomeTaxDisclosureLineItems" xlink:label="loc_oabi_IncomeTaxDisclosureLineItems_1707604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureTable_1707591" xlink:to="loc_oabi_IncomeTaxDisclosureLineItems_1707604" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1710438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1710438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_1707595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_1707595" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1707596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1707596" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1707598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1707598" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1707612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1707612" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1707627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_IncomeTaxDisclosureLineItems_1707604" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1707627" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1707739" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1707739" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1707741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1707741" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1707742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1707742" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1707744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1707744" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_oabi_DeferredTaxAssetsDeferredRevenue_1707745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_oabi_DeferredTaxAssetsDeferredRevenue_1707745" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_oabi_DeferredTaxAssetsOperatingLeaseLiabilities_1707754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_oabi_DeferredTaxAssetsOperatingLeaseLiabilities_1707754" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1707758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1707758" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1707760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1707760" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1707762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1707740" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1707762" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1707739" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1707766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1707766" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:label="loc_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets_1707768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" xlink:to="loc_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets_1707768" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_1707783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_1707783" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1707772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1707772" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1707773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1707763" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1707773" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1707799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1707799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1707802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1707802" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1707803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1707803" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1707804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1707804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1707806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1707798" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1707806" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1707317" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OperatingLeaseAssetsAbstract" xlink:label="loc_oabi_OperatingLeaseAssetsAbstract_1707324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707317" xlink:to="loc_oabi_OperatingLeaseAssetsAbstract_1707324" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_OperatingLeaseAssetsAbstract_1707324" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_1707327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_OperatingLeaseAssetsAbstract_1707324" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_1707327" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1707327" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1707329" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1707327" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1707331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1707327" xlink:to="loc_us-gaap_OperatingLeaseLiability_1707331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1707350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1707447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1707447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1707432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1707432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1707420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1707420" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1707422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1707422" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1707423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1707423" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1707425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1707425" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1707368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1707368" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1707370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1707370" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_1710337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_1710337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance" xlink:label="loc_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance_1707376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance_1707376" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1707380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707350" xlink:to="loc_us-gaap_OperatingLeaseLiability_1707380" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1707391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1710345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1707391" xlink:to="loc_us-gaap_StatementTable_1710345" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1710349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710345" xlink:to="loc_srt_RangeAxis_1710349" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1710351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1710349" xlink:to="loc_srt_RangeMember_1710351" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1710352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1710351" xlink:to="loc_srt_MaximumMember_1710352" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1710345" xlink:to="loc_us-gaap_StatementLineItems_1710348" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1707465" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1707467" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1707471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1707471" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1707472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1707472" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1707479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeasePayments_1707479" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1707509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710348" xlink:to="loc_us-gaap_OperatingLeaseExpense_1707509" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707406" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillTable" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707406" xlink:to="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1707438" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1707442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1707442" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1707443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1707439" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1707443" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillTable_1707413" xlink:to="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1707429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1707428" xlink:to="loc_us-gaap_Goodwill_1707429" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1707431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1707431" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1707433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1707430" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1707433" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1707435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems_1707424" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1707435" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707362" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsTable" xlink:label="loc_oabi_BalanceSheetAccountDetailsTable_1707371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707362" xlink:to="loc_oabi_BalanceSheetAccountDetailsTable_1707371" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1707499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsTable_1707371" xlink:to="loc_srt_RangeAxis_1707499" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1707501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1707499" xlink:to="loc_srt_RangeMember_1707501" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1707504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1707501" xlink:to="loc_srt_MinimumMember_1707504" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1707503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1707501" xlink:to="loc_srt_MaximumMember_1707503" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsLineItems" xlink:label="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsTable_1707371" xlink:to="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1707375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1707375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1707378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_Depreciation_1707378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1707379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1707379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1707381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1707381" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1707383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsLineItems_1707374" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1707383" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707386" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707386" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1707396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_1707398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_OfficeEquipmentMember_1707398" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1707400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1707400" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1707401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1707397" xlink:to="loc_us-gaap_ComputerEquipmentMember_1707401" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1707387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1707390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1707390" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1707392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1707392" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1707394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1707389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1707394" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BalanceSheetAccountDetailsAbstract" xlink:label="loc_oabi_BalanceSheetAccountDetailsAbstract_1707464" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesTable_1707469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_BalanceSheetAccountDetailsAbstract_1707464" xlink:to="loc_oabi_ScheduleOfAccruedLiabilitiesTable_1707469" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesTable_1707469" xlink:to="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1707477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1707477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1707480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1707480" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1707483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1707483" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SubcontractorLiabilitiesCurrent" xlink:label="loc_oabi_SubcontractorLiabilitiesCurrent_1707485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_oabi_SubcontractorLiabilitiesCurrent_1707485" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AcquisitionsRelatedLiabilitiesCurrent" xlink:label="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent_1707492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_oabi_AcquisitionsRelatedLiabilitiesCurrent_1707492" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1707494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1707494" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1707496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oabi_ScheduleOfAccruedLiabilitiesLineItems_1707475" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1707496" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1707111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1010" xlink:to="loc_us-gaap_StatementTable_1707111" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707111" xlink:to="loc_dei_LegalEntityAxis_1707112" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707112" xlink:to="loc_dei_EntityDomain_1707113" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707113" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707114" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1707111" xlink:to="loc_us-gaap_StatementLineItems_1710456" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1011" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1012" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1013" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710456" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1014" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1031" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1031" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1032" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1032" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1033" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1033" xlink:to="loc_us-gaap_ClassOfStockDomain_1034" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_us-gaap_CommonClassAMember_1035" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonClassaSubjectToRedemptionMember" xlink:label="loc_oabi_CommonClassaSubjectToRedemptionMember_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_oabi_CommonClassaSubjectToRedemptionMember_1037" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1034" xlink:to="loc_us-gaap_CommonClassBMember_1038" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1032" xlink:to="loc_dei_LegalEntityAxis_1707117" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707117" xlink:to="loc_dei_EntityDomain_1707118" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707118" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707119" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1032" xlink:to="loc_us-gaap_ClassOfStockLineItems_1036" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1040" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockNumberOfVotesPerShare" xlink:label="loc_oabi_CommonStockNumberOfVotesPerShare_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_CommonStockNumberOfVotesPerShare_1041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesIssued_1042" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1043" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1044" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_1707121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_1707121" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfVotingRightsShareHolders" xlink:label="loc_oabi_PercentageOfVotingRightsShareHolders_1707125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1036" xlink:to="loc_oabi_PercentageOfVotingRightsShareHolders_1707125" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/ShareholdersEquityDeficitWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1092" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1092" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1093" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1094" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1095" xlink:to="loc_us-gaap_WarrantMember_1096" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PrivatePlacementWarrantsMember" xlink:label="loc_oabi_PrivatePlacementWarrantsMember_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_PrivatePlacementWarrantsMember_1106" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PublicWarrantsMember" xlink:label="loc_oabi_PublicWarrantsMember_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_PublicWarrantsMember_1107" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ForwardPurchaseWarrantsAndBackstopMember" xlink:label="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantMember_1096" xlink:to="loc_oabi_ForwardPurchaseWarrantsAndBackstopMember_1108" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_srt_StatementScenarioAxis_1097" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1097" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1098" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1098" xlink:to="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_1109" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1098" xlink:to="loc_oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_1110" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1099" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1100" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1101" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1102" xlink:to="loc_us-gaap_IPOMember_1112" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1103" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1103" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1104" xlink:to="loc_oabi_OmniabBusinessCombinationMember_1113" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_dei_LegalEntityAxis_1707104" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707104" xlink:to="loc_dei_EntityDomain_1707105" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707105" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707106" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePeriodConditionTwo" xlink:label="loc_oabi_WarrantExercisePeriodConditionTwo_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantExercisePeriodConditionTwo_1115" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1116" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_1117" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_1118" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MonthsToCompleteInitialBusinessCombination" xlink:label="loc_oabi_MonthsToCompleteInitialBusinessCombination_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_MonthsToCompleteInitialBusinessCombination_1119" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_oabi_WarrantRedemptionConditionMinimumSharePrice_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantRedemptionConditionMinimumSharePrice_1120" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_1121" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1122" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1123" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_1124" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RedemptionPeriod" xlink:label="loc_oabi_RedemptionPeriod_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_RedemptionPeriod_1125" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_1126" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_1127" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_1128" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantExercisePriceAdjustmentMultiple_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantExercisePriceAdjustmentMultiple_1129" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_WarrantRedemptionPriceAdjustmentMultiple_1131" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_1132" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_oabi_UnitsIssuedDuringPeriodSharesNewIssues_1133" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1134" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1135" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1105" xlink:to="loc_us-gaap_SharePrice_1136" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1155" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1155" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1157" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1165" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1158" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1166" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1160" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1167" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_dei_LegalEntityAxis_1707047" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707047" xlink:to="loc_dei_EntityDomain_1707048" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707048" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707049" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1156" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MaximumAdditionalAggregatePurchasePrice" xlink:label="loc_oabi_MaximumAdditionalAggregatePurchasePrice_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract_1162" xlink:to="loc_oabi_MaximumAdditionalAggregatePurchasePrice_1168" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1163" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1169" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1164" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1170" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1707761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1161" xlink:to="loc_us-gaap_AssetImpairmentCharges_1707761" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1190" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_dei_LegalEntityAxis_1707077" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707077" xlink:to="loc_dei_EntityDomain_1707078" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707078" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707079" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1192" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1193" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1197" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1194" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputFairValueOfUnitMember" xlink:label="loc_oabi_MeasurementInputFairValueOfUnitMember_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputFairValueOfUnitMember_1198" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputCommodityForwardPriceMember" xlink:label="loc_us-gaap_MeasurementInputCommodityForwardPriceMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputCommodityForwardPriceMember_1199" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1200" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1201" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1202" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputExpectedRedemptionRateMember" xlink:label="loc_oabi_MeasurementInputExpectedRedemptionRateMember_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputExpectedRedemptionRateMember_1203" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember" xlink:label="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1195" xlink:to="loc_oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember_1204" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1191" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_1205" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1196" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent_1206" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1221" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1221" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1223" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1224" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1227" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1707080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_dei_LegalEntityAxis_1707080" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1707081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1707080" xlink:to="loc_dei_EntityDomain_1707081" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1707081" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1707082" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1707678" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_BusinessCombinationContingentConsiderationLiabilityMember" xlink:label="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember_1707681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1707679" xlink:to="loc_oabi_BusinessCombinationContingentConsiderationLiabilityMember_1707681" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707684" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707684" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707685" xlink:to="loc_oabi_IcagenMember_1707687" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1707691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1707691" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707691" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707693" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1707694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1707693" xlink:to="loc_oabi_XcellaMember_1707694" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1222" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1225" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1228" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_InitialMeasurementOfForwardPurchase" xlink:label="loc_oabi_InitialMeasurementOfForwardPurchase_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_InitialMeasurementOfForwardPurchase_1229" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1230" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss" xlink:label="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss_1232" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1707626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1707626" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition_1707631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition_1707631" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition" xlink:label="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition_1707641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition_1707641" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1231" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1707710" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1707710" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1707724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1707724" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1707726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1707724" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1707726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1707727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1707726" xlink:to="loc_oabi_XcellaMember_1707727" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1707712" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1707717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1707717" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1707714" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_1707719" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1707457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1707457" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1707511" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1707518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1707512" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1707518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707530" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707530" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CrystalMember" xlink:label="loc_oabi_CrystalMember_1707537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_CrystalMember_1707537" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_IcagenMember_1707543" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1709247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707531" xlink:to="loc_oabi_XcellaMember_1709247" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1707548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1707553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1707553" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1707556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1707556" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1707558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707550" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1707558" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707459" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707460" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1707478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1707478" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1707488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1707466" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1707488" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1707579" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1707579" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707583" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707583" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CrystalMember" xlink:label="loc_oabi_CrystalMember_1707585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_CrystalMember_1707585" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_IcagenMember" xlink:label="loc_oabi_IcagenMember_1707586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_IcagenMember_1707586" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_XcellaMember" xlink:label="loc_oabi_XcellaMember_1709248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1707584" xlink:to="loc_oabi_XcellaMember_1709248" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1707580" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1707581" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1707587" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://om.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1245" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1245" xlink:to="loc_us-gaap_SubsequentEventTable_1246" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1247" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1247" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1248" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1248" xlink:to="loc_us-gaap_SubsequentEventMember_1250" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1706992" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_WorkingCapitalLoansWarrantMember" xlink:label="loc_oabi_WorkingCapitalLoansWarrantMember_1706994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1706993" xlink:to="loc_oabi_WorkingCapitalLoansWarrantMember_1706994" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1706984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_dei_LegalEntityAxis_1706984" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1706985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1706984" xlink:to="loc_dei_EntityDomain_1706985" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_AvistaPublicAcquisitionCorp.IiMember" xlink:label="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1706985" xlink:to="loc_oabi_AvistaPublicAcquisitionCorp.IiMember_1706986" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1706997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1706996" xlink:to="loc_us-gaap_RelatedPartyDomain_1706997" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorMember" xlink:label="loc_oabi_SponsorMember_1706998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1706997" xlink:to="loc_oabi_SponsorMember_1706998" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1707669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1707669" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1707670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1707669" xlink:to="loc_us-gaap_ClassOfStockDomain_1707670" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NewOmniabCommonStockMember" xlink:label="loc_oabi_NewOmniabCommonStockMember_1707672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1707670" xlink:to="loc_oabi_NewOmniabCommonStockMember_1707672" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_EarnoutSharesMember" xlink:label="loc_oabi_EarnoutSharesMember_1707675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1707670" xlink:to="loc_oabi_EarnoutSharesMember_1707675" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1707734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_srt_OwnershipAxis_1707734" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1707735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1707734" xlink:to="loc_srt_OwnershipDomain_1707735" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ApacsExistingPublicShareholdersMember" xlink:label="loc_oabi_ApacsExistingPublicShareholdersMember_1707736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_ApacsExistingPublicShareholdersMember_1707736" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SponsorOfApacMember" xlink:label="loc_oabi_SponsorOfApacMember_1707737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_SponsorOfApacMember_1707737" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_RelatedPartiesOfApacMember" xlink:label="loc_oabi_RelatedPartiesOfApacMember_1707738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1707735" xlink:to="loc_oabi_RelatedPartiesOfApacMember_1707738" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1710457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1710457" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1710457" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_OmniabBusinessCombinationMember" xlink:label="loc_oabi_OmniabBusinessCombinationMember_1710460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1710458" xlink:to="loc_oabi_OmniabBusinessCombinationMember_1710460" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1246" xlink:to="loc_us-gaap_SubsequentEventLineItems_1249" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_1251" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_SaleOfStockCashPricePerShare" xlink:label="loc_oabi_SaleOfStockCashPricePerShare_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_SaleOfStockCashPricePerShare_1252" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_1253" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1254" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_1707004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_1707004" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_1706999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_1706999" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1706990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1706990" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1707649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1707649" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_CommonStockSubjectToPriceBasedEarnoutTriggers" xlink:label="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers_1707662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers_1707662" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1707683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_Cash_1707683" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice_1707699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_NumberOfTradingDaysForDeterminingTheSharePrice_1707699" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1707703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1707703" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_VolumeWeightedAverageTradingPrices" xlink:label="loc_oabi_VolumeWeightedAverageTradingPrices_1707709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_VolumeWeightedAverageTradingPrices_1707709" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="oabi-20220930.xsd#oabi_ExcessPricePerShare" xlink:label="loc_oabi_ExcessPricePerShare_1707713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_oabi_ExcessPricePerShare_1707713" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1707690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1249" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1707690" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g305908g02y03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g02y03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1I*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BZ^9P(X0DE-! 0      !H< 5H  QLE1QP"   "   < @4 !F<P,70X
M-SA"24T$)0      $!)5YMZM@%P=\4:MU;C'0@<X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q :1C,P         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4
MS,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"24T#
M\@      "@  ________   X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!$0      !     "   "0    D      .$))
M300>       $     #A"24T$&@     #:0    8              F0   3R
M    &@!T &T ,@ R #$ ,@ Q #$ - !D #$ +0!B &, 7P!P '( ;P!G '(
M80!M #0 8P!L '(    !                          $
M!/(   )D                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   )D     %)G:'1L;VYG   $\@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "9     !29VAT
M;&]N9P  !/(    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     <X0DE-! P     #U8    !    GP   $T   '@  "08   #SH
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MR,.B^P6E[V6 !H=6XM.T'>6Z?O\ YZA^SL?@6VAL$;180!/_ )%)37^RZ_\
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MN, "MI.@+S^;^:QCG+-;3TIH<[[37L:-Y_0U$@'2-SJW>U;=WNK<UH!?'LW
M[=P^@3I^\J31U0P'UXY#1H3))(D?V=VUKDE--N/TVL/99=6',]@+\>O0@MU'
MZ/W_ $7U_33.Q^D-.E];1L:T@TL/ #O4^AX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  #_X<\3:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 Y+C M8S P," W.2XQ-S%C,C=F+" R,#(R+S X+S$V
M+3$X.C R.C0S(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52
M968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @
M("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU
M<W1R871O<B\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$
M:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O
M(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S Q
M=#@W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SIT:71L93X*(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @
M(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N
M9STB>"UR97!A:7(B/D9I;&4@3F%M93H@(" @(" @(" @(" @("!G,#%T.#<N
M86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R,#8P,S0F(WA!.TQO
M8V%L(%1I;64Z(" @(" @(" @(" @(# Q+49E8BTR,#(R(# Q.C,X.C0V)B-X
M03M%4U0@5&EM93H@(" @(" @(" @(" @(# S+4UA<F-H+3(P,C(@,38Z,#@Z
M-#8F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XS)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @0V%L:6)R:28C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O
M;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<P,70X-RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,#$M1F5B+3(P,C(@,#DZ-#DZ,#4F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,#$M1F5B+3(P,C(@,3(Z-#DZ,#4F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,C4N-"XT)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R
M="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L
M:6)R:28C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,BTQ,2TR-%0Q-3HT.#HU
M,BLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I
M9GE$871E/C(P,C(M,3$M,C14,34Z-#@Z-3(K,#4Z,S \+WAM<#I-;V1I9GE$
M871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTP,BTP,50P.3HT
M.3HQ,2TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@,C4N-" H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HS-C0U,C U-BUD-S8V+3@S-&$M8C8V,BUA.3,P9F0S.&5E.# \+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D
M;V)E.F1O8VED.G!H;W1O<VAO<#HQ9F(Q-C8R-BTT8S!B+6,T-#$M.#0P."UB
M8F,Y83$R9F5F8C$\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z,C)B8F4T,#,M-C=D8RTT,C S+6(P,C(M.60X,69D
M,F)E9C@P/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.C<Y-V8T-V1B+3-A9CDM.&8T8BUA9F)B+6$T
M,F4T8V$V,69A-SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E
M9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D%!,S$Y0S@R1#$X,D5#,3$Y-C(W0D-$13DT,C5%
M.#%"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 R+3 Q5# Q.C,X.C Y*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HW.3=F-#=D8BTS868Y+3AF-&(M869B8BUA-#)E-&-A-C%F83<\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C(M,#(M,#%4,#DZ-#DZ,3$M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R(#(U+C0@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO<&]S='-C<FEP="!T;R!I;6%G92]J<&5G/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR,F)B
M930P,RTV-V1C+30R,#,M8C R,BTY9#@Q9F0R8F5F.# \+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#0M
M,394,#(Z,C$Z,S(M,#4Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXU
M("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C=D.6%F,# S+38U-&8M-#<T-"TX-C-F
M+3@W8V%A-C$U-S9A,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,BTP-"TQ-E0P,CHR,3HS,BTP-3HP,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C4@*$UA8VEN=&]S:"D\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C,V-#4R,#4V+60W-C8M.#,T82UB-C8R+6$Y,S!F9#,X
M964X,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,BTQ,2TR-%0Q-3HT.#HU,BLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(T+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#
M<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z
M0W)E871O<E-U8E1O;VP^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @
M(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%10
M9SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-
M87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=$1I;3IW/C(Q,"XP,#$V-38\+W-T1&EM.G<^"B @(" @(" @(" @
M(#QS=$1I;3IH/C(Y-BXY.3DY-#(\+W-T1&EM.F@^"B @(" @(" @(" @(#QS
M=$1I;3IU;FET/DUI;&QI;65T97)S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^0V%L:6)R:3PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT
M.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C
M93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M-BXR,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FDN='1F
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@4F5D
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@665L;&]W/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#35E+($=R965N/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D--64L@0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!";'5E
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@36%G96YT83PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STQ-2!-/3$P,"!9/3DP($L],3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$U+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP(%D].#4@2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TX,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XX,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T]-3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],S4@63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S4N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-2!-/3 @63TY,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR,"!-/3 @
M63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXR
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3 @63TQ
M,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TQ,# @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P($L]
M,3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C$P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].3 @33TS,"!9/3DU($L]
M,S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/CDP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C,P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,S N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TW-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,].# @33TQ,"!9/30U($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.# N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXT-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-S @33TQ-2!9/3 @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3@U($T]-3 @63TP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STQ,# @33TY-2!9/34@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STQ,# @33TQ,# @63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STW-2!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STU,"!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STS-2!-/3$P,"!9/3,U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C,U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],3 @33TQ,# @63TU,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C$P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T].34@63TR,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXR,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,C4@33TR-2!9/30P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,C4N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXT
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @
M33TT-2!9/34P($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^-# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-#4N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXU,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXU+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TU
M,"!9/38P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU-2!-/38P
M(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-34N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXT,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]-# @
M63TV-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C(U
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C0P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C4N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,P($T]-3 @63TW
M-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],S4@33TV,"!9/3@P
M($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C8P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/38U(%D].3 @
M2STS-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-# N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-C4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXS-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-S @63TQ,# @
M2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-# N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3<P(%D].# @
M2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXW,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STY,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXX.2XY
M.3DT,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3@P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<Y+CDY.#@P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-S \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-CDN.3DY-S P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STV,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXU.2XY.3DQ,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TP(%D],"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,SDN.3DY-# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STS
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR
M.2XY.3@X,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3(P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$Y+CDY.3<P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^.2XY.3DQ,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TP(%D],"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^-"XY.3@X,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#
M;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D)R:6=H=',\+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3$P,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T]-S4@63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],3 @63TY-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@
M33TQ,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @
M33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP
M(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C8P
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,#,Q,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,S$P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(" @(#QT:69F.DEM86=E5VED=&@^-C V/"]T
M:69F.DEM86=E5VED=&@^"B @(" @(" @(#QT:69F.DEM86=E3&5N9W1H/C(Y
M,SPO=&EF9CI);6%G94QE;F=T:#X*(" @(" @(" @/'1I9F8Z0FET<U!E<E-A
M;7!L93X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^.#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/C@\+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3XX/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]T:69F.D)I='-097)386UP
M;&4^"B @(" @(" @(#QT:69F.E!H;W1O;65T<FEC26YT97)P<F5T871I;VX^
M,CPO=&EF9CI0:&]T;VUE=')I8TEN=&5R<')E=&%T:6]N/@H@(" @(" @(" \
M=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(" @(" @
M(" \=&EF9CI386UP;&5S4&5R4&EX96P^,SPO=&EF9CI386UP;&5S4&5R4&EX
M96P^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C(P,#<W-3 O,3 P,# \
M+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N
M/C(P,#<W-3 O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT
M:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @
M(" @(" @(#QE>&EF.D5X:69697)S:6]N/C R,S$\+V5X:68Z17AI9E9E<G-I
M;VX^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L
M;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C$R-C8\
M+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$
M:6UE;G-I;VX^-C$R/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" $E ET# 1$  A$! Q$!_\0 '@ !  $%  ,!
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MY;<@7<//)/T.82SWC2W.^T413O2X:]Q'729B)C"7!]L 00Q((<  8#TOB>4
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MQ$'J*ZV:FENPURG8-I.?B+.EDU+M<+1[9^N+!NV;'.FY:.E4W2J)#B=$ 4*
MA0@ @$.QR&QB*-N.%<R%!J<&?B]%27&(S!]#KQU6V7Y18=LES9VD;--Y.#HJ
MZT=6C63!JH,A#&B7-RO+8$ATPB'31TW,N\60[F.NHB)C&4SD8XQI7:[U%7QI
MLY0N0 <ELW&50 QZ7\.U?-U/T?O64N+:)A4] YR;O#5B_M.W^F^J20PPQT:A
M!-;>%_(.YD[XLI;1+>5CW[PHE0(,F8_1-^D54.49?!HJ !P7SQIGUJ RC$FC
M;"V8 K7-Z[&HY"N"&T*NP=6KHC-16.J1Y*2VADM4K4NZTX:T7D ^@4$8T85=
MW>3MN>X(%O$(M745*V^HY0R@L8D<V617,8T4:C&C$G':S-M-"'#[*J79G#[P
M*D@;B,<#Z,=I-ES2;RAM=3K@G++;V]>-U:N:BRRDJJBBK+2ENR$\=Q"G%^!E
M%^]IFP%,S9]("2) #"1!'(P2[5< !N5@XZ<\^A!YSXZ>!:BWQH[J%*&UFT_)
MI--O]5;\VAV^HE@:VD3CAAX"RRSD%)1<P:Z1=A(Q"UJP\?(07E:33!PH=R!&
MB"S5TH<.1BP8TXK$;\",L=HR.+T7'BN7(#@FHV;>9@&+X5VC<39ZTS<V/?.T
M9/O[-:6^M=^J[J4A95%FS1<3UOGAHOF.05;@"IVYI(KU0J:H@8%U%CB7)Q,/
M$FD(SKQMCU;/P\RY#$[*-0#*OA\-<25I[=^A>U!>25^Z[1CFV(:X!UEAM7;1
MTRD[-47OU:*TL7+!6O;_ )<4KC38,W$W:C>3%)J,*NF129Z!54QEECEY CW)
M.3$O1W?GJU:.V"XUQ PB):(5(?(Y BN-'Q=P<H:8VG)PVJE^IZAZ!S]W7)J#
MJJ[ONUM4'D= OH^W+*FH%-.(:24L]>%>13JR4E%[<<PC=$[A07!E623AN90X
M0?<N"&&(S>M0*OEGG38N09SDXH<CX:%WP'+BZQ1I%H%/Q]E[.MKO-&%[=N?2
MW5^Y(;4>55BHI!.0M27:70899A*M%#C-6Z]8RK-F<X")@4YJ)T@Y@#4O[6)S
M4@,').(=\G8;Z"F(3$BAH]:;.GQ;\%\8=G':(N&RM4[(7CI%@MHM8LSI!H=*
M/'S([C4.W9>ZV5QR%P1CE50Z#!U*V,U;6 HWE0*B"R E7.5!18P0< 7J:D U
M!;TN:;=U(%7!%!0':,FIDPKBX>KNML=EO3Y"'NV\;V1C-4X!:8M:U+;D8>]+
M>M.TH(CJ *L"01T/;+9J5]*1R*G>]><.FHW=-")$;KJE !J"2P=CB:$G';O_
M )EG4L.,2V[#PCIKT"@6[M0I2B)1$HB41*(E$2B)1$HB]&3DX^&CG\O+/6L;
M&1C-S(2,@]63;M&3)FB=PZ=NEU3$31;MT$SJK*J&*0B93&,(  C1%K8EM@Z(
M.HBX)MG,SR\? 0OEC[H7LZZ8I">M\'K9@>9M5Y-14<RN2-37>-N>\BG+A$$E
MB+ 84C :I((RW48UZ>6F;=, @@D9;CR^!9RMR]H:Z)"X8V,3E"+VRZCFD@H_
MAY&.9KJ2D6VEVAXIZ\02:RS?N1VB"SA@JX11<=(V4,55,Q:X]?#YZL<%/7P/
MU=E^UQW?%6PO;C>13DUCW1/-[<C1C(F1E4TY%TV=.DE)%6/;N$XN/!)FL561
M?F09I*BDF=4IE2 ,]?3UR17,!R\!,4![,@'7NW#OWT16/J%J+;FF=O(7-<JK
M@L8XN.U+73,R0%TKWTO*Y(RUH<HID'((C*2S4JZG!)'I%! >;B@8YBO7KX47
MR]2]8+&TD;6^XO5](MCW3->5^WF,1 3=QRDO+ P=R9FC.+@&$B^4,DQ8NG*I
MQ1!)-)$PF. X"@K@WBV;>I<,H);KZ%]RP]0;/U-MEE>%D3K.?MY^=RB@_:]*
MF*;IDN=J^9/&S@B+IB_8NTE6SUB\11=-ETSI+)$,40&2""Q0%ZC!7CSR9QSR
MY$,@'.#(APSC.<9W9J%*<XN<<XN>S(9]3-$03D !$3%  XB)@  \8YW>G1%7
MG% ,B(8XYR&,<<Y\6^B*G.+G'.+G&<9#..&>/#.ZB(!R#G!BC@<#@P#@>P<#
MN&B)SBY$.<7(  B&0R #P$0SG X''BHBKSBYQS@SQQD,X[:(K%N346VK5NFQ
M;/EEG1)G41]+QUMD0:J+MU7,)%*3+XKMR3W&U &21S)"I^&G\R7?Q;=W7T*'
MJW+X&].Y7W12E$2B*%YY+!^+;8C_ &J:[?7;2JH)ZL3XE_3(PBY1XE)+Y*_\
M;:V%O#LKZ)_8%"!]JD. Y!XE^$?NXOWHO&5OQ4KBE$2B)1$HB41,!Z_7ZG9U
M41*(K$F-3M.;?N-I:$[?-J0]TODFZ[.WI.=CF4LX1>*JHM%4F+APFX,1TJ@L
MDV'F87.FH1+GF 0J6)P!/,HH6KOY1Z%?.2CU@.0W<-^=VX?N#]JH4KQ4622*
M8ZJA$B%^".H8I"%R(%#)C"!0R80 ,CO$<!OHB\N<4=V<]>X1\>=WKW=H415R
M';QHB9#M#MXT14$ $<9WYSN'?PZ^O']0#P"B*N [/#]+%$5:(J8\(^K]SCZ>
M:(JT1*(E$2B)1$HB41*(E$2B)1$HB41*=>O7S(J &/7Z_7NX &",RMNZKPM2
MQHL9R\;CAK7B!<MV??*=D6L8R%VZ,)&S4B[M1),SAP8#%21*85%! W,*.!P1
M>]!ST'<L8UF[=EXV<B'R?2,Y2)>MW[!TGD?-(.FJBB"@ ("4W-.(E, E-@Q1
M &;9]>I_%%];(;ASQX>OZOT^%$3(=H>KVY_IW414R&>._P"[_5ZOC"B*N0[0
M]7UY#Z7J414R7M#?X>SZGBZ]_:-.M<T0  =X>/\ IQU;P[ WA1%4  /7Z_7C
ML"B*M$2B)1$HB41*(E$2B)1$HB41*(M<]K2T[HO;9ZU-MVSFKB1G'<$5<D.T
M$0=3[".?-)&7MUL&0!1Q/131Y$HH&$".%'8(G$"G&I&(JW,[*#A0/SMX5K9J
M]K5IYJQLX7M9>G4?<SRX4-.F2R\ %E7$P6M8&,A"-%K=EC.8U%",FD%,)IPP
MJ=.LFS651*=)(#C(!!%,Z5Q&T,7;EYZ*.,"(FP8AZBI&\5Q\RQ;=#"^KAU!O
MFV5W^H[&VY/:?V?HPPPLE/Q(I6>YT3B37"TCWC!1$[.$<215$Y86BB2'=1U!
M4,5QYH(#/780,VWT8$[">7 *3[FC/QA49U WD4!!QH6. 7L$C;^LN\8^QK4<
MWZ%K6OMN0S.VD'\A/2:2-HR^D%PS#YBXDGZSA=W:25S.2=&D[<+,6ZPD2#!B
ME H@')O:N<,<'KMIZ"@9L7]L:,0U10YXN^[<O0T[N:VX72R\;BN6*U>O+:<9
M6=?@ZKVB6:U&C^:\4N!!L]*MW(KWKB8YJ@HU=6NYA2=UE@DGQX(BGN4AI-:
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M9A&WG+8K*'[ZK&&+C3NA$J;<$A76$RPGGC&I A?VH%!E@1B>4X\U5#8,^))
M+"HJ3T99L*X+%<JM.%F+B07?ZE(;6+':58,[1B6SZ[4XDNDK>]V",4NQCRJC
M:RNG"NF!7!YITNF=!64!R=X;OH!#BQ9B&$))+@U()9RY=ZC"E(<U(S)S-,F8
M4I@2P?\ _P"A3YNFLHYN?7PD[<EUS,.M%:SZYMH2>D934@I-1S M.,[0L&/3
M79H:?N$8=FW4<1Z$=).3#WN*1DW%=5<H&+&@PAV/O)SK1MQ.%%%'P-(GK@6P
M:F3/@06SJ5<UFQ"-B;*^CEPW=$7W<L_JS=-OMM2;COJ]=046%J@D-QJ-).[$
MXMVI)-;>:E33AVL8DW19.'CR-)(GP!#A.,30LP=F P <L#BU:="5:KN7?:Y>
MI8CQTI6CKT-*8&[M0K?V=[1NY_J8K:+G5?:282C=*6O."!_9<9<$D6R&,L[6
M=-YT8%)B5J$(E).>E.U30(!C)AS1./;&CD0D. ^%<1OK3-1D -L7RFH2!M(#
MUQ SJOUTSM*ZK65V>KI:S.JXSDEKIK#IG=,C-3]TS1D]+8F%O\MMM9"-D'*S
M(&D<:#@EHI\=J5PL[*54%U5G(@>#NH&AHU0X?%GSJY\ZD85#$X[R.3D=A3'G
MSSL4NU8^<U#LP'3^^V\)$VR\4UG!_=QFE[O7SJ:!>.GX>YU56\3?<05(@SI8
MDYT547+05@1YJ:)41?F)#/@VQLJ_B<@Z7J2 V;5?.CD#QK ZMUSLMM'6&^MF
M#NFT)<FOVHUKWO"#,Z@2\V[LIC;=QE9R]UI2"IK9B[7N!^VCY6TV30AT"HG;
MF8*@<%R -  :N'! ## XU+Y&HY*,G[3UQ8BN0Z ,Q0XXK]=/K9ONUX_9GU!A
M7VI[O4*^;TU5MN]59^=N64:NH4\!>DA;[&6B)-RK&1[%C+14&6'5%JW!'(E(
M<PN#\Y$0#%@V(8#<3AAGM\*0U%7S<$95Q=S0;^5PK:T&:QTEJ?L>2JGL5)/5
MIF.HQM>E;G&\'D5"W@XM643>(SY9@3P\3+J28*I0B,>5$JL0"8) +?H*DCW5
M&J#1L*XMS4\%25$+!F8T().)P.8<\N0S7:6N"YI1$HBA>>2P<^7;8CQCXE-=
MN(9_);2KPA7"(@,X!\W@/4+^F1A%RCQ*29R6/XVUL+;L>^KZ)[@_:%"^L?#7
M(8"KTQV[U^$?NXOWHO&5OO4KBE$2B)1$HB41*(E$7*;6G3"^-9=HO:7TVL^V
M]/'[*[-'M"X:X;NO=V]"1L9-Q(ZAJH2EK1+2(=A*R*"1%'K8#RD."+]%J<5S
ME 0+R!9BY%36''+:6KAA@SXA<37C!@7I4[11Z'#+J_IWYK9<UGZJVQ&V-J!J
M([:6WM!Z5Z%7)#W1)6<2TY)O+1D8QN!I&6SW":\'IA;K)RQ+B<.4P+(J+&2<
M+M  E  02=A(Q<5Z&Z5)HV^CT#4W;=S>!6C?B&H^HFR_K?J7>.N.H)FS;4:X
MK>CK>BD[?B(*W;>M?51!@R5$Z<*9^NZ;-$OP3)+O *= B93I@5,QSR&$0P&!
M)VO#@7<,7V*#@7.9:M!7&F;9EV-:+,&H,CJ@_N^^K6M?7Z]H.W=-=FBW]0XB
M1AFUJ/G]SW.1>XE0F)B5<0KE%XS>(1C=%VQ8)M4'11 Y3$YH\Z ![IL8F(J0
MW)4TYR<W0EQ0T9WPJ]*[V+T6.9'6[7S4Z?D&%N7D%ER<3H;HO?%G@E/6O:MO
M2URWW%+2MQ35P(7'&OG-Q0C5Z@2'&,C%T"QR:B@&+W2X15(  V,27=W(#5I@
M>5N="]6QHS&N>+Y=.?-E=20USO"Z-I&0C]<#VB_TWAXJ!LJWW*,(TT[CKGN*
MRX]R\F)Z1<1;F1?M6\JLJ,*J=P"$>=4KI9!US03I0"$LX..U@6VC*M#SE*U#
ML6!#85 (JU:N#ST6=]DR_%KULZZF<E+WK*W)9E\2=J726]9* G56$TT81KI=
MI 7%;;5K&SMN&*Z(ZC7H$[I '"B+DB*B70IP<2S-1FV=&.W'I=2,&Z6+X[]^
M.VM:K:NH4I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6CFW-WR& V?2P<
M7$3L^.U'I)WDA9]XK'PDG(=)-B1K*/D6,FHT:&3!0ZBY(]X)3$('0'R 5( <
M_NFN>0:E6KMH64'$;''B/+N(ICX,)!IMK!I>[TZT_;Z@-M*)':%UYU%O&\&.
ME;9J\B[6BG=IMW25JVDZN"+.FB<'4:#UQ-$B6?3/GCA0K(F[,BKN':$XG%LR
MQZ!R J#3:Q.5&] I7GP=6]<VKNI\?&ZLWVTUEN!IJ#I=KW$Z6V?HBJE J1UU
MVZUF;9AFJ,O#J107!+2EZPTE(7(I/,W:***J)5HX&S1LJF,M1N*_M3[:N.VM
M  0P!\+J"7:K$D4? =#E\_"P"^G9.JFJE_[2"T(UU1N%@RM/6C4%A=%MJ3=C
M-+/?6';;;N>W[?CH([0]U.)IP].0SHQ3E6.)'"ZRO<_1 6"/:NST%02[DUW4
MKL:E7H9)JSU&\"F-:OSMD< 5ZUA:BWVMH/IS?-^:TZNS5UZV7X[MN%86T>Q;
M<9PZ<5<=S)I,22LU#D81+(\4P3))R#ER:0?'00(S(*@F*8V- S N23BU<<MP
M:N:GE)J:4YVPV;>9?(T]U;UDU3]EML=;5NYX!.Z;PVE;9NFYX$EM.[BN.*TU
MCV2]N'<2W>A>(+(ME'!B*2D8P23<@GS^:8Z@FI%"!QLP.*Q#L'K1AARGG*@%
MV)HX-/E,6V4;%]KT7V-(=1M;"-MG:]KCUGG;G4U.N#5*P+@A)F(@6=K(,[80
MN!*W;C,W8QK9VC,1RL2W>R[TKPK:1*=R04$4^8%" 20,@*"AKQ:5<U?E"@'
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M_P!ZFN_UVTJKC$#D =K_ ,^5?TR,(N4>)23>2PW\FWL+8^18T3[?TAPO;4C
M<@\2_"/W<7[T7C*WWJ5Q2B)1$HB41*(E$2B+YZ,3%MY)[,(1[-&5DD&;60D4
MVZ1'KUM'BX,Q0=.2E!5=)F+MR+8BAC%1[H5Z,"](;)%;3G3?3]Y<"EUN[,ME
MS<RIF)U)Y>&8J2IU(Q4J\<J9Z=$5Q58K$(HU5$_2(F*44S%P%.O3CTHOK&M6
MV30\A;YH"(-!2O=_?.'&/;#&O^^AE#R/=C/H^@<=W'54,ZZ4ANF,<PGR(C1N
MO7QHO7CK*M"):E91EM0C!H6'1MX&[6-:HI=XFX* A$"4B8 :.2!54$VALH%Z
M0^"!SAR\W7S*&'@;F7R9O2S3:Y"P99^Q;5F"VR5(EO!(0C!R$*F@"8(IQO2H
M&[D22!)+F)H\TA>87!=P4<[5*^ZYM.V'C::9NH"(<-+C2Z&?;+1[8Z,RCT -
M03DTS)B5X0&X B!5P. )AS0  HB\K;M:V[.BF\':L'%V[#-1.+>,AV2#!DB)
MQR<Q&[8B:8&..\QN;SC#Q$:)YU]ZB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$7S9&&B9<6!I6-92)HN0;RT:+QLDX%C)M.>#9^T%4IN@=MP44!)=/FJ
M)@<P%,'.')%Y.XF,?NF#U['LW;R*557C'3ANDJNP662%%95FJ<HG;J*HF%,Y
MTA*8Q!YHB(;J(K==:>6*]NAM>[JS[=<WBR0!LTN9:)9*3C= "F(":4F=$71
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M6:^S:CI6X@TNI9VG(O'+&0?L6$E*I)=SI2TG#-7B<1(2J: $3"2=LE7@D33
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M!C&X!# CNJE\7"&UC=C)[-<X(!KZW5< [)N/+0D9U:[,'!WU:&="#9KXXAC
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MW 0>K'9X?M\:(((1@!UZ]66O6UC"Q2&S3K:="/:)'+I]/'*<B)"F R;83E,
M@ " E, "'J<!KHVLP_U?Z7BK&XK<X?%I;CP@%=\U7P0^R)H:>*"8;_L)#U9Y
M@!;8XH645W(]#D1#\*#JW_ >,.NLU"_$J0'A;!B:;7H<6QV[EIQ^UM]MY^92
MMME6/8EV<M!'9&J)'(Z0:?F%8I !414MB.$XF-UB81$1$<CG/4-:7ZN"3J_T
M*<NVB]R ;@+OL[#'E.&?3F%K*AA&L33D@!SI7?Q)9B3ZY6FIW_R6Q%=U72E"
M\\E@_%ML1_M4UV^NVE5<(P2S#;YE_3(PBY1XE)+Y*_\ &V]A<>W98T3'_P A
M0GJUSPZ^A?A'[J+]Z+QE;\47%*(E$2B)1$HB41*(E$2B)1$HB_%PKT#==8 Y
MPHHJJ\W..=T9#'QGJSC&>JN$R/L<N.-GXD$4;;>+"2V>+;%SEP\>."!VX\<,
M+XMQH@';-G7%=]RM-P,W\@R#0Z*4!D^=M"G&^G)#*E;+J(@H)0MPX$$X$ W,
M$PXSC(XJI<_A.6N3.GR1H?(B[#-FR^,;XC#B7&8.,1Z@+&(C $\^*MW)X+]B
MFR9$[\LK0.S29,TPBY99XIF00QF$'UP#B'C,[59V&"Z7;,FMCK:"TC@M37EN
MHVNO,.Y5J:';R!Y1)OWM>JM ,#P[5F905.CYPY0)S1'FAG C5@=7VEL>F^C-
MCT@F6&&[H[5-M$LV6&<;0(.P38I3B:9<HGCL[<2C$$JO6L70^7H+I3;-')5O
MBO*"RR;+-AM<=G%FBF"T289K=AAFSA#Q78'CE\6"Y6\K7GV(6C8!N'RI75OQ
M_P ZQ7K_ *JK?PG7]>M$V+'ULO/RJSJRG!=^)-+N^MV>26I8!Y-X/?M+,'&
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M"YRN-V:3Q1"3V65[HD#WR%\ < YSJRB"3@F"<F\EWA,20FP.2[WBPC@1* B
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MQ$4J6!W=N=JE:XC;.&M17;"(10'3NX.D.A).EU,BVP/-34CD"CYGG" "?>.
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ML7&67J1>]IQ2FG$&\/&VY<TK$,3O%9:;25=&;,G*21EU$T4R&.)1,)2% 1P
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MY7>M M7][ZP[QMUV7/:;OLT^P6"*\)L5X39LJ5%)AGR;.88(I,F?$9G'G0$
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M;<F]OV5+.^7-U?7MS5]-0G<VNGYS>(WTMDT=.U4"X0/=-O;YG=?D4M:.\K6
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M-$ (7>\;Q<C]D>IY-3GQ1A0$@G"J[H)F$Y"',04S&*!A(82B)!$-Y1$@B41
M=PB B&<X$0JX*ILO.B)1%CW5>3EX33B]9J!FF=O2T/;,U*,I9^T3?-6B\?'N
M':9E&JRR"2G..B4@<]00 39!-0<%IF.4;?2'Z=FY#@6QR6H*FM>I$0-HWI+S
M)Y6 O+3&VGEK0MMFM]TDE=[^QG<U*R5WPQD"W(:+-(I%<-'42N5BS;I*$>$*
M40KDV(:H-27I5FV..@[LH=N5L,L\!B!TU;D&8]G6_KINYS>T7/3Q;NCH1I8$
MK$W45LS;@\<WC:X3D[#D&/109G1@'_,;MB 07:#9RDB^457)SS00 S9X\@<
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M8 C/9BHRBPAT"G'\*'@ ;\@( &_KSV[M^^LZHO<Y4$)+[/2&YG*TBE^[A_>
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M=\&;>U>.%+$!>^AX+N;JO%A4U]6PGSCIZ+KY5:29O=&]/BMEND$-1DQ'S"A
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M/5]A>C.>PSZ]?,J_<*+XST3HWZ#>/.T^SU?E)I^"NOE90 -&=-<  9U30#<
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M[T#RNT^9G72?DD\>576+'Z8+9]3O?(X^W7OG!A^*]*Z4]<+"V\=AGGGQ5?\
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MTK >ECN\FF $V<#T.-G(O.N%&0+IT2<@?K"\6KEZGD^&A7<D! 0R Y =X"'
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M[0[.X!J6.(79]"8!%IIHBYBII+<9#$BOKE9L>+4C:*OO8-$U2^%D]P8Z$N>
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M4.F$HZ9P"@BNX7<GYP2\Z7//744.'F2EW ; [Q'>(U57A'O%I_9"6<:.V X
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MY;I+"4HP:@B4O2$-@!$,X#=G?5@.##2Z-+6)#WM806)%(;'$V&QRW*J\\*0
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MDP@S9,+!NR2V#!@T89AA3+!E#TE@*66ERE "@27DR@' H<U\N!0P&X   #<
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MO'\5V:VM_0SZW?,\N#^*C5L=9G<_TO[Q6[[(JH^J_NAZ'=_K!]J%%*S[BQO
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M,[G^E_>*W?9%5'U7]T/0[O\ 6#[4**6&]+<&,)XR(=A<;OI^+P[ZS2=Y3MA
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MT;J\@X3GQWHEWLO/P6JS+V/@NMZR:74KZZ76>0>I;3^(;G6O_)O![]I9H_\
MNW?'@#'E==#Z8\0SXPKHVH/NG74_^H7PW/8)QY\W.U=ZX0/<PO?Y_<WWA*7<
MS:R]#7K9X-/+A_B9@JXNLSM TN[R6WZBIIJO[H>AW?ZP_:]=BB@K?":W4/<Q
MLB.?SH?ZOJUFF6['$U/:BN1]J&;+"BTWE^^P?OP_6&U2WMG7S@M%?F66']C,
M;6G>@O:5HE]&[D^[K,LN-/.W?2[Z27U]XVA< .4+]%=?^,9[BMO(#UB,&SZ^
MP [-XXQN#%4EUZN-9-\_-[OV-\$@9^G(O0XJ\6HAO8TN3;V:\/+)SML+5Z<
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MOBVV(N'Q*:[\3"7\EM*NSC4%LP_,_F*_ID81<H\2DF\EB.>3:V%A#Y%?1+[
MH4*# 9T%=J_"/W47[Q\96^]2N*41*(H['*B*I!M-LR&4(4PZ9VU@!,4!$.^4
MYOP(AG>..O/"J*<(V*'V0) ,4(_4%AQ(Q[-:V%3C4'BY@OG6^O!N@C.KN=$(
M(C#^45X#C"$F$?HUCQ.&2^WR4ZI#[0UY%*8AC%THD>>!3 82\ZZ+>YN0 1X\
MP>/97]?!KB?3B]:@_P!')^!! /J^Q4<$U9R1O=?R<)F&(:!W3$88@#I/( )!
M +7=;26+-^T%T]Y0<Q2;)&JQC"!2@E:PB8QN:!0"\8 1$1'=N !XU8C7@0-6
M.DI) '$N[$@?]JV+,MT9X*N.HN&*+6CHS#"#$3%>88 DUNFW#)SFHQHKH "6
M5$\=*W*'FRX$3*IE  W]8B !X]VZL\X(X7E D%YD#8&O'#-7(;%HN)<P\9H(
MW$$9]R: 0DDX9 *9':WQ,V[\HXK^(H5JS=];!8B,/4EF^Q@63%XOZX6]\?5E
MJ=\7[/'BHNNV2JD&U1KB7I$P,6\LB'/+G\28W("7("&-^<AQ[1#-9T:UXX?9
M(TO'& :]!5Q5K-9P<^6&N!!V+2+5)!'[&>AAXD3&Z17BEB]JM#5;J]%TGY)!
M5-6U-9#)G*<"W';9!YH@;!BQ\@(@/-$>HP#@=X9X;Z]]X,,0BNS2IH@?T^PF
MA=GDSR,]A#JOO"DABAO/1+C0Q0O=]X$<8$.#/L[$9$%C@KJY6E0B6C&F@J'*
M0!U5;@ F,!<CY5;CW;Q#/;Z5?2X39;1*X"X'](X*DLWZNMPQRQ9\B<5\O@OP
MQ1:7:0\6&*)M&9A/%A,3 7G=]2SD4>O*N/\ LXK)CM"Z'E!4G./J=:?-+SBY
M$0D2&'  .1' =7J#56] (X3ISHB1$"/7Z[SDX_/BNULMF&T*UNGT$9T$TR(A
MB8:.7H8CQ20!V BI9A4C'\1+,D/A![^Q'/\  GK3&?[Q/_A3<_[D6:R_D>_R
M?XLOZ\*AOSBR/?V?$%DQYLS*E,/2%$ $KU<!#CC<("&!'(8\-946V.'U9;CQ
MH3^EVCC>V&'9HB<VJ^VCAL5K)8Y<P6*Q@P1 FR6<CVI=C)@8LRD=<FX<JFRE
M99R"!B&E[I,4Q1R40&:<XP(".?#X:OMJ#(.K6Z""_P"DWCFY^%S"QY!$'PJJ
M \(*&*'6=>\,0((L=U@@@@TL<L&AKB"M'.5M53)J'HT4YRE,-I76( 8Q2\X.
M^T3VF#P^H.*\?X3L<,-]Z)N?^S+RS 9[59FQ;&K/BQK1E[)P7((C<>EY )'K
MI=> )_LMJ%6PJ? M?^3=53/M;V:F10@G"U[Y5YH'#G<P(!P0PX <XYQR@.[B
M._ANZ/J"(BUG77Q2#Q;OO@ECML,WPDE]X!.17>N$#!&-5U[1F&(0F\;EAXQA
M(#FWRX@'(I0%=S=K4Y2;-&MQS#@I=.[B$1$<   S,(B(]7#CVU<76:0-7^EI
M) 'K);*_X%3/5;"8M8NA@#N;_L% '?\ .[!CMSP43Y9P@#%8_3)B0&QQR8Y<
M8Z+CG._M'UC6:,4R'L<3%QQ6#<7Y. !J2X+!L6 JM.H)<SLT$/$C,7980W%+
MOQVP;:I<6SH(>P"T6Q^I;8?7D/B8C.%:?:"]I6B7T;N7P7=9P?"LM=/0VF^E
MX8C^DE]4./QC:,5'\Y0Q9,-J_4 ICIE.#"VC<T3D$P ,*S !P(@.#8'L\%4C
MU[10C67?(XX<6>[W#C.RRZ$.!F_)4U5Y-0T$?L97)$((N*9]X,1#$Q(M<QV+
M,7=RV:V?Y)!5,]Z:S@0Y#B6W[6*8"& V![ND39' COP8,Y'._?7H?!BBA]==
M*@(@YL=@+ N2T^:,7.T/OIC1>=<*2".&Z-$3%#$ ;?>1!,) ([!)%"=[T;)U
MW*JX:IFE$2B)1%ZKYZTC63N1?+IM63%LN\>.5C 1)NV;)F6765,.XJ:21#'.
M8=Q2E$1W!1%:-C:B6KJ*Q=O[7>K.4V#DC9XW>,G4:^;BN@1VR658O4D7)&LB
MR52>QSD4P1>M%2+H'.7G85'5T5\414P'8'J!1%6B(( /$ 'QT1, ' ,416C?
MX9L.]@[;1N0/_!GM?+OOXEO?O7>'DDY?4N/XZN?OI=_E<E0[ 71%,Q^F2YOF
MQR!RXXB(@(B./2'QYSOK*T1PM$>-"&)J"#5Z.7(8O0'P%:O]CC?B\2+C4IQ2
M]<*,I0>P28IMD;18Q1 2F@)(Q1*("42FN2:,40$-PA@0X>+B%:+ZF.YCHC\P
MG\H_3[6P.;MMPPR6;^NP&'6EIA"001>$@$$$$$6"R!F/\ERIY4Y=$-H:WR"<
MG.]AU%Y*)BY_%21'/-$0'@(8P&*K5PCXX8=-[ "0XN24X</6TS34.^ ./F(%
MF>#5!&=!+?$((C#Z_6CVPA)A^#R,V;(K\>2T534VC9PI%"&,33F7$Y0, F #
MR,8!1$ '/$HAOIP<(H3IU;V,/Q%:,PY)M%G)ICL<98G%<^$I!&- ;%$88A#%
M?]E:(PD"EFM#A\\>K+J[MZ*%3V2M93G,!2A L $PF H!F?B0SD=U64USEM6>
ME9_X*3SGU;9F'.:*LFI.&*+6CHE##"8B;=/  !)^ VJK $TQ479=9$K8YA63
M !((@(J%WF$,%QYK AG?U]7I9T&*#BAHH#QF'NG-6I"S[_2M(9<N,S(8>)&X
MBP$)>F[=B1LWJ8IIUYW]C9X^4^VL^/O,RK5&X6]8[F8@CUJN\AL*V245E!?X
M:_;Z&R]KR'_O)RC#;8BJ8;4VNA!42R6^7/.*)R\X,Q[ 1SOZ@X@(;ASG'7GA
MK5CA]DC3 $PUOB86) 8=AE!V\!I4XG;HWJH@C]C70N+B1-%<DECQ2Q_/3Q0M
M7<V1"Z6\D:<BEF:T"F<IRA>%O)B)# 8.<2"-S@W"( (<XN=^<CX*L%P8*W-I
M6000;VL3,7PL9!/(X(?;"1B"J\<*6&*&]M$!%#%"3=-X'VP(H;<&QY"KKY6-
M5-/1K3P#G*3G:C)B'.,4N<0DB7=D0SO.7A7TN$Q%##HG<CD![\A(!(!(ALLT
MEGQ:CKYO!@@CCTLO[BPQ1-<)?B@EOTR3BP+8'H7'K9R52':"T73!5,3*:D6M
MS0%0HB(EDD#^9#(B(X <>+P55G0"*$Z=:)PB($^OUW&L0+_I$!85W<I-%:K6
M##&-!=+HN)&1#<%X\9H20'D1"M*5(Q/G4LY]\)/,C@.Y7&1'@'N$^\:TSF^]
M3?X<?U2LP9-9TFC_ )R73,^V%-JALRRZ(R\R;I4S8F98HX4*.!)(.0$!$#;L
M" YX]7964MKB@]5VT\8?"[4'!P_/3&)8X4)WAC@RUGLLN8+)9 8(G]264@<4
MYR)9&74J1YR;!BGV3[-.00,4T[>)BF 0$! ;C?X$!#(;ZOKJ!;V-;J8@_I=Y
M89?IDVG,J \(0&'6?>P((/J&Z'!!!^ 2<BM]*]I7B241*(L=L-5+)DKU<Z?L
MY4RMR-T7ZA4A:N2L':L2+8)ABPDS)@Q>R,/W8T-*,&ZQW+(KA,RR90$W--GU
MS]"AQAGL61**4HB41*(E$2B+C+RD>ONK^D^KE@P>G>HDW9\7)Z=*2KZ/C%6I
M$7DAY99-F#M0%D53](5N@BCD!  *7<&1$:JCK\TWTJT7TFN:QW%?EJNJRVBX
M3:9TFSF6(9EH]<+3*[)%QX(CQC+@AAIE ^15MN#]H-HII3HM?EMO^X+'>UIL
MVD$-FE6BT0S3'*D"[K--$F$P1P@0F9,CC+@ER7HS8LV%]I;7+4;:1MNTKVU2
MG[GM]W 7$X<PK]9H=LJNU;$4;K&*D@F?G)'$1*.=P9W8W5UO4YK#TRTAT]L-
MV7SI%;;PL$RQ6V..RSC),LS()8B@B/$@AB<8BK@[EV/7/JYT,T?U?WA>MS:-
M6*[K=*M]@ER[9(AG".&";,B$< ,4<4($0H:8<H"[):^^<9K'O /[%U^;^ ![
MR\IO]8^G5JM-^TW2K?H[?.+?[.M&.71XE4[0?MST3^DER88_&5FV ^)1$TUT
M.Y$E!63YG<R?FN>4, *8#DP\[&/ZAX;\O^-"((28H?<LY+<5H:@L6<8-4DN%
MJ;'+C[)%#Q(G,9#<4NYB;!GS4J'8F$!V5]%,8$!LQB("40$! RBXYR''LSX,
M<0&M(M4G<XT2[TR?'%3FP*S4UP@C67I@"""+WFN"&/N8,M^*Y-\JRHF7:$LP
MICE 3:41H\T3% P\VZ+DXE$<CQ#Q[L567A*Q :;W2Y':W(&(Q%X6\L0<>2FZ
MJL]P9H(CH)>\0AB(&DUH<B$M6[;OS_PE6-R9ZJ9]JN*(0Y#&+8EW',4#%$2E
M$(\ $0 <\0'JW8WU\C@^10Q:R+/Q2"US7I0$?)DD#%G8$MD 2<"OL\(B"(:L
M[5$82(3?5TAR"S@SSCA@0NYNT^(!L[ZU"(@!0TUNW.1P'XD...=W;QJXNL0@
M:"Z6N0'N"\PYH*V69FJ8ZN@3I[H> "3^45U4 <G]+EC ;,>91,0<( U XK)@
M4$0$3=(40P"8#O'..'U=W&LRQ,@[&_&%(6QW-@Y<\Y\:U",N9V3B<2/C&-FX
MI<GC8,1GAS[5*TV0-^S#H<.0'.G=O#D! 0'+0!SD-PUI3JOIJ\T/ RN&PAMX
MEU&X@N&R-%F5K6?V1],P001?]N!!H01,;!<<>5*53+M*PY143*8=+X#!3& #
M#B:G\CC/A*&1^F #55.$?&(=/K&' )T=L0J0/[9;C7FJ-@+M56RX-D$1U>VN
M(01&$:1VX&(0EG]26'/##Q+U^2X53/M.OTRG(8Y=++H,8"F 1*!IFV@+G B.
M\2FW[O@>%<.#G$#K#GL06T<O%V((#VJP4-=@>C/BV*Y\)*"(:N9$1@B _*6[
M0(C"0"?4EX$L6V&M<:+LYM<" ;,NMXB(%#V'EP;S"   BV$ R([@WB'&K8ZS
M2(=7^EY) 'K%;JD@ /*(%2V)8#>0JCZK@3K$T. !)-_6%@ Y]]&0444SE C8
MRPK)\PJ F,//+C $YPCG/9G=O -_"LTN/#Q,0?:,S@UYRY8TPVLM.!+F&9Q1
M!'QN.S<4NY/(I9.RONV:M! ZPTAT^Z\_WL1H!O\ 2K3+5O30#0P$,1HS<H/*
M+OD..8N.5UF#K+KK#TWWZ57[DW_:-HRR6>Z[JND*%UY+# 1O;8BQ^E37?J ?
MR6TJ[1"N)RPYXC#XL5_3(PBY1XE)-Y*_\;:V%O!LKZ)_8%"#]NN09@V#!?A'
M[N+]Z+QE;NR<,>2?1#TLK*L BG"C@S1@Y!%I) H0"=!))"0W="),<XA ,02F
M$1SOHN*^W1%ZSMJF\0.W5,J5-0  PHK*MU P("'-50.FJ4<A_:G#/ <ANHBP
M[=>SIHE?<H6;O?3:V+NF"-4F1)6Y&!9F0*T1,<R38';\5U^@3,H<Q$NDY@"<
MPXR(B/P;ST6T:OJT"UWQH_<EZ6D00RA:+PNNQVR=V*!^)+$RT29D0AA<L'9X
MB6J5V"Z]+-*;DLQL5S:27[=-D,R*<;-=MZVVQ2#-C#1S.Q6>=+@X\8 $47%<
MB&$&@"_6TMGK1BP)!Q+6+IY;MG2CMF:/=2-LL^\KYPP.J1<S15RP.@JH@*R2
M:O1F,) 4(4_-YP -3=>C&C=R3X[3<MP7-=,^9*BDQS;MNVR6*9'*BBABBEQ1
MV>5+,4!B@AB,)</"#D%QO;2K2>_K/+LE]Z17W?%FDSA:)4B\[SM=ME2Y\,,4
M FP2[1-F0PS.)%%!QP.-Q20[*Z;BTSLR[H=Y;UUQ1KF@9 $@?0T\^?2T8\!!
M8CA$'#)ZY6;J@DNF18@'3,!5"$.&#% :^E;K!8KTLLVPWE8[+;['/XG9K+;)
M$NTV>8)<<,<''DSH8I<7%BAABAXT)XL0!%0"OF7?>%ONFUR;?==MM5W6ZSF(
MR;989\RRVF5QX(I<?8YTF*"9!QH(HH288@3"2'JL7!LA;,@"!BZ(:=E,!BG
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MQ$ER3%%9G))JY<OM"[C#K"T^AAA@@TVTK@@AAA@A@AO^\X88880T,(A%I
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MTRE$YS&QD1&NRV&Q6.[;+)L-WV6SV*QV>&*&19;+)ER+/)ABB,9AERI<,,$
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M+GV>?)CBE3I,Z5$(Y4V5,@(C@F2X@(H(X2##%4$%BL/^R@[,6 +[ [3G !@
M\K3#AC& ]Q[@QD,=E=5]C_03_<O14G:;@NLQ'?QO4HB?>[KMWLB:?_[[Z68O
MVP7IB[X>J6%=@\[Y7@].K2MB*8P5MQZ\!"1B(-HZ(AI*2C8UBW#>"#5FT=I(
M((E$1$J:9"D#(X"NS6.QV6[[-*L=ALUGL=CD0<219;-)ER9$F%WXLN7+AA@@
MAW0PBM<R_5K;;;9>5JGVZ\+7:+=;;3%Q[1:[7.CM%HGQD-QYLV:8HYD3-[:(
MDE@Y*M&[=GK1B_I!"6OG3RW+QE&S0K!O(W,S"9>HLB*G6(T2=/S+K$;D5555
M*B4X$!10Y@ !,81^9>FC&C=^3H+3?-P7+>MHERQ)ES[QNRQVR;!)ABBCAE".
MT29A$ CBBB$(H#$6Q*^K=6E6D]Q6>.R7)I%?=T6:9-,^.SW;>=LL4F.>81"9
ML4NSS8(8IAAAA!C(,1  )8 +U[7V;]#K'EB3UF::6O:<VFW6:DE[=CR1$D5L
MX H+(%>,116!)7FEZ1,#\PV-Y1KA=NBFB]S6D6RZ-';CNNUPP1RQ:;ONNQ6.
M<()@:.'LEGDRXN+& !$ 0" R_2\]+]*[ZLL5BOC26_;UL<4R";%9;QO6VVRS
MF9 _$C[%:)TR#C0N6B9QM=7Y*6';<Y'/8B:;.YB)DFJK&1C)24DW[!\T7(*:
MS9TU<NU$5T%2")5$5"&3.41 Q1 1K[-HL\BUR)UEM4B3:;-:9<4FT6>?*@FR
M9TJ,-'+F2HX3!'!&*10Q @BA!"^%9;1:+%:)-KL<^=9;59YL,^SVBSS(I,Z1
M.@/&@FR9DLPQRXX"QABA(((#8+$(;(.S'C Z':<XQ@/>;8\,8QGH^ AU=F[?
M@*ZM['^@F/Y%Z*\;$1>L-V<9\B3ZF=\B7?-W9NV^R+K _P!^-+,7;U_O-GY/
M5+>"AJLM0VGUKV]%,8.!9NH2%C&Z;2-B8B4E(Z.8-$@PFV:-&KQ)!! A=Q4D
MR%*4-P!BNSV6RV:PV:38['9Y-ELMF@$J19[/*@DR9,N'W,N7+@AAA@@ARAA
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M3' 9EGDRXC#&883%"2Q(!-0&7II;I5?EF%COK22_;VL@FPSQ9KRO2V6V0)T
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M/'&?K(70$#+="Y":O-F"T<:,M4XQY56'=*YG0*&,4G+BDBC.^!+9C&E!C7/
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M@=JX\N JP%,M^<5SQS;#FJ7Y?0MM#G*F4QSF I"%,<YC"!2E*4!$QC&$0
M $1$1   ,B.*A2M+]2=H\YY.,]AE>5ILX9F$FG*RUQPTB[A9&X6O0.(.V7DF
MFX9*6[&W6S))$A;L2;23!T[;J)M^G.B*"O)FA)(+N *LSUWDXBA SY1'1GMQ
M!9FH,L7IOP6TE@W4G?%DVI>*;!Q%DN: BYL(YT8AW#$9%HDY,U5.01(H9 RA
MDP5)@BI2@H4"@8 #B:$C8I7R;\U.LW3X8MK<T^RAW\\JHWAR.DUUB&5*9%#N
MMZ#9-0646W=.FB+N1<BBT0.Y0(HL4RI:,[[,\LB:;>;?L18_TSU;G7D\32_5
M*&1AM56L>,L8;90D92S+AM\ZAR-KDA9<R @P04.7N5[&2QV[MF_*)$A=-EFS
MA22*<8%P[-@0-X<CGSRS @&I#,6<Y[L:=!%/'L)4*4HBA>>2P?BVV(_VJ:[?
M7;2JHP+UJ ,"<'V<J_ID81<H\2DE\E?^-M;"WAV6-$_L"A.']-2, ^P8]0OP
MC]U%^]%XRM^*+BE$6D^K>K,U<<NA:MM1FI,-%PTA*2,[(6TR12G+HM>*Z>!E
MI>T$5$G;EZ6T[F=QKQ_%+MFZ\Y')*'CTWB.$E9 S8'+';@_AS#%00X9SOZ[/
MY+[.B&G,U*O;9U5E7TG;#\&$S#7';[*#&V8_44T8_586A>=QV\Z2*:+E&\,F
M94$6S9FN=9T4%%3-$6Z!1QP#95=AB0-H=N1L2@_##' .>N%<J9JU4U*3TYB$
MW"<%/SKETF[44"!CBR(PD:T2*9]<4DD=5$#Q\7TJ2JK9(YWKP1Z%H@J?G $
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MKF<&03$!-&V$D5<M2@RQS#=!4T=_%F7.+5IOH*9K;(I0*  &       P >(
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M)!$I@ V!$!P 416QIQI_%Z:6LPM:+?S$LFT 3.):??J24O(N!(FD+AXY.!"
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MKK''ZE%2(WRVY[ ^Q0)0/%J:OLHR>W>M_P"0#V1:S]XB'G^375^Y14F)@[9
M]*DR0/VCELS+(/DO2_P$ ]D7L_?G\OR:ZOW**@1N"6P;/;S*#* !+FG)M(\R
M\?;O:_\ &?9%K/XX\_V:[,_J45R>K;G\++EV .W&. .6;^A>0>2]+_''OB]G
M[PSY_DUX/UJ/#7$QL],"V/+NW+CV(;3GLRXW_P ?"J^W>=__ ""]G_1\FO\
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ME'H"J/DO2_P$ ]D7L_?G\OR:ZOW**@1N"6P;/;S+CV(<7C.>2FUD#R7K?XB
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%>?T+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g305908g06r21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g06r21.jpg
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M 0$! 0$! 0'_P  1" !8 8<# 1$  A$! Q$!_\0 '@ !  (#  ,! 0
M      D*!@<(! 4+ @/_Q !'$   !@$# @,""@8'!P4    ! @,$!08'  @1
M"1(3%"$*%18B,3@Y=G>UMK<7&2,V074R0E%7<9;5)"8W>(&7UC1#4F%B_\0
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M(%4&%1185TA%2"HSD&4X"1_#>&[O/OA(XV^4&,$8<AO:]LPHE<9W45FAZ]2
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M]\^,&>9-G6Y;'+MN1TI/8<O"\2FH4#E)9J_"N;+4W(E, \BSL\/$.R\<& R
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M;1,X 5G*LY6)C<-:"@Y'=T'H/QTCHJ8*![>JNRM6U6FE*:4II2FE*B2ZH'5
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MJ2.GU;:K_P"\CVA>T6EA*T?9M3'U"8NTUF:V8<A-HUY<?!. IG6J%+06DX*
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MRZ$G4,O[EN6PT&E8CC5S$$TID7(E=6*FB(AWJ#%4!>]3A%"AR!4'4:U4,<
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6KSSKA4MQQQ9*E*4223MKV>LBL:O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g305908g11i99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g11i99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Y2^8#8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+N@Q         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "M0
M!W8          0                         !              =V   "
MM0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MM0    !29VAT;&]N9P  !W8    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   K4     4F=H=&QO;F<
M  =V     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MSM%A$C<[VL8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M               $ 0,%!@<""/_$ %<1  $# P(# P8("0D&!0(' 0$" Q$
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MDX!B,$ 9\8Y]C[^W\RI2C@>WCQD_]$#!D>/N/92DD@DQ &/!'TD#( Y@9S]
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MMNB]TPXWI9B_K=LEN707K\TEJW5M*ANIH!<*NEI**Y5SE0V##MKYBY2ZI!*
MU</6RNUTI)<8C64PH@IY@S, D@5.NN'W%HIE#@2X7[5B[3V.M8#5Q_1A<H3I
M7."((D@!1)IH:_;O7]J1?W;IH;6-M:TF]2T^J7+AIB]T3>F7ZX)50L:@744+
M:;*]6)4A=&S<C2KJ4E):2N0>I >944!+K:BY/9@+22N-RF#Z0',B8J,IAY.O
M4RZGLB YJ;6.S)V"Y'H$\@J)Y5;.Z'UHQIMG6;^D-4L:/J'134^JW=/W9K3;
MU05_###-^52"U.O%SY RW5J7W_+V=V.JAUHK[,.(+@$EL+25@=Z9D>RJ%ET-
MATM.!HF X4*[,GH%QI)GE,U<HVZW!<TY_3!&@]9.:1^ ]4_TH3I>^+TY^7IE
MANHJ/VZFA-L++*R$O.BI^&TM7:XI),&G;,Z^S[5KM)CL^T3KGIIG5/=%5[!\
MH[4,N]G!/:=FO1 W.N-,#F9JPN.D-66>S6K45VTQJ*UZ?OO<+'?;C9+E16:\
MEM(6O]E7.II6:&XE"(6H4;[P0DR0 9-0XVI2D)6A2T?&2%)*D_\ $D&4^L"O
M*FW$I2M3:TH7\1:D*"5?\*B(5ZB:][/H;6^HF6ZC3VCM57UEYBYU++UFT]=[
MHT[2V,4ZKS4MN4%&^AQBT)K*15T=2I35O35TRJM3(?:[Z*=:086XA!&D>DM*
M<JG2,D95!@<X,55++RP"AIQ8(492VI0*41K((!PF1J.R9$Q(K;]!;0ZBUCK?
M;#2=[*]N[1NKJ.T6*Q:[UG9-1TVE&Z:YW)BVNWY%1;[375MXM=M=J$KJU6*D
MN+X_XM+96H#KP[<(;:><1#RF$*4IIM2"N0"0F"H!*E1C40.^*NLVSCKMNVN6
M$7"TH0\ZA8:A1 UR$DJ2)DZ H]!4ZMK/PPM8;KW78BW63>'1":??G>OU%;+V
M*[M674=3;:"I]/.G*[4=QU2H5+5MKZRSZNI:!Q-EI7*"W7*C2\PY<F&EJ=89
MQ;_&FV!=$V[DVMO:/J25(!4+I02$8U *1/I&5 \I&:RUOP!RX79I3<M?SRZO
MK9"@A92#9(*U.9TJ*70(0"$D2"J,@0KUMLI5:2T=LMJ>UZOL&N+GO-:]1W"G
MT9I:AU,]J;2-58=2O::8L]]:K[%14-?<;RZT:NVHTY6WEOX:7&:A;3J6DO9)
MJY#CEPA3:FDVY0"XM2 AP+0%ZDD**@$['6$]1/+%.VI;:M7$NH=5=)6H-(2Y
MVC10O0$K!2 5+W2$%>-XQ+=7#0^MK5>W]-731^J;;J*DHWKC56"X:>NU'>Z:
M@IJ1VOJ:ZHM-31M7!FD8H&7:QZI<IT,M4C;M2XM++:EB\'6U)"TN(*"8"PM)
M223  4#!).(!F<594R\E9;4TXE8&HH4A06$Q.HI(F(S,1&=JHKM%:RMEUM=B
MN6D=36Z]WQBAJ;+9JZP7:CNMWI[D2FW5-KMU11MUMP8N!Q0NT;+J*HB&%K@]
M ZVI*E)<04I)"E!:2E)&X408!',$B.="RZE24*:<"U@%""A04H*^*4I(E0/*
M 9Y587W3]_TO=:BR:FLEWTY>:(MIK+/?;96V>ZTA=;0\TFIM]P8IZMCXK2T.
MH#K*"II2'$_*H$U0M#B0I"TK2=E(4%),;P02#[:\K;6VHH<0MM8W2M)2H3M*
M5 $>L5EJO0>NJ"BL-RKM%ZMH[;JEYFFTQ7U6F[S3T6HZFI*!3T]AJWJ-#%X?
M?*VPRU;UU#CA<0$ E0!\AUHE8#C9+8E8"TDH'58!E(\8KT67@$*+3@2X0&U%
M"@'"=@@D0LF1&F9J3/K ]']W]'5XVZT=K#7MJU-N%JS1=JUAJ[25HTMJZT,[
M?&^6:QWNUV=W4M_MM!9]6U3E)>5,5[VG':ANTW"VU5%<$,.+IE.P["_3Q!+K
MC;10TAQ3;;A<0KM="E(4K2DE2!*9 7&I)!$B8G\2X:KABF&W'DN/.-!QQM+;
MB SJ2A24ZUI"7"0J%%'Q5)*3FHN7#2.K+1;;->;MIC45LL^H@I6G[M<;)<Z*
MV7X)""HV:OJ:5JEN83\5LDT+KX2E:)CN3,U+C:BI*5H4I'QTI4DE/_$ 24['
M>*@*:=2E"E-N)2OXBE(4$K_X"0 KU$U(STV>D;<+U!^HK;STXUHK=J-2[BT6
MIKE;+KKO35]HV6*#3>B]2:R56_LMYJBKZREN%-INHH*2IIR6#4/H<+BD-K'4
M2[OVK6T=NTP^AHH24MK29*W$(C4) (U@D=T5-L>&O7MZS9*U6RW@XI*G6U@
M(:6Y.DZ20H((!&)-6VYOI0UIM[M[Z7]=6^L.NJOU0Z)U9K73&DM*V.[UM_LK
M6DM8W'2-3;*FG914NW:KJEVYRXMKM].$M4ZE-+2HM%U5&+]MYV\:4 T+-QM"
MUK6D)5K0%ZI,!( (&3DU1_ASK+%@\DEX\09<=;;;0HK1V;JFRD@3J)TZO1&
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M&'%IW2TATI4F0$I"/1@( #0>O[=JKO/H0T-M+N;ZRMKO5MOI8?6/K#6===-
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ME*VHH?VK:T..KI+2[>X1=</>1:O/O]AP]I]-Q:ARW0EM*5+=;NB9MGF5%14
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M\N5GT_?&]7ZII[8_>+A5"WO79VBIGZUFX5S+UKM2Z0XUAWM3P1;]ZJT*[3B
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M_P!&Z)U%HW0U5N%?]1W=K2:+SI2Y:/M=;0*%R_,N4^EK3=J]%BL2WDV:G+H
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M2B,R<SG@02/&"<@2/YP2,J4$@ CF3XQR3_=!_N/2E'!'!YCC!D ?KCC'! X
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MC3[Q4I6I0$*7 41Z)&%#',$00,@B(!R-F2-ADP!!R1RV)'=,C>>Z0ZMMHZ=
M20 ($92#,IQ!GZ3[8/OU!>6M29 .CJ)D[C&.L@]U7D]#R,Q \,]_*#G:.[<*
M12&P%!/@A)"8@')XP)X'!^HGJ,0HI  4!WB#$P)!$],P1G&U2VRVW!*@9'=
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MM]]ETI^=*%'K9O)/\J'NM7O^IJM0\MOR,C]=8_9OU#\_KR.#!\B3.3[C/Z
MGKI5<FI9,B,<\^?:/KYC!/'C"E(8)C]?')[I!CV^GGSTI0,9/GDS@3R,\1$_
M?'MTI57'Z?X\<GG$?ZIZ4JD<CG'(C]<F2,<CVF!GI2E,R/\ '&9C$>,^<Y\G
M 4H@9&!]@1P/)Y^HS,9DB>E*,B?XQ]9,>9SB1&3^O2E((C!F/YCP#],G!C/L
M.E*"/H/8$<B(@^_OQ]),9Z4K?]J-%-;D[I[:;=/W!=I:U_N!HO1#UU9IDUCE
MK:U7J2VV%=Q;I%O4Z*I=$BX&I13+J*=+ZF@T7FPH.)M/N%EAYX#46FG' DF
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M6. ?D>Q_PU_MG*XIY3?EWB/^*C]@U7,Z3X'W^GZ2 /?&<YCSF*P5)]1D@G/
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MV) M%)WZ$# &(.#7Q48G]<\9F"//B<><8/OTFN%4<_;(\R,\_3/&#$<@<*4
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MTVO]:U#RU$<'1^NL#<_W;W*L_GB/('&", \>_P!<0(Y'72JY/09@S]9B/;$
M\CW$C/T,=*43]8( D#V$$_PX /U]YZ4H) _Z7UYX_F)^TYC('2E*?ISC/W^N
M?I@B)CG Z4I./!$>TG \28]H ^^(,]*4I\>(@GZ">)XCZ?3Z %2DS DC'O$\
M8//,@\GS/B.E*(R1[Q['@YY\Q_')Y$=*4HG$YS(/^//U/Z#[2I0/XR>?;SF!
M').?K,D=*4ZNPZ0=\METG(.[.W"?OW:RLO XX[A[>/H/2/CH_P")/UBJC<>(
MK[MS3 (;$3!2>. @3]OK] ! QC*3,F9WYS.<3T)Y#??<DQ=F# Q&Q(Y\H[N7
M0[3M,-_475_"ME0@*R7""!S ()_0@01XYZVS@B9$_P"Z!U$F 9[QR]8K&79A
M4^OU"9Z'VQX4U&Q=K2Y5:624&"PY5*^7)6\\ISNR/^:Y$D>Q&,=<FX>HW/\
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M 2DD"5.U??PTO1;JBI_-5&QEGMCO=W%.F[[JW3E.HR)!H;-?J2B2D1A+=,@
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MI[_OJ=FYNF:JEO\ 36MRHJ*JB9?8:!74N.6Z2Z*=RH8I 4--!("$H42D(0F
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M:N$I47 I,B3&T;8'=GNP>>:GH<*")!.TF=HW@]_J^G#K4*$PD0. 9'G(XC!
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MI[2J 53N<]Y//QB?]>^I6@<D@@;>CTVY58+1\-3;;8;(#A[4A/8&TJ4A*5_
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MO45AU#5FS5+E*XF@J?RM076W;;4MH"70ZMM+K+C94'$?.,$#K7JV@0,>_?\
M7F-J^AW\*EVP>M+TL4-?<F:"OW$VV*;9=0_\(W&F50,M-!P$CXX0HI!C^THI
M@0K*JU!#\83TR.ZLVV>U31T+;FJMOJAY][X*%?'>H&R$K0M02%*"V4J)"<!7
M;S!Z53GS^P1^^N'GI9U1=-X+IIGT^;E^H^\;(>GN[7VUT-Z#]/>]0$JJ*U%
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MWI482J7$'YD_$6D @*$D",G<</\ *&]94A0M+5*D@*;2]Z:X$:5+],@3DC4
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M[$R<A1^4]HZ#;G'*>4;?PG-*C;<JMVNJ'G7%=ZW%*45$'*B.XY()2)([<1(
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MQ7%W5=.;;ZD[XGM*?B7U2L\P_0L/2(& 201.>V)]NO'D^YV/EWQ9O(\[X5U
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M49,J@@#)H3'O]/\ I7KW]_?V;"%"'4K3\)#@6  5DDI7$@$]JDF0D @@S^Z
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M%)"EI6D+2E(_LA9DJ(P 1JK4W4\6/$KK@#;RG.%)O[:_N@4)" ZA#:B0X05
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M[=?8GUC;:W'_ "F4-KT=<:"[U5+9:)5NU;K33[>I$V"L=M=PN2:ZU-6VJ8^
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M0@H X!'6AO\ DQPVYE2W+P.$1VJKA;JASF'=8@R#!CH(K,6_E#?,I3I:MM$
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MWM2/,XA$D 005R$D$3"04G .,=>"9DXQWDYGO$1W&!G$[!(.V?75+24A95W
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M"@9(D&?,J! @GZ1$A1X. XOQ=%M:KA1"E QC .=Y,08B#N!D3%;#PO@ZGKE
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M)9%ZC=NH;_\ @K]@O+>!( '=5,ONV]"292E;E4A,@R<CJ4UQ1#A(2R\I8W2
MD@;""K4$I$G/2/549RR*2"7&TI.9)()YX$'.#$3,TQ=59]0IU(U?[[I:[T^G
MJBX-N5*PPU5N)I04]RWVJ)U]P(  4ZE$R@* *E',%]+CUVE]ZS6&04A:4PI2
M@D$!2M&\SGG @]3*:*&V"TBX07()2HX ).PDXZ#.Y)Y14Y-#JT77V$FTHTW7
MTJFT2FC%N?[ $B4OL@%YAU)PMNI0AU"I"DA6.LTT_8K0 WYOIB"DA VQ"DJ
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M<>M6E,,J*NP;<"EJ3J!6%*5!45 0  ,U)M5V%JAQMJX6'71I+JVR DB=,8(
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M_$-XV_FK/MG;[#%:9Y3 FZM0-RP<=1K5/>(W\<<ZGGHVVTSSK25ID&$Y$D2
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M,3.=A$<H[O&*F)!@#!D $1@QCH/''0S5G4OH6LRGM2\OM04GMGM?SV]P1^<
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M"U1W'7VT,WG$'G;L&TU04, EE2QS45^CD8U 05$X-9=:W;6S:;MB+G3J"G2
MX$] $>E@0 F=H@B#4MKEIC3]RL;7](:2IK6&V2HU=[N]S?+,)[RL5=?7$,1A
M7=\1(2),@$GK,*M.&)0>T::TC\YQTDR?]]2Y'TS[9QX?OBL%"W >:4H !S_9
M"-)B<2,8)DY$,K?JA.G-R*NW[?UEIKZ13K4O5KCU;1(4@!+B&ZAAUIVI0RHA
M 4VXI*C\H6KM[NL6PIY%RZSPMT"T$*5VHUMH4H9T3Z9D\TF3&8 FISJ6E,MN
M<0:)N#Z*0UZ"BD287!TS'J!)P.<L:K4>XUSM1:I]2Z>LSKM,XT7K?IMRH<0'
M$$=S3ESNM8EIQ(42AY+"76U0MM2%@$9-:;YQ!0;\-DSEIA*2/!1451 @003/
MLA)\T0H*%H5] MU1$<Y&D F.1D2!@@5#6VZD?T3N75T&I:BX76J?+;AK+?3N
M7"I?^.5N"H=86ZFI*G!\RQW.*2$B 40>L7;OGAKSMLMKSEUQ067F?2=4DC98
M(G?)$C),DS4YYH7K3;Z5AE"04!MS#8(5NG3B>F-O54I+KNJ*.T_%LNC]7ZBJ
M%TRB&54]MLK"#D .NUE>]5SB2EFA<)!$$+,#(N7MR$RU9.DQ^>IM(]8"E$CG
MRY9$28B;5C5"[EL9_,"E @C)!*0 ?$F"-\5">T:GI]8;B79W6=%2VQ]56@HL
MU4^*1AA282EASXZVEU+B$! 4MPDOE7=V]JDI3B&1;OO.O<0*?."L2TOT4I3I
MQB1JP(R>4YF#D7.T::::M0>Q"".T2"I9))D8.,S,",XC(+OW-JC:KZAJWMT[
M5$@MI9:I/A_ED ,ME0;#1[(+A65A)_?[@K/=UTGA1;/#[;L@D-Z5Z0B-(':+
MVC&\^NN0<?"AQ>]USKUMZM4@SV+6\YVC?E%6&"!R/^C)_20",>/;VZR%8>E'
MB<^)YF?!_2#/\_=2IO\ I=4$Z2OT84-2K4 #!/\ X+MF,@0)/GZ1!QUVK^3)
M,\)XC_\ F&T2?ZLS]'AOD5I?E*LHO+4B)#!,G8 N+&1WY$XSX5-C3UW%$ZA8
M5E*P1XR.24\=W D <GQ'6XWUL7D$1M)QS(V$F<'[/&K?#KU+!&I:1LH#,1DF
M#,208P3)(W-30VRW$IJ8-H<? $)"I6 GN!C(_M*&,'[3D$<FX_P5;BE*;20
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M3^W-N>33.W2N0W45S@444%O,.5=:OM"CVLM)6J0"08!S@JH3'T?3BOIJVF]
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M$I"2@T"J$5:7$<%*62>X=J>Z(,H75NH1 (SZ):G:.02?5W=-Q:4PZ-E$=^L
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M99<.8$=9W]<9^NL6Z%8@.?.3!(Q$CW)"P/:,',F)ZLR>XXG]W7!Z]QJ2VWH
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M8%;E6"]MEJH79KJRZ1W-N.V^X-.&0I/<VY\4*(*4D$@F0"(,=>D?&$^_AO\
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M[>R:8/XI@-H$PE(A().HJQ,$G..>,8%8N_NEO,7*W75+=4PZ%*7!) ;4$B1
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M22?(,KE,_P#-D'KFOE9^54C_ -HS'?Z;OT;=V8ZSUGR)_(R_UU_]FQ3,ZCU
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MP;$SEMM>9F?30KWBD3J&[B"FI$$Y!88,'S_ZO_<YC,C'GR9X.9/FR\_^X?\
MO*R8\K..@ "[2 ,#^;V_W5>O])[TF(JT^3_Q#'T__5&?L?TZI\&>#_)E_.'_
M +R@\K>.C NT?-K?[K'JJL:LOB00*Q(\3^7ISQG_ .9>WOYF/J^#/!_DR_G#
M_P!Y3X6\>W\[3\VM_J[**]1K"_@"*U!X /Y:G(]O_F1'/''^(?!G@_R9?SA_
M[RJ_"[CWRM'S:V^ZJH:UU$"8K4@X$FEIO_\ 3P(/TQS[/@SP?Y,OYP_]Y5#Y
M6\=.]VC'_MK;[K_2JQK?4@_^[T#$9I:7CGCX6,D8,P#&"</@SP?Y,OYP_P#>
M4^%O'1_YM&\_U:VW._\ LJK&N]33_P O3CP:2DR.)_XGWS,YS'3X,\'^3+_S
MW_O*I\+..#:[0/\ ]M;_ '5 UWJ>/^7IS&11TG!'_P"X]YF?'WZ?!G@_R9?^
M>_\ >5Z'E=QX?^;1Z[:W/_\ E2_T\U1YN"?:124HF8'EH^_(^N,9?!G@_P F
M7_GO_P#?5/A;QSY4W\UMONH]M)_3O4Y_^[TSP?\ 1*3/MRS(@08SC&2#T^#/
M!_DR_P#/>_[ZK\+N.C'G3?S:W^[Q/^D0(#KK4_\ \\$>!_R2DY\_^IQCCZG[
M=/@SP?Y,OYP_]Y5/A;QWY6GYM;Q[.RCU5K-;6U-QJGJVK4'*A]25NN!*4!:D
MI"$D)0 D#L2G 2!A1B>LQ;6[5HPW;L)*&F@0A)45$ J*CZ2B29*B<DU@[JZ>
MO;ARZN%!;SI!6H)2@$I2E ]% "1"4@8 VDYJV*0K,G]#CJ_4>CS@3&9CZDX\
M#^\R#) RI3-;D;<W36=TM]=05-N8;H[>JD5^<=J4N*<-0^[*4,4;Z2@)6/F*
MP>[NE!@*.:X9Q"VLV7&WFW5*6[K"FTH(TZ$)A6I:"2"DD<H._*MBX/Q>WX;;
MO-N(?4ZX\%@MA!1H"$IA6IQ)F03 3&QDG9N/\A6J!$W"PD#ND_'N ))((.+<
M>!C^R/M)'60_#EI@!NYCGZ#0,?YV<2.59A/E59@$%F[,G^RSM!G_ &V"9S]?
M6Y&R&II -PL1QD%^N)P,3%O S]QSR.#[_#UG_=W/_(U]]7GX36,89NP>0AF.
MN_;2/8=JN&=E-1-Y_/6,\Q%17*',XFWB(X ^D<">O0X]8SENZ[OQ;)YYD=L,
M;8YQ[+:O*6U49[*ZY?FM3CD?QVQY^W>KH;/:C"B166;M[8/^D5H)(! ( MY&
M<'!B9GF>KGPAL-4]G=D 1_1LB?5V^)W_ (YJS\(+2([&X.9$I;^],\YD^NA6
MSNH>?SME@#R_61(/,"A)F,9,8]^?9\H[ Q#=WSP6F8DYG^L&9SZXV%>3Q^U*
M@2U<0#(!2V<^MV/#%.UMCLOMI3W.UW;=C4VJGZ.CN##]?I71NE[96-7:C8=[
MS1NZGNNK;0_0HK$I#506-///MLN.)IJIIY+50F(YY1H2H&W97 _.="<8.R$N
M*$@P9)VVSM<5Y06>G\6W=!9!DE#0"29@I':K!C!\>HD'J(SZAO2Q3U JJ;9:
MGIJH @5+&U^W#%2"8B'VKNAV/E$0LD=J8)[9ZPQO4&95<>D2HCM#IU'*H!<(
M )Y#'*(J(>.)(3Z=T5  %15"B!B"0Y)$=YZ#K3@4?K:VCH*9%)1Z>UU1TC:2
ME%+26+35/3-(!_=:IVM5-MMID<(2! @8ZMBX8F5(</J3/A)4<>,U9/&9YNG?
MXX"P)Z:G%$=(! SF:RS/KKVD2I/Q;%N&!Y[++IPD>.#J\%6>,I!^W7A;S"AA
M"\9$A.=L'TO'G].:JWQE"224K B/1;0#O_B ;9\1W"MJH_7WL,R$_%L>ZX*0
M!_5Z?TH4F).>[7*!/[TJ G[1!C%4F8@1&^=STZ\I)CF#4D<;M=]-S(S\1LF=
MH_IO#E$8Y 5M5)^(AZ<FP/S&G]X%\ ]FFM&B0((()U^DR2(/N 1[CJVX"H )
M!($[J  F=H&_?BO1X[:'=%R2?]QN/VP,D;P8R8WK+?\ ?%O2_ /]&-Z.X_\
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M2I+02%+0I*28>5 !()(!,#:<5#<)6H'E*9GHD ?3!V/=L21R>_YV)\F8B8S
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MX/\ )U_.'_O*?"[CWRM'S:V^ZKQ<V[TFM06JWNRGVKZY)A4S(%0,D$1/!'@
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HS])SG,#WSXZ4JDB)$F %?3P.8CW/W\]*4J3] ,3_ #5_+''WZ4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g305908g17b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g17b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %E*^5Q0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&M'"D         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !Y@
M!6           0                         !              5@   !
MY@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MY@    !29VAT;&]N9P  !6     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   >8     4F=H=&QO;F<
M  5@     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MW$/_ &Y5_P"E%*OH'7JGBQF)[F\;GU.&HV_1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( -8"70,!$0 "$0$#$0'_Q  >  $  00# 0$
M    !P4&" D! P0* O_$ &40   & @ "! <)"0L&"@<)  $" P0%!@ '"!$)
M$A,A%!49,5>5UA87&")!5I;4\%%866%Q@9>AP2,D)28X=Y&4L;7C)S9&T>'Q
M,C0U-T)3=86VQBDY1$529J8*1TE49*3$Q=7_Q  < 0$  04! 0
M     0($!08' PC_Q !9$0 ! P," @8%" 8&!@@#" ,! @,$  41!B$2,0<3
M%$%181<B57&1%2.!E*&QT? D,E*3P=0(%D*BX?$E,S1#8M(U-D1%5&1R=%.2
MU7-U=H*#A+2U)K+$_]H # ,!  (1 Q$ /P#[^,4IBE,4IBE,4IBE,4IBE,4I
MBE8%\<'&HWX3(NF-86 B[A=K@\>+I04E(N&#=A6HU(4W<PY.S35< =Q(JM64
M>F8J:;D4Y$Y3F%D<@\WZ0M?)T6S 1'C,SKA.6M8CO.+;0W$:&%OK+8*@5.J0
MVT#@+PZ03U9%<\U]KI.C68*6(S4V?-<6I,=UQ:$MQ6AAQ]9;2I8*G5(;:! "
MR'3GYLBM=/EF=C>A6D_22=^K9R[T[W;V#;OK,G\*YEZ<;G["@?6I/=S_ +'=
M]M/+,[']"E)^DD[]5QZ=[M[!MWUF3^%/3C=,_P#04#N_[5([SX<'@,_DD<^6
M9V-Z%:3]))WZMCT[W;V#;OK,G\*#IPNG?8K>/ =JD9\_['VC;^/'EF=C>A6D
M_22=^K8].]V]@V[ZS)_"GIQNGL*!]:D[?W/=]!SR%/+,[&]"M)^DD[]6QZ=[
MM[!MWUF3^%!TXW0_]Q0/K4CS_P"#X'O^]Y9G8WH5I/TDG?JV/3O=O8-N^LR?
MPIZ<;G["@8_]U(^G/J;?Y^%/+,[']"E)^DD[]5QZ=[M[!MWUF3^%/3C=/84#
MZS)_Y,X]X%/+,[&]"M)^DD[]6QZ=[M[!MWUF3^%/3C=/85O^M23SSR]3?_,]
MV[RS.Q_0I2?I)._5L>G>[>P;=]9D_A3TXW3V%;_K4CZ?['N^.?#+RS.QO0K2
M?I)._5L>G>[>P;=]9D_A3TXW3V% YX_VJ1X?^CQVWQ\=J>69V/Z%*3]))WZK
MCT[W;V#;OK,G\*>G&Y[_ .@H&W_FI [L]Z.?T\M\T\LSL?T*4GZ23OU;'IWN
MWL&W?69/X4].-T]A0/K4G_DV.=L?QVIY9G8WH5I/TDG?JV/3O=O8-N^LR?PI
MZ<;I["M_T2I'V>H!SVY^_%/+,[']"E)^DD[]6QZ=[M[!MWUF3^%/3C<_84#?
M_P U(SRSRX/S]E/+,[']"E)^DD[]5QZ=[M[!MWUF3^%/3A=/84#ZU(S_ /Z?
M9]O=3RS.QO0K2?I)._5L>G>[>P;=]9D_A3TXW3V% Q_[J3_R>_/A]-/+,[&]
M"M)^DD[]6QZ=[M[!MWUF3^%/3C=#G_04#;QE2!W=_J?Y=^^U/+,[&]"M)^DD
M[]6QZ=[M[!MWUF3^%/3C=.ZQ0/IE21SY?V.\_#[*>69V-Z%:3]))WZM_JQZ=
M[M[!MWUF3^%/3C<_84#ZU(\.\<&1\/M(%/+,[&]"M)_'_&2=^K=_ZL>G>[>P
M;=]9D_A3TX73V% ^M2?+_@Y>?N[SBGEF=C^A2D_22=^K8].]V]@V[ZS)_"GI
MQN?L* ?=*D]^X_L>&_V#)IY9G8_H4I/TDG?JN/3O=O8-N^LR?PIZ<+I["@>7
MZ5(^G^SN-QRIY9G8WH5I/TDG?JV/3O=O8-N^LR?PIZ<;G["@?6I'_+W;YIY9
MG8WH5I/TDG?JV/3O=O8-N^LR?PIZ<;I["@=__:I!^&$;Y&_V#.^'EF=C?+I6
MD_22='_^,&/3O=O8-N^LR?PIZ<+I["@?6I'C_P"C\G;>GEF=C^A2D_22=^JX
M].]V]@V[ZS)_"GIQNG+Y"@?6I'_(/>?<<9P</+,[&]"M)^DD[]6QZ=[M[!MW
MUF3^%/3C=/84#O\ ^U2?$#]CS_#/.GEF=C^A2D_22=^JX].]V]@V[ZS)_"GI
MQNGL*W_6I'+Q'J_B.[SIY9G8WH5I/TDG?JV/3O=O8-N^LR?PIZ<;GS%B@'_]
MU)\O!!\??]N'EF=C>A6D_22=^K#CT[W;V#;OK,G\*>G&Y^PK?G./]JD?3_9[
MAN?A3RS.QO0K2?I)._5L>G>[>P;=]9D_A3TXW3;_ $% WQ_VJ3MGQ]3;\<[[
M5SY9G8_H5I/X_P",D[W?F\&_U8].]V]@V[ZS)_"GIQN?=8H'B<RI(P/_ ),'
MXUQY9G8WH5I/TDG?JV/3O=O8-N^LR?PIZ<;I["@;?^:D^/\ Z/#?_#>GEF=C
M>A6D_22=^K8].]V]@V[ZS)_"GIQNG=8H!Y?]JD>./V.7?YT\LSL;T*TGZ23O
MU;[?CQZ=[M[!MWUF3^%1Z<;GM_H*!O\ ^:D_3_8Y8Y>/D-Z>69V-Z%:3]))W
MZMCT[W;V#;OK,G\*>G&Z=]B@#ESE2/'!_L<A^=B#3RS.Q_0I2?I)._5<>G>[
M>P;=]9D_A4^G"Y^PH&__ )J1]GJ;_DUSY9G8WH5I/TDG>7]/@WG'\GY\>G>[
M>P;=]9D_A3TX73;_ $% ^M2//_@W'+'CG-<>69V-Z%:3]))WZMCT[W;V#;OK
M,G\*>G&Z<_D*!CG_ +5)[_\ \GN]W?YO+,[&]"M)^DD[]6QZ=[M[!MWUF3^%
M/3A=/84#/_NI(\>7J;\OAO3RS.QO0K2?I)._5L>G>[>P;=]9D_A3TXW3?_04
M <AO)D]_+^SO3RS.QO0K2?I)._5L>G>[>P;=]9D_A0=.-S/*Q6\]_P#M4C_D
M]WYYO+,[&]"M)^DD[]6QZ=[M[!MWUF3^%/3C=,_]!0/+]*D^&?V-OO\ LR\L
MSL?T*4GZ23OU7'IWNWL&W?69/X4].%TY_(4#'_NI/+_Y/\AO3RS.QO0K2?I)
M._5L>G>[>P;=]9D_A0].-S'_ '% P,[]JD?\F,YVQ_E3RS.QO0K2?I)._5L>
MG>[>P;=]9D_A3TXW3V% ^M2?#O\ 4V^GNW\J>69V-Z%:3]))WS_U;]?ZL>G>
M[^P;=]9D_A3TX73V% \OTJ1_R>/O[O&GEF=C>A6D_22=^K8].]V]@V[ZS)_"
MGIQN?+Y"M^>[]*D;_P!S\?CM3RS.QO0K2?I)._5L>G>[>P;=]9D_A3TXW3?_
M $% ^M2<?'@_''OVIY9G8_H5I/TDG?JN/3O=O8-N^LR?PIZ<;I["@9Y?[3)Y
M^_@Y>?\ ':GEF=C^A6D_22=^K?;\^/3O=O8-N^LR?PIZ<;GM_H*W[\OTJ1]'
M]CO_ ,LT\LSL;T*TGZ23OU;'IWNWL&W?69/X4/3C<_84#Z9,D>?['\.>W.GE
MF=C^A2D_22=^JX].]V]@V[ZS)_"GIPNF?^@H'UJ3S\/U/SOML:>69V/Z%*3]
M))WZKCT[W;V#;OK,G\*>G&Z>PH'UF3_R<N?PP,FGEF=C>A6D_22=^K8].]V]
M@V[ZS)_"GIQN?L*!G&?]JD<O'9!V/YWS3RS.Q_0I2?I)._5L>G>[>P;=]9D_
MA3TX73V% [^4J2>7_P"3\G:GEF=C^A2D_22=^K?DQZ=[M[!MWUF3^%/3C=/8
M5O\ K4G[/4W)'=\,\Z>69V-Z%:3]))WZMCT[W;V#;OK,G\*>G"Z>PH'UJ3X_
M^CX>/=XUG;P0<>H<5D[<:?9ZM#TFV0,>SG81E%RKE^C.PHK"TEE"%>I)+$<Q
M+I1@*I4^T(HA()G ""@H)NB]'W2/_7*3.@S(<>!-C-(DQVV7EN)DQ^+JWR X
M H+86IK."0I+H.!P$GH6@>D/^M\B="EQ&($R,VB0PVT\IQ,ACB+;Q < 4%L+
M+?$!D%+H.W":V.YU2NG4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5Y7SUG
M&LGDC(.4&3"/:N'KYXY4*BV:,VJ1UW+EPJ<0(D@@BF=550X@4B9#&,(  CE#
MCB&FUNNK2VVVA3CCBR$H0A"2I:U*. E*4@J42<  D[50XXAI"W7%I;;;0IQQ
M:R$I0A *EK4HX"4I2"5$[  DU\>_%QO=WQ$[UN.PA45"!!SX@IC501#P.HPR
MJR,2'4-R%-60$[B8=I_]%[).2AS  SX=UKJ-S5&HIUT)/9N/LT!!S\W!CJ4E
M@8/)3F5/N#N<=77Q3K/4*]3:@G7/)[,5]F@((.$06"H,Y'<7"5O+QMQNJ[JQ
MIS5*U;PY[_?O^UX<^0Y>X4Q0G?!\^1WQ_'Q/+RR13%1W[]W(G?.,\_ X[]MQ
MMD' 8IGPY^.XSCXY\0<D;[G?!8I^.1MMS&QSR/,8R-^>,TQ0;DCER/GCZ<8Q
MMY@<N[#%,\O>1Y$YSWXYD'!SM]@8J<\\[9Y[>6,X.<#EOR[C@TQ49R<^1QMO
MY@ _VMO=Y')IBIW^D8SS)[\=^_/S[]R:8J,X&![ON W'/WCD-B,XIBA.Q_CM
MMN=\^9( (W\QR8I_#&#X9 \<[[<N>#WD[L4[N_E@[?#F,8Y[G<#GN33% 2/#
MEMSQL.>>6.6^>6Q&>3%/+Q&XP<D?#8C<>>P'=ABA[O 9'+Q'(#GMW@$8 (WQ
ML^W^_P#WXIG.QWW.W/R&^.7,' \CWY8IW[\@=AN/'W9[@ ,[9&#N:#]OE^W[
M/EQ4@\]N_/B?I\,8VW.?[/<*8I^/@3W'&!S.W/O&,8 Y,5&>[ W&3G)\!OG?
M&W,CSQL:8J3S\".7+..>,9Y^[(^)%/\ =BHV'Y/>!CWDX!(.^^>[)8IDG'+/
M=GZ?#.>[(')0!Y8IBF=MN>WT$=Y)V\/?W=V&*G./IWQW\\_$[C'>1GQIBH\A
MR'/F!RR-B?<",@DG?;.6*'GMSQC<'/D<\\<QD=^YSM0/[/NXJ3[ML8QR\L'Z
M.6^"?HIBHWR-O'QY'PSCOQG8@>7*F*9P<\QG&WF>[Q\Q^MGR-/M]ON>;% <<
ML=^3[OX8.<^>3D[%BG@2.\X]_>.6<YY9YD=V13%3G;OSMXY/=[^[?F0!MW&F
M*>_N.W?GS\O+]D[9YBF*C.VV=^7/NP#S^P\O'ORQ4YVSMW''<3Y;G?8X //G
MXTQ4;=XY]P!SR//Z/[/<.6=J#BF>8V&-AG/,9]VVVQ!R,9\@Q4Y/V9^C)Y^&
M1@C/@0<<Z8H<[_1N-OQWR.6^QVR3@L5&_P!.#D^'/EC'+?N/> 2=BQ0<QM\
M=MN[NP=MQRY'&:?;[?;NQ4Y.V ?=Y9\#RQORYCE_PL5'?[MAL<<@-L]XQN <
MX[\Y%,4V)QSP1G;[_ASQG& 2-Z8J2?'PS]&#DC!..?/F1L,XIBF?#OW]WO\
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MMJSLP[F=?[0;[<@Z-/PRY',DJM.1ETK\BTG:T^F321$TY9^P3.E(09U,JO\
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MZZ#EVHFQ>,B)E(U7C>R6;E(!4CD H %T]=;]*3$#\ZYOHC.(<@AQ^2XEEUL
M-KC!2B$K0E(""W@@# V%7#UTO,A,02+C='D1W$.0@[+EN(8=:P&G(O$XH-N-
MI&$*9P4 8!&!7@87C95=LDA=(RV76$MSU9PI*6EE-S<=8':TF<5G9I"91<HR
M#A1^H JK^$.#BY.':*=<Q0$/-N?>8DMVXMR[A&FN%1?F(=D-2%J>R5%UX%*U
M%S<GB4>([[XJANX76-+<GM39\>:M2R[,1(DM25J>]=76R4K#BE.'UE962O .
M^*]\9LW;M<\?.XB^[#A!L;OPFS.6%FL4>,X^62,';SBR#Q+QDZ41<'#M'QEE
M3IKF#F)5!Y^C-VOL3M+C%PND?M:\RUHD26^T.*3@%]04.L64KP"LDE*MMC7H
MS=KU%[2MFY7./VE?'+4S,E-&0[@Y7(4AQ/6K*5XRZ5$@G!*3D^.4M>SIFO1=
M.F;%>92K0A4%H:KR4I.O(.*(8ITVJL=#N5E&+,G4%5-L=NW( $$Y$A O,,H>
MF7J3%:@/R+D_#CX4S$<<D.1V<Y2DH942A'>E)"1WA/?7F[-NCT5F"]*N#T..
M$EB(Z]*7&9!!2@M,+*FVP<E*"A(VR$GF#V)77:4:9ZX1M5[8&?5Q*JR*Z<S/
M-3.JDR1*V1KKQ0KA/MZ^U;]1NE%+&-'HH]5(J!2<BY(GWQGK%B5<FNLB)ANJ
MZR0CCA(2$)C.'(!CH1A(;5ZB4X  %5)G7=DK4F9<6RN*(3A$B2GK(2$A*(RR
M%@JBH1A(95EI"< ) Y^5_L#8SR B*E)W2Y.JO$&;NX*MOK!-+0D:9(1,T<1<
M2N[,R:]D/,6JC5 @)CS%$2]^>3MSNKD9B$_.G+AL<+D:*[(>+#>Y*%M,J5P)
MP<E"DIV_LFJ'+G<G(S$)V=.7#CE+D>*Y*?,9DC="V65.=6C'-!0@8[N'>OVW
MOFRF,A.NVMPNS24FY!E/V5RA.S:#^6E8I\$O'3,VJ1T5P]?QTD8LFSD'QE%V
MCTQ7B*J:X@IE:;C>&W92T3+@A]]UN5,*7GTN.O,.!YJ1(P>):VG2'4..9*%D
M+!!P:E-RNC3LA:)T]#LAU$F6M,J0EQYUEP/M/OD+XG'&GB'6W'"5MN>N@@G-
M?B%N6QXI=VM7[1<X]Q*2 6%ZI$3$TV6D91,'S4)MR9FX(=T_3"3DFX22HG<%
M!^\2[8/"5BGICSKNT5JBR9Z%/N]J667'P774AQOM"B@Y6M(>=1UAR1UBTY]8
M@PQ/N;*G#&FSFE/N]I<,>0^A3KHZQ D+*%)+CB>M>3UIXE#K7$\1XU9\K"YW
MEDI!(1EIM+1:M)RK*M(LIF515@4IP%DYMI"D0<%/&IRP++DDT&0(E? JJ5T1
M7KF :&Y]R0J,AJ7,2N('VXJ4.NA<<201(0R$JXFP\%*#J48"\GB!R:H:GSVC
M'2S,EH,1+[<5+<A\&,F1E,AN,$KRT'@I0?2V$]9D\8()KKJ]FNE)DG$S3)ZR
MU270;*LG4I6Y*3A9!%FLHF*[1P\C5FSA-NJJ@D*J*BA4SJ(DZQ1,F7E$.5<;
M>\Y(@/RX;Z$*;=>C+=9=0A9'$A:VRE24J*!Q!1 )3ON*B)+G0'5R($B7">2E
M32W8KKL=T(40%H4XRI*@A2DIXDDE*B@;<0%5I/8VU6AI9ZE>;\W-<UVB\X[)
M8[ F:T.8Q0PL59-<'8#,KQZIQ%H=R=R=J<W[B*9ASW%UO:.O6)]R3\H*0J0L
M2) [8MHY:+BN+YY3:CE!45%)/JXS7NFZW=!?6+A<D]N4A4A8ER09BVB2VIU8
M<S(+9R4%94I!/JXR .R4V)MJ8LL98IB[; DK?%-E$8::D;!8'5@CFBB2R:R<
M:_<.CR#1!1%5P14K51-,Y%%@. @8_.MVYWU^:S)?FW1VX,H4&'G7I*Y3:"%!
M0:4I1<2DA2PH)P,$@[5+MTO+\MJ2_<+D[.:3PQWW94E<II!2I*@RXISKFTD*
M6DA!&059!R0:*G<;RQDX1\E:+2SF:PP+#5UVG,2K>2@(P2."$BX=8K@KF,9"
M1\Z*#-F9% 2NW =F(+J=:V[?<VGXZ^US&Y,-L,1E=:\EV,T>+YEG<*;0KK%^
MHG 5QJR#Q'/B)]P;>8<3+F-R(;98BK#[Z78K6%?,L*X@MAOYQ0#;1"2'%^KZ
MQK]IW"^MW3MVG9K8@])6RT]\Y)+RZ;DM2*T2C"5AVJ5P"@5\K))%@6'6-XN!
MLFDV!N"9"$"1.NB7''!*FI<3$$%Y?6O!8A! :$1TYR(W5I2V&5_-\ ".'  H
MF=<4N+6F7,2YV005J2^^E?80@,B&M7$"(O E+8CD]5P!*.  8%=9;)W$E$PD
M''WK8Q(2M/&<M78EI8[($9!/FXJF82$.R1=^#1SA QEC,W+--$Z1C*"@<HB8
M<N6[I?PS&CM3KKV>&MM^*RV_*ZJ.M/$6G64)5PMJ3E10I(&-^$\ZN&[M>NH8
MC-W&Z"/%6AZ,PW*E]3'6CB+;L=M*^!I2<J*%-A*D[\)!&U$LTY?[M*)S%QEK
M=:YHK4C-*3L;V7FY,&3150Z;9-W(J.7(-FRSA4Q4BJ=DBJN<0*4RINMX3'[M
M<7TOSW)\R0$!"79)?>=#;:CA(6YQ*X4*6=@<)4KN)JWER;E/>2_.?FS'P@-A
MZ4X_(="$*.$!QTK7PH*UD#/"E2CD9)KW-MA;1.O9"-+K>CNK0*"]M*WL$Z9>
MP#&EZC=6P%3=BI*"P* %24D 7\& .13)AW#6FZ7I2I:43KB5S"E4Y*7WRJ06
M]DF0 K+A1R!6#P\ABJT7.[<<K@N%Q*YG"J:$RI/%*+0PE4KA62]U?)*G2O@&
MV=L"NANS>RSTMB#:VU59!HQ<11)P+I:SNVT<Y7:NW<<62"1%5%FX<M&3EPU!
M8J*J[9LLH0QT4C%NAJ#4RE]K3=KPIQMM;':1+E%2&E*0M;76A>4H4M#:U(X@
M"I*21D"KKY?U"IP2OEF\%U#:V1(^49I6AI:FUK;ZT/92VI:&U*1GA4I+:E#(
M!%)D=G;;EX1>LRM_V#)5U\+N2<P#ZSV%W#O!>/7$F^?+QBST[-R#J07=2#IR
MHB<%WBJ[I4YECG.-N[=KX_'5#>N%S=BN=8^J,N1)4ROC<6\Z\IHJX%A3JENK
M6005J4M1R2:\';M>'XYB/7*YOQ7"MY<=R9*6PYQK4ZXXII;I;7QNJ4XM1205
MDJ6>+>O!.W?8]L@XN+LMLN=CK=>*FC#Q\U-S4K"PQ4$2M4B1[5ZY79,01;@5
MLF"!$^S1ZJ)>JGR+GE(GW>=&9:E2Y\N)% 2PV^\^]'8"4A #86I3;?"G"!C&
M$X3RVKSDW"Z3([3,N;.E18H CM2)#[\>.$I" &D.+4VT$IPD<(20GU0  !5H
M&9NR) N=JY(@8A5"K'05*D)#B $."@D @E.8Q2E, ]4PB  />&6)9=2GC+3@
M1@'C*%!."0 >(C&"2 #G!) [ZL"A82%<"^' (44X2?V2#R(SRYA1(&>6/V6/
M?G*)R,79R%(54QRMEC%*F<HG(H8P$$ (8@"<IA$"F+\8!$O?DAA\@D,ND !1
M(;60$D9"B0G !&X/(C<55U:R#PH40$@YX%<(203Q9 .4D;C)QWY.U=:K5T@5
M,Z[==$BP<TCJHJ)E5#D \TS'*4#AR$!YD$0Y" \^\,I4TZ@)*VW$!7ZI4A20
MK8'U20,[$';.Q'C5*DJ3@K0I((]4E)&0,?JJ/#D;^/+!/GW&BI,IA(>.?E.
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M@-9R>ND2$W><$)(!9?8.%8)&=>U!IQ5MOKJ)$<R]3VKY1NL<!*%HG1UVV/\
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MKK)@81C8JIP120M4AXL.X CXNOL(YFU,!2BJ1+MU %550P\VU!<E76\3IIX
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M3%*8I3%*8I3%*8I4"<50"/#!Q&@'H)VW^;^(,_S$/Q@'?^;-GT3_ -<M)?\
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MM7]3)#X9+J>T%D1'6^N#?$'.K"\(ZS' %83Q X%2EP/KIN:-L9=)<CDBFQ8
M>V34!8ISET/I,BG[H43 8Q5"G(?O$0.4Q1[P$,S/1ZH+MUU6E06%76-ZR2%
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M^25:DNDZV("@Q]>@CB9VB=Z"0S;]!*+8%5 7J[*I*<GR'/\ "J5JX1MS[A4
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M$R,V^S-:3DA")T='J[./.'*S]=6G^DEI'5-K8LW2_HIB\*: 2+G A0YK*UX
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MGLH$CR+*X=G5?$(793T6ZD;DNQ)CUJ@.LMW>23*E/\*X%E<BLR;DUV>)(6Y
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M?=)PI"&]GTET>0]*7!^<U<YMP"+>[9K3'E-QFT6FT/765>78:%L-H7+4J9*
M[3)*G Q'CM  AU;L(QG1KZUBE&2Z%[MQEV<%K",ZIVL7X&I*ZVV93]@C:09
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MUNR3TI"5<\G,S<D_D?<^QC@>K+@+D%022 B@ '+[S4\8J:8I6N_C>F):+FZ
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MV ?N\IF1^4.8C_QGNY#W\@^[W\@R,).=AW]WT;<^_88R 0!N>$TI[K;3\Y;
M/GY_PS(A^3E^^?, ]_R<P[A#E@I3X)W//EGP.<'Q![^XG)R0I[K;3S_SFL'F
MY_\ +,B'?\@?\9Y=P\N[NY]X<A#NQA._JCO\!R'F#R R!R&1MWA3W6VGYRV
M//\ ^^9'\H?^T_(/W?D[AYAR 6$G^R#G/=G/V$@[$Y'/&-U<H\=_\/S_ !I[
MK;4/^DM@_&(3$C^7ER\)^00'Y>\.X>[NR<#EPCP W\!W;\L9V.?#F"6?AX_Q
M]WG3W6VKE_G+8/7$C\O/N[W/,!#E^<!Y<^[ED823L!]GCCZ._?Q)QGB!,UDM
MPES\[([GAVS^:EGK<8F?,+=Y).W2!A+&K&(84EECD$Q#<^J(EYAW"'R90X$A
M)P #D#EX=V=L8&,[9\=P:C/+GS_@?P_CX5MARWJ:8I3%*8I3%*8I3%*8I6(/
M'_\ R)N*;^9&_P#]PNN7Z\E/,>\??4*Y'W?Y_971T?'\B'A;_F8I7]UI9*OU
MC4)_5'Y[ZS%RFJJ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6B/@"WWH
M[4.\>D;8[6W%K'6SV;XNK<\AV=[O59JCJ4:-92R(.74>A.23%5XW07.1%59
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MQ,GC7^T?R<_P^BE/>!TP'FUQ6/ZC_B9'&O\ :/Q_/T^/?2GO Z8]'%8_J/\
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M]ZYJ;U";ZSC)\3\30H2>8'Y_._C3R;O E]ZYJ;U ;ZSC)\3\33@3X??3R;O
MG]ZYJ;U ;ZSC)\3\34<"/V1OSIY-W@2^]<U-Z@-]9QD^)^)J>!/A]]/)N<"7
MWKFIO4)OK.,GQ/Q-.!.^PW_CG\:>3<X$OO7-3>H3?6<9/B?B:<*? ?G[OR.5
M/)N\"7WKFIO4!OK.,GQ/Q-.!/A]_Y[J>3=X$OO7-3>H#?6<9/B?B:<"?#[Z>
M3<X$OO7-3>H3?6<9/B?B:<*? 4\F[P)?>N:F]0&^LXR?$_$TX$GN^^GDW>!+
M[US4WJ WUG&3XGXFG GP'Y.?OIY-W@2^]<U-Z@-]9QD^)^)IP)\/O_/^.]/)
MN\"7WKFIO4!OK.,GQ/Q-.!/A]_Y_)\:GS4&@=,:!C)B&TQKBLZXBY]^C)S+&
ML,A9-Y&0;-_!$';D@J*==9)L (E, AR)W<AP23S)/OJ0 .0 J7\BIJ)-WZ\D
M=HZ^D:?%/F<:\>O8MT1V_!8S8A&#U)TH4P-TU%1,H5,2%Y%Y (\Q$ #*DD)5
MD[XS^>8J#GN_#^!K6A?^C@V9;+#KR68WRD(-ZA/&E'Z;I.<!5P@9Q&+ 1J"4
M>H4RH Q5#DJ=,O,Y?C<A,)>8=(&AY^KM0]'=WA3(L5C1U_5=YK,GKNLE,E^V
M.AN,6FUIZT"$Z/G5(1EQ.#CBKK?1UT@VW1NF^DJRSH,V4_K73J;-!>BECJHC
MXCW5GK976N-K+1,]L_,I6O"%^KGASQKKHX-F4^5OSY_>Z.X2M=G<S;$K5.=,
M=NW6</EBIN05CT@!8"N2 8$S')S*;XP\@$:NCG1$_1ETU].G2XDIO5NII-\A
MHB=;QQH[TB:\EF2'FT(ZT)E("BT5HRE6#C&72;TA6[6]JZ.X$"#-B.:.TI$T
M_-7,+'!*D1XT%E3\7J7'%!DJBK*>M2A?"I.0#Q8H-FZ,O:4W=;796]^H:3.>
MU[(U%JBL2?!PB^>-2MR.%P)&F3!J4P"8XD,=3ERZJ7/N#7]3=&-UOFM=6:F8
MN%O9BW_H]N.CXT=X2.T,39D1$=N2]P-*;[*A225<"UN\.,(*N6PZ7Z6K/8M"
MZ-TK(MEQ>EZ;Z2;9K65)9,81Y$"%+7(<B,<;J7>UK2H)07$):SG+@ %7WKKH
M]-BT^EP5;D+Q3'#R+0<)K+-$YHS<YE7;EP44Q58I*" $6*4PF( ]8!Y!RY<]
M[Z.=.2=&:,L>FIS[$J5:V)#3S\7CZATO3),E);ZU+;@2$OI2KB2DD@[$8)Y]
MTF:KB:WUS?\ 5,"-(B1+O(CO,QY9;,EI+,&+%4'"TIQLJ*V%*'"LCA(SOD"W
M]9]&]LVEN[LYD;W1W(6:Q*S#0K,DZ(H-SG=&!-QVL>D':B#@H&!,3E 2CR./
M=SP'1IH:X:(EZWD3YD26G4^I';U$$3KLQV%N2UAJ1US;?SH$A(/5E:-E>L=C
M6Q]*72);=>0M!18$&="7I/3#-CF*F*8*9,AMN(@O1NI<<(:)CJQU@0O"D^J-
MP+CV#T>VQ;=3)ZN,;Q3&[N5:IH(+NDIH$$S$<H+"*HI,55.0D2$H"4AAY]7S
M (\MCZ0]/R=8:-OVFH3S$65=HK;#,B4%EAM2)3$@J<ZI*EX*62GU4$\1!.0-
MM9Z-]41=%ZXT]JB=&D2XEGF.2'XT0MB0ZE<61'"6B\IML*"GDJ]9:1@$#<#,
M=1'1C;487#6]A5O]",UIM+;UN01(2P"NX=HLI1L*S0#1@)F;F.^3, JG2.!2
M'^( @ &YS9^BR[V[6'1MJ-VXVY<716BV-,SH[?:.OERFH=TC%^*5,A'4%4YM
M0ZY2'.%#F49X<]-O/3!9;GHOI1TRW:[FB7KO7<C5=OD.&+U$.(]/M,M,:9PN
MESM 1;W$GJ4K:XEH]<@$B>/@-7KYY57S^?LI;F ?)RY,PY?C .0>;.\AT#N/
MP'A@^/G\22,\OGK?RS\?'GMRY?GG%59Z-[9L+LF[W-Q?*.I'V5LS09-D4YP7
MB)FX->L9R!H\B)0$4#@7LU5!Y"41Y#SSE.F=#7"Q])6M]:OS(CL'5$:&Q$BL
M]=VN,8R8J5&1QMH9PHQU8#:U\QD<Q77M4](EMOW1?H+0L>!-8N&DY<Z1,F.E
MCL<E$I4LI$?@<4]Q)$A/%UC:!ZJ@"=B?)/\ 1K[.E=H1=X0OM&)',:I(02C5
M4D\#PSIVVG$"*D L:='L"FE$1,)E04Y)J<B"(%ZUO?\ 0%RNW2?:M<LS835O
M@:4N-@<AN!_M:Y,V+>V$/HX&U,]0A5S9*LN!?"VX$I)X>*[TYTF6NS=%-WT"
M_;YSMQN&L+;J-J:T8_8T18,FQ/K8<"W4O%]:;4\$<+?5@N-Y7CB*8_C.BKVZ
MRA=<QJFQ->&6I]Q>6*0.4EB%-PT</(UP1%IUHH!%P!6:@&!8J:?6,F 'Y=8P
M<]MW0A?H5CZ.;6N[6A;VC-8S-1S7$IEEN5%DS+;)2Q%XF H/I3"6E77)0@J4
M@A> :Z/=.G_3L^_=)]V;LEY0SKG14+3-O:6J%UD25&@7.(N1,X9!28ZES6U)
MZE2W E"\IR0*DW7O1P;,J,[L23?WND.$+?9#S# C4DZ*K=L+J57!-T"L>F0%
MNH_2Y@D91,#$.'6$.0CTOH[T-/T;?.D6ZS9D24UK+4B[U";BA[K(K"I=UD!J
M5UC;:"[P7!L'JRXCB;7E1'"3RKI(Z0K=K33_ $:6>#!F1']$Z818Y[LHL=5+
MD)AVB.78?4N.+#/';G#\\E"^%QL\.0H"W9[HR-IRMSOED0V!0R-+30WU59(J
MDGP<(O74<T9D<.>K&'3!N4[<QCBF=17JF 0()N8!K]_Z,+M=]9Z\U(S<+>U%
MU7H*=I.&PZ)':(\R5;HL)$F3P,J;[,E;"EJZI:W>$CA03M6S:>Z7;-9]#]'N
MEGK9<G9>C^D.!K&;(:,;L\J%$N4N:N+&"WDN=I4B0E*2ZA#7&DY6$X-4PW1=
M[8&NZEB/?!H'A% L!9:34ZMA[)V@$JF^%-D(1?6%7LB"4.V*D7M!Y=;J\S9B
MU]$-Z5ISHFLHN=LZ_H_OXNUR=/:NJFLBZIG]7"'4%?6]6.#Y\-(X\;\.]95'
M3;8D:FZ8KW\D74Q^DC3CEFMC.8@>@/KM"K<')WS_  %H.JXSV=3B^K'ZI4<5
MD1\!F]<O\\:IS^7]REOU?O/Y?E_5GT5UPQR.?H.>><[^)Y?PVKYIWSY?GR_C
M6?\ K.JNZ/0JM4GSEN\=P,4C'N'34% ;KJ)G4,*B(*E(H!! P<@.4IO/S#/%
M1RHD=_Y[MJFKYRFE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4K$'C_\ Y$W%+_,C?_[B=9*>8]X^^H5R/N-='1\?R(>%O^9B
ME?W6EDJ_6/Y[JA/ZH_/?68N4U53%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6"7%9;^)6J7W74?IQV^7A;ZT>5."@
M:ZUULK,N=DL6-EMKIW/K[(;D:(5%&G0*[E1>+E&KI)>.=H"BJY?1X&Z7HF!H
M^;;+J[?VVTR;8XW.DR9;EW3'1:'7(D%"(R+0LN+G*N$I" EYE;:DNMJXDH;=
M-<FZ0+EKFWW>S,Z:<<7%N[;MOB1(3=D5*7>VF9UQ<<EJO:4M(MR;;#6X5L2&
MW$K9=04+<=8!R#T'MMGM_7<-..5XUM>8M ]?V?5&CIDH]IFQ*^^?URXP+YBU
MD9,[)!K:(2;0B%572Z,G&(-Y%BZ>-%TW!]6U18G+#=I$9"7EVUY0E6:<XAP-
MW"TRVVI=OE-.+:9#BEPI,93Z4H2IEY2VG4-N)4@;CI#43>I++&E+4PW=HZ50
M[];FG6E.VN]0W7H-SAO-MO/EI+5PB2T1U*<6E]A"'FG'&UI69JS7:VBF*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L0N/_\ D3<4W\R%
M_P#[A=9*>8]X^^J5?JGW5Y^CX_D0\+?\S%*_NM+)5^L:)_5%9BY355,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K6#I
M1G.:8T=IC>]8E;G+5N=5@6F\Z&N]L]U8/HBW692!<;-J<$/CJ2@;-3Y*0CIN
MPMJPV2C9^H-9\'T.O,-HR1;=EU$Y&U!J34.F9K%O8EQ1*7IJYI;AVYUM^!#$
ME%FG2OT=F3#GLM.QXJYJR]%GKB]7(3'6\TO@^E6I6F-*:9U9 D7.1!EKBHU9
M:5.S[HR['N,\Q%WVWQ/TI^).MK[S,N:B"A,>9;6YG6Q5R41WF\CHN<?[WV[K
MJV5VNVB%U9IY:T6%.U7"M35.=7J[V2J2E)CXVJUZS,8NQ*UR!K]CL3Z8L;^+
M8,'THXAF4$I)IMY5=KJ3\9K3-BNT&7+AR+W?DPHA@P)D>X-VVVQ)S-Q=>FRX
M;CT1,N3*B1&X\1I]UUIE,AR4&2ME*]VCRWM6ZBLMQA0I\73^FU3IJ;A<H,JV
MN7:ZSK?(M;+%OASF8\U4*)#FS79,UUAIEY]<5J(J0$2%M6'P-4^U5]CQ!V&6
M<11JO>.);>LM4F:"YGDRU-%[@V% 6%627&*C@8L'<A&HFBH(KR<!HLG+3/C1
M'W0^)HG)]),^%*=TK%80\)MMT?IEB<XI(;CN!ZP6J5%#*>O=+KJ&GE!^46XQ
M<26(_4*$3M$C$=%-MN$)K64R0M@P;KKK5TBW-I6793?4:FO426I]?9V.J9<>
M928\0.2^K4)$KM([;V:/G9G-*ZS3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I6(/'_\ R)N*;^9&_P#]PNLE/,>\??4*Y'W5T='Q_(AX
M6_YF*5_=:62K]8U"<\(S68N4U53%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*UAQ.SYS7>D*#I>->VZH3M5V79M.[9N%
M2H-DV)9=<UVMI3MDC[!%UZMUNT*H2&RX ]5]QD[)P[N%CVUI6F!2D'4*+%3L
MC]GBW74=TU"ZW G1IMGAW^QV^?=(=IAW:7,5%ANQ7I4R9#"V;/*$[Y0C,OHD
M.KA)8RTB1UHX1&OLNR:5L^F&'+E;I5OOL_36H;E;;1.O4ZR0H*9<YF8Q#A09
MY2[?(9M_R9+?C.16F[@J20ZY&ZA4NPNQC+MJ8PHLCMJ$T[K1[+W[<.ZMVL+I
M7'$E78J-G9 M0:.MKQ<5:K">3G'C-_,2+2-0KM<K$*O%,GZ;EQ'1J6!D6GA7
M<';DS8I%_O#<>UV'3NG7;=+2S+?>BM=O6W8WWX40,QVW&F&5O*E2YLA+[C2D
M)=>5LD6]<:+8S:7]11=-6)R3=]2:GU0S=(2WX49B6Z+:VYJ&/'N$PORG&WI+
M[3"(4*!%5':>2M;+"9:X6HV48Z5@9"8C7D.]NEGV?L\D1(HF;245&[8VE<]E
MPD=)M3@"C2390MKCVTDT5#M6KY)PW4 #IF ,'K5YEW44EJ.ZW(;MT.S68OLJ
M"V7GK'9;?9Y+K*QD.,N28+JV7!LMI2%#8BMAT"P^SI>(](9=C.72??K^(SZ>
M!^.QJ*_W.^Q6'T$ MOM1;@RV^VH<3;J5H5NDBLA<U6MRIBE,4IBE,4IBE: ]
M@<5.PT==<;%VD>*JU43B=U>[XA(>C\*K>.I,/&4VFTB9=,=?VYK 2].>VRVG
MDJDE$W<FP0FUJ[)N)KP)NV\%1*S%5&2<Y.",[<ML'_/F>5=6V>++BKC-[J5G
M85A'AY32V[P!P$90:M?J?>HF9KFUIO>[3829[;,ZY@U"'MT=6(A:59$8 O!A
M7VSIH_317=D/&=\>[^/EWXW^D[8WC)^&-N>1CEL,9. ?(9(VJDQ7%GME[P[I
M;5@.)JS73BZE]CZ7B]C\*;].CU*'U,\L/$?2*?.:\3KBU)&UU%D9B_4U\M9[
M)*2YY1A,.K$@*K@&CAG/Y_/YY_"IR0!D[GNP>1(]_F!MW[4H_%OM*:VWP:0E
MDXE)Q%K?ZQ<YC=D'8;+K?2AHK=D=O.IUR<T^K"6:@6Q])!1&LI*TR%US$OX6
MSVN%;-[&A;A.Y!^Y4"LXWSGGW > &WO'B?';:[^%GBKXK9C8O!EKO;ECF)^&
MW;L'>5OBK^W@(IFQN>N:W4MLLG.L[:=LP*W86;6MYKD!*Q[N/\7*SU4G:X<_
M;N8Z;(=09R-]B3X>>V03R(Y?1O@XKV[N)S=4!OS;\3&;LLE7W!1^('35$X?>
M$-I5J^O7MX:>M)*$-GNCX7E8>VNQH2R$W?7<A;X"RQT7KDU.21?E0,1R1VH3
MN=]P1@>)/CGN]Q\_"H4U/OGBNO4[O5A>.(3:% AG6M^+:XZD>&)K-P>Y6;1&
MZ+#%1T7K%4-;N/$+:C5.!1C=@5NV2$U.V2*GV%@@$6C-F\DFL'OW/+D,?9MG
M- 2=\GD=L>9  \QWCOJ1H#?W&+38K3Y*C8K!OY_L'HY9?B+N9=C7*GT%2IW.
M9-5W*EM@GD+JUZC+A5!=N&L%4'#1L+EN]6,_E7"B1#A-"2,'?]7?R.,DX\=O
M(=W?49'XPN(IQ7@G)C?]MJN](+77![)\.G#ZVIM:<1O%2;9NO-=S>Q;++-G%
M4=3ET//6V<NM<DE*3+UYEK(E<*^?)HG(NHM&^//;_'\_8>]ZV._8#Z=OCD'S
M^@]\J27'!=G6L;M47F_6U4N41T@NSM9[GML4A6)>]\/'"HTVE<X&)N(PJD2^
M8P,"R=,*90V=]LT%),(="RIRT@HX<E3<)S3BVYX];!Y<CG'^&,C;.^]1W)<8
M^\(]A#PM@WI:FO#3[Y?$5#Z\XL!-1Z),;R8:]@J"_P!74N1VK-4>2US4F4]-
M3FPX]IL5.HMT-@DHC=M!K%4-(*NWY]_Y^BHXCWYQDX.PSRQG(V&._F>[E5;/
MQU;8>4^_L&>P;Q6+WMW3G 38>$>G7!A7G^P;?)WFQ.X;<J]?-%U*+B[9/.TD
M41NZC*)1CX45!?-(Z#9G*(*!1P>?,8WYX.^YQG;G]O>3EGT?F];UM?<G%1 [
M"VTM;9*F;:V_7ZY1G=^H;UQ6ZA5]O6&N0:Z>L82C0MPJS1E$-X>-;V"PV^R-
M;"FNFX0;,U5.L9]/Y%2DDDY\_ =_AC/Q)^-;7L573%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*Q!X__ .1-Q3?S(W_^
MX762GF/>/OJ%<C[JZ.CW_D0\+?\ ,Q2O[K2^YDJ_6/Y_/GYU"?U1_&LQ<IJJ
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*5".R='PEVEAO%?F['KC:K.%4A8S8=(D$HZ5<,$Q<.&$/:(QZUD:Y<X!F_7
M5=-8JU0TJE'*N':T0>.<NEES[':-1R+<Q\FRH\2[61R2F0_:KBTIUA+IX$NR
M(3S:VI=OE.-(2A;\&0PIY*&T2 \VA*!JU[TK%NDCY5ARIMEU U%5%8O-J>2S
M(6R.-;,:>PZV_"N<-IY:G&X]PBR$L*6XN,6''%+.)>B6#3=#W7T?O>Y;'VC9
MBZSKVU#5FX/*?%:V;W:"MLK4+O#&I%#JE.96-_K>[0K%1/W;DLB,>YE(AVU1
M;RC/PK-XU,ZO3[=U=TU;[1989O$NR"9 1<'[PNVR8+$^VR!<;G.GN1&KO;I#
MH/R<8BGD,/H<4IE817.]*,M:G=LT?5MSO=_GBQ0M0&#<G;9'L:;K$N,FVW6-
M\EV>WVQJ:[8[I&:*?E1,U+*Y$9QM*)#?&-D6<DKMM,4IBE,4IBE,4IBE?GLR
M=<5.H3M!*!!/U0ZXD 1$"";EUA* B(@7GRYB(\N8XI7ZY!]S%*_($(4QC@0H
M'/U>N8"@!C]0.1>L8 YFZH=Q>8CR#N#EBE<\@^X'W?-\OW<4KGD'W,4K\B0@
MF*<2E$Y0,4IQ* F*4W5$Q2FY<P PE*)@ 0 >J7GSY!BE?KD'W,4IBE?D2$$Q
M3B0HG)U@(<2@)B 8  P%,(<R]8  #<A#F !SY\L4KD2E,!BB4!*8! P" "!@
M$.0@8![A 0$0$![A <4K\F23,GV1DR&2Y 7LS$**?5+RZH=00$O(O(.0<N0<
M@Y>8,4KD2$,8IQ*43$ZW4,)0$Q.L'(W5,(<R]8.XW(0YAW#BF!X<N5?KD'W
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CF1BQ!RKV[@$$S&,4%5NJ3M#\S#S-U0Y]W=E!))R=R:5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g305908g57q23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g57q23.jpg
M_]C_X  02D9)1@ ! 0$ ;P!O  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M_F*X35?#&B0?$70]/BTV!;2>"5I8@#AB V"?RH ]%CO+6:V-S%<PO;@$F59
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MT[4]'T[688XM1M([F-&W(KC@'IFN \&>&=%O]1\1)=:;!*MMJ#1PA@?D4$X
M]J /2+BZM[5%>YGBA5F"AI'"@D]N>])<W=M91"2ZN(H(R<!I7"C/IDUQOQ1*
MKX?L&8@*NH1$D]AAJ@TR!O'?B+^V[I?^))82%+&!NDSCJ[#\OT'8Y .ZFN8+
M: SSSQQ0C&9'<*HSTY-/\Q/*\W>OE[=V[/&/7/I7*?$S_D0M0^L?_HQ:UA_R
M* _Z\/\ VG0!HVUY;7L9DM;B&= <%HG# 'TR*6.ZMY9Y((YXGFBQYD:N"R9Z
M9':O'/ VH2^%;S3)KAS_ &5K494L>D<JL5S_ "_!O:NQ\,_\E'\6?]L?_0:
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M\\COFKMMHZ17L=[/<2W5S'"81)*%Y&[=G@ 9[<=JTJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g305908g71w52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g71w52.jpg
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M-E:!MO 6='6%AI3!TQ,B597A\174%!<R(T)%1E)F@O_:  P# 0 "$0,1 #\
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M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (" ZY!QR;-4^RU:^X
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MVUR>R3!V "6CZ2AY,;.C[;-O1Y#+FN?^^KC6^-V7M&WFW&]9/EIJQJ#P9W!
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M39JGV6K7W '_ $Z,L$J]][\S/)N7<O(SZ@D( @" ( @" ( @" ( @" ( @"
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ML<@OGP6QT34[D2JY>P"VM\$\17]Y,VG LPB4N-(+!8NI8>$G#A]DLD4L^D-
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M\IDY:4N1+D2DY,J1*2E292::31]U]F,( @" ( @" @.N0<<FS5/LM6ON /\
MIT98)5[[WYF>3<NY>1GU!(0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M*!Y8=[_#]#]T12K;ZQVE>F_J-"<*FI:!U8]$%!_:%.\6G1Y\KHL] ! $ 0!
M$ 0! 7&>E'R8NGO\F.-?= 2K8.C+1U43PC5[A4U*?.E329T@^,ZR\8GAO];P
M:$$ 0! $ 0! 0'7(..39JGV6K7W '_3HRP2KWWOS,\FY=R\C/J"0@" ( @"
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MWLH'EAWO\/T/W1%*MOK':5Z;^HT)PJ:EH'5CT04']H4[Q:='GRNBST $ 0!
M$ 0! $!<9Z4?)BZ>_P F.-?= 2K8.C+1U43PC5[A4U*?.E329T@^,ZR\8GAO
M];P:$$ 0! $ 0! 0'7(..39JGV6K7W '_3HRP2KWWOS,\FY=R\C/J"0@" (
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M"J=V2?RTN9/Y<>_VMI*K-ZP6EVMOW%\-4.6H=7#0Q4[\0?%%-D&%TR=X! $
M0! $ 0! 7..GK^ /!WY/\9^Y816W5%]2*F^%:O<(F93=T@^OU=_%]9>-3TW
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M\*U>X1,RF[I!]?J[^+ZR\:GIN!;4:@$ 0! $ 0! $ 0! $ 0%6WLH'EAWO\
M#]#]T12K;ZQVE>F_J-"<*FI:!U8]$%!_:%.\6G1Y\KHL] ! $ 0! $ 0! 7&
M>E'R8NGO\F.-?= 2K8.C+1U43PC5[A4U*?.E329T@^,ZR\8GAO\ 6\&A! $
M0! $ 0$!UR#CDV:I]EJU]P!_TZ,L$J]][\S/)N7<O(SZ@D( @" ( @" ( @"
M ("J=V2?RTN9/Y<>_P!K:2JS>L%I=K;]Q?#5#EJ'5PT,5._$'Q139!A=,G>
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MF+I[_)CC7W0$JV#HRT=5$\(U>X5-2GSI4TF=(/C.LO&)X;_6\&A! $ 0! $
M0$!UR#CDV:I]EJU]P!_TZ,L$J]][\S/)N7<O(TXSTY5!KEASE/<W;).,%&K/
M#I,DOE^H#[IB,<AO6F-&<:V(X<<CV F^R#V(YKD0Q,E'6!6I7>/)B(O].V%E
MD?=^EP@FX_-D8>9V8UPK3S3-Q[I\X-(W+D$!RD\<%D6XY<%>:O6J=4PAJNO/
M19,:)B,(HP5B0/FQ"(TGHZ6B%8<T:5EP=T7NAWIQOVDG39_2]QW/$1Q&"=UA
M:R!=Q!7 C L6(Y7D<'R&?=M-X%W>9F"YF6U8S\F;/WEA&P10)H0(CJO/!"9T
MF XSG^O8FKH=W^XD07S;%:TXQL9(MIIMAMMEEO1IEG31IIIO771MIMO7&FC;
M>FN,:Z:::XQKIKKC&NNN,8QC&,84$G[0! $ 0! $ 0%4[LD_EI<R?RX]_M;2
M56;U@M+M;?N+X:H<M0ZN&ABIWX@^**;(,+ID[P" ( @" ( @" N<=/7\ >#O
MR?XS]RPBMNJ+ZD5-\*U>X1,RF[I!]?J[^+ZR\:GIN!;4:@$ 0! $ 0! $ 0!
M $ 0%6WLH'EAWO\ #]#]T12K;ZQVE>F_J-"<*FI:!U8]$%!_:%.\6G1Y\KHL
M] ! $ 0! $ 0! 7&>E'R8NGO\F.-?= 2K8.C+1U43PC5[A4U*?.E329T@^,Z
MR\8GAO\ 6\&A! $ 0! $ 0$!UR#CDV:I]EJU]P!_TZ,L$J]][\S/)N7<O(SZ
M@D( @" ( @" ( @" ("J=V2?RTN9/Y<>_P!K:2JS>L%I=K;]Q?#5#EJ'5PT,
M5._$'Q139!A=,G> 0! $ 0! $ 0%SCIZ_@#P=^3_ !G[EA%;=47U(J;X5J]P
MB9E-W2#Z_5W\7UEXU/3<"VHU ( @" ( @" ( @" ( @*MO90/+#O?X?H?NB*
M5;?6.TKTW]1H3A4U+0.K'H@H/[0IWBTZ//E=%GH ( @" ( @" ("XSTH^3%T
M]_DQQK[H"5;!T9:.JB>$:O<*FI3YTJ:3.D'QG67C$\-_K>#0@@" ( @" ("
MZY!QR;-4^RU:^X _Z=&6"5>^]^9GDW+N7D9]02$ 0! $ 0! $ 0! $!5.[)/
MY:7,G\N/?[6TE5F]8+2[6W[B^&J'+4.KAH8J=^(/BBFR#"Z9.\ @" ( @" (
M @+G'3U_ '@[\G^,_<L(K;JB^I%3?"M7N$3,INZ0?7ZN_B^LO&IZ;@6U&H!
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M @" (" ZY!QR;-4^RU:^X _Z=&6"5>^]^9GDW+N7D9]02$ 0! $ 0! $ 0!
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M'?D_QG[EA%;=47U(J;X5J]PB9E-W2#Z_5W\7UEXU/3<"VHU ( @" ( @" (
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M! 7..GK^ /!WY/\ &?N6$5MU1?4BIOA6KW")F4W=(/K]7?Q?67C4]-P+:C4
M@" ( @" ( @" ( @" JV]E \L.]_A^A^Z(I5M]8[2O3?U&A.%34M ZL>B"@_
MM"G>+3H\^5T6>@ @" ( @" ( @+C/2CY,73W^3'&ON@)5L'1EHZJ)X1J]PJ:
ME/G2II,Z0?&=9>,3PW^MX-"" ( @" ( @(#KD'')LU3[+5K[@#_IT98)5[[W
MYF>3<NY>1GU!)&/J[:WD\*EH35N@U)Z<:K\=G!4D<!A[6YB?J_K1"M@KFNQ4
M'$M_>/JC28UJ[&D2WHHJ?#)P2,@7-^I-ZLC^G;[B)3@G;!ZN_#WD+A5R@F*'
M+'3;3>^.PO&W _.1ZKMM<MGY#+7*-*N?T(N1!W <1$O7T#0<[ X=1#'V9D(,
M-/[ULK7]78^\&/.M.QQ<F-BN?9=;K[NT^5:H6JQXJU-6V70P4=:U6^J%6E%)
MU9KLXY'^B&I@(1*,1>]Y:^C%) ^.\0C]ZS^]KO,O=YOO>?WZ=SW.?WX7P?9D
MICTIAG&\2'].=SOKKEGZ0U&[6F<;9SOWQW&=<]SG&N.Y_P"^>Z[>/W8R@,7]
M8G/1W/M:%_BA$7@]W,?6)ST=S[6A?XH(O![N8^L3GH[GVM"_Q01>#W<Q]8G/
M1W/M:%_B@B\'NYCZQ.>CN?:T+_%!%X/=S'UB<]'<^UH7^*"+P>[F>._51V.7
MEOJ YXO/+82S5  ,M>*UB,)*NS7Y\7ZCJ "N/=_=B,;1]N_R!#LAKO><]RR\
MWKOVM\;8QY2Z2NKU3=>:ZTU6F:5AHN8S>D_^/_AS6<S:=Y3+9+_PJ*F-'RL^
M7DEF//ES65E).;=)ER4[4SU_T6]9.@:@U%H.J4]JU3$_G-%?\E_$G<UG,QD9
M#*_^=2\_I*1F2,K+6469DYY)R<K.5LN1*:_E:(]_L@.</3Z@?T+?#K1?1.K'
M[64)^3G_ ".P/3#JO['U@_.4;^X/V0'.'I]0/Z%OAT]$ZL?M90GY.?\ (>F'
M5?V/K!^<HW]P?L@.</3Z@?T+?#IZ)U8_:RA/R<_Y#TPZK^Q]8/SE&_N#]D!S
MAZ?4#^A;X=/1.K'[64)^3G_(>F'5?V/K!^<HW]P?L@.</3Z@?T+?#IZ)U8_:
MRA/R<_Y#TPZK^Q]8/SE&_N#]D!SAZ?4#^A;X=/1.K'[64)^3G_(>F'5?V/K!
M^<HW]P?L@.</3Z@?T+?#IZ)U8_:RA/R<_P"0],.J_L?6#\Y1O[@_9 <X>GU
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M\[T9ZG\U4"]6*16:_.*[S]8AXB*E$*Z=$![2+JQN-6[,5J!DE BC;*-!'9T
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M%TH=AJ4.3HXYJWJU"E&8<9J7(QW6'-F&=MG-6L9<SC&N.VC4,-J?D2;&4 (
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MA?;&V^RS4=(']'W+T&N52.Z3KV)E/&\*-/!0Q^'AFPYXUL/4X].%QY]EX^.
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MZ$9D[=YADH15]EK;[+80CV8WLEW/MLQOL]^+)T+Y)" ( @" ( @" ( @" (
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+_P#[_P K[/@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g305908g72q97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g72q97.jpg
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M 0$! 0$! 0'_P  1" %& ET# 1$  A$! Q$!_\0 'P   0,% 0$!
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M6XD?AI*C-W7ITMQ'X^6<U<WVOKP'+GXV/!5&#R?1N9QV]9[-)PA.5+\\P/\
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MR+4:?%'S_6=4\@;O/O/UZ=JK/XJ?_COT\IR]_P [?6-3KW#W#ZM7$?BX_/\
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M3\WUC4FCD1[_ )E^H:8O]U'O'U:.12_W-OF_[PU/+_<V^;_O#1R/4>O<^_\
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MJ5GMCOGLE.,J5GW83C.<^6,\JOX?/]FI0">@!)Z]!U[NI^@=3K)#CI"04]@
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MX>_[#I^CF>_</?\ 8=&CE5^\>[[3JQHY4?\ C?Y7VZ->_-CZ\_H3RH_</?\
M8=+X#WGZETMUFQ2M1LE?M<$1D2;K$W%6"'*QW[C2D,<Q(@/XQC*<Y]$4,TYV
MPK&<^'MWQ[^)#/)5FALPMRS5YHIXF'\62*19$/S,H.K-*S-2N5;E=^2Q4GBL
MP./XDT#K+&W0CXKJI[QW:^U76MZBMG:]I6PX3./9=UK$+90V_'A:AD2X#!BP
MGE8QCL2"ZZX&4C.$J;(8=;6E*DYQCZIH7(\A1J7H?[G;KQ6%&^_+VJ!BA_PD
M)*,.\,I! (U][8K(PY;&4,G7V[&_4KVD&^Y031JYC8_RXV)C<="'5@0""-/?
MEO6AHX:-'#1HX:-'#1KY;_AS-8?%[?.L-J"C>B"V1KXB".=2CR(L.OY3P$D.
MKQCR<7 6:N"H2K/?+<?G*>^$JPG[,_L;\SYUPUF<*[\TF)RBV8E)ZK5RD.ZJ
M!O\ %%FG:<D#OEZ]XW^$?[*?!^9\5X//1IRQYK$/4E8#HUO$S[,S'^4:EVH@
M!\(NG<=N(R?=CZL?HY]"MWGWGZ]?,B]P]P^K4T=/6[;/TY[DHFY:@P,9,TJ5
M<*]FFJ6V%,1<@"7#SL,4XWA3C+4M"R!X'K3:%NAN/MF,H6\PWC//<5<.T^*\
M!DL!>9XX,A $[:, R0312)/6L(IV#-#8BCDY"0) I1B Q.NEX0XGO<&\28KB
M3'*DEG&3M)V$I(BLP3125K5:1EW*K8K32Q<X!:-G$B@L@&MU-\[O^#QVN)L7
M85=T/O*K;QOD=.2#4=\9J^G54-?YUIYUVSXR).^W#&V9<A<JX U$QT68_A2%
M1 S#JV$^=<-\.^5+"OBL7:XEX=N<.XV6M$TOF=DYFQC*S*HI??*WF\9:!1")
M3/+-&IW$[,H;7I?%G%'D=X@CS.8I\)\4T.*<M#:F6'SZH,#6R]I69KWWNWYU
M*JV':PT2UH8)7W!KHC%0G[HZY(FV]0'2WO77=4F!".GK6^LZF;"VQ8#"+#*4
MF:G)&62,_%%R7J\3,@2WJ#);B4'C*4X_D3"FFL+7 >3N>CPSQCPYE+L#IQ/E
M<M=CL4A*QJPWZ]>*$NDR0\\T$L':M&"8W "=IL3M#Q-Y5*U_B_@/BK#8^S&_
M!^%PN/FK9 PH+DV.L69; C>O)/R06(;!B1V D0DL8SR@&7^H[X0'7&U8J?.I
MUDZMGY"X3\!*3NG=B7&COZ!$BAYR/F+'61 HEHVT2D-),A.Q\<(<L08%!:G?
M5\LL#!,X/"_DSRN%EJQWZG!*Q4:]F&OG<51R*\2O,]:6"K;>2<QTX9XFD$LK
MQAWD*!>8,SR-TG&/E?PN?@N2XVYY06FR-JG/:X<S.1Q3<)1UTMPV+M*.*NLM
MZ>M.D;0Q1RE(XA(6Y.54B65-G?";Z3M<%U$@P,)U)/N[UTG):[BJK;K357]7
M:LFGZF_61AJ)2HN00-&PACCV)*>GENOS1CS26Q8@1EQUM6)B/))GZ5GA>2S8
MX45>'>((<I-<I4[BYC,5UNK;=LCD)HR\MB,+V5:L%6O&K$O.[!6&_G/+APOD
M*G&,52KQJ[<5<,SX>O1R-Z@V"P-E\>])$Q6,@F"059&?M[=LL]F1E"QUXT9E
M.NP_6WJM.A^E6,?IFP6^H+I LP\MKHT4NN_N460!^[5R:G&+=E]]=I2N1K5?
M:C1AXH!E04LM1N))X5S(S?22< 9C^$G&,JWL8>&N-JKPY2-TM?=FK(M"U!6:
MERJ*A$5NR97::4B2$!.S#CF/%KY4>'UX5X"@;&9@<8>3J\EC#2QR4_X/W87R
M=*S;3(%G-\&>C4$"+!"O963VG:M&>17EU2]?%!W;2K^FC7/J_@+-L4:/&.UG
M9[E2"=#U\<@R/590(\6/;?M<M&F1PYX\<&5F-'',-P5EEH9EF/9H<(>3C)8'
M(8PY"AP39J8MY'CRM2CD$XBLLB2^:22/(5IPRI*T32NO:LT:%.9G9I&T>.O*
MYB.*,7F%Q62\HM2]F8X8Y<)?R.*?A2FCRPF]%"D(?(6(98$F2&.0PHDDHDY5
M15A77+H.ZEJ/TM;8N%WV#7K19J]:M3V;72P*CF+Q*MOV&<JLCDK*I<Z/%0.V
M'!&-*6EYQY)#X^4LK1Z12.I\HW"N0XNPM*AC;-2K9IYFIE!)=[;L2M:O<BY-
MH(Y7+&2Q&=BH4JK[L#L#QODHXVQ7 G$&2RF8IW[M._P_>PQBQW8><*]RU0F[
M3>Q-#&$$=2120Q8.Z$*1S$2K8>L70^KM-;)T_P!'FG;C1RMS1N(#9&SMH682
M<MY%7RR6*17(0"*61&A,EAR,B&HU!(V&1SC'%1Y,BL&1C<&OP/Q%E\[B\WQO
MG*.03!R"QB\3B:KP4EM;QNEFQ),J2.4>*)^S*.6:-!VJ1!XI=ZWY2>$L#P]F
MN&_)QPUDL7)Q-$*F:SF=O1VL@]#DDC:G5A@:2&-9(YIH^U$B!%ED;L9)C'-#
M>L77I"IV3T-;#I5>M$<1TM:UI>OKD/(JBVEVH6,C0(&X,0"Q) E*0IR Q+@!
MN26!'6U&,N/CIPA6,15_)Y83$<?XV_9IRKQ9E+F1HM%VS"F\LTEBDU@/$AYZ
M]@PR.(N<$(P5NH.I\AY6:JYCR7YG&4[\+\"8;&8G)I-V"F_'#%!4R*5#',X[
M.S4\YBC:?LV!D4N@V(TX-C_"*0*^IGI\VUIW7TI!:MZ?@)\>#UU8B(\(L\K8
M1$^G99;;\4_*A1Q$W%S304<_^_/528T<T@=W"G!LU,9Y,[ X6XDP^:R,,^6X
MCDK-/DJRRND:8U:YQ:%9A%)*L$T#/*OH<ZRLBL-@PL9KRR5&XWX0XAX<P\]7
M!<(Q6TJX:X\,<DLF8>V,W(KP/8BA>S!96.!MY!&\"2,C E"I[XZ\-=WLB'-I
M5XZP940S;-*O=IU]M2U44W6T56ZW96;<37*K&PKC\Q(OC3 ,3FNOSTFRV",
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M=^J16Q7:G<M:T>,U;70[3;9W9T]+5V#!A",G^F/5)1M?G6!AHYF-**DBI+(
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MON.YC,(C^WJK:&TSF5C?>$L.Q-?<IZ/*2=MR=^\['8^S8'H->CRYRW-Y4K^
MDNH^"FX5>26BW8FK).ZQAI9/1].9D)B+,Q8P[1?$  T5K]MW)L/X+@L+7UN*
ME)37ETGH;90+4[# FQ6B(JCSS1D$6/(D"N$0R0BXC(T:(EV1/::4@!LIYAUO
M&5SSR8=A$^[1NPE',H(KJC<RD$C<<I&P'4^&^O-JM_/Y7R,/'BK[S3XK(6J^
M8C%JO'+!PU#CK2R5I%F="U?LWK\D,8:651M$'96 W+@)(7'6U3WAY.%87CX.
M:.&8+DRA?9+)_P ?\J:1(K=4IGT#:O"X6RYC.?5L.96C*>_+@(^Z<9#+_N3W
MDCE![8'KX;>)]FN^JRI\(E!DFKJ?@EA17F=.P67[JD@3%B5Y1T,BD'T =P1J
M#+1*S]2Z;=70W7O/0=CMDQU746R5P&1EZS:)$?5 4G N6.3==K#Q@;]65%)M
MB7O55O,MQ$W&165LJ(!CQJ4K-'2@7+.C2-D(70,8W(@#(78\A([/E$NY&XY&
M5?$#7.79K5'A'"U_*;9K6[MCC?&VZD<T].[*N$CFK&W,S4VDC>D8!>YC&6 K
MV8825+1Q)-ED/VC%7WJ@NF^+;5Y/HDL.I)@/6XB[%4)*LSA!0<'BK@4V'CRG
M95$VD=J8&]+@=I4C+OAO1RSG/9I(SY6L)+D9KLL;8B2JX@'/&T;E@@C6)5//
MS[!ATVYG8%=SRE>DN2YF#)<8Y#B6]2F\G=K!V(\3'YW1EIV6>.L*<6/KQ.TP
ML!%L(6Y5[6=XWB[0]DZ-36CFT2:)T RG3O;*U!Z'@PJH!OQINP56(&S;2CZ^
MU;8RS!2C[)\I,SDLY/ 0P4:R2=BR'-&^C&R_''IK5S:,.!?'RQ)101+?':1(
M.V+()ED5BK/([]HL80%NU(;8;JVJ.(.8?&^3";A6]4K<-5HJ47$RBU2@4W7E
MJ+>AN1SLLDUBQ.;,5>.%7D%N42!4YH9!&P)D?N_?'75T:S4N.,'M6PKO^N#W
M5H=' O=-Q!&G)$RC*\J=EHR-CBB%-8SA,=79!*O%A]3;E$%;][/X21@%MR&Q
M6;H0L\)C8[=_QPB$[=RQL/'69%)%Q#Q)Y1N [$R+'F;1R>*E)!2+)4/-I) A
M!)WGABB=B.@BJR@[ABK<[>O'9D=L+J'L<36E(31=31\;IZC"LK\8H\+1&W(X
MU0RDY]$ZP3/JF'A26\=GH_(./$M#:%<Y/B6VMG(RI%_M>D$I5U'<J5P4;;P(
M,O.5;Q3E\ ->7>4C+Q93BBU!3(&-PD4."QR*=T6OC@8I"A[BKV>W9&'QHNSZ
MD '6FG.3?N'O^PZX+1RJ_>/=]IU8T<J/_&_ROMT:]^;'UY_0GE1^X>_[#I?
M>\_4NO.0/\4_-]8TJ?&'S_4=*L'+R-?F8N>B"G I:$D09>+,:SV=$D8TIDP(
MIO.>^,.#DLM.HSGW*1CD(EDKO'/$Q26&1)8G'>LD9YT8>U64$>T:M0SRU9HK
M,#F.>O)'/#(OQDEB821N/:KJ&'M&OM-U#L2.VUJZ@[*B_1I$NM5AYY3#:O$D
M$PT-M4E&*5G*N[L7)8+CG\>)79X5S'B5V\6?K'%WX\IC:.0BVY+E:&?E'7D9
MT!DC/?UBDYHVZG9E(W/?K[PPF4BS6(QN6AV$>0IP6>4'?LWDC!EA)Z^E#+SQ
M-U/I(1N>_4C<OZU-'#1HX:-'#1HX:-?#!UOZQ_<?ZL]\T1H? L>'L"6G(0=*
M/ VQ7KCZ*XU\=KRQA38L//!BX4GR\3"L9[*PK&/T<\G68^[W!'#629N>63%P
M5K#$[EK5#FH6F;J=B\]:1]CUV8:_+3RH8/\ @[Y0.*\4J=G#'E[%JJFVP6GD
MN7)5$7P*I7MQQ@COY3OL=P-5T^_'UX_3SLV[C[C]6N"TJQDI)PIXTI#R)T3)
MA.>F#D8PL@ \1WPY3Z48P5QHAASPJ4GQM.(5X59QW[9SCE2:&&Q$\-B*.>&0
M<LD4T:RQ2+W\KQN&1AN =F!'34L$\]69+%::6O/$W-%-!(\4T;;$<R21LKHV
MQ(W5@=B1K/\ ;TZJ9Q9,S4MFQ>NIE/;V9$S,U[3PYA_$C[4R]Z]Z]A[&'L%^
MG]8P[C#F'/'CORJ:U80&H*\'FO9F'S;LH_-^QVY>R['E[/LN7T>SY>7EZ;;:
MD-RWYUY]YU8\][19_.^WE\Z[?HW;><<W:]KS>EVG/S\W7??2F==+C+BFQ\K;
M+-)@2D@F7DPI">E#1)&50PR.B3.&)*=9+D$CC#,)-(0X2ED=AK#N$--I377'
MT(&BE@I5(9(8^PADBK0QO% 6=S#&Z(&2(N[L8U(0LS-MNQ)L/E,G92:&QD;U
MB&>46)XIK=B6.:P%1!/*CR,LDP1$02N"X5%4-LH O.76Y/3,98GK;9G;!"-#
M,0TZY/2JYF(9#4ZL1F,DU%Y- :%6\\L9L5]I#"G75-83EQ><Q#'T%@FJK2J+
M6L,[6*XK0B"=I  [30A.SE9PJARZL6"@'< :E;*9-K,%ULC>:Y65$K6VMV#9
MKI&6,:P3F3M8E0NQ18W4*68J!S'>])WV]3:9M$S=+9+HLQ IEC1)V.8/38"P
M4CI"*FTE&.XE2 TAB)%?/P0Z.D4?#2D88:\->/&XZNT!KT*4!J(\=4PU8(C6
M23F,B5^2->Q20R.76/E#%W+ \QWCLY?*VC;6SD\A86\\<ET3W;,HN21+&(I+
M0DE86'C$<81Y>=D$:!2.1=E)S:.S"@Y:.)V+>B(^=&9#FP7[=8'@Y@0="VV!
M945R04Q(#,(6M#+!:'FFT+4E"4X5G&85P^)22&5,7CEEKNTE>1:599('8[L\
M+B(-$[$ LR%22-R=6/N]G)8K,,F9RTD-I$CM1/D;CQ68U#!8YXVF*3(H)"I(
M&4 D  $ZPZQ>[O25&KIERM515(M)9D%5BPR\ H]E'C\#1N8HP3)32/&OPMOY
M<2GQK[8QXL]WWL=C\@J>?T*=WLCS1>=U8+/9,2-S'VR/R$[#<KL3L-^[3*.5
MRF+,IQN2OXXS*%F-&Y8J&91OLLIKR1]HHYCL'W W.PZG6'"VJSUN938Z[8YZ
M!L*5$+3/0LQ(1<RE9>%8*6F4!(8.PHG"UX(5A_N]A:O295XL]VV*=2U!YK9J
MUK%;EC'FT\$4T&R <@[&16CV78<OH^CL-MM05;]^G>%VG=MU+G,Q\[K69H+.
M\@^^'MXG27=]SSGGW;<\V^^I#H>PX9RY5I[>K-XVGK*-.G9"9I8]XE8HTPR8
M E%>O1DH2X:B-.S8#1IJ1(;8]+*9:*8)<RHQQWF3E,9,N.MKP^<?B,I+'6C@
MO&A#+&B030_>Y8D$9EC\VC:"-2VT7,C(/0 UT&-S%4WZ;<6+E<]@H);,UK&1
MY2>"622S'/M+!.[2"&7SR5+,SA>:?ED5V)D9M2%U8=3!O4S?(*:%K ]"H-!I
M\-KS65!$D795BKU"!;4@5DB0<9%]?DRUJ\91>!6/",R!'X],W'MD.Y'!W"L?
M"N/L0/:;(9'(W9\EE<B\8B-NY.=V*QAG[.)!T1.8[NTDGHF0J-/R@<;R\;Y6
MI9CHKB<1B,=6P^#Q,<S3K1Q]5=D5YBJ=K/(3O)((TVC6&'TA"';72-L$]"L2
M8L--R\2+-A9CYD:,DC0&)<!QM:%@R;(KS39X:T.NH6,4EUE277$Y1G"U8ST5
MBM7G>%YX(9G@820-+$DC0R [B2)G4F-P5!#H0P(!WZ#7#17+=5;,=:U9KQVD
M:&RD$\L*683S Q3K&RK-&0S QR!E(9@1L3K"'>>'=9('=<8(86V\P^RXIIYE
MYI25M.M.HRE;;C:TI6AQ"L*0K&%)SC.,9X2*K(RL RL.5E8 JRGH00>A!'0@
M]".ATD;,A1T9D="K(ZDJRLI!5E8$%64@$$$$$ @[Z=MDO5WNV0EW.XVJW+CF
MELQZ[/89>?4"RO*?&T&J5,+R*TOT:/$VQE"5>!'?&?#CMDUZ%&B9!2I5*8D(
M,@JUH:XD('0N(43F(W.Q;<C<^O6G;RV4R8C.2R60R)A!6$WKEBV8E(&ZQ^<2
M2<BG8;A=AT&KSFP+Z]6D4MV[VYVG->'T=3<LLRNM-^!S#J/!!*-S%H\#N,.I
M\(N/"YC"\=E8[\@;'T%M&ZM*HMP@[VQ6A%D[@J=YPG:G=>AW?J.G=J4Y?+-2
M&-;*9%L<-ML>;MDTAL=QM5,O8#8]1M'T/7OU1'7>Z1;<*Q&V^T1S%;((-KK(
M,_*B-0!A:GE%%PK8Y;:(HDE1)*B'P<,.O9(?RXM677/$V6E3E\X:2I6D:R@2
MPSP1.9T0 (DQ9"954*H57Y@O*NP&PV=5R>2@$"PY&]"M+M)*:Q6[$:U))"2\
ME8)(! [EW+M$$9B[;D\QWHLELM5RD,2UOLM@M4KAE ^).R3,C.2&!V\J4VQ@
MV3)*)PRA2UJ0UZ3P)RI6<)QE6>\5:K5IQ]E4K5ZL6Y;LJT,<$?,>]N2)57<[
M#<[;G;1=R%_)3><9&[;OS\H3M[MF:U-R DA>UG>1^4$DA>;8$D@=3I$1[L_7
M_9CD^JFKB??CZ\?IXC=Q]Q^K1J_R#1JZCW9^O^S'*L_QQ_BCZSJ5.X^_[!JX
MGWX^O'Z>0-W'W'ZM/U*FE[\]JS;NLMD,+<3FD7JKV9]+??Q/A1,P(7("9QCM
ME39H#9(CJ,9QXVGEH[X\7,C+4ER6+R-!@/[<I6:X)_BO+$Z(_O1RK@^!4'6Y
MPSEFP/$6#S2DC[EY6C=<#?THJ]F.2:,[=2LD0>-AXJQ'CJ>.OR@LZ[ZN-SQH
M*$>Q[%9$[ A'V.WJA,=L($6WJ<"4GLA0K!\N<"WZ/\&G(BT-]T(QGF+P3=:_
MPQB9'W[6"N:,RMOSK)1=JNS[]0[)$CG?KZ8)ZG75^5K$+A_*%Q)#$!YM=N#+
MU73;LY(<O%'D28B.AC2:Q+$NW3>,A>@&M/6_QT_7SJ6[C[C]6O.D^,/G^HZS
M>0:FUG1\G)1+V28N1.C2%(4TI^/+(#>RVKMXF\NCN-KRA7;'B1E7ASVQWQGD
M$\<<@59$21=R>5U5QOTZ[,"-_;J6&>>NW/!-+ Y&Q>&1XVV/>.9"IV/JWVT-
MR<DRHQ;,@<TN0;<9/6V60A1S+JO$ZT8I+F,DMN*QA3B'LK2M6.ZL9SY\C,<9
MY 40B,@H"JGD(Z IT]$@= 1L1H6>=3*5FE4S K,5D<&56.[+*01V@8]2&W!/
M4ZN9.-RI2\F%96MKT"UY(>RI;/G^!4KQ]U->>?P><Y1YY\N0<B;;<J[;[[<H
MVW]>VW?[=)VTVY;M9>8KR$]HVY3^23ON5_P3T]FO</OJ8;'4\ZIAM2EH9RXO
M+*%JRKNI#><^!*L^)7=6$XSGOGOGSSR%E7M&;8<Q"@G8;D=>A/?X#Z!J57<Q
M(A=BBLQ5"Q*@D]2%WV!ZGJ!XGUZS2):4*SE14E($JR.V)E1!A+V<B,X4EH7.
M7'%9R.TE2L-L_P"QHPI6$IQC.>,$4:[<L:+L2PV11LQ[V&P[SXGO.I7LV)-R
M\\SDH(R7E=MXUW"QG=CN@!("_%&YV'77GK92LCKR21E8V&_5EY><RH?T>4Y;
M] K*N[7@RE.4>CRGPYQC*>V<8Y!RKLPY5V;?F&PV;?OYNG7?<[[]^^FM)(64
MF1R8R!&>=MXPIW4(=]UY2!MR[;;=-9#\E(F./+,/-+64YAXE9)3[ZR'L)2G#
MKZG7%Y><PE"$X6YE2L82G&,]DX[,,<:KZ*(O*-EY54<HW[AL.@]@TKSSR\YD
MFED,C!G+R._.PV 9^9CS,   3N>@]0U?>DY(GPX(D3G\)&;"3AXLAWPAM>+#
M0B?&XKL,WA2L-L8[-(\2O"C'?/> QQ@':-!U+=%4>D>]N@^,=AN>_H/5IQL6
M'(YYYG]!8O2E=OO2]%CZL?O:@D!/B@$[#KJG$@>D)<:DXQ,<X]@E8&"7L!+(
M3C"4OK%POT"GL)QC&'<MY7C&,8PKMC'(>1.;GY5YP-@_*.;;U<VV^WLWVTKS
M3"(0"63L2W.8>T;LBXVV<Q[\A8?RMM_;J\N5DR11P"9$\@$/'<0)\PAT07/N
M[CC..*98SVSG'X)"?+.<>[.>5Q&@8N$0.WQF"@,?>P&Y^<ZE:Q.\:0O-*T4?
M6.)I':-#UZHA8JO>?B@=YUZ;*2<DMC$C(GR&!6_0C8-+(*P.UVQ^"8].XYZ)
MORQ\AOPI\L>7EQ@1$5N1%3<DGE4+N>;O.P&_SZ)9YY^7MII9N0<J=K(\G(O3
MT5YV/*.@Z#8=!K$Y7?O'N^TZBT<9IS?Q?\4?;KU7OS]>?T\KZ;K'5[\_7G]/
M*DO?\[?6-/7N?W?8=74?BX_/^G/*C_&/S?4-+'X_-]NJN5)N\^\?5I1\=O=^
M;7B?=CZL?HYGR=S>_P"W5D=R?-_W3KWE-N]O>OU'2^(]Q^M==!.K;_7 T7T9
M[U;_ 'P7*ZHDM-V<G';+B9K4$TY%@O2&<>\V7%./,0M?=QX<=*\]F\-8YAP;
M1S7(.X"83*/9,NYV]@( []>L>4 _=7A7R><3CTGGP4W#UU_$6>'YW@C:7_C+
M"2RR GJR(#\7E&N?J_QL_F_1CEG7DR?%'S_6=4\@;O/O/UZ=JK/XJ?\ X[]/
M*<O?\[?6-3KW#W#ZM2GJ*\U77]H7-7/65>VS $1)L655+&?)1(_C*=&>9DP9
M6(4B0CI,-8WA8)'SXO0ODLYQX7<YQG3C=^_;H/J.NAX?R='%7/.<AAJF=JO!
M+ ]&W+- F[LC+-%/ 1+#-&4V1TZ\KN/'4L;TZH9/;U.IVK*U0JIJ34-$/+F8
M&@U)<@:V_/'));?G9V:E77#9B30T<>TP0MH=24R!JB,E.O)<;HO\4_-[/$>K
M70<2\9S9[&T<+3Q='!8'&2O8JXNB99 UJ3F#6;-B=C)/,!+*JL0AVED+\[,"
M-6N59/#Y_LUQ^COGOV[Y[9QG.<=_+.<=NV<X^?MWSV_)WS^7E6;XO[^L:-'*
M;_%/S?6-&CE=_BGYOK&GOWCW?:=5+_&S^;]&.4=,UYWSCOC&<]L^_'Y?/OY_
ME\_/Z^57^*?F^L:-SZ]4X]WYU?ISRH_>/=]IT:JSG.>W?.<]L=L=\]^V/R8_
M)C^3E9_C'YOJ&C5]C.>^<=\]L8\L=_+'?/GVQ_+RF_Q3^_B-3GO7V$[?.#OJ
MZO.>V,=\]LY[YQW\LYQ[LYQ[N^.^>WU\HO\ QO\ *^W2ZVCT+U/*Z>:Y95T[
M654,VS+^V0Z]N*7+DGYRF0\]%1T86##P:<IB721E!$G 2)"L.M$2)+!+1D>I
MT)^[1ROW-AF,-6%KC\XCNNS&2!)$5"J1_$)!!96)WW8@@J2#W'#'&!X6IVO,
M,12DS4_G,=7.SO*UFA!9ACB>."O_ '!F0QO)'*W4-*ZNLD1:-M6G'''G''77
M%NNNK4XZZXI2W''%JRI;CBU9RI:UJSE2E*SE2E9SG.<YSG/.?D)(W)));<D]
M22=]R3XDZY DL2S$EB2222223N22>I)/4D]2=4<SW[A[_L.DT<JOWCW?:=6-
M'*C_ ,;_ "OMT:]^;'UY_0GE1^X>_P"PZ7P'O/U+KSD#_%/S?6-*GQA\_P!1
MU6CWY^K^W'*LOQ#\_P!1U*W<?<?JU]#_ ,$[O6((TG:]8VJ=!C7M;6I!<&N3
M,:$:57;NDZ3;#&R0XG#JQ;#'60LCT>>S:)(;"D)SG"G/;?)AFHFPUG'69DC;
M'V>:$R.%!KW \@1>8]2L\=AFV[A(O0=Y^E_(QQ% _#]S$7+,<38FX'KF:14'
MFN0$DRQIS$;E+,5IVV)V$J;@;C?L-SU?7N6CAHT<-&CAHT<-&N8G4AT9::ZD
MM[6.<F-*A76UPE.H[=BLQ^Z[?K0=]4@Y96(F,9AZY3;2P<7'1<.PZ7)$/!N+
M&.CA4,N)&RYSV#A/C_/\)<.5:U?B&3'4K%_(&K4BX?H9=E[,5&GF:>W?I-$D
MLT[".%%D4-'*Y92^VO$>,_)IPSQKQ1;MVN&X\E?K8[&+<NR<29##(W:-=6O"
MM>GC[R220P5T:29VC8I+"@5@A;4-?>GM)8_WMU=_K8;2_NCYO_#9Q"?^%MO^
MI.%_;FN;_P#W?^%?P.J_U\SO[!U5]Z@TI_%OKO\ 6PVC_=%QOPU<0?A9;_J3
MAOVYI?@ X4_ VI_7S/?L+57WJ+2N/][?7?ZU^T?[HN-^&?/'_A9;_J5A_P!N
MZ/@ X4_ VI_7S/>'_46O<?!1Z6QGO]S?7?ZU^T?[HN(?+-G2-CQ7;_J5A_V[
MH'D!X5'=P;4'M_AYG?MP)U5]ZFTO_%OKG]:_:/\ =%QOPR9W\++G]2L-^W-+
M\ 7"WX'U?Z]YS]@:/O4VE_XM]<_K7[1_NBXA\L6;)W/%=S^I>'_;NFGR <*D
M[G@ZK_7S.?L#7N/@I],8]W3?7/ZU^T?[HN)\,.;_  KN?U+P_P"W=*/(#PJN
M^W!U3KZ^/,[^P=>_>J-,_P 7"N?UKMH?W1<#Y8,T>AXKN?U+P_[=T[X N%OP
M.J?U\SO[!U[]ZITS_%OK?U_=7[1_NC[?]7&GRO9H_P#"N[_4O#^'3_VYI/@"
MX5!YOX&U-_7_  \SO[!VUY]ZITS_ !<*Y_6NVC_=%QI\KF98$'BNZ0?_ '+P
M_O\ #.:<?()PNP(/!U0@_P#OWG??X8'7OWJG3'\6ZM_UK]I?W1\3X6\Q^%=W
M^IF'_;ND^ +A;\#JG]?,[^P='WJK3/\ %OK?]:_:/S?_ #(^(?*UESW\57?Z
MF8C]NZ;\ '"A_P"!M3^OF>_86JOO5>FL?[V^M_UKMH_W1\0^5C*GH>*;O]3<
M1^W=.^ +A8?\#:G]?,[^P=58^"NTYCRQTX5O^M=M#^Z+C#Y5,F3N>*+O]3<3
M^WM*/()PN.[@ZI_7O._L'1]ZNTY_%PK?]:W:']T7&'RHY$G<\47OZG8G]O:7
MX!>&/P.J?U[SG[!U[CX*_3N,]\=.%;_K6[0_NBXGPH9$_P#"B]_4[$_MW2KY
M!^&5WVX/J=01_P"?><[C_P!0ZJ^]9:=_BX5K^M;M'^Z/C?A.O_A/>_J=BOV]
MI?@(X:_ ^I_7O-_L#7N/@L]/8]W3A6OZUNT/[HN'PG7_ ,)[W]3L5^WM'P$<
M-?@?4_KWF_V!KW[UKI_'^]QK7]:S:']T7#X3;Y_X3WOZGXK]O:/@(X:_ ^I_
M7O.?L#57WK?4/\7*M?UK-G_W1<;\)=W\)[W]3\5^WM+\!'#/X'4_Z]YW]@ZJ
MQ\%SJ+&.V.G&L_UK-G_W1<8WE'MN=SQ-?WVV_P#-#%?M[VZ7X"N&QW<'U!_]
M=9O[< =>_>NM1X_WN-9_K6;/_NBXWX1;1_X37_ZH8O\ ;VCX"N&_P0J?UZS?
M[ U5]Z]U)_%RK/\ 6KV?_=%QOPAV/PEO_P!4<7^W]+\!?#?X'T_Z]9S]@Z<5
MKZ1:CU%3Y9]RT#7)22U0+":5$D5]2]XC/6HFG5^*D@NRXO3C3DHL;XQNA%2L
MMZ25).&*:<<R(P$E-.EQ3]Q(GCJ\07H8K\\V3Y1PO0EWDM.5D8K)G@(-WB/+
M!$3$L81P0[NJW,AY/,7QC;DFR7"E2>; 1UN&HYCQGE(.TKXZI!-%U@X?5IS'
MYXT4EBQS3O+'(K-V:1@-['P7VI<9QG'3E6<9Q[O_  J]G_W1<N?"%8/_  EO
M_P!4<7^W]4QY#.&P=QP?3_KUG/V#JO[V%JC^+I6?ZU6S?[H>-^$";\)+_P#5
M'&?M_3O@.X=_!"G_ %ZS?[ U[]["U1_%SK&?KZJMG?V:AQQIX^F;OXER'3_W
M1QG[?T? ;P[^"%/^O6;_ &!H^]AZG_BY5C^M5L_^Z+B?P]E_"7(?U2QG[?T?
M =P[^"%/^O6;_8&JOO8NJ?XN=8_K4[._NAXW^'3_ (29#^J6,_;^CX#N'?P0
MI_UZS?[ U5CX,?5>/+'3I6/ZU.S?[H>-/'#$DGB/(;G;_@GC?#?_ /3_ +=.
M'D0X>  '"%/8;_\ #G-^/_4'LT?>R-5_Q=*Q_6IV;_=#P_AN?PCR']4\;_G!
MH^!#A_\ !&G_ %YS7[ U5][*U;C_ 'NM8_K4;,_NAXS^&G_O)D?ZIXW]OZ7X
M$>'C_P #Z7]><Y^P=>X^#+U;C/?'3K6/ZU&S/[H.!XT!Z'B/(_U3QO[?T? C
MP]^"%(?_ %SF_MP!U[][-U?_ !=JQ_6HV9_=!QO\,5/_  CR/]5,;_G!I/@0
MX?'_  1I_P!><U^P-'WLW5_\7:L?UJ-F?W0<;_"^/\(LC_53'?YP:4^1' 'O
MX1I_UYS7^;^O<?!G:OQGOCIVK']:C9G]T'&?PLB_"+)?U5QW[?TOP)X#\$:9
M_P#KC-?9@!KW[V?J_OXON=JOW_\ SJ-F=O=V_P"*#B?PKA(V_A%DMO\ ^E<=
MZ]_P@]>CX$\!O_YHTO=_#G-;?_Z#?\NO?O:&L/XNU7_K3[,_NAXT\45SW\0Y
M+^JV/_S@TOP)X#\$*7]><W^P->?>T-8?Q=ZQ_6GV7_=!QO\ ":O^$63_ *K8
M[]OZ#Y%, >_A"ET&W_GSF^[^@-'WM#6.?][O6/ZT^R_[G^-_A'5_"')_U6Q_
M^<&CX$\!^"%+^O.;_8&J?O9NK\_[W:L?UJ-E_P!T'&-GZ;'<\0Y3^J^/\>__
M (0:4>13 C?;A&EU[_\ RXS?[ U5CX,_6&/+'3O6/ZT^R_[H.,.;H$[GB#*?
MU7Q_^<&@>17 CNX1I?UXS?[ U[][0UA_%VJ_]:?9G]T'(VS&.;OS^4_JQ0]W
MX0:/@5P.^_\ !&EN?_?C-_L#7F/@T-88_P![M5_Y/_"GV9Y?_P (/T]^1G)8
MMM]\_E>O_NS0]_X0:?\  Q@^G_DC2&W_ +\9KU;?^P->_>T-8?Q=JO\ UI]F
M?W0\C-W$'??/9;K_ .[5#P_^H-'P,8/\$J7]>,U_F_[-.&3Z5ZU\7*ATME]/
MU5*J1!MUW5#,JZEKZIR'DZ]\4*A*H]L9T_B4:9E,7D5X:*3E4>^Z))&N9;)'
M9PYD2W\,F8J5ERN49;6.R%B:R<%45X32L8V*&%:PS;+*+'GTK-,T\1A\V"+'
M/VQ:"]-P'1..I<%2<*T7H&>_Q#60\8Y0M!-6%.A/_;'W $ZK,,@A2 ;PNRS2
M-RNB\S?S\&CK#.>^>G:K_P!:?9G]T'-+M\)_[<RW]6Z7^<.J \C&#'0<)4OZ
M\9K_ #?UY][0UA_%VJ_]:?9G]T/&=I@S_P"O<O\ U<I?YPZ7X&<)^"5+^N^9
M_P W]>_>T=8>6/N=JOY>[_PI]F?/_P#,@XP_<!N_-Y<]_P#P<I^/NXATX>1O
M"@;?P2H]/_??-?L#7N/@TM8X\L=.U7_K3[+_ +H.1M%PZQW.:R^_K_@]4_SB
MVTX>1[##H.$J/]=\S^P-'WM/67\7:K_UI]E_W0<C-3AH]#F<Q_5^I_G%IWP0
M8?;;^"5'8G?_ ,]LS^P-'WM/67\7:K_UI]E_W0<8:/"Y[\QF/ZOU?\X].^"+
M$?@E0_KMFOV!H^]I:R[]_N=JO\_^^GV7\_;_ .)!_)QC8[A5NAS&9_H"M_G'
M[-(?)#B/P3H#_P"MLS]N .C[VGK+^+M5_P"M/LO^Z#C#B>$ST.7S/] UO\X]
M'P0XG\$Z/]=LQ_F_H^]IZR_B[5?^M/LO^Z#C#AN$3T.7S7] UO\ .+2GR18D
M]_"E'^NV8_S?U[GX-/66<]\].]7_ *T^R_[H.1_<+@[_ -K9K^@J_P#G'H^"
M+$?@E0_KMF?V!KS[VGK+^+M5_P"M/LO^Z#C#P]P81M]U<U_0=?\ SCT?!%B/
MP2H?UVS7[ T?>TM9?Q=JO_6GV7\__P R#C#PUP4>_*YO^@X/\X]'P18C\$J'
M]=LS^P-'WM/67\7:K_UI]E_W0<:>%^""=SE,W_0D/^<FCX(L1^"5#^NV:_8&
MJD_!JZS3W\/3O5\=_P#\*;9>?TZ@SR,\)\#'H<IG/Z%@_P Y-*?))BCM_P"2
M= ;?^^V8^WA\Z]S\&OK7/OZ>*O\ UIME?W/\C/!W 1WWR><Z[_\ J:+Q_P#J
M31\$F*_!2C_77,?YO:\S\&KK//OZ=ZOY9[_^VFV7[_\ [4'(SP5P">AR>=_H
M:'_.32CR2XP;?^2M'I_[ZY?_ #>]NC[VKK3^+O5_ZTVR_P"Z#C3P/Y/CWY+.
M_P!#Q?YR:=\$^,_!2A_77,?YOZ/O:NM/XN]7_K3;+_N@Y$> O)V>_(Y[W?<B
M/_.71\$^,_!2A_77,?YOZ/O:NM/XN]7_ *TVR_[H.-/D^\G)[\AGOZ)C_P Y
M=.^"K'?@K0_KIE_\W]'WM76G\7>K_P!:;9?]T'(SY.O)N?\ UAG^N^_^Q*==
M_P#ZET?!5COP5H?UTR_^;^C[VMK3MV^YWJ_S_P"^FV7\_;_XD'\G&'R;>34]
M]_/_ -%)_G+H^"K'?@K0_KIE_P#-_P!FC[VKK3^+O5_ZTVR_[H.-^#3R9GH;
M_$!'_P J3[.)1H'DJQP.XX5H?UTR_P#F_KW'P:^M,9[XZ=ZO_6FV7_=!QA\F
M'DQ8;&]Q 1_\K7[.)=.^"S'^/"M [_\ OIE_LX?&HMV9TQZ0T%[$^,6C&(SX
MV>TO4_8'53LA'I_87J'K'K?CUG'=_1>V6/0=O3=O2/=_1]\>/>P/D/X$S?G?
MW+R&>3S;L.WYJ,D6_;=MV6W9<1OS;=E)\;;;?ION=L/,\+X+A;S;SOAF*'S[
MMNS\UXURXYO->RY^TYL-%W><+R[<W>W=X]P^,U]$Z.&C1PT:.&C1PT:AW7&<
MDWS?QJ_E+9V37((=>//&0([3>KY1#>,_/Z*4L$QA6,>27%+3G'BPKF[E?0QO
M#,8Z!L3:LL/'M9<]F(23[X:T&V_@ >XC7/XCT\GQ3(>I7,5*RG_BX>'\+,!\
MTUJ??;H#OX[ZF+F%KH-(-EM-:ID.18+;/1%;A!5CM$2LW("QH+;Y;[8H8WK!
M;K3:RC2G61 A4*4084\T,,TZ^ZVVHT:\K-JKMRB6IVK3 ,Y$O/$#H- >PZTD
MD1U3!0SR<X2XP4,\A33XSZ&WV5X\+C:<]N&C2_PT:QQ2Q#6U/!%#ELH(+$6Z
M*\V0V@N/+> /%4XTI:4D!'#$!%LYSAP8L=X=Y*'FG$)-&F3<-J:UU\8 !>KY
M4Z@7)C$&@M62=CX;TX0CXXQ)OC/?8;:#8(+&8=+>6V.AY]IM3F%KQCB[$]P)
MT:=PLH :8> *2EXJ,P)DUI*7.S.#V,DB9](I&&G</,8](G+*W,)QY+RE6<8X
MFC2APT:.&C32N-]I>O8\26O-I@ZG&GR&(H(Z>D1HT8N2R ?*>HCNDK0ETE,9
M%R<BMI&<J;!CS2UX2P,\X@T:<,?( 2X ,K%'!R<7)AC2$;)1Y+)H$@ :R@D,
MX$P9;HY898[K9 Q([CC+[+B'6EK0M*LFC6*?/1$7(0<4>>R-(V4TJ.@A%^/+
MTB8#%'S9;3*4(5A.!XN,-+===RVRE+26O2>G>8:=/LT?;I6X:--Q%M@'+6_2
M&C7'[,)!C6,X <"1(9CH@TPD".(DY-D1R)C'I0H&01$@GG#2$LW&2I$<*4/%
MR#HQMTW^;1OX?OX_FU@O["I \/&SZ[3#+AYJ/DI:%.'-:+:F8Z(BBIN2,ATB
MY><E&1(@(J0<4 @C.1FLN(PK"D>)=CW?OZOKTF_U;Z6IZ>AZQ!RUEGSV8R#@
MHTR7EI$C#F60XX =919*TM(<>7AIAM:\-M-N/.9QAMIM;BDHRG?I=*_#1I@5
MK:VM+E-&URJ7NJV*< 9,))BX>; /+]5CC&HV2*';'>7ZZ+%R3[$;*$AY(8C9
M)]D YP<MUME1L?5HW'K_ '_<'Z-/_AHTTLWRGH/F8UR? 9+KIY49.X?4XPQ$
M&A5>'NAC,B8\V@,1(U5GX>;>?>(0.@(YI2G<.)=;;-&G;PT:.&C1PT:A71'[
MYJ=GF%>;D[M_=AWC^9T4':UNK\0\G/ORAZ#A(QQ&?\!2<8\L8YH9+I/#'X14
M<>NWJ9J4$L@]7221QKF^%O3H7;![[7$/$LN_\J.+/9"I78>L-5K0,/8=N[4U
M<S]=)HX:-1/$[AK4L?;^X4M$U&DES\7-;+GGJ[#T-,W59)B'LD,@TVP-SK!$
M1(N/BOGR5? @B5Q\AF.ES$CXRM=OI/AUWZ]WL_+I-Q]'V:6L[6U<D=TM6R:"
MD5B&;L3Y.;C7<#LU]W$3EJ==>S(^C;AG<3T%EN36I(2\343E+^?:(?IDV/JT
MNX]>LM6Q]>((##7?*8DN0KJ[> *JT0:2#JFV,X8Y: V,G8=)KJ!&7BES3*5Q
MJ1FG'U$X:0I6%V/J/J[O'U:-9P-RJ4K%3$Y$V:!F(BOOR0LY)1$L!*!Q)<.S
M@B5"D" 'R&Q#8YA2'30WU()&0M&76D86GNFC4,1O5-J26C]2FA2,KE_<@EB.
MK,43')CY&'&J,!9)^SNW7V@2*!3TP>*G.PYV9DYC'MP P$?+Z )(@)>4]?9T
M_P!6DW'Y"?F'KWVV]7O]QTJ+Z@ZJB2DX5<#:$3,.1,"R$>\NH#)'?@-8U/:$
MMZ26*MK$ @4(.\5>J/R;DLB*;N,JV&LY,*T1/-&Q_?W[?GZ>PZ"=OGW_ "#?
M4EHOU(6=-16;A5D2]::#=LT0JQPN9.MH/RVD/,\&V<X]%8*<>:;&68EILA;B
M$CK=\:,J32ZQP=E:YDU5Y$;?Z5(+MKTD/5$ VJ"+59B(9U;$PQ7DL'N9FGHE
MYMQF2:C<$K!=;6V4EI:58PNQ]1Z=_LTFX]8U7.;%U_63C(RQ7BHP<I'P9=G.
MBY:QQ $F+7 &W739Y^.),;-;AQ&V'ED2*F,"-8:<\;N/ KLFQ]7L^?U:7<>O
MV_-Z]1[$[_J<SKRB;""A[,2WM!QIK7E3CV8.;MEJ62"9+C8$8@YZ2@@$XA8\
MN6E"9J?C :V*.0BS%PY3#K"%VZGJ.G>?#]_W&D![O#??8>[]^OJ[M/..V76G
M<0X=E?:U]:)MF5(!HMVF:J#<'AX51?M D:.B;#-"2@; X3YRC860DP\ IR2L
MA*4N80;?./7UVT;^'C^_7W?OWZ:5+Z@=<W,2/,S(+J*)5J@-1K5W+@J^3(6#
M8U1B;O"4P%A<T2LVWBP$]!ORD,)Z=3;TL&T _(^)U;001^7\GC^0_1I=_P!_
MW]^G9*[8UI!6Q^C3=YK,1:Q*L5=C(:3EA 2 :H$0D8F<.<)<:&"!;<4I7C*>
M:4MA@HI"%#"%/-&Q_+M\^C?\_P!&KEAV74H"A$;(9D&[+6$C@NQI52?!G<V%
MZ5D18>'!K[S!B(^2+EY<T2,C\).;'=,(;;60VGQ+2FW[_OZM&L #:<)Z(EZV
M %ZV0%&BR9OQ^FZ+%J"0838FF!S$1EPF5#.N!UF2F&WW\(CGXM*UC'/%@3(<
M8NWS^'3?V>SV_OTT:M6K<^MZD-5'3+5"2)=[DZ;&TN'AYN"+F;6W>++"UF(E
MZZ"[*#+F8)A^<&E)*5CE$CB00YTDG+R!_1K-C]&^_P VD)V^D#Z=2EQ-+HX:
M-'#1J%Q<^O\ 41.8SY_%32]6\'?W)_= O%P]+X<]_>O]S1GQXQC^ WXL^:>9
M"^GGIO\ DV(K;=W^_KMO?;QZ_<X;^'0:PD^^<36/^1X*IMW=/NED+V^WCU^Y
M2[^'0:FCFOK=T<-&HVM&RQ*W;:_2!*O;+;8)Z*D)Y8]8'@W&(*"C9.'B'I:=
M)G9Z"9&&>-F6D!LAJ//+0%)N,!J2"YG*@>T#W[^._J!]6C2Z??:+%QOMF3NE
M3CH?,6).8E3['#AQN8600^X!,>O$&-B^RS4"DK$D/2^J$H&?4R\O#+F4FQ]1
MT:C%74WHY4D+'B;$K![2[)8:M*S#$["L0-:E*Q&CG2N9Z6D9$$9@1)1\1!C$
M!9/]:G9D %I&4X-?#-CZC]'[^H]_JTFX_.?5XZDTJ_40*5E((VZU(2;@PAI*
M:ARK'#CRL1'&/"#AGRD>Z8@N/"+?/!8&*+998?>-$::<6LAE*TTNX]?[_N1]
M.D*R;5J\$#5"8S!UY.OJ,O42%HB09TZW!H ;E'I:*-6>%7AZ\/'/BE$VB9FX
MJLL8.BQW)=)DO$C&KMW^&W?OX:3?\O=[?'2;!;HJ4K;T4"7;-I-U>@(*='K-
MR-K$?*G+G9"Z H@XIB.L4LF:G(QBCR$Q+,0SAX0\'*0,FP>4S(J]7-NF_AOM
M]7Y]&_7;]_'\VEK]UO5.&IE_.S=>X9KAF(ZPO?'2M^B@I#+4B1@&9<]I>"+,
MRQ#R[V!CLL/9:BI%SP> $E31L?4?W_UCZ=+K*7L[6S;]D%<V%1VR::UEZWCK
MMD"E^JLX>]7R]9&5'X<@VL$?@,N2B14>F_!=_'\GAL?4=&X[M^OJTW ]]Z3/
M>LC0NU]?N(J M?.LAJK5#-142):AT%5TDB8>+;BE,RS#C#@CC)CJ58)$PK*5
M%#I<-CZCUW_)WZ3<>L?O^_U>O2_(;*I89F(H:Q0$O-X(@T$0$=9JNF9# G'P
M,-S1(,E-QRTQ04;(-SY*VU.FE0S2W88*5,>"!+-O'P]?AHW_ '^C\XUAB;DU
M">(S( [4UN: 1,#5X<T2\5@D1^?-;P\'!LDLRBV79@MK.'1HQ"U&OMYPMIA:
M?/AL?4?7W>'KT;CUC2K?+S$Z]@$STL-)'X)F8"N1,3#,#D2TW8K3- U^OPT>
M@PH"/;)DI:1$&P5)R$=%A(6LN2D PF'R&T_?Z-+^_P!.DDO;%,AX_P!-:90.
MGSS=5E;D71K%,5UJ[!P,((:;+&+A(Z:DDF, #QQJWC8HN0C/".XMLY;:%+PN
MQ/[_ +^L:-9,9M&B'C_OJS04#+BU0&Z3U7GIZ!!LU2KYH(AZCK5%-RA*H<<)
MLX=LXYUU<8TZM/HSGFEM.N&W[^O1JQ6MOZNN5I/I52O]4LUGC:U$7$R)@9H*
M6=169XP\"+F&WP77Q"17RHY]#OJK[SH2'XQ\YL9B9B'3C8]^WLT;CU_O^Y&F
M["[[H$W<9BFH(,CB8HT^,:EY7,6+#2LI%W836YT8&I$H_*@'?'HUFM1#-BB8
M+-M-;,?IF;%'1YQHYM^_Y?J[]N[QVTF_7;]^_;[?GU-/$TNCAHT<-&CAHT<-
M&N6'PC=&F-DR^IX>!RKUFL1UODY#"4J7^ LQ->% SG"<IRGNY6)#MG/?"NV<
M8[>'/?V3R5Y&OB8,U/9!*6Y:,47</2J):>7O!\+D6O$_*WC;&8L8.O5&[TH;
M\TO0MLMQZJ1=!W;FE+W]^WLUU/YXWKVS1PT:.&C1PT:.&C4/:8SZW$WJ;5W]
M+-[AVQAWO^-_J4NLKKUCOYY\L"4T?"/^;PC';&/+F[G_ $)\=7\*^"PNW_3<
M?#E&_P#OOOO[=^_7/\/;O!D[)^-9X@SF_NHY&;%)_P#CQZ;>S;4P\PM=!J$M
MLUNT&V'5-VKD U<V]<V><EY&G9DH^*D#,3E1F:R+8*Z3,N#0CMCKZI1Y@<27
MD8<1Z&FIY;4JR>R&*:H\=SMN/S'K]'AI#OTVZ^L?OT^8ZA_9^L=O7S%[N\,N
M5J]H*A=0P%+JS5S+PU'P$/93IS;BVV(6PP<"U=;;5+98J&)+>VX]UG,3%JB[
M97F7L3[2@CIO[=_L]>X!ZD;?,=!'C[!M^7?YR.F_?IE!:*VLU*4Z)<1:9"NQ
M\]J^S@S$_L5L;X@@Q^U9S8VSZZS78&4?&/EY@1Z%H<(P.J8A8K6S68 .S^GC
M"4VDZ;>'CW#OZ  [^K?J?;X:.N_=\_L\1M^_K)Z;:1];].FT(27U*',(L=;J
MD3"U*R64&KW 9U49N:/OUDN6TIR1-)M2LFUK9:D52,&R!7[--'5=<]!FYH#T
MS/DS(2#OT'L[^[P^CW[>P]-D /0>SOZ=_7Z]]_K[SJ=;G7]LN;.V9*U>BPDT
M+<-84S7=6L-FL<:+5('$<;?I.R24]#,MR%D.043<(Y#T/'Q&6)UFM@!O2L4A
M]9XJ=-NI\3TVZ^'S?E'=IWC]OU?6=1K":%W%#M0U7C;5+QU>;F;!KNP3#]L*
M]=1IA5$U-78NP5(4$A:X^Y2(.J&85E]?LF0J5IN]ON,<LQM/BGU)'S]_=X[G
MH=]]QU^< #W)L?LZG?<;#K[^FWTG254>GW;I\BWB_P!AM[>9*_AHOQ45=WXF
M!L-(AI.W70 FO,Q5ED;%A!$V!0J:@4I505$TB2FH"-KHP Q)DH;CP [O$;]=
MMNOL\??U]FDV/<>[[-]^G4^X=VWMV&DF;TEO ],H#&"V&.I4OLRRR<A&N6R/
M+V/(0$O#2"J^DT_-Z9J)54H5@FI42G#/&YD ZR'3%3-$G9:FBX/ 1\^WJZ;[
M]W=UW'?\XWV/0V/OZ^PG;YSX=-CZ^\>)V2NVH[19[7IUB+O5NK5:UI6KD^]:
MHXNJRMT/N)496:?6GBUW2JVR/,454I#8RYN83%C26)$L)0QC22RVU)OW]!U(
MZ>SK]NWCI2-R._IO]/3[-_#U]VM=<]/VX*^ 37]?XF:TBH-6R$B+$SLZ3;3;
M-4>K"UG6^JJ@!F1(543J]0&1<F6R7#B"HG9T$/:(HV85:[#.AKN/JZ;#H1U]
MG>? 'N/AL!I-CL1N?'KTZ^KV]/FZ^O65(Z3VD\[+E-P=NC*U)PNT<4ZJ5J]P
MDE:=:OV]W2$-%1^)*T68",?=+"HEZM4V%$61V+:5L"VU@2<SE<=+R*[CV>&_
M38'OW[@>G=X>H[=-&W3Q]G4DC?Q.Y^KW#O.I?N-(V.;1=,Q2ZH'.M04:G.R=
M=5"[R-5A9"RN4UX*,98L,J>Q)2&O8"V$$D$@%EF2JQD0LTQ%3DA"-Q9+1MU\
M-_9OX^'3O]1Z#W;[A>HV\?7]!]?M]OSZ:VC=9WJE43<5C5@V>W-*BIJ4/8+,
M9,"O6N3U7K"LZZCI4IR>==6U$6O9%8M%R"E7V%**CK4F1].4*^TZXI.^P\!]
MIW/</5MX=X[M \=_7^8?02-]-0SIEOE-;U^!3K?;[17]=ZWJ5"#$G;1$"/C1
MQ.R=1)O.*MD:.A%118NIJ'9HR.*/D',DN6% "26\^LNK-P=]P!UW\>_8^LGQ
M(]GKTFQ'B3\_7OZ]>@[OG[^HU&=.IMOWE*V%EF0>DX]D:EPFP=@PNR"IVO7Y
M^R;LB[YL)FM'14@5&1P=8U]KN*KE1@@'(^=ID;LA<>2!#D>M)(7NV^?;IU'3
MIOO[3N>\=.G=MH[S[-MO?N3N/5X >![]_#6T\;IS8.-4W2E"[!F*B?/8WU'P
M(;1 T\%#!7NQ7K]S@W,U(CFV<5RJ0,Q6CL!14T,R/(@/"->(3&&N-W'JZ=/?
MT[]O#K[=+L?7OW]/ [D[>&_=^_KA^T5?:>R&H^N0>L2-39T55Q($*$ G11WK
M<S<0*_7Y<'5EK!0# ,T^*U^+<HR%(E)6"G7;LU6?C! TH*(8D)-1L.N^^_\
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M[<;^ONZ]2?5T^GZ]&QZ['O[^_P!W3J-OK]NIO/TG@FF;WJ84ZQ%+W<7+>D-
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M]LP]M&AHRD[2.UQ4-6(@X4QB\$UZ^BZZ,C+5)G"OV9NT7ZR8.:H6:O)UX*(
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MAUV[_5TW]W?^^VEW]_=O]NP]W3W^O6T.M+BY?Z3!VYUB%&<F&S'%BP,O*S8
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M9)#7<M5V(N3 %. IXI&6["/ 7^^5Y*0[<LUEAX6ZF^IP"0RK$V*>/(#<-AS
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MZ7SZE\LJ_C$/Z>EDA>JRIX:U$O4(BS!I!0)8'B(!V9&3&"V<&-2Q)+<46U@
M*[7$0/"'D^K#6JPL,^!J9D$D)YO8_O$W\T_Z.CSVC\LJ_C$7M_P_:=-Q-5T
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M_P"K?]'1Y]2^65?QB+]/27,S5'GHLZ'.ML<T)(L*&(<B+H[7Y-#:\X\60YJ
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M1-Y2>-7^-FRWOQ^+_4?]6G? KY,!T_@I7V_^89C]H_ZM>X^#'Z&,>>-"1?\
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MQL?CS[Z-3_P=.'DG\GX.XX>C^?(Y<_7D#KW[W#T6_P#$D%[NW^[39/NS[_\
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M"O0=,D*M6_:<(\/-RT:P;*RYH5I<S(/AQ,>2>^UDID)5C1AL2&6"A9'T5B^
MN'(J%=;=8Y"RT2S-=-NRBV2R(P[)()A *X=W,?-'SF,Q++&\A>-O+LAQ%E%G
M=TF>O$)#M#''$W)$JILA[2-9#(.8EMGWYHG[-BA 7J/T+[5M'43IE1]OK$^)
M,4Y0D"[=)(9W$7?/1*/%S(B%+:1CVZ J.]%9(_TA) 3Y(!)!3SDAWQY;Q[B:
MG#V83S&U5>OD%DLK0B=>UQX^]MR-&#S+5E[3GJ,55>5)(E 6+F/7\-W[&1J/
M'824O4[.,V'#&.R&5MN5R/2FC4 3$,Q8LLC;&0J-BY6)>C7LI4E66\YQC'?S
MRGOW[=\_PDY[=DJ[=^_EGS\\\Q#(DJ@C;?;N VW/3?\ )L3X=VW3;6K+#L6*
M@C8]1MT ]VV_Y.OJU-_3/_XP3?\ \EY'_P#J$1S+SH'F:=!_MA/^Y+I]+^ZG
M_FVZ?Y2?D)WUOESD=:>DJ<G(BM1$A/3T@-%P\4,X9('EK\# P[>/-2NV%+6M
M:LI;99:2M\AY;;##;CSB$*FK5I[<\5:M$\T\SB.*)!NSL? >  &Y9B0JJ"S$
M*"1!:M5Z5>:W:E2"O71I)I9#LJ(O>3MN22=E55!9V(5%9B 4JO7.#LPR2@<3
M<?ATYZ/'%M=5M-'DRR6!&3G?48>Z0T!*GCH%?2O)@8;X>5ME,8?R^&6TQ/:H
M6*;E)/-Y=HUE9Z5VGD841I&C7M)\?8LPQL77;LY)%DV*-R\LB%J]3)5;J!XO
M.8=Y6A2._1O8R>218UE;LJ^2KU9Y4$; ]I'&T>X=>;GCD55I,O%+5X$2<>M?
M9_/A2:,I789ED@G/AP[G/8<<D=]_/;\$R^RZYX4.H4JN8)AU,,H'H]\;_P =
MF1/#^,RLJ_RF5@-R"!9%B G83PD^ET$B$^@JN_0-_$1T9OY*NK'8,";K<@ Z
MWAYHT1UE65X2ZV2RMO.6W\BN8PM*\ISE!.,C+[9^2_C+.>SF/#QIBD4\K1N&
M&Q*E&! *\X.Q&_5/3'K7TN[KIPFB8<RRQLIWV8.I'1^0]0=NC^@?4_HGKTTA
MBW6GFQC$T+9X%Z)*8D2A9%,J%ZF2+$9=]J%#OJ>PAX8###RRGV\J:9;;4ZM>
M&^RLV7Q]^.9J[T[*SHT2/$89.T1Y^7L49>7=7EYE"*=F8D #?IJLF2Q\D"64
MNU6KR)-(DPGC[-XZ_-V\B-S;,D7*QD=254#F)VZZO1=KK\RRV5'2;+PA#P#
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MZ+-)-92JD,89YB[QS2;JL7: C[WR>B2Q8CT>\ZT*?%-&X;)Y)(Q6@-F5R5Y
M@EBC.Q?LR#]]#;E>4 ;%AOTD*;W%KROR%0BY2P,,E7BP,U:M889+/9-FR(V2
ME1PW2@!R10,$!Q1BF"3GAQG7D-#H=R^0PVYGV,5D*RK)+6=%:01!F)7=V#,$
MV?D;J$/4KR@C8[:TJV:QEHNL5C=XXS+(I4D+&KHA;F4LO>Z]-P3UV!VT\R+/
M7 C(L R>A0SIXIT*$!+E QC9@T<,B0?#BQ7WFR) IF/#+.=&%;==:#%()6E+
M+#JTTGAL1=9(955FY065@"3NVP;8@MR@G8,.[KZQ>CLU9@>QLPRE1S$+(A(7
M<#<CFY@-R!U&^_AI<\6,X^;MVQY=\?GQCOV[^6<?/^;D9W^*.FYVZ]XZG?O.
MY)_)W=^IAU&XZCV=?J_?UZ>57SC+)?;O_LK?O_Z*^_GWSW\^,8[[>P;=?S>&
MI4[C[_W_ ']NG3QNGZ.&C1PT:A;;7[ZL6B87/FW+[D8>(3[^S58UOLBZ,N+3
MYY\"9.MQS>%>Y+SS/?.,YQS(RGI3X6'PERREO=6Q^0N*2/5VE>,;^#%=869]
M.SP]!X3YQ2P]E3%Y2^I([R.UJ1#V,5WU-/-?6[HX:-6GR&!67""7FAQV49<>
M??<0RRTA/FI;CKBDH0A.//*E*QC'SYXC,J@LQ"J!N68@  =Y)/0#VG2,RHI9
MF"JHW+,0% ]9)V 'M.JFW&WFT.M.(=:=0EQMUM25MN-KQA2%H6G.4K0M.<*2
MI.<I5C.,XSG&> ((!!!! ((.X(/4$$="".XZ 00"""" 00=P0>H((Z$$=01W
MZKXNET<-&CAHT<-&CAHT<-&CAHT<-&CAHU;4ZTC.<*=;3G'OPI:<9QY=_/&<
MXSCR\_JXNQ]1^C2;@=Y'TC7GIV?^&:__ %B/^WAL?4?HT;CUCZ=>^F:_X5O_
M .?3_P!O#8^H_1HW'K'TC7OI6_\ A$?_ #Z?^WB:-QZQ](T>E;S[G$9_^/3_
M -O#<>OV?/ZM+^;?YO7[NH^G1Z1O_A$?_/I_[>&DW'K'TC1Z5O\ X1'_ ,^G
M_MX:-QZQ](UYEYG'O=;Q]:TX_MXNQ]1^@Z-QZQ](UZEQ"\YPE:%9QYYPE6%9
MQC\N<8SGMP(([P1[]&X/<0=5\32ZA[>V?'KSU#/^Q3M\U#5RL?E!M>W*/6Y#
M';^%CU&5([I]RL=\9[8SG/-WASIE.T_C5L;G+B?\Y2PF1MQ?_DA7KK XFZXK
MLC\6SD\#3?\ YJ[GL;4E'SQS,"/'NU,/,+6_HX:-'#1KDWU%0?6'HJ*V'-ZR
MZI=)7FT[JZADV'7NI>JEV(J%/&U7FF6,68T)0G29;"K)*E215?.2AB1JB%PU
M?++>=:.EIMR2D4J=MU( 7J5[]]QZ1]70'U^[3""-^H.Y[CZNO0;^O<>K42=
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M.$>-+[#+?B2E>'G<=_!)$D,4=>OE(K%J=Y.6&:.S8GWD#%E*JTB-$ZJ.FR[
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MR)<192W)SA0(&D+,2-^H7<]-08[A_*5S?66NRI-C,A []RAW@9HNCB-B#,B
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M8#<Z;YVB]KGO*==AQ.W?.4I]M1>?//\ "5GUK'?/;RQC'DG'ECWYSF1,MCD
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M#'0Y*32$KPXPD@L R1BTEJ[M)<#:!!=<5XL#9<QC.4739GFBGKW)GB@E)BB
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M_P"[X:-_8?7WKW>OOT8E3\^ZN2V?J*K_ ,__ ,N^&C?V'\GY]>^U)#Z-R_\
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M65R6M Q$_%S<X"!*XEHFN0#;CL+79HQ)@TVX$\9%2$. [(&(#4=6?.1U0YR
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M:_*>048<C,?OKQJ!6J3Q/8=F6-)76L':RR1-6UO2)<DB WX&= ;;F['"1+1
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M2K+8[+KR_"AM6<9Z0S2I-)'%))'719+$BJ2D$;R+"CR,.BJ\KI&I/0NP&^Y
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M"%'FD,!A!#/EEEE.H'%%%&:4\002^ZI+;+##2%NO.N*2AMM*EK5A*<YPH!)
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M2G,94GR4KS[]L]^^>_;/?'_9^3SYYC9![9^I!!(.VPZ[G?IL1W^KZM=GB_\
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M)94#RK(%>1+",\@,IC]-MNBG05VQT9=-?Y,:DJGO\NW[QQG]'Y?F\^?7?'P
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MO79$C:"%HXW66.,Q(4CD1N=)$4KRHZ/Z2NH#*WI @]=0Q(V6FU68L=%CJ)6
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MI3\P,LH:)YHI146.$O5GKAUAA[59#&NDN'TE4H21K\L"3*-&UW,6H7([5>C
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M2KYL^G34Q;1TU&U3E HU5J3[M3AIJ3/).ABCYWU$\H+(4;F%+?>0^*">Y-L
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M&2EI]#B$OB%--$C/83AQA]IMYI2'$)5C%>-) %D1'4,K .H8!D8,C ," RL
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M*LXKDM;2'(M ]@UWC1HIG(E:,Z,5C%K(8ELP&PV(\U&5-2<0+D&OQ6XYNQ6
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M++PIRO9<=I*1SL"BJ7+NJQS/RF0KIYYSC'O\N:FQV)\!WGU>_P#/JCN/6/\
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M_H'5-?*OTL?"PR'39L.H?%*@R>B=V5JSV#INB)#7=.KVOVX("XV6(E:+ $A
M5L)NR2$A%3DF5./23ZIO);+^!Y@"5'-'S [GF!&_4D^'7W#3#T)V;;PV(Z>
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M$;POMW\QZ?Y(_.?HU%(1N.OA]ITC1JL95V[X\N^<YSGWXSVQGM[^^<8]WO\
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M]9R&NM?S6J-=1VI8RZU[6MG</58:/#2\&JY*K4^J4D)61;F(I4B^-*,FR)9
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MJ%2K5=2ISW14( -^(PGCS9GYXY#*_/""(VWZH"[.0OO=V/B=V.VF]G'LPY0
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MJ\:?AP) LDNY85V*@[C=E5Y -O25"V[;CT5 Y22 O*-MS(T$$;F%K,*N#]\
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M=M2:VCTUWO-->>JC2Z^(1:!XUBA35KEG'VH#U"LAR1JTJ<CT,F./$ 3G,E9
ML#*MADM<X&]R[48U08%-E8Q1FLREA!R5TD<[E '>W% CYS+3C"5V5;;I=[0#
MFOY"BS4P:R-;6)<=/<F+"MV=2.60@M&%>V;OVQ1I[<:]K\XJV'1L?Z.E!3;A
MHD?)(BG++(QQ<\'3G%A3R8BPT@0G$FEJJL2$KX53L?&1I\^>CYNQ'((S0=K3
MQQ[5$F+HD@B-B2-YTJ$I.(IZ:MVFU822[=LD<<D[MDXCM12B%L;(]QXHMJ,<
M[2)'*(3:EB>PE$F.P(;-!'[4+366;;SB.**2S)2-U$R0J$JG:[6&TYLH[3I
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M<(D5:U)>S>S,J$R*&BL.EF.^VXCBBL7)7FN=#YO"L4<%N6N2\HY(A'SIR5@
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MLV&.CV17'P8Z.9C@IFY=]SSQMMW^!(]HWZ]/6-^_OU&-]@/18>KQ[^_;;?\
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MM8PRK*VL8:+QA*\X0GQYQZWV4O"6T(2M7B4E"<(3G"/+D:X/$JH5:, 4%B
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MKQ'1^/< 'CR[>0K&/+\GXGN_DXFY]9^DZ-AZA] U[[/ Q[@0\?\ R,S_ /\
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M<L,T<2+7J0&41O6J=G);:S8C%2L$F B&[WC*S6X0>0$AJ]!Q(DL22;*BQD2
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M\;*68H-YP=]"'F%N,J4R\A#C>4K3A6)H. >(ZLHFJY&A6F4$++!<OPRJ&!#
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MCH^$W _),O\ B]+]?T?=U:C^CNQOLBL_M?P^#G-_*L5_/V_U'1\)N!^29?\
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7BVS*HV7?FWV!W:YY]KT?1PT:.&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g305908g73a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g73a33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_24&AO=&]S:&]P(#,N,  X0DE-! 0
M    '[:^@1@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   +&7  X
M0DE-!"4      ! (<:-3ND^@WR QR1@26JHN.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'&&-4         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M            !,\   ;H          $                          0
M           &Z   !,\                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P  !,\     4F=H=&QO;F<   ;H    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   3/
M     %)G:'1L;VYG   &Z     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    "3A"24T$#      5,@    $   "@    ;P   >
M - @   5%@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M&=T:!!HJ&E$:=QJ>&L4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"*CPEW&XF((:"CD&/%C8<#_L, N"?[022U;MKCNM(97>]^RD,#C7/_+S$O\
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MKL?$9>_!X:RR,?"?]/-^)L+,'Q.HZ0W8?C^'P_Y\9XCAPP-+GN%S/Y'%;A;
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M9Y_"OZX>(\)@EQ>D%_L4&6*+I1\:_AGG_P *'H6=83,7^). <RC0W,MXG@N
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M''VA/9NMU2ZIUY<]S)E*QS?J=ZH[P*R[2QW^JL$YQ)/$;D30S,J&10=0T/$
MV<P#.G:ME _(17 278?NX"$]FY _NJHF\;[R34][,\PF#&6^Z.)(+O@SP+8G
M5T%[-R?]U%J?M(=S]&><&&(Y",]%07#QRWNB"]G*#^\+.:\K?:= U.VY[F%*
MDRXPBNH+^E4%[.54^/[]RB>26:.7,6%3>PP?0MS1P#Y6/KZ$GL@O9PI_O%->
MZ(;^=0UEV8>7.^\QS3B%P[Y>XHV=D(YNLO$?I7F/.;0^88%^3=_DN<IGF)R
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M7SFQ))8B3.+M+"P!O4=E)5K[YZK>ZH58@(O5[%]*0XH (L0(4@]T) GJFJE
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M'5.5I2Y=?)&T1YF/"#1L<'9N4Q,UJ3>([2I(2J+<VR0'[5>A=@>5OT3>*@!
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M)])!YOS4OGD30Z@BRZSJ>A8G6-)WR4OZ@RF$5*>Q2<_4,885KFG)GTC?-/\
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M8#XS\N< 3!/$&,PDJ5("]/=F1#5OAE]H#?\ E2!+9&*CU#N'K4QKX=P\2?\
MM,QRVUJT5X7-;,&9F8,6M5U],OP>P'^5_"7X89=X0Z<#\/N#L*719Z!P]ET-
M[S=*[MCPPWA\ _X\/HNO'_GQ_P#EQ,]6<LN1FVLI,1)B),1)B),1)B),1)B)
M,1)B),1)B),140^Z:!W>AEREY[48N0B"X =BT3C4=C4I_$-!S\(]%TGSENQ"
M0&9G@T&%X%ZBLN"**3I<-4'_ ,0/K]0Q"0SQ>HX7MIC$2Q?*7^FE7>2#JJ_1
M58DO0%JMP@C"&KB9#=E!XN@R 1/^(/*^D_NQ0D8#1@.K@R*17 7<%PB:*O\
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MZ URW3T<.DJ25">]_*7DQ9<$TNTTM-Q>&Q<P7#^*>]>LID%=>B\F(""*QA-
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M.#S!-JE^9&.J**GF!0'26B+(SV5JPT),D8SB[2(NX"+SW_Q#.,'LC^#>>Y;
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MW[(>5X3+@-HB@7ZS !5*6D:\CH0T??IT10+^J&:)33E0)*@/5B(9?*RT7G]
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M\.Q."I(NPPO$.X@&Q#.(+42\9O/RE)?21LIU8Q_4UIUZU-$?AEHY1[G4,Q8
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M1670@-A::*$YH):$&54#+Y3[-[J7 U/3]A3="T6<Z5EO>BD5-*EG(6W2UO9
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MW!=P26D!V)SO>^2GXE7==2%W59 U ZK1J;@%J"EHIU OH'=%(1/RGOF/K-C
MXEYY$SEA1C<36OVIUW5_B0?IHHF4%!H*D+5$U-VC 4J3#6B;%KP>0@JR7>6$
MO+SBXOF?9$=?%!SE.M *+,7*D=&A%<F>.&A:\ $?&))CFIPAR?VQD6#Z%.'U
M-N@52@WI,&4[,(#4] ;Y%LR2.3,JYQ=IE\C5P7<,W/-2#^HGS ]2.K9XF@B[
MY4H&R&/ZO"2( Z@GG OT[E8E4IJDB*]Q/S:DM( N#$-:EFI <"[++>CWW[*)
M?&_>83JLJ(4!Y,<D 6.1(>3A<R:]'"OEK(CN]YAIJE\R7FB^ONFBM2"89F$E
MK5C&:!G!EW=HPQ&&\L33![L7SH.ZWG3W>[5CC5\01=YDL2+L^9<.MN^=C7'0
M,H?,G6A5%L3O(UJ M-FC<,L9QLQN*"X%1>+&L;AA-K@:$VGG2J7S"DRH,@4"
M6&V^L@2S^.)9@TG%I=F=Z"SFZ,: ,1.8APU>M7("7S$!F.?/1/7GHU_@'(-K
M.]OD5@'"5 "XASGE8_";YG_<*)8#[>]F?QICF<"\UBX+,[FZ,:MA;&G51\>A
M[DT34+HFZ2LPM_MY%Z": $5)'R"KS%:P2YU(.>61!9>,%5,]9_8>5M& M &Q
M5PPD%LRXT0BF#Y4,ABY@S-,RF$1!SJG6G*AIU:"2'X39[ 26+7NY*I&8:6<@
MFP;"E+Z6ZU_K"R^)F_Z:/B_AH8+S^'X9<S8),B'D.:Y;G<8I.7R,OB@D%0"3
M:<XGG^+ ,T=:.]<8;57A8-_+D*$SC-A;3+YL'<;X@07NY1-I*ONE\/'=OH^Z
MVP%AT53$AR.X0H(()*[2T"B?>5U8F-\&Y>_9:5F&3PXKK_BANO6F >7F)+YL
M57'^9\+08H?2&)JH\-4MW!WVU++9E[1$FK"'EB>:XZS+@?#OA_Q89VY)#E%K
MY6!G9B2#5\ Y<TCK4EXJN/\ %<%1L'%,?+XN(P<<2$;"18N&BH"H5Z$7'B[.
M;CQ+I F"U!(H4+RSTJ&J;&3-)YN A0\ZXPR@AV-\C-X+M1BX1@8KPB@=Q&'#
MKJI_NBP(Q69+;'B8A](/P@)FF-8;4=:49ZK-83X@96^\[#S+#XO*8ID\8T)[
M$852DG<1AW7GP%57XT" Z+EMCBX3><#K065!?+7;?(FBVW"X["8^'\[!8O#X
MN$4_?AXT.*YL"8;SP!'_ !*$40-558+P%2Q%$OU1/O[[2D9L1#>?N20)2^P\
M_K=JT/1BQ?;]NLL4/&/8]UMYHQACRO;Y+:(A%XFM[>^_=@?I@);>*+$1<'B>
M*^).#OAGE#Y.=_$;B#"</PA">_U<#DKQ>Q/$V<D";KF59# S#%.$EWQQG'(<
M,F(772+\(/$:BDRYOIC3"L(O?S+\%A<KP&!RS 0',-@LNP6%P&$P\()"P^%P
MD%S#X>##=4^%V%"ANN.!2CKH;R$.9Q<,/7$4?/)%:>(F22FJ(=+=/.3 &8.T
MP 8.-1K\T8H%Y*&HTE<+6YYTW:!RX8,_JQ:0=98S:B*!>))L-$Z=2FJ>C5A!
M,G$EJ3R$6^44"4KHMO>G=J7^*]V:*XBZ)B2EI&D]2OE.E%*3#1\+BHB6S/+(
ML'>A1)G_ '$*9<B AFDJWW :-'^(+9O0EP(J[/#&A10\1U/?W^+-O5$S$3$A
M2*HJIL?=9Z VC^K==[E$QG)#UE>HY<M.HEA]/OLB8JAFA,["6DYT!(I=4:""
MU<X?$^H#9!G%"\R/\1[BW^B^'>'X9AQ778G$G$'#V3%T/'YH@X&+%XLBQ(7A
MF0\]DT+"1U(!A8A]UY2?"]V\/A?B%VEG8Q?W@69-[[+R2RZ'X(3@04%KR4GG
MS5O8@ZUZ?06?ABB<Z==/M*6S%*3H._VK ]\ND^;%40%2J50V2X6>I4B_<L16
M74021"BE*]3);@:RU9O?1%)V@114;U2URSWVZDO6)Z[V58)2<RIM/6WD:,F>
MWWS3';[HKN7>$8J%%?(\.'#^*>+U$PT-Z/,%*EP">K9XC UIBU@X[WB"Z<FW
M-'7K%\,,E/#GP]X/R=]P0X^'R' 1\;#%'<RS"%_F.:!U9^%[,<7BB%"D%7IJ
MWE\Q)+%A)&CP*.:ZJK>GB3,]4 \T"\DIR;)<CS$U+'?Z1,"LIW"IH4541LHD
MLD4^4BH10.8!LFBM7#,TO!L*(F'(;D>]5Z(H4R $T1(E%)UEM21E)44R\T80
MSY%N>]T<D@"% FI('46L-+TOKRXD!V-;:7Z\T3\S].>]Y(9-?( SM20]<WYB
MV2*)(HA*A56HG=:5JS^!+,^;PUY>P^D3>)"15*(9(E)_2[9)8P8%+VFN\$.4
M;WN4Q>28O0*"G1)<ETT1GF+5Y8-R]+19D45)N??I[#3S&9K5%Z!?X=F$=/Q+
MX_S(@+A.!\-@02DCF.?8'$)JI&5KR"RJ,@MQ@U;AXHU/"WHIQOY"W^[A?IQ?
M/->OCL:=: ?BD[JK=?.;M%IWIS<47!MXH@C&U%H"5HN@TT-*M?,*881=@P?"
M8,*WUF6[U[\T3YYVK<&4IT14J**%E)6OFX<;89Z/TS=13=C(JD+J"BCE,ZRK
M*DVL5^;XCYHCG?MAR4_GG>NH*&4O66V[ Q;M)R?40-:WEN@W\64Q%U/0[\JZ
M:>3&AI#:?>C4RHKC3>&W[J8B:H5H01R\SV[!I-V(SAK"U3H)<8*Q9P<KW.@&
MLQF401=ZZ]A7OZJ:R 68AL)!#U+NWL+RHSN8MJYE@!TII#L01%LHLA]JP# @
MS@&P8T)@P8>]0C-6#MM,Y1 ^B3G<"FZI;Z;-DN&?(.1E:\0V;O)9&=VMC6OK
M*('RL[E>DJ>^QF:\"@$L'&):#7#*ND4@_0'6MI4*'Z_5&I-6%@0;FH%"2;!]
M2]$4W7Q9;II*_19*DVKR 8+AA/>&-Q%"VH*8>Z2*)3L92-Z[%HS0Q )9J-!P
MJ",XJ[TN=\_NNGPI!]ZQ YDBLQHM4Z+=K(O<V)]&;/-TC,\V]C^EBB]+E62S
M6YHLTF95HV6 ES!'H Q,!PY%8[+3DO FGJX!>"SF)I51+U9V66N@43[2]!XJ
M !X@UJ9$B8AV>KRZ>7*[%\&J6,8UEXBL2^B@2.Y4^B#<6HF@'B+MJYK-!@-&
M/($$&$.>0$06M)R/N&,2\2$D.7TTMV:L>*/XPSUC*@80(Q%10($_REV=FP>[
MWQ@T3%XDHL]%ZV]TV:@7(#N_/]GL^"R6>-/; 5'JQNH%\"OUUY:%9?9: +#X
MU&$;*$GY>O/%L^R;QB]E4U K[ZM&$P&'>]&8M0<YJCG$[SKKRR9>,>TE3W^"
MK:VUM-%'ZX^ZC\PBJ2K7UU-AZM)OGUH[-A/.D)HA&*;'F5TM*4S)9L<2Q=FO
MB?0"^KT1+YIN]2XVH2"E9K.W)#U%6;$_))<3DF]]EKG&.20.+N$>*.%<4APW
M$W#N=9!'4!X"#G&6XG+GS.I==Q!>&X&[9)#$&_)BSAQ4"!S=V5%7PMCC;N:<
ME\G.(P\?!8G$X+%N&%BL'B(^%Q$)Z3T./ B/0HSCP,P7(CCSI%O"EFY+NA!Y
M002;H-PFLTUT.MR(3Y#X+I&YNFO59:3FC$6,BX9T^*EY$"PK2Z#IJS>?7JBQ
MD3+G(GB_:'I&@5.E55;AF\]]?DM?QG#\*(I#@WDI[6(IKLQ1JC'W6HX_A5UX
M/?Z0(FJNB7U,]>PDQ3RWODXK#UB*YXT.B9GP5"B>(&$ JC^TFM25.PZ,48BW
MI9V8!I8E\^AX_P ;P-&PL8XC!/XC"1W9B+A8L6!$&WCAEQXJ44%0;M02)!9
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M*P/=$04(-0PE@Y^]MTE$Q?TD$7[SL/LH2;9)#MI6)J(=^3"=7!0^;5?*11:
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M7YF4</X=\A Z<%A8N9YBX[3^Z-FF%#Z$SA"X4>;B)<-)8F8J6J\NPZW0L.9
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MDOLS"?2=Y*7'/V^]F>V'Z5<F.(XLS[.GW5A9+PY P0#SLAB^(LP&(<BPR?\
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MOD3-R BMPXLZKVJ-$O\ 0"["*6MDU@1$-&1I5%>AQK2*TYR$]?2[8/,9/8/
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M/3E?K<$[!?$L7$6Q+Q<TY 6 \#)$ K*TZRGHM4[-%8!O07=W=@7)'>NL@>"
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MGM;SY54+9BC[I76ZEX"%-U'6PO3II*X(""V=/7=K54"ZA6BE:"?EYC4L5=U
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M%9K[[4'T;!(=W%C@"13-A@6#C4@JD2(03K5):J$7?S6I;!RI5M'KGWI),G8
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M,!0*O7I0$S.^XNV""#8L0'I<GD0UB&#"B+'1<*2H2GK>Z_E=PU!PFN+LT?\
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M "O&XOX^#^-^/XOB\;#@*^Y_0O\ I[^H_P#47B_U'POZ;P^%Q<7],_I7Y?\
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M^G/Z3X_XOA?TOP_S_P _\_\ K/X'YOYGC_D>+^3^/P^!^#_1P/R/Z7X?]/\
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MS9+.":B6!QL(EV9H560A"2!44 7._OT#<S9X)!)PEVI/W6I17H83H /9]>C
M0[G%_OX$YYE<A*$YRI26G7?5MAIERSD6)O6S$ 6:9(<%<<"FM/?OFUH S5:8
M>?5QVA%:AFV_?NNFB2:37$2U(=B##"7GB!Z(K;AN!7<34SV2T^P1I?RDF!#
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MB'O-.TG8;$KL-W44I8+R]BK=!\N'>'>)%7$O@6:45MP2$IE*>2^P)M7#N_\
MCEJX'1Z$UED5AQQ2)(:6EJ>Q&]J$!A(9W<"6Q-NFASD05H#8<K?27TFV>$,Y
M-X=I]VTNXK"*VX%Y#UGT4+=;(T, "\OH_5BUB,2BLNNJ%-Z2!]0?8;H^+]#[
M ^NJ+L6\J%*I[ZZ-T=RP@$O+$P'ES1W-9<KSAK[[% -1(]0;?G7UFVP!#-7"
M.T8&:Y0UQTQH]@\X@MU:L'KS6A2@2:+SFLU)  229,&3=[L*-@#=V<D"Q=49
M#$:XRT12U7-7$0JS0FX]V_AMBD=WO.(QL:J&#-L,HN^%^:$\  =.1WO,DSMI
MJC"6-#.E9Y^VDHS\IW;WF]@/ 7).B)H%)E.QKV 5HYH(Q=Q5\,3?)Y<*(1"@
MC7^>TK-GB>K4AF!!)NSF9AQA-D02Z4Y3O6:%.4["6K9($MCE>STW<?R%$3C!
M&(AYZ4_8GG/^(%"9K/R-+7/FT=G!TAJAQ/4OCW5!>IJ9YWKB!9@V$&J\XDEM
MR($NH4R^NBV6]YME'0$$YTB<ZP(',2+S6B 354((*@;S05&Z:M#ZX[Q5&&%*
MQS+S/2S*J8:DJ==!3=-Q78F2,50HCE2ES.E2ADH*6UD9,157H>HOZ@KV13N-
MU8BJON&9O*\K'I4;>K$0GG?P4(3['WLT;=KVYSBB"7.JUV'.2^7VA %FPP<&
M*:GK,LB&]#DG,*4INA4H+60!9M!-#@2+/)AQ#D#N<$0'H7\UU.W5?L1KS#,:
M@XMWLB$]"D5K,4GT6]Z7ZM7!H407H9"^^5):^FK0@&HRSZU1#\)HAE)._<2.
MH8PJP?[=$,N ZH5_BE)]-U:$49H9G?2U.5Y9Y1#,)5D._P#&O>HHT/"]R< 1
MGB!2*!CB0Y1!>@S5*W*COJ>C0@LW8?RR< APVK3!L2$</R)-Q+OK9)C6S# A
M^'!W/R!?W9Y*N]A]C=-ENGO55!8"TL+5?#&E#!%;"0B ]A[&<YTJ.WM0U>I$
M0*C&Y9Z"CCG4(A/0-4"^8OJ/?<"[-+6J7L9;VOR*N] =-92D$'G_  QJO,RQ
M-:8" #1R .:(+V'"%!SH:V^AD9)9&>4: &[C,U;DU)))D(J[^&LF]/67*V^K
M0\&$V;I@1F9. P15GL(#5U)K9>8I]--6R 6B8F_)F;&)KF$59_ \E/:RI0)W
MLJU:N<"8%IQ<NY=W9[%P BKO80A9"NG?<]O2=\TR\!BQ>9K(#X,<JLQ">PNU
M])>:)T"R):CB#5MGBW_*;S$@35$(X5++K(:'9.OHSSCV%WIH;T:;%$)^ ZE
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M,DWO>*QD7 *JNKMYTN;DTUE)KO6-]%,^_.BH/Y8X3-P<D/GV:/D=X.T*H/\
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M\, \AB"8"6)T64I\D,J'H6T[US<ACFUXHYQJ B$_"*IY+7E*\Q]=+PF'M:D
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M2?7T1-X!1>M_X\]PDX>$%J19OU[C)% P@2DE31)4%#_# +QEDQ+S4]9NTDE
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8[5B(O@"S[;WZ>>[$1_E[^5?:[ZW8B__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g305908g76r13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g76r13.jpg
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M4D="+"!I="!H87,@8F5E;B!C:&%N9V5D('1O($--64LN)B-X03LF(WA!.^*
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M$@ DG 4%F)Y!0"2Q\@ "2?2LD1Y'6.-6=W941$4N[NS!51$7+.[$@*J@ECL
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M9+6\TF!*D&"$1HF(]8PC1"6Q1274%Y6HAD81PE4T],>*&F+=2Z9 6&5D'Y3
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MQ[>_?ORAVUGO_P#'YX]NH'C\?R 'SY5)VQ\!^.3^N/E2N-B)D>;EDEG"?/\
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M.+;<1%5[5^P=X20Z%=E+8>M%CV-J&+?6A.<(P2W0VFW,Y4YAE'=*<09NSD0
M2UU:]8@@F6ZM[./(_P E6.VN7(8;A"V5Y%V&YE2QSD* -_4_ Y'+RQOY>7H*
MTSR@=2ETGF+)-$*Q^TF'T3JX$'OVQWRT/+_:$MM'?/?'GD7E93C&%*RK'FZP
M6^TD !=$C89SF34+QF\L$Q&%3\DV-"#G[Q ] /D1D9]3D[GP\O*<H/.*IOJ/
MKG(736S16_+G%5V9HN5JA)W;*<K1]O\ 7NR?2BG'$XRA!*M:S+3&5^?(#Z4)
M;7D+GL_,O#-IM]:L3GO;2]28#(S@07-KG!P<L9R<#&YW&/O+LN&&>;$Y\/(X
M^0\SN,"OJN6EKUJ\D;E#HRS:?CL]L?VH4F3>W5I)&,*2EPB8MU?@8.XT8-K"
MT+)D]A:YJU>&QES&9]Y#675R-)CNE#:9?V]V_O<5G-FROEW]U5CF8P7#L-^"
MVGE8_P#$'('H!GQ&>?/ Q\3MY>0'F?!VU8MM<ND+'62I3T+9Z]+,MDQD[7Y(
M27B)$9W&%-D!2(#Q A3*TJQE+C#SB,_O=4\D4\,C13PO!*C$/'*I5UP2-U8
M@^8(VY;T((.#6R=8U%'2E'2E'2E'2E'2E'2E'2E'2E)KN0ML#4NS#G0GY)H2
MAVPET ;+F""VF8(]QUAGT5MO>JXVE26_26ESS9QY,^;MT/70Q3E7'K7(E-NM
M=CD-,/207P4:]$DV$@0\QFOUAD-P_P"-*.=>)A'YE(@TZ])E!"-+!$MC</ -
MGR<O\2Q'EY^OX]>E*>'Q+&UK.;:IE2NTF8M[YY),/'!VJ)@*R]7W\MM1PE=A
M2R$/A8*,6W(E/"Q<2X57P4&O2*SSUX.GKKK:G7E73&FJU8JIXI0[#.*TY"(B
M6P0RUH\L0X/Z#7HDL/?$)\S6/.V6AW+JUXR]AU2^ZNE*CVYF\(=&W+CJNLC%
M/ZWB*%.V+8X7RI:"W+5:I.%D07 YTJ5><D#2)0PL-8QS1[9\<2& L)UE@1MM
M"E<P>JJ:D'9<]7L2Q[U9 2&S,Q4-\>N3G1):-%CRZO=@2A6!_EX;H1[+2@%2
M*)HMM[#@V%/+92I4F?&[6&NKIOG5HSJEN:R#F(*MN5"N28SCT^= 0;<E5FII
MP/+ED5%UHTX_X\$Y<:1B,%2R>ZM N C'777PI^WACK\1ZUT^,M-L--LM)2AM
MI"6VT)QA*4(0G"4H2G&,82E*<8PG&/;&,=L=*5<Z4IF7)C0NV;WM/CSOO1MF
MU]%[)T!_:Q$#UO:D=8B:/;:MN. KT-8F2Y&ID(GH:8AB:G"2,,4,(<*1G!@A
MK*6W4N8ZG0=8TVST[6]&U>WO9+#6?LZ4SZ=) MW;7.ES3RP%4N5,,L4JW,T<
MJLR,/<9&R"*L+.Z@BANK:Y25H;KN&+PL@DC>W9V0@."K*P=@P)!&Q!II<=X9
MMO14*O7IG:58D)9_1//6A;#FQJW(B!%;%YMVB%MY$[5()XXS(]4HTD/(B#A2
M<OF5/%8C2/5:)()2+TDG;ZV-S<S1:=.D0U?L;>6437",Z6/9.VEM5AN)0B\5
MQ=QM&S/'&(T8R+@J%XMXZQ'QR,L#A?:=,EB4N"1%IR-&%=L#+R#A)(7A!)VP
M!E0J#PGVW%S>;]9;=J2&V8'P%BN(E6GZE4SI^/IEXKUOV',0NQXD"X!X^-B5
MQMBJIDU"%Y:^;3L3),$,YBW!,]:5YVKTV2$64%KJ4M@W;*7M-<0W-RD,EU:3
MVUC%+8R/:M[L@D@N%BF7/=Q21LI[P-7C+J$#*8T2=H6U-KYT=PADC9(@T3&,
M[-Q*X5A]U6!!XLTCFM?#=WC%6H6\['VU59ZR$\@.(NYI\A,_LFY'FL<<*KL&
MKV(9-ENRG)1V2MZK7'RL*,P-$U^LM-OU\&/'CHT$@NSO^W6D26[6ECIMQ# N
MB]IM+A7N;"U1#KMQ97$#=Q: 1]W;"W>.5F:2><D3/(SNZKL3:M;,ABB@=4%K
M?VZ#@AC -V\3I[D?N\,8C(8DL[D\3$DFM.:\*O<LCJD?4%AVCJ5J#U1QDY(\
M<])V"M5FT1UDN..04I#%N6_=SA)!(K3E>%@1UKAJRF73)V*5E[)F1&<<Q'O;
M9_J+I<>I'4X=/U(RZCK^@ZYJT$]Q;R06IT6.9!;:2%56(G:9@);CNS'!''!W
M;8[P>GVU;K/WZ0SEIKRTN[A'="D?LH;$=N  3Q<1'&_#PJ G"1O7C<N^&VYJ
M-9T[#TVQ(* MN].,]EP5J6E3DY8-41FB^,>W]2FV%RKU-8MB.3/S-IA8R-54
M@SU@1SWISK;48EUM?IV9[4:5=VYL=49 UMH^O0<.I7<4,&HR:OV@TS44@%Q<
M!H$[F*WEDD]I9.-US#F3!&5CJ%O(G=7!&8[:\3$\BJLS7-Y!.%#N"@**C,W>
M$9(]W+8J4KA1!6&K<4M%5>TZL3I69K-"CJXYK+$R7/KK,?!/$Q4(DF2D"39)
M1LO""1T\>%*&F2L4;*/Q4F42>$0\OY[VKFAN.T>KW%OJ/VK%<7DDXU#NEA%P
M\P627AC14C"12L\*-&JQR)&)(U5&4"EU!D>]N72;VA7E+]]PA.,L S8  &%8
ME05 5@O$  13HNN?K3JVYG&$+[X[]DJSGV[_ '?U[9_TZ4J&?A_LG^RWPY[E
M9@_3<L!&].6U<IP.58\TI=;3RGVK7ZE&([8<SCXR=D@6G7?36V,QZI+^4#LN
MK3HZC<"ULYYB075&$:D@<4CGAC&^/\B,G_$9/A6EJEP]O:S&)2\TP6WMD R9
M+B<B*!% ]XEI61<*#SS@XI=N$%&;>4_L9_#;\'4:E"Z(U?**9SC$] 5 ER1V
M#L !2FFE8&V)L9\Y;;Z6FTR4?5HJ3[N-E,+52:"HNI9-1,9[F.*.QL9,95HD
MR]Q*IQD"XN'()(4$0J=PPKZ/KEI'V/[']F>P:!/M"-1V@[28#+(FJ7\*):Z;
M)LJ<6G6J=^RIQ*DNI2JS%UQ&XG;7*36FKYMC7X#LEL?<\P(HBL:5UX.F=ODQ
M[>1DJ1;PXS#4BO*>RALBXWV5K-4#SG"2)G#RV6'>[M-(NKQ&N&*6EC&0L]]<
ML8K>(-DX4XXYI6X#P10K)(Q! 78D<,JG;/,[CQSO\L[;\AM@>5:/JW1-\N-\
MC-_<F"8D_8$4T5G6FIH(QZ5UWHL0_"FG2 2BTI1=-J'@.+"G]D.!QK8(CY5>
MIT='1+AY\YZW-[;00/I^DAE@8XN;UU$=S?'.<$#/<VV<%8 SLQR\I)(5,BWD
M,='E\_';&XQC.5KW[K'&W-07W7R'D!F3\"0B(.SAMSY;8(]3<I79).'$JQA<
M=.A1YC;GE4MM;&'&_(XE*L<]>6XN;::$Y!=05P<8=#Q1GY,!],U7:E:"^LKB
MV.<NG]O!.1*K+)&1L<$2(I\?45Y?'?9N=L:FJ]G.1\'9QQE5Z]PZ\XR1 7VN
MJ^4VZ$(PG.<>H#-#%(:6G.6WQLL$-9RV\CJ+*X-S;H[@+*N8YD!^Y,FSJ<[[
M$$CS&#R-1IEZM_9Q3#:1,P7*8(:.YA]R9&!WRL@(S_D"K#(.:6.0!%D@2X\T
M=HH,X=T0H9]M#S) Y#:FGF76G,*0XVXVM2%H6G*5)5G"L=N_6Q(BR(\; ,KJ
M596&5*L,$$>((V(\JM(99+>:*>%V26&1)8W0D,KQL&5E(P000"#M3.-"3KVD
M+67Q<NYCB!PUR,QH2P&.=VK9KOU_7S4OB%K5A%CUVLAN&="6EI9L"F+D@T.M
M)-RQSVD,=-F;1KEQ[I=].EP0LUHI![C)RHEM^(H5)#/'AE& <?2NU=G_ -4Z
M;'V\TJ)6+K#;=J[2,QF6QUCAX?M QH>\:TU4(;D2A3'#<=["[ E.)[K;J'/9
M.<YSV]_;Z=O;/?/XXS[9_CUTF=\>/1_'.WG7S#Z?4=;>/D=CO5WI2OG?'\?]
M,_ITI1G./O[]OXXS^G2E6%L-N)7CMA6%=\92K&,HSC/UQG&4^^,X]O?OW^_\
M>E*9$9I#:NAIB5M/%(J EJ9,'O2UDXQWZ6*@*(T:6^HB4E-*7".CY1[4<I*O
MN.FR=4*@;#KF8D5J)!BJ;(FRLV=<>W6^H!8]6#I,B+''JENBR7#(  HO8V9/
M:EC PKATG4?>DE  $]>7Z;#)/+GY"O63S6I-589'W3J_?NE)U2E(=CI_3UQV
M%$*6GW6Z-?-&@;4U\\QC&<*QEZTBEIPK"'1&W<*1B?L2>3!L[K3[U&#',5[!
M"Z@9V>&\>VE1C@D)PEL8P-QG L!SR"/G\\C(Q\ZJ5SZXP/92T'9]B2Y"L]D"
M5_C_ ,A)\W*ONQ\)"ZM/?QE7_APIONKOCMC/?'?$:%J62&CMH\#),NHZ=$,#
M&<&2Z7BQD9"Y(\J@NGCG'+/ Q Y<\*<>'/\ 2OA?)3:-I[MZ5XH[@MZ'49P'
M9MJ&5K0-,\^?+EMPYB[GE;;:$6WG*L.@Z>E'$+[)6RUE6.I^R;2%D-]K-G%G
MWN"S$^HRJ#S0I#W=L''(\=RH /$O'CA.1)(ROX['Z$ _4;9WKS7=,<G-L#HQ
MNO?K.KX4C&7WZ!Q:#-KD@UY\_M1<INZY(DKC+L(1YD9DZ74]322U*SE"V?(A
M69%YI5KCV/31=RA64W&JL)E#$^[+#:1=W'$4YA99;E6.Y&#PT!89R%Z^(_6E
MBUAQNTGJ(IV5HVOH(&T%M8;E[W*,N678]B5VQAPBS;%LBI:Z6(EW.,J<>F)P
MQ7OG",H1G*,:EUJFH7HX;FYD>)0%2!#W=NB#[JI;Q\,2A0 -DR<;\A4D[>.^
MQ(SG?.>62<\]_EZKEVPG';"??&?;/9.??[OPS^7TZTB<_MX5YA#D'.V1SR#]
M*,9S_P"+&<_A[?S_ )=163 G&#CGXD>7E\*KQG&5)]OIGO\ =W]L9^[&<Y_+
M[NE0JD'<CE61VQ^&/],=*SJR0PV0VIIUIMYMQ*D.-N)2I"T+3E*D+2K&4K0K
M&?*I*L9PI.<XS[=^G+<'A/F-B,<B",$$>!\/"E,NLW%21HLY(;$XH68+3=Q-
M>(D)S7!09)G'K8AQ#BGS"K1KJ*(CFZM:91><H=V'1'(JP>LM!EA"MS(Z8UVV
MCU-9D$&K1-?0JH6.XX^#4+< $ 1W!#B6-3@F&=)%(]V-HS[PRSG ..6,\_7\
M^9 R1]*]S6'*J&EK8!J'=E;,T3OI\=QX2AV(Y$G6+LR-YL$2NI]CCCCUJ_QJ
MO(M_,6TN*O$4-C#EDIT(K*<*PN-*:.)KJQF.H6*E0\Z*RRP,^2$N8&)DB/,!
M@'C;'NR-L*$>((QUMGQYYWQMG(&,4[A+J%_3.?\ G]^?X?C]_P#IGJK)\,$G
MT'G^'7H:QJYU-*.E*.E*.E*.E*.E*.E*\^5%'.C) (L?)8A818Q0N/-W)'?'
M=9>'[(SA>?6;6IO]G.%?M>V<9[9PI7)5M/4]EU$6_7F:)-46#D[=8MPUU3&9
M0,&S0=7F1$CP(Z9-X^>FK%$)EU0CT<6".^?'%+*C?BU"K?<==>7QIU^U>?I0
MX/79=>VK#QM0.)N$C91[&K"9-%R%5%R,@],Q283XHQF+.2WAR2.?'P.ZIE*A
MTB&M1HP_0_'%*<QK3Q#]F:I+NQ\O'(V46%2AE168X?->#@X'(S4;6R)Y$L<2
MLH&'+'QYS@V!"Y!.))Y,8XE_)>7777PI5!&[-K[OU7+KW;,0$Y*S*+8S$Q69
MC,(734RI"DCH&'BGI10*GP&PW(N;<<?D'/54(V)&LK>9:4J,S%&O4;9INLN5
MJSP02IN-)(M N2G'CHH\+$A" PDPL1IZ2$"F&EMJ8C& #67VB?(H=QSU<JCX
M<NNCSS4O/A=Z,O!&U(W<R+5/SU0C 9Z)?,F %!LXS\*J'2"*YAE@8LIUX409
M3K"7%I !,(+3\4>R8\J>NNO"NAKI2CI2CI2HEXGG3R+M''#;O-2O:BT\WQKK
ME WM<-91LK?;AC<$X'J9%I!K=CM,6+4LU(6)O$W5"$OU^.G$2U=B9($SYI,/
MMD#X^D2=D-#@UW3.RD^IZF==GO='M=0DCL[7[,A?4C;O/!;R-<^TM+9Q7*XF
MDA[J>2-U[N(%35X=-M$N[?3WGN/:WEMHYBL4?<*9S&71&,G>%HUDV9DX792.
M%<YK5ME>(YO'0U*V9C<>GM79V#%<6F>56ICZ!>+3+4*XU=BX5&F6.I6L>?K,
M%8ZM::X==(.0PL%R<B)N,+<6.<"2"\.[LV'8;2-9N[#[+U34/8I>T1[.ZE'>
MV=O'>VMPUK=7=O<V[0W$T%Q;W"6DT>'$,L,B@,CJZL,X=)M[J2+V>>;NC>^Q
M3"6-!*CF.21'3@=E='$;+N%96&X((PY/B)S1QO>.VR1?RM/QT+KG8L-0:KN3
M65_*G-(;C)F*C&VDMO7MCMD9723YBI/GN5ZTQXBI85F6&7@&1)0EU+5#VF[*
M_8\FFK9+JCS7UA+>W.EZA9+#JVEK%<R6ZF]@MI)E2*X5!/;R,(F,;#CC4XSI
MW^G^RM (Q.6FB:5[>:(+<P!9"@[U$+ +(!QH3PGA.X!IO0'BLU0ZUP^KD,TC
M.XSO$!D^))FO$R4[F3$UF%MB:UXULY+F0\#*EW (\.27'9*R%\44MK&,-)QC
M%VW].KE;:742;O[+3L6G:5;XI#W;7[:;%?'3\<7%W0=VC#\/'PJ&YUM'17"-
M-F3N!I@OA+A,&;N%F,.,YX<DC.,X&=Z6OCIS'OFU^6NY.--GB],RH>M*"Y<S
M;/IZXVNPYI-B9V";2'=4WI-MK5;^:6Y X;\R7*UD-F(C<!N &CI>/CW%U.N=
ME[/3NS>EZ];R:K&U_>"U2WU2UMX/:X#9)=_:-F;:>?N[;B81+%.YEDX@ZMA'
M U[NPB@L8+M&N 9I>["7$:)WB]T)>^CX'?A3<* YXFSQ#8$5(QUP]55'2E)+
MN1>YTU!>=$!ZS.O29$+"1]L2MLA:EF(4K.)-2S:=#3LO\Q2UV4"U@'(KCG?!
M#S:<=#R..?A2N;'7WAW>+)<-<1</)7CC5K.OP>T=^6.$US;2;\24!G8&W;[.
M2,U\17JK+)?%M<182VX@U<LB8:I\R@)QJ"D299E_7&FZ+=\?VU9W6H^^#"D.
MH36"*G".-)%@1N\XF&['!"GASN:]='FN-&U^W[0))!=3V(+:=;7=I%<6MC,8
MC$+E4+IWEU&29899.,1M@@'&[WP^*7B<.U:.JUPVCHZ?@8H(*.9J=7W7MS3]
M*8AH\= K,,%&Z:X]4.VBQ:!6TLM N7HIE#"6V%9=2WE:^A.J6%J(UTO1K"Q$
M2+''WJO?NBJO"O"UT7C4@ 8*0IN,D8.!-U//>W,UY=7$]Q<7$TD\TLN[2S2.
M7DD=CEF8LQ))9LG&235_AB=S&F-2.V?0NA?#_P!55DV\;"KQ\7FX[W"FY.:U
M_=[!0Y"9G),;7<@=.OR9,"^<S(R\D;)/,E)R6M)&7$)T+R^O-0<27MS+<,HX
M5XW]U%Q@*B+A8U . J!0!@8   \OUW\O/EX?AZ4[O)WB?(QC&*OP-QC\<;"Y
M#9S[]N^,85K-./KV^O?O^/OUJ  # &!4=>=:50;MXK5SK3DM8-0\,M>GXG++
M%8KEIV-NIV46#"STC%1DWZE?I4U&_+[+'AC3\6C!OQC<?(#M2 XIJ'QFIYCR
M_,5.P\<[^6Q'Y]<Z3[&G/$MKNR3MD4)/"BED6N0%.V151[QO25IEX?%&2*F:
M7$EZL;)KUQ4,R,(_98:1;P:&(.S*1<BXT.^QJFW,;O);LL9ED#S)C(D(4*6'
M_%BH +#&>$9!(S54VG.EV;FQN3:=ZP:[C[E)8;G;A#,K.ACD'NY:,Y( XMA7
MSCUR%\1WD91)2]UK7W"^""B=B;*UP0'/W[?+13TEK2ZS5*D9(= &NSFOE\B5
M#N& *6ZE_(SJ,O,L.X4CK8QQ* <C(&<'!SXC;UYU:#(YX.WEC/KC)(^OS(-;
MAL[6GB#[=KN*Q>:!P0E0&3&)2.*&V5R2CIB"F0U>H!.5^:C]:BR4+-1[G]\%
M)1[[!3#GOAQ3:E(5I7VG6U_;B"=255A)&RNR/'(OW9$=2&5U\&!]#L2*NM#U
M_5.SUX;S3+CN7DB>WN(659+:[MI1B6UN[=PT5S;RK[KQ2JZD;@!L&DWT5%^,
M1'DV1ZQO\7'JI%6*TUBO5C;-KV&;;C8^"EU P]P%O%&UF%F3K<\"SD^#'L,,
MS9\"$H5/OJ-1G'7G9V=W:RDR:@]Q;E56."2%.\C"C_*8<+.2,[LN=MSDU9Z]
MK?9_5K2 V/9>+1M6)X[V]M-0N&LYV+,7$6ER*T5HI))58)1&HPJ(%QPN/R9X
MH6%=_LSP2\OMGMG8/(+.>V.W?ZZP]\_AWS[^W?MW[=6=<EUUSI(-&;T\27>]
M4G;97:)PEB0H+8VS=</#3M[WTR6_(ZRO,[1I ]G FN26<@R1<$\<#YG,/I%>
M:20TV\E:<.NOK4D8Z\J6?XKQ1,>_V7X%_P#IV%R%[^_MC_\ &/;^?W8QWZ5%
M:+0KWXK=K"L),_J#AG0WXB[W"KQX%DV-N9Y^?A*W.EQ,/>(MR#HTPS]G;F .
MU/0+4@N/FF8\MIN6B@#,."-JG;;?XX'+TWQ6\J.\3]+>5KJO!!>,86KR?VB<
M@\YSC&,^W_VP]\YQGMV_#/;/?Z94V]?I_-(]I7>/B/[OA+I.05!X3Q(U,VUM
M'4A3,S>]\-OF2NK;A)TZ2E!<C:[*;7'R)4:X4#G/D>]%>$OML.)RUB,#)/7+
M?D ?Q-1T>O&E=4]XG*<>IBJ<$,+RC[M@;_QWSCWQC/\ W7XQVSG&,9QYL8]^
M_P!^>TD9QS&#GF?78Y)VW'T&_.L@0,[9R"-_#(\-_,G?G^0TFDW+Q6+0'8'Y
MG4/"ZDOQ%SM=<CQ+'L;=BG[!"5^:)BXBZ1JH.C2S"82W!#HG(<<UX668CBV&
MY6.!-2Z.C'A!.2-_/)S@';<8ZYYJ,_K@<P/D:W3XSQ0L]L?9;@3C&/;O_:%R
M'SGMC/O]=9IQG/OG[_O_ (=95%(CQ_Y!>)!R @[_ #L%KOA77VM?;BV7IN08
MG[UOE@@Z7UG/K@)"8"2)0C$YB95Y&"HQ;RF"5C*3EX=I7MTZZZ_*A \<'QZR
M*759/BA=^Z:SP.RC&??']H/(-.>WMC.<?]V:^ZL9[_XNV,?3^2FPY5HM)NGB
MN6?-K^<:AX94G[/W.>K,5BR;#W4O-LA8ET=$==87Y+1Y?TX&P)?6J/9D\Q\P
MW@5W)L6+A367%*WA1GBA83C.:OP.S[^^$[!Y">;_ -/_ '9]^_OC/NGM^/;Z
M]*;?/X?KG]*1+1^_O$BWI%WR6K]%X31+-#VO?]3',S%_WTETR6U],9ACY(/
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M/776:ZG>"O!R%H?&>%!VO!Q&=CW:(C)LP^/; +F*6VZPP5$"14_ALAI,LVA
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ML_@9N;2%9X\7OC\V%M78_'RHZ&H,16PZ'2'8X\C5L;R3B92_R=2NVV]6QUE
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;I2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g305908g77s33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g77s33.jpg
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M(B,W<;$81I&UML0D)3)"4F'1\#,T-CA(9H'_Q  = 0$  04! 0$
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MVA<!^D%M-272UGQNX8[!5K[@&DXG3*WKZS*1#D1,4J,D2'.\,S.<Q#@0%P3
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MP>>T]IO(SSQY75#[<>(BCJ69H974XVR3":S'&Z&OR>T,ZU[=R=SLP.>,N_\
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MF-.PZDQ-RG'==I_46(EMQT'W8ZTT\=JO/4MDP7J0MN,;Y(9(Y.J<-[;;GO\
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MR6MS3+:WU2_U]E/:X9UC4#JPMH6,NKDA9XET=OIIW78I"):!$QKI:6*=I&S
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M5(\3?MV;BG*FKL]I6G93-YJ,U;KNH3%C.TL[]F=9HQL]BE&;"*!87S0AWJ*
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M#I9V2T;/I#2.)OS0SWHHK$[,I-E,WY))-#7=/D(JT+*D3Y)8:T<O&2_JWO\
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M1T3WPE^4O31 NA?)&>*&2-XX'N #@#L00-"_5YU_<-:="'D_6[Q"KP,VMO\
MB+"FQ76:N#GB++RWKDU"O/$9KN$0*]C7K=P5,5 53 _=5(0P=F>O21EL=F=1
M17,799:JMP.GJAE8U[0V>EB*E:Q%M(UAWBFC>TD M)'(GFO'H>P>6T]I:S0S
M5-]*Y)J?5-]L,CXWO-7(9JY:J2GJW. $T$C) "=P#S&VQ.Y/I4_9F< /Y/..
MWY5U?-"74G^F[\3OJ5?O"I3")A$PB81,(F$3")A%QV!_ /\ 8&$3NE_\(?[
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M,K88HV ;DN>\@ GL: >)QV:T%Q 7C8L05(9+%F:.O!$TNDEF>V.-C1VESG$
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M'N,:LHZA)9/P9JKV&+>N8:T5*=;B4@H3-8L,?)0L@7N%(HNR,X0[S99$YZ'
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M "PB@^L?[MZ%]SJW_N=GDN[3[S]5#>P>X?13G(4K@1 H"8P@4I0$3&$0
M[1$1'Z   ^D1'Z #"+4C6WF[.I!8;9:J]M^^\>>$-9LT]2:*OIZ0)6-Q<E).
MKR+B'L=Z7V&HV=/:/JM.8:.X:N1E<03F;,DWDW,L[8&(S(VKY-W!&[O;V-^'
M>?CL.S;M4=NVQY<]_;X?#Z^T%3I[TSJW4&RTWQTY)\IM';*;$,YB[,KN6U[1
MJLG)D#O-PONN]COIR N$,94!,[C0-$*J"<3)/$1*4,<?K-:[?MY 'X$#E_5-
MOUS_ *@;;K+W#SD5>]J?TGZ;WS PU4Y,<=Y^+K.TX^MF<?-*X0]@8J2=$VQ1
MB/!%XG5+[$H.'*3!T(NX>39OV#LC<000+#@.T=A[._;Q&_B/IL>]3[U=?*43
M")A$_P#?\?\ +"+2)R!]$YF0$7R?JFPK%4^-FOD;)5;A"7&#LM/N#*>IEHDX
MR<>52HR;$C&7E+6HXCH.$=OWC 2/DT(^3%LJU>,6GSWTS:+R>8NU=16L['1T
MEAL:TY.KUTWE,,C;$KY),?5$9JV+N0;-7IP&:6$B9L;9'&';;F6N\%;O3Q92
M;(MKX2A5WN0\<@F8YLKR]U6$-,4UBRU\<$76/9_$#&N)9L%)^.G%S96V*@QM
M1;=+\;=03:)'%3H^L##'WNSP9@$&<_=+J8J,E++R:/<=I.)@)-N]*<'$7"5^
M(/'M1PFB>C_.ZBQD.0&3LZ%TU;C:_'8C3YZC+9"F><5S*Y;S9[+K#-I&/M-G
M9*#UE>I1KF&,X_3^F<CE:D=KRN73F(F:'5*.*(CO68-O,GNW2!)*Z4;/!FZU
MKALZ&&O%U;3G:P<6-]Z?:+6WCER)V39I*(*+T^MMN2R5KA+2B@ *KQR#HQ6+
M!B]=%(9% 0BVBJQU2)DFHDQ?2\V^[T>ZPTS&[):'UMG;T]5ID_8.I;+<C4R#
M1LY\#)"(8(9I TMC/DT;G%P'E=;;K5G)],9W$M=;T]J#(V9(O/.-R\HMP6FC
M<F-KR&,CD=S#2(F%Q('70[!XM8RW$O 5/3SW:]7D*9=-JS\'2@J[$[:93A[?
M,1\B^(W>/$70$1CC(Q;A85 ,X<L_&1:.4C."+&+T./4[Z6.TS+J+'S8O*:AN
MU,4,?"YEMM7)VH9IFQRRM> R'@KO<7;O?'Q-C>TO#MMG;ES7JXE^4K/IW,I8
M@I>2L<R80VYF2/#72-=PB/AB<[<%SF[M:07!Q$BINV(&[W;95$C(JSL935TA
M#1TX^F88S"&DUIMFX>ME*\_%=49)%%-N<KDZJ+0Q1.@J@1PU<).#7V+U%3RN
M5SF(@@OQ6,!+5AMRV:CH*MAUN)\L;J4Q>[KV,:PB0N;$02US ^-[7FXJ92"Y
M<R-***RR7&R0QSOF@='#(9F.>TUY"3UK0&D.)#>XM#F.#CE#,^LDF$3")A$P
MB81,(F$3")A$PB81,(F$3"+1-^TE_9!\C?O/H?\ //7V%4STA\?H5=[I4_9F
M< /Y/..WY5U?"/\ 3=^)WU*OWA4IA$PB81,(F$3"*NV\]%V/;[JO/*]O+:FH
M5(-N^;K-]?3CF+83(/%&ZA5Y1NS=QZCERU\ 4VZBSE5--)50J:*9CJ'4TC5V
MD;VIGTI*6K=1:9-1DK',PMN2O%:ZUS'!]AD4L#I)(^#9CGR/:UI(:QI+B[7\
MWA+&7-=U?-Y3$&!LC7-Q\[HF3=86D.E:Q\9<]G#LPEQ #G -!))PS#\!: ]D
M6,MM_9.WM[N8Y8%VL?L6Z2#NOIJ$,!B'^3TE!D#CV%3*JDM,JM'!2>&NU.B<
MZ1M7K=#F&FGALZGSNIM825W\<4.;RL\E)KAZ+NI:[KW'8 .:ZVZ*1HX7Q.:2
MTX>'0E!\D<N7R.7SKHCQ,9D;LKX 1V'JVD2'N!:Z9S' <+FEI+5$^J% L8SI
M^[CC8>"33JU9'44M-5^#CTTFJ6NJCN?7$[=V;:-9IIH$CF](BIL7+5,B3<&"
M2Y#BFCWC%ZY4KP58X:U6&*O7@C$4$$$;(H88V,X8XXHV!K(V, #6M: UH
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M3PY::K:=%*&UKM=A@DM0%H/'9J@&*"9KMVGJ9'1O',-9MN_+&;$LJN#?4/\
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M3")A$PB81,(F$3")A$PB81:)OVDO[(/D;]Y]#_GGK["J9Z0^/T*N]TJ?LS.
M'\GG';\JZOA'^F[\3OJ5?O"I3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(O"V;-F;=!HS;H-&C5%-NV:MDDT&[=!$@)I(((I%(FDBD0I
M2)IIE*0A"@4I0  #"+S81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A%HF_:2_L@^1OWGT/^>>OL*IGI#X_0J[W2I^S,X
M?R><=ORKJ^$?Z;OQ.^I5^\*E,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PBT3?M)?V0?(W[SZ'_//7V%4STA\?H5=[I4_9F< /Y/
M..WY5U?"/]-WXG?4J_>%2F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PBKUR$Y'5'C]$UY%]$6*][)V"]?P>H]04A@:3O.SK+'MDG;R.AD!
MK*+B8=LNA(6FV3CEC7JO$F%_)O"F.U;.I W]FW,D]@']3W^"@G;Z?-5UL?(?
M<>H-9T?6-ICH?9?.[=2%PFZ1J>E(O'51J))NRR3EE(VFP&130C=1Z2BY:%@K
M/=)15J[M2L&=*&;N9::023D-WWY@ =YY>[ESYG;D$/9V?+^W8M@48B\;QL>W
MD797\@@R:(OWQ42MRO7B2"9'3LJ!.PB)7*Y3K B0 *F!P(7Z"AE*E>[A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M$W[2
M7]D'R-^\^A_SSU]A5,](?'Z%7>Z5/V9G #^3SCM^5=7PC_3=^)WU*OWA4IA$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(H7L;8=,U+1;7LO8<\RK%(I,(^L-E
MGGXJ>C1T7'I"JNKX:)%7#EPH(%09LFB*[Q^\509,T%W2Z*)P!/(#<^ 1:\ZQ
MM'J&\H636^Z<JNG.*.E)M$KZD/M^5^T;(WE<H)R4JT5:GU!K4_6:M0HN79G(
MY;04Q.R\\1,Z2ZBH-U4C*5D-;N#N2/5( ]HW(.^WN4<S[.7Z[1]?DN)7DMRR
MXEO(Z4YK5#5M]T%(RC&(DN27'MI:H8=5KRCMO'QLCN/5MI=33UK5G;]TFW=7
M"HSSUA!AX)9",57>MR&<+7>B2#ZKMN?+GL[D"? ;#WJ?]%L9L5VIU2J,G?[/
M:(" H\-#*6*5MTM+,F-<80*3<'9Y=S,+K$8IQ_HPE6*Z%?PE$S$%,QN^3MKK
M5K%RQ#5JP2V;-B1L4$$$;I999'G9K&,8"YSG'D  JV,?*]L<;7/>\AK6-!<Y
MQ/8 !S)5(U>IIQ>D4$4]>!O#<5@?$ \34-7<;=[3D_, <GBHF9K2E!@Z\BU6
M2_M224E/,(DJ ^D*/TV_]KFVC06H8R771B,7 W_F6LCGL-#!%SV(>([LTY>#
MR,<<$DO%YH87;A9$8BX">M\G@:/2?-;K-:WW\,KG;CU0TNWY;;KK4(?FURC7
M*[LTN^X*:54,4S>J5!W5[IRJN;,3F,4]DN2[2PZWTNU72\!4(BIL[Y;$S^,W
M<V>(,(HY6Z72FGV\->)FK\J >*S9%FIIRJ[PKU6O@OY9P.X,ME]*L>3F5Y!L
M3/%CZ8V8T9*P.U\@?'2C/?P1@LEL?B>8F'M#"!SZ?8O"*V4^!J%WT5L[;.TM
MSZJVY0MIT1IR5WC;;I$N$&"<Q3MG4]I<)IA8IRDP^R=:W"Q1\ZC&,9.&5E8J
MLNTJ\DLR%8V#RN:?ES"9,=AZ'4B1H_9&,KXX2-D+"T3LK\#)C$6?PWO!E >\
M.D<" +*S9-G@)@JPEG%MY/"V $.V],,Y/X=O-+AQ#<^<>6V&-B[PO.P]\\9&
M:NAMA:XYB:8WZC5YZI1L9.WK4U@X][,KQ&VV+$WWPTK,#2W%&5J)8ZY1"<TC
M$6YGL&B,(!2G"[['1L2-@'<P6N:>_8\0[!MV[[D>(V.^_:K8[]NW?L._D2-S
M[.S_ '6=>0O4TUEQGL=SAMC<?>8RU>H\C%QDIM*M\?Y24U$]7FABT(P\-L%U
M-1L)((/)*88PB"GB)"M.J?)2!570ID/NN$T%?S\%66CF]+-GMLEDCQUC-1QY
M-@A$CI!+2;%)*PLCB?,X;'AA'6'9O,9>KB)KC(W0V:'%*'%L+K($XX2[?BB#
M2X$!I=MS\W9W85G[CARFC.22MO2CM'\F-.?,].!454Y#::FM3)6$)XTP5,M2
M/+NW(3QXOY'.,X5OW!C2R$2*O>]/3[N'SNGI,$*I?E\!E/*C, ,)E(LD8.IZ
MK<V1&UO4B3K1U)._6<$NVW =[6W2=4ZO>Q4GZSBV\EG;/P</#Z?"!P\7%YN_
M;L[P5HLUY6:81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(M$W[27]D'R-^\^A_SSU]A5,](?'Z%7>Z5/V9G #^3SCM^5=7PC_3=
M^)WU*OWA4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(M:O4>9M[8?A9J:P=
MA]=[8YL:I@=BQZX=Z-L\)6Z_=K[$TV71,!DW,;8+55H(Z[50!*X-'$2,'=,8
M0K9RXCWAAV/@20/H2/CXJ#[M_P!<OU]5LJ   .P [ #Z  /J /X90I4;N-2K
MU]J5GH]NC&TS5KA 2]8L<2\(!VLE!SC!Q&RC)<H_0*;EDY62,/T"4#=XH@8
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MIJ^T#X6>\_I;XTPG _U7?E/V3S0^FK[0/A9[S^EOC3"<#_5=^4_9/-#Z:OM
M^%GO/Z6^-,)P/]5WY3]D\T/IJ^T#X6>\_I;XTPG _P!5WY3]D\T/IJ^T#X6>
M\_I;XTPG _U7?E/V3S0^FK[0/A9[S^EOC3"<#_5=^4_9/-#Z:OM ^%GO/Z6^
M-,)P/]5WY3]D\T/IJ^T#X6>\_I;XTPG _P!5WY3]D\T/IJ^T#X6>\_I;XTPG
M _U7?E/V3S0^FK[0/A9[S^EOC3"<#_5=^4_9/-#Z:OM ^%GO/Z6^-,)P/]5W
MY3]D\T/IJ^T#X6>\_I;XTPG _P!5WY3]D\T/IJ^T#X6>\_I;XTPG _U7?E/V
M3S0^FK[0/A9[S^EOC3"<#_5=^4_9/-#Z:OM ^%GO/Z6^-,)P/]5WY3]D\T/I
MJ^T#X6>\_I;XTPG _P!5WY3]D\T/IJ^T#X6>\_I;XTPG _U7?E/V3S0^FK[0
M/A9[S^EOC3"<#_5=^4_9/-#Z:OM ^%GO/Z6^-,)P/]5WY3]D\T/IJ^T#X6>\
M_I;XTPG _P!5WY3]D\T/IJ^T#X6>\_I;XTPG _U7?E/V3S0^FK[0/A9[S^EO
MC3"<#_5=^4_9/-#Z:OM ^%GO/Z6^-,)P/]5WY3]D\T/IJ^T#X6>\_I;XTPG
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g305908g86l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g86l12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X45=:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3$Q+3$Q5#$X.C,V.C S+3 W.C P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$Q+3$Q5#$X.C,V.C T+3 W
M.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TQ,2TQ,50Q.#HS-CHP-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C<R/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G05-!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ:UAM*S$Q*S1T3$TV23=*8W=8
M46YL0W5%1'!(1DEW:F5P5W%34V-&23DV.7-663!,6#@P<F1,=WA3)B-X03M.
M2DYC33@Y=4]D=3A58GE1<7I23C9P6G=K8C%724IT559B-%1H46EB;&9Z3%5"
M27!*2#1#54-:5G-36%536$A!<TA+56M+*VAX<#A))B-X03M(3&M+-UEP43%L
M9F9M5F17.7A,07).>'9F4D%C,F=+<$9,8U)Y:%-&44UI;%EG>$E$3CA81VQA
M-'$S96%:*UE6-39J;5<X:&19>E)&)B-X03MN=&]K85I98G-J,"]264XV6'%T
M04)Z*TDO=&1+:%9&-G)D*V),3'EX2&4S1'I*<49R4$DQ,'IT8DQ(4G)A5T]0
M:'<K17<K=3AD4%8K)B-X03M)9%<R1TMT95@S.'HS="]P96]Z1U<W<S5&2'(S
M2'%H259544UR+W5O-5EK9'9R04Y'.49W>6Q30W1.,5=B-$9D:7)S5F1I<G-6
M65HU)B-X03MO,"]Z;$QR<W,K:VUF-F]B1C0T9VLT:FI%-6EU041X37$O2'IA
M2V@Y32\V>3!O>%9,,G9F>DM-9W194%9K=G)E,VIK=5EP4'%+2U)+)B-X03LY
M>6]B:T9)17)E;DAW0SAK6&9N6'%65C@Y="M:3C-P,&MC<'593'ER*VU9<$Q.
M13E-,F-G449O>4A-<'5#;UDW3#!+.&%B2V]Y,7-V)B-X03M/<6%B<D9N2SEY
M,'9O,U-A4DPV<T)"-5-.-DIA570V+W)526]394%8+TMX5DI.4#%,>FIR='9*
M3$9*3&1Y5S=Y9C901DUK2W%Z*VXV)B-X03M0<5!"2F%.>$A#64UJ37I*5E-Y
M=&EH-F9G4VPR<F$Q1G W5SA+=U-85C5D<U9T<F%%07-E27%767-11E%B5EDY
M36]Z6GA#:%)-:GE!)B-X03MA-35/1VAZ2E-,>E-N;6$O,&E.5VAU=%!G4U5Z
M6"\V275&92MA,VET<'!F5&E*4D-(861):V]L4S%A9$LU4$9+6BMO5CAB+U%M
M2FME)B-X03M9<$=F;"]R>38S-5,P*SAE.5,K=D)%<V5O4TMV0FQU5D$Y4DA4
M8FEY;C)&9G1$66I,0WI:1FER<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M6
M9%59<3=&6%9'2W)*-VE#,VEA831K5T=&3C-K:UE+;S=B:S=:1U5H15=445%3
M0G573RM8+U!7;F%T95-756EF5DQO2#EY:G-'16\O)B-X03MY5V].+V)W>E@V
M6'1+1U=2:5)W>2LY,F5P-TYL:F=-:U1X=U!52C5Q5W!796Y78VPU95-#2T-)
M5EIJ,4HW041U5&UD;7I2>'A-<$=G)B-X03M(0W<T6EI*0TU26DM5*U=03CEP
M<F]K0V],85)7<$9#.&EM4U)2,6-,<V%$3512-C9/93EQ*U!.=C$R;$=N;4E'
M44UI3%0O33EW,UEQ)B-X03LW1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ>%A6
M9%%L,'IZ55I&<S-V8G)53%=/1%1U3D9!2U--6E5:=7DO17)S86):<G,R430X
M,3%X)B-X03M'56%J*VXY8FEZ;G<U3U9K:EI$>BM9<')05U!1=CEB.5,U=&M3
M82\P<E1T3VYU,&E2:%=K:VM3>E-2.'5O3# R,W!43#0T<S%G;5$Y)B-X03MW
M1S-Z-71G:D\W2BM&3&9+;6HS9#4U:6LX-%-A:G Y,T1D5W!T27!.3&EK:E,U
M45-+5FMN-7EZ1&Y(=TM51S0V1G1Q6FQT>DY-0W5X)B-X03M6,DMP9D8U:3!'
M85I96711=#-L9&=Q4G))<%ES9&=!2S513E1J2F]31BLY<D=70DY7161&3$A.
M16MS5$(T<$9$;S9M;UI71E%19F-:)B-X03MC0T-,1$U',3)&3'-69&ER<U95
M8C,V,3E4;BMQ548Q-F(O5BM8,F95-&YH6#(U6D1*9D-E2&Y7>4I85S-.:&YL
M,WIB9'DV:$IP*W!X)B-X03LO5CE54FE'5VQ&96TU1D]X<#DK66UI,2]'9D1Y
M0W!U1FEZ;390,4UR=714:FET+U5"0T1I6&0R24%25C9K+TMM8DAH07-N:TA+
M;&LR)B-X03M9>&](;5!63E@Q+VAP,%9.26AR.6)U2D)U*WAP46YP53E",3AC
M,6-.9%!.;'%!+V1J<30R2$Q+53EV<%IB<4YH8F%H6E175GEP84-D)B-X03ME
M3&=':#A14699-6Y:8UEN17A027582TEK2TQY;E=022MS85EB=65V2WIS:SE7
M,W9664$Y9&QP6&M$.'5H>FU.5#)D4$AC=6MD=UA0)B-X03LW0GHU8U=8=U0V
M<U5V<R](5EDP=70K8TQT3%ET-G-L:EIR26M(24M*6$A"5UEK;%9$3GIQ5#=5
M>48U3EA,:"]M>#5D+TPY8G9D5E=I)B-X03MW4VQI1GIL3&)Y-2]91UHK4V9*
M<C98+W52,4$Q,4=294MX9R]$16@R<'1S5%0V0FTV,$=H.% Q4RMR-VYJ8U=/
M4FM:>DYZ3$QS,F)K)B-X03M/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<%IQ
M6CAY*W-"<&$R6FA+0W!U:DM'16Q46%I!459P5$UF3#1T*VIH<GIT<FYX+W<Q
M.%5Q)B-X03LQ2S Q97@P,U5F358Q2VPS<E9L65A$5TYR1VA.=$4V>&-G23!.
M6D=:;51D=5%*0G!K8U=#6$9X>DYY.'51.3,V,DUC6G9I:V0O<U1N)B-X03M1
M9$\P+U1D1W,W3%1M1#)535-I1U5&5TUG235'5FU50E=A46YM>F1Y835L3GI'
M9DU'=G U9#@Q>51W4G9D<F4R54UL+W P24A0,69R)B-X03LP1FY"3V]!,VMK
M4S5D9"]T:4I6<4]/1E5:1C5S,7AR*UA2;3!65C%X65DW=$E29&-R5#9T25=8
M;$IC*VM'4G<X8DIW15163D-#5C5-)B-X03MQ<4EN.'HS>E-A9&)71VTO5TPV
M+V=U2EAH;&Y71DQD<E-32TM:2FY66F9S=DU6<D=R9D5.9U9*64)53EHV>$YQ
M,G$V438K=EE84G1T)B-X03M5171R-G%V8FEE>G5)8E-26EDQ03E93$MX36)H
M:TY/,WAB2G5T:T95.&=*96IY.6%S.'-B5W!%,T-*63)%9V(Q;3--:&-G:G)T
M=T@Y)B-X03MD9C)A2F5%3GA7+U1Z-S<O045/4'!B-$(S9G1A,%!566)+>'1Z
M2S!R;'10,#!243@Q26%365-2;VM33GA!6FEN>$5T.#9!639F2TE2)B-X03M&
M,SE%4'1S8F9J-VQX5$%!+W%X5'%Y=71595EX6'1K<T,X03944E1#6DLQ;U5A
M<7A-1S<O04=34&9-=44U:S%+3F9'+S%.,%I3=F-))B-X03LS3%=B<U9D:7)S
M5E%D>G!/;7DS4S,X;'5J6&M3:U)Z,"M)0VA(561E=58K1$%Y16E054]R07="
M3C%U:$E967 S145Y:#1P561*15!1)B-X03MQ=UE%9E-->6-S45EK2&M7=4EV
M6DU,1W=S<D<S1G9:=W)"0T-315%51E0Q3UDK4$A'07%);TYS66E);TLK5%I*
M4C5U9VUU4$Q7;U)1)B-X03MO6DI7:5!&1D93845(65II82M*;&AK0GIP>D]Z
M-6E/94I/=W1H=C5C859Q5G U:&QL=6)A4T=.-T)E3'5P05!*;RM/-3AE0BLW
M3E(R)B-X03M4:&Y(351)165J.51U=3)-.$HT44EK13AF-C%4.#4T3E)V3D9J
M,#E&359L2WEU8GA+,5-:0V%+,40Y:V<U=$Y8<3594T16=S9V234X)B-X03MX
M9U)T-E5K+TMR.'IR-%AS6&Q(>D]38C%14EEA:7I#:VE)<%E,27@V+T-P-'0S
M-DAF37E'4TTT.%5466)O5$5H65EV-3 O34174%!/)B-X03MP9E5D1VML<U!,
M,7$Q5VQQ56MM669T4'A0+T%P.4HY<614<5DT63-,;C!$6&QZ0T%S=F(O04-F
M4'%%,VPK,&$K:3E+4E5#4D$Q-4Y')B-X03MI:%9:<6LW=%-U3VQY5&Y$:6M+
M2EI9<$=58DEP3V-Y1W@R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<$)$;T=T86%G
M=#E%,5-+2%0Q,FAS)B-X03LW-C)A-T5#,4Y%9V5/83%C4FET07)L*TEO1F]O
M<&ER;3AP:')2,&QV<&)M.6UU<DLV=4PK-%=.<$=7>'5)-3!H5EEL:%9)+S-B
M0E9!)B-X03MO0WI.=5-A<7!H1G!0<#8O9&%V-G1F<DYP8C)N;SAF<R]6-4IP
M3UA+=2],-GA3;$\S=FEQ:EHV1CE8,4-#.#EF;C9+,S8X3T9++U@W)B-X03ML
M3&YR52]9.5!J-SED<U953DTX<V95=%%G=E!R4'%E:"ML4&<T8V$O<%,Y4S<V
M.&HO9&5N=R]Y=74S5$958F]/;&9O;E-O3E Y6#%V)B-X03M2-2]V95!#=DXR
M9C=.5S9C<61C;S K2'<T0TXS5%AI:'=X<$),-5AJ*W)24DYC2&Y"8C)C345Y
M26]:2DQ*;EI:4GDU:C1V56]25' X)B-X03LX<2]+0V=,-4-)*TUB,UEE1'1Z
M-D0W17AT64Y4179/-W4T-49!;W-515!P2V$Y,S5V37AP,C1K93EE,3A)>G8Q
M2#5#=C!L<VE*9%-I)B-X03LX=%IU>%94;G5B841G6C55:45J:4]0;7=8:S=D
M1E=V56YW=VE*4$I"2W!G4S1G145(;V-64455,FU*9B]!1E9:9CE,:D@Y,F$Q
M,T9F)B-X03M#:#)/63,X;S1J;$](:4AI9#,R<R]W071)4C0V.4M0>DI92650
M54Q/5S=E,&IL1%A%635/9W)S0E%D96YF35='='=Z>6Y&1U%/4U!-)B-X03MF
M:C-T<W-->$5323E*4D=:5%4W1E9+-G1B939T-4QE-&I%<T5O-'E2='5#1&M:
M=T5H4C5)24)&1C1,*V1E:#9B<$=S-D1"67AE;6IX)B-X03M81$U34WI(9&5P
M3SE-:F=W4GAX-%DX;4U-66=+1$MV>58X=&%,9F539$]V-W$S16QX1DY0>$I*
M-&MI43!,2TYM*VY)6F1.0V-X2U%S)B-X03MH17-56D5%.4AQ=5AT:G-657!,
M<3%I;6EH:VU22G V*VI%>D%-+TAD=4MK,6%L9#994D5K5VDQ6$%L,DMS6C@U
M96)N,%=/3T-Z0U-A)B-X03MJ2GAD67!68V]9>GE";U9++T9696QC,3)V,7!W
M:6\O6#4Y>F9P4$)L;$5-<W5%2&PW,%HU6#@P5U=V5UAQ4C!J=6]W0F-7-4\V
M;GA()B-X03MI<#=(3$Y&<EDU-#)0<39H=C$R:&QP-55D-&YK5T5F;40K8W)A
M4G%Q-D@U6F=H,4A65F9J9%-3.&UH:DDV>#!2:TQ/4#)J>6]V>G)4)B-X03M-
M;$E21FY93T)+44%S=E$Y13%A,S%85&]R>4)U4W-/3&YI>6IM4'151&(P<FQE
M2$Y(2DAI:GE9=VU*0W=J<W1:=7A6,DMU>%8R2W5X)B-X03M64W5R=3!T2796
M=7!O-$EQ9V5P2W=286YO2W-136I/8UEI>6%#2E-!-7(T-4DU63%K:EE01S1$
M239K1E-P1E%14C%"=V=G:7=K1S$R)B-X03M&6%EQ:'13=')I-G-:<F4S=5=S
M-35&;VQY9T1-:'(Q06)B2E%K06))=$)&:&I8*T0O3E O049..34O>4EG+W!M
M5BM9>"]W07=F3718)B-X03MH>2]N2#=%:#@V95%V3C$W;S8R,%=R>C8P.&MY
M05<X-E<P4U(W2#DX5TDU9D0P*T0T=#AV,"MQ>'AL9D-)+U U3E=81$EI<G8U
M37,X)B-X03MK-D)R1VEA3W1N<6UQ4'%5=W!X-40T66=0,D5::'I99C8S,$%:
M:6%N3$=C<FE+8CA51$555&))37@R>#549C(K=390<F%7=#E*2F1F)B-X03M7
M2D(Y579I>$Q-86A6*TEM=%)T558R>FAU,65Y.&YI0U%*.%@K1UAF.&4O-W9C
M;E$V*V5N;#1E5#%9-69:*T]O6DMF33)O,T=N=S)K)B-X03M1+S K5GI#6D)S
M84-L0U!":GEY:RLP1V]Y-F5/2T$O9GEL=S,X=G1.=3@O25DT-41)+U%"85%E
M5C=F5W18,5I*-TM34S$P-C-C1V4T)B-X03M"2VU3:$1'4%EJ;'DX3VYJ;5@R
M2#):3T5U24AF*TM8-DA1-G)8>C%5+U0V8U5F=&5O6C)I6%EQ-T972BMC+WDU
M,&YZ6F8V9F0S='A.)B-X03M#8D%3<'AH-"]'<W$K3$$P2W-!9G=X5DUF2FYL
M5S(X<F58<F92<F5:-VA)4WI.331!3$\W1FU.0C!'*W=X5D<V,5E8=#E:1T-Z
M=C5.)B-X03M.;4Q"=G)-4W$W54A685!T=FQM3UEI8DET:DE%:EDP>"]W1'=F
M-7 O-FTK."]W0U)%2#E->5!Z1U K65!M5W9W-69Z:CEJ1W9/9C5D)B-X03ME
M8V13*V]1439R2G%H16I-,3%C:4-&8E=L4&E"465Q95@K4C1B.7-Y9%!Q.&-B
M2FIW*S8Y,FY,:&MA,W0V1#5C,'DO,'I366)/*S%#)B-X03M453=M369(9%-G
M0FHW0VTU02]Y:50W-7(X,'A+5F=C26-M15-"4DYP;&Q43DIF32]L97@Q,C T
M4T%2,V-94#%E-4$S52M".%90:&U*)B-X03MQ.4I(3DAF-G5H86,R151(;3AZ
M.'AA9G%F;$HO<D56=V\Q1G)#.&MA85!D87)#+T4O14)V+TAF3DY$5'EW86I(
M=G9,;3E$;S5Z;F]:)B-X03MX>4AI-$]8-D5(*U8S-5I186PU93 S5R]70TQF
M97%B,&YE5W-6>$I(>&I.2T)3<4PQ4%AF=WIB87I3>GI3075O9'IZ96)#6FMB
M*VPW)B-X03M86E=6<EDR<V1R85)I2T-)55)&+WHV-6PT.&-91&AI2T1F1TEI
M2T-V:S)345-E84QI-S%+-C W44Q%86I.64])-S8W;6PK<C)C8W!")B-X03M*
M9SE:56YD-59&3U-P1U%T9FE92&)&5E=X.'=82#94:C!R5G)),D8Y36I08E-*
M27,Q<E!W,UI)2FE);DQQ=3=).&%N66M656-S5E1R)B-X03M&6%EQ=&UM:6AI
M96%:,6EH:55V2DDU0W%Q<4ML;4HR04%X5C5T-6]U3E<Q:E=F<3-#-71R5C)A
M,G0W9%$P<3-147-23D9'=VII26]1)B-X03M7678X26]19',P1W-L:WE:3T@Q
M4DA+=C4S;4)S4'0R9&)N37!3<F-D4&5M+VPK9E5V3%9G6713,"LV:C T1454
M0U=+-D5*879.:7-9)B-X03M6,&HO04=J.7(W>FU4<'!4=U)Q8UIC4'9%<2M8
M5#5T,DEN1U!51%AZ6F5B>3!$<VAN:D1O558Q-4Q51U4P:D)&9'5:*WHT-71/
M3U!F)B-X03LK1'EC=FE#<FMK=7A6,DMU>%8R2W5X5C)+=D\Y3"\T-FQN+WI%
M+WA84$ME>G8X87AF.$Y0*SEE<#%(.3-,*W(K=#9*;G%Z>7I(+U!-)B-X03LK
M<5)E6#=J-FI#<SAC<79&94%G;&QH9$-R371#3GA8,WI',4]F2FE!;D%!:T9X
M.5-:8T)R-'-!.&UE9%HY0VU3=W4R33)K4W121U R)B-X03MO4S-C9C50:5!P
M1V)B1&UX-C=(-&M.<&IM4'@Y:&1D<#E38UHT5#E0,TDO>C<U-'5,<65F4DY,
M8C W84UM3SEU4C%C9S!:1DDO6C=()B-X03MX*UA755)J,#)0>'-V=T@T-G1M
M<C%2:U1#4$QQ5U%F;&I,<4(P27=446E/=V=01WEK;U$P;DIN855M<#-!63=5
M1V%F0G)C;7!L3$I))B-X03MC25!*>61&9D)85&]Z1$UL>DA9<3=&6%EQ-T98
M67$W1E=%9FU$-58Q5%<W:4TR:U%L:4YN8W=304]Q3GEE3F="5G1V:3550CAE
M=6%N)B-X03M885A,4$Y#94]V5#-U,3!M<7AW=U1H3&Y*1R]L8F\R;S9.-40P
M<E1T4FA-1C5%<WI3=VMG;&96;FMK54=N9FDT<FTR9%5Y<D9867%X)B-X03LS
M>4YC4FY3<FUZ6G$S,6IF6&ME;TM15E!R4UA-:S-Q54E(=WER24I&<'12<U95
M+T\U9VUF46)&62]6,4MB5F)797E25U974F)74518)B-X03M-,4-Y+T-T=4A1
M.60R03=J1E5K<R]-+VY"=DLK9S8O4$IB9E=.66UT<E(W3# O,T5A6&@Y3T<T
M,E!Q331D:V1L-6A3;%4R8C0X2V]R)B-X03M8+TU8;5!1-#E9:&=K5%4U-U)D
M3&YS4DUI>$\S-E%V2'1P25AA4&EL4#-8=TYX1DLW.'%62W$O>DYQ97-A5D)F
M,C$Q3D)Q54TK:6%L)B-X03MF1TMA,T%15#)A>$%X:%$Q1W0S134K0BM494QT
M6%I61S9/.6]M=5=B>5),0DQC-E1B<%EH1CE/24MJ33AS55DV9D161'A(4F-W
M.6AN)B-X03LS-6U/,WI.+V]A9&AK,S=T;5134U)X>'1*27=33D%79#).04%.
M>5-4,$%Z2TI!1FQU2EEO,&AJ.'<V-'=65TIN,&AA3V]99DA+1G)1)B-X03LY
M>%A9.6IV;75*<DQ0,S0O=F-5;7!Y+WI5,71Z<75O971C4C-9=$DT-7!98F%&
M23%C2#!*1VE,5$9X>6)K>59O:%=G-VYR;5)(:FY:)B-X03M"<F-G9D$Q=BMY
M;3!C570W<CAD53%H.5@P:SE9<5IU23E1<%5,>7!V>')5,')M5$<V,S5T9UA9
M575X5C)+=7A6,DMO6F1-,#E(5C%T)B-X03LP1$DU:U5H4G,W9%1M2DA164EK
M15%J65!&>39N<3-(4$UI<E!+:U1M5S!U>%8U,RM:3V=A4G S;#4U-TLR5T-7
M-'5O>DM63%5.1FM/)B-X03MY:VQ6-CEH;50R5' T63AP35)6:#%U=7A2:D-W
M3UI59DE7:39:<7,K=5(S.$%N4TLW5C!5<WDO141)4#)32SEE*U=D<31)6DEW
M16AD)B-X03M),&U/36I++S5Z,&Q%4TY&4TY1:4M!1E9244%$;T%";4-"5W=D
M;3-H5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9+3E<X<396<55R)B-X03LS
M1$=E>G986&<Y-UE4>3)K>DM0<V@R:%I0530O<RMO1S0W,#9N1E8K:V579$LP
M=5@V>$-S:SDX62]292]U-5I,;35-9%%E2')433=Q)B-X03MN26-U0S!7=3E-
M5E=,-5@P=&1(,#-344I0<6UL4&)35W9X9D9Y<S)6;W52<'9U9W)I<2]59DQE
M;39H3E!.8V,K9'=,3EI/3%5&3$,T)B-X03MA-6AP="]V>5$X=D59<3-R2&PS
M5'173$<W-2](6C-69V5$8V8S3C9%179B-U@W<&%(1E8Q,6]';3-6;$)A>6]F
M.4953&%Z<65-,%)5)B-X03M!0FMK1S9N-%)L5UA$2$E.+VXQ2'595'AI6$Y"
M42M4-TU/4')D.69A:D-#1#E7=DQG>5%L;$E91FM!54Y1:F]D<V]J;V\O>%-L
M261X)B-X03M/>E=.3T]P2CDU4GIA2%I.9%A.>5,O<5A4,C!K;T)&2S)J0C0V
M8F5),WDP-F5.:SDO1"]S9510=WA:4&98,DMD>#5E=#5,:#5O<G$V)B-X03MT
M1FQB;E!"8E-M3TXR<E5M;$-63&9T1D-P4&9"3%1!;7=:4CEX+T@R56<T:&9-
M:$TQ5E552W5Y<4%!4%E::T%.<F5+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%9,
M4$U8;"MZ,3-4>%DS8D]K66M744Y'44=Q=GI"-F=K6F1G>DA(2W<Q6G-)>5)O
M<DY#.'171VEY,W-L<7IK,S!V<7E")B-X03MZ6&HQ;V\R-E99-&,R95=10RMI
M35=%475U<6):43-/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=B\Y:ST\+WAM
M<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R
M/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/DQA=&EM97(L(%-I;6]N/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \
M9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/C P,3PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&
M:6QE($YA;64Z(" @(" @(" @(" @(" @,# Q+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(%)2,3$W-3<R)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" Q,2U.;W8M,C R,2 Q-#HT-3HT-"8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" Q,2U.;W8M,C R,2 P-3HQ-3HT-"8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:5)E
M9W5L87(F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@
M(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @
M(" @(" @(" @("!G.#9L,3(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @
M(" @<G(Q,38P,30F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$Q+4YO
M=BTR,#(Q(#$X.C,U.C4S)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$Q
M+4YO=BTR,#(Q(#(Q.C,U.C4S)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @
M(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[
M1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^* HB T
M(&AA:7)L:6YE(')U;&5S(&-H86YG960@=&\@,"XR-2XF(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @0V%L:6)R:5)E9W5L87(F(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @
M(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.
M4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6
M:7-I8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I
M;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @
M(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-3,Y,3PO<W1$:6TZ=SX*
M(" @(" @(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#8R-3PO<W1$:6TZ:#X*(" @
M(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @
M(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&
M;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:5)E9W5L87(\+W-T1FYT.F9O
M;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#
M86QI8G)I/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SXU+C P,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FER
M96=U;&%R+G!F8CL@0T%,24)225)%1U5,05(N4$9-/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \
M>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C
M:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \
M+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD
M:60Z,45&,$,R134U.#0S14,Q,3@U,45%1#,P.4(T,C-"140\+WAM<$U-.D1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z
M,45&,$,R134U.#0S14,Q,3@U,45%1#,P.4(T,C-"140\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#I%13%".49%0T-&-#)%0S$Q.3A",44U03%%0D9#,S=!1CPO>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,41&,$,R
M134U.#0S14,Q,3@U,45%1#,P.4(T,C-"140\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,41&,$,R
M134U.#0S14,Q,3@U,45%1#,P.4(T,C-"140\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#I%13%".49%0T-&-#)%0S$Q.3A",44U03%%0D9#,S=!1CPO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%13%".49%0T-&
M-#)%0S$Q.3A",44U03%%0D9#,S=!1CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,2TQ,50Q-#HT-3HS
M,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,45&,$,R134U.#0S14,Q,3@U,45%1#,P
M.4(T,C-"140\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,3$M,3%4,3@Z,S8Z,#0M,#<Z,# \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( ',!GP,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0
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M'+#%1$J19PX=(TL&9&?K.$)8:<#;G<;;=R2 !]O;S';VU'B'3KW[;;G\*DF
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M>I^M-TVZ?MZ;_>>M2(=U0_V^35LYG/Z?=&_[9;+_ *_1S45W_CHQ/_X_OO\
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MAWG;&T@S6H[LMC+O.6=FUMGK0VT=NV"$DK2A'#I+<VMK,4]+:ZF15$Z1I)L
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MM?S,?T T7_I3PW^RW_YG5@_2?4/^9=__ -]7_@Z?O]NYO]EUM[_-!C_:_C]
M-%_Z4\-_LM_^9T_2?4/^9=__ -]7_@ZH?WFW!O/<56@]H7GHQO?KQ<M,M2DC
M1=Y1.^&*\W2GI50>2DR3)- C Y$0T@$+"1Q)"(G7GFT"1LNRDE\8K/M"8;!8
M:[GQ=AKO3^H[+-&**_P4V >Y-\L0<*8F6_D>)XUD<\31RP*I+RPMPJZ8SJ7(
M9/(01WESIK)XF?'AWMLE'E%B%L7*\7&#;(KJQ5?55XY20%20;D-8[Z7/?#M3
MV((;HNT]33&Q*I#MK$)[$0XT?6Q(=X=CU,@7%DU4; 6:2>SEEM2JBMFQ#LK:
M+.KLHETJ3:QOQ4T#I33:F_Q67AQUW,0Z:<F:6Y>96;9I+-DYMQ;1#9B/3 ;9
MF!1+F(A(C=M%ZGS>6(MKVPDNX(_5;+1A(5C('1;@-P13.>@W@(E ]9HGW9QO
M(YHJMDTXI6E+OUOW<E'W JA6*OAO:.,"A)&O"YC!FGK,XU'C*FI@"U*'(,C[
M#"2YA\>T&TY\%@1 +DK#GB2>5&<0?*AAOM6M?: U7C^+0]_'8WN*E@ACCN_3
M[>!2<QC\FT<CPY/&W<]Q +<EK5K9A%>V=Q;7C<["_P"ZIK'PQUU9Y;%1P''P
MQQJ+2>%6M\Q8RI%Z?;RW !EC?F\2+RG0V[QV\YC;=&>/M1;?F-;RL;?=?2R9
M:O2W\"6*]A;(4R,PIM9<'.@I<>S&3L;[Z/6CUNOQ[C[)T>1(0T@*7)?,33FH
MO$[Y)/B+;9S!W7I^%R)X'5A-'I[6^$@E4S6-_ &D]!R]B)AQ)Q27V$NIDN+:
M6\Q=[#/DOH1ALUH/Y0FB$O;*0"5!PRQ,8_GG3.5*=8Y5W]:-MMP1^Y<A;@,I
M#J##N=UUM^E[*IR[E$2; 08#"G+$)(D,CDUIYEE3Y+4JI:TMM,-MH<>9.\X%
M)'0IYM>/0ZAK[;^%7CIX?^+>A'U[@LO;6%AC;9I=4V65N;>UNM)7$%NUQ=PY
MII'2&&VBBCEG@R7$+*[M8VN(I!P31P\L:GT5G=*YP8.]M9)Y[B0+C)K6.26+
M*QO((XGLPH+/([,J/;[&:*5A&R]49]='8[LM(;/,?HE!=*&I#;V62RV\.#F6
MYYI659<>2KT.#0+64>ZP([Z%$X1@V1PC&&A1?E?\J7Y6&<\:\LWA9X4C(KH6
M6]2PEELHITRVO[X3!8@8%5;B# "4!K+&LJ37Q"WN31-H+*SZ8\-_#+'Z(L6U
M9JV2UCRL%M)=LUU)$MEIZU2,O+(\SMR?3%BXC<71;EVZ\44#$!YI:%0_8B\T
M.^Q<3U]0Q,W(TEJ#=E6H0>RYG7S"A\9K59CB6"$N@D/LMM&38[:)"2<QA$*0
M#&M+-FLI^3SH+)^#M]!FL5RLCXCY>W&,GDAMXLG:XZTNYH)9,!B8BLL=U/<2
MPPKD\M$"\K(+3$2Q6*3WN6X]\<_E(9'7.7ATSH-2FFK"^4I=/:B6[U%?H7B2
M9(94+P8]0[K:PA5N)BYN)C&W*CB])$$_*DPD,3.B,1\X1%1[\R ,[[XP4JZ(
MRY(B#O>I?O,#%J>9:=]:_<;0E?J5Y\Y^P-F]S):6KWD20W;VT#W4,;<:17+1
M*9XD?<\21RED5MSQ* =SOO5/ TK0PM.BQSM%&TT:GB5)2@,B*VYW57W4'<[@
M [FNUY4UZTXI3BE.*547OOKFX;;Z9]D=<Z_AW;#=+7JJRQ];@AW&FRIF3;82
M8Q&!J?6VRHX[ RA@FG'&TO%N,LY<1Z_5B9" ZD] #4K#=3M^>M>/>R_3U[JH
MZ*Z=$1ULVP18,=H=TSI5-$J$N7>8N N.N]%5JNSTU3AQG+!#0TA-:^M JI"4
M $'#;$$-.6,!*QA)=3QIS">(;< &_EN"2>OYW\J\]CMV/<^7N%>VO0U9F:5H
MW3--L0J0K!4M4:[K,Z$EYHA(DS U"'BI05) ZW&'TCFB/M8>9<6T[A'K;6I"
MDJS2GJ3\37J.@'P%2OR%1JEW9KL1V'TW9Z]#:<Z@6?L;#2T"N3EK)!W\6H,0
M$FF0)$3!O!D5"QJ*>6(RR?@E)(Z<()2U[&<HRXK-M+Z<T[FK6YGS.LK334T-
MP(H;:XQSWC7$1C5S.KK>VO H<F/A*MU4GBZ[#'LSELKCYHH\?@)\O')$7DFB
MNEMQ$_&RB,J;>;B)4!M^(=#MMYU6K]_1WG_LN-A?YV1O^U_,F_0+0G^E7&_[
M"E_YM5G_ $EU+_F5=_[23_@:?OZ.\_\ 9<;"_P [(W_:_C] M"?Z5<;_ +"E
M_P";4_274O\ F5=_[23_ (&M8G>S;V_#)R![.2_4O:_3_<-:&CJO"[@![#QJ
MP9B,'+>)9K4C2RJ+%9L_C!AF<@PIP3A(CSWWX:8BQL#L[1T%AM/I!<:7AU?B
M-98:Z>2ZGPSZ<E#P2LJJUU'>ID)O1=^!!S)T=5=5Y#0RMQ-AFIK_ "C2Q9E\
M%?8"_A588[]<O'PR(K%A"UNUM'S_ *S'@C92RD\Q9$78;2_IG]O>S'9VGNN;
MLTN:%!QH'\D;[CV1:U7;N4RM#/Q%50]8SYIZ\)?<)GZ4T764E-N!$1T$ZEM+
M^JO$_1VF-+7H&#S://+)]-I^0O=7-BI!;C]+3C"1C=0EO?%;HJ>8LLX)X<UT
M=GLQF;<G(XYEB1/H\HH6&*Y8=.'D-PEF.Q+2VX:$,.$I&=M]JW-3UF].*5^*
M2E25)4G"DJQE*DJQC*5)SCQE*L9\XSC.,YQG&<>,X_+/($ @@@$$;$'J"#W!
M'F#3OWK1AW1Z/RNL)$O>N@ASAJX 7]]L-8A%/-R5$+9=^2JQ5GX^<$9KK+N/
MD%",9]^MYQD@?"H/#F(;D/Q5\)+C3T\FK]&1S)812>EWV/M"XGPTB-S#?8_@
M^D] 5AQR1H2]@?I$WLP1::4U=HV?$S'.Z?YL4,,@N98+=F2;'2HP<7-HR$.(
M$8<9"'CM2.-#R >1KZ7#E6ZM6'<-.:Q6+!K<JMR-Z&AUXB F7IR99BH*[5#X
MF6/M#[L^L0>8KP7LM14B4-+5E+<(^3$5;G'*X5[RPOM98-1C+O 2XZXS4-HW
MHD<4EY>):V69Q')X/1':_:%+NPAX%M;B6.ZQH6S>6UQGTE^25\I2Z\3K8>%O
MB# <EJ&#'S0X_,RPK<0:AQD-I/)<6F:B9607T5G!,7N'0P9"%")N&Z)](QGZ
MG_U"MZS75#KUJ"/L)<$1MN)V)C=%FB_; D[Q!5"?!KL% X)%RVX!'30[I95V
M'%2PF>>;&#RIJ&)DXPSO[P2U5D=:>'V(S.9?G92.2[Q]W<A507<EC</%'=,B
M *LDMOR3/PA5:X$KJJHZHNF_'+2.-T1XC9K"853#BGCLLC96Q9G-I'?VT<TE
MHKN2S10W'.$'$Q9;<Q1NSNC.T$Z;ZG276F8S3I"%7/=DYMH.#GR(QK$JY3%6
M0 ?*M=T# F'E%31PLBB,N=N#]3\JMXNI5=QNJ?>96^:B\9_$W+Y#*77A[IJ&
MZAC6:.QRDT".;[+7,ZH1C;2.,&5;0\Q8YN$<V^<F(!;4,+KD'6^I[V>\ETWC
M$F39UM[IXPQN+N60#]RP*F["$AU60@<R=B8QM!Q<_P!*?27H^!HX4+96QV!I
M+;APB\@A)6@F/U^&<.IE\(-Q&5,F6,@9YP:5E6E+8&:<>BXI:QU%GR>;>$_A
M)#I&.+/9U$GU+-$>3#NLD&%BF0J\43*2DM_)&S1W-RI9(U9K>V)0RSW&2Z,T
M6F%5,ED563*NAY<>X:.P1U(9$(Z/<LK%991NJ M%$2I>278]S>E;#IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2H0VWOW7FI@Y4"5M%8S?D5J4G*Q0I"Q1\1,68L80M
MR+C1_E.?Q94T>-]N!=>1_&"%*;%;(>1EK.):EUGA--QW$-SD,?\ /(L+B[Q^
M&FOH;:ZR$D<4K6]NG,/T9NYH^1"SCUY"5C#L.&K-E<[C\6DJ2W-MZ<+:6>VL
M9+B.&:Y=58Q1+QGU3/(O+C)'K,=E#$;53OKU]1NM['MK6NMN59&K;:;(9C(D
M[)9+M>+E%/99;A91,BP.?7I-;WI'8R:H@,@GRR\0 ^IAA_6&B?'.PSN27!ZE
MQXT]DI9C;VTW,D:RDN2Y06EP)D2:RN"VT:<TO$\FZ,\+E$;$<!X@V^1NQC\K
M:C&7;R&*)^-F@>7BX1!*)%5[>4MZJ\?$C,.$LC%5;9GS?E;'IQ2G%*<4IQ2G
M%*<4IQ2JL=A>G6F.T=CUO.;D&M%AC-9D2Q<92!K,;&4B>*EL!>2+1#AH01(/
M Y!1@1P.0C5.,/$A2.9"/>R)C*].ZSS>E;;)P85K6VERBPI+?-:I+?6ZP\SU
M;29R5C63F'C#QR@,JO%RY%XZLF5T_CLU-:2Y!9IDLS(4MA,R6TK/P]9XUZN5
MX1PE73<$J_&AX:L;7:W7JA!QE9JD'$5JN0HK8,1 P,<'$0\6&UY]L6/C0&6
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MRWN(O;N.ZPSP\;7OAAKRSR6GIG%IS%COYB=\7E,26XI+>_@+C=]@>7'TGAN
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M&<9QYQG'YXSC/[,XS_UQGF[:SZG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M
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M&-I>*H,D#G^*PW!D@<@"2(D _60K(JN-*H/3C<T'6]Y5S;M/,$H6L]<[$O\
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$I7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g305908g88n35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g88n35.jpg
M_]C_X  02D9)1@ ! 0$ ;P!O  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /:]:U:'
M0]*DOID=XT9%VIC<=[J@Z^["M+-<SX[BDD\)72Q1R2,);=MD:EF($R$X Y/
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J%% !@>E%%% !1110 48HHH *,#THHH *,444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g305908g93t94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g93t94.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1J^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &J*^:!@X0DE-! 0      !X< 5H  QLE1QP"   "   < @4 "E5N=&ET
M;&5D+34X0DE-!"4      ! D3E+ ^VR; 4%119QXSD 8.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  0"4S,P  0 !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))301$       0     @   D    )
M #A"24T$'@      !      X0DE-!!H      VL    &              ,7
M   $\@   !L = !M #( ,@ Q #( ,0 Q #0 9  Q "T 8@!C %\ 80!P '
M<@!O '8 80!L #0 8P!L '(    !                          $
M        !/(   ,7                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   ,7     %)G:'1L;VYG   $\@    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #%P
M  !29VAT;&]N9P  !/(    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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MR3[V?O#[TM[/WA]Z2EMO\AO^OR2V_P AO^OR3[V?O#[TM[/WA]Z2EMO\AO\
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M2R_K1_XG\_\ XHK(ZM]9.J8?U@;TZGTCCE]#27,)?%I:VSW"QK?S
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M              H!!P@)! 8" P4+_\0 >!   0$& P(%"0T.#PD-"0$  0(
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M+61T(:,I0ZT]*/$G ^!+ 2+BSIQ1KWGVH*,I-.E.RCQ)R?A26<8W.>V>?*C
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M(9=/M3L>D/::5^(PWQ;'.9WE&&0W!!3LA%K2:5BQN/.,-KG^Y])8YS.\HP.
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M['I#VFE?B,-\4QSF=Y3BC(?@G8](>TTK\0AOBF.<SO*,,AN3L>D.?H-+,_\
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M$8B,1&(C$1B(Q$8BAA\*M<[<>+1%AYWIT;C8"50UCF+[R389-<'@P\BK*O\
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MOE?N=[77W[-9!<M8%W>>OJ$M?2LAMD4WVL=FM7-C-0:2+D A<^@TJ!TM=*E
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M(G)%5>VU'N#!_G#$3DBJO;:CW!@_SAB)R157MM1[@P?YPQ$Y(JKVVH]P8/\
M.&(G)%4^VU'N#!_G#$3DBJO;:CW!@_SAB)R157MM1[@P?YPQ%7DBJ?;:B_\
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M6<KCJ%/9?ZIA1T\[7"X,/(FRM458&^EB*X3ICY0UP L\-%/_ - /4M=EKWZ
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M^Z54E@W=1ER_=)3R6H\K%HQ$8BL#C0+QDAS(\[1VAM^NP[00^)&PLL2'-Y#
M7'-_8KK45;L1IRPL.1X'+IZ@B_OW;(NY>_?R<ERD3&_5)Y<RQ8VJ("I7=4X
M3R#KRH)!(8/%ZG9?'4M(WJ("!J94P<QB?3%%B\3&04)U$/'$O=K=0_'4IX]2
M]>!"DY48!,0(!\$L2;M?9E$1(%[ $/*=^![.L;JX?1$7.L?<97U1SQ6)V$>/
M=,4CARY=3V8PL+#2-</3(10XD#F+=2N90%0)FLPB8IV]@GL9&/7@6'QZ@;0,
M!@029/F'-YE@S2=YHV+D3&)(ORUZ[G6UJ'4I;ATM8XJE.T*4G2RE)!4+$DBR
MB18G*W>&*R^_MVWE<.-C8F%4D.9=$QJ5"Y4X+OS)RR(6I-CX?>8L26-SR?7>
MW+?=+G7S^6X[/TOS3+^ O?\ G-#?O6T8G&_9BW-A[>V"*G4<!YFGYH3T];V^
M^Z^\QB,N0@]';6G&_9BW=N=>'+DQWT[-/##G?O\ GNEKL3C?LQ;EY&=QVZGY
MI;?=+FX_YW/O;M>E.<KM8?##>^S6@BS$0OP)YV53.XW*U/S36Q%G'O'JNG2T
M3U77SZ/O3C?LQ;EX\MS&YM3LSMNN8?P?INK3R]N?MBG&_9BOP'/?T<ZKRW'Y
M7IZ::9VZ@3??H]T\+.W:Y.-^S$.3MUJIG<: 2)!-";"PXK@7/\[_ &;V">3[
M>L@#ML>#&0?DQ$9MU7_CM3EN/ME3\SO;>'&=_P#2Y=(.G2R>KV7[^TU/&&45
MWZO-VZ%3EN/M?L?F9-M!U#7F-WORU8G&_9BPP[7=LU3EN8V^IZ9=R[CXW<Q.
M-^S%N7DF=QQ^FIZ:)Z?.Y^!X?EW@R9N;E_$=*<:_P8MQ).Y4,[C\K4],S<D&
MY<7'_.#+P]#$XW[,6Y.6H_M!,NG)SX+]5S[S&,[I&4V<9S"&(!I1'9"9*O+4
M?;ZGYG?+]HMTG],[UN?H:6/[/^83YY#MA../CQ8_\I>[+L->"IRW'9^EZ:;O
MVC?T]5SW:=^S1/4^J8=3QC^K%N5>6X[/TOS0<QLX/P/2>D][NLGJU]33WW\B
M<:?R8MQY\E3EN89GL?F>EQ^D7[_SW(^'PY,3C?LQ7 W'.Y\Q?N0SN.O]3\T(
MO;1S>UM3\\Y^8%B<;]F+<J\MQVZGYH1T]0'PO/R^'1V[=MZ<;]F+<J&=Q]S:
MGIGQ1O/4+G+F#V^NC!KO[7)QOV8MR<MQ_M>FF=K9./?^>_C#$XVJ+=VZT$[C
M[F]/32P(TZA>UB21\]M[_P (8G&/ZL6Y5Y;CM>Q^9@99?."3W@\[G<SN&,6)
MD<F(',[W^U.--N+%MXI;F?LRIRW,/:],CS?I R[A>7OI[[&[./;VWIQM45[?
M)._9M5#.Y@+VIZ9'^8%_"]8S7MR$'HZ5''?]&/\ RD=*IRW,?:[,_##_ !S%
M/&_9BW?>O(SN/RXM/S,\X/4!;,C]L -K7/=%KM(#X@;2RCCS XL4\6Z>I4,[
MF&5J?F9RN?TG+H_3-6C.Z_7,9W!3QM46Z[4O,3J.MG3\T!Z.M\^Y\]^%B<;]
MF+<O'EN/OE3TTM<YDP]],C;JO/T_E8G&/ZL6[LV[VJ@G<P/^3TS'?AR?>>L3
MC?LQ;EY&=QP( IZ:'G_2 !SY]48G&_9BNRQR^]4$[CRF_8_,P;Z6<:=]Z/?L
MQ.-JBW=/W.@G<?:ZJ?FF_(=0)TRT>'N?+,QOEO[$;NETXTVXL7^4MO\ 8ZJ)
MW'7^I^:6_P!!?=NZINSOW+:M+:Q?U=L\KV4&)BW%B,@Q8L7Y,.URH9W'\:PI
M^9D<Y#C+_G<^\QC@W*0.=2(G;P8A_P"D]N::<MQU[=C\S[MG-KV_A=+Z99M
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M8-KC&B@=<_V?@]=V0RY[^]X&EA/O5TC$IV/7</\ 5'F7W61]-V,?]IU4[?A
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MR&GX=9V$<2#>+E'@!UN ;M8!<V;+ -.[MKVK,_@Z5I3MW;+ZEJ"$BO)J"5D
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M6X-[6M;7/Y#0\V^4D7+,0'+WRPU/<7O&>$P7@<#?80P\/_Q9B3^&<U#5*X7
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MA.K\_6LF_P#3OEK9CZ@=_MY\I*&+NY;*>37ORH*?G 'U83HF^O6LF\%N3LV
ML\ARO[?OUIQ9WELG/2Z=C\WO<UA.K9Y=:R8?_P YCZAM;L.92VOG/MEO3L?G
M%SZ<)UW.M9-E_P!7-/&NE#+5TS1I,YP<N<]LLI*G8].!_EC.^_"R8_#+F@[
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M>#K9TZ3QE(>)00I)R0FQ#6 X"W_.6=\-G%C<!QJ<-MD3G.2YCPC?*L@M^G6
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MOD7T(Q%'5X>[Z79F-@;1>(Y(/V/3/O\ RS:P' 9?I+YNS?65E<OX1W/N0/\
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M$2GFO[.^6[F:6NF)Z^G;]UZASETY[/9NFO'LCG'M.G1_E,J_/?E8L89CD?K
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MO*ZHC$5ML9OK08J?<YK7\&YDWH63]*V8U_NA4_M-&OEKWS*N>BUCU4:_/_B
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M3ZSZA= X.?GUJS<][5=[[^ZQ]GWJ3JU;EUI&(O%?TBOWJO@+$7YW\TL)Q/\
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M_1QXM7-OG%/;K_L3#<V?RZ&N%P8>1-E?O5CUL6'9N5<)TQ\H:YLHM_$A(F9
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M&+BPQ$V;6X3Q@#)Z,B1!$IX%BM'X0(1%8$4+$/6J$^"3"?TKB&,U$O\ -)N
M]?D6'^,/S\+SX?A:U,C^C!_DARONOQVKCW$ QB_S1=9;7=>N;*G8,^IAZ7K_
M (\/4].Q"+1+]-E.)S!/4 @/!Q@5) 4%9$$@@WSPI2!5ZU#Q(/"JM9AG!#)Z
M&D&4K]Z_*. 14E!QC&>)6:K$&CB#F"GHX@[$. 6!!<$$BYU^A5"2J6O(6%6N
M7PBEJAH?C*5#NE*-G* +J*;FP &?,U!(@!%$P;PHKMI5G1"" XO ?=VFN1R1
M*^UT%XLZ\AL5+#(;DY'E1UEL$?Y,Y\ABCBPY:^WLN48;AVX&&<XYX"O7*"Y/
MS*ZC=\5PM<.@H<U6D.PI#I2$JX@6H()3<7LD[FLIP'-[BV\.+"7M2KQ$Q0@E
MS52Y!()?$S:0=V"Y#PBT<)M6R2>,.+4*T(>+%$!X^B9Q"0"0\N," '8S(6CR
MQMD\B+\;+Y^^&^^]Y??[V=@W;.+#^I1G'Y$+\LM7.M#9Y&(EQ>8XCED<WQ%[
M FX;%^"9A7;W;OPT4]+UZE5-5G9#U^^>NKNI<A:5=34M3LE)6;70;6O<6;GO
M"LWO%M$&&#YU4A\B!VBI"&=@6,NK!;)H91P^^BIGPB>]JT3X41A<" B3LX+$
M%G;E4R7D>5=KH+6_J9UK>_\ O.=J@KNYAA,F&Y.1Y5VM@O%G/D,4<6$8=*"4
M2M*@I,N@DJ2;A0AG0(/."$7NR^]2PR&Y0DN$50ASMP[2+IR@(0*Y0>*E("1Q
MI++5*( YU%14=+DD6:Y_!]+0G1QKA42!L%/2@=##4RX#I+Q??%:PQ%8A _Y4
M#@<I/5)886"N8;@!GD.?I[MM-[;BO#<POCBY+<@^X7G!2"> 4AX>)FNU$B(<
MNGZ"[PP/%>NTK3^EU01DH$:@'?8]YN"<.H!H]%R0'A]U&.(G5@0,I,^<ET?@
MWG26X#-XJF"-D%,+Y9D8*1D)-*1I+8'Q5SY#5Z74Q#"),-RKR/*NUL#XLY\A
MBCBPY=*MSC#+)<ZPCQ44Z@H1TI6'%;(*D.'2#Q54Y,N,DE*0>*K_  A>QMSM
M]]E &U;,<.UHU(@,\Q6:-B->6M?-781WG7+@]5K .4Z**]0#8@$1,4G_ #V+
M%AD+!^NULM+:',-?"'Y,'[D'U0JW0GY3N&B+;.,6#<FTNO45 Z :>#73Y9[V
MD3(&:EB 7+Y3EE-Y3Q=]4U+[X':!@XG80P[ZYA8=^15F)1^?.D/,U5G- H^;
M"LR  ;:@ '0-4KA<\N;2)9^]K/!(9RU4HV?8Y9]N*[1H%"/>S4Y74]>OUURF
MWY8W:EM"$GE0TEL".Y#.=VG^!N;FBW+B@!F#;,DY'E6O)L%?GZV<^0Q!"!-N
MW;%:P^&'@H.%V!\4>MX9PX],^%J_G+I#NZ_FBTVGC'B 7/%)%SG8V;I7!%"/
M?W9D3 Q=[6F 2)M[GUB3X EGSQ6GZ=@#1BOX TM1=O3: "[#VG$J'\H9G,:G
MGY^Y;P%K;+B_LONYKT2/GD)J?/\ +PH96(,:Y'/EW^X-681^;I/5Q+\Z4E@Q
M(\.CP/ZXQN.Q?H%8<2N6O,.Z!4\@81XH452R0I<.Z4>*))!6 44DVS.5]_2U
M":^ *_7F#/7*R3K/=HYJRE4'Q6K$B?>]".3N<.&Q=SY(E7:Z"\6<^0WRKZ
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MQ$8B,1&(C$1B(Q$8BLAM,V_0Z8[7T^9#B+^"<U;V='/*"P_XO9OVRA7G6O\
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M?A[K<39FTN(S$<YWWPU,"]QI\CTM8#@,OTE\W9OK*UV[%<OX1[['.5)63_\
MC .S3=E'8.9S.6?.>YK_ %-8!<VN$@YY YQU+-#@Y0/T>&R]EI74VSO>]Z*J
M7+HM?1M2T_\ (;2?T"B^V5=>QHT#[Y[#G_2*Q+5WG6->OF4W]J6*P*,1&(H8
M?"K>ODQ9.\.*<L,K9RJ'YK7SS[NI+7!X+_(JRKOE5C&?C3V/)FN$Z8>45>#_
M *%%L^0,9L^)9:[BG*Y%CF;#+(:]P_*S;^M;!P!)E(G,OC+(X:GP6]G@';?-
MAQ]OK\SVF3NL?3 \^0.?@LW$.'%O<FP?3ZR__(P70.#E^_[5?^[5=G9V[K'/
M/>,)*3HU;EUI&(O%?TBOWJO@+$N7YW\S(Y7J#,W[)*CMJ,N7)@,QIIKO[S7]
MHO$5?T:K>HHU60#X2F(8@UFLX?XBDF\S>+I3GDN(D#4FUM+Z7[FO<;-3$\A@
M97SZ#*4[U+?X%3UD<DM_P@UY_2B>[\M[54X9/+6L:ZA4/5=N1=BX/O)VBN^=
M5KUL7/GRK;<W*EO",18(<)GZQS'_ .UB7_A')FW?@X\M;!UUJD _Z>FNUK7-
M+?)^T?-0^LA4)U((0@"]@A Z/I0<^^6N5%>=IZ5P>%@ ,6< [&D^H9W:EQIC
M82Z8#*W6<5GSV<JW'=8GGWMG1>-HO.0?6"_*L>(IB1=11GDXL3L79]TF!FI]
M6S(;[-^ !'_ MA=WO21(\FHMI+Y1V]_&;3^VTZL?9'T59OH%4]11J^#>(O11
MB+0WP\-_F0X'@9_1'F>MNT@Y\MS=OX#OIFVOX9!ZXKG'"/\ ,;-:_OV+;XO\
M6;D490FYOW/@:R*Y;[?OY[UD/LB'^^OV:\],:*!WD@>F""W6[V5]&U[2T?FK
MI'>WN/7KO-&7L7W60/RW8\OZRJC77]U#SY7GFIY#4@5BT8B,16!QH/GR0_8T
M=N)_78;F:">S$]"B>!&Y^L*Z]%?4E3FI]!X',_P"/D.ALC>=I077 :A@NSM"
ME&(C$1B*AO8VU8BU)5SPS6RI0%=5IA].9!C _GM"51.:3G+R!HV >2YY,I'&
M/8&,>0,4_G\.I_"E\Z7U!X7*5/$644)SMU6H<$&E%H5&I6A0UBR(:"O5:BK5
M"*2N1BD%'30".$1PB@B$,3&8XQ .-SZ16-/K#JU:K53CH[0-+4Z>.KTIAJ<1
M@-)1EHN)&8P(X'NB$C/DZR.'$V1;CC4WC0D;R*.E2B!;4)[),^@-]9X%-*P)
M5JQ3E\=I _\ [=?G_*'87]G:/_2?_P#3VK./9,VQL+-LFE:EJ_"N JZ EE+3
MXT[,G57R9U)HQ4<'"8@+AG3F-CD/7!=J'F^J)(.13GEI.E>B%J:'UJK52U*2
MJ4E+6JN*Q1FITT5- (#$86B)HX&B<7,O?L/2"H:04--3U 5B&"KTIH:05BA-
M#&(Q.4,1)(R(D5EBVJKW$8BLAM,>MTQW^Y!B-^"4VW:-[.CGE!8?\7LW[90K
MS[6^BK2]!K?J(U 8@[]:0]O- P[JY-S;S W\XO\ U"S7JI/&1_OQ=)5<*&=%
M1/>((6V,-PDT]8Q"]R\G:R#<=36K_DD9BY\//EW,8;QM'2OTB,HC)Q#G@Q+.
MPP&O-LYL'!D^L6V=OM-??TW-6IMPD2TWTA&5=&_N%$_/<N\:(ST<LD_X8?6B
M6>#:.MC1B+49PU?K,WWW2:0^]39NK\#?EA#E[GUM]GP:TG3[Z!B]*H.<1A1)
M"HYB]P=]K>!K4KC8%QN883$^UXWE<Z4V$ZI^ULY_([FYO?E2$W9ZG\N@S_.G
M^;UKT6L>IC[<R@SCH7DU8H&U_#0&_D$A*8<G#]#>"]1PGV,X^](:@L?RXOWH
MNDJS4-PV#H7);%2C$48'AW_KX8!@G+YE]3Y6U/98[W]X-97@/'Y$MXM_6E5&
MSXK$N0\(S^ZEE$'^@5OU]#-]06B\ 9$Z6.8W&^IS!-K_ "LW:UH9,R'+N-<F
M$IA@X>6:V1<$L"-NW#*VG8S7&NEN37&G/W><"[<\X53^8]I"?SNS[O.1B>+/
MAK,ELNAC>^:I8_%ZV'U\6#6S-,MBTA<IEC5"7=48B,10A.$9RVY-I$Y&]<NM
M1D/0269997.N>;7/X/O(G1V7]"B'_?I3UJO^DH_..UI_TD.V'P<#.=>6PZUA
M7?/HO>VYMQ7C-*^;,^*D(\ =G-]J(\[O##+F^=53^7H;@O#KXG1C_BGUJLNB
M\&_C;;_>J>[BTLM2D?-7E=41B*VV,AMA%BF3H,.JU/@IN9-]]E3M2S1_CZG]
MHHU\U=^9UOT:G]5&OS_XFXBHL6RZ\B[>,/=#W+>\U\!\F#]R#Z@5;8/TL/"B
M$L0[A]:]-O@)\%_R-*R)D2,.PZ0I@W WY[!^'9_^*\2?PSFK5*X7/+BTO1Z@
M_P#TE%=R,NSZ!>3-3\_7OME,MI+<T6Y(Q%J\X8WU@^*7VRX6_P#F/35O?;I?
M!'Y<V;Z-:?\ \?6%J&G?DS7?.U'[=5QUMRJ'JK.^8)!MH0=^7-ES^_I>VJXJ
M+[I'&65^>K=K;Q2?GL*2?\?EVN_SZXUOX-=[,(_-TOJXBOSI7XH( ^5 [^<A
MWXW\R_09PU^MU07VF4Q;73D2!MKOYVH5:'S^NX?&ZS+_ 'T:LK5/FM6>_N%#
ME_9PY27=F^1?0C$4=;A[CYC9FSM:,Q'.>_SM3&7O;[#I%FL#P&7Z2_N6;/'Y
M=9ELFN7\(]]CZZ2L\O@P7WJ.T3N\S8YY=WWB-.@%N_KFK--SE,O?+#7?K&2S
M1X.8C]'?LO<73L\FU^?*BJFM?GOT<W,+-J6G_D-I/Z!1?;*N.M>SHUQAI-8=
MQ>LUAS.7Q.L;I;^=3?6I8K HQ$8BAA\*MZ^/%FP'&ZA3MNFTJACS@:GX UP>
M#!_>5967&K#_ /-B;HZ<UPK3#RAKS_JT0<7MQ(=6WD6N_C!70;6URZ;]&7OZ
M&S;^M:9B3@X8,\@&Y)EY9:UO8X!W+&''P;OF>TSNMI4+SO\ >;B'#A]$V#Z?
M6?4+H/!W\_M1[^]:"_731ZSJ4G1JW+K*,1>*_I%?O5? 6(OSP)H/1BH#IZ8J
MBUW^CD?I\M;=Z_M%XBKY=[5;U%'AR].M5E?PZ88BL5@3\_2'#L6.2XB2 -<S
M>XU/1;=S;C?O99I$"6VZFORO,B<0I;_ J'^\DDHM:V(-=C3+]5$_(M57AE\M
M:>;_ !"H>I[:LC@.Q\'WDY0^DUOE^&B_!;;6Y2MW1B+!#A,_6-[0'VKR[G]L
MDFT(T/3NS+;OP<%M-K /^*I-?]&IUKFEOD_:7F1BWZ<.*A/(-D(Z4)N#F 2D
M9CI:Y45YVGI7!X'(!,B !+4)@RN?(\X7#F)M+8\@BX@XG(C(CJ*^]KI_6V=#
MXVB\Y!]8+\JS.@I@T^Y1SNGQ3(/G-VNZ)]FS);]#?@!;+Z"N%Q\-$2-J+:2^
M4=O_ ,9M/[;3JQ]D?1-F>@53U%&KX-XB]%&(M#G#PYX0X'YV^B/,_P"A1S;[
MV/PMW#@.^F+:+?U; -?COQPS>Y<XX1BU2LTY5R+E^#,NM1E%?3%K(+EH+AQ)
MWZ2LA=D3UV&S7TXT4#<\WI@@@/RG^MO TL(&BFD9Q]QZ[CAW&*\,=XF)YA?;
M9+^[=C,S>Z54VGX0-R.=6(P4\EJ/*QB,1&(K!8S^K)#]C1WWV&8HQ.P=,2NM
M11O2--_Q/ :?P"/E\#2;SM4CVW[>S:EV=H1&(C$1B(Q% HVI@$;3NT7Q,@<:
M\1-"?;)'?DM^75KR:+N=&='B<;&J'-00JNEK "VK8 ?Z2K<WSI#?KU]"L/QC
MSEO<7PL)XO-MWLQZ%)VX" <7!+&9/_S2=GOF0P)/>N2>_P!UJW<.'TU8\_ZK
M9LOAH^W(NH\&X:I6GZ:\[YT<)GKSUK>RW$%TA&(K(;3'K=<=NG"'$4>&DYL/
MQM[.CGE!8?\ %[-^V4*\ZURUE6D?\#6O4QJ Q"$=9PP-[APZYK?2)MS9;]&O
M52?+C_?BZ2JXT(/<Z,L/DB]WNGA?K.'*_O604*R ^=O ;#_V3GF+=[PDZ-B+
MQM'2OT(+1 F3%B6R(;69XN"<!)37^#)]8KL[?::^_IN:M37A(\M](?31ZBB7
M>-$?)RR?1A]:)9X-I"V-&(M1O#4@'8S?7O\ 7)I#07_6IK[S=7X&P^F$'\/K
M7+XN7;#6M)T^?W".7?5"^?Z3-KYE$BMI?('?JUJ5QQ\IG7)]=UVL!ESY1^K<
MA &79!)+G/Z7E2%W7^%OSIV[WK+_ -VK'J8]TG[26)?CT&([O0/M%-!C+7A]
MWZ&T%ZBA/L6'^](:@L?RXOWHNDJS4-PV#H7*;%2C$48'AX!]&[ 7+_<NJ?/=
M]5CK^T]#64X#_H6W9CZ3JTL3\5/;?R<CX1?I2RC_ (&M>OHN<X+1=<CY#H_(
M&[8M"U[.W.?Q6R/@E"3MUX99V]+5<7R%C:6N>C(V&6F]N><*OD/:7I50Y?A8
MSU/]SK9=#9:35++O>ML+YF& N2>6[4IEC5"7=$8B,10@^$9]?)M(ZV[.77/:
M_(LL^$"^[6XR:Z'!]Y$Z.ZJE%R_#4OL;D8X+@&DH/OBM=L:R-_<X<>>XWW+"
MRP)-B!S7TM=MP7BS N?//F#$[E(2X X6F^U#E:[O#"U];=3JFW3DW!>'3Q6C
M'_$]GRJMR+HW!OXVV[OE5.0P\&EO_$Y8*1ZU>5U-&(K;8RFV$.*9YL.JU/@I
MN9-Z%D_2MF?Q"I?::)?+7OF5<]%K'J8U^?\ Q.<3&:YQL61N%^N7E[WTRMW&
MO?#\F#]R#ZHO^^:K="7XQQ$40.QS< ,6[, /2+V.5]">C5I4Q2<O@9%F-W;F
MQ4P;@;_6'X=_;7B3^&<U:I7"YY<6EZ/4'V]Z46>IEVC0+R9J?GZ]]LINW0MI
M+<T6Y(Q%J]X8SU@^*7VR87?^8U-MTS@B\NK,>[O>TW_^WUA:AIW/1FO><J7V
MVKMSL>10\E$DGH)'>NUM%Q4?CM1)/5(3HF$NM>UA>-<?#NW,PC\W2>KB7Y4K
M<4?O08,2./")'MFOT&<-?K=4%?/TF4Q_0L%\&C4*M"=?KI_Q=9]=&K+53YI5
ML/B]#ZN%=V;Y%]",11UN'O!ZELSV]F8C?^&IFVZYUTOWFL#P%S.DH_U=FG7\
MNLOJPVR7+^$>^R,NZ5G8/!@O[9*.Q8C46;OZYNLT^#G%MN_9>!M]7<WM:_M*
MJ4[\_?M:_.VH\('D-I/Z#0_;:LO7T9\IK#,_G%/E/XG6!-C/"X9/@TWUJ6JP
M*,1&(H8?"K>OCQ9YPXITC?\ L3"][N[PUPN##R)LK]ZL/_S8N6Y<*TP\HJZY
M;P:(G"1HQCS[EKMM?2Y.9/O>]G\@V_+6W+SD[-MF_,VK);V> =O\V''R^?T/
M*9M_]P/-=6XAPX_1-@^GUGU!70.#KY_:H%W>U W_ #8[YG\%)U:MRZRC$7BO
MZ17[U7P%B+\[^:7Y8GQ/MDJ2P/-RY'VZ.[TM?VB\15_1JMZBC590_&IA)^^*
MR\O\12,XD9BY<).H[O\ 9X&S4FX[,%+BX%7UD<E^Z#7G]*I:JO#)Y:4^NH5'
M=W'VNNQ<'WD[1>DUH?\ =/;H)#+;:W*5NZ,18(<)GEL-[0!R^I>77OS=DDEO
MWVW;@YGIK8'I5)]FIUKFELM'[2/^JA^O"H3J3=*.A"!_R1?WVN7%>=IZ5PB&
MX/D)98^S<ZXLR'H9'DC6"BOO2K9Z#.^OOMG0^-HO.0?6"_&LD=QIGPHX\?V"
M\M3X/?M:?7LR>MOP '-@KA<#W>PB1M1;27RBM[^,VG]MIU8^R/HJS?0*IZBC
M5\&\1>BC$6ASAX/K0X'ZW.(TT .Z_(J;7%CX=W1O[?P'M[L6TY_JVCYJ8]KQ
MJU<XX1_F-FO=W[%M\47QRNOQVB,FK4_V?*VC617+1=][OKY;UD/LB6&UALUF
MQM\VB@3?4GT?@N\"/[0;$-K^EH)T5TC;_0]>&&-#%GU37W60?RW8[S_*55E-
MA\*,9&;*>0U'U8M&(C$5@L9_5DA^QH[[[#,42?6PW3;K5U:)%J1IP W'(\#G
M_H4\_-HTF\OGVS4CMV[; NT-"*PT[VD<*Y#78P^CIK,U3=W/I/2TPF4)(YI&
M4U):EGSA$3*9#.ZAAX=<MEDSC8=ZY>H<1+Y =!\Y#];I3U"52Q9[Y.SBX/@[
M[U'&&N]KC(ZS=^(5^ 01<9@M"E58B:,10)-J1\[>[3VT7U-:2!C7B("GC D*
M[)(ZX-B<QTVZ+Z->71@&'1G1T$$?D:HM(MXB#4W.JYVM'";:MD NUIUIY@_S
MADPF\Q)NA6, &=RG=8W\/R+>VO@,4]CN"PG)G)ZBI.7 //$O,$<9E(4% XI(
MS201=,B@D&Q!(^F2H'>+9M6[AP#6U8[@@^Y>(_UT?;E74^#<PFHVD82X[]U&
MZCA#.";B"-5V"WN-Q!=(1B*Q^TS;]#KCJ#OPBQ$'_9.:M[&COT_8F?NO9VO^
MF4.U>=;'T5:5WS&M7W>)CO4!6!4A<%"*0I*@8=T00H'+J:;97\'/=KV4D)$<
M8((\.(3#3<Z@JY4$0-%1D%P8(2,9,[NYP(OY'7O>K=H=/E/%I2E#EZI5U)&0
M0HDY\POEW,\\L8828@ "2X%Q+$EA(3O]FV:2.$0Q<:*$#BDWAY!RTQ/'$7NI
ML?!D@?H%=G6QN%44M8-[@I>3B9K20<P04J!R._GNU->$CRWTA&5=;=0T0/.,
M9KO6B+'1NR2+C5(",7<Q%^6]9X-HZV-&(M1G#6*"=C%^HJ"0G$FC[E2N*,W<
MU2,^DD#\8;J_ V_OP@;_ $?6O_YK2-/RU@EV;OJA=RV,3=+<NQ1)"1>Z5)MH
MGS0/>&9W\^0:U3'([EQL1!F-^+$!LIAA(-=-<N5*"9Y3J2I(+RI) Y2"I(*E
MO9M")0@7.94H@"VM[7T;"EA)J]:D2!5:P26,@*&,F[4#N6,<<(BH)@DUBK !
MP"YIZ,"1G,EM2_0Z@A:#A!S0S@?\TAJ!Q_*B_>/259R&X;!T+DMBI1B*+]P\
M#Q(QQP$=E20?F75*JQ(%PJJG9%Q?3S)&5[V-M6LKP'![%MT@$_E.K38R^*[-
M>+;V7(^$4CW3LH$@'O&M8S\=1>U:,E?ODY9:@<YTO;Y#I;M:T%P+SB\B^#9:
MM_(MCO!)OD#;OPT=A:2I-,UM<!0N \ESM(RUMYE5[CIO:S<^X582-!K2+%N^
MJCAE21/TB5V. 6R:&QPG2>I0@@D5:M$AP\X80);_ ,2 9F+5 7=D8B,10@N$
M86@[<NTD@E 5V<.3FH7'&D<M4FZ0;]'Y;-=#@]!]Y.CIF1WE%-C<*>DY&&8O
MFJ_Z3&'WQVN'#BL0N':^CA,W&1#9X%EA;D,P4G0WN/!K;7H;<%XO&#WC'[NM
M^12$N ,(>S3:D>H4E:$+PRAU<4@\5ZEQ4[Q2#;('B+2JQSSO;.[<&X=@8:+1
M8%P8H;3B G\GCU8 SU@S71N#8B*DMP@@\6DJ<,1!! C[E&3"UX8$&>;W$*1Z
MU>%U1&(K;8R"^$6*2<L\.JU&9MK3<RWMZ%D_2MF?Q"I_::)?+7OF5<]%K'JH
MU^?X]>(7$1EEH41'1F84DZ1+P$9$@9Y6WVNU\!"1# X/BX#=^P#-5LAB'A3E
MQHYB7Z1P&R]R9[6\24@$J6D<4'4@"PO;.XR_K:0[AIG5KVC6V2R,0AE)L22)
M8%R2SRQ(P4P/@;5I>;!N'*TD%*ZJQ(6DI(*5)56<UXI21<$'46/?:I7"Z&TY
MM(,Q[WL\$,0Q[SHG%P[27:- (N-HQ4XA,&FKI!!<$&MTTQMR6TMN9K<T8BU=
M<,>M"-@;%$K(2.R;"T DV%_FC4V=3S $]YNF<$()T[LL $GO>TI /_5]86FZ
M?,-%Z\26'=:C,R'SZKM-0]38E5BDYG123OZ"UM>;:#>+\.TKQ-<7XT-SCMVP
MNQ7CQT(?006M">/,I8@!2DBZE1SCBZG6^@WW:0"1&6) HJ4F^X4<3S&XY E?
ME31PB$.86-)1!B0')I(6 )D7+<NV7Z#>&GUNJ"T^HRF#ETR6"+4)M'Z0KWIE
M9]=&K+5/YI5<^]Z&67P</8'%=V;XU]*,11U.'P4E*-F;C*2"J,Q&2 H@9F%I
MI0M?7)*M-+%K \!8)BTF8$M1V;(!Q\NLWY&[DFQ 7+N$B( V."P)I*RQ)N\"
M W:V(S,@-<=NPM],+[LQ8@;[]_Y;N_\ )=V9<VXPD<+M8OPY.7DGF=P<BT';
MRV7W06@O.S><O0@*3QBAW1E1<<VN#8<<7.8S%\FU+A!!&@FD\3%N\J$.Q9S7
M:O)QB0"O8T:,'OHL.'C>$:>L'BN'(AJ=.+G< $AY3N*G M2Q6"1B(Q%# X59
MXC]'+BRGC)XW6].JL2DY&50P-Q<FV0MD,FN%P7@G0FRF!;C5AY8]UBU97\FM
M<)TP(]\==A);X.B+ @$O".N[K"UX"PO<BUK$\8 #IUZ,P>^&W\.X:_#/.Y:T
M8@0"#<79IROEUC>MZ_ -K=KQAV@2E:5\2@*80HA05Q29\M5B 3G;,WSWZ!N(
M\.0(LBP"00]?K3."+J# F\:[EO\ P<&$U^UQ"02*O5^,Q!(^$C8%KCJW24G=
MJV+KB,1>*S9"R= E1/@+-B&X]NE?G>S%2%SB?GCIL*DJ5)\T#8HGTP00<\C<
M9CG'3E?^CA(H:O(SJU5(+%B#5Z,AI<ZK&(Q%'3\5B16:T"Q<O#6*8$9EB&Y=
M_%NE *E%((SNI2;?#KK;<TL3<"=@?H4F(9AA,X$ZIMTZC>I;_ I+2\V(9$M)
M"DJK^NE)*2""E4T2001D006JMPR@C36G!!!%0J-X:0HNHNZ['P>D1:.4)!!!
MK%9((+@@TA8N,\,UMO;E"WA&(L#^$U(3L-;0*B0 FEH%9*B +(J&3J.9WV%^
M=MWX. 3IM8  <FM1B3EGJ],'87]&:UO2T@:/6D3("A!)R CA4)UV4*=H*%)(
MXB#DH6S2G3/PZ;@-&N7$""7!$S>-97!X"&$X6(#-DQ[2FYG)<*:O';J5S%2U
MI2.LXA-U+2E-U.E)3J1J59;BWZ4$,1IJ("$D]T@DQPB!R7Y5J*&&@IC$80(:
M*.\@7PD-.7.[R9C.?ALRIXNSC@$DZIP8PP2K?YI-$R1)'>(L;9 BVYJ*:2^4
M5O:[9M,[Z[3%60L@$659H(8BH50$9$4%'+DN5[V\1>BC$6ACAXGCM.$F!SM2
M@DG$2:K%U 9<C(03F>=0!YAWF[CP'0DVO;40!/Y-@#AS,TI/5SSNGS?A'B J
M5FS :N1$NP_FRP>]R2)9*,N+'0IL=#<'+777?W=+M8]<LXP8.7D+G%XU:CGL
M60>R,^=(VL=FI)6D*.,U"J "D\8AW/(5:S:][!*2=- 3NR\#2R"*+1320@%O
M<>N@EBTZ,@:K\RONLFD$-N6*#%"3%:=6XL+@DB&/C'F#]$U/,:CRL:+ACKS1
MB(Q%8+&?U9(?L:.^^PS%$GUL-TVZU=:B[=B5.6TY'@#X8=!8@ZSS$KLYT-]-
M[%*UCUQ2%=JFN/&$[FA)]$S#&?&REJOI6K(%PZ?2&!I1,)2Z9E4DTF*7@$$_
MIY_(G\,^@WO%C'@?0IAT/$&YR# N8B& #8NY9GDQ<.>2943N9IN[RP?H(NW2
M6S-P@NW+EVH\92'3M"E9YJ2@))SS%R+V;%2OGS"7Q,8MVMQ-(N XJ2E28<.2
M%WT)#QVHW&F1]]F';MVF\FAB[OL'MFQW/<Q"X DDQ"D*[(IDKB*"K*1"\4V(
M-E!+H<8&UB+V(R-[FXAW </+7=@<^11Q3^L?O?HU="U_53P4&QG6=4U+6=14
M%,HNHJNGDQJ.?QSFH9C"=?3B;1*XR.BR[<+0A!?/WBU\1(XJ0;#+)M\JO"9I
MI4ZK5ZE5K8B@JM4H:.KU>B-!0QBCH:*'BP0O% 26 $\<9K6*70S1VGIZ>LTM
M0A-/6:6.GIXQ''#W6EI"\<<0A(G$>20R7P_[CYL-W).'<X-[6]-<YL+:9%^0
M>^+=#?O_ "JZ=_Z:/_2U8;VHY\JP]Y&C?]P_[M)RXXK)[ +9%PFV89%.Z;P3
MA)E2$FJ*:)G$UA$QJH\1$P2[#KKGJD4E:TK4@%*@%6(U;6;>TDMG26GH*S;5
M<BKE-5Z,T-%&888.+1DOQ6A#,^KG<GU[+L6SK&HJ6ALVKBK4=-2&EI(8"3QJ
M0WQ%\3CFY>:O]R',;?5)-.GS$+W[?.2>XWA+TV+_ "BPU#GSY0J*D<R.E2S0
M?\2$Z/W'O]WFN62['[MO83CBQ?K'MRKX53X>PU8TY/J2J*<3282"II1,)%.H
M(J<N1%RN9PSR$C8;JCIVE;OJ\.]>.E+20H)4;$$AOWJU8I:G6:"MU>(T=8JU
M+14]#2._$I:*(1T<0A(;P8P(@[A[POSIJ"&GHJ6@I28Z*FHXJ.D@N$4$8(BA
M)$VBA)A+8%:_77 \;##EV[=.\.9LAV[0EVA#JJ)LZ0E"!8)"4/0!8;Q9M]_E
M6T[),45M1&(DDDU>KF^^^C)ZM2UB'0;1F"$00V=###"!"(121@ "0#.S 7,%
M5YP/.PT\2M"\.)JM#Q"G:DKJB;K24J!2JX4^4#<$C30LAX5M.H2XMJ(3>57J
MX+B=X@>^[+!2=!]&H@1%9\,0(((BI(R""&(()N(+%9PX8X+4Y@[0M-X:X>1T
MRD-&4C B6R"4(6YB1 P25K>)<!^_=J>/$I4M9!4?\(BS:3:=I5RUZ_6;2M"F
M-/7*W'W2L4I#&DC8#C$#P06$V$\5L53J57L^JT-2JD H:M5X(:.@HH9PP4<(
M $(!N FP$AE)=_Y$F.^I)IWD0GQ(;X9:[\^S]I+Z0(OUN;MVW)R),?;)-/YN
M$^):99'?]R-%^MS!6?QOV:L/-HVAU8<XP(F-5T@N9PDW5+%1767&F$#U00CY
M3Z%0AX>HAZLI3< %9.9 +>M8MN6GH]7A:-D5F*J5L4<=$*4"&,]SC;CPM$&F
MPFV\27P6C9=3M6K&IU^BAK%7,4,9HXG X\!>&*1!)!S=[UB$>!\V'#>V'<W2
M3;(55.0!SV ?@#O <]FVS^573K_31_Z6K_\ @O$]Y&C<VL\!\J6DW?*7L<<$
M%L00T5!1SG#N:"*E\=!S*$>/*EFC\.8R B'<5"/@A\]6DER^=(6!:RB,]2T1
M<*>G,<$<$5M1<2D@CHXQ#5Z"$Q04D)@BA)A@!8PD@J#H/HT8H(C9\,1HXX*6
M#C1QQ"&DHXA'!& 3?#'"(AK$EL6=T_'.DAV[J*9H0A"':$I1#62AV@(2G-T<
MP$BZM223E=N?.Y)+DDDDO-R7)<NMKXIPB(D!<]R\^1)C[9)I_L0A_P#P?+I9
M+([Q[%'%B_6-[W??=J5#(Y@18U'-/YN$OX>HY=ZS).['6#%MNEL?VH88F;C8
M93WS6+6/VPE@!M/3ZGJFQID,PJR=4M*'TBDL<)G$2YY"RR(BEQKYR1!EV%J>
M1"R\4LV)-A< !MFL+3'2+1J@K%6L6T(JI0UJEAIZ:CXD%((J6&'B"+PP9"&3
M3;67?QK2T=LFV*2AIK2JL-8IJ""*CHHXHHH8H((S#%'"#"1*(P@Q9L,@K$#@
M?-ARQ^AW./\ [KG(W;OG^7>OS] ]S^573IIVT7%Q[VJTLI&BFWW+SO>1HW/X
MA>7\;2?^7:Y7(PBX-C9;P)Q E>*&%M*3*G*VDT+%0<!.%3J+F"W4/&H+N*<E
MW%E:%(>H-B#NRWMYMKZ?:5V[4*6S+3M2*L5*FB@CI*$45%1@QT?R2\$((8W-
MO7UU#12PK,K<%>J51@HJW!!%1PT_&BBC$$;<:'PB9%IYK-02.8@?5)--_P#@
M0IU-_P#"=$^'N:-ITM>^>^?WK8.*7E$1JOZ3/E5>1)C[9)I_-PGQ+3+([Q[$
MXL1_2YFZ"G(DQ]LDSN-+HA+:[[.1?+=I?G#1(C$'4>B7XJ.+$_RL=>NZ?-=F
MZP6Q(X+_ &2<6J[J;$JO*+F<XK*L(U,QJ&;HGT?!/)A&(<H<)>J=0JT.T .G
M:$A*19(2D)  SW>SN$73"RJC5K-J%K14-3J='W*KT)H*&D%'1N_%!CAB)F29
MSFM=K6B-@UVM4U=K-1ACK-8B$5/2B..$TD0 A!B8AV 88LND_P!Q\V'B<\/)
MO:^@JN<W\/5L^^&^S^573K_33/E5:L.BC7X>\C1O^X#;W6DW?*61FS]L68*;
M+8JP8'RN84:*WB);$U($QRX\S!]*73US O5+C$O"A;ET^>(N/I@JQO;/7K>T
MKM[2?O7W;KT5=[R%)#5GAA@[G#2Q"*D#0AB(H@]U\]2].R[!LNQ>^/<RJP54
MUJ.".L&%R:6.CA$$$41)<Q" "%R\@!< LD^0YC[9)I_-PGQ+:]+([_N[9E>N
MT7ZW,_;M>G(<Q]LDTTWNX3XGP_C:-_;D[=!HOUN8+YDWHTSZ4S613:=S*+E4
M[ED=*)E"GJ#OJ\#,89Y"1CD+=NDJ=EZX>K=]43YM(42FQ;.BI(Z&EHJ>BB,%
M)0TD%+1Q!B88Z.(1P&88M$ 6N.(6,=$*2"."/PH:2$P1BX&"($1"4W8EB#>M
M>G]Q\V&RI:SAS-$J>/7CY74ZGFKL%X^6IXL\5V]2G-:B<@#T[VZ#_*KITP'N
MU%X,(A#U>@B/%A $,S \@&OW7+5AH/HT':SH0"22!21@$DDF)@0')))P?!4_
MN/>P]G]#R;*!W*JF<J'<(4_4".@BQ;'^533J\6TQP(JM7'1 &Y%/O)T;QJ .
MVEI/_)9E8,;/-$;/N'TJPMPG5,*8HB214RBY;*4OD1O6SZ;1:XZ-(?1+M3Q2
M7L2\>/ E1/$*U6.;:C;%LVC;]H4MJ6K6#6:[30T<%+2D"'C0T4 @@D  XA #
MM-E[EFV94[(JE'4;/HA5ZK1&,T=#!\F$TD9CC9P;XHB=I.:NIR',LO3+,[?P
M4(/!\Z+>7M7W,<(B_(1N95Y#F/MDFG\W"?$M,LCO'L1HF;C<K.><JU.-&SO0
MFT)A]-<+L6^4*IHF<QLJCX^5+B!!E[%26-=3"7O _AD(>(#F+<NGW%2;%:$G
M_!#>G8]LVC8%H45IV36(JI7:&"EHZ.F#1-#30&"D'%(8\:$D%\"5\-H695+5
MJE)4;0HH:S5:4T<4=%&[$T48I("[OX,<(B&L X+#@\#YL-DW.'<X[B:JG*1G
MKDE^/ ,@VWCA5TZ%UM'EJM7/31]N1>'[R-&O]'PG_>4G5$!GO7B>![V'.,Y>
M##J:EXX?N8ITIY4TU>\1_#O$O7"PEX]6GYV\0E0!%KC1I_E5TZ8CW:C:*&*"
M("@H!QH8AQ8A* %B"1>\[\\3H-HS$W&LZ"+BQ0QP\:DC+10$10D/%?"0"'=F
MDMA\LI%])Y;+I3+Z@FCB!E4!"2Z"=6AU]3A(%RB'AW94MT2HI=.TH*CFKBW-
MR<N?4M)'2TE)2QGC1TL<5)21$WQQDQ1$!I.22SX[]J@HQ1PPP0DB""$00B]H
M80T(<N[ 7WKZ'(DQ]LDT_FX3XEL V(W'[N?F63%Y1-R/VU9*AD<Q/^4LU'<1
M"#X'/]?2TRR.\/T*.*?UCVY5CAM ;%N">U"FEAC;*YE6"J,>1[VG%JF#V7J@
M%S-#MW&J!@^I]44^0Z=@E6=D)%\@VP6#I5;NC'?7N)7HZGWZ*,5D"&&D$<-$
M28 T8(#$FZ4W:2\JT[!LRV>X>Z=6AK/>T4<5 8C$#1Q1CBQF$ABYA>'83FPQ
MR' ^;#=L\.IP5#0]E<YL.]U?/WFV/^573N;VT22T^]:MA_NR>?:Z\OWD:-W=
MX!LNZTC;?E?=J7=<->#!V2\(,0:6Q2P]HV8R2N*+BHF-IV<KG<9'K@8F+@W\
M!$*#F,4\=O$O86(>NBE=T@*T.[X;2X1=,+7J%:LNOVM'35&NP"CK-"**BHQ2
M0PQ".&<$((:.&$YR.I?O4]$; J%<J]?JM0@HZW53&:"F,4445'W2#B1\7C$_
M*@)!PG<LY!(9D#?LDF?^Q"W'/;YR/?;298=+]06R $"9?*79]Z]G(<QT[))I
M_L0GP]1NTRR.\?\ BH(B/Z3;!]_2J<A3'/TR34Y9>9A@ =WTKH'NW+)-<=[=
M77RXIQ2[\8[NJ[F6%6+G!K;*V.5>SC$W$ND)C/:SGR(=W-)NZG<; +B$PB [
M<)ZG"%#M"4(2$@) L  &W&R>$#2VQ*A0V99MJQU>I5<Q&BH3145)Q3&28IQP
MDSOF\R5KU=T4L*T:U25VN5*&FK5*(8:2E,<<,40A^2/!(  R"MO_ ''S8=OE
MAY.+7]M<Y)MS"[_*W.WI?RJZ=2_+-S_T6K"^_P#FK^G5>OF]Y&CG]Q_[M)_Y
M*_. .PK@+LP3FHY_@E)IE2,TJR7PTLGL1RD]F*HV$@WW7$*A77B7A2IT]*B%
M@\;,B^9;PK>TPTATFH:O5[;K\5<HJK21TE!":."CXD48:+Y  8B\,'Y O1LS
M1ZR;&I*>ELVJPU:DK,,$-/%"2320T;\5S$3,.6-^\K*02*8 6[))IWG<(/?Z
MC=M8[._4W7]_L@1#])]H^]T,DF5OJDF=_P"#A+?>!\'=9+!^4O[&1C)XB0-3
M<Z\3(8]84E[44R>(6A;M;M2(;BJ2\04*S2Z24FQ/%4FQ2;$&[,C-P00068@O
MRB0<8HQ=^,=ARY&G?S+7.]X'_8=?Q$3%/,.9FE]%QD9'1!<U+-7"7D3'1+V+
MB7G$=O4@%X_?/%D"XNINA0\*FG4,,$/NW&88((*.$&KT!(@HX1!!""8#(0@!
M:I[QM&08XH;.@A,=)24L7%CCA!I*6.*DCB8%GBCBBB.LE>)X'S8;-Q\SJ;D'
M(@U5.%#O@OB#T@Y-D.%73H?UR>2JU8;"&HY$9WJ?>1HW/X@)AITM(1N,7*1<
M<9++O _9JP_V<J&AL-L(#,J5HV$CHN8P\H3$)C4NHN.7U2*>)?1+M3PA\\LI
M043<@'47;4K;MVT](J\;2MBLFMUR*"&CBIC## 8H(!Q8 1"&\&&0EF,E[5F6
M54K'JL-2LZAAJU5@),%%#.&$Q%XB'N<DRNQU*\/(<Q]LDU_V(7XEO(E*_?J.
MKF8KT&B_6YA[57D.8^V6:?S<'\2TRR.]^I&B_6Y@N@8GX*4QC+0=18:8D14Q
MJ&C:JA40<\E2GCN%$9#.WKM^ET7\.A#Q">K.G;PA) )0,M[?=9EI5VQZ_5K3
MLZGBJU=JD1CH*:%B8(B"">+$#"2Q(!:0?-?-7*E5[0JU-4ZW *:K4\)@I:**
MZ.$X$AI726#R>!ZV&TI"4X=39 "4I 15$W2FR<@ D/@D"V5@!SMNO\JNG>-M
MQ$YFK5<G"\F D[_OUT:#Z-!FL\ "0 I:0!I!FAB&0W+PB.!UV%XEP]AG^'$T
M>N7R"AXA[4TU>H*38Y)>/5 6L#H<P#JTP<*^GD$4,4-MQ"*$N"*M0 OK(@!F
M"7'4%C2:"Z,4L$5'26;!'!&.+'#'''%#$,HA$2#N6P>F:!=4A3LBI203J9P,
MBIN3RZ12>#'6[WK662J%=04##AX\=%:PYAG+IV%*)40D$DG,Z!6:Q2UNL4];
MIXS'3UFFI*>FC,N/24L9CCB82#Q1$RS6U45##0T5'0T?@T=%!!1P0@?)@@A$
M,(!+F4(9?;$CF5LZEF9_T<(/A<GPW/Y?Q&OF/W+,PDF41';D5>0YCOJ2:?[$
M)\2/>L62['[D:+];F"L#C]LB80[3TGD,BQKET?5TNIF/?S*2NU1KR 7"QD0A
M+MZ^*X0(4\*D(2D<8^9 ROJWO6%I+;6C5-3T]B5V.I4E9@%'3$0PT@C@A)(A
M:,$ .7DO+M.Q;.MBCHZ*TJ"&M04,?=*,1$CBQR>(&$B99NA8P#@?=AS?AW..
MX*JG(&FX=7N,^D_DV3^533N[W;BN 'Q:KOB]]'C+G7D^\C1O_1X$F\;23V^$
MOO4CP4FQU0E74S7-*T/,Y;4]'S>%GM/3-4_F$6N FD$\#V&B$NXE;Q"PA8!*
M5"RM^=F_&M\)>F=>JE9J-;M>*EJM;HHJ"L47<*& 4E'&&BA)@A#/F XP7Z4.
MANCM7IZ"M4-GPPUFK4D-+04ICCBBHZ2$,(H7,C,C)BRS]Y#F14I1J29@*)/%
M2B%L+F]A\YR'1IT-H8#2F1K,]4VW]FV7BG]8CMJ;DRZ/I2^ B(,K+^9Q<>%
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M!4TNJ";474T[E8A)#5D#2T2N%GBY?$]54MP]AE.GK]S#13MV^BH1VN*=IX@
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M1D3AC"RQR:N@YW3DNA9M/.KN5Q"(4RV EL;!1AF3I^MP]=QD+Q,WO%3(!D[
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MEX[*DI*[)-,AQ+/,=>TLH<D @/.Y];/-EW'!3&"38XT0XKRGY'4TAE$7,)C
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M8\852+#^--.;1M74;5\KJIU,I7!RK#F5.)33,OFTBG,O#P1"8JGTTXAU#.H
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MF<5!P"YK&0TOC8B$E;MZZ<O)E$N89Z\<0"'S\APZ7&/4HATO7Q#IVIX%O"$
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H^+2Z5%1T9$E'5 @Q$2^?% )22$EXM12"<R!8$YEICO&SVJ!<-@7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g305908g99c14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305908g99c14.jpg
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M 0$! 0$! 0$! ?_  !$( $4!,P,!$0 "$0$#$0'_Q  =   " P # 0$
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MK[9]U.&FF9CJ^V0D8\E(@SDOM-M E2(BHBE8ZP9N_K;]:5HT44M'JQ?=)?\
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M\CWLX"9A.S. 5SZ2.MON]H]&G(;VY<]5K7&=W%86S9HY0JX+.,D=K4IF  H
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M186Y5J;F2#B2E<KDD*\1RUDGA6;9Y,(L$+331]0]$W9*H!U 4D<>[Q](YBF
ME)(]/'U>/Y59V"QGN2Z\N<K-DNU6N:PQLEQA9W4#1XP$!>*F,B0A_0U^#%=.
M)F<DR<2X;/[G<)19U'U4DJTB8U.49(-(=1,I9&."EGG]>'QY\*=Q6<\D_'Y?
M7?BF:I] 'I^$K8P9H_,*LJ+;P_3(^2C!8P5[.SU@-$X-.H^?N_I0(-7%KW_
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MQ]'JN#0N,\/P[HR,!CNO/SD333F)AJB> @C%2*\D9AU/75XR6(TG529*B&D
M#GQQZ3WD_7A48&\K/=W^CPY\^7A6ZZ%AHJN0\37H*/:Q,'!1C"&AHIBD5NRC
M(J+:I,8Z/9H$ "(M6;1!%LW2( %313(0H !0UB5+6.7=PB1?VAFBD4*!BAN)
MV:*@ AR'>A3L,+IC_P#I5$R&#^X0YUE)_8G_ "K^*JB/G^T?*MENL6I:-%%8
M_?:2_P _>W+\(;#_ !FYUDL<E>L?"HW.[V_*M:U"03:T:EMD2@5)O4ZZ@D4
MX J:,.S3(4 #[  I0  UC5)7K-%%9[O://N?X;_U)P7\K\I:F8\\_P"4_$4Q
M?(>OY&KP]';]&SM=_P NW?\ FK?-,<\]7KI4>:/;\32=/:7OZ^V=?JC.O[[B
M74K'[_\ M_\ *FN=WM^5:0MJ[<C3;#MQ:IE J;; V(&Z90^PI$<?5Y,I0_P
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MK<:!E2$#AVN1(4/.JP^O<UK^C117X( 8!*8 ,4P"!BB " @(<" @/P$!#X"
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0]&<6A"TW[UNJM$4:**__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494440352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001846253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OMNIAB, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490807376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,125,000<span></span>
</td>
<td class="nump">$ 785,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="nump">21,136,000<span></span>
</td>
<td class="nump">$ 15,875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransactionCostsCurrent', window );">Transaction costs</a></td>
<td class="nump">5,931,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,237,000<span></span>
</td>
<td class="nump">1,406,000<span></span>
</td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,015,000<span></span>
</td>
<td class="nump">22,542,000<span></span>
</td>
<td class="nump">16,649,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">902,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">166,274,000<span></span>
</td>
<td class="nump">176,321,000<span></span>
</td>
<td class="nump">186,644,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">83,979,000<span></span>
</td>
<td class="nump">83,979,000<span></span>
</td>
<td class="nump">83,979,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,375,000<span></span>
</td>
<td class="nump">6,795,000<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">21,456,000<span></span>
</td>
<td class="nump">13,332,000<span></span>
</td>
<td class="nump">2,499,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,449,000<span></span>
</td>
<td class="nump">1,496,000<span></span>
</td>
<td class="nump">2,129,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">306,450,000<span></span>
</td>
<td class="nump">304,465,000<span></span>
</td>
<td class="nump">295,380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,275,000<span></span>
</td>
<td class="nump">2,924,000<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,092,000<span></span>
</td>
<td class="nump">3,746,000<span></span>
</td>
<td class="nump">3,956,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition', window );">Current portion of contingent liabilities</a></td>
<td class="nump">1,693,000<span></span>
</td>
<td class="nump">2,538,000<span></span>
</td>
<td class="nump">2,115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">9,202,000<span></span>
</td>
<td class="nump">10,790,000<span></span>
</td>
<td class="nump">7,157,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,530,000<span></span>
</td>
<td class="nump">578,000<span></span>
</td>
<td class="nump">579,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,793,000<span></span>
</td>
<td class="nump">20,577,000<span></span>
</td>
<td class="nump">14,277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition', window );">Long-term contingent liabilities</a></td>
<td class="nump">4,119,000<span></span>
</td>
<td class="nump">4,826,000<span></span>
</td>
<td class="nump">5,089,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">16,021,000<span></span>
</td>
<td class="nump">21,962,000<span></span>
</td>
<td class="nump">28,925,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">25,016,000<span></span>
</td>
<td class="nump">13,272,000<span></span>
</td>
<td class="nump">2,012,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">5,493,000<span></span>
</td>
<td class="nump">9,226,000<span></span>
</td>
<td class="nump">8,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">295,000<span></span>
</td>
<td class="nump">1,308,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,740,000<span></span>
</td>
<td class="nump">70,158,000<span></span>
</td>
<td class="nump">59,843,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Deficit</a></td>
<td class="nump">232,710,000<span></span>
</td>
<td class="nump">234,307,000<span></span>
</td>
<td class="nump">235,537,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="nump">306,450,000<span></span>
</td>
<td class="nump">304,465,000<span></span>
</td>
<td class="nump">$ 295,380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">19,847<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">404,021<span></span>
</td>
<td class="nump">744,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">423,868<span></span>
</td>
<td class="nump">934,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">237,612,743<span></span>
</td>
<td class="nump">236,684,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,302,429<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">1,217,031<span></span>
</td>
<td class="nump">107,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccruedOfferingCosts', window );">Accrued offering costs</a></td>
<td class="nump">314,154<span></span>
</td>
<td class="nump">314,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty', window );">Convertible promissory note</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="nump">88,294<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative - Forward Purchase and Backstop Securities</a></td>
<td class="nump">1,595,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,267,408<span></span>
</td>
<td class="nump">438,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">4,025,000<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,292,408<span></span>
</td>
<td class="nump">8,488,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value</a></td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(13,869,115)<span></span>
</td>
<td class="num">(7,554,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Deficit</a></td>
<td class="num">(13,868,540)<span></span>
</td>
<td class="num">(7,553,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="nump">237,612,743<span></span>
</td>
<td class="nump">236,684,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember', window );">Class A Common Stock Subject to Redemption | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued expense as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering costs accrued but not yet paid as of the period date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable current asset and business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable non current asset and business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the derivative - forward purchase and backstop securities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer), excluding the amount due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransactionCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransactionCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494117536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - Avista Public Acquisition Corp. II [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Class A common stock par value subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember', window );">Class A Common Stock Subject to Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Class A common stock par value subject to possible redemption</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ClassCommonStockSharesNotSubjectToRedemptionMember', window );">Class A Common Stock Not Subject to Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_ClassCommonStockSharesNotSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_ClassCommonStockSharesNotSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490333840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,910,000<span></span>
</td>
<td class="nump">$ 6,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,732,000<span></span>
</td>
<td class="nump">$ 19,468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,748,000<span></span>
</td>
<td class="nump">$ 23,268,000<span></span>
</td>
<td class="nump">$ 18,318,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,189,000<span></span>
</td>
<td class="nump">9,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,445,000<span></span>
</td>
<td class="nump">28,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,232,000<span></span>
</td>
<td class="nump">24,796,000<span></span>
</td>
<td class="nump">13,208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,582,000<span></span>
</td>
<td class="nump">3,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,697,000<span></span>
</td>
<td class="nump">12,603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,947,000<span></span>
</td>
<td class="nump">10,225,000<span></span>
</td>
<td class="nump">8,651,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">3,256,000<span></span>
</td>
<td class="nump">3,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,774,000<span></span>
</td>
<td class="nump">9,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,968,000<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="nump">10,304,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense (income), net</a></td>
<td class="num">(208,000)<span></span>
</td>
<td class="num">(817,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486,000)<span></span>
</td>
<td class="num">(546,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="num">(818,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,819,000<span></span>
</td>
<td class="nump">16,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,430,000<span></span>
</td>
<td class="nump">50,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,357,000<span></span>
</td>
<td class="nump">48,891,000<span></span>
</td>
<td class="nump">31,345,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,909,000)<span></span>
</td>
<td class="num">(9,806,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,698,000)<span></span>
</td>
<td class="num">(30,536,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,609,000)<span></span>
</td>
<td class="num">(25,623,000)<span></span>
</td>
<td class="num">(13,027,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259,000<span></span>
</td>
<td class="nump">1,895,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(14,909,000)<span></span>
</td>
<td class="num">(9,806,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,698,000)<span></span>
</td>
<td class="num">(30,542,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,350,000)<span></span>
</td>
<td class="num">(23,728,000)<span></span>
</td>
<td class="num">(13,027,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">2,313,000<span></span>
</td>
<td class="nump">1,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,544,000<span></span>
</td>
<td class="nump">6,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,308,000<span></span>
</td>
<td class="nump">6,171,000<span></span>
</td>
<td class="num">(562,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,596,000)<span></span>
</td>
<td class="num">(7,890,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,154,000)<span></span>
</td>
<td class="num">(23,970,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,042,000)<span></span>
</td>
<td class="num">(17,557,000)<span></span>
</td>
<td class="num">(13,589,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,928,000<span></span>
</td>
<td class="nump">4,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,922,000<span></span>
</td>
<td class="nump">14,254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,084,000<span></span>
</td>
<td class="nump">11,883,000<span></span>
</td>
<td class="nump">5,568,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneRevenueMember', window );">License And Milestone Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,826,000<span></span>
</td>
<td class="nump">5,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,664,000<span></span>
</td>
<td class="nump">$ 11,385,000<span></span>
</td>
<td class="nump">$ 12,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">582,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Formation and operating costs</a></td>
<td class="nump">2,344,863<span></span>
</td>
<td class="nump">170,579<span></span>
</td>
<td class="nump">$ 180,550<span></span>
</td>
<td class="nump">8,744,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,344,863)<span></span>
</td>
<td class="num">(170,579)<span></span>
</td>
<td class="num">(180,550)<span></span>
</td>
<td class="num">(8,744,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investments held in Trust Account</a></td>
<td class="nump">1,090,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,438,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss', window );">Change in fair value of Forward Purchase and Backstop Securities</a></td>
<td class="num">(1,212,110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,147,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,466,430)<span></span>
</td>
<td class="num">(170,579)<span></span>
</td>
<td class="num">(180,550)<span></span>
</td>
<td class="num">(8,452,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (516,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NetIncomeLossAttributableToOrdinaryShareholders', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (2,466,430)<span></span>
</td>
<td class="num">$ (170,579)<span></span>
</td>
<td class="num">$ (180,550)<span></span>
</td>
<td class="num">$ (8,677,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">12,250,000<span></span>
</td>
<td class="nump">4,755,274<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">12,250,000<span></span>
</td>
<td class="nump">4,755,274<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,399,457<span></span>
</td>
<td class="nump">5,155,063<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,399,457<span></span>
</td>
<td class="nump">5,155,063<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividends related to the Forward Purchase and Backstop Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives - Forward Purchase and Backstop Securities recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NetIncomeLossAttributableToOrdinaryShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to ordinary shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NetIncomeLossAttributableToOrdinaryShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489196656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Avista Public Acquisition Corp. II [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Avista Public Acquisition Corp. II [Member]</div>
</th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Avista Public Acquisition Corp. II [Member]</div>
</th>
<th class="th">
<div>Common Class A [Member] </div>
<div>Common Stock [Member] </div>
<div>Avista Public Acquisition Corp. II [Member]</div>
</th>
<th class="th">
<div>Common Class B [Member] </div>
<div>Common Stock [Member] </div>
<div>Avista Public Acquisition Corp. II [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2018</a></td>
<td class="nump">$ 204,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,589,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2019</a></td>
<td class="nump">218,243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,557,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2020</a></td>
<td class="nump">235,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,455,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2021</a></td>
<td class="nump">227,600,000<span></span>
</td>
<td class="nump">$ 17,214<span></span>
</td>
<td class="nump">$ 24,425<span></span>
</td>
<td class="num">$ (7,786)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">235,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,970,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Sep. 30, 2021</a></td>
<td class="nump">228,002,000<span></span>
</td>
<td class="num">(6,903,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,904,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">235,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,593,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,042,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">234,307,000<span></span>
</td>
<td class="num">(7,553,698)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,554,273)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class B ordinary shares to Sponsor (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,786)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2021</a></td>
<td class="nump">227,600,000<span></span>
</td>
<td class="nump">17,214<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="num">(7,786)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,307,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters', window );">Waiver of deferred underwriting commissions by underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Sep. 30, 2021</a></td>
<td class="nump">228,002,000<span></span>
</td>
<td class="num">(6,903,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,904,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Feb. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class B ordinary shares to Sponsor (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,593,235)<span></span>
</td>
<td class="num">(21,555,404)<span></span>
</td>
<td class="num">(7,037,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,232,604<span></span>
</td>
<td class="nump">9,232,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,298,375<span></span>
</td>
<td class="nump">12,298,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516,442)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(516,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">234,307,000<span></span>
</td>
<td class="num">(7,553,698)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,554,273)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Mar. 31, 2021</a></td>
<td class="nump">227,600,000<span></span>
</td>
<td class="nump">17,214<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="num">(7,786)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,625,000)<span></span>
</td>
<td class="num">(2,185)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2021</a></td>
<td class="nump">226,403,000<span></span>
</td>
<td class="nump">15,029<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="num">(9,971)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,245,327<span></span>
</td>
<td class="nump">9,245,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,314,397<span></span>
</td>
<td class="nump">12,314,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Class A ordinary shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,307,828)<span></span>
</td>
<td class="num">(21,584,149)<span></span>
</td>
<td class="num">(6,723,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,890,000)<span></span>
</td>
<td class="num">(170,579)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(170,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Sep. 30, 2021</a></td>
<td class="nump">228,002,000<span></span>
</td>
<td class="num">(6,903,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,904,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">234,307,000<span></span>
</td>
<td class="num">(7,553,698)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,554,273)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ReclassificationOfForwardPurchaseAgreement', window );">Reclassification of Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,282,000)<span></span>
</td>
<td class="num">(4,361,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,361,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2022</a></td>
<td class="nump">224,921,000<span></span>
</td>
<td class="num">(12,363,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,363,893)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">234,307,000<span></span>
</td>
<td class="num">(7,553,698)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,554,273)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,438,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters', window );">Waiver of deferred underwriting commissions by underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,154,000)<span></span>
</td>
<td class="num">(8,452,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Sep. 30, 2022</a></td>
<td class="nump">232,710,000<span></span>
</td>
<td class="num">(13,868,540)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,869,115)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Mar. 31, 2022</a></td>
<td class="nump">224,921,000<span></span>
</td>
<td class="num">(12,363,318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,363,893)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,276,000)<span></span>
</td>
<td class="num">(1,624,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,624,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2022</a></td>
<td class="nump">226,943,000<span></span>
</td>
<td class="num">(14,336,566)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,337,141)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,090,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,090,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters', window );">Waiver of deferred underwriting commissions by underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend - Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,596,000)<span></span>
</td>
<td class="num">(2,466,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,466,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Sep. 30, 2022</a></td>
<td class="nump">$ 232,710,000<span></span>
</td>
<td class="num">$ (13,868,540)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (13,869,115)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accretion of Class A ordinary shares subject to redemption to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividends related to the Forward Purchase and Backstop Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ReclassificationOfForwardPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of reclassification of forward purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ReclassificationOfForwardPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Underwriting commission waived by Underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WaiverOfUnderwritingCommissionByUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=SL6757427-112606<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490739680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning</a></td>
<td class="nump">$ 226,943<span></span>
</td>
<td class="nump">$ 224,921<span></span>
</td>
<td class="nump">$ 234,307<span></span>
</td>
<td class="nump">$ 226,403<span></span>
</td>
<td class="nump">$ 227,600<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 218,243<span></span>
</td>
<td class="nump">$ 204,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (as restated)</a></td>
<td class="num">(12,596)<span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
<td class="num">(6,282)<span></span>
</td>
<td class="num">(7,890)<span></span>
</td>
<td class="num">(8,625)<span></span>
</td>
<td class="num">(7,455)<span></span>
</td>
<td class="num">(27,042)<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Parent allocation of share-based compensation</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="nump">3,848<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">3,379<span></span>
</td>
<td class="nump">15,065<span></span>
</td>
<td class="nump">9,165<span></span>
</td>
<td class="nump">6,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncreaseInEquityContributionFromParent', window );">Net transfers from parent company (as restated)</a></td>
<td class="nump">13,084<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
<td class="nump">5,680<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
<td class="num">(3,861)<span></span>
</td>
<td class="nump">10,747<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end</a></td>
<td class="nump">$ 232,710<span></span>
</td>
<td class="nump">$ 226,943<span></span>
</td>
<td class="nump">$ 224,921<span></span>
</td>
<td class="nump">$ 228,002<span></span>
</td>
<td class="nump">$ 226,403<span></span>
</td>
<td class="nump">$ 227,600<span></span>
</td>
<td class="nump">$ 234,307<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 218,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_IncreaseInEquityContributionFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in equity contribution from parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_IncreaseInEquityContributionFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489677776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,154,000)<span></span>
</td>
<td class="num">$ (23,970,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,042,000)<span></span>
</td>
<td class="num">$ (17,557,000)<span></span>
</td>
<td class="num">$ (13,589,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487,000)<span></span>
</td>
<td class="num">(546,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="num">(818,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,429,000<span></span>
</td>
<td class="nump">13,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,252,000<span></span>
</td>
<td class="nump">13,137,000<span></span>
</td>
<td class="nump">10,917,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 5,279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,273,000<span></span>
</td>
<td class="nump">11,605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,065,000<span></span>
</td>
<td class="nump">9,165,000<span></span>
</td>
<td class="nump">6,660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,840,000)<span></span>
</td>
<td class="num">(6,325,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,325,000)<span></span>
</td>
<td class="num">(6,185,000)<span></span>
</td>
<td class="nump">557,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain from short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,265,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intellectual property license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,610,000<span></span>
</td>
<td class="nump">12,721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,019,000<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
<td class="num">(4,290,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(817,000)<span></span>
</td>
<td class="num">(188,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632,000)<span></span>
</td>
<td class="num">(497,000)<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(938,000)<span></span>
</td>
<td class="nump">1,621,000<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,000<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,000<span></span>
</td>
<td class="nump">2,759,000<span></span>
</td>
<td class="num">(570,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,384,000)<span></span>
</td>
<td class="num">(5,118,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,717,000)<span></span>
</td>
<td class="nump">1,328,000<span></span>
</td>
<td class="num">(1,875,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872,000<span></span>
</td>
<td class="num">(3,953,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,876,000)<span></span>
</td>
<td class="num">(822,000)<span></span>
</td>
<td class="num">(2,153,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,556,000<span></span>
</td>
<td class="num">(1,232,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,672,000)<span></span>
</td>
<td class="nump">3,619,000<span></span>
</td>
<td class="num">(5,195,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,152,000)<span></span>
</td>
<td class="num">(2,548,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,070,000)<span></span>
</td>
<td class="num">(1,753,000)<span></span>
</td>
<td class="num">(255,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payments to CVR holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired', window );">Cash paid for acquisitions, net of cash and restricted cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,127,000)<span></span>
</td>
<td class="num">(11,840,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intellectual property license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OtherInvestingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,112,000)<span></span>
</td>
<td class="num">(2,548,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,025,000)<span></span>
</td>
<td class="num">(26,980,000)<span></span>
</td>
<td class="num">(12,095,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,183,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments to CVR holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,545,000)<span></span>
</td>
<td class="num">(1,050,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,050,000)<span></span>
</td>
<td class="num">(2,325,000)<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Deferred transaction cost payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,183,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,284,000<span></span>
</td>
<td class="nump">4,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,747,000<span></span>
</td>
<td class="nump">25,686,000<span></span>
</td>
<td class="nump">20,290,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,556,000<span></span>
</td>
<td class="nump">3,780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,697,000<span></span>
</td>
<td class="nump">23,361,000<span></span>
</td>
<td class="nump">17,290,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenueRecordedInAccountsReceivable', window );">Deferred revenue recorded in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,344,000<span></span>
</td>
<td class="nump">8,451,000<span></span>
</td>
<td class="nump">1,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of fixed assets recorded in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,561,000<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,550)<span></span>
</td>
<td class="num">(8,452,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investments held in Trust Account</a></td>
<td class="num">(1,090,543)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,438,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss', window );">Change in fair value of Forward Purchase and Backstop Securities</a></td>
<td class="nump">1,212,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,147,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(880,112)<span></span>
</td>
<td class="nump">340,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(744,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,292<span></span>
</td>
<td class="nump">6,286,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty', window );">Accrued expenses - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,988<span></span>
</td>
<td class="nump">1,109,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(966,382)<span></span>
</td>
<td class="num">(920,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,136,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PaymentsForInvestmentOfCashInTrustAccount', window );">Investment of cash into Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,750,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,750,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,750,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,750,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,275<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ProceedsFromIssuanceInitialPublicOfferingNet', window );">Proceeds from initial public offering, net of underwriter's discount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,350,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(615,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(698,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_RepaymentFromRelatedPartyDebt', window );">Repayment of Sponsor note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Deferred transaction cost payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(615,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(698,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,078,585<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,076,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,203<span></span>
</td>
<td class="num">(170,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">19,847<span></span>
</td>
<td class="nump">362,203<span></span>
</td>
<td class="nump">19,847<span></span>
</td>
<td class="nump">$ 362,203<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="nump">1,090,544<span></span>
</td>
<td class="nump">28,307,827<span></span>
</td>
<td class="nump">1,438,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,593,235<span></span>
</td>
<td class="nump">$ 28,593,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities', window );">Initial classification of the Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">448,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters', window );">Waiver of deferred underwriting commissions by underwriter</a></td>
<td class="nump">$ 4,025,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty', window );">Offering costs paid by Sponsor and included in promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,725<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses', window );">Offering costs included in accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares', window );">Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accretion of Class A ordinary shares subject to redemption to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for acquisitions, net of cash and restricted cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Deferred offering costs included in promissory note - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredRevenueRecordedInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue recorded in accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredRevenueRecordedInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives - Forward Purchase and Backstop Securities recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses of related party incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_IncreaseDecreaseInDueToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_IncreaseDecreaseInDueToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of initial classification of the Forward Purchase and Backstop Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OfferingCostsPaidInExchangesForIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs paid in exchange of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OfferingCostsPaidInExchangesForIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PaymentsForInvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for investment of cash in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PaymentsForInvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ProceedsFromIssuanceInitialPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash inflow from initial public offering after deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ProceedsFromIssuanceInitialPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_RepaymentFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment from related party debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_RepaymentFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WaiverOfUnderwritingCommissionByUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Underwriting commission waived by Underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WaiverOfUnderwritingCommissionByUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497736384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANISATION AND NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANISATION AND NATURE OF OPERATIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Nature of Operations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Parent&#8221;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#8220;OmniAb&#8221;, &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221;). OmniAb is powered by Biological Intelligence, a multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand completed a multi-step transaction that resulted in Ligand&#8217;s acquisition of OMT. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;1, 2022, Ligand completed (the &#8220;Closing&#8221;) the separation of its antibody discovery business and certain related assets and liabilities through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">spin-off</div> of OmniAb to Ligand&#8217;s shareholders of record as of October&#160;26, 2022 on a pro rata basis and merger of OmniAb with a wholly owned subsidiary of OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II, a Cayman Islands exempted company, prior to its domestication as a corporation incorporated in the state of Delaware (&#8220;APAC&#8221;)) in a Reverse Morris Trust transaction pursuant to the Agreement and Plan of Merger, dated as of March 23, 2022 (the &#8220;Merger Agreement&#8221;), among Ligand, OmniAb, APAC and Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of APAC, and the Separation and Distribution Agreement, dated as of March 23, 2022 (the &#8220;Separation Agreement&#8221;), among Ligand, OmniAb and APAC. The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#8220;New OmniAb&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Closing, New OmniAb expected to have approximately $95.8 million of net cash. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;2, 2022, New OmniAb began <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">regular-way</div> trading on NASDAQ under the ticker symbol &#8220;OABI.&#8221; Ligand continues to trade under the ticker symbol &#8220;LGND.&#8221; See further details regarding the transaction in Note 9: Subsequent Event. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div id="prewrkfin305908_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Nature of Operations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Parent&#8221;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#8220;OmniAb,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;). OmniAb is a biotechnology company with a Biological Intelligence powered multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand acquired OMT, pursuant to a multi-step transaction that resulted in Ligand&#8217;s acquisition of OMT. On November&#160;10, 2021 OMT&#8217;s name was changed to OmniAb, Inc. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANISATION AND NATURE OF OPERATIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avista Public Acquisition Corp. II was a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. As used herein, the references to the &#8220;Company&#8221; are to Avista Public Acquisition Corp. II, prior to its domestication as a corporation incorporated in the state of Delaware and change of name to OmniAb, Inc., and its then wholly-owned and controlled subsidiary, Orwell Merger Sub Inc. (&#8220;Merger Sub&#8221;), unless the context indicates otherwise. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#8220;Business Combination&#8221;). The Company was not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company was an early stage and emerging growth company and, as such, the Company was subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through September&#160;30, 2022 related to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination, which is described below. The Company generated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest and dividend income or gains on investments on the cash and investments held in the Trust Account (as defined below) from the proceeds derived from the Initial Public Offering. The Company had selected December&#160;31 as its fiscal year end. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of 23,000,000 units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including 3,000,000 Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note&#160;3). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#8220;Private Placement Warrants&#8221;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $12,350,000 (see Note&#160;4). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, cash of $19,847 was held outside of the Trust Account and was available for the payment of accrued offering costs and for working capital purposes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and invested in only in U.S. government treasury obligations with maturities of 185 days or less or in money market funds meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public&#160;Offering, (ii)&#160;the redemption of the Company&#8217;s Public Shares if the Company had not consummated an Business Combination within 18 months from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#8217;s Public Shares if the Company did </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not complete the initial Business Combination within 18 months from the closing the Company&#8217;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company provided its holders of the outstanding Public Shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision was made by the Company to seek shareholder approval of a Business Combination. The Public Shareholders were entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro rata interest and dividends or gains on investments earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There were no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company proceeded with the Business Combination as the Company had net tangible assets of at least $5,000,001 upon consummation of the Business Combination and at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60239967">two</span>-thirds</div> of the shares voted were voted in favor of the Business Combination. As the Company decided to obtain shareholder approval the Company offered to redeem shares in conjunction with the proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. The Sponsor agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of the Business Combination. Additionally, each Public Shareholder was given the option to redeem their Public Shares irrespective of whether they voted for or against the proposed transaction or didn&#8217;t vote at all. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of the Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company did not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company failed to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor had acquired Public Shares in or after the Initial Public Offering, such Public Shares would have been be entitled to liquidating distributions from the Trust Account if the Company failed to complete a Business Combination within 18 months from the closing of the Initial Public Offering. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company was unable to complete a Business Combination within the Combination Period, the Company would have (i)&#160;ceased all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:hidden60239959">ten </span>business&#160;days thereafter, redeemed the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption would have completely extinguished Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidated and dissolved, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There would have been be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which would have expired worthless if the Company failed to complete a Business Combination within the Combination Period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters have agreed to waive their rights to a portion of their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company did not complete a Business Combination within the Combination Period and, in such event, such amounts would have been included with the other funds held in the Trust Account that would have been available to fund the redemption of the Public Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb Business Combination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb, Inc., a Delaware corporation and then wholly-owned subsidiary of Ligand (&#8220;Legacy OmniAb&#8221;), and Orwell Merger Sub Inc. (&#8220;Merger Sub&#8221;), pursuant to which the Company combined with Legacy OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, Legacy OmniAb and Merger Sub entered into that certain Employee Matters Agreement, as amended by that certain Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022 (the &#8220;Employee Matters Agreement&#8221;), (b) Legacy OmniAb and the Sponsor entered into that certain Sponsor Insider Letter Agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c)&#160;the Company amended and restated that certain previously disclosed Forward Purchase Agreement, dated August&#160;9, 2021, by entering into the Amended and Restated Forward Purchase Agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company, the Sponsor and Legacy OmniAb pursuant to which they consummated the OmniAb Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and Legacy OmniAb (the &#8220;Separation Agreement&#8221;), Ligand transferred the OmniAb Business, including certain related subsidiaries of Ligand, to Legacy OmniAb and, in connection therewith, distributed (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of Legacy OmniAb, par value $0.001 per share (the &#8220;Legacy OmniAb Common Stock&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Legacy OmniAb (the &#8220;Merger&#8221;), with Legacy OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement, along with the Separation Agreement and the other transaction documents entered into in connection therewith, provided for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i) the Company redomiciled by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) (the &#8220;Domestication&#8221;), (ii) Ligand transferred the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, Legacy OmniAb, and contributed $15&#160;million in capital thereto (less certain reimbursable transaction and other expenses), and (iii)&#160;following the Separation, Ligand distributed 100% of the shares of Legacy OmniAb Common Stock to Ligand stockholders by way of the Distribution. Following the completion of </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties consummated the Merger. The Distribution and Merger are intended to qualify as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;tax-free&#8221;</div> transactions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;28, 2022, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-264525)</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Form&#160;S-4&#8221;,</div> as amended on June&#160;13, 2022, July&#160;26, 2022, August&#160;22, 2022, September&#160;13, 2022 and September&#160;27, 2022) with the SEC, which includes the proxy statement/prospectus/information statement distributed to holders of the Company&#8217;s ordinary shares in connection with the Company&#8217;s solicitation for proxies for the vote by the Company&#8217;s shareholders in connection with the OmniAb Business Combination and other matters as described in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4.</div> The Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> was declared effective by the SEC on September&#160;30, 2022, and the definitive proxy statement/prospectus/information statement was mailed to the Company&#8217;s shareholders of record on the record date for voting on the OmniAb Business Combination. The OmniAb Business Combination closed on November&#160;1, 2022. Upon consummation of the OmniAb Business Combination, and after the Domestication, the Company has one class of common stock, par value $0.0001 per share, which is listed on Nasdaq under the ticker symbol &#8220;OABI&#8221;. The Company&#8217;s warrants are listed on Nasdaq under the ticker symbol &#8220;OABIW&#8221;. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP, whereby the Company is treated as the acquired company and Legacy OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy OmniAb issuing stock for the net assets of the Company, accompanied by a recapitalization. The net assets of the Company were stated at historical cost, with no goodwill or other intangible assets recorded. Subsequent presentations of the results of operations presented for the period prior to the Business Combination will be for those of Legacy OmniAb. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb&#8217;s existing stockholders have the greatest voting interest in the combined entity; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb has the ability to nominate a majority of the initial members of the OmniAb Board; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb&#8217;s senior management is the senior management of the combined entity; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy OmniAb is the larger entity based on historical operating activity and has the larger employee base; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The post-combination company has assumed a Legacy OmniAb branded name: &#8220;OmniAb, Inc.&#8221; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreement and Plan of Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the closing of the OmniAb Business Combination, each share of Legacy OmniAb&#8217;s common stock outstanding prior to the effective time of the OmniAb Business Combination was converted on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis into shares of common stock in the newly formed company (&#8220;OmniAb Common Stock&#8221;). Holders of Legacy OmniAb options, restricted stock units and performance stock units (determined after the Distribution (as defined below) and the division of Ligand equity awards into Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) had their awards converted into equity awards of the Company and adjusted pursuant to the exchange ratio. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, at the closing of the OmniAb Business Combination, holders of Legacy OmniAb Common Stock and equity awards received shares of OmniAb Common Stock subject to certain price-based earnout triggers (&#8220;Earnout Shares&#8221;), with 50% of such Earnout Shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $12.50 per share of OmniAb Common Stock for </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, and the remainder vesting upon achievement of a post-transaction VWAP of $15 per share of OmniAb Common Stock for any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, in each case provided such vesting occurs during the five-year period following the closing of the OmniAb Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the OmniAb Business Combination, upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> of the Company to Delaware (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares converted automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into shares of OmniAb Common Stock, (ii)&#160;all issued and outstanding warrants converted automatically into warrants to acquire shares of OmniAb Common Stock and (iii)&#160;all issued and outstanding Units separated and converted automatically into one share of OmniAb Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one warrant to purchase OmniAb Common Stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Separation and Distribution Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Seperation Agreement, pursuant to which the Separation and Distribution were effected. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Separation Agreement also sets forth other agreements among Ligand and Legacy OmniAb, including provisions concerning the termination and settlement of intercompany accounts and the obtaining of necessary governmental approvals and third-party consents. The Separation Agreement also sets forth agreements that will govern certain aspects of the relationship between Ligand and Legacy OmniAb after the Distribution, including provisions with respect to release of claims, indemnification, access to financial and other information and access to and provision of records. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Matters Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Employee Matters Agreement, as amended by the Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022, which provides for employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and Legacy OmniAb, treatment of incentive equity awards in the Distribution and the OmniAb Business Combination and related covenants and commitments of the parties. Each existing Ligand equity award at the time of the Distribution granted prior to March&#160;2, 2022, with certain limited exceptions, was split into (i)&#160;a new Ligand equity award and (ii)&#160;a new Legacy OmniAb equity award, with any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> value in the original Ligand equity award split between such awards based on the relative values of Ligand and OmniAb at the time of the Distribution. Each existing Ligand equity award at the time of the Distribution granted on or after March&#160;2, 2022 was converted into either an adjusted Ligand equity award, if the holder was a Ligand service provider following the Distribution, or a Legacy OmniAb equity award, if the holder was a Legacy OmniAb service provider following the Distribution. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Insider Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Legacy OmniAb and the Sponsor entered into the Sponsor Insider Agreement with the Company and the Insiders, pursuant to which, among other things, the Insiders agreed to vote any of our securities held by them to approve the OmniAb Business Combination and the other Company shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their Company securities in connection with the consummation of the OmniAb Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to 1,916,667 Earnout Founder Shares (as defined in the Sponsor Insider Agreement), to the same price-based vesting conditions as the OmniAb Earnout Shares. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Forward Purchase Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into Amended and Restated Forward Purchase Agreement (the &#8220;A&amp;R FPA&#8221;) with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;R FPA, the Company agreed to, in connection with the consummation of the OmniAb Business Combination, issue and sell to the Sponsor 1,500,000 shares of OmniAb Common Stock (the &#8220;Forward Purchase Shares&#8221;) and warrants to acquire 1,666,667 shares of OmniAb Common Stock (the &#8220;Forward Purchase Warrants&#8221;) for an aggregate purchase price of $15.0&#160;million with such purchases having been consummated immediately following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> to Delaware. In addition, the Sponsor agreed to purchase up to an additional 10,000,000 shares of OmniAb Common Stock (the &#8220;Backstop Shares&#8221;) and up to an additional 1,666,667 warrants, (The &#8220;Backstop Warrants&#8221; and, together with the Forward Purchase Shares, Forward Purchase Warrants and Backstop Shares, the &#8220;Forward Purchase and Backstop Securities&#8221;) for an aggregate additional purchase price of up to $100.0&#160;million, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $100.0&#160;million. Pursuant to the A&amp;R FPA, in connection with the Business Combination, the Sponsor was issued 8,672,934 Backstop Shares and 1,445,489 Backstop Warrants for an aggregate purchase price of $86,729,340 in order to backstop the redemptions. In addition, pursuant to the A&amp;R FPA, the Sponsor was issued 1,500,000 Forward Purchase Shares and 1,666,667 Forward Purchase Warrants for an aggregate purchase price of $15,000,000, on a private placement basis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern Consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had $19,847 in cash held outside of the Trust Account and a working capital deficit of $9,843,540. The Company incurred significant costs in pursuit of its acquisition plans. In connection with the Company&#8217;s assessment of going concern considerations in accordance with FASB&#8217;s ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Presentation of Financial Statements - Going Concern, management has determined those conditions raised substantial doubt about the Company&#8217;s ability to continue as a going concern within the earlier of the Combination Period, which will end on February&#160;12, 2023, or one year after the date that the condensed consolidated financial statements are issued. Moreover, the Company needed to obtain additional financing to complete the Business Combination and to redeem 21,713,864 public shares upon completion of the Business </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Combination, in which case the Company issued additional securities in connection with the Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2&#160;million was deposited in an operating account for the Company&#8217;s working capital needs. In addition, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $750,000. As of September&#160;30, 2022, the Company has borrowed $750,000 under the Sponsor Working Capital Loan. The amounts held in the operating account were not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the remainder of the Combination Period. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry, the geopolitical conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals and entities and the status of debt and equity markets and has concluded that while it is reasonably possible that any of the foregoing could have a negative effect on the Company&#8217;s financial position and results of its operations, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a 1% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> U.S. corporations beginning in 2023, with certain exceptions (the &#8220;Excise Tax&#8221;). Because the Company became a Delaware corporation upon the Domestication and the securities traded on Nasdaq, we would have likely been considered a &#8220;covered corporation&#8221; within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax would have applied to any redemptions of our common stock after December&#160;31, 2022, including redemptions in connection with an initial Business Combination and any amendment to a certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (a &#8220;Business Combination&#8221;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of 23,000,000&#160;units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including 3,000,000&#160;Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note 3). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#8220;Private Placement Warrants&#8221;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $12,350,000 (see Note 4). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $13,662,256 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $1,012,256 of other offering costs. In addition, as of December&#160;31, 2021, cash of $189,971 is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and will be invested only in U.S. government treasury obligations with maturities of 185&#160;days or less or in money market funds meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public Offering, (ii)&#160;the redemption of the Company&#8217;s Public Shares if the Company has not consummated an Business Combination within 18 months from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#8217;s Public Shares if the Company does not complete the initial Business Combination within 18 months from the closing the Company&#8217;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The public shareholders will be entitled to redeem their Public Shares for a pro&#160;rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro&#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#8220;Amended and Restated Memorandum and Articles of Association&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#8217;t vote at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor acquires </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within 18 months from the closing of the Initial Public Offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:hidden60240023">ten </span>business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2&#160;million was deposited in an operating account for the Company&#8217;s working capital needs. The amounts held in the operating account are not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve&#160;months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern Consideration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497503008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Restatement of Previously Issued Combined Financial Statements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Restatement of Previously Issued Combined Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subsequent to the issuance of the audited combined financial statements for the year ended December&#160;31, 2020 and 2019, the Company determined the balance of accounts receivable, net, as of December&#160;31, 2020, was understated by $7.0&#160;million and general and administrative expense was understated by $0.7&#160;million for the year ended December&#160;31, 2019. The error as of December&#160;31, 2020 was the result of the omission of an unbilled amount which was also improperly excluded from net transfers from parent company in the combined statement of changes in parent company net investment for the year ended December&#160;31, 2020, resulting in an understatement of parent company net investment. The error as of December&#160;31, 2019 related to bad debt expense that was not properly included in general and administrative expense on the combined statements of operations and was improperly recorded as part of the net transfers from parent company in the combined statements of changes in parent company net investment. The errors identified as of December&#160;31, 2020 and 2019, each resulted in the overstatement of cash provided by operating activities and an understatement of cash provided by financing activities in the combined statements of cash flows, in the respective periods. The Company has concluded that the errors identified were material to the combined financial statements as of and for the year ended December&#160;31, 2020 and 2019. Accordingly, previously reported amounts have been revised to reflect the correction of the error as well as other immaterial errors identified through the process of compiling the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">carve-out</div> financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the revised results for the year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,796</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;January 1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(225</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,779</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the revised results for the year ended December&#160;31, 2019, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,924</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,685</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,976</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,386</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,386</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(657</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(562</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,565</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(648</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(570</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(450</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(604</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497735552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s interim condensed combined financial statement accounting records. The interim condensed combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records certain transactions at the parent entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January 2016. Transactions between Ligand and the Company are accounted for through the Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The interim condensed combined financial statements include all revenues, expenses, assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a percentage of total operating expenses or other measures that management believes are consistent and reasonable. See Note 8. Relationship with Parent and Related Entities<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. The share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See Note 8. Relationship with Parent and Related Entities for additional discussion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the interim condensed combined financial statements are based on assumptions that management believes are reasonable. However, the interim condensed combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Financial Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined balance sheet as of September&#160;30, 2022, the condensed combined statements of operations, condensed combined statements of changes in parent company net investment for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed combined statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related footnote disclosures are unaudited. In management&#8217;s opinion, the unaudited interim combined financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, its results of operations for the three and nine months ended September&#160;30, 2022 and 2021, and its statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 in accordance with U.S. GAAP. The results for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. Therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of Parent company net investment in the combined balance sheets and as a financing activity allocation on the accompanying combined statements of cash flows. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s revenue was $23.7&#160;million and $19.5&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s net loss was $(29.2) million and $(24.0) million, respectively. OmniAb expects to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the merger between the Company and a subsidiary of APAC, New OmniAb was capitalized with approximately $95.8 million in net cash. This cash and cash the Company generates from operations provide us the flexibility we need to meet operating, investing, and financing needs and support operations through at least 12 months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have described our significant accounting policies in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Summary of Significant Accounting Policies</div></div> of the Notes to Combined Financial Statements included in the registration statement on Form S-4 filed on September 27, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of interim condensed combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the interim condensed combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the three and nine months ended September&#160;30, 2022, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and the allowance for credit losses was $0.1&#160;million as of September&#160;30, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, we have generated revenue from intellectual property and development milestones, and have only recently begun to generate revenue from commercial milestone payments and royalties on product sales this year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and the milestone is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval. </div></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the three and nine months ended </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022, the amount recognized as revenue that was previously deferred was $4.0&#160;million and $9.9&#160;million, respectively. During the three and nine months ended September&#160;30, 2021, the amount recognized as revenue that was previously deferred was $2.4&#160;million and $5.2&#160;million, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation&#160;of&#160;Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;23,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;19,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div> for additional discussion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s net loss was ($27.0 million), ($17.6 million) and ($13.6 million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb qualifies as an &#8220;emerging growth company&#8221; (EGC) as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb&#8217;s historical results are included as a part of the Parent&#8217;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This may make comparison of OmniAb&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#8217;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Business Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year-ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A, B and C in 2019 represent different customers than 2020 and 2021. </div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and recorded an adjustment of $0.1&#160;million of allowance for credit losses as of December&#160;31, 2021. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill, Intangible Assets and Other Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill attributed to OmniAb&#8217;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#8217; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgment. If our estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone <div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> regulatory approval. </div></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $7.4&#160;million. During the year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $0.4&#160;million. During the year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $2.4&#160;million. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our employees participated in our Parent&#8217;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#8217;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted stock&#160;units (RSU) and performance stock&#160;units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#8217;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#8217;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> in the period of adjustment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $2.50 per share, our Parent has not paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We grant options, RSUs and PSUs to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under Ligand&#8217;s equity plan. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> directors are accounted for as employees. Options and RSUs granted to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors typically vest one year from the date of grant. <div style="letter-spacing: 0px; top: 0px;;display:inline;">Options granted to employees typically vest&#160;1/8 on the six m</div>onth anniversary of the date of grant, and 1/48 each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two</div> months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;Topic 740&#8221;). Accordingly, our income tax provision was prepared following the &#8220;Separate Return Method.&#8221; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#8217;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> initially, including issuing varying forms of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;stay-at-home&#8221;</div></div> orders, and restricting business functions outside of one&#8217;s home. We have generally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could have on our business in the future, the continued spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4,</div> of which this proxy statement/prospectus/information statement forms a part. </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> as filed with the SEC on March&#160;28, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The valuation of the Forward Purchase and Backstop Securities required management to exercise significant judgement in its estimate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 or </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">December&#160;31, 2021. As <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div>September&#160;30, 2022 and December&#160;31, 2021, the Company had operating cash (i.e., cash held outside the Trust Account) of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$19,847<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$189,971, respectively. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in Trust Account </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury bills. The Company&#8217;s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in gain on investments held in Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of the investments held in the Trust Account are determined using available market information. At December&#160;31, 2021, the assets held in the Trust Account were held in cash. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares Previously Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contained a redemption feature which allowed for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognized changes in redemption value immediately as they occurred and adjusted the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares were affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,438,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">237,188,875</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#8217;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">their right to redeem those shares for a <div style="letter-spacing: 0px; top: 0px;;display:inline;">pro </div>rata portion of the Trust Account holding the proceeds from the Company&#8217;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, Income Taxes (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed consolidated financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>no<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>unrecognized tax benefits and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>no<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>amounts accrued for interest and penalties as of September&#160;30, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Ordinary Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>15,900,000<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>shares in the calculation of diluted </div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income per share as the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;5, 2021</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,973,144</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(493,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,762,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,399,457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,755,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,155,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The Forward Purchase and Backstop Securities contained within the A&amp;R FPA (see Note 6) are classified as derivatives in the condensed consolidated balance sheet with changes in the fair value recognized in the condensed consolidated statements of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note - related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed consolidated financial statements. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs associated with the Initial Public Offering </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A&#160;&#8212;&#160;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses of Offering</div></div>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February&#160;5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman <div style="letter-spacing: 0px; top: 0px;;display:inline;">Islands </div>Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement. </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from&#160;February&#160;5,<br/>2021 (inception) Through<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(335,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(181,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,321,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note&#160;&#8212;&#160;related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;&#8212;&#160;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;&#8212;&#160;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;&#8212;&#160;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August&#160;2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#160;amends</div> the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for the Company on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549596711616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationAndAssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Acquisitions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As set forth below, we completed four acquisitions from January&#160;1, 2019 through December&#160;31, 2021, of which two (Icagen and Ab Initio) were accounted for as business combinations and Taurus and xCella were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. We did not incur any material acquisition related costs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taurus Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;9, 2020, we acquired Taurus, which discovers and humanize antibodies from immunized cows and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cow-derived</div> libraries. These antibodies feature some of the longest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CDR-H3s</div> of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The purchase price of $5.2&#160;million included $4.6&#160;million in cash, and a $0.5&#160;million holdback to satisfy indemnification obligations which were settled in September&#160;2021. Taurus stockholders also received nontransferable contingent value rights (CVRs) representing the right to receive up to $4.5&#160;million tied to partnered and internal research and development and up to $25.0&#160;million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We evaluated this acquisition in accordance with ASC 805, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations</div></div>, to discern whether the assets and operations of Taurus met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">xCella Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;8, 2020, we acquired xCella Biosciences, an antibody discovery company. xCella&#8217;s xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity which expand our existing single <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> assay capabilities in the OmniAb technology platform. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We paid $7.1&#160;million in cash (including a $0.5&#160;million holdback to satisfy indemnification obligations which was settled in September&#160;2021), and issued earnout rights for up to $5.0&#160;million tied to our use of the xCella technology for partnered research and development and for up to $25.75&#160;million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805 to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(142</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(320</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The core technology is being amortized on a straight-line basis over the estimated useful life of 15&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Icagen Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;1, 2020, we acquired the core assets of Icagen and certain of its affiliates. The Icagen Technology Platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and in silico and computational chemistry applications for the discovery of therapeutics targeting ion channel pathways. Icagen is partnered with several globally recognized pharmaceutical companies for ion channel drug discovery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The purchase price of $19.9&#160;million included $15.1&#160;million cash consideration paid upon acquisition, and a contingent earnout payment to the selling shareholders of up to $25.0&#160;million of cash payments based on certain revenue milestones with an estimated fair value of $4.8&#160;million. The fair value of the earnout liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants&#8217; cost of debt reflective of Icagen. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 5, Fair Value Measurement</div></div>, for further discussion. The liability will be periodically assessed based on events and circumstances related to the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">underlying milestones, and any change in fair value will be recorded in our combined statements of operations. The carrying amount of the liability may fluctuate significantly and the actual amount paid may be materially different than the carrying amount of the liability. The results of Icagen have been included in our results of operations since the date of acquisition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaids and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities assumed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(812</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,685</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">821</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1&#160;million of customer relationships and $1.7&#160;million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6&#160;years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years. The total acquired intangibles are being amortized on a straight-line basis over the estimated weighted average useful life of 9.7&#160;years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ab Initio Acquisition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;23, 2019, we acquired Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has licensed a patented antigen technology owned by Stanford for the discovery of therapeutic antibodies including against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">difficult-to-access</div></div> cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase price of $12.0&#160;million included $11.9&#160;million cash consideration paid upon acquisition, net of cash acquired, and a $0.15&#160;million cash holdback for potential indemnification claims. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20&#160;years. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationAndAssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination and asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationAndAssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494185568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_InitialPublicOfferingTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;3. INITIAL PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60239985">one</span>-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50&#160;per whole share (see Note 7). </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of 23,000,000&#160;Units, including 3,000,000&#160;Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden60240047">one</span>-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50 per whole share (see Note 7). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489182192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant was exercisable to purchase one Class&#160;A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company did not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants would have been used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants would have expired worthless. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant is exercisable to purchase one Class&#160;A </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549498940976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Relationship with Parent and Related Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Relationship with Parent and Related Entities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Relationship with Parent and Related Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the future by OmniAb. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Corporate Overhead </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> method based on project-related costs or other measures that management believes are consistent and reasonable. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of $1.6&#160;million and $4.9&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $0.9&#160;million and $3.8&#160;million for the three and nine months ended 2021, respectively, have been reflected in the general and administrative expenses in our interim condensed combined statements of operations for our allocated share of Parent&#8217;s corporate overhead. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Management and Financing </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We participate in Ligand&#8217;s centralized cash management and financing programs and will continue to participate in Ligand&#8217;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a Separation Agreement, entered into among Ligand, OmniAb and APAC. Completion of the separation and distribution is subject to certain conditions. The separation is anticipated to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> to Ligand stockholders. Accordingly, after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> separation, all of the related tax attributes of Ligand will remain with Ligand. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-Based Incentive Plans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our employees participate in our Parent&#8217;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options or incentive stock options, restricted stock units (RSUs), performance stock units (PSUs) and other cash-based or share-based awards. Stock options granted to our employees under the incentive plans typically vest <div style="letter-spacing: 0px; top: 0px;;display:inline;">1/8</div> on the six month anniversary of the date of grant, and <div style="letter-spacing: 0px; top: 0px;;display:inline;">1/48</div> each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two</div> months. We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation costs associated with our employees&#8217; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. The following table summarizes total share-based compensation (SBC) charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,902</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,279</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Relationship with Parent and Related Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in the future by OmniAb. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Corporate Overhead </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> method based on project-related costs or other measures that management believes are consistent and reasonable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of $6.1&#160;million, $3.6&#160;million and $2.8&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively, have been reflected in the general and administrative expenses in our combined statements of operations for our allocated share of Parent&#8217;s corporate overhead. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Management and Financing </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We participate in Ligand&#8217;s centralized cash management and financing programs and will continue to participate in Ligand&#8217;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a separation agreement, to be entered into between Ligand and OmniAb. Completion of the separation and distribution is subject to certain conditions, including final approval by Ligand&#8217;s board of directors. Ligand is targeting the separation of OmniAb during the second quarter of 2022. The separation is anticipated to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> to Ligand stockholders. Accordingly, after the anticipated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> separation, all of the related tax attributes of Ligand will remain with Ligand. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-Based Incentive Plans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our employees participate in our Parent&#8217;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options or incentive stock options, restricted stock&#160;units (RSUs), performance stock&#160;units (PSUs) and other cash-based or share-based awards. Awards granted to our employees under the incentive plans typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two months</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">.</div> We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation costs associated with our employees&#8217; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. Total costs charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations, were $15.1&#160;million ($9.0&#160;million in research and development expenses and $6.1&#160;million in general and administrative expenses), $9.2&#160;million ($5.6&#160;million in research and development expenses and $3.6&#160;million in general and administrative expenses) and $6.7&#160;million ($3.9&#160;million in research and development expenses and $2.8&#160;million in general and administrative expenses) during the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our eligible employees participate in our Parent&#8217;s ESPP. The ESPP permits eligible participants to purchase Ligand&#8217;s shares at a discount through regular payroll deductions of up to 10% of their eligible compensation during the offering period. The ESPP is typically implemented through consecutive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> offering periods. The purchase price of the shares is 85% of the lesser of the fair market value of the closing price per share on the first day of the offering period and the fair market value of the closing price per share on the last day of the offering period. No participant may purchase more than $25,000 worth of common stock per calendar year. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs charged to us related to our employees&#8217; participation in our Parent&#8217;s ESPP were $0.2&#160;million, $0.1&#160;million and $0.1&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Relationship with Parent and Related Entities</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares included an aggregate of up to 750,000 Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part, so that the holders of the Founder Shares would own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred 35,000 Class&#160;B ordinary shares each to three members of the Company&#8217;s board of directors (or 105,000 Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year&#160;after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#8217;s Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-</div> trading day period commencing at least 150 days after the OmniAb Business Combination or (2)&#160;if the Company consummates a transaction after the OmniAb Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note&#160;&#8212; Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $119,275 on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000. The Promissory Note is no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of the OmniAb Business Combination, the Company ceased paying these monthly fees. For the three months and nine months ended September&#160;30, 2022, the Company incurred expenses of $30,000 and $90,000, respectively, under the agreement. For the three months ended September&#160;30, 2021 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021 the Company incurred expenses of $20,000 under the agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party consists of payments made by the Sponsor and/or an affiliate of the Sponsor on behalf of the Company for formation and operating costs, along with the administrative support monthly fee and are payable on demand. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Promissory Note </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;working capital loans&#8221;). If the Company completed the initial Business Combination, it could repay such loaned amounts out of the proceeds of the Trust Account released to us. Otherwise, such loans could be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination did not close, the Company could use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Company&#8217;s Trust Account would be used to repay such loaned amounts. Up to $2,000,000 of such loans could have been convertible into warrants of the post-Business Combination entity at a price of $1.50&#160;per warrant at the option of the lender. The warrants would have been identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. The Company did not seek loans from parties other than the Sponsor, its affiliates or any members of the management team as the Company did not believe third parties would be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;14, 2022, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of September&#160;30, 2022, the outstanding balance on the convertible promissory note is $750,000. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;24, 2022, the board of directors elected Charles Harwood to serve as a director of the Company and appointed Mr.&#160;Harwood to serve as a member of the audit committee. The board of directors has determined that Mr.&#160;Harwood satisfies all applicable independence requirements to serve on the board of directors and the audit committee, including without limitation the applicable independence requirements of the Nasdaq Capital Market and the Exchange Act, as amended. In connection with Mr.&#160;Harwood&#8217;s appointment to the audit committee, L&#226;le White has stepped down from the audit committee, which currently consists of Wendel Barr, Charles Harwood and William Klitgaard. The changes to the audit committee&#8217;s composition relate to the Company&#8217;s communications with the staff of Nasdaq on August&#160;22, 2022, regarding whether the Company was in compliance with Nasdaq Listing Rule 5605(c)(2) following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">phase-in</div> period provided under Nasdaq Listing Rule 5615(b)(1) because the Audit Committee was not comprised of at least three independent directors. The Company is in compliance with the applicable rules following the board of directors and audit committee changes described herein. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the OmniAb Business Combination, the Company paid Mr.&#160;Harwood a $10,000 fee for his services as a director and member of the audit committee. This fee is included as part of accrued expenses on the balance sheet as of September&#160;30, 2022. In connection with Mr.&#160;Harwood&#8217;s appointment, he and the Company entered into an indemnification agreement and a letter agreement, the terms of which were described in, and the forms of which were filed as exhibits to, the Company&#8217;s registration statement relating to the Company&#8217;s Initial Public Offering. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares include an aggregate of up to 750,000 Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred 35,000 Class&#160;B ordinary shares each to three members of the Company&#8217;s board of directors (or 105,000 Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#8217;s Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20&#160;trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-</div> trading day period commencing at least <div style="letter-spacing: 0px; top: 0px;;display:inline;">150 day</div>s after an initial Business Combination or (2)&#160;if the Company consummates a transaction after an initial Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $119,275 on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $46,129 of expenses were incurred during the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s sponsor or an affiliate of the sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;Working Capital Loans&#8221;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#8217;s trust account would be used to repay such loaned amounts. Up to $2,000,000 of such loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#8217;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December&#160;31, 2021, there was no balance outstanding under the Working Capital Loans. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497243936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Income Tax </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in various state jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> expenses, stock award activities and other permanent differences between income (loss) before income taxes and taxable income. The effective tax rate for the three and nine months ended September&#160;30, 2022 was 15.5% and 18.3%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% was primarily due to the benefit related to tax credits, as well as the difference in statutory state rates and the tax impact of stock award activities. The variance is also a result of the valuation allowance established for state attributes. The effective tax rate for the three and nine months ended September&#160;30, 2021 was 19.5% and 21.5%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% was primarily due to the benefit related to tax credits, state taxes, the tax impact of stock award activities and the valuation allowance established for state attributes. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have historically operated as part of Ligand and not as a stand-alone company. We determined the OmniAb income tax provision as if OmniAb had joined in the consolidated federal income tax return and combined state income tax returns separate from Ligand. We recorded a current state income tax expense for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 for certain OmniAb state minimum taxes. We recorded a deferred federal and state income tax benefit for the year ended December&#160;31, 2021 and 2020 to reflect the change in the net deferred tax liability for the period. We recorded a deferred federal tax benefit and deferred state tax expense for the year ended December&#160;31, 2019 to reflect the change in the net deferred tax liability for the period. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,779</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(569</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at federal statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,983</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(350</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(188</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">847</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(573</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in uncertain tax positions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of the our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of the our deferred tax assets will be realized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,088</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance for deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(526</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(403</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,942</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identified intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(817</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(703</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $27.3&#160;million and $12.6&#160;million of state net operating loss carryforwards that begin to expire in 2032. We also have $1.9&#160;million of federal research and development credit carryforwards, which expire through 2028. We have $2.0&#160;million of California research and development credit carryforwards that have no expiration date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Sections&#160;382 and 383. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying combined balance sheet. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions based on tax positions related to the current year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions for tax positions of prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions for tax positions in prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $0.8&#160;million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve&#160;months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021, 2020 and 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States and various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating loss and research credit carryforwards arising prior to these&#160;years are also open to examination if and when utilized. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497727968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Commitment and Contingencies: Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies: Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration and Shareholder Rights Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) had registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters purchased Units at a purchase price of $9.80 per Unit (i.e., at a cash underwriting discount of $0.20&#160;per Unit, or $4,600,000 in the aggregate) upon the closing of the Initial Public Offering and the exercise of the over-allotment in full on August&#160;12, 2021. In addition, the Company agreed to pay the underwriters a deferred underwriting fee of up to $0.35 per Unit, or $8,050,000 in the aggregate, which would be payable to the underwriters upon the consummation of the initial Business Combination, except that the Company&#8217;s management team would be permitted, in its sole discretion, to allocate up to 50% of the deferred underwriting fee, or $4,025,000 in the aggregate, to third parties that assist in identifying and consummating an initial Business Combination. On August&#160;17, 2022, Credit Suisse waived its right to 50%, or $4,025,000 in the aggregate, of the deferred underwriting fee, and the Company has determined not to pay the 50% to any other advisors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Purchase Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor which provides for the purchase of an aggregate of 10,000,000 Class&#160;A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class&#160;A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#8217;s Public Shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward purchase securities were issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities were used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the A&amp;R FPA with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;R FPA, the Company agreed that, in connection with the consummation of the OmniAb Business Combination, they would issue and sell to the Sponsor 1,500,000 shares of OmniAb Common Stock and warrants to acquire 1,666,667 shares of OmniAb Common Stock for an aggregate purchase price of $15.0&#160;million with such purchases to be consummated immediately following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domestication</div> to Delaware and prior to the OmniAb Business Combination. In addition, the Sponsor agreed to purchase up to an additional 10,000,000 shares of OmniAb Common Stock and up to an additional 1,666,667 warrants, for an aggregate additional purchase price of up to $100.0&#160;million, in </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $100.0&#160;million. The A&amp;R FPA also provided that in the event the Merger Agreement was terminated by Ligand under circumstances in which the Termination Fee (as defined in the Merger Agreement) would be payable under the Merger Agreement, Ligand would pay the Sponsor a termination fee of $12.5&#160;million in connection therewith. Pursuant to the A&amp;R FPA, in connection with the Business Combination, the Sponsor was issued 8,672,934 Backstop Shares and 1,445,489 Backstop Warrants for an aggregate purchase price of $86,729,340 in order to backstop the redemptions. In addition, pursuant to the A&amp;R FPA, the Sponsor was issued 1,500,000 Forward Purchase Shares and 1,666,667 Forward Purchase Warrants for an aggregate purchase price of $15,000,000, on a private placement basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the A&amp;R FPA, the Company evaluated the modification of the equity contract, which resulted in a reclassification between equity and a liability, in which the difference between the fair value at issuance of the original forward purchase agreement and the fair value at issuance of the A&amp;R FPA (the modification date) was treated as a deemed dividend. An amount of $225,000 was recorded to accumulated deficit as a deemed dividend upon modification of the forward purchase agreement on March&#160;23, 2022. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters were paid a cash underwriting discount of $0.20 per Unit, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August&#160;12, 2021. In addition, $0.35 per unit, or $8,050,000 in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the Underwriting Agreement. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Purchase Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of 10,000,000 Class&#160;A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class&#160;A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#8217;s public shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497746640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain OmniAb legal entities lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of September&#160;30, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity Dates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining three months ending December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September 30, 2022, we had a lease commence in our Emeryville office, which resulted in </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an increase in lease assets and liabilities of $9.9 million each during the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, our operating leases had a weighted-average remaining lease term of 8.8 years and a weighted-average discount rate of 4.3%. As of December&#160;31, 2021, our operating leases had a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 3.9%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3&#160;million and $2.2&#160;million, respectively, for the three and nine months ended September&#160;30, 2022. The operating lease expense was $1.0&#160;million and $2.7&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The operating lease expense was $0.4&#160;million and $1.0&#160;million for the three and nine months ended September&#160;30, 2021, respectively. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain legal entities included in this combined financials lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten&#160;years, some of which include options to extend the leases for up to ten&#160;years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12&#160;months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,012</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity Dates</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 9.3&#160;years and a weighted-average discount rate of 4%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.7&#160;years and a weighted-average discount rate of 7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.1&#160;million and $0.7&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $1.6&#160;million, $0.7&#160;million and $0.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI https://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497297296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsAbstract', window );"><strong>Balance Sheet Account Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsDisclosureTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Balance Sheet Account Details </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense for the three and nine months ended September&#160;30, 2022 was $0.7&#160;million and $1.9&#160;million, respectfully. Depreciation expense for the three and nine months ended September&#160;30, 2021 was $0.4&#160;million and $1.0&#160;million, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and identifiable intangible assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and other identifiable intangible assets consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense for the three and nine months ended September&#160;30, 2022 was $3.3&#160;million and $9.8&#160;million, respectively. Amortization expense for the three and nine months ended September&#160;30, 2021 was $3.3&#160;million and $9.7&#160;million, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition related liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Balance Sheet Account Details </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to <br/>ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is <br/>shorter. Depreciation expense of $2.0&#160;million, $0.8&#160;million and $0.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, <br/>respectively, and was included in operating expenses. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and identifiable intangible assets consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">224,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(893</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20&#160;years. Amortization expense of $13.0&#160;million, $11.8&#160;million and $10.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Estimated amortization expense for the&#160;years ending December&#160;31, 2022 through 2026 is $13.0&#160;million per year. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, there was no impairment of intangible assets with finite lives. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subcontractor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions related liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BalanceSheetAccountDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet account details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BalanceSheetAccountDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BalanceSheetAccountDetailsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet account details disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BalanceSheetAccountDetailsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494114928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;7. SHAREHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference shares</div></div></div></div> &#8212; The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of September&#160;30,&#160;2022 and December&#160;31, 2021, there were no preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares</div></div></div></div> &#8212; The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At September&#160;30,&#160;2022 and December&#160;31, 2021, there were 23,000,000 Class&#160;A ordinary shares issued and outstanding, including 23,000,000 Class&#160;A ordinary shares subject to possible redemption. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B ordinary shares</div></div></div></div> &#8212; The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;B ordinary shares are entitled to one vote for each share. As of September&#160;30, 2022 and December&#160;31, 2021, there were 5,750,000 Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the Company&#8217;s issued and outstanding shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Warrants</div></div></div></div> &#8212; Each whole warrant entitles the registered holder to purchase one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days&#160;after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire five years&#160;after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class&#160;A ordinary shares are at the time of any exercise of a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume weighted average price of Class&#160;A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">365-day</div> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18 months from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#8217;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants ), and will account for the 3,333,334 Forward Purchase Warrants and Backstop Warrants to be issued in connection with the OmniAb Business Combination, in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference shares &#8212;</div></div></div></div> The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December&#160;31, 2021, there were no preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares &#8212;</div></div></div></div> The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 23,000,000 Class&#160;A ordinary shares issued and outstanding, including 23,000,000 Class&#160;A ordinary shares subject to possible redemption. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B ordinary shares &#8212;</div></div></div></div> The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;B ordinary shares are entitled to one vote for each share. As of December&#160;31, 2021, there were 5,750,000 Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the Company&#8217;s issued and outstanding shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three&#160;years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Warrants &#8212;</div></div></div></div> Each whole warrant entitles the registered holder to purchase one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30&#160;days after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. Accordingly, unless you purchase at least three&#160;units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class&#160;A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division</div> or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;&#8220;historical fair market value&#8221; means the volume weighted average price of Class&#160;A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">365-day</div> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share , (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#8217;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Company&#8217;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the&#160;units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the&#160;units being sold in the Initial Public Offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants), and will account for the 3,333,333 Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div>. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494159584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 - Observable inputs such as quoted prices in active markets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3 - Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities Measured on a Recurring Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;5,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;5,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">xCella contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">certain developmental and regulatory milestones. During the year ended December&#160;31, 2021, we paid $1.1&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. During the nine months ended September&#160;30, 2022, we paid $1.5&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liability is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September 2020. During the year ended December&#160;31, 2021, we paid $0.7&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. During the nine months ended September&#160;30, 2022, we paid $1.0&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of September&#160;30, 2022 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,505</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(487</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to their relatively short periods to maturity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Measured on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recurring</div> Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We apply fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on level 3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the nine months ended September&#160;30, 2022 and 2021. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Fair Value Measurement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;&#8212;&#160;Observable inputs such as quoted prices in active markets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;&#8212;&#160;Inputs other than the quoted prices in active markets that are observable either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;&#8212;&#160;Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities Measured on a Recurring Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Crystal contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $1.8&#160;million contingent liability on development milestones to former Crystal shareholders. During the year ended December&#160;31, 2021, we made no payments former Crystal shareholders for contingent liability on development milestones. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $0.5&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the year ended December&#160;31, 2021, we paid $1.1&#160;million contingent liability based on revenue milestones to former Icagen shareholders. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders and other contingent payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from Icagen acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,770</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September&#160;2020. During the year ended December&#160;31, 2021, management paid $0.7&#160;million of </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement. </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to relatively short periods to maturity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Measured on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recurring</div> Basis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We apply fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level&#160;3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level&#160;3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the&#160;years ended December&#160;31, 2021 and 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of September&#160;30, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount&#160;at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237,188,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237,188,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liability - Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Forward Purchase and Backstop Securities were fair valued based on the difference between the current fair values of each of the underlying components of the agreement (i.e. the Class&#160;A ordinary shares and the warrants) and the present value of the contractual forward prices. As the Backstop Securities only apply in the event of and to the extent that the funds in the Company&#8217;s Trust Account falls below $100&#160;million as the result of redemptions, the valuation considered an expected redemption rate based on redemption rates exhibited by similar companies in the market during the third quarter of 2022 and the expected post-redemption Trust Account balance. As the Forward Purchase and Backstop Securities will only apply in the event that the Company completes an initial business combination, the value reflects the probability of completing an initial business combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the derivative liability for the Forward Purchase and Backstop Securities is classified as Level&#160;3 due to the use of unobservable inputs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of March&#160;23, 2022 (initial measurement): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;23,&#160;2022</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Initial&#160;Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>   <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of September&#160;30, 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 19%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of the Company&#8217;s Level&#160;3 financial instruments that are measured at fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement as of March&#160;23, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">591,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,039,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(656,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">383,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,212,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $1,212,110 and $0 within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the three months ended September&#160;30, 2022 and for the three months ended September&#160;30, 2021, respectively. The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $1,147,120 and $0 within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549486804016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Subsequent Event </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of the financial statements as of September 30, 2022 and the three and nine months then ended, the Company has evaluated subsequent events through the date on which the financial statements were issued. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination closing of APAC and OmniAb </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November 1, 2022, Ligand completed the separation (the &#8220;Separation&#8221;) of its antibody discovery business and certain related assets and liabilities through a spin-off of OmniAb to Ligand&#8217;s shareholders of record as of October 26, 2022 (the &#8220;Record Date&#8221;) on a pro rata basis (the &#8220;Distribution&#8221;) and merger (the &#8220;Merger&#8221;) of OmniAb with a wholly owned subsidiary of APAC in a Reverse Morris Trust transaction (collectively, the &#8220;Transactions&#8221;) pursuant to the Merger Agreement and the Separation Agreement (collectively with the other related transaction documents, the &#8220;Transaction Agreements&#8221;). The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#8220;New OmniAb&#8221;). Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain assets and liabilities constituting the OmniAb business, including certain related subsidiaries of Ligand, to OmniAb (the &#8220;Contribution&#8221;). In consideration for the Contribution, OmniAb issued to Ligand additional shares of OmniAb common stock such that the number of shares of OmniAb common stock then outstanding equaled the number of shares of OmniAb common stock necessary to effect the Distribution. Pursuant to the Distribution, Ligand shareholders as of the Record Date received one share of OmniAb common stock for each share of Ligand common stock held as of such date. Pursuant to the Merger Agreement, each share of OmniAb common stock was thereafter exchanged for the right to receive 4.90007 shares of New OmniAb common stock and 0.75842 shares of New OmniAb common stock subject to price-based earnout triggers (the &#8220;Earnout Shares&#8221;). The Earnout Shares will vest based upon the achievement of certain volume-weighted average trading prices (VWAP) for shares of New OmniAb for any <div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div> trading days over a consecutive <div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div> trading-day period during the five-year period following the Closing, with (i) fifty percent of such Earnout Shares vesting upon achievement of a VWAP of $12.50 per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $12.50, and (ii) the remaining fifty percent of the Earnout Shares vesting upon achievement of a VWAP of $15.00 per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $15.00. The Earnout Shares are not transferable until the vesting condition for the applicable tranche of Earnout Shares has been achieved. Upon the closing of the Transactions, the ownership of the outstanding stock of New OmniAb (including the Earnout Shares) was as follows: Ligand&#8217;s existing shareholders held approximately 85.0%, APAC&#8217;s existing public shareholders held approximately 1.1% and the sponsor and related parties of APAC held approximately 13.9%. Fractional shares of New OmniAb common stock were not issued pursuant to the Merger. Instead, shareholders received cash in lieu of any fractional share (other than with respect to Earnout Shares). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Closing, New OmniAb expected to have approximately $95.8 million of net cash. On November 2, 2022, New OmniAb began regular-way trading on NASDAQ under the ticker symbol &#8220;OABI.&#8221; Ligand continues to trade under the ticker symbol &#8220;LGND.&#8221; </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE&#160;9. SUBSEQUENT EVENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as mentioned below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#8217;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised their right to redeem those shares for a pro rata portion of the Trust Account holding the proceeds from the Company&#8217;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. The per share redemption price of approximately $10.32 for public shareholders electing redemption was paid out of the Trust Account. For more information regarding the Business Combination, see Note 1, Note 2, Note 6 and OmniAb&#8217;s Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on November&#160;7, 2022. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. SUBSEQUENT EVENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March&#160;15, 2022, the Company drew down $500,000 under the Sponsor Working Capital Loan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed Business Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;23, 2022, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221; and, together with Ligand, collectively, the &#8220;Companies&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), pursuant to which we will combine with OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement, (the &#8220;Employee Matters Agreement&#8221;), (b)&#160;OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c)&#160;we amended and restated that certain forward purchase agreement, dated August&#160;9, 2021, by entering into the amended and restated forward purchase agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company, our sponsor and OmniAb. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and OmniAb (the &#8220;Separation Agreement&#8221;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001 (the &#8220;OmniAb Common Stock&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i)&#160;we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#8220;Domestication&#8221;), (ii)&#160;Ligand will transfer the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, OmniAb, and contribute $15&#160;million in capital thereto (less certain transaction and other expenses), and (iii)&#160;following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;tax-free&#8221;</div> transactions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $0.0001 per share (the &#8220;APAC Common Stock&#8221;), which will be listed on Nasdaq under the ticker symbol &#8220;OABI.&#8221; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#8220;OABIW.&#8221; </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At the time the proposed OmniAb Business Combination is effected (the &#8220;Closing&#8221;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-money</div> equity value for OmniAb of $850&#160;million. Holders of OmniAb options, restricted stock&#160;units and performance stock&#160;units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 shares of APAC Common Stock (the &#8220;OmniAb Earnout Shares&#8221;), with 50% of such earnout shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $12.50 per share of APAC Common Stock for any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of APAC Common Stock for any 20 trading days over a consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period, in each case provided such vesting occurs during the five-year period following the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the proposed OmniAb Business Combination, upon the Domestication (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares will convert automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into shares of APAC Common Stock, (ii)&#160;all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii)&#160;all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one warrant to purchase APAC Common Stock. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489545648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock', window );">Basis of Presentation and Combination</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s interim condensed combined financial statement accounting records. The interim condensed combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records certain transactions at the parent entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January 2016. Transactions between Ligand and the Company are accounted for through the Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The interim condensed combined financial statements include all revenues, expenses, assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a percentage of total operating expenses or other measures that management believes are consistent and reasonable. See Note 8. Relationship with Parent and Related Entities<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. The share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See Note 8. Relationship with Parent and Related Entities for additional discussion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the interim condensed combined financial statements are based on assumptions that management believes are reasonable. However, the interim condensed combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note (9)</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Relationship with Parent and Related Entities</div></div> for additional discussion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_LiquidityAndCapitalResourcesPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. Therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of Parent company net investment in the combined balance sheets and as a financing activity allocation on the accompanying combined statements of cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s revenue was $23.7&#160;million and $19.5&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#8217;s net loss was $(29.2) million and $(24.0) million, respectively. OmniAb expects to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the merger between the Company and a subsidiary of APAC, New OmniAb was capitalized with approximately $95.8 million in net cash. This cash and cash the Company generates from operations provide us the flexibility we need to meet operating, investing, and financing needs and support operations through at least 12 months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s net loss was ($27.0 million), ($17.6 million) and ($13.6 million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb qualifies as an &#8220;emerging growth company&#8221; (EGC) as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OmniAb&#8217;s historical results are included as a part of the Parent&#8217;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This may make comparison of OmniAb&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Financial Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying interim condensed combined balance sheet as of September&#160;30, 2022, the condensed combined statements of operations, condensed combined statements of changes in parent company net investment for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed combined statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related footnote disclosures are unaudited. In management&#8217;s opinion, the unaudited interim combined financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, its results of operations for the three and nine months ended September&#160;30, 2022 and 2021, and its statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 in accordance with U.S. GAAP. The results for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#8217;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of interim condensed combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the interim condensed combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Business Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year-ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A, B and C in 2019 represent different customers than 2020 and 2021. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the three and nine months ended September&#160;30, 2022, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and the allowance for credit losses was $0.1&#160;million as of September&#160;30, 2022. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic on our business and recorded an adjustment of $0.1&#160;million of allowance for credit losses as of December&#160;31, 2021. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill, Intangible Assets and Other Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill attributed to OmniAb&#8217;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#8217; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, we have generated revenue from intellectual property and development milestones, and have only recently begun to generate revenue from commercial milestone payments and royalties on product sales this year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and the milestone is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgment. If our estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone <div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> regulatory approval. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenuePolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the three and nine months ended </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022, the amount recognized as revenue that was previously deferred was $4.0&#160;million and $9.9&#160;million, respectively. During the three and nine months ended September&#160;30, 2021, the amount recognized as revenue that was previously deferred was $2.4&#160;million and $5.2&#160;million, respectively. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $7.4&#160;million. During the year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $0.4&#160;million. During the year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $2.4&#160;million. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation&#160;of&#160;Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;23,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;19,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our employees participated in our Parent&#8217;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#8217;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted stock&#160;units (RSU) and performance stock&#160;units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#8217;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#8217;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> in the period of adjustment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $2.50 per share, our Parent has not paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We grant options, RSUs and PSUs to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under Ligand&#8217;s equity plan. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> directors are accounted for as employees. Options and RSUs granted to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors typically vest one year from the date of grant. <div style="letter-spacing: 0px; top: 0px;;display:inline;">Options granted to employees typically vest&#160;1/8 on the six m</div>onth anniversary of the date of grant, and 1/48 each month thereafter for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">forty-two</div> months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;Topic 740&#8221;). Accordingly, our income tax provision was prepared following the &#8220;Separate Return Method.&#8221; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#8217;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock', window );">Impact of COVID-19 Pandemic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> initially, including issuing varying forms of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;stay-at-home&#8221;</div></div> orders, and restricting business functions outside of one&#8217;s home. We have generally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could have on our business in the future, the continued spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards Not Yet Adopted </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4,</div> of which this proxy statement/prospectus/information statement forms a part. </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> as filed with the SEC on March&#160;28, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 or </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">December&#160;31, 2021. As <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div>September&#160;30, 2022 and December&#160;31, 2021, the Company had operating cash (i.e., cash held outside the Trust Account) of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$19,847<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$189,971, respectively. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The valuation of the Forward Purchase and Backstop Securities required management to exercise significant judgement in its estimate. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock', window );">Investments Held in Trust Account</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in Trust Account </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury bills. The Company&#8217;s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in gain on investments held in Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of the investments held in the Trust Account are determined using available market information. At December&#160;31, 2021, the assets held in the Trust Account were held in cash. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares Previously Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contained a redemption feature which allowed for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognized changes in redemption value immediately as they occurred and adjusted the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares were affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,438,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">237,188,875</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#8217;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">their right to redeem those shares for a <div style="letter-spacing: 0px; top: 0px;;display:inline;">pro </div>rata portion of the Trust Account holding the proceeds from the Company&#8217;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock', window );">Offering Costs Associated with the Initial Public Offering</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs associated with the Initial Public Offering </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin Topic 5A&#160;&#8212;&#160;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses of Offering</div></div>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Ordinary Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Ordinary Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>15,900,000<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>shares in the calculation of diluted </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income per share as the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;5, 2021</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,973,144</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(493,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,762,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,399,457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,755,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,155,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from&#160;February&#160;5,<br/>2021 (inception) Through<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(335,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(181,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,321,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The Forward Purchase and Backstop Securities contained within the A&amp;R FPA (see Note 6) are classified as derivatives in the condensed consolidated balance sheet with changes in the fair value recognized in the condensed consolidated statements of operations. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note - related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note&#160;&#8212;&#160;related party, and advance from anchor investor approximate fair value due to their short-term nature. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;&#8212;&#160;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;&#8212;&#160;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;&#8212;&#160;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, Income Taxes (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed consolidated financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>no<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>unrecognized tax benefits and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>no<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>amounts accrued for interest and penalties as of September&#160;30, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s condensed consolidated financial statements. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for income taxes under ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February&#160;5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman <div style="letter-spacing: 0px; top: 0px;;display:inline;">Islands </div>Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement. </div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed consolidated financial statements. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August&#160;2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#160;amends</div> the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for the Company on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assets held in trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of accounting policy and business combination [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination and asset acquisitions [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy on common stock subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of covid nineteen pandemic [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_LiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_LiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for offering costs associated with the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549499832960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember', window );">Combined Balance Sheet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the revised results for the year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,970</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Balance Sheets </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,924</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and parent company net investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember', window );">Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,796</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,728</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Operations </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,685</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,976</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,386</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,386</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(657</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(562</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember', window );">Combined Statement Of Changes In Parent Company Net Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;January 1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of changes in Parent Company Net Investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfers from parent company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent company net investment&#160;&#8211;&#160;December 31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">218,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember', window );">Combined Statement Of Cash Flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(225</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,779</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combined Statements of Cash Flows </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(546</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities, net of acquisitions:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,565</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(648</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(570</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(450</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(604</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net transfer from parent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">604</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue recorded in accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549486804064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of revenue</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;6,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;23,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;19,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Revenue from Significant Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year-ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partner A, B and C in 2019 represent different customers than 2020 and 2021. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the balance sheet</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of Class&#160;A ordinary shares to redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,438,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">237,188,875</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds allocated to Public Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,813,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs allocated to Class&#160;A ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,029,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,593,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235,750,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of calculation of basic and diluted net loss per ordinary share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;5, 2021</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,973,144</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(493,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,762,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,690,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,399,457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,755,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,155,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Period&#160;from&#160;February&#160;5,<br/>2021 (inception) Through<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(335,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(181,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,321,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490216688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember', window );">Taurus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of recognized identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember', window );">xCella Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of recognized identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash included in Parent company net investment and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(142</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(320</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles assets with finite-life&#160;&#8211;&#160;core technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember', window );">Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of recognized identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaids and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities assumed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(812</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,685</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">821</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember', window );">Ab Initio Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of recognized identified assets acquired and liabilities assumed</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(83</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489402416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of the Company's Level 3 financial instruments that are measured at fair value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of September&#160;30, 2022 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,505</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(487</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to CVR holders and other contingent payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from Icagen acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of level 3 financial instruments as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,770</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustments to contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities from xCella asset acquisition<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September&#160;2020. During the year ended December&#160;31, 2021, management paid $0.7&#160;million of </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement. </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of the hierarchy for liabilities measured at fair value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;5,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;5,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">xCella contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">certain developmental and regulatory milestones. During the year ended December&#160;31, 2021, we paid $1.1&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. During the nine months ended September&#160;30, 2022, we paid $1.5&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The xCella contingent liability is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September 2020. During the year ended December&#160;31, 2021, we paid $0.7&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. During the nine months ended September&#160;30, 2022, we paid $1.0&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. </div></div> </td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Crystal contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icagen contingent liabilities<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $1.8&#160;million contingent liability on development milestones to former Crystal shareholders. During the year ended December&#160;31, 2021, we made no payments former Crystal shareholders for contingent liability on development milestones. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $0.5&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the year ended December&#160;31, 2021, we paid $1.1&#160;million contingent liability based on revenue milestones to former Icagen shareholders. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of company's financial assets and liabilities that are measured at fair value on a recurring basis</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount&#160;at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237,188,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237,188,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liability - Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of significant inputs to the valuation for the Forward Purchase and Backstop Securities liability</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;23,&#160;2022</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Initial&#160;Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 19%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to Business Combination (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount factor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected redemption rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of completing an initial Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Forward Purchase and Backstop Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of the Company's Level 3 financial instruments that are measured at fair value</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement as of March&#160;23, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">591,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,039,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(656,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">383,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,212,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;1,595,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494051408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred expense (benefit):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,779</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(569</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">557</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at federal statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,983</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(350</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(188</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">847</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(573</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in uncertain tax positions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,088</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance for deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(526</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(403</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,942</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identified intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(817</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(703</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at beginning of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions based on tax positions related to the current year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions for tax positions of prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions for tax positions in prior&#160;years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at end of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497443712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Relationship with Parent and Related Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">The following table summarizes total share-based compensation (SBC) charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,902</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBC - General and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,279</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549499131568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities', window );">Schedule of Operating Lease Assets and Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Lease Assets and Liabilities (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,012</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of September&#160;30, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity Dates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining three months ending December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,787</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity Dates</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549497736000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsAbstract', window );"><strong>Balance Sheet Account Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment are Stated at Cost</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment are stated at cost and consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab and office equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and other identifiable intangible assets consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite lived intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and identifiable intangible assets consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,979</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Complete technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">224,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(60,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(893</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total goodwill and other identifiable intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition related liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties owed to third parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subcontractor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions related liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BalanceSheetAccountDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet account details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BalanceSheetAccountDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549484627936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANISATION AND NATURE OF OPERATIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_LigandMember', window );">Ligand | Avista Public Acquisition Corp. II [Member] | Separation And Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution', window );">Percentage of common stock shares issued under distribution</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CapitalContributedNetOfExpenses', window );">Capital contributed, net of expenses</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition for future business combination, number of businesses, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash held outside of the Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,847<span></span>
</td>
<td class="nump">$ 19,847<span></span>
</td>
<td class="nump">$ 189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_InvestmentsMaximumMaturityTerm', window );">Maturity term of U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">185 days<span></span>
</td>
<td class="text">185 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares', window );">Threshold business days for redemption of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumNetInterestToPayDissolutionExpenses', window );">Maximum net interest to pay dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,843,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumAdditionalAggregatePurchasePrice', window );">Maximum additional aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings', window );">Amount deposited in an operating account for the working capital needs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination', window );">Number of additional financing public shares issued upon business combination | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,713,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransactionCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,662,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,662,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="nump">$ 4,025,000<span></span>
</td>
<td class="nump">$ 4,025,000<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent', window );">Threshold percentage of public shares subject to redemption without the company's prior written consent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WorkingCapitalSurplus', window );">Working capital surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 496,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants', window );">Proceeds from the Initial Public offering and sale of the private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business combination shares voted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0067%<span></span>
</td>
<td class="nump">0.0067%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member] | Related Party Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Outstanding balance of related party note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination', window );">Minimum net tangible assets upon consummation of the business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Private Placement Warrants | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Private Placement Warrants | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Private Placement Warrants | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Over-Allotment Option [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember', window );">APAC Common Stock | OmniAb Inc | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of Class A common stock issued upon conversion of each share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfSharesIssuedPerUnit', window );">Number of shares in a unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember', window );">APAC Common Stock | OmniAb Inc | Avista Public Acquisition Corp. II [Member] | First Requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_VolumeWeightedAveragePriceTriggerPrice', window );">Volume-weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest', window );">Number of days at volume-weighted average price to trigger vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesToVestMeasurementPeriod', window );">Number of consecutive days volume-weighted average price to be within</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember', window );">APAC Common Stock | OmniAb Inc | Avista Public Acquisition Corp. II [Member] | Second Requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_VolumeWeightedAveragePriceTriggerPrice', window );">Volume-weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest', window );">Number of days at volume-weighted average price to trigger vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesToVestMeasurementPeriod', window );">Number of consecutive days volume-weighted average price to be within</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember', window );">APAC Common Stock | Warrant [Member] | OmniAb Inc | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants in a unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_EarnoutStockMember', window );">Earnout Stock | OmniAb Inc | Avista Public Acquisition Corp. II [Member] | First Requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice', window );">Percent of shares vested upon the combined company's achievement of the post-transaction volume-weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember', window );">Sponsor | OmniAb Inc | Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalAggregatePurchasePrice', window );">Additional aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember', window );">Sponsor | Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalAggregatePurchasePrice', window );">Additional aggregate purchase price</a></td>
<td class="nump">$ 86,729,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SponsorPurchaseBackstop', window );">Sponsor purchased backstop | shares</a></td>
<td class="nump">8,672,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesBackstopWarrants', window );">Shares backstop warrants | shares</a></td>
<td class="nump">1,445,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumAdditionalAggregatePurchasePrice', window );">Maximum additional aggregate purchase price</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember', window );">Sponsor | Warrant [Member] | Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional number of warrants | shares</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember', window );">Sponsor | APAC Common Stock | Avista Public Acquisition Corp. II [Member] | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalNumberOfCommonStock', window );">Additional number of common stock | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember', window );">Sponsor | Earnout Stock | Avista Public Acquisition Corp. II [Member] | Sponsor Insider Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions', window );">Maximum number of shares subject to the price-based vesting conditions | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,667<span></span>
</td>
<td class="nump">1,916,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate purchase price of the additional shares and additional warrants under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalNumberOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional common stock to be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalNumberOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount deposited in operating account for working capital purposes out of proceeds from the Initial Public Offering and sale of the Private Placement Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_CapitalContributedNetOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of capital, net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_CapitalContributedNetOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_InvestmentsMaximumMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_InvestmentsMaximumMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumAdditionalAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate purchase price of the additional shares and additional warrants under an agreement in order to backstop shareholder redemptions for cash proceeds to be limited to the maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumAdditionalAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumNetInterestToPayDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum net interest to pay dissolution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumNetInterestToPayDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares that could be subject to the price-based vesting conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum net tangible assets upon consummation of the Business Combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MonthsToCompleteInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MonthsToCompleteInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional financing public shares issued upon business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of consecutive trading days within a specified range when the reported volume-weighted average price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfCommonStockSharesIssuedUnderDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of common stock shares issued under the distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfCommonStockSharesIssuedUnderDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of obligation to redeem public shares if Entity does not complete business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the initial public offering and sale of the private placement warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SharesBackstopWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Shares back shop warrants .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SharesBackstopWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SharesToVestMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days over which the reported sale price is measured when determining the redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SharesToVestMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SponsorPurchaseBackstop">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Sponsor purchased backstop.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SponsorPurchaseBackstop</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ThresholdBusinessDaysForRedemptionOfPublicShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold business days for redemption of public shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ThresholdBusinessDaysForRedemptionOfPublicShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of public shares subject to redemption without the company's prior written consent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of shares that will vest upon the achievement of a post-transaction volume-weighted average price as determined by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_VolumeWeightedAveragePriceTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume-weighted average price that would trigger the 50% of earnout shares vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_VolumeWeightedAveragePriceTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WorkingCapitalSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WorkingCapitalSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_LigandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_LigandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=oabi_SeparationAndDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=oabi_SeparationAndDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_OmniabIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_OmniabIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_VestingRequirementsAxis=oabi_FirstRequirementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_VestingRequirementsAxis=oabi_FirstRequirementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_VestingRequirementsAxis=oabi_SecondRequirementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_VestingRequirementsAxis=oabi_SecondRequirementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_EarnoutStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_EarnoutStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_SponsorInsiderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_SponsorInsiderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490470864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 894,000<span></span>
</td>
<td class="nump">$ 894,000<span></span>
</td>
<td class="nump">$ 766,000<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="nump">$ 556,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 95,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700,000<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="nump">23,300,000<span></span>
</td>
<td class="nump">18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,596,000)<span></span>
</td>
<td class="num">$ (10,276,000)<span></span>
</td>
<td class="num">$ (6,282,000)<span></span>
</td>
<td class="num">$ (7,890,000)<span></span>
</td>
<td class="num">$ (8,625,000)<span></span>
</td>
<td class="num">$ (7,455,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,154,000)<span></span>
</td>
<td class="num">(23,970,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,042,000)<span></span>
</td>
<td class="num">(17,557,000)<span></span>
</td>
<td class="num">(13,589,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends, per share, declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends, per share, cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember', window );">Share Based Payment Arrangement Nonemployee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod', window );">Share based compensation arrangement by share based payment award description of award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options granted to employees typically vest&#160;1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member] | Restricted Stock Units And Phantom Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash held outside of the Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,971<span></span>
</td>
<td class="nump">$ 189,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits accrued for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal depository insurance coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,786)<span></span>
</td>
<td class="num">$ (2,466,430)<span></span>
</td>
<td class="num">$ (1,624,916)<span></span>
</td>
<td class="num">$ (4,361,240)<span></span>
</td>
<td class="num">$ (170,579)<span></span>
</td>
<td class="num">$ (2,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (180,550)<span></span>
</td>
<td class="num">$ (8,452,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (516,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Avista Public Acquisition Corp. II [Member] | Common Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition for share</a></td>
<td class="nump">21,713,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition for per share</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business combination</a></td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_Unitsissuedduringperiodsharesnewissues.', window );">Sale of Units, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award description of award vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_Unitsissuedduringperiodsharesnewissues.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UnitsIssuedDuringPeriodSharesNewIssues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_Unitsissuedduringperiodsharesnewissues.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=oabi_RestrictedStockUnitsAndPhantomShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=oabi_RestrictedStockUnitsAndPhantomShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490173776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,910<span></span>
</td>
<td class="nump">$ 6,277<span></span>
</td>
<td class="nump">$ 23,732<span></span>
</td>
<td class="nump">$ 19,468<span></span>
</td>
<td class="nump">$ 34,748<span></span>
</td>
<td class="nump">$ 23,268<span></span>
</td>
<td class="nump">$ 18,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=oabi_MilestoneMember', window );">Milestone revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">10,164<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">7,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,928<span></span>
</td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 14,922<span></span>
</td>
<td class="nump">$ 14,254<span></span>
</td>
<td class="nump">$ 20,084<span></span>
</td>
<td class="nump">$ 11,883<span></span>
</td>
<td class="nump">$ 5,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=oabi_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=oabi_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549487867280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Partner A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Partner B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Partner C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=oabi_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=oabi_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=oabi_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=oabi_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=oabi_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=oabi_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549499821808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TemporaryEquityProceedsAllocatedToWarrants', window );">Proceeds allocated to Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,813,334)<span></span>
</td>
<td class="num">(9,813,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TemporaryEquityIssuanceCosts', window );">Issuance costs allocated to Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,029,901)<span></span>
</td>
<td class="num">(13,029,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption amount</a></td>
<td class="nump">$ 1,090,544<span></span>
</td>
<td class="nump">$ 348,332<span></span>
</td>
<td class="nump">$ 28,307,827<span></span>
</td>
<td class="nump">$ 1,438,875<span></span>
</td>
<td class="nump">28,593,235<span></span>
</td>
<td class="nump">28,593,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">$ 237,188,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,188,875<span></span>
</td>
<td class="nump">$ 235,750,000<span></span>
</td>
<td class="nump">$ 235,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accretion of Class A ordinary shares subject to redemption to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance costs related to temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TemporaryEquityProceedsAllocatedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds allocated from temporary equity to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TemporaryEquityProceedsAllocatedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549486880384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransactionCosts', window );">Offering costs</a></td>
<td class="nump">$ 13,662,256<span></span>
</td>
<td class="nump">$ 13,662,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="nump">$ 4,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="nump">1,012,256<span></span>
</td>
<td class="nump">1,012,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OfferingCostsReductionOfTemporaryEquity', window );">Offering costs reduction of temporary equity</a></td>
<td class="nump">13,029,901<span></span>
</td>
<td class="nump">13,029,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs as a reduction of equity</a></td>
<td class="nump">$ 632,355<span></span>
</td>
<td class="nump">$ 632,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OfferingCostsReductionOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering costs reduction of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OfferingCostsReductionOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489616496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489107664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (1,973,144,000)<span></span>
</td>
<td class="num">$ (118,394,000)<span></span>
</td>
<td class="num">$ (86,633,000)<span></span>
</td>
<td class="num">$ (6,762,069,000)<span></span>
</td>
<td class="num">$ (335,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">12,250,000<span></span>
</td>
<td class="nump">4,755,274<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">12,250,000<span></span>
</td>
<td class="nump">4,755,274<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (493,286,000)<span></span>
</td>
<td class="num">$ (52,185,000)<span></span>
</td>
<td class="num">$ (93,917,000)<span></span>
</td>
<td class="num">$ (1,690,517,000)<span></span>
</td>
<td class="num">$ (181,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,399,457<span></span>
</td>
<td class="nump">5,155,063<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,399,457<span></span>
</td>
<td class="nump">5,155,063<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490378480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 09, 2020</div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Jul. 23, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 83,979<span></span>
</td>
<td class="nump">$ 83,979<span></span>
</td>
<td class="nump">$ 83,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember', window );">Taurus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business combination recognized identifiable assets acquired and liabilities assumed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember', window );">xCella Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business combination recognized identifiable assets acquired and liabilities assumed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember', window );">Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Recognized identified assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember', window );">Ab Initio Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Recognized identified assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember', window );">Ab Initio Acquisition [Member] | Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets with finite-life&#160;&#8211;&#160;core technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of recognized identified assets acquired and liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549493306208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Number</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfAcquisitions', window );">Number of acquisitions | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember', window );">Taurus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues', window );">Percentage share of post clinical acquire product revenues</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses gross</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business combination consideration transferred liabilities incurred</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationConsiderationTransferredEarnoutRights', window );">Business combination consideration transferred earnout rights</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember', window );">Taurus Acquisition [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationConsiderationTransferredEarnoutRights', window );">Business combination consideration transferred earnout rights</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember', window );">xCella Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageShareOfFutureMilestonePayments', window );">Percentage share of future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business combination consideration transferred liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationConsiderationTransferredEarnoutRights', window );">Business combination consideration transferred earnout rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember', window );">xCella Acquisition [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationConsiderationTransferredEarnoutRights', window );">Business combination consideration transferred earnout rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember', window );">Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment', window );">Business combination contingent consideration revenue milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationCashFlowDiscountedRate', window );">Business combination cash flow discounted rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember', window );">Ab Initio Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationCashFlowDiscountedRate', window );">Business combination cash flow discounted rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims', window );">Business combination consideration transferred to holdback for potential indemnification claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member] | Taurus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member] | xCella Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member] | Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member] | Ab Initio Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=oabi_EarnoutRightsMember', window );">Earnout Rights [Member] | Icagen Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business combination contingent consideration arrangements range of outcomes value high</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationCashFlowDiscountedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination cash flow discounted rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationCashFlowDiscountedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationConsiderationTransferredEarnoutRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, consideration transferred, earnout rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationConsiderationTransferredEarnoutRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination consideration transferred holdback for potential indemnification claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration revenue milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageShareOfFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage share of future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageShareOfFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageShareOfPostClinicalAcquireeProductRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage share of post clinical acquiree product revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageShareOfPostClinicalAcquireeProductRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_TaurusAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_XCellaAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_AbInitioAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=oabi_EarnoutRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=oabi_EarnoutRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488857472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">83,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">306,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">16,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Parent company net investment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Parent company net investment</a></td>
<td class="nump">232,710<span></span>
</td>
<td class="nump">$ 226,943<span></span>
</td>
<td class="nump">$ 224,921<span></span>
</td>
<td class="nump">234,307<span></span>
</td>
<td class="nump">$ 228,002<span></span>
</td>
<td class="nump">$ 226,403<span></span>
</td>
<td class="nump">$ 227,600<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">$ 218,243<span></span>
</td>
<td class="nump">$ 204,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="nump">$ 306,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember', window );">Combined Balance Sheet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,875<span></span>
</td>
<td class="nump">7,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,649<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,979<span></span>
</td>
<td class="nump">77,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,380<span></span>
</td>
<td class="nump">262,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,277<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,925<span></span>
</td>
<td class="nump">35,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,843<span></span>
</td>
<td class="nump">44,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Parent company net investment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">218,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,380<span></span>
</td>
<td class="nump">262,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember', window );">Combined Balance Sheet [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,870<span></span>
</td>
<td class="nump">7,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,644<span></span>
</td>
<td class="nump">7,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,066<span></span>
</td>
<td class="nump">77,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,410<span></span>
</td>
<td class="nump">262,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,790<span></span>
</td>
<td class="nump">6,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,185<span></span>
</td>
<td class="nump">35,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,603<span></span>
</td>
<td class="nump">44,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Parent company net investment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,807<span></span>
</td>
<td class="nump">218,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,410<span></span>
</td>
<td class="nump">262,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember', window );">Combined Balance Sheet [Member] | Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Parent company net investment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and parent company net investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedBalanceSheetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488203840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="nump">$ 34,700<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 13,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,445<span></span>
</td>
<td class="nump">28,207<span></span>
</td>
<td class="nump">39,232<span></span>
</td>
<td class="nump">24,796<span></span>
</td>
<td class="nump">13,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,697<span></span>
</td>
<td class="nump">12,603<span></span>
</td>
<td class="nump">16,947<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
<td class="nump">8,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,430<span></span>
</td>
<td class="nump">50,004<span></span>
</td>
<td class="nump">70,357<span></span>
</td>
<td class="nump">48,891<span></span>
</td>
<td class="nump">31,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,698)<span></span>
</td>
<td class="num">(30,536)<span></span>
</td>
<td class="num">(35,609)<span></span>
</td>
<td class="num">(25,623)<span></span>
</td>
<td class="num">(13,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(14,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,698)<span></span>
</td>
<td class="num">(30,542)<span></span>
</td>
<td class="num">(34,350)<span></span>
</td>
<td class="num">(23,728)<span></span>
</td>
<td class="num">(13,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(2,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,544)<span></span>
</td>
<td class="num">(6,572)<span></span>
</td>
<td class="num">(7,308)<span></span>
</td>
<td class="num">(6,171)<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,596)<span></span>
</td>
<td class="num">$ (10,276)<span></span>
</td>
<td class="num">$ (6,282)<span></span>
</td>
<td class="num">$ (7,890)<span></span>
</td>
<td class="num">$ (8,625)<span></span>
</td>
<td class="num">$ (7,455)<span></span>
</td>
<td class="num">$ (29,154)<span></span>
</td>
<td class="num">$ (23,970)<span></span>
</td>
<td class="num">$ (27,042)<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember', window );">Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,796<span></span>
</td>
<td class="nump">13,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
<td class="nump">8,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,891<span></span>
</td>
<td class="nump">31,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,623)<span></span>
</td>
<td class="num">(13,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,728)<span></span>
</td>
<td class="num">(13,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,171<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneMember', window );">License And Milestone [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,894<span></span>
</td>
<td class="nump">13,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,240<span></span>
</td>
<td class="nump">7,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
<td class="nump">30,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,736)<span></span>
</td>
<td class="num">(12,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,841)<span></span>
</td>
<td class="num">(12,386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
<td class="num">(657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,896)<span></span>
</td>
<td class="num">(13,043)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | License And Milestone [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Service [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member] | License And Milestone [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member] | Service [Member] | Combined Statement Of Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=oabi_LicenseAndMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488841088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning</a></td>
<td class="nump">$ 226,943<span></span>
</td>
<td class="nump">$ 224,921<span></span>
</td>
<td class="nump">$ 234,307<span></span>
</td>
<td class="nump">$ 226,403<span></span>
</td>
<td class="nump">$ 227,600<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 234,307<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 235,537<span></span>
</td>
<td class="nump">$ 218,243<span></span>
</td>
<td class="nump">$ 204,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,596)<span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
<td class="num">(6,282)<span></span>
</td>
<td class="num">(7,890)<span></span>
</td>
<td class="num">(8,625)<span></span>
</td>
<td class="num">(7,455)<span></span>
</td>
<td class="num">(29,154)<span></span>
</td>
<td class="num">(23,970)<span></span>
</td>
<td class="num">(27,042)<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,284<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">10,747<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end</a></td>
<td class="nump">$ 232,710<span></span>
</td>
<td class="nump">$ 226,943<span></span>
</td>
<td class="nump">$ 224,921<span></span>
</td>
<td class="nump">$ 228,002<span></span>
</td>
<td class="nump">$ 226,403<span></span>
</td>
<td class="nump">227,600<span></span>
</td>
<td class="nump">$ 232,710<span></span>
</td>
<td class="nump">228,002<span></span>
</td>
<td class="nump">234,307<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">218,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember', window );">Combined Statement Of Changes In Parent Company Net Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">218,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,537<span></span>
</td>
<td class="nump">218,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Combined Statement Of Changes In Parent Company Net Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,807<span></span>
</td>
<td class="nump">228,807<span></span>
</td>
<td class="nump">218,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,896)<span></span>
</td>
<td class="num">(13,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,353<span></span>
</td>
<td class="nump">19,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,807<span></span>
</td>
<td class="nump">218,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member] | Combined Statement Of Changes In Parent Company Net Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489994128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,596)<span></span>
</td>
<td class="num">$ (10,276)<span></span>
</td>
<td class="num">$ (6,282)<span></span>
</td>
<td class="num">$ (7,890)<span></span>
</td>
<td class="num">$ (8,625)<span></span>
</td>
<td class="num">$ (7,455)<span></span>
</td>
<td class="num">$ (29,154)<span></span>
</td>
<td class="num">$ (23,970)<span></span>
</td>
<td class="num">$ (27,042)<span></span>
</td>
<td class="num">$ (17,557)<span></span>
</td>
<td class="num">$ (13,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,840)<span></span>
</td>
<td class="num">(6,325)<span></span>
</td>
<td class="num">(7,325)<span></span>
</td>
<td class="num">(6,185)<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,610)<span></span>
</td>
<td class="num">(12,721)<span></span>
</td>
<td class="num">(6,019)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">2,759<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(5,672)<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="num">(5,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,284<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">10,747<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,556<span></span>
</td>
<td class="nump">$ 3,780<span></span>
</td>
<td class="nump">9,697<span></span>
</td>
<td class="nump">23,361<span></span>
</td>
<td class="nump">17,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenueRecordedInAccountsReceivable', window );">Deferred revenue recorded in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,344<span></span>
</td>
<td class="nump">8,451<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember', window );">Combined Statement Of Cash Flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,557)<span></span>
</td>
<td class="num">(13,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,185)<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="num">(4,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,759<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
<td class="num">(1,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="num">(5,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,361<span></span>
</td>
<td class="nump">17,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenueRecordedInAccountsReceivable', window );">Deferred revenue recorded in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,451<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Combined Statement Of Cash Flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,896)<span></span>
</td>
<td class="num">(13,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,960)<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
<td class="num">(5,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="num">(1,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="num">(4,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,353<span></span>
</td>
<td class="nump">19,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,028<span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenueRecordedInAccountsReceivable', window );">Deferred revenue recorded in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member] | Combined Statement Of Cash Flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,451)<span></span>
</td>
<td class="num">(1,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,333)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredRevenueRecordedInAccountsReceivable', window );">Deferred revenue recorded in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,451<span></span>
</td>
<td class="nump">$ 1,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredRevenueRecordedInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue recorded in accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredRevenueRecordedInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=oabi_CombinedStatementOfCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549493410320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Combined Financial Statements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, after Allowance for Credit Loss, Current</a></td>
<td class="nump">$ 4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,136<span></span>
</td>
<td class="nump">$ 15,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="nump">$ 5,582<span></span>
</td>
<td class="nump">$ 3,697<span></span>
</td>
<td class="nump">$ 14,697<span></span>
</td>
<td class="nump">$ 12,603<span></span>
</td>
<td class="nump">$ 16,947<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
<td class="nump">$ 8,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, after Allowance for Credit Loss, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494179424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per unit</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants in a unit</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Public Warrants | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,666,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfSharesIssuedPerUnit', window );">Number of shares in a unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issuable per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Initial Public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488391856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price</a></td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="nump">8,233,333<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price</a></td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489161760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Relationship with Parent and Related Entities - Founder Shares (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_FounderSharesMember', window );">Founder Shares | Sponsor | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TotalNumberOfSharesTransferred', window );">Total number of shares transferred</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfSharesSubjectToForfeiture', window );">Shares subject to forfeiture</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders', window );">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination', window );">Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_FounderSharesMember', window );">Founder Shares | Sponsor | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected ownership percentage by the founders after completion of the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TotalNumberOfSharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total number of shares transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TotalNumberOfSharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549499163120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 5,279<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
<td class="nump">$ 12,273<span></span>
</td>
<td class="nump">$ 11,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="nump">7,243<span></span>
</td>
<td class="nump">6,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="nump">$ 5,030<span></span>
</td>
<td class="nump">$ 4,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549493638368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Relationship with Parent and Related Entities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,279,000<span></span>
</td>
<td class="nump">$ 3,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,273,000<span></span>
</td>
<td class="nump">$ 11,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,079,000<span></span>
</td>
<td class="nump">2,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,243,000<span></span>
</td>
<td class="nump">6,902,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">1,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,030,000<span></span>
</td>
<td class="nump">4,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oabi_EquityBasedIncentivePlansMember', window );">Equity Based Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oabi_EquityBasedIncentivePlansMember', window );">Equity Based Incentive Plans [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oabi_EquityBasedIncentivePlansMember', window );">Equity Based Incentive Plans [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oabi_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock expressed as a percentage of its fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.', window );">Percentage of their eligible compensation during the offering period.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equity Based Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/48 each month thereafter for forty-two months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/48 each month thereafter for forty-two months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equity Based Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/8 on the six month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/8 on the six month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,275<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_PromissoryNoteWithRelatedPartyMember', window );">Promissory Note with Related Party | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty', window );">Offering costs paid by Sponsor and included in promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party promissory note</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_AdministrativeSupportAgreementMember', window );">Administrative Support Agreement | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_RelatedPartyLoansMember', window );">Related Party Loans | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumLoansConvertibleIntoWarrants', window );">Loan conversion agreement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WorkingCapitalLoansOutstanding', window );">Working capital loans, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember', window );">Service [Member] | Director [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Service fee paid to a director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=oabi_GeneralCorporateOverheadMember', window );">General Corporate Overhead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Selling, general and administrative expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs included in promissory note - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of their eligible compensation during the offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WorkingCapitalLoansOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital loans, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WorkingCapitalLoansOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oabi_EquityBasedIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oabi_EquityBasedIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oabi_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oabi_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_AdministrativeSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_AdministrativeSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=oabi_GeneralCorporateOverheadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=oabi_GeneralCorporateOverheadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549498555328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Avista Public Acquisition Corp. II [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ITEM </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ITEM</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities', window );">Maximum number of demands for registration of securities | ITEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PurchasePricePerUnit', window );">Purchase price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredFeePerUnit', window );">Deferred fee per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AggregateDeferredUnderwritingFeePayable', window );">Aggregate deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalDeferredFeePerUnit', window );">Deferred underwriting fee per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalAggregateDeferredUnderwritingFeePayable', window );">Additional aggregate deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties', window );">Percentage of deferred underwriting fee payable to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties', window );">Aggregate deferred underwriting fee payable to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties', window );">Aggregate deferred underwriting fee company not to pay or allocate to third parties</a></td>
<td class="nump">$ 4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties', window );">Percentage of deferred underwriting fee payable not allocated to third parties</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_Underwritingcashdiscountperunit', window );">Underwriting cash discount per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_Underwritercashdiscount', window );">Underwriter cash discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalAggregateDeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalAggregateDeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalDeferredFeePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional deferred fee per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalDeferredFeePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AggregateDeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AggregateDeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate deferred underwriting fee payable decided by the company not to pay or allocate to third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AggregateDeferredUnderwritingFeePayableToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AggregateDeferredUnderwritingFeePayableToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredFeePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred fee per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredFeePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumNumberOfDemandsForRegistrationOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of demands for registration of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumNumberOfDemandsForRegistrationOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of deferred underwriting fee payable decided by the company not to pay or allocate to third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PurchasePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PurchasePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_Underwritercashdiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UnderwriterCashDiscount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_Underwritercashdiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_Underwritingcashdiscountperunit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UnderwritingCashDiscountPerUnit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_Underwritingcashdiscountperunit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490426304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details) - Avista Public Acquisition Corp. II [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantsToBePurchasedPursuantToAgreements', window );">Aggregate warrants to be purchase pursuant to agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumAdditionalAggregatePurchasePrice', window );">Maximum additional aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend upon modification of the forward purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (225,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember', window );">Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember', window );">Amended and Restated Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price private placement</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalAggregatePurchasePrice', window );">Additional aggregate purchase price</a></td>
<td class="nump">$ 86,729,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumAdditionalAggregatePurchasePrice', window );">Maximum additional aggregate purchase price</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Termination fee</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeemedDividend', window );">Deemed dividend upon modification of the forward purchase agreement</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SponsorPurchaseBackstop', window );">Sponsor purchased backstop</a></td>
<td class="nump">8,672,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesBackstopWarrants', window );">Shares backstop warrants</a></td>
<td class="nump">1,445,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_ForwardPurchaseAgreementMember', window );">Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Amended and Restated Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional number of warrants</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Amended and Restated Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesToBePurchasedPursuantToAgreements', window );">Shares To Be Purchased Pursuant To Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantsToBePurchasedPursuantToAgreements', window );">Aggregate warrants to be purchase pursuant to agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharesToBePurchasedPursuantToAgreements', window );">Shares To Be Purchased Pursuant To Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember', window );">APAC Common stock | Amended and Restated Forward Purchase Agreement | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AdditionalNumberOfCommonStock', window );">Additional number of common stock</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate purchase price of the additional shares and additional warrants under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AdditionalNumberOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional common stock to be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AdditionalNumberOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividends related to the Forward Purchase and Backstop Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumAdditionalAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate purchase price of the additional shares and additional warrants under an agreement in order to backstop shareholder redemptions for cash proceeds to be limited to the maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumAdditionalAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SharesBackstopWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Shares back shop warrants .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SharesBackstopWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SharesToBePurchasedPursuantToAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares to be purchased pursuant to agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SharesToBePurchasedPursuantToAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SponsorPurchaseBackstop">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Sponsor purchased backstop.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SponsorPurchaseBackstop</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WarrantsToBePurchasedPursuantToAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to be purchased pursuant to agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WarrantsToBePurchasedPursuantToAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_AmendedAndRestatedForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_ForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=oabi_ForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_ApacCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549499153712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,756)<span></span>
</td>
<td class="num">(3,662)<span></span>
</td>
<td class="num">(2,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(569)<span></span>
</td>
<td class="num">(2,523)<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,840)<span></span>
</td>
<td class="num">$ (6,325)<span></span>
</td>
<td class="num">(7,325)<span></span>
</td>
<td class="num">(6,185)<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (1,916)<span></span>
</td>
<td class="num">$ (6,544)<span></span>
</td>
<td class="num">$ (6,572)<span></span>
</td>
<td class="num">$ (7,308)<span></span>
</td>
<td class="num">$ (6,171)<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489633184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,214)<span></span>
</td>
<td class="num">$ (4,983)<span></span>
</td>
<td class="num">$ (2,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal', window );">State tax rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (1,916)<span></span>
</td>
<td class="num">$ (6,544)<span></span>
</td>
<td class="num">$ (6,572)<span></span>
</td>
<td class="num">$ (7,308)<span></span>
</td>
<td class="num">$ (6,171)<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489421360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized Tax Benefits, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="nump">18.30%<span></span>
</td>
<td class="nump">21.50%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=oabi_FederalResearchAndDevelopmentCreditMember', window );">Federal Research and Development Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=oabi_CaliforniaResearchAndDevelopmentCreditMember', window );">California Research and Development Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtySevenMember', window );">Two Thousand Thirty seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtyTwoMember', window );">Two Thousand Thirty Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=oabi_FederalResearchAndDevelopmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=oabi_FederalResearchAndDevelopmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=oabi_CaliforniaResearchAndDevelopmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=oabi_CaliforniaResearchAndDevelopmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=oabi_TwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549486776832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,618<span></span>
</td>
<td class="nump">$ 4,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">2,803<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredTaxAssetsDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">3,088<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(526)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">16,942<span></span>
</td>
<td class="nump">9,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(35,114)<span></span>
</td>
<td class="num">(37,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(2,973)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(38,904)<span></span>
</td>
<td class="num">(38,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="num">$ (21,962)<span></span>
</td>
<td class="num">$ (28,925)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredTaxAssetsDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Deferred Revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredTaxAssetsDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Operating Lease Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549498717808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior&#160;years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions in prior&#160;years</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490186000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OperatingLeaseAssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 21,456<span></span>
</td>
<td class="nump">$ 13,332<span></span>
</td>
<td class="nump">$ 2,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">25,016<span></span>
</td>
<td class="nump">13,272<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 26,546<span></span>
</td>
<td class="nump">$ 13,850<span></span>
</td>
<td class="nump">$ 2,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549498531632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining three months ending December&#160;31, 2022</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022-2023</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">$ 2,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023-2024</a></td>
<td class="nump">3,408<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024-2025</a></td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025-2026</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026-2027</a></td>
<td class="nump">3,885<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">14,745<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">33,651<span></span>
</td>
<td class="nump">21,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less imputed interest</a></td>
<td class="num">(6,075)<span></span>
</td>
<td class="num">(3,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(4,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 26,546<span></span>
</td>
<td class="nump">$ 13,850<span></span>
</td>
<td class="nump">$ 2,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities, tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549493414576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">operating lease right of use assets</a></td>
<td class="nump">$ 21,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,332<span></span>
</td>
<td class="nump">$ 2,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 25,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,272<span></span>
</td>
<td class="nump">$ 2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">operating lease right of use assets</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549498505104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 83,979<span></span>
</td>
<td class="nump">$ 83,979<span></span>
</td>
<td class="nump">$ 83,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible Assets, Net (Including Goodwill)</a></td>
<td class="nump">250,253<span></span>
</td>
<td class="nump">260,300<span></span>
</td>
<td class="nump">270,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software, Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">227,129<span></span>
</td>
<td class="nump">227,403<span></span>
</td>
<td class="nump">224,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(68,980)<span></span>
</td>
<td class="num">(60,099)<span></span>
</td>
<td class="num">(48,321)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (2,975)<span></span>
</td>
<td class="num">$ (2,083)<span></span>
</td>
<td class="num">$ (893)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489637584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsLineItems', window );"><strong>Balance Sheet Account Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 3,256<span></span>
</td>
<td class="nump">$ 3,278<span></span>
</td>
<td class="nump">$ 9,774<span></span>
</td>
<td class="nump">$ 9,740<span></span>
</td>
<td class="nump">$ 12,968<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="nump">10,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsLineItems', window );"><strong>Balance Sheet Account Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_BalanceSheetAccountDetailsLineItems', window );"><strong>Balance Sheet Account Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_BalanceSheetAccountDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet account details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_BalanceSheetAccountDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490266944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 24,569<span></span>
</td>
<td class="nump">$ 10,087<span></span>
</td>
<td class="nump">$ 4,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,194)<span></span>
</td>
<td class="num">(3,292)<span></span>
</td>
<td class="num">(1,306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">19,375<span></span>
</td>
<td class="nump">6,795<span></span>
</td>
<td class="nump">3,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
<td class="nump">3,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">17,639<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494599264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 2,249<span></span>
</td>
<td class="nump">$ 2,320<span></span>
</td>
<td class="nump">$ 1,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SubcontractorLiabilitiesCurrent', window );">Subcontractor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_AcquisitionsRelatedLiabilitiesCurrent', window );">Acquisition related liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,092<span></span>
</td>
<td class="nump">$ 3,746<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_AcquisitionsRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisitions related liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_AcquisitionsRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SubcontractorLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractor liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SubcontractorLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489630080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details) - Avista Public Acquisition Corp. II [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490178480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details) - Avista Public Acquisition Corp. II [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | VOTE</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | VOTE</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember', window );">Class A Common Stock Subject to Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | VOTE</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1', window );">Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfVotingRightsShareHolders', window );">Percentage of voting rights on share holders</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjustment of redemption price of stock based on market value and newly issued price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfVotingRightsShareHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Percentage of voting rights, share holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfVotingRightsShareHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489869328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details) - Avista Public Acquisition Corp. II [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>Day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | Day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement', window );">Maximum period after business combination in which to file registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective', window );">Period of time within which registration statement is expected to become effective</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">365 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">8,233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantExercisePeriodConditionTwo', window );">Warrant exercise period condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantExercisePriceAdjustmentMultiple', window );">Warrant exercise price adjustment multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember', window );">Public Warrants | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">7,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">365 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_ForwardPurchaseWarrantsAndBackstopMember', window );">Forward Purchase Warrants And Backstop | IPO [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="nump">3,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MonthsToCompleteInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MonthsToCompleteInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of business days before sending notice of redemption to warrant holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WarrantExercisePeriodConditionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The alternate period of time after completion of an initial public offering before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WarrantExercisePeriodConditionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WarrantExercisePriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WarrantExercisePriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_WarrantRedemptionPriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_WarrantRedemptionPriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_ForwardPurchaseWarrantsAndBackstopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_ForwardPurchaseWarrantsAndBackstopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549490247632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract', window );"><strong>Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_MaximumAdditionalAggregatePurchasePrice', window );">Maximum additional aggregate purchase price</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">235,750,000<span></span>
</td>
<td class="nump">235,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative liability - Forward Purchase and Backstop Securities</a></td>
<td class="nump">1,595,500<span></span>
</td>
<td class="nump">1,595,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">237,188,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative liability - Forward Purchase and Backstop Securities</a></td>
<td class="nump">1,595,500<span></span>
</td>
<td class="nump">1,595,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">237,188,875<span></span>
</td>
<td class="nump">237,188,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative liability - Forward Purchase and Backstop Securities</a></td>
<td class="nump">1,595,500<span></span>
</td>
<td class="nump">1,595,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative liability - Forward Purchase and Backstop Securities</a></td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the derivative - forward purchase and backstop securities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_MaximumAdditionalAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate purchase price of the additional shares and additional warrants under an agreement in order to backstop shareholder redemptions for cash proceeds to be limited to the maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_MaximumAdditionalAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549489099952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details) - Avista Public Acquisition Corp. II [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>item </div>
<div>yr</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative - Forward Purchase and Backstop Securities | $</a></td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent', window );">Derivative - Forward Purchase and Backstop Securities | $</a></td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="nump">$ 448,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Fair value of Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities | shares</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">10.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Present value of Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities | shares</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Time to Business Combination (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities | yr</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Discount factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities</a></td>
<td class="nump">99.8<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Expected redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Fair Value, Inputs, Level 3 [Member] | Probability of completing an initial Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of forward purchase and backstop securities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the derivative - forward purchase and backstop securities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputFairValueOfUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputFairValueOfUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCommodityForwardPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCommodityForwardPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputExpectedRedemptionRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputExpectedRedemptionRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549484582048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss', window );">Change in fair value of Forward Purchase and Backstop Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,212,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,147,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments to CVR holders and other contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,505,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,812,000<span></span>
</td>
<td class="nump">$ 7,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | xCella [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition', window );">Contingent liabilities from xCella asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Business Combination Contingent Consideration Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,364,000<span></span>
</td>
<td class="nump">7,204,000<span></span>
</td>
<td class="nump">$ 2,659,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments to CVR holders and other contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,770,000)<span></span>
</td>
<td class="num">(2,325,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,364,000<span></span>
</td>
<td class="nump">7,204,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Business Combination Contingent Consideration Liability [Member] | xCella [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition', window );">Contingent liabilities from xCella asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Business Combination Contingent Consideration Liability [Member] | Icagen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition', window );">Contingent liabilities from Icagen acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,390<span></span>
</td>
<td class="nump">$ 1,039,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_InitialMeasurementOfForwardPurchase', window );">Initial measurement as of March 23, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 591,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,212,110<span></span>
</td>
<td class="num">(656,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end</a></td>
<td class="nump">$ 1,039,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="nump">$ 383,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,595,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives - Forward Purchase and Backstop Securities recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_InitialMeasurementOfForwardPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of initial classification of the Forward Purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_InitialMeasurementOfForwardPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=oabi_XcellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=oabi_XcellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=oabi_BusinessCombinationContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=oabi_BusinessCombinationContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488390480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payment for contingent consideration liability, Investing activities</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=oabi_XcellaMember', window );">xCella [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquisition, Contingent consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payment for contingent consideration liability, Investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=oabi_XcellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=oabi_XcellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549494045120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 5,812<span></span>
</td>
<td class="nump">$ 7,364<span></span>
</td>
<td class="nump">$ 7,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">5,812<span></span>
</td>
<td class="nump">7,364<span></span>
</td>
<td class="nump">7,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Crystal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Crystal [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Crystal [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Crystal [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Icagen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">5,332<span></span>
</td>
<td class="nump">7,364<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Icagen [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Icagen [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Icagen [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">5,332<span></span>
</td>
<td class="nump">7,364<span></span>
</td>
<td class="nump">$ 6,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">xCella [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">xCella [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">xCella [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">xCella [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liabilities</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_XcellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_XcellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549493434944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 2,325<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_CrystalMember', window );">Crystal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember', window );">Icagen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=oabi_XcellaMember', window );">xCella [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_XcellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_XcellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140549488136576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 95,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oabi_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers', window );">Common stock subject to price-based earnout triggers</a></td>
<td class="nump">0.75842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Amount of drew down promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember', window );">Avista Public Acquisition Corp. II [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0067%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 95,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfTradingDaysForDeterminingTheSharePrice', window );">Number of trading days for determining the share price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_VolumeWeightedAverageTradingPrices', window );">Volume-weighted average trading prices</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ExcessPricePerShare', window );">Excess price per share</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | APACs Existing Public Shareholders [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sponsor Of APAC [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Related Parties Of APAC [Member] | OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | New OmniAb Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">4.90007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_VolumeWeightedAverageTradingPrices', window );">Volume-weighted average trading prices</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ExcessPricePerShare', window );">Excess price per share</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Avista Public Acquisition Corp. II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Shares sold in IPO redeemed for cash (in Shares)</a></td>
<td class="nump">21,713,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_SaleOfStockCashPricePerShare', window );">Shares issued cash price</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Shares sold in IPO redeemed for cash</a></td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Redemption price per share</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Working Capital Loans Warrant [Member] | Avista Public Acquisition Corp. II [Member] | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Aggregate borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Amount of drew down promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_CommonStockSubjectToPriceBasedEarnoutTriggers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock subject to price based earnout triggers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_CommonStockSubjectToPriceBasedEarnoutTriggers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_ExcessPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_ExcessPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_NumberOfTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_NumberOfTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_SaleOfStockCashPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount in Cash received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_SaleOfStockCashPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oabi_VolumeWeightedAverageTradingPrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average trading prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oabi_VolumeWeightedAverageTradingPrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oabi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=oabi_AvistaPublicAcquisitionCorp.IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=oabi_OmniabBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=oabi_ApacsExistingPublicShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=oabi_ApacsExistingPublicShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=oabi_SponsorOfApacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=oabi_SponsorOfApacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=oabi_RelatedPartiesOfApacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=oabi_RelatedPartiesOfApacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oabi_NewOmniabCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oabi_NewOmniabCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=oabi_WorkingCapitalLoansWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=oabi_WorkingCapitalLoansWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oabi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>d305908ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oabi="http://om.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oabi-20220930.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:EarnoutStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis">oabi:FirstRequirementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis">oabi:SecondRequirementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis">oabi:FirstRequirementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ClassCommonStockSharesNotSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:RelatedPartyLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandThirtyTwoMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">oabi:TwoThousandThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandThirtySevenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">oabi:TwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CaliforniaResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">oabi:CaliforniaResearchAndDevelopmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FederalResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">oabi:FederalResearchAndDevelopmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputFairValueOfUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityForwardPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputExpectedRedemptionRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ClassCommonStockSharesNotSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:RelatedPartyLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis">oabi:FirstRequirementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oabi:VestingRequirementsAxis">oabi:SecondRequirementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:OmniabIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_SponsorInsiderAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:SponsorInsiderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:EarnoutStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_NewOmniabCommonStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:NewOmniabCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_RelatedPartiesOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:RelatedPartiesOfApacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SponsorOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:SponsorOfApacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_ApacsExistingPublicShareholdersMembersrtOwnershipAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:ApacsExistingPublicShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseWarrantsAndBackstopMemberusgaapClassOfWarrantOrRightAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:OmniabBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:ForwardPurchaseWarrantsAndBackstopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="P03_15_2022To03_15_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:RelatedPartyLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputFairValueOfUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityForwardPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">oabi:MeasurementInputExpectedRedemptionRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">oabi:SeparationAndDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:LigandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To09_30_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P03_23_2022To03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oabi:ApacCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">oabi:AmendedAndRestatedForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="P03_24_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oabi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">oabi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_XcellaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_XcellaMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:AbInitioAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XCellaAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:TaurusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShareBasedPaymentArrangementNonemployeeDirectorsMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">oabi:ShareBasedPaymentArrangementNonemployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsAndPhantomShareUnitsMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">oabi:RestrictedStockUnitsAndPhantomShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="P08_17_2022To08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-17</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedBalanceSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="PAsOn06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oabi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="PAsOn02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_IcagenMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">oabi:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EquityBasedIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oabi:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:LicenseAndMilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">oabi:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">oabi:GeneralCorporateOverheadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020_XcellaMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">oabi:XcellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:TaurusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:TaurusAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:TaurusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="PAsOn09_09_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:TaurusAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XCellaAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="PAsOn09_08_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XCellaAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="P09_08_2020To09_08_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XCellaAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:XCellaAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2020_EarnoutRightsMemberusgaapContingentConsiderationByTypeAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:IcagenAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oabi:EarnoutRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:AbInitioAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:AbInitioAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:AbInitioAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">oabi:AbInitioAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">oabi:AvistaPublicAcquisitionCorp.IiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">oabi:CombinedStatementOfChangesInParentCompanyNetInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">oabi:BusinessCombinationContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Unit_item">
        <measure>oabi:item</measure>
    </unit>
    <unit id="Unit_ITEM">
        <measure>oabi:ITEM</measure>
    </unit>
    <unit id="Unit_VOTE">
        <measure>oabi:VOTE</measure>
    </unit>
    <unit id="Unit_Number">
        <measure>oabi:Number</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To09_30_2022">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To09_30_2022">0001846253</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To09_30_2022">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2022To09_30_2022">OMNIAB, INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory contextRef="P01_01_2022To09_30_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To09_30_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To09_30_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To09_30_2022">false</dei:EntityExTransitionPeriod>
    <oabi:NumberOfWarrantsIssuedPerUnit
      contextRef="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="hidden60239985"
      unitRef="Unit_shares">0.33</oabi:NumberOfWarrantsIssuedPerUnit>
    <oabi:NumberOfWarrantsIssuedPerUnit
      contextRef="P08_12_2021To08_12_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="hidden60240047"
      unitRef="Unit_shares">0.33</oabi:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      decimals="6"
      id="hidden60239967"
      unitRef="Unit_pure">0.000067</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <oabi:ThresholdBusinessDaysForRedemptionOfPublicShares
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      id="hidden60240023">P10D</oabi:ThresholdBusinessDaysForRedemptionOfPublicShares>
    <oabi:ThresholdBusinessDaysForRedemptionOfPublicShares
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      id="hidden60239959">P10D</oabi:ThresholdBusinessDaysForRedemptionOfPublicShares>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21136000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15875000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1406000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">774000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22542000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16649000</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">176321000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">186644000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3480000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13332000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2499000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2129000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">304465000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">295380000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2924000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">469000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3956000</us-gaap:AccruedLiabilitiesCurrent>
    <oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2538000</oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition>
    <oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2115000</oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7157000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">578000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">579000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20577000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14277000</us-gaap:LiabilitiesCurrent>
    <oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4826000</oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition>
    <oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5089000</oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21962000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28925000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2012000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9226000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8232000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">295000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1308000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">70158000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59843000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">234307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">235537000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">304465000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">295380000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">11385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12750000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">20084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">11883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5568000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">34748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23268000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39232000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13208000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16947000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10225000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">8651000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12968000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10304000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1210000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2070000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">818000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">70357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">48891000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">31345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-35609000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-25623000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-13027000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1266000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1259000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1895000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-34350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23728000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-13027000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">562000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-27042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">204882000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6660000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20290000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">218243000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9165000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25686000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">235537000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-27042000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15065000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10747000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">234307000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-27042000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:ProfitLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1210000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2070000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-818000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16252000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13137000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10917000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15065000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9165000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6660000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7325000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6185000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">557000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1265000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1900000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-161000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-6019000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-339000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4290000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">632000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">497000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">938000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1621000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1513000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2759000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-570000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-6717000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1328000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1875000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1876000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-822000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-2153000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5672000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-5195000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1265000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired>
    <oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27127000</oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired>
    <oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11840000</oabi:CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4070000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1753000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">255000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1900000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">720000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <oabi:OtherInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">500000</oabi:OtherInvestingActivities>
    <oabi:OtherInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:OtherInvestingActivities>
    <oabi:OtherInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:OtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-4025000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26980000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-12095000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1050000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2325000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10747000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25686000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20290000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9697000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23361000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17290000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11344000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8451000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1425000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1231000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">471000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="P01_01_2021To12_31_2021">&lt;div id="prewrkfin305908_18" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization and Nature of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#x201c;Ligand&#x201d; or the &#x201c;Parent&#x201d;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#x201c;OmniAb,&#x201d; &#x201c;the company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;). OmniAb is a biotechnology company with a Biological Intelligence powered multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand acquired OMT, pursuant to a multi-step transaction that resulted in Ligand&#x2019;s acquisition of OMT. On November&#160;10, 2021 OMT&#x2019;s name was changed to OmniAb, Inc. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. &lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ErrorCorrectionTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Restatement of Previously Issued Combined Financial Statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Subsequent to the issuance of the audited combined financial statements for the year ended December&#160;31, 2020 and 2019, the Company determined the balance of accounts receivable, net, as of December&#160;31, 2020, was understated by $7.0&#160;million and general and administrative expense was understated by $0.7&#160;million for the year ended December&#160;31, 2019. The error as of December&#160;31, 2020 was the result of the omission of an unbilled amount which was also improperly excluded from net transfers from parent company in the combined statement of changes in parent company net investment for the year ended December&#160;31, 2020, resulting in an understatement of parent company net investment. The error as of December&#160;31, 2019 related to bad debt expense that was not properly included in general and administrative expense on the combined statements of operations and was improperly recorded as part of the net transfers from parent company in the combined statements of changes in parent company net investment. The errors identified as of December&#160;31, 2020 and 2019, each resulted in the overstatement of cash provided by operating activities and an understatement of cash provided by financing activities in the combined statements of cash flows, in the respective periods. The Company has concluded that the errors identified were material to the combined financial statements as of and for the year ended December&#160;31, 2020 and 2019. Accordingly, previously reported amounts have been revised to reflect the correction of the error as well as other immaterial errors identified through the process of compiling the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;carve-out&lt;/div&gt; financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the revised results for the year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Balance Sheets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;288,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities and parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;288,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,796&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,728&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (expense)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of changes in Parent Company Net Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;January 1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfers from parent company&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Cash Flows &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to reconcile net loss to net cash provided by (used in) operating activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in operating assets and liabilities, net of acquisitions:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financing activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfer from parent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental disclosure of cash flow information:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue recorded in accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the revised results for the year ended December&#160;31, 2019, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Balance Sheets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities and parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License and milestone revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,685&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,976&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;675&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (expense)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of changes in Parent Company Net Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfers from parent company&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;December 31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Cash Flows &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to reconcile net loss to net cash provided by (used in) operating activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in operating assets and liabilities, net of acquisitions:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(450&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financing activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfer from parent&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by financing activities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental disclosure of cash flow information:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue recorded in accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ErrorCorrectionTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-5"
      unitRef="Unit_USD">7000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the revised results for the year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Balance Sheets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;288,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities and parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;288,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,970&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Balance Sheets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities and parent company net investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">8870000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7005000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">15875000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">9644000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7005000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">16649000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">186592000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">52000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">186644000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">84066000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-87000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">288410000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6970000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">295380000</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">3456000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">3956000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">13790000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">487000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">14277000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">29185000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-260000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">28925000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">1295000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">1308000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">59603000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">240000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">59843000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">228807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">235537000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">288410000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6970000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">295380000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P01_01_2021To12_31_2021_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,796&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,728&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (expense)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License and milestone revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,685&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,976&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;675&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (expense)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(657&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">24894000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-98000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">24796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">10240000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-15000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">10225000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">49004000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-113000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">48891000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-25736000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">113000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-25623000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-23841000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">113000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-23728000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">5945000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">226000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">6171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-17896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P01_01_2021To12_31_2021_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of changes in Parent Company Net Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;January 1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfers from parent company&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of changes in Parent Company Net Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfers from parent company&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent company net investment&#160;&#x2013;&#160;December 31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;218,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">218185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">218243000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-17896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:NetIncomeLoss>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">19353000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6333000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">25686000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">228807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">235537000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P01_01_2021To12_31_2021_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Cash Flows &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to reconcile net loss to net cash provided by (used in) operating activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in operating assets and liabilities, net of acquisitions:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financing activities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfer from parent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by financing activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental disclosure of cash flow information:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue recorded in accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Combined Statements of Cash Flows &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to reconcile net loss to net cash provided by (used in) operating activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in operating assets and liabilities, net of acquisitions:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(450&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financing activities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net transfer from parent&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash provided by financing activities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental disclosure of cash flow information:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue recorded in accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,425&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-17896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-17557000</us-gaap:NetIncomeLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-5960000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-225000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-6185000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-1096000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">1435000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">339000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">2337000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">422000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">2759000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">9779000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-8451000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">1328000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">1323000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-14000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">1309000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">9952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-6333000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">3619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">19353000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6333000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">25686000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">17028000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6333000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">23361000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">8451000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">8451000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7774000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">7924000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7795000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">7945000</us-gaap:AssetsCurrent>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">77108000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-86000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">77022000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">262320000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">64000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">262384000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">806000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">877000</us-gaap:AccountsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6139000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">6217000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">35388000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-86000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">35302000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">295000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">309000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">44135000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">44141000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">218185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">218243000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">262320000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">64000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">262384000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">12685000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">65000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_LicenseAndMilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12750000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5528000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5568000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">18213000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">105000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">18318000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">13137000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">13208000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">7976000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">675000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">8651000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">30599000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">746000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">31345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-12386000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-641000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-13027000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-12386000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-641000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-13027000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-657000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">95000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-562000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-13043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-13043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:NetIncomeLoss>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">19686000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">604000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">20290000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">218185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">218243000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-13043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-13589000</us-gaap:NetIncomeLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">653000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-96000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">557000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-5565000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">1275000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-4290000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-648000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-570000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-450000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-1425000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-1875000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-1959000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">110000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-1849000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-4591000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">-604000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">-5195000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">19686000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">604000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">20290000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">16686000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">604000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">17290000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">1425000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <oabi:DeferredRevenueRecordedInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"
      decimals="-3"
      unitRef="Unit_USD">1425000</oabi:DeferredRevenueRecordedInAccountsReceivable>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#x2019;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#x2019;s net investment in these operations is shown in lieu of stockholder&#x2019;s equity in the combined financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#x2019;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note (9)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Relationship with Parent and Related Entities&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#x2019;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note (9)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Relationship with Parent and Related Entities&lt;/div&gt;&lt;/div&gt; for additional discussion. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#x2019;s revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#x2019;s net loss was ($27.0 million), ($17.6 million) and ($13.6 million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#x2019;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb qualifies as an &#x201c;emerging growth company&#x201d; (EGC) as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb&#x2019;s historical results are included as a part of the Parent&#x2019;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This may make comparison of OmniAb&#x2019;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#x2019;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Business Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year-ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A, B and C in 2019 represent different customers than 2020 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(COVID-19)&lt;/div&gt; pandemic on our business and recorded an adjustment of $0.1&#160;million of allowance for credit losses as of December&#160;31, 2021. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill attributed to OmniAb&#x2019;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#x2019; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgment. If our estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;or&lt;/div&gt; regulatory approval. &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $7.4&#160;million. During the year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $0.4&#160;million. During the year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $2.4&#160;million. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,748&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensing&lt;/div&gt; costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain of our employees participated in our Parent&#x2019;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#x2019;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted stock&#160;units (RSU) and performance stock&#160;units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#x2019;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#x2019;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; in the period of adjustment. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $2.50 per share, our Parent has not paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We grant options, RSUs and PSUs to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors under Ligand&#x2019;s equity plan. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-employee&lt;/div&gt; directors are accounted for as employees. Options and RSUs granted to certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors typically vest one year from the date of grant. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options granted to employees typically vest&#160;1/8 on the six m&lt;/div&gt;onth anniversary of the date of grant, and 1/48 each month thereafter for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forty-two&lt;/div&gt; months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;Topic 740&#x201d;). Accordingly, our income tax provision was prepared following the &#x201c;Separate Return Method.&#x201d; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#x2019;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Pandemic &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; initially, including issuing varying forms of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;stay-at-home&#x201d;&lt;/div&gt;&lt;/div&gt; orders, and restricting business functions outside of one&#x2019;s home. We have generally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-person&lt;/div&gt; access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; could have on our business in the future, the continued spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#x2019; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In addition, if &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4,&lt;/div&gt; of which this proxy statement/prospectus/information statement forms a part. &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#x2019;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#x2019;s net investment in these operations is shown in lieu of stockholder&#x2019;s equity in the combined financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#x2019;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note (9)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Relationship with Parent and Related Entities&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#x2019;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note (9)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Relationship with Parent and Related Entities&lt;/div&gt;&lt;/div&gt; for additional discussion. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. &lt;/div&gt;&lt;/div&gt; </oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock>
    <oabi:LiquidityAndCapitalResourcesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#x2019;s revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#x2019;s net loss was ($27.0 million), ($17.6 million) and ($13.6 million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#x2019;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &lt;/div&gt;&lt;/div&gt;</oabi:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:Revenues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">34700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">23300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">18300000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-27000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">-17600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">-13600000</us-gaap:NetIncomeLoss>
    <oabi:EmergingGrowthCompanyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb qualifies as an &#x201c;emerging growth company&#x201d; (EGC) as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb&#x2019;s historical results are included as a part of the Parent&#x2019;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This may make comparison of OmniAb&#x2019;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used &lt;/div&gt;&lt;/div&gt;</oabi:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#x2019;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Business Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year-ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A, B and C in 2019 represent different customers than 2020 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year-ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Partner A, B and C in 2019 represent different customers than 2020 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerBMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerCMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="INF"
      unitRef="Unit_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(COVID-19)&lt;/div&gt; pandemic on our business and recorded an adjustment of $0.1&#160;million of allowance for credit losses as of December&#160;31, 2021. &lt;/div&gt; </us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <oabi:BusinessCombinationAndAssetAcquisitionsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/div&gt;&lt;/div&gt;</oabi:BusinessCombinationAndAssetAcquisitionsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill attributed to OmniAb&#x2019;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#x2019; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgment. If our estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;or&lt;/div&gt; regulatory approval. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <oabi:DeferredRevenuePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $7.4&#160;million. During the year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $0.4&#160;million. During the year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $2.4&#160;million. &lt;/div&gt;</oabi:DeferredRevenuePolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">7400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2021To12_31_2021"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,748&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,748&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">10164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">7125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">7050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">20084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">11883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5568000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">34748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23268000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensing&lt;/div&gt; costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain of our employees participated in our Parent&#x2019;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#x2019;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted stock&#160;units (RSU) and performance stock&#160;units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#x2019;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#x2019;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; in the period of adjustment. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $2.50 per share, our Parent has not paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We grant options, RSUs and PSUs to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors under Ligand&#x2019;s equity plan. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-employee&lt;/div&gt; directors are accounted for as employees. Options and RSUs granted to certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors typically vest one year from the date of grant. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options granted to employees typically vest&#160;1/8 on the six m&lt;/div&gt;onth anniversary of the date of grant, and 1/48 each month thereafter for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forty-two&lt;/div&gt; months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.5</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_ShareBasedPaymentArrangementNonemployeeDirectorsMemberusgaapGranteeStatusAxis">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <oabi:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">Options granted to employees typically vest&#160;1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months.</oabi:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsAndPhantomShareUnitsMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;Topic 740&#x201d;). Accordingly, our income tax provision was prepared following the &#x201c;Separate Return Method.&#x201d; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#x2019;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <oabi:ImpactOfCovidNineteenPandemicPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Pandemic &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; initially, including issuing varying forms of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;stay-at-home&#x201d;&lt;/div&gt;&lt;/div&gt; orders, and restricting business functions outside of one&#x2019;s home. We have generally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-person&lt;/div&gt; access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; could have on our business in the future, the continued spread of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#x2019; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In addition, if &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact. &lt;/div&gt; </oabi:ImpactOfCovidNineteenPandemicPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4,&lt;/div&gt; of which this proxy statement/prospectus/information statement forms a part. &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <oabi:BusinessCombinationAndAssetAcquisitionTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As set forth below, we completed four acquisitions from January&#160;1, 2019 through December&#160;31, 2021, of which two (Icagen and Ab Initio) were accounted for as business combinations and Taurus and xCella were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. We did not incur any material acquisition related costs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Taurus Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;9, 2020, we acquired Taurus, which discovers and humanize antibodies from immunized cows and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cow-derived&lt;/div&gt; libraries. These antibodies feature some of the longest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CDR-H3s&lt;/div&gt; of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The purchase price of $5.2&#160;million included $4.6&#160;million in cash, and a $0.5&#160;million holdback to satisfy indemnification obligations which were settled in September&#160;2021. Taurus stockholders also received nontransferable contingent value rights (CVRs) representing the right to receive up to $4.5&#160;million tied to partnered and internal research and development and up to $25.0&#160;million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We evaluated this acquisition in accordance with ASC 805, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations&lt;/div&gt;&lt;/div&gt;, to discern whether the assets and operations of Taurus met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands) &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash included in Parent company net investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangibles assets with finite-life&#160;&#x2013;&#160;core technologies&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;xCella Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;8, 2020, we acquired xCella Biosciences, an antibody discovery company. xCella&#x2019;s xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity which expand our existing single &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-cell&lt;/div&gt; assay capabilities in the OmniAb technology platform. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We paid $7.1&#160;million in cash (including a $0.5&#160;million holdback to satisfy indemnification obligations which was settled in September&#160;2021), and issued earnout rights for up to $5.0&#160;million tied to our use of the xCella technology for partnered research and development and for up to $25.75&#160;million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805 to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash included in Parent company net investment and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangibles assets with finite-life&#160;&#x2013;&#160;core technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 15&#160;years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Icagen Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;1, 2020, we acquired the core assets of Icagen and certain of its affiliates. The Icagen Technology Platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and in silico and computational chemistry applications for the discovery of therapeutics targeting ion channel pathways. Icagen is partnered with several globally recognized pharmaceutical companies for ion channel drug discovery. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The purchase price of $19.9&#160;million included $15.1&#160;million cash consideration paid upon acquisition, and a contingent earnout payment to the selling shareholders of up to $25.0&#160;million of cash payments based on certain revenue milestones with an estimated fair value of $4.8&#160;million. The fair value of the earnout liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants&#x2019; cost of debt reflective of Icagen. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 5, Fair Value Measurement&lt;/div&gt;&lt;/div&gt;, for further discussion. The liability will be periodically assessed based on events and circumstances related to the &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;underlying milestones, and any change in fair value will be recorded in our combined statements of operations. The carrying amount of the liability may fluctuate significantly and the actual amount paid may be materially different than the carrying amount of the liability. The results of Icagen have been included in our results of operations since the date of acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaids and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,685&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1&#160;million of customer relationships and $1.7&#160;million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6&#160;years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years. The total acquired intangibles are being amortized on a straight-line basis over the estimated weighted average useful life of 9.7&#160;years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ab Initio Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;23, 2019, we acquired Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has licensed a patented antigen technology owned by Stanford for the discovery of therapeutic antibodies including against &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;difficult-to-access&lt;/div&gt;&lt;/div&gt; cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The purchase price of $12.0&#160;million included $11.9&#160;million cash consideration paid upon acquisition, net of cash acquired, and a $0.15&#160;million cash holdback for potential indemnification claims. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets with finite-life&#160;&#x2013;&#160;core technologies&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20&#160;years. &lt;/div&gt;&lt;/div&gt; </oabi:BusinessCombinationAndAssetAcquisitionTextBlock>
    <oabi:NumberOfAcquisitions
      contextRef="P01_01_2019To12_31_2021"
      decimals="INF"
      unitRef="Unit_Number">4</oabi:NumberOfAcquisitions>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="P01_01_2019To12_31_2021"
      decimals="INF"
      unitRef="Unit_Number">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">4600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <oabi:BusinessCombinationConsiderationTransferredEarnoutRights
      contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">4500000</oabi:BusinessCombinationConsiderationTransferredEarnoutRights>
    <oabi:BusinessCombinationConsiderationTransferredEarnoutRights
      contextRef="PAsOn09_09_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</oabi:BusinessCombinationConsiderationTransferredEarnoutRights>
    <oabi:PercentageShareOfPostClinicalAcquireeProductRevenues
      contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</oabi:PercentageShareOfPostClinicalAcquireeProductRevenues>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands) &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash included in Parent company net investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangibles assets with finite-life&#160;&#x2013;&#160;core technologies&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">5155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">5202000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P09_09_2020To09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <oabi:BusinessCombinationConsiderationTransferredEarnoutRights
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</oabi:BusinessCombinationConsiderationTransferredEarnoutRights>
    <oabi:BusinessCombinationConsiderationTransferredEarnoutRights
      contextRef="PAsOn09_08_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-4"
      unitRef="Unit_USD">25750000</oabi:BusinessCombinationConsiderationTransferredEarnoutRights>
    <oabi:PercentageShareOfFutureMilestonePayments
      contextRef="P09_08_2020To09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</oabi:PercentageShareOfFutureMilestonePayments>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2021To12_31_2021_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash included in Parent company net investment and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangibles assets with finite-life&#160;&#x2013;&#160;core technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">240000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">142000</oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">320000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7298000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn09_08_2020_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7076000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P09_08_2020To09_08_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_XCellaAcquisitionMemberusgaapBusinessAcquisitionAxis">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">19900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="PAsOn04_01_2020_EarnoutRightsMemberusgaapContingentConsiderationByTypeAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <oabi:BusinessCombinationContingentConsiderationRevenueMilestonePayment
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">4800000</oabi:BusinessCombinationContingentConsiderationRevenueMilestonePayment>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2021To12_31_2021_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaids and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,685&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,055&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1173000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">812000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3685000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">821000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">12800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">9055000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">19940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <oabi:BusinessCombinationCashFlowDiscountedRate
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</oabi:BusinessCombinationCashFlowDiscountedRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P04_01_2020To04_01_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">P9Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <oabi:BusinessCombinationCashFlowDiscountedRate
      contextRef="PAsOn04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</oabi:BusinessCombinationCashFlowDiscountedRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P04_01_2020To04_01_2020_IcagenAcquisitionMemberusgaapBusinessAcquisitionAxis">P9Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <oabi:BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-4"
      unitRef="Unit_USD">150000</oabi:BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2021To12_31_2021_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets with finite-life&#160;&#x2013;&#160;core technologies&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">28000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">83000</oabi:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">7400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4862000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">12011000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <oabi:BusinessCombinationCashFlowDiscountedRate
      contextRef="PAsOn07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="3"
      unitRef="Unit_pure">0.12</oabi:BusinessCombinationCashFlowDiscountedRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P07_23_2019To07_23_2019_AbInitioAcquisitionMemberusgaapBusinessAcquisitionAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Fair Value Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#160;&#x2014;&#160;Observable inputs such as quoted prices in active markets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#160;&#x2014;&#160;Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities Measured on a Recurring Basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the hierarchy for our liabilities measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Crystal contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Icagen contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $1.8&#160;million contingent liability on development milestones to former Crystal shareholders. During the year ended December&#160;31, 2021, we made no payments former Crystal shareholders for contingent liability on development milestones. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $0.5&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the year ended December&#160;31, 2021, we paid $1.1&#160;million contingent liability based on revenue milestones to former Icagen shareholders. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of January&#160;1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to CVR holders and other contingent payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from Icagen acquisition&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments on contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,770&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from xCella asset acquisition&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September&#160;2020. During the year ended December&#160;31, 2021, management paid $0.7&#160;million of &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to relatively short periods to maturity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Assets Measured on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Recurring&lt;/div&gt; Basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We apply fair value techniques on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level&#160;3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level&#160;3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the&#160;years ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the hierarchy for our liabilities measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Crystal contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Icagen contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $1.8&#160;million contingent liability on development milestones to former Crystal shareholders. During the year ended December&#160;31, 2021, we made no payments former Crystal shareholders for contingent liability on development milestones. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the year ended December&#160;31, 2020, we paid $0.5&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the year ended December&#160;31, 2021, we paid $1.1&#160;million contingent liability based on revenue milestones to former Icagen shareholders. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">6404000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">6404000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7204000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7204000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To12_31_2020_CrystalMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To12_31_2020_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of January&#160;1, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to CVR holders and other contingent payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from Icagen acquisition&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments on contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,770&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from xCella asset acquisition&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September&#160;2020. During the year ended December&#160;31, 2021, management paid $0.7&#160;million of &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">2659000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-2325000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">2070000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4800000</oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">7204000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-1770000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">1210000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition
      contextRef="P01_01_2021To12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">720000</oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_BusinessCombinationContingentConsiderationLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2020_XcellaMemberusgaapAssetAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2021To12_31_2021_XcellaMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain legal entities included in this combined financials lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten&#160;years, some of which include options to extend the leases for up to ten&#160;years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12&#160;months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7&#160;million and lease liabilities of $13.2&#160;million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Lease Assets and Liabilities (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,012&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturity Dates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less tenant improvement allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 9.3&#160;years and a weighted-average discount rate of 4%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.7&#160;years and a weighted-average discount rate of 7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.1&#160;million and $0.7&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $1.6&#160;million, $0.7&#160;million and $0.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">12700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">13200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Lease Assets and Liabilities (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,012&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13332000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2499000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">578000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">579000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2012000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13850000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2591000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturity Dates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less tenant improvement allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2178000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2249000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2433000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10414000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21780000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ReceivableWithImputedInterestNetAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3603000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-4327000</oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13850000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.04</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P4Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseExpense>
    <oabi:BalanceSheetAccountDetailsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Balance Sheet Account Details &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment are stated at cost and consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab and office equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to &lt;br/&gt;ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is &lt;br/&gt;shorter. Depreciation expense of $2.0&#160;million, $0.8&#160;million and $0.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, &lt;br/&gt;respectively, and was included in operating expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite-lived intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite-lived intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Complete technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;224,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(48,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total goodwill and other identifiable intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;260,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20&#160;years. Amortization expense of $13.0&#160;million, $11.8&#160;million and $10.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Estimated amortization expense for the&#160;years ending December&#160;31, 2022 through 2026 is $13.0&#160;million per year. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, there was no impairment of intangible assets with finite lives. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalties owed to third parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subcontractor&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions related liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </oabi:BalanceSheetAccountDetailsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment are stated at cost and consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab and office equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3495000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">732000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10087000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4786000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3292000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1306000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3480000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">three</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">ten years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite-lived intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite-lived intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Complete technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;224,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(48,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total goodwill and other identifiable intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;260,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">227403000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">224758000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">60099000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">48321000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2083000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">893000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">260300000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">270623000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">11800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">10300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalties owed to third parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subcontractor&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions related liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2320000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1495000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">296000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">272000</us-gaap:AccruedRoyaltiesCurrent>
    <oabi:SubcontractorLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:SubcontractorLiabilitiesCurrent>
    <oabi:SubcontractorLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">482000</oabi:SubcontractorLiabilitiesCurrent>
    <oabi:AcquisitionsRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000000</oabi:AcquisitionsRelatedLiabilitiesCurrent>
    <oabi:AcquisitionsRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1500000</oabi:AcquisitionsRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">185000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3956000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have historically operated as part of Ligand and not as a stand-alone company. We determined the OmniAb income tax provision as if OmniAb had joined in the consolidated federal income tax return and combined state income tax returns separate from Ligand. We recorded a current state income tax expense for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 for certain OmniAb state minimum taxes. We recorded a deferred federal and state income tax benefit for the year ended December&#160;31, 2021 and 2020 to reflect the change in the net deferred tax liability for the period. We recorded a deferred federal tax benefit and deferred state tax expense for the year ended December&#160;31, 2019 to reflect the change in the net deferred tax liability for the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense (benefit):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred expense (benefit):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense (benefit)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at federal statutory rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,983&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State, net of federal benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,253&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;847&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(573&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in uncertain tax positions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State tax rate change&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of the our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of the our deferred tax assets will be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,088&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance for deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identified intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $27.3&#160;million and $12.6&#160;million of state net operating loss carryforwards that begin to expire in 2032. We also have $1.9&#160;million of federal research and development credit carryforwards, which expire through 2028. We have $2.0&#160;million of California research and development credit carryforwards that have no expiration date. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Sections&#160;382 and 383. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying combined balance sheet. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions based on tax positions related to the current year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions for tax positions of prior&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reductions for tax positions in prior&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $0.8&#160;million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve&#160;months. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021, 2020 and 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States and various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating loss and research credit carryforwards arising prior to these&#160;years are also open to examination if and when utilized. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense (benefit):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred expense (benefit):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,779&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense (benefit)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">17000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">17000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-6756000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-3662000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-2779000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-569000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2523000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3336000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7325000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6185000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">557000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">562000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at federal statutory rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,983&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State, net of federal benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,253&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;847&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(573&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in uncertain tax positions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State tax rate change&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7214000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-4983000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-2736000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-350000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-188000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-207000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-168000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-12000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-172000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1143000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1253000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">847000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1064000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">573000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">119000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1596000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2840000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">228000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-39000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-66000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">562000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;772&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,088&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance for deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,942&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identified intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(37,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(817&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(38,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6618000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4492000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2803000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1991000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1703000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1373000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <oabi:DeferredTaxAssetsDeferredRevenue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1768000</oabi:DeferredTaxAssetsDeferredRevenue>
    <oabi:DeferredTaxAssetsDeferredRevenue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">772000</oabi:DeferredTaxAssetsDeferredRevenue>
    <oabi:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3088000</oabi:DeferredTaxAssetsOperatingLeaseLiabilities>
    <oabi:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">577000</oabi:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1488000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1015000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">526000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">403000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16942000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9817000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35114000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">37479000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <oabi:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2973000</oabi:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <oabi:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">560000</oabi:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">817000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">703000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38904000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">38742000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21962000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28925000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_TwoThousandThirtySevenMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">27300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_TwoThousandThirtyTwoMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">12600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_FederalResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_CaliforniaResearchAndDevelopmentCreditMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions based on tax positions related to the current year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions for tax positions of prior&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reductions for tax positions in prior&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">766000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">556000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">33000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">894000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">766000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Relationship with Parent and Related Entities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in the future by OmniAb. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;General Corporate Overhead &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rata&lt;/div&gt; method based on project-related costs or other measures that management believes are consistent and reasonable. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs of $6.1&#160;million, $3.6&#160;million and $2.8&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively, have been reflected in the general and administrative expenses in our combined statements of operations for our allocated share of Parent&#x2019;s corporate overhead. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash Management and Financing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We participate in Ligand&#x2019;s centralized cash management and financing programs and will continue to participate in Ligand&#x2019;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a separation agreement, to be entered into between Ligand and OmniAb. Completion of the separation and distribution is subject to certain conditions, including final approval by Ligand&#x2019;s board of directors. Ligand is targeting the separation of OmniAb during the second quarter of 2022. The separation is anticipated to be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-free&lt;/div&gt; to Ligand stockholders. Accordingly, after the anticipated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-free&lt;/div&gt; separation, all of the related tax attributes of Ligand will remain with Ligand. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity-Based Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain of our employees participate in our Parent&#x2019;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-statutory&lt;/div&gt; stock options or incentive stock options, restricted stock&#160;units (RSUs), performance stock&#160;units (PSUs) and other cash-based or share-based awards. Awards granted to our employees under the incentive plans typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forty-two months&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt; We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation costs associated with our employees&#x2019; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. Total costs charged to us related to our employees&#x2019; participation in our Parent&#x2019;s incentive plans, depending on the nature of the employee&#x2019;s role in our operations, were $15.1&#160;million ($9.0&#160;million in research and development expenses and $6.1&#160;million in general and administrative expenses), $9.2&#160;million ($5.6&#160;million in research and development expenses and $3.6&#160;million in general and administrative expenses) and $6.7&#160;million ($3.9&#160;million in research and development expenses and $2.8&#160;million in general and administrative expenses) during the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our eligible employees participate in our Parent&#x2019;s ESPP. The ESPP permits eligible participants to purchase Ligand&#x2019;s shares at a discount through regular payroll deductions of up to 10% of their eligible compensation during the offering period. The ESPP is typically implemented through consecutive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-month&lt;/div&gt; offering periods. The purchase price of the shares is 85% of the lesser of the fair market value of the closing price per share on the first day of the offering period and the fair market value of the closing price per share on the last day of the offering period. No participant may purchase more than $25,000 worth of common stock per calendar year. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs charged to us related to our employees&#x2019; participation in our Parent&#x2019;s ESPP were $0.2&#160;million, $0.1&#160;million and $0.1&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To12_31_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-2"
      unitRef="Unit_USD">6100</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-2"
      unitRef="Unit_USD">3600</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-2"
      unitRef="Unit_USD">2800</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">1/8 on the six month</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">1/48 each month thereafter for forty-two months</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">15100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">6100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">5600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">6700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <oabi:PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.
      contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</oabi:PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">25000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      unitRef="Unit_USD">200</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      unitRef="Unit_USD">100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      unitRef="Unit_USD">100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Commitments and Contingencies: Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4722000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21136000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1125000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">785000</us-gaap:PrepaidExpenseCurrent>
    <oabi:TransactionCostsCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5931000</oabi:TransactionCostsCurrent>
    <oabi:TransactionCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:TransactionCostsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1237000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      unitRef="Unit_USD">621000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13015000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22542000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">902000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">166274000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">176321000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">19375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21456000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13332000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1449000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">306450000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">304465000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6275000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2924000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4092000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</us-gaap:AccruedLiabilitiesCurrent>
    <oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1693000</oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition>
    <oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2538000</oabi:ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9202000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1530000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">578000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">22793000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20577000</us-gaap:LiabilitiesCurrent>
    <oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4119000</oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition>
    <oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4826000</oabi:ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">16021000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21962000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">25016000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5493000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9226000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">298000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">295000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">73740000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">70158000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">232710000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">234307000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">306450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">304465000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14254000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">7826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_LicenseAndMilestoneRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">6277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13189000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">9925000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">35445000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">28207000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5582000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3697000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14697000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">12603000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3256000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3278000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9774000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">9740000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">208000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">817000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">486000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">546000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21819000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">16083000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">59430000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">50004000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-14909000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-9806000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-35698000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-30536000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-14909000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-9806000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-35698000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-30542000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-2313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1916000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-6544000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-6572000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-12596000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-7890000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-29154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-23970000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">235537000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7455000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3379000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3861000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">227600000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-8625000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4417000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3011000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">226403000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-7890000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3809000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">5680000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">228002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">234307000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-6282000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3146000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-6250000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">224921000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-10276000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3848000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">8450000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">226943000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-12596000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5279000</us-gaap:ShareBasedCompensation>
    <oabi:IncreaseInEquityContributionFromParent
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13084000</oabi:IncreaseInEquityContributionFromParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">232710000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-29154000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-23970000</us-gaap:ProfitLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-487000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-546000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13429000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">13779000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">12273000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11605000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-6840000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-6325000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">133000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-35000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-17610000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-12721000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">817000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">188000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1755000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-567000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">432000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-6384000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5118000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1872000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-3953000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3556000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1232000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">12152000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2548000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">960000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-13112000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2548000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1545000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1050000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4183000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">15284000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4830000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9556000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3780000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3561000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">114000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization and Nature of Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#x201c;Ligand&#x201d; or the &#x201c;Parent&#x201d;), which are Ab Initio Biotherapeutics, Inc. (Ab Initio), Crystal Bioscience, Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology, Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences, Inc. (xCella) (collectively, &#x201c;OmniAb&#x201d;, &#x201c;the Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d; and &#x201c;our&#x201d;). OmniAb is powered by Biological Intelligence, a multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand completed a multi-step transaction that resulted in Ligand&#x2019;s acquisition of OMT. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb, Inc. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On November&#160;1, 2022, Ligand completed (the &#x201c;Closing&#x201d;) the separation of its antibody discovery business and certain related assets and liabilities through a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;spin-off&lt;/div&gt; of OmniAb to Ligand&#x2019;s shareholders of record as of October&#160;26, 2022 on a pro rata basis and merger of OmniAb with a wholly owned subsidiary of OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II, a Cayman Islands exempted company, prior to its domestication as a corporation incorporated in the state of Delaware (&#x201c;APAC&#x201d;)) in a Reverse Morris Trust transaction pursuant to the Agreement and Plan of Merger, dated as of March 23, 2022 (the &#x201c;Merger Agreement&#x201d;), among Ligand, OmniAb, APAC and Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of APAC, and the Separation and Distribution Agreement, dated as of March 23, 2022 (the &#x201c;Separation Agreement&#x201d;), among Ligand, OmniAb and APAC. The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#x201c;New OmniAb&#x201d;). &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of the Closing, New OmniAb expected to have approximately $95.8 million of net cash. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On November&#160;2, 2022, New OmniAb began &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;regular-way&lt;/div&gt; trading on NASDAQ under the ticker symbol &#x201c;OABI.&#x201d; Ligand continues to trade under the ticker symbol &#x201c;LGND.&#x201d; See further details regarding the transaction in Note 9: Subsequent Event. &lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:Cash
      contextRef="PAsOn11_01_2022"
      decimals="-5"
      unitRef="Unit_USD">95800000</us-gaap:Cash>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#x2019;s interim condensed combined financial statement accounting records. The interim condensed combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#x2019;s net investment in these operations is shown in lieu of stockholder&#x2019;s equity in the combined financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records certain transactions at the parent entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#x2019;s ownership. As the entities were under common control, the financial statements report the financial position, &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January 2016. Transactions between Ligand and the Company are accounted for through the Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The interim condensed combined financial statements include all revenues, expenses, assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a percentage of total operating expenses or other measures that management believes are consistent and reasonable. See Note 8. Relationship with Parent and Related Entities&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#x2019;s combined statements of operations. The share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See Note 8. Relationship with Parent and Related Entities for additional discussion. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the allocations and estimates in the interim condensed combined financial statements are based on assumptions that management believes are reasonable. However, the interim condensed combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Unaudited Interim Financial Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined balance sheet as of September&#160;30, 2022, the condensed combined statements of operations, condensed combined statements of changes in parent company net investment for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed combined statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related footnote disclosures are unaudited. In management&#x2019;s opinion, the unaudited interim combined financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2022, its results of operations for the three and nine months ended September&#160;30, 2022 and 2021, and its statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 in accordance with U.S. GAAP. The results for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. Therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of Parent company net investment in the combined balance sheets and as a financing activity allocation on the accompanying combined statements of cash flows. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#x2019;s revenue was $23.7&#160;million and $19.5&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#x2019;s net loss was $(29.2) million and $(24.0) million, respectively. OmniAb expects to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#x2019;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the merger between the Company and a subsidiary of APAC, New OmniAb was capitalized with approximately $95.8 million in net cash. This cash and cash the Company generates from operations provide us the flexibility we need to meet operating, investing, and financing needs and support operations through at least 12 months following the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We have described our significant accounting policies in Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt; of the Notes to Combined Financial Statements included in the registration statement on Form S-4 filed on September 27, 2022. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of interim condensed combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the interim condensed combined financial statements and the accompanying notes. Actual results may differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the three and nine months ended September&#160;30, 2022, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(COVID-19)&lt;/div&gt; pandemic on our business and the allowance for credit losses was $0.1&#160;million as of September&#160;30, 2022. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#x2019; product sales, if any. To date, we have generated revenue from intellectual property and development milestones, and have only recently begun to generate revenue from commercial milestone payments and royalties on product sales this year. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and the milestone is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval. &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the three and nine months ended &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2022, the amount recognized as revenue that was previously deferred was $4.0&#160;million and $9.9&#160;million, respectively. During the three and nine months ended September&#160;30, 2021, the amount recognized as revenue that was previously deferred was $2.4&#160;million and $5.2&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation&#160;of&#160;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,950&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;23,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;19,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#x2019;s interim condensed combined financial statement accounting records. The interim condensed combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#x2019;s net investment in these operations is shown in lieu of stockholder&#x2019;s equity in the combined financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records certain transactions at the parent entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#x2019;s ownership. As the entities were under common control, the financial statements report the financial position, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January 2016. Transactions between Ligand and the Company are accounted for through the Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The interim condensed combined financial statements include all revenues, expenses, assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a percentage of total operating expenses or other measures that management believes are consistent and reasonable. See Note 8. Relationship with Parent and Related Entities&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#x2019;s combined statements of operations. The share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See Note 8. Relationship with Parent and Related Entities for additional discussion. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the allocations and estimates in the interim condensed combined financial statements are based on assumptions that management believes are reasonable. However, the interim condensed combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented. &lt;/div&gt;&lt;/div&gt; </oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock>
    <oabi:UnauditedInterimFinancialInformationPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Unaudited Interim Financial Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined balance sheet as of September&#160;30, 2022, the condensed combined statements of operations, condensed combined statements of changes in parent company net investment for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed combined statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related footnote disclosures are unaudited. In management&#x2019;s opinion, the unaudited interim combined financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2022, its results of operations for the three and nine months ended September&#160;30, 2022 and 2021, and its statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 in accordance with U.S. GAAP. The results for the nine months ended September&#160;30, 2022 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. &lt;/div&gt;&lt;/div&gt;</oabi:UnauditedInterimFinancialInformationPolicyTextBlock>
    <oabi:LiquidityAndCapitalResourcesPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. Therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of Parent company net investment in the combined balance sheets and as a financing activity allocation on the accompanying combined statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#x2019;s revenue was $23.7&#160;million and $19.5&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, OmniAb&#x2019;s net loss was $(29.2) million and $(24.0) million, respectively. OmniAb expects to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#x2019;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Prior to November 1, 2022, funding from Ligand was our primary source of liquidity. On November 1, 2022, with the closing of the merger between the Company and a subsidiary of APAC, New OmniAb was capitalized with approximately $95.8 million in net cash. This cash and cash the Company generates from operations provide us the flexibility we need to meet operating, investing, and financing needs and support operations through at least 12 months following the issuance date of the financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying interim condensed combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &lt;/div&gt;&lt;/div&gt; </oabi:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:Revenues
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">19500000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-29200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">-24000000</us-gaap:NetIncomeLoss>
    <us-gaap:Cash
      contextRef="PAsOn11_01_2022"
      decimals="-5"
      unitRef="Unit_USD">95800000</us-gaap:Cash>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of interim condensed combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the interim condensed combined financial statements and the accompanying notes. Actual results may differ from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the three and nine months ended September&#160;30, 2022, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(COVID-19)&lt;/div&gt; pandemic on our business and the allowance for credit losses was $0.1&#160;million as of September&#160;30, 2022. &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#x2019; product sales, if any. To date, we have generated revenue from intellectual property and development milestones, and have only recently begun to generate revenue from commercial milestone payments and royalties on product sales this year. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and the milestone is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <oabi:DeferredRevenuePolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the three and nine months ended &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2022, the amount recognized as revenue that was previously deferred was $4.0&#160;million and $9.9&#160;million, respectively. During the three and nine months ended September&#160;30, 2021, the amount recognized as revenue that was previously deferred was $2.4&#160;million and $5.2&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;</oabi:DeferredRevenuePolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">5200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation&#160;of&#160;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,950&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;23,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;19,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents disaggregation of royalty revenue, license fees, milestone revenue and service revenue (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,950&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;6,277&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;23,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;19,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_RoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">2455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_MilestoneMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">3264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">14254000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">6277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 - Observable inputs such as quoted prices in active markets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities Measured on a Recurring Basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the hierarchy for our liabilities measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Icagen contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;5,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;5,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;xCella contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;certain developmental and regulatory milestones. During the year ended December&#160;31, 2021, we paid $1.1&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. During the nine months ended September&#160;30, 2022, we paid $1.5&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The xCella contingent liability is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September 2020. During the year ended December&#160;31, 2021, we paid $0.7&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. During the nine months ended September&#160;30, 2022, we paid $1.0&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the level 3 financial instruments as of September&#160;30, 2022 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to CVR holders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,505&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from xCella asset acquisition&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to their relatively short periods to maturity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Assets Measured on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Recurring&lt;/div&gt; Basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We apply fair value techniques on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on level 3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the nine months ended September&#160;30, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the hierarchy for our liabilities measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Icagen contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;5,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;5,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;xCella contingent liabilities&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;certain developmental and regulatory milestones. During the year ended December&#160;31, 2021, we paid $1.1&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. During the nine months ended September&#160;30, 2022, we paid $1.5&#160;million towards the contingent liability based on revenue milestones to former Icagen shareholders. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The xCella contingent liability is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September 2020. During the year ended December&#160;31, 2021, we paid $0.7&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. During the nine months ended September&#160;30, 2022, we paid $1.0&#160;million towards the contingent liability based on revenue milestones to former xCella shareholders. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">5332000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">5332000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">480000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">480000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">5812000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">5812000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To12_31_2021_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2022To09_30_2022_IcagenMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2021To12_31_2021_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2022To09_30_2022_XcellaMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the level 3 financial instruments as of September&#160;30, 2022 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to CVR holders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,505&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value adjustments to contingent liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities from xCella asset acquisition&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of level 3 financial instruments as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-2505000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-487000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_XcellaMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1440000</oabi:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">5812000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P04_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Income Tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in various state jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-deductible&lt;/div&gt; expenses, stock award activities and other permanent differences between income (loss) before income taxes and taxable income. The effective tax rate for the three and nine months ended September&#160;30, 2022 was 15.5% and 18.3%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% was primarily due to the benefit related to tax credits, as well as the difference in statutory state rates and the tax impact of stock award activities. The variance is also a result of the valuation allowance established for state attributes. The effective tax rate for the three and nine months ended September&#160;30, 2021 was 19.5% and 21.5%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% was primarily due to the benefit related to tax credits, state taxes, the tax impact of stock award activities and the valuation allowance established for state attributes. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.155</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.183</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2021To09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.195</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.215</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Commitment and Contingencies: Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain OmniAb legal entities lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten years, some of which include options to extend the leases for up to ten years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Lease Assets and Liabilities (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Maturity of Operating Lease Liabilities as of September&#160;30, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity Dates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&#160;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remaining three months ending December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less tenant improvement allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the nine months ended September 30, 2022, we had a lease commence in our Emeryville office, which resulted in &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;an increase in lease assets and liabilities of $9.9 million each during the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, our operating leases had a weighted-average remaining lease term of 8.8 years and a weighted-average discount rate of 4.3%. As of December&#160;31, 2021, our operating leases had a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 3.9%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3&#160;million and $2.2&#160;million, respectively, for the three and nine months ended September&#160;30, 2022. The operating lease expense was $1.0&#160;million and $2.7&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The operating lease expense was $0.4&#160;million and $1.0&#160;million for the three and nine months ended September&#160;30, 2021, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Lease Assets and Liabilities (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21456000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13332000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1530000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">578000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">25016000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">26546000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13850000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Maturity of Operating Lease Liabilities as of September&#160;30, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity Dates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&#160;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remaining three months ending December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less tenant improvement allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">848000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3455000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3408000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3523000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3787000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3885000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14745000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">33651000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ReceivableWithImputedInterestNetAmount
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6075000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1030000</oabi:OperatingLeaseLiabilitiesTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">26546000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2022">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.043</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:OperatingLeaseExpense>
    <oabi:BalanceSheetAccountDetailsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Balance Sheet Account Details &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost and consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab and office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense for the three and nine months ended September&#160;30, 2022 was $0.7&#160;million and $1.9&#160;million, respectfully. Depreciation expense for the three and nine months ended September&#160;30, 2021 was $0.4&#160;million and $1.0&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and identifiable intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and other identifiable intangible assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite-lived intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite lived intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Complete technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total goodwill and other identifiable intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,253&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;260,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense for the three and nine months ended September&#160;30, 2022 was $3.3&#160;million and $9.8&#160;million, respectively. Amortization expense for the three and nine months ended September&#160;30, 2021 was $3.3&#160;million and $9.7&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalties owed to third parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition related liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </oabi:BalanceSheetAccountDetailsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost and consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab and office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">17639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3495000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">487000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">24569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10087000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5194000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3292000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">19375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis">three</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis">ten years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:Depreciation
      contextRef="P07_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and other identifiable intangible assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite-lived intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;83,979&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite lived intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Complete technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;227,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(60,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total goodwill and other identifiable intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,253&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;260,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83979000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">227129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">227403000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">68980000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_ComputerSoftwareIntangibleAssetMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">60099000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2975000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2083000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">250253000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">260300000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To09_30_2022">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P07_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">9800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">9700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalties owed to third parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition related liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2249000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2320000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1679000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">124000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">296000</us-gaap:AccruedRoyaltiesCurrent>
    <oabi:AcquisitionsRelatedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</oabi:AcquisitionsRelatedLiabilitiesCurrent>
    <oabi:AcquisitionsRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000000</oabi:AcquisitionsRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4092000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Relationship with Parent and Related Entities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the future by OmniAb. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;General Corporate Overhead &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rata&lt;/div&gt; method based on project-related costs or other measures that management believes are consistent and reasonable. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs of $1.6&#160;million and $4.9&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $0.9&#160;million and $3.8&#160;million for the three and nine months ended 2021, respectively, have been reflected in the general and administrative expenses in our interim condensed combined statements of operations for our allocated share of Parent&#x2019;s corporate overhead. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash Management and Financing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We participate in Ligand&#x2019;s centralized cash management and financing programs and will continue to participate in Ligand&#x2019;s centralized cash management until the OmniAb business becomes an independent publicly-traded company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a Separation Agreement, entered into among Ligand, OmniAb and APAC. Completion of the separation and distribution is subject to certain conditions. The separation is anticipated to be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-free&lt;/div&gt; to Ligand stockholders. Accordingly, after the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-free&lt;/div&gt; separation, all of the related tax attributes of Ligand will remain with Ligand. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity-Based Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain of our employees participate in our Parent&#x2019;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-statutory&lt;/div&gt; stock options or incentive stock options, restricted stock units (RSUs), performance stock units (PSUs) and other cash-based or share-based awards. Stock options granted to our employees under the incentive plans typically vest &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1/8&lt;/div&gt; on the six month anniversary of the date of grant, and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1/48&lt;/div&gt; each month thereafter for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forty-two&lt;/div&gt; months. We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation costs associated with our employees&#x2019; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. The following table summarizes total share-based compensation (SBC) charged to us related to our employees&#x2019; participation in our Parent&#x2019;s incentive plans, depending on the nature of the employee&#x2019;s role in our operations (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SBC - Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,079&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,902&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SBC - General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,279&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P07_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2022To09_30_2022_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">4900000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P07_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To09_30_2021_GeneralCorporateOverheadMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">3800000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">1/8 on the six month</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2022To09_30_2022_EquityBasedIncentivePlansMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">1/48 each month thereafter for forty-two months</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2022To09_30_2022">The following table summarizes total share-based compensation (SBC) charged to us related to our employees&#x2019; participation in our Parent&#x2019;s incentive plans, depending on the nature of the employee&#x2019;s role in our operations (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SBC - Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,079&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,902&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SBC - General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,279&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">3079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">6902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1415000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5030000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5279000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3810000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">12273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Subsequent Event &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purposes of the financial statements as of September 30, 2022 and the three and nine months then ended, the Company has evaluated subsequent events through the date on which the financial statements were issued. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination closing of APAC and OmniAb &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 1, 2022, Ligand completed the separation (the &#x201c;Separation&#x201d;) of its antibody discovery business and certain related assets and liabilities through a spin-off of OmniAb to Ligand&#x2019;s shareholders of record as of October 26, 2022 (the &#x201c;Record Date&#x201d;) on a pro rata basis (the &#x201c;Distribution&#x201d;) and merger (the &#x201c;Merger&#x201d;) of OmniAb with a wholly owned subsidiary of APAC in a Reverse Morris Trust transaction (collectively, the &#x201c;Transactions&#x201d;) pursuant to the Merger Agreement and the Separation Agreement (collectively with the other related transaction documents, the &#x201c;Transaction Agreements&#x201d;). The day prior to the Closing, OmniAb was renamed OmniAb Operations, Inc. and APAC was renamed OmniAb, Inc. (&#x201c;New OmniAb&#x201d;). Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain assets and liabilities constituting the OmniAb business, including certain related subsidiaries of Ligand, to OmniAb (the &#x201c;Contribution&#x201d;). In consideration for the Contribution, OmniAb issued to Ligand additional shares of OmniAb common stock such that the number of shares of OmniAb common stock then outstanding equaled the number of shares of OmniAb common stock necessary to effect the Distribution. Pursuant to the Distribution, Ligand shareholders as of the Record Date received one share of OmniAb common stock for each share of Ligand common stock held as of such date. Pursuant to the Merger Agreement, each share of OmniAb common stock was thereafter exchanged for the right to receive 4.90007 shares of New OmniAb common stock and 0.75842 shares of New OmniAb common stock subject to price-based earnout triggers (the &#x201c;Earnout Shares&#x201d;). The Earnout Shares will vest based upon the achievement of certain volume-weighted average trading prices (VWAP) for shares of New OmniAb for any &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt; trading days over a consecutive &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt; trading-day period during the five-year period following the Closing, with (i) fifty percent of such Earnout Shares vesting upon achievement of a VWAP of $12.50 per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $12.50, and (ii) the remaining fifty percent of the Earnout Shares vesting upon achievement of a VWAP of $15.00 per share of New OmniAb common stock or upon the occurrence of a change of control transaction that will result in the holders of New OmniAb common stock receiving a price per share in excess of $15.00. The Earnout Shares are not transferable until the vesting condition for the applicable tranche of Earnout Shares has been achieved. Upon the closing of the Transactions, the ownership of the outstanding stock of New OmniAb (including the Earnout Shares) was as follows: Ligand&#x2019;s existing shareholders held approximately 85.0%, APAC&#x2019;s existing public shareholders held approximately 1.1% and the sponsor and related parties of APAC held approximately 13.9%. Fractional shares of New OmniAb common stock were not issued pursuant to the Merger. Instead, shareholders received cash in lieu of any fractional share (other than with respect to Earnout Shares). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of the Closing, New OmniAb expected to have approximately $95.8 million of net cash. On November 2, 2022, New OmniAb began regular-way trading on NASDAQ under the ticker symbol &#x201c;OABI.&#x201d; Ligand continues to trade under the ticker symbol &#x201c;LGND.&#x201d; &lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn11_01_2022_NewOmniabCommonStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="5"
      unitRef="Unit_shares">4.90007</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <oabi:CommonStockSubjectToPriceBasedEarnoutTriggers
      contextRef="PAsOn11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis"
      decimals="5"
      unitRef="Unit_shares">0.75842</oabi:CommonStockSubjectToPriceBasedEarnoutTriggers>
    <oabi:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P20D</oabi:NumberOfTradingDaysForDeterminingTheSharePrice>
    <oabi:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P30D</oabi:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <oabi:VolumeWeightedAverageTradingPrices
      contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.5</oabi:VolumeWeightedAverageTradingPrices>
    <oabi:ExcessPricePerShare
      contextRef="P11_01_2022To11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.5</oabi:ExcessPricePerShare>
    <oabi:VolumeWeightedAverageTradingPrices
      contextRef="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</oabi:VolumeWeightedAverageTradingPrices>
    <oabi:ExcessPricePerShare
      contextRef="P11_01_2022To11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</oabi:ExcessPricePerShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn11_01_2022_ApacsExistingPublicShareholdersMembersrtOwnershipAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.85</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_SponsorOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.011</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn11_01_2022_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis_RelatedPartiesOfApacMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.139</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:Cash
      contextRef="PAsOn11_01_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">95800000</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">744542</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">934513</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">236684513</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">15440</us-gaap:AccountsPayableCurrent>
    <oabi:AccruedExpenses
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">107734</oabi:AccruedExpenses>
    <oabi:AccruedOfferingCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">314153</oabi:AccruedOfferingCosts>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">884</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">438211</us-gaap:LiabilitiesCurrent>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredOfferingCostsNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8488211</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">23000000</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7554273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7553698</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">236684513</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">516442</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9857143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9857143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5321429</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5321429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesIssued
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9232604</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9232604</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12298375</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12298375</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">21555404</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">7037831</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28593235</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-7554273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7553698</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-516442</us-gaap:ProfitLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">744542</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">15440</us-gaap:IncreaseDecreaseInAccountsPayable>
    <oabi:IncreaseDecreaseInDueToRelatedPartyCurrent
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">884</oabi:IncreaseDecreaseInDueToRelatedPartyCurrent>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">107734</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1136926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <oabi:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</oabi:PaymentsForInvestmentOfCashInTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-235750000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <oabi:ProceedsFromIssuanceInitialPublicOfferingNet
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">225400000</oabi:ProceedsFromIssuanceInitialPublicOfferingNet>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">175000</us-gaap:ProceedsFromRelatedPartyDebt>
    <oabi:RepaymentFromRelatedPartyDebt
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">175000</oabi:RepaymentFromRelatedPartyDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">698103</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237076897</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28593235</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">314153</oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses>
    <oabi:DeferredUnderwritingFeePayable
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredUnderwritingFeePayable>
    <us-gaap:NatureOfOperations contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Avista Public Acquisition Corp. II (the &#x201c;Company&#x201d;) is a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (a &#x201c;Business Combination&#x201d;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of 23,000,000&#160;units (the &#x201c;Units&#x201d; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), including 3,000,000&#160;Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note 3). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#x201c;Private Placement Warrants&#x201d;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $12,350,000 (see Note 4). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $13,662,256 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $1,012,256 of other offering costs. In addition, as of December&#160;31, 2021, cash of $189,971 is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#x201c;Trust Account&#x201d;) and will be invested only in U.S. government treasury obligations with maturities of 185&#160;days or less or in money market funds meeting certain conditions under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;2a-7&lt;/div&gt; under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public Offering, (ii)&#160;the redemption of the Company&#x2019;s Public Shares if the Company has not consummated an Business Combination within 18 months from the closing of the Company&#x2019;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#x2019;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#x2019;s Public Shares if the Company does not complete the initial Business Combination within 18 months from the closing the Company&#x2019;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will provide its holders of the outstanding Public Shares (the &#x201c;public shareholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The public shareholders will be entitled to redeem their Public Shares for a pro&#160;rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro&#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 480&#x201d;)&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#x201c;Amended and Restated Memorandum and Articles of Association&#x201d;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#x2019;t vote at all. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsor has agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor acquires &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within 18 months from the closing of the Initial Public Offering. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company has until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than &lt;span style="-sec-ix-hidden:hidden60240023"&gt;ten &lt;/span&gt;business days thereafter, redeem the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#x2019; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indemnity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#x2019;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2&#160;million was deposited in an operating account for the Company&#x2019;s working capital needs. The amounts held in the operating account are not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve&#160;months. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Going Concern Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#x2019;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; </us-gaap:NatureOfOperations>
    <oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_pure">1</oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <oabi:TransactionCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13662256</oabi:TransactionCosts>
    <oabi:SaleOfStockUnderwritingFees
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4600000</oabi:SaleOfStockUnderwritingFees>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredOfferingCostsNoncurrent>
    <oabi:SaleOfStockOtherOfferingCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1012256</oabi:SaleOfStockOtherOfferingCosts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <oabi:InvestmentsMaximumMaturityTerm contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P185D</oabi:InvestmentsMaximumMaturityTerm>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination>
    <oabi:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</oabi:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent>
    <oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">1</oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MaximumNetInterestToPayDissolutionExpenses
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">100000</oabi:MaximumNetInterestToPayDissolutionExpenses>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <oabi:WorkingCapitalSurplus
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">496302</oabi:WorkingCapitalSurplus>
    <oabi:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</oabi:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <oabi:WorkingCapitalSurplus
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">496302</oabi:WorkingCapitalSurplus>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company complies with the requirements of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and SEC Staff Accounting Bulletin Topic 5A&#160;&#x2014;&#160;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expenses of Offering&lt;/div&gt;&lt;/div&gt;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for income taxes under ASC 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. Since the Company was incorporated on February&#160;5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cayman &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Islands &lt;/div&gt;Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement. &lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&#160;February&#160;5,&lt;br/&gt;2021 (inception) Through&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(335,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(181,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,321,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company applies ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note&#160;&#x2014;&#160;related party, and advance from anchor investor approximate fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#160;&#x2014;&#160;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#160;&#x2014;&#160;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#160;&#x2014;&#160;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August&#160;2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40)&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;)&lt;/div&gt; to simplify accounting for certain financial instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#160;amends&lt;/div&gt; the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for the Company on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <oabi:EmergingGrowthCompanyPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; </oabi:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock>
    <oabi:Unitsissuedduringperiodsharesnewissues.
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</oabi:Unitsissuedduringperiodsharesnewissues.>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <oabi:TemporaryEquityProceedsAllocatedToWarrants
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9813334</oabi:TemporaryEquityProceedsAllocatedToWarrants>
    <oabi:TemporaryEquityIssuanceCosts
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-13029901</oabi:TemporaryEquityIssuanceCosts>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28593235</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company complies with the requirements of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and SEC Staff Accounting Bulletin Topic 5A&#160;&#x2014;&#160;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expenses of Offering&lt;/div&gt;&lt;/div&gt;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. &lt;/div&gt;</oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock>
    <oabi:TransactionCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13662256</oabi:TransactionCosts>
    <oabi:SaleOfStockUnderwritingFees
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4600000</oabi:SaleOfStockUnderwritingFees>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredOfferingCostsNoncurrent>
    <oabi:SaleOfStockOtherOfferingCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1012256</oabi:SaleOfStockOtherOfferingCosts>
    <oabi:OfferingCostsReductionOfTemporaryEquity
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13029901</oabi:OfferingCostsReductionOfTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">632355</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for income taxes under ASC 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. Since the Company was incorporated on February&#160;5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cayman &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Islands &lt;/div&gt;Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&#160;February&#160;5,&lt;br/&gt;2021 (inception) Through&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(335,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(181,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,321,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">15900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&#160;February&#160;5,&lt;br/&gt;2021 (inception) Through&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(335,384&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(181,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,321,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">-335384</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">-181058</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9857143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9857143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5321429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5321429</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company applies ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note&#160;&#x2014;&#160;related party, and advance from anchor investor approximate fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#160;&#x2014;&#160;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#160;&#x2014;&#160;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#160;&#x2014;&#160;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August&#160;2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40)&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;)&lt;/div&gt; to simplify accounting for certain financial instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#160;amends&lt;/div&gt; the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for the Company on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <oabi:InitialPublicOfferingTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of 23,000,000&#160;Units, including 3,000,000&#160;Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class&#160;A ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden60240047"&gt;one&lt;/span&gt;-third&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;</oabi:InitialPublicOfferingTextBlock>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <oabi:NumberOfSharesIssuedPerUnit
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</oabi:NumberOfSharesIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <oabi:PrivatePlacementTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant is exercisable to purchase one Class&#160;A &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants. &lt;/div&gt;&lt;/div&gt; </oabi:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class&#160;B ordinary shares (the &#x201c;Founder Shares&#x201d;). The Founder Shares include an aggregate of up to 750,000 Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#x2019; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the Company&#x2019;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred 35,000 Class&#160;B ordinary shares each to three members of the Company&#x2019;s board of directors (or 105,000 Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#x2019;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#x2019;s Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20&#160;trading days within any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-&lt;/div&gt; trading day period commencing at least &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;150 day&lt;/div&gt;s after an initial Business Combination or (2)&#160;if the Company consummates a transaction after an initial Business Combination which results in the Company&#x2019;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note&#160;&#x2014;&#160;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#x201c;Promissory Note&#x201d;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#x2019;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $119,275 on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Administrative Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $46,129 of expenses were incurred during the period from February&#160;5, 2021 (inception) through December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Due to Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#x2019;s sponsor or an affiliate of the sponsor or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#x201c;Working Capital Loans&#x201d;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#x2019;s trust account would be used to repay such loaned amounts. Up to $2,000,000 of such loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#x2019;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December&#160;31, 2021, there was no balance outstanding under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <oabi:NumberOfSharesSubjectToForfeiture
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">750000</oabi:NumberOfSharesSubjectToForfeiture>
    <oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">35000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <oabi:NumberOfSharesSubjectToForfeiture
      contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">105000</oabi:NumberOfSharesSubjectToForfeiture>
    <oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P1Y</oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P20D</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P30D</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P150D</oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">300000</oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty
      contextRef="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">55725</oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">119275</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">175000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P02_05_2021To12_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">46129</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <oabi:MaximumLoansConvertibleIntoWarrants
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">2000000</oabi:MaximumLoansConvertibleIntoWarrants>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <oabi:WorkingCapitalLoansOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:WorkingCapitalLoansOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6. COMMITMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration and Shareholder Rights Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters were paid a cash underwriting discount of $0.20 per Unit, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August&#160;12, 2021. In addition, $0.35 per unit, or $8,050,000 in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the Underwriting Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Forward Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of 10,000,000 Class&#160;A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class&#160;A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#x2019;s public shareholders. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#x2019;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <oabi:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_ITEM">3</oabi:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <oabi:DeferredFeePerUnit
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.2</oabi:DeferredFeePerUnit>
    <oabi:AggregateDeferredUnderwritingFeePayable
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4600000</oabi:AggregateDeferredUnderwritingFeePayable>
    <oabi:Underwritingcashdiscountperunit
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.35</oabi:Underwritingcashdiscountperunit>
    <oabi:Underwritercashdiscount
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:Underwritercashdiscount>
    <oabi:SharesToBePurchasedPursuantToAgreements
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</oabi:SharesToBePurchasedPursuantToAgreements>
    <oabi:WarrantsToBePurchasedPursuantToAgreements
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3333333</oabi:WarrantsToBePurchasedPursuantToAgreements>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">100000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7. SHAREHOLDERS&#x2019; DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference shares &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of December&#160;31, 2021, there were no preference shares issued or outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;A ordinary shares &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 23,000,000 Class&#160;A ordinary shares issued and outstanding, including 23,000,000 Class&#160;A ordinary shares subject to possible redemption. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;B ordinary shares &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;B ordinary shares are entitled to one vote for each share. As of December&#160;31, 2021, there were 5,750,000 Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the Company&#x2019;s issued and outstanding shares. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#x2019;s shareholders except as required by law. Unless specified in the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-thirds&lt;/div&gt; of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#x2019;s board of directors is divided into three classes, each of which will generally serve for a term of three&#160;years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#x2019;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#x2019;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#x2019;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#x2019;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#x2019;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Warrants &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Each whole warrant entitles the registered holder to purchase one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30&#160;days after the completion of the Company&#x2019;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. Accordingly, unless you purchase at least three&#160;units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#x2019;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#x2019;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#x2019;s Class&#160;A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#x2019;s option, require holders of warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#x201c;fair market value&#x201d; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#x201c;fair market value&#x201d; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption of warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30&#160;days&#x2019; prior written notice of redemption to each warrant holder; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending three trading days before the Company sends the notice of redemption to the warrant holders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#x2019;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#x2019;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-division&lt;/div&gt; of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-division&lt;/div&gt; or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#x201c;historical fair market value&#x201d; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;&#x201c;historical fair market value&#x201d; means the volume weighted average price of Class&#160;A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;365-day&lt;/div&gt; period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share , (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#x2019;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#x2019;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#x2019;s public shares upon failure to complete the Company&#x2019;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Company&#x2019;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#x201c;Redemption of warrants&#x201d; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No fractional warrants will be issued upon separation of the&#160;units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the&#160;units in the Company&#x2019;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#x2019;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the&#160;units being sold in the Initial Public Offering. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants), and will account for the 3,333,333 Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt;. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <oabi:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</oabi:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <oabi:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</oabi:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharePrice>
    <oabi:WarrantExercisePeriodConditionTwo contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</oabi:WarrantExercisePeriodConditionTwo>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P20D</oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
    <oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P60D</oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
    <oabi:RedemptionPeriod contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P10D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:RedemptionPeriod contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:RedemptionPeriod>
    <oabi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</oabi:WarrantRedemptionConditionMinimumSharePrice>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P20D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <oabi:RedemptionPeriod contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:RedemptionPeriod contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P10D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P365D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="0"
      unitRef="Unit_pure">100</oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">9.2</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">60</oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P20D</oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">9.2</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:WarrantExercisePriceAdjustmentMultiple
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">115</oabi:WarrantExercisePriceAdjustmentMultiple>
    <oabi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">18</oabi:WarrantRedemptionConditionMinimumSharePrice>
    <oabi:WarrantRedemptionPriceAdjustmentMultiple
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">180</oabi:WarrantRedemptionPriceAdjustmentMultiple>
    <oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15900000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">7666667</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">8233333</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">3333333</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#x201c;Sponsor Working Capital Loan&#x201d;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March&#160;15, 2022, the Company drew down $500,000 under the Sponsor Working Capital Loan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proposed Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;23, 2022, we entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#x201c;Ligand&#x201d;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#x201c;OmniAb&#x201d; and, together with Ligand, collectively, the &#x201c;Companies&#x201d;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), pursuant to which we will combine with OmniAb, Ligand&#x2019;s antibody discovery business (the &#x201c;OmniAb Business&#x201d;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement, (the &#x201c;Employee Matters Agreement&#x201d;), (b)&#160;OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#x201c;Sponsor Insider Agreement&#x201d;) with the Company and certain insiders of the Company (the &#x201c;Insiders&#x201d;) and (c)&#160;we amended and restated that certain forward purchase agreement, dated August&#160;9, 2021, by entering into the amended and restated forward purchase agreement (the &#x201c;A&amp;amp;R FPA&#x201d;), by and among the Company, our sponsor and OmniAb. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and OmniAb (the &#x201c;Separation Agreement&#x201d;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#x201c;Distribution&#x201d;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001 (the &#x201c;OmniAb Common Stock&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#x201c;Merger&#x201d;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#x201c;OmniAb Business Combination&#x201d;): (i)&#160;we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#x201c;Domestication&#x201d;), (ii)&#160;Ligand will transfer the OmniAb Business (the &#x201c;Separation&#x201d;) to its wholly-owned subsidiary, OmniAb, and contribute $15&#160;million in capital thereto (less certain transaction and other expenses), and (iii)&#160;following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;tax-free&#x201d;&lt;/div&gt; transactions. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $0.0001 per share (the &#x201c;APAC Common Stock&#x201d;), which will be listed on Nasdaq under the ticker symbol &#x201c;OABI.&#x201d; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#x201c;OABIW.&#x201d; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;At the time the proposed OmniAb Business Combination is effected (the &#x201c;Closing&#x201d;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-money&lt;/div&gt; equity value for OmniAb of $850&#160;million. Holders of OmniAb options, restricted stock&#160;units and performance stock&#160;units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 shares of APAC Common Stock (the &#x201c;OmniAb Earnout Shares&#x201d;), with 50% of such earnout shares vesting upon the combined company&#x2019;s achievement of a post-transaction volume-weighted average price (&#x201c;VWAP&#x201d;) of $12.50 per share of APAC Common Stock for any 20 trading days over a consecutive 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;trading-day&lt;/div&gt; period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of APAC Common Stock for any 20 trading days over a consecutive 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;trading-day&lt;/div&gt; period, in each case provided such vesting occurs during the five-year period following the Closing. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the proposed OmniAb Business Combination, upon the Domestication (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares will convert automatically, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, into shares of APAC Common Stock, (ii)&#160;all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii)&#160;all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one warrant to purchase APAC Common Stock. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement. &lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">750000</us-gaap:DebtDefaultLongtermDebtAmount>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P03_15_2022To03_15_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19847</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">404021</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">744542</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">423868</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">934513</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237188875</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237612743</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">236684513</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6302429</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">15440</us-gaap:AccountsPayableCurrent>
    <oabi:AccruedExpenses
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1217031</oabi:AccruedExpenses>
    <oabi:AccruedExpenses
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">107734</oabi:AccruedExpenses>
    <oabi:AccruedOfferingCosts
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">314154</oabi:AccruedOfferingCosts>
    <oabi:AccruedOfferingCosts
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">314153</oabi:AccruedOfferingCosts>
    <oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">750000</oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty>
    <oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">88294</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">884</us-gaap:DueToRelatedPartiesCurrent>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1595500</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10267408</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">438211</us-gaap:LiabilitiesCurrent>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:DeferredOfferingCostsNoncurrent>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredOfferingCostsNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">14292408</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8488211</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237188875</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ClassCommonStockSharesNotSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-13869115</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7554273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-13868540</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7553698</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237612743</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">236684513</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2344863</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">170579</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8744341</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">180550</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2344863</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-170579</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8744341</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-180550</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1090543</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1438875</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnInvestments>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1212110</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1147120</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2466430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-170579</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8452586</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-180550</us-gaap:NetIncomeLoss>
    <oabi:DeemedDividend
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DeemedDividend>
    <oabi:DeemedDividend
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DeemedDividend>
    <oabi:DeemedDividend
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-225000</oabi:DeemedDividend>
    <oabi:DeemedDividend
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DeemedDividend>
    <oabi:NetIncomeLossAttributableToOrdinaryShareholders
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2466430</oabi:NetIncomeLossAttributableToOrdinaryShareholders>
    <oabi:NetIncomeLossAttributableToOrdinaryShareholders
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-170579</oabi:NetIncomeLossAttributableToOrdinaryShareholders>
    <oabi:NetIncomeLossAttributableToOrdinaryShareholders
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8677586</oabi:NetIncomeLossAttributableToOrdinaryShareholders>
    <oabi:NetIncomeLossAttributableToOrdinaryShareholders
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-180550</oabi:NetIncomeLossAttributableToOrdinaryShareholders>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">12250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">12250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4755274</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4755274</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5399457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5399457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5155063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5155063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-7554273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7553698</us-gaap:StockholdersEquity>
    <oabi:ReclassificationOfForwardPurchaseAgreement
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">223380</oabi:ReclassificationOfForwardPurchaseAgreement>
    <oabi:ReclassificationOfForwardPurchaseAgreement
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">223380</oabi:ReclassificationOfForwardPurchaseAgreement>
    <oabi:DeemedDividend
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-225000</oabi:DeemedDividend>
    <oabi:DeemedDividend
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-225000</oabi:DeemedDividend>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-4361240</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4361240</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-12363893</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12363318</us-gaap:StockholdersEquity>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">348332</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">348332</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-1624916</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1624916</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-14337141</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-14336566</us-gaap:StockholdersEquity>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">1090544</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1090544</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:WaiverOfUnderwritingCommissionByUnderwriters
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:WaiverOfUnderwritingCommissionByUnderwriters>
    <oabi:WaiverOfUnderwritingCommissionByUnderwriters
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:WaiverOfUnderwritingCommissionByUnderwriters>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-2466430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2466430</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-13869115</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-13868540</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-7786</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7786</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24425</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-7786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">17214</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-2185</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2185</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24425</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-9971</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">15029</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9245327</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9245327</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12314397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12314397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">21584149</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">6723679</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28307828</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-170579</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-170579</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-6904229</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6903654</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8452586</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-180550</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1438875</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnInvestments>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1147120</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-340521</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">880112</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6286989</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">33292</us-gaap:IncreaseDecreaseInAccountsPayable>
    <oabi:IncreaseDecreaseInDueToRelatedPartyCurrent
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">87410</oabi:IncreaseDecreaseInDueToRelatedPartyCurrent>
    <oabi:IncreaseDecreaseInDueToRelatedPartyCurrent
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:IncreaseDecreaseInDueToRelatedPartyCurrent>
    <oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty>
    <oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">20000</oabi:IncreaseDecreaseInAccruedLiabilitiesRelatedParty>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1109297</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">40988</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-920124</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-966382</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <oabi:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:PaymentsForInvestmentOfCashInTrustAccount>
    <oabi:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</oabi:PaymentsForInvestmentOfCashInTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-235750000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">119275</us-gaap:ProceedsFromRelatedPartyDebt>
    <oabi:ProceedsFromIssuanceInitialPublicOfferingNet
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:ProceedsFromIssuanceInitialPublicOfferingNet>
    <oabi:ProceedsFromIssuanceInitialPublicOfferingNet
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">225400000</oabi:ProceedsFromIssuanceInitialPublicOfferingNet>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">615690</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">175000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">750000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">750000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237078585</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-170124</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">362203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19847</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">362203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1438875</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28307827</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">448380</oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities>
    <oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:InitialClassificationOfForwardPurchaseAndBackstopSecurities>
    <oabi:WaiverOfUnderwritingCommissionByUnderwriters
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:WaiverOfUnderwritingCommissionByUnderwriters>
    <oabi:WaiverOfUnderwritingCommissionByUnderwriters
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:WaiverOfUnderwritingCommissionByUnderwriters>
    <oabi:DeferredUnderwritingFeePayable
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DeferredUnderwritingFeePayable>
    <oabi:DeferredUnderwritingFeePayable
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredUnderwritingFeePayable>
    <oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty>
    <oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">55725</oabi:DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty>
    <oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses>
    <oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1689</oabi:OfferingCostsIncludedInAccountsPayableAccruedExpenses>
    <oabi:OfferingCostsPaidInExchangesForIssuanceOfShares
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:OfferingCostsPaidInExchangesForIssuanceOfShares>
    <oabi:OfferingCostsPaidInExchangesForIssuanceOfShares
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</oabi:OfferingCostsPaidInExchangesForIssuanceOfShares>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Avista Public Acquisition Corp. II was a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. As used herein, the references to the &#x201c;Company&#x201d; are to Avista Public Acquisition Corp. II, prior to its domestication as a corporation incorporated in the state of Delaware and change of name to OmniAb, Inc., and its then wholly-owned and controlled subsidiary, Orwell Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), unless the context indicates otherwise. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#x201c;Business Combination&#x201d;). The Company was not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company was an early stage and emerging growth company and, as such, the Company was subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;5, 2021 (inception) through September&#160;30, 2022 related to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination, which is described below. The Company generated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest and dividend income or gains on investments on the cash and investments held in the Trust Account (as defined below) from the proceeds derived from the Initial Public Offering. The Company had selected December&#160;31 as its fiscal year end. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company consummated the Initial Public Offering of 23,000,000 units (the &#x201c;Units&#x201d; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), including 3,000,000 Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note&#160;3). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#x201c;Private Placement Warrants&#x201d;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $12,350,000 (see Note&#160;4). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, cash of $19,847 was held outside of the Trust Account and was available for the payment of accrued offering costs and for working capital purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#x201c;Trust Account&#x201d;) and invested in only in U.S. government treasury obligations with maturities of 185 days or less or in money market funds meeting certain conditions under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;2a-7&lt;/div&gt; under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public&#160;Offering, (ii)&#160;the redemption of the Company&#x2019;s Public Shares if the Company had not consummated an Business Combination within 18 months from the closing of the Company&#x2019;s Initial Public Offering, subject to applicable law, and (iii)&#160;the redemption of the Company&#x2019;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A)&#160;that would modify the substance or timing of the obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#x2019;s Public Shares if the Company did &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;not complete the initial Business Combination within 18 months from the closing the Company&#x2019;s Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Class&#160;A ordinary shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company provided its holders of the outstanding Public Shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision was made by the Company to seek shareholder approval of a Business Combination. The Public Shareholders were entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro rata interest and dividends or gains on investments earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There were no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company proceeded with the Business Combination as the Company had net tangible assets of at least $5,000,001 upon consummation of the Business Combination and at least &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden60239967"&gt;two&lt;/span&gt;-thirds&lt;/div&gt; of the shares voted were voted in favor of the Business Combination. As the Company decided to obtain shareholder approval the Company offered to redeem shares in conjunction with the proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. The Sponsor agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of the Business Combination. Additionally, each Public Shareholder was given the option to redeem their Public Shares irrespective of whether they voted for or against the proposed transaction or didn&#x2019;t vote at all. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsor agreed to waive (i)&#160;redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of the Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company did not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; Business Combination activity and (iii)&#160;rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company failed to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor had acquired Public Shares in or after the Initial Public Offering, such Public Shares would have been be entitled to liquidating distributions from the Trust Account if the Company failed to complete a Business Combination within 18 months from the closing of the Initial Public Offering. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company had until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company was unable to complete a Business Combination within the Combination Period, the Company would have (i)&#160;ceased all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than &lt;span style="-sec-ix-hidden:hidden60239959"&gt;ten &lt;/span&gt;business&#160;days thereafter, redeemed the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption would have completely extinguished Public Shareholders&#x2019; rights as shareholders (including the right to receive further liquidation distributions, if any); and &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining shareholders and board of directors, liquidated and dissolved, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There would have been be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which would have expired worthless if the Company failed to complete a Business Combination within the Combination Period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters have agreed to waive their rights to a portion of their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company did not complete a Business Combination within the Combination Period and, in such event, such amounts would have been included with the other funds held in the Trust Account that would have been available to fund the redemption of the Public Shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OmniAb Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;23, 2022, the Company entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#x201c;Ligand&#x201d;), OmniAb, Inc., a Delaware corporation and then wholly-owned subsidiary of Ligand (&#x201c;Legacy OmniAb&#x201d;), and Orwell Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), pursuant to which the Company combined with Legacy OmniAb, Ligand&#x2019;s antibody discovery business (the &#x201c;OmniAb Business&#x201d;), in a Reverse Morris Trust transaction. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;the Company, Ligand, Legacy OmniAb and Merger Sub entered into that certain Employee Matters Agreement, as amended by that certain Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022 (the &#x201c;Employee Matters Agreement&#x201d;), (b) Legacy OmniAb and the Sponsor entered into that certain Sponsor Insider Letter Agreement (the &#x201c;Sponsor Insider Agreement&#x201d;) with the Company and certain insiders of the Company (the &#x201c;Insiders&#x201d;) and (c)&#160;the Company amended and restated that certain previously disclosed Forward Purchase Agreement, dated August&#160;9, 2021, by entering into the Amended and Restated Forward Purchase Agreement (the &#x201c;A&amp;amp;R FPA&#x201d;), by and among the Company, the Sponsor and Legacy OmniAb pursuant to which they consummated the OmniAb Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, among the Company, Ligand and Legacy OmniAb (the &#x201c;Separation Agreement&#x201d;), Ligand transferred the OmniAb Business, including certain related subsidiaries of Ligand, to Legacy OmniAb and, in connection therewith, distributed (the &#x201c;Distribution&#x201d;) to Ligand stockholders 100% of the common stock of Legacy OmniAb, par value $0.001 per share (the &#x201c;Legacy OmniAb Common Stock&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Legacy OmniAb (the &#x201c;Merger&#x201d;), with Legacy OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement, along with the Separation Agreement and the other transaction documents entered into in connection therewith, provided for, among other things, the consummation of the following transactions (collectively, the &#x201c;OmniAb Business Combination&#x201d;): (i) the Company redomiciled by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law and with Section&#160;206 of the Cayman Islands Companies Act (As Revised) (the &#x201c;Domestication&#x201d;), (ii) Ligand transferred the OmniAb Business (the &#x201c;Separation&#x201d;) to its wholly-owned subsidiary, Legacy OmniAb, and contributed $15&#160;million in capital thereto (less certain reimbursable transaction and other expenses), and (iii)&#160;following the Separation, Ligand distributed 100% of the shares of Legacy OmniAb Common Stock to Ligand stockholders by way of the Distribution. Following the completion of &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties consummated the Merger. The Distribution and Merger are intended to qualify as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;tax-free&#x201d;&lt;/div&gt; transactions. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;28, 2022, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;333-264525)&lt;/div&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Form&#160;S-4&#x201d;,&lt;/div&gt; as amended on June&#160;13, 2022, July&#160;26, 2022, August&#160;22, 2022, September&#160;13, 2022 and September&#160;27, 2022) with the SEC, which includes the proxy statement/prospectus/information statement distributed to holders of the Company&#x2019;s ordinary shares in connection with the Company&#x2019;s solicitation for proxies for the vote by the Company&#x2019;s shareholders in connection with the OmniAb Business Combination and other matters as described in the Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4.&lt;/div&gt; The Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4&lt;/div&gt; was declared effective by the SEC on September&#160;30, 2022, and the definitive proxy statement/prospectus/information statement was mailed to the Company&#x2019;s shareholders of record on the record date for voting on the OmniAb Business Combination. The OmniAb Business Combination closed on November&#160;1, 2022. Upon consummation of the OmniAb Business Combination, and after the Domestication, the Company has one class of common stock, par value $0.0001 per share, which is listed on Nasdaq under the ticker symbol &#x201c;OABI&#x201d;. The Company&#x2019;s warrants are listed on Nasdaq under the ticker symbol &#x201c;OABIW&#x201d;. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP, whereby the Company is treated as the acquired company and Legacy OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy OmniAb issuing stock for the net assets of the Company, accompanied by a recapitalization. The net assets of the Company were stated at historical cost, with no goodwill or other intangible assets recorded. Subsequent presentations of the results of operations presented for the period prior to the Business Combination will be for those of Legacy OmniAb. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy OmniAb&#x2019;s existing stockholders have the greatest voting interest in the combined entity; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy OmniAb has the ability to nominate a majority of the initial members of the OmniAb Board; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy OmniAb&#x2019;s senior management is the senior management of the combined entity; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy OmniAb is the larger entity based on historical operating activity and has the larger employee base; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The post-combination company has assumed a Legacy OmniAb branded name: &#x201c;OmniAb, Inc.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Agreement and Plan of Merger &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At the closing of the OmniAb Business Combination, each share of Legacy OmniAb&#x2019;s common stock outstanding prior to the effective time of the OmniAb Business Combination was converted on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis into shares of common stock in the newly formed company (&#x201c;OmniAb Common Stock&#x201d;). Holders of Legacy OmniAb options, restricted stock units and performance stock units (determined after the Distribution (as defined below) and the division of Ligand equity awards into Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) had their awards converted into equity awards of the Company and adjusted pursuant to the exchange ratio. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, at the closing of the OmniAb Business Combination, holders of Legacy OmniAb Common Stock and equity awards received shares of OmniAb Common Stock subject to certain price-based earnout triggers (&#x201c;Earnout Shares&#x201d;), with 50% of such Earnout Shares vesting upon the combined company&#x2019;s achievement of a post-transaction volume-weighted average price (&#x201c;VWAP&#x201d;) of $12.50 per share of OmniAb Common Stock for &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;any 20 trading days over a consecutive 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;trading-day&lt;/div&gt; period, and the remainder vesting upon achievement of a post-transaction VWAP of $15 per share of OmniAb Common Stock for any 20 trading days over a consecutive 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;trading-day&lt;/div&gt; period, in each case provided such vesting occurs during the five-year period following the closing of the OmniAb Business Combination. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the OmniAb Business Combination, upon the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domestication&lt;/div&gt; of the Company to Delaware (i)&#160;all issued and outstanding Class&#160;A ordinary shares and Class&#160;B ordinary shares converted automatically, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, into shares of OmniAb Common Stock, (ii)&#160;all issued and outstanding warrants converted automatically into warrants to acquire shares of OmniAb Common Stock and (iii)&#160;all issued and outstanding Units separated and converted automatically into one share of OmniAb Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one warrant to purchase OmniAb Common Stock. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Separation and Distribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Seperation Agreement, pursuant to which the Separation and Distribution were effected. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Separation Agreement also sets forth other agreements among Ligand and Legacy OmniAb, including provisions concerning the termination and settlement of intercompany accounts and the obtaining of necessary governmental approvals and third-party consents. The Separation Agreement also sets forth agreements that will govern certain aspects of the relationship between Ligand and Legacy OmniAb after the Distribution, including provisions with respect to release of claims, indemnification, access to financial and other information and access to and provision of records. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Matters Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the Employee Matters Agreement, as amended by the Amended and Restated Employee Matters Agreement, dated as of August&#160;18, 2022, which provides for employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and Legacy OmniAb, treatment of incentive equity awards in the Distribution and the OmniAb Business Combination and related covenants and commitments of the parties. Each existing Ligand equity award at the time of the Distribution granted prior to March&#160;2, 2022, with certain limited exceptions, was split into (i)&#160;a new Ligand equity award and (ii)&#160;a new Legacy OmniAb equity award, with any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-the-money&lt;/div&gt;&lt;/div&gt; value in the original Ligand equity award split between such awards based on the relative values of Ligand and OmniAb at the time of the Distribution. Each existing Ligand equity award at the time of the Distribution granted on or after March&#160;2, 2022 was converted into either an adjusted Ligand equity award, if the holder was a Ligand service provider following the Distribution, or a Legacy OmniAb equity award, if the holder was a Legacy OmniAb service provider following the Distribution. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Insider Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Legacy OmniAb and the Sponsor entered into the Sponsor Insider Agreement with the Company and the Insiders, pursuant to which, among other things, the Insiders agreed to vote any of our securities held by them to approve the OmniAb Business Combination and the other Company shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their Company securities in connection with the consummation of the OmniAb Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to 1,916,667 Earnout Founder Shares (as defined in the Sponsor Insider Agreement), to the same price-based vesting conditions as the OmniAb Earnout Shares. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amended and Restated Forward Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into Amended and Restated Forward Purchase Agreement (the &#x201c;A&amp;amp;R FPA&#x201d;) with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;amp;R FPA, the Company agreed to, in connection with the consummation of the OmniAb Business Combination, issue and sell to the Sponsor 1,500,000 shares of OmniAb Common Stock (the &#x201c;Forward Purchase Shares&#x201d;) and warrants to acquire 1,666,667 shares of OmniAb Common Stock (the &#x201c;Forward Purchase Warrants&#x201d;) for an aggregate purchase price of $15.0&#160;million with such purchases having been consummated immediately following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domestication&lt;/div&gt; to Delaware. In addition, the Sponsor agreed to purchase up to an additional 10,000,000 shares of OmniAb Common Stock (the &#x201c;Backstop Shares&#x201d;) and up to an additional 1,666,667 warrants, (The &#x201c;Backstop Warrants&#x201d; and, together with the Forward Purchase Shares, Forward Purchase Warrants and Backstop Shares, the &#x201c;Forward Purchase and Backstop Securities&#x201d;) for an aggregate additional purchase price of up to $100.0&#160;million, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $100.0&#160;million. Pursuant to the A&amp;amp;R FPA, in connection with the Business Combination, the Sponsor was issued 8,672,934 Backstop Shares and 1,445,489 Backstop Warrants for an aggregate purchase price of $86,729,340 in order to backstop the redemptions. In addition, pursuant to the A&amp;amp;R FPA, the Sponsor was issued 1,500,000 Forward Purchase Shares and 1,666,667 Forward Purchase Warrants for an aggregate purchase price of $15,000,000, on a private placement basis. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indemnity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#x2019;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As of September&#160;30, 2022, the Company had $19,847 in cash held outside of the Trust Account and a working capital deficit of $9,843,540. The Company incurred significant costs in pursuit of its acquisition plans. In connection with the Company&#x2019;s assessment of going concern considerations in accordance with FASB&#x2019;s ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Presentation of Financial Statements - Going Concern, management has determined those conditions raised substantial doubt about the Company&#x2019;s ability to continue as a going concern within the earlier of the Combination Period, which will end on February&#160;12, 2023, or one year after the date that the condensed consolidated financial statements are issued. Moreover, the Company needed to obtain additional financing to complete the Business Combination and to redeem 21,713,864 public shares upon completion of the Business &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Combination, in which case the Company issued additional securities in connection with the Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2&#160;million was deposited in an operating account for the Company&#x2019;s working capital needs. In addition, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#x201c;Sponsor Working Capital Loan&#x201d;) to which the Company could borrow up to an aggregate of $750,000. As of September&#160;30, 2022, the Company has borrowed $750,000 under the Sponsor Working Capital Loan. The amounts held in the operating account were not expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the remainder of the Combination Period. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on the industry, the geopolitical conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals and entities and the status of debt and equity markets and has concluded that while it is reasonably possible that any of the foregoing could have a negative effect on the Company&#x2019;s financial position and results of its operations, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a 1% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-&lt;/div&gt; U.S. corporations beginning in 2023, with certain exceptions (the &#x201c;Excise Tax&#x201d;). Because the Company became a Delaware corporation upon the Domestication and the securities traded on Nasdaq, we would have likely been considered a &#x201c;covered corporation&#x201d; within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax would have applied to any redemptions of our common stock after December&#160;31, 2022, including redemptions in connection with an initial Business Combination and any amendment to a certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. &lt;/div&gt; </us-gaap:NatureOfOperations>
    <oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_pure">1</oabi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">23000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19847</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SharePrice
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <oabi:InvestmentsMaximumMaturityTerm contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P185D</oabi:InvestmentsMaximumMaturityTerm>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</oabi:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination>
    <oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">1</oabi:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:MaximumNetInterestToPayDissolutionExpenses
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">100000</oabi:MaximumNetInterestToPayDissolutionExpenses>
    <oabi:PercentageOfCommonStockSharesIssuedUnderDistribution
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_pure">100</oabi:PercentageOfCommonStockSharesIssuedUnderDistribution>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <oabi:CapitalContributedNetOfExpenses
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</oabi:CapitalContributedNetOfExpenses>
    <oabi:PercentageOfCommonStockSharesIssuedUnderDistribution
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_pure">100</oabi:PercentageOfCommonStockSharesIssuedUnderDistribution>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ConversionOfStockSharesIssued1>
    <oabi:VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</oabi:VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice>
    <oabi:VolumeWeightedAveragePriceTriggerPrice
      contextRef="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.5</oabi:VolumeWeightedAveragePriceTriggerPrice>
    <oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis">P20D</oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest>
    <oabi:SharesToVestMeasurementPeriod contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_FirstRequirementsMemberOABIVestingRequirementsAxis_OmniabIncMemberdeiLegalEntityAxis">P30D</oabi:SharesToVestMeasurementPeriod>
    <oabi:VolumeWeightedAveragePriceTriggerPrice
      contextRef="PAsOn09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">15</oabi:VolumeWeightedAveragePriceTriggerPrice>
    <oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis">P20D</oabi:NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest>
    <oabi:SharesToVestMeasurementPeriod contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SecondRequirementsMemberOABIVestingRequirementsAxis">P30D</oabi:SharesToVestMeasurementPeriod>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ConversionOfStockSharesIssued1>
    <oabi:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1</oabi:NumberOfSharesIssuedPerUnit>
    <oabi:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2022To09_30_2022_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</oabi:NumberOfWarrantsIssuedPerUnit>
    <oabi:MaximumNumberOfSharesSubjectToPriceBasedVestingConditions
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_EarnoutStockMemberusgaapStatementClassOfStockAxis_SponsorInsiderAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1916667</oabi:MaximumNumberOfSharesSubjectToPriceBasedVestingConditions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <oabi:AdditionalNumberOfCommonStock
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</oabi:AdditionalNumberOfCommonStock>
    <oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">1666667</oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:AdditionalAggregatePurchasePrice
      contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_OmniabIncMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</oabi:AdditionalAggregatePurchasePrice>
    <oabi:MaximumAdditionalAggregatePurchasePrice
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</oabi:MaximumAdditionalAggregatePurchasePrice>
    <oabi:SponsorPurchaseBackstop
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">8672934</oabi:SponsorPurchaseBackstop>
    <oabi:SharesBackstopWarrants
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1445489</oabi:SharesBackstopWarrants>
    <oabi:AdditionalAggregatePurchasePrice
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">86729340</oabi:AdditionalAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19847</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <oabi:WorkingCapitalDeficit
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9843540</oabi:WorkingCapitalDeficit>
    <oabi:NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">21713864</oabi:NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination>
    <oabi:AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</oabi:AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings>
    <oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">750000</oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">750000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; as filed with the SEC on March&#160;28, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The valuation of the Forward Purchase and Backstop Securities required management to exercise significant judgement in its estimate. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 or &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;December&#160;31, 2021. As &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of &lt;/div&gt;September&#160;30, 2022 and December&#160;31, 2021, the Company had operating cash (i.e., cash held outside the Trust Account) of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$19,847&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$189,971, respectively. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury bills. The Company&#x2019;s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in gain on investments held in Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of the investments held in the Trust Account are determined using available market information. At December&#160;31, 2021, the assets held in the Trust Account were held in cash. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A Ordinary Shares Previously Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contained a redemption feature which allowed for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognized changes in redemption value immediately as they occurred and adjusted the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares were affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,438,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;237,188,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#x2019;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;their right to redeem those shares for a &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro &lt;/div&gt;rata portion of the Trust Account holding the proceeds from the Company&#x2019;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company complies with the requirements of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s condensed consolidated financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;no&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;unrecognized tax benefits and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;no&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;amounts accrued for interest and penalties as of September&#160;30, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;15,900,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;shares in the calculation of diluted &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;income per share as the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;5, 2021&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,973,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(493,286&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(52,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,762,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,690,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,399,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,755,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,155,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The Forward Purchase and Backstop Securities contained within the A&amp;amp;R FPA (see Note 6) are classified as derivatives in the condensed consolidated balance sheet with changes in the fair value recognized in the condensed consolidated statements of operations. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note - related party, and advance from anchor investor approximate fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2014; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2014; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2014; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; as filed with the SEC on March&#160;28, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <oabi:EmergingGrowthCompanyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;</oabi:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The valuation of the Forward Purchase and Backstop Securities required management to exercise significant judgement in its estimate. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 or &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;December&#160;31, 2021. As &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of &lt;/div&gt;September&#160;30, 2022 and December&#160;31, 2021, the Company had operating cash (i.e., cash held outside the Trust Account) of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$19,847&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$189,971, respectively. &lt;/div&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19847</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <oabi:AssetsHeldInTrustAccountPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury bills. The Company&#x2019;s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in gain on investments held in Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of the investments held in the Trust Account are determined using available market information. At December&#160;31, 2021, the assets held in the Trust Account were held in cash. &lt;/div&gt;&lt;/div&gt;</oabi:AssetsHeldInTrustAccountPolicyPolicyTextBlock>
    <oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A Ordinary Shares Previously Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;All of the 23,000,000 shares of Class&#160;A ordinary shares sold as part of the Units in the Initial Public Offering contained a redemption feature which allowed for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class&#160;A ordinary shares have been classified outside of permanent equity. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognized changes in redemption value immediately as they occurred and adjusted the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares were affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,438,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;237,188,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#x2019;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;their right to redeem those shares for a &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro &lt;/div&gt;rata portion of the Trust Account holding the proceeds from the Company&#x2019;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. &lt;/div&gt;&lt;/div&gt; </oabi:CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,813,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs allocated to Class&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,029,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,593,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;235,750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of Class&#160;A ordinary shares to redemption amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,438,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;237,188,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <oabi:TemporaryEquityProceedsAllocatedToWarrants
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9813334</oabi:TemporaryEquityProceedsAllocatedToWarrants>
    <oabi:TemporaryEquityIssuanceCosts
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-13029901</oabi:TemporaryEquityIssuanceCosts>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28593235</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1438875</oabi:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237188875</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">21713864</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.32</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">224000000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company complies with the requirements of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants. &lt;/div&gt;</oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock>
    <oabi:TransactionCosts
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13662256</oabi:TransactionCosts>
    <oabi:SaleOfStockUnderwritingFees
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4600000</oabi:SaleOfStockUnderwritingFees>
    <oabi:DeferredOfferingCostsNoncurrent
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:DeferredOfferingCostsNoncurrent>
    <oabi:SaleOfStockOtherOfferingCosts
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1012256</oabi:SaleOfStockOtherOfferingCosts>
    <oabi:OfferingCostsReductionOfTemporaryEquity
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13029901</oabi:OfferingCostsReductionOfTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">632355</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s condensed consolidated financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;no&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;unrecognized tax benefits and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;no&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;amounts accrued for interest and penalties as of September&#160;30, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;15,900,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;shares in the calculation of diluted &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;income per share as the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;5, 2021&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,973,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(493,286&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(52,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,762,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,690,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,399,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,755,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,155,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">15900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Period&#160;from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;5, 2021&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,973,144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(493,286&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118,394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(52,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,762,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,690,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,399,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,755,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,155,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-1973144000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-493286000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-118394000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-52185000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-6762069000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-1690517000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-86633000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-93917000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">12250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">12250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5399457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5399457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">4755274</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">4755274</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5155063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5155063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The Forward Purchase and Backstop Securities contained within the A&amp;amp;R FPA (see Note 6) are classified as derivatives in the condensed consolidated balance sheet with changes in the fair value recognized in the condensed consolidated statements of operations. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note - related party, and advance from anchor investor approximate fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2014; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2014; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2014; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <oabi:InitialPublicOfferingTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;3. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August&#160;9, 2021. On August&#160;12, 2021, the Company completed its Initial Public Offering of 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class&#160;A ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden60239985"&gt;one&lt;/span&gt;-third&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50&#160;per whole share (see Note 7). &lt;/div&gt;</oabi:InitialPublicOfferingTextBlock>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">230000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <oabi:NumberOfSharesIssuedPerUnit
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</oabi:NumberOfSharesIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <oabi:PrivatePlacementTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant was exercisable to purchase one Class&#160;A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company did not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants would have been used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants would have expired worthless. &lt;/div&gt;&lt;/div&gt;</oabi:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class&#160;B ordinary shares (the &#x201c;Founder Shares&#x201d;). The Founder Shares included an aggregate of up to 750,000 Class&#160;B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part, so that the holders of the Founder Shares would own, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the Company&#x2019;s issued and outstanding shares after the Initial Public Offering. On June&#160;16, 2021, the Company transferred 35,000 Class&#160;B ordinary shares each to three members of the Company&#x2019;s board of directors (or 105,000 Class&#160;B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August&#160;12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year&#160;after the completion of a Business Combination or (ii)&#160;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#x2019;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1)&#160;the closing price of the Company&#x2019;s Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-&lt;/div&gt; trading day period commencing at least 150 days after the OmniAb Business Combination or (2)&#160;if the Company consummates a transaction after the OmniAb Business Combination which results in the Company&#x2019;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Promissory Note&#160;&#x2014; Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#x201c;Promissory Note&#x201d;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the Initial Public Offering. The Company&#x2019;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March&#160;22, 2021, and the Company borrowed $119,275 on June&#160;23, 2021. On August&#160;12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000. The Promissory Note is no longer available to the Company. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Administrative Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of the OmniAb Business Combination, the Company ceased paying these monthly fees. For the three months and nine months ended September&#160;30, 2022, the Company incurred expenses of $30,000 and $90,000, respectively, under the agreement. For the three months ended September&#160;30, 2021 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021 the Company incurred expenses of $20,000 under the agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to related party consists of payments made by the Sponsor and/or an affiliate of the Sponsor on behalf of the Company for formation and operating costs, along with the administrative support monthly fee and are payable on demand. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Promissory Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#x201c;working capital loans&#x201d;). If the Company completed the initial Business Combination, it could repay such loaned amounts out of the proceeds of the Trust Account released to us. Otherwise, such loans could be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination did not close, the Company could use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Company&#x2019;s Trust Account would be used to repay such loaned amounts. Up to $2,000,000 of such loans could have been convertible into warrants of the post-Business Combination entity at a price of $1.50&#160;per warrant at the option of the lender. The warrants would have been identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. The Company did not seek loans from parties other than the Sponsor, its affiliates or any members of the management team as the Company did not believe third parties would be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;14, 2022, the Company entered into a convertible promissory note pursuant to the Working Capital Loans terms with the Sponsor (the &#x201c;Sponsor Working Capital Loan&#x201d;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon the earlier of (i)&#160;completion of the initial Business Combination or (ii)&#160;the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of September&#160;30, 2022, the outstanding balance on the convertible promissory note is $750,000. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Audit Committee Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On August&#160;24, 2022, the board of directors elected Charles Harwood to serve as a director of the Company and appointed Mr.&#160;Harwood to serve as a member of the audit committee. The board of directors has determined that Mr.&#160;Harwood satisfies all applicable independence requirements to serve on the board of directors and the audit committee, including without limitation the applicable independence requirements of the Nasdaq Capital Market and the Exchange Act, as amended. In connection with Mr.&#160;Harwood&#x2019;s appointment to the audit committee, L&#xe2;le White has stepped down from the audit committee, which currently consists of Wendel Barr, Charles Harwood and William Klitgaard. The changes to the audit committee&#x2019;s composition relate to the Company&#x2019;s communications with the staff of Nasdaq on August&#160;22, 2022, regarding whether the Company was in compliance with Nasdaq Listing Rule 5605(c)(2) following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;phase-in&lt;/div&gt; period provided under Nasdaq Listing Rule 5615(b)(1) because the Audit Committee was not comprised of at least three independent directors. The Company is in compliance with the applicable rules following the board of directors and audit committee changes described herein. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon consummation of the OmniAb Business Combination, the Company paid Mr.&#160;Harwood a $10,000 fee for his services as a director and member of the audit committee. This fee is included as part of accrued expenses on the balance sheet as of September&#160;30, 2022. In connection with Mr.&#160;Harwood&#x2019;s appointment, he and the Company entered into an indemnification agreement and a letter agreement, the terms of which were described in, and the forms of which were filed as exhibits to, the Company&#x2019;s registration statement relating to the Company&#x2019;s Initial Public Offering. &lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <oabi:NumberOfSharesSubjectToForfeiture
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">750000</oabi:NumberOfSharesSubjectToForfeiture>
    <oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders
      contextRef="P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</oabi:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_16_2021To06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">35000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <oabi:TotalNumberOfSharesTransferred
      contextRef="PAsOn06_16_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">105000</oabi:TotalNumberOfSharesTransferred>
    <oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P1Y</oabi:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P20D</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P30D</oabi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P150D</oabi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="PAsOn02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">300000</oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty
      contextRef="P03_22_2021To03_22_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">55725</oabi:OfferingCostsIncludedInPromissoryNoteRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P06_23_2021To06_23_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">119275</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">175000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</oabi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P07_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2022To09_30_2022_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">90000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P02_05_2021To09_30_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">20000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <oabi:MaximumLoansConvertibleIntoWarrants
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">2000000</oabi:MaximumLoansConvertibleIntoWarrants>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">750000</oabi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="PAsOn03_14_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</oabi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <oabi:WorkingCapitalLoansOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">750000</oabi:WorkingCapitalLoansOutstanding>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;6. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Registration and Shareholder Rights Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on August&#160;9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) had registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters purchased Units at a purchase price of $9.80 per Unit (i.e., at a cash underwriting discount of $0.20&#160;per Unit, or $4,600,000 in the aggregate) upon the closing of the Initial Public Offering and the exercise of the over-allotment in full on August&#160;12, 2021. In addition, the Company agreed to pay the underwriters a deferred underwriting fee of up to $0.35 per Unit, or $8,050,000 in the aggregate, which would be payable to the underwriters upon the consummation of the initial Business Combination, except that the Company&#x2019;s management team would be permitted, in its sole discretion, to allocate up to 50% of the deferred underwriting fee, or $4,025,000 in the aggregate, to third parties that assist in identifying and consummating an initial Business Combination. On August&#160;17, 2022, Credit Suisse waived its right to 50%, or $4,025,000 in the aggregate, of the deferred underwriting fee, and the Company has determined not to pay the 50% to any other advisors. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor which provides for the purchase of an aggregate of 10,000,000 Class&#160;A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class&#160;A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class&#160;A ordinary shares are redeemed by the Company&#x2019;s Public Shareholders. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The forward purchase securities were issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities were used as part of the consideration to the sellers in the Company&#x2019;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;23, 2022, in connection with the execution of the Merger Agreement, the Company entered into the A&amp;amp;R FPA with the Sponsor and Legacy OmniAb. Pursuant to the A&amp;amp;R FPA, the Company agreed that, in connection with the consummation of the OmniAb Business Combination, they would issue and sell to the Sponsor 1,500,000 shares of OmniAb Common Stock and warrants to acquire 1,666,667 shares of OmniAb Common Stock for an aggregate purchase price of $15.0&#160;million with such purchases to be consummated immediately following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domestication&lt;/div&gt; to Delaware and prior to the OmniAb Business Combination. In addition, the Sponsor agreed to purchase up to an additional 10,000,000 shares of OmniAb Common Stock and up to an additional 1,666,667 warrants, for an aggregate additional purchase price of up to $100.0&#160;million, in &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $100.0&#160;million. The A&amp;amp;R FPA also provided that in the event the Merger Agreement was terminated by Ligand under circumstances in which the Termination Fee (as defined in the Merger Agreement) would be payable under the Merger Agreement, Ligand would pay the Sponsor a termination fee of $12.5&#160;million in connection therewith. Pursuant to the A&amp;amp;R FPA, in connection with the Business Combination, the Sponsor was issued 8,672,934 Backstop Shares and 1,445,489 Backstop Warrants for an aggregate purchase price of $86,729,340 in order to backstop the redemptions. In addition, pursuant to the A&amp;amp;R FPA, the Sponsor was issued 1,500,000 Forward Purchase Shares and 1,666,667 Forward Purchase Warrants for an aggregate purchase price of $15,000,000, on a private placement basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the A&amp;amp;R FPA, the Company evaluated the modification of the equity contract, which resulted in a reclassification between equity and a liability, in which the difference between the fair value at issuance of the original forward purchase agreement and the fair value at issuance of the A&amp;amp;R FPA (the modification date) was treated as a deemed dividend. An amount of $225,000 was recorded to accumulated deficit as a deemed dividend upon modification of the forward purchase agreement on March&#160;23, 2022. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <oabi:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_ITEM">3</oabi:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <oabi:PurchasePricePerUnit
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.8</oabi:PurchasePricePerUnit>
    <oabi:DeferredFeePerUnit
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.2</oabi:DeferredFeePerUnit>
    <oabi:AggregateDeferredUnderwritingFeePayable
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4600000</oabi:AggregateDeferredUnderwritingFeePayable>
    <oabi:AdditionalDeferredFeePerUnit
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.35</oabi:AdditionalDeferredFeePerUnit>
    <oabi:AdditionalAggregateDeferredUnderwritingFeePayable
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8050000</oabi:AdditionalAggregateDeferredUnderwritingFeePayable>
    <oabi:PercentageOfDeferredUnderwritingFeePayableToThirdParties
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_pure">50</oabi:PercentageOfDeferredUnderwritingFeePayableToThirdParties>
    <oabi:AggregateDeferredUnderwritingFeePayableToThirdParties
      contextRef="P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:AggregateDeferredUnderwritingFeePayableToThirdParties>
    <oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties
      contextRef="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_pure">50</oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties>
    <oabi:AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties
      contextRef="P08_17_2022To08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4025000</oabi:AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties>
    <oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties
      contextRef="PAsOn08_17_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_pure">50</oabi:PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties>
    <oabi:SharesToBePurchasedPursuantToAgreements
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">10000000</oabi:SharesToBePurchasedPursuantToAgreements>
    <oabi:WarrantsToBePurchasedPursuantToAgreements
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_shares">3333333</oabi:WarrantsToBePurchasedPursuantToAgreements>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">100000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <oabi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">1500000</oabi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <oabi:AdditionalNumberOfCommonStock
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ApacCommonStockMemberusgaapStatementClassOfStockAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">10000000</oabi:AdditionalNumberOfCommonStock>
    <oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1666667</oabi:ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights>
    <oabi:AdditionalAggregatePurchasePrice
      contextRef="P01_01_2022To09_30_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</oabi:AdditionalAggregatePurchasePrice>
    <oabi:MaximumAdditionalAggregatePurchasePrice
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</oabi:MaximumAdditionalAggregatePurchasePrice>
    <us-gaap:BusinessExitCosts1
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</us-gaap:BusinessExitCosts1>
    <oabi:SponsorPurchaseBackstop
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">8672934</oabi:SponsorPurchaseBackstop>
    <oabi:SharesBackstopWarrants
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">1445489</oabi:SharesBackstopWarrants>
    <oabi:AdditionalAggregatePurchasePrice
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">86729340</oabi:AdditionalAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <oabi:DeemedDividend
      contextRef="P03_23_2022To03_23_2022_AmendedAndRestatedForwardPurchaseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">225000</oabi:DeemedDividend>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;7. SHAREHOLDERS&#x2019; EQUITY (DEFICIT) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &#x2014; The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of September&#160;30,&#160;2022 and December&#160;31, 2021, there were no preference shares issued or outstanding. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;A ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &#x2014; The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At September&#160;30,&#160;2022 and December&#160;31, 2021, there were 23,000,000 Class&#160;A ordinary shares issued and outstanding, including 23,000,000 Class&#160;A ordinary shares subject to possible redemption. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;B ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &#x2014; The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares with a par value of $0.0001 per share. Holders of Class&#160;B ordinary shares are entitled to one vote for each share. As of September&#160;30, 2022 and December&#160;31, 2021, there were 5,750,000 Class&#160;B ordinary shares issued and outstanding, and the holders of the Founder Shares own, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the Company&#x2019;s issued and outstanding shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#x2019;s shareholders except as required by law. Unless specified in the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-thirds&lt;/div&gt; of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#x2019;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#x2019;s shareholders are entitled to receive ratable dividends when, as and if declared by the board &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of directors out of funds legally available therefor. Prior to the Company&#x2019;s initial Business Combination, (i)&#160;only holders of the founder shares will have the right to vote on the appointment of directors and (ii)&#160;in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#x2019;s Class&#160;B ordinary shares will have ten votes for every Class&#160;B ordinary share and holders of the Class&#160;A ordinary shares will have one vote for every Class&#160;A ordinary share. These provisions of the Company&#x2019;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#x2019;s general meeting which shall include the affirmative vote of a simple majority of the Class&#160;B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &#x2014; Each whole warrant entitles the registered holder to purchase one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days&#160;after the completion of the Company&#x2019;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class&#160;A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire five years&#160;after the completion of the initial Business Combination, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class&#160;A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#x2019;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class&#160;A ordinary share upon exercise of a warrant unless the Class&#160;A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class&#160;A ordinary share underlying such unit. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#x2019;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#x2019;s Class&#160;A ordinary shares are at the time of any exercise of a &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, the Company may, at it&#x2019;s option, require holders of warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class&#160;A ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class&#160;A ordinary shares underlying the warrants, multiplied by the excess of the &#x201c;fair market value&#x201d; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value. The &#x201c;fair market value&#x201d; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption of warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30 days&#x2019; prior written notice of redemption to each warrant holder; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending three trading days before the Company sends the notice of redemption to the warrant holders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&#160;A ordinary shares is available throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#x2019;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No fractional Class&#160;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&#160;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&#160;A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#x2019;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class&#160;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the number of outstanding Class&#160;A ordinary shares is increased by a capitalization or share dividend payable in Class&#160;A ordinary shares, or by a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-division&lt;/div&gt; of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-division&lt;/div&gt; or similar event, the number of Class&#160;A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class&#160;A ordinary shares at a price less than the &#x201c;historical fair market value&#x201d; (as defined below) will be deemed a share dividend of a number of Class&#160;A ordinary shares equal to the product of (i)&#160;the number of Class&#160;A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class&#160;A ordinary shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Class&#160;A ordinary share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Class&#160;A ordinary shares, in determining the price payable for Class&#160;A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#x201c;historical fair market value&#x201d; means the volume weighted average price of Class&#160;A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class&#160;A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class&#160;A ordinary shares on account of such Class&#160;A ordinary shares (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class&#160;A ordinary shares during the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;365-day&lt;/div&gt; period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class&#160;A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a proposed initial Business Combination, (d)&#160;to satisfy the redemption rights of the holders of Class&#160;A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A)&#160;to modify the substance or timing of the Company&#x2019;s obligation to provide holders of the Class&#160;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18 months from the closing of the Initial Public Offering or (B)&#160;with respect to any other provision relating to the rights of holders of the Company&#x2019;s Class&#160;A ordinary shares, or (e)&#160;in connection with the redemption of the Company&#x2019;s public shares upon failure to complete the Company&#x2019;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class&#160;A ordinary share in respect of such event. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Whenever the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Class&#160;A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Class&#160;A ordinary shares so purchasable immediately thereafter. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#x201c;Redemption of warrants&#x201d; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class&#160;A ordinary shares to be issued to the warrant holder. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#x2019;s Initial Public Offering except that the Private Placement Warrants (including the Class&#160;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#x2019;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants ), and will account for the 3,333,334 Forward Purchase Warrants and Backstop Warrants to be issued in connection with the OmniAb Business Combination, in accordance with the guidance contained in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40.&lt;/div&gt; Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <oabi:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</oabi:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassaSubjectToRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <oabi:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</oabi:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:CommonStockSharesIssued>
    <oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1
      contextRef="P01_01_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1>
    <oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</oabi:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1>
    <oabi:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</oabi:CommonStockNumberOfVotesPerShare>
    <oabi:PercentageOfVotingRightsShareHolders
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">50</oabi:PercentageOfVotingRightsShareHolders>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharePrice>
    <oabi:WarrantExercisePeriodConditionTwo contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</oabi:WarrantExercisePeriodConditionTwo>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P20D</oabi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
    <oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P60D</oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
    <oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P60D</oabi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
    <oabi:RedemptionPeriod contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P10D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:RedemptionPeriod contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:RedemptionPeriod>
    <oabi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</oabi:WarrantRedemptionConditionMinimumSharePrice>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P20D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <oabi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_Day">3</oabi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders>
    <oabi:RedemptionPeriod contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</oabi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <oabi:RedemptionPeriod contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P10D</oabi:RedemptionPeriod>
    <oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis_WarrantMemberusgaapClassOfWarrantOrRightAxis">P365D</oabi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis"
      decimals="0"
      unitRef="Unit_pure">100</oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <oabi:MonthsToCompleteInitialBusinessCombination contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">P18M</oabi:MonthsToCompleteInitialBusinessCombination>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.2</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">60</oabi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P20D</oabi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
    <oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.2</oabi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <oabi:WarrantExercisePriceAdjustmentMultiple
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">115</oabi:WarrantExercisePriceAdjustmentMultiple>
    <oabi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</oabi:WarrantRedemptionConditionMinimumSharePrice>
    <oabi:WarrantRedemptionPriceAdjustmentMultiple
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_pure">180</oabi:WarrantRedemptionPriceAdjustmentMultiple>
    <oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30M</oabi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">15900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">7666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_ForwardPurchaseWarrantsAndBackstopMemberusgaapClassOfWarrantOrRightAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_OmniabBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">3333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis as of September&#160;30, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237,188,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237,188,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liability - Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Forward Purchase and Backstop Securities were fair valued based on the difference between the current fair values of each of the underlying components of the agreement (i.e. the Class&#160;A ordinary shares and the warrants) and the present value of the contractual forward prices. As the Backstop Securities only apply in the event of and to the extent that the funds in the Company&#x2019;s Trust Account falls below $100&#160;million as the result of redemptions, the valuation considered an expected redemption rate based on redemption rates exhibited by similar companies in the market during the third quarter of 2022 and the expected post-redemption Trust Account balance. As the Forward Purchase and Backstop Securities will only apply in the event that the Company completes an initial business combination, the value reflects the probability of completing an initial business combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, the derivative liability for the Forward Purchase and Backstop Securities is classified as Level&#160;3 due to the use of unobservable inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of March&#160;23, 2022 (initial measurement): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 21%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;23,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Initial&#160;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to Business Combination (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount factor&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected redemption rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of completing an initial Business Combination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the significant inputs to the valuation for the Forward Purchase and Backstop Securities liability as of September&#160;30, 2022: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 19%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;September&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to Business Combination (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount factor&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected redemption rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of completing an initial Business Combination&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of the Company&#x2019;s Level&#160;3 financial instruments that are measured at fair value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement as of March&#160;23, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;591,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,039,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(656,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;383,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,212,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $1,212,110 and $0 within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the three months ended September&#160;30, 2022 and for the three months ended September&#160;30, 2021, respectively. The Company recognized a loss in connection with changes in the fair value of the Forward Purchase and Backstop Securities of $1,147,120 and $0 within change in fair value of Forward Purchase and Backstop Securities in the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022 and for the period from February&#160;5, 2021 (inception) through September&#160;30, 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237,188,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237,188,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liability - Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="0"
      unitRef="Unit_USD">237188875</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="0"
      unitRef="Unit_USD">237188875</us-gaap:AssetsHeldInTrustNoncurrent>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="0"
      unitRef="Unit_USD">1595500</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="0"
      unitRef="Unit_USD">1595500</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <oabi:MaximumAdditionalAggregatePurchasePrice
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</oabi:MaximumAdditionalAggregatePurchasePrice>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 21%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;23,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Initial&#160;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to Business Combination (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount factor&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected redemption rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of completing an initial Business Combination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 19%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;September&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to Business Combination (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount factor&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected redemption rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of completing an initial Business Combination&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Forward Purchase and Backstop Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_shares">10.34</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_shares">10</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_Y">0.52</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">0.95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">99.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">85</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">32.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">448380</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_shares">10.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputCommodityForwardPriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_shares">10</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_Y">0.08</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">2.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">99.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedRedemptionRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">85</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_item">50</us-gaap:DerivativeLiabilityMeasurementInput>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">1595500</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement as of March&#160;23, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;448,380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;591,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,039,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(656,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;383,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,212,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;1,595,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn02_04_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <oabi:InitialMeasurementOfForwardPurchase
      contextRef="P03_23_2022To03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">448380</oabi:InitialMeasurementOfForwardPurchase>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P03_24_2022To03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">591310</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">1039690</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2022To06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">-656300</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">383390</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">1212110</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">1595500</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1212110</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P07_01_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1147120</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss
      contextRef="P02_05_2021To09_30_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE&#160;9. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as mentioned below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On November&#160;1, 2022, the parties to the Merger Agreement completed the Business Combination. Holders of 21,713,864 shares of the Company&#x2019;s Class&#160;A Ordinary Shares sold in the Initial Public Offering exercised their right to redeem those shares for a pro rata portion of the Trust Account holding the proceeds from the Company&#x2019;s Initial Public Offering, calculated as of two business days prior to the extraordinary general meeting of the shareholders, at a price of approximately $10.32 per share, for an aggregate of approximately $224&#160;million. The per share redemption price of approximately $10.32 for public shareholders electing redemption was paid out of the Trust Account. For more information regarding the Business Combination, see Note 1, Note 2, Note 6 and OmniAb&#x2019;s Current Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8-K&lt;/div&gt; filed on November&#160;7, 2022. &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">21713864</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <oabi:SaleOfStockCashPricePerShare
      contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.32</oabi:SaleOfStockCashPricePerShare>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P11_01_2022To11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">224000000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn11_01_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.32</us-gaap:SaleOfStockPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'J&?E4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !ZAGY5\[/GT>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OIVG10^CFLN))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF
M&YA>1Z%#PN<4(B:RF&\F-_@L=-RP(U$4 %D?T:E<EX0OS7U(3E%YI@-$I3_4
M :%MFCMP2,HH4C #J[@2F>R-%CJAHI#.>*-7?/Q,PP(S&G! AYXR\)H#D_/$
M>)J&'JZ &4:87/XNH%F)2_5/[-(!=DY.V:ZI<1SKL5MR90<.;T^/+\NZE?69
ME-=8?F4KZ!1QPRZ37[OM_>Z!R;9IVXKSJFMV+1>W7'3\?7;]X7<5=L'8O?W'
MQA=!V<.ONY!?4$L#!!0    ( 'J&?E697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M)[@@41!%#K].$US'^G6<P?T>KY26N/U_VD*L';KM#N:;N%$536#DX:%7(%_
MBS]^"/O!9P=?M^'KNMSC6Y%L\(1K\K2O6M??+5]^"AT0O0:BYW09(T%J*>XY
MS=HHW/HUY0H<'/V&H^_TN2LUTWLR11)).9GAF=J1;[!O(W([!4$0#KK]J-=Q
M8%TU6%?G8#U"QLPIPF6:TZ)UL]P^WQ_FL_'D@LSFTTL'UJ#!&IR#=<\XGO I
MU9 )V;I4;INY*#_1),%+4J)'6OLY\*X;O.MS\)8%Y9Q,-@J[E6K#<]MHN7$=
MK3!XO>6"<WCN"I 9*S/R!1UT3J:BJ&C9NF[O&+Y'=G+_AF>1[<@3GB[%;*Y:
M@&0B;<5RN[WY,?HG*<(L@DV$BB1B4^HZ6S2M3;(=URGF=7B=J1^H64-%.*Q1
M&EQ>X?T@Z^175[2H;,)9"8WIRQ9S_&$ :09@_UH(?:R8"9I?D/@?4$L#!!0
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MQ(TS@$:YMW0.M"BQ 05S"LS1@"&/@ 8%[?K'(C&\0]R\ VB]R\NLG(H#E0(
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MC,DS.U=9DA B3FB$&*P&ULA]''N>2D@B_B"PYT?'2%E94/JF3IZ7 \M11!"
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M-N55:R#^_E"6S<N+UL%S67U;'^;U_P!02P,$%     @ >H9^58M@F2X!$0
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M&W2_OZFJ]MLW9QW_J:J_;GV<_Q]02P,$%     @ >H9^59#+XAE#!   .1
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MS (.ZGQ3]=HFM?.5;*&[\*G^A;IN;NH,J][\Y@NM817ENVRWO,2P@MK>4%H
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M%&WX&>CS";8^G]">C5?L7C\@8CR)3;LX^K64'P^C.\>!5#>UR=M<F(YMC?Q
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M10;?&NA7O+G\_-/PT\7U\.;B\E,P_'0>?!K>?/G\+KA\'UQ>O?M,GU^_>EK
M5-CAZ5B&?<O##CJ&?1Y\3)-BE@?ODDA'+?W/-O?O]^\;X/R> 08;!G@*1'*4
M&EA*O1UL'/%:+WK!X4$8# X&@[8=;>Y^KL?0O4_=^VW[^>;NM=T<NG,_I/&.
M?O2Y;QZVWPLNLZE*S/\H%NLD"CZIHLQTD$Z"RX7.Z/,\N)EID/EQ.E^H9&62
M:0 _CF"P*)B81"5CH^(@+U2A0<44>6"2<5Q&T"6.<: ">^>Y+O(PB(T:F=@4
M1N<T7:9SD/D<FZ75?/!;;NY NXUR$QF586OX[(.98I^KF0(=,M9E8<8JSH.+
M9)QFBQ0ZPX)V__&WT\'@X"6WI5_Z+X,THU7(=U<J@W7*=WMAL)R9\2R #X/A
M"$:#U:7!6Y-"CTPM:!I8.<S2"W9= ^AVEJU@TS$VS<=&)V-M6\DWT.9B#.HX
M"8,/'\Z"7?X%/@72)LCQZ3A.$QCA1H]G21JGTY4=X?+C#;2[4656YMX$N8S$
M7^P1">]0#ZMZ(QZ$O]D+=D'OD.J^U3',(%2XG"=F.!(JN$^13&=\T,VOEKKY
M29E; N-"Y,.TS"QI@;]HDL#DP2)=Z@P.:+3"I<)>\?!@H06LT4R9>BJ8 S>8
M_7RAQ\PAA1FET2I8Q*I JQE,Y"0CDX_36YVMD"_F0$E:P<A0SXD9!][A!;-R
MKA([&(SKEK7(#)A/$Z_ ^&1 G1SX\58GI0XF63H'9AV#R81?-'Q#,[MS0G'0
M.5!Z;F(->C_!%MAGH;(BH8TNLG2:J3GS>:ZS6QBM/CXPOU89L)YM"@M+@G]3
M20DV/3A%]=$_"2W;H_C%&GG<D:G0BZ#(5)(KMLO%3!4B4M#,)$$E!?UG+V$E
MX]]*DQMJBQ+^\:8')P C)XE8]J4I9D3@7,-.E&O)]*)5\YAA)2M.$BIV%\;U
MV'-I0!F,-&Q"@[P!/\+)+5&#-(6<IQ(6!G)\@F.>CW06L#H=M-!CUY/MLSC-
M04-9#FS9BRD\QJKX:%1"/SA26O189P6@,*!E3%J%U1=]Y6NP8I:EY1141Y O
M3+*?3B;!,+<J3U82!I\ 3PD!]1WP)PY8I,%,W8)>7,#9WP$7@ABL@B?/CWNG
MR%*QK#4!*#E6^:Q.B8&EA#?R2 -18+W3,E;9_E*MVHS>1G. F/5%O@#%^GIG
M@:R9W>J=-__X6__DX&6;"?R&P1X-SJ/!"2V)/(,C!]W\:JF;GSS$X"@P!ZFG
ML6425G&JRP@Y._5HB3HM$9D1'!B8)@P699:7L"74:3_4,M64/T/Y/G[C.B4*
MC8G*@_%,)5/6JC7S\9>V;1O\@B/G%QQM!/##6P-K"Z[*$3!(,/1H> 8*"O9_
M$?S71R+@?[=Y!QL'?Z Y./N1@YW_H,%J1#UV1#W^?9RMS<-^NKQY%X !/']W
M??;YXHI&QR%IMO^L9GO[Y?KBT[OK:V\R$+R+?_]R<7YQ\Q\AM?GI\N+33\'9
MY:>S=Y\_X;_7%^?2.-B")U!D0#O&*OD*HJ/'7YUN-+YE,PGC&+5"I7610_L(
MV#@)WNM11HKAF(6RAZBGS*$+J#IM0$:P7Z8G\!N:!Y1+'Z+5W LR@]#@_G6'
MJ"51]Z6$X2(0MQPM,D,)W))=/'[0MA6"#"B(YX#KEC@Q@3W2'@2W4*$TE$A(
M;7!"&"$1^=YG^688FA09FCM/W,'F769+T W!1YU-07U=ER,QD4*#ZO,*%91)
MC/B3#2*8I+L"UAWA!E%[H!E9FESW"!R=66.FR![,$1F)00)]O$ASV@^ #K F
M )],PLJ99@V#?(9[UW>\\Y#!DJ^#;1,8"]KDT"33J8_<8*[<@,51606<&:.I
M2M>"+<*&\Q1&LJU@*[O*<L);V_6LZEJ9\N8^D[0 0S@W@I\563@S1L"+A"KS
M HUP%DPUVK %8"S$P[@:)(V0A?0PD)<BIP72!J! RS+6IP<9 !L)NAVX:,J<
MHY&@.,84= QLV(H1V1#HDI?C&0N#/Q"PR:]@DF@/%6#-3/XUQY-( =WB%HF$
MV\U(2((]CVN]*-ADVNA7?0$S%1$AH>,<A1.9>.5!81@'UD0!7E.L*J8"/DHC
M-I)-\0]V0=9@6NB^YURB]74X9TJT@:<&R)IS5-RZ!=C"H D&?+9@G0#N%7.S
M%:(+^5YTQJ5\7TD4X1U<' L5.V26X!V]0X$(!(=P^PI!$:(YA+-N36T\8X$]
M@,](Y^/,C##>@<'Z.C<!C-"LEY(4O$:F/2SLAK3F%/2@Z##GXKAS:!*M8Q/$
M9Y$>@VC +!H^Y=7#F,-R"I(2/+>J^])]U&>_LE]G&"<K.MI$-J3JX# \.#C
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M0 ,?& K/7($:@1Z^U8#)0$%]K:V'9V?9W 2G6XC.BA^DR!2R%:%R&T4=' M
MDS;I'Z@YR36Y:0(3ZKJO2U. 8QE31&=5C6W0==(Y*\S((+>1]PON!0@DN<&L
M&C@"#7 1'4(Y<!9B4L:M"\$Q46X7F;XU;,E!/D")K*%C_!44,_N?ZL[7,.PA
M ?&(@@D3;LYV3Z3K81S8BL<:FL B@O7SK/DUWE*0CS(-OCB**P4!W5? ,:6X
MX"CT9F(HU0)<.4?''61?@XD%V>O8QR;K@@I_C+,JA/].HM^[](&<!;:]1G6A
M,CBRMRG\XS9K_8SWP^NW3CFT]CM+(XSU,AUMM^'UF>MUDRY@=4>G8+W/ 3U
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M);TG@>P(9X"5U%P(:%?Z\R_#*P<WN1C/E@<ZCFFC#-E 8/C! :(HXA2N[D*
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MQYE6H&2P 7P_2<%]EU]P M0)M+PW_PM02P,$%     @ >H9^55+[N%._"0
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M=VLEC@>L9S2&UXG"-S%94E>@T3A5E0Y!(L'^4-O*HIN%-5+-Z4"O:UT"<N#
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MQ_P(3G4FUWAQ-"C5/S20O-I2XH[E<$ZZMHH8+:4Y)IPU<BC,G_(Q%,R^VD8
MKQ->G,C>2>QKR<I3J]/L#%164D=:;%XJ84#]ROTSK:J)EQL_51C1EKXW-941
M])7T-WX&(?]RXT)_#'*%A.9^H5(JS"\^B@\'._'.SFZTM7&FMU%)"Q_[XKKM
M;L+;_>%1?-0?P @7^0*F?I^V>C.N>YE2%!QHY'B'A_'>T4X\W-G;^#(8QQU=
M'&"T^&"/X?,M%CF(=W<.X\.#+U]C![;A,1[$@T,>^%T1G6/G<'QDH(H/9P%6
M>F,=_OD6[$F\<$&+%5R-,M.R\[2=V [5?R-'"*$](/0!'.+A_JX1&EW,<IVH
M(D%RC\Q0!7DBN28FBQHI6=1TF9\]U8#=_GUNQ'O<<8'UNAE#19H28.LU1CH&
M;8#%[NPJB]T>A!EH=BSG]%V3SH0CK>:PF7PW_%6=F3U]/#30@]CNM#L%J&4G
M4S]1O<3.I15E+GNA*Q-J35#;9D-E]]GS*M_;_7OH?;YA6RR,H.$'_DQ9.3J7
MS6J+-*W-@\<S;4H>T8LKUB4^C=+@$B6R>.YKBTA61*N*M ORKN1VI)E2Z ]T
M"\7:'W2-\05U)DR@75]M(A:G?WH4"K.H@GN';-+=H]P?+CV3K]WRF(7&84V7
M%% IG6VDBK*C9J3J0A [2OM=\E+8W# ILY9N_>8N$_Z>,E-]-I->:HKL0/#'
MY_\K<.+V%*Y,NRLKK%-=HI8=U2(UE^9R'4XAC4."[JWF7 QBZP4**PU;/_@+
MA\]!J/^,B'X!O"'DG/0;$0'FB(?R U$5N=9"E!A*Y:8(G[XC897;%#DI*G'8
M @M,.5^$TI9(Y:(AMR@.LW(M='?Y4^L:$N^(HJE5B7B( &!,9'\T5=RKZV3N
M72Z1UG\ZO7N6^OQYWVY<?"WM94AO8'4H4CXZA6A9SY7"8[TUY2;P#Y(E6UOK
MQ WK2MS1W[ ]R7(*,/36E+.2=E>+WIJ/)0I.Y9/ 3<?B \WI7(L[SA_K6"=8
MC8A-0J5$P8""O9A;+S<^D(?G+7MX3LF8Z= L'O+4(#K'RH_[AM([AR_8 T[<
M_$TZJA:X]CT9:1.$7TJ*SA;.37E&JV,YW8G_?14]\N^-5W>#E&#U<N,<3*P*
MFQW 1_WY.2BN\='!3CS8!<T7_]Q%G?-PG_\88#7ND?RR-P2=;(\_[\<'^\.X
MOW\DS\7[1_UX;W# ?Q[NQ_L[._P9ACO"[S=>I]BVK> %K*YXA8 [J-78]4Z-
MC0;#>+BG7^Z 7;B[=]#]Y"Y\VHN'![OPW0 ^]?=W'@0ZW$:_UY>]!I\&JY^&
M1ZN?^D/[:2.X$HUT;I;Z=!_:&W.)GB^HY'X8IOFATZL-N^+2OM9M:Z)14%<-
M29P0%SHY7[TS*C$R+I-;8$A%)Y,\)A,VFV'J/2?3<Z]1]!I+=N]K[KV @<BS
M @0A:2$GI9PGY1H2Y\,@F=_EF=FEY;V:H5>3/V':#9566TKB6/8!]FOIK'4D
M39[0*R)^&@$MWZ5+3@$DS@E2O7UQ30<XSLP^'.S%9G/,3O^63JXHF><-&?-N
MYVMVX@+O*Y?KL+H5MK!G"\B,ZL?B^X(R01/?3J)A. ;%I3@(5Q"Y2P$R8MIH
MH&_38Y/H#;[R#_6 W']PE#J 45,/'^P!889Y:_0D:Q' <SZ]@1U!7GU%M6U:
M);,4B]8).*QN9>$M.Q2*#/1.Z:ZNF4[^47<3!3J5=61686$EDNL1@(P;MJ>?
M,ZD/-E<3D@K!?:."AC ^?9NO!^42#^RLAR5O:+O*]2"P/9\X+EI$V_243+PD
MYQ@1>7$DZ0.3.IR;E@,AU.DG:,VC%H_6.&NM>^&;J%D==D)!&A+P'@;7&= S
MZ"K+P+00]QS"S58+FYOUL ?QD@.KG[,9ED7C=-+WIQQALJ1TQ05M3]M:%"M/
M+HK59\FNZ<*&7O1NY6%;#+(2T.T"#!\E3I]Q<R/3-IN/TB3\2V&,-#>P-3@R
M-, T\9=#\*67<DFI37'17DC.1\CPP[LU5O=OM\3/.8PI;XM@EYW+4>VO]:YO
M_\1W6/RF$%/C> 5NY!RD=KTVU]&%)M0Y:@.^C+,M?VE'R5OH<YQ*9J.I-2J]
MK[^F+!VQE=K?@Z&(ESNCY*-$U&UG-E$;"^G3(5U_I.![?$V.$XS.E)**\YG#
MW8;8)"K,SB(3^>0$QU[T,\(K&E"2V&#XG;T-PWHH2%XM"G5NQR#N2NG.BHB7
M<V0<X<HI+'*HJ>2C4)HG89H6!/@56GZ14(Y4"SMC5\<73IJU9A-/$N7]CZ7)
M^(K<TQT/W8X?O+"5\):L8UJ:8A#I/K_&T4-@U&)=TTF-JG@IV^\VY:NB)L#V
MQHW><\F?UP,FJ"3F:;EJ&PRV&YMG9\:@.R*Q5#E?*F!I&-B\@]+.XZ'4P5[]
M.H,;[,QU=V'5)?69S7[%&"0Q9@!>0P$*[/!NV0YE9/CDV34'_I[.QE;]7 2%
M.-%;GX+@JL!7BGX>5NX3=^9.4:F/K]FZI^A'G0/=$OP17JM>U%6A\1]5@/"'
MK31XRAU^RAU^RAU^RAU^RAW^K\\=_G,G"3]E S\Z&_@/G?;[1\VX[<BM79>G
M\1^:1WAO%F']VR81\E4_VF[=BGK6#!!A2=J0\V/=%%UI-D_YB4' _8OR$TUR
MHD95_WMS$Y,O34U\RD%\; XBB(PJ=654(<Z$&7W\W5=G'1( ?))A*W.MH^/2
M;Y6YYIHM8\,C'?,;I[/]?ME.OV-:4QT]Y34].*^IN/-U:KGHM&M=D6O_L+JJ
MM<I,R_'DO9$( >P'F:HA3@Y.15N^OY%57M8.65>,Z%95KY*KL2XA#FQ<2WWO
MQ*<Y@6%8E/.%5NB;D+-979JYEEQ]2"GJFTM0GJ.S&E@L]FOZG?+!MO]P^6"#
M/6#P@5+J9'"09Z7Y+.W\,321*#WT*8>LE4-V3TI7.TWKZ]*N=D!([AQ*:M7@
M<!#W]PZ_3984J!%[!_%@%V]9V $5:7=X])@TIQV7JH2?_JRI2L\EIZR;_GWW
M9E=42 22U6Z5)#>]MT "4H%/2>\WA]%*L8<M3T8PT+@<?N-Q>[]Q.LZ_.7"N
M\<JG\/E3^/PI?/[;A,]]T\PSL*L75ZA;^VN:/$/I?.55B?T!--+ZYOCRE8NT
MRATAG:]]G).'U2?[?72OX=3;>)'N[D%_>]C?PFS*[=V^^Z']H/N7G$+URM?Z
M[X/2 A[3"_2W3PYX<!; ZR_( EC?6O$%L?'7@%,_?H^1E?0$R)"\R04,/WAF
MOD51\,.SX\'+X^&S%_"F?_S'[^< [K<)!F: ):93>+7?.X"%4HV;_M&4<QP2
M:[2:<D8?KU-@&A4^ +]C SO] R? E$Q:WH__'U!+ P04    " !ZAGY5F*4Z
M&P<,   :)0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6S-6EUSVS86
M??>OP+ANQYF195&V;#E-/.,XVVTZVZXGR;8/._L 49"$AB18 +2L_?5[[@5
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MS+QMK1<SU5K!):XUF+:NF?Y^@4)U\R .=H8[7E;6&<+%K&$EWJ-];-::>N'
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M^/W; '3_(.@[5C7^3MTH2S>T;U;TAD+M'&B\4,KN.B[ \"I;_ !02P,$%
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M3.4MVPNK(27=A P># $(C6DMY[3WYA)AQL"RCV7( GF7((-,"*/YV& 3XZ6
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M!_-P@?_38+J,CH#A >*;U2C@"<'+<AFBW,WZR[?HD_#K.(F/JE!U%)CW\1)
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MH;-:YODM!))H8BMG,POUO/I5:"=*XX7Z5@$'80%L91,E!'IE-6R0V4*1@KJ
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MNMAHM\Z@[2F0NQI?\UN(0)5=4OB0@58]RTQ!$Y:T"3'&$;! 8^J\J=:;>N!
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M&]X2#A<X%O-[LQ/CO2GXZUQ);!(MP/.I,;ZY( 'MJ]IG_P502P,$%     @
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M6%F>B3ZLKXB6ZU9(=K/D5J4)A86&K(:E5&:2XG)U:%2)Z;V=DXY1I6TD<0:
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M.G2'0?UBU,[^(&&EC%&9?:1C2FB:@.]KI4S]0ALT/VFY^B]02P,$%     @
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M@O42&B7G<XT1&>)Y+1D)HONU--K=A[F[:G!+Z<B8V!QT1";*>(W4P=P%#*C
MJ%@3+=O!6=OV<TFC9(YKIF#.D 51HH$LDMK]$JAME+O$)[;,*P+P"N1LQ)6\
M7\E"7-L<)&M15PG8(-C&,*].Y$I:)]RF?.26VF0DT P62EV)QE@Y?#"O:$*U
M ,L"1=Q)G9-DT005>,\1N+(&H0/[?8:@"X@S0/'K"BP530=>F(%(6=,3?0AB
M@7DC#\!9YB6S%1O_4M[1JL)@DH3K,2ML@"#Z4A<.S,ZUV4!+FVA8!Z4:/$@
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MH3_C=Q:.,;8L7(*#YH"LP;H)L#:5,2"!2A"-D8<Q,2!MZ%K4FV7@G;"?\6M
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M\!\C8\<+.NME7#F1PEIG +5E/B_#[^N'P4CS_VH<7$)JPUA8C5O+G(&E@"T
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M!7!_K%2:?\$#BE]/'_T/4$L#!!0    ( 'J&?E43MYV@C@X  *LO   9
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MQ&8*V*K0Z)V#KMS8\WT,<0,F9S /7Q&+][),Y=>_= -W7?/*_""^&&^Z_'_
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M0EJ YU-C*O^%&(3W\U_]%U!+ P04    " !ZAGY5*FB7 48\  !I' $ &0
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M3@UWDEV%7/BN+L00S-[+P<EH1')=LB3V! PE?&B7?EWF4UP5N8)PH+_6RQ4
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M-!7D^QH4 X!@T:LF#1(QF:=FYEF!0)%(4=[<0\$(P96^(6O''"[?CUHNK).
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M/)KH9\LC)6?/ST);+PS32"9KV$@]:YGEO?*&I3P2QA!6G.M%;OTN5I.2T$@
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M:=D4EO'=*BE+!9_%.O10^)POZ-E7MX-":\=J([L5G!HMT+KLQ.F!_*$Y2-L
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M+6_%#4,G7&@9_?6;*U )*#47-4SL;](^+]/^UN<X[F =H?%HG2WKX)0Q6R&
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M>.HQ&8^P@Q/&=W*!3NV6DY:?]V:H=MD^MW@%A'J+//^,FVBD1*4 'JD_?LK
M*=TO>=%KGKZ69?%.7"%6PR$,>(ODDTW+5J>10[/ ?V2^H-^^M+Y3"6D(K&<"
MYUK"4^MOTHH9Q1MKTA.+[E*SF#9('@-2_T_B@I4R*!.SXMPJT :/8L4@CE!U
M;-"UV$O85&9G0AY0-:GC#$T+!WW$# ;CV!]+^<LJ21E-[$5'TC U&$W#9Q.I
MDNA::4QSPR/Q 5"6<'(7+I"\/>1N=6UH,*>&JF;PL6:M\[%143KIM(.=NW)R
M]5";@U\+<O[?^7T&R5M5F&4B[C*Z7,T 5\]W$Z[HJCT>HA?^FXV[T-)WP$@9
M5B[Q Z*Q%6S(K$V-_D1J>.__$?SR(<3;<!P7K40]A0>OCFV;J/1+M$0  N&H
MNLV[Y%37(6'0W2+A@A/??TV^;-"HGK0API..=OZ8T?S]1A>V# _S9=MC/4+%
M.<V<F]WSQEM;7^J_[:A<T/J<%"DGIFTJ.)4$+1#1'4V-F($:3N)(>SC[<6C6
M,4LLDPM'>H6)[C3F!7<T ?QS8MBIJTYU93OOG5%35,DVVY%.K:=79]*5=3?Z
M-0>@C([V^W$4G&#KAG)M;8@.;L(\;"Y/M#;YPAQ5V;N*-"FUG=ZN>;V;AYP<
MG!K0-D96YHMTFE2;QB&.!RLK#)"AS+O+'S@F@O-%>(E:\H]JU]EJ#5QJ/-;2
MU93P#&_=<J=)&+ZUE!2NFO++=:GW08K-A28Z>R?T6 9H*"_W;IL+-$BW::ZE
M[<&SDSDV0U<O.E\KFK5>((LR*SUM0/GVM"4AQ$^D5ME1;V><2&##IGDREMAL
M*4FO=V7&<69TR=H0B@/87+"&OYZD",O HPVN*#FFQ)9QB5MJAFEBT+2>,,HE
M;5?OU]GC.!&UT-VM]4VO**\&9=DE9\C97M@<4.N5E=U4?VP]3^G>MD+- %P1
MUKFF(-V"I0B4%R=DANZ+*N[L<<6=/<S(VD,XO<A4S;&D@ R*5"C 8;(MCPL[
MH%K6F[U87J<6<?GX9J,&.I# $.*$F=KZF6'G2;\\F]"$6&RIKODL=<A%:A"[
MQFGK[[%IE"0P[?F(.U3R> 8+TCI8<8B 3O0".8O+7A(B&2DWX=MQEVDE@*I=
MZ8,T*/SH<#<IJ!IB-MTTG]<*8?.4XB8FY6K#I!3-"F!>TP';\HXZ@(+DV'8,
MQS[4M_) XDX5U@='@"F'&!'L74"' #1TO7F&W0TO+JCB/D*@5M,'V1E ;IE.
MVN2A[M&VE8>>=+3S[7=*IBC]PWX0_@^X<+>75'MS !)MSYZ")@N4$ U\:Z]=
M9+8$%EW5^A/ZH>OB7+N"87>[@E9!YCU@VM^!79U.J8UQZPT^HD' 0^;R4GO'
M9H$V#,&!S$MY9CN?ZPMQ!^^[2&JO<B@06TZ@E.:L"/H\3U@KU5KXI76$I]9U
M24Z%W_NV/?+E,>?4 9O_A%-7G\/_IK,/D<%U AAV=P*XJL?"2*(W5&^O%?*?
MM!W DXYVONW^\-YM934I,8BB@PN-%7&9ZPYHB2D7'QJVV%;K<HN8@>"R*K!7
MC9@/9NE"8IWXKTU=V_'7JS=G4EN-Q&RO1* AF\G$!''Y*K\%L>A8A$]+]BRI
MZ(]L30+=_5&#0A\^H($JYHY0SLNQ8]?'M9H7>7T]7]LH!?E?2XGQ/"BFGD5O
M,<7H:F\_[H)E5\-VV%W#]A2DS"J)+KG9O=?S <2E8@4R^$7T?]_1+?V_5BA_
MTKJU3SK:^5.-%IZL*YLT[$XF?)U(VO^EU].[]0P?,<YZ@WN_T>M].G@>-!:7
MF .UQK3T.0W(-0BRZ0JC ;U:=Q.TMCJ-YU-&-5"O*L:J672Z-&@TMM8.[)EJ
MS1WD*O/<VV0/K[7RE5<G3-<->-ZS/L^@4';1WFZ>6[%3PV^GL[2>C%4<6M0R
M:O3JT-@=.+J\62N(M]Z(& .X_$.+1MXC&U*!?G.QZ]PI"_:;T>-H_DEPS30^
MBK+1;)[J?\)&Y^B!O[%7[_QG:_WE8QLU&C1SH)RHH.H=7S\HJYDM+9HE&A];
M?0W(^IOUBLO':J,3VIG(72-M!B9$M2H3M'=K80NJP-<X#G((-4\A9#?N))P=
MRL^.:>EZKZY+BUF]KT-:US2G,(FBZ3] <J(56R9XUF@%3NQBT-_[/ZT$]Q'9
MU0^D1_^VA*>5U3Q1EGK(:ER&S+ [0^8-[)(Z_?T,KV)R-I]O*[-YU$A!&$5*
MI=#E0(V^<,TO" 3$JL,FKIDQW-$51Z%'PYUDUQZJ\R>=3BIJ:+0D"[DSH_^U
M7JX BHJ*DLUMGZ8K_*I>T7M<JW8PC';P!5G<7S^\OL(?]<;9%9FR69=R/BG^
MF[(G/?NX^6+4FTLF%XP S.O2,Y.*,.@9BI/ 7D7>"%*(N$:/5R/9/DWVY-;3
MXU+*G6T-607SEC*UN:MWCA9@N7I,7Z 0!Q(HN?$-K\EOG9$"D4!IMZPT-<';
M(!R-7MQ^?]_>6U*,$[B'O0]?%L"4Z.[4%NN8;U!A"^-,B97A$4]J]NV'43?D
M=&72"4OD$V=\!+'^RYU'3*3@>>.N;!B)MWALM<?&TBS/QBFG<\#-IR6FQ]V@
MM$#A*ZU+(E\ZNBMQ%,QQD&PZ=I'?1=?X=8:15LEDCKW.;/J<&"(U;)U?1#;P
M%HLLHXE-3W70'^Z,=[&=MIRM JYLK^P %-IU-RA@/Q%*#;RA&HZ.,GL04%J=
M'[_ ',;T!M4T-]&.N,NT?XA3^+C &KK00US>I,18G[LS"*#ZY%5J2[BC*,<C
MVR$]$/:B-+Y($ I,N"L.@<T8L=51,,.V=R%ZI:*PDCK@_9DK[)VOL'" #?XQ
M7RHVJ9.NS(J55P^\N;P6NL*IL;GXM!D*6EGY,V%_)NS/A/V9L#\3]G\KPG[>
M3=@?JUNXQ+=A=[+:I=.[T)EEU=1-QJQ'I"]U3/%U*K,:#=3R4+?IH,0X,'TG
M!XUR+[\ESW0]+M-I2NUC3A>+H, \&6L41&P[*6D?X>SAGKT7Z7N6.!77;6^#
M,^A)$\J>:K00?EQJT; [U>:,^H["Z= '[/<--':CT^0124 ;)PAD&W5?E&1!
MHJ[:>Q21Z-J)BB<A03MB"MB(M:?0=F3CI3%.4M+HL0L@2BH4T*+!PQJ*2L8@
MXQ829B%H9P"FA]G=VN/2NV^]F@#.NN8SH= (>+P5D)Z/TQYGR\&U8LL3I:&%
MV.(RF8;=*3Z?N%C,&W5)M2+)(W*.FN/2$;*QVUH\MZ.L:[8Z"OHA&[FM"=5F
MCW06X0WUHOQ@>N:4KKP3BXUFZG>L[8A0\Z75F5_B9M,[59#](@&-#SX4&\S?
MLDJ;/^>E<C13-GK1.\YK<0=BCS(\-AMD7[;4-.I%%Q36:EL%>G6E5GE94G,?
MVY/-ID:H8,.G3;9T&Z./+5:JVA55X%["7>U'O^HDU5CO;=K+DD+?#0 >&6<Q
M"0BE:-E$++%/KCTURX88CH[426H8<7$BZ8THS7L FM."ZFJPPW;=\:(5M-7N
MSU-Q)*/J*$%G=294+B11#N(MQZJZ%#>$F]?)Y'-9Y2M?TK;R[@,OWVB^C7\D
M&T2,;T1#_K.)Q3-5V)HJ_%NC?ZN \409PZ& X5)0AMTI*&<YI?@6SK%EK6X?
MT_)SJ[SQB,R/8!K2ZCA8'^>(WMH[][-LN2Z>US,.E+!_*"ZKM,?YGHT=2"(
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M2-]J=*=%J.]"GU#;PU\+??[4D[9%+$0-I20('&3D^0'ZT'%)WPU*Y]F^;M"
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MZCNL9CP;4XE7MGW2]VUB^6&UCOBA13PLW4PW\(GO.&4;V85ZO#/BF5BC:XT
MSR7>FN<L768^HI1+OHM)4>180V6Q!A=>"JKT W4<8EF(][_=H!/B7<_K-Z_$
MNX7GX>70Q3&*+<MWCC*=5L,ZMRI=#UKT><L.G[<L>[_5E(E;8ZPY=?P @4]1
M]7,H<3#S.4&%!!K@?=T+WL:I>#9X>$BY^A+H8#'DVN%+O.+4EM6MIJS\"M-^
M/ROW]MXET5!+\[ZK\"S#/%0^4=:C]1/RP+R<]KXM+]^?[YA<)IF"E"^0U#KO
M8U4MRS?=LI.+C7GEG(L<[RFFN>(LYE(OP/F%$/FNHS>H']:O_PM02P,$%
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M=@*.IU*:;<,ZJ&[&QO\"4$L#!!0    ( 'J&?E6>P$BL#@D  (\H   9
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M?26P-]G&?;;Q&/KB"9^9O"F!B WYI0;)=,&WQ') ;I0"K0CC.;DKV*HH"UV
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M+]U=<'Z_O+M1?Z1JP\%%P4HPQ:\3:*FJNZ5V+T8V[J*WE@9:A7O<PL6>*;L
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MN/!7G4S,BP31*V,F9/3Z&DH+H#32\1[=Z<A9A-]:UT:]/2N#/@-'T72M*7_
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M^")/M@72>4CR/-F4GZY$*,<#10+Y\\<DR0]?% 4\)^G7LGJ7_P)02P,$%
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MNV,/?4)VA!E#%IK3($Q$12-OBRDPY&6KOT71(4[0@C 6KB) 2P@@3HM"_.
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MUD7+GK4<<)(6+=.*<-& %:=;T>8#S0'B_IH0OA_D$]0_'(S^!5!+ P04
M" !ZAGY5Q:BGB&L#  "Q"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6R=5FN/FS@4_2L6NZI::3>\ I-.DTA,F&F1-@\-DUU5U7YPX))8!4QMDW3^
M_=I :"8/-C-1E&!\SN6>XXM]ASO*OO,-@$ _LS3G(VTC1'&KZSS:0(9YCQ:0
MRYF$L@P+.61KG1<,<%R1LE2W#,/5,TQR;3RL[BW8>$A+D9(<%@SQ,LLP>[Z#
ME.Y&FJGM;SR2]4:H&_IX6. UA""6Q8+)D=Y&B4D&.2<T1PR2D>:9M_Y X2O
MWP1V_. :*24K2K^K01"/-$,E!"E$0D7 \F\+$TA3%4BF\:.)J;6/5,3#ZWWT
MATJ[U++"'"8T_8?$8C/2!AJ*(<%E*A[I[@LT>AP5+Z(IKW[1KL$:&HI*+FC6
MD&4&&<GK?_RS\>& 8/8O$*R&8!T3W L$NR'8USZAWQ#ZE3.UE,H''PL\'C*Z
M0TRA931U49E9L:5\DJME#P63LT3RQ/C."X,0S1_0XO$^O)\]>4_!?(:\F8_"
MY73J/7Y5<V'P>18\!!-O]H2\R62^G#T%L\]H,?\KF 3W(?H3S9,$&,G7:$*Y
MX AS3B."!<12CM@@L0$4Y$00G*)%N4I)](OQW@>!2<H_R##>EG"!]Q O^E$2
M3JKZF%!6]% 0H&]3R%; _I7H9>BC][]_&.I"&J'DZ%$C>E*+MBZ(-DTTI;G8
M<'2?QQ"_#*!+!UL;K;V-=U9G1*]<]Y!I_8$LPS+/)=1-]R'J(=N\2/>[Z2%(
M;VRCHEL=:NRV*.PJ7O]"O'9M(K6:9_*YJ_E.Q5<[RW9LVJYK68X[U+>'NJ\%
M^IT9J<WOEA<X@I$F=S<.; O:^-UOIFM\ZM#;;_7V._4N916P'9.5)C4G &<E
MUR'< R5]UU"?(\57XOS.E-XHV&D%.YV"?9 +S.3;61XI1P5^QJL4SAG@G @;
M&,X9 Z[$^<Y):?0-RSG$O=#FMMK<[N*5FPU#]']+V#U)TS3,,Q5\)<[OS.J-
MZWG3:KYYQ0LKC^.XK(]5FB !64&9/-(1R.U4/)_SXN94HVU8'S\:YI$9UP+]
MSGS?Z,:@=6/P&C>P_+ZTY+(1@Y.:=&W+=IPC&ZZ#^9UIOM8$_>"0SX"MJV:)
M2XUE+NKSOKW;]F->U8;HO^!U,S?%;$URCE)()-7HW4@EK&Z0ZH&@1=4RK*B0
M#4AUN9$])3 %D/,)I6(_4 ]HN]3Q?U!+ P04    " !ZAGY51OFPN_4"  "7
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RM55UOVC 4_2M7F31M
MTM:$4+JU Z00:!>I!-2TJZ9J#R:Y@-7$3FT'.FD_?K8#*4P4[:$\$'_<<WSN
MR<UU=\W%HUPB*G@N<B9[SE*I\L)U9;K$@L@37B+3.W,N"J+T5"Q<60HDF045
MN>M[WIE;$,J<?M>N346_RRN54X93 ;(J"B)^#S#GZY[3<K8+-W2Q5&;![7=+
MLL $U5TY%7KF-BP9+9!)RAD(G/><H'41=DR\#?A!<2UWQF RF7'^:"91UG,\
M(PAS3)5A(/JQPA#SW!!I&4\;3J<YT@!WQUOV2YN[SF5&)(8\OZ>96O:<KPYD
M."=5KF[X^CMN\K$"4YY+^P_K3:SG0%I)Q8L-6"LH**N?Y'GCPPY \QP&^!N
M_R_@[!5 >P-HVT1K93:M(5&DWQ5\#<)$:S8SL-Y8M,Z&,O,6$R7T+M4XU1\$
M293 Y!*F-Z-D%-\&M]$DAB >0G(W'@<W/\U>$EW%T644!O$M!&$XN8MOH_@*
MII/K*(Q&"7R&6-?;-9<2IBA@(C+*=$E LB0"X<,0%:&Y_*CCI%F175=IZ4:
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M*]V7[7"I;TX4)D#OSSE7VXDYH+F+^W\!4$L#!!0    ( 'J&?E6DFZD+-04
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M3G, N_]""'T]R0>H=UPG_P%02P,$%     @ >H9^5=;_S187"   9ED  !D
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M^>I#7DKO'JCML1]2HIJ/:@&JA:@6H9I M1C5$E1+42VCM,,Z;F\1&B]VC]!
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M\U$M0+40U2)4$Z@6HUJ":BFJ991V6,MMCLEV7NR$&0T^H9J/:@&JA:@6H9I
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M+%RRM!#P[U=)DK\=% 4<WZ0Z^Q]02P,$%     @ >H9^5<"E&,=#$   K.L
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MA6HQJB6HEGJZNU=->B>)=&6^'PQ<&?6:H)%G7F?G-9.4S?3HQD/S1:@6H9I
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M<VAE971S+W-H965T-#4N>&ULQ5C;;N,V$/T50ET4NT :76S)E]H&'$NR VR
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M2I85KVN@,7!E@-]7C,F7AG)07Y1/O@%02P,$%     @ >H9^59M*YF5%!
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M2V"U./2*./12].ZQ+(HT:QH< L'7:Q LVC1Q[K7)N26P&N=^P;EO7?O'+16
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M@3R61#+[_U[<+<Y+INDI@5V:9X<MUX1O:210 !OEZG3.5(WP[/PB&T@6IT<
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ME-:N($VP694GFP]MY=X9>I3OXNAB@\:@4<U -1/5+%2S4<U!-1?5/%3S42U
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MQO<BB+/[I'S=S\1=N87>Z7GYUYLE]P_;;XIT^?5$/5%NTZ)(Y^LOJSY-9-6
M\N=W:5H\?U,M\)1F/]=W\_+_ 5!+ P04    " !ZAGY5<C4'DWH$   3%P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RM6-N.XC@0_14K.UK-2+OD
MPJ6A%Y!HR.[R0$]KZ-Y]6.V#20H231(SMM-T2_/Q8SLA3;BXB<8\0)RX3E6=
M4REL#W>$?F41 $<O:9*QD15QOKVU;19$D&+6(EO(Q),UH2GF8D@W-MM2P*$R
M2A/;<YR>G>(XL\9#=>^!CH<DYTF<P0-%+$]33%_O("&[D>5:^QM?XDW$Y0U[
M/-SB#2R!/VT?J!C9%4H8IY"QF&2(PGID3=Q;W^U( S7CGQAV[. :R516A'R5
M@WDXLAP9$200< F!Q<\S3"%)))*(XUL):E4^I>'A]1[]3Y6\2&:%&4Q)\F\<
M\FAD]2T4PAKG"?]"=G]#F5!7X@4D8>H;[<JYCH6"G'&2EL8B@C3.BE_\4A)Q
M8.!Y%PR\TL [,FBW+QBT2X/VL4'_@D&G-.@<&;B#"P;=TD"E;A>Y*^)FF./Q
MD)(=HG*V0),7BGUE+?B*,UDH2T[%TUC8\?'T\V(Q?USX]X]+-+F?H>GG^\?Y
M_5_^_73N+]''&7 <)^P3^AU-GF/&,7K(5TD<H$GP+8]9K,2>$KIMH?D<_;>
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MB:M@78(X6FW_!]^J'V(GP!D>"'"K /?8 *\*\-X&C X$#*N X;$91E7 Z-B
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MH#0.I8F*9IO2L]+QCS#FO,:8\^S&W$<J;'N?M#UA9S5#+3XHC4)I#$KC4)J
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MZ;H@>5R,^ES459;8C^IZ/53U,D_4RT)?:<Z7!0KR&&*%WN_6#S_2A]UZ;'8
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M!*YLI*JHP:':^KI60 MG5'$_"H+8KR@37KIP<_<J7<C&<";@7A'=5!55WU;
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M5U<HX#I K2\8D^\3?>BVE[+T+U!+ P04    " !ZAGY5JP*Q%^4#  "8#P
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MV;WG5)R-!8Y/OV!A/ .?P%44Q3)-* &?L^*:D-EZ/\<<Q<D'4?'M?@[>O_L
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MJY'&B^K-OMHHGI?ONBNN= LJEUN,4BR,@3Z_YEP];<SK<_-]9?8?4$L#!!0
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MUFB<C6K\0@5.AC*?]:YFSFUOULF\'^5Z\TY0V ^R'=\8SMMM\G;'[PW>EC>
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MIN93@-("S/E*"/VXL-VF^;A$?P%02P,$%     @ >H9^5:3&>U@-!0  YAX
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M98+:3]]4@-(L*,V&TAB4YD!I;D5K) 0U-?,X(Z!^?12MF1-[^I[>L]01<9N
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M(!'$G- 8,=@,C%&]-^TJ^]3@B<"1OVHC%<F:TF^J\Q ,#$M-"$+PA6+ \N\
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MG0JAJ'X;%8UCH9G4:;]-*_KKAVML]W!'B6DLB2H[:+6)*IZTVF\:J7; %';
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MX5R*J0R3@/CU61"HSXOD5KS\7LW1?U!+ P04    " !ZAGY50K%\F3X$
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M7D:1Y<<-^4#0=;8]/J="T#B[7 &6Q9 :R.\7E(J/0;I >>C3_Q]02P,$%
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MGRB"5<6T83L81Y($0Z 7W3T:QTAU8OBXUP?;)5&4)&X$,+>"*,(0V(TX@BD
M#1@21>8YN/,\"M;/J:#]=_SH+U!+ P04    " !ZAGY5EXJ[',     3 @
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MCP4  !PQ   /    >&PO=V]R:V)O;VLN>&ULQ9M=;Z-&%(;_RL@W3:5N'6/
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MYY;KY2_+[YV3N_>"<WU;,3S]!5!+ P04    " !ZAGY5'YV%;PD"  #8*@
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MH?7F&5!+ 0(4 Q0    ( 'J&?E4'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ >H9^5?.SY]'M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ >H9^59E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !ZAGY57IG]9<L"  "."   &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ >H9^5>^ 2/(;"P  "TD  !@              ("!#0L  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( 'J&?E6[F8I.(@0  #X4
M   8              " @5X6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " !ZAGY5*L6.29D-  "J@0  &               @(&V&@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ >H9^58M@F2X!
M$0  2+L  !@              ("!A2@  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( 'J&?E60R^(90P0  #D0   8              "
M@;PY  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !ZAGY5
M@6?&H',3  !+O@  &               @($U/@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ >H9^59U!JL,F(0  NY   !@
M     ("!WE$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M 'J&?E52^[A3OPD  *,A   8              " @3IS  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " !ZAGY5:$8T*6HW  "+]P  &0
M            @($O?0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( 'J&?E68I3H;!PP  !HE   9              " @="T  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ >H9^52D_$(XZ P
MH0D  !D              ("!#L$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " !ZAGY5_O-DH#($   9#@  &0              @(%_
MQ   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'J&?E44
M0YK> !,  *]1   9              " @>C(  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ >H9^53B&9>00"P  =1X  !D
M     ("!']P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'J&?E5R*1#HO0T  $D]   9              "
M@><5 0!X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ >H9^
M51.WG:".#@  JR\  !D              ("!VR,! 'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " !ZAGY5*FB7 48\  !I' $ &0
M        @(&@,@$ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( 'J&?E5+\(T7TP@  .0A   9              " @1UO 0!X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ >H9^5>-^5=S\!@  9!<
M !D              ("!)W@! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " !ZAGY5'*$*^,L$   E$P  &0              @(%:?P$
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( 'J&?E6>P$BL
M#@D  (\H   9              " @5R$ 0!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ >H9^59L6&' W!@  ^@\  !D
M ("!H8T! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !Z
MAGY54V4;0TX#  #H!@  &0              @($/E $ >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( 'J&?E5IRC:,XP,  +,+   9
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M970S,RYX;6Q02P$"% ,4    " !ZAGY55'((M&@#   5#P  &0
M    @(%0S@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M 'J&?E7_7/S["00  $00   9              " @>_1 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ >H9^5<6HIXAK P  L0H  !D
M             ("!+]8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " !ZAGY51OFPN_4"  "7!P  &0              @('1V0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( 'J&?E6DFZD+-04
M 'T=   9              " @?W< 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ >H9^5=;_S187"   9ED  !D              ("!
M:>(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !ZAGY5
MUV7<Q_T)  "8;@  &0              @(&WZ@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( 'J&?E7P\.TLE1   /GL   9
M      " @>OT 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ >H9^58YO;>@1#P  ,]H  !D              ("!MP4" 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !ZAGY5YE08"D8(  !550
M&0              @('_% ( >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( 'J&?E7 I1C'0Q   *SK   9              " @7P= @!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ >H9^5<(]84P]
M!   -!<  !D              ("!]BT" 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " !ZAGY5FTKF944$   .%P  &0
M@(%J,@( >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( 'J&
M?E5_(&H2[ ,  %$2   9              " @>8V @!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ >H9^5;WP8-R)!@  [RT  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( 'J&?E5'"I4T.@0  .H8   9
M  " @>YD @!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M>H9^5>K]OS(E!0  /QT  !D              ("!7VD" 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " !ZAGY5B.2)9D$%  !Q*@  &0
M            @(&[;@( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( 'J&?E7U@Z,VU@,  .L-   9              " @3-T @!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ >H9^5;(YR5M@ P
MH@H  !D              ("!0'@" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " !ZAGY5=8,;)\\"  "@"0  &0              @('7
M>P( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( 'J&?E6K
M K$7Y0,  )@/   9              " @=U^ @!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ >H9^55I[RWF/!   &1D  !D
M     ("!^8(" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'J&?E76W-C9=P(  &@&   9              "
M@2.8 @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ >H9^
M5:3&>U@-!0  YAX  !D              ("!T9H" 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " !ZAGY56/*?/=$*   %90  &0
M        @($5H ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( 'J&?E4-=@D80P8  -,V   9              " @1VK @!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ >H9^55 I'G.%!0  DR<
M !D              ("!E[$" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    " !ZAGY5/G,(\JL(  !K8@  &0              @(%3MP(
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( 'J&?E5A;,F=
M[P,  % 3   9              " @37  @!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ >H9^5;C,"54^!@  MSD  !D
M ("!6\0" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !Z
MAGY50K%\F3X$    &@  &0              @('0R@( >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( 'J&?E5#=?<,]0@  .Y9   9
M          " @47/ @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#
M%     @ >H9^5376GU=K P  FQ<   T              ( !<=@" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !ZAGY5EXJ[',     3 @  "P
M    @ $'W ( 7W)E;',O+G)E;'-02P$"% ,4    " !ZAGY5%?,@+(\%   <
M,0  #P              @ 'PW ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ >H9^5<?7<T]' @  U2L  !H              ( !K.(" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ >H9^51^=A6\) @  V"H
M !,              ( !*^4" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ %( 4@!U%@  9><"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>468</ContextCount>
  <ElementCount>442</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment</Role>
      <ShortName>COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/OrganisationAndNatureOfOperations</Role>
      <ShortName>ORGANISATION AND NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Restatement of Previously Issued Combined Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - INITIAL PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/InitialPublicOffering</Role>
      <ShortName>INITIAL PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/PrivatePlacement</Role>
      <ShortName>PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Relationship with Parent and Related Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RelationshipWithParentAndRelatedEntities</Role>
      <ShortName>Relationship with Parent and Related Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Commitment and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CommitmentAndContingenciesLegalProceedings</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/ShareholdersEquityDeficit</Role>
      <ShortName>SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Restatement of Previously Issued Combined Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/Acquisitions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Relationship with Parent and Related Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables</Role>
      <ShortName>Relationship with Parent and Related Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/RelationshipWithParentAndRelatedEntities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://om.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/OrganisationAndNatureOfOperationsDetails</Role>
      <ShortName>ORGANISATION AND NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/OrganisationAndNatureOfOperations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/AcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>Restatement of Previously Issued Combined Financial Statements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - INITIAL PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/InitialPublicOfferingDetails</Role>
      <ShortName>INITIAL PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/InitialPublicOffering</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - PRIVATE PLACEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/PrivatePlacementDetails</Role>
      <ShortName>PRIVATE PLACEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/PrivatePlacement</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Relationship with Parent and Related Entities - Founder Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails</Role>
      <ShortName>Relationship with Parent and Related Entities - Founder Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail</Role>
      <ShortName>Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Relationship with Parent and Related Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails</Role>
      <ShortName>Relationship with Parent and Related Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Leases - Schedule of Operating Lease Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Operating Lease Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail</Role>
      <ShortName>Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Balance Sheet Account Details (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetailsDetail</Role>
      <ShortName>Balance Sheet Account Details (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/BalanceSheetAccountDetailsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/ShareholdersEquityDeficitWarrantsDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d305908ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://om.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://om.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: oabi:NumberOfWarrantsIssuedPerUnit, oabi:ThresholdBusinessDaysForRedemptionOfPublicShares, us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired -  d305908ds1.htm 13123</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" original="d305908ds1.htm">d305908ds1.htm</File>
    <File>d305908dex231.htm</File>
    <File>d305908dex232.htm</File>
    <File>d305908dex51.htm</File>
    <File>d305908dexfilingfees.htm</File>
    <File>oabi-20220930.xsd</File>
    <File>oabi-20220930_cal.xml</File>
    <File>oabi-20220930_def.xml</File>
    <File>oabi-20220930_lab.xml</File>
    <File>oabi-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g305908g02y03.jpg</File>
    <File>g305908g06r21.jpg</File>
    <File>g305908g11i99.jpg</File>
    <File>g305908g17b02.jpg</File>
    <File>g305908g71w52.jpg</File>
    <File>g305908g72q97.jpg</File>
    <File>g305908g73a33.jpg</File>
    <File>g305908g76r13.jpg</File>
    <File>g305908g77s33.jpg</File>
    <File>g305908g86l12.jpg</File>
    <File>g305908g93t94.jpg</File>
    <File>g305908g99c14.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1665">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d305908ds1.htm": {
   "axisCustom": 1,
   "axisStandard": 34,
   "contextCount": 468,
   "dts": {
    "calculationLink": {
     "local": [
      "oabi-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oabi-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d305908ds1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oabi-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oabi-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "oabi-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 713,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://om.com/20220930": 4,
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 7
   },
   "keyCustom": 151,
   "keyStandard": 291,
   "memberCustom": 61,
   "memberStandard": 39,
   "nsprefix": "oabi",
   "nsuri": "http://om.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://om.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BusinessCombinationAndAssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Acquisitions",
     "role": "http://om.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BusinessCombinationAndAssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:InitialPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - INITIAL PUBLIC OFFERING",
     "role": "http://om.com/role/InitialPublicOffering",
     "shortName": "INITIAL PUBLIC OFFERING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:InitialPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - PRIVATE PLACEMENT",
     "role": "http://om.com/role/PrivatePlacement",
     "shortName": "PRIVATE PLACEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Relationship with Parent and Related Entities",
     "role": "http://om.com/role/RelationshipWithParentAndRelatedEntities",
     "shortName": "Relationship with Parent and Related Entities",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Income Taxes",
     "role": "http://om.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Commitment and Contingencies: Legal Proceedings",
     "role": "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
     "shortName": "Commitment and Contingencies: Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Leases",
     "role": "http://om.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Balance Sheet Account Details",
     "role": "http://om.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://om.com/role/ShareholdersEquityDeficit",
     "shortName": "SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://om.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://om.com/role/FairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://om.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Restatement of Previously Issued Combined Financial Statements (Tables)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables",
     "shortName": "Restatement of Previously Issued Combined Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Acquisitions (Tables)",
     "role": "http://om.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://om.com/role/FairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Income Taxes (Tables)",
     "role": "http://om.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Relationship with Parent and Related Entities (Tables)",
     "role": "http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables",
     "shortName": "Relationship with Parent and Related Entities (Tables)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Leases (Tables)",
     "role": "http://om.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:ScheduleOfOperatingLeaseAssetsAndLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Balance Sheet Account Details (Tables)",
     "role": "http://om.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn11_01_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS (Details)",
     "role": "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
     "shortName": "ORGANISATION AND NATURE OF OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMembersrtOwnershipAxis_LigandMemberdeiLegalEntityAxis_SeparationAndDistributionAgreementMemberusgaapTypeOfArrangementAxis",
      "decimals": "0",
      "lang": null,
      "name": "oabi:PercentageOfCommonStockSharesIssuedUnderDistribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Disaggregation of revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_LicenseMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue from Significant Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_PartnerAMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "oabi:TransactionCosts",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "oabi:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "oabi:OfferingCostsReductionOfTemporaryEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Ordinary Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details)",
     "role": "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net loss per ordinary share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_09_2020_TaurusAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:BusinessCombinationAndAssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2019To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oabi:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Acquisitions - Additional Information (Details)",
     "role": "http://om.com/role/AcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:BusinessCombinationAndAssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2019To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oabi:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
     "shortName": "Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2020_CombinedBalanceSheetMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
     "shortName": "Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2019To12_31_2019_CombinedStatementOfOperationsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
     "shortName": "Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Changes In Parent Company Net Investment (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020_CombinedStatementOfChangesInParentCompanyNetInvestmentMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
     "shortName": "Restatement of Previously Issued Combined Financial Statements - Schedule Of Restatement Of Previously Issued Statement Of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020_CombinedStatementOfCashFlowsMemberusgaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Restatement of Previously Issued Combined Financial Statements - Additional Information (Details)",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
     "shortName": "Restatement of Previously Issued Combined Financial Statements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - INITIAL PUBLIC OFFERING (Details)",
     "role": "http://om.com/role/InitialPublicOfferingDetails",
     "shortName": "INITIAL PUBLIC OFFERING (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "oabi:InitialPublicOfferingTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "decimals": "0",
      "lang": null,
      "name": "oabi:NumberOfSharesIssuedPerUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:PrivatePlacementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P08_12_2021To08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - PRIVATE PLACEMENT (Details)",
     "role": "http://om.com/role/PrivatePlacementDetails",
     "shortName": "PRIVATE PLACEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:PrivatePlacementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn08_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To03_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Relationship with Parent and Related Entities - Founder Shares (Details)",
     "role": "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
     "shortName": "Relationship with Parent and Related Entities - Founder Shares (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_12_2021To02_12_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail)",
     "role": "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail",
     "shortName": "Relationship with Parent and Related Entities - Schedule Of Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Relationship with Parent and Related Entities - Additional Information (Details)",
     "role": "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
     "shortName": "Relationship with Parent and Related Entities - Additional Information (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_EquityBasedIncentivePlansMemberusgaapPlanNameAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "oabi:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_ITEM",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://om.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "oabi:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_ITEM",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oabi:WarrantsToBePurchasedPursuantToAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details)",
     "role": "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Forward Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P02_05_2021To12_31_2021_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oabi:WarrantsToBePurchasedPursuantToAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://om.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details)",
     "role": "http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Leases - Schedule of Operating Lease Assets and Liabilities (Detail)",
     "role": "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail",
     "shortName": "Leases - Schedule of Operating Lease Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail)",
     "role": "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail",
     "shortName": "Leases - Schedule of Lessee, Operating Lease, Liability, Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT",
     "role": "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
     "shortName": "COMBINED STATEMENTS OF CHANGES IN PARENT COMPANY NET INVESTMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P04_01_2022To06_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://om.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail)",
     "role": "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail",
     "shortName": "Balance Sheet Account Details - Schedule of Goodwill and Other Identifiable Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Balance Sheet Account Details (Detail)",
     "role": "http://om.com/role/BalanceSheetAccountDetailsDetail",
     "shortName": "Balance Sheet Account Details (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail)",
     "role": "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail",
     "shortName": "Balance Sheet Account Details - Schedule of Property and Equipment are Stated at Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "oabi:BalanceSheetAccountDetailsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail)",
     "role": "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail",
     "shortName": "Balance Sheet Account Details - Schedule of Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details)",
     "role": "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails",
     "shortName": "SHAREHOLDERS' EQUITY (DEFICIT) - Preferred Stock Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn03_23_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details)",
     "role": "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
     "shortName": "SHAREHOLDERS' EQUITY (DEFICIT) - Common Stock Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "oabi:CommonStockNumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_VOTE",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oabi:MonthsToCompleteInitialBusinessCombination",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details)",
     "role": "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
     "shortName": "SHAREHOLDERS' EQUITY (DEFICIT) - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "oabi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Day",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "role": "http://om.com/role/FairValueMeasurementsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "oabi:DerivativeForwardPurchaseAndBackstopSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)",
     "role": "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputFairValueOfUnitMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_AvistaPublicAcquisitionCorp.IiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "oabi:DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details)",
     "role": "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details)",
     "role": "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Company's Level 3 Financial Instruments (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2020_XcellaMemberusgaapAssetAcquisitionAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details)",
     "role": "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn09_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details)",
     "role": "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of the Hierarchy For Liabilities Measured at Fair Value (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_CrystalMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn11_01_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://om.com/role/SubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "PAsOn11_01_2022_EarnoutSharesMemberusgaapStatementClassOfStockAxis",
      "decimals": "5",
      "lang": null,
      "name": "oabi:CommonStockSubjectToPriceBasedEarnoutTriggers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - ORGANISATION AND NATURE OF OPERATIONS",
     "role": "http://om.com/role/OrganisationAndNatureOfOperations",
     "shortName": "ORGANISATION AND NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Restatement of Previously Issued Combined Financial Statements",
     "role": "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements",
     "shortName": "Restatement of Previously Issued Combined Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d305908ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 104,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
      "http://om.com/role/CommitmentsAndContingenciesDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/FairValueMeasurements",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsTables",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperations",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntities",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficit",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEvents",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
      "http://om.com/role/CommitmentsAndContingenciesDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/FairValueMeasurements",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsTables",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperations",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntities",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficit",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEvents",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_AbInitioAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ab initio acquisition.",
        "label": "Ab Initio Acquisition [Member]"
       }
      }
     },
     "localname": "AbInitioAcquisitionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accretion of Class A ordinary shares subject to redemption to redemption value.",
        "label": "Accretion of Class Ordinary Shares Subject to Redemption to Redemption Value",
        "negatedLabel": "Remeasurement of Class A ordinary shares to redemption amount",
        "terseLabel": "Remeasurement of Class A ordinary shares to redemption amount"
       }
      }
     },
     "localname": "AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accrued expense as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenses",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AccruedOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of offering costs accrued but not yet paid as of the period date.",
        "label": "Accrued Offering Costs",
        "verboseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "AccruedOfferingCosts",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AcquisitionsRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions related liabilities, current.",
        "label": "Acquisitions Related Liabilities, Current",
        "terseLabel": "Acquisition related liabilities"
       }
      }
     },
     "localname": "AcquisitionsRelatedLiabilitiesCurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AdditionalAggregateDeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.",
        "label": "Additional aggregate deferred underwriting fees payable",
        "terseLabel": "Additional aggregate deferred underwriting fee payable"
       }
      }
     },
     "localname": "AdditionalAggregateDeferredUnderwritingFeePayable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AdditionalAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate purchase price of the additional shares and additional warrants under an agreement.",
        "label": "Additional Aggregate Purchase Price",
        "terseLabel": "Additional aggregate purchase price"
       }
      }
     },
     "localname": "AdditionalAggregatePurchasePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AdditionalDeferredFeePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional deferred fee per unit.",
        "label": "Additional Deferred Fee Per Unit",
        "terseLabel": "Deferred underwriting fee per unit"
       }
      }
     },
     "localname": "AdditionalDeferredFeePerUnit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_AdditionalNumberOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional common stock to be purchased.",
        "label": "Additional Number of Common Stock",
        "terseLabel": "Additional number of common stock"
       }
      }
     },
     "localname": "AdditionalNumberOfCommonStock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_AdministrativeSupportAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Administrative Support Agreement.",
        "label": "Administrative Support Agreement"
       }
      }
     },
     "localname": "AdministrativeSupportAgreementMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_AggregateDeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.",
        "label": "Aggregated deferred underwriting fees payable",
        "terseLabel": "Aggregate deferred underwriting fee payable"
       }
      }
     },
     "localname": "AggregateDeferredUnderwritingFeePayable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate deferred underwriting fee payable decided by the company not to pay or allocate to third parties.",
        "label": "Aggregate Deferred Underwriting Fee Payable, Not To Pay For Third Parties",
        "terseLabel": "Aggregate deferred underwriting fee company not to pay or allocate to third parties"
       }
      }
     },
     "localname": "AggregateDeferredUnderwritingFeePayableNotToPayForThirdParties",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AggregateDeferredUnderwritingFeePayableToThirdParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.",
        "label": "Aggregate deferred underwriting fees payable to third parties",
        "terseLabel": "Aggregate deferred underwriting fee payable to third parties"
       }
      }
     },
     "localname": "AggregateDeferredUnderwritingFeePayableToThirdParties",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_AmendedAndRestatedForwardPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Amended and Restated Forward Purchase Agreement (the \"A&amp;R FPA\").",
        "label": "Amended and Restated Forward Purchase Agreement",
        "terseLabel": "Amended and Restated Forward Purchase Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedForwardPurchaseAgreementMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount deposited in operating account for working capital purposes out of proceeds from the Initial Public Offering and sale of the Private Placement Warrants.",
        "label": "Amount Deposited in Operating Account for Working Capital Out of the Proceeds from Offerings",
        "terseLabel": "Amount deposited in an operating account for the working capital needs"
       }
      }
     },
     "localname": "AmountDepositedInOperatingAccountForWorkingCapitalOutOfProceedsFromOfferings",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ApacCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in the newly formed company.",
        "label": "APAC Common Stock",
        "terseLabel": "APAC Common stock"
       }
      }
     },
     "localname": "ApacCommonStockMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ApacsExistingPublicShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APAC's existing public shareholders.",
        "label": "APACs Existing Public Shareholders [Member]"
       }
      }
     },
     "localname": "ApacsExistingPublicShareholdersMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_AssetsHeldInTrustAccountPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assets held in trust.",
        "label": "Assets Held In Trust Account, Policy [Policy Text Block]",
        "terseLabel": "Investments Held in Trust Account"
       }
      }
     },
     "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_AvistaPublicAcquisitionCorp.IiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avista public acquisition corp. II",
        "label": "Avista Public Acquisition Corp. II [Member]",
        "terseLabel": "Avista Public Acquisition Corp. II [Member]"
       }
      }
     },
     "localname": "AvistaPublicAcquisitionCorp.IiMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
      "http://om.com/role/CommitmentsAndContingenciesDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/FairValueMeasurements",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsTables",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperations",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntities",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficit",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEvents",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_BalanceSheetAccountDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet account details.",
        "label": "Balance Sheet Account Details [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetAccountDetailsAbstract",
     "nsuri": "http://om.com/20220930",
     "xbrltype": "stringItemType"
    },
    "oabi_BalanceSheetAccountDetailsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet account details disclosure.",
        "label": "Balance Sheet Account Details Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "BalanceSheetAccountDetailsDisclosureTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_BalanceSheetAccountDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet account details.",
        "label": "Balance Sheet Account Details [Line Items]"
       }
      }
     },
     "localname": "BalanceSheetAccountDetailsLineItems",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_BalanceSheetAccountDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet account details.",
        "label": "Balance Sheet Account Details [Table]"
       }
      }
     },
     "localname": "BalanceSheetAccountDetailsTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of accounting policy and business combination [Policy text block].",
        "label": "Basis Of Accounting Policy And Business Combination [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Combination"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyAndBusinessCombinationPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_BusinessCombinationAndAssetAcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination and asset acquisition.",
        "label": "Business Combination And Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_BusinessCombinationAndAssetAcquisitionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination and asset acquisitions [Policy text block].",
        "label": "Business Combination And Asset Acquisitions [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionsPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_BusinessCombinationCashFlowDiscountedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination cash flow discounted rate.",
        "label": "Business Combination Cash Flow Discounted Rate",
        "terseLabel": "Business combination cash flow discounted rate"
       }
      }
     },
     "localname": "BusinessCombinationCashFlowDiscountedRate",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_BusinessCombinationConsiderationTransferredEarnoutRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, consideration transferred, earnout rights.",
        "label": "Business Combination, Consideration Transferred, Earnout Rights",
        "terseLabel": "Business combination consideration transferred earnout rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEarnoutRights",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination consideration transferred holdback for potential indemnification claims.",
        "label": "Business Combination Consideration Transferred Holdback For Potential Indemnification Claims",
        "terseLabel": "Business combination consideration transferred to holdback for potential indemnification claims"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredHoldbackForPotentialIndemnificationClaims",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_BusinessCombinationContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration liability.",
        "label": "Business Combination Contingent Consideration Liability [Member]"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_BusinessCombinationContingentConsiderationRevenueMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration revenue milestone payment.",
        "label": "Business Combination Contingent Consideration Revenue Milestone Payment",
        "terseLabel": "Business combination contingent consideration revenue milestone payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationRevenueMilestonePayment",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued liabilities.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities",
        "negatedLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued liabilities.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Liabilities",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_CaliforniaResearchAndDevelopmentCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Research and Development Credit [Member]"
       }
      }
     },
     "localname": "CaliforniaResearchAndDevelopmentCreditMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CapitalContributedNetOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of capital, net of expenses.",
        "label": "Capital Contributed, Net Of Expenses",
        "terseLabel": "Capital contributed, net of expenses"
       }
      }
     },
     "localname": "CapitalContributedNetOfExpenses",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for acquisitions, net of cash and restricted cash acquired.",
        "label": "Cash paid for acquisitions, net of cash and restricted cash acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash and restricted cash acquired"
       }
      }
     },
     "localname": "CashPaidForAcquisitionsNetOfCashAndRestrictedCashAcquired",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ClassCommonStockSharesNotSubjectToRedemptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation that is not subject to redemption.",
        "label": "Class A Common Stock Not Subject to Redemption"
       }
      }
     },
     "localname": "ClassCommonStockSharesNotSubjectToRedemptionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights",
        "terseLabel": "Additional number of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.",
        "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1",
        "terseLabel": "Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_ClassOfWarrantOrRightPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Price of Warrants or Rights",
        "terseLabel": "Price of warrant",
        "verboseLabel": "Price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for redemption of public warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days",
        "terseLabel": "Threshold trading days for redemption of public warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights",
        "terseLabel": "Redemption price per public warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_CombinedBalanceSheetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined balance sheet.",
        "label": "Combined Balance Sheet [Member]"
       }
      }
     },
     "localname": "CombinedBalanceSheetMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CombinedStatementOfCashFlowsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined Statement of Cash flows.",
        "label": "Combined Statement Of Cash Flows [Member]"
       }
      }
     },
     "localname": "CombinedStatementOfCashFlowsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CombinedStatementOfChangesInParentCompanyNetInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined statement of changes in parent company net investment.",
        "label": "Combined Statement Of Changes In Parent Company Net Investment [Member]"
       }
      }
     },
     "localname": "CombinedStatementOfChangesInParentCompanyNetInvestmentMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CombinedStatementOfOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined statement of operations.",
        "label": "Combined Statement Of Operations [Member]"
       }
      }
     },
     "localname": "CombinedStatementOfOperationsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CommonClassaSubjectToRedemptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation that is subject to redemption.",
        "label": "Class A Common Stock Subject to Redemption"
       }
      }
     },
     "localname": "CommonClassaSubjectToRedemptionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes that each common share is entitled.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Common shares, votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oabi_CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy on common stock subject to possible redemption.",
        "label": "Common Stock Subject to Possible Redemption Policy [Policy Text Block]",
        "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "CommonStockSubjectToPossibleRedemptionPolicyPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_CommonStockSubjectToPriceBasedEarnoutTriggers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock subject to price based earnout triggers.",
        "label": "Common Stock Subject To Price Based Earnout Triggers",
        "terseLabel": "Common stock subject to price-based earnout triggers"
       }
      }
     },
     "localname": "CommonStockSubjectToPriceBasedEarnoutTriggers",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.",
        "label": "Condition for future business combination number of businesses minimum",
        "terseLabel": "Condition for future business combination, number of businesses, minimum"
       }
      }
     },
     "localname": "ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oabi_ContingentConsiderationByTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration by tranche.",
        "label": "Contingent Consideration By Tranche [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTrancheAxis",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ContingentConsiderationByTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration by tranche.",
        "label": "Contingent Consideration By Tranche [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationByTrancheDomain",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration payable current asset and business acquisition.",
        "label": "Contingent Consideration Payable Current Asset And Business Acquisition",
        "terseLabel": "Current portion of contingent liabilities"
       }
      }
     },
     "localname": "ContingentConsiderationPayableCurrentAssetAndBusinessAcquisition",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration payable non current asset and business acquisition.",
        "label": "Contingent Consideration Payable Non Current Asset And Business Acquisition",
        "terseLabel": "Long-term contingent liabilities"
       }
      }
     },
     "localname": "ContingentConsiderationPayableNonCurrentAssetAndBusinessAcquisition",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_CrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crystal.",
        "label": "Crystal [Member]"
       }
      }
     },
     "localname": "CrystalMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_DeemedDividend": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "oabi_NetIncomeLossAttributableToOrdinaryShareholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deemed dividends related to the Forward Purchase and Backstop Securities.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend upon modification of the forward purchase agreement",
        "verboseLabel": "Deemed dividend - Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredFeePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred fee per unit.",
        "label": "Deferred Fee Per Unit",
        "terseLabel": "Deferred fee per unit"
       }
      }
     },
     "localname": "DeferredFeePerUnit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Deferred offering costs included in promissory note - related party.",
        "label": "Deferred Offering Costs Included In Promissory Note - Related Party",
        "terseLabel": "Offering costs paid by Sponsor and included in promissory note - related party"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInPromissoryNoteRelatedParty",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredOfferingCostsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.",
        "label": "Deferred Offering Cost Non Current",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredOfferingCostsNoncurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Policy Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenuePolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_DeferredRevenueRecordedInAccountsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue recorded in accounts receivable.",
        "label": "Deferred Revenue Recorded In Accounts Receivable",
        "terseLabel": "Deferred revenue recorded in accounts receivable"
       }
      }
     },
     "localname": "DeferredRevenueRecordedInAccountsReceivable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredTaxAssetsDeferredRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Deferred Revenue.",
        "label": "Deferred Tax Assets Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredRevenue",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Operating Lease Liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredTaxLiabilitiesOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Operating Lease Assets.",
        "label": "Deferred Tax Liabilities Operating Lease Assets",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseAssets",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.",
        "label": "Deferred Underwriting Fee Payable",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeePayable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DerivativeForwardPurchaseAndBackstopSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the derivative - forward purchase and backstop securities, current.",
        "label": "Derivative Forward Purchase And Backstop Securities, Current",
        "terseLabel": "Derivative - Forward Purchase and Backstop Securities",
        "verboseLabel": "Derivative liability - Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "DerivativeForwardPurchaseAndBackstopSecuritiesCurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives - Forward Purchase and Backstop Securities recognized in the income statement.",
        "label": "Derivative Forward Purchase and Backstop Securities, Fair Value, Gain (Loss)",
        "negatedLabel": "Change in fair value of Forward Purchase and Backstop Securities",
        "terseLabel": "Change in fair value of Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "DerivativeForwardPurchaseAndBackstopSecuritiesFairValueGainLoss",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_EarnoutRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout rights.",
        "label": "Earnout Rights [Member]"
       }
      }
     },
     "localname": "EarnoutRightsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_EarnoutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout shares.",
        "label": "Earnout Shares [Member]"
       }
      }
     },
     "localname": "EarnoutSharesMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_EarnoutStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing the earnout.",
        "label": "Earnout Stock"
       }
      }
     },
     "localname": "EarnoutStockMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_EmergingGrowthCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company [Policy text block].",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_EquityBasedIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity based incentive plans.",
        "label": "Equity Based Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityBasedIncentivePlansMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ExcessPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess price per share.",
        "label": "Excess Price Per Share",
        "verboseLabel": "Excess price per share"
       }
      }
     },
     "localname": "ExcessPricePerShare",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from acquisition.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Liabilities From Acquisition",
        "terseLabel": "Contingent liabilities from Icagen acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAcquisition",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent liabilities from asset acquisition.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Liabilities From Asset Acquisition",
        "terseLabel": "Contingent liabilities from xCella asset acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentLiabilitiesFromAssetAcquisition",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_FederalResearchAndDevelopmentCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Research and Development Credit [Member]"
       }
      }
     },
     "localname": "FederalResearchAndDevelopmentCreditMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_FirstRequirementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the first set of requirements needed to be met for vesting.",
        "label": "First Requirements"
       }
      }
     },
     "localname": "FirstRequirementsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ForwardPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Forward Purchase Agreement.",
        "label": "Forward Purchase Agreement"
       }
      }
     },
     "localname": "ForwardPurchaseAgreementMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ForwardPurchaseWarrantsAndBackstopMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for forward purchase warrants and backstop warrants.",
        "label": "Forward Purchase Warrants And Backstop"
       }
      }
     },
     "localname": "ForwardPurchaseWarrantsAndBackstopMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Founder Shares"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_GeneralCorporateOverheadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General corporate overhead.",
        "label": "General Corporate Overhead [Member]"
       }
      }
     },
     "localname": "GeneralCorporateOverheadMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_IcagenAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Icagen acquisition.",
        "label": "Icagen Acquisition [Member]"
       }
      }
     },
     "localname": "IcagenAcquisitionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_IcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Icagen.",
        "label": "Icagen [Member]"
       }
      }
     },
     "localname": "IcagenMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ImpactOfCovidNineteenPandemicPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of covid nineteen pandemic [Policy text block].",
        "label": "Impact Of Covid Nineteen Pandemic [Policy Text Block]",
        "terseLabel": "Impact of COVID-19 Pandemic"
       }
      }
     },
     "localname": "ImpactOfCovidNineteenPandemicPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_IncreaseDecreaseInAccruedLiabilitiesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses of related party incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities, Related Party",
        "terseLabel": "Accrued expenses - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParty",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_IncreaseDecreaseInDueToRelatedPartyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Due To Related Party Current",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartyCurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_IncreaseInEquityContributionFromParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in equity contribution from parent.",
        "label": "Increase In Equity Contribution From Parent",
        "terseLabel": "Net transfers from parent company (as restated)"
       }
      }
     },
     "localname": "IncreaseInEquityContributionFromParent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_InitialClassificationOfForwardPurchaseAndBackstopSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial classification of the Forward Purchase and Backstop Securities",
        "label": "Initial classification Of Forward Purchase And Backstop Securities",
        "terseLabel": "Initial classification of the Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "InitialClassificationOfForwardPurchaseAndBackstopSecurities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_InitialMeasurementOfForwardPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of initial classification of the Forward Purchase.",
        "label": "Initial Measurement Of Forward Purchase",
        "terseLabel": "Initial measurement as of March 23, 2022"
       }
      }
     },
     "localname": "InitialMeasurementOfForwardPurchase",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://om.com/20220930",
     "xbrltype": "stringItemType"
    },
    "oabi_InitialPublicOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about initial public offering.",
        "label": "Initial Public Offering [Text Block]",
        "terseLabel": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "localname": "InitialPublicOfferingTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/InitialPublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_InvestmentsMaximumMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Investments Maximum Maturity Term",
        "terseLabel": "Maturity term of U.S. government securities"
       }
      }
     },
     "localname": "InvestmentsMaximumMaturityTerm",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_LicenseAndMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and milestone.",
        "label": "License And Milestone [Member]"
       }
      }
     },
     "localname": "LicenseAndMilestoneMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_LicenseAndMilestoneRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and milestone revenue.",
        "label": "License And Milestone Revenue [Member]"
       }
      }
     },
     "localname": "LicenseAndMilestoneRevenueMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_LigandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Ligand.",
        "label": "Ligand"
       }
      }
     },
     "localname": "LigandMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_LiquidityAndCapitalResourcesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and capital resources [Policy text block].",
        "label": "Liquidity And Capital Resources [Policy Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_MaximumAdditionalAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum aggregate purchase price of the additional shares and additional warrants under an agreement in order to backstop shareholder redemptions for cash proceeds to be limited to the maximum.",
        "label": "Maximum Additional Aggregate Purchase Price",
        "terseLabel": "Maximum additional aggregate purchase price"
       }
      }
     },
     "localname": "MaximumAdditionalAggregatePurchasePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum borrowing capacity of related party promissory note.",
        "label": "Maximum Borrowing Capacity of Related Party Promissory Note",
        "terseLabel": "Maximum borrowing capacity of related party promissory note"
       }
      }
     },
     "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_MaximumLoansConvertibleIntoWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.",
        "label": "Maximum Loans Convertible Into Warrants",
        "terseLabel": "Loan conversion agreement warrant"
       }
      }
     },
     "localname": "MaximumLoansConvertibleIntoWarrants",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_MaximumNetInterestToPayDissolutionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum net interest to pay dissolution expenses.",
        "label": "Maximum Net Interest to Pay Dissolution Expenses",
        "terseLabel": "Maximum net interest to pay dissolution expenses"
       }
      }
     },
     "localname": "MaximumNetInterestToPayDissolutionExpenses",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_MaximumNumberOfDemandsForRegistrationOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of demands for registration of securities.",
        "label": "Maximum Number Of Demands For Registration Of Securities",
        "terseLabel": "Maximum number of demands for registration of securities"
       }
      }
     },
     "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oabi_MaximumNumberOfSharesSubjectToPriceBasedVestingConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares that could be subject to the price-based vesting conditions.",
        "label": "Maximum Number of Shares Subject to Price Based Vesting Conditions",
        "terseLabel": "Maximum number of shares subject to the price-based vesting conditions"
       }
      }
     },
     "localname": "MaximumNumberOfSharesSubjectToPriceBasedVestingConditions",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.",
        "label": "Maximum Period After Business Combination In Which To File Registration Statement",
        "terseLabel": "Maximum period after business combination in which to file registration statement"
       }
      }
     },
     "localname": "MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_MeasurementInputExpectedRedemptionRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected redemption rate.",
        "label": "Expected redemption rate",
        "terseLabel": "Expected redemption rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedRedemptionRateMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_MeasurementInputFairValueOfUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using fair value of unit.",
        "label": "Fair value of unit",
        "terseLabel": "Fair value of Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "MeasurementInputFairValueOfUnitMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Measurement Input, Probability Of Completing An Initial Business Combination.",
        "label": "Probability of completing an initial Business Combination",
        "terseLabel": "Probability of completing an initial Business Combination"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfCompletingInitialBusinessCombinationMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_MilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Member]",
        "terseLabel": "Milestone revenue [Member]"
       }
      }
     },
     "localname": "MilestoneMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum net tangible assets upon consummation of the Business Combination.",
        "label": "Minimum Net Tangible Assets upon Consummation of Business Combination",
        "terseLabel": "Minimum net tangible assets upon consummation of the business combination"
       }
      }
     },
     "localname": "MinimumNetTangibleAssetsUponConsummationOfBusinessCombination",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_MonthsToCompleteInitialBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.",
        "label": "Months to Complete Initial Business Combination",
        "terseLabel": "Months to complete initial business combination"
       }
      }
     },
     "localname": "MonthsToCompleteInitialBusinessCombination",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_NetIncomeLossAttributableToOrdinaryShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to ordinary shareholders.",
        "label": "Net Income (Loss) Attributable to Ordinary Shareholders",
        "totalLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToOrdinaryShareholders",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_NewOmniabCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New omniAb common stock.",
        "label": "New OmniAb Common Stock [Member]"
       }
      }
     },
     "localname": "NewOmniabCommonStockMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer), excluding the amount due to related party.",
        "label": "Notes Payable, Related Parties, Current, Excluding Due to Related Party",
        "terseLabel": "Convertible promissory note"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentExcludingDueToRelatedParty",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_NumberOfAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of acquisitions.",
        "label": "Number Of Acquisitions",
        "terseLabel": "Number of acquisitions"
       }
      }
     },
     "localname": "NumberOfAcquisitions",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oabi_NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional financing public shares issued upon business combination.",
        "label": "Number Of Additional Financing Public Shares Issued Upon Business Combination",
        "terseLabel": "Number of additional financing public shares issued upon business combination"
       }
      }
     },
     "localname": "NumberOfAdditionalFinancingPublicSharesIssuedUponBusinessCombination",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining the share price.",
        "label": "Number Of Consecutive Trading Days For Determining The Share Price",
        "terseLabel": "Number of consecutive trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of consecutive trading days within a specified range when the reported volume-weighted average price must exceed the specified amount.",
        "label": "Number of Days at Volume Weighted Average Price for Shares to Vest",
        "terseLabel": "Number of days at volume-weighted average price to trigger vesting"
       }
      }
     },
     "localname": "NumberOfDaysAtVolumeWeightedAveragePriceForSharesToVest",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_NumberOfSharesIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares in a unit.",
        "label": "Number of Shares Issued Per Unit",
        "terseLabel": "Number of shares in a unit"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPerUnit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_NumberOfSharesSubjectToForfeiture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.",
        "label": "Number Of Shares Subject To Forfeiture",
        "terseLabel": "Shares subject to forfeiture"
       }
      }
     },
     "localname": "NumberOfSharesSubjectToForfeiture",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_NumberOfTradingDaysForDeterminingTheSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days for determining the share price.",
        "label": "Number Of Trading Days For Determining The Share Price",
        "terseLabel": "Number of trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfTradingDaysForDeterminingTheSharePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_NumberOfWarrantsIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants in a unit.",
        "label": "Number of Warrants Issued Per Unit",
        "terseLabel": "Number of warrants in a unit"
       }
      }
     },
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for offering costs associated with the initial public offering.",
        "label": "Offering Costs Associated with the Initial Public Offering [Policy Text Block]",
        "terseLabel": "Offering Costs Associated with the Initial Public Offering"
       }
      }
     },
     "localname": "OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_OfferingCostsIncludedInAccountsPayableAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.",
        "label": "Offering Costs Included In Accounts Payable Accrued Expenses",
        "terseLabel": "Offering costs included in accrued offering costs"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccountsPayableAccruedExpenses",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_OfferingCostsIncludedInPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs included in promissory note - related party.",
        "label": "Offering Costs Included In Promissory Note - Related Party",
        "terseLabel": "Offering costs paid by Sponsor and included in promissory note - related party"
       }
      }
     },
     "localname": "OfferingCostsIncludedInPromissoryNoteRelatedParty",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_OfferingCostsPaidInExchangesForIssuanceOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs paid in exchange of shares.",
        "label": "Offering Costs Paid In Exchanges For Issuance Of Shares",
        "terseLabel": "Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares"
       }
      }
     },
     "localname": "OfferingCostsPaidInExchangesForIssuanceOfShares",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_OfferingCostsReductionOfTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of offering costs reduction of temporary equity.",
        "label": "Offering Costs Reduction Of Temporary Equity",
        "terseLabel": "Offering costs reduction of temporary equity"
       }
      }
     },
     "localname": "OfferingCostsReductionOfTemporaryEquity",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_OmniabBusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for omniab business combination.",
        "label": "OmniAb"
       }
      }
     },
     "localname": "OmniabBusinessCombinationMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_OmniabIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to OmniAb, Inc. (\"OmniAb\").",
        "label": "OmniAb Inc"
       }
      }
     },
     "localname": "OmniabIncMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease assets.",
        "label": "Operating Lease Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_OperatingLeaseLiabilitiesTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities, tenant improvement allowance.",
        "label": "Operating Lease Liabilities, Tenant Improvement Allowance",
        "verboseLabel": "Less tenant improvement allowance"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesTenantImprovementAllowance",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_OtherInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investing activities.",
        "label": "Other Investing activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherInvestingActivities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_PartnerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partner A [Member]"
       }
      }
     },
     "localname": "PartnerAMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_PartnerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partner B [Member]"
       }
      }
     },
     "localname": "PartnerBMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_PartnerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partner C [Member]"
       }
      }
     },
     "localname": "PartnerCMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_PaymentsForInvestmentOfCashInTrustAccount": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for investment of cash in trust account.",
        "label": "Payments for investment of cash in Trust Account",
        "negatedLabel": "Investment of cash into Trust Account"
       }
      }
     },
     "localname": "PaymentsForInvestmentOfCashInTrustAccount",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_PercentageOfCommonStockSharesIssuedUnderDistribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of common stock shares issued under the distribution.",
        "label": "Percentage Of Common Stock Shares Issued Under Distribution",
        "terseLabel": "Percentage of common stock shares issued under distribution"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesIssuedUnderDistribution",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of deferred underwriting fee payable decided by the company not to pay or allocate to third parties.",
        "label": "Percentage of deferred underwriting fees payable not allocated to the third parties",
        "terseLabel": "Percentage of deferred underwriting fee payable not allocated to third parties"
       }
      }
     },
     "localname": "PercentageOfDeferredUnderwritingFeePayableNotAllocatedToThirdParties",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_PercentageOfDeferredUnderwritingFeePayableToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of deferred underwriting fee payable to third parties that assisted in consummation of initial business combination.",
        "label": "Percentage of deferred underwriting fees payable to third parties",
        "terseLabel": "Percentage of deferred underwriting fee payable to third parties"
       }
      }
     },
     "localname": "PercentageOfDeferredUnderwritingFeePayableToThirdParties",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.",
        "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant",
        "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant"
       }
      }
     },
     "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected ownership percentage by the founders after completion of the proposed public offering.",
        "label": "Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders",
        "terseLabel": "Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders"
       }
      }
     },
     "localname": "PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of obligation to redeem public shares if Entity does not complete business combination.",
        "label": "Percentage of Obligation to Redeem Public Shares If Entity Does Not Complete Business Combination",
        "terseLabel": "Obligation to redeem public shares if entity does not complete a business combination (as a percent)"
       }
      }
     },
     "localname": "PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of their eligible compensation during the offering period.",
        "label": "Percentage of Their Eligible Compensation During the Offering Period.",
        "verboseLabel": "Percentage of their eligible compensation during the offering period."
       }
      }
     },
     "localname": "PercentageOfTheirEligibleCompensationDuringTheOfferingPeriod.",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_PercentageOfVotingRightsShareHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Percentage of voting rights, share holders.",
        "label": "Percentage of voting rights, share holders",
        "terseLabel": "Percentage of voting rights on share holders"
       }
      }
     },
     "localname": "PercentageOfVotingRightsShareHolders",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_PercentageShareOfFutureMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage share of future milestone payments.",
        "label": "Percentage Share Of Future Milestone Payments",
        "terseLabel": "Percentage share of future milestone payments"
       }
      }
     },
     "localname": "PercentageShareOfFutureMilestonePayments",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_PercentageShareOfPostClinicalAcquireeProductRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage share of post clinical acquiree product revenues.",
        "label": "Percentage Share Of Post Clinical Acquiree Product Revenues",
        "terseLabel": "Percentage share of post clinical acquire product revenues"
       }
      }
     },
     "localname": "PercentageShareOfPostClinicalAcquireeProductRevenues",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after filing within which the registration statement filed with the SEC is expected to become effective.",
        "label": "Period Of Time Within Which Registration Statement Is Expected To Become Effective",
        "terseLabel": "Period of time within which registration statement is expected to become effective"
       }
      }
     },
     "localname": "PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_PrivatePlacementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementAbstract",
     "nsuri": "http://om.com/20220930",
     "xbrltype": "stringItemType"
    },
    "oabi_PrivatePlacementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about private placement.",
        "label": "Private Placement [Text Block]",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/PrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.",
        "label": "Private Placement Warrants"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the initial public offering and sale of the private placement warrants.",
        "label": "Proceeds From Initial Public Offering And Sale Of Private Placement Warrants",
        "terseLabel": "Proceeds from the Initial Public offering and sale of the private placement warrants"
       }
      }
     },
     "localname": "ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ProceedsFromIssuanceInitialPublicOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash inflow from initial public offering after deducting offering expenses.",
        "label": "Proceeds From Issuance Initial Public Offering, Net",
        "verboseLabel": "Proceeds from initial public offering, net of underwriter's discount paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNet",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_PromissoryNoteWithRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for promissory note with related party.",
        "label": "Promissory Note with Related Party"
       }
      }
     },
     "localname": "PromissoryNoteWithRelatedPartyMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.",
        "label": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_PurchasePricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price per unit.",
        "label": "Purchase Price Per Unit",
        "terseLabel": "Purchase price per unit"
       }
      }
     },
     "localname": "PurchasePricePerUnit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_ReclassificationOfForwardPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of reclassification of forward purchase agreement.",
        "label": "Reclassification Of Forward Purchase Agreement",
        "negatedLabel": "Reclassification of Forward Purchase Agreement"
       }
      }
     },
     "localname": "ReclassificationOfForwardPurchaseAgreement",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.",
        "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00"
       }
      }
     },
     "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.",
        "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00"
       }
      }
     },
     "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_RedemptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the redemption period.",
        "label": "Redemption Period",
        "terseLabel": "Redemption period"
       }
      }
     },
     "localname": "RedemptionPeriod",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_RelatedPartiesOfApacMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties of APAC.",
        "label": "Related Parties Of APAC [Member]"
       }
      }
     },
     "localname": "RelatedPartiesOfApacMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_RelatedPartyLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for related party loans.",
        "label": "Related Party Loans"
       }
      }
     },
     "localname": "RelatedPartyLoansMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual monthly amount to be paid for support services.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month",
        "terseLabel": "Expenses per month"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_RepaymentFromRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment from related party debt.",
        "label": "Repayment From Related Party Debt",
        "negatedLabel": "Repayment of Sponsor note"
       }
      }
     },
     "localname": "RepaymentFromRelatedPartyDebt",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_RestrictedStockUnitsAndPhantomShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units And Phantom Share Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPhantomShareUnitsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.",
        "label": "Restrictions On Transfer Period Of Time After Business Combination Completion",
        "terseLabel": "Restrictions on transfer period of time after business combination completion"
       }
      }
     },
     "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_SaleOfStockCashPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount in Cash received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Cash Price Per Share",
        "terseLabel": "Shares issued cash price"
       }
      }
     },
     "localname": "SaleOfStockCashPricePerShare",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_SaleOfStockOtherOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of other offering costs incurred.",
        "label": "Sale of Stock, Other Offering Costs",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "localname": "SaleOfStockOtherOfferingCosts",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_SaleOfStockUnderwritingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of offering fees incurred and paid for underwriters.",
        "label": "Sale of Stock, Underwriting Fees",
        "terseLabel": "Underwriting fees"
       }
      }
     },
     "localname": "SaleOfStockUnderwritingFees",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ScheduleOfIntangibleAssetsAndGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets and goodwill.",
        "label": "Schedule Of Intangible Assets And Goodwill [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillLineItems",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ScheduleOfIntangibleAssetsAndGoodwillTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets and goodwill.",
        "label": "Schedule Of Intangible Assets And Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ScheduleOfOperatingLeaseAssetsAndLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease assets and liabilities.",
        "label": "Schedule of Operating Lease Assets and Liabilities",
        "verboseLabel": "Schedule of Operating Lease Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseAssetsAndLiabilities",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of recognized identified assets acquired and liabilities assumed.",
        "label": "Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedLineItems",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of recognized identified assets acquired and liabilities assumed.",
        "label": "Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed [Table]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_SecondRequirementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the second set of requirements needed to be met for vesting.",
        "label": "Second Requirements"
       }
      }
     },
     "localname": "SecondRequirementsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_SeparationAndDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for separation and distribution agreement.",
        "label": "Separation And Distribution Agreement"
       }
      }
     },
     "localname": "SeparationAndDistributionAgreementMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award description of award vesting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description Of Award Vesting Period",
        "terseLabel": "Share based compensation arrangement by share based payment award description of award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescriptionOfAwardVestingPeriod",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_ShareBasedPaymentArrangementNonemployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Arrangement Nonemployee Directors [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeDirectorsMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_SharePriceTriggerUsedToMeasureDilutionOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.",
        "label": "Share Price Trigger Used To Measure Dilution Of Warrants",
        "terseLabel": "Share price trigger used to measure dilution of warrant"
       }
      }
     },
     "localname": "SharePriceTriggerUsedToMeasureDilutionOfWarrants",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_SharesBackstopWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Shares back shop warrants .",
        "label": "Shares Backstop Warrants",
        "verboseLabel": "Shares backstop warrants"
       }
      }
     },
     "localname": "SharesBackstopWarrants",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_SharesToBePurchasedPursuantToAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares to be purchased pursuant to agreements.",
        "label": "Shares To Be Purchased Pursuant To Agreements",
        "verboseLabel": "Shares To Be Purchased Pursuant To Agreements"
       }
      }
     },
     "localname": "SharesToBePurchasedPursuantToAgreements",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_SharesToVestMeasurementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days over which the reported sale price is measured when determining the redemption price.",
        "label": "Shares To Vest Measurement Period",
        "terseLabel": "Number of consecutive days volume-weighted average price to be within"
       }
      }
     },
     "localname": "SharesToVestMeasurementPeriod",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_SponsorInsiderAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Sponsor Insider Agreement.",
        "label": "Sponsor Insider Agreement"
       }
      }
     },
     "localname": "SponsorInsiderAgreementMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for sponsor.",
        "label": "Sponsor"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_SponsorOfApacMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor of APAC.",
        "label": "Sponsor Of APAC [Member]"
       }
      }
     },
     "localname": "SponsorOfApacMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_SponsorPurchaseBackstop": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Sponsor purchased backstop.",
        "label": "Sponsor Purchase Backstop",
        "terseLabel": "Sponsor purchased backstop"
       }
      }
     },
     "localname": "SponsorPurchaseBackstop",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_SubcontractorLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontractor liabilities current.",
        "label": "Subcontractor Liabilities, Current",
        "terseLabel": "Subcontractor"
       }
      }
     },
     "localname": "SubcontractorLiabilitiesCurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_TaurusAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taurus acquisition.",
        "label": "Taurus Acquisition [Member]"
       }
      }
     },
     "localname": "TaurusAcquisitionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuance costs related to temporary equity.",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Issuance costs allocated to Class A ordinary shares"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_TemporaryEquityProceedsAllocatedToWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross proceeds allocated from temporary equity to warrants.",
        "label": "Temporary Equity , Proceeds Allocated To Warrants",
        "terseLabel": "Proceeds allocated to Public Warrants"
       }
      }
     },
     "localname": "TemporaryEquityProceedsAllocatedToWarrants",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_ThresholdBusinessDaysForRedemptionOfPublicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold business days for redemption of public shares.",
        "label": "Threshold Business Days for Redemption of Public Shares",
        "terseLabel": "Threshold business days for redemption of public shares"
       }
      }
     },
     "localname": "ThresholdBusinessDaysForRedemptionOfPublicShares",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of business days before sending notice of redemption to warrant holders.",
        "label": "Threshold Number of Business Days Before Sending Notice of Redemption to Warrant Holders",
        "terseLabel": "Threshold number of business days before sending notice of redemption to warrant holders"
       }
      }
     },
     "localname": "ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oabi_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of public shares subject to redemption without the company's prior written consent.",
        "label": "Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent",
        "terseLabel": "Threshold percentage of public shares subject to redemption without the company's prior written consent"
       }
      }
     },
     "localname": "ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.",
        "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences",
        "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences"
       }
      }
     },
     "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.",
        "label": "Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination"
       }
      }
     },
     "localname": "ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_TotalNumberOfSharesTransferred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total number of shares transferred.",
        "label": "Total Number Of Shares Transferred",
        "terseLabel": "Total number of shares transferred"
       }
      }
     },
     "localname": "TotalNumberOfSharesTransferred",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.",
        "label": "Trading Period After Business Combination Used To Measure Dilution of Warrant",
        "terseLabel": "Trading period after business combination used to measure dilution of warrant"
       }
      }
     },
     "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_TransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of transaction costs incurred.",
        "label": "Transaction Costs",
        "verboseLabel": "Offering costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_TransactionCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs current.",
        "label": "Transaction Costs Current",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCostsCurrent",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger",
        "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days",
        "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_TwoThousandThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Thirty seven [Member]"
       }
      }
     },
     "localname": "TwoThousandThirtySevenMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_TwoThousandThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Thirty Two [Member]"
       }
      }
     },
     "localname": "TwoThousandThirtyTwoMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial information [Policy text block].",
        "label": "Unaudited Interim Financial Information [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oabi_Underwritercashdiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UnderwriterCashDiscount.",
        "label": "UnderwriterCashDiscount",
        "terseLabel": "Underwriter cash discount"
       }
      }
     },
     "localname": "Underwritercashdiscount",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_Underwritingcashdiscountperunit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UnderwritingCashDiscountPerUnit",
        "label": "UnderwritingCashDiscountPerUnit",
        "terseLabel": "Underwriting cash discount per unit"
       }
      }
     },
     "localname": "Underwritingcashdiscountperunit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_UnitsIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new units issued during the period.",
        "label": "Units Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of units issued"
       }
      }
     },
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_Unitsissuedduringperiodsharesnewissues.": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UnitsIssuedDuringPeriodSharesNewIssues",
        "label": "UnitsIssuedDuringPeriodSharesNewIssues.",
        "terseLabel": "Sale of Units, net of underwriting discounts (in shares)"
       }
      }
     },
     "localname": "Unitsissuedduringperiodsharesnewissues.",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of shares that will vest upon the achievement of a post-transaction volume-weighted average price as determined by the company.",
        "label": "Vested Percent of Shares Upon Achievement of Post Transaction Volume Weight Average Price",
        "terseLabel": "Percent of shares vested upon the combined company's achievement of the post-transaction volume-weighted average price"
       }
      }
     },
     "localname": "VestedPercentOfSharesUponAchievementOfPostTransactionVolumeWeightAveragePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oabi_VestingRequirementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categorizes the requirements in order to trigger vesting of shares.",
        "label": "Vesting Requirements [Axis]"
       }
      }
     },
     "localname": "VestingRequirementsAxis",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oabi_VestingRequirementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The requirements needed to be met in order to trigger vesting of shares.",
        "label": "Vesting Requirements [Domain]"
       }
      }
     },
     "localname": "VestingRequirementsDomain",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_VolumeWeightedAveragePriceTriggerPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Volume-weighted average price that would trigger the 50% of earnout shares vesting.",
        "label": "Volume Weighted Average Price, Trigger Price",
        "terseLabel": "Volume-weighted average price per share"
       }
      }
     },
     "localname": "VolumeWeightedAveragePriceTriggerPrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_VolumeWeightedAverageTradingPrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Volume weighted average trading prices.",
        "label": "Volume Weighted Average Trading Prices",
        "terseLabel": "Volume-weighted average trading prices"
       }
      }
     },
     "localname": "VolumeWeightedAverageTradingPrices",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_WaiverOfUnderwritingCommissionByUnderwriters": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Underwriting commission waived by Underwriters.",
        "label": "Waiver Of Underwriting Commission By Underwriters",
        "terseLabel": "Waiver of deferred underwriting commissions by underwriter"
       }
      }
     },
     "localname": "WaiverOfUnderwritingCommissionByUnderwriters",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_WarrantExercisePeriodConditionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The alternate period of time after completion of an initial public offering before a warrant may be exercised.",
        "label": "Warrant Exercise Period Condition Two",
        "terseLabel": "Warrant exercise period condition two"
       }
      }
     },
     "localname": "WarrantExercisePeriodConditionTwo",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oabi_WarrantExercisePriceAdjustmentMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.",
        "label": "Warrant Exercise Price Adjustment Multiple",
        "terseLabel": "Warrant exercise price adjustment multiple"
       }
      }
     },
     "localname": "WarrantExercisePriceAdjustmentMultiple",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_WarrantRedemptionConditionMinimumSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.",
        "label": "Warrant Redemption Condition Minimum Share Price",
        "terseLabel": "Warrant redemption condition minimum share price"
       }
      }
     },
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oabi_WarrantRedemptionPriceAdjustmentMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.",
        "label": "Warrant Redemption Price Adjustment Multiple",
        "terseLabel": "Warrant redemption price adjustment multiple"
       }
      }
     },
     "localname": "WarrantRedemptionPriceAdjustmentMultiple",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oabi_WarrantsToBePurchasedPursuantToAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to be purchased pursuant to agreements.",
        "label": "Warrants to be purchased pursuant to agreement",
        "terseLabel": "Aggregate warrants to be purchase pursuant to agreements"
       }
      }
     },
     "localname": "WarrantsToBePurchasedPursuantToAgreements",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oabi_WorkingCapitalDeficit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital deficit.",
        "label": "Working Capital Deficit",
        "terseLabel": "Working capital deficit"
       }
      }
     },
     "localname": "WorkingCapitalDeficit",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_WorkingCapitalLoansOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of working capital loans, outstanding.",
        "label": "Working capital loans, Outstanding",
        "terseLabel": "Working capital loans, outstanding"
       }
      }
     },
     "localname": "WorkingCapitalLoansOutstanding",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_WorkingCapitalLoansWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital loans warrant.",
        "label": "Working Capital Loans Warrant [Member]"
       }
      }
     },
     "localname": "WorkingCapitalLoansWarrantMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_WorkingCapitalSurplus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital surplus.",
        "label": "Working Capital Surplus",
        "terseLabel": "Working capital surplus"
       }
      }
     },
     "localname": "WorkingCapitalSurplus",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oabi_XCellaAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xCella Acquisition.",
        "label": "x Cella Acquisition [Member]",
        "terseLabel": "xCella Acquisition [Member]"
       }
      }
     },
     "localname": "XCellaAcquisitionMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "oabi_XcellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xCella.",
        "label": "xCella [Member]"
       }
      }
     },
     "localname": "XcellaMember",
     "nsuri": "http://om.com/20220930",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r162",
      "r278",
      "r283",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r233",
      "r243",
      "r300",
      "r303",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r536",
      "r539",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r233",
      "r243",
      "r300",
      "r303",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r536",
      "r539",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r162",
      "r278",
      "r283",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r214",
      "r215",
      "r278",
      "r281",
      "r498",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r214",
      "r215",
      "r278",
      "r281",
      "r498",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r213",
      "r214",
      "r215",
      "r216",
      "r233",
      "r243",
      "r289",
      "r300",
      "r303",
      "r333",
      "r334",
      "r335",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r536",
      "r539",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r213",
      "r214",
      "r215",
      "r216",
      "r233",
      "r243",
      "r289",
      "r300",
      "r303",
      "r333",
      "r334",
      "r335",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r536",
      "r539",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r96",
      "r98",
      "r99",
      "r101",
      "r102",
      "r117",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r117",
      "r177",
      "r178",
      "r375",
      "r427",
      "r428",
      "r429",
      "r430",
      "r460",
      "r470",
      "r471",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r117",
      "r177",
      "r178",
      "r375",
      "r427",
      "r428",
      "r429",
      "r430",
      "r460",
      "r470",
      "r471",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r1",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r101",
      "r102",
      "r117",
      "r177",
      "r178",
      "r375",
      "r427",
      "r428",
      "r429",
      "r430",
      "r460",
      "r470",
      "r471",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r97",
      "r103",
      "r212",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r97",
      "r103",
      "r212",
      "r301",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "presentationGuidance": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r29"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties owed to third parties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r204"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired finite lived intangible assets weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r339",
      "r340",
      "r341",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of error correction.",
        "label": "Error Correction, Type [Domain]"
       }
      }
     },
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r257",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs as a reduction of equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs",
        "terseLabel": "Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r231",
      "r257",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash provided by operating activities:",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "presentationGuidance": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r23",
      "r170",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r188",
      "r196"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Asset acquisition, Contingent consideration, Liability"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r66",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r81",
      "r143",
      "r152",
      "r158",
      "r175",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r412",
      "r417",
      "r447",
      "r480",
      "r482",
      "r515",
      "r525"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r26",
      "r81",
      "r175",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r412",
      "r417",
      "r447",
      "r480",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Noncurrent",
        "terseLabel": "Investments held in Trust Account"
       }
      }
     },
     "localname": "AssetsHeldInTrustNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r299",
      "r302",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r299",
      "r302",
      "r388",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/AcquisitionsTables",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business combination"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business acquisition for share"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business combination shares voted",
        "verboseLabel": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition for per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r399",
      "r400",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r397",
      "r399",
      "r400",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Business combination consideration transferred liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r65",
      "r408"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in estimated fair value of contingent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Business combination contingent consideration arrangements range of outcomes value high"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r398",
      "r401",
      "r406"
     ],
     "calculation": {
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Business combination recognized identifiable assets acquired and liabilities assumed assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets with finite-life\u00a0\u2013\u00a0core technologies"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Recognized identified assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of fixed assets recorded in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r9",
      "r482",
      "r551",
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r9",
      "r68"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash",
        "verboseLabel": "Cash held outside of the Trust Account"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r448"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal depository insurance coverage"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r79",
      "r81",
      "r107",
      "r108",
      "r109",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r175",
      "r218",
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r241",
      "r242",
      "r246",
      "r250",
      "r257",
      "r447",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficit",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r265",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares issuable per warrant",
        "verboseLabel": "Number of shares per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Number of warrants to purchase shares issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r265",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r517",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r217",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A ordinary shares"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends, per share, cash paid"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends, per share, declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value, (per share)",
        "verboseLabel": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, shares authorized",
        "verboseLabel": "Common shares, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued",
        "verboseLabel": "Common shares, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding",
        "verboseLabel": "Common shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r189",
      "r194",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r162",
      "r444",
      "r445",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r162",
      "r444",
      "r445",
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r162",
      "r444",
      "r445",
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r126",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Business Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r131",
      "r132",
      "r162",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r129",
      "r131",
      "r132",
      "r133",
      "r444",
      "r446",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r162",
      "r444",
      "r445",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r267",
      "r268",
      "r279"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r267",
      "r268",
      "r279"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Number of Class A common stock issued upon conversion of each share (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r371",
      "r378"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r371",
      "r378",
      "r380"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r371",
      "r378"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r130",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "Debt Instrument, Debt Default, Amount",
        "terseLabel": "Aggregate borrowings"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r372",
      "r378"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 37.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r66",
      "r82",
      "r372",
      "r378",
      "r379",
      "r380"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, net",
        "totalLabel": "Deferred Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes, net",
        "verboseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r372",
      "r378"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r367",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r351",
      "r364"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Identified intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r141"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Fair value of forward purchase and backstop securities"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r27",
      "r85",
      "r221",
      "r223",
      "r224",
      "r228",
      "r229",
      "r230",
      "r475"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Basic and diluted net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r104",
      "r107",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r429",
      "r430",
      "r520",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r44",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r107",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r429",
      "r430",
      "r520",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r83",
      "r353",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r37",
      "r38",
      "r39",
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r102",
      "r119",
      "r176",
      "r257",
      "r264",
      "r339",
      "r340",
      "r341",
      "r374",
      "r375",
      "r428",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r471",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting error correction.",
        "label": "Error Correction [Text Block]",
        "terseLabel": "Restatement of Previously Issued Combined Financial Statements"
       }
      }
     },
     "localname": "ErrorCorrectionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of error correction.",
        "label": "Error Correction, Type [Axis]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurements",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails",
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r431",
      "r432",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurements",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails",
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of significant inputs to the valuation for the Forward Purchase and Backstop Securities liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of company's financial assets and liabilities that are measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r432",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r431",
      "r432",
      "r434",
      "r435",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r234",
      "r290",
      "r291",
      "r296",
      "r298",
      "r432",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r290",
      "r291",
      "r296",
      "r298",
      "r432",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r432",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of the hierarchy for liabilities measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of changes in the fair value of the Company's Level 3 financial instruments that are measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Payments to CVR holders and other contingent payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at the end",
        "periodStartLabel": "Fair value at the beginning"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsDetails",
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities",
        "verboseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r189",
      "r192",
      "r195",
      "r198",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r195",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r189",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r195",
      "r499"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Gain from sale of intellectual property license"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r47",
      "r66",
      "r174"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Gain on investments held in Trust Account",
        "terseLabel": "Gain on investments held in Trust Account"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedLabel": "Gain from short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r182",
      "r183",
      "r184",
      "r186",
      "r482",
      "r514"
     ],
     "calculation": {
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r304",
      "r305",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r66",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r143",
      "r151",
      "r154",
      "r157",
      "r159",
      "r513",
      "r518",
      "r522",
      "r533"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r354",
      "r361",
      "r366",
      "r376",
      "r382",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r101",
      "r102",
      "r142",
      "r352",
      "r377",
      "r383",
      "r534"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "terseLabel": "Income tax benefit (expense)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r348",
      "r349",
      "r361",
      "r362",
      "r365",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r347",
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Amount",
        "terseLabel": "State tax rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r187",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfGoodwillAndOtherIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r40",
      "r140",
      "r456",
      "r458",
      "r521"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 15.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "verboseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2022-2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2026-2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2025-2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2024-2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023-2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining three months ending December\u00a031, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r81",
      "r153",
      "r175",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r413",
      "r417",
      "r418",
      "r447",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r81",
      "r175",
      "r447",
      "r482",
      "r516",
      "r527"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and parent company net investment"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r30",
      "r81",
      "r175",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r413",
      "r417",
      "r418",
      "r447",
      "r480",
      "r481",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsDetails",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fees [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputCommodityForwardPriceMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using forward price of commodity.",
        "label": "Measurement Input, Commodity Forward Price [Member]",
        "terseLabel": "Present value of Forward Purchase and Backstop Securities"
       }
      }
     },
     "localname": "MeasurementInputCommodityForwardPriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount factor"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Time to Business Combination (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/FairValueMeasurementsLevel3FairValueMeasurementsInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r123",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANISATION AND NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash provided by financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r34",
      "r35",
      "r39",
      "r43",
      "r67",
      "r81",
      "r91",
      "r93",
      "r94",
      "r96",
      "r97",
      "r101",
      "r102",
      "r110",
      "r143",
      "r151",
      "r154",
      "r157",
      "r159",
      "r175",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r430",
      "r447",
      "r519",
      "r531"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "oabi_NetIncomeLossAttributableToOrdinaryShareholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss (as restated)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r93",
      "r94",
      "r96",
      "r97",
      "r104",
      "r105",
      "r111",
      "r114",
      "r143",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 17.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r85",
      "r475",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Outstanding balance of related party note"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of businesses acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Lab and office equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "terseLabel": "Formation and operating costs"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r143",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail",
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "presentationGuidance": "Long-term operating lease liabilities",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 35.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "presentationGuidance": "operating lease right of use assets",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/LeasesScheduleOfOperatingLeaseAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r467",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r25",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 36.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 16.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other operating expense (income), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments to CVR holders",
        "terseLabel": "Payment for contingent consideration liability"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/FairValueMeasurementsSummaryOfTheHierarchyForLiabilitiesMeasuredAtFairValueParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "negatedLabel": "Payments to CVR holders",
        "terseLabel": "Payment for contingent consideration liability, Investing activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/FairValueMeasurementsChangeInTheFairValueOfTheCompanysLevel3FinancialInstrumentsParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs",
        "negatedTerseLabel": "Deferred transaction cost payment"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r52",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire businesses gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value, (per share)",
        "verboseLabel": "Preferred stock, par value, (per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred shares, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred shares, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred shares, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r180",
      "r181"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromContributionsFromParent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital.",
        "label": "Proceeds from Contributions from Parent",
        "terseLabel": "Net transfer from parent",
        "verboseLabel": "Net transfer from parent"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Issuance Initial Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Class B ordinary shares to Sponsor"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from sale of Private Placement Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of warrants",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Aggregate purchase price private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from convertible promissory note",
        "verboseLabel": "Amount of drew down promissory note"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from promissory note - related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of intellectual property license"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r34",
      "r35",
      "r39",
      "r62",
      "r81",
      "r91",
      "r101",
      "r102",
      "r143",
      "r151",
      "r154",
      "r157",
      "r159",
      "r175",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r411",
      "r415",
      "r416",
      "r419",
      "r420",
      "r430",
      "r447",
      "r522"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r203"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r205",
      "r482",
      "r523",
      "r528"
     ],
     "calculation": {
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail",
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r205",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment are Stated at Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableWithImputedInterestNetAmount": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The receivable or note face amount less the unamortized discount or premium.",
        "label": "Receivable with Imputed Interest, Net Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNetAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/LeasesScheduleOfLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r297",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Service fee paid to a director"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r297",
      "r474",
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses incurred and paid"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Selling, general and administrative expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r297",
      "r474",
      "r477",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r472",
      "r473",
      "r475",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Relationship with Parent and Related Entities"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayment of promissory note - related party",
        "terseLabel": "Repayment of related party promissory note"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r345",
      "r497",
      "r559"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r264",
      "r482",
      "r526",
      "r544",
      "r549"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r102",
      "r176",
      "r339",
      "r340",
      "r341",
      "r374",
      "r375",
      "r428",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r138",
      "r139",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r162",
      "r277",
      "r278",
      "r498"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 14.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r41",
      "r81",
      "r138",
      "r139",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r162",
      "r175",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r447",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Redemption price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r131",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r388",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of calculation of basic and diluted net loss per ordinary share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r337",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesScheduleOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r101",
      "r102",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustments"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BalanceSheetAccountDetailsScheduleOfPropertyAndEquipmentAreStatedAtCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of recognized identified assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r79",
      "r120",
      "r121",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r250",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficit",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r129",
      "r131",
      "r132",
      "r133",
      "r444",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Revenue from Significant Partners"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service revenue [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Parent allocation of share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, terms of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r311",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r305",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock expressed as a percentage of its fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share issued price per unit"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r79",
      "r81",
      "r107",
      "r108",
      "r109",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r175",
      "r218",
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r241",
      "r242",
      "r246",
      "r250",
      "r257",
      "r447",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r37",
      "r38",
      "r39",
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r102",
      "r119",
      "r176",
      "r257",
      "r264",
      "r339",
      "r340",
      "r341",
      "r374",
      "r375",
      "r428",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r471",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithTheInitialPublicOfferingDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
      "http://om.com/role/CommitmentsAndContingenciesDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/OrganisationAndNatureOfOperations",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/RelationshipWithParentAndRelatedEntities",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r119",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
      "http://om.com/role/CommitmentAndContingenciesLegalProceedings",
      "http://om.com/role/CommitmentsAndContingenciesDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://om.com/role/InitialPublicOffering",
      "http://om.com/role/LeasesAdditionalInformationDetail",
      "http://om.com/role/OrganisationAndNatureOfOperations",
      "http://om.com/role/PrivatePlacement",
      "http://om.com/role/RelationshipWithParentAndRelatedEntities",
      "http://om.com/role/ShareholdersEquityDeficitPreferredStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r257",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor (in shares)",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r257",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/RelationshipWithParentAndRelatedEntitiesFounderSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Shares",
        "terseLabel": "Shares sold in IPO redeemed for cash (in Shares)"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Value",
        "terseLabel": "Shares sold in IPO redeemed for cash"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r20",
      "r21",
      "r81",
      "r172",
      "r175",
      "r447",
      "r482"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "terseLabel": "Parent company net investment",
        "totalLabel": "Total Shareholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CombinedStatementsOfChangesInParentCompanyNetInvestment",
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfChangesInParentCompanyNetInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Deficit",
        "verboseLabel": "Parent company net investment:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheets",
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r264",
      "r266",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEvents",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r455",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r455",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEvents",
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r455",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r455",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r483",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS, LIQUIDITY, AND GOING CONCERN CONSIDERATION",
        "verboseLabel": "Initial Public offering"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/InitialPublicOfferingDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/RestatementOfPreviouslyIssuedCombinedFinancialStatementsScheduleOfRestatementOfPreviouslyIssuedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/AcquisitionsAdditionalInformationDetails",
      "http://om.com/role/AcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of Class A ordinary shares to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r218",
      "r223",
      "r224",
      "r225",
      "r229",
      "r230"
     ],
     "calculation": {
      "http://om.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Class A ordinary shares subject to possible redemption",
        "verboseLabel": "Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesClassAOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://om.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Class A common stock par value subject to possible redemption"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://om.com/role/ShareholdersEquityDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the balance sheet"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r346",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions in prior\u00a0years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits accrued for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior\u00a0years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CommitmentsAndContingenciesForwardPurchaseAgreementDetails",
      "http://om.com/role/OrganisationAndNatureOfOperationsDetails",
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Public warrants expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/ShareholdersEquityDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted",
        "verboseLabel": "Diluted weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic",
        "verboseLabel": "Basic weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://om.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://om.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=SL6757427-112606"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "https://asc.fasb.org/topic&trid=2208923"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r562": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001193125-22-295453-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-295453-xbrl.zip
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M;BU3K$I\CW%V)D)^S[6 9S2$*H8!ZX@)<&;GS>'1R?%1]_A410F/(1/H'N.
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M6C T$LN!Q%(Y*_^VF.N:%4)T&9R5&5A6:;YE"\NV"=CFG14M8"MP5K2 E47
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M8$K#O&#>!3X\.!K=N?"REF<G%YV/MB)O>K[QRZL+";&=/+UF9LCZOFNW!\/
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M(9$LNGIBV:39W$];D2@[><P3KG@S'DMV0 )>&$279L0X[!J-_7HC>53R6\I
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MO<?SN?8>2RUY"VZTG9=7X)9C!WV8O^)SIL_*V_)15P70^3;'JP30:A\JKP1
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MD6UN@%<2 I@NY:#LF:Z*$\QY,CT. V3+!#:?--]U?IK(Z8D<IC0L%]Y?!(]
M50A)CTJ1JR4A#;:DBTT.4Z4RX3:<",D K_+%IS..L".-L"4AS#1@N8[V4\8
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M=8L@>]E^>+QOGW^KG(]VHL,*U0'LZ=[GZZM?P9K]VGI\K)I1H/<2*H34,PR
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M,#UV(,[;&<SR/7_@6&GR=R@/8 Q]UZ$A4P:TZO3F<E3QR0L?8X!_ ?KAQ>(
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M-@/PX(H6"5KU>=$W4<:-,L(+"L!%;)B$$)1(-P\F+)2IFH3'X3;^TGV*;9H
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M.0321[H]KNSCROXH*]L:GG."=< ?D$:KQ%,5YVF /S48]G%U'E?GA_,:!OV
M:50P_"NU=X;9P<HE;WK9A <;HIGVKL\_9E?>Z>-C6]Z':,L[&I;_:PS+]66!
MN#9) ;0A9@_S;RFI+FJGAR./HOFJN,@7.Q>ZYQ7Z+)":37AKP!G343X2(CO
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M0NTR!NK^X- S?$*P 86W)O>V$R]=.VD%VCV1$&4.DQ?99$,59SKXX(AXP4A
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MPA(.-V/_=CQN^^G)N/EMDE+/I\?\B^W)T>[-P4);;(*I^^!./ID]CYD,B.L
MBY?RGDFJ!*E%-MV4NFOTM?<RP"VJ(@=?;*8TY?]C]=X;V!DIU[63YFB<,[EI
M5T28A.LW& R>6^Z>QB#2"W:LH\;GMNJ>TVM=!JL\"P&J* SI*&;<;+.?#'=L
M\PXFV%UKCPQ$MR?!?H#KQ69[D#JZ8<:3->K8+[B3OY"42L]1RB&"L$^?POB'
M),^O:0H&M#5D7S?D8/?"DJ,)AGT#J';CYQJQX9N>*Q=A'"NZ 0<_T6Q,U43
M'T?/QZS^+D'[X!_/SQ_2-;Y1E8O9]Q)L)!_[YOOP,233E%@/->!W> 9\6>4
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MM!P6!$Q.&@BDR56RE>:/WKN^ #HGU%Q-X(=5P[YL#WL<(WH@UQQYU_U\KPX
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M2(3_.*RF,-' -(>/H!L#N0E8_.!E^-MQ<73WR*![$+=;2'<1I0F$C&\G#R%
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MW2;1;4VKN6$<5RL]E?;&;E8JU>7+%B5F^Q#),R]L5)?E,E[X3DUE!DLE:<9
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M:4(ZG B^FUU>67:=2S5:JY))B#H&DS4AG36M66-26.#.+;@$]1LI]VX8%'&
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M+9RH7J/_GPB'EMH<8U!0?PT/O?LC%P7.CD6!^UX4B,A.SH@(YB,;=.&-\ ]
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M_BBEP=>6*J;+ F4[RE+, &EY60]E&W?1SJ-49=-*C6>="S.14*3?83^QLE,
M*#0A]!%9VFGM._+]&3*[2"E8:0<U_G!ZT\'&F% J.+KQ+>I+.N7BV5P0*06G
M>S0')]W"4YUFP].82 &DJ8^FDQH'Y'I*_2Q<8O!1PGKE[@*Q884[M^EMABBO
M+ 5D\KD-4&2%;MP07S%A=B*N"2^#//HB-I/%3@=X'VOI/!O>D%GT)SG9,R86
MUZ3AQ$R%)UAW!9$7G<Q^D:(NL+-$X;-+5JTNVG1RT[7O9XH' @]'20:V6I)H
M\2/B2?\YZ8(N1,NW++2SQW]PTW21.B>2_FH[F+ H;.GF846 .PMQ/\L#$=-2
MNL(49LF;5KC#FS'G">9^=%",IB2&Y!UW/2$7107U'"5"L.=11PB_F-\@R@T'
MD:%TUA*A([F(EY5.^#8A@U162%ZGDUD(Y&/IC^5T13F9@\S:Q:J==H$>V%84
MT<IMI?,,*]ZZ*US3IM"%P']-^O%IS_#<V5[8-\4)4V0D_;R/)TF4A:872E2<
MHR,NFC=.JELZ^2S3K*HXRHP3;,RPF'Q7#(SV@GM>CNU%17M_O:V-MT[?"%T=
M?E-6R@*U&G.[F.\Y8-7QMW:M2GR/J+XB7"BYAEB[Y!-O@VM4%<N+8N\EHM"*
MM%JG9I]_@K0/I6 HP)9G2B?8/L#\@OR)9M5?0Z1$N3$0YC&@3:T#AZ',2IDE
M4& $5^'0HJ4B5[(1YN.6JZHY6Z-9R_2V3N18:&Z4RV-;+V2H1G[_RE?T]2;A
M!%@RE!HU%"?\DW3P4@K5J&ET#$W@*HY[EH"9(R]C+(V$*6]STUIQRT3+V);4
MU1"!0%LTBG47 =,BTY%/G LXJIDG<"4 ;B7MXP\DC9!:+LPIJJ.[AM_1Z:S#
M:RN ><&Y1T6 @HR<\L>!WI%3=R!KC3!OJK]P<,[T3I$1$QYDOKW _262#0$A
M>05&YED53!*@,ZRL]D4/1 YG@HU@0-?P8B845,8Z[WBL7",4_ %Y5YN(][(+
MPF>02JVYAX[K<0_O&<@?PH*J=B&4S\;DH;:;E0\ #C[?-0L& IT!V7[RV\B+
MF0WI0:5[9H "=-\(WDFRXL+&?0LG6==LY.RRA9-LN[*3")NEK\0CZ0H *-]S
MR.\"D?0^*X-LV]6VHB&6ULQEOB9G%Q%^LE[,"#D!B/&%T;7!RU\.7LJ<T!%>
M$JI3#6I8%%21;X@,N-VB;L+&+M=@3MDZ@[M&Z!,JZOX0S$$#=8.PLS8A#+=;
MV>:E;]X8KL_SQ=M'VXU&ZK&<@S*.;$&$$M)29?F4X"*EH[6Y##MBP241"/.U
MP40L;O$(*F>:165".E,+&Y"D>S@, NC-6$ CW'O=,?V9_H&[0*NF$Z#SY%H
M2=[>I6#)Q07E<S@+E<A".#/U1ZYT/#E6.NY[I4/\X-M05YI3H'%.I.DS^9*1
M<A3!_)C1(WQ::57B%]-*Y3V,A5[Y%Q\&UTYL+VVPI221@5ZD8]]34J;$VHZO
MW:B_I:5]P<Z4X:(9:SP4Q)L(2??&FG<1;]UR$,U-VC> HO)*X)=K(N!;2GOD
MWFO3Q^+U11"P8';9L,'_$8XX"D4&\$(-9<2K*E2_(#Z?(NZF7:P0 *U6L[SO
MI2R5GNU)+0#2/&"^-JC-95%MN#4EMI],ON"FW("Y&@_,S,^%8"'B@G(< 'Z-
MIC2$3J]0J9H2\4A<TJU I(-E[;':L8DLT^&LP\S! =M20__))6 K.2M*9WOD
MII7!'51( =DH&W?"1B7GLHO=V]/"C&$J$*AQ\,2P%-MH))D=/SK?EA6Z-0IK
M,Y;028,7YDYQ8YEB&L:]W?R-N-1=+FFHFL==-L9-9-0MD8#*;?Y4'F](Q1[#
M/H!L*-A6-@U>D])P@APV'C$;TE@HX1B*GJC3>*4V_;.2Z2N'+XWBKR%(H5I3
M&.B*C*V6UD9<--P/W?QZ<RKLHVDC<X:B&(J\: ,$-5,G^-OELEC&"I:%OK74
MO21I&#," Q$WV:):CH/.9KLM^\Q17M5.'=CC#6QGL4RJ/+"3PG&4@&H ?&NT
MIX+Q?=)1,V6/BJEC!3+!OFR*TIK9\GNJI,>5F@ZLNVYFO5DFRD/C)#'O/?4&
M9!3)["2J9X.AF+ YHI46A3Y<PBYFB 9!>5&'5RS85IK1NLN#7-^?7[[3Y:!#
MH*7>Y<1@9#(22N<DA==P,#"9TO[Q&>4J)H?%W- 5H;O]KET,SR@C,5GZ4?UE
MCZC==B-OUQ5UV;3)@SFF=?<)>5PE9=#']<10SEX,1+_Z(E\S[B+VT8HIKRHY
MA[0*9+GV>.PJ&E" D+2Z4+)+=)L</9H[\Z>IDG?\,!SS4@Z3#O:%M$F:9S!X
MG]%0X;7DE!SZIL.H5QCD(]7,D"+^LFS-5&"MR+)D_LZJ-RD/G[6DSD4=*-YU
M%VT1U1M8X;N"XKNX(?# !=!P\+V,#S5>4:=!A&) &]_S;]F1;<W\!7]%4GG2
MIDOA[3Y=&;$F?2H$1,UK<I)A'4M9.'K1=KQ0#>SL\=?"(1N6/GYQ^G4XJE>>
M)$DJBA7:H^7EK2&X4Z(Y_4,\FH"CJO+%6\Z/Z.76!>2I1 !"WXM#SLCQN*9$
MMP&-^ $DU0+4M+ZN+7O7:7XG(-X#[B:"7@RY6Z;[[$*J]>*ZN8:F:T(G2D!F
MF#_<8!%#!I$K1YLNS&)R/4H];FOJ=^UB17>S#6[B0E!7;)HMUBECHW3'P%UX
M+Q$D8RW&0V-^NW--1A3+(MGS5;/(>TEMVRUMA >V@-S93=%LJA 2O!X](9<Y
MTLL3["HZWHG3Q E]$=O8DU2OE?4M*DJ>@Y-64^1PB:@F-941SZ,0VG [X3RZ
M,<>9!S\FV!7+<') XG9<4>+(N2ZT>UAO@-$V*2MMPW86,I(MWT-_3"/U=; @
M*7'RO[9E5SI::BM#BL:]VQ\S0:#Q(0#Y2*]Y;V"W&'%Z"938]#T,_\8G6T0$
M4.M$M14=D*YO%F\OPPL[@$)S+?$P8#',5<HZ >'TW1(+X1P&)BD HDIX9U"K
M),LCK;Y=9)E(YH0E WH& GU?7DAWAX^4W.>1C&UW5%B>?5,V:N+"S+Q:] W#
MB(E8XGP>PF#Z!B"ZVXKPN:=?2??B@D@(9G0U KV1U71$=)'T8'!;ML!M82MD
M95>2ME>TYF:SWYX%)S!WCX>5\R8$^@9T?LS^Z4_YM@WC,?CD'SG/_]DQSW_?
M\_SI0L0Y&VWB9MMVVR33D&Q6A[<H5"@<FV&0O)_VAB"49L))7O0WV6IB@[4G
MJ_#LVJ-VIN4>UUC-BE"[$B8]CRUIJ_RJ:;V^)+5VB)+B3Q.>5A01WO?4[AE-
M00>92).]]6W/"E:)D4&8IT>L;A4I/J&EHN!.G$9T .^9FWTQ0DP?25CBYS/)
M R'_FM08(HO]Q'?U7AT1EE[TEXH*G( [2AK23X(,$O5D%LE9.=\E8\SG+[,K
M3A:5X"N1?Q4=I89%/.5\7R;BAB/A1OJJT[ ;=+-[;>H]5_4]+OB#>.R+2.T[
MS.[$$UT6L(3")'E!;T= +E;Q1IQ^ 2Z*TM U0VVR(@&INE YR7M<!LO!#0#!
M<ZV!;=W3!R0)A4@!P_U+X>%8C,FM FGZ]C-KX&CRI]<,P$3\:5=8ZGK29P+9
MI]#J&)F7^# ,L',-1_.\?HNI"L%5T]8%R<F1GAIU)Z32@-0WT8G2TH'WC&S6
M[I>C!BQ9??"YD.KA5!<X/.+K9YXJW=X/;3C2V"KTG!TZ$XQ?6SE?Q-=8;AE8
M5PSE(9Q\*ZRO+L8RFI2]H8D\#5:/1 $$4C8*8>0'%@ZSJ8]_(%$S+62QDGTC
M]8$0CK4]*:UPIJ#>6F.0 "HDU$U]=0I3A\VAXR<E[S?;LT^< L1U2Z%2LUH)
M5"/,T 6:3J*[?]$T2X1.4TVR^U14I^OBOT?UXQ>3*;P(PT8L@ .U6'^@;ED6
M>&%=_\:K;Z:*Q_,NH%$)L@LH(UFL'#[M>(JAT," FC",%PV"^:$(( =JSHQ&
MM+N-#:M.]BH2S6CY)NE.G#S<$F]%N>/A_X<UM2@W7%=F=8&IH<U\N!EV+1_Z
MT6,(3D4IU-O2!$9H2'63; R<V:8T5]%YSO+#46AV1TOU?.@.X&7"BS06HB8%
M[T0@0GKOY0S5=Z4D28)VH^\@T[WE0B=U&.P2<&V57X=O4%*HDG_W^6]B'95S
MY0X8Z1L9V&*X7KJQAVNGR^*RH;&C&2>R0(78E9S558J\I-8L6C*<0Z!E:]Z%
MI:E=4B%,6G0?5UNJVGB?T6E,"'383G/G,E.O9N;%QUDT/O8U*]R 8.%T<W"5
M-% NO6K( ZOVIK0U*9.D6,1(1^+X ^-R#W-3+U>#U(\[Q:6EB &@PO>*#V(6
M5$ 7351-R[(/9N(,_1W&[2I?J)ALO'HV3&'2#M]**5)"O8/93'6&Q,7]M6C"
ML;XDH,"=UAWWYX\/YF7[@BU_V>E ,#E].FB<7V:?ZL6Z:'=7Q,J;S9Y13CDX
MG&6>S9YOVTNJ]/PCC XXMILJ;'9)ZFP7'6W/\[;\G[#-I$"?^FU#I6B20<G;
M-2\ TG^01O-D)=1,G *W)41)BM4-?[HQ*QR&[A%E1C4K;/C>*)B\*-O%=LV-
M^;0L=XWAA@1O[AHH2@J^PT#WE\&W>TLR/,3HC8,KFPV@KH)(IN[[EO.E;=L$
M.[]F$U++[?.>FB&(ZWXQ0[] QJ$[M>P;+1WG.1F>VVQ[I(80I'&=0EGBP]5+
M.Q59N@F4867OP"D0:0]'56P^YB/+I_D3I6TME&XWP@>QW00'9UGXD*-<@Q_"
M> +3[IKWZZQ!C"CBD;$Y!FD),AW28D]>.U+S7"SV)7=F55?>?)'<7H@&&;^3
M!#]^F8*DVB] [6VS,IRG?D8IXPK\_MTE#5_Z6)E,@W?D]3(^W$=CF(S;.X!*
M6>G 7^A6&%,AVUJCQ#I\?\G:Q*TJ8O7@E .ZYK#M!$;>MG=XY'BXMO#3139K
MD/K!2_&SM\HY!W97TP&S)9Q-I8UB@Q"NQ"BVX;% 5(.P<O@*E\MV0E4GGT.P
M)N[L3&-\FG]!"FW(K2,Z "\!WX *PA1^-;(6'; K&45($OB<8/(E44 N.Z$#
M.GPT3:>%--7FE8\0*:D:JGHW1DYH7 [)X]]!%7F1M^@'U&(YN..Y/43MB7C!
MMD1]/\)JX-W/T1D-8*25WW--R%R!M;DR3!XYWZ/4A-R\:?U]Y%'B??2BVF+O
M=-#^T 6-I\>"QGTO:"AM6:H"QZL;^\7@AQ)8,]+)LI*>CR0::40YT#=GC.YT
ML>!.*;"#Y2.=")Q(\G\$"G(,J'FX*BD&WZ[]Z7;9Q&!J$=RDMP6#.!CV_@:.
M%U],_ 3-T*3@+$:3M?F:O"(I<L03)','?HCEUN"$_'7;[E@\+^\O,_,_$="(
MWB[C@\7N.[E6==GYT=D[Q&41UG*6@PY#L#<OD$&AV\-C!?L?.V,U];6Z=[-F
M](GJP,@)G'),)#\:LZ(WB+G>L_#T%?KZ]72(?/NC;N,-"Q'QO@C'*085/FC,
MXW#^ACWOJL@)'K;M)">$0#55Z&.5S&5:W;@[*@!!RDT<P71,DL-TT;32WPP\
MCPG7)=4@,%"2);4E8Z.*[!S@1=IL&(=CR?30P=*$07@C;9%(K.BWKXLI&)^6
M3K1K5P=SE[F,V78=SAW")<"1 CU:X[2.Z3G)?#K@B0W IS=SYVF=<T(+X;JP
M5-&@)NR22D-=4*%MHA6Y$M"B59FDDY,'.5)Y^ ;8B<<H)8,S4FU+=TX*Z9O.
M?+GI'(M3]B ',N^5&SG ;^;>T?@[&[]5<XJ0NE[>#HW;5M:*2X7TC,LUPKQ"
M5SA^U45*FU^WRPN.;(G$OE@*(\CH:0_4BWY_VCDEJ$5,(?@_["K%#%&D-FRI
M4157N+U,3U/>(*CXL;Q\S90;ZVM,#G+"@Q,:6BE!X8?Q:#WS'<<\!@/G$V,=
MDQE*9B/[W>]S-_<VA\- VV<8V0\R?E;8I)TW93;_# Q'@X"3C08.M&BE1!6?
M#6#>?%WXW(Y>:BC"V>N##<8@OO!$LX6'R1(0E+4!VZM":R'?-'F[S.(_$326
M?5]H]CF"G<U(>F0UE>LS8C(OV$RLIFIUMKVM !5W#A/%*_0Y,@ZY8:AW-YR<
M.\FPL$WDP=C C,5ZM!B(M'3PD?;I/71TWBAAP1S]M 7*1IR#$JX-3>/%2%<3
M9=:61$49\%M>I2P5KEJ7^ .-$:#@V '# ^=QB?5:N_[]E<1]CT4T=Y[[0M_!
MB9MP5N_*L7K)>QQ<9LP?B4-XE*JXCMV [!KUM,GC:-,<>>MO(8+^8:)2J&O2
MLE4.EAI'G$IF2\7;B$0=T](QR=Q,2*A=VW :%&#1 /%0:#VY5E%IV_B(#&)>
M5Y+*M/ XD<K-F&&AS1T2Y,;4?E.'B>@MLV\<(V20JV:[%/%HW(?#>WY"OB?S
MKK7D9"5T'@-RHK!\ET+H*&]&+VN](.G%F31G^DW),UX3B7UXTVO*$[GRL$[-
MHZE=,3GQPYQ@\GG7[SS<7<DFB0;.?0Q#A"8)3U+%"3(.$SG!*GX6>QU45[KA
MT=7>" <^79#^["@;V7-I'1<^X$WH$J7&3S(,^.6V=G+D?+WAI=;!P5GY,H)F
M^6SS0;8ZYDT=9Y[0+G%9(CR\.AI+RA2[NE WLT3+U,LKF3+=E,FB3#_)YWQU
M@3&%T5P)M>A7,>WN>TI3LY"F$10)54:T0W&95RNG8=4GI(/C/@ME$@Z>V27J
MLUM3KWYO3:7,AS2\E ": .E9'OT<AC5MA#) >J^$="=V9,MF#<9=&N>I4*#B
MOZX'*ZEQA%@%_0,8?M!=_6N+"%T.+O;()E86)#A8^K#+P\F EDWC]&/JV%7+
MLEE2UVA6?5&;ZC2!E(+[0E<D2 9!-;9U.(.7%I_DLY[@9OUT1C^"<02<YAZ?
M*WDB<&-N5$([IG1#!O;Q*,FA6\ >.;M3:QX0IBP3*5?B!%"!5"YS<9$7"_H1
M+VCMB8^293B)[-1H)080A5-9D%WA=5^P1KB@AV>TE8WF)SH>,0TX8(K:>KU1
MJ2'E3&M<*/_8Y$&?'W/P]ST'/^W(DN= SK<ZQ8-8(7(+,EAN9^%G.-2;/L4O
M.\1?<NPB#9P<.+[GMZ>8V25.3"?%Y4@&1XET0DX<KA,G\P%.U DW2D'O"9M9
MB%CSQ5LP'UZ&?QCN?54(H#K\0>G)#*VQIC4+O62U6H8[)WA%77"?E>'-"#QB
M5TN/.W5[^;@%;]PJC))"%NU^0B;'%Z/0 T>GBY0D2J7YF MA4<N8/ZT:CD(I
M>A(YV6+%W8\G8@ 6?-&\$L74F!!VTI.9$A<\D_Q)M=/)(LQY)4FS<,VJJ-W3
MZOSR4\>:Q"2UVQ"27!47%!MSJHPY3"@W1OCZD]G/4\M(F^>7)&YLJ&^)Z>A,
MV%=L@1/-Q=A1%6*$6#X8'=Y!1M=<'V@+N"UJ\=%B1Z0!>AB/\XIP# 0;'1:!
M]LGBL,8\QN2PB2")+\!%]+"Y[?(>)IXC9JQV"BU?9JI5P)E"^D/PX.KH2\MT
MJ^NRU:" \1O\#7;9LTG9@XDRHVH63 (5'-J2W;!+Z<;E+% KI$\-U1#JG<L;
M=_H\DGK&@XM+$;/ A*]L#3]08]\CPU:11S;QMMQ)S$G@^"Y34R9-QLW"@_9=
M:TPS67P:)'G75+V,RHUR3:"WK#V3'S664&Z%BULTC^SFZJZGDLX'>Q_B!CR8
M+Y-DY$3*[!XFR9+>7;6XP*@Z5U7RS;WDFYTTF).'"8ND3BM6T8E7$;TIBN0F
MF.X+9_/X3"  O/P:87 XP&QL696)TS[" 1T>DJTALBY<)9XY50-]F:3*.0FH
M"F&*6!HP&I/%*>V/6,$]7?$.RY;SHBJ+JV)T7B34>6[VA$5/J@)^RB1\_/;Y
M><:U!_925.S-"<_$0])-HA94OM-4>#->3"3)P[9HS[*2IVK 1$&,8?ZA7OQP
M[B"K\0F7X4I=SP#109N!",X/A+QCC.GN;P(=-+64F<*UO: BKW1-!6P2E0E*
M7O9BP!63C+0B$<1U:VZ\BFU1F;Z5W@#(%%ZHU\ SA@O2:SE!<P1Z>HS2*5JT
M2B>I%U,P?">^#7TF-_*^N:HH (TA"KTQVN7B@6XG3++M-#;7RA0X'T#K3#.T
M:5W#7MRPV\X*M8GR^GA:_-NF6.((TI-1RUOC"'"KT!MP34/*44OK\54XR)\I
MY,7K1FY$9H(YD4NZ<7-1-?-M5=9=.L@00J7N0J!1G NR;^AB&B0V["5\>!!=
M(K[("\N,:YK3[2>]/YJF5,766J#T)J*W(^;4!LW.HT[8[);,9B6%LZNFE 1A
M'#]&&1]\L1Z:=P6K0LJNHL7<3NSO0U<:9*I8\E>70]TP]S@#GKAZN)%*@6O9
M=;T5NX'V:1B.'0^%F$3T^PV^NZ$@B)63%__]PX_=PTQME1!CF;R?^B!*;A2=
M("/$(B*0<)'IQRNEZ[4ND,_IM7<C/%@KG=A(V_!]F5FSVM$%\ X82&^7Q);=
M\B3S!+0J>^*'"!U+<>,D&ZJHP0*Y=&9Y)#O.3ITW5=XVBMDR8^=SMWL,<\I#
MSXVDOVY)!X_]=EG.%+1*,WQ2+4CD: 5"RPI63:K/<<V=T?1KRE+V%01@P (6
M#L3RJD2[Q:)%LV[%VN(BPU;_&JG]5>FV*\K_89)S_<U2.8>Z3$C9J)_9?2"<
M?>&5Q.$73!L'L[2F4M]T;Y_J3;S-^[W4$3W-??=0!_&Q;FX4=GCK3J#ZXN&$
MC$<J5;M2 6N5&]2<[<2RC'MDU>9;EEC+YW36Q;*@NSJU)WK'5Q:=F[]8]PT?
M^XN4'>T):)OJVG-KG1>F6XPA,JNV2/\BF>7<\_151<]:TS]4..4$ Z@2G-H,
M()(,',-&O&1Q\)5"/V2HE5C@KGSA[_9.)$L&E+F%%#%3O\EW*#-!GK*B@@PU
M,JZI6-PV4?"L!85_42]C-8U.@S ?AKP'/9:3)G:<()'F5O)O!DJB$S9&*K&%
MA4LQCH=7CDTN->0M!'"47G"(5)4*1X000#2GVGV0%1L=1E, 3ZFIR04T^Y(\
M*5_)[\<_<EWBBV-=XK[7)93/2P!/A77 IMG0U]Y'V*)7T.\444!G4 KX:6^R
MZ0K)!>JSJ:KF.NSAOP[/TO@RG\>5OG?A)PL]3!/W),BEOGGU^OF+UX^>O?K^
M^_,?W[SXJ_[C\*H>#N<<\=U?'R?K:%%4U89*U_7%?_[I,?],:33YF9_%EJ9;
MQB4BT;\BLI"/+=.5\_3/\:7ZY>1'GOSY:ZHUD.\HJRL,T)]F^.=__HE6%UWB
MR[.SS_=?XW3R&A-W]E?52TQ]T\WA+)VVV?Y5>\LY&.RC/_T78N:3-R>V#L^#
M!_GH[R&")4T=Q-';OE _(IP2E^6\A'\(+E"VZ3UQO=-!"()- :(1<)'ARJB[
MA1-0&,&1AA5].%'"!-MF45Z)>QS5IH,[NJV-E("S-^RA$R$K_P2J\$7>24EH
M]K8$ORT16R#D1JOC-4$OA9B&3]QP9W0X@S[$$2 'ZVB9Y<BAP+D)7"HYJIL5
MN\H(^!HCRLW<T2L2ZH8N)1))-@,'][X1IFNG\@\0HFCY,.4?RB5!KGG86=>T
M1W3:$"-B"-:5!IX]=W;"HI"?DMWR'./IB:R?6M\YP$+O?TFD"L &^Q0-KJA0
M5FJRY,^%(?D:A@@+/_RGI?^0+3F:IJ-I^IVFZ=O@;1>S9UPP.A<<-L<GP1@Q
M!-,"%:%KP1:<ME:BNF!!3[Q:$GI'LE ^[?DCX;I=B.#G%;@)P)=<SOI\K77Q
MS"I:CCG:MF@IO%W11DJ>BZTB,[%*P6]>Z!^+I6'+=$AB])5I)8WYL=CD.(*5
MBO$%<,RWE:341(P\E[_#!JUEXV/YDC";",1P*7]18*1<'46QX#0%N_W/QW5!
M%RT"GH;:H#RF=(DX>AX#FUJ?WJ#ISID=M68'SS$.*HA8FO+ADZ/"#X%!W+:T
M0(P4?+C\CH;N:.@^CJ'C5,/LI96N?R2!!>G$H/UP+I2$\BNRA6&1GG[UU>>P
M'M^]_/'\7'TV-G/=E)V+[1U,%HX^%%;M65P&0\ *#AK+[[QW(IQEZJ4@USGG
M].]\)Y3@)$DZL<,VX$;O) _$IBUJ30IZ)V8@>Y9I+7;R5X;>,ZI^OLLXG;I4
MBCJ2+5WN'-S>/+3]#Y])N0?2Z]H528F;V8/BY.)$ 3]\?Q#5/\0@[O-PZ:7+
MU4[5>\EDBF,+Z )0T1O/HK82&G\UQ_7._B:7\[9Y@G 21 T%22BT+)40CP":
MV?&KT\G&&I'FLI[,WDB#U,"&[XD(\J/?>33'_];F^$?-Z\Y^Y,W4S=YL*;58
M%V1RU<!*W:0ST-B YG?%I7!RI>#$9**O7BZ$+0*A7*5$P8X63YN*L?#8R&D0
MF%D$J+'JL\NR6K9%+1W6W<0I(K::68"H/"0[_3DI(S,!;GA:^1X]VG>H5K]1
M[VM/2YJ^MV]V(6" 5S%T.?('X4@I:^6>Y%36LA& Z%)D2X)=WY  ==_R3YMF
M6>;\ Q]@ER5UHC"N]&$6A2W@XM^(S:J;^I$]DO52X)'IH6G>'MC?A3$H1UVL
M1G]9\E%RO4L6]^:_JN9=QX6THB/T/<\Y]2*XJ]%C<_MH.(+*CFN7?!'Y7C]Q
ME9V[!H^&78:_NRZ7UZ2>\U"0!00]A5I*0RK+7'V*>E(IL2,CCXP1&5-9"/'K
MJ-)!,A[EFE8PD)#8<:K0=#3(1X/\00PRR=0W%Q ;1Y)L.BNN:3+^#*$!'[U5
MIX79K<F-DB 9E[!2$Z7C685'5#=]:6Q88C+B L5S.>]JZ%-UD1<"Q;E;V:48
M(^>5FJ9Q33%%L;)\D@!V.Z;< 'F*&S%%8 TT3R,9Z@"H 3<X_2QE5+N^W=D9
M$\: XI 48WFQ+9>0C(T0RW!:%%>JD.<^QL#<X/)OJPNM8$[G#\#S(SAO/L'H
M;>CMZ70=G+GQA-MS9&WT0.^;H5$;E2F3:F^Z. ")"<\$U Y7;<L%M]_;;7DR
MCJ;P: H_@"E\\;-;HXJ<#;L;3))7><4:@RL6%)0XBQ.A'K-$.X/_Y;!72R*T
MJ)06._7>&*H2MTRZ.[@'\>3F-?[1&T%>D 'D9.V0.FD,:H@MPE!F\Q"U6)Z]
M":[ L@UT%!2I.@,1D8!:$QJU0@2+Q_+V/4$]"^I!B[OR!@.<CA(HV8M%7*$R
M3$W@$1L3*Y"HN\N2UVA8K@%+Z?^P]ZY-;AQ7MNCW&W'_ \+W>(*,*-(D-;)E
MZ\Z)H"C)1S.RR2'ET><"4.@N$ZB"Z]%-S*\_N=\[L[* ;JK%;HX1,2.SNX&J
MK*S,G?NQ]EIVLAT!="A.^L0$(7_WD<=P$*MK:,.BA/>F'9LU_SO8_2C):VFA
MGF_);$LTGFAVL\ 2/.T1"YB#04V!6--V$,R>%7%&+481^A*"HI[6=7_1=B+H
MJB4+"(8PPN%%D@"L"-0-C0U,,IL) 9U-X(/3O9;/&07SU1D%\]!1, ;U<T5T
MH*JN^U8J4S?" !8W! #&5 ?YPPQVM?9X$!9YBA@'/I0N?)U<9U 4P?RZ2.MZ
MSBC[);J6/=K[<KNMI)?H)FPJX-R;_ZLBFNQK]W)2,]043F,9!L*,1X%YMYND
M&^?F/9J./%(P[C/$/MF&,J6X6%<;II!0A@5K>&5JHS 9RXK)J DROH@AX[XM
MQ'=CF^"L]F5C]5#TBBM65.*N!-=K"&QDIT>F)T$8WA*+NH/K/TP:BQ(!K@<(
M67YE#8]X$-$^@Q) U0&H!H@EB"9_$N*Y QX[6#&07(6W%?'U2$-\V_ *C>/N
MX/*LRVXM/&VVU7VO'1Z\Q\G 4C4JS28R([JP1=Y3(YRR;<Y["GSX%A1UTTYV
M3OH,V)4\EN@%1#0LK(H.^4'F!DK:&[?AYWY5[JD5V5^"KZFO3SJ%>VU(,PE!
M$*0O>VJ.0D24$$Z:VM&Q2Q/SO]=%F",.8Z4S1A6PJA_G!%C 3$C*1O((M4Z)
M76Z3-J_"U%^GB*KLO/.44^,2:=T#OFP$I%?$C12O?LB HFV:YV"BF^+D,$\!
MB*YK;S?MGSG<5Y2MD,FV0V'Z-;*G59=NT:>+[RP %#<9B(ULK5X%UU.#/2C)
MEDKA !QJ_!9<_D5Z'<'OK:B-@U4D_0ND92"ZDMG^'[,YV7=S[;@8W'@-V /'
M<JX79]HYPX>$U6D9^&X\&U[8'7I]UJ3]XD*_Z)TPZ 3+N-5:RIY@>"$!U53<
M/%]3%=31,Y UYJ)EF&*LT&/@8K-AZ_5^6$.%-0@S7)->9O![RGT-.'_M9$UM
M )\.X[::OM:Z45/X]V#6^C4CHI,>3=B2WXU0Y0\V*.SR<-4_,_/PMW"W-W:W
MM]9:_.C/W[YY^YA7JQ7B;&^[",EHCJCMCV)O"WIUAQ-MX[(=8PP7-R3H(+]C
M;H7%R[ M%H^^^^[EXZ>+EQF\&7P+QJF(C,ACC3M.]?SU)H>H"(EF+;@'QBW)
M[Z@7)M5>-&50I#;YOI8K+TM\WO#2P'5:$ON!T/'&L\"^G'3 JXCV]"&,J(*[
M0GNN*OHIQ/[Y=D<9YNA&E*+MW2@I+065K9:R'*1WR?6V ?$3&B)+CC[JP?)+
M$4X^UAKI)W-+VQM?[G<OZ1%J)&P=@T^CA5GN&1WHI-1,A6A3.(HP7:G2G9J\
MB5B(/.E<CLCX)TO'IYHP?X#3HAQCV&(N29-^\0CX\^F-7(#M)L+!?_G_OOKB
M]__Z]8MG3Y]1>!],P[8F0,>__E:B#);4A%YE#+>0:/XQ^20X)-;2;'!*2ZU%
M=-* 7/+9V21KE;U%.K]$%T1:R;?M^H)TVK; X-)+9^H>ZBH].#TN<0;N:O5>
M>S8!-%ZM16:'33XJ!S>]Z0EQ')HB"MVL<?H4'M)%/OBI?R_#I$ 9!*;M>0'*
M!L\+5TFQ-O,DCT0SUC 7#[[V_\!?*E)U:"\J-!M:@REWQ 87/IF:0 !^O7CV
M_*N"Z8A[MU(:^((R%81=3N^,[[?8U:"415^@%60H*AH08)_D3[=:/X_@QR^^
M?OZ'IU\N^'>/;5'Q2@JQ; /FFD:EUO050'N(78[ZX-L]XGP:WE@KZ+U>U3WG
MPE X4-[4W_XC#!J(;?1LLKV.K^V[OW%MFLY:)8L,<P*S#9;>I1;Z<E.!3.JZ
M3YKDP\>G@\$6/Y'>8IZ&#WNFD/_WL:E@D7P9)AE19L/,,Y_,(735$P#-PO])
M H',6U-=][]3$DPP5#(TH4/9X0*AMQSV<1U.?ZZVN0$H%R6DK9E^\*?+N-$U
MK.SA&A:W3 87^<+TUHU^TB-#2J)MU@,K]AG<V%;;"L@KT(:C'\6_ @)LN%7.
MXYAZD/ J5'R,A@D68=R1:0G1,BK%[>A&<.EDM2"OT=K. UP@1/LD!XGR[L/U
M\&I"3BL$1$A64)5KEDF3964A3A0$(:G1=BMDIA3\?'I'\%7"[3"3(8@"U*-^
MGU":>>IP),X+;P\I60!"@]QO+EM0B]P[)1/,'^ +L*X6VG74.G,12/4!>$,8
M7DJ==U.E2O0+B72/.H\Y&J"#F<4/P/V%J@CU"I2KH_683&8-AL<;('%YX^@,
M0>DE$NFH:XT+F]VNTU';T7A+TE_^+;5=G,1A8@0D)8YJ[HYH1=O&F:4!/_$Y
M%Q?^>"XN//3B@G;3<)'L*$V&N)Y @<*]*5FB"SP=/U9'9/&0^-;>(M'S6\.U
MP('T#M"<1B3P+10EZ^6HOX 6_[?^.$<S\6.8,L:IW"ZO^NLFMYU$A[AY]GQH
MMY!YDT:OL*1E.,G7OL14 '4.LL5"G.NR 5IA*#0WZ=B;503DD&JH4-9["WR&
MK*/R0#C:7"05O=A+TK*FI>"E).HMHT*R^F384+$#GX@98).9)F\>6265@QMG
MG_>)JJ,2;U=P^;6.C;@MT<SAI++Q[9/;Z=;RS:I:&8D6?828#<585D5UAM%_
MFXC%YQ[4W9U\;3+;?0@LJLQ:-CL5]GIPC@;.P$.0">BZ_2#H<@7'==BE+)3[
MY \#76S%J-[,>AC3M$0RNFI;[YRZ!)1O)WKQ(CI$[T#5$\&%0_+XGI7)D*]*
MQ&RT^DKN)0O'"N><CGSM=7-RQ)!19XU^3SS.7%,-A@2EN&U_A1@P_'HKDB),
M&!L<,?#M&')#+M_ 9/FT2O'(28U79)E;P/9W%T*WBAF$";,2SN"V)H8FD350
M* ZWWZ/_>GU)600AI7NYY&VI]+6HN&1A#($:61'X4R]YS:Z(AH!QLXEZ%20!
M\H97GF!?]L;OC]]VYGO=8G6F58Y^:5$2H3>(JI5$1MC $\PI*T%3I@_S^&Q<
MV9CR@#A^S:\HOP!TCZ+?[48+T0=_CG4T>7@8D2;;SHV<4 STK::ZAL6_8DY
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M 6\RK0E4_<(=*-2M;A+=B>L?%A]">Q9Q]2.O1D]4(^&RQ/= 5KGN=.;JWE7
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M[,/;+A4OW),C ^]VBPF+(4F28%W25?6TX$@L(+3ML9Z+BR!F2+@ M53:HO0
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MX%EROO B!$!*1)D?M'IL853CBB'[T.+1H!G:W 2$"*&>/7%$^B0^EPWZOC!
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M,8MNY#3**IUTP>>H+:;$\*(VJE>QE"-LB'OSIG@E\-O&;1GV*#@0,!PMPZ2
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MXHG%(POF/ :KP7U8O4PP 1!?P8+", V7):TTI L1Z'CU0?I&R0OUC(CQ<O?
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M#MM.D*KAU84HBQ2EZ.5\YDG\K\Y)_(<,P/^(@"[6>&F=5I_JO7!Y#0_ _M)
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M[QEKCOIR6CL533[5ONU5@>0#^S-* 8![J&F!0R7ZI'[ I92#Z2[WU0C,A^%
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M05>- BE\^;T1(X:D-T[2HGTR1A]Q=M-?8>3Q9@L)S9#R:)+#E*E)#AKYJMM
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M!FY(),PX<RCC>:SS7^4YK-0CSL4^2QHWQ+;FO,<X*)[671BZU$]6I=?@D/>
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M&AU4O,'(R<71A^YII5JR&DFY=YHX7I\HJB KQT965C$:40V1>)Y&$7S;FH4
M81A8X=@:P?-><(>?'F#(O6GW3M?S9Q^.T*NX.F!$H,%#16[*1KF&L=">(XY<
M.5T[8O<L2 _&9WEJMZI51F8$D6' 1A!57!!ME&L8\Z=$WH2%V4,':0-UVY4*
M"QG18UBN$3T5%ST;Y1K&!GJ.3!I[@1.,V %+I"KQ7".-#!<VTJCJTFB+DNC
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M",PO^@N^LCMG]/C[, )Y>34-O+,A__GX'UZ<A!$N^&;KSJ%*8>3L^NS\Q>,
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MK+P#3Y&^</V/HW!J?6;#*///=@7I'P.5@VR%;[V!;T1A>C?9\2VI@FS]Y@1
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M@^C6<^3M.%GN"V$\8!K"1WZ(OJUEK,?6.0L</-(\"@ 2!;!X$?N9H29.(?M
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M@*\TLSHN[MYNVKU>#_[?ETO\TXG@@E,F$H'P.8P>G,BUKM-H-'%BQJ_FW,,
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M1*;+@DG[T:GVWZIN4XU$;[*>Z$@!60;-+S>L>U;A26Z;1.,N*AT$PSLZ11_
M?&*[_*#WV&+ON<E*Q?[WOS:V\>FQ;&Y(39-EHV1'51CC"_&W)=U;+1KCI'JV
MJP[,<"]!19SQKM3"XX(V)%<)74R+8&)@%B9_C<08$4J$H&D<>+7YHAA\B[RI
M[.;L2VG-.[Z!MLGG -RPZ-[##N[*5<-=ZA?3F1\^,F9]<Y($[<"LO)+&?&BC
M.?RL%3RUCPN*0P(X].(<8I""V%LNEB^FC6:#$S+5(JOTFNLJ*N9:Y=XQUP-<
MHX@MT<"V>R"O?H6UX2@ZJ\)]?PE&$?T%4'*.)['7&YT_1T[$Q%+)TL%_*V Y
MV:BQ*OKTE%$VBX.W''A2"+E>_%8-T)*BB#<T1W+FK<QY?G3,_9?,FJ5#$ ?2
MF2,]%X7!-/).%;MN9W0HQG*0$*::S<(6=9>(IAR+=;/KKVY\P33,Q@TMO=<:
MMA:Q#'@%&U%S<\"+\+KH;$2ZDS0H$3G B;DA+*L>B$'-0@P,(P(FS'%'HOD"
M+UR%/4] '@,HQ-OYZ!OG)S7/LG. QF2Z*.Z% Z:_W-K"J19&_&](#+)O%]?$
M[A@<M>C@Y;A@J7O4[!\'J(S%/!,UZRZ6^;3Y<5&B\R^FKT8T:@H-HA(BQ#O&
M#S"'5HV=PK+(W!_A)'\ /08XDH6HCGJL:[TU"XXNS2E@\SDP<BEL% _:>B1R
MFY?U"<\-3L+Y!4PD1>,ZF%_!#43M*47"9[D!7+H$*2/C#8X5JFDJQZE)Y=CY
MO+GM&@(;[5F]>6M@2\/VUBT7V)4&;KI>[V@\0;WF$Y01-5Y3Z;+/V2:JA;\F
MX/(CL7+:0[$[:)S.9F&49-8,5<#E'3-2OY,S>.7D%A3BZ72:&\IK4C_VW."]
M3AW>%Q2=<:L&LQQ4@=CS,HUN"SIQKI#.&V>6QX+10+:::+BXJXV'[@PV%;%F
MM/[5P"$U'EP-TAIOH&H-M^6ATQ,LO">MQ2 $M023\'$@E;06X;&IN8L[;)9>
MBV[ISQ [V/N)#XB5&2'QXD$,AM)VV!J]%KW1%V<?$&>?H!L'26GL>%I4Z3G5
M1JKC%O!Y7K.TI'#1%"#5BL99G<I_J:5<CHMJXR*'+&!C+Y'-+,AQ*SUF\.?\
MO-GREGH\LI+UY<\I#VF"&=HTF!*Y-B9+=$\:KPVQ[K# LVX5GB4,6:BWKH>C
MYP-7$J3AQ8:\[VI0#9J?'1TMYLSSDW&YBQ7-1=@%X+=D NV[YU ;M>5\#KFA
M2UJCN0(%S%'(1FF2D\%I[W5&G;KG6WJY1<EB)&L7"V34!TKFZ"G^O4 8' 'O
M,_K4"&OYSUM;F YTI5MFK8Q:BNNL .^2^[GT^6=^"Q0&I"BXM"UUMU4\9"ZF
MD LY7 +GY6_[1IYPY?Q_'L!;>WZ-K?T+/?87Z+%?9U.&?);AF-#+7S<?/#D@
M6IH+^1B26HQ,N2"7.%(H-D\:J!K01'GK;PWZIZB<R'<^<1H8E-L#<>UWQ\VU
M22X3\QLC.Z[W@H)_%X5IX+X5D?_1B+'Q^ F"_"4E4E=>$+^8FJ#'G=_*#Y\5
M?/XBTZ;!(EE>D;9J*9K2)S?!MN=C HO(:/TE)&53&L31AZQ4;SMP;6T?=4#%
M-@1!L_&D)*C2Q5/>L5R4>P63#<<YI5-*?]&_*1[D(YBTIV,/K_?B\."0P>X"
MS2D!RJ/OX31-%GFA*_/24)<\C(M-&&N]WSZ -;KAS;;=[3?M3FM0]1O^HF3N
M,_V,AW)#FPV[R>NVS,7<."J,Z/V>K\!]LNSV4*[5<59KO!9@;P[A8FT#&4;F
M+;QS%SA>7?:5DX6R^8XDO\=I2<RAWWW]WBK;UW'SS>^_P5<^',SU;-JMTS;\
M?STKZS!NY^9Q47(Y-0J>_5S1B;AEC_2SKZMPO%$!"WK=?N:];KEH7,6 V+;7
M^Z7B<I\:WB$PXMZIW>_W[6ZO\>+-CT';;G<&]NE@FWZ! V/#;7YKW3#%G(=]
M\8[G0%%E1EQO;(KHD\RJX76HF\FM.9A4KA7RM)K53],JMVFH;$?KK2^+V;'N
M@*=S85=44< ^-T=9+/F%UY@7.@C@$]]8=*?_0>]@H)6F8ST\O T>P-X!Z'TD
MLLEZBHFZ.%@1-HOU_ '\@8J!9+T\;PDRFGCLGJW2HG6%HEG=T#Q];M'L=S;&
M7@LA[[O7L<3TF*]A'%O7\!="OQ@0PP,;7KQJ?7 V[N=+5A%/>!JG$;5#T"KE
M93HIT-XH]57B:5:$LD)$I];5]OV&J;:O6;5]YP3^G%AT66;RLBQIH;.5LO?O
M^?%]V%[%EP#QQH'R2F'=9"P;=&HEPRO<+%NQ2D\+NFAM4V(YC "99,!X^>:#
METR6=;B5\=<DZ_O[C+"K;'>RL!YSR+1,WZS8$[N&N%EUIJB=F O?\K!MG,5M
M[3+^M$J<&3G>?%)QR4$10F0'*0TI2M3PYC"(L7#QSK/64T4@*"H-(BQB<T'I
MN<Y/&]&H]I"HC,RJF*G\KF&MFJ;<^I4TY?ZVTI2?M?!A) 5N*__2I"F_B)S2
M;>'8I"F_6)(R:<HF3?E0PL?7RIQ6ZN<Q)4>%:0R*8OQF3T'@5YN,>;;;=JN&
MJ1D;Q4&K9P_P)E4\(Z..-V<E<WG.WCN4[(K3@=UMF:#>=E!A$I^>([FTN0)5
MN6X;Y>&-DS6S56LOQ1HGK;Z181NZ0R4.[*>%FN;NW/8M6SM#81M/5@9:(QH6
MBH9<^9;H<4_D*^HL#T7U:MJM0<]NMGLO7O/:."9>NFQ0>1>"^IWI[+WJ(#QS
M(FS@]/R\\N/6@:66-SMVKW5J]]I=<P4WC@HCX58<,A-C3:.4;<^\E.T#NY&F
MN\!NNPL<6(YQG<L3JI9A7&=<OG3];QN^@6=*ILZ!22;C*-^MH_S )%.]ZS6J
M)IOJC<W?\]4OINZ%,XZ#JGO)3R^;3Q<6,I?]Y!,K55WW@B8 >@7+[NIF^'C*
M;1?-(*J"%+/4M,X_:L:;ZNS<L=M=,(<:3?D(C289/N;V1@/)&UT;+N+\8[ K
M.@]XD>M%L&@8J4XG"VMW7M"U:AW,M9*#8)MVM]'0B6%!0ZF9Z" U1T_+.DT-
M[!YO0;3FXB4=JPPU<M?685"C8O+$EX@<"^60O\K2BPQ;SD8KJ;;<1]WC"Z+6
M3MVHM4"CVYJ!*FD_R8UK&+*1D_(AS?!743,VM1["%&4ULM?$(P"]>_:L40PO
M=/!']^G!'^T5J)@*@WN+UVB6KE'RYJW2_XIG,$?_S9;=:S7L7F-0:--\-9-S
MC@V=&3I;G\Y +SRU![U^@<R^W_P9$]?,?WR-'QO2,Z2W =+KV[U>#_[?Y]T[
MKWGRU#^=*'*PH-Q0F:&R#5#9P&ZUVW:[W194%GGW.(CPVG=&W&UD",X0W(8E
MJL[6%'FA[;ID[*"A/D-]&Z&^3J=K=P:G2ZFO;+[E0K=(+1L:-4U#HUHU-"HY
M1,MS_SB*PFF[T3UM#/[?Z=&';V>79W^_^'9Q>2M2[F^L3U]NSO^\N?ER=6F=
M77Z"_Y]]_=?-EQOKZO.27D@[VL"'SU\NSR[/OYQ]M<ZO+C]]N950?K^X^?/K
M+0%Y=7WQ_0S_<+,$7HJO;KQYTWPU//W\SDM@%T",?P8^MO>AQD-(CC\3*\3.
M:0]>C-V _IUZ%.N+L(L;"T:\ Q/U:/OVB9*XS]#S*YJZ<?O1EMW<Q*</K/A)
M&LL/T/@4'X9I)#^-9,^XO%V*#WL)^:9!C'A.Y#'LGN2%D?0^GZ\RM?<V!SW\
M[+(8#A08)ZPRBT*</DQSLAV7!P !,FNL6LWAP&M2*F/>?LJQ N2_Z!BTQD#)
MLK=3/,,F5?=JI+S8Q%# I.I)X)B \4A?N0Y:/)'>1X1%M+[Z*PVTWE<"=^OT
MR]./@L.H0).+EBQPH[!@6VF0/;CDG=E7Z%TR^3\($SVZROR8/4RP29<D-#@2
MPF4:SYT=_Q+YBE'1>NN'X0_JZ:5>=8+8L-"Y'(_26/:U]Z:S,$HP;#%V>-"5
M.F*-"-_<$0R?IP TGY8>(VFXWAC)$N>?1[ ?_S$[;OD4$6[$*8E+X9@M <ZV
M8L;D&9X#/\969SC-0CZ!"!VQB+J&"67R[5>Q3(;.$WF$JJ_%0AXSV$J;NALV
M<R+1?!%1\M6[PQ/><9^Z:\D)1N%TYC-]LG@&H"WO(4X)=ZR'28@'&3[0*'O)
M5QYI<!YMXL3Z)^.!IJR?'7X!+K@C6KYA]4KV!:)M#$K1^C%_,;-%V9C_^#:)
M')="7E,XJ\<3ZPJXRTC>EE(VD_5; X8$',75L:PNJ]9OSQD!)0<B6#<"#3Y6
M>1.J'QNVPW2LG'B83Y0[^C!RHGOV-DP305L44X1;=>8#B([/^,JC,,9;C=WU
MX'/<>1PS<<]]SQEZ/DUH%TD.@#_X>PC;I-G7R,>0Q4K.B%?/N_>21P)8,0;"
M)V(M#/!FB)-=BCF>R;$<N8X?ARHZ#V<;CAPU<$9&/N]8 ,?MVY;C3KT \,S9
MO:UA (CY!R.,LY\S9($98BB'A!XL.S8X'N!%Z*T(QV-OQ /Y]"#)84E5$CF,
M6%$J#C0/KN2H'/FVCGG>7K'P:B_ D"YO1XO8G<V 0E$Y):(?,A]CJ7Q^N?8B
MG1J!$TX)M41,(*5B8&"HW1*5O+<FX0,L$?'&ALX4B9+'?O&"! S4B1BD.-!#
M)'M,.KK(E-\@YLQ#<=G;L[:+PMYYZA+AF'41)@ZH2V'RR%=6EUG>5LG:!>[=
M-))-).=Z-H)\X:UF[6+3RU(HILXC[9UD.L$OMOM @, MD*($]0Z""Y%N(X6&
M4V8=8U^"-W;Y>V:@_' >AWH;[ [8X<B))];8#Q_@W<BQ\<T"7^,T2:DGI,:G
M9'6KXDZ2^Y&R2[B6N5L9S\]G9]W#B89 H)Q\'?DWH2T)E!Z3+A>H&P9@ F63
M-0M_^0T %XD$-^GPC:Z7R:AP1I&PH^0!3U5<"O$&Q9 S;49<"S"*_?"1L?P-
MH>^&L/D[0>=.DD3>,.4^%81 '3T7,S8V]J1;.$Y85,0)_N'! V9X%\(%R#;*
M&VS"^A-O%B\ O6Q!U&-DK+HHT8"LD>F,$KD R4#D_RG3<2=AB%ET[XT4)Z&[
M"RPMB&6O5;J]A&J-3X\)8UE\7*TBV0[I/%F[Y82-)@&8R7>/-FI9BA%)*#0A
M1:@G<LF(>2ST7,'I<HPW^R/G:X  PK7<:&XS^FXY?I[:A0]6!S![Q9EM#<!%
M@'#AIY\B7G67C8AH24\$?87L%/BOT$JS[K8ZXB)X?>3.'[3>/?Q6[1 >$#LX
MRZZ:!F_VH;;#(@6!NH3N2=1&J2NL:*\++-+'MK1"0WW*ECP7)_L]1^-\!")_
M]3681; N0>\(Q-']!.55Z&7RU[-2QB&T$$WCW;&J^Y&N!C"7:R6O8$,[UG11
MJ\'K0SR:+I"POY:+0"&T%@NJ3( LD$*CB1/<<1^ $#&DY&0R)DLX%#<\<JF7
M,QWAW\_.KA4#!V 48<.WGJ^(/J'Y@>"BCL?6T LS5B0%&\@SX.ORCL$+/!#S
MH*KXX6PJM$LO",)[?LOQ)CDS!O;9*,:4R5D*I"V^"W<;F)@8MNU&Z1V9FLCT
M'S,6"(R/*_IH*P3XL-0X9Q,'[OV(UD;-'56]$H!10+'@SKGCZ@Y_3P;O2=%R
M!T[HIB.A;''=5/@W)  @QJ9<]TH#5X@;Z:*(R(9QD$_]0[-Z[+R:/G%B@B[R
MT. O<7'H5M2N_5Z(;(W&EU\,>1A"=<^INTBO2G"F,_0;:%R?],=Y\Y"T3"&-
MA'*,[D*P(0!\5\A7O!.PJ)1)<8K9]+I!0%:5S?/AW$Q29<Q=V"5E$I);9 3>
M$)X:>XDX'1NU:G21X0KQ,K5"3^TL5^-TU8->)40?">,R#2057X]1EQ5*?ID$
MKO.4A98)2E0Y*(&+"[^<NL6+-& 4<S^YS./:,-X"]VTZ0T<78YGV*>\ >1*
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MQ]S5QILI,H^06:NAI'P8ZJF*K.@1$XZK:_BJ"*C*Y2_PF@'GE+$/08^_$ C
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MN%F%TQ+C+V<V&%26>,&X&@$N>%%JB0$*I2RI97?P-W PHE+M4Q OR;<X 7N
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M8(:"T;-UVL!>V/7L/SBM.Y+8'4@EG8F/#O3T39(X:BKZY)*3G1$XZ(RZPUV
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MT<3((D0+Z3/@_6] ST>F'*Y&H:OV ?>GH'^@(S+#HX49N#B+0)OCF/]13$_
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ME0OX!-$.8[SNQ7GH1Y"<JTQEQ56#9B:5$)A8F"<%W;">7K4.]'PE9-W+\!(
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M=[XF2S=/B>8SQT?.(G0CEJT(B02!E1:#HD"4LVYA;:CGE)"=<'*;"0)"XD0
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M>AF>#_WA$LN*Y] ;YWB*G$Z!?02/'O,@1B$0"I;8)+P2MK>A7"T2L7[*]O8
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M[HWV]HX&;^_!O;U;7;=/PBXJ'(-^ZQXGZL^A<:I=)8" GGAK92K&JDP76+[
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M=]VD^V?4_\.1.RA+ E+BPJ"J/7O E$]+T\D7!_5' ^[1-#6H=X9Y4&@L,/7
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M1#S!LN4,:Z^Z71:B.;8#,LW&,#DM[6=:3&D"T[Q"0Z6\R+<<G*+I9)1+&:G
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M"V;(H@=##@,T_R+ZJ:?(PFVK#IM1@OPJ_DR89P3A8P; FM#'$7?'J#]26!X
MK9C\P1CF-=04W9GQW8)Z<F>X4FA3+1&C(YMM%8XDL]$;2I@K AZ1+X/$GG*"
M3R+]HE8YAYZ8AS%F,.-J!>S4L9$MR$\^YMA-Q%"#.R5#,V3?,9Z?*>%]X535
M:8[E3](=(E6J%UL:;U'68':"7AS3WW<8QPBB=0K/,,PZA"@<OQ"ZLM 2/RZ(
MB-&\F!#>Q(W21T%N0>?X6D)Y/K[#]*&I88!)=:DU@C*@3"K$^BMOF9Q#*8.2
MO1- ^M14UG@H?#7EE,& (*9&MO)JTI4GE*:MNE>W3<^1K39HHS^->:K]$O'
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MJ9XOFH(K@]-O;K?2!\7R&G&'G\V0^N[+&NDR[JZ1#IM/#?#4\L8R'$^:8K$
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MOCN0A^%,S[[AQTRG>F$7-R*8^ YL%HD=^SN#W\@,A>;9N+E9QH2I1S66$[?
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M&/'.XY?2NCX(U+5V+*G5W0CH30SAEX>'=Y-*WB[Y\XV7\X[HE=<LXW45O+1
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M$5\>VC(8K0[BH0P7U;[Q9>D!_M.ASI[2943 Z<O1&K4"IOABT\_"'>8D!ND
M<))QG:W*65&6NB5F;BM(EGT]T-IK^T3N-RRZC"GOXPCG]"^4(IIK)9Z7A:,X
MY8%)0/'(>TT0A-ZBM)Y#.IP0AM(%B<-VJ2 +*R7H48$039U2XNAXV)8*R4"W
M(ZY(HYAU,8*VRG&1W+T!53A#CRS&*IJG_/)P;(IBPFY&.M].1RF5"(XL.['0
ML6KJPH)>B+#YD@V;!)=]I.H&,V_/Z@O)'Q1+:?K3Q5E!&3;YF3*4RR;+DQ(F
M9MUB&8VLGU\D5.UK#?\ ?T!(?[I[43 5,;07">%4G[=&;1':3$"T"PW#-R@)
M*3P(-BY!*!!*&*H0"@!10:/=J<*)5<R;WG&@T@M>%;<@HBT''8<L("0A<,UO
M7,:DB+76H;ESQ<L<*9'I,FL8D><XK;FU#RJ2>JA"708YUI-2\UW+_JEG;!\^
MA DVYW(!#GCN6I-GUS9',W$:HKLM559S$G$KE03\)D(?H] %8C3NMFBW+=?]
M2P\G>@:##2,R(H8#6/0M)NT.I;2J&ICB>./;&7,9MZ>GR#!RSIQ5>(5]OM.K
MA];P>J<P<JF%\L4(&QFZL#:'?GG;P SD]:.MM^R]$2E4=H7T7R.TY"RWH[*N
MT)=@1NY.(S?%E[XLM9YC0S4'(U1H9I <+K'ODQ8%M@MD?8?1QIW:B/1<NK13
MTKPLT=I#@4YE3TRMQV:P,]Q7E+TKI2<ULA$)(; 4S&%]R1<6U H:#MYYB_#J
M-!)RFCCY3RK6/C8PT_HM/DR+%3.G".FC9UC"T\P\T"+'<^4-L Y]X6W]YCKN
M+A'S9L/*AVM4>8K"I5*?E(K7&6),EQ.%DNB)-,S;TS&IU6KCAD<)#I?4J/7/
M]A2(CFVRU[AN+)DYI;-9=C)R;X[?OXU\!ZY_NWMD-Z\Y/+9H.D)ZPX4>JA<Z
M!Y)IWJZ>U-N4]+Q9%K[KS>B+ET!T   ^8]J% 8A4RBW\":IM?_2RUP$]H?_A
M\+-L34<+)FN85&2D^%KCO$6-='P8H_[Y3(^[_1[Z/=DO2'WG;5;FG;$E(]"S
MUAE6QM22=,U%Q\'[D([2%EF$T[H)7)-VSD/6)AG77S>LTKY+.87[XZI0%)%B
M7]IE1&-=3$BWY0!$(91.,>;MJF1XGW[UT&]*</DI)-PSPK6?1 F7,L*U&RGA
M;@-QER'./I<2<D$0:@59DWL+.\&;)Q=_J-$Z!/_<G<>/#^^ZM$S1!ATUNO]C
M_Q0MRA4-"4U$R?![4>23,]HRNC0+6=OGDQQE -]X)<IWNRS)MU6)LJ%(7ZOM
MDC!OF5T8_0$#W9QWJ8;(0'N?Y!X(I*JP(X;-]&ZUM6>!-F= H:8<W.>@0G 0
MQ63KOA=92B"LZ:9:+3N,/L87J#0XV\OZ4C) W\X>!3"7\DZ]$^O%?D$KA[RJ
M&893.O]KMM@<25>XY+8NM;2;DY7 $GA>?:'5:[681SG-NDQA8^U/W7)TPK'Q
M 8&=-466VL4HN%C*7SG8PD74]OV4G'/<(>3M[$X/@HQ6?Q82\>R"'>*O]'6T
M;_2/W,C:K"[X.N1?/]T& </#)O]8+(,+[]J*/T$ \:)N/MA%I([QK[0N4[IK
M;X_TJS.0.^]_O3O"Z@04PW#1UP'M38WR%*'JPL5)<Q<\(U^7W6"'MTT,'CZ-
M^'!;EE^1C3#'M(>>=^AUL'"%._HJ\-_WOQIX]+=X'@Z-ZDZ<SMX+K5Q+@HWT
MZT?YA/5H=S$<XVIL&*Y+J/4S1OE3A2S5:5F?\$G)6&?@6%=D]"[%+[:@!>_!
M27Z6E3/,%^4:HLO;#8,.T7%)XYF136N+=]/S4"=G[T$;^B"<1O\/MHVS8A&^
M.ELM&>D5*PR7"'=.FC5=)V7I@2_O>#)XT5$=:MOC.H_NO#M2Y)86& ;N=_,1
M$W&3!;XG,Z6OFHIMDW"R0>"U:H9!X\DM$8@'3$-S1$YRJ8W+I:J-?]4N+U*<
M.'CSX3$6&FDU04YWWLI%,+5DQ/E3PR.*&]>Y^ES=_)<WP^%OP(J0=>7H*B<
M6!S%"^:*3!I]R;T2) /<YKCY$ P?T@@Q4&UW-\F:!FB;7 ^8O'G?(K(AAHQ
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MHH%($]HMC&XIVN+!QA1?;=!0>@W=N,P_POT"@7!C\NND2X)A(*76>E4Z]LW
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M+22TXAF[338D,4_RBN,=SK\EHY F2;N8C#M$R(SHS=KXAE1Q>DZADOE$6(\
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M07<BO1/IZXNTEVE3VUW4EI=JCIU=5:J_VRK5>,Y.LG>2_4=(]I!H=P*D0Q4
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M)08;FH%$^7DT)3AYX@F,$Y7+#S?+6\_6'B@L$DZ/"&->MU*4G+5PEQ,Z>$5
MR!UPC&A\T7?+O$+<0K;EP1*G!C;8C.Y[,F_D (4P%?TJ!$NN,=0 &>TKJ"37
MXYBABLHME2D"DN)X/?HK^2>7<.:+*)ZZE'/D]/9B$5J:4?A%K885?^C(RH?Y
M7$UQL<F5?\#O4/W$X\H,Y&C7<[^K,PP0?0+?YGA,%.6&O.1J*[M$HQUQ#6)X
M0TYM;AR;9?]*</D)!P[<D&D;N37^+KHX"NYV>H.XF'1N\D#4J'RU(.N;=\;$
MR=3C \>.0QY0@%9#M.=JR]V_0=-W&=,,* 'S8@*?M$M$*3":VJQQ._@5G=,*
M/!]4(MKIX&G8X@N9&7LA#\%H$N22AG_XUDP1R 1N5H#TV XC3=M%U,A\GLW1
M]R3OBWKR.9S6>1@TU2$JX< N@[]P.^J<D$TS!^$5'_!9&OAE>$W[<)10_ACE
MB'%_LAW\HO*O<P2:;3Z0'_$[S4)V9ZN<R+5YM8U@F^2BN@#."X1';9O7TKE#
M3YG6\@@WF=#3*5';P?^IP//\#>.5LR)KW;4EV3_05#!4#8-?!:_&DO=7$S4Q
MY&5TXXG2(1D;]?1E%CCF#XPWLK>*73AZE@7A-Z/#1^ZS1*RGVN:PQK:>_\Y
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M49)<!1Q6AX_.50E24(2F096&L@LF@H"\$9HG,GQ-?9CN^O>?3P+4X4&T6GG
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MKEKHW(0?CJ0JP\8W0XY1IQ&-$-1!D?KH'1YNJ'!>-],/?X<ZJ% T8 R$D6*
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M,!5:I]0814U/TE/EV* BRR#8LRKQX_C:M"W.07VS16=%@AH4MH._SK'?J$:
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M8&11&]<S-AC92!37PZ[3I ![1Y,<66:N(M2?:/RA&$QC"LBDNN-51SQKM2%
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MRFSZJY\_Z9ONZ2?+_](#-6Z4\+[AY^]S0QN$!OXR]F+ZJ 77=N\E[<T!<M_
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MP^L46$H'L>VJJB6D>Z79*\U[5IJ?Z+X^T9'WMQ@+_84B[QR@7:50/ZV(W/.
M=(GUSJ2 ATJ]="O?LG(W6[_.3R#M-L4\&CX@DVX BA.#0')5/H,\A@9;C*(?
MN@<N7/*Z[6#E9D0O.WZ"VXY@5#==!&.W>)"2JCI6CEV16N+]N+.[6:K'=3K
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MH\W66[^_PA.HL4_#XG 9*X6=*G#J44,6H2[?:-=0K#^(<^CK;*<U><AO5?3
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MU)35;30I42]:S<VOH'6*48);B(NB8GWL'D?K&A=9[HH *Q[FOC)FS=RVQ+C
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M5!T@EM E,0W6>JE&:_4:E);8]>T$J1%SUDU"U^9KSJ!(H9<GGUPG8F+"=Z$
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M C0]"'$+UQ?(?J 4H#.SI\^P)P-9FW=0Q,1@P9C5+$:[ NM8\9]_&0S\O=Y
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MZ"RB3LZBZVLP^H+A%S6+J Y3JE[;^KO()1LV+Z]R0)+08)8K9.LMXH>W Q9
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M@,;G],::7-)5^0IL;NK4PI[?[>_YG?[ 66&#H7_?!4KOZB 4H;W$[N-P)(-
MK5Q"W3Z>G'W'1^JH)CBE6R-0S9EM9C?=2*!&\\XQ;7P2^C@J@RMSP?;"/$KT
M >1I3!]*>8ETP"</ Q;O<]0JO46)?1.JI#]9UXZYI.(#=;N7J@(YTUW6'F"/
MS@3KGS(X8[?C.:,R8 G)+.&I-EN!-0!2G@]U*NM,TL]Y"^1F0N7?][:NK,=
M)T97KLYV-"?:&EH_XX/30(B;%#/QN8&FCXF>PXPR,C"^KQOC9-KS9?FZN)!N
M9"VKHPO5@,*=UB<'"+H/2IWIFI2J'[]07'4N L>$-1HI9X'XP\@'9J,270+_
MUF\B8BL_3^$">MG(\2%C-K#VT/C(J1^>/3%$OV,%WOC:+7:%,^?#94A$V8^$
M23XMB#V<D2\9?D&D%H?6R/A<)R(N_II\>GK4H03H&/!-P".T)# HAQ7RT4)B
M>F"HN;G23>1,T5]W@#'ZFD9IR".HP;R/54%'TQH-5X<]NMP1=399G?'\&-4U
M=]L[MM1]5J"4VX@609Y$7$5X"35[J3*3:HC6:N,EF\PG-+^C"7>Y;[&@),=@
M2'84JK$N>DB'JH.TV1WZ-M.TX-F8!/Z'EQ"_<;IVS5XIN1=V%84WBM5C9Q,Z
M9EX';$8@<@]O#'-<14T\,?&E>G##;Z> N#S-!8V[.!Q= R4F:7.KLEJ6D\P7
MM1Y.G9>$+SK+%297SN@=U,52\>>%N[+@WKNSTEU1@1=4Y'M5RHTN;O1SWN?K
MCG:(D1L.U/"W\D=% ]X[^.D%ZX+5[ROJ+9]<WKFC'N)'EO_]W18F[74M(\-;
M&[#D UYKOS51FTVU?[XU]5%WNX._I#H-[W\Z]']OJ! D#N:O";]>(3Y5MKMI
MC/]S,.7DH,/1*"/F,?8L1?,4N?PO>5E#%WL#8$]U5L]6]^4O/\,C;[5AL08$
M%0$M&EO#%&D(S*V>-N>4@U467 -P#>]<S%5T@:/4G5^N,N_GMRP==<+]9@=[
MUH#X2</@5(G];P$#D:IA1O=&KNR<"(9?T+)-1J\DE#$<AN%XO(*0[V2PVW$(
M!#?&6FP)_DI]>*_5((.?O+]S,TRK^./;\6OY4X_[RR>VY^\A:[J=E<+FFW&T
M?V\X>G@3@>GB'>(,$4FM_7CFG9QL*BMZ]RHK&G,HFOC>MR^A6#&9HB_>]O;\
M[F[?W^GUO\^^GA] NMN[W[2CGZJ"XT<2&O='D)>3=#I#R_E]&"0M%;94^/RH
M\/D0V_O@)L**F^P:A. DWMQ$:@FN);C')[@?0.R]B^$(Y]2DY"09;F]*A_T?
MC Z[0(/] _]@T&WID '2W=Y[\G3X?,@-(TS_&R287CWR_H;Y YM2W,X/1G'[
M_DZWYW=[O9;@"!Y[V]^F K1R;RU"Q$+JW/L[EBA2O)1HT9O%PTWI<?"#T>.>
MW]GM DWNM_1(\-C=_C;.U,H_F^Q^C^(X"J8>J)U1!AJGCH1_"I) I>5\_'BT
M*17N_F!4N.OO Q7N[1ZT5"A4V'GR5/@GB)R]-PFPR<@SG8%.)4NVC:>U\;3'
M$2S8AF("__P=>]F$DXT=BGL_F #I^;V]7;\W: 6(P*,5( ]!AD>3(,.,^8MM
M[UV8?9EN'DK;_\$(<3#H^)W!3DN&!(W_[[ZVTTJ\?Y99X1UN>W\K\R(8Y^G&
ME';P@U%:=V??W^E_F[>ZI;0'H[0?0-K](YTDWL=M[^_1-:R>;YSGV_G!*'#'
M[_8/_/Y!Z\MG>/2W!T]>Z7P^U'849&D\3[QSTBV+]+__C7SO;++]?OM'H1_I
M%_S]-]A"II5O:U#<19 %$^]=.A^&&\NV^RUB>7P,W!M@I7Q+CL]#N7P^-/:/
M,$DB;'A\E XG69 HD;8IO?UH&9'= [_;;=TFSX3>?@1A5R91[)T%11AO3'P_
M6AID;[?G[^U_F_'24E\K[6H\)OFD#+S+ )9/Q^.-">U'RWYL+;[6XGLZ"2 U
M_0VPR?#(R?JHZXVFNZ%Y6P?4-.4F&I5!G+_\4>ATS]_9Z_K[!ZT!J/*QODTU
M7_!LPCJJ<=YS;3F]V[:<OH^6TXA1S[_EYLX:_30=O=+^YC[EQ!W1FG?X$3O:
M4"=@>RI#0\/+/\_%48>>)WYU"[W,L+/:B$=1J8G=7F":%JDNO#SA(([RA0YM
MU!<0&V8.#O8[WM_3K*">8ED8%KYW40+K]W8['=\[GH;9_":*L2'@T:%WL+/;
MV6_LDOHG0IK>TT>:\W &^$!S8)9WCUMH0N==\(A#W_N4;;,(QD8*/'I8?6(5
M?'M;^)",((77 C9AOSL>AY7+4,J7.-VEH>5LD"]V$JQ=!^>]70PGX:@$+.OV
MW^-0MW!D!JM>'!]A.]S*:W;X/=LH%G,@AMP9P]@=^/O=/?^@O], )]^:R+CO
M]_I]O]_OKVSSB*-)&8S8RA(^3'0_0!I)>":SX\]BT+"H;$(U?ZQOM<GOIWZ;
MS;U[8:/Z6/[N[B[\9^];=BI#;?7.\!ES11_2#,>3>F<R[&99C]#F/2-6;44W
M>ML[.P-_9[^QC_&W;_L\'(4R>_ =&'DYD.!==LXM1F67&6$K]E$DQHJ]3:GG
MJKP2FTKJSL.\Z>UUB4M&\$F;5.KV[S9]5'LP35[U2_"?-U%6E.KMD6Y"C/-.
MLS3FCL,U'8S^=H:U.][)B>X(G;LC(X.LD!D#SJF.1?9\ EF4Y=N>/IQ])FR]
M&P?1M+FQLM6DM.9<#/LZT5?+.G#ONP/86EYX@P'P"I9T7G<?_OX0I\CJD)/^
M*\V VC__RP,A@Q?<RKG^CR#GM&P;EPD.4Q[C*%"2-20X*FT34$Z]#X<6P?>9
MXKOU@HI&=<WUF"=+//WMY\,& >6,_NWMV0QE :FQ&7)UBZBX*7SN 6TIS<U"
M8OD+47DP:%&9B^V?/2K7-_Q=[$30C,3WAL,?PJO,FE_=68G$-;L$/ ;D,)^^
M2TL< Y>!;?,IB.$^,(0>)DD^CV^") J\[D&_Q>9"2M6?/3:O8,R-=?T/PJ,W
MQN\EVP4\[W6ZWKLHGZ2S_!KU_N.CWB>O?WCL>[\E-,3PGX ZHW3:(C=7@#][
MY*YGU>L6S3]%!K[VWI&M#SI@-N$(BO/H!J> C,C4_6_@>T=@3@37*:@RL%R2
MHF[>@?_7(CY7KCYQQ*_X4+RNW^T=^+V]Y=X3#WZSV^NL8]1K(YAJ?WE<1AX6
M12R#M\?.J!"<J)I%0R2%G)8J@9OF'J(F?KVF+2].B(C/T]WS^V N-NRULC^<
MQ$'3A3#T05,VT(@&^]]V2M@[5H-;]/R5._D>6EK9?WZTTAL,_(.=)H^<4$IW
MX._N-V)?+:5(>>Z#TTIO;]_?@4]648K:7TLKCT0K!\^/5@XZ?K_;*# $!U]Z
M@WV0/XT^;HV!NK"VQ<%'B[-VGA\2=OV#@SX.0%S.L@>[_FY_,^5&RDR?+,M6
M^VO)Y;'(Y1GD)2SH-_N@NC09 H9G[^SYW;WU-)Q<:1!8M]:BSP;H\PPR%!:X
M;0_0I[L2?7;]G>;X^WO%P*0$JV5@CX:!SR!VN("!NWU_KWF&LD;!@P._T]M=
M*42I *G%P$?#P&<0\CN,BPE-7-9(H^IIS-39A80/'/#9I) "HF'&"$WX!/:'
MGF+,^/?"89JDTV@(GQ0AJI7H.I9$&37UF;S(42B89Y8P#S2-NEJ";L\S 7RO
M30"_CP3P[W9IU>J6FEOTHM&O+[)TVN\,#CK[?W0'+]Y>''_\>/+Y;Q@!^>W\
MY/)??S_]",SOXL&'$V.(Y2+$\,<U_"^/W9WP&,/:=%V>0(QT/88#>06L1[EN
M$:658<4YBJ8<5N1)V%G-K.<Z8:8SY,S$<'Z5FU$7Y=XL2VFF<9G;H[6#.$_-
M9.TU%/HA\-L CB;)HCKBJ[)$V?[-:.(WG@2GF8^ ^24,D7.,:>UT!F &CVAN
M?:C AUSK<%B\K!^OK25JBB?C9$67;0+(E%$-OS^_^(T+I,[@#U]GH-$\;+-G
M+\IDTC-74'FWDY!FD/.8<[.QJ@Q7H]7QC34"'7<_PA@Q_5T!_N^3,,$!UD#U
M" %.>!1P-J"4@BVAE+.<O["2&H/=B(6^&61/HZ-#6&24)O2_!2!3#HO1/X(\
M!V*D/P$>PS#/5=69'M0^C0I\B?682![8-R.R)!<VGPLS@FT!M2["T[CZY9!^
M#*8P3F. ,9Y5E+2PR(4P%>E$"?Q[&I#LA>W>@*9$R E(!9]<A9,@'J\ '"9_
MPG()O6<2+@$378=DH!*C@7<MLB!X.Y4<U+]N-3-IVF:$@(S&$1Y0<T UAWUD
M\ UWA<?7]1$X&CK-\=,Q<T)@B!XEA<(Q32:L1:$5=$@DZ14^F1LHESD'T>TK
MR,+K(!L)))U%M[U/(.DQOY8K-:S7+1Q,>"B\.)Y7?WP5LB?P&DF2+@". P@>
MQ#RM&H&":B*LD69P2#P 'EK(P$X<=E5))[&V_@JVO4,@0V"8R37#. EOG>-?
M ^M+<'& S?*E?#FD',8 3:!1(+D;[F(!0/;I+T,RGSGJ56B),B"6P,(U8$.S
MF7*S D+ 'Z,I97 ([V,09WPP4',+[9)5R.#@+J8Y!)0'#4<;T\9OD3DG(3*[
M()L#\)I( N^,Q74< W],IR04$JS,@M=5Y8=BW$2!L-HV+*>9_JH^[V=Q0#C_
M'L\6795X.NGMOJTDPT.SNC.N/@.MV,KZA@->!42TB=?M[OC[O0ZV:6JT="0M
M76D?/?33^YT^YL5F"=C3'L\H9Y3J@L6.LXD&NX:YV39WL,J4?DCPG)* I%H]
MTG_R(5R<YA6 *&&<AX!KH%;4R72%1LLD #HE4,("&0-*!3$@?TR(3U=!7 XP
M',F$Q3 J93-@/J$2Y/B5UH060&0=MV<LO4;#SS'TM(>BXB]8\"?<JP?#6%?&
MF<'[?-W1]HR:TJYJ6RM>B?[N3]+$O_I];>FTO+/WDS,C8/G?[<+MP@^X\/=H
MK[%O-;G)TEN41+^^Z#6YY-3>%]H1;.ZH8[I6'V%/#?@E:)*P^?_IT/^](<TQ
M#N:OB0.]0HY3V?JF33<^!_@+%$&'G$H9;MY;^!L:Y=B_'Z8Q WM7>TJ5JT26
M6@-"#6];U$(<*!@K_9>KS/OY[3M+#^5/3BE#=I9%:<8?*&/A5)0>/8_F[@!X
MQ@!C]?T"ON-_*[G_%*#3W7E$\*@,,X-/_ GA$_])QAW_B3 3?+L'P'UO[GCG
M&^D]_(4H)9VARYHZ_TWJ^F/BY\-#0YD8?ZY3MSC0X@#C &^I100"B7%V_+G.
M_><D@/NY[5^XCYKR-]R;=O%#M#9\\;8I#6%3R^I;&FW7_/XQN_SN^9B\M-/[
MMHGCWTYZCP^*;M?O<P^9;]K7\P9"BP\M/MA >!K-B5N8M#!I8?(#=)&_/U7N
M6X<]?\NXAJ>%9CU_;Z<'8NHQIEX^+4BT3*C%CA8[6IBT,&EA\JQA\KW4NQ_
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MU-K6X5^#Z>S-N>=L[9RW9GFA;EGMR4+ PXQURA+X$%I_&(LA!1)9$V@<B*^
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M"2@ NT"$.+Z14'"@UU_X%@,#Z9"<:Z");;Q!*V>$#VNB7"I(B:8X\H4A>9
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MF]YH)X4LN_QM;$&!F\GM#H/Z9J*Q$=_6*R(Q] T@[PXBR@*DUH08)E%5M@P
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M9J')[[H=?Y#9HV)2:CJRN/6(XY'$^V6.@X#):6J4+IV^8R,(O.HFS)0;JM*
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MBJ>M^V+)-AS%WOOK?\JT>%/1[_E#VR3PNK;9@*J[5V-'T&?N,1?\A$J5CA(
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M)7X:+T&_6OQ<V-NA!!<_Z-BI<??7<+L%U&F@!,6(K-9OZSQVM[MCHO_!7M)
M8W+7)#B<?2CTVZUZ.N]^0F#"Z,C^]<7.B^_REI:-W(F-/ QC,'[E61;>9E_
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MP1\14).7EU=@=$1@B*Y)2SX-PP9JC&[">$[1]5[GC3KFH?>NS $4>;[N<K1
M]XTG)K*L9X7IX<N7ZTT4]&F%+(R)YO6EY(XQG^IH YS$^ ]GW U2+M5+P@(^
M5=T@V9$W1#? 6+L!%##QG07Y!.<T'$9R"<36#Y>.BL%E[3TG9))L.1#.,*,!
MQ0)8*@ &"TCZA'5)"0ITVP!N+RTS.#@1.0-IZ:,>B/6<FF &41;/?3Q2$,=
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M;=</XX!:MI*A.G+]!\/Q)(@">/2>ZS55XBU<2XAI7/:WL-?S$+R>G\1(!(%
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M<TYF\%9:OF41O&,0V#9[K6(S\]@35F)X=YE .@!YGA@YD?%&10'?'B;(VT3
M@.!0;O&/DB@5$ [[K7%NGIYP%Y?:LMZ^ZI^W"LT!9IXK,<]ML]I.LU?14"![
MP78$D[Z*R'#!ZCA,2/2$T06+KY2OO!R>JF;/[!=P1Z5FGJK*\=Z>H%"[?<I0
MJ%YBKAB9U>ELOWKN@C?HEUSAN+1,7!G+QIV/+>].A)>>K)!_+HO($K/H$K+E
MJR?7YWIRSZ\G9\N=-AS/4-T0U&8;"/_2[>9J<]6O-M?@:G-<;8ZKS1W]BTO,
M<<FK7? 9EYBKY+9QB;F*;AR7F&.O]JMZONF3U6\UF^J _=OR8BN8&:\!":7W
M$FVQG5+SM*0.A?W6HVOVS6:?LP68$??G+N]L/^6-V:]Z[+==H=;B%NNUA5*<
M(/#JR%D)Y %G#E2)*^O"E)Q24%H6K(M@K'"N ;NHJHZKHL#RPA$(.UFR)=_-
M]S !UWJQ<AWXMA##Y Y<X QB.NKX@102518V^RT'?&JV.WQ/DQFTA(BL:[;;
MS)K,FKOQ:'7,;I][+-05>#TW-JCSB(Q7I1!57+B\M,UXN63(?J.#K;[9;VS?
M+JR7ECL01MP;SNJUN2,(<^!6Y5J[8W;:A<JUZEVML<+Q9]=_V,%5J>=>H.GQ
M!9KG7Z#!_31H0_F*3/6OR+367I'I%'.7I;S#UOWF0GVOR/PEK, 0WA#D'=^6
MX>Q]OBW#V\:W90YKX_BV#'O$G^*HI'& @:;[O1,Y(GR_4R_WBQ8K$7X-7\)4
M9BI7X24<!DV$?KMT0I_S^E^?OKHK+R]G[U>)]PZ+]3A'O[2,=EA"CC/Q:V'^
ME@\)9=@5'C. IWW/=EQ!J6$(D?!3_-O&*. T\.\=])@/9L:;.(0_'.]MIM,\
MF]!5> E3F:E<A9>P"9THCD[I%,<G,1( @8:9]I$B-%%5U-*HUN38=NN-FIG9
M'?.TN_T<S8.SL@^>&8LSO#=LH-?:?B4KYL**<6$!?-4MI$8:V^0'!:VNHK$(
M#A-%K9<8M'#LXPHG7$H-)3+*+RMV>;MJY#R*X;O_B<#'_>ZWFJT/"R)EFWQP
M:'KK<)EP7RVPNX5VVF.F*S/358:-V)U48LQSGG;IR803PE!$H6%Y0YBL-7!<
M"BV0DPDO)EGVW[$3.L3)'&\H[TN8RDSE*KR$3>=GJI%>Z=3(F6TC+@DQD"V<
M>[SO6=^8! !)X,50?!+R?R\]39YO"77*CR_+$9AHF@U._]M"7_I#8,A]6=GF
M29O[:S '5BC3E$WN*F"EJ36CPAAH9UNV'<0B9V\?)G9ZJ9RXEL3"\RA)]26E
M5/DEQWZ+P)GM8DLE,6-6ES'W!*I.6BWF2.;(8HO$F;U.16$6.ZYVG4X+>EEX
ML6#0A9)$4^6;)$KYA<9>\=6IV>OQQ<&M.TVKQX3[SI[MFR>=[8?R:^\LK1PC
M;M/WV6X5VMR5/54E!D>U38A=E %$BJ1F5:4,JOTV@ (!PDUVMHZ-JLR.^T9)
MS1.&2"P>BP%+#?8WE0E2E:_NQ]=E)3V6%?*H(^P"XN"QOU:D^3C[(\1KC(E<
M.4NH4WZQLF>/U&F'XRNO+V5U.-RX;]!53+/-FN&N0^+(+>92F=UF\;#KEZ03
M5 8XV*ZP AIIC,CC,8$9.KM]79.>_J:89F6/GOYV6O0L]K;"#U17)XNH:2R@
M.D5$55W>>"80?>&R=X/1/K_+OGCAZ_ZR/DS9CS(_SK6K0C ZOTXQR:'R@0!6
M1U3N/EBS,&&A7\8)XM<= !J-GSX8FMW:N*(,;F]VVJ:A_P.X_>>579[:QZT^
M_C@WT>-N;\E<U<<?LO7_#6H  -.TC'& 9_D?D6\?_>N6\MJPAQ5*(1 ,O_QL
M+:'.$D;*;[KN[W3<<8"+LH\COD]F&,BYR&Y1.0. /I)B-<O/AC.<ZU1V-IT*
M;ZCZE?6;WYOKVIK-/]S:Y UI+[1-1^[U8!K<0$LUT.IP ZWLGZ_P!1Q$,R-N
MH,4-M+BA#S?0XFWC!EH'MW'<0*MLD83R-=#Z['B69W/U[ZJ\A*G,5*["2S@C
MK^3AXRBPO' D F,4^!.@=O!2?%?Q:,AUX-M"#,//0 ;T,P;.(*;P!'YP360I
M?QADO\EYIV:[P]EYS(9[NP9:3%B8&;!R#+C%6Y\=L]O??LD@-IX/#4<MI.&-
MEEC4=016*]),$H=#E=),]HNO>F:CV.M3S(W5XD:&6<R')>##+:*MMMGF\N&U
M#4+<Q-.I2UQFN09\:[M^& >4^D7P:@3<;#B>9"%@# Y0E/<E3&6F<A5>PN9W
MY<WO^:I+U/\Z&%)74RR%.5]+O$Y6N&\-G/=S)4>^*?)4LVPN]^ABGBP=3^[)
M$B^F1!-S836YL$)\-7<);H,;8AKQ+-PM>=[UL&:K;/?#;L<"!G&!03!60!0)
MC6D@0EBN$8T1S=P[(:&;,'8!R,#.T>>S]9G[S5.3'K-27H)U#V6!</QBFNA/
M&%HJ4,.:2+ 4^4883X!,L#!Z6(Q&P*EHB<LI)7QHP('*C_;."4,L/FZKHZ C
M(6#3)[]*5S$E/@X-9P($PRF\<7! & GF&;X]-O(WXYYW]>JT17>>MK2S.3[J
M;\Y':Y-S%Z_2R<QA!:J?S4XKQG,B.*+VDHYM>I,^6BYLDC!NQ@*[M2W>2EQ_
M_31WKEYV_U0.\?H+J'S%35YQ:ZV]XM8MYBY:>8>M^W6C^EYQ6ZX=RW@;XB 8
MK<;W;/A>6P6WC>^U573C^%Y;V6(#Y0LIGU'S:0X4E_<E3&6F<A5>PIE#)0X!
M+^D87:<HK\XJ7(Q:8)ZA=&#-Q2_.PBM/QRV:ITG<0KD!R0MX2)'<A1!'S^SU
MME^ZNQZALXJRV[XZ/G<:S&<UXK-MRJC35J$RB@W<RB.?6Q^3I560RK#(W*TE
M]*&5EU8H[!OKG'98!QTT?S&X8<8J/9HY*50*L8>FQ#CE-]\?/CBN6T=LHM=>
MOM.]7UC2,YL-OM#^RL8R)6:N?;>)*:!P2\UZQ)27N;8JAAJM0OM;L9NE\O!%
MNEGJ[EXIGQC8*X!I=5MFN\4&\(&RUK[*ZW!8\C 9:LN"IU_1T%#ET$CYLAHS
M+;$YM;&\+V$J,Y6K\!*V3RMOGR8)D%-K5O?LQVM)@M*&U/9JL_8;A5:S9C8K
M#YOMR7[M<46:>C#8%H52K\>V;$V1BV)O Q4@G@5_I K&"!C*"N&_J;%;1U0C
M2T*++T@+;??/2BL3N#H?\UVMP YCG1IQ647XAOTYE4=%^6L=-8= F7!':47#
M7ITZ7;/9/F5-=/A,MB^4PUFZA\]<VQ1'K69% 0Y#E^VU8W \VY\(([(>16@:
MGJAE7VE-C4LBQJWUF!$%7T4)Q<!>@4R[8[;[K&Q>>26D>CS'-T7*SW0'QG/;
M%5H-OD#"J&@=*KJ*QB(P7-^[>P>_F]3=I4/DR(H(W[/+:ACM]XX)5^ZH$ZOM
MJXP'WSFI#Y-M$?DT"O4ZLYNGQ(!&1JAJ#F,R)[Y\YWRON.7DQ&RV&;H<,GOM
MZWXL,]7A,M5V!=!)\4TLV2M3Y8NTUQ;EU]C^9&IY,XQ1&8YW+R3?\M7:\KZ$
MJ<Q4KL)+V(0ML0F[5OK7T9R]B7S[Q]AWAX#@+_Z.G6A6/H2X7V]\LV\V^VS6
MUH#-]F3==CC[Y?"9:[L"J7729C.7@<YS?/6&Y0UA7QC^K/*,P7&M@B#A\I?,
M=+6!1EP8LW:L5KV2F? ?+-KR+X/>A/1TO-B2KYK[P'"&OQ[= KEOA"MI]KW;
M:)TT.KW3(_C]=J!"%KXT^ROPRW,[KR\\37\G..?9^&3%> Z@%L=>4C)$<:)Q
MHUDGQ+(A5U,1$&%#(X]>TO\N4E71JK4IU%LVV<P0SUVY9I_,%)$9D84,6[BN
MZE+_ZU'CB/ZM!J9_JSG(2=(+#"N.?(#5?@"'6GZBLI (7@,/.\-H_-[HG_ST
M*DPL7X"8W;6F(7RL_TJ^RA'@:(GYD/64YHZ?FF*W^=-21ZW^&A:P4DBGOWKR
MS\H,^PHKK/\:/[*6?HH1T[-PW*'3\%Q5N'Z<A=& L8"5O%^/FBG#KQI:L9[\
M9]:@;)@&_M_;^4?4[C0S+*V^4?(L]%V@4%;1 MR&\STG!5XM[M8*V[^$%1@"
MS-FA\4G8I' EF=I-L)!!,[_(5-MD0^O.<ZVZLIRV(0OC+-ZV(K8MQ=B\<97:
M.&4$%7?>V(=;^52E+PXP9BC(<POO X[Q/6$$XEYX<2W+/7^32Y]/8FPTOS>D
MQ^+67^*]2$S&JU%J+Q;N,5.;!Q_^KK<N\9==!_XPMJ.KX$8$]_#<WOVZS9;9
MY1@W<^=J[MR7 YB9DIER%5-N5?[UBFUKSEF!)09:BJ<86E5#3CP?*7U7.[PC
M<=(Q.RU.ZJH/0SX+'.V8%T\X6Z,^C+AS,=<M5,RQ#ZORT$KF(3*PJH;XV*<+
MJF^VFH5F-3.SE8K9]E7WJ,$NI=HPV5;%4[M94;##,.;5, ;83%B!/:98W! .
M@.M/ZWIG0M,"3MJGE!(7CU-TWE9 *.P7YK3-9IM;2-6< [E/*S->Q?%0VVPU
M*HJ'V/FS(]3TF_" LUT"3=9PXGA.&"&GW]?2$Z2H@0<R1XOJB(^](J>>>=KC
M0H"U9\%])2+UV&U4=][;'C?US6ZGHH4J&19M*2;F2[[U[@PA3T MRVE?:2HH
M,5 %K_)^^Z4US,XI=WZM(=?MRVETPJB[?MRV18'5--LGA8)G]A15'A)]\</0
M& 7^1,,B8./#A$-/-/),9(7LJHATJ8"T*!H1;=;2LXGU?KBM9TU9<-\-9;L%
MM)Y@UJL"ZQ4ARMIFH[7]-(&W["*J$!X:". 183AT%HS(>JPE(DI%P6? A^>R
MFAX0,3W?'XE.21MJ$5X\1H'E!T,',,GL$LXM-6>$7P:^ZY)T@<V (UT!V<+(
MBEGY4%B9$1JS<+59F)$>^\?V@@<O$PP(J- 3(R<RWJBPX=L:HT*0+\JG_E%2
MI0(RI!R(KMLI5N8<! \>+ ON*91XRCE4M15[!<BP3K=54=S$B.C5B.BKB P7
MS)!:HA]8?*4\Y.7 /&AJ%= X[>!@SZ$QW[[]3IT",JB8Z<K-=,6(KTY_^YF?
M"XCGEZ2?44:SVZZP AIJC-#@,<$!NO/UNEX[_4U!Q\I6._TM==I9TJ)IX1-C
M 7@I.JHR\<8S4> +%[X;&/7Y7?;%"U_/=1I1-,Q\E/EQKN\4XL7Y=8I)#A++
M\"9 8O?!FH4)$_TR3N"V+N7?:/STP= ,U\8599R-S4[;-/1_WGXX^GEENZ;V
M<:N//\Y-]+C;6S)7]?&';"%_@RKYPS0M8QS@P?Y'Y-M)_P(O=MT/.9@N3\8M
M-7;R1P;ZRE&(_/*SM=B@ZDFFFVL/IKLZ'7<<8+GL\XC7D^4$<N*R1U0.T--'
M1QLT*#N;@J$Y5&W*^B!:-_F1[FK6+Z:KV3-.406;FMECR[L#FCB>H=K5GZM^
MK6CS7";]6KGE6<E:GAF+OH)LSS,CIZ07FYXM__[)/F+R9YO\7;FA"8XLH>HV
MVE$9&T&F#1JM;&.@Q>&X"]J_-FQ]MKV-9':K=4.F%0W0>.=*OG-K>J#QWI5\
M[U:V02N'5-]2^LOZQ<AHSZ(!R.&>)\(]QN:<LOH,OL+_^?(1]N8 /9>VY:4G
M+4ME6-+8VJSD6-!K../M<SF,.;,\G%G:0!%S9#TY<L=1I*VQ68&8B]'4EM!4
M%%A>. +))N_=3Z6KV99<?K@P:[WDN Y\6XAA<KDA< 8QG6;\0,J!*LN3_9:^
M/C6[JRZ1O89+#E"_U9M)]U7BL7'"S,G,N:NZ2*V&V3I=T9QO6QS'OJ]#0&O7
M.6AF> #>G(3AM;CHMYI-)35TX,Q8%C.K$YJ[B7S[Q]AWAZ X+OZ.G6@V)WK.
MPBNO]")GKZ"MU>R;S?Z*>SNL&.O'C'L"9YT5O2:8!6O'@ML5;JTBH@"+&"Q-
MJE[,0'Y>#F:O][U93%IEL[\10#KYZ4 2+<^M<&Q\=OV'D%,I#R&5LK4^E;)3
M7+YC^8?FW+8ZIU+^):S  !4"(I"S*CF_B[,J>><XJ_)P]XZS*MFSO!%;)?66
M#;1\[YW($>'[77N+7[1>?>VXCF]A2C.EJ_06S@;+:H%VZ;0 Y]9O)U_4"L?D
M3:QZ0) SZ)G_.$^>^:YL?,?9\/6QE<N'DC(\"X\9P-B^9SNNH'PLA$_X*?YM
M8UAQ&OCW#OK;!S/C31S"'X[W-M/SE^WMZKR%*<V4KM);V-[.:I).Z33))S$2
M (R&F<Y>(C11=QRN!;X>B&J*;+N\^<&8Y$_T<B@XA>U >/ ):ZCZ3+AON_R4
MS7(6AEO-^E[5I88O2#&@RN3WIA53,Q9V& HPU2UO").U!HY+UC;!+$S^M>R_
M8R=TB.G9!"_[6YC23.DJO85-\*S&Z)5.8YS9-J*5$-VXPKG'ZQ,';H _W5@,
M>"T4GX3\WTM/D^A;0J'R(\]R1,8[9J=;P(W9^EE"!\*4>[HRVS1;/;ZXS;*Q
MN.CY23$53#AX?KAX:VK-Z*XJFN66;0>QR)GGC+\69,RUI!B>94FO+RFYRB]U
MRH'(NB<%E(]@/'8P3+HGA-;CHB8L.G?:,;M78;C&0&R;N2>@CH47"P9<B=30
MI/DF*5-^ 5$.;'72*5JF,$-6A2'WG8#2-$]:['EE;BR.O_I%N%39X75P..LJ
M&HN P54B/8@>2;F)2MEAY8!93?.T4_1%M0-ASCKQYKYBB\V"*]<?""O624X6
M@[=.*GP[MX)(JGSW;K_J*[7J%NW22[2U15I '3S@U^JZ\<?9'R'>'$@DR%E"
MHO(+D'( K1.S<]IDH,6\62[75B'=J9@I*\V4A>2N-D_9PU4^7%:^VJ&?'<_R
M;*YE4JVW,*69TE5Z"UOGY;?.=2?I;"/IPS7(]]C^]% ,<6X3S:RX?[N;FT$S
M"^ZVG FW?&98]<R@1[:.Z&B)Q5U7G+7"C9<X):KDQMLOW.HRW&*.9-3%G%A*
M3MRBH.M5&GQ5$%:5+V9Q$T^G+K&:Y1KPK>WZ81P(K =':&L$+&TXGN0CX Z.
M9Y3]+4QIIG25WL+F^2&8Y_.W:*D;2#"4^8G68FVYNEGIOC5PWL]=&/NF2%3-
MZDF[M-%'SJ,8OON?"'QD@'ZKV?JP %NWRABUL9 .D"_W5ERND)NVS(F5Y<1*
M\9:$8?!?I"W^ 2]# CM>;*FWS7]BJ(W\&D]@\?:<S^6C%3KAU0BT0XC6)?X"
MJ',#TW)&,$4@D=Q2@!?7ONO8C@AO83<_NK[]8\7>MIKIWK::1X8 \DT1C@7Z
M]C7,30S/@(PXU(UPY6Y^[S9:)XV3=F=K\"@+V9K]%9CMN4WJ]P3=VL<&[17:
M_-G=HHIT-_$$5C;#[S);9Z1[9^C-,[*03@.[90Q"!UUQQQP/S(!#/L8AS"L,
MY<FEF<CO"N6.9K=]4@AW=(MB#OH[ ?[/WO45XSD12 Y[\?'5')+9IR4LH!EA
ME?%T\M.<Z?2TN?="ZN[F,-V.!9D[DZGES?!XV$H!Z5BEY1J)S@B-L74OC($0
MGC$-!.:)#0TD*SX"-JOE^AY\3:2G\I"! /T1./<X'&:6?7'NX'-"Q+T/(?)X
M"$=E",,O?9\VQ'!>TCX+CPV<\?I).I[MQD-A1/#DV DC/T 5 R.$L1L14Z@+
M:/!Z,S/$U)?=)&CNB3>1?G U\9RS =J&,&=4?4XT,QZ<:&R@IH2)D+X.C3OA
MP<BN.\.IBRE^DUG#-("I.5,7'GSSQ_'-L?';V=GU6[FD=$JX.G@RQ%^H]R(A
MX=WW:+[$(6SR'4P7UDHA %"6/K[1?_!DE%E2^9B$7C"$8=R9.4]Z[*'A>/="
MH@0<'*@5YJ8!FQB.85#\TG5$C'0 8MH_X'6PJ\E0XN\8J2&'6+\UQ\9.3EFS
M5;9CIO91[2R\P@;@8P')L@=G;EN!S1 'V6/R<P<B$AF:9ES<N%'6O>6XB(1@
MUT.UU_K(R.Q.B<'@R8BV*?.N&?SC7KBF 7SKVW+(B8C&_M!W_3MB, '\9TVG
MP 5#[)&J)Y_X2> S]6-X;I)\IKDWI!7$(5[_',4!7I &(0)GJ^[\D!YAI' ,
MJPWT(9KX)&NBP'?QX.&G,MT*R6DI80;?F$APD!0^474$V^P'X<)Q1]D0A&-G
M2OR!@RU[=?ZU)CVW5,(&Y#B9^UZ+3W.YI%TB5?'WYU+UX*J Y>*[,7V:)"3#
M4RBJ,JV $G$#! ?QA3H)E)!MQ^3.LVC@?UN ^8.9M!? KNJ"C,T>@H&('E")
MJ8."_Y^;2R T;R/#CP.:ER)_'BWD ./"OXU%U$),T]_4C;H,]Z0C/)?KM/VT
M[L@I0\P62-]7G;IGK&E']YW>95^\\#46Q%@$@OG_R?P^)V#0OSV_5/PLX^H?
M")#8Z.IW'ZQ92.$$.>8XB2,\.,-HC*MK@+S3GO(VKBH3#6AVVJ:A__/VP]'/
M*[FLV3YN]?'7N:D>=WM+9JL^_I %]@8A>YBH98P#-%W^ =H?(".5_X93AOF@
M* Y^^=G:D)WFPA)JO?WCC@/,E'T>PP;)' ,Y&RN._+FX GTD'3192]]PABLM
MZC6&U=ET*KQA\NCWYL8C2VML<1\.Y. H\V ):)1Z3"+8R,>8/#XC1B,@CI;P
M(+DC&;)7GX1"2F\]; Z?.*A=1DA<52LB#E),.;!<4#8PY%B0.@BU4'YZAF>N
M2Q=HM4=@]0P(UFO-0!8,3)YP3\;ZL9RA1KQ3\J0IO8T*B30J('W22,>&:OZ(
MZW+)TD$$Y0>@00DN): KS-I(6?@4"+*4'%#1\M<#H4@,EA4 ?TG@(0%&4K";
M0'$-!"-G(E*5JSR<#U:8!,3VC]$VM_B F#J@I\""IKV%VP+?(GA:VE80("KZ
M4M%R"T,?7H [1:R Q!DH)X_.VYUEC,+LT%X61&-.BD+*RBZ45O%PXGA@EB(N
M GX22]@#8%S2[7 4>W8*H$(1W#LV/)U-*\8S(@\"G<109/@K&3YE7@W5LTP&
M1KNTY249C#@$S67XB-.I9ZD)I@BQ-6XVG"'9;RNA3R FED,8,AT\&7(LK"&!
M*1S/DB $#@WJ!'K)2(F.M"Q,,FGX@02V$V%AG@^"1&!<8"?X)1UQL",<V/$P
M/29A1"B9#" K]#UI%MT(L41/[M0G]=6'_7AS^C8',_8[);D9WY#SD,7 0)![
MJDT-(.(WQ987RF#(SOYX&3#:D52X2IC>0-[#8Q8F'I)P#-^\DQR(0AZX29Y)
M6+XT@JW,&2'[]U@?!3&9NOY,X!FS,#KA3/$9DJD^'"TX>'>!-8&328?90$M(
MG78E=-.WH3Y8(D]H&)J(D\BN8:JL,OXQ)?0RHBYG4QT;_^<_P.0#::NM7+4Z
M3R #0BD"DI?BC.#%:]6H5._:KI]*AZH8;JAFX%AZ?@1#@M0*87M<M-V&CBVE
M'RQG%$>8P6<]6.BL0*).K!G]1@$!)6&D34GG7^W4@Q^[0RG8<(6!(P <#*6!
MG'6L2#<'RX!"9 #!#FLX)-M?)67&80C_V*=TV%>7)#?QUF2!'4&1$* 6.8DW
M/C>)!@41$D^F<JRU"C"K\7*B82/\!&<)=#Q,3Q_ @9@[JZ_U^*1^=!I)GGS@
M'R?Y"KTY$J4 U@$!#',T<X=Y&@^ C5T"[3AEY<,<Q@$BAQ209R35/(3=,#),
M@;\OSM^Q \R-H;YS:XJ'Z)L( 7&!.-M"G*]: =[="J:$]#)N)XEO)-3GZ-V_
MSB1&P9,ES48S48WH=!?HST 9$4_]Q-E)XEJ**0>-53_X07$_15YZ)+FF&*"W
M-9!2PD3%J@:)R:8BMPZ8-;""(<8' M^RQV3>XJ'/R*C\H/C:+(:Y)<N"K&9/
M_5:#C7 J;++8*:06R>O'Y']*31=<T%RH;T$"?, G O+ F?)/A%[Z;3F'PP9!
MK%Q@3<Y72SJDU[WE2GH-Q8!L'FW9:9]U!H_="R5H5]AEFTTHK>24\V1D+,J,
M+R'U;!,KT#X"[@/9*CTT"/Z4[E^($*YVQ7@*=RU<<9TI[4(?>8LT2-^=-9WE
MVY9'IO-H.%4P^_=4[,NQ+4^ !'(S806A@0=_:'P"T(TY8_*;=M,T4 71?QNT
M99AS9LZ;'3HE&F7(/]=?5%-Y;ZNNH<VKOO7Y99TDOZS[1'Y9^^2XMR*A%NCM
M$B1YY<P;F9DWMC?S5ONXO7[FM"^OFWP^IW![DV_VGYH\(<&I]DR"8-HN9Z)H
M<OTP)-9\\P21OHKHT@.A(;[ +[;/H)M58VSUCA=O+!J*6F_-[2SBY;RZ81'O
MWO'B_?)D$;1=VUC'*]AVPW6TUZUCGG>U.^@1/PNEUUZ&CO!O\N\3,ZI4#3)H
M? 0<@@"*-&ZDE^@!V^4FKB09 E$_?8"WXV!4/=X(XP':.I$C 0]ZEI421@6,
M@UN!+>'&$)U6_E3E2>G[P#2U"3J'!;F%(V&//<SCD" :]$:$)#)1?_T0D?(I
M(QR$AT/?C961Z<.Z 4])I3V$@_= 2!.S"$RT]E, 9[G9'"KIODF 7S9-)9R%
MH+8E5( ?@YWJ"1??%,932B? *<Q9CY+*&>^"C+#,N]0R!<41@T@347NSCN>E
MB/3YSW([FL>D" [GT#-.+O-#?R S8#(S4P Z;]OB(J3S'S8^8PM3J"<+@C_'
M'D&D; P(,QCAM=/ H9Q6:?<@YG%SEI%ZFIQ[OG+(.U[B!<_,6@4-@.+ 1"/U
MQM4[H#,?+)"ZP)X10!\E[8%L8V1[0&P/VNQVPC F2(CY?(O. LX"VT*R)3F"
M-,%UN@J)D(23Z03<^7)XV([ ,U4:&0G="8H $2J?*MIN2; J$Q@C;S)\$8Z4
M-">F2X-EBLFE(P &CH.0MES'R8Z?3I.9<\!PHDQY^/2I1)DF)\ILD"BC7^3%
MKOLA)]CD=>*U>30I&<N;5+.8+_.,Y)K6T3JOZP5\ C.Z^RWP'Z*Q$G0E=;<^
MX_B6V=NJ26Y(FB?:A;VLRA#X.P;"C1R93&)Y!N+)5N.#T'2[DW13ZIV^;7XP
MWES\=OZ64J#%B%0]J,X;>214>NH;ZZU&2_!%'$@->R83J)JG[38Y7N%LH.$,
M%F/^H;?T[<0?XM0H&P0'^G<\F0*2 $B'87)]10EO*011/$U&!SNK9;SY]]7'
M&QIJ_\ L1YEFH_5F\/9-,R&/GBC8)H!C *HLISTESR.,'HB,#UOE70'^43<W
MT*8AY^R]$^8@6.;&!@6>*"Z-'[@(Q>\)R2<O>D/Q."<T55R?_IGX=3&:9<UO
M:R#N5/J/[V4NNX"9ZA+(2W*[<'I#7PT$_[0,>"(DKV>8#BF'H]RP-(/\XM$>
M6]Z=H'U5H<'E9" <]QQ2R'2 9"^43:$"DU:20V##$1$R? _FTA2-BR0E$)A)
MNH'(72TOW:@T.O*DSTTO&X50KYGB S!P3O,MN33Z[,,.^NB=9BMU#A:8:Q"C
M93639I16<-EE8EI' -3T;1F*36*;H7P<5HZ;FB>,'&TE932*GPA+1X$?QB*Y
M? 4[0Z\% P%CQNEFDB$9T;M!1HR$#.KC90[E:Q^2/8 N#&4W^\$BGVM7G*F$
MWPJI9]*V6T-<UA+&2F::33Y</%-/_KZ&F05S/HPE]]KD)3$5R)=^$!4;3"^/
M)+]?:G!*!L-Q1HZ;37_,"#!DIT2X $:8.)3K 6KIXOPMW2[1EU.26"2PLOU#
MW3I)1)OD.ID/Z:,LQYCD7>P,R86@^%,%^IPHF]F7S K(ZY&X4]RD@E;J=7-#
M9T;4;\FD2"31-CQ]\CX3\:#RXJ1J0+V*@IW N,BWY.[ X[-:&Z$=CJN  XHW
M\.&4A>-EB4J)QVK?>GAO#A*@$":?3*P?BAJ!$TKWP]P!6,[ R!J6)U-&\UY
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MR.*\>EW_'E5#+QECDZ:G:R3EF$DU_P?N8.,N-<44Z285$Q\81A7I<AK..2_
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M3,?.SL[<0*AF2*'CCQ^\X!ZF*"8D1LA,:)[9+RT$7[VUH2$>\!+=Q\,:/TW
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M<"G]_.F<J"3>\(#E4@$27!4N?N6.UP!BVP.%7;#D:*)3=/WQ'AS4!.Z.2$0
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MBFR)[ T4X#'H+MA$V:45%VU?W/M-,8D$O725;#[H#MB-E!!/%Z8R%82!3?)
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MH17RC $1JLRFQ2P*#D68RRA3H@-,2"KCUO[3]^/_]*+,]J,\:[#P^!TBVM9
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M:@!!55N-O!)XZJQUNA9Y:@4;YQ##L.0K5Z>_=!M/6#P.1$>SC%?"J%*VDK3
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M8M@1J W;FN(9&28L?T+E7->3>2OC9:&.3K=NL8YS8+Q*-WEF>:B C9XQXEO
M0L4? 7'$Z17A[Y;O0]+6J*+HB$$ST_."I\AX1RHZ2"+X/GK_RYSXK(A,=-\<
M(.-#[.!F@D^2VZP\S+#1BCT=[M2(7<C-76JZ#D]?,LFE";YBI,$2(_C%&<5+
M7]"HITN$?=#MI:H+&N<\BVW4Y_]:<"J&,ZYJA(5YJ(@2RXHP?@=_9N&4C_+'
M?)0W"E++C<9:4_?1.?OQ"K3@%<4@Z?<7'CAG1?9R+*Z<I&N>]L\:VR9/:Z@"
M--0W&7L N_[BO]\-&0=$>RT FR]<%JBHAT(J9)AE6NE=.6IIA5:Z!8YYO,!L
M.R=_[W14!,2'SS8JJUYW,=3P9BEZ7Y&VTE;7+JPNR_DCB>)4PZWH\[G?ZJQ2
M;?9OR_6_!%%T11%AYESYEU;HP\\.5;EMT&GM07/[%&ME58"RNEBJDHQ1&$QD
MA-7*PL,'J:H"($O1>BHCNPH3 $178O'[H[%VT6;FQ-Q9#W:-55!+7-L#6695
MQZ_V*&H<QUV>*U"/XWO_([D-.9;W AA(.Q+UT%%I)'=Y5L?^QSEJ%[;-I__L
MG4+:+FS;,0=EA#ATV';O%)@.VS8I;+OGRFV#3NMV=-CVH)75NK#M\P7S/$OD
MY*O!V^7)B(/^JKJ/N;=^R!X:MGK39U'LOZ3L]#!T8;5Q8>3F%L'AYNG%'_\/
MDU4M]<'YQ1;LK'9U7%C'A0]NF<V+"]=;_ \WNMF,<Z51S63TD=$L8+5#6:<&
MD-, <AI KK'0 B(4L ),P,UA"3R-F9^'!K!G^).0P:YXA!]@3K[X/CO?C7N&
M* ,1)N>CB+>,KVD)/OZ2Q_/@.2O>@(0R[_1M,BB66"CMLQ^]-K]_+<:I?!/@
M"6A$/TC4PN:G(/$<H!C5MS[XP%R@*B__5^(TAF/%!/!WRZ:Q<HN/ZWII^7F&
MAU!P&?J5_XBH!B\O0R^&,2\!"!ALJ$$/1J7 ZVFE7P2BUN(FB@/<09;G!;:%
M0"$"$\16P$U2X$R*@8*62UCN'L=&[7?/"# $8Z2HO<+\TV(KID@FJV"&-F(2
M[FV5/IXOMA6&,T)1F8"_'^-A,0U"#CYC! E6;Z&#B' NEF<A;FDT9HQC0 &=
M;?F0S5QR4TU1],7Y9F8_$:>+4A<&7X4)#,R>I\R/$)4&<6Z>"6=%19D1O ^9
M9R'.C#>#*< 4C2GP*W#H?@\> :4:S^;A(XJA:XZ+P^VY*( ,"<=P@?B+L7QN
MP JCX\7,7#&>&\-FM)<@-/!])7$P,.?#REOW2SS>%T_J.O"/TQB%8 J%*HS%
M6X<E/"MR^YVNY-OOA+ $8J7(7,SLL>_^E;"H),J QCD.YRAS3Y2!G1/8+BE&
MPE["">$&G0:(9TG)@A.P!$(R";P@B@@7R9.:%/?L0Q X3W VF@82;^3Z.&'/
M?:1='5O^@TL[46Y1V)%>X#^(7_"/Y4XZ('4(<L X+A5+*<A!K382$7[F)X0'
MA6I1X0\^CF8Y>\1"6#>TDTD4HQH%N;*!^S@VG*$Q-PC!DDQ?/$'=@><D'XTY
M+0,FF%K[<XA3>/(AY[GVQM'0^LIP>"RAQU,T%@['92K 6X35;(5_PG%J6U/2
M&W^G/__B/L!23#QHGQB2)3(H3">L58GN%27VF,#%W(C4/KS<MJ*Q,4*L%A.C
M:/A]R&#;P&&=QC;YK6<V 1,&@,T1 ST#3B+^KZU(L 6W..@:/CZ'L)81;,GJ
MUAPN^[TQP$X ECWA?[9P *]2Z;\8PR*V]"H*\^.*G&&N3J=,3W/1]51TB)#K
M-4I=:G+8+ N*G#S5$#U,)_4[N5RC\QFM]3Y3T*5-=E7-<,>70H2MQWL^**CQ
MKH8:WP)J?#V6^$[@P]<#W7T!8YY%-Z,O#':^TJGX3:AUPN<&1^T\7HH^?M;M
M%R;HK]Q5+W.TJMF#IRV#\V.)J[,#)V=766X">=5C#^"XH/_"X]8RJDSH?>#T
MI%&&M"0J@F<0B388C5P;[3Q;!KWQ4&)_)2['D9Z&< "'L!0XGAV&MF#H!@F8
MUU,*>,*!1^. ]78#A^C\I\;8>L1@[@0FB9^BL.,9#,:\@68FV(I3BD\Q7SDT
M32-"JQ$T [=HQ7)@=+J5QP> J4Q$V\6;T#-8-AB?&%]L&JP"$SH@(QDGA 2T
M_ QV%@/ZKH-3Y(;O0V*%%NQK%IFYW\2@(@B9UPX>&9!5F CI3[@=+6Q\/O6E
M5*+(' <7SJBMN)R"-S-UI98#0[LP!>E"(!<C@;D;,;SHIW^HD. 9C[E3BE8/
MEX>4B#@'=R)7<+ 6^1<N+=+W= 2?U*LAI-3B)07LLPEV'Y*&I062%88(=LS!
MGLG2!\<Q?[$$#X.(,Q(1[J9:XHWL&7@<"56769Q3Y+'/7TF'&HI)@K_P^3;U
M>,R1$EQ17-)]0D)IKEA3?N#@'HY0+EX4 OQ3#J' 8;ODZ:7N)7U/,-9SY)LC
M'!K7'-]9(6'J&^)(<B)*36?NU0$Z_/E5@2OLV0G?-=P#Y>ZJS1-^8$/>!V$8
M/.$W(04AF _[D%"FIU//M<D<$<%RBIWGD%53!IA 8@], .[@3O!)X"B-2)>!
MEH/[5[*77_GE!<J+@E2GH>))ID!!C#;EUTC-$3).H8CXJ&]2>> :=+5V1,8+
M'<245= ])A="F&T4X!QG*8@WR5\\#J)L1 J8W*,TLM!V(XR5'*ABN(+][#BN
MW!0HL@;>0YDI^80WN7 0AHQN7.C\)$&3;#;3J([K@S5)VAB9CJH$(TO (@./
MSYB1II:[*QU'.4+DY0"PT!<L=-B4$3- R' TG[S;9VHP!E)ATG84-P3*#;>R
M][GZ"%3!=$GH\ ;.2:TPBJ72\+2U^8X$8G2ZXBX12#^.R(7&O2.#5*GW+/9]
M[A;$3&_4Q0RE+HL8OZ,XIK?(LPM^B]\OD-Z-5#5#T3H\.%%O'B-?16!XB4HY
M6#G'JRL'3P-;")D[4K3P_,&(F(2H"</@D:42XKD35[0ID!RDM@7J,90ITI"4
MIV4 7_QH!(Q O>O&Z!^&6=L$KI"6:2WXN=1.!\NT%^/NDR_-([B!$6$,'3:N
M#_-:L):S,#8JMTOPCF>/<"@P8PS'W5]@'\=XX>AC"@S&ZS*3%=@.#*6+8OR6
M1A>H2<+SH'?)V#6<^HDG;D=)F=BA./L6C&9N]P#?DTPBX5\;\C=NY"BDMK[C
M&#>CWR)&@<OU*;U?K6=WDDQX8D84QM_1K"NX'4!W8R[&<LOMI0M/LU2N U^D
M4NQ^\;U6=]/BUR'82SN7;FCF+3=^/,&FM/CUC;@W5WTPQ7*G_*(LGBNNPN<5
MR[)8$94\W=ICYB0>NQGEJ<XOA<]]1RE=>G.G@[>HL!=<ME=[?9[235BZY]F)
MH]!N;7<"W:- R8P:O C^?T<]"DY/?UJ>8Y^&LU>W'L@]M\W?)8W]EK*AX9NJ
M@F5Y@Q"@3(9;?9+B%U?OK!]H<3@0"1 "_]>C[M&FH5^?E[Z0U)[+2U?3X]*;
M@K>DJK\L%+YP,/WS/OSY7ZC \XJI(!9H7NZ"E^T2>=F(HL,&0P_4\2*+FS:[
M00FHI!1NG]ZB*5W$6S1V2KVQ4V[F0BW6@HHZ)&S,UX>,"@0TZIF]WF)TI')
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MWB,3K (RC*-#QMA*I0:;L(.H13%AZ(":LSS"=E)J:59!/"%06PK/A7AKS(]
M=-<#HN;@>@@?5=D6%HPX 8D"Z;4\!1AH^1P)<7'D>DR=1LA!FJ2R0A&&@6\1
MXHL#OCU:(:&Q<8#-/Y+0C1Q7)!VAJ. /"'@*?Y#@4S !!;J-PX%)]$CQH_QO
M!%Q6A(AS/L]D@D>P$(ZFB#%A6:,D(++XH'Q*2Q;S "(/;_-F8N2%@0?*P *3
M,C?Z]2*.*-(B!6-<"KX(A(KPYRDT7HSH>TKZ%>DG ABE^1  :89GYH[H'4]C
M^(J#ZB&6VD9;<AV2UW<NE-\L!&L-+3_BBB7ZY$8V+"H)WP;&98BI,.<\GK,
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M+)YD *NP##_!X -UY00YR!D9H,/AS/?<D<O$\0HVE; )L]6D<YV;*IC&/EH
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MQ^1^358A0WCNG^#VC8. TLMYS;:?OD\B0TP"Q"N +Q)_9#T&(>5TYKF%( 9
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M;M!*NB"^;7SN.Y>2-!6:LV=F;Z!#N+MA:!E:^=0<G#4W!U:KVR(2L#C G/\
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M[P0=OG$R5%MUCO4W^Y>Q6&,FEE)X;IYU2RZBTM9@[95IF#!'M0;KH4]WA?_
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MXX(IIU[U]<2[+'.R?6GDK*%KXX+94U5K281]:;?+<+P8O\O!.B1.Y)C&[W)
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MQ?VAU1\ZP1.($R_FI/&CW!$ MN[&+"(G,)>P!J/@KA^'8!-9J@3@G;F 5U]
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M30,P,\\9A0#&_YI. 3IDX&\ +/*"P.UJ -J^#%A67MQNEMPXX#B8?WE76])
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M,5KO!G=>/\P[-\KK0<GP$SFF45X-1ACG[8FHI0P^KIA"^O>#UTN,!_8TK_M
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M*1?\Q/<1AC'^FIR%MN7+=K0>2U-Z$C\F'A]FH(9_<>^'Q9,>]US/B?#IU:2
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MMY0LP@\\73)Y@< !E).XWX]PI2\H=)3(ZMYWKQ6ZO*-PFO4-V$4$'.A+&$4
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M&*7;DO)&VA4%NJ.08D*1C4.,].(SC%J2JA/#26)1SB<_X5*S5\OFU!,/9<O
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MQ$06N.BQ><)]]!A<*;H91&<S^2Z9'"FN3U1<J CZ7\#_1'43Y6#@#O#@\$^
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MU#ID!:[)%Y:L,Y]=-)>Q"V5QB7^>:;&9NFWA_[V;?D0%=C1+3GXC?3<\] %
M2_G0QJZ=A8B,GI-7H8^YLCU>6<-<V:%=F:&R@[NR\JAL W$K7(-SY:W5<_I_
M/E'+(/TNFO6V;35;E_"?3N?=,JD,0"Q2AI4#_8PR'[84(IFK#.?B_O3&%16W
MW7C=O^6=Z!NI8.L2<U&KIS?_^OMF"^CT1@D8,L]BZ9R$>3&YFQ^RQ*&+S: X
M<Q^='RM%];]+V'XA79='\;W(J[V+'D00HOO#X\OBF*TTCME:%L>\G(UC;GH7
MV[)GJX((5-C<?+_-71X;B$JGE<*HYXYIY>IR-JO!(,(N::4\U<$H!5NM<:V
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M$OI%6?KX$NZ.;.M&H)XP078,0:Y"D&@T[(PD.\W9:30'09)&DNZ.<,\-X:Y
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MR9W[X@%K<XKB3R4AM+H%\<;]MQMFN]<"TA,[Y QFSJV0/:&Q<Q^32"3N,RO
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M)H^3\4J!MW72D=OM4OLQ&#Q8%"^H$AXTMI_<:K+2#X2KHV=T" J!GI->A8S
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M<1AR_5N).S+92(RJIRL!.8VV@[AM>A.@3]B3Y2"I.$?-*:)7"T'Z,F0R!+F
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M^08ALH7'3$<]L@Y]#RX^0U"NK YH'(' ]\8($G8O0 TA/B?5AXWE;_'&Z-G
MOV[PB0PF1N?-T8BT_^SUKG.0M$4 QPQ(-1+WJ:^"-!(\YN)LO[#7Q<%?M5VZ
M%_ )[-;]/Z/P*7F0%%C?$9^B#XX.3SJ'6Z8/5BL(U'Y:O*&:IUM18(8!$#@T
M4.6-0I'LGDFF#$D%&IJ' LX!AG9VG-T*R-#>(*%B2@()]+(NSO]*1V,X(U%B
M7:51YKW>X$?I6!=C=@X..[D"S/^Z^G1CEE[:"@1V1,6S/S$C\>@0NA\51\J:
M4/%+ \*2K?GH1-C*"R*$II_ BG/]@XSC&@FS?Q"S.I2XD?D4IHTGC*LI*EU)
M0H]P*F0IJBT[NA/+]T8>1[!M^O>=,%[%U2FBB3D>=(ZJ3,L!OHBE!BPV2.9V
M[^C@2&^>$]TYL!E[5[]\,>$-Y"I6:O7$WOXT$KD(.;9E1U1DR^6:Z(O@BXL@
M=A2:(_HR'*6!]V2RLQ27"-I:!=DR&)7?L*H63VQ39:!H$.AWLKL>MM^+PTAB
M-U,C<>4K4;ZH#FX8SL4]?AR@2^4,'K "=>Q,^,F%7G Y \E=/RS%NBJ2N,G9
M+@ ('W1V[G9W#K504"=7;FW<<%)HQYO/0@#+"!'%'78;(82U+6,<@5C/6F&
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MLGCJF@V1_-3?:<*A#H5#)A#;7#31,-9=<'G8U(I)%#4#)8O^BP'QIB9F<?M
MQ9!'?+0Y[;;F$?6C=<O7JWH*PL:20;YJ%&2%GL6%6G*H)/Z<[&FV6Q$G/0+?
M1,T)Y]!'Y%(+!#T/1XUS1"Q&NW8XU/>_1S+0I,E -L!2,@K53H+@53&(WYP1
MC+&<.R%P3;(4!=;1NSE;?%QRX3<\.CW8.SS8N_GPP<Z),8.I])@_KD\ SA8R
M+"M9&5DV"HL(X,H#*A^-3+(:3Y'F )XI)J'1?@6B"@0D^AB\![*U!1.=-ADJ
MC4>1C ?>GAGOOAGC/R(Q",%'_#?<F9TE.LD&R1@IT!N-A.MQB[%#D0FPPP;8
M6$4Q!RJ.YX#%0#;H91"#!G<7J8:^*H](R(L8_JUR00-JC")0PG(HH!\,T('E
MIFT0KO(?BFO4VV3]T@VO0Q53Y.!RH1=0)$***(0^HUE\\2,E',^%O9=<H7K]
MB+I 9_)RL8!)8#>P >A65=71HA]M;5W'45NTL3S<HA:V:"N*$-KZCLVI[]CX
MNHKY8(NXN&2.2I3.S)4H' A9FCFW<9IL!K2'1M<UL\]UTL&<92.&LFY!&G)W
MCD_>4OR X"=<9(+]KIZ?79/-$TI0"?PVI1][XWBY.1-P"[0!5S.:7) #07IN
M+1F __@_?R?Z@FSU_3':Q,$]A3OPWW+Y#/=@VBE$!JD;[VB: G]"  Y!0@;&
M1TMJVI/3XFF9CYGY 7MP4]\9Q_"Q^DM_E=LF7E-4L;79MV[!&'C_?IY71&,K
M<:MO!/=YQ+C"P/&5UF*V>^']M^?'\)^H8@MFEY2&E>M1;@%,KL?0<V&[G<'/
M^PA\/W?/L&$[!T<@J;JG\)_CX]WB#A=W PYQE?&F)/L>&=]+MMWR]B0]$>7(
MGK+2931[;>K@GQ%(<0UWEK<DBNQ1P^U*)"K!..//K"KW^]T__O*R&WPTC$BR
MZS^R)5"/6)1#5XNQY7,@KH;?=+0!_!%Z ?CS.I*#NRBTO!68/)WN06VX^J5;
M96SX\B1!>\9??,8_BSC^;:5'^UF+8YW]RA[2JL@YCT]WXXZ/4A"46ALH\%.9
M15,(FQN@.1=QERKUN=.0."XX-XI4/46IVW #($ASVA)+Z_[SW=X4M?G!/CWL
MVMWNT<*5YFZK-;?CV"M;4,(.Y@Y_4XBDE00H"13USI!XVW7VX> ?=#[8'P[*
M&*#;<?A?J66P>8;UM9^VAO6K,ZRW[F!LGN[L#0:1AODO5);D*WOHLU>L,ALT
MIB;2U9!+&Z4=P85YNK8XJRLU_Z["T=[0"-2I??RA:W>ZY<&GRP] 228N9P/6
M*?N>R;GO:JM(:L6$3)IP!<?X%Y;G>2X9 P>VA?^W.XO@6$"V]TVM<36!T=;*
MV\A2C1=DSZO:!M:B#%]R,.;;I+\\:[6S:]^5+:0YQU1PCM4PC!X5M_:2)/+N
M4LK-WX;7#J;5-WI"!JAR^_UQ74YI4?NYRMVKD>:M43%-X79!X>(@#91CK]:J
MV)!%ELP*^ _*C"I,P!EQ.L@/4=U%%*KKQ7$XP(8!]P\O>:B<-M8V,6]BOZ+N
M$3OC<+7>QZSAJJZK;(/:%?/MQJ.QC_@4U2!/B.&]%5U4"[]A]TBU9>T=5NP:
M]IY@_]H-]JU9V>P ZU/JX_#%P+H-Q[#_QSVE,4X[AQVE.-;+Q1<*1@1V5_&G
MN;A]LQ<R)A '<(KB1(' $_8[MFU%X5#$<39B+P>H-A3"F$%ECD_*EZMF0YNX
M<-57^9^&TU1Z0Q<X=I!@_Y5AYZF;>"K)1.B_JHN0>N8<]A/R?6^>OD:5TD;4
M[!AS2V@Z4+#'JENM\#+8%EIXB($C;3S(B6O18B*AT%Y<L[\LWYROJ1OF7X#[
MN:C6-VP<@W:+\%;\<54.:;,LXL.N?7+2L3O')^6>8+DW-&]&-D'6">(=R<WX
M]Y0I<4:+\W=LM7U"I+_@_E*48+8VBU)']DE=\S2%BN,'1BB4ZR$L(P(9LAO)
M<2X+\W*VS-<PD%7*&TV24_N@QIG"@^S*E>7)0A(,3^:,/'*%_=HYXFPT20[M
M@\.:XP1<PAA\><&RNV_U8NIOMPM]QE)$-A$J1YAO2HQ>#0MN^U:$VQNRUT2[
M@CC.*PZ43VK-6M'4<YD*;_2R(5NW84\WVUX[GML/U"!+9,,^04QL9&U (U%/
MNAV[>UQ.8,Q$T6(+>1T>@FD+S(P(H3#9ZL=.U_<<-W6M] .<AW;K_-I@")M.
M9]L&DZW6F.8]M& 3-PODT;03)>8H6Z8>OW!"+\Q Q>CBO3\ZL"O:P-9&RQSY
MU/PH^:)J/LR^>O,\+*2$;5"B02MW6'*=O8V$ ?H]2/17.7L\&V%I@KC>B>0)
ML2R:(1SA67=J6%D#C*2"D-'/E%![]'L1B*&G'!38*.\1+R 0/?C:QZ82]:P!
M+! NI3( O.D3(T0K^F3@#/XD(Y9C\<!.PH3!]D >3TN/0U07D"S@H[F,&\:S
M,@D.T/=^(M8%N#0!0R>3;^/3 %K'(A"*>M+3W%J>AX/HBCYPMKM.P ]-(C\.
MT3F+T#>+)99A-G$'EF:. \:A-^9!TE AY#ZBEXFMU> PQZ(9\IBGY(!,!K=5
ML%K+N!>AW.(' C*"RT;"0;Q1'EB,1< Q,V[E?<W;%'], )6X)6HP*0U7(GA*
MS8?,!?PY@2'A]9$ Y@SVK4OB6L1QE#P:R^LS,MC%1XQP>/?=$B;!(DON,4ON
M(4ON 7-)=N*7BN')#LVU2L<T,\@9*20D'%CE_"(=G\*"&,G=.#;($QI8W40E
M0I1-36!;._4#!=Z$NR]BGE(.;KSC)P3<;7 4<1!<Y8TD7(MM8LK2N=;@T_O6
M)T+LJYDT*_0QMA6\N 1#RLV\93@IGF650S_5C)W;,86@RI-Z,F[RIHV[-<?(
MWG@\\3I31D\\FEQB0_&B+L5=E((YS.&Q8[-1.EL;_1)(A4:DR"0G7DKO3</
M&0Y*S<:FJ;,!8K<R>+>1&C:X8)W29P,0)PV4(V#/*"415L6^9G N#0R)9R@K
MLLTSR:B"6&H4^A/^I]G/^6[<&2R!3_*^&^1*[\5B@.[+$SB]L0AP5D'9:6D@
M$-#T623(W 6U([T ?#_>JAYOW;:12:%;*\YC"[62^YJ!1@MC#V5,RI^0J>$\
M.9%0P]\89U&:OCC( $X7R4?&*I911)!RIHA4 ^)L?E-8.($C.RC $>0?;B/#
MWFB>T3R\4,GNXJME*,V.&EX(?T\?2-9"5VTLX,>+1I(=MR/)VI%D+615"UFU
M 2/)RAA/<P!"=;=\VMAR-VM6K"R*N"Y_)-H96#1@?[RDD*H?^V"BJ;"GCC8&
M-/U*3I:7%ICA>>7B)KF )/B0?FE<LW(W^775(Z7SEYLXOX]Z(8;?TF/M_(/4
M".<2>-8,?FS#:*99P*DNG"B 9<77(J*VD[:V:Q,#^5]%8GW&D"IL4P&+?I/B
M^NO2-$ ="CB/,2N<J[AGGV8T3B4P,+R@1].Z _4;.1:>=U^X>\ZCB'"&.SB'
M=Y1D+M7P(S@T3D>CZH1LV)'"-2[.\<.#;;A5^5D\]&B9IV-4^!G2?6H&WEBG
M^K"=0([.0+_-N;_'R>B,=3XE<PO'T?5\FE.>C:"\^,6Q.81$.B/R.9P0+XH+
M+F!?ZE@ F<8T@?Y?^-*?)M4W6/RH@,-C^\.440$:[]H?T$ DF9S ER,]0&H"
M&9NNQX%-*FBIAT45^<CA<4AJZ!<%EBG:..#( V>893*'AR7I-+*'4=G8G!:@
M;_M$(8@[Y+#$VU/D>[,SO6[+P)5*@<=56XH9MX$<S\:;&S3(K1VL_$'LPRBV
M8:<'8IQD7* B4[NO#"GS9O @W!1KEDI'%HG7"]QS)MVKQM!\?[+Q&)HG\(K/
M0\8T?S7US\7?]@7=F*<OP0Q0C4"28[)#MW],QV[>MKWF^Y3N!AP >Q[\Y[N3
M=]/N+%F$_VGVE69=+_E+5'3.8#WYC;21J1\WUYU7&?A:;H/792BC\B"9^8]K
MLM?X;PR,\U_%;-_?[Z*__8/2>#NH>*E-<Q=L/*H8IR^K@_[/:X.;@3W>.@=W
MWBH'FWW%2^.N=NN6O'6?-E$PM$ #FX&:\ZG912#;OX6;VMR'M%1N0;U>,:@7
M.>U. O*_E4$;^Y"6RILK@UZI(76\>9)*FDT; *6TA'$6-2B\*HH*B^=J3,P8
M]AX=SV=@(6-N.0_KC<G>W*R9SHM'\^UVC^WNZ7)QO%NV6AM;?5H36QV>'MH'
MQZ?K0(ANX:<V#9GI32QRWCAARQ&O?9'M *@M\=S/11!21UGKNV_R0UHJM[[[
MF_?=RTD059MIJ=K,<B'F!CCZJQT@H+RR/R1M>DR:KU2U"HX/4>@J(] 6N/HO
M*[5\%IED.5F)6J^94!_LT^/W]N%1M\)U7=YXAO8\KO$\/B]&\@;/XSH(=6QW
M.X?V4>?#2L]CZZYM>1W(!E@\JX]!5Y:%;[:R_GYS_@,V[0>];X.,F"WJ/!]Y
MI#A]2P0ZV#]8@6'SUG(_:SUWS\[PO)5SMPD$6OVYFV4"QLQHIV=A@'7!# __
MS8M_GA%F(?[5MD!O1 MT;H<(9X51)7&+VA[H?UQJ9 "PQH&9&)^ H*/&(>+1
M> 2OJ:$.C";E)"0P/DU<@K*2F)T14E>-6"!H1D)HEU"!#+XXS#W:2U(&^R.T
M.]M";#]<LPWDFE GHVR"OA0N^'Z^=2X(C2J,)E8_B-.(4 S/0AGJJT?!UT<7
M7NCRO']&/P:/LJHC>;/ S3LU:._5O>.(4A=YV+7KD@N @4_LY_5BO0V$H>D$
M0"_J!K\3OB<>)4ZH >XE[Q;&#)-G0HCA/M-]J>57WG=_"NY7DT"]=+R(1I1>
M#35K]C/.9)B)C<*2/GS?RM\&^8L;:M&.XIG,Q(VQJ9LDAG,0TV,>(X3(J3SY
MYK2S?D!I@Z!?,OS;6FAI>&4%+2UEJP&#C-B\PP@.X%,8_22<0H;4)71@? Y/
M7D8YD4<1=@5(;XU&;5R*H/0$30#R6]^9P&?9!(/7X1\C0+7QA)AQ ST:R#,0
MZE4]?AQ]QC?5: *1& @&CT:$YH"AF!%#9^QX/&L'H6:' N&;%4+UI X@1T\!
M(@3$$'$:W4<0<" :PS1&5ODI$HF"3/44"!6=#9K1^-GRPK&#UBG<C^9-\2--
ML&*<#\12VZ#!@P>J*QH\3'(XU?!,N8W6O0A0\^70K@F4&1<&"QXYO[P1<#P]
M+F6 A_ N%M$C=9Y[P3B5B TCV+SBE6E0OI9 LJM88M^Z*ETL00P893J.4YY-
M*HV)*L+P5N+C89&XQ0H216]EMF_XUHA@X(*"\L,QHK(H]&!Y:Z"I \N5J,@$
M61F':30@K Q7(*J7Q(EF/'6"](8',OWVK>\5ZS>7Q-=IC@F?@MPJ*U]'H6,4
M?OMGZMY+I.R[,%TRQ132>HEN-+8*(4F]@,T.@M56!9H:8,2+!ND( ^H#T3 2
MHL7RW&HLSY,6J',*4*=Z4)#Z_L><+<)E)$TXGAF_M9B>FPL\V6)Z;@ZFY\8#
M$LV/.MJ= RT3?<JE.3\;IYQN"?2*)YMK\/02IF5^PB8:_1A2LK-Y+/EY6K:&
M7R]^/@;3T(MC#!P%82(J9IFJF0!H>TULMJ30'8"GDUT)?ST0R.<CF$_H?8SA
MGF![(W*>8="[J1K7Z6'R%>S-/:#+R H<1%![LP!HG]$494(?5A"_5SU8B*:=
MI8%#$^-P% N^CG#9-8SATEC.W4"/[%$H\UG\&CPXP3V:KGVVZ>4 56.?3,^,
M,/6+?H MPUMQX:%>X6ER&!7N&^8FU'0@PRSW3!OZ[>Y[IV+?9]X>5^ IXMDW
M,9YKN1M(>PP*$#XO..<\W[:>F6)P@7TGXJ$)/@D?O#%*#KA"^+A_<@@O0_JJ
MO^O90T]YP"DP_-B))\!E&Z01!U:=$HO1D ;,R<%;2_:BV\#B6UY!9*R7\$I%
M4"/;+=@HDMFTX]K[9GF?3>A)Q. A\/X7QVM0. 18*$%+/\*)0Z:S+WYY:E*R
M=LFG'?X*M[DI.@Z$SL9R7T=A$.*8(R,RWL(P;V(,_!M))7.B^@T6*.(XNTV*
M??<#JY?>@WJ50OH H]V4<M-1^\HE? KA?W30^;)W\TE%G'DNC5O]L^]C&I.>
M!:N_ZY\M?)X:KF7OX,26M#T7=TF%6,&/63> $_\HHE@-FJ,IR-:5#,_MW*1W
M">4#%OZ>1^\/]CH'N_(U\='G@E";O4>I3WX7+NS<?<7;8^"!Y[*#77*1CSA>
M/<%'/$1VB6]_>GB\=Z3?WMC8I6VHXIAL-AYH];'O#2?%08=J&MRP*N&-"8KE
MO:1\.>%[U$LG4R@2P]4:A:[PI6D@X_I6+,#UR!" :586O?,@SY>45#<^&PIR
M+6)V4_B+Q&/=EZ7;\)>23%D^1W&9%0_"L9#0P7A//2%PS!0D.RE4(XGS0P*I
M L!D0YV?R,7-^;><  E ;,52)O!L0K!^HM!-T:3+1GP:<P19Q9J+<_'<TN31
M2 B-L5XJ:"!<=Q"BOSB/3600J,S=Z:^Z7";&XPN*/G!CQ<BX)[*&5\@J,0/'
M6>V)S;C;KDH#&$,F:*!=S!D>;ZC()7!H9O(0RJR9[]<QR4I.A!=+2'OD.V4W
MJ>PK<--_.4&&J<H J4>\;0\:4YQRM.SX6</4EPD\%UD;YYX!*\5C^02:76NS
M@ >B@KWMN"$S.8[:!KL.TR,"Q"LQ>?4+%,:RT1U0PZU ?FA25;V6](4HTUB]
M?+GQF  SAG#B8C09X+L5+,3U7*HI>7#@K9QLX)P:3=PPAE@QB9Q]26*N<M!F
M#G8W8=C=VCE[;\Z]^I(5_;BAB.7H8JK^D:(2#R 9/=JC9E/.MN[2A*Z?8'1%
ML61N"JP2YW#64/+HJ87RK-@RC5G<?C7=8IY1K',/&*SRKD)PSWZ3@S/8"U)C
M,UI':G/R!U9WW^I_[=]B\D#F:*XN+R^^];_^L\*)6E/I4 3:(U;%III1B[I-
M,W7=M!:<"NP*++E!_:_E?IAWT#XH^765__RP8PX;5IH*Q]D W='82>J?7#OX
MA0X)UB_&?1($YU02PF#HW'<'%*2OBF-M#TY_P!GAPY+]_=SZ]?[U5:YL/;V+
M/=<#\7_CX "(.9KMYBB\[&+=967M)5.<Z&(:8YM-PRNP^'J^'R;(G.S5KIRF
M,Y%4EGP)&LA$D81Q&L6IP^8M%2]A\/8I ALERD:'&P-N\"98$[SGJ/5:TM9!
M7Q#L1:HTGE(JS'O#>W:-P6;5L%%1+OSBW9FYWZ(S^SBA@_VJ24+H3^ C;%E9
M1LK[/J)VP2C$@NMXACKJ:WDICD]"$J%?<A4QYW#(89F\O+CBZNY!+4?N6Q?.
MX(%HI8K:XRF2,M_ +5E'1'B+C1"//_C.<DA6;/Y&-@#)KZZB;V@/O.SXE\9F
MAX$H\Z,YJ: XUX@&C"_:+?D[SA=0=\1WW/-^[3UX+A@*O_'_4#K^X.B]?&.\
M_A][R8,7N=+,P!++ /6^*\2(L@QR[I4.?TD-*\FI E:2I?)?<@#"ES$91D7,
MS6B;TM%0M7&:$?6XLC,0A<+]-,$7R%^[#''V>CDRD:/.6==PB?(,;2=5:[F0
M=R'EHK^,Y;?QX=9OS"*4V.'^<8T2>X*C(M0 M%@(ZVN8".O];GVY:JT;>,TS
M$J_5B,1U>(!3>TX.NA]:-['.33S:MZZ_]?_5@S^O/_?.J,9L,QS$-5'EQANE
M?N($V,G@3SC\20D(/XRER]<P.92=R)LQF#W86R$UD3OGN- Y55-1 "Y%_A6/
M^HS"L/"K%>FKLCP\M3O=KMWMEMNG+?F.EGY)96#,X*-N\HX]UV_=G$VKG>I:
MOV6K\H&=J28,*<A*,M78+:_UV"["FJDU9FHYP=IYCB>N-V6I;N=F;,KSSN1A
MQ^[6=%:KVF.MZ;3?5KM)GCY[Y UNN_>V 1N[5*>N.8'4MK!MCAD[K87M?=O"
M-J6%K;%'K>U+VU2OMNU+VYR^M!D;N"A 4Z<^-JB+K?R*KT195,1JMS!"NP'&
MUW(#M[0[7(.F,XY4TX5&=X-+3-ZPX[I<R)E0&6E2<8NZ*@?&1'C SAQIX=\"
M872%/LC48:YV0A=)J2(*8*=/6' GXA@ONL.Z7N0D#7\B<A]SBM^66";%MXP=
MULK3%NWY/KYV*G&8AJE$E\#DTT@7\-%=>+V<?+1V-'I76*P2I30FU5 .R#;P
MG:==C5HQ[5W$KS$6*X.UG3SX0 G:2/Q OF@0FJ]&UH#LA_E?K%^E=+.+Y3+>
M7<J5]9HDN>W@D"6L9&PLHO[E7MAC\XV;/Z^Q]_,V@WB)SW4!\@;F!+H?/IP<
MMCF!NIS \;[U[>(S*/9SZ[KW[?9_K-MOO:\WO3.THJKT?+U>W$!3:<7P4R&%
M&Y5LV:#VI:N@4 J<KX/3*0R$ARIF+Z85 *%R+==L$0I7;<E6QPBP=5YJ"LP-
MV_I#;A3OD_F3&@%'/Y)$FN'R^-/$_&;!0(?5T3A"G'P463,/8AP&$MGP3CPX
M_E!I0 U?&.@6<%V%Z<G8Z/2T5<V^3ZG5>_,;_Y(,R;']OBX8:P3N/A6J,<#(
MP9U5+8@Y&965W*"=69!?G X3)8&0CI';9B[PNF$+ZS:\#*.A\+ )J^6*!7+%
M\WC"L'N'>E^LNTE.'TA[$C:*NJ8PV59(JL4RJU:71%,(J>PANBJKQJ !!")B
M6W&8W5J.NU6BJL"19#V'3X%-/4W!XJO>G'A/=X-)92T[HQK8'00?AHZ<>W U
M62#V M>8M,(OWQO"FU1V4IR%OL]5[/[D=_"[/DWD9>8 X/;(%([,.*USNO<Z
MTW1H^;#\M: <=;)8YI71[S-FHZE3Y."F-KG3U(#P7VD@H70.3ZK:#Q0:)W8T
M+$/IGOPX/%&\HO]^2[SRHF+\&H.K4;H*3(22](P$=A?B(N(Z%KLCC #XDD%4
M0KAR!^3C(A5LRP$OX(##@^>P (:Z0G 4=RU6;5X$EWC@FE&K>IP4JC%O"WK5
MT)GRQTU5*L7V)^7>@;)[2$%[!6'I_2(Q0C>AV@[(WNUD=YT]H+>&,8+@[0Z8
MH401!^V&[-65TX,P M07KEKT8[O6CN#&3E/X$M:-=Q_@7_# .$1 6>![GZT@
M)_(]N <<U!U/3<VH+9:]A9,?H^YF"0U'$\AY&][*I_7H05?1C?#]7C"1T]DB
M%:<C8^&, ZJP"K K6+VHP*H10-VLB2AK.>K%,@<WC<PR!VL"6U<J8,A4]T#3
MF<<Q5$:O@1]V/+7M!$% WE @P;BKN@EC0M>6\5P<WP!/OA>1+1,OVO>&6W,_
ML4+=,M&S^34=/.EL8%2^G43(B%-?8DN@2*C6-O1P968_.(\:'P'C:H1>H=Z+
MY4Y#G7]L0 W&N@HG6\\X"A$88[*/H@0#U=I\HB;V$%S*D,IH/3A2AP9M5?FM
M3DM5+:3QQ<3_IB#E\55X/$;<6+BW^%-)!X(28K= 6-CU]I@N(7O6J>W=DPT/
MJ#(D*B+Q*G\,3A_UI/*_!LZ8 KK_=J3"B$08W3N!^4'A&IT&\KV?8E>B[$\:
M6B<6SV!:O\"M\4B=.Y,*'_'-\5B%*G"=B>GR*04@I0U3#Z3Y)%892MK*A??3
MK8,WSH!*()<QM-"RR2QLTBVQR9Y"'<H812&L(#2E"&C. &A?7SA@U,]L$-)V
M5NQ=/_@##8J;,0@Y!*HQ]NT/8D]DC?*7?-,S?J.JL'N[Q891:)[N>0_RX?$!
M,@&S15QC5DZSU]":[$B#QQL6K,<@3D<C!DE]ABG(]JAA"R["")S+W*MWN6@T
M#1X4-84$+URXJ,7R@[UTO)\K=%U&VOJU8'!>9ZC?7ZM1O^7QLNA\;5%B.YO4
M)J.X8(02ZQ)0=0[K7"4[5+C!3)J5"*2&1IGM1E6.("&QA5$4/LFLV8S)==(8
M7W!F43KZ1+_'/(&#^Y],KH:FM,O>#5]M&4/Z?N0?@6K(?($9Y?G",N#=NCXQ
MG0+7J6\%5B^WMC9&?TM%4[D])IRAA8LF>-\]!82M\DO"H;H[="GPF6-GPJ7H
M06W4J1JKK1RBT*K$*']KI$%13>3J0E2,+3\S@(.<^,\F5LY27?"3/N>5W7Z0
M9RR3>8H&3/='1Z>[]-^O@Y^/C^WWG>,2.ZLQ;T^.SL3KBDPS$Z5F/^@BR3P;
M.Y1V^(+#TR1TL1:0RHE5XHH%%3QECEXZDT ($5Q./'2Z6>)!_OTZ]NWP\(/=
M>5_>. +'U!F_3G<N)+)(\(B^FDUFDZIJGZ<7:GV#6T^HL#6O0*JV;<$-D!NU
M;>^KLSF5:8[64,RWV[@X'9%!_![!5$K'."G0ZF%6AK)2&V09KG%@CSK,U$_$
M,RNDY2?I9)NQ@VKD0IO:8YT)_6XX]'Q/6HRFC>JP]IUF2-8<JPMI)J$<-[WI
MX@F]%M$7(,O#C$&%'(](%M$<,JOSOV;$L\,:$Q-#RR.D!<=\<TNU#1Q6 F*6
MIP-G;'@T(/+[6!IUA8Q3LT>?5Q#D1P_0A4;ND'Y[+/BM_(DU%/0DJ2>\V&2Z
MJ0KB16SRAMCCZ,0^['RHT/S#S/=@5(J ('Y=R^4IL<O"9VZ;M#>_[VY:D_9I
MVZ3=SAEM^[G;?NYMZN>6S75;W<^]@:=MM6[=.0_CW-@@_YI.C"1+;N)I#N-8
M#CXU>G.-Q@GTW=!)*(1+:12/'BG/G]5V:*DY]49,V!6P1+=A^&$;LBC,ES.9
M^G,(?D3+VCC.+HPD@C)[K2*7:F:^]/"/(&!ISYWFY*N";<7!Z!F=UBSM+(\'
MU4N5PQK&UUFRH?)&<*C I8[X.&5E\R-GPD-8\-!@?6\(#N*]3 '9E@^[GSM?
M"!,08X@<?LC):>K^=W/)OS_"Z">>WS.N 6,>RAKG^L7TO2K^I';*1A)Y"3T8
M8[X3GKR);XAY2CGH.82E2 J8J//X[X10 .1DF2RK3I.M]GDHWY,7"SN[K[%*
MBC'35%7Y!"8$@3Y@V-ES1?DA."684U*/N6ZPQFJ$#!W"#_%M3%+AZ^ 8+L?"
M&("1HWJ2%)=5=U/>BV5T'0EY)$\%LD21I?+W?%)#M!2B1.T3,*R#%\R0R27.
M.<N&BO6#)*R!(%Q,XM8,H=##5QUL[]3.#<"]+K-F?N(:)M45JH8Z!B"8]BHY
MC0?4K0ZM<Z-V9WF0FPJR7Q[V,(>EXJ,BB#AWK'=*'YULV/<,N"07U+&!LCCF
M$?:H;.["1RDS:/ITGF>H;!Q.L,W3LKB=0P3F#&S4#G#XL:4&=%86"HUY('$)
M/"6[^3Z^;-8!FP_83I?LE0 Y&!J4SQ'BIV1\DD=H6E(I%=51@62MJ=IB_6@3
M:JW6GK$ERX\+;6:C;)!9(IP1DK;RM;+A9E[DZE=1]5KXOQ(6B-0GD4CJS8"*
M:!Y1*CNP_Q[67CCW#HY*M+3Y"K>1\#9JX2!CD6 2ID?7J!6438\64AWV) )'
MLD:C_H1+S2T5-QTQHRUWT\_TLU ]@[!\C'6%@)%0SA+)E>;-"W&"L$+4HSZU
MN!=@%3+B&6&Z2VPV5-#10??PN(4*JH,*.MFWSJZ^?.G?UL6,6FR@!C_4F'Z'
M@O$F*\&UV,AH\^AF3:I16>GD9P=*=:*U>3[/7IM.GX8N83>!NG%UGHDZ+RU6
M65F:CLEKUM.FX0F5@M7:(:4(RK&Q?8U@>- (3E7*V 2MGP) EWO7^O>K%?Z[
MK/S)JHJ*;&M4CAMZ70WGSJ$:A/+7:!5H(#^:GLJX^T8-.7EX##XRRA75.C.]
M0<8*C%[(3;SH!K )AS$%248],-(U @^-19%YIHF%^=[4Q\F#J<A+'#D_Q71\
M'.D.JB[^<PKIQ9=A9 H)$]A\&:9*T>+HWUY\>9;)01@'9:N# Y5PJL0O-54C
M?L!Z"+Q7]JT.(V05<))GR-+,:$WA!S7T/'^<B5-5Q$A&;<;>_?UD[\X9_)2A
MFDH94G0 JF>4XH1=W. XO8N!T44V7F*N0H[\=&QI8#N1/-ZR;$!7#%0$WZAK
MUO/E8!J\"=&HYJ7;&/&LNOF[PEU RK9*.%_,E@.EH*(61@FD1J#L6PE8RM&S
M*9&7<\%X"Y="5,]]7(J 6T"8Y&"_ CK(F!4*>J9IW3W5^:$(8#(>$H/3/,OU
MAQ95 F6?U$7VBH-![,R*F6VN%JGYHL%3P#^9 GQ2T!9-NV)N O*TXF+8UK1B
M).F2=^/E+-JM*$E'%DUG8='OV6DW:;$5+'EJ'\PZJT:'MU1FM3PNBKL=77E2
M\X(.JW?!L,8J2%;J^K*AT/>&BZ;<7Z4B5*ZB%G0;H6B$/U'?%1(P5;@CU6')
M MBU#JKB/ZJ58%M@^'H*##^T!8;M%)BV:K"M&EQ[U:",L[=5@]OL-5^&T1,"
M5UZK&7ZMYYPKL*J*WLS1D9U/(N=;R= T)=KK^8E9!%0_ZT9EB]DLMPR+W/I\
M#4+1AAN=.1-8MM6/?0S'H=,U&F.YE )2Q'1P ,;J@S=6#<DRY1MKS'C]$AP"
MFV'T,;D:''6_#3\)Q4&N"OK?AIJ75@9ETYL)RF8ZKFC_Z^6<;693P47+^8&Q
MG\;ST%KE!M9*[<72CN8[5\]XQLDZ8D2F7):S,8:--I(6G*H5#<%:7?A@+IZ<
M,I+*EG!W!N]IPLXZ1JQR&F_$P[HN8/4S-Q,^[]3+S5GQ*-V#^L-N*\]^++-Z
M8Y75X_""+&,EZ,&L<J-!";@AE?:X8BP0N!Q1H035%DW-/&)&B\^/4!FY4AW2
MF#65"2+5D&Q8$53P&D/DI8TP,H0JT"3SL#59G4)<='H6J7Y2VBPO0T6MA#43
MZ0)C:FR K92 LAPABH7O8ZBJ!D:LN0C.R&E5+GH:0AK*F6(IL#HG6 ::+UBG
M-WMAW9(Y<('E$")6;'C)TL%)6[)46[+T?M^Z^;WW[>+WJ\_G%]]NU+22\XO+
M_EG_=EH)T^I=E!?[;)OL,5Y'&"9'@$JE;23(7*V_:";,$<L@31["" A,Q18D
M4J<,S.!'@D*CHRTGL>B[K,(H>]G IUKW8%RB)??GH$RW'G'XVDQVF$F=:R<"
M(PP]'Y[>=BT1.]=JNA[-D?D"0ATVP4$3A:AD MQ7[SY0^,Z/8:*RCER!K<J*
MJ,!9T=EL%#)JS%D!@R@@G8G_6V,UE<=\S%CDC/^9G\N77.G\?#8O%1#-OS:>
M@+/ARZHHQ9[E&$M#$4O6LAU<YPR.-Z.>R"^J4T5OA@IUCN'2537'XE:FIY<1
M^YM#LS=$ YH=]&>H>8.RJ]3Q+Z?P*JR"?>OWK,!W:FC$+/9MZBW,**ZJ?/\%
MGF2\V>3^%WA,SU)U85!1 /R(L)3HP],P-$GK7O)R:Z<D*);=U+5623$G+99G
M&JV7#)UNK;R<4X!63W2T)<@N.@+-)+\5HW$8P0TY0K1R%G3TO+]OPL5T'?Q\
MD[:CF?I&"=HXC&/J]([T.EH[M[5S5VKGEN<VOF8[=[9Q+8NU<V>2$^5MV$XS
M]WD$7J>96Z;\%IFYSR/W*LS<Q<3UUF3=K4%,V,^;8E]GRZG1!LWCY#=NDGQU
M%0(-,,0=0-Q^92G5U)G(6?2?L+[G*OCB1#]%0A*P%[A@(_D3YB#Z=;$FY>#P
MQ\'A^J:$;>* ]W7:HU<Y7C<X.1(#. <E.8V3;BN$D43/XIFP0#)J/>$V:;R:
MOKJ;%(HY,C0>5\2#R+O#8A#AAT^V>:2:HR5 T.IKJY0]O-LC#V&ZEX4JV,6"
M-1$^5D? ;XM+ $=BA+ ^+K>)/X9)[:38' &%7II&>X/E^\X3HJ;[6(80J_%Z
M=64/O1$#X.$2OPGJN'4MX''P"@,W'='GO2CQ!KZ@M??B.!QXLBHBC(K/=L9C
M.%I4KD:UE=17E%\+%F_TP&O"'V=7QWATLE%M4>H+.>\:P8$(8_)1:,HX0+H_
MP<Y,)KJEKK -U%&$+,.,X1FOB30>X]N)K.^8=R+'150SDN.D'OV*9Q2H%FT)
M(,_;KJ #'*:[@Y_$H9^2;&1Q72A2A;VR@1L5GGKE6O4\QD7+]>0IW".D).E!
MS49+UD@FL '^Y@5\])&W0%%2#@BR'+RC(LP+;L_03;1UE!FEMO(TP6DS/,2:
M,!JQOMB7TZT5/"0G4'4Y3M54J7(B%%D-B.FYJL*9, 7XW"-+DS2#'\B)2,@V
M]R(0$<B#"<U78*'G4$<;[PC\GJ4-#O^6[@0C'@9:H)AOP/P$2PX1WY*./CT5
M?T[+0#1_!,RR!NDH]36[X:^** +$E7PGJL8S'V1G]4\\HS'KXS.D)>R18!RP
MXP.MN21G\7E3Q==US[$&6*+)7YKCP(WD<]7>Y$1E4</ +P4N.W(2DC^\97@D
MGQX$B#:'I;XW1*WM.U%605BQY3GD21^-!]@<Y]'Q?&Z81(K#(@M ;/-5H.F)
M:;3S!6-P*(U!4P<1D@3MC1J$R1(E:*8UKCH;O8823FDS7;V5J^:G*_Y,(R]V
M/38"373+@KC;41,]24[&ZDVT5-6R#D03@[CI)>)+,%(Q,D!>0NW:18(T#%BO
M4=E,+A'(!Y'A 2;O)/_3MG=TZWM'3P[:WM'5#*>8QG6%KKE%-9K.Q^P;V/NV
MP9VFJZ+M&VLUW8KNT1G;8;&&NZ'0&YPH,+/TI3\J)VZ\$DV4-S2*802R4YK+
M8Y1=DH^'%,V2XB_)'([K/?"%>/]4/DJVZ)WTU60$H,KW':/S0U]C*P]%)L@C
M^)!Y!*7%/X";CE#'_':T^CQ(B%Z%])_ G1/LPY"1"??Q?>U-UD<28@^A1DH!
MA2:+,9> X+;1K(M([AO#$>=\CIGL[['I(C0WS^1@@<;U&,]3A_(93%F.K!1\
M"T;Y'U'T1,(TJRLK/*.AQ',&XRB6KSQO^TP9:)]4C6H?SGMYNFL,:TXY^(9!
MY7N)?:<?6(Q#$H0,2 Y1!M(N550/P@B+)F O[Q'(B2=.J%#>,/1]FG ^)\[V
M9C6=O>IL^;>LI5;CC$[+E%]@_ 1$4M:&JTYV+.,?C/0HE(3/->FB^&Z0U[,!
M_>O&+OP))3V6DCM[84/IB]'[I[;L&E4WCDXG47C?BP<IZQD.[SL,W4Z-#,:0
MVLJV.;.U7/<_TW1+\'%8QMX^A4MMY>4?*):<<0.*.5XWC5QG\NX?W8-BD()Y
M#[Y$O/U$]MV6A=2\?9$ZN:*I+S,-'A#<15!_GV+LV.*)U!\[$4AI9_RP;UT7
M8LAZ/D,VYM71'\IC1?)?P>DA\FXV50-M$0Z=\D$-4J6<FJPL-)8\4&L"$8WI
M'D[AH,L^&?54EX_K/5@1@6Z2*;[GOO4UM(:2?8%ZV42)? \MH0G& HEB; *_
M*IXMCL?1:^5>2MXHB1P74_2# :WJWI_8<"3)OIJ$J=%-K>-J63"9;F_3=:;!
MHB#>5( 4C0I\2I$LQ4D9> OQ:^QEA0#5?:F*OWN!RVE>H]SP5D2CI0BU11TM
M73XQ1-)0.+X4"VPZ7,V'"7;I^+># ]Z>\?YHWR:]_C]A]-,Z0XL,N8VR;O!@
MWT,<1&2?K.00O_(]H(J;LRG6;4VLN(4]ATHLN=H<G@5ZR>?Y'M, !(I)+A/'
M,SOQA%&N7;4@-" .>$Y(DF""$W-<VG90-Y*'U:D!/C80$C($;<J>5N5I&M="
M=_+5E&T35!W_'1AHXI0O0^>1;I[&/#50_C 25!IH$;(S2N@"#F,I"0._C(<3
M Q# !( H9.0;,:PYW8P5=)XKP7V05M2SF*,>5C*JW O)845U)7LE]4G2J>J:
MJ4S#Y9!.HQU'Q[&:2>1&3]FF EA^-<^ 1.?I0)G1:5O_FP)=*-%/2)\$><&5
M$4PJ@Y,,$ 7?>=+N#S$=UV1@^B88Z!J$LG&KAIOID4?5X]0&RG3*!N,\A3G#
M8(QJAHM4T*OCUE0Y\(Y9!Y=49 M-5A,[74]4RFUWA1NN"9F[FL?<&Q^@VE<G
MFLLV&<J75-P3#G7"':6EPQ6\<E;*!CN9@_C@T0'XEX0U+84"<9S2IV4:UHH%
M3TYATF=6I5 S(T7MC9W#M8J8*U'WDYYU0",A\4MTHY43.C;% !">N "-HQY)
M]Y*@KNJSQD.2"2)Z+/Y^L[S?->DK/-=D^KIR]T%ZAEB_@$$AM"2I4H:'0GH&
MT^$@)CEIJ]ZUD7,:V*7IH8FB;!##!.D'?V#H[#:\]'QA#G#0A6X;A&54Y_ET
M2IX/4$R:6T7O9W:H&KNL)7#>([F5$88[?17D(O$-)Q,D! \&\WQA(-E=G-4?
M:YD>EPZ'P] PAF+&**L:#9()YM)M='5))>!1IM=144K<'#:&9,0LJ\JJ?L"N
M/N=Y_5QGK-@S1;OSJJ\(F9Z)LTJ-/>->#!R\D"&&&.5 8EMG1,:=\II.$A^A
MJR&*A#_H8CHTE<>E'U_0H#SA(EH=/NE"/6@+3M+)DDX2[2 .F/%( ;'B4G2A
MRY4JKV%PME"E"5IMJ>(!":?AXZ5 ,3]O#DO]C@?"0 ^C>J!2+64I7O%1 4I*
M">Y-+4:I[LR5YA,%%^1TE&JKDK(I:)MQ5:S%% ;"&S:>KJDDBBK;;*(L<ZZD
M$D/:,IDO4(-G!AC?QF$Q?+>)&C\C*\\YBB^'%9SNW.WN'.XJ#BA*@$(,GYQ=
M+\F&((^9-50%I1&:ST(,#X;M!O?SHAPDH@NN5LAD4*\/EA99W52MKEZ>BC8Q
M7D)Q>Q+,N95T=YS=G0\U"T'6LXO8]=G*X 4HSTFE<9GU:9J I ["*.-^3_E>
M\.)3$;_:.J/-L=VFU1D=UM895<5E%E1I9+V\U*BV&&'E./5M =$F%[FT!41M
M =%B"XC*M4%S%!)U7G$A4;4=;&>AYWK_9V+Z/WH@(1@@'#$T^EP4'J_A_]UA
MV"O^.>% H8Z")V2$9S'6_K#>IR4;4D6=%^  EF-?LB[_Y  L.7!+GNN5Y!-X
M,5NI["&PY8S6. \>Y_X)QPR:-W@JX$YQ <D$T]C@.U*+0=F'I9#;T/'T_$UI
M(,[P'#LCEY$/7:XE3#$#CACH:/S<WOE*N%,&TLE<EPTX,F3\%*8^#@:8Y-,[
M'.#$3D)R,=V,@35U.0("3LQL669+X(+4.Z)8\"A2<X<[S)5QU(&"S]GY)9LO
M*' ;A6XZT,C&,SZM)MEC6Z/43SP@8-;.@AG\6"<!)+\ %Z*'@AVW'/M6++-#
MGJ+*U^Q:.JE1H%WQT,+#=B;&LDH/X'3RM,?#\4MUB8$79\4$LMH/L_BR6\1/
M1]B7CJH=4_8@A,!VSK]=(PE5B*L^$&0T,-.QWK3BD!_9"V;-U7^ Z*'B(85K
M<#6D&QCM^1?(JO%5A(VSPHT/$8^!'QA'B0YMW8#!YL"RFT-(A^40$E83T(1-
MC"#)%C]9%&E\E:]GY ''@1'6!,DC=S*K!HE5T8)F[BQ"4YK_MBA;81YHZ=77
MN:FZ ".,LG$XT2NTHZY0T>4%DXS_9BGA<KTI1P$Y>6VTU>M[[(B*%G.T$KR@
M,D]?/^]\][<I/,J+/WFQ47^R()O^/_[/W[E_<B!\?XS5R,$]%?GAO^6-&3R#
M7^$.Q*R(Z $J?DNQB(]6+ECQ I;@)^S!77UG',/'ZB_]56Z][W@-.F9B1%@\
M&B+P&^B.T'/5A6XAV'#\5X,PB5M]41>6A/ 98+?XRM\%.G_\:#C %*+ 6X&F
M.VFXUV'-O1K>8L9'U[KF'#U9<M##0B;;4U$J*2+7)BCPY%*U&]JSZ&YX 67*
M/A9#M$AL^&]$_\63D"?CP!=.A)&OY %7_4LOD'FO/>;M,6^/^?J.^4R%]_5P
M1E,AC%ZK2W Z@TNPA''@=:APTA)KA7,KG%OA_&J$,X6!\_VB;3!F%LG[G)X@
M-4V*PRY/$<*1!4:4Q6@RP!):QZ@7Y5CJ1S*56P'<"N!6 "]: 'M#.^L#PW^8
MR:W90]J4@XBI?XBE2:/%*X54)K=T(^07+\!:XMI&U#<E;!?? 8M/;1K]M8-U
MXM3Y*K'3^.,XO<,4$N$]V/(S.6K2^[<:#Q:),+IW O.#PC4Z@^=[/\6N;N"O
MU[Q3/*.R4W3[ ,R(2N.6P_WGH'[>,@?-4<B>RYW(2F5G\<"0R]ALD!Y81HI)
M[';?YS33]N2^2WN#TF-<2: A,A%C,L<=7!^8KTXE?,-\]BQOUYDYL\(TY&58
M<ROJ[:EL"C62.CJ1DTO@.'>(<?+L!LU<W8LG!X,OL!&BMG'SY67Q9@,ELE:8
MWC\@Q"6EPU<G:UJ7[EFR CZ71\TXVRPNN%(K, J0BGG0*,-&R8_^K$#A,4KQ
M2RT.QJ,9?A2+;PK]$,AG:9#A#507_YCM@MD)([,'IX3+HB XU#DP:4RO%OI<
MWW@W/'87(L(7L'G\(*2)AY 0NLE7[Q@(P 3Y)3! /5@:(JA-Q&T/3NX7N %9
MB[.LC\MWL9#/0AMEX<!:;PB;16)*C+QT5-0^^7HB8ERJ&P*==A\RO)+N+2;K
M5S<+%RO0J'$;)7BETBNUEU6$-K+&\:HNX@<<A/# C&L DN0+6.(!T#S%GQK/
MQJH6A!)[0D0WV:<[LS.'1W#HT'MAYSQ>W^8O%EG2M"K'SK3 0%8B(#ESP4K]
M/'C6D\##&6\C*ZV,+384'FL'V8,+%B0B=HT@-8JC#;Z3DM%3$T3>;#M^'K1I
M.CAG <A)T1K5E9W_"*&L<D7'=]5X]([Y @C?#\]*&&1=XI^5JJLC!&BTW/!)
MNW"!<.AG11RL.2J(&3M$+D[>5D%;X>(*RCUC)KO@4D5YO!4&Z%(-I;+CG'([
M4S5>$8VGU'[+Q\ +L$)O )0JFYOH^)$Z3J-'[U&A-$H8^RH[MJEE8+>PU!).
M&,ELK#Q7RZ69L<5F@J9:Q"GD:MM%MZB'9UJ[:*=M%UTN-+U)QK:U=*/;']O6
MTK:U=+FMI9UY6DN[K[BUM,GDRAN;.V3.% RGW:S##X,?,V#PZ$!?;>@\R4#J
M)H5H>*[5K(1"MVZOI5\TL<UVD6DA=R\8(,$4BG[>7;>T^^_*0578M4AT <NU
M>0_AIW3'A8?NX_1N3X4BL@ERQ:5I)/;8 W([D>K#3&C.5EB _Y&M7A+_9QH1
M[-4LJNK=9W6D-/\6<CFY.*-V)C4/8+]!%([AT"@84:2'^EZY*R9_E7"->QQZ
MQ][.(:>B1HCCB_B)-$(+(TGXZX1/*WYHP.Z4BD?(6<6[J(M,A/-F2*.LRCHK
MY3.Z31] 'H01%N>4^T)UXRGEYG*]IXIH$NW2*1X00C)Z3GNNT7.KIZ[-L>/@
MOJ<\S0\(A3O%4%:%O4!IFLDVSF)H"#;$"THF9@:C\5YZ0*,<T^NQ7,!!JE')
MG6QZ]]W"^#<$KA^!CHP+;<O#8I,R[BU6J#0!/Q*:9-T2Z+EFAW 34^Q;E]R=
M&Q.RY3BDR8IZKZ3?7WR$)]-&&5%?2BY"@G(%3FID'$V#&%(Z3[\%YTL4,R?.
M3TR4T6R+P2!, \:PQ_F4P-4R_:S;7'6$@==JFV%<_)D:#P)$=$9T,_5>A=QR
M)&F!4J_  W,<4@91GZG_NOD$80(199_0Z EM*_9R6[$+!273&K*'7A0G%6W9
MS3%%PI'/!N"H=*U&J*/H7?%;9C3,8-RGJ(*?$)<#:Y]428*>;ZEBJ,:)6&?2
M-S>>)Q^+S,^F /+YA;9DE)>F<L<CF08,3@A6SYC0%PU5A^?QI^#/XB3R[GCN
MDA<0W+!M"KUL,DX<"S;):^T!:6'/,[0J#+3@4E9<X_4[F7V8O2/)OXRK<F0Q
MA/:N;49$=QPIL<IE/* <[M27*$T1@MG5$U]1^O$G&>EB?KS-I1(#BOHJE,6L
M%)/@5.2X8"07O4SA[KAU%;<G;1C.$/8V!> V%/J]@>J^EXCA[LEQ0\E.I116
M+A%/(M:#0NALF2(@=_3=4$B@)'KIQHQN5LE]RQGH[S$BUGX!5R.-Q+G'4]PR
MDFW*C(ZM+@<XJ,[DFDE_-:D>5"_#Y4=BZ!-2: ;6K$<@Q1*?'N?=48!F%B%'
MG@,/[V:G$R=M9U.5BG,OI/FFS8 %^L"[A&O.DVZJ9I"/E$JA?]W?@SF QV*F
M56KO#N>C: ^T/1%;<2(R;0M:?* \Q#"'7UPL-XPK+)=F#BW/)70X ,/!F,;)
M[.XJ7\J87*@'LQ,P/-WZ)0,]=WK9.D:AJ]'7V"J4Y]X;&8!ZQ6QY?O"-Q,*>
MRWK,V?-J@KVGAT\J/.XJTB13$/ZDV))UWPUG'TX)9HS 7;T:_C,*XQA\@>LH
MI(-Q&]Z&"1Q2BL^H#YME0]$(.OQQ</A6C*"\B!BG><EP,'O94T7AG)X<FQ^^
M6BCZT&:0',;%:8I&/I%]-8>GS*2P_N0AYCE#9M^=?'I?WHIWPKI2T2;@MIU/
M\D"5YM=H]:U']!9J](WH5>G\S($F3\'_':'B8M6'IEP-6YH9D:,PA8X0IS*-
M2/IHRLY;0,,Y@(:R7R/$*^/BMI$I,.<(965M-9D$&;B71>V9-4'6 DC%OTFX
MOU)L2P'P-WC0RI4C<Z9QNE.@N2#W7F^P-!T%#I8]SV-&RFS#;-E JD"7AK1=
MT=ECS\)WVA('OI'0F450S>)/\].M9,B,MMJPJRD?IPK]\K'T )U")PFC;(R+
MC@TOC52SO',I0@^<&8[P*+_P7>,P][KFRU!LG,YV,;G;%KMM=%7!M&*W;EOL
MULY&: O8V@*VMH#MF05LQ9JT19J+&Z=.BJFTG,54;/3+<M[-B2I59K$'#_F9
M3;E2[:6R]LB*'(]Q5F2A05WL88YA YS]DR-E=4S5\&S,+X:O/&0Y<R"Q__5R
MYH#!A_U.32BQX)+MT/YQ<=4LV\%],:KF@R-1]V'HHN,(-\HW36LO^"YT(BI(
M<KT(;AI&<6Z0V,"),S]3O0J%W.JF*H-)'X>ZY=09#CT?3>;8R(P[/ZGHI5A)
M,@RYV$B>@@?A:[1TXZYL_!NWQ;2$SLG;!2]!O>ZNM6.4=8$8 !.^SRU$Q)BR
M3F37SCL2633_'L-M&!1A>"**N>2>0(4A\-[HD(P8WR*#A5M#,&_=&<W%A=A.
M&B)L"9))%:6IW6%(*MVB1JX:30#1T!%JA,(PE>G,&21C(>5)IP.X,AV-'#-"
MU7B/'1RSG&M*BW?Y;7?^;;!=78V2*GJ9O1=[IAHEF1=OGL"[;=SW/.PBE>:&
MUXR2V>8_3 IU1E+G:]Y O3PML+M#HH2VU3;K3[]PN.]?1BG;+H:/N+.^U;DO
MUKE&Y^J4.3&EP-M.H:5U0/.'Y61[E=:=CF)W(1]+>]730:TO'-/;. "[!69.
M#H_KY?H#/"_K##:/@48'*"MQ>RI 0(L<N$CDP'F.X%3LP%JPB3+N%1J)4D!6
M3Y)15;_+.K,%2(DW=6I/&ZRQ9YW:]3=';02D0TG1F/ -L1@;Y75 1[;W<%/C
M#'^5017R-Z+*Y@K4AXKI]4M"@2C!3<R("C%'GJ8*$B(/E/1FF>SVH6FJDRQD
M$=&(V4@G_>.L<P?KUPB?.,/H*\W0$P2"AHU #HV^2RK8M ;'HJY*04ZN4E/A
MFQ:QXP6JM'"J0]0,8=@P_RHW-AU.51##BW+( 1[GW7,W*8._R<XI'-#9U!F"
MA8!TE,#8OI5W9"?L:HC\4.>*G7%9 _RU>7JFPNUZ@CV(18"0@ 0 6O*_C+&H
M>F6SN=.224S\%=\;>:CJ^2MFY>I053@<@OKA@%<^_*5*8.!+_#V&W) L&'_5
MD2>W7-NE>@ZSBI@&?N*QD@U<K?1 +? A25U$V<ELH%B:<:KB-FL8DS_5%3M\
M&&-@1]DJ4(1\X3.E)EKF3K)QW.6AKCG$ZY>ZMP:Y9*RQ-$"SRM!#*REF*^6<
M0BA\+LD$QD =?;7<+H+^]95YYF[2N]AS/1!E-V"H70W)N*^R[5C0/=M./[8_
M'!S8!U7&NE' 0IJV)MU0)]$-,?TZ*+\(2_QEN_7>/CDY@?]_7]XL27TM3F@&
MQBLA.PM-+3/7N &G=J?;M;O=;L4&U,M^8SRZ2H"\+IGT(C#"E^T([4;UCER&
MT1-FNZX5-H ^'#D'XAD5W';5Q'+\T7WJ\2>X*8Y*R_5NSA;?,7=Z>+QW=&#7
M5A:L=,+ON2#N!X^1)<_OPKW7,/'\WWWK!H/>FD*R*#_.3'ZM;XHA('1+T!(?
M@\W&1@KEXV0::(",1B"^N#7[%F?1]M3'<#5N!G(%MVW*C04'>L31<1>SX%1N
MRW6VV @*WX<#,OOHLUU\^[L8GH@'FYN$R<4Q?J;>$EXRO _ =B'OR ^Q:396
M^2/Y'@KQ1W*B\:YP3UZ7 7=?KC"L\C+2> _/W6_9BUY@26^,Q1N?8#4_ERDJ
MWEFP9\X8+;TH%4V01K)PY.A@83[R<X=@;VI)D74*W/;]T\W%?W^_^'IK7?QK
MEG*B5STMVS3K!9XV.IEQ=B*I>%TB":-GS2I RI9P0),(7,/QO .G'850_""$
M1 ](Q[D9[UHJ#4'F!X@CE<U:0&B+2&B(VD^$DR.+FVGV^Z,GGNPB1B;(_%%,
M0.8^]7)14B\?/W,].>.78C##B:S#*"Z3WHW#=A30B5!BT *S(FGNPL5'I9%&
MZ:E:R_J=MJL 8\>#!_8Y#X]L"P11)T\9JCLD\8A5)*@\1D#^,)H@O40)D?6/
M,**BDS-9.O4Y)#P0#GS%"&C@*^7\%7]_G*GP&UE[8A:0J,^J;JOSM#F@@"PM
M3,'5,(K")\EBV-BJZTSJA[TJ<7XN[I)S,712/_D,N@37@!_UJ'&D(HU[T/UQ
M>(2BO/-<JT^NUC3FOF%/D'"OG2B9W!H'[-/$_(9_G5<_1?O1^.IV,A9L/3)9
M)55IKUZ(;OV\9,?[XVI/F&,W34R 2?J%6WCP"GLJY"Y/YYUP-$A1#D"',MI.
MY'L</M<(1'-&V)#O/1-I*B\+GSRNGP%&EG=3LJ,0XFM;(#9(>TYK@3AJ6R!:
MO-^V7:)MEVC;)9;0+I'YN[/B_!X=_#A\S3B_V10$7=G.%E8:4 /S&$R<@3<&
M&T6Y:=+ :;3 Y-"#$I)B!MG%-DR8:S!7MS200>M-\GH\JME&S;3F^>+JRVH1
M6N1^,T=EQ3&JR*50WM"4DMVW"I[I<95GZD9P0JBZ98HCI^KZ+\%W1:<SOF8#
MOAB6 P:AL%SG-LS^?L/,\EP6.:[+:QIPWPT"I2$NLO&QRM4&_Z\5.E&E2UG6
MZV\M>IF7(IVNDB)/HA#6"JR>GB"$'CZ()%)47T2$];%F1$I^I*_/&IH0T0''
MKXY"51^ED#X_>_=T5Y"[(Y!U*8E!K,@:@! )(X?Q*:QSD )/C&_)'U/IC7PN
MWR-[VM4H\'IW-B\-[K1?>P>>]AGZ_F0/A*4,WW(V$=<H7TX]A^^K"GNI12T)
M[P5%5"E4Q]?;Z"'Z;$/XDUPO!2_;$W'VLOB JXA@B27]0(I94]_::7IO4Q7L
MY#<';IX]VXQ02H *B>XA(3UY69*>5D9GJEU"+-2[T)U03!?G^8*MHPZ;R1;\
M<WT0L\=3Q>8WQ#F)A?4EC"*POFY!&"=FO'S?ZOEQB-96);]REU5ELE3\HHG:
MF5U5Y$\[ T6MX$G%1_0(8VMRQX.B4 .P[1QXB8O1V \G JN.\3#&N2<9!*F_
MSF@!5(BLQDN$::2[$.O?0EWA,2:VE SF'+"*(')?7EQZDXR<NH0)$5OEL^0S
MBNA+N4?(6^M]YU8S!57W)!B?3:*R10J5+;>DH4R::T!])R.L2Y?WTGO@&[[E
M!^*-0Y(Z1";=Z<G@1A5/JW] ;BF]_^>,QA^_69?7O5EDF[E?=,QI*]>?VUA7
MFWH5CHYQ+BN&&%!(V1!2CG635:'CE^<FJ&NOR!4.,6:UW*A51=E.Y4]*]N"*
MXRI_R[7F?&^5:0/:<!(09/2?!F9G5O%L#.M5'F#%PVQ=\4N7%*2J;665;>K8
M1&PZ9\K!8UA#)=_@13+I8A?$*'6LXN&W62-HS%"1(XNY 6;621(DQFH<5?")
ML=2L;16[@_A[_$SI&%BW+%WX"T+H'59I$NXLLJC21SVS/54^=J_[<&Q4#;JY
M-97%07,R95E]&EJ1>&2$_\[N33*WXBCQS[+#8Q@9*ASE904JM=,HY=/IS,8S
M&T3K9Y3;2EHZ5)2397PK)(!N8)*B)3.2P-<?I%P%(!O)3/.@]F#K<B?0?U5B
MRZ[M,#<XS2QMV*FU? OBRO3&%"/\EF4(E1D*2PA'WL#CXO$GAS8S%]K4P)-G
MS@1VQ>K'X)^X1 9M.U-M?0B[A\Y%(IA;*BWKBD-RPV3C]^J>GBH*Z-__4P0B
M0C@5XSZ?G2=97EF\0^?@1#-D_HVU;T!3OG9Z,9K&."EU%P.!OJ!I]&"2:QN[
MU =>P%C1 +T-M,_+<DTC8U=L(_EJ:+E&952C.$W]0+/@JP^L=N"4'%)ZYR^'
MQQ)T%%[ 4P,<.#I"7 WWW2$X&*4!S2.2]52(7V,1Q$+#'GAZ@7D!FKUY3L&;
MJM!4:0HY1RFSG)ZRZY1BQM=%F8US?,S7*:?-,8EY'Y9.885<9^1E20F<ANUX
MCYR55Z22TQDRJ1\+J@A.'@KRUC1(D,L0I !Q"A\<\AL5XH#Q$PY[YDPUPZ?B
M\L>$K7)X76R!I3*C)50O2)9,G%][0UB%9$BI"DP:OD',T>]8LE$EZV>1(WR2
MLEJVG"BQ=5B!*L-0B%%Q*0OSS XL67]@_F7-V3E'[+IW5FD&V@6@3=^CGFNX
M[*L3N\[_&G%6>+N?>//)Z"[TM9KJ?>KOJPC/54I7!GOFK)E2C^QS'O&'?D:+
MV[E%6<)I12O';=%*B]O9%J*TA2@K*429#Q2SKH!C \M7EF1RU:^HETAU/1*S
M>TZZ5(0P78P<#WMAF45"P/=LPU3[!OE9=ID-5328*X'(*=.AP1AI"?EXC;)3
M9!%*5J^> 5MDGDO)L,+.;#G9+<A&$9)79.(\WM'T)7#!)"SC$N8ICR.Q!Z\E
MU# PV6G%YB*V+DK*8JG,Z?%!SE/<MW[/QD2HZ[@SWZ8L ((@".F9%7%-P 2E
MG#[U9A0OV#&(T+!U5+8LYR8;F46Y!@PDN'*N'W#F0_771F Z_T6QT: ^O[1K
MF.$)C8Z1MX@P;@/;C$XAO4;^"87T#MGZ"L^H^/0\DVS,B$E9:25/IVW.#:DZ
MDF7R<ZLLYB(5#HUPH@#!1//C9U5;"[ ,HY::F+N'QUC^@?_?>.@J@MX7\F'<
M:EL(GAYS%()G9L@+Y?T?T0^C\GA9L*:G-0X*6!0@ICSQR)%&F@X-,C#9,T,H
MC FY5S.W5F6:__5'[UJ'>O T'G;VCP\,3ZYRR<.01SQW#DR@PYA9TB$:4SH7
MZ-X]6+QTD<\L#1NT]?&-Q,CQR+7+D70ZU9 >3(=C\&FWE@Z>'.%"<+PR<NPR
MRRF"4%-;#O!S".^Y-P&65*"6^0B;/(UK%A)5Q0.S!3WTH<K%.[(X-H;$9$<W
M)_ S/=\\XADN-B[X5+I %FF01B<G!D,V VP@MGD*Z^*'H2[ZAJ#*]X#9]^!_
M<^8?0<'8K(4:9*09EVX@<SY<4TFQ0DDN(4)3[V*CB"Y$CAM>@3 3^/D20TVH
MR';=RV"(K$%&$([&,O8C>? B5^X#/!E?0V&8)6%6'5%ZHS<8+KVMR8S-ZCL8
M 7H5@C>"[TYL#=.(0O(9\$!-'+X=_O.J@H@G;1#QK72^8<0&W-JGZ.?0"[H'
MQQ\.3G^<OFOCD%L=A]QRVIY=?3V_^'IS<0ZT_'IS];E_WKN%?WSJ?>Y]/;NP
M;GZ_N-C:QKC_^#]_3T@N#(3OC]$M#^ZI9P/_+6_,O?FF<*4'R+-\!X:XB/@3
M O ($A**B/-L2,T7[!<_80\+:9QQ#!^KO_17.0J\XU5%%60SOG8+\NL]O"2*
M_L2M_AZM->I8 YM4'1/>JOS/9OE[.;>&_T952Y_%2""KQ=")7,4,LODQ]-P2
MR6I>UI+\D['P_C$QL>*[$@&>=Z/R[8 A@ 4"GAW>?&O),?S//4-]']@6_M]N
M\1+%Q08GRF]D^TX<^D"CCX;\U(K2/+TO[NYI%(TW8IQ0XY:LRCJP57%5IY.7
M3 O:A*7<J-W'<S$PM_$PV\;#)6[CVD7'_%RU"&&PYKW>^1XXJ8NPR+O/V]OG
M4^UY]'KI\U["9FP*U/*9=><,?MX3AKTI##H'"%/5/87_'!_O3N5&V-K*T@?E
M2.V1/[EDJ_C_9^]->QM'LD31[Q>X_X'(J1YD K1+BV7+E=T-R%N5^F9:'LM9
MA7E?$K04LMA)D1J2LM/SZ]\Y)R+(($5JL;605 #=6;+$)>+$V=>D=41O1(0Y
MDG:G*!<MB?+<Z?=!.\XTX-]/ZDM8WYNVR77$PWS+&X1[A7;__K=LD<%5G'7M
MR)+G]BF.AF!A\)OF1P5_B^9'A>5'E56XFL7C6E8PWC6KRHJ??OCG+^]\@FIP
M44  @;JP&P_NO>,.\3_8,/S9<C!RT0DO+=]_!>C1&+.L_DWGWYNU][3DV5BW
MTOJYV3Z9GP3Q[K/8A.E7<2380+OT32%!^]P\/ZMO%PNT]EEL/G[G,VJ<)XLM
MB\'3-_*8]6E: ..:PT(HYH5FY">@VI ;MC*<O.!'7QSV?79R8K9.&OMAWX+E
M9(0N"V&;K8^]N=DZN8Q=Q&MXGLST)P_5I*(]RUG])K*R#FZ;.^!.50'5@6Q3
MAW3>J9FV"J>9/GC8,&20\(X>M';:(1"40BMM-,WV:5MKI=L^\N)HH^=-T$;K
M\Y,4M3/A@$)971=+S'B#LS'C,Y]YI]@.GUVJ^7?P!\"EZQ)4;CUW4 )NWFB>
MF?5VVVR?M31'WRT2%(>_-YHM,V_&F?8X:(]#Q;>I/0X:([3'02>1JOZ)WD/G
MB['/5-)L8;J[7/%?WIC]O[(FM;.=K**S%5Y'/ZTWS+.3+!-\8Z>TRS.99[][
ML!(T,>V,F(IDZYR:I^T\?U:EB$E;6RLIG4U0.H?>#&N2*ZU<%V:?);"W"@.K
M0]FG#@54UI;ZTNU<=+]T'[K7?:-S>V7T_^C<7__1^W)U?=\7C0^-J^N;[F7W
M05?ME>(MNDI&5\D4F0ONMK;/L:U'V[%Q HLN\"OZ6S3K*BSK*B%3*E[)A\C%
M" #,-$2^&&[KW5=P23C<<3"4(;'NU&S6&N9)X[Q"B1@%/OCBN"3K+?/D9$^9
M%UKE+!EW][&]]4$7]'F@;O\F("%*NHH=OZN;C?J966OJ2KYMGWF!>'KMS#QK
MGI26J6MVO4%V[8U&S.?3LX,#K7-1";@GP'&)T"@TYV[63\QZ:\M4?"A\>]FQ
M%X=Y\V,O;[V+ULAWYP3F V1LC*!.?6]B!X'GO\*RPH*X7O9!\+>P>VF WS/'
M"MGPCH\H%^;X]<^!,\,FP5<S]N IE[P66ASLI$:B\N)@L]BQ-ZDQLG^RX='_
M,M_C,^WKC<]SB+$U2M::?['% F N3I7R.>X"L %Y#U(>2+=LFI1C:B\TQV^W
MS<:YUO]W>_S%,03:[?)Z<+01L#MN#W;MLT7S8(^,&\_'8<7&G9S4B),B+^ L
M GB"T6>#F4^Y(@<I#D@!C,$E8"5!U7&'$E QG,H@)NIFZ[QEMK1I4!#,T$:!
MKO<H?)'Q@6RS!-4>10'5@6Q3>S)R==NB=^I3<IT/4G^5]NR7& ZET$]K9N/T
MS#RIZ;9]NSGZXK@P3L#4;]3+.PA NS%VZ,88,4#H(: >Z PO:&2Y3\:(L6(E
MD^_',.6@2>0PE*3%'PX1:.FXY1YPH#A2H&W6='\_[8'0]J;V0&B,T!Z("G>;
MX)W[E)X3A]F^[ST-UDK7=DPQR0NMB==/S,9Y(\<-4ZG68SLU!LJQW8I159%L
MFY-VGH^K4D2EK:M2*9D'LDUM76F,T-W3M0V6*(J:3&PQ*@BS'R_A@7 C<P>@
M2Q@? \8,+ (Q3C^]TSA;,L4[7@8.\U87L3,SX6=@_^;:#N"4/V,H/=_N?BU)
MAZCBO&6S^+$=A5?CA^Y35BR!LB,1X5A!P/6$C@$ZC.U:_JL1C"V?!:;QRV+"
M?6"3J>?##== >^'KG>7W_'Z(M25_6LZ,W3&_CP_:!A%_1Z8!5^'RK?[L\=]L
M$&)ERQ"6A+?S^V8!KI.6A.R%KNZ-^J$W^)'#";Y/F?]=K#HV@D]6-H*W!;!W
M2\6B JQV7*O5LEP&J2^P=L]X1BB91L"7CY5]4R\(J.C;CW;RV5CK$&CM06\6
M E!=K'8M#;IR*E7!WKV]V0ZFK@*D8J+H^X#4:&*P/B=@G\90_BK#"A5DY"A;
MC*C'GA+U4JAT:?G^*V!09X+] 3MAZ-N/LQ#3FAX\8(A%S^+1@SH+AAK%<8 7
M9GQG.*<;2W7S%'7$#9D. \^!1;I<V)?X-=HS=GB>,=)GQK BY@?1[ LVL@=V
MN)\\A9*8\\5YBVX@7UBN5T)^5KPB@#L?TYR9.V"K>F/X'6!ZD"VT2V?,SOTH
M;][J-NR(W7M EGDXDN#AMGMG%HX]'Q!RN L,V*9K8NW=;?S0W[>[UAM<"M'V
MWG+TW2"8%>_8CP(V0."\>/XP8.Y;3CUW8WL]\;F-P:;8"F=MTVXH4.O%CK:#
M=ATE#YV8>Y&<0WOM,G((_J'5SE]WF=%NB[*J^>^*O_)XR<[5?35.TREFH/5M
MD-EH!&MOD-F\/:% <Q?&Q/NAN$WS8SU@% "EWFFM<%ME6_;*'#2W9ZQ\)T#-
MO?#6"_<1:U[3_)E;]M9C\8<#+(U9JU%@U9'*]99SN-5Y8+8Y;WQDLJN^3E/2
M:4I[3%-:G$3WZ:#]3@J+VIK3:2.V0O'=%(?@IEH!70I@%)4"7718NC3^JHLR
M^JLNM+^J:)"IE+_J;5"LJ+]J'\!H5<==52JLVJ'157IH'!IN;-.CM&=NLR#A
M?\.>(VV0[] @?[,R]+;*D98N)BJ?%5XU'-$))1LUT#O#(6&4Y216G'4.:UOA
M4\L>PK:%,!A84SNTG,J*!N&$TB[*O4))>^:*[9GK# :SR8S/.1[.E[)5D"]\
M7*P/W+/0 M ,KRW?!0@&"H!$J=^^<XD#V,T_/APMZU;;--NGYV:]O@7Y_ZEZ
M?' ;6+'3#./5L.+,;+5.S,99<\M(H9N=EJKGXX%L4S<[U1BAFYWJE@YS S(+
MU]BAJ$W,2]HJ?XEV1VXW<?P\);!$.G[;;)UD!1)*V3S_TWL03X^DJ *=%=1J
M:IJGYY49_))+9MIN*Y7Z>B#;U':;Q@@] O!0+++T"$"C<WME]/_HW%__T?MR
M=7W?CRRTZYON9??A,"VT7RJC-*X\QZSC#HMGJ2UM^WM:;YAG)UD.]U*JC@=F
MH&DR*X:AMH3,3LW3]HG9JE>>S+2!MI*>V@0]=>C-J#JUROIX8?99 A.M,+ Z
ME'UF&&GP+S;F3^YPX##+I^V/<7<_HS5*;L,?G+:Q!-0&8&@Q/\7/EIM\*ECK
MM3S 9K!M^AS!;VWS)N=YF(II#S*LH3$SK,' FTPM%X<<P'M#K#WRX6O7L&'K
M3[[E8)%;:'@C(X3+9ZXU&]J8T 4B&\S0@'\BLYWRO$:V:[D#&VX+9/YQ<)PZ
MQ#F0*P!LKVJ89NTV?L(FD&U[.+'&GG9C%]\<J2^>^_GT+-,.SCO.!/JCQR"]
M5?Q.<8L\,M# T"WBO%BO@4*5XT@/>;&'X9B(Z6^?#4G"3=R5$O&NMYJF(?_Y
M]/G#K[E85F\>-]IX=V*IQZ=G&:L57W]6]2J#%"M8J&6,?=0Q_P.4VF@8A#MS
MG,\)5PUG-@_(GI"2<* @$L;??[4RJ&(IZJ68N(!-^[AE ^*IUZ/3)MJ/SU=N
MS4(OY=6AK^1#[>$_/DQ]]N+_ %)NUEKGM?;W\P\K$\+F/5 E<2UU_NSV'SK&
MW;>++]U+HW/Y7]^Z_>Y#MW=K7/;N[XZ-;M?((J)UF,S!PO:R=WMU?=N_O@)8
MWO9[7[I7G0?X ^#]</WU^O:A;_1NC-[=]7T' =[7@'XKH#]^N^U\N^H"<#\M
M Z+ZKL:[A39_Q :D-BJ'Q&8'S'&FUA#K%,G(Q[_%@[GYK\HJ>H%@C5S=Y=\,
M9C[.>"(9 W:[*H3><2I"H8:G.M8T@*_EI^BG! 0^Y-ODM0R;7*RR>?JW;&M:
M_'X&>\B?CJLHVBM\UH^./[\G8-1^5[Q(.E\$UL>$=]R:AF_QCRY^T/SCHKE8
MC0_+'BWPG/^I9BW&%F7R$DE["OV(7X3-1"9(P@T::4N[\ZP]@#;(.&"^PL5C
MT9?F&M3 88*?/OJ_[G!9?38-R4_*E].LF7M<#,9.WN@XW1%F:YQ>&:<1=8J&
M776-7>7!KEOX3YF02[.N$B'7C2?0)AP+)+MCONWM4Q2/?&_"EW+#'OV9Y;_R
MOUK[9IK&1]L=L/E.JSM>2CCVO=G3.(_V\>LMLWA=J;/=O+ =>;0IIH^Y"-2T
M:,I\^,M] J88H-_UC<&SC>9S_;+S?C0]"89+A$+''5[_G&(,)TAE8-3.OM<H
M^Z+QX!4HX<ELGIR8[=,MU!?OK>:\!#A05W!@[]DX];.:V3H[UQBP"PRH%Y$+
MM,TSX +-DZSVK!H'-HX#C>^U5O&X0!NX0"NK,'$'W85T-EPAJS8.9)LER(4K
M"J@.9)L:(S1&:(S0&*%+&@^RI/&+%P0&>I6ED\MS@Z1W=+]>KOV7M92TIFI)
MOXO(@NNZ V_"$ V*XL5;K?'%(G?>QHZP$(TO*EJ^J.FM(![3%1LZY;I.-;65
M8+^:V@KBG5Z-VA:YJ36]E6"_FMX*$@E84;KEA@2J16TZ.Z4*V2F_6[9K>%AC
M^\R"D(IDC3%SAO"%\>#/@M#H# 9P$%6?E["8*2&4D!/UW&X,IZ(8N8NYD5D[
M!WZ4V9FGK$'J,B#!/J/4>J9Y$3"AD#DK=?,$Y&=;C]3;$1(4(6E%SZS7^E]^
M0?O8<I\8:GLCRQ8CQ+$QQ(WGOUC^T+B;^8.Q%3!*7KX M3R AQE]-ICYU$:M
MXFIACK'J68_V;U?,MY_!5'UF E@25AUW*"$5 ^H&P$NC-R7?*(GZ".S"K->W
MD.%6P?%:NT>6@Y4KU4"8';*7@JJC]9,SL][0[*58[$6KK3KENDQ990>R39U.
MJ3%"8X3&"(T1&B.*EW*MH[8%3<R^9:'A@)9_F,G8U9EML21S!HZYO!G8)Z>G
MYDFS^EDS%<U1TT2FTZXUB6D2VSJ)%3W7^J35,%OM4TUDFLC*2V0ZP;H()*9C
M$.4:!'4H^RR!A[$PL#J4?6J<T#BA<4+C1%%B$16/,NPF;G#%V(0-#7@Y0-8=
M&D<Z*WB%1"R$V94 65&\\(7)JSJ 1+Q5SO]@\^JJ<?Z+TW87(4"QW9>-1LNL
MU70R[E9Y@,ZMU7ZM,J4/'<@V2V"M%@54![)-C1$:(S1&:(PH@C]+Y]86/+?6
ML,+0MQ]G?.1WZ!F K+9K^:]&,+9\-H8U,U]GX%8SJ8*LOD1&14?!A@>O)W"A
MKZ!"45R#.D%7)S9I&M3YNYH"-07NGP*+[1]OFZ=G9SJ]5]-@I6E09_\6@0)U
ME*1<F4V'LL\2^$ + ZM#V:?&"8T3&B<T3A0E6E+Q.,AN(AL75F /*,%W:#NS
MD T-KLC"!PL "K#GH8W \&8AF 8N6!9/IG'I6$' S[F3"H(<9EJPK+C\2T"O
MPX%W.T.+J3>ZXL E@RSHQ9#<9GS@^Z4WF<!5>%0=?M$LP$7V0RMDV,B<?NJ-
M^J$W^)%EQ_'S5$VY[NW-RFT_WP2H.0@1@E893(TF9F/F9&3J]OV%(,=-.$GV
MC6<[(,<J@*G>,!LM38Z%),=-Q@WVC6=;),<J@4E+Q^*2XR9#"/O&LRV28Y7
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M]30^?KOM?+OJP@GL$XAKJ%5%!.+#'_?7UT;G]LJX[=Y>&U][MP]_](UKP'/
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ML"(VA^Z5H26TAI*&DH:2AE(!H?2>3@?ELP-6=%J;IXT3\[Q^JDV"$F%0>?%
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ML!A>I="53TY !6I7J=56>1&D""JRSHW4:K)6B;2:K'&B(&JR5H WH #_9=D
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M_)L9,O$+\9C+^"G \Q^Q?8+\B05?;=>>S":[=+H#"-@JGM6C@ W0N_KB^<.
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M+RX56$&Z"4_J!HV6MY/*AS,N[5$.3!0U_PG8'DJ(-HE0*$$H,WW(,!Y/2:D
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MCO4(?&#5^#7/8%FE6(+Z=[NS2=2_VW/97,CZ"&XXHA\4*@$=Q@YX!5Q<0I%
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M /AU%G0X+"5*\MFN'+\2[6FX- (<I"<K\[;4C.$E&+!)).)=4KG4F\>C5#4
M3SJVN1;BQMG%&0LPY91DGCG+VVM%;?69_XQYAX*-^ O'^N#R%N)9YHL2UZ_Q
MO@,RF?+F-&HSZ3WB>ZT9FVQNM&9\"IE3,O%O.?TRP[[*'SPD;U(&;5.K4GPP
MMCN;^0:&H'PN66F^-%<B)J1\D@[/5A*)Q"GI_7+A2J/,2#<04^#G*Q,RYCBY
M? (W.DP9^Y&:6RTVP,LDHC?&6\DYR36[8QX;=ZEUYAY<:@PG&C QS&6B_VQJ
M+':$?K5^VI/9).D/[?.['SP*M5Z@7!&1LLNHG?62>/F;.F:^(0]?[%] )W,.
MS VV96%?L#RB&S7MZY"J=_'Z%5NXT%/5QZFWWW/5ZPY-2:5* >Y5?UG-&[=.
MI\^Z>5X_-4]/S^;=<C*!_\;C/3=%(K]:8214B5SL^63&G<PG+%$%(D.)2NMR
M47$N$#=9/Y V#'5&>*DSPELZ(UP/GM&9MCI[7&>/5Q+NAYX]?K).]GAK%]GC
M^VYDD>6\O?%\<N_<R:CORE9[0AB>I!OHE- =OBY\U$FMG?^T)M//]\;-72>J
M=XTGDDC3+>U/GC<"E><D5QI9?+E;7WL\ V7?B B=XZ3-T,5Y6V27\?R+*\I
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M)6 #.USF:OV+WW;)[[KB-VUNQLX6 8=P:YJM#/=E4C: .,*YGD,CL)]X:Q2
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M^)$* <7YGM<_!V/+!?8!+_Q$9+V('M<"!7?21F<ADC\E Y'<UAA@*-VA/EK
M<Z8A9A1)ZN2Q>B:4&E$^3F3%O>6IY65P-=FK92NY,!*M!!',(1<R/AIDC*UN
MI'6D;A/$D>T#-+T!3QU0116FNM$]+!J<K$"'/S(?/#Q*@6DH@4R38]CG3IX.
MO9H7?2@'*J0+[[Z%M0Z4@<*E CU]2)$X]& +'DR->%*XGDC2YOUGW!P2A)\'
M-*(!MY:!8=%R17X*96S,$]?2^Q&TL&,4FQ,4FW2K#ZS336GB4;QC'0U?I*MD
M",Q7<1"8\,=L^CT?%M1E:,'/_%%X.!Y%204JH#;QM(Q<\#CM 6;N89QP$F5'
M/HI4*P&%J8?^56HF(,Y_P*+&"O.\+E %P2IF@[3XOP4X'"@(J6YGR]4TVD98
MPLJ^\?./CN/0C ,>K(\BMNO9]G-)#I2&1S%^(8Z"3/ZBM/K 8@=D2BPZ $IM
M ^X<S74@6<83D[F@0XT2&?8D<B?PIFVB0B+N#X9_JXKL2#CNGHBUY]P3IO./
MUVO,(=+KLE:),5,7$V:',U^RK=@LF8KRC!WKEGO"O:\6E=C$QQXA3!(Y0(OU
M*2U3=0#]>S9\P@N.C2[I$7!F#K.",#\'GB2$>%>D8(ED]Q$OR)-E>\!99U$J
M3, ;_PUL?S";(/,?L*C#'BJ4PW?BBTRIF"0*+&3B+6;8 'E1R@OF%J,V+S9A
MB@Q^H<&*I"$7@_"83R_[RV'3&=C&Q /T%S%WI%D;,^X!^L\\8SZ='B,;6LJ0
M/W\5EXK22$,]/CH]KKWQ8A E]V/563^QWKWBX?,KA*TI5_$65][BGE_[<^<M
MR30]J35/ZEJ>9U4)81(1HAE]4,[RT 1[7+7+V4E :5_!&*3-$7$(VWUFLL9%
MYIQ[O@V; ,J?8,)7U,@34XI$)A$P$\H!)Y,J+N+@24&4P<5BF">-NJ$]5,QT
MLGZ3EXORG[PT)9P1O(# =?>D<J<+M76ZD.Z>5.%PLDX!TBE 58/[H:4 S6?W
MK)$*U( =K)1D)+3[[?=ERLS3KE,;$O7=ZX(6A!.':&[".>CGV>^>;]8<UPJ0
MNOC1/F;'9D8;X[D>QABC?L\NUB/ !,H?:H/I/8$;T*E:!UUO?&^29Z&^]X-N
MGYOG9_6,R5$^D^,!G->UZWYY3S)RP/X!1-QUB7(%X5:Q9K/L;I6NXBSX0S0_
M2G:,/R#W2B?,;]&E]"3'C!''D;Y0$6[(GP5$7:/DSQ1(D=T+C$?;<9+.%&6L
M1WPP"^8,H=\7TR)X9I;%6T%00#-RPN+[TM^EREI%GPF1<FD$8VQ3986\^(^W
M^)"^=FR'/N(3=.9#'+]CSQP>>?%HG$A&6Y[8L:T\G7H:S&]X?K-JD2IVZ#$H
M-6G9G0)VJV2[)BN!XWI.?DK2)3U4%A_EO:Y^9$H/?![HCCHMR+XJ2KTJJ&WA
M0JUJ/0Q$#>O-R;&7U!*#AC_U9X__!CGQX-V)@,Q]U/EBWXQ^N9.]>:ZE09:3
M'5D)1[&.T</($18"BW&M=W'"G#A[] [+TS?BX]^+R.C$''G)W#1$7CZIX(K"
MM;Q]'M\DK(-^VFKVQG=.17P,:6+(FN0]8GAH-&3MS=/8Y@<AK*XB-IJY\T7E
M_ /T5JHHXTF4$;_3-$802MB^1YX.KBN:TY;7.1>!;Q%_M)2..L:(4;VZ+%=W
M'&J2*2N5E0ME,IDZ+2ZWYV]:]"IC^D1N\OQ],BLYZM,3S5B;&U BQI2)CFHT
MQW9A/Q_>;3;57P'+QF4]!3QC-(J>'_5/H@1AG.1!<D3TF<,>=OXL$9*F!J.\
M28-(Z(9]X!B9C:<3;OR!)^W:4;UVU#\_-Q/<13EYRL@,*,$$8U* @4QD4PJ4
M0]3R/2>5(B<CU?,H'+,ZY2TB+!9K7LK0)5 9@)%A')N? 6D./H4I3%(<%Y*,
MTD-CQ:?O+*/D(0&N@??DPC-DI@)1EP(AKM?9DPD#/D5MK*V =^CP!F+&$B4$
M4;L*QG-K!L)\CI5"!:'3@,(T@O_!9(84Z:^AKG;= 6KB?.P=\#WQAT04N9JX
M+_>"Y9".Q;.9>(D$@,5'L,A&DDH;\HW3Q=2RAT>V*S!!]JXF^ *P*<\$4__Y
MP*X88Q8E3CP /($A^:_7A&84G2J6T5[V3*F%/:&7NU(7RMV8:47I4@J) #,2
M.=AVIN%'"?/8D91:EXAK1AZ*6TIO0USX;4D^6_&B /_W__R=5@["UW&F2([N
M$VE!^+=X,->/U$@TO4 $21]I2C;_1O34I@@R=DFDD.O9:7H2XGHHQ%]P! ]U
MK&D 7\M/T4\) 'S@F_(SH*;\/$S'A6OK+!(#ZN$P^TFX6VIW#PJEC*/Q,WWO
M"TIU-_SK9YW$ZHQ*R6>P*:OG-\-Z]NPA'+LU^/'D@_P9'BG)"HW:"?"")C8.
M:K4^S1UT^DR 3C+#^;(AR1$E6FPY\IE,,: W(JT>R80,WIMJ?^SX=Q\X933<
M(Y6M,H<D.6@O&8]D/ZO>9V2I 1_^^<L[G_!9B7!3NL=G'JK,MX[5P2!H":-8
MP$$.4N^YC =<W($88:C(D?69IQ+4'[SB1#T:S5JN3?ONPU+/?(LL01/[)N8@
MLR#X;=<T_J;]<4%>O;=HH5D%.I+B@GQQ TN,1!%>-SG<JABR="./R1*H'Q?,
M1DI9T1)<'0FM!T\"J2CR$RLR_O'A:/D\[7K3;#;G)^2^^YP^:3E:'OJ7*J*8
MD9[@ HL\%)HE2)8@(7B) "P7$P .4&N<F^>U^32BTG !K2OL3E=P9EKGKJK.
MO8Q"HG/41+)X.!R;4&X8D]-N%OKYDT%)'J?:,86M+T57=TKQ;-+!P&?X96_$
MTR($#'A,/\I"BM-/U,]9B;@%=4VUS=9YTVPT6_OQ3 FDS0@;[)7IO1TM<ZL*
M<UF#"+'P<.'TIT%)@:0.U$P#__=I%6:QB7J5@]OFKIRG6MTK0^;A>N%L,R=.
MGEEVO"=+<W=E+/-TMHT8TLZVLSA:E;*E9?E-AQ2A3ACZ]N.,8OX/WIV5,P*[
M0"I LV7F3;/>X($6 1NU%K*2>&Z">,;)F<COJJR&%&:?.HA;(EM9.Y3V_9;"
M:^K:[:3=3D5S.VTF27I3=>#F"1!3^TQ[G8J@[Q7%'7,@V]3:GO8G9?F3<FHR
M#M.A](OV):WL2RJ.7&\TS\QZ.T^R:U_2X>D6A?&Q',H^,[0+^!<YB.BGE#<
M.R'[3]+%6F4O>^RYQJWWK(C7NFRQ0[,Z+)_ZTXAB^J_,?V*^T7GRF6RB/IG"
M&T7!<#1T[-*;/.(@0"J?_X/&05%UY6*6+V]7^+-(RL->D"P( ]XGHN=3EAZ<
M')P7K+LWXE8@_S4E!^J*G1=_WEVK"*5%2^8-0KP!'#V7NI;A37W 0@:/Z;J
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MT^]D.A,CZB@-!8G,E?>@731&)1;AC"3^S'SK":B%ZE[(AYJJI<71A"&0(46
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MJ%N4P%U3X:M1X6:5QVTH%>X.D&K+\&V1X4X)P]T!4FT9;B05;E8-YH92X>X
MZ0BHL-MHGQ2U^ZBI<.>H<*=DX>X J=MH 14>'A>5BJ^."NO<U^T)#.>'/6U
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M!QZD\0<SKN$&B:Q7 H<N*<W)Q$'*UP12&TQN#6)?A(GJ,(F'O;__=-IN'W[
MJ^$Z^JOU85\:!H"M:"7;0-,!VA ^4-.3YW\G:32F99 S:82-? @XB(\,))!B
M:4@"B#FK=FG,D(#KQ2LW#;D3OD^D9!3*/Q?45#!Y)D#<0NV2I11_Q^L]:4Q8
M /.2\M-E^8DL>&+:I.F".>4&0^#D9LRDIXHG29 B4%HG'P)\ *#9!/ ,7]\#
M8\NT'D%>@G+M10%BQ'?!YA:\*[I 0.32^M(XZ8OP28 TE1=.3'2XP'K$W?B1
M8^ULT@@\AY<BBWP+UI,7H.\+RK_SWIC4!K6D*0.M6N%GTD<6(\D%WFE-'.I
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M*7J1RHT);!9.6^&Q"4%EIMOR29.H@G)1[@&P<.KKHM7YQE)O@!1>1N)*N[2
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MQ'EZ194Z;\"!>\!SK&A,W_?\T!XXW-2O%P3>P)8USYZ??;8YF0 *46T]]0+
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MG4*+^T8<?\O +LO(X&%[4^VU<@_@;(=9CP?RB^*\%R#!.,-%9NMB:HG,WW:
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MC\0LF?&U E]$;4UN-I.YRL\Z*A^-M!FL9LVN+K(D)9@T5G,]S-B46>4V[J4
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M,XS^E*\D '$VH82I!HY]O SV'"39@T.X/ZE;DM"Q"3 ('].P))XUT%F%.-9
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M\0*+R+\9.:B@T=7I/R^EA-.-(H'5";&+;Z>G1]U6"=W,-I:64U)323G/2/M
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MRZH(I2G-D03PWTT5*;U/15P-'-V!S34QZ8(V-8Q\UPY&1A!-)@YY%$S'@0N
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M2 C4-%<0FC$OA2 ^B-76 7[EW2S +,CSF'M>Z1_N:OF$F;+B?LDY/)CW4ZB
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M#M'\^/P^]==X."5?QJ_^ U!+ P04    " !ZAGY5:R+4[$=R 0 85 ( $0
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M+SJ1>'.X+])&?[O-DK%Y 0L\%NMAC23ZX[:Y>2-(9!: !0 /P)+^>0"  &L
M$D $^ -P%!%FW!+WHAH=-!&SX!&+FS\*341A*"I)UTP4;ETSAZWS(50C\U/+
M?E-CCJ]JO U'1&$Q!!*5AU(O'!&S6 E2)=WP2Q=6G@2S+R5XC.Z7"PSQRX6I
M&YJP=&'N20Q8NM#W1>LM79#B^$6U#L+'<R$0\PX"K QU=$F_:"CG[D"@.];?
M30M['[!X&.(QW]%TT-_SZ>#=;6PQ1 -1*S01\-6A@W8'_HAN14 3*72+(+06
MBO=:PSR9.0")(&+Q>G B? D5%IX6A$54D,\7?NM2@H#T(/Y(O0T)W#^B6R/0
M\W0+/$++88G,AL!C<?9>2%+CDMH+A?%<C!@KN<"*Y),.EDC$^J*Q&,\%$9;%
M$K(+7]'7+M*M4)Y>7Q>L62P@^;9$)B.'9G;>!T#2M6ND9J%:_$U!U29*&>N7
M&FP)7I!Z/A\P4I>F'/-4VK44*KG_"E&N-WQ[3?."<LVTJ(V*(B7!MJ"+:I%,
MX7U%.3<"R'MXD$K0I$_Z!:%Y2N:)U"4*F/+I2/I<I$ HG[)?*!2=;RGGN$6O
MEQ\TC\C%?WT9)1:,"W&F@)]::_YGH4QOJ8SZNS*AI1C.7_.1SVA02S6C'-3N
M)!9RF_"1,HHO*1Y@ (CR P(H =Q)G[( -P "L)-4=W+^\21]PDE\2B0:FG2^
MU"&_.;ZBD763;?R48>GXDGX &'\T>KY* 'HWK#_&G;"L]R.(H,6JD;O,5W %
M+,,U0&<)__-N6"W!FU)M>@(:A4 2[-"FY Y*]8T=.DH9Z82#],- N3#6^THW
M@R<>ZX_[AD2/Q:,\44NY5]^:++2-0B-=KX7[$[&&2 P2#R<B*=[8[,(M#AW,
M\\QD"KG$V-<3^%^H/XT_'OW- $0)_K<4,X+GMX,4/1Q-M(%[?D-C12!)<L@@
MHC'!R,;,=#$-,BZ2OV%F\L+B=VNC49Z+D5HW7WFC13(YNNY(#[@_)0\R!2#Q
MQ!^PVRV2OV5?X^:IBT5C\5\%EWU>0,=PJ8#LACD60_[-1,3B2(,= ?EUX)C1
MI$!^1V5QHR34[^AK\.2TN8Q,Z762\W)D.&]Y"OA"9Z><4LUG,EI.RA6Y0>?G
M(61^P#J[A8"=)C<"Z?0^ '#4E417!? "J#[W?YX%L&B[8]V0.W7- -2?YP"L
ME"N >S!9[O,0X!" A9&1D8F1A8F)A7T-\QIVKG4L+.NX>->OYUJ_GI>=A7(L
M_/KQ0;5VS9JUK&O96%G9.%E963G)'ZR<\R+L_XF"SPT =D:2\Z=IJ$0 U.Q4
M-.Q4GT=(%67^W$2UA>0E'17E6 @C#8"*FI:.GH&1B7D-U?)"*@ US6(A&X"*
MEHJ&FI::CH&>D8Z&19%4R$Y#*\P!HM.VA*\7\0L!TW/&9Y;JB(IQ65UQ4U3"
M'^S691!/L'XZ^@Q!@'!G70C=I)=HXZY_-9L(Y;EE.X9\7G:HL<?_P0L#B:2<
MP^7'FFZ/O\RM:+XS\<K.(R#L^)G*EMZ'KY4-[3T#PY//5K7V3;YA!U!3D[RE
MI?C$0$\'H;@@#.*@)7G@)[*>#AP2STGVX(I5]U-%,;=1_,$$76LN!$'IF3@]
MV0&&39"KMTA.9/.XZ]M"B<BQ)1=^[H'$%Q<^#P)8:"@VV0%; "_-3_<\W1@2
M,XFP<D:=3_#!SE6]DW*_W^-4 /NH&9WB>9M_>Q\K]/$P-(O8.05+*6=89V/I
M%*W6TCM=A,%&F> O=02N>V[&;]3G^!GP?&-JKH=0T<OW'BIA6XU9[DQZ5CVJ
MZF^O<&QKS/I E_L$&4P?;C?64RXX4;O_,V R;__UUOM.7FCV\NU:ZS\#XHW-
M#ER8^0P0MRR/W]AUD&$2\[KNT\&:#\IG#PP['IBM_ P8MQQT[ VI==4[9;*O
MZQF)?:!>[=-8SV> ;]5G@$CRX[OIGP%^J,^ RB&2-CN+<QVMEP-SGLZFJDH8
M&YOQ*PQV#O<2.V0+S(Y0Q2I2!\XQ%32QED"O']-U-$K>']-PZX#B</D;Y6;+
M Z;9:%O_\H2MD3[7.%SJ;]V;$,O9XOY>3D,N0BX<*B-^?E!C*'OXB<5GP)"W
M#;STA@]F*LGNED8OX"K54Y:!&E[B>]VJ-7,G:/<?;0"$5G)U_;&KRNNX^.60
M&(2SZ<59-+7_.[$SA6_3I</"':*W53=05R9FR&\Y^>X\(JW,:9N)%^%2SXZ6
MV,F7$ ZJ6\JJ57OL1NY.#_<&[Q3J:I@=U@Q1W?\\I_L."T-?G*[!H7:QR(T#
M(Q5%QF;0!R\'&P>0=\(5^]<\F[EY<,3PT<?/ /U7'Y6NMTZM5=WI9-!2'KIU
M'4#M]GLAP.JQ>JP>J\?JL7JL'JO'ZK%ZK!ZKQ[_[^#QZ8[T7D8A3E9?'$.3@
MY"T3.0365SX(CI,'R2G( ]2W!.'@"!\D$>B&]$1A-$2>U%T6 :+<-43L(68*
M9CA=I!?*:#<>:;W;W :QVP>AXBZR19-9/4@UR!?GBR3"@4&^: Q!-4A#A*)<
ME71.)LN+ "DL1!\-$<I&#7"[F050%XM' E7D%&01"@H*0&45.9 R" %6]M@,
M!"N P?(*,'D05!8$4U4 JRHI A<.$4UFTJ<ZWMU#U4K/8,$>Z4I#9*%B@8&!
M<H&*<EB\ISQ(145%7@$L#P;+DCAD";LP1'B0+(8@.J]D48\>DH# HR@W>X#D
M:[@;UI^H(2+"#/SJF#?DCEBR@_/'HRE6W!'R2#32%XDA$DA!!,G_2(Y4]R7!
M'T;^)T)F9K\OYNO[0TD"T0KI\?N2!/).H+P5DH#UQR.0)';1'RO2#R#^&47Z
M :0X_% 5"HWV)Q#Q<"(6_V.%7S'\7DAL+#Q_WR&B/,[S)U'10_G^)Y4AL2$Q
M!/*]OY\$Q0#S'P7% /N36)"J8?C["GY< YS[3UJ55$ 24_RQT.+-XY^(+A;_
M-.A$E,=/S))+?BJ&#$+]1(Q<,B^F^45.W1VAZH'%^\*)FBA?N"=2'HDC>*C+
M?Z%^RTI$$=%(S6_,4CJS-IKX+76Q (TB^Z6*AF-(^ F27=@S%]&<OSVN+C_/
MLTRC_/<J*2XMMT[VR/U+&OD%O_!('!R%%]$T0*&10/(]<M5E0O/^RL%1FT2#
MM-5L"4@\YGLN/!ZL %505*+PF&(1<#30!K6<2P$D:X!TDR4G6]*YJB),50E*
M$="WMOD!.U!!4=8,CD=XS4N H*H*2Q+6E)H#[9!X<K?Y(@>6FR\W_M*WOV$"
M0>44Y!0I+(9X.,X+A0 223WG*\,Z<#Q0UPN.)U*8*!_2TM(V7D@@#H_T0)/O
M/0 17DB$#Q!% )+ A4,CB4@YH 4:"2<@@:1N[$\:9'SA&']2""A\!""<1%GD
M= ?BD'B2*BP"22#(D31_,4.VX8%%H[&!*(PGZ8R4WRFB)+L$4I(#HC! (HG%
M'8OP)R=_58K0%\=UX6B4&Q[U,WT(\MV8/Z50!TT:F9<;,7/8^L6"[/_/@V+A
M5U$)4@&#%/X$*E54E514%2"_B\JO^$'@K_C_KY@$0^24Y)16,;E2,/DG4_>/
MT[0Z:4A6-2--5=WA1+@>G(C4) -*%@22!2O9@""J2C!5"%A& :*JJ* N_QWO
M<CU8=Y3'KO](RQ?.93IT\4@2]8L.!=)_D,U\AR#I4U!655C0\17GCW1@\398
M+%IS?MK]->;). =*VJ,P[MA @M17NA8DOE5F9J9JC"$0X1CRDP":)((<"N6N
MJ@A5@H 5(%!9=V4H5!:FJ 27=8-"P;)P%44%#W=%&!()F_?R6_'O5.LMX(M4
M-K]P( &.I'YI;J(*\G #D11#9940"FZR""4ED"Q,20$FZ^:&4(&#P!Y(4OFB
MH:^4?6=H_H$$./HK'G]_DB6('E@!I@)64E'4,=#3 8%40$K:,(B*@IXB"*(
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M1GH&!EIJ4FW8J6F$:>E VO0,EG!&#C^2:^NAROZ9I>57NCFY>$3 BDH0*V+
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M0]Z=F,RVQ]?21*Q"HJB%&=VVL]! Y8]H;[@08#0U>V3;CJ(BWXT#/(D,UEE
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M>=[P3:O6\.I"(LM%!<H\+I[$)!5QI23LG9I&Z>E#A-7*\U2W.Y_1"TV7U0G
M$/J>#IXMWGEEG^R>OJ$MGB<UTB>"RD\D>'T*T&3*<:GM4F$Z?/UQB^V+EX/I
M5P%!;WES=IB9;F9@QPJT^P/.*'">T6'1#U73O$$/F=HM*<:R,V6+9?FX] 5B
M["A:5_]":DJU<%96CGX>Z&A\/+H]NW2W57J>LLO5R#/GDH4[W#MT>5LD7Y1V
M417)]Q5O$TDO;RS>81OE\?I(#^^ F4XE0H+WQMU4 C_M)\?;ON(;^)Y-5\E
M3E]5B#EZ(J!%N+.J\"BH*>--RK!IO+T*RSDMC_*&+9%M4[*C#\TO7HR6 =6.
MCN@6R$W,2(ZGG(DP$YOZ(,PKD0\<\1?-Y=&^VF41,"R0I<^\AO?,^J3VR @\
M;],.W[D9E^&QUXU[PC;LB2S U_HQ)B7JBW-@<%32^6#IK/NY#2'A8D(HO3-0
M9K>(>&<;O2QQ<L\R$;'DB$BB7$13^_1V<QM<[Z[<V_RZU\^K[NJ3(^76>YB;
MBA,/V[XSAY]( 9Y/B&@$4X><AFD5Y!WTF*(3%C85!G+,.K^[.%6V"W/)_\T#
MR)FNQ,O%:P %^=T3R5A'9;&8H<9R ZJ>-3VUU *\EQ5/XZ7]M)C=\E*1L/P4
M,4+$?=.]LO7O1]MLMIC/SK5>J:^1OB#=\S3V]M[$R* FSE@9ZS9VSZY;BASU
MDVMTU>@XY0FA1R6CJ/-X<AM>J/3GS?05G]BVHWZOSZAH7N_ZHW&*>SKZMXN/
MVT5$<TZ*QJT;'TII=@BUE FEOIX(,K4&GK*A">9)%7%[N/VQ5%V!C,B=/GZ[
MT7KY(>'IQ[[OG,!/?3S+S,T=HGR&BX:O0E+IQ@8%IN3$:8<%V;:F9L81S<5
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MLB1&L3]3Q&2?U-4\(7,48&;5Q.X)]DH"F,[:-9G2I!5Y2[4,C]<0(E409:Z
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MN<P!NT(P#6##B$,!NKL /=LE<'E\@\R6O&?*$\_.\56AANQ-H"\F$QTC;D;
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M!$_[0V_W%:9MFBTPM>]!G2#*CVR5EJXT[/<_QUYK+.YI5$_?LITE>\V-VH'
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M5,U]8U^UZB)8(>2(>WUU(,?(HQW "[)).#<I*=XK8L,']WY"Q66DQNLP\"O
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MO%<1U.Y2@!:A30J<-)N$ROS8[XJ(ZMG26@I?R]BD93%\UZ\A@T%9B7;-=04
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M[Y5BPQF^JU&C$Y#RC#*-9],-8@*S<(E%XD=!7VRBK:1*FNT:$X:B,_0KX#L
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M[XQ<+T2*3I"';9\*L-%E[,:ON1XS((0>ZP0C!.^VFD\!F9".DQ+#/*#/5]X
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M.=T],SVS9MY[]>/YH776J:,EJ6I7U:Y=17[1^JP</;/JK;JW$7E 'MV6C#>
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MS\!<CAFGMA7ED<WN9=5$S;J@=MJ3EN"*[.8N(LL&["<UU&+9#$*GB274*^2
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MN@8)$44%?+_[,7'U0S$GJ(O] K@QA!#]X@[/75ZV0<1Y5;@&D>!=."/$['T
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ME0,T6?<# , F6\Q/K$<?;"^\',S1ZT8 23B?'L\!=DT% IHW;IPDT)J>&^I
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MC=@9S?KB]KA5+Q74U"5>SS5W^>!#?'G+O!SV"+X9Y0<;PF=98EL  $0::A0
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MM_EZKM,9:27,M0/C31-M*ZJU.T_ G8X*G+0& (#K#E7=3HM@\-B5[OUK>3"
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M\9&ZV)XZ=PHQJJ+M:4U;@T.4RD)W;"9YLX?G%#?0>Y^:W:!WOCO")+U.Z(A
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M=*D-7 S40G_%Q0H"!*D/BGW R?KC_M)W_S03+7Z#(\]S?AI^:E2)<K4-6^(
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MT<P3:P1R=Z)%#CR2UX[8/5-7JXU520>K.9IB?2>==M1I8IQ+#RQZ<24&7!I
M+;VT A*D"0;N;&R-G-_\ASVGO4%,]P3NJAXKLB>U86[%QZ?;FKK>I0#"2)E0
M*X!422JX#/"*R8+<C,=V#W8K\MN-:QB36F*NF29.H6R7<[Y7_J=WW,/+>ZEK
MFT/&&7XCF=](96JJ,HGSB4/@JI%ZYJ94K46M"XEH).[\W(P8B$:8\!:@S7OJ
MI9@W:/D=#_I-39G\9_0F0O1>X5LIS%X)PY?9UR,=?AKKO$=+6L8\BP6/P!.<
MRTBV=(?:9L9/YY7#$YACS<%M5=W!=UB?C%RN8G=#J.Q>W=9HT+IZC.$=".*T
M)7A4ZJH8J$E^KS9XR4I/XF0;(&W*R.L =WASTAJ&*+$8?84^^)!5J#ZF))FA
MM:"84'Z&5G4^TS(0@R *%4N:=-GU6V;V@ZR7G?W_,*A7R>F9JZPF,ZRC"]$,
M=[D6+"0A8VKLS,9?S/2DN71OZDC.G 64\78Q"S24;"+$'6&PJ$Q>@0 V)9?[
M_%0%AQV?.=,&^[FAO2J%>IKA%+HNJS0J'>><.FW3E!!D*MA7/[&7_;LBQ5E1
M5AU\1DCQ6\ZYSVKTW1"F/&?S=W#W!$ND&OL8O&><*"'[RI>OC$#8DK!\GR5A
M<CNUB@?7[Z9(35JX8Z/K*G05FLJ3N6SF,D8_<SB#R2OQ%0+"OBQKEV?WC1:.
M$B?[K.J$ 2?#_>.^*9:Z%X6C3#S=,7IU"2#&@N-4F\L!DYE1+YI*FC9R8Q U
M!A$6EM$0R:>+FJWL5%HGJYL1NX9SUQV([;?%*9MLJ\KI#=F,Z8)+0W9],F2Q
MU9XN#/3=9EV/6:]?1V7Z'-95>Q*IU?R=!SARS>#%3%DVU6A=U^L<<AF["L;X
M'"O]]C"8R60'+"S,3<#A^'AME>0(=0"C$PXIN)GE4 .;M1<E^CIQ;.T0?/1Q
M"MV%X0!\LO]MVY77"X,"SB_@*Y+%O=9HF;J;X*_#XVG?03/7&J_<G2R_LB5=
MQZD$&L?J^'<2I]_\UUI]YA4/C[=>J+I+XXWM,9.631?UV=2M]9_/EODA#FU=
M_KB1MK-]!'(T'+;U6FA_&5O6I3T"#'LEL*2^AZ]!@NY')!?1OCHD/1>?^"ON
M29H4'W:/B.6:!6L&?9MHO#)DE_*2[&/UA /_#VG<\K^E,2NROS^BE(@,4C*5
MD%<0R.W"J$J^G3<>70;.<DEEZ.%%P5+-WSCR:-@G'+FWKVHNQU]XR]DG5E=R
M _$C($9]_)^(\K&>6NI9Z;7NQ$>7IQ8I@*>V4Y/$J]^Z10/IJ49JBB <M>TZ
M_.3OG'):G^%_B@W$QZ/@]O6#?0]9%B.[U>X^E-/_^5^O'HC'^950##DY%%#?
M'UI:V%W;58_;:VD Q;;T0IHO*FWUZKX.[1)QW4YE+>!M$ + &2P%=5 .7"85
MD,T3&L7_"!1430(GH@Z"EH:],[A<V[GG[",Z.??3S44J9#7-=+;[#D<DZB>X
MC*KECX"_AJ^YV2T!GL*B"(%VLX?5K?NX'G??N8IUR/[MC#TZWY4*"5\K>'QM
M1G.BS/G>>,>'_.+KEXI+35("I.ZFP=R;7#]C!;0CT5.(8DK&QZQ813)5ETCR
M@N?FXT?>(.$%KRU$\HCS\OB+]O:Y'L-,CQ/51^ 3>;<G[=GSGH/2_MT-L[.4
M,=V9A_XP'P&UM6&PF_K$LHAB\"\?G'KASVV0AZ$Z.V':TWK6RR<55V!O/ZD&
MVP!7Y8]4A91#V8JD<L#<ND:3Z4T<5#')Y2PJ83D4]@MC:LJWQW<0O76N@3QS
M<N<1^"^*Q[]"!\&/@'O&'7W6>]ID=J$'Q1/3>_</?.9^^.:\1\EQ2S-0-GO]
M?$UE6Z2)Q%_G%[J%YO?[\AO= @[S?P&]\ >9'@%SE/^8$7V\G-7GE'P&[6*>
M!U@V60W>?[?/5F+&%!JSMT]9\)5Z;7'%J&&NQ&GMZK-^V(*_6JI(VJ$GTOY1
MZ"+'XZ&T:=L!JIKF=,G\O 5[Q\V'N86VILQW?>E<2S-H$F_B9*[5=BO@ MY;
M8KD\^BL/T5!CE@#"R3J.)CBH%?)W282=?A2M^<19*_.FK>FV]>1PRD;'G=+$
M/]I8./[9QK*$0M]"'A"_3PYEZSU>R:1N==^L>LMZ&FD*_\%V\$U%\LAV]:I^
M<]L3O&LZ'U)5D8X7<3?PC[KD.8R^@826.Y<,T^XGCL=!Z,;KJS_\+I81[:\P
M_L..VN+$5V'!Q,)"D([0PN5BV0KE>U-]$9YO7,YXFK:;!9HE74\X4)W S'MW
M<_V0=P7V=10D!]H"?714/)E5YFY-%V5@V;ND!:S=W?-[C"!2>R%&IJ7LA>4C
MTE3;-\2P9^6X^K@62=XLY"]C(>#_IQ\1[,9@L6:A[;?I@M_#V]HO:W=RL08'
MX9*NETX<TZX?6^4S"$KF+IH#"V]XUG.Y1ML?7>3VE3XD0)VTC6>BDKN7+TD5
M/'WWJ9H(A_6#>:;(T$F;YM(P-&SA_79I,'CXM]H5JQG)_?8S%:UT]>8Z?J65
M9NAM:_C00[,T)N*GN+C,\_W8X\##-OW?=]4;0\*];USO;-2*SUXUL?QH#)I.
M"6IK8A4F76SZ9*Y<"NP#)M,@3TR^RX@R\L#/';<=[9KR(N^:CDKM9WUJ+E(2
MK%S:3D@'LW8A2+']FK)^=UX^(K=ZIZ=]_6Q>1J$MTN5\/:G-I"XG=T!'"6E0
M"YSF1MF[[1LC=+>F?ARMOKC$D^1_VQV$GXVU_Y8E(8(%>\(B"K6+;F&AJ]CI
M/& ]J]9C0VCNVV/H9$> @Y]$1,N@>N83@2/@$>BOP& .+6?8WS" N42S/#*O
M)&0Z'%XG20J=VE4?76%YLCM,6Z;<X[FN-ILC,L^Q+!YG,<747U1E"H%O.#K9
MOEY^M2==BHB&FOMIN/,:<ZEQ(K0P?Y112[J?9W#5HIBK=H*+V[*Z"-)%'!VI
M7?XM2KB8ZI:>/4%"H=23*8-712T=X-V$9"=+?N49;OTI%.+3CO#P& #KRI%Q
MFGSAD <CM/9[SN1#2:T_1ON!'N%(K2_M7Q+D3Q-;]#6WSQ\N&.@1.'I"@XGA
M3]1,^JT>,='?_QT::&%MZ)%:HGG]_Q =QJ^M8OV>Y\X6L>&>='JGJV4L.K$-
MIWZEYS.[R(!0K904[.(C*IC@RT?D.9#$K],'?7)98*Y6_&Y1'JNU/V8<9U&E
MHUYZC9,?A^I4^/;;,.A#+]6+$%[J$()L:F1_QDJ+3ZE256_/S?HL$^!ON8H?
M@4:FRW .0RRY##J7YF%FFX:85"EX!RE<-M0VRC>D0L6N"8<?.J;7BJBHPCTZ
M-E(EI8]; LF=C7U7NGFBS<,FWV5=LMVSM?2MHGC^7LM];U%ERZP\\**D2X3T
M+F7 ZV9@'I*QR1W$=-L"_%;;A93WO#-D*^D0;H=1.=!&@A>/P&O+*I>7C%0-
M\S^\U_L95)@WG,,R5%$14),[/I?LE#"Z?#_[)418MXB7,CE@6K 7QSYBF84%
MLMD)[ND&F3BJO0*9Q%J&?\#14GO^8JKP1MD 4OK=1HV1:XM;-W/ W%\NCDXC
M! X5>QDW!!.*8J,3LJ%^+C;3PAZV.$2FQ:Q?"Q!#K,J/XUX77+W3'REZ\0C<
M$ON]ZWZAEA7$8U%7.]SO);U0YZ9G:N1DB8P^P7HGZIVK>^=FORD=BC;OG-'1
MTA8!O2.7VZ,:E#CAV@FS@0>3;5S62UQQUKCM[I[,LMN+L!^:C2V&^EA>I^FF
M7/_:+:>K%) </<J]*HR5_S"@KMML$3I*7-*_\2H-DS5 NB*;!?,1""-N*:_B
MY<'$.N6',[BWJKZ[S7D$&(?R=2L?#I(_"KB*5"ZT3$3?]Q.2R[M-QNU"&C9#
MW4(Z+JW_W!#>WMO=*O*O%3*HY[Q]Z<M1P UU/V,3?J'**WWY")B@#^>Z4O I
MU,ZS[M71_OMVT/DAW/"W$)KT2:G[(M SK>MBCU[AAM<SN\B'3D5P[.M-TG8I
MGO[[/+6Q%N*7K[M:[9.\R<TR%0QV+A*195ZT'V'!T6OX-%-6=H]ZLW F6"\2
M$:W]^NF8_G"BW=Q;#/Y'OBP&PP% -N%G)<=/'GHH=42OP-?83/\0A,(!)<_>
MWOI2\W'NLJ5KZWW'C/:OD2]^[*3"M_C13ZTLSO?/;]B<?)8HS9BK!'(L>T9+
MKHZ(Q8<3GG(03:<:?*<'E61L)_3E\Q(BL;.J*RAKF+BN6TPM!6^PG,#8L?JT
MH6NV-J\?&&Y>7B(]UPG5[_+%NJUO\60AU#Z1ZOH7JCG%*= 3NT;;5ZC+VB=%
M^_:'2![Q7M_%TGR/K)_KX>UDYP]KY1_CG-97%2*-K_O9226!I<V1[L/F^(:E
MN<R*]U63VDT$M_5$64L8*J/>SZ6^1UX9W>3+>TY D^M\E3L? 4SQ&KVV8^+?
M&_F2,6S?0,_:<[]A6WU[HLBA&8'+@BGTD:;0+M!Y]YI XQUQ3UMW5:[6T?[G
M_&7#O7S%UXE#'HXO#:?%1PZ4KSA_+9YC,%27QY[*;O77?C=Q/I*P]<PXBNVI
M")V].D25.AQDN+[W][MY>6:>\,+W[^#%TD/F<%8:TXN9_G["D0RN@TOZ[$M&
MQQM(8\F.0ZI]GT# \5UNT.&>FS[O__"FNCIN>;%Z4G=*3V=8FE/Z8[C*^J_M
M&!,>[!77?<&X=L[A$B'7/:=^!,A(9L+6STHT"Q=R+,$C V/[*(DJCT"PWD.G
M\]VS/7GSV\ZC%?F;STQMGX]._2)9]MJS!P2@$+XL,+O&(R"@?2/=M5Q:5 >S
M"['F2#/]@O((K$D.CEI76J.%/K5BS3QT(_R+97JZN7MSN5E1\.4V=4&$K\F[
M]FE%_5?^(D)KY%"MLOO+]J([0KZ+#Y]%5CUIBW,O[SM,EA\X?I>F6RLUFE.5
MQSK0.#GP@Z5+T*!I]8T?:G>+DWW8+7>B.<Q5RH\KI)!%M\\GZF_&<6[I%A0S
M J'MV3_$>+X(^'']PZ-*Z\9AS2*A5GLWS$R^&E(2_23]ZYH2A[\6%?PG_*R4
M %5^1T$Q/8VYAQ[F)4'JC=2C64AJVHEL;R$W$;::WF'XO>F395.+3\"W_9@S
M$.O[A7\!T%WQ2S:,."AWT"P7 R__:C75 VN7'BQK.A?^:++T&]4^^A/#,,^I
M4W)LDDJHJ6=+=XM.O+\>-D=O/9Z@F<I^^%Z1B#[IA<#.8IKX *<+-:G RR&>
M[E_O^KG7D?S<Y #R3E[S+ZMJYO>UT(0]#<<U'^J]A\;S=Z@*>XD)=3<)BW,M
M0KR?MV;?_,)_LJH62D)6W*\%$^8]ZQG^ETTU8@EB0B(Y6\=9P@%#VJU]QH[V
MCA8N@(0]VFD#[IFTHW]Q@3(V: 5H/21Z(![R'G@]YZYEBDDWL\_=<-J'#M^G
MYA%'06,&KQ3XQOKVL '[0#UCP2P5]7T9WBU-^+= L0B=/<D&1W\I,=9.4:K<
M%R2B&_BS%3F8IQO/A@!>Y.@JPDS7XVY^UD7=N7K[W6)<KI/21)$R&_>L?6R&
M-ZA:U589TR50%Z02'GA=[NY<L,YKH-9C=3!1F&S')NTKOG"1S5F!^L'Z ?Z4
M4!?JP4](-7'!".U\77*L$1+U1W\<&02Z(O]X?X0M( PP*U<K8X%TR%032]N7
MC)IPV%[>TO35IL2TH=8;@Y[KYLA0(0N54D<R8W88;Q:%5)4+0-Z<G\D<"A1\
M<++;:YYAT$W\T/=9 :33D"@G^,"D0E4J*<4YE4;;D_FA]6KE]0G:VCY_Y*J@
MT*RL.U(=6!^][$(_V,UNRM?6<: [:$5E/DAK)8F_9IX((E5W=3.R/NFRYZ1]
M0VTF(!3JK*]#]?OX57_L0+$SV!2X-LDH':]Y1^:F Y6]_&1\=!_7=\!8 G&_
MP>&*ZX!MY36/NE,D1ZJ :R_-;+A-V='_:7)MFZ*F^Y248:*WRP#_+-,&ZT:P
MR!$?\P>2B+&AW;NC06\\;EPR3((0+V$;*@EL=_>DE_]EDK7\ATGV7;TP=0-D
MRF#A/O%]OP(%].;VZ,?&1E6\D6LWUJ7%14^;-S^Y<A"JISB)-&7/-VO!W]L5
MN;PVN9X9#V>*QF%OQD7.2/0'-YY?@YG?9?T>]C=&AV0QP@XL%L">>\[@?EHA
MD9TAAC8'(VBN'%%6F0UG6XLX9=B<(O^_PZ5\+9?;SD^B\2QU;"F5W0LBT>3D
MFV1@WX-54?@G-O/-^2&:.WWO7^"V9Z<#_&N+0RF7(MM#C\  V<3-]I*0CV^"
M:@;LP99D%>(#I$C+]S/@6\I&D#I;]H257Y(^$GD)+F?05/S3M3@FLZ9E^J^Z
MM-*.?]>EG7:AWRD _AB0<*7C.^&U\N^IDS UVG(8G[3>2=[NFU22H:4=:_69
M0&GC-FOM*_^[:5'U?!S?V;HL@#Q_4>/NU.YG[?_9D\;D@E#,7=;GH9/(R9>_
M,*@E#6^.?P3?KA2M^PQ+O5Y.N$1<LAR*K<N%4(P^KIY,QXH_;PY$[&]MWWET
M]Q>FF&C%R_L?8Q+]8YZ);7V4;O;=>Z!BJ=+C[>Z-_:Q=PCUIL^]1-?/8E_M&
MBZ11;?"1 'O8J#CI3['=;1E8H>8U]!;%:#,2)@.T4]&7[J'V ?WCR7-@G)4>
M88(TO_"WUD8.W?TW]"M5A!CYHQ7@?# YT<C!>S?>$>;S/I'-R(IW7:DWRX=)
M^?>7:1<4>RLZ61MJJ <(9N ]%>)ID26I?MZ;(-6LX&0?GL;F:)FM>V/[0L4S
M@A*^MK1JZ[D=KL+#N0:-]%11ZAIYX4,\H7EJ$*#$Y'MRC'APW\0[U;-\NT U
MN&@]ALH:TSR%[+N96'ZO^V$K$Y)4?7Q[.#M.&?#076=Q\QG=61U'P^?O2$^Q
M:4GQSF88SVV'R[5.#8Z1+Z;^PS/G%E^^M$I(S[T@(X<A"\!)TZ9GH!4],'0@
M5=BS@-\V<%ZDOA](N?]MVP&TO[/0TG/YRN[X1L>S1/9"YZ$GE>01V"?&F"D=
MFJSX:,MQ= %I8W,<2Z"!FXD+6PJX)&@U'DO.0H5:%1^#RK.F]Q3[!G!(ZKMG
M[&T[*SN,:O[!T/OA*U=VJ_!CD9 Y29="&.OH1^7$WGXY":E ]KMR(CYWD/YH
M^1W_NOB]NTQ=Y7A&KBSS$EKBR3GSH*W]MOGD(Y"RT2H<PX6%=1[D/E'Y_\BI
MMGX4J$?1R^1+"_)#YSMVM2<:?$.E1UZI#-Y?Z;WEX]"RO=5?/2LRM"D%B#FW
M"<Q/L\>6Y/"J#8Q'YU_DS]8=P(E?/LC-9XJ]//G7-576$TJO_]> L+KKGP).
M;VT;J::V(_KR.XZ3N;?URXCUL8.?7%N27_RKIC>.CXG'Z;=(ZQ#N;P[?*O&+
MY]6*&91G_YO!6LMP-0GU0EQ)"DRK.\2A?F$DNR0K5R,5&T6KW=G+"O+"(I.
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M.55LY<RR>HZ1SNR]B%Q6$[K4%IEN@SXPO/%.?YZCFV"SFF(287>OJTD?3T$
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M0QY>?X+NF_L:W7*Y#@V>^^];-3J3VHVZF?LI[A+\4@4VVVL1SR7#262R01\
M<<DM!UD'-L0L4(T+BYO5F;2-^D+B78V>\VOU:OR/:AZ7FDX4@02E50>(%A'/
M/L?A$ZGC1XBZT33^%/#IE.*8$5!5LR;J:OR24/8)TRI"&L.+ )@WZ55>-D2G
MK)?V<55PZ_2)XDQVS#%&FU\FPMDK"P\G($J_3)AT(42^5!Z);>M43\-&$/F@
MG0&B;+5BCX(B\@5])N<$DT+[@X='=[%(.V8TMY 1^3XZ=B>N-SNB[;,77#V7
MDLE3[28XL?)2@707O+!N$R>;J_O *6F1;K JG<Z4%EXUC^QR[C'T( 2!3I8N
MG$@R<>-T,S.Y*CU/ F0#_)F744ND?K_-OT_T';!HM>,K7_6\?U;Y'.;BUV*_
MRJ[!J_T2*/LEPBTL/IQ&E,H4)A+$&B #,PC@$,A3 #"?B8:BK1LFWR0;:H\,
M3/15R7 -E>OVL:3@:HG\!4%9#%BNT1(]!AH%^OC(NBY*2H5F^TK*33MLG06R
MX2<W0QWZPF \Q4&  "M![^54BX,AC:ZG>A>-4/,1[=?G,IGCQ S#2N>J5Y\P
M$<]&J$1I-%CH: 2$<G[NRPP&G2+U_99<CI7['\T5/L5QE_'-%H01-\0H8'';
M6@=+PJO02[O'(_D9_#[H<^%*2Y8#1F'@?ADJ<U>J@SHDH-Z59&_CV""0O/^>
M,@R@NDL!88NB&UX,M6J>P R<EDOM;Z9:V\+E6#*\9_A\P3U..<8+$^:4*L7:
MUL\'A\CK'X+TO7C1'V\L \MH7?_*1^RKY7%E@7>TUGJ9:Y;_1QSY '1TD)Y_
M4 !9(2>#&OB+(<K@S@ 6"=*AM,0PHFWK#"XN#":/='H8<BCIO4L!QUJ4;*:D
M,MQTP<3 )')F3LVPU< UIKBY+"*!]O=^5%$KZ6>X-F%(*1*;#L#+@E8 >,Y&
M10"@>G/7"E*"8/Q; 1<$4ZFZE=I-UPO=7 #CQF+.R\[,MLN:]._A%_EZGF+?
M, [>E6DDG[ECJ4XQ!X],1&2-E$I8\%C.NGPVJD"D/P;B(7'QK14Z];[E1\ (
M;D(]#HE)1#Z9OL6>&R7 (0!NAOOJB[-QX_RFGT2B=5_LJ)X:GOR,%2(H(>W-
MP5NO-]M;"8TTDF@_$R)@G?W]E<@LD .<.ZCG](3:75]%7^>\DX7=:VI%V!92
M,3=\#G5Z/L/+## KL!C +289,G%P:RO3G,9XQGS#?\GXD=36T"QO W=*?G+P
ME"JVDR&8W&,JOS>^"Y.T&Q-M'M[;9>0" 8MHL%&&#F?/YRS B*Q-$%/SJR$-
M5C)7;HOG"CR\5GDS#!#DKA,<"(.!MD;WRG%:8D4<]N!APJ$2K=9NLD:[FU7L
M_<Y"*X(RWM<"!\"*#I4@&&85$'3W1].Q-9/"_(7&;"0Q[]HKATU&1L'D&@K4
MHL,6>'X+P2D50G,7LWYHPW1X+C7C\VO:RCKZPX>)Q1'E7F=(\C+Q56C]3UAA
MU OCF[,W5+R?B40P W3]@S*-D0RV,BP[&W\&7:W<M,FQF"?SFE;C2XUK,0NI
MHN774B3O<HINL:;.@MB"Y8V>!<L;XA!(.E%147\F&EM C*#.]J0^R'F=JTZ!
MKH!4-NF)\LL.5].^,(=\P(>5"NN@.O$V[->'FS6+HEEMKC9T);6#.5L5/ZH%
MFA'YLM>5#):8.!0$!C-A89A?$%"7G81\?%1EN7;EM?J;92/G7)\W%^0]1#+G
M'<"C#FPEJX.55K%*!,(  *<"  R0=IRC@0(3C\ 97]E:IDP]_EYUV[1&>MLY
M'61T;*I6DIUG,#R<Z+  W""Z*YQ[@!?C+RB;8W;3>2FLQ'0I+!T3\OZ8A>;7
M917G$8\I%%:TL1QF&.OV$\I6)A]%NB\U&'07\Z>8X3%%!>]C@E_A!K^">?L^
MGA7A%>(R@-8*TUZ.4C#0_S1<8'KYE8@:HR@N6G]!':%U%PW,Y9J8*K1MBQU5
M++_ :<LL'2X5?-QH96[^,0(I00#+*=5,N7(,1F;T((2KG(^#^]E//N=SCYV1
M*\XIN=SJ%;Y/*FGI#9OF"GB:<B&KJK&QH)0V5B8=8KBKAG0O47N\3O18.L36
MQA!-57Q-4W0Z9"Y>@!MU85@?#P5)[X?GJ^\<!4Q9N/GN(U4Y,>U&+]KI2Q%8
M0^"[$% ,8# 78I:B)YC?P =3D(@*EHR>MB"<I++<==7=-/+->BJ'M/WZRGV.
M?$A@47E2:?M0#G+-C(WB1@\^_?'/7WO+.LT/ZZ$7 !W$?S":N]<E.1"B); A
MA=%*6L=EX.;:SE%FZWNE_68#.X/;MM<([)$9(MHE#\^XJ>\HR:R]DA/F6]*$
M\ R76W:(;=!'(!:9JKG<P3 8K&NWV@FG;!,KM@$/BROF[P!+JBF">KC(.SRV
MU"%,65J6;WE:C"!!Y#$=H>*HU90W\RV>2>)''*>I&YL-OJ8,O02I:FI.<2CK
M?)44#L$61;*D*(!$W03P^S-*N;!A7;*.8'4S,>&%H&L(K=AXVG>6KDQIDUI:
M!F1[^:0[!;AI]&[[J@[8?5"+GK6%L\^;^(XV1BH8R<,&'_897OR=3'8L)HH>
M )/NL#:G6A?\F6WGQ[PL&[G&.MCVO21W>"M:V1MT"]:<[W=$HD3/[0'6BX=1
M#41TF]-G J1]._I@VC.UH<NP9(519%YYSD,3,:Y1JD^]S5$P9R_A<'F00]%A
M*=?6VIH^%ZJMDOAF5Z,HMXB8.T:38+W3T71>>07SBY&  FOO/F8B$LN\^O,*
M&<($6F.VD99-=NG;ZBBC!2/Q-\G%%!/P0RIXOC1 JU%,;@P,YEJK=(>:NLZ(
MI(MI?E"4QG0>-DDEU8(99<=$M'AI:D((N2D:-A,,WLPR'H8VVE=,=,ICAURR
MEO9=P*40_(%-<PR31-05<-X;#)&O#L%PPSB26$/1)_)!0BG[9%Q<^L$I@NA7
MK60_:2HB;YCX=P"++0X+JTRQWBAL/HF-35*FL?SX>2J,22SPHA4@-F;*:5D)
MUJ^;QO1'._)(!&"T;4YUN.WTXYL9." &>:G:2GN>EICA!=HKOV!-Z-^^]Z\T
MH$* 74:!I4XW]CWI,D^LD>7O':-^(=M,Q\<LZ\&N5VAG#VH=>..B@!RJUHA'
MB8K01P/  0*<=PBO&B7Z>(C);H8FE3V[<BMI%^QQ S<:Y9Z]9;5"CO]!B>:/
MA;K,8^ZC@8[*V<A9$X[AI2%F)$59V3EMXS1?W'2<!RS>4&A@,Y=TERGY:".E
M)$SUEQ&3]4AS0G].5UL96]&CT-D%6H 0T67D=0K>KZ-2P%((- V7G$/E"4!A
M\]\:*/2_Q3S+[3)+74<RD$/B&_$>0A7'RJ\[,7CXQE&CH4W#ZA,PG&M.Z>HJ
M'[$W&4U3)/-Q^&OM-Y+05P2AK_IY^N2587[_+&5T3$%<5'^O:.D6H7[E"S\O
MPQ@85>KRB\OTG@H#CG+_BJ#:7<)B$@GS2KX)^#DQQ;O0O91NY_D2SF2!3#KC
MOO;^]TX=9Q19.2AH$<"^*?A.IPD>GS<)OGFVM#T.F<.DO0U"4XM*P&F8;"C_
MS11#UH#>-+]?"3: =KT?IC5[T+L>EY78'P!X@&6VQN^)DQC%!Q"$\E'I5QEL
M(2>AHEH#)B(Y?SD "?UZZ?&=[*4KU4W37H^6$;_:X-OKE5GN+3 -$];(] __
M@'W6Z@ 0![-%.: T-P9&4)?(%6 KXFH=<1,BU<J[$E]NLGW ""8@Z[MJP/17
M"-QR IRFO!.=V&RR$%J:6]1^9+BG_J]0JE0XU^T0AZ:PZ=366,T&8ZGE-Q_T
MT>Q'@'E)Q&V6VX5@'?(F6$7^7&Z'MN\J(472E+7C8T^X%.Z5_1Z%/<RP':^+
MB]U2,@"#2K/2%5QK4K>6J),P_O5/B571.YMW!#/Z4B*643T3FIZC:$]#7.I'
M(%Z&I+5[D2MU=NDP(?_^*N/"0"=S0QWU ,D,RIG#0S#DRV"GL^[N>?="L_ZM
MZ]''99'<]VQ'GU:6S3U?F+MSN$9[V=P55/O,N9E&5/)Q5NU/2-H--PDMM+@Z
M#D;WWOP(6-FO^-QVU:B0<G*1>F[\=G3H@1S[5H?R-E7+Z\+%?:M\XT!DVW6R
MLMNQH,YMTDWL\A'(XYWH_$\ -R)E=^,18/DHU++(6-)AG="?8Z78+@=Y@*_O
M]A-8%KA7;*343'[>$7 %6W/-HE,ULZGEZ3.R(2S4KWI+#G(U_+5"/GX*!_VF
M%K];SUW!R8MQB1:T'_CSP*KE.W=*RZWOPL@,_;)IC]Z']%MV1Z',#F*_D),[
MC:RE*$\HE*'X&'3PT!/Y\$[CV\SN@'M;R?"*6DN0N?.M_JB 6ZP&?D6?<\"L
M[7'HKO9'_TLP)-+8KZ(:KI4\"XG]ICU+G3PN":Q87'Z?9N%#\&^3W1)MD]^+
M_W;8D?[?#KO2VTCB5BD1,L'>"[ =$EC5+%[ZS$:LE*)R(+%\X]L 3."?2K0,
MN>>F]A+O L).+C$MCXHV]'A>%/#7'?IE&S]H/)6#;_^9XSHL'3TQA[/O&(75
M7?X,<M%9;,/J?Y^86[!ZGD[,B/62I)6Y^PO5G_X]R&5\!(BM#?U.-$8$_;XH
M96:5Z'3#541D/#\&+W3=CKCW+T4P/Z4.0$L,%+=G3+=P\@>EQN#5^&TPZ3S2
M[@3>"J&"2(SK/!Y^V_W-5-!(D:HWE =C]]1ME+'U$3@HE1A<83QP^@!R#6GB
M,;[%Z5MK)],\&%:I@].?:JNJ\YKS!0WQK>S>8IX9QCZ\PR'-T=67+7T$W+2G
M%#W$A)[QEST"[372XTT')R5HY<<WE:/Z\Y#*H[)P]==OW)1&TGTF-D)$<.=:
M4J-\[_)@.C_((!&BW9W?^_B6F>>]G'L+M]%Z^ @PX S+<[M7J\-@S:#J?R@"
MS[;@X!WU\V:M(JN5:@C#&5WGI^T;:/*XWQG:76^4'*PI>\PQCBB4D]=AKHT+
M[41WLQ)W"I*[5N5JP]UTCUX-G:,] ODQ/X=TW-7 N^"&@I"K+QZZ^1_38A5=
MRDK]:I^;[WR+([HZ1/7#LU0;UF$"G&4RU_+5'W#]"+<3_;[HB=B;G1B4EZO9
M\V5P7A=37C(Z0GF131";DYYECA^B"A@'D="[SD6K#_RCCM3Q$3![!"3IPGVM
MI[,L[0_(KE]&=\RT(E6 =55_  =;DDOD^H=;7!5;V<>H/*O_I"MKLI,C_[@/
MVX+B3";/,E(Y_/XV4RZH-(.HE]8? 3S]J4\2J6XGKLX;G5DG72T%WXMGM:9L
M*9OQ+08> 2(61"'>LG]@)ZW_&SM)?$NT0/$(E"X*/ *U"L,I2LR8I'_B#-)_
MQ1F>L,J7^2X&@D*7X=W><!?>+];N7EKZ;*<0+B0E,(*+2SLZQ$(9+H6?AU[0
M);F-[A%@7&@K%^TERNE?\_S 2[0_L(+"/ +2I."YIUC#Y;M&_7OQZ]-GTVNJ
M3\X^EA^W*\XHATTTAF.CD*2:I.P2;6'S)(Q\*.9<3\AN_>S/ S@YKSZ;FXA4
MJS_AGH[+W 0I!-V?DY@][3W+!)B8,J).9.C"%61-8Q2$C@9Z&!@OHKWY!#)*
MWE%<3;/?K7/.' 3^3\0R?G794^C4YZ_0:<9_$,L8K]20K!;$T-:@Z'/#!F;/
M$I?/ZVY<?BO_+4WU5@+7YW!G,P:^TAVV9$_-Y#$NYD[O?Z0>#["H*1R?N\/.
M#,D*>CA/ZA@(;979_G[7I65=;LYZ>K;3"1XX1EN2%X8Z6>D^CH5^V@-=/+65
MOGIJ*Z46N? 0\K[U^N]L WY /*4DT W@( >(2@+R%+!4"##DG+PP)(@. !5O
MZ\I4+%BO(5COH]2J<P)[.,B _BVL,4$[PBL8M["PL-][I3T6UC*<I#A)!"ZJ
M!$R_ 1QN%R9V<@XA'*X$!05EJT28/5H[G*1:YA=OL<6E&N*X/8[9:[>MSKH6
MSR,,FO3F_)Z3B>$EN9;^]:\>&*UICT#:+EC/1^D"I"'0@0]M,A>:<-SL4<?-
MJGU^3F/1TT\H"+W[/FB^LUFMHD+ZDU-B$P_<9!O)ZS+YT*]E +U9,?=[!$B-
M=,HVY#%\\99('M254X#]H[PD<O25'O+"QMK?B_;B42=7#U/&[[UDB S%N82M
MK:1:V\^OC$S17*^.MB6'W;BCT%E$APHZ[N!(/E;B6-BI%K)P(Y6QU+8\WW <
M=X#2MW3[,DY+7=WUY)S.FJ4?CUP_QYMRYZB$MMQWTU/M$=AE]Z[]64*7[U6X
MG31<Z(%6%*^71,*CPD?.-C$!V;W)SB)CY(\\X1.U#:C=4K.YSK"$?Z*9A'9S
MJ\H+_#.<X=-Q0CJX^">;D4=.KN]SU=14ZQ2E-IV,5L35*2J]NC(D\56Z7L/U
MXN@8*;]#L*9$P7@GY.5%Y^#1=8IX(<.I<:5%=[% FH6Y!XU/Z9/1#M5#8=+;
MX73!SG@+.Z4$KBTDZ4WBU6S'NNF?3$;([5-45'6JOV.+JS![[FM?Z ,2K;Y<
M<(N5&[-^A4'Y\$A!15(;N';NJ@G+PS;#<<^<M;MYN]><<E^ZQA$B$*+:0GI[
MY<-0P@^GP#.">71S<[!N_Z'5AW#CA]:@@6MT/D3(X$\,H^5?,8RU';44A=(G
M&O5#D>:GIR94;#V"V\K D//FZ_ 85'0Z6FFZI?06QZB++=!#*U!:6)-4,R>!
MHE6F*.\GQ&KKQE4\*?<O&G5PW1RTB.34UA/7YBAI*LE^)_K*[J8Y-?#0VD4Y
M<\K#PV:Q.N?_8%#^3_0''LW4$N^@R762?HO1:<+$^5SU N.-@/?]DD7. 3_&
M7$&XZ3U- [^04Q5_V*C8(?PQB1*SM*LP@.17N$=6VAX,A\J$U%"4*V#^8_>6
M.XJ+[HG 3T[X/FTZ2[B_.\)WC-"X[G@".@G>C6OH#G<K4 31ILXN_ZVL=GF8
M%9U*UF:"JMP<1\/:+IC38CCVSG>KCN,Q"J[42,MD>IJY'R#LO"4";6E_%37\
MO P8<UWH[UX?/5>5=+>Q;FW.XN9<3*IHRP*WW38JI+D,> H3WF34K?^QQY5E
M_M#5X]MKT%;T)+THV;1UO;=XLL9EY%C^98VC8S M*;;<#/.A;&PJ?Q]>!#</
MD'Y-*B&1!5$V.8()W*TY#/.0KA!%R9T66:4\WSZE-^E/#M]7_/Y#_J)=WX,.
M[A>R L2KLU07GG F:N15FAEE>MLWYDM[]E//04U%E!EY.1(7E77WE$>=#\('
MJGI8;></O2(;$/S$N12M![2,X0,_F8-%68/?[^$0G&5A]LV4KBCA6J/1S'"%
M&WKC'93OVR3N2I6T/06?C[K!.58BPI^DYHVLZ_7KOYC6/HFV]CWDA@MM=Q]\
M?'ZD[<Y8<S0\)%U%+%Q*??#Y!S,_/^2\#I$UDYUR6L?NQI<%_6;PI<>[:5$&
M9PIW*RC4JGKNM]+LVGK?_A?%Q">S'4WP%B]J>/8IHV!!A%]WJK=^^DPDXJ>"
MF9OD6,@CX'ETU%3&LJ)Y"/F^@X+O*X?,X64CU;&JH@L-\:-]*FSH_$%X\PB$
ML+#_74>>GD@>7?>M#N9JXES1S[Z)A(5\CVC]%1+%'R/<4V93^:F,'-?U6IEC
M_R=G]\DED;8VQ&?FG?F.*MX*\=Q%)LC'X%O=(^ [^0!(K_X^M_!<"69 9"J0
MEFZXP.A^_+?>"91''7IP';>XLG9[T,(Z./>C"TDON+"IBV.;@\6+;/*1/NAA
MW70ELSZ1<U32Z7'R ?;NC8+Y;>-BHT?_L^VW$_8/+\HN3>TG0J;\G$EI[P<@
M1]HXT!>.X_8N:$3W>\.'D4Y1_@;\S"W<8?YA1U!V)'.T1:QCHZI1(@+NDR^4
MNS[CE"&K@^*WB9$<@2(0_ GJDB*PUA(.]V\%5;'Z2JUDX1$ OFW=D*:V_/YB
M$.*2PJS;%[FU;24>@:6GM 3Q9>$4.G$%90]Y-%M;P$(KQ]JY/R-_3<4"M=R5
M7D#+>:*G^]N_@Q+H8-7_CZZWBHOR:]O^AQY2FD$&'(;N;E0Z!P6DN[M30!0'
M&(:ANY7N[A()Z1*0[FX0E!;]X^^^[^=][O_[>:^-:^?:61OG6NM[KFL=QV'P
MYJ15;9#EC*O\]3VOX;,G S?L#RAE2F'_\@VG]N)-VKVID&FSQAOK7%.^]HZ5
ML0>.,@K ]II]7II+5Y5D&(FQOSE9E=?MT,KRU^'#_@^@SGD17)76%=QX#+D5
M>K+B@S5 FXFQ&C)!/W#Z[4XU!JXLZ;+<=JQM])7D7GR"P6!U]AW\#?N,_7]I
M0C\%?_T#B!?[C7E12':_X?N],/!_QU#M9/TRSKQQ9_KE[O"/ET</.I=/\!_
M2<S7!D3/=XXGHTY_ );H<57_6PHZJ^XUW3#Y?,,5G'%GM=)V]M!!XG@M+N[X
MFOP!'/T3YX[PQE>X>N>OJ_-[W&?"=**U/3ADM]^?:65XO,NACL=RK76EUMZ;
MX[!@Q@^GQ/DYTL6[ZE=&U^F"?MX?0)MO?Q#?MO?76\LO IMX>PO!)UG>SV]#
MOR]=XO9_%)'0]5_'6.J^NKD?O0HI6!HM_T3H/[\V-1QVG0;_UZ6NDW/#M[F%
MZ?^^;7I?98QBY7C#W*1^Q5?+\'$L[+:CPB;-I9_LU0)J*[#89AB/2R3EM/KM
MK^=ZSIHK_Y9$)#^9&W'^*X=(RC55.'G95C[,+?BC*9#[5CDP<-/."+"-_U/7
M]+HO +4X\$@ODN991R?1Z&:D"X$VTVQ9E-7J<Y&V2Y$NB.W^P"<B]C,'^D]1
MW&H/Q'0^.+:(KUL$&+9M8<)9F=(/D*PR6*GR';R?.#NKDEOK6VFUMUG56+[[
M/ 5[:U3:?AI*U2O.M(K?/[A5N:G=J37]?_KO0>?6GV0N6:]FH[!;&^VFO3FY
MQ.NWR#6OPE4VI.&:+%AX;6'<R V*H8FG,YT1<H47[[EE63D\M9$.>/AQGK,V
M2R)T@?V.;(2ZX)".(X1$=:5CN9JT1:.++FA_" YI)*>0+<0<PKM+?*6D1?36
MK4CAX_.UEI!Q03QL#*'B )_]D_:#Z-&K3VEUH6,!LJ^V#9HYWTSRYZ/<%.BI
MH;J1-'@C6<+^&WK],GR4+DOR(ABM.&')-EQX+&P$%P>^)X<M;]OPY\3W"PV%
M]^_3ZHW[&F9+B<]@&BF9WKS*8='$IX[$3A/K<1:C=2(:;Z;ZN*=+)^W QUCK
MUG34$]&8G-O5G@A0IL!^Z3RAU'7PI\\.(BPSM@WGI^/AKF\O5NB4Q0(E8C;+
M/G:DO$L:5#___6TY8'S?K.?B6569OLD:,%@B-2,_X>OI1G=Z<_Y]M=ZN513H
M1IYM.N8TV;5L]H-0;FOJB7FN1/D#RW&%VE*VWI78A[WA?&CG]/HS/E(,C6DM
M87]-_GZR6N1N>.5R9<],<\^YV=]:9@N\^M78UF14>_OTE=BO@^'OCL>4JZN'
MB@GSL^N#KI_M!F,!U[3B:4?KJ\ QM'Z:LY[23'" 7Y-&^D;]PPH2\<RP=O=_
MJ2=4RS+^44]4+>,#+FQS96]_45@UC/_C+?Z/=D)-Y>KE!,_'%^<TFA%#-WOD
M@$.8W[(%G2U:#-U3;J$L41EIFW[:<L4@VE_O[0D^^V*/\>)X3ORWW#:T2Q6U
M<VH</&C-F?>?G!']OSDCTF/?TC=H.KAIL45/3K E R0M+P\?>&Z9 8;%\0:V
M(,\XZ*Y3]?Y_:.Z^_N(?V<2R[1%^Z](C35RI)[HGT^_7>LX4DJ;[*QN)^8:^
M^.RF;?\[9V2EK'\X1]>4 R=SY<.OB83;?J;#GX?[;BG'+[9.C^A4)2H=M[__
M*^3>Z#-AW87D<$R F,OL/6C\D85\6=SX$Y^*7WJ;D=ZO'2KLR'X;V27A]%_Y
M*I8RS::<Z53I8?PU_7BNQ_.<\('LBOXML"6;28-=M7QLH9KFX-VZ.ZK:D+Z
M(X[ZT"ULZ>-.OU0!UJ^?ONV@CSPI+VCD;5AD,]4QR, 3O/[1ET9P,U.K3_,M
M69WVDZHMS?T.P:\#1:,,_4LMIZ.STW_EC%1F!SO,'-Q,;V=L.J5[K.[_*VED
M_@_@&W=,V]:QX;;)UW:U_UNU_27][K.L4*2$5^NO.ZK$RJK"^\)]TXG%W9,[
MF;]D]R'\^=VP1^"VC<9CU0 /,U$H[/(4QM?\E/M9X<$(_0D  Z@PZXG%*@Z^
MI<SO/]FXWVNW5K&U,!\;NF7'B)IQY%WN\2C[+ZZ[_3?7K2$ +<^'*F)LB,;
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MX_Z+^VB\";B\7\"DO(R<.A*0HS[Z&+.W6=YNC7,(7K&!@!BW,/4PO,-G_;=
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MFC7\+]N',Z:4B$WOM46*]TSMT2. @K,JV7"0'&\7X;U?SP/_8#X@4'T0?0@
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MK5=DLARO]CB)OK.(AQDDBHFNF@S9 MARHW7>DN.\ 5-:@*9PA-YAC]@UF>%
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MJPF!,\\5>]!CO?-PD8 @XX0B222[_1C+EZ&6DG0Y! ]&WQS[*K-99CS5#W;
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M7[G31NIV&-E?7^K/>(HC:_<FF$S%+G;H4G,8$]W-3)UN23O?G^-P%!H PEK
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M1%]J\TI\T@CI]EJS3\"Q:5G"KJR%%N"%"A96F'R6#A%L3%0NN/_0ZE5/7T(
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M]N(3'"N:L;DRW\)&5=%'*9B=&RV&RC&%H?Y\J*2Z>O)MUV<%0R1'DY%D$P?
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M,RR>.5%Q L2=+)H$PI3#)Z8LU%JY4[GDF<9$?8;D@^?Y!^?OTO\!4$L#!!0
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MR,]R1&3,&?6$XYY0,+_\;]P12L0[%A34SG_DR"DBG+_H"2>B_@HMA!,@_62
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M!QTF*L2=RS:$51R(,$P>?]*IIDP^,.U->54$GL) G0^(!3D4WQMV"\P>R,O
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MEUM^/X;'2>H8$2>F9X"D500"]-PM<2U#&4I*3($DP,<$;*[-!1AD7"U =X1
MA!UEN%$<=B;I534"L/UD;N'#P@E&0!G.EJ]5# X=ALC(L 9P RC]6T=9L(@L
MY$QHC&F8X64A2DXD@M.-@-R"*F6 6 ;)P(0>%7$!+B;S&W/ =G-9$%WYE&$O
M#IB3$1"#K&[4S%%Q96$3BH%<2I3B\)PXH;1%(K:(CY$ .#H4%Z$8%0*@B(P;
M1TE4Y#>$HEPJU\'R4)Q0FXT6"L1T/I0VH$S,B'+]6IDPF'9&>*8P%/5$++@
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M<D"8S71P"2>3Q0$).M=P*!;(_;NH9=%=_;.$\PRUSZ;^;.K_-Z?^M],TW4-
M;![%8Z(XC\?D4#"+B1)TPB8=/"Z/ZZ38$,_Y'Z5IB$FG9@BL6,/RBCG_>)J&
MGJ7I_UK4_A^>^M\.6 Y,.=D@2#!!-D0Q.02",!$'!V=R$"?,AAP41#I8?R-@
MN>4!RX**(?!9P#Y#[3^&6GHQP"9)F&#"!(S2:U@09SHX'(2)4I"37A!P2(3Z
MC[Z/_!6U7'H!6\R&GJ'V&6K_N9MFI!,E80?!Y$"(D\G!G203A9T.&F\L$*)
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M!_%A^0.SBZJ/HG[9ZXJ@_$'%+GA>@;NE6:=GK@(%!-Y?OW4LYVC-/_MRH&U
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MN?^8&BPG!!SXOT/!NC.B.[3%7]>; &\\UY]]']$M%0%4AP,;1>Y4CWN"?P&
MY<9K-;L;,$[OD_^HX93>RC_+W0U)LS&;XUILF-/4"PA.F5/[R33RK_25"K5^
MO#5 ,O&\-3:,BKPGT%TRZ0G_F3+:$NE-A@?KC?>?'/<QZ.:&EY2_<,X7G.9
M6%&9WF"] YG>].Z_FRH,9F7WZR)_>+\+D-$P3#*_J8UY%=O]-/P6=13<:R\$
M]<_VE_E/YO-UL@"M2"9VF2K(.KU+1/<#:[JG'4Z6=I\2)+^Y7=\0^(DX9],E
M_E @2ERN\;*:&B]VE>=CP(1;"]G[U.85[5.XI)DPS+Z.#O[XKTLM _4M,"C)
M$&NC@_MU]+W"ME 80Z]O&++ED/J6^_.W5-<_<3J6:3_&R>C]X8F*M"Q0=.>E
MV4;J;:#W3:TU</*7>I7O%26O'X1R>!^D]"/T(6L/Z[@KZDZ7^H)]-T_79X,
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M,,J1"E.H+@DY@9^PC-&B65$?D(P)QU/AXEX6"''5Q*X4G!E4A*6%J9/!3L_
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MR^^%EC&&FOZV[=+7FH[O>B#DNO@,SW=[152S&I1%A,"QWU;$PI]8!+1[AP$
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MG^6L0@:+$MA/.FI'P[!1Y")"R6V<4#&] E=!V&']@K89_'?]_P!02P,$%
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M?S84RZZ(P^7TCKY>P^+[QMZLVWJ%7,FM;'TP_G9#V<C..S0^KXK0/_%NDQ5
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M^7 $;*6U+/*+2G2QN^H\F[<&T"0J8//;+D"K_]KUMR(8K"#OPZW>_N?FIED
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M+]/9;K,9"V#NK](@ZU5\6T^YM(0M#[(';CHW9T/&VGQPE]NP@EJI07854<8
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M>66=L/%:\5SDTK/'O[#CX#Y!1PC%S2:N%I_/HJ*)S/8Q56<2S6S0OX#_)'U
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M^<X:3 90SKZG]OOBLUHC$YL5N[N[];::C:IF#:<!>O .ZB-WD;\ 44:(GIZ
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M6*QDB[W3:KQIQ26)8XQ#>W>W*_@L8FC,?!'1?9YB]%-B:NDSF4R[5AT)<Y
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M&DD13;5MDNIO<J'^9Q./\-6]E;])J<:#41RCH ?\"QS#=[(4BR/ZRVHBOYN
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M1"=%HO<N.E%&+SOWN_=^C_W?Q_-\.S^<U]G66=;O6.M8UV.CLNO<"Q^Z=/H
M*AI*;=TUE1*(BA[GQ6%[J9&V@@;%3LX;R:_/HQ_$Y*%+X\S!96ALL78NBQ,<
M+K@-H1LODL.1>8*!)\N7LLMDS;[?KF<P!)1A.,?1D=0/4Y!@5'Q(A(,<D19G
M&%?<@H)?<[M958M>ZVI8VZ";.MJ<+"D&+3S2(V=2_M E.<LX?2=#:C?[^=WV
M&F9@7IM?%P=$"^),SDPI2UVUIOW^V[C! 2 \B@? U<TUMK)(J7H)P<65%9<%
M$(8HB><.9&A]U0TFU]-HCII3X"\U\W)4@>'"B9"Z=83XRGC+(_K9QN/'9#^*
M=I 4R )'./(UX &8LO[B?1;3>"X4'@>'XTR4R5. AI-X4 _P$D9\ C[37[UT
MJ7CY*F_^79KZ)P\O59K-T^_I"WI*&PWOI/@7JWU3O8O*,0T+KGHJAWIZA<-Y
M<UY";&Q"6M1>/SY!&R3Z:RJS;5[R-/_$6Z1FUYU+0=4E\%5QRK[!:WV_34EX
M:H)CO+TR^4-Z-75.N JZ%_(FUAF_)Q$'A]7(:10:8N.H!=5^*G?E5SK>IHHY
MMZ1+;]Q4U5&V=R_O0;2(::4;>!3I55TA\;FWGB!L.WXI[M8?UG*539;[V:6,
ME04UO/-:%$<TYS81"P\ZR+DX!/9W<:DZD;#A04B>/&Y'1;+)<44^4V%A&S&5
M:&CRPXIP:2. FK:S@ZJ.OQYVR:F500I4GBH5Q-/J>J7^ZKC1<KJE-[U;$U)'
M5T^^._'6SPMLC1B;$FUUI*XZ10EB7U(#S0+IJW1-VVA=4CI"=^+JLEN]N)-\
M?=:_-C:IOX@$+Z#5_M&/P"/ ]7])3*85V8K+ $N>&2_*H$"F";^TN]#;U12I
M6F=+8QL=UBG#"R-C>,BB5?T-;;%I45")^N[UNL^J1-8Y*4H;: B79X$.,980
M>*Z!WM/B=>TF2!_!TS"R\ADXBGY@2P6&+V2R@T]!# E9K):I +DAAD:PCUK"
M9JM"!:*X5!8*("1'AO/GR.6CKBVNL0\WJJ#))(E%U@=\B76D7J\T%0:_R?X9
M">84FY5H(GK)4DM%N1R1G!GB_K8KCX!@AZ.LEQ,%H")X&TZ)*T<YQJODUJ#J
MW#A/46#M(PLZF7[<*+E&P8UHG$1Q@O-4LF+YE? 5UYA=Q!B531RA%R4@VJ7@
MM9T:OY\8%IU3YE/:'+631>$WC3G02Q2.3)MT8*G 5;Y87ONVKII_WO[N("@9
MAY9O8??@?-<X87'ZNSQ5 0Z4*X<4R026E?1GH!0XW&\H8UI9VWERQ='3^KF2
M79 S-)8H/CX_V,P1_V?4.$C)JME[G7(0[P<KD^;Y5]*R,% ,\Z%'WA;##2E7
M8LG/%")=XIQO5GRAB?< 0H+D$H4)&S)E="?<"8\L-WR1$D#(UY0=$S[T U^J
M%6N_)>)=$% 8FB6SK_-#>OAC+YW*ROF ]GL[K['4YXI#.5<_G$[*^.WV!U@'
MMI=[OZGEN[1ZO1G&$0L!:=*FYH'N/EYYHEDXII?S7ML"R7"N+H:>R.AQ@5SZ
MPHY\Y^D_]_WS#R(]E\>FL*T1J^K2HN#1QJ<Q6N;L&=\:KF#@5>7[4J7$,VR#
MG_FA:?@WR;^8Y_Q"S>,>,,9T9!8^> \8= Y.\+C6T4D=JZF2,K>?N#;?OM::
M/AN!.YQC$443[I/C&?ZYN"F_:U['H<;U#28*XXC\WA$,!%(3\Y086\XJ.U 0
M="-4IRKLDDJ#[O1$14X4YT3H-79W>38*-ACITSQUO7;D H6 EMSJ4C808"1_
M8V&O>!84"F5NA^KA;'Y-5\N:_H+% 7O-(?[Y4]3BP#CU:^[S]C^^/%4[59#2
M:E+=F9EFD<NHK%*3 ]%A8]580Z>KR8G$<31D'R^)"VLF.:^I1F_41O\V-R4H
M+B7[BP/:.VI*;=9AV!Z#Z4X0=X#BJ/!$?-%B_8U/@K.M&11T<[O:4G(/6$XM
M7?"KTE<?'*?2C?&,^"5X!(?'PJ-?4U"]24YF"V[C:&N+U)%:O+X^.8C_].'R
MPFSOO#20!5IQSN'3\+!C!OZG5'6"!,FZ6NZ? GM_0M:)].XM?RI+@#;8EAX)
M+IU2DTXX%?HDOC-;I5IZSG[K-DK<6)I3[5C/D\:;(C$UCT0)I]BU-1,NIQ0R
M<G_+.K.J' GZ(U5P_%V35$$_6%G"KN8>8+<?:<94/J5+@IR:G/*>,.#[,TG1
MT4=61*&;*14*\ 6,P&I\!Z!22[M3YY[<4\^/MQ: G_[Y/HQHW#[T]"XEEQ\E
MBRCK**&B&R:R<= *D8_5AD@5 (F8<@-'.A;\#,@^4UV1+8WHSG8J^GWR4BT?
M]33!*+^=1!_&89WTZ9VVFG_^,IX#NL%$V!KMF;EQ<QMI5$,>_E7I4U'3V%&&
MQ=:%K9DV<F),2AI^TOG1^0EZ"WZ%$H,Z9DWDY2G@F^X4*ONW![]./$L[ZZ1N
M&TXZ=SN=F@147<?$)[$N5:W['24-NB)H+Z<)K N?30TAZN6K\-L\70=:$^9D
MO[WOAHBF)9O1_%Q.[5W;8\WCPH,&_[N2"JWCN6-^&3.K,]=Q&9D:UG""P50Q
MZ369 D!>JYZ[HQ$_*\/)YJQTAQ7>T1H1_ F[C#E#WC:^5$?>OS\WII7V%0B5
MC#\BEPGP]T3K#6S?2;K[]@:7^\$Q#(EN@TE3["H#K+,6=FB(VM^"8+"U(E^3
M]LCGP(&!K"T"0QE(.?++OO5;QV[#^#DN!B;5?'-6%:WO/D-4GO+:RF3^(1WC
MP!?8$X>'28=/DP_&A!\>#HRJV:&Y@V<3J";7#_)F$6/G#V>-IZY#BTX5IO0=
M4@TWJJH,,#R-U/,F*)/QK7(SBN?X:*JO9:6J._:"KYPY13]H-AM9;H:,&SL,
MX$)#BB(@;S1>OV8GUMOU#C\GYM=#29ZH4^.PL?2AZ8H4>[^IY#5@'>Z<V6/O
M 7.D>H$$ET_JE>\!\<%CDF]WH1?6FUNG 2OF'F:/EBG-4?.7Y4%W22>6@IIW
MTWYE1S^^&0?&W .VDGY[C*VDYA?_.HD,_"Z-(W2E/I)=>KC%?,Z;#=:\>^M7
M-M+QS5CFFO7T?\5IAJ@'I7K\QEQ?F9]8>FK*_.F>D,'R.=P='K]GE*85NY)B
M%C68'_M?E:DWT^J4H'M #ZF>RL!=%(^D/_--\5W'R7_2>@\0IE3\]B^O;HKH
MW_[45\I\#W#[Z]Q_94Z5^=/S/^H369..D[#7=[G_P81_O593ON%M,+A5,_:(
M&;F#RRP2U&[_&1KYM779W?$['Y!]R[[Y7>?\-/@#L"CXK&?"',MG?YY_]S=
MA^?_G:][@F/1^]6OS/-[P+"T7P"_QZF?])N:EM(N]DYHRXGN[2WS[V[[G'O
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M8NH%LLKT$$Q#X)]&/TE(M"*O6S[2E7_VG/O@)_[TI"E!X@VJ"&%08:;3Q$6
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M!\RN$6\]KT<3;\VF9^FD;K&L7D6CZ@:0G4*5T@Y:[\A-!F.J*'UX@?ZH]CR
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M$Y-Z'!G]\6\5===W81@J3S0C1!FF/8K\/PCSG/,UQK_@VVKGVQ!YE6"UW3W
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M-<2Y.O96.@^_?%GU+W[1M:+/#;^J[U?N>(8R!T/PPH$$Z@6TYV?C<X-+YW<
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M?(70WFB0K?>P84F=:G;9Y,-W6I/C"^;.QF3W2CQ-Y^X?\YTVKL:0BP[@@$5
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MH&!XWKRB^P\Y=?\!)H:IHNZ/]]-&GWD=WN?7[T6RO=54SB&0+W/Y[9Z_/=D
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M#-T).Y/2BG@I_ _PR.3DIXCAA9[#F7O*5$69W*L]_MEV=-#VQ/?".]/NOO\
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MB5%"D-TLYD;]T[<C:JRRFXUNFI+(2V=JT!%?4GFE8Q&GN9D>=IDW8!/XT6B
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M^> GKEN+,^RS!SZ@UTM44-X1+2[NIW"O.N ? (N$8O-\4E<E(LFF5W?)T8]
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MQ#[<T/MON%YSZ3R'#!V<8(K_ 2@3P W)PX=W,)6:=,!_@,469UD@2#TLC5'
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M]CF/J^7S76?F9A;G=VV[FJDS_4G]\5?0"V;54D;5C80P!R="=0VQ'TS)7AE
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MBO(@J&C\)$.[0G_<*<#Z=KW^]?O#XT_DO35Z").F(64-38Z:/LWD$%)A@_G
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MH3#$MFD!85-\CB8I6U$=TC1J_KP\"K2_!X;63_@)J[Q3YTR"S72N&/M\4Y-
M@F%<$(=-8HCI[Z> S+)^*[_CEY!/Q=P6A)_GF848S=<R(841 G'\[O[PUZ]L
M$3>EZ=.7Y+Y_=;L['/9;# KK3G7[K7"T2<<7;6%VCRLJ91HD$D@2\@1"&EAL
M6+9'-*9^UF;3VB<K +Y]_C+05&TL&>HGI-[KFVEO[S7-LW#UVOZ#N+'@_H+S
M^/J:@%]5:I'7G$K2Y<9GDF#Q-%!0GV5?R^>LDM7$YV-I.!E&B68E0OU):EQ]
M TU5-GN@5I$2V#XO_JA^KM6\^V[P1S!3F.EQ>R14F6G5NLPA:K-O>CG!/HD%
M4&#@WQ9&6[8Q[G$0'Z?S3U"3.0?PF4M]D6OZ C9VZ9&9*- .240]D2Z^N=4#
M8#B885GJ2C4Y*0!LJ VH_47&[3XT!JP21\N4<=0NK9>^#_D2@(D,P\XD/@V.
M I_AC)0CX+.)_A #A3GH!)ULZ,A9>ZNWR1TUIT Y6NDZEM&()K@J6XJT,E8
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M[7=(G%!^A3!H^XB:W)J02CO:$!'5[2EM$Y+<ZA<6A,+@]=3@W9(9?02UO5.
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M+%)81M,08/Z):Q!]QD4&#A':U.(IK_M90_*VU:M(\FVTY6T%K+RW'C#H;#5
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M@Z?J\<]UJC G4S.(MR8;T,/[YV)0]7!B_A4?"/?P/N4;7?50=M?"5_[&QD>
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MXF(_Z_AIY=]UH/+I9.]M_U_2\O/:[S$7^EO0_Z?)<'+\D0M/'YC':<J='(5
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M0AJ-=XW@&GEBL[:\X+TZ_%B.>LD(SKVT47G%QP&^8;&S7XDYM',)DV=>[FY
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M59YE&*%A<TT)H6MMILGF03JA'\D=@Q;93CP";N"%>*Y*/P77.:,U&T.R>?/
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MKQ^-6.0&OI@8B6?&3T[65*ZXG_X>/YO\L=5#&J.)<7)%XTSSR+3BT89/+PZ
M$VF1(X4N$;H7W(QZ,8%." 0R/=RNEN_ZF*C9FXY-G0&,-86(2;GVJ^\[LY;[
MN_GWUR?#RK"FM&5A!5Q8T[RM10:@>/C-UD;W^9W71&L1S\>J?!+*11=T3/CF
MO:"RNYF\;RU-RJTKK%#%=L&XC_,A8ZO=^7@'!5AS&U5'8SIC7W+:TVQWDRKI
MXK05<""DS$! @YTJN2A78*U=SG?LH%>ZJ56@9MFQ\DU,IO#.G@D<6%W=I4)>
MKYVT8==LFT*JT415<SF$8OWE:H%=>6!L+I!K:ED35 9<[H^FQ*Q&;BGN(]"!
MI!CV;B;@[1)<VFZ*\-V)APN3@BEL=0/-M44:,8#XD6B2-B9I756 *[& ?AUY
M-KMG>&*>*0! =84NJX:=(*<BF=F!2O6>-Q6OJMH--&)\/$"HR>TN'CV,U\(W
M "170=&@D9*XNK>:://<1@9X "96D5!MP#)FHMSJDSOV+#8$LT]8-*1UOB23
ML(KUWS9F=DE3 B4$P:)[N\9[@50F#)5I(KH9S[A8(X5)E7$= -G%9.BWVV@Q
M+\PDTP:&J@DF HQ9ZA/)-56C\9Y@0DA8I:@LS&M(\"F5M67>6N#J8.XX8:0F
M-?7U!!F\'JVPT*82JYKRUJZ&:Z\6%(!,90![>CT\RK.]RGZ)ZC*X)(K;STQ?
ME>+Q@3NQ@LJ E(F5(>]U,.1($8.=5U_SZJ:$UO$P)YBF)B6*?"J7EZ'_N-NN
M>*T[)H4G/"H^R"28W8LG4YHGN (WE),\YC*SF3HF!9--Z@*SW;7#2\Y);0,*
M#6)[%Y W$K,_M3J%XD1C$JT^+II] !Z(8T3:*8 3S1H/;G28-?5*#[[N>%##
MG?B,OWU5)Q6S6[;20B^"&Q=PNUOVLA&  H![(QA.2I(J2L6X'VKZM ] KIME
M"2!V2DX$T-$I^F"5D(L6CR:BL:>67@9@!R2(/38,'F(-+-%7#\\O=]'34RTU
M,HIDSA"+LHSBI@6H1PGYZ3%V$V^3$=[1 >+BZR9KXZ,IAP)],9T(0V68M%KR
MB]30E./Y&4AER'*_7M[#)*%XUD:G;S+D<=DO):P1UIP3I5!-+.P:X\CF >O6
M"AJ;\7!L<YRJ[BWFR88Q;*ML,FP;!O<,2S$\,%3*V]L]!KCXKG>)7OO*M!,V
MC8<QD/*8^,G2[1)Y1_L&*3;P9\4XI[AY*'F78MCFDP4_$@9'QY1@/]AXC*\O
MA$0^. @# $&,[2[H%/,TOO!+22 !B"7CL6^$A"(F;N=O[1P#Y%UHN0+#LG>'
M>!WN#G$%V1Q@P)N7^Y]*RS!GXSN4T,_CS 7J]"T8$,L=#!H2@1(P4BS>&?"*
MK[8L8CS,OGY%E5,EP6;!;;?TBP1%0YIR)\^3N,PW[9^C1T7=,,RL6-?#19\/
M$TY^4@A:/&\Y=LM-!Z:60MY?N1 N2)%?[.D=[#G!^K[JUN5MGKHF-* &Q/9\
MFY>CA969NXY-%"='>E8?GHU$*&?1T[!55FZOX;NY5)+I %[M^_<#CQ"/7_[R
M_[RAR%ME7V]-GU?8KF= + 0[F0G(IJYBCA6D2Y&+\VBD\&U+)Q84W+5+H=XM
M10LG!S,M^=E_["&<9Q1SS4M=OWG)49*PGX=5"_^:+_A^*8ZH\K-6OBX2=G+R
MR'0>F]XAII4P_<\E(,@'.D!_+97/1XQH)+S3YXX6G5'<%D$?YBP1KV[DZLS2
MC*+Y_71?Q<]QAT0'F+[!7K,S#\2[E-M[%#_[Q?FFA*5D)US/'7I^<-16N^M0
M,@#K\:3/3FI$?)QDB+?L:R_F%8D/@%R;6K[-^+%OFWYC-;C+4!Z^0[\U,Y.[
MQ4 *PPY8B8'MS-#/>]ULY*+;V>H^<LRB8CC\N/R07'.,_A"<2#PMPQ*3:].\
MZ34T_^4^1JZ+IW(O99?,1M/F#!UR91*Z.=,F33(>X^<(;IC<7<QI9KA*T9\V
MYI QT^2W\'9K:*J_C2'20(4"AV2OCG=P;522*+]+YARF1@?+1D[YP$,G9->[
M*G1B)LT0 U%^*YEUIK8$S'2: 635"+T,52N66(NS1@-G?IU.:P-#0ZU,%$>1
M_OO2U>'*U'E+!7?P_0B(1-@H"Z\A?FT'W!]\Y'WA?;'&>/5&<_1 JPBOAWS\
M/3XT=W<Z'Z)['#WTLQPC+%=F+Y'J-MABU5RIMTY[V':I*2'IT>3=H4Y6H,KY
M9O+JT=OJ%U9=E][[M; H]->9F.F.<S&(A$:'F++3Q"">*1A=N8R9531ZUW8C
M<4FYV09UBT:W46+"85_Q+H6.4,'93WBZD;A[O+:-9W<2P99;K]>$=,-MQS4T
MN^G3^#0+W#3IH]9(5WD,L%)[9+8C6M#0?^"*%\4ZF42$7]LJ\)Y53N36:%DZ
M/=@&QZFXDNXA]Y[!05<H/;BK2^;AJAVCY2N[IDF^U>>9/JN"7-83\PC.#@-!
M^[7^?=BJH#MFLE>1J]L-._Z+89*;<M33 ZL$WE%"0*M'-1U5U+:B-P2SQNNF
MFO++53DE8,T^!F7]L1?8^SPER40BQ LQ.>SK_&M+!79IKB9VK:3=4NPO0H8V
M"L74H@1X59T;O9N+TB=M^XJHZ(0XJO#B>/+C,4NWNT1\O_!=FNT2H*.IUY1S
M$KT;<"!<T\7:]\A?*: VA\#&GQ^A2[%RX8X7V% Y\V.<\7VJ4D6C9QRR6EK8
M\Y'.RY=CBR)S'+8OMA1,[>[!QG4IZ"J5HQGK'Q.4.Q7M#^I1QEYQ)6N2?4V%
MQQ!4Z4#7-.:P8E^2\1![L_+)H5]9' =>W/1=B!88+#!ES")4#+-GD7PQX<C!
M:/_,"2LY[/H;Z=3XS*FD32Y?]W2J_2:QZ#"' RV77O/;-9/D=6ZU[FCGK-[P
M9_K$5JQT5Z$;=*;@B/(HJ6C%XR^:^M&ST9O5LAE5EVRMF9J^<V9KF&^T8).<
MVECS-M5YFU:]'>OIM5]1F4QO<F?DUOUHU1HRGPN&,TC3V-U;M%?,'5D@4SDW
MD+Z-X.U7[*P.8651GC!5FC>Z1#P+3<ESH<^T>1]_*.A<TW@_$O_2HVAX]"C&
M>9I*KM:LU1UT?H*-I<_" BHM[XX%Q=-OD(^]&-&WDM$04\WI1V.TE25C2\D;
M7;H1-Y'N@=@.DW7/;$:#"79?JS3H=Y!UX#TH&";<[\5:Z,BL"1?C6[8!=?+8
MX_I'3G>5(7JJWHD5RU6\H&%=AU 7+'3?)GV^ 4I[K4!.:JO.TR]0E*$DV\"@
M.T)!L@VJJ3 %P_CO(24?F4/2*65AHY4P8#?A9(5=<,)MS>>REKD.R3OY[Q=U
M+ 3]Z*0P[+!2EX0K.X7]B=?(I]R(!EJ[;H2OKHD_I5H)Q!=Q%.,0G2%<QG>O
M1)Q+O6?O+&W59\]N+RXPP?%X_'5_R_]AYJVBVERWMN'4T*)%2O%"L"+%'8J[
M!;<6+Y9 <*<M;L'=6CRXAB#%BE/<"8'BQ8N7 N5C[;7?;Z^]W[T._N_H/\A!
M1N8]QYS7O.8UYSW&DZ<G]'U9><(LT;8)KH[!L!AP  ]"-OKL&US]+<Y>J^QO
M6&1B\04LUOB-DX+[%=\#W[=$"X7HS4N:@('FFDPRO//6ROKB&B("V#G$T:/A
MAR;=O=3HM!AG2<+"K=3$$KZC1GO2GDQ27G[Q@D4(1T)2R@%T&2$O*S R[R'3
M=01E!9#R7+'1.1^FW=G^JL@(@1;*JZ*UWGJL06U7@)D%[L86>0\4/COU7]JL
M=0EJ.R'RWP'@%9P,0A[&7H6-.BW3V! 0Z*UL^:F^(D-41>;#Y'E8+Z8"LP5V
MDVV639W2 &:])KES+&=)FJL OWRZX)&/():TY^O?.=HABCL]%<#M_J:0;\PX
M8 ZCA&KE<*VG5,K,8ME:A2,?R1LT(E J5=L36\0^\0X:ILZ0W5[YE_6%92 ]
M?"508O]^Q%[EPM>II^ $<+*RG"(,IR+CT4B[[EK7'K\'[VDYH>,3,,#@)*^<
M,FDC4SG%BS;(*OUN&<2NE-+@%S@0<'T45=/R2LE25F-RJ)&<_#B^20S^6("(
MBD\Z3=.= )O:3-IX=;4K%#\E8J;!:*Z9LH DA>\QFJ_,/N5;,V5^>")%?1Z7
M'JADEP"X-#GS Z,3IPL!?V$!V<=TU_?N%ZM^)=BH7\]'ABR5B"))A*%(#6T_
M.[%O4M$0^O(N;I,IEI%8V$?@U">QYZFI6L:XEIO$C&IN-PU,X9JDP3,IU7L0
MLL92XJ:;E!5&:.-[9L&E;MCL@PZ,I")?X/*K NH6&X&3G@]*J$W"M^^,^QID
MW!/BIG<H]Q:6C:DL'S0:;]2PQCDG[!($$_L**/AON=F'*%@/+ IDBUK]N "[
MESY0M[5]W@0UR^/YT*A3  1=L-4;,V6<&3QS<\_#T-4[3+S0*X]XPE,E-5:B
M?$!^Q9;L[N._BH=2_:J;ORXN2L4* L-C>2AA%L\SP0(;\L%3R$,X)W,#_)M0
M%BZC6N_56_W!*O46J>;M]++:Z[#B_)!*W<_(27.17[[8UO7&C[TXAF!'*OF(
MU/O*J7T-=N)1%=AU_/N_Q[LM?1_8'C QV+!5/SZW@#34XQ>Z/G$5\\LS&CM#
M3KM;+D0]<F@(PTOQ^42N.WD&@E@%%^,&HRN>[X.10]-8"2D-*ERRT>AYM@9N
M&Q/OC49M>VXC@9 O4E&DBB_HX Y=.@#^P^/LL@UCZUZ;$MD"_K)G\?B\^IHM
M.KX\"]G3(IE:X1/E!])V6N85.&XAK! X"UV0'B]ZO.(Y_ I65;OOZ/%88GS.
MIY(&_ #\X,#7@8U.IPHOQV@WY:(&BD^:F&<(JE*OM])C+1J3JJ>?TL7<$EK3
M#ZRO(;XBV^5O221WR$X.FRAK'$K4<B(\8'&QLG, %Y*#)ZY>?+=C>25/1*T,
MHF)<F_5OX,>XPM_E+LLD]\W^%#9^W-2N:H^>VRH<B&?F2-OA,BX,G]"<<\2X
M45PO$>VVOC#.EY<?-<#E;]A.$1&A4K8?2*D@\K&SB;6@$W)UT%#_;A].%$CQ
M2L8QU]5E@D,.&%1?Q;8BS=ZJ;$VU4+7@G;I>>#5%H:E="B9 !#>_!CO*3[)^
M2.\E7.62L_G^O'77CYE)6 N'_9VK0[O=S/K /GDXS_[VM$<$EK3>&Y5HA4F\
M3M43@IE=2X7F\"J1:)9'\B_H4J &OT;?.D96J$0 (28F.@>-=J9O=9Z1?-9W
M4&[W*\]Z_54ZL.,%3 P'J ?B6$F?T[6FH-&)(8L^5E7,I$O1!<Q,>C5U!Y4F
M"QI]R17>->%*6(KP<H><E:,GF<LB*S&2PHBHFW# 13^,5=_-XOI#E690+:;F
MG=/R 74A$M_.2FD'JKI:Q=8*SR$1B=,]^CJ#&=[<XZR*UA7IJG%S6 2L_./\
MW?.;@N<P.ZOY@\IGL$ZX.Z()5<ZT#^(JP^)OFS*8/A_:!E6N6#W34"C]=N("
MRG[EO18>6FE:7F4%<5.:_K2O48Q*]#1!467R5\YZRYQ0N[ 108,7C8=@R7 E
MV93!%IF1./W9ZI#R9*;6I6FY?24SV;+:8D.K^0J],A2(263]550THVQKQ3>]
MCQ$<R=@$XN_:FI(J>EY@?/P>%8)K#?4*:;<<ENG84<X.\8Q&D8)H.,2]RYZ6
M&JFQM2UN0A1Z,V+?AWVPFN=^964RP'EDR>0^J\._R6P,65CAA=0R]-5V)C12
MOM)DOTZW!9M^>&B5\&[%OV2O>D%*PZ@19TH*E&Q 9F-<V3S]!!);0S.$#\H"
MB[VJY4CQZ&_LB,S5$5Z@C*$1M7TD;K]D'(E6UK7VA=$U,(#?BW>;X+7AC$NZ
MK+B@-1!Z3G$U_)<.XN=53H7=@I9F\.K4FAI'XS.B4K7Y(&'/O.U6G: NW+>/
M>-T\+>'E=LB!J:.MWE2F@(1T'"N5*';Y -,NJGY58-/+L=.B\>.8)FSI^S1O
MGAFY=W:TZX!WIA Z)NL[7B<,*HFBBNKO!:A[1;6R4UTB1!8'*1.Q&PL%<I/V
MAX,_"IR\MS6?AI'>3_IEX A6(8FG/RW:""N@&,7TB-QG@GA,%"H;I4/JH%A+
MOQ82627>O_]"2?+X06.TCA=:W07/(&H]9DZ,Q3RS(3[N:?6R9<?:V'%>1X#L
M%^SOO-;V;HN)][8!A6H#,10.CL@L3,UE@RQZ+])&U]I:D2B\LW J(QHK16*@
MZLN<(!&]0K6>ES0)B;V+:>,SB,')A%5*3L:D<AMB]P;WW9R7/YV0PLA7RC%,
MDGJ]^S<E'Q3,7S>@OZDBYRN6R/:37([5^C]$6\Y6MUJAO9,98-?=Q&P98;/9
MK0NSE7SE&VK11XUY8^B#'^^,8GC\W&FF><M!E,9P915PJ4JX<BX'N6+7>R'@
M$D?9S(*1RV:?%VJAKLZW%0A$3D*(NJ*;6NW!A4+OD@4F"BKJ68_'#?M9F:SC
MEWRHE?$W$JQ%'QTDAG]V--[\^D$19+M2,8&-OH^[R.Z5)1P=O3<&]H43*:X_
MZ1V6XS07NJ>6?N&.D2V 6NM/)@6=\5<(4I:[)2'J1V ;".%W,RX^V\1//+,(
M$^Y9G^.3?I!WWY<J)@6W-4<0??VL87\IOTOU\)-M-K7'W"V F4]]8Y[KND:<
M]2FP>$&K'Y"1W.ZF1>(?$)^%=E.I+$(LNDV.T#1$:\U24,L&/]JI8ZN[T#W+
M,^*;L=6Q8]\LF_PP/?IZL"6>%&>OK*3)WWH'U\[GVU[F3?.*=;I(_V9&/7_/
MS/Q#WV %G^D^;46Y<NEW$40%2244RLY;,3ALI9O+'#VHQ%JN\^USN[IR3KM,
MF4?^X&1N"#>U-DQ.&TNN\.5'P>=\L$<!*7JNW21J;SB14=-ZV:-*#=P+JH3!
MI8;(JB"/X]V O?WR@DI^[**I".7LQ:^*A+\J#9G&P7!X=90PG#>2/3%(F5H/
M7[=?N)1]TJD:V.!EQ[TR.,,]L[X;KKJ)SL90IA/&69F&%8U=X+)^H+0ZQWX8
M0JZ<H=7/I6VXL4RG"CF8L)3.+,]'KE_%/2'<^^Y"Y.1#<OQ^:GY9V5"5$,78
MX9=4TJKBH(>MM6';#W4Y--M7:;%C:R"U1LBDZY.[@%//X2(-_EDQ%DT4=O'
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M?=]I\1"45C%!?V/LC[T#><-B*!DH^.468(8I?NFZC/PSB-T22?(?_T&L6\#
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MJ!/5#+ZP C%/.'\B\Z%LO^YPH?UEE5*$J"KJDU*N2Y.1%:M4:IZ\#94=FXG
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M:./H\N83ZFE0/M^OR/>GW]P'^EDAI)_-W/-V5@ZLO@Y7@QKOO0*]!6=H'T3
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MQ=WYO3#P8B,.HY4*>+&0N%06'$KWUY:_/>YG+)FJJ\UA5\CL6BF<DZ0<,E[
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M-,0"K"47F 'P/Q6MD_Z)3P.,#((HJ16(IA3]T)6701:&<=S5UA8&D%+(^L'
M$F==1,ID0AU+$4%NL)\5QQ==FAA-D%2S8SIN'.V9<:/AQ'M6'TUC],W%*OB#
MP*53L7["@DF_XT_=#B*!J^Z!["L'I7[H$P]%8*PK1-(J,5!D!E0M_K*_C_SO
MX!/C98[\8GC'JQA5<MF-S<+/ZZK\XB_K HX'1OSS.%LQ7*_93)K+S@/T7_1
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M$I+:&,]LWGT@[7%.U*2^XBR3<5&;,[%"76/R@('@TZ9/.VR_A4GN8(A14"%
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M6-=LL60BP'>=5L":0]RJ2G'8EP .)^LHF.;(LMBOU0.54@BW-E@2-:W9[G$
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M1 IE&!U+A0_?VNYK+19CY<G- O*KDF@"HBNQQE=BF<<Y%FH(P!_(W6@/;/'
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M\-_9&*SSZJSCT^1AQHN=QG!RCELMT 29+9XI[F.:.%9 X:E,99PF1[;:JK$
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M&%\PGII=UJ@;@76K #5, SL^?N?\M#]Y;?%1=A/)QG5Y2)>^:)O2JG33"-%
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M\YIG/)L_,5>7BEZ46$/242L%=7!U-4?1:)AK*+]/^CT*\)J7_U>1;&WP;,O
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M\7)O@!<A@+^&*&N"D8SNLX$7'F'P <!_?7E5DPP4-;KVAS/%LE.ZJV]I(07
M"WM'#3"LBY&M]$W^NUS</@0B#":;//S(__)5=$,ME?%;Z-([FI+[2&V8;GN+
MTQEG ]A>B0(TJ\-"6!UKD"^SQ?XX'A:-+^TFP3M>G=,.KCUED[R06Y#3E?-
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M*#B^LTST-4)CW"B%;F#XY=2UGV"H7VB*JNS =DO,>:&)22F+&M6.-5!=-XV
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MH[$4\M;U0J IDT+PG"(&>W5K!&K]CHPCQIH75E#/5^MENVO=]OW%,W;6DS=
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MZY2TIH13>_H_N\+VC&R%SP6!DQ<RCAYV9\[W4=WKAJ"ZR^J5.O(\+%AX(FP
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M=%%T6HHK5C"Y@8HS==;':;:S?J\GCE.]%YS=#>+VT)[79)$6XM<-AV!N,=G
M^E]Z,;FGD(FJ).ZCS[U3U, *4NMQU3\*K-S7BO-]AQ0,9$!,35(M,S[,R<<$
M=V OO)"X##$8_ @\BDSP$=F:W3_G-)F;0-W3<2D T31#>1_C3F!'SJY7E5]
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M5=W$^VB;70#,R05&SP!$8*_SS3?%_LV_D+21FIO2(BR*%#39.4:DO?E4)&\
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M:_1:V/=P[WCAB%H64%LWFVW<+NC>&]07+W%"!XW'F*4)08K&NA1!-1=SO'5
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MB:27H 4V4,Q0@%)0SC!2B28% \%@BD(LAEQD ,@<*QJ>OM=N5_DM> ^-Q[4
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MHT$[XDG*@>"% )8\0"6Y 6Q$1-23PSP^"47X9@()TDI0,R:6.V($OR.!D.2
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MAN2P.U(81!1+:R"%1?@@("5XO+QXL02(8E4 RV+7V4G&CQ1(:("' 6PTGP!
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MV/?84WQ#4@4;);78:X.T]\&9@84+&94)0AF(\.R%1@W##N%)Z,_3,4Z&T!F
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M1I[1RA+GSF?38C_%8TG7? BQVIA\Z1>1RN])\#QYS)2XHRBX^CB"81#?A)-
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M9ER<(X$N89#QY;2/(5O9@6I"V-V"."IU 8;[X\K <5*=7W#D(F4G ?^8IQ/
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MFB4,$EC*'UG%D]&+[7\C8'GB1KMWKS5M?\CN$(_QA_)J25J%7SW12?!<W[^
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MA!24L,;+F):H?9MF\MYK6C0ZB4\8%C@YRDIW@XUK26K7E6%1X&==Y*!=Y/O
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M=.AZEI8R<8 V=>Z=AI(4-<V03UN'OVZ3]7IUPA-ZK5MYO>Q=NSF#L"?%M;V
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MRS,3P*?C=6[<!4Z>5V N\0HJ'U9-TOUF#M>(?7.*E]0BZR5K[-^\0;>D$.9
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MXFI\,XS/2&]F:B5\-29"D/'7/"$#0+5W #8+F&?EMKZCP-^N_WT#[+\L A8
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M+E)S&J>G77!X3YA*.XP73!)D]B$R=O&/V1_DW$'@CT"&YI*ZWZ-N_5#:!B1
M1AO7CD-F"E1Q]7/^R%CGZ0^6;75<E4UKLDRKYU"(!&V:W[?GCGF9%"0=KU#M
M;:#"BY+L2Y9VUUZI01-,R3DD8[M"%9"%(86L$P>;>:CD_(+\4:/S6Y2\-._F
M8:F\1JP+EJ(DC#^;V*ISN\PYA]3W^'0\EB8'3P^FX%8WXI6X+M*SN_0W;?IE
MR2T:%<\,%(M>N\B2'^T"5/*Z$O$7YG,4NWE#+9VI@J+QY'[7L<W 97)RP:T
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M3MYZ]EQ#!PQ"HB/%B9RD."*"+G2 ZHEG]@*<9  #EB/;AL-W9EG2&1PK+X0
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MH2N\MYU,K$,'H,QYUD"^L\00P]%G>(HH$!9>Z,IP(4@DKC9,)LAN9J7=P0Z
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M9X2CHY'E1Y6TM80K'NA2&!0C*P,#",+ T@!F::"OJ&Z!,*@%T IL#K2RL$:
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M'W-'1]?#F?#QW/I992/A=(5C3-6HVJ'<=:-/.*D4(F>E'HG4?A)CAHC#8^(
MQY+PE%!IY@0C_WAC7%1'YS*^\E+=IA>MZN'!:8&Q%\5C62^(:$ @:@V7?<#:
M-&\B=EMY19F?06!6NSS5WL%_2^;*S%!?QVA=@)BT.ZXTM9&^NF@J&B3NK\^+
M'>Z,H6_I*0J6]73.X9LMO3FI]!9XKSHQTC@S\&3!ZYY1,-7D@<R DUKHZOAP
MJ,S_?HN_Z2)T:8^?.*4HA_129ZBGRHL'1:V(,4V2Q,/D0>\&=VLN=$GN*/K!
M+L]TO#>L_+GV/NFQH)97 24?XJX]&WN0DN4V=L9P;#.N.3OA4&'"3SM59VV0
M>XIORW,VO3RD/J[1NU\>HEH8 )9TF9WR&VAO72')(/;TYO@UPMVWD[.,'TO1
M!Y$3-R+>GTH>N6R4DN5J$IWML[Q8O48MUM%X4DG^8[99HIRSXTYI'+*S"6H]
M<C$!6@B,,;E*RBCN:&]5.>HCCXH5U"R<6"FH67NPJU#J4[_=O^I,QR"L.+(G
ML:$[/2U)%3*!09U39"LYZ6-5U49$\@WW")M))7++?->$1I)9R.V#AK$!Y>.]
MI[+0<6<GE53@@9O(]V0J#VE1V:MYZ4$=EN,[6_*'[=_-[ZAK4VV9GR QZ)Q4
MTHQ*N#ZHO.S2*:.T9G9H_>)^E<O+JJ36IG#YM:_#5_K)FC;F@_;'%ZE7$FC=
M354>FW;_"-V5UOFD9O@:*O"BT:TL)^F*@8I0*)LK63M\5F5L(J;U=4553>F%
M5XKLKZ\:S5[\9N7QH&UXIQC0W2MAC7;R3&B.=F1,HOIX66\#<E6$^YAW;>?5
M/0&"EGQ!ZCS;\:(C4NJ@\9)= SM2-]S,9;G?V!Z>92 (7+OP_EUSHKMH_YZ
M0TY^\I.#^;?BD'I)*S&A=)C"'-MC)]JZ#P0W#KVYD925D=OJ2$1MK3T$:1L*
MGSW:F;K90Z.BO29UQ[XL!=,T%=7I&#PQ^8/ET)B[,B&-$-L]Y#>4 0^S<@<H
M![OK5HU*136I[!Z06_X8LS<I:^O\D@>WSU2NC9;(8K#1"F36\;Q[H^T%P!I.
MV*@/6WS[2?YY0D@Q!W?;7YI__(/V!HUN;8U^[9<GDU8">YO4N\/TGFPQ5FV8
M_\;YAY&[5'WH,'S3""^M4NCV0ZI&5IBOGS@-YGFJ1'/Y\6=T6'M(B"SUK,)8
M=]^J9[J 8O-1?F1X6[WB7ZA66!<R^_*-#1</KU;?C19MF(=Y';A_J3(JJ^/!
MTSK&7U>:)D5IAABZ^GM4CV0S#\/5E,FM/7N4!0MZ G.3&DTV?MO3':Z]]H<4
M@B5G6Y&WH7I,0M;2FS6T('(@O3"-#MHO>1^A$KG3>7;@CEW7YQQ?[AM\%M^P
M,4B-FUGOL3"("O_Z^5#25W%'%\G//C:%G5YR5*1B=O&Y_^IK[E>^7U9,JO2!
M5)HVO3P[+"*\[I 7A[]\NB9CM*CT:FF:7TCQM8A.>6GXZ[Q4P:!FHGWBV#[K
MI(2J\$3-^&.&LL&X)#N_">K(@41D/;EW(K3'L$-C4NE6\[/J@!JOX@ZKJV+A
MJB'Y^Y$#%X)" WE7F/5!9N\GJ@U1X?+WH]ZBHT&' WG7F8YK#PZ.%?0O!@8]
M")>.I BW!MU/?3&I)&7*/G[Q:O -=V^J&8X8 3Z-R_#+>GUEFKS$9S.5*[H;
M_:+_J$-F;B7\A@>RKKYW(J8G>HS<&X# : L&Q_?AA/,[-3I3FD=N:(R->U2$
M65?)*P-OV*_R"SI8XUI<;9[0TF):KLC,[ZPU8-8%#(UTCTB/3M7'+Z?F>C.^
M*BYI%)A_9TPPL66D\!*JOG-TW@/ &Y^ B)<\ZYV'- ^<B#?T;GY5B:QOC"E^
M,9"5,5\W$&*RPEI9^^7]&$E_[ OM!2ALMLG#2:7DL9U/RB)>&6?1XZYE5E:+
M-*G'CBWIN!?*2NML7-.!1E/KS098SQ(B C=HG!RZ^ZR+:SXZ[)^'("NOG%CC
M9.MQ<E()D&!^ORG.>+>T(TP-O#,H+"[IX/1<8'"]X8GXZ]7F5U.$,!-XT!WK
M,&0\<6U2/.'X4)JBD$\P^2'+V"^J_4UK]ZKJ&MJU.H9W +PMP'5\;=(E;F^G
MF?M'\74G3;-R<Y)P7@>\OI]!R/"3E\8?8_1(_2>5:(G(;#/"0'UD_^;,2:7\
MH-8)9=6:;T>+QMO5[N<G59O6,%[&A[Z.'LJN"T]U3ZR)2S)+B.RK(G_\MJES
MN*)5S7?0++W-Z$'X$WG3.*P1.:T:I\PTH]N+=UU5:%-XHAW<V"\;\F#6ZZ*1
M.C&ON..B1^U%QN)7(_NN*0^5L\"WQX\'&2\>[?[0\GP_?!>26YU<];QV80[A
MA<=HB;6B4L+L("H/59]$3)1KOQ_H&]!0F52BCIT33"BUO2:O6O/DY++LJ.<U
M+WIN_Y#M>.4BX[GQ_9$.I?D(XLF(-:F)3V/DE%K5ODW'2BGD5 KY85T@RIA\
M.Z"L/1RP79A[[43%][YA7<I2XW&CGN*S7D\;SF+[;/HV>G^ 2=07?#!UV[6R
M5;@&UL_BQ 1^R!%]T+[DUG%RH"NABYK04/]>GJYIN,7FX'=5R_LG; 9&P;R.
M4];0B<' %B[$Y%3"[H?ORS2(\]Y)?5-N';US=[Y+I@>U;9Z)N\;$@48R*SM$
M4SM[KZWIF&EO179ZEI_?\,(P4(V:IN_64?!V65O+EL87U*C D*@-?.XLXR41
M2SH7Z]S)&CQ?7HBL6D,-;8+BA85Y:>"8JV:'KS<NV]J+?A$7".<2])[<'WT3
MT#1TI'60^:J;L%S[<9U#CX\F$GC,/3ZM[Y9QAD%*$2;3]NC^AL#S@WYF.O(8
MP[N=7G8G8^KO86/0))U!LJ;.ZCQ!8PQ=8]?5[<Z=XR^,*X:.M TPQ_P9>5OF
M U8*M@TNN^>S91;\9=-.S;@ W:/%-=CX6AC2J>(H,6<L**0,+\S"&Y/O!3"M
M.CX,0\<T_%+C3!I-W]SLVV2UY#NG>;EIS#Y_O[QKL]82'L_MS$Z(3!L/*CCS
M0-S1,>!MY$:^$7;]0/N'P8E\0C 1;VKZ0UU&;V,%/"4JPW;L$$%<7Q-*-KDH
MWV/3J986ZRQM7'[\R>J]YLU%C(O]/KT'*OV6U-MOZ&\M4:K61&;I;NMJ),JO
MKU^>-:$[/N9^=^E@N(:LJS9PNW9!;JA$[J6!7,,.TNJJ*$]D-(+"O]T+C=:2
M3'A$/S4:R7WX<&RTO?:2!*ZB>\<Z7Z^Z^PQAWZ+VYE:L2_I@4=R1DFM%TMZP
MX:[&P.T)!;D5]XP)IV18;E)RZ[N$Q[[RU/?%P3TW&F=!*@ZVJ:<.O>E.JFEM
MNE@Q:EC#6ZQ(^D[U7S<+T4R'N]MA3M9N9+7O:E+DF491W3I+KKH.WTX C66.
MI1,@;4IH*+S?P^/68E</G0FG4M*8UGLESAW/6PG-9J)]RSJ-7,FU%JW@V.H(
M2FYDN<;:D8 @2_0A=X_]18F$O.% 8@\Z.-MD+-S'Z^SXL85-&IJ//5XD>GP3
MZ_3MT9XN,W1]77>\*#OH LZHKZO,V]3XWDY6+;9E/&9@]]D8-*76M";>(@%6
M" QK+4K<Z"^-[*U7S3'I+5?M:=_9<2F[47L\^$U!8U+XJJSWIB.<9C(K/.ZG
MQI; <"<U KV6T?+LYH0A^*II=VB@VND>/[I&/[GX?5DOH:CF0="C/-@R&E<)
M79T=#<_NOFLT+*@/[H3Z-(^Q_93C?KI]+DC[COTW_H!S+JDUK[YK?N77I)X)
M1CV/4PZ!Y?GY9M:&Y_5T^W1VR$-RFZJ7Q3U(J".8&K:N&0UP.>KJH3OFE=Y)
M4!JO43OZ*#4]8F/FA'%G6X7]]C'@.=N$[.M.*?O*.L.J#\\>R./'U9(?W-,9
M*A3UTE,I8T,$5>F)#QM5F7'X@BU=DTJQ1N?\LP3\H;+"M=RL%4+6Z\=!#U[T
MC?ON7E9[O)I8&, B,$,$P618OWBGO-"Y1F/CH#"?0*47W1ZEJW:&?2#PH.$K
M=LT)@MQXS>O,RAY^L<L#$&,#:<HEK1&-.0<8<>ZK<\W<SXWG!M:GXO*R5N_^
ML2:D1-SX59MTM.DG1]<#'>& B-"T'],!V4%1"AN4RN-["D4J]6L0 <T/)37W
M&]1K4->3HBJ?5L3-"N5FRMANJ-@7!6T!F0%O<?3:N/L;'K6ZK;\]8+([\H-N
M3[P/RF\@1]CHG[1$$!<H"E9D/MH:$Z ACMZ:&'\D#W=  UX6C8\H:!\_F;WX
M->=93=0&?:EZ>DMV8E)2^:7C$VJV&X<"6 E.[GDF[F:$MY3%=9TUN;4%9X>R
MY[.'_'=W9:]BUVMH#.4[=5?H/JY[TU_6SD]**B7>I9IDVT':H6Z0SIH(_6?9
MB9QN(2?5<71P@/=R3]"!DYND"J3Z9WN*CFQHEWBTQYDM618"_JEZ.UT]O0F&
M$C15K&X(6F"CM.,0J>.!<BDVX.RM+(\?C45=UX_49.M2/7CXBKK703Q)==7V
M\*ZB-Y&U_3>^)M,;FK;U^U623"-[2? 3][0/F442NYHTWS4=';*^N>3%D=/B
MFI<I(:W!W@S_C%<*7(V7^GL:2(%9+UHV3TS$MF]/[GK.6D'6N'N9%]KTJ :^
M5Y*%TFN*$M?K;G3_,#B658;W(W=).V/E.8XJV1!(69GZP*EE;WQ3&YO;FSO>
MM#;6+ V$S%]O%+3R!:VUI6590FH/@Q1^ &FKH_K,Z X3'+?$Y/0+F_"HQCJT
MS_;98S$^/1[<EO;W^P=[X,L$WW'+QKX?E"6W]CY_<,[_P1Y(U:WA[P/L&(;N
MT?T03()[".\T*]$@6@R>.(?+*(W%=!$6]9F>6E=<"_5V[MT#7+_-PV)ERCV+
MU>MV'"M9>3UE9!>#V+W!I$_ME&<Z/C,-U?5V[]9Z;<[P)BOO^9[?[5&=MZ9/
M*WRQWXZO;U&NO'Z*XS)+$\VY\XRYGLEJ^3$/E\[Y:L]J'Y/K"TRM8\:2$WU_
M26-O6OB#U7+KXVPWN =KRM==A2R6!/0L#5]SM/1ZN6_T%K@Q>9L]JL"AI$#F
MVK[_LMDBPM,\4;AD0IY15#D!\V=EO:0+)"W7EMV.Q@X+O[W?FJK_R+V2U:I_
M3&%N[>,14+,'@6C,ED,9E:91"8*8Q4^OBN]!Q ,ZKG=0UO#9&IF&&QH2XP2L
MWOJ_$]D_E\B^[AQI%!L6#TPE6OW7[RI?N7:L?%AF08Y[P=IS=O]@M^$/V_8M
MB82&2@KM\U;%:&<?*0)EMP6I=MUSXB932)D_I.1>?F_5>W:!+UO6OK+3[''E
MG'N94?N#RI,V93E#_4<PM6S/-+GFZM9;P1D%@"WJ]7<NJ,W^;E+IE7<9[Z:L
M]VYIV(?:>%SJ4//(T#2IKR/JE>-:C%XTJ$4C-T3D-HT:*'@&/IX_ I9I'@DO
M&A$]75.?>C^P"I6M$M ^P+RY.>JCH/-'\-/;7"F!$#.S#T5JDTK+QVI<7S$'
MM;CU'6;X2#]Y1H O;%Z<=DC1 #/%K[<_B OS<&'5C"5,9+_K/MJMG#&I5/TR
M,>;:>'W5P#DUZ M8]I&)+:/>+9G#([TC,@_'$J.9;R[NDTKGLI(3DD2C6;F)
M5\9V!0:]CL5.:P6#W#V<587+C_")4X@_OCXUO9<ES5K2NMR?Y]*UO/G)$,LX
M[*KX]8 E'=KVW2K5V?H+[EMD(<YL"S12]5_GOKNJF[RH4"]25'Z2EK#Q2'=K
M@7KP8-XX^GFH_'UIHFS#_6],J&AUKW;[@U<H4M]WS<U6QZ^\WUC69WKI"NO\
M_&%W4SFJ'5>^*/C'9RY1R/C(Q"(' J6B_>0(;('M[ V+D<$>6^%+K;Q-[S2%
M5=UIDH<LW>+=<G.#-SP/11I>DC'0;RL8;/_I%HQ^B?;"]D %9P<C5']Q!D1,
MNG=<I;.H>#RM<<8B6N9--/9-*HVZ=0<=C7NAT..[:O[.O>-T;,_T-F/SVT2S
MPW$3QGT],8HBP3B C$GB#RHG$E0^UB%%T?5Q_#?-W<BB_G.X?.5IA;>#;_";
M5(*$X:;D#=;-&.[NI_<E1-*&LK.O>Y5F7)X1Y<OXR)JZN.A6-;_!<)^WWBZ3
M2FO,HOO()\4O,/DS98M:KT9G89)"&('=':.HHW[Y1=WA+_H7JV7),SWP9NBM
MV4_,#$O L$Z/H#)O[Z+HWDDE^I;L[NS\4?&#VTGO%#HI'^A)',/T!I!=DH2C
M16_>)D;&I?E-Y"9\>.\WJ!Q4)O9J)$S97TM>&#:H/BARX$-I-@2>,;&_)WZZ
M.6M.=>"ETM> 1V;W)DS[/N"4>C(-2BXD+_OF0$GVFIH5UX^L]\T8/5/H+[58
MLOO 1C%]M;W%8[VW*VKSO@T7]WB?Z'V^!B.IWD5I_W9NAW^U\/5WCP?'1"9,
MX[V/S_N(1PJ>%K(ZPK^&0Y#OXQ9R6K]'M;^7'"%>>SS8MA%RP;ERZ5=SWA@%
M%TXJN:=_LK@0_""LY&#EV65\YJ221<BA=%:!PUHW0BA],=ILJ7UD77(P&=K]
ME=$;P<'.QGH27#K8>Z'6Y-%# 60^Z#D.6.Z&IU5D)F[_L$/;\8&M:\'J 6 I
M*$]J_CA&^['K^@MQ6T.R\8LGE8XP6N\G:'NHWMBNK\P,>S"DYK;R;4G%00P7
M<FF=EYLP\@*CT.7BCFUYRR,WN18NCZE7% U3N\6P$?8"K6_-Y\Y>8+Q7V<E<
M?<&&*QNR/4X\7K')]=M\&ZVC![7:S#7F:NQGM@24C22/P+[VB9.-].L/*O-'
M[KK,^+:2Z1K5.^B8UZ]VNIO10<^SG8J]QMB!02]CK<=S:P;48<9%Z>UJF4_O
MZH993"JICM4XO0%,*\<N7M-8345>\\NAL1KN3<&,(MG&']>8W@>_#!AT[M3$
MAUD!!B'#V9V+T1__7QONW%HY.JFD'V0-6S:MCG.FR9/-%-6')K8.9R5?C9H*
M.HD?9CP$9B9N4#K@"B-BWOQNVLV8X>)KXA)'!4\KTD;#BZ]Z=O*ZU[2JI3\U
M&-^-3#?S&" ?.+H+G:WI;H9620]/&W<#3\WUC=^=?D4U#L,'A9D]T22^N5H9
M,*FTIV3"?PVF.[=??V5FK,_B$L,;\_<T^VFLB*$N^8IS\YB30^-=^D(!U1'Q
M9/];45.=3D%-#'UOS[ZY1W.3?%4R8\!O8;X3M_K9V^Y7>L\BG2)L#-)VO]_@
M5@GLSG ]XEB /"R !:JE9SU6O;V\VB;J9)_G ,M\Z;ZZB2[QC\]F;< FHXL;
MW_8M+;Y_U76AM?^DTIP-2T3=>7>;0NE=E- 6D^[085G]ZB:<N[3MT5>GPPWP
MZ\*D%:5KK]Q>-US\0^EI]ZL0>'O^RE4GGNC@MZ&RGYU-2?HFL==(;SCER#-O
MPO_'P8'Q&G'W'.+!:YZ*K'#CU1+?\8O*BS)6/XL<=MYDC3ZB/@;7WF\ABBV7
MLYNR0.&Z-%?SC1AKOXL$1$? FPG$#?_=S0+9=AI*LZ-LM!A@E5S1&;G)]B=>
MN]?#DM*Q=6 ]UCF7ZLNU_$C\ !_W(GGWIH4Y+GS#TR0*9;&<%Q&CXFE9=^MB
MHRN!VU(4OBT/F'S3_:R.O_1T3GW  /"4DW&14#A^#E(J:V3NQPXU:=-2W617
MF'0FO&*AY[/2PPR*QES39$J'88W\YLBKB],<@S9-!XC6PIVC4:\GE=I93R8@
M088?Y.O?,*;=_4*[4Q<O+'0IN4O:8B&(W&J'%^R_M#4/%+F56 @,):\N%,60
M53MG\K6$[VV59MMJ*<UKB/A):;Z+;8=:VBA@2;;%*$JOQ[B68_+VK&!UH=YU
MDHW[THN#*/YUGSSC>FBAR9TP3-35YE;>'4PDI6\WT776@UO;<L^;FI>%Q68N
MF)$%_45W41J3,A3?-%)XK7'^4,+[D;Q+FBJ*6!6-V[3-W6_3-KR?CFE$:)/I
MB9BKQ/:PX;:3]=OP 64H4,PPV>3:A*99^=7OM,_/C<V<[]Z1\$$==1L1=NP8
MIDQIV9*GN0^<H=\0GCVM-ZPMV&]VP"G;,E?:N_.F=">R*S(,=WIIYKQ)I5:U
M$]!+4:>MUIY8[M*QP3H0J]Y1>;[G2C?YEH:V:\S'4/?&%[9[VH4D9$L' Q*(
M"U1#QO5/DYI.Y.BWYC,NI9W:B3)NE OW-RV.5\T312;=%H3284516]H"W*R0
M>Y[@3F]Y[WG-!J?>>$]=J3_VK+R1,#W/Z"1@QUC+U+K;5!3[4)IQ?<85ODQL
M\RM6N$]%KCD5_#"Q_8/C(81=P]EF \(CBC [EI1JG[AM0GE\>Q!OVTP0W38(
MR!AWO':?./U^4& 8/9NOZ&,=AIL.O=>]&I$3AL,>W*-^O>36H@_H;693S?;O
M3)M:=HLCWMVI"+I?BA'T(P[WZ>WD?OM6L% 0J/)RSZK59Q-/*F2)M;\\%[O@
M=-MU:=O7>9BP"0-)%OJV.SG.KJ,"<>)0R[FB'S=[9)62)U0H7H0*PT)3PM,!
M7H?'2KD=LC$I.FG3RKEM/^;S/*./9Q-TPW<;:=RS41]M;5&.'4^ZF?*KI?>A
M7:WAKH'UXSMYUW00[UR[)=^D]&DU(X/OZ92:@(7?J\>6Y6#+DI<].A2L7? X
M)R(V?^HU+8#VZKCTRL6YL,V!,H]57^W4G7I-:ZQL5+?*]IO>DA.HK"7* K6Q
MFST)^R:6R"SJGKLET!=1VW9>^YZ]\C(Z:A-N5<F&O96"SE:+)8^_!5-GXD5K
MQ932WU3W"TD+<'O+/2+64G?PWG$]I>]90Q[A^M*EPI7DV6YKC%>T/-\8>0+[
MG;K;6OOY=HM7G#Z^J !P47\)^\FM7O*-NX) )^E9=Y7:M5F2#%OPM9>(Q38-
M<^5-A.U6+JLW*>U]F?-:TA&33W%]3OIA#U+6\'I_;7T@.(??>,9]D<_F6-8K
MR^^BGG\H/MM^L,YS 9%N8U(-@[E:]QQ:=,MBR6OO%<5FZ)>6[3>^3C32?<D7
M/_5WZZ^B>SY%C%17K41MI9D?D7(KG1IM-^Z/@6Q2#8/N<]@)5RF(ZBN$UD'#
M5KPKU#ZG%V-_IGYB0W)@D'Y^Q1,K<L2\KN=+"^J/+J<<O'!T=.4I@S"]BMOF
M^4JFI:L%G0L(@>MJ390CX"L2CU[75V7"SB0.Q"#6=JW>=MF)LC',=OCQU8J+
M+ADG(AN)VT4KU^F0QM:<NC9WA_*XS/MB^Z02*Y>%Z*==5<G)>5!96+9RRP?0
MW#V(& 2P.]+YTE=1)^*VRI2.GXZTMZ4"-\-#/,<27S\K>Z:9MII9]AP<FB(+
M?;T_0M/"A$-DY[5U7V70'G1EJ.#-W^JD;#P%6G]V.&Y]:C<NV5B@N[3$XZ .
M:=/#=RH7CVB?B-HA7'1BO5SGJP.+5 I/T>\U//X0$;Q(YVFM#G],$W0V[X<[
M';C,7.1;D)J:Q3R ](W.K5-E>Z]N<EV$]>K(+2C*6[A&-'?KYIJE3E>NAZ6-
M':9?OU51>\IX::W_Y=*"AEM]._;<ADJA8<8@?G\K?DOAF;DW-)DY4AW'C2D;
M3VPF!&]^O[0W8<,*,6W?P8SPMP_K0&>,=B&/%+G6$J^5UH5Z&]U?U$/6J#RP
MG#FP(W<M;,N/9]Q@U4L0RAMC6C2VJB >+'H<=K9LYTY7GB^J&(0IJ;A7D\CW
M7C.VW>LGQY3Z'DHQ8.46FY'&EX(YMYRM+J^SI1?O][;=4**^P+-<\V18@6EH
M+G5(M.Z 0_$=^S7,)VV<0VZ/UI'L3X_<><;\_ERYRC</4XV_)T12I%6&)[@5
M!WI7CVFNJ ?U[-FJB]2QNVF\PVW%E15G95LH'?C#L3:EEB=L32I[>JQM^"^6
MVD(Z._;?56<E%$;1Q0-/]MYIKTJQ51'40?K/%'<R[H^:JJ6K/5G+F%<6DBA_
M)3)R=LD_Z37?;D_QCE?Y_9+,^;#<+&<0?BCZ2&L34+*-Q+]VQZ:1.2OW;BOV
M*3'R]F(51GN!/\%ROP5EP<LV%5AT='R]\J:UQNC]T)4UB]\SJ^MTM21[57/=
M:77I^$[/JQ9I5]Y_[1X*S38ZL7.>]Z%S&ZLN!EHU'I1D/VHDE;S9?8GR?>5R
M3@3KIP][?20_M?YTKRR'T58(V+'GH/$W#:[\0>OUU;E9Y5C/8"$P^8@M!\*"
M?N7GRMMZ]_:9M5;V4(<#V^)4UGS]_=/R9#M<1G'>V#T=PIFF\Z]G9WX?%6.W
M&[;0NGV^:5P/3#3_4)'[U<?2C.*)%2O6'$K&MC1H^0O=-LE:*N_.];YM/T>T
M9O/L RMLC;^[?>5@6M:BEI7996MJJ/.3/T0ZABQV;^X99,^>5[]D8Z7%YMJV
M%,L#W+G U)WF6];>L;1=7 O0$BWD?(U2)_A6NPIAVWE+ZBX^:= E:]]YG-8B
M=(TW+CW]R-3AD+3@PE?';EN/'7T0=73AFBO%15II,=8>A^\(WB=C02NN=@42
MUBUVB/1J)ZQ,=']\L+&M 3\KQW8[J92V4)'BGVYAE^X1=Y=RC[=L/3XBOO#!
MM.CBW?)1_:N,-Q/W57:>6[0=MD'CX)E];IG.6P.&2LB'^!FV9J<VC@?"NC3"
MO'\<SK@>@V[H-<O=7HD^7F>RTF_32MU&!_G&DL2,I$4+S\<L";*BZEMO:(LZ
MJUN(.TYUR82OU%W<<R-W%R6YBZ:]/RTZN*N'UCW8I7[)5_+CWJV-S &6>ORL
MZA4'K(\Y5$8<(DG/KB3JW:S2\C#LWJW[$T;GQRWWMG+#S<L--F\U@+G5#IZO
MW[L7]*W/AELR1E36L>VQ2R2XR\A0//(<;$-*PIO@31H&%W)?"KC?/7H,6Y3<
MG5C7 PC:L/BB/..$J[/IEO2-;8*6;M7'5F>=7[C#R?E+0K,C8E)7Q<Y__/7:
MK8?ODY]5PF)<ZH&8UU%;UZJ\B7AQ6_^01Z'^S8A##OE7Y\=SG8X\-W]S&(W8
MN7X\L>]NSQ*N"D1]-&4S."O]_-I'/^:?,F6 %J7LIES$1BY904L]O=J,=2/Y
M,/AD2HF;>G_6J>ZRFOHQ=^,=,?(B=]'.$($3I8>H^M8P6*V4]/ZD9ZBOBUL*
M.V?=5Z\@VV7G+"*28$^&=5Y0;^T"G4ID7KG_Y'X%=!=\/39RN\W)C*:BVZ(7
MR3977O7:OCB /6&U*./*DX>O>TEC&J]7'-Q.W%)Q(BKEQ_.0%RP'=A.I=2!M
M_I:5K09/P>^.6+"50HMOWSZT[W0XMF]#]?=[8TFS4NST6.??D\?B<X5%T1XY
M[H]?D)7IAH>7$1,H% 9NK[WNQ9+C1XVMYS),JKW?X_"Z^0Z>CFM+CQ<L9T:7
MW=R41S]_];&!E&7$>O44P[:V&+]R]8G6RCJK;!OBF7605L,-Z5<.0MN_<5F;
M](C.F<^S\$JKZK]"&[",N1VU8:?*L$%^R97K;V)N9TMBC]II0G>9V+L>"/W!
MR^<(F&YIF^4*O+W:WS]-$1XBOB:;:BN_WY-GM4#%S?M@+G,X36>'ZL8JYX.(
MBH(]MVQR')=>/)&W8J!--N\IXC$.BE^RH[:">+5I,],YI>[)=K?ZMZV4=HLY
M^3^<,WFK=L'-]IN[3?2PA?=/K0O^$&Y85:D;\V;-J1L!*XT2#?EE/D2W<Z_=
M]UWW9&F_6]WFQBI)*]D.U?+1#+/9HFIUS^_V#_6ZH4;VVSEKU@K>JR*?O^??
M2^[<E+:U_LH3X2EKAYA[Y':=X1MG3X"%UU>B?KJS3_70"$BHLP?;XRZL1,48
MYF;8(W:L-6 WB%8;JX[%:FQ?N_R2BMNJJS7!7,F1%\J>2_7OK*ZOBC???ORV
M47"SPXNMJ/,<M9*<O15&<>0SALI?B0[L2\8M6IGK+F,_0SCB=Y@?VJ'6>MHK
M)-Z#<,F\;1YF8I[:PT3=O/F'(PQ]UAVY&Q:W[%3>Q:5%=HS6G80DDNS'V*]Q
MZK612/WKUR# .S]VR$]OIJORO\D ACUN8M"V=<^; ]IQK5B(NU9Y8://UF1B
MHEM\(+3MN^<KWLXSR<$>K:&Z/W_V?WA[RZ"XNN[MDT!P=]?&+;A+D$!C'=PA
MN#O!);B[.\&ML<;=:9S@TDAP=PD2DO=^[N>=JG_5.U]FIFJ^GSIU:J_:>ZVU
MU_6[3M78KZ/3/QON5?^V;NU"7;#?<B^C=;>8DCIJE[,K;UD[)3KX_U[T#O_[
M1/R7?3)^#ZKSMV]K"5J%>XDW\LL>K%[4WU;YGI97>#UFAHL=4+:)/I<:LFG_
MF _WUMQ[. DZR+7NRQ#[P*S,U\VV7X6NKA57(3SJ[L:/]X:^:/&4R:I7O?^P
M9AV^RW2(V?Z8D+,\N%\V9,6MY^UUX>I#IH?2+XJW> XU^= L:#TA=2Q%<\]D
M8'H=K0%?^6 +V:?MYM01X"D2Z/DZS#2X$20*3Z&P,&U/V679YO 91,L*_49<
M?&,-:4K;2_NIY&P?X7K"N3N"!2,5H;KWY6EFCERGP4F]NKGZIS%+)">2G,!R
MLH/QB\WF')V,2;#/6=9 [6QU5E?(?B!#'5]?[($=*V=3_ ;?SJ/_1P>]W7]V
M[.>@LVD.'%H7 2P8<3EA%40N&]?XH,2$.<9^_3390>5K>5A!X3]G2967D* ;
M+K <X+F(\0/:;:'PD4\R=) [M<;RH'YDS9AVY(B<=EIE>3')K#1.Q--E&)[/
MC)2"!_]8QSL&,=FP]2^<Z0VB-HBDWFL\$?-:$M<E9 ?#!YA+C;E%'S(D0]-H
M-6=KG@T>(+:D^=*[E3"O.*_CG2'>,6UPO!6.77%,;E\96%S,9^_G$9JPS!_1
M<A%I.CDU''GLDEU5: I$.&>^Y5*5+=J F%R$TB',IHT[LR-UQ1IJ>3J4;5AA
M(W(:[JYIT)ILAJ2I 6%7&$80KG0H6_VHNA'%>U:$0O**_6W\?TY!TC]<>V0;
MG$(QPI8#<X:?IGIB<>3'6W(E[-D#[='9DX$DX"A #MXM.,Z,N%2$N6:ETW<%
MMKO6M\.V[TBF4FR76&]4JD@N:=XYS!,^,+>KB.3ZN&7E>$52H3>%)R:$]R7:
MLO^S83'7$'XL^VQN3V1M>(X'U*">L*MXPQZ#D,&,L8VUFU5&5IR^+AXP5<."
M%<([==*=K5HQ2)+ -N;J:)>8/VK<%#LLP&G+L3&^HFIG=M:MG2>R[KB7<9\L
M0RAO=SJG:$V14A;Z$]H@M7*!:[M.*NJAX5'3)>)G7**O3U+Z*J:VQG6Z"/KY
MM2\V)6-N-""=GV31#D]IEH'$(VF=]:-_EO<+JG4];=%D;(NW:L1.CU'M71.A
MWOXHXL4>> KE B.W4MV370OKH(_V\72A!WES@0G?W*4VKRV*Q& R]MS\4XJ^
MUE-TGD8A3=2$+!L*UA32&=DXJ\:G)SXF]H>>0+ZM.2UK!T=]F5_K*J1D,TO"
M&F8L:O63(P@>Z^\(%AGDC'5IMR:D OE6$ /28_)(E$J:[SAO%KGT.N=4+V[N
M.6K9M.-/KU=YD'&!#S8\V0XCY V(0_4\2=!T*=K50KJ,NKEA>7LAFZ.[=NBD
M.;<YJN_2^[H?+5%TXX>['C6)36+ 8=D;X-B$^;H\,WCY^SV#5M;2B[N-PY\B
MNH>/N6XWIBO2'\GK&=DAWPU,+U*7:$J0?!D]$++61C]VR\;EY=C?<"EWAB79
M*FD(!?IU&YBQ/8L0<,U;D%.JH]?R;"2@;#6G%T%NN5(X+9A3$65E^%*2@)].
M$2D^IW02<?F+YL^X^I.@/(6R.&.E,PSK=9BQA_L]WMQ(D>LTXTG1M^@=%KBJ
M]VB94.F(=:]7+1)E9YS<N1KS_5[\WA2I@8WR=2I"- 2;A9H#FU(2)Q#!8V69
MO'1X(NR$=C^D@5;1VR)-47_HTG'GUO60N\6-6VZ.(<U]C1?)9DO8F!0_"XZ$
M/;E!^\#8<JU#)R 2891"T#S,.Y5E:-DZ8;']I%C-BIZ[]$:W'K/S]M$R;W06
M,6IRU.A5D#UX@]E\Q2GAZY_BVN,+*468[Q\LW^WEL-X96:,4XPYJ)@[9\N$%
ME82Z5%)&H 4^BF9S!F#?9 HGV= EE^2*P?LK'[NS\*Y#@O2H!L":VDFWYGKQ
MJQ_0/'LO82D34L_U%:-8C8Q8@:#&@49<P#'W^#,3A?#0??L_.S!/*JK&F?:
M==1!QG-$R+HQ9G0@/H/L,\:\W)7>N<KJM#9P#5U\T<G)!LH8>HH5]WD50JDP
M:O#(IUWWK3SBB^>JX8BOM!-?GGR^!9;>4A>5S>V[&#0V"X+YP=@<3JFV=0<N
M0R^.HLL2AN$JD!CO2@7#3NX)/)1']FPFJ=D$6;INRAI-1DRQ%&^Z]=5'$,N'
M/Y=;DDPJ>6H@)! 58V5K1!@\1!-CT#@S4I3.& T@R/G$/6"GH+4HC^NDNN!
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MBK]PZRO 0*Q5H%[%2]7CL*QA6].+>0\%<G,_SE\X-6%P['$<_G*.UU*,?6\
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M.)D_YJ^7]8V"AZ:6A6+D(<5BY^AHX7%W*P<1P(Y<3WA0';GI9"_,27##7.&
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M !O"K/6IS_69TSB2O/"C;&/Z\(NZQ]WY;<ES<0]TYILDT#JO952U\$0NO;<
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MJ7,3=$F/"1^2FPRJ.@A&[V? UMHRGH7,65JQB+;Y^JG8[S#;OCXR0RDT-.S
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M&D;'F'.3Q;&PQ*K>=Q3T]E"KWQ;W0"%,-=I!*/4$FJ@T1N_9 M,O6J+>MU
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M![N(AF;;+5?>T#O4]2P[ZV],0*R1K^B9]L#]92=2J:NBWN=/5!OM?>5/:&\
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M7-TRC;WM&2H[W-)F>.%"D]/BQ:(N/BGAZP5H,335O\L=>H"6\$,+842]FX_
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MJ&F[ 3F9'F[TN<8>:@7?W8_%8K.<H,U;@2T!*F>@8O1*=ZZ0)LA!,ZA-Q[3
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MEFR$5/%>CG+P6)\ G$DK4H"=IV>.2IS+F#:3I?<UG0Y'@$MMR3LONC\ZG=@
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M0Y QU;2D'(9V- +!"ZZ0.5<A[B^!,U+-"NRE\=O-E.*V#,4,E"$&#9\^Z)5
MR4FIV88K<>IG-\5]BP/8;JW=<<KV&CC7 RZ-)DKAJ;J3=B)R*2('5NR6.#-'
M9=?+?B!?TTHK'-,1&BVBU.#]>C=R.)LAM?RDE)M\<7V%A-!YVOBI.<Y%^58(
M2%RGV1T$/__5T"%. 9%KQ.M/HDB81,CO-*J!>Q]@7O4;-_P+\':KV9_;3),6
M^BQP9$GZ&P3E^D%NCR>*,XH-P]M!@8^5^0WG&1E*^K#*+T %#BS\1 7\>J 6
M3F=%)/<[$$5TVT7(]<!Y:6D9JU H__8P09M&XI_S$NX9TES.B'FOA#RJ6ASU
MC,(P(YB8ED#1V\9$CZ:<R4(WPZ:G4!Q)RV3<\'"4N&>/-AH<.1O;"777U @"
M^ _\22KHE3%LI ;_FI1'M\$)I_E*G"AA,+22EPL0/57_(',*CR$BD%**U,7D
M<@5IMP^1J7V3_CF?D&X?6Q_-5D_'.$^.TYTX)C^N9K;=?*:QJ1)L>7AXZ)A=
M95E]=T9A,S_'^]#R"IC.K_3U\EXX38<TC$= &GP7+X_75Z/4!3-N#@1B#S_X
M9%+[9C6NS#>..46#7"^/GSIV'I[:;=?\XL+;7P&*G;=>;K?O5M<[QG/U'FO6
M+[U?_-*>.GC13@%":\\WRW9^^EA>T?9<$#*/IZ;C^W9K/[OQWNL[N^I_ZRM"
MF6/'[6T_*CGW(FY>5OP67P'ZV'[OYFT:!"-OUY>O7D2K)RO9[]FC01#2RVLS
M,CW6K 8[$(3P:47@UF:Z4K&=QJ;I<+[#)]HM*!)T2'XD^0JX[FM[!5RI7;\"
MYO<&EEO=;M%> >AO#UG+LV<LZ-OIX_5T;N1,ZG\=*WUN[RP),#7N-:NL1]GU
M'5J]5C^JVRE+IRBRGXP'H'/8,1%>#!&!.4]WI9S*<<([&@8V*:CGH#L69;F[
MP;5TOK_0FKLVO\B3DGQA&#8HQ3R,LE[]D.X]^P@6O*(@O>9RTM=N_O]Y</#_
M"'ZD6>\!\42L1(75\9BZN)S'X$3WCX1R>XCF3JP_;04U=]ML[3E8]//<6:C=
MA<.1O"=?C;"2[[ /91&[B'M![BL;/4+0T%$Z2N?N00DV>PR/TQ@X/=:+'\0@
MW^"**&F?XF:,$J1"Z\S-1:WB9$;KMG@"+YH@V=32W6/\RN=[^>I$N)BQN' R
M-C+RS<.4)NX2JE@_B<>E*H*+J88K;:\&H"?K!!"U]?U;>M/+0KXX3/7#\ZN4
MR\#FN67;^6*CK?* A4=R_5]/@7MZE@Q,>2+:6#MJ.&KU1GD;V63:40+$N5"@
M4S#>8NS+3PZX=K9/J)U":)VWV TBSG."Z.EV#;YKHT[RN6@5FPU2\_NYXEHL
MJL*E1U>C37/&GJZCB233];]POX"[4FVC5X]Q#T?X-1B?40\3^I=K?U)2"WR:
M[#?95NAKHO%:E$'IQ"4IGG"S=5WQ?/#UTTM%VT8++C[PNMD7G7>I:(M>)E*D
M7D^>KZ>]1+H_#Y'+H;]W:]B6<K4E&O.U[HCP?O&\>][L.H=_P69A)?KV"L!T
MWA9[>@4X\G<,SGV6/FT:(ZE\WH$M*G3<65(3CS;4G(RSO) LNQ\8[N(U7/UG
M%!W%*X5$T=V6WFD>@2DVF<X>7@@7766#K=/_$C#AC-S3\-.KEE(B(T\P$L68
M-^827^/@Q#>.R3KT0/0O5+J?W$P%[PDOV=?HDP>V^A>+<3BD*HS+X%4@1T.F
MQT>#39HSLK=YVR3E2YX(GSRTQ^P_\W@K"F3R>%YHICXJN)B92:<VSZ<]QI^S
MFE+^<CQI'>A-9J<5>SHQ/\YC^7/ 45?B2HU;_D6Z?@&'#?\K0EQU:$(CGN5D
MV+L1F,@4W2J%Y$\A1ZF ,R#>OT_NGX/M_;TBYF]H[#_S(CFNX+LW4#OFR0*Y
MH2_<_%M8V#8]L5L[QX)$(Q>L9EBY0#DX?E-4W\(;10>;-/:?47]Z<48&C@;-
M+]"D,8,^BK@Z/I5YW#S^/0AK\X)PGBE-TP:]"SG..#H7)0GIU*;3[9,%$N"O
MF/SI1G6O#II&Z,MS78AF*"".L$@*MUC@7= H0]H:WHX.V/+I/_./I9)Q&U9A
M[,'CH&;:6*EUO'2L,F6!*YBRI>&X)D?WUCEOY@:)8$D=>%#5!M>Z?%J*TA9A
M8B 9GGC0BZ6Y<'3$+]+%RR#OL.$./C&O>V11!:"E>;(OA8S*+EI=WXLQ35;E
M=]#]T^- F5@CI6X3:(J!7IE^91B4#.9\0.U:3.$D$8QLX<*8\Z"D5.;1_*Z%
M "U*QF6,*4[%1X2Q69Y2!0 B'+TAR96XH,CFJIL"KK@4E)84?@)7?YFG$&-&
MDN)XH/DV@A).$'&3W?Y:PK=_F]VS']VV+1+R#Z<^;_1S:@SDS^49]T##RN<D
MDGJWDX*EZ HZ?WBJWG$F6U'FF"=.D1FKO@+Z2<2W?^+WM7]G93&UI;&>4Q'D
M7$\$%O!61^4TQMS7>;#32*/J>.N[A]H$3)9(-L49^>9N1#-[D&'_?;+]@AG:
MW1_9OV40]<'].,6TBN?8N.I\Z,=NM3FG7!\'?%1_CC7W;Q]6G?4#<:?>R;6(
M N6^5!,$M!<9]E,3[N_E"\'(&.;S0ZB.)X-84T1I/[X5Y^V2<R6,UH.5!5P:
M@Q\Q[_"10N*H;[W";!3@^J ]P7AXFKL-@S01ZD2[M0Z]C;O,E++8]B1PW)Y)
M-\KG+J5DE@L@*F T _K2*EIL#"U"V59MDKT@CYKHM-&/;[GK)S\%O.P43X9U
M6EV"&"60+%5;O?Z@*NM0A@T!V:4_RO?5&',AZ$/0H>PLO"B"!0W^,PUIU];Y
M:]+$VS5!=RQVS7=IA,7EHX#?A[%-<KT../FT"9,4O3,IFIEE)N^J!M*&FYM<
MV'?._1+*]DBVLKNV_T$.N[5FU.?D CI-W0U3FXLUK>7\<=]X$G4AD#@RN4/?
MHZ&2?RY.SFKM=]3"E!=0K;\GQ3$P;7Z+D\#9L; NDD/JL(+] ]7%]CA'-3_=
M.[W@=EUR$L1[VLU9*P[,G *J]V&G^THF?'H@5;XDK+%X('BP*95?TKKWSN'>
MCC_4BV"K28L87 9A/YB21[PD^KY@_K>:9NE2MAJDS6)D/47P.XY::XX6#XF2
MIRIY$:9AQYT0<3$H-W/-,#]DG&(4!MF;SR^CJ=$3Z-9P5#U>)N=ZVAZ^A,7:
M:Y@ 9!9LXJ]G>THXV^W ]]+,_L14'(BTD1;O2^ YK!9/2<F1GS:WPCW["7[@
MT_#>>6H=ZGTH1YGSB*A6R_<;)]NRG^.)H(JO[MKY#KMQ<J3UG35*[)K'ZJNC
M9:%*(^V96(2.)M6!<#TD.)<'(*,$^W2X)AS8=7<F">^;#1D-(-!QXZENS6."
M/*L8>--\^JB<&VI,&!NXU)^;X1,^;/?()J'"^D(C+JID0O6Z&== Q^A KH!Q
MG17VX;- %H-5E'5SI$,"V%24JAO^>27@K(*Y(&R4$4LOK-)&K_AK.=]7CM7!
MP%R^)'+NC9A+ G:6./V@^+*D\JHF/<E2$_,M[0B.0Y19.V.J;.ZQOMD_GZFN
MNMS--^7URXP&_HALM>]KC/2=00H[ -X^W%QE/3<'K<^*$6M*2K>AQ5-Y9?6$
MS-KO./7*9>7 C@3:NGOUP+)C18:_9Q24/5*U-A_+@*&]1J!M*1:%+3(/1[J.
M$?VT8.!X5*4F52$8.%IR4R&..C;UE;&"$7G>5!,%"KJH]1",QI%=ZC,]DK#,
M(4@J[1?MQ;7: 2YY5"RG(2B/"CA]DZ\)!XTF9\XB$@F/T1]VPC;-\Z8&%[]2
M<M9&]%EH(9HIVX25Z3H1V4:9ED9BH65+-@70G7CN[!X!0<P_-D^QX,2L"<):
MH***U> /*6I'[,<7DRH-UD(Q."0"VP+@,4.6<>L]&$-JHCPO3..>_.1W/V3-
M"Q<,<G;4[!UWEJ0U;:$68_\FA70(";O)D8=CT77W$Q)#A@0[0 T,HBJ^X,>&
M?6EBCA^4UFNKCZ,#NL"NW]13;3R5YI@F!^<?*]H1(_9YCG(MIW9&AXN+.&4.
M_E#_6AD"GJY&!4MZ9=A'@W-P&*,PD6+?]>=FR,EB 4DIV0;&4%JUM%IWTWQV
M)X]SD\#5*^"GNDD T;GD\E(^CEUXMKZ@(7R[PUY-7CU541/Q]Z)BN-40YA]Z
M>0UD@<7;43!QT_/-5(QQH113[@.]5(GA;>#9LX4@M?H(4RMW8;-#_+9KB\%D
M?)L??Q,JP84:4R]W0XJ5OK2=(!L;GM1>!?OL%%TIMCU@Y.O\($5)=DO)%BW_
M>8I=_=>\*,[<K7_G!FB3EJ3*B5N*Z)\Q,9"J72Z@9SNRP!GN(GD+QI5*4QFF
M)4GYZK-K1*O[9.78-P:-=UQ/!3OO84Q&\1[->5"GCGTFHVO!E2^UHT;EK9,:
ME2E;++H00N*+H^;.=F]NO;3KQMCZ'0A6#O+^!>M?$G+/"WYO>NA3:;R2W-H'
M-E,M2N$;ROLZ\C6J X>@S5K-4X]1:EZ%[1%DLQA926+;U<)50!.'+>&(^CYQ
MFQ8ZKE:81ON9FCFPV/\QC;NY\QO.O%DE2%,ZT1JF%6!NH1O%Z 1)0P*ZMWI]
M#*\?9$XT[PV+/UF/(G!RMSX>HWXL1B4VGL]$QCV:3\,F43+,*S9"JIR :D]L
M3PNA-%FGQJ>-GMNHTD1J[1P0_#-=4_28:_OR?Z*4--!VK]_7R#^9&E[;9O\T
MT3^33H$LURB/;EUX*F65\Y6Y]?F*.:6;D9%<BNDFX2OX1=(N3Y%ER %5(=&5
M16QI.K/?VAUL;1[GZM&##QG6-X=IQRAJ#/P2B)6%VW\N%I>F//Q/ZMW*L:UR
M60N^TU_O2]/H>5N8]48_S/@N.#)C8J.)-O/%NA6K0S)%0H>M0&9L;"?T\29_
MUOM\B%/.-\SWI.43M:XC(P)387^HY#5Y9:C%L7UV-8;IUK\Q$,L05,%7=$/:
MF0O81]F"XK'SBB9''D%E!X^NDQU,9 K+?N+Q[X>;U@UA]#XN+M@UFV$Y[]Q
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M#^+]_!?P:?]\2H (]1BK;7%S^O>FZL=TS5W 5,<_;N;M?'&Y'*IM/JR^D,-
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M-H,Z+H$8@NO4!.2=*-Q*<AG[SR :$_XS8;C3S<*CC:W>R"JCKY]=T;2'L&.
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M4XB]"K6<M1VQ\(4RM*SPQS2?V;4Y^'[B;L*2$*"VU>8=%9.3;:*=&(PG3]K
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M3VI$N22"VNGY5"WS *3/V-)PO6!-3&['FA,?)S_J 1 3P2H654K<'HGRK=W
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M]CF^L 567*$DCX!B\-#1@0>Q5Z->(8$DWA8NC]L(,7=FQ3"[8OXG:E16E%=
MM9:4K;B6!<$$O7^[\=L/!>BZ3ZZG)+[,LY^5%0NXE_\*PCT&_@5>Y; ?X+\6
MF?[O"ABX4$=)#(5->JWT:;BD<(Z%PF.XF@\O46L_Z%W'C?DN])(.@=XV(?O2
MDWS4(S[?P^^9\UMLT*NUZXC %,GJV(DU^I'M0DKR8%(Z5RG+E:W?4#[&?P>H
M&9CBKBX:=LHM,EBMMGA6 DCZ:OZ:J]=T?=(\KI8GTHCXM'IW7[=EH'MQ999<
M=U59<6HY_*1#8 TY>@$UT<3X@ DG-O8)JQ ^:'5R>@FQO5_+W0U.P,Q\<>9S
M720'U'?+:)BP61H5B=+P[("'!D4'@8:+.LS&=.9QB/'15+_;-VK]OSAHC7O)
M"P09$>=J]S6 OEIB8B:U0\?PLSY:]^EQH>5)@21!6%5;9=)$I1<JY4VEO3&E
MAI%1"U\M:0-4]/JN:3$'"S7[3>MC-8-N!('!XL[G!B4TY5.VD26+>4R_U!1K
MX.O$]OO\G)=PVP5LC'&>I3256.!RT>X%_BE&12%38+"N9 <:E9#[ =-%$[9>
M+A/K&4P]R+\AS6T8_TD.+T01/+Q5ILY>_;5U4)/TV\>%&'<!W_A.+)BQP4@1
MGU6+#-R]X;A1D38EJ_'WL=7S=),%A<GR9<JD3+84QHIS9>NC[92'ZO*SV%%5
M+O6&LX#0PC*6)TS9)MT]LONH,N2-3>E,7I&5LL8!QSOM7XNJ6@_;@5QTTU/Z
MPS)*\8J)E47&+KM*F.F,[LRSQ8(2[!V6Y7HK;HT6!FX[/EKBY"[!=(F3D-"*
M +")(=IOY_8#E*HJF8KHT:K?E]DB;PMO&4;Q,1 P%)4_ZW,"G#6:I0[1S%?\
MIV8C0XYT0195.8S*NO(:DMWG%-:/+ZULD1+YEN5O*(3U%J+]XG:8/T^M2R=7
M:HQ4J.0"1QU,Y1?6JXRL"A6T[_%_>T4.V[LGI(?QXU.? #V1BM/>_3R,#5DL
M$-C^@J2ID=EW#/0/PY!D/<D_Q)/<5M,-Y<]LHDT@\3_TXKCE5CX.=,;UG3P\
M3"ZE5J+D4RRU:<=,WT*%9\.O\,;2I3PV^QM"DU C0J34:DPSYF)!(55ZF5)G
MN[7+*G9B\6K67W?M%QZS1<;VBIHA _V$729$<1=7?J/2='!;LH38X4^,I8@.
M($BG(Z_"8-, X"I $K:S_&6'OZJ/Y/'!DFVV#CY=\LS,W0S*%#F1"9SQ[3Z;
M#IZJ[+&ZQ[!D86WK>064VMQ:H8T)Z!O./(>YI82'BB2$U:+-CX>GOB\\G+H'
MJB&8FA_.U.$@*[3GULZ7"\33F7'F-A&SP@ZX!D63]+>F:$OX76'(LBQFS.1*
MVFUY=#O$9Y_Y75VS#*!'\\TGC4G[;4TNQP;T1(3TI%RW'@HS<XTR*_3:NDO+
M#+[$0J@>MGW0;C'B/J>04F Y8UF?ER<U!54+I6\.\#Q%C\RL]/>?WM"[X"R%
MY85CIV;S36A,): -)$M&_"> 3OMS' 4E8C!73%]_H,Y@[. CPT]B&T=VQ"<Z
M1W11XBSU*H?C!OOI)4L+2\5U=>>=D$:I[6\GXT=(@^5$LK7UL;]&:W?>]P@4
M%BKK(-NF2E<>EV W%J3&3#/,Q4[8)%30FT1K$C&YH\KT)998J5FNV\ZB<VBE
M\FKQ#I7Z?S<5!DC^&%$Q9]U%T4 KDCDE'763HH)JU2D7?831R%0Y\%W?!K@Y
MWIPNV_O@+]7C;I:J5Y1,NTP[+'R'N%0C$V31IV,J\JO/8^ID939L/%3VA9YO
MG/U\FCMQ6*CD1IF&34="YTQEXQ<\U6WR^]'3N\&MWX.[4P]Z##4,=$[=PP^)
M2GC<TL6FF'L%V=_H!G<U(%YT#[ !$+ERJ!"PT1N)J 9A F B"THIN@;9Q' 4
M"5O&RA^88F1[Q!0]+B 5S:"@:H?94=[ZV/8S4,3M(JD"V-6\0 +DOD$TVR-M
MQ^OJ;Z,UMNTPHA+5O%II'3&R>V9&IDB6I*W<.AN%_\8M+YR54@)K3,\BH02/
M2/>KJ$/"C8;M*T X9.5T@/7*:!>VO1<5G0YO[ Q\!2B>O42CG5 NED-O!NGX
MCLNVE4A ;(&,]NQ8U_? ^O9BWD%'%EI)69@@I)@4"\#A.AUUT)LBDPA9+#?5
M=C%H^!@Z@G %@W>CIK0T4DT']#GT4AY[5,36WITT$Y:[9' ?3BATIX@9\/.B
M>G+1RX\TVW4LEH.X*/G]#R3HN>"1-T#++X5_UXKW7;AL:QK,%-H@=( PQT;-
MBMMT*4J\( ZIR>EYWK!%GETR"TN3W6YRI_:>VI$LFJN$/2.J?M[E0G"NX2'L
M:ZINR52Y(HG\B@O]I7JN7CT6"SF+!95WBB-JM*ZAD9ODF_!&-MQ2CI9W&N*#
M/YI<:5TX[(>'<"LBTU5$*]K*00HYI>1_@5:J]0JG\R2@WH56UT,D7[X\CTCW
M14=.G8%>R9H2>$"\U\)<VXKMHD('=H8&#4BOT%!.<+7HK]_\QW(OI_)Q47X$
MZC><S._2DAQ4&%N_W?].^X(G974\I1Y'?R&Z?_%F%#N-<HA<;Z*.7EH=I;RS
M<I#W^S51EDW46 NM_6SCVHPT59N#YR:#:L->"<F$^M+2H9'E@;=B[8UI]I]8
M5PRCL$)=KI4/WV=;,Q;GAVH,CUE3H&K[+@0MH65JRD-4N.\LO,DGX(>VL%!G
M<)_JQ0TGW1ABZ;MR##'.7@)[X#=ICKN'R:)]=VT1WE4UE*%97'^D7CE]K=EY
MYW>)7Q%L_8V7LSI6DWKMF[:GQ=^=MJJ^VS/<<[.UHFN=V,"9;:7TU\NL3:8
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M-G62F<#18%:>OSK*X^AXTLQB U^C80M29P53+HJ<YH<B71Y7H7GOE[,<A8U
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MGN=82B;LM<M"Q7RPYJNF5+6*&_,<MQ6.!_BT4VJ[9S .U8W#>3Z*])@YXQ(
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MUD>\L6V+9=WUCXCAM_<2,%;W'#+H476B<3U!;,"#V A6O_-=&CH%L4*29=7
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M<77RM+%AW0WZD'HW\=^E(/W*?/GHA37PE-2DH!1Q(G:LG.B(3$O3V"V(B4'
M_9AHOI]H?FU66'V=XKJOCJ6TX7O:TWY[/OOE[9OBFS$#$&?YHE^M/&6[7;GO
MXO4%L[]_+M1&=SP.I.+Q<#O&'O\8< T;WA QNHU_N+HZ./U.4WG]OON80M!6
M;"OE],5CGL^9D+, D[U@$M:>$?"/RP+?C/KJ'P_+*,][Y=8]3SI^.P0.W]Q=
M+?(!/6"N:PW>KJM.?>8HW:.?VITF4H9<841C[.=# 2\^KK ^0?^>YIWC@[:O
MF_/["X+_B([8$U_P?DH GO\!MN6]4W5]^1REY) %_2''D7(@CBOJ(<(N:[*0
M!4I+([U((P;9WO&%]U$I<<G.F_*Y1FTZ'J5%8:>;$^S+ ?1PR"68 *=$2-+H
M\0CP"$R *?^58,I0N)5)FD0M-&9;ZD@=-.J:2@^3GP-L-%G_8AV[&M&1*<E-
M],RIK&J:O]WSP/QZ01CT'_F6YKLXE26)\(8G:8=T73/&I"5<+P\X;E78DX9:
MSIRHF!289="_J1 $H^,. ]WA1\5B%B"B>K*69.'/\F+&O\1(3P75Q(3ML?7A
M:I00H;KH,X4#UTU3:"!MM0F#16WM?Q& 4YKH$HU[,D.'H3J=&EET* B[Z3@0
M*']\IH%6-Y%EF&+ZO$7:1#!,UC#4UQ1!#CXD'=S-8?-13X7_D$$@T%Z2J&%U
MF(8&E*KXSOJ]Y[LSC4Z*DH]B^M8@&J$6!L.Q#$02K!5@XWK7I";%WYG<3J1G
M^LG<1RF[^:DV25O+KG4FW8*[T.QG]2WF C!?]BB/XC55>@U8S9'^:#V3D!Q4
M@J,3ETK9'BT;5QMF:P>E-K<=TG3% ;>="*+-@>1\3L(3%>IW%6F&SHCL;K3
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M-2K@?()Q0L'.<8BAK=XXQ'5>,U$JA6#YS@3Y<J>AP4@1CR6Z),N/.;I>.'>
MO'<_,.EY8+?=X**KKX('@99$X/N,$E<AXN^Q5\_H,NT2F;OUCTQWL[%5P*QP
M$-^=@O?B\4<F_BMQNR&#@''GV&Z\[2W!WI(&KU<9KY[IF/[MF <@A2R_V$Y0
M"L;45;_7JXI24KO^W(BBFHU/%<.#LJZK!@8B(QG0K?9='90M6QG3=' ,T3ZL
MTH8>.==[;PZ?FI-ONJXLOA <CQAZAM:4MY:E"C7=(H@&"O*,L%W2]'BLL%+T
M0VK ./LL%B:10VP3L_(*"O0Y-3>1*6?8PTT)I3[Y$M/$7V0R^A510-.#*:7"
MM:9W,V/CY4X"K][F=+.VF] 5(SU%U+9]PNQX2S<VMT+'3W&X?P%CJL":4N7V
M3P[)JB7$0"$F5]U(10[&YHTZSML:HLSN;B2TKF*P\M1X#VC]ZAQFG*.1P$Y@
M41%33,+JN[]#S:1A!@GO?EJ^U^4Z$AVX?2_8;[Q4M*.!GIL<.CDO/:0XHJ]-
MD/S%S(!2YB[%/5PDF5:[LL*(87XX@=E6K2&5G-+D^P+Y&BFH"?N<SY(UO231
M[P(=*H@\MF_]WGRW8UL\X?GW^W$3SY$GV3&5#T3#5I# 3P,7RKYK5V+=WE8L
MI#)&VB!R'OH62N@%TL$[RE<NI I\3GY_(H5.1XH4OJ>,M'W&\2.= %]SHIN;
M<>ZTO#;']K/3RYVB%^'G.XNMZJN=*=Z'B[6;,_K$I9;_W1G C7;JO*/-<L6=
ME+;5MN^;LE+P&8T[P;ZNJJ$E_B\@.$O^/#5+I?.3T .$,_>6YL.)[JS2+JMN
MQ#WJ^GF@-,+&ID[RR^0J(>E2ZPCGHU*NY9=K.S.HARZ6":2VPAF)Y7)Y83;0
MZ<R8EW(4XC>>Y$DS\5G'-SA:?W63F'W-(IFFVL#&U49!Y9!)_1LL5II]3_Y#
MKBE_;BE8K26Y'3A+=H9V2W"07G28\!0,=(-B=" FM*^?0(E*.O4-4#:U$VTH
MAARPA$"4'$6D]7\FB!R0=P+;22)*:E9QQS)G@!8):F@A R!X\< FBLR,0<6N
MIDP!'FDC5^()EE2B&C2G=CZ-&UVN@>0#H-_V(:1/7;+)=M :7VAD)/UX@C95
M>/THU"H%&&F/!F 'KHSVN3HY\W',A*^$Y\7N(R2=4YM_H18YR;)NU:Y=\.)&
MQY.:9C2([%Y/.2 XGU:33-_G>F$X$O$T>8_$V"PYN#Z.!*^,22&V^1=07-5I
M9IM%@P1H9?V6;$%CA8:)Q8.\PH&\%\7!B95,6D9V[I_Z'C\'PGQ\(;3FSU\S
MBY^YP;0,F77F;VQEEJ,%T^J5-Z#!ZG])(@AZ->AE2TIEQ:LN&E((VVE%VMW#
MQS?8)B>V7*CW0,[>E?<Y6A&5-:4SET(H))"N?8?"];(1+S[!&>?'13JR_VI"
M$$URTZS!=W9"JN(YO13MPDN1%9[4&J%B;!;.H7')S%>4P'E4M)=J666G^.ZD
M72\#TK=U8YODMFVR-0LP;-LWP%.+31U:F&6<8P*O+I+%B=YC>">0@')C]#E+
M".+U)\P,V$@QHF_5TKGIL5G%&D:=^+L)@K=H7<_HN/3L J'IJP,8&S'9BE50
MRAEI3NI!>(&G16 BG"2F'@[T@.RE,/A: M_DLH-MRAD3Z"9+Y&F]\B[P.M-V
MQ<[TM%> ?7"#VT<RM5=_EJ'17LOZ983"Q3)M@L#;I?*<ZNC64CB>/34*#$9Q
M3!R2/6(7TR>NE8SDNU!,SM_T%$\1B$RUQ #*+[TC)+T"=V ZV=E!_FT"V]5?
MI<='5U=/;P%!_[2Z-SF5(,;KEXSA^BRPHBGQN,-C#V@\X*7;^A__'>[,3W_F
MS<B8/9YV;22]_:A&_M;7^WW^SG,Q\1]-M1^N3 G@YJ09N^[TX7YU>OT#S=P+
MZ'WM9)[31R*]H^(AQ?QW.C\X[RP=W9_R_05T)^;]>?7S/+D[,^?/J\FV^UXS
M8E#E-558OL=]QNUEUI>%A1:KRI %]W@<Y\C"TGIXO4$[+O.K3KA PG?.-=XZ
MO7Y@M6JSMF&C-?M6%+B>+\;!93F 2+[,SK2V#]>OI#&A;=_BI"$G2->N[3=D
M%'/^XI--_0/T/DN"T"CZ+GA90KC"(2Y-GU$[LOBL,[:<8\D+@?F^:A5HXZ[C
MKTFBQL+)8>J$>%@^_(6O I4M"H_ ^!X/OE1'RD.HZEH;/5RKB:9A0Q.@?.\P
MUZ2>?9CI!='+FB+E'#C76X\N/-?RE<<?;0YOL:+.@Q(XC47#ST N=?5<5S]M
M-;0LS5V:VT/L!3.\J4GZG"KQBQ($WE<4UN!=)XVWZJ=7PQ^'<'?^7(LCSXBJ
ML8^6A=EENP/C0%Z(78XQOMG\+;)]+*._K?3:X7QC>,1"Y9?&%F)O5B0:&[@L
MT^57QX?)ZY(XICU)RI+Z^7 YMLPLMXDM$]LQ9-1G6$A6LG.M3;5'%$]K6ZX]
M][HT;TLWD+\GI![CPC'1'M.YF%MF97]43(77ICF3XTDNE*H;66TF.Z!2""4?
M!-6OW=HH2AC7"B6$T@T$@K=)SX+J8U#0]#88DH$TXA"O;)?S&CTF]Z4#_6N=
M\QEF4_56=*2)&%_$U'$A"(O,?&/*>3\G,*6T/-:E]$1=(%31-X%)0J>)>V=V
M"1Q3ZQBMDV+1C)'%8A17D"9'.\F_R6^::.66OC29WP4L7/RVB&3RPG2/1!_*
M5<X*;6-:\@HINHB@^I-.3VJ Q .P^?8A/M)\0"Y6@@;!%#SGT(?RM*H%^1"T
M.*S<3-.TE3BZ8&G6,G KG[[(1\A%DQ+O!D)-G?"T?;1]D<RR"M43-'"TT$W8
M=AZUIVQ;1*LGS;>I'B>PB.7\*2C#*%#K94$MO=3U;=8<W4&N"><FSL<O^)P(
M.1'AAUVO9.UJHCEUE8)MRE2CE+*NE&7$,P^>B8=#":HUJ^!7O,0 CT]X/6Y.
MK5I&^.5#J%HU73=@4>U\4(5HA25>.JS\6 4E-I4 ,7F2V9U07[Z!A.B> +K"
M.-$3GEQ];PJU)%">/J;E(>O."OMOG;__I2^)1=W?=7\!BG=!/J%++YRT?][(
M-NNS<W Z'[R4W6,#VMASC[N@$>;DC>G>VW'?=G->'M;G]OB%EW]:=1OW"3M+
M+ V/#^OB^05H),%>+X)GLH0C+V7>K1=8O9E^[C=O=_U_O/RRA-"S<FUF2E@>
M2G9+.'-:8,PDWBL$DTH%X\<!V# 1&4>T\4=2%RR"LFC+E/$NH6=Q,?T'^;[3
M7P#&>V>**Z>^+\_SC]SM.O*;SN[C=V7RY;\QEO*'PMF'0?=30(R22N."U>O0
M23SAFD_H,G0;MG54188$/PR83Q@F]K:I5*WPLPQ":YDB37333?P'A>IVH:1W
MGU-O,"0U@[U.A;=EYF^_EA@M_:0Q\7AH\;,IVA9P#$UL6$1%U-5SD2Z+D4ES
MVM6-3PHKL)LDPZY%]_AUB3Q-IX"I6%E!R\+'7!6_RS2B3,2.L7.U4P2\NP^D
MN!#V@E7,+SEU9=^-!3JQ/@DTW,MMC[:Z7'T=FQ\5C(=TF8_^1E/XB'QUZ8P\
M)FA.-,[3_!:^OKG?U8:&T5[SXA6O)PW[TWW1WQYHZO)0@:0\>=5<,.=\]K8P
MH11C]!<P,5[_?;:5[1;-X'DMJ+I$,7EA=2W,^ETQH*NW3YY?A4O DO*DK<-
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MU=XTDG6W*^<X][[HU%_(-0!10^LP/C4?2\X7TU:7I-0. N[5THOH=,LP\'7
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M']+T9X97)@(\_^_BQ3^04>FY*WM?6:?BO@@3%]J0I[T1TCWY56(Q$RGLB,"
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MNLS9);8()*%ZMGGE8AH.EH,*$E>8T[0I/6=:QQ@[<([S)"HP"$C[YW%Y\[H
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M2(X^UX5.*4N+_3%TP@JVT9IFUX4*,Z7#F$1@5< KZ4;1P/8MVP*[<)YUE>F
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M[+C';@08-'-MD:O7W=8L<78$;JG^7G/QK\E1,7^K>5<S[EAGTX'<)C4Z;B;
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MCK'2BX(=E>=2-:66M2F*_!&I\^:")J?M$OS,6U=GIFC1&RXT([A38>#2CT-
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MV8'X<]4.!QF500JFE78=69?AY1-K"I&HJ:6KT@2'>9?T_-*59G:V/# R,J^
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MVGZZ]W86ESDC;\!;^/F"0"W6'8 Q)M;/=!#4GQ;;^518=K8>&#W/?]L\ ._
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M7IH0Q%'6R>)P>#B:FBT@"0[Q5>6<L"FC5@1V^V*Y!-X/LOI&7JXZ+GCU"TP
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M=9OW*=[J(T(=CNHN=@ZKI.7I<E@"U Y:S"@%J\P0 $#//IO*%9E?&*APW6F
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MM0H-F\6T3Z* QB7?4]D&0G'N-1(,,>UMV_Z:G H,JC8JS#FX^4!6,2][2=:
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M<>VDSBLYR!$G2@U.9FD:!DZ"0EZ<B)R4 YQ0>=R=9>G9^F<600-82#)U%CN
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MN'F[PLT.C6#'":OO@#J+Y*_=^HNT<*_Y'-4ZTJ.#2/S>D<\E_ED%=,)N]2_
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M/^6%16S7!]_VL/T7#K'Z]_I_ E!+ P04    " ![AGY5[F1]TU=J 0"PP $
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MX^WGZ_&K"=V/FMTF_$Y._T-NX^7A^?L*VA\5I+;]%.]F#N33]S9 &K85 3
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M^95K0JPS/43Y4)V*C\1)/=G;-K5LZ8],X  (=["'A=7[F93K6>VN6&JS IF
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MJ'$+-ZYQ5PE?F#B1*V)MQ>&C[.##+!S)%D*S@B?5YR@-\/W! 9'WX),:#<#
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M3M8&627;D% =!"!4MK,>18$D6I#AC9 QII?LQ3! ^6K#CZW@[74B-4H \/7
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MW48QGQ5<^,;/\B(E,=WWF43^)OU,4MS:)DPB8MNXN'D[AD78D%_B'3" T[#
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MS-4F]+<Q]CALPG]N=1]@GB,],II6\? K#HG^-3:JS,[_[SO%*+U1[M^DG[K
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MX%[0WA;\@P/Y<U4,="((U_4;[2W=H?CD3:U%![M&9<5;3M]>8FK">23@M5
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M<;]W!1_\+PXB %AXTR@6I(-X#ZS=6]ON("CVW)0M8^WJRLRW%X^W-LI&Z)3
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M;"^($PFXNF?;A8L:Y^X /?;8Q$PWDO5X)D1DVY#&M<'2/GT?&NX5BA>E$IN
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M&W7)SU2J;[;E$+=+I-/-$P=!I8[AS,9'@16P?=KS#TK<*#FV,[T#78H2:AF
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M^PR?*?D4H]O<!>VQ3K7/=V ;4"HC!YD=9ES5)9DF3W^WWR#-;QJ&@-Y-VG'
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MX"HHSO+Q#^;5KHJ2KR:(_$W2CR(D4-\AK9!Z9!D=T-=]?/S8J[ %R18B)&(
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MX9P6:/PX..@0(3F-Q$%R$,-B8+N&MYD EL8#0V!@N'.LHM!S/AG.2Z_F,5_
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M#!%N$,2 LJ#E(<[:M4V>^^2L@):P72I^YV#$10 H'*TR:RJ1J2-YH0Q%9="
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MY)B] H*=$ER731&>8M7E@W+TM%F114FY]^GL-/,9FM47H%_AV81T_$OC_,B
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MH!F2.H8Q1L7$N>]^W*)?5TV-/3UGR[*D&C $EZVN7P$A^H8*QKV[FVK*!/0
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M5\/$L3)PX2#\L\-X/!\.1@*@")B,JC1T0(]&>!'B!)]G@_X#%R^<NZ+6X!
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M#@*P#!$:%[%$Z&BJ9%4F #):+>X)FBS;(8&6D%Q!HQAL;#Z1,M:"M0=!-/\
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M^/>ZAOTSWZE8<W$R128^E4"+3HV.)R(S?'!Z4%VJ-414W(Y3]1]FK8@<1HX
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MS%<?PF'?A0GL/E>29='B0WX^6Y)A"_$_IH,5^# ?QN,C1(^89B] @#&8E^'
MP\"#";"!R<ZQA#6EI)*@+Z0V- 9G->OO!N=Q3AX!B/J]X79$DS02._E=35L@
M-IO]-@U**KF_+,[=+KG[T,@193JE3*5]"UWN8W"+;L-F;KZ D#<;I5*>DB9-
M&%VYX/&5^[*59J>VV6;@8QPNA"JR!4'[RIYRLV#PN7B*@2YT%YY U*JR,/$.
MD#]P(Z76N_+LV2X)@OC/8X4!=]9178<5;R%U4CLI-:RFEE:B&<6:'=B^@<V:
MLW16W'@;E3K?15FNED2[;!PO0>[X8U+G&$5EPR3?Z<U7RDPD@O9BX%LW,&>U
MD1W"1>_I.2UW%E630L#1X:]R!U(H2;,BMN/%%6<U]TIMYMDP69PW\1LO6]6<
M7@K3CW4%9:[<[!:\BK)@6B<+O(<.Q)(H*T9%9=>3Z?A97/LEM<-!S>.H8"S!
M@X)%H1&!%:C>7VHVT1P04GUU2ND_P6(K#DP!2T_+FH3FT)8$SRJBLB@Y>]&C
ML[D&;$1U,:41<T-Z<98>A=B9SSG#'SMODXZJ)$UH-:>:ZE9B9NB-@B3R<PX>
M,:%R3 ?FZT##5.%>S8!H,"SNADK_ !>YOH%))*[%H)T)FHO#G,M7S-8BBU(-
M@0'!<&&L&M+ ,,:*/OW^6Z,]=<+,U\[X+#M3YN_Q9JJ#SQ%$ZR\C, \ETJ%?
MH8]9RKA=3][&ZJL\_J!*9)6J3*'G=HX%PU<Z/1H%2>4V15WWNTSIMV1:6(DV
M'>28R() >3E)#78$*M\7K@,[-L5HC_A5#/E)=%M*8U6H268GGL$5?,-[7A#V
M[SJQK;X,A8Z-%0H:R"+9.I U.M6BZ#J'=[D^FF#!LL5'BDW4GQ<P2[):IK39
M48M+&17S.Z<JSUE*PU*<H2V]_5;(L1'BO$^53/4S1?X56"D[RA_4RBPV*B@*
MLY&ZZJ3.XG0ELE^)@(F3/[AB+2W(M8QCZ@C6RZT/TY=F<5 ;U$%BTV]\]46H
MXYUU[Q*!-9$>=T%"!NSA=LJ#0"!0#%SDV#%HF:X)R,Z\X0BJLEJ:?24ZS;4O
MZ;]WY(N(^(.#L'CG'W8D$%01X@Z%,B*)YFAJ%9VKWO:_[$IOHNL''7P1@X]V
M,_AX04@D>$%9JBN)YA;G0-=TWO1-[W9=3.(N N,>$(D1_+1$B8=PDG"QW'H^
M$> L'/$(D"4S\B)"4H7O$B$F]T^EI4#CW!8>,,+Q)@H^18A?!_4Q''\1EK[P
MDIQ+D,/X8&9)Q,)R$X CT<H"2CXQL_'HMV@1L/BX,/$X/$0<5AXKH>A1\/%A
MQH,1T_[G(L-YYQ]TZNDC=BJF0;CN+*%_%E1BDXX_710><J1+;U[R3VA.N/U'
MW1"(D0GE]]V*%X(D-GUC)P&EST ^Z)@][[S,M0HN*!BH+@'8W')57W2FXZUD
MGI.U1)"Q5 8BS6 >6"1_Q>(\AZS\F(LB'B9RD9ZU HJ2DA(0)5B)P-1I1WJ"
M4%Y@CH$#&^*G?.J)R >5QX#ZHHWFT;7J?E2<NG6_;D]TD'MR7H2>ZL;7J?E5
M-R447]E9VEU%>:JE4F:97ZT3 +0B1G^T=$":+*<^[&VY53(IY';6P.UIZ(Q%
M(*JH#4J%G65"E343ELI%*1Y4"22@[SE60EN11?FX\"5)!"2FFW,$25=Y $7D
MK^KS"'#_ !GPF*==1W'<!Y$7GK/1L/G_ !7#?"'_ '.P3 !(_P!OA6@;OX7=
MX>C$-^N:+@."?VNZH!U4'T;N3(U]1Q?!=3#6>A5]RE_9--I=U:W&;CG4>A51
MW#-/9J5]]I2']' TI>I1$8"#1$]JCE/[)=JH^1UCY?LESW_"]>J=&*IR1)!1
M:^^9FLY49COIU[(N]/Z+XH=QWQ ADA(^7\*Q'1OA<3Q&Z^DE,\7#TZMP\8.>
M&@CBD\NO=G,4<N^)V,P%(,ZJ3M)=)JBSEQ_B :%X&/,6;&\9(HKL"@OHI22F
MGD-IMFMZ F8?U<[LB8E52E;"_P"2.7*41178^RGYY3:@.^0?IN\(F6I,@%N=
M>6VIKNQKFF#L:177 W10\7AD*7D5!O);;JI7H?"F!FU\9IV9$Q>)]+TI<G^;
MLQ,?9!TPY16B*+1%$D"_NXYC2M-VL3VRWVS14<?F&"RS!XG,,QQF&P. P<)[
M$8K&XZ-"PV%PL%P+$BXC$1WG(4*&Y)7WWG71<ZI#,9(MG;7=474CCKX[9MQ+
M$BY%\-OGY=EC[Q@8GBZ+ >AYACH95UYWAS!XAP/X*$^/$/\ -L;!&)17\#A,
M.^Y!QIL"LG# Y_'5J*$BG7+[D1684OAE\&<;FD5S%8N'%APX\4XC$8C$/1(N
M)QD:*]XXT>/B(I?C8B/%B%XQ(T9]Y]]XDO//5:$DU49V)H'C&6#@Y>MEZ'?#
M_@[+N&L+ @X6 ZZ\ZZZKZ /%!4D34_@Z-%8,C=EV7X>QS\'P.A40(%E99FGN
M[0ZMO"\\S2Y57+V5YB\0Z2\]K6G-1Z]$N>@. JP<WO[<T6\X'-9@//DE.Z^2
MZKYM4TV%M>%S!0"Z]+F/+O::-*/G/8#V4UB]>O2-5L&'QP-2LY\]E1.]DW8)
M S#\L,Q+?:;ZD>G[99J#C"@F33S6768,PFZ3R>$.]*R+1A%&>'>797?192%B
M ]_N3\<@A#8<BV#!G$L6F0\R*VHZ+)0HHUH FFZ(53^&V.(7F:QJ'H!\B'17
M78CJ@BX]>RVE_(LD9B8F02]1$@LS]()6H;XDIZ?932\E)1LD/9\#,C,M4,TT
M>:.2LN/NB2BM0AYCR:?R)# A@UQW@/)P'5D5APDHDQI+>7F>M=6VXT(,OT=\
M2(#L6D9E<<5 I"6[^LZ?5K -W.6CV&#YV>$17"A-AN?R+:;-45AQX@RO+O>D
MCR1H6OO7+6$1@]*IJ:/6DEC432S0\,TX>8?',(N;C,)KY?8TJG5$;N9M6K5M
MG%7 .ID,> @OA2:_(T?E40+]:WM0VO3S4:2:/Q%Q#EX9K,6G7IR6O*!)I#D$
MG.PTR8B\H9-Z?3\::!KPC(B[&F$8'66+9IQ$,P(-G%<9QSSE[(;SQI8IVOW!
M%]**VLAA#BUX<%J#7MG,XV/26,U.;:.!\B=%L@L=:R19*DZ&K#^\>W[HRB"\
M\!6:^^U!]&P2'=Q8X D4S88%@XU(*I$B$$ZU26JA%W\UJ6P<J5;1ZY]Z23)V
M #,R6#O$'"O:DL"J,5\(2],D34JF]*+0>;1; :!B].QS(PI@(6/BO$E02!/[
M#< ^5=&+2Q45^:U-)ZS[HC$6-COD ]:CIYKK1LP2(P.;RSZ,7!N6U+$Q7T6?
M+4D\UZ_=&I+(L+BIJA]SZS3E,K*38!+L:X\^'E\PTE%KF+!*UN"-+UJ>J\I,
MXH%J!LR+M0!GI@SM"+6<4Z?W5//U-#0?Q?7#1J?<TRD<BF[^RU7&.%2#JI,N
MFT])UDR_IFYF)Q#G%*K7<7!!5729$&2U\R52:HE:JVJJ7,YZ? @Z\EK6+P$.
M*H>=!55$@AUTGYSEH56CYSPA@,QAONQL,X^H(4N!0*('@%DMU5&,R+KEQQ^G
M[)<Z<C&'A7'7WO%2&ZZ\>:#P/5H0[-9DR:/1V#Y]>F(Z (NFO$_Z?^*^#L5'
MQW"6.QV6O>,Q(D'#?NPL<NF1Q& BNQ<)B% 0/OP8CS@_M>!0BJ-5H=SSQ6CP
M^.N(,@B_TG&O#T4N0_VO9ODT)]]R7^[$99&>>BN! 'GW\-B(Q>>)^7A7 CH(
M^^O3FPS6_93GN2\00#B,FS'"XYQT 17(3X$> 31S$X:(',3AGS_PQ$)Q_9)L
M5JLF^X4F#+EZ[Z*+48H;M[[Z(#[MJ:% 9<_LC$8OE@32KVWR"JON::FG.9YR
MLNB*K%53?$S)$UU/LR5:S0(Q%D<N>G$=)G(@<[WV6TK,195??EY>3$3@Z@F]
M4W*RF+[(Q$\MD*:R,ZS%%JA'FQ%+P;UV/G^;R9.S]*'B +>X]RG\$U7L$^LF
MDX#K?IW[(^X^=M";P@26>BA29%%E*2!16>C55[X>RB0BZT2_,?19I.4F() .
M*=0$KNNQ,J@*$ G704)$E1#(K,*DR:FLIH.B@U4BD0@/5$"5")7NM2B3#$7E
MY^M7#C#<>\"XGPG_ /$.'\^PY> DF39G@(@!)N?\])=%2/%5 W7P[OEZG,9H
MNK.'>5QU38A?O:1JNC>IG;#O4$>BAFF([&=W5]R9IOHE#Z@,:F(/T>Q+*HSJ
MJ$U:J8G'>B.)A;-D/($- Z8S6+%IY7>^^J3:1+WW]R8B3$7=/]&^)\/%'$^$
M,Q'X<=Q!%UPN:8.&#S_\60FI;AXS \!-CQ'TWMP7H,460'<[[_<*)2;S$O*)
MO*MJ4N?S]R)B:)O_ "@51RG07+$45("D3,JGH*F:+/<:EM0*U[9/8XU+C1B4
M2]84T0("M*!09SN#WEY?-I*:U429SVV7UF>LVB)O?\M8W).Q9[51#+X30E=#
MM/WW$BTY;?Y^"XW^('Q0X8^'F%<>S;$/XS-\6X^_EG#V7B'&S;'D*'8AA%YU
MW!X$/@NQ<PQCT'"N$/.0WHV(\&'? /EB30#W. $EH!1=/LXS?CCXPYK!_P Z
M\4+*G8[L7+N%<O>B/91@7G7C\F/BWGG8;^<YE#=(7'8N&[#A/O1'L!A,#"B/
M0S26IUORP&5<[+)+B),1WDNS$<C(FW:+X:_!/#8!V!C,W@NQ8_[7G8)=!==1
M"CZR344  JC95 ;VRC<YG$KMEDV2X?!0W(<*$ZX' ZZ Z  CH0 !VG3N5D5O
MO>[7Y"RZ%X2ZDI "UQY&J6+-[T$(N0,M>^7X%L!NEJ(I7H+64D7(>6XPD.A=
M$6B).:5)_DELMV=R*UAP'=P]M *(MWP6))\,YHAW'D+":4UHU&X;LY[MHBVS
M!8LCPJ4HEIT2J [=]JBV?#8I70A*Z+3J@4IZ(39HV_;?K*GOO?HSMGL-B0$!
M.FZ>E"LNHD"UWO?2BJSD#$25=$[]-0*[!LGA?OE6X^*%Y4W@S;K3WRT#$V)3
M0K[I.2?G'%PM(FCUKZRXN\FJJRL*.J35=5Y71>=FHXK=@'L^)FKXY%RBR,-\
MF:V7=5]BB4ZZ84:*'22#MI-X**]"*B9Y\]P";5EI0H&A%+- BPHU"Y(82#5G
M#DE>A/(BK0#ZB0J@ZSUDT=N*+N;BCN[B'K0R!:45ITE9369G,\IS+:!<6PNS
MCE H1TJB,-Y>;4%Y1&=I51;;9;M41@21(S4J@!K15(WZ)LTI  8:CV+[Y%SH
M17LL_P ?0MZ#<78TKEZXCNO/AOVWFA%TG19!)C75#RJJ5LW-FJPF@$M<@D=)
MG%PRZ.&-3!-8Q8@%I>8# R+J!%17G+^&WPTAVL]8Q(H'!QAADLF39X=J<L32
M]7U07SH9 +L+HA4<TE9&H_=>PGL6B+J'EV[T[AYDT59X@F2])<A5>LD2P#9X
MH$7-<'N&%"TXDW4W.6OHJT0&Y6\]U%TFM**@H"V#:S1W):]C(.A5!GXBC&VD
M]9(52(_XB0E^WY( 4STH T,1UR.^70%=.$$,9IU^IAV:K252BD!:SI.2).7=
M=#96BT)RQ%WSY-\K&17EKHHDFM=!O,\V*K'12L[%2A^I\MFAH=],\$6+C7D#
M2>B>R#LF[09FYYO3U :CO4L06-B@S.AG]#,]N<I,XGP>'&1'*OJS8HL-BJF0
M"+7WT6=.30 O(-FAF9P_N1F818+$NJLM1I=1TF+'U87(J36G0QBQ. >P)1:]
MBW""956U4MK;2YN&G"<Z5K3&F<Z#4%K^*@JI2A[<_K*\Y(N^DX?/,J9;RW2#
M2BP,> I(DB&G6=9).G9&"*OSELGSL3.,PC=B_9MYK#QL+(H+>[!*TO;5JH[$
M/3JW/;/5F6+C0%572DD!EKYRY2W#%I8N-@G'U!<!!UK.B#\"E4::[:>2+6<P
MX<PN,<>=B0''W39]T'LH6>H0SH&-RT:N)A%PGQ?\%<CSR'%\6"A>(AZ9<"S6
M8? )&WB! M9&+]MG[P1=,N._TOQ\'B7LRR,XG XV"7GH.+P42+A<4XIG\O$P
M"X\A*!YWQ /.R>=()#53MIS_ 'JN&XV/^)/!$4X?/\M/$N7PI&/\MW 9O#<"
M#Q?,<AC!XQ!1R)!@Q7S.)C"5)).N=^E-9&0LMFR3C?AGB!]W#X?&?T68O'PG
M*LT<&!S /U+D*%%>^7BB %+V!C8EQT(2\&)!UK@>=VU6T/P9$ WETOYTYBH8
MAQ'. Y]-]#0C0B)I]$.OW[SFA5/@'DC$?\G3W!'JIY75&(LR@4ZU,^8]VT8B
M=B):;>_:,1$D@4(NPIK_ &FIMN&(G !YT(0%"NOAY[:2#$2+H-/, 7'_ &K[
MO-B)>%++27;_ +0LQ?F2%8H^1[1W]$Q=))224H#2DM5UI5BJ;^U1)4T7FDD
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M=BE!H)HQ0B]6?F]7R^(6PP(M$.EN_P!2.H.C0A\>6_U9D&WW;T8N5FL/%>!
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M,_I7Y?\ 5_R?[WB#PQ_8_&/A>%P>#X1+^?\ *_,_+\?\;\+\/P.$>;\C\O\
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M8+UO,M :D#G(20+.5$2LP6\IDF787R=ZTT#\E5P?\3/C=P]P&_&R? .#B/C
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M)E-@3<!9#I4B5M"&N]=]Y<*(1!"2Y^?/132^D\<0N*]X;T^)LB \$)T4I;V
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MGNOENT8Z2\3)N7>*=S@B 8(/B4*E:"6YY:=BT:F-@"X!!8P=<(N091!.'"*
M-)<CRG.VTJ$/Y$]P\,'I#X0XF<&)!>PPG+R]\Z]6@)^+B'P,01'EP_CB59[#
MSI[GJBJ5N5JV@;<N_P#QHT."!6J(3^'G1=3KW!'U4SN6@+AKX$SF+,QK#,*&
MB*N]A@32?*T]%'ENU(X6<YY.3-VPQR15WL+.BVU^A/HV?*&.KO1IY#'UN B
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MHQ1[5.'OIF'5^%AP$4%:4"J))*=R974%6)7ER?"']:$4F+CD(B4TI32DJJQ
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M/+K5Q%.00WQ(E%H.\CSL$/12RC\N9,9Y"G5*MSY 3AJ:E +LC26PILI]$29
MHU^L1OWH5$$@:;!0+63H?.C<R&<P'NYC+L"&!:E)5G,BI^?M">=1"*4O/N3W
MG3=6R<+W-YM)9Q=VPU07@T>U7T$30?H)="A+KW Y(BHO.0"-#$&L=-M@T@Y:
M!<.1'#A#.1G6O03)0GH:H1(4I6IE2173JRKF-!&^]R<] L6$WD\I;S3&(K1
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M*0+WY A/87:DZ%;S%-?IH&HXLGS=A2!7BPQQ=I1#.'*@@*.LJSN1[E=KYGN
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M&$);)S)_G^-6H$8L"U_D.\UFE(!%=@T*6G8'TZ=4NV@ ,C&K!@?B,41A"HB
ME+7[[UNR1FSER6[!W-S%9NP*P[ *RV]J:4.RE-&A.,0:N+"P)=WY2B.Y!,M3
M(H2OJ@YK*NS"7<U&;,#G_JY,YS=%8=A4%%]:(:=J<FS48M:P P@U9G=]0B.[
M#E.O99]4M:=U:D4L]@Q:#E+5AVEJAR.[#(L9R/,+N$[AD$S+.0"Y<$Q()?I1
MXA$<.HG5->H!O*O0!M@=FL;"&)]C&KDD9UR4_4^?F.I:HC.PU&BT_,O1H8G
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MM4.442Z)BFO/Z&WJ+-6EWTO%GN0>S&;HA/PE5-RLA-#7947IHQVB[6>CL.>
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M\7#9!FA7"8E@3!AV,,[G9$A+J*3*J#7DI5+GRVRW:%L<3L!-'.&K!GL.^8R
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MX(HET&R<@/LQK>I)]?1$W@%%ZW_CSW"3AX06I%F_7N,D4#"!*25-$E04/\,
MO&63$O-3UF[224##""RZ5ES9Y<QS&F#8#OR*)<%O/ERU^NS99H897N!>16CD
M'*Y+P._86&G;WJU EFUEW8!W<-+Y&LHI"&%(*3*<DTD#KSDMVG^D%X (9JO
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M771- $'>9*6,@4/M6(B^ +/MO?IY[L1'^7OY5]KOK=B+_]E02P,$%     @
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MXTDHI!!\%;,JC'J2JC0LLFX]K4V!,5LV8U<Z0<85!VG2;V\&1%AM0="'9.?
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M>(J@$M+*^@X;PQ;<4RF%4FG:;X[S:,$D.P BJD==>D6V$#/I4A52X K&N-M
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M."V0_Z#^DT%_A>8MDCS+4WGQ3Z%^&_%''#<N-2T8I2KDOWC ?D3SIC64&O6
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MT<2<.4(S21>*])7M[V$B'A(]/:J(BO & 0Z5I]6:)\VN17#R64Z$G)+IE&#
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M-$V>4GIS:"%-S+J#3_Y7E'!_%4R.TE9R>((94\GAFT-8FQP<;_3/9UL:#''
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MW"A*\-)M46?PJITK3EL$[CX=Q(X,H'WX $"C'PS0&3:P$D3!PMF%2Y<BYGL
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M(1<&%NU?CV?M^LY7EDI5E'KX%?\3"B*[?T-IP::YZ?%J)LK4BL!G4T]^)+W
M$GX6>U!@0IRW,D2PW%I9*SV=R?Y_0J^CX[?9.R!1@HCR'?!5XAUPQT'E_])V
MK_\."/]:0?E&\/55+\;4Q^[KPS;2.Z#U'?!\R5+FW(-G$B^C$)..*F !%A/
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M'_/OC,7(N]WPBWV[TB7>NZMX"8V<SZ$:7"Y,#]&^DHQH@]2 . QH?.W/WJ7
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MC69?,_>2HLN8(5?FN)\ R736@<MS\5DDBY7/@R4>Q'4VK:8KV=TE_!S47N\
M\IB4E4\URW',\9GF6*P&W-H@.0*Z'2)\@][8/G$;Y"3\"B#&,%>>(*0]@+[.
M)_/&@3_37S9#F/X*!CTC],$6FR*4Y_,],"3D&9IF1 D:<BHW^;CQ T^M8VJ2
MU]V85Z]I&XY7+5(NNHJY..Q*V4HD1![S3SG<1 &/$F7C0:D?4OE,RE)RDS:I
M)#6_M="MUQ]9EC5"![V]10]4W6!^HNX](8^R1D&HS3M@:<;3O;?S7.I%I&$D
M@QM8<E9-44GG9G^U$31GO&Y-IJG@H/)E-T575),N4)7F98S8IP'/UKN$@;\-
MSM:\,14]1&F*NY:RZSJ#M,HD@S0NMBG!P"UHP^N[1?-8T.=[S%(;5?99-UN;
MQ0*(E''>A.NTI9IU];<0NAL*S\\&E5^ Y=0&KC:F+N+.90\>+?!G:+0E#@.W
M)[L;D$NU0D_&G#6/]@1:;)]O;M>*^"7Y6>':%_IALM$;6R@@M1M:SC'RTG=
M3@.F4B(A L+00J5L[SPL7HOA$>+,]_V5P8^^'G-;-3^N::4"AY+*1',B+C>*
M;FPQA:R(890@.<8#G8R:INLX* H[YWQ2Y(?XB;+(B_%WEG:E&$A]<<K. <W/
M)JH48ETZZ?E.X9O/$]R-:^%FW,-T[/.JI,,T5K%"^*7UDA9#=7#$B#C)[51/
MRW?5]S'P9H(;1SBGV"ULMU/1\529:9OV]FB>42/&]4P8L,CY=(BAC+VR_45$
M)=%*@_!]$@]U1&BD17*614O3)#I_9(YUQ<8 "?B_P1C\G\8I;N%/*\8X1);6
MRK,B9](<W3>Y(CY@SM-S36-,(NO26BYT8=8>?VVI.^W]ZN)DN_L<)/[#'(58
MQ/5& $>T#\$I\'E%31)0^ %I,./Y=%58B9GY;>&"X&_8D":U2X_YQ>LR]V)"
M\1*'T<\%Z:CO?$%YL[7$C#;E\[1K?Y;R]I$Z(O:#ED^/G!%]! B]O]-R=:\P
M]"8+\@<H$R!X"\&A5V//[)TB9-6G_C4F_?47R:7+1@.?YFI4+:W=#.W5JW01
M4A9RO5.S;NSPB12^W9T;TK?,47K8'-3E_?A&&2G^+\#V]?'Q>M7\(\\9\/P(
MZ6^]K=#YZ*AX+X5)-=-V5TIIJ1UW9JWC57OH"J\3(F* &K%YAU&YR9/PI7 #
MH8@+,9LE=+S.]V<?HL6IB==6=PN=#:77CUIEH$NEL2^,%4TT"A1)3Z:E2HL+
M7V:'QH,+&!4]*$,OB)H4MQTHS9[6=U[6P^":).^,Z.J\)H7A@P?:%RC9&:+D
MUGZGI#$[-WQS8P=YK=[_2O6:0TO_D^/L/U+M2#H.UE(MA@3/F]0UV6NL-3/D
MEIEDS>&>V7YBVE;UX)RY%MW>I')F_\49'IAS>M_P$@!A__=9DV"O+4?:?1+L
M6O=-V[R=YY$^NSD"(S2/),/)]C_)])\H=MOM/=S]_0[X.DJQ;8GI 1,7%V_]
MJLJ8F2PGIWUF7$/$ERE6Q X-H,7@+J<_=& "98F%$N85MV5TXVFFI["QEI=;
MRX[&]?S4MI_YS/=TE+"SJQG!E:K2J0S;!V2T/::<\$!%,? (G<G(1G*?*(O_
M*SR5L:?:O1?#B\Q&#\W*[?.Z1_16X1HVP#^;)>XU$/*MSR%0EAACYJ%8ST:M
M 0,:VHJ20M#:NBMB"B)T2Z8.EWB**KG0>NF4R:W2T N3O^6424LW[G!S5P Z
MEE(BZDRG+^?E116I!X@DVG3U:+LTP=@N@V7R&,U$,D$J4HAI+2(-:=P3ZOC[
M];3*K)ST^N.\1[B>K(C> 2I>^7[_ZT=(YBBN;]0&L_MY[X#*WI<W<BGBC;1A
MGS3$G:3U??>>./RT?/#/1H>\W')I>0DV%E#1:/>M(ZGX1T[^%2 ,HB2;?#09
M2ZJ<!#T_L*;=[+==/2]F?E2WN[X,'FWW N)W=YHL<)>Y;35BL-7%;;+ZY &H
MQW0[]AG? ;0D8^;A8^"C0('[V]$HT10W=>%FZXBV 3E#%NX;C_M?8WO'Q;;4
MJI9*#$:<-YMTM(>)!,ZQYM8)Y^IQRIC5E3EFA'&GQ-?+K%!5]'C\^:SR^-AQ
MTC!R8C74)%<I1&PI!$1*I9$?;]#_9;3213/#23B;X2RL\"AT7I\-WOEO^U9B
M73ZS2EH<S4)8%;Q_D49&UOF4ND/7!RS/CQ1AUC"OXU-!.X=C<1'Z#5;K[CH_
M(UQ,NEN3V2;266.]E4^/?HX!]J!X;S]9D RQX*B?2'HL5\I'D/76DT=U_XAK
M<*[7OV<MCG< \+7!^^O\_#_=]0R[X4=E']-YJD_D]C,<@FJ:OX8W0O.W'*6;
MSQC9:]5;9KAWN#,S-B'MM7CEZYO5 G^'\]S9)2XOPAVX\YOZE.&,J>2WZM=]
MQ!]T0_J@I.:^AZ[BI.3_!3%J\4\*OTW"RMWU;H>%0T'8EJQN@/X%^3Z=,,&Z
MLL6Y7**5 U';2L0I<C_;W 9XZEC-(LU'R>VC\XPL0-G4Z#Z:*ML9<G$X]@Z@
M-[BL-XDDC6!+/S*-/-&!SDB'"-Q+("1/3I(^^_FC+HH6>3%Y%EB.\TI#7X!1
M\\+MV $/H_^CL:^,B@+ZOD4%I1&03AF01KI!NKMC:!")H8<NI6'HAB%4NG/H
MQAFD!6& (80AI$M*ZOE[[WUX_Q=KO2]GG8]WK;O/WF>O<]:]P2V2?4LD*.7@
M*T2AXI:#*/Q5336]6X/Y(3,&A4)BM'>N$![<G8N4.$K[N[ @X\[Q2RF,&^+4
M(OWTCI.S,VCQ>7S9W^0Z+PI-UQ_F9SMD%KE?MIPC"U#LHS\N'S$L#XK4V!&D
MD,^8U6;C+7#CG1&B4AQ0 %[AU'BW@%/;?(U6$$K]9PX^Y)>LMPN4EK81"L5W
M\Z.\'6M:CPYH%#LY$[TA$FCOKZ_:*JTWZT[MD/_*M10J(=5X7Z%GO[IBIDHY
MF):-G=-F_,OZ2-!Z:7"ZR?Z2O*/:.!H.A#NNRIN"O01SCC*$<\/<?1^NR*"+
M3;T6]W,FVW980PUKGY8"3!XQAFD__GX>K!1PWH\8/MS:?)%[XCN7 /+:Q:.S
MK]266]R?&8=IV!^&JJCZQQ$7P%\M/E$)/WWZ:G2FQH&']SQVZABLS:P_!%"4
M?(M9,2SI56D,)!$QPHC8QD9E_6&,B#!G-?GY?ZX,ZKETX+D2J#<3^K!NYI'$
MN+),/Q_+883E?I)"F#C^,'</K!/.9.E3=?*>@ 8(;!].7TQ_$S.F;QW)0-7Z
MBA'P_DFQPJ+^HRI,@BD)=[F(EO=XQ$ADV[%\0WR3$2NX/^. "5#'5+?S."$H
M8GU[RJ6<752/1I:RKY]R@5S$8)69G"VY"4$[:1J2'KX5.;AC<U=G*-U!8QOU
MUT11GR#F7BR27$#U*.,!V7J5FG-D1'E=Y](_CM%PJIJ+K]S(D,#?:-ED8C+'
MY)]/YI*/^$L0R-QP-<PZ/B]YF!7CM8>$],08].[MJB6[O3^)45INW^L<^?:N
M=H--'\:=1#&:]6FYU:QDW5[60VRFU-)+9H8%GTL(XJT,"_9\'=Y0X/"1!H1K
MS!M8E9?B"[P((D'TF#YYW2Q 1G"ZGUY 8B9H<K9W9:U&]O'!DN8S_9C:$SVV
M/.ZVAE\+^F,.' :YIUTF+M5E-W-?Q4L[:B)R/M5VZ-2I0M"S.S*R;2Q&SD[]
M9UNINN"O6N_0 V*>);:\!DU!U3+MV @+\$GYX7I2'_&^A33_K*L@BIN%#53"
M IN&VK#+O82RL*EY0FS8_P56RDLX'XJ.W5A<+S?[C2#/8L^AM.1Q#\U[Y(\@
M5IDP%^)G\Y<EX-@\*5AM^R_.Z?DWZJF5*7&_G6)MG3W2>+_AOQY,A5*^KBEM
MT]L6+WAA,NOZY]!=:>[PV+YA/G0R8ZI<]>D*"KCKK<V%I;>EP?^-8WF"MFH<
M(@57&F&JX3HJCJ>I=LG(_-QY1-G-]4EE=:4@)?Q7-><+Z_X4I6%J)\]5*M@?
M XZ+W8)2DY2L,(7S^:B&;7CM2"RQ.46^;ZQY &FK"FN2 &".;49^)%94S^LF
M4]((H')AQOQ)[ZTJJWMMXL3X#Z?9$GGC ]!6AJ8'9-=N4<()9$03)_>6[-LR
MB$8 09E(.=+.09'@OT]\.C+V+.JR@-\DHYU9L1R@1(9Z]I9QG3EJ';.@X;D!
M!Q'.Y3)PU7W>W+<D>O'C"3EG;*;3WTR-W>N_#AL][@O>+[OHF?'"_:\7,N$+
M566:<A19O2 )4N8!_&WN 8'YS!WG/XNOR77,]O061%Q+#X6&1438\;.-TE$F
MW[@AR<ZK!Y]4>,C9LZ66]91&@_KGT#R?G[$GDOA&M0KW^OAAVR>F,?[@@QPL
MJZV;A,Q9RVY, /*00W[^W\RBN@]"6@T+FTA'")F.G,Y(WS6Y*><A:#FZGM?;
M4@F;-T$S?-56JX'!-6SC!*16-2VHBQ,[1%(BYJ>#XUMPB:K;?)8X:)B7)V$)
MQ$-VY,JM2]CEZ>#YS(\\7'D%A>>79/0^+> [J23D:*^+U'E^/)JM&"SK$N86
M\8FR7\2=M+R#H6N($A+-W-PAJ:'ZIF6[F^.**ZF20<?$-ZG4F<C ,SU-TGO&
M%W?N_0\Z^W9TBE[*MP[WE4D26::6+7\3XOEVYU&'65;;S.RF]PJ.M,-!*,>_
M":6(2CHMNG=Z_'OB#Q%USM/:GN[,Y.6*2?;D2RJ&1DR^N>%9Z"Z^ 5H//U#2
M26!(JUOSU2[^5EEW2U>[L@\[0U/TL.\O#&T*8EKWH<%B5AP:9.)8+XV;LU"!
M!)%F(V,Q=]<LY!)(5NFDGYY%H$OUY1K1=L$.H^"X$$JP%1,X%\XQ&9DSB)"R
M5I;:G83]M+4 A1;D'BIE^KFY@I5DYI>D>UX0EOJ]XG7F=[XOGA5Z%0X$/O\H
MD5.[E:;M9(\&CXNE8SK859B/%,P-4"4MG?))QE<+ %=E176.<)_&0R96B=.D
MEF$<>NVZ6#;5GNJ*AH?BC>)&[YOEDNK$:AKY@7_W^4ZT2<FPT^Q+<(15E<8&
M<>@D_?6B<SE?N7X]U7,@\5>0["N\K/O@)J%<O6R^]\[YFV< ,UKG*(O8XQPK
MS9+RAQYOJMH4KJ!SXTAJ',!028<=_%RYI\,G?XELZ^V:1R2:ZYDP!H:-22:6
MC!'>, :F_I?]HEIQV+9GY-M>B4NUYB*W1PR_B\.B/[MJT:$,!T4';4.%6^^)
M9KWZE?YLM7I!"0V3!4OG9T=#JJTJE0 PVDEI?E\5\@*_67,[OKVT!QT)GEIQ
M\<3^UN9"6UFP$G$EHZ?*3C1?[[L12-$IE319:150JJ<&SO)6< !TF(*?R\/*
MQ$8L<Q7G9$J!2R3Y:R/;[:5N?H#V@>,)Z@1,G<$3.W<6[R@Z_ =+)IO9E[#_
MB9I3J34HKK%(#-2;E:^1$6+&H=V5F#$XIUI<T9FEJ0 /RME(@L,U',R8QY;5
MRJF>;JR/,$=ARI5[#/8FUYDI+SP@+AT;/I >8O_TC6C)P6]Z4QF&RU*7_V84
M:@:N\CNH'*[D*>5HI@ J;?@BV87*ZO/MK,(/LA#+YT_9XN&9R(@RWQN^PTW[
M2O(3-._/^+/"41HF=$AFS=RS28^T-QYGBS:K1[,JG=U*[;9967PIS6O QOA5
MQD51_22Q4K=G Z\XF2&R3WR9/4;+7<\EDFF/SR919S36 4;)U3Z:9^A@R-IR
MSAOF^X^O?IC.Y^5A(TK!JPDO[]C+53"_S&18"'_^)=I0?BG_$0[#3LZT+%=6
M5F@/."]L$X%-R_P-3:.RMDO(1^K239Q.>LA,>8.@9.$"S;3=)6ED_-R;?#^V
MSD]1-! [,;.KHT;X\D^*E>"8%*KT$V8FQH/U-FESZV1]K\Q%YO7A:DJ@SV_=
M;>&=3'60JPW\+HF% R$5X,8#*HO<I- Q?D'I(ZE;E/[DSX2QL]&GOZ,;"SL\
M1:@!,9)JKM34Q@$2IB(&74LKNDLW7WA9]>*D\L B@LIP?UG\')+Z)*2N>DOX
MMQPO=(>^6$#^5706=*L-/H8I!(6=B2=P1GB[)?WBJL[9E@G=_-Y<.7G[4N6<
M4C)1*3>P[=)30SA5 &O4.CIIF\'+WMIO= 1[ZN9I#3^ADUT*IBFC>K*@;SS^
M^LK+ST4@(GZ93>&R0H=YZ& *VDVX]?4',Z],%M/!1E2?.0G32#(-QNB>86:T
M037^2^58@*UDU0R5?5L>^[JOJDTJ2^)TRNAI@X,# /.E#..A!EI.JZ>$V^'4
MZ\@NEE9H9/R#^I,D/^?%NOLP*Z&WL69SD2872R-N5--965FNN+:;$?*US,N-
M4T[X/HOY2AV>1]DAXL"7S6;L+]J_C\:!KN/)F 40T;KAGG_JYA8?,>;$74.Z
M9[X8\32@?.MF!*BR$";KZ[<R\)AN%TV#UQTD47Q#GJN#!SA:K)VH"N]%L4EO
MU!IJ%X62.K]&2R\^2/GDKM%+,2 D I#CTD6Z\ZO2RG8]%KMJ-VL,B'N!OSZE
M5)/2#_=]2?])3<P)VC/1,+(H/[A>C1W;I, %W#/C%BUZ>76\=GP7J)=+G"?O
M_-LISES[57QX5ID&_9_6=(C?KFTQ6R*U^1Z3GKX:$/!UB_ZG5UI]^VX36*[8
M57S;5M&9F;+*-:ZIV1$8!.XM)I<R$=>(;414F7_Y[C&"@?O6[KVVLTG_8+M/
M@?)JF@X&*3)[M^&[9,<-[D7ZA+.F8;3RBGA?Z*[J'+N*KWB8-M#WE5Q6$;A3
MZ%SI8ZO0^;@=U6!C=BU3%I03VT=I93 U[I8D@-?UJ.7VIS6"SW( KX)J<;T[
MR$DW"0=GT)RR?]GQ:;_W"&#G?&0$,5EE+-W>?ZDW[1L2QR/7O/C4^/H18T3U
MW*N^BP$'KUH[C,KX@9:]=^\X:6$JV&_X@UF6RH?#K_W?_^F-C_PSJH&T7?_&
MU)0.P&AQI_\.;7/_,"'PI)R>]A%#[=J*13BQO"O0.%[BTVJ,+O3%^Z5HHQ8"
M@:DB'G./;9Z=3-@2,6B'8ZAX=U?Y9>]W<VX'D[W0[RU1*6LNPIZ.J[^:2??X
M*R2G2Z16&CQ'3I<K,$[?THMJ*:3Q]R4A?LN\TX7YU0NM\'V?:!#GZ[S:%^]]
M!7&X^DUKAK^T&6$9_/ 36';4P:2&YADDWE:RWP5+:3*W<HK)+9Z]-DT-*#5#
M+_SYX<=FI.]9U9 K3WHT1E!BL>SY:IO<U,TP:=/Z9)J<:L2R%W!1FF#BV:6Z
MQU20^=7E-R,(JS5ZZ]@+TN&P<,GB"Z=EFFATC<_J-(GS$QV%!MIZ? O:P1XE
MAGZESC8K^QPHZN9F[Y^!I?+RRO=WQ%&5.6*() J#()V5YHR,^1#=.PS9"=[)
M4IV2>K"LSG9EI6LH"G9$2:47A76=3&W]V5>!/JR2;;_<I#U,G6*\9X-[/V(D
M4$VM']X]8F3KFO*R4HKN;"AG9P]6PSTS65&[A?^$*,S5\0CN731VM*M3);N<
M9)B*8HA^-TO'*=XD3Y"RE <N6P4-5Q(*;^B5<.-I_0L<<+T63JJS2@ZX1\F.
MZ%1;*+3M1>1-8BR""7L TY^!"%>?I]E33RE!['6CZ.?W>)K+FOYQ.!,>.O:Y
MB-I83T+V<]P6EXHO@/QJ,P<*Z.>5& 4OCH%][N<F<FW\XG86L&1]TQ39:@7D
M=%54$CHY0J<-XR6F'Z9HEI#H&ZH91<!*XE?IDS&Q?M$MR/G%W4T*O_),SX3-
M:(63BS5UC*_1^ ^)W=-E?S6ZV$W5>9[QQ.T!DLXBNR31B^H[Y^Z$,#X0#\?I
M*V'>K;0"[)IRW$&TVH<-EVJJI,^VI?*3\6-<^#>O>:QM[6//GX3[H^@/$AL^
MTS-"P+#@@)U@$/0C1+]=O<)J5NP1HVBM:/WZ_A%CM[#J^\D ZW3  UT@-;P.
M+/A?YT'G6XJTO[]C)#"PQ)HH0G3:S_V8_1#@[)@#R'K 1;Y9_CUTW:KU$.H(
M\RCU,FRYD,K6);\/R&.>(R?46K%=%IKCRY49:):=VU90.0&4::)WRFIT<;(-
M #^^?9+80;QJ^AK*+5=[10?>.BVW:@WXJ_/K8A%\6$U$HR.:'YF8$43=D"L(
MC#( 0B)F^50CK[]2)8AQKW\'%#$\ZRS3^SSSNE8)\D[^]!O[N(OVR_O<*O4N
MAK>TB1DF!I\SR7+6SRT)"5\ A&C,F0)($"1-'V.X@@,F"3[BI6@Q%VK8Q86Q
M;"$M@MD-B+N$>X_GO/97FE^2IC6SP01(R7(A@Q2:&I6X*K\I_<M+7^$6/6E8
M3LCW1&S27A@ ;)6:VG*=U"#CNO6Z,*?.L<QJR9=J^8G,"3(=[(BD>$DN%;EG
M.+R-U($J,F74YLZV?.$$#I=Q9VQ^M!=>%==>^U^GA-Y*4P3RGRC]3%P>:=6>
M,@ \*8P+_A[^BD9T:K"*CC%^F\K:=A2\KD"EU9!-GO*$]]/LJ7*3W6AAY_Y@
M)_7_N)N*[+@=;:9#6@]4]\]Z9V[)->K]#()#CWG=IC94M CFK\!<\A077PD-
MDU:NGU%QW9ISV.H7U[O#ZL:V]A\%MM.)8#+7?Q4*4J9_(7TF1[4K]QPM"J^4
M6W\R)TTB#T:L](2/)<G/A*9:6F">P+HW:?1[ 0#PT0:6IB6=\ ^>PS]7A>BE
M5?,/VYRO0@9SQQU^4'Y?)4^T7\P5M<A((IMT,5JT!.0CY/5@[T7H"^<6%_B
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M@2=3:VUCBE(LM3S-!I54KZ>?=XG59X]D$JZ'L[N5WD'V^,^Y)*( M1!/MA<
M1L<7+Z0![I;@#_QBOPZW('_1S,GUXQ'FT9/SA8RWOEWQW[8_#N#H4/'%J6Q$
M+P+3DG(^Y1)8%I-FWE3<.W-E</T,*EK#8J&_Q>+=Z:75=]8C*PTI-[="Q;+J
M&9JHTG V27J]74FE4W$ GUB'$ ['=TY?W.LW(Z//-=J/+%4*5S?(#=.6CI9T
MXT!NA\N"QL)G]9VG:G4E;ABNU)I_#*P@"@'"RC7NIYY[)8;QLR;U1L(3]3;Y
M;L+2N!8R0\M8W;JM.:;IM5-/)[4CZ(?P)XJ>DD1I]W[5A8)W'!W]7-CYG8D\
MW0R-1)FC)$8&D\]R/)K3!+IX?)<WYPI[:B_#C%K"%RXMN6F,6),N+V=UVEW$
M%IHIB)V\.!4_E*096F<H?<6-I:#E>??&_[.-Q</XB?K88>'B@N2GR2"[MK"Z
MAJNI]37IAY5;O\.Y B\+\&0: 56/I*I?CY[OHL47CRQF-N[$9O#0D-;JU2Q+
M'Z"F7J#%Z=EB?]YFEA=^JH<V+5'NN'2JI1.S(.J[F<=^?:TJY?YH5EC\J0*B
M;S$4ZU]?M ",.CX^_,]W1I</8;Y\:Z6*'UHXU^)7:CAQ!/Y&1/N(;/!<X7;[
MDVLF=A2&AI*TB0,UI#:X1\0%A]XYNED3_OR#IX>7G/=>$I:?%8\Q+@IP+H"M
MH3^.S08;G7WMUIY9->JLQZ2 V#B?A7V 1DQZ0^RDU^X;KB8]"U?Z\"^GPLH,
M4,C=NQFI4K_DV(?CR$XM61U_;1(A 1"(3D5?0*3G!+6MMH>*+!!7TP$FUHV"
M/,]8E-IUQ*92CQ7]U0\;-KSF <^8+\9"91B&?_H$GI:"M?VAY?1E'-"7@V?)
M7=;N=WZ34J>01XR54#Z4&)P/&M"8'/J($1JD2H7@BRAT1-JE^2Z'/+_;9Y29
M7!P!A.$G$]Q]7RO:%,S3'/MF.TWW\:9 ?G!/_91"PL)+4IT>OA(?.H!CE?>&
MAVF7ND)<L!DGL@U3G/4U0FC=(2>).WK+[J,03Q+$7U8,$"8)_4771KE?Z"SP
M]Y?WLTT7G^NI5UR7B$4W3#3EY?']9R\&L4/([3TXSQ-ZNW-\^X@18VJ@!T \
MR/JG>#TE?,20P*J[-K9RL7+CSB[;I"SJ<<_"%K<RG:I[*F?-'"?')Q:7&4#)
MP>?._LF(/ST[QLER17R_?C22B):!OHD=;"K-9G%;UMQ_\)7J"G$9,2*XTP83
M@(:MY-U64QT_\"P@9F_8&[;,N-_L;G0X3M3O4,=$&Q0U7XGMC1MQY1.!WPJ/
MF&0K*X#G*39; L*TGO=GSU=<VI\S\*YB^;WYEA EE/VJ=EWI'V!%)YWO"*?Z
M>DD; G"V'S%F'S%\0VYOT=*[A]>7?_^4K;V+V2^:2>5FZ.M6:2NQ.#/K4UP7
M5!>4J@_[B1#@"UM3]?D."N'+L=N,Z ^\CMP0W6G,5KB8C[DK.-D'53?Q5B+V
MKT-?;.4!^:WB23RAVZT#1%N)'T<4'8]OFVN];X+^5)0\Q 6<6K25H<XG1(8"
MJ:O;@@B,_KG2Y Z@Q2 )E2N3]!5.+*[!(%7M(LEYDD(C5_ON=II$3EH<EC.H
ME1UI5;^O!$<"'U"97KM!(OK7?A9[CNVS)0,+;M!P28U>\:;&!(<V<';%Z\&W
M],4QL>@WL<>.T2'E?%'HU?F];;C[A^;VK"6;U%6%+9JHCDKX>'FJ$2;OPJ;!
M9E+?NW=%'"Y0@:13G+XE-U>E(XNPN@O"+Z@N!@U3Z_>L/,"/&1QVP.^$)-A?
M^AI_&ZH[NWBI!:TW6!2Y:%"^A+ TVE&:^SMUZ58MJ*7E3Y LF1:HJ-:^3^NO
M_A5^B,^P8$O4[4E]NKF9YJS-Y37YZQ?ISA:Z?=LCE&9R7SI,M<_0Q#Q'SJ-U
M75J#W1\N.3K(EQG 6W,U2;IM[.K8%GQY/,?P3EO+_\^-D9#W?S%!-_\QF<CK
M1PRN1PS:D$<,1"EGP9&+RZ3YLI@0AF"BS=@=/HM7Z)RY,VV1'!-/+:%%XG>G
MG#X+C7"ZY&<,F.R>90T*N:*8O,,<RB2B#FI/"IK/A8BICTX$D_H;FT#.CM2/
M&&XHBL"2I.M$$B[3PV\:2+O*)O?/FB+4Q(V<^5@S='\0K]>CWJTC?W=OK/@X
MF=OW7-KLESI4C1%@""UUY.P3$.-C 9PJ%JNXJF14?B_S0BC>AS?)2S]B?,=V
MTHHTN*YZ(>K0EJ?TJE:Q-NI#U=00<A,!6]G\EE9M) S^^(TWQ&P(R@?@R\$M
MLV-!Q2D!YK X]=\[0.OHPF@S7E\FR._OB:_5W#LAK1"[VD;\NK4]0A1/' L3
M(OL*<KUEZ+'N>JB48V^\#/&LXIY<TN&.V<JKFTV$;([Q47[! 8LZW*'Q^XI0
M.P^]:H5:."Z^K?,U;P1(W%2E):.9BKQY#^3M\)+&IMC=\&DF(_>/>&0_>&3Q
MQM#):W)%KA_4%^_7A=$^8K1*\Y3]]^FA[B11#('XF[B6EFZ>VTU,97I?33^0
M#-;GR"PD9XF.9X<)5+%@+^-SWG+UX$""\#?VM_IU"]SZAK^=;%^Y_)CA8>G3
M[@A=L5 -*M^;^;W$U;D2^==UHD;0>/#H_. K47/MN$LH[..F"B!^VQ_TI= D
M!B/UN;<SV(G:Q(UZ?J[NLS_M<F9V=P8JDWV5+4<Y[2574D7=6-O+&G9M_!X[
M4)GKWM'XLCG2:1'VOB!AVFI):-#<DLC^\]Z'RNLQ"3!="($NDLQ9D'>&U*.1
MG]2+1$@U-]<+$&F:IJY.\%F P;T5SZ5'.HC@K?)L<<,<\[QB8HTQ'&]"3<6^
M342D:<5J>67\^ZNF$K9L/D62+DR()^UFY_"/[WA#[J"G\A+ *[Z:;A*-T1'[
MS)+<35NR6!TZ0]E%I3]],B?'J@I6(BR36HU4/I!E9"=L-@W9%G^H-"%7X;IW
M;TJ&HWY/S:34O<Z;%51CTEAO;@\516BF)+E.G^%%C5AW.G5I5ZL[EBXA/%EJ
M\@P+)@OH#DNNA*^RS8*OWNQ)2'S7\VB6=0*H<*<P82;))<*)1<&6#^M?VB!B
MB;4;_IB-S25-<L>K7'H-[@$ V^5GSS!^[3RC_DI+,P] ?G&);5[CIWW'G[0]
M?<RV]*#J[< 0EKW@-F]IQ-GN9&"OKO&2Q@8VZ_V(P0/*X.C_XM$$7)2J_8E_
MIGUP:;-UT.FK&X.YS#3 ];61-/EXTR+GBQ&/:DPW\Y6DJ&[1DH!G\XER5@-U
MP&+C<FP6#]]QV"9'\<[19I$?C9%O\_J?$-:0=R/[93LH\WJ[J+J25A:NVO@"
M=UH"5HLQ4ZQ6!GS&);25+IE-&I/!:X^MZ(6#Y3H%%P*;97'TL%C4(X;39M>/
MZ"B7TMU.PX0UY4J+VN0VB94UQ6?FS'5(9-LG[&&WA4\+\I1V4&LL8J%;5=!!
MZ@!6-S?'%&-"SQM50]SG;TP=?CU1O0*L XO"B4CK;%O^)]64-8];%#4)3L;
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MVI+$H))+B=<\%GP#_J?X^\&A8 J@Q3;\<!'E IRIU?Z1-GRP:UBY!,1\:BS
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M.?$H'2F+-K+,:*#;5'9QCLEF#P[D1X-MRI*<=34^741=JI&_)N+$%9VV_\B
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M<HI-AF34GO^_7B_H>US\;U!+ P04    " ![AGY5&E[ZSZRP  !-X   $0
M &<S,#4Y,#AG-S=S,S,N:G!G[+P)M-/4]C]^&41Q0!$1%!0$ ;%"F@YIPW"U
M0](VZ9BVZ:"H29NV:=(V3=(VK>(\H8(BB H*B((RB<P((HJ(H((R(X,(BHHB
M@XJS\L^]145!G[[W?FM]_VN]K$L6]V3OS]EGGWWV<))SCVX]^G[#.1CJ0AM:
MM&C9HMJBVM!P=+=G2$:6A0$ D)?Z4\D"S?1/%'* 0@D V%\+- RZ4A&H!,?(
MW6DFS>8']SBX9%F/[FQR<(^(T:/U"#8FPSIK(A.L>4.)&I> DSVN;#Q]D#)
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M(5>IA@"+)63T %"3KF 7YP0L=J(^RY%0V8QH0GZ-:!7T0%V+K/COM34#_B.
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M1>L.ELIXTID@P,,XB'!:W VG2R&7D>%2=I;D'$:[G;7H0!JH)DH>Q6GV^V-
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MI,@G,C5#7/5H2"QKJAE3/IGW!_W^9+Z(FN(52P00H&Q5HV;R4#:7;P8,LHZ
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M5LUEK:OH#I50P6UU)VI1>PC)!9E8,>(-6'"\*#@*%@N*JFXW60U2QJID3CL
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M8L[/69)*) =$ZYMI51T&']OF.7:+B"[1!]F+&0L-$6H(.+:M\B]O6'WI^?0
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MJ-IIW,S?(^# 66VV1H7VN#2-LSZJH?!!8I$F3PSAR3 Q >&XFNH<8'8CO;V
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M1K$'-/01A.J@L,8N899(KD%.NS_0QFY9:-^N)2GN6U=L@ZI13GI1,96JIS3
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MEI_LOI1N[U<8.D\)75I9FU^T37Q +:I?CU8(E)KR_1P79A)B"RMO+J0(S#*
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MD(_;S1#<PZO6J/FDLU.EA5\!"6#%1A<%?@G!7Y["WXO@@JOG8@$L->5QY@$
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M9O5:?3ZCQ:)/,X7=1V 0;@_'P%GR<_Q,3ESU2&.H3D3<9XNHI(#)*4TD=?P
M%581"0!+1-%=?V:5HC-IY& E9:)&'J>OH-COWP&?7(@]2[,'O1_F1%L?:.=$
M'&=O40VY#,(KQ=M@\;-#::.5[S:@E'_16-?.19=Q;L94;6J2^+GFQ0^LA1^%
MXI,IF6+%OJV5]:TX5*4-R7.$KSO5+'4<8/ BC(+56.K5*FE_>X@$9=($,<#+
MY+5_B$L*/(;;B1:>N+VYE>[9N%;QPO2%W_H.?17"VLCFGW94'[KG[3#;MU ?
MS7#DZVFJ^JME7E&&<!K*P8[+)=4OP70@<\\E/8V;?,1,5.4I9@DGKTM8N<G7
MW@?S+9,:IFB=#)P VW)TS@^"6[M=ZT]Y/8!N09_7>O;J'Q^90K-66T3E;F/D
MX^(G-S3LX_FM^@? SU-)?AHY'<X-B 1^#MSW>PLK%1L4#,HX?*G[ARH.#S.#
M$KH0\SQ#G':6F3EQ,)0?WFGZ8 +5'WAS>47\)KA)W/4.6'_T\'&5NEI;SVYT
M8U"[OHQM&2'DI+"^#OENHUO%A>1+5;2(0KOVEP*C V*6VRAKVV&?=C1QJE+K
MI@ZK9-'X_"#K25=$GFBV"R"B&LX9=NS@/MAK^8IUL>Q9,KWQ_')>F/$\WL/S
M.C;I--S5U&'1AE7S![8:[%X>Z- \3Z<)O">\+M4NZZP7$701":O6/CH%([UV
MT<R>MH4P3A@4P%A)3A*!YE$',.'6T+G6<Z2_$T\SA?IO7@Q<KMV/@S:G25$/
M]+E(1E9\:HJS#FXNV9IB_)BN&\EI+/2')"62[#1 \N>$Q+KEE29ITM)/+JJU
M3> /^WK>XDUZ&'\#IG(K=^8Z/4K"*H4+Q@][2+7&6],=KQ+?#-:B<\!;XP=?
MJ[TN8 -ES]=M7LF;M6U]I%CD=:T*BM?<_I+SV*RC[C#D"[U&K%OR+E"<1NM"
M+49(6B\ZD X!DQ+YRS,54LUJC/KA'^6WGS'BKG[D4WWP$!'Z,544E5"XO.[;
MB(Q"0*?I1T'ZMT'U2NKT(--U^U2>![SN#*U?M^/#6ZQ\7J?NJ.@[YN':/E5P
M9'6&CH<&ACIV-*L)=&LCY;L6O /*> K^SLSU[&3&N!G%O0.FO[F_ _8_*[_&
M*-KIE?P=2GX'7'@;/T"P!97$IV?.!>:RF_A=S*IM4Y\/" 5MPEALZ/@:%A/8
M5!&[["9B%B@GX]<PZ0^NM\HG.96L]J]&$("X4"</-)\B?2\"8W!(<NK'=4G
MB-E.(GF,K:,IHPNB 9-Q"MD)%3L?=6L**D:?8TQ>3M3SD+VR>\2R%^MNLO/R
MLGCE$E",9 F^5='R_-,< ='OO3XNF')1O%(O?LMP)YN&&RNC9' \2!93XY3#
MSGX,17-L_U-" +]LBM)!9=4ROBB\D]$X94<_CC&B6&*_!N3^;JFKQS#]<TAG
M0\2X0B_+L#DK?IOS\E$G/-NOB 6UY>X1V9T$78>FFQPR"(!PSX6$1DTG3+>A
MC*K$'7KV22_)5BA8FW\*'7<26%R_/+KCLY_$^T(<MJ^9!"&OE54,5K9%L7E,
M4M5$',;!(25!/ UKT^6:7J7YLM&04BYHI75AR(99FJAMQQB!3/L3"WVS-K=9
MBJW"'2;OO('P4-^?8\)V[%#FH=XFZ'J8TDHGD#*!&7-YWVUUN.UGD8.&0*=&
MD,7?M T;-RMW<9K$SJ:IS_$!6DWG7TWLL_H'\&\.FZ9L/BG>TM?\;ZY:IDDN
M*O7VK^Q0,VC1#JFKX"*T(<B.>&%CN9,R8-#/:K&IUF32P\GV<U="=!N2L&GC
M-?YQ21_@T/N8S!>;4KEX-'[,W'VR^S6>PSY<_HMSJK7S/.#T=:=D%T=3$[UP
MR/AH]]#.8Y4(40$!@F(JX)[#)3R[ ]-W3K'&*!14]Y(*@GC^[##P*W 6%?HM
M*C#V%3377VK,D,8+X4*B$@\D#'&GHN!"*>:W&009OIA6\9//)@9 0BOZZPI5
MLA3J^>JF*N=<,1O0@PU(^[ETQT320F&]+HQ\0@:KM@:R'\G /\?]VFXDDVM\
M+9$6<C_8>4MEC+%KN]2X\*6FQCJ1#?ZR_Q9T9[5<Q!'/(M,A^_<\<)PSGXPR
MR0$3"VU+MB/=%RFTA)_1Q6G(P(.9E'U@_HYT15JXY/D=(/EU7ZNBT[A%&=GQ
MWB9 YK<=\1JH=6LS1XHS_9?]7+NZN?IREV(#Q'%#-MW^4P!=7%.DY%[AV/94
MDD2TBJ'%-CIL5QX,]#;#_Z?</2]LF5-JM:SS=Y,ET_FXLI.J\):29J+XP@*"
M'$SFQ2)'CB=NQ'I/*/Q<P$4O]61\? 3HWFI0PY#WG]2DM$[D!R3F!FX+'O9.
M<L-%6F>#,U))K.A;!*7J95;UICY?]<?OI.0WP<Q'7(,'8(T]DI,9=O[#XU(W
M%D]:&4[,1T-.B3X5K# !?@\.V,OUUUD-XOC!R343R*OX]JZ=#&_BED#\ C^\
M-C=G2/L/';MD*3U$@E$J+2-5#M.I63G!M")+#C!:UC.,9(-[Q'5:C8KS1JC_
M$+K?F\>Z[ZPAM*H&JN6W,^23Q>$-JE@]M;<2:.YD7U*<)MH<EL'7"2Q>[#OA
M\V6F1-DABE)U_H;PH7P[PWAI$EYUQY7['A0PMOA#5OJ3O8IL0M(X%C'LUUU)
MO<&Z+F@"J-[EMX2BEW7AU=*MWH4ZJ=V4D^)Z",OITTF]<O/- \?0&G9[FHQY
M%LD;G<!&&@3WH<-TTB*Z'X;.?B%3K@INO?KP?/7TTCC$SC+>09NM@3.=Y_CA
MT/E (K.%?FJ],#W54&-6YC,]_2\$=7SVU9SDK)2,!9Y3!TS]$9.;A?(AHY&!
M%$>5NH^?V60.ZW[>C"RE=DV:B^ZZ_?A8&6/4V7S-*U?+P>?#<]:T8^ML\ZU!
M*X5GU6"7<,9H&SE+!'@A@]2M[4X,#7I$S.D,E>5J=]/0I^] V*$B+!FY56M?
M336P6,3$F(VFE;3\50A,'S U;%$(QW''ID>F=#N^:YPR W9A3E)9(=PU9XZ:
MWUKH_,AHKMRNPS8S!\1EHKAG--2.&L@,A<"W]<;8QWQHIKYS.V[II@[9J>,J
MWT?3)SBU3B66ZB"<(>[,&_\8O1L9G0?8%9>A*2L8ND3E9/M>5;%:-'2T6'E0
M7-BT,&FVHO>C0?N+U?Z& HK2/)ZC#W[B3*3__:I#"85Q&WVEP@_F1?;0@I;;
M@=X*#DIUD](3B%VT,$ZF^O;YS*AJB7^PO=NX]0-8JEM.#IHDRE'?S!"G<'4L
MSU-@WV(N<"*=/A_?0VR,_7>(-6&26LANZ;37JI-=[J0S94%K/[CFM-#GB29"
M&I; Q(UP6V\-K=P8^@>LG@BT0ZI159-2*5^TO?JZF)50W5N\2#G8E3.D3D/P
ME?E@5M.5''445V&>.P0U.^)'IN*:TF290S]HJ: L=JC=!V;YKR%OMJLWYT='
M.('@;7VCR3+*C7W-X+B!.7A=.O#L.7X;VSR;5WVM9JE%$F'C=MPTE2<L(8^C
M[KHDQ]1WK)Y H,YO\*[_&TAG,MP2#^XY]"_\W]H(M,KO'=YXZZ=;+]DY\AW*
MG:\:W+4^H;-*KMC%&/9"BT/=$M<0FTUN//A"&[<FE!I3O8-6SXHFTA&([<UC
M:A$Y-1=)8:<D1[S:3\>Z )N,01PZW)LZYOURF39T782AJ/)U=-B6=92?Q!T>
M'WA10F-!8X(%+5NUKSY@ UFH44D'9]EIT@6-G1"KL"]@\7!E-?.MIVU9A%N[
M,[.,<!+> *+;GIULEVMW_;%>."I*=ZL@03,TWUO45<0$2OD"6/L>+M#5V?$'
ME(N&!NF_/-_J]=@^&Z.!]>(L</=I\VOJXLYF_L/DOJQU=,T*SAYLJ:K+#TPO
M2R? BS;=7LY6*^Z#(Y?%WK6OH_L"F5OG85_!JV9:G_,"2/T& ]!,7MU$ %L]
M_ALO[P C9+Z;$O7-!VMX#[CT8G$:ICI';Q*EQ$\?O7A*]S=UB;3F8B5_%A7F
M-(8ZJ//3)=X-*\]:J*"A3\&PPEJP7+5B+:-Q4#B+['=F]2SB95?U^2V6V,2=
M3#@ _=,22B%YTU1X^(DK][LJ=I$8R4F>8^2_%.H^*\N!_\ %GU\2N,:)+)O"
M_,[YK5$=TE'<C(5J;N_8>(%(>9R\B2-C^T>W)MET0;6ZUZ6!3HMR!QE?>BA9
MEWU ?(270.L\*1Q&!)A^Q:-)&;,UN?8. +_X8GCP^Z@;,QD,[C2O!(0J'J"I
M:?X1!_JE<62I6Y+G.$1,M<244&:9EY2.C085C-W52ZO1)2[L]=;2?0&75:^/
M_1;($@"_A;6#:*[?[*H&=9FH.AAD.(W\7T>&&U1$:8"TDO;Z0&^'S&2755?T
M:9(FV?ZQC8@OFJ2?1H0BOI5A.DLE,.%( AFKA7*L@CL-GR3N:C3]Y%GY78:Q
MH[8]D$.Y! NOI1[B#@6K?&3<1'&7RGO!51'@ DQ1*]XOR4'0@5$8>#/>QNA'
M^Y I^Q_.RS^TZ,I$;V[#]K62M8J:]KL3+7;<-$0[;_7NWRJ(ZHOY6!D""]>1
M4X[QC\Y!<VR&I8@B4&)Q+A6*N%V=TVRJ;R"(6=URZ_UA<O#E:V:O2U(#SY/!
MKK[NKE1/973PP)6XT82UB5E" >+/=A0=3JLDN&P]QX4T+=ZAXOGZIN?X!)G@
M==%U1]"153V=?NLM,2P1N=-WX7JOIO;T"M6\X_VGISZ%[F#6NAIP<8+:K$,6
MO,M8\E-Q5%J7F @6ZUA@XYZE)"OJL[Q4&[;A+R\G_KGF\O#E=:$$4&3(]QV]
M*2LVU>4Z(YH;GS*M&'PKBYW">]=F9"!&AS'LDZ7EP JQ99IIA3@2R^?$B50*
M[WFJ%&H>A[V/C-$)7(HM*)XQBC$#?!0-:\F7>JY_"VEP33(4Y!U"5VM<U"M;
M?'Q?EHO5IGY](7.H+*0AQO! B;H:;8NWV<!UC*9B+G"1F=)*<)5V6ER^)31G
M.\TFF8^9C#I?]5'?O3RH]Z"JP0FGURSQY[V0@8STDV,J$SE$L)N-I^E9?+M!
MM (KDX=U'G_KQ!AGEGSJ'.3G=IQZ2F?("T%F3/" Y\VRX)/B8.VR&.S (R B
M)8_DV8MZ/?5)KVT>P*E9\C"'@IM(A@);C\K3)_5JXQ&9CE&,:.]KQ5<(V52@
MQ@F\UJ.4S@YYU,[."O9WG.M-FTEG%FFV>_<6K=QFS/4Z5"Z)P%@;7 6,,:LH
MK1YL)=8)LF\3MJ?K,&BXU?,-F[DZXH[%2"NI,QR5G->=UUJ5&\6GJS</]UPZ
M??ID49T?"#V5,2^_@&/I*U0F3Y>$N,H\VZ2:Y3CYJ\S-U0MLFH/CR,AD'R73
M#!OO/6,Z\G;.O6LOM.B[O^;'E95&T&TN+1"3SY9/^$&17%=D\)>!R;^R!B$#
M%D0SA,R"S;G$JV+*2CK$FI?VK:T 6WO) 5U!92/<I;J2Z+/X1BEFK9'YB.C\
MV?X#U+-(1FVTNUR"X"EX?P ,0%?053% [AL+E.I,WDA#TK+D0_[&K2?<6.6.
MI7Z=Y4UB*O/Z,[)XWJ)U.0%FIR$5$?7*!UJ-?J_>J)'!Q==M=WC++ C?\E"]
ME7KT5/R%A2K!?H(L7VDDA>_P#[F'=JFAH5:8.A6\OPFDJU9U[7H*;S(K0,-J
MMW![BC.#QU;6HJJOE"ZM>'"-Z-A;;&/7_P') #>\Q_;K>>"^TZ8?VI^CFMIR
MZT(A8;'J1[G<!O8?I*-'Q#WTIT_2SZ"_2L_)_E?_?W;*?S(MKF^EP<IQQF:R
M'8604Y(+FM$LRP%L$<7\8$L60(<=7A@A02>389M42([TB4X$ (O0N?P_1RW4
MHWXM[*E'B^_QNA,^RNGN*\N)>WI%ZMB@]Y^8 GRGR0+_K:C8(3WIN.8_U7SI
M*_HO$QC_0Z%1\47VNP4IA?_M\?=I0;]@=4'RZV<<CW:-U_0LP)LR#_2/MG:?
M\+S'KL="Q6.PW+\!'-'EBA6_2"(L 8GWPS#K.L\.N/]+4K" '0*7V'E^QNAC
MD=T9$R(B4IF_:[K&'!1<O,)S$.U=@VGZG?JJF%]KJA#E-=.-\@'F5?E[0 #X
MV7?1O>Z&U.44Q5IZB2OMV"]U"KH0W >*+SN1Z717+4T C5,>)$47_[90%^-6
M/:%ML]%A$)Q3U:J&RO5FTUI=6!;'R?*B;/F;P&QZ^;2Y'8+WT1_ OCTM9LO8
M9E^!0\,M\6#M&P0VF\C'08FJL?M=&6III;&?_ CA!M7JE0AQ@+*?OX.?D0CD
MDB_^ Y+N?R[\E]BS_V_AEP_0=)Z3"1=2_T!T2S_X)1'AN=\RQY_>F^.;@;=8
M^>F33;PVJ@$MF09!O4W$)6FG)IS"C.'<<;[SQQM8MVT,^ZFZ1N^0F^!$_8NL
M\I,IVA/91KGGN!=_;2B0PLL@+RNI0E(O5\5>_3ZC"8G9,'WDH!%[X+SS&HM/
MOK246Y."3A<%M'TA<R\#N\I-=MG2)LU^?O ,)35.V-5.6*_?U1\Y4;+7X'1\
M%)498PU+V$\E6=7[%:I90POM]'6(V5ML3E57UEO,[OF6Z:&-%'6[A&ZZG2+&
MJKG90I[%Y)$O(U31?#2>,[6/> 5$\\Z]TR>H,RQ;I(_*?INV^?&CH%^<SBRY
M15Z>S=S ]$.B,]C+@QVY4HIN^)DEV:P=YR\5%NLG=F"WTNJ95IWK *==+U,F
M%Z6#BNA'4(JNA==*I3D^<M81B0B@PIR488W(T6WSAG") X]WX $ SZ9)H5U6
M@E>H(BGH">QWT2%%1\-265QWW)Q/O 6X>I:F9\PEX?/=,&G)OZC)RBJSA-/#
MGB )*_8\M#5'?RHUIX)(4>#!?C_4&SFJG>G%$PSSC#F?3PT<&2;"E!\\#,$#
MX4J8,7_PWJ+Y63#GNW3&6?5X-78$$E29@_YQ;#]3"3V$T$(8.C@Z+I!L-3^K
M<Y=K$"_^HYRV!JRT0<&$_0YYU)8YJ+;\;XTO] Z7*0/3>]QNUF$L$;SZ17,9
M?IV<NU8U8S\\*U=P[6S'JJ]J-&L"WG1_7WQN-I:KVS_4CG-0N#8_B4Z;3:CE
M-R;S_58@^!<C8-3!GR8MS4<<@>C9+[*/P5(([I?'K#Z_ Y1INKSY -EVEM!5
MVW,-%,^,;I(UR&^MOFI G:930L?R0J.WSJAZ6SK$FABBI45?#Z6_D6?#B0X<
M.\Q-94EG7?8FEHDO>)!BZ^:164%&ECBO^3T:)9G;[].;!-_))_T!4-]@L;)-
MC52;XN*X?]4,$&^^Z^<5#G7B:'5!F<[R<@SA8K[J/!>\'9*R.W8,KN8-+^8^
MY?0Z37*P@)ZIZ_ \-C ,.#8S*C[VRTV@, T2Z(6;5ZLB3E)@@*QK;:+(L$N0
MNX>E!J)_>+#H'>:\QJ*? \&7;204YMVOY<N7:RW^_3WQ%&[GY^\ ]VPOY(5Y
M79><8;>0Y76_0[;%4X$H XOBN:KK-S5U54$C&[.9* &N7G=.(")9X"A="$L8
MW2XE@U+9C=HGS9EB\8M6Q4_?A3_IVAS>-5@WCUK$$IMS$GEQ(4C$Q,G+ULDR
M(%.$W_(X>)H2FZYT#AE5?[&/BIY9^35(Z^+ 7/]Q+ZC#GS90_B=,T9K;+=C#
M5/<EAJ@X:C^A^:Z@\3LUQ]'$W;:&II*X;5F50G(0332+QKB:0$<+N8!G3_P4
M>[#3.O[<B$1$UZ6R<D?HU,D)BUB9OS%,TDT!"RQB4B2ER:EWU60\4'\AG&]V
M(;%'MY=YS9D8ZCCGKE3C@T-SQM-\H[LF#(^&5M('CX:'E]D#FKK2BN0\L/H_
M8,>:*A:\,GU,GW3+*HE#(3[FF83%\&;#U<3':P)4H!YP]\"\Y2P+ 3=K,[*F
M'L)9D\K':A0BB2CB>7RQ9M==P9U0\VU9V&.9IZ=2(>@[P*#'6+,^#P X_V<_
M V!/ 6\$8LG UH4*R&IR3BPHRI%=JU5$?HG1Y2L"O#T5/$_O@$,!U9BP2/%!
M8G("R^L'%6[/?#@ .FS=.CC&%&]:JV3]OH7(ZB2]DDNK>84H(S/+^'NJLLH9
MUK7J?7:RY9[?JQQSL;JIF-(P)I=>UR?U;U/'8U:3)A&5\U@5/(T3 RN4RWW-
MCFG#!XZ[@^\ \F\J\N">A.Y+&&X&[?C>^?JL28^_K(U;VTH/[%7?J&99KYMN
MX%]$[?0FXR0;2-D_^UD-C TY'85M]:0OH7%> %H;P(T_9/@_JN?R4\=ZHY"V
MMQ985=P@[7W..@R"M)^9:3=KNKES_1&58H,2;*6&ETK-;JAATA5?5JQ19+($
M57!Y",U.I!$*!OY51F/JO97^(K,<&[+O=G$T\7#>R7UQ>75TO]8P\/("UHV5
M<PTT6WFD3"7EA<V/SG^(6.#VD8NR<0PE:+1Y?.8P.'<']Q4:_DJBLAQ'9C+2
M F$09)P'T>'@ULN,-KAV8,"&_6S>ON!>ON B>_2(GS;?6@_T?P= [I"1[(6\
M02 )"-41#V3  ^)<K'>AB;SW<K@1MN3.!4;*KC;#X)MD\SL0L[Q?[2>')26P
MCM.D1<@H<F9TJ75B0J-:&\V;\A3AYUT#@U&F6=#"EMT><S^N/Z*\^&4'O0CF
M"G:T5=:N9;FG$\.+;7ZFY9*Z< 1N1@Y'6G74=EFCV$" F,,M>W>+U<Q^&NC)
M5B?>BN%KH2&*)2YTQP_09(>#,"'RV1@2"Q _XM8R</#NK?R[I-E;[0\28_W,
M8[3\T?P@H=C2[W.PVJ^\W7>F[X J%^,[MG? 7V91*Q;A/T7?^\W?-C73O0C&
M$:O,:\M6865.0U]N$[17;\\JW6& 0'I-M>3J N,@\8WXQJ]JG_?C*A:'3*1(
M".#B71MP>8-2(J,L3SZ1QX;WGHRX8E=9N:Y0F]9J'%E*;[ (;61ZY)(:C.&?
M.OA:#<84NM>WS4EB8V!0QL+6;Q913V*G5"HP:(3WL=/9QM_(2>W2FG_$ZPF=
M<J&JLO=*J.C:RNG\N;=0W%CN&AA1EQS>U=M\'U()\3 T;-+H/@U/9X"N$C:Q
M$["R7"3"6Y6L53BS.3G.JMPFSP:UUP:D6A/8F+R695J!BF/ZK5;\AW(6G.IP
MV8%Q(YME\4,1NK3Y)6JVNPFTZ2"[APJ='"[-!!WKLW(AFRTJZ[IUN4,!1WLQ
MZ_G6HWH$Z@PM180(<%B!V^IAH\SA*# '",R"N+"T8O:AGN[:*(FA0MMNM HY
M5:KA25I\JGC0 JP/C+.-HN5*]=^<D;\G4KQ)7?X]O4-+%+ 5NOR%G*O$7>B)
M<,:;17.>T0H44H>\K0UPT_4NNOLK#H(6C4HB*[_KO^G'5N[$SN]LWWI&1V=T
M*Q/+\CS]+6_-!9&0H.S[\'CL"AB%O)QO;C1?ZC!XNC5^VTA,XWP''$\PDAX7
M#<MIO=[59.=2^S[]V:Z:%,[8C9T\VN+N@CT,BQW;+IPN?/:$'QWQYG[XXR 5
MRZO#,;#5R!>[J7 PP>*4<)\CNQ]0\E?JU8?OHF'L^X$C'AK<JW7VX?K2T!]Q
MVI[JG9LUU\6UBJV*TP'K6'_RP1[=X_.-YKN.)8T]$NC&VDE'=*C#'"MAIJQ>
MA4JSH<";T5/AT%+#X 1"FR6-6WY#U2\4.4<&)' #8T$(A(&M%R^:0*Y1]CJG
M@#AFVJQ.QW65\V9NOW[Q**-;-5X-P]Q^%"WC^'3CVZ$^*$;E..=:BS9'[VC@
MYO>P[)YKE_=PN66HLAEW6PH@,@27MS.+(JZS70P"FO.$E?W8"&U^@' .FOT[
M+N%_G1WU/Z0(]:Y',0?[0VD)OX:6E>5Z?D]!P$)YRPB%##QYT'+*GU9E6JZ4
MGWC*5VC**O"8P]55)?.*J#!$\G8DE&3AS<_/A?9&W@$E33@ZE?<,):?-B/.\
M!VI-+M:@W\4R)V6Z].[MDT5<R,V_:7.FR\&*:B2]F,](UOUX(^)33,2<2.5C
M8GSP%\N,![H[-)F^%WX;/1BKPJ4/I4\>;@\^@EWO@/R"#F :5[59KZPM*J#/
M@$;L;E;N?CHEA<\R([O8_9.4+E93K<)B(9/+C&L'GCDNK^::IHF]P^=1 AJ4
MP^SQ^,!/PY3<H9G=*%#*%VGGZZW<'\K6(6MO/2W331ZG=H2@V(-<Q6AQ&3-:
M3<[O)&WF.M7/,M0%O7+,%.*U:JJ[ ^1(A8UU*=X/JK,(:>U>9/=*)Z+F>, +
M$F4O4C;9E^+UX=87G^&($7WW1,WGV*O!N:H$37 &<FH%M\%)TAA9K<RQ5)$J
M>QA"L;,CV1\ "P):T$FO\'FI"3Y)8%>UT^Q)"XLO/YYY_0_?(<]"$[1W *&7
MF2K)]#O :2_MQS^ZB[4)?0=L3E>ZBMR2^")SO0.>592Y8HG? 7F&VO)#I<T[
M!R9J"F794ZO[:ZEP'["+-<UO]!U*=NG) #0\E FRV$=0%LH,"^A%7![Z;4?X
M ]KQAS*5HHZ]0FY3^&XJY6K?KT&JEPCHH0?=50;;(B2;?026FAHBPA5;O)/W
M80?6<Z1WL=_? 0IOS9*NWKT_8I6K)@ ?*&X3)?U@[F+? <Z$/=S54<+WU0QO
M(<;O@) 1QB'X=P!'S9/#]S6Y_#6Y>^3^*=^5/[#M,J=8L9VQL\]K.E3MN!90
MJ+&Z U3?HI7?5KU;T"HPODP+_%&RC6;FP19-.E1M$+\!O@0D1ON'U,%/MDDJ
MNB9XT'D\H]?R<A^55K"J(7%XWW[1OG+>/-*W>)#.+D7>2(A. A,1'_$6167H
M;'E(JUJ\2J.!<5.Y%2V#(.VW,3JE2SL-^Y2YAP=R"S !IE_@\A <M5[I^5KQ
MC2D"SZ\RE]4SD=>OZ\QR;>U^LR3$NM,V),*%O?9+\(9&2H7"V$3%S&+8BK9;
M^5!;;KSG8B;"/>H>7<%=LS$>LS5Y>H #RRMD86:^Q*^ZPH>*X>IAH"HB*8O+
M-Z-3='[<2B83$%\K-=PN"\##7_?+.%QXT#G]/=.^O)<ZD6)FW^/\!3SG[@"Z
M_.HFSHT"2! ;\>[W.64FN.G)>'Y,\-!Q9)OW=%P6$CMYF>H%XZSB]E<HGCY+
MJDT2P#O&?6&QJ)NKPM&.OW7^NL61P*:\ER/=[#VIZHRK^UE(6>-DDLX#5LV@
MH@Y_M#9=+BD3LE%@110]SKG%J>7$&K!AS^C+7A<3&Y[ >F$^C'23T?AX8GY0
M!JPDO.*KO);@.0B'9DC739ELK+.Q;C?]QF@E.P<CE8#6%*3)FJ9U4#7/\KN3
MYG!1&>>^A33V5/>>^W*-)R\YZ\-9O0.$51DCP5.6=M>82\=CM_P?:/]F,GP9
M4M]?S*9</L6S&-!.18X['E8RVH[]"I??EM(C6\]Y:[XW,BE%KZ*WS>R@1151
MF4(*0RU3X&M@&KS-L#K!6=2KEO33M,6BCD,DX%AB*KR.\P43=GT)+X7$!!T-
MD>&8))IDE3I9.=)*&3'+4:^'9%9HEA2E@2<E.H[&YB'L$5,A&(H!)9DNX>EJ
M:9<'%WIMW.AD7PHQ^]:XQ0XD:-61[\9?W.?LW;K0JZ><!OT;8?C_QL+6MLC'
MCQ\!(OX__S4]\>T#[/_="WR.5M-P@E;Z/=0)$J3T^_E%*.XY] G\ZOG_N1 !
MH)7R"_<CM)ZC;9,:.RV^_&,HGMX!1T$&^$4\'DIJ:3TB#_B WE785=AE,O([
M!$#H%3IT^"R5THA&4:_;H8.[*LYS=DY:=%Q;IGBG(0B;-EE"6U0MFRI!)9]*
ME1/)C"B?BE7BHSA5M9N,FX'>89S>80*$(\8D ($L< )=%+Y.AA)=E"S&)+ .
M?@!CN7W$>\.[BRA)XN-G#B(YI(@1R?XAMJ@825,5'!PUL]&/0.J\<L"O&(D(
M4Q7 [A>G$D&J'-M]MDF.!KF=AL(4Z5&*'T" T8V!U'HSC6,;G=OF(Y[@E$^L
M?=;N$<F%18(/'M9B^4%9[&B*)X(^D0V]Y)MR3J0Y\_"P<DN__BPENG-H1*[-
M(_;5RSZ4Y#C49I?@L/JMOG.NEWJPTWGD*;?/1QH+V;#N$G@>[;/L8;[>O])A
MH >^6D?7MLKD"N>DP,YH44R0B6]7Q))DXU)LM_R \8%,+4!")@A AT4G$DP+
M(P( P J,9QD8&<B',S-3IN*16 X\7,CR9S_REZY?=A^Y363_N?!1>EL\!_RS
M_  PRS!_ 6S8_X6>T>KYXA954.X=24[GEX)-KYZ!<L>I@D%'+(.FA2J!L(5:
M7+G%$*"^MHY\[[28G+[>J(3\8+<HV!5C>HT,FEFH*=I'5YX>\4D]8_?( >(M
MW?J4:]9A9./'Z9?GR_B8.[=%:*K^^QV@N97TFCB)5ES3B!:<<_NLOZ=  _NJ
M[:_^H,PAE-$](X3K,WWB%,V2A79O^$=Y16#FV>Y%Y$GW4KBHFZ//67C1XT#8
MXE;\I (*NV/=^9;R-(_XWYC_C?G?F/^-^2],/:NS/U-36*#-E)<S ]MJH^M4
M^W."#MQ4(\+H:N[BA@[](I7P]20O6\V"BN0.CJ2.A0*SE8YX_P*K")P"W&KB
M:KJ\B CL<GL#!*IJV($ _M3WE?\+4$L#!!0    ( 'N&?E5@>4'!>YH  !>_
M   1    9S,P-3DP.&<X-FPQ,BYJ<&?LO =T$]?6-FQZ[Z$Z$&-* (&ED30J
M-C91[[V+0!A)(VFDD48:C2JAA!9Z"R7T)/2.#=AT0F\!0NB87D+H@5!"2[ZQ
M!0D0R,U]W_O]Z_O7NB-KL,_L_>Q3]MGE:(O?3_Q^/J.^7"P39U2H4+%"LD(R
M(^/W"Z(>7H((Y5*IP4@.Y,(<<(X3"U 34(@*Y-"H&5V[)4*0TP\360[8@P3S
ML^^LWYR=A;CRLRV@BJ8*"6 O(DWAL"&E-CI3?B?7E=VMH&;71&XB$ K !)25
M"*#!2&XB/[L</)?\O:R9FIU53D+X\[-Y90^RK"IME@##X2PPA]'%20. +!8K
M!V""+!;0.8M. ^A4&OG#Z@(P<T%6+IV=]>+*+JA)WKOB+G>N7BA^(8[\*S_[
MQ;CB\7A.G)&#X1XJP.5RRV#H]"XD19=(,DA B2[!2)LTR$L<(1QQXDB(0+!@
M5MG?D .+$OG9V36S7KE>C"L0^D/06R?P'4P26<#S]XP>*A+P4/_H6%G?2+Y<
M 0Y#!"PDWP5T&AWH I3]& %.+H.52V-TH;%S:;2NU#<HWX:!X48,0PO2DR]#
MT6B$P,M:LP0&5E8'"Q)T8?%(QU>@7C"\@:7"7(@[^8[^,%_MSRN4;V*0"N&"
M".@?H;Q*^P:.T1L-.((0@D8*7IOU\D7EH<3KK2\?H$CY(H<@/ (;DR$X/UL/
M1[ H[H2S_\+P0E+9ZN7&$1?A+:"#K/*.O=+T=TQ>&/%XB0(V_4^F%TU_Q^7&
M\ !$%,BU(LF??"\:_XX/"4 >N(#*]5&9/)[.X+?+]1X>G^<1\0P\OHS'$U+9
M.E[$)/'&7!)N"I)PXS*A*JKB\9@Z/ZKF46B\\HO/(^G++A&O?9L$+X^G*V,F
M+QV/3Z4P>4*_V.^@RU&>Q)AF<%,=/!GYT*,3\7DF$=]C$O,]?@E?9Y,+XAX)
MW^-1"GF80A#'%.6 0CY/)>3%R]XZ(8^I%?$X&B%?913S=491(NZ0)").:8+C
M_N,=%TGY<:=:R*/92 DVB=>D%^NQ\F?E@*\1_YMO*H<<J,Y##EG$X\5%^O20
M>3(]3Z?2DT,3\:#RT4MY9:/3B7A_7CHQ+RZ3D-,B%?#\Y/#(9QZ9\$VZ%W/(
M$Y"C)>?%*1/H,"7Y6$ *$/(\.@'91LX("114D8NETI/S+Y;I90F=6201T46(
MTR8RJ4(2+S]A2>@0+;\<T$1(O:J$'>$(]$E/3(3J4GJC/ZQ(VAA:@=JD"_I9
MFI3:ZS+9I48A+2J3R3&57.#UV+UR<NK"!IJ94)L5?#S)I&I%Y8" QDBS6RUB
M%+( "9<5Y5KL=&\("A 1AP6,V1AZP!5T,6%KB.V6 A0W0R/RVB I(@LH$&92
M[<,H C]H,*,AV!:PEP.&'4$Y'0Z""E](80F$6$@H'(Y&<(@5P_3D_)+#EPGY
M.E)==#:1@%0(1]F<>45"OD!D4)E$8I->[95Y[ F/790L!\0<TKA8)=4S#6J!
MV"Q'G#%12B[4"SU>R&!*6A ;6RG@,[0&-2P7>1(NDS_N*1^RW&<72Q"7WR4V
M,3AA32J>](3* 6D4;<HK-_@)E=$$:O6HRV8QAQQ6,0!; 3UJ#[@PR!+"'1(@
MZJ#_J^&7 U*$J-QB04'$'@A%G4$[R^T/:_PA" J&%8%PF)4D\# E1H5(11.6
M:82H3,6$'![7Q RSQ5;;J[=RP#?:RFY^:X " !0FH52Q9&RY,V[5!5%!5"0,
M2<6RN \.6<(&@U,LX[*X$;.-IK1R:+A+&4\8R@'5<K53Q>%&-:XHQ^1(ZL(I
MO9H5LL?]#L BDQ,FLX-I].H0!^I.*4U\64@N90I, KLY8K":#%8I+R)5F/P*
MBC<1XLC26T_I5[!M(1V NMT!L\O"32AYN#H1<^MY3KI'$1(KG?JDUR#6J1#4
MYDG(A&J.58)"S# #ANP4FQED^0(6CM=E2^G%Y8!! O-#=ILCXJ-1]38URQHF
M>/P4148E7 JO6<S"712'4IE,2&&&,"4/BW&M#*"E"(=2JL<ABT;KC5-$<4J4
MX]*:*>6 ,I>%+E$0L)7!23$(:@C&4A(+.P**I3A#&O;*S":="J=&,=#F=\5P
MGEK"%<>3J$% J &+@REV(7C$7'ZSV<&T'M*H*52)1R(4?\#-PAQB)M/C9_I\
M(A")\H0)59@J34$*+U=%925I6,*LI,?<*87*0]BT9G\,AQD^?]06TH85"GW:
M'G*3F,,OEHEP."B-"SA^JSMH#9O-'"Y!L:L9(9K?&8K:E$F<$K"%E&H15T5W
M>G1B+"E5A:("C%1[FH(#.118$HC$R@$U8<B!BX,*;I(6PQ@&2*]D1?A\T*!F
MR2$3P:+B)AEF@'E6JB)AEJNU@#+EPXF87"F6*UU)"SOI9FG%*K\BG*($6>6
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MVYGV>DZ!0"E420"Z6/E"HTP.!@O@&H.4L$D,L!Q4,\5*=YN80:^5#MJ%<K<
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M)&((Y#:ZR.,  @R5U^DA/6%<FK8V+C<=DL,B=<)"-:;8;"I/I-&&'$P^PTU
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M/ B9 B$&S\8V22 W'W<&0JA2GLZDG#*M/.D2N_FDZTP)56A*^OHI6+EO!LV
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M!31+E*LR6\@DD4:XI#2&02?7A@,HZ98LL81;G(S0S5A4'XI%/3@2IIK<2CC
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MW6&]M_)ZVW:TCYS6"SI_@YOSOJ_/SKX_TQ=.8F17GS5G7#? ]87[E+#Y_HU
MJWDM6NKFKAPXX6*W5L^?/,J,/NVXXEFU,\<OZ5>VZ&X8@?7XN4\?L^/TY<\.
MUYSJZT!T>[3V(^G("3,5-=25A,^F(X-W[3[P%;'O_09P3=WH%8+=W2/%I3,V
M+YI6Y]$OSW[/,,E.#Q9/UW_5\O&)6WV.KZ&I5W.(U4.21X<9YEA.\B9U[[A&
MG[FU4E.*W%JC9 9<I&G#"=2*UAY]TKUF-P9-W=<#(E1S&"[E<?;QD<Z=%]$)
MBG[].G1:+VIUOJW\P(BV!_@#MK2QP:YA2VQG!%#_P:U^VE#2:/RD2=JZ>=,F
M_\02GCOZD;1.&_0K,H!MTPD,C#[3\O'J!<CU1]8%#ZYOR2F^5/^1 A>N6E-K
ML5K_#?W^9<JW72>91JX=<&-I[JD5RR^..)"_X7S(M[EY4?N\?1_4N]N$\[BY
M+8"O;=U*N'U[R].K;\W>ND73,S!@1=9,0V";]69R5)0P)YA')VY<2<O.+-U4
MZYO/@W.F7.CP47[BUD BKW5^W<%]O\GM:Y#+^DA+J(Y5M28_5OV>L2(JDBPJ
M'2_BJW;\\-'8FF[[=BUU=/=YQQCF98*MQX3,%1^UEUNSH%V"PG9RS[2SV39'
MYN#6LG$5SCG77-NT+;SI>2QS]/HZ#Y=<OE/8.7?&AD>5^LYW'NY37-KG\V!I
MB_OC#B&^09_KUCW*5)U<O7]-%87^^X7CV?;MZ]JWV3]CR=&+WUS9V7W1_:G-
M*S39NLOXZ8H+^ZK_T"+X$;#[0<F8IN=&E61&/\1*-I<^ZDTYVKON^ON+X9>^
M]I^])BX^,^7!>SWGWIQP8-&:&S=K+#W_747:C3QJBUNS:A1T%>@\+;H=[J\:
M<,^.GZC4SM.@U>#WN:/'SQ$M_O(!=6^S:]T:W&$6.S7WB%LCO^^N^4(RI:BW
MIK*A]O38T^KM"\_JME7N=;!M3<]H]X01AB-/NE\^OV[7MLPN/08><5S2N[+6
MK"O94?3MFMF[UTRJ-&+\Y49,]G9A8EG;[.I7H<ICYWQTILY$R\WZDQ9(U[<+
M&INO:?[5E^.&3QK5NNBSKMD-!A=]=*=D^EROF7&)\VS"X NJ-1/6#/ZP91NH
M'TQFR[LO+?MJ8^'&P3E=@DOGV'K-;%[U6MO@G '5;^<MK&*M6KFN:[?S3B'[
MN/7TQ#D/V0\->P)Q))(IRM]P=V;3T=(3%9?4P]I7IH^?T^@TOFS!C1X]BNX\
M]_.4JT6S13O//<RXTSK&.\<]UFO1[%^W;JH]K'5J9OM/)UQMOMU9"[OUW>+*
M4L[D][X51@X./UO@9#:^V.OG2<4GGST+SF_3Z,#=$Q<OE0X5A-NVGJEX7*':
MH;'+9W]]:<; ]P8_$6RE?G',L)WRX4%/<!GQ<,:X9LYVH\^T^CVC2\Z5Y,-#
MFB+)F*$#ZNQ;G%*,[K%N8CUFW&_M\?Z)=;>_Z)UZ?^HO#T]M;_?9K]G')TN'
MQ>Q=(Q,:C5XXK\D]^Z.[-PL*=]DJ+9Q_)*]YI,N'463Z/E_+_,$'\J>O>;3/
MV;FHGA.X./[H[5N7IF_]SE1KT*4'+6>/FC-R\9??EV0<6C>[]M2(WA-J<$XP
M?DR=B9MVSGV6T=FB\(3;5NSU]>7J!QK%1\JR1OTZ5GI!,/W.Y+TK7L]6WO4R
M%]^OW&':P#4M)Y9:VI=.[*8]L>7HD\L5#W^^:UGU1E_P,MMFUGTRGCOF(G#\
M1!_.O0'M?^PAUI=HYWA'-?6WFG\WKZ?OXT5+MY]R/VG9;>"03WIT;C-XV85)
MB7&?+Z0\R9-ECCX8CVUSPY1E/VOG=3=?[[KT1,--[2\ 7]X/;^]RC,'$I</[
MSB[I4+3BQH9?QA6"70,]KSVXHU/D]YBU9AG^?=ZB7E./TJK=+!I0,.MJ;?\
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M>R8E2C2041*GP()142O)@A'*F61%\!^5+[F&!/U6 ]"8^$^,J3$#X,T/P&?
MYS?:"P!V&P#@[1B %/ 6H0EA#/4P=BDS&:+6ILF'![C]O)AX@8E-]C@2UX9#
M->FG.?Q9.!P3L8,$ZK%*F3G4'_UY(K."S+M]!P9_$[?8>3V\?P)Z&+0TV?(%
M4]'$[]COIMC3)/A92ZUNIQ-'M>!HK!K*-R\9&"G5LD2A 5VH):>)N4O0"VQ,
MR/@4L!=OK6V$<%"V: @]PAL= CH:296^Z(77+96>'PPGO\=H)/3>"]AD:(GW
MOK+&H S!4Q@%*439H4S.-LX7XP>QX7ZL;/YAV;2DOJ)O%#D9P4;=P[F^"U8@
MW"^R$['.<Z#)&B-1]2$V=>:\]9O4/SEAG8?!6.^I56:U;G+7$X531FL5J+DA
M%SE+=I/UNO]%,Q7W-X1>IF2]7*R)O5C3"^+N.;R@S(76>9)/U]6VA,@-;!6Z
M/;1^>#JZK5%M>2E\H'[L6MY\!0AI^%=?;]Y?_QBH[15[!2Q,?70Y57NAX/US
M+(8M=D,O8IK\]UJUWUDO@[W&"_+G*3L^)BR>V<S,R[K^DBB<T*+8C0..Z&!5
M&@L.+Y2P&$V4[\1[-N<WIR'CB9/!.SKNX!JVD%SYZJ5;='&,[5_CQO/B1+1"
MK*:<-S%*#_2$EOK1^>EPI?-@HY$%LB_C*)&V1<D((7YPYVW/CM/U-?!O7NZH
M3XU3H^WKFVJY0*"2MT+SBL8R(D1^6'--YQNG1$7_FGJH=N.5NZC9'"QY%E66
M:>-#\@KXOLB:[ZX@,74L2&$V917P:,>DP)HS8DUE^.AL? U2-Z%=NOCXN7$(
MV;J[XQG$,93,)Y1\2QIWR0R1ZCS^<WF\:<D<]NZY-[4I\.GV2?C!YR8D:$I:
M6P*,HJ#_^S?![VTZ&KI9'@LJB7@LFQSM$A#-YQ4K.71B)X9(4W\$+B[\QQ3:
MLCW]RC^P/J?1[,6[HW*O,]+ZL[+K5P!WF:.!@ME01L8Y.F@Z-4"!]B<EL'D,
M2L3$;<C3L724&[K39TU:/C:S*\\3A/3X3-KK!G0_Q -2*]" N,J L@D&N^DK
MT3HR2+G_G#-$$("NER9=QR W0C:LE1NKYJ,$R]2H><T75P4* #]=??&\YC:_
MZL>/RY5AS!;39].)[U261E'X"Y9K^!C?(#0BD&HGRF-"Q B1HTI\\EU5D:J3
M: ]*]7WPW_%)^DJ^ GR=;>6,=JZAY!_9E C]0]^QV()^?149&2XE5^AHY>#G
M&_Q$6>1 %[^!3?.[A%J";R!UF%BA=6DEGYF_N[VS*V%V 6P2#S80M-3_LE<D
MY+<2,<\39\AQR12MLQ_@O']5GZK*^/\OAC%'2X,QOU]^K9A0K<]3SU?[G*9[
MP?I$5S+^E')E>U<X&QS4973GXHY45S6Y+1H9UT7*Q[&D3Q:1Z8#>$A*$L'(5
MU0E\\SX2?Q.VZ2ZG<GN+]?X@(#W83"<U=Z4PC'IU;WE M4_XV!6)B$!2U#\Z
MB8*:HR6>IQ)&(@%U( 0.DM/^+ 'GN/3:C/1NS\.PDZH5!X$%5Q.5]4JY?JE_
M1CV] ;""LM7/X_/YUAV3?:?ZKP#VQ8Y/%I\074*2I4NF^7<%;QDDE8JM6U1D
M!:PM,Y6 G?X$5#RMP3Z_9-<"9@" .X20LD=^N,7 M7:Q06QS0,:IJ-3)9LC+
MT;1HMC?J$RU[NT_<_;>5XNZ[_#9K?1OU(0=1&2PA,EDB$DW%P> #Z63"[$6L
M(U,#PIT4[S+:P4VM> 5:V>>WR;&M(957\R6??HH=\^^8D2\8F?UD!F]6R510
M$6 =T M=]=3N%0TANSSI_2)LF):6Y,W<(;#E0<GW+E(&$@T22FC)]OR^$3Q
MP90?34L.N=H\)_=6'H"*W2;KK%=-<L+(C^O1T53B\:=A 2Y-.9*&I#@=JAW'
M*"@+33#.*/-X[HS+*=_1^KO+2N,)<-T!YU74*Z#VD?C1D4SMPFVP8Z3Z)IFI
M\6> :'5<(_2]_"<%Z:5/;[\E4[RU2JWD&ZY1L%K(3#MIF>"HYM^\(Q-N166
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M^3NHVRL6:@*C!<I*!"2U>P\$5#D*[ B@G&/#<2U IIK6)C;),/WP)A;Q]3@
M0/7  N*8GB5N"4"*8Q$'-!,#%$AGOGV838/U\JP,?*DH?@7TJ(Z%;FW4>K0^
ME;P"U$.W':\NR7'O64._9.L9.)@X'"=..+0+;\0N5KF<E AZMPF*-^P-4T[M
M+&4V,JCJ9AX0Z)6+UME!A=5;JD.X:@S\(IH1XMX&A,%=WZS\:R?\IZ9?$ :'
M/PR>8 RY8\## L-\B!]]JH_3J_\[2H3YX+NE=6]XA-SX."EME;#PYJ1\(M#Y
M2T'JT5W3YR))F-*J7$<E5IN%@:9GDLJW)Y*9=WL7>#M;PB3F[QA'()A8FB@F
M=RN1'3\Q:+>WMDF,@.YG IV^\$371U?D31?(H9D<[7_EO^J]D6["&B;0BK>V
M(/ "D>D5*RESP K]1P* 60'J,+RZ>ZCG#N%%TL'E+D@^7?9R[#MU,I&<U:H&
M7BLGO.&[!/V69BL3LQ!I%EXK[@I3A((8 *51A+3CQ.U/(N3[^K5-S1UZLA&^
M9*LNZXC>'OX7:^5T:NO%W(1L3KGR+YG<6G5"895;I5]ELL8PI=L%E/F1[H?J
MV=IGU,@+YPR$]^H"+&&RSE9"^FOO8K:-8A?UQTX;RKG/!ZV4%BT^GI;7]^H9
MQ[8;';(\".UF;&]&YSH5W,7ZPXGEN0U33CJX_@C:V2ZM'DNYD/:81X':2D@^
M*WDZ.7&J*3E5IVNKII?E P[%_';XTR2<"D'J0&(O[+XWV04\)#[?\73[5(G)
M8.XQB,UM\WC7=<SZ4C*4; I#D'!W?6PCR'<WXGKO88[#=3D6OH .Y$Z+S/,A
MMRKJ>%^'^NQ2F71MS3M=^;=C"&NKC0PJ2/5J*:*(Z_:"!XMYCHR-/-[#O9HC
MQ].>E>59W_39]"^$5PY\4!P"=GNMZ]MW"/WU/AD1^>_'.LPC>W<06+3W7LVR
MLO),JM S Y>-335CX"XHFDOMM2B2P"QF 2AWD9>.IXX_^T/ELZFSD8_76?EU
MD:5U%0J*MHYKOBSH*VG325>$HCQ*Z=%!:9\F81V6Y3S*U47Q:,-L[6F3HXR!
M:I93E?Q@Q"76VXAALF\89<VG/[SO_!_?9X@^GOB065_?WUT^]CYUU-Y=)ZX-
M.ZK8J!W%'/3 &GHL+:=M"V+3_"I.VIGD8V6B[!_JE#3WT;@4[BM+*ZS'>+!,
MZMJ%N(*46>JB[+\KDM>R/)G,_74QY@%_-NI)S"73IQB705>)[^J.8*0%$[CB
M>W(G?_5* ;K]7OC\3%*73)*: ',29MVP< ?_X5D0$@:N4U$;*+#8S\R5E4I1
M>\FB421FGHCH,>GD!PJO>F?_[Y,B=(Q.;B_@,$6V,I^R8YW&YKW98@:611?=
ML82==HMP$KE(@5$]P^:GBMUURGTB6:)/,/5:76//GX>J.N7G^D&[D/CLQ:4
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M^-;5_[\U[/]_7,S?^?\ 4$L#!!0    ( 'N&?E5GTTB\1C$! &JM 0 1
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MZB6Q(>7J"M[Z*BP__OZ-(LO=OW4A 67[FT$0>WY+AG1#_8:,V+-(IKA*IX"
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M ,,0'Q@K @ 1% HA![<5D[:5A4#!-C*RTF"DA*0D6!8A+0:& .LO"!PN*8:
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M?^U<$6@/\1M**<DIUGS]Y!8RZLTTE%3D%)MH 02WK8#Z5!3DFVCH&1AIZ&D
M='(0\0O>F*BY(9N5:;9M-X(QL[ >=CH;$5W-P[=WGZ2LZ9&8ZQDU0SMX^<6E
M90@NKIE/"M[7LDE(J:J;P'%X9_^HK,_#.P54U#00?@&1FL9FOC>24U)O/GJ<
M_<$&:6L7&%M85/P*D,Q.1OQZN]4ONP,:V69R*NI-E!1 [W$F0!%R*DIJ&EI
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M3\BSD;I2WF?LMC)I0KJ$+YOE1YTKDL A./D+LKF%MCWEN%:[@JEE2"66YA\
MKK/;BN>S1T5_R7OK-QRG:*G+'M;I=*DE/DUD46X#4PG< Q>?73_D+=Y=@8+C
M=[R.*(%!]2WP3$,NW=\ "E7VZ*?/NB/7X$0T72^!N^F;Q'DJ,I983:/A$<TQ
M7SL@N5!]R[XII9WX+QEAFCA B[4836$2NU^M\( O:[$Z^D5SW/[)'((57DG4
M'2*GGT#*!C1WAO:41ZX.-(*D><XBQY/&'9(_6/<6P)]Y9=ALG:XL/P-X0TK&
M5DC>^9]UISCUPR"-2(.,G5D= GT1RPI!"92C&-#0_X^ LK8FY2__@1E^CHI?
MS( ;7&N&']7\16^CG[SU-S 6U5RUK>*KL;76E4^Y7F)C]@:J;[WL</5%-7,7
MU0R4D1S1W.F_3KB+_#"P/UOO=P#75?MV0%[P_VJ<?Y(N$2]?G"W_H\$%UA'R
M>6VL._T,6 S^OW;)W_>1C2@U3E9FJ\EOXW?1&+^D(&U=NS3#7ATU!5/Y\>2>
MZB^CV7?T!R6WIK),]KTKY7/$6-T4/$*Q2QD2N9MVND'IZD0=QM&"]G/-Y/;S
M<^]9>[!O;UM["/AIU?BCRH;D![^_DGFB!N&UN#@5]PGW=>I9H%-=I !G1GSA
MZP\:9B,Z;X;/^9M:P)MTK(OW&FZF<1N\K7#:9IOQN!4BA<\WRO'ET29:7_[T
M^YN=<B[E:5X_^KP;OLO8RZ)Z/ MB7$NH)3! =(8Q=WQ-&V"[16YU;=6/[9E)
M48V[O17"R%R; /6F+9(+4HE/I5'68I!JRX@Z9,6/%_L0DJZ1R+MS)T=.["EZ
MB>G3+Q3ZMYAM$;(4#34^O)."AB4E3.@P$T//L([V,] +G7,[FL21GP2X=I=B
MFF\^30C7\M03'M[LL #ZVF %+.5A%YNVFE0S>6JGNG_K9D-/>G\DK;1U5,R$
M=KD<5 ^)-6L7:V4TR6$GX1[N\U!1@J5Z<],/HTD[)U6<RP'N?LE,0R]5^EM9
M^9;-MJ1E+7><098\Y\6)*T1J5A)'A PE2Y^_137J:,;3T1#I9_/=U<!B_$4R
MQ9G#?=YJHE\E,P^<[EAE>RT-P3,1I5,\#N#ZC*(7%T/6C?=7N+(L<MT[.:.S
MQ4-%1.W*$5'[Z9+=+DGW!X@3?HCX[LS<30>X=VFGGIZ_'CCUA*C7RQ9R0-T]
M#ZM?Y%?"\L"DE7:%V3Y+*?B%71XJ6OOTA/F.2U#0Y\_M)@T73_4Z*J.'X9B?
MS@@KIU-@&8>/96M^PB+5_<F)5SW\\&K.&IWI.=45O1WU2U,.W(R9\I<I)BX
M-7;2%] ?X(;NE+RW .)>UL(*U F@26?SZO3).(=(#XZ1B /Z]CQ<H@Z1*<Y8
MHO[)BE;5%?2? ,^HZ%7&FGE[9P1VY_<O;6(!5\ASYT[O,O-Y"'MV/\WDR65
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M;S]=B040)+"GIMO]U+LOS17]QB];.("P:V@*%7Y842O6NN/]@_LB -/ G3;
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M]]/_Y=-(;A*4-<D;H)> E/]E,6M=?%.12V0JI8W,S2!-G=)I77:0O\ Q9PQ
MR+V3TVR$5Q_$&NB8NK&Z/Z.*=<'+K-]=YP_H/7E[(S&+9OIZ1?0DS5G\2!-+
M?!>%? RZF6AV^AZ U(BT6>W@_\H."@,G-27"E(0TU\.<V;&-!F*752_<FS":
M.)XG#Y^L,JVFF7K&2GF37[&)',' !*H#-TZ)4V1:1X\HQU-V_XE=W#XXOXLI
MYYJR#['&O)R.6RBZQ6HRQW0-OZQCVIEP"8PY"'4)S0LO[UULIJK$336&],?8
MK<T; 8"E#HQ6M?MJN04CB^O/3.;*3LMQD_J]]\R.J#)9<:[8SDT$O9#?5J0,
M?7"=D7<U,9H<SMUB\$UQ'JTONDCBV, /YPV.)6VLI)2#?AC,YY8E.8R9&/0F
M<&%N7_5#7IHP?Y5$.9P4OV2N=G=D7% S'JJ,,5\C$4LS0K9%O*EO=<O-<N4!
MMFFJ+#*V9JRZ7:"Z,P%1FA3;QM8_W[":"3LO;V(Y7>[<$QRZBG^PR=-[0'$-
M.^+#%_R*N.GD:C"';GM D7;A@@4?O[(!JPCOR/4UB0."3))255'5OR6G!W%7
M'6??>NZBUCKO1H25[18W>I6A1G(Y^R5G9'?^2DW!WI],GN\/F9C1))W? YXA
MMT,J>P*.*TZ*D&&ZO8"TG0<VG;&NV8*SR%)\DYMNPFJ^ZEU3P_:_2AW'!:'N
M64;]J/:SSUYA8&):H3]XE_%O[\)P?2:TMX3YJW2VRT4Q;7D/V#&8<2R=8"_X
MCQHL?B$2#.3JG3AU_Y4?W49O.N?U0VYZ%UM5=LZ(6#P7@A-.F=BR@?/.N6?@
MI'5[>4"5#56'MI?"[QP2M^"ZKFBE/<%C.=5C/_!IJS<7H@A?]O;N&C$!T+LY
MS#V3LNT!MYKLPO:0GQHYC8_0FI?NU 'H/W+6%>F<*^*+3UY$&,ARZ&M@W0X.
M98>/N2A4/-CO'P>]G3/R8@$7X=&4M@/\"VO:$PQC(LNGW*IQ 7*-Y"Y%Y%AF
M.)HT>VU5_MXQHJ6<?JV=,AD35 ;'//EKE<8H-34!$TDJ7.B2B*0Q]<[9+RS>
M1*$5(=X#5/E8MD-> U_6='#WS^_,ZMD.2 ^)SRC'K8'WPB=IA0E>4[BJDJQE
MB</)8Q&RPJ%ZM;6W\N9^VD)>J+,6&EFD%"92CPNR'.\-]T4:P*>0QX_6P:V(
MN5CEZJ O?:0-TR26?]C+ '6^O?OXFWDLH1AI.Z*^\OT>\.87G1GE[T<^_N(1
M;_5*ATR+UEOBK[SYR9ENR:84OC:B.IQT"]+""5G.E/^W!SX_4I,I>M@,J ^[
M?C7X2=SN2Z\*OP?@^%YT_$5?_K<VF>T0BM'_> ^9Y5A*51D$]]=39+(.NE(S
MPFXAO#=:;U;MT)#^!^_]G_3]T&;TGW->8M'];!TO.GCT5QOH5229M3A!D_=W
M+,B'07^1H?]A.S9FY]+_L"=3]C]Z@^VE?;#GS5_V]+2 9OES7C]% ?YS#?[M
MF4?>^I\+^5-WX)_33+K0+9RG[ELK/HA!G0.&>CFF^C*4C>'RL=AG_/@2@4?K
M]ZG["5/?=*OK^O5NZJ5<WW-)?9EO#BP,\03-A^H,UC<25:.&A1K;AU+SMCG/
M^5!/^]2RADNUK5YJXNG]Z)I>25[Y#&[!Y(52;_-PTL"5GJ')MZ:RGV0)<2YC
M-JI[R[!#L$UI2F7;]:K>H-@N_A:1@ 6*MNM%#9":)*X/\VO@7CVIBSE;9U.K
M\3M?36(J+)SXZM??M@?GZH!HD<-\JH9/%TF) E=?L+7*%&' ;/1G4'- ],(_
M:GU)TVSN@H&9J)-PQ^^/3Z6 L2M6I]Z*;(NI/;9G#I(;^M<.L1)XL+XI%6*;
MV8.]@UFDU5U-ZW_O(Q6]_!BB?UM,F4<*_C]-?/+/]?Y/$_^QD_30*?[>;FHR
M,>?I;P?O 6&_G$SD5H2=G;W4O/3#5-+G0RIU=Q2_GKIL?WOF/ OQ]V30SP+1
MW@HWG IC)X .,%TC8)D]^I]I(N.5*:P1OI@&^K[8=^DRN+!)\K(@F*>26H11
M_F8Z\<1*MQ<P6E?5D$]WP2H7N3=7=A7]PRO@R!!6$:!JK2/D%?*1:XE2#K!=
M4,V8WO+DY295Y&L%..]71%U/%J(<D@+!P]]=CA6^[A=^B5-1RY9H-8CT7K;K
M%Z][V'?EW[ "WW296VYN!XO&/KB9AGWK?_>JM$78Q"=$WP"!YL(D! !D6" +
M4O1'#$\@CBZK#/V%S)BW27N@R*>1-)S1[F.R9T_??U[T[+/#.0*QJ2#!]VZ*
M1X[B&+8=<,&C=>P^G&/1SUO5GLTAPOLS'WQMY+O#EJM'A2WM6N!F*72Y!X1*
M7)OMJ#BM.O3-^I@H19]<P!*F+I6ZX4>]O.V-1.#(BI2Y7/[,G);ZF0Q.$2H
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MF-]D*+[?R6 GP.F"YOX..X9HS!*O$N@/AT PC_&CY[V>HO6K_5;6(X6?TG<
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M1PBSS_.U+DU#\9<ZF2R%3%+#;U[DBN]%J' /(X6!1(>FPBP1N8;LL A/-(@
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ML+;58DU9G*0]=0\8[Z=F\^FN9MEK>!/FVD+DH# 82Z)U'&J*4N@22'S@FFT
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MW3S-TGN#3M"UYK)X5ZW:&6F\YC=T4OI"-;)C>9: _.DF*;GKPWJ/669=>>Z
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MU</Q73LO&U>M_L/+O<278FGYBF[R A-D5'W?'O*T/@P,$[YZ0GW)6P/+8]3
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M2_]L9"U]8J_Z O,?PXF72:%_#"?>.<$1G+V[GMQ"AA9&"2FG5I*]QY]O(V+
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MF8+T#;)<IXG">\BVSE6H$BK.JTO]=,1VQ.G@6^0B7C1SQ7RY)EEO,+@7PRN
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ME.2.7$/RS%JZCG#>P\Y?)LHY' +3SZJ>C2,(75W%PUO9DC&! '8/<,&. *F
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MA9AMHL#\JFZ\1@;)_.S$-+F=?A-%_]%$V4N]52Y>SED:U5U.]G'-P=LW:$X
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MW'^Z#\Q%>2: &KI _R(F*;X]FI$8^=<KX(F.-3-!^[E\-$[8-R +Y3,Z!D,
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MB;SJ_8N[@W SJ<>#WCJGE/T;[RAN_Q:[$>A8H24Z_L(X\V^X8^#_ACNDOKR
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MK!HMF5QHNH4N^66JJGS=>&#.LS<U,8G8)%B8/W1(:;:P)@U&?%XMT0"?@HJ
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MA9YP:XUM:\_2O!3\9,\GNJ>%R4VXP*S?5\UO"<#Z&648#^F0341,!SA5#4;
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MI<JYO>.19:OMX/M+;[&E"ERC;9>$?\Q09&82&8P 'D:F;B+'3?1?G3&HTKQ
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M9"%R,C#8SI)P$\'PTNQ!BEF2! %-5%GZ@NE6@?.#:&$3UZ!WXV'[(S'7Z4%
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M7;;PIOJMX:1QMOUD]%BMZ# QH-ZY*RTV/G/N^I(0Y5X1VX2L([4S*L:_0K@
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MGE2%O:I4:Y4=571J&CH"+IOB0U=AZLWK9'9^G8VN@R:=<-U)5)XV#><CCJ&
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M8KY%3E^KYAE^!W.<I,-_I*)I#H\'P9QR&E7$[0P6F'P/4T$X2Q-)L=@0&RZ
M><407,QAES.(C:9'D/^.'N(5<WZE-Y:ON\!"TF6N\1L7NXA;?E_^F]/_CHB-
M%K&+*N8HI9U1K\]=D&"\[ &Q?#J1CM"!<I+REW;MVIF\9$&4)JF@S^--%+B]
MI#M0X(L7,%X6#9()LJA %R2=<;* <=0DD[E#SG"267XY7;S R8S\0DD41$F:
M@8JXR7B\B$'^34R9#"H2#$;2OK"'80A&Z I>1G"<"?X"7[@@P= 0$7>R+*<6
MEW/]-F\=7V/2:L3,WA$)%C!KRQ; <('P(2*AVJ[\323K_\NK7,+?]/%'^W.9
MI[MILLR6C_!R(QE[G)>7*"+><($ADOVS:?R>OWP:?Q36D4DSQ6IFOR:<":?(
MF2!+RER2!9?]F&"HF%WV T!H,0?J"/Z!]F&<".&CLO\1RF^4#V$(RZ9(/AH#
MQA_$>(#R41@1VL0X3$E%[?%@U B%Y=5&01NK+TQ$TO&V#\#=9WH(S^1-AEQA
MIR\8_YO)J.R/J)..DV4)OU/A+WM>X1\8[DLJV_R+TSXBX2UAH]SR>3TP]&=,
M7K(L@DNXT&],]X?^C.O^;J#0B:6_\?UAB_@CGR_D]) E(.X'$3Y?;PPX% 8/
M7\#WB/E&OD#.YXM GIX?-TN]*4**YYQ2/"T7J9-J/A_1!X(:/@#QRR\!GZ$O
MN\3\\J#BZ\N8F4O/%X  PA<%) $76Q'D2TT5#!3HXLN9FQZ]6, WBP4>LT3@
M"4@%>KM"F/9(!1Z/2L2/*(7I2$4R$ GX:A$_7?:K%_$1G9B/:44"M4DBT)O$
MF;1+FHF[91F,^O4W+98)TFZ-B _9&0EVJ==LD!@BY??* 7]'_#=_08Q9J-[#
MUS'+Y:?%AHHE\^4&OEYM8)8FYCO+5R_CEZU.+^;_=NDE_+1<RJA%)N0'F.4Q
M]SQRT<-T]W7(%S*K9?3BE@OU$15S6\@($/$]>B$SQFB$ 0JK&6.I#8S^)7*#
M/*.WB*5BMMCGMHO-ZJC4*\A8,WJ?3E"Q*R9D7G7&X<.$AJPG)0[J<P93(*;,
MVCDZH<:L#P>XVIS&2Y@=,I,(2LKEBHA:(?1Z'%X%H[J8$;(D-!:E@,XBH$Y<
M#@AK39##9I4$G58X0]B"N-7!]D:=H43<9453=HX!)L($0MJB/$H& Q1'*_;:
MG3*?/*3T(5F-/P(( ZC1$HR2]I"C'##F"BO89!A5^J-*:RC*]45CL62<=G)3
M$0.C7V;Y<I% S[B+WBX6,@[A*M.95RP2",5&M5DL,1LT7KG'D?$XQ-ERP(A+
MEI:H90;$J!%*+ J?.R7.*40&D<?K-)JS5I^=IQ(*.#JCAE2(/1G"'$A[RI>L
M\#LD4A\1("1F#A;3YM)93[0<$ )T.:_"&$BH36949P@2=JLEZK))8-(&&X*.
M$!%Q6J.T2PHG7>R_6GXY(" **JS6(.ISA*))=]C!I0(Q;2#J=(9CRE LQLTF
MZ!B0 IV,HXG*/$)<YF(BC(^;D1@6 ]4F#'.)#(HHH8(JK"Q.87PS%(O#V0SM
M2B>@: (DU5I<I"=U9KM>8I>Y !N8YJ.@+BQ%DP[:I\V$. 9>3,].) Q)KU4B
ML'A-R9A,%(]I*B(%U&K D"<#NRPJ%4RA%"=J SU)&:9V680FP$3E0EA 0*=,
M/!]IA;PZ1<Z>3>@DB92%)C)F#ZGP1]06!\5(1;%R0#8[8C(X'6C$HM)RW5XY
M;C A=JE.+[280+[, 693<9";Y'MM<;Y<'M.DW<)DQL)6/O*E'/#W8W&=+@S(
M25(0T4EUW"#H)E.I'! /XZ&$T^T$!<8P.PDX:<#L!>R8"I %J3"@";O K)7*
M<BKJ1QYFTZ:X.H2#Y]1J-AV3V6,\B57"H<)^LYW2.0&;Q>/5Q!SR &[&4N:H
M0DR'\5C8DA)I#+J$T [KO&9EG'+SPK**6M#%Y]HRM$YBP-F9:"CD(J!<W$+X
MZ+B%M(#A(&!WL[U<,N3A.N1VW 0+A!B6#?D-5E1A0RA!5"A4XEX;6RL6F&5
M12S+4(,U&'9:P9 L)^ K$OH0/QBGE7J+42+2QW@Q,N[E>F0\'9" C!8R;9=4
M2+.#H11@#@9I/*JAI7Z]2D1#Y8!V5=:0\0A<$9';ZX5P4]J5@G1VCR<6E*%B
M*B1QV_2ZH,KB$,(95\0*90U@0JK1)=+2)*H4$106BO!$8L9D28'-7A'+/(G-
M_L<7BQ1/N8R9A(+.8D&K$$Y Z@"4"_EB,5X@+#&',!J@=$I.B$ 17)HRN(UL
M (M75)]RS.4U.@4>F1 V W* H0;+[!VUH%$XH9% 6FXJI\_*4U*!"8"50%;$
MPW,\A]^9,Y,2OSJ9,G&2EDA"@[#-^G) +D&Y 2IE3NK,0,(=0C' 1KM@%$8M
M**FCM/(XQ\5)"),2G$]:"+?)FA F7)@,YV8QE=? #IH<8$J+X'&>R\#U5_BA
MVQZ$N0".Z*Q<5]H=]4)<$M7$LV$QH_PL90;3HJS;26$.'@7RE5YFV6X.H,/X
M&3^>)F-I$'-PTD$PZ</MN8IL$P[^HCC E1 D0(P$PSJ=FR/'G6E_4J$*PG:^
MGYMP!A1"6A0U^,265#B0]*6B,OD#2@?<NIRY0H=6+$R%O"XG&N5B<IXW@AL,
M$K8L)@#468JGIID9"A,!#\U5>T*^L-<?\KG"$F6$U&0@95SI 8F Q8;\@EP.
M^)!US3&,R80(I=8%N0#D=)K34=* Z:QFBU(ME%IB%HE3'6'3*1\MTF43H-+H
MRA(Q"X?YH11$.2!'C2D2D8#/'/-E@C 14MAY<:.'Y[(S7APH]^*L"F,G*"#!
MI251M<KBC1NR(3Y7ZLB F5B*FPNK\#@W[ O)1<&*],7CT-HTKDK;<P&=UL91
M #JY'$0M..#/R<"D)8H37$K"Q95 &.2K!9@LE].  0[(Y]N\- Q:,)*'NK0B
MD"^,@N6 7DI&18 P0H YCE&&10E2$XW%DP&3QBC%94JQ+*((R$!IUH\)0A*V
M)D9*'1[2G$JY>8F<R4VJ'8*<'\_!.6V$-)4#WG<.1L(OSA&3F;2.'(6 F!UT
MRV)Q'<@7A"FA#>"J8$^ ;]&F9684RF5C?AEE-0?"T0Q';,I2665%9QE,)059
M?M:@B(C5.5] X!!8K*C;E(E8HW%17(FJXWP,(HV@&"(0E3=%>P-JDS &6G4T
M!>NU<M"$N--A.(PHW4#%%J#S(A"@TA**("6A8BD$LXFR,9KVL5$8HF.X7"#U
M2U,F"PB1,E^,EZ01 K#@KI3#PU1*.3\ISZ$1V. '2="<\I8#@FF!.1O-@MZP
M48(F<*'CP33A38%,P9B.N4&5GR\*&4B!GQ/1Z:,V7LXKC(<P+C<32P:I !S%
M\2B>*P=4.#DQ-COLAY&<(9.U\-D@XV,"7 -J;+E,C.WA6E 'E@1HDK2CP9 V
MXO0A(J,HJ$8-%A7(CUCEM-60#">,26FPHIS39 "+#LWZ) F]-!5R NP 0$<I
M&S^HP/@\@1W0@W",!(2P 41=8%@4DT3=G) 7(*),;1 *^ T<=Q9S!)U\<59?
M48KX70%8 HA!)YU(F>T!I5<*AS$XE5,E'6%($H)L68R6:K4F6.JQ>"&=UL)W
M**11/*+ Y!F+BG!C<2K$A*?!GH+@"L>.80F.4Q^0DD8A:76()43*X@WQ!38.
M$J!40AKF80E*)Z;"HBPW 615(DJOX6IPOA<0,[6Z-TB;,9L@I@00GJ.BG(ME
M* Q(J<DD5Q%-!K).$V5DFW(F(ZV$5&YCVF*1"])>JS9'A1PH&X-H.V %%4XM
MS [2(B"0,&OX/*T<%M-,4I-6Z%"/RE'"2,4!GC&9U&4]H"9BD/)L.0T7QG1^
M1,A+>C)V%Q-J6;4@A5BB?F>$A\53.2V6T9/V%"8#W%I#2HAZ$[QRP)"=;Z35
M&M@7D -L&>APT1#7PU,(4U:"" 4]D,[LB(24QHP5RF62VHC#GM4;,+_'@M*
MG@K9;+@[@3M=%A[7BJLKV@HVXE7GW$FYV^B.43J?6F'A9CP6%4[!I,RHD2<3
M^F#4*!":S6!"2P1L7*O6[ QKU59U3F?(:E0>K4TN%\4P/^:I"#V#A@;YBAB0
MM 4==IKP$QQ7 H#EUIA'!\0!,"O(!8%<7)!S))561(J2<9XIYQ=X$#M/# 0H
M/T?G4G-Q)(&$4:!B7_:Y]#J-/J4RQMV6=#K)LV2 G%P:0V1 #&#*.)\:E254
M0K?6Y?/#'!&;<I!N!R83J=Q^*,S1V0@A[)19<'F",/@J2A$KHE=G<5+E=\"
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M0G@0]U=QJO^ B_]KZN?_!]2"$A;G/KG@?XZUA9UX!>I.7*S WHE1>8&R$U0
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MM7>8W_18F^MU7'YO5_;HC[872T<ND*P<OC!KS&_7K\6V_B?BJ\55!M9<^];
MU[;1O>?T75FO[@LW_$U+CW=>_L'9+OZB=<,/'S2\NEH:&OKZ=4W]>NWB"XI/
M5^_3U05\O."9L\4SQHP5SUH'7"Z\M85>-'^%;T!7F<[U5<NC/-:AVC,E+=\?
MST)D7\Z:H73>VE>ZJG3JU'&KZBWXH#E]<[!M:0/1()?[3=655HJU'=<1^7G7
M&TV<#56#&D[6&#K O?-ZYIT_/?W\EXD%!^H4U^N@>M6U3%;MLWV;QJT84??
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MZ>HOE9[:T%9]NY">[NS1.N^'WHW[1-X<.K?9^2GZVV^T<W6X-V;CNG?.67X
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MENL[Q6;6G[=KP2F0_VZL8#[JXE2NF1&#Y=6469GL9!=FA^</A1]"G'D0X]:
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M+X #'?4(_%."?4.5I^@7 /LS>V5BX0DM^[)SHSV$'VSP=//O+4KYNC_2-[P
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M(APB$KIC"-PH)TM=6=BWFH6%G">]VZ/8G32A&T,CB+4^E#]+LAR6#4HGM<]
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M;>^$  ).IAS ZP[AQX?#MRJ!?\-5GTHSVEA57 99^Q(@@3HQ,T^D+P#2G1<
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MC,_)RBI35G 0:(.1<'! E$<$3U4_\1T<5=GL'1T&&2N YA43 =Z,:?<+P#/
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MW.91?0%4D*L9U!7 _;Y8)DSQ4N@LLZ-WH5<+M0C.70YF]-$S/-9IF^ X)7W
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M&(CQ B8*?\EPL&>:!_9FH&0\)9)LXUK;5:(JX2\$DYU':$]O-,D&46G8UUW
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MLV)C^M/XZ'C\_NC=:^@=T#[ R =W8#YBG_\0K5?@XT$(ERN?BLU^6V P_WB
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M;^8/"_ 9DF4(NXOU)<*YSZ?%21]O6E#2W3:^Q[K =7PW]MD OB* "UT!7B-
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M#=LNQ.LGD:>M#8ABTU9SV A"#L]U32B['[93Q=S<I>9ZX1H(3]RRFK:2J0R
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M3SU/DI;/*+O)7XMRWK96@F?OJQ[5L7[J"HB;S4I8KVG[N]<' NM"0ZQK1EF
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M5[?H\5;2#Q^F,5NI >&KW,?6Y!\D2V[RI[*IZMLBCQ77$&XK4(?738NNI2P
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M#X&]@BTZ@5!)DG82W$=I<I-?1HNTCC(I*\)V@,^K/TR;(04T]@J[:+#U0&I
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MCJC<@!/&ILI]KR@F="]=-4S$5UP6>=(JYKHHKQM:3)LS8]XV=,;<W#5.JM]
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M5'6['O%<)K+U"&O#H(5P_[K>>B0'A/F#W)*UD>XVFL,_=6[EEC=F:'W?JJ[
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MR!M>BKXR$1PH!@[^L$M(X[@D771.NZX@R\IF.>G_&ZM=;.C-@#V\!'N<1E.
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M6:%]$#N&CE8GV&G+L'HM=6&3;Q1N$/6$.,CK-U*NX0\=Z>A;&'ZO@:8VZ58
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M$RJ.Y+Q THQ!\.JNQCHY9R.FC,9BVOPZ7+NM3-*4\1N(0X60$"%NUHI^XK>
ME0X1JF@D:>1N9BH[:9@GEOQU?M=])=0(JVX+>]K+T#NQY9,REF-YLN^ITH2'
M!)ZZ+>5IE<)0# S;7,K,CV/7UXVZR+(\.?1:1DAQD/%9U<*(<.HV-\!=FN7)
MD5<3:!2OFB@19DV<WV\J@U9U!9BR)J$6\W9L0=\LP*Q6[1<]GQV$>,+_19KG
M-1 I0J)CATA9Q(0DU34(NQ7,35YJP:@4-0-T@==IP[.WY+@0UEQ?<[KH*E95
MV\:[A#51,T 7>($SG#4Y+H0U$]X51' V<[<]J;^GV@W+NB?E;T5>OV'3J*'7
M@QH"OV4 F5R-XD>Z01!)"JJ(A.-[U)M!1R%&/2I. 0:@(]W#Q$TP[)2P#56^
M+/)W4M;I2T9N\KI8U?_$9@"%IB!^B$'T\M&MC VAQD2& [M,CGWOKGQ(9V]U
M6S=Z_<N*_1;E2.<= "C$@'LY6?H@D?17$\D/?Q3E7UU-!5J<L^U O7L/,)[$
MK4#H$*/OY<RHP$*X<.WAX6="M755H6_U?J>_SO'>\GQV&$R"K*$U#8>)4.S6
MX8,4(=J4UKU8[A?>_1J5R1,IYX"J_;> ?"/O?SXZ_'!Z>GQ\Z/<>TU&%1HSK
M >D^_BI*]%1":Z;#5";QDUDPG@U]>*WHT.]_T9Z.;"@(Z8EN76/MZ'F1#["7
MW0&V/M3N3*/N^N'NN+N[KDDVNUGYZ%K!0>91J4]Y]I6#]#['(5+,HW5=E ]D
MP>3?$EWDGI4VW@">W,9Q($B$51,NP/XM;$]O)"T_9^F,[F/[W;2[31'^O#HN
MZ"HP_HQM54:]=(-\FAL:<^ 1VMVZ_%R5)%T!MU0?S<&@'@ 48=CR=2-TFDGK
M=@*B=X04>0T=D.1Q2BKW140WI\X*94/W'^X2T/1.'K&IL+_2PGC\'?2,SG"<
M9Y_/CKSZH$7*X<U3* 0#)3P1%5^1[M[7:R)3\/Z3()O7]5Y3O1@  T4OQ7[Z
MU66[5V0>Y4EG8LS8GH;647XD,2P^M(RPQ&NO_B) YO6$3I.:@?@,%*W$4HYG
MLY+, ,.JT_P.\WCYE7X\G]$.%"V1"K4ZS0&%5^>])DM:J P4JT2+2*UJ;:M/
M7J(V(*]7NU:7!2D4 R4GI:H?.T!T7_1\=NS5US68)"U\!FI8*NPJQ9(\%4]O
M:=D:W((5:>C[ *?7^NNZ)MDHF :J6(Y;G]2X'/0R0.C5]6=G[>)A-%#5<AR+
M[>7H\&^PAPS2B;P5,'O=[]OA50C67KU+]>D#!%Q[*TS/P/B[ ;_7(TMKL[$,
MLL5"FGV!XJAZ2](JIF?L"U(V @M5TJRK[G8X)7>&,B(3%39E9$#/Z8D@)6'[
M\4[42?F2I$A,%-0TYVJ4WO>R]6"+XO#4#A_"RUS469!);O(NV>%!%38K.QZ>
MVG%NZ.4E8^K?(DL(P4,YS2$%!0]/+7DQ!I=M;+6WKVB^Y!,IC@FR^L[G-:!N
M:=E&$RX')V4;#S]Z,6#Q?LS;HVB!D132='\""7NF?MC+NC#]]$XFSSZ9,/ Y
MOKVMDSL-G^=6N^<SOW7",86IN3<Y4.R=6K;G^=53<;'^+.V>51/!.E^L.RBZ
M=59L#O!#.Y[!"-%"9._ <Y6X,9@9Y1< DM .;3!N-#&%<!,?-SGG\S<PN]-U
MW.-NDLZA8"X>]#Z81$([\N%0; !B"/?Z]7/5;RK:-4'@\C&B%9VZ:F>B"%%I
M8P :VK&/@$M5//8.6NEA;D4_39(N,+&+1NRF^5ORM?T3.HNJM08,H9W@8%.H
M#J 0[@'D3@:KZ)9-%,MEE&4DN5@J)(8:>C.H*+33'=TY51>LQ4/8M16\DDD<
M4"]O!!*'=AXCWP*@..P=G'([QKY$@T::V0^ )D(+Q,,8-8S9WJDJBQ8<N@]7
M; XH0HMNQ9C30F3BZ'/T GG15("JJCY_2^NVTI5H][#_,""9P,Y<)K_%<\\K
MNJ5,KM+W-"$Y+P&:\Q0(-94M-4]PBS<$/BZ*O"K*U6"ZB.*_JKI8H.XE_N//
MAP=^[]?6\2<)(5B\\:\SZ5??DU6SX3]-I9S ;E..P/C)HS'/P*N &;6&%.($
MMI]:8(R?8;J,J3C[:&?,Z,93"$C@26PRCL*MDV"-AAG>[<Y)4@L>;0/*L#.:
MQD1;= 2)J>0#,7&;H"DO3BN:M!3X_L. Q)*O1;E\NT3+0J_+'A)[]PFZY<1W
M_(8%<J3Q'&YO1.@\0:VHY]*:W/L/PQ+@U7S#!@#"""*_B?L(,<?C(HI[WC9)
M* WO81#1J_&EIF*9_/:N'QSKZY<LXV@;T$((E[@I+^,2(/;N+1Q+D.K:P6L%
MV'Q?WB;1NP99?4A!7']HA:Y0UGP;O$FO?7/K+V!B2M?]K>=@/O=Z+BD=&GQF
M.!A,7(F(99.5Z3OUZ6=1W,[.*^^#>/T7MP*AO9XX:BI>&9&)&Q!'#X5KJD_R
M)7VG-WC44=X6G3JO*E)7%\O?HC^+LC,;Q<:"QEM 92'<!:=L/FA#,W&?HDU:
M-S(KW4BJ^2;0@:^[V0<SIDT\#CR(.QR]DA^*&>.O%TB-'1,!!N?S-FGB/$\>
M2$4GLP3+@9!LO37? TN7UV"10:.2MV4?A-O$39 (H</HDPKM-5W#%%DJ* .Y
MT%'E8EF),:7^$E!8>/FK EM*%UD0%SIN7; E6S#W'P8DOI)>AZI=3EX?FHF[
M&4,@*13#Q29;TOMO312_8X$YXH5KZR&8P8.IRMWOVIREB".W\1L2K58\L!2]
M;7C%$(IOXG)#%WGXML*JAU<[.-MSX.*2&[\[T)J6?<_<!M0MG9B-U')S4NW
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MLSS]%TE !1<D!^7756>P@450DJ@B5Z3[KV!VU7H/LRB\\#W8 342:1 EV^_
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MZ^H=- ""I[C<OD[5)'J4*'Q?=(S+O-VKW+>QQ="]TJIBA'=?O4=Q>4<%9&F
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M^1D+(=PD6/Z">'?>8[-Z>SA DJL#RZTR8,N*AK.8+3O.E* B_8$@ #@%P$@
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ML'U 8O)/9(SF4F1.PJ$@6?#5?6G'NF(1(IVIB5-V7YY<3<!IDT6?TF4+Q[:
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M;*16U#QLHG;<JC904:FU5K&<""*M4[Z_T'\ 1FTQ4CG1!%0RVD@1^XB>$W1
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M'F!XSC*4/--Z'";>1WM2#@][ _AL+Q<A 2B-E? 4"C( 2TM)"+ *)DMQ$D[
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MGP-V-<\=WT_D_99&G>F[.=1H/>-O@Z_9G+B'Q27.K[2+5RUFLA9M16:R$$Z
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M"J\.'W;P6J('0;$V_0"3+XR;L-@@ACF_Q+F'17\\OKR]R\!4Q8@5^=GKH%F
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MLA,,Z.K;":<%GES;E*@M0DN-FS[ *BI:K:]%ASBA%ZN>QD3UT:8Q2U8PUZ[
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MY 3--37W9=S49J #8XOB5T*S]C2T_,@XW6<YCU:2I:8,XI16-&2;+O%\F5(
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M24_>_I/C1FV5=!LV:0U$,X+2IW093!EPH1I7\<#?U.4@9E?\2O;V;CKDP6E
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MZC'+VID#R Z*^![IKXB^&\B>61GQ5]M0NMNCYJMHFZ)K"93L1Z@O<1Z_!/"
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M J4-E*5YXK+L^]F,\64WY0IW&Q75Q^FL,'GFHF_A<7?7N\?T-GQW@NLJO-7
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MY[L."[U#E6C0U=QI@B_87#(/;/J6%R"A)M=]+0B3DXJR'NPN_'PC5',E9]<
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MDT.*UP_E=X\\) ]A06*?TT+SS+WMOTY9FD;&S"'%!3SBU[;]F--"<V1J<_L
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MUD9$HDV?Y/*]/9S^G?.G$)<9] Z6WU+<R\>*#6*W!D&6P1H,^R!&M(?63O@
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M_62>G=>L*8'7DW=NMAS)AWAW&5!%$T!LAJ=YG<@#! C_*A/H3"V:DX^'(LH
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M[/?T[-I%KV#)/,HE3DL&9@%KCR_C-H6@J,^=-HR:N8)UD$"PCNP>NXA]DJ2
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M"#88CQ27=F%6U )Y$+^YTE!EP6\;D6?1<IHSBNBN)CZ.K"R (K9\:"4N<8?
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MOY2^*1H9:9/0Z"L_?J$.6-2=>%-TKD*".'TE<#WC>Q* V]9>5O I#)N]%54
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MTO0X^VBD<5/,'0UKN9SFT[>4<5@@P@;\R:P$R9<E_.DIR6IE0!>@L3KP>'A
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M&:3KYQLPPZG' 7A$M:P-E8Y3E(@]=?VPYC3/H/4J@7/795;E\\"FFM.'JBI
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MZDK!VC-N^X#X J:#:)$M( +.B_"I0X:XV#X@-K%CDE_E2=E]+Z*<#A.^8ON
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M]=IIT0J(V1>#FW8UM8;E65)5-WJP!&J4/,:R)1 <L5.;-<O6RH+C)DORBAV
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M-1=HPW[A;"2!LQF[AH'^\)6E[^RW/*M>5;:MKDTV(J7.NCB  BFQAGZ:,Y4
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M/WU5RVFUNH(/OV23O&#/K-[<W^=5/?1NB!CE@@A-!0.7OP%<^GB49&!6/="
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MH:CI99(318/!1ML6*"*.GQMN.#%EPU4];%*#@<YWEXV*15EQNH L>9DC@U9
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M     &0S,#4Y,#AD97@R,S$N:'1M4$L! A0#%     @ >H9^5<WD6-]D @
MJP4  !$              ( !X ,  &0S,#4Y,#AD97@R,S(N:'1M4$L! A0#
M%     @ >H9^5:ECO3N<$@  !6   !               ( !<P8  &0S,#4Y
M,#AD97@U,2YH=&U02P$"% ,4    " !ZAGY5Y"\USX8'  "W60  &
M        @ $]&0  9#,P-3DP.&1E>&9I;&EN9V9E97,N:'1M4$L! A0#%
M  @ >H9^50?_9 K[;08 .]Y&  X              ( !^2   &0S,#4Y,#AD
M<S$N:'1M4$L! A0#%     @ >H9^56LBU.Q'<@$ &%0" !$
M ( !((\& &<S,#4Y,#AG,#)Y,#,N:G!G4$L! A0#%     @ >H9^5;C2]"L&
M?@  \,H  !$              ( !E@$( &<S,#4Y,#AG,#9R,C$N:G!G4$L!
M A0#%     @ >H9^5883R>>_OP$ !Q " !$              ( !RW\( &<S
M,#4Y,#AG,3%I.3DN:G!G4$L! A0#%     @ >X9^57ZW29^$- $ OI ! !$
M             ( !N3\* &<S,#4Y,#AG,3=B,#(N:G!G4$L! A0#%     @
M>X9^557([I+<7P  L;,  !$              ( !;'0+ &<S,#4Y,#AG-S%W
M-3(N:G!G4$L! A0#%     @ >X9^55::;6>7\@( EE # !$
M ( !=]0+ &<S,#4Y,#AG-S)Q.3<N:G!G4$L! A0#%     @ >X9^5>YD?=-7
M:@$ L, ! !$              ( !/<<. &<S,#4Y,#AG-S-A,S,N:G!G4$L!
M A0#%     @ >X9^5?:BZY3_K@  T-$  !$              ( !PS$0 &<S
M,#4Y,#AG-S9R,3,N:G!G4$L! A0#%     @ >X9^51I>^L^LL   3>   !$
M             ( !\> 0 &<S,#4Y,#AG-S=S,S,N:G!G4$L! A0#%     @
M>X9^56!Y0<%[F@  %[\  !$              ( !S)$1 &<S,#4Y,#AG.#9L
M,3(N:G!G4$L! A0#%     @ >X9^56?32+Q&,0$ :JT! !$
M ( !=BP2 &<S,#4Y,#AG.3-T.30N:G!G4$L! A0#%     @ >X9^5;A"%_?U
M9P  +[,  !$              ( !ZUT3 &<S,#4Y,#AG.3EC,30N:G!G4$L!
M A0#%     @ >X9^52IUHNG2(0  27<! !$              ( !#\83 &]A
M8FDM,C R,C Y,S N>'-D4$L! A0#%     @ >X9^5>_.H?M.$@  92D! !4
M             ( !$.@3 &]A8FDM,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( 'N&?E5',E=:.HX  -/U"  5              "  9'Z$P!O86)I+3(P
M,C(P.3,P7V1E9BYX;6Q02P$"% ,4    " ![AGY5,O 36]ZW  "RR0D %0
M            @ '^B!0 ;V%B:2TR,#(R,#DS,%]L86(N>&UL4$L! A0#%
M  @ >X9^5=1@4<=8F0  )#<* !4              ( !#T$5 &]A8FDM,C R
C,C Y,S!?<')E+GAM;%!+!08     %@ 6 'T%  ":VA4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
